<SEC-DOCUMENT>0001638833-21-000034.txt : 20210310
<SEC-HEADER>0001638833-21-000034.hdr.sgml : 20210310
<ACCEPTANCE-DATETIME>20210310172222
ACCESSION NUMBER:		0001638833-21-000034
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		106
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210310
DATE AS OF CHANGE:		20210310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surgery Partners, Inc.
		CENTRAL INDEX KEY:			0001638833
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		IRS NUMBER:				473620923
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37576
		FILM NUMBER:		21730858

	BUSINESS ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
		BUSINESS PHONE:		615-234-5900

	MAIL ADDRESS:	
		STREET 1:		310 SEVEN SPRINGS WAY
		STREET 2:		SUITE 500
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sgry-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:934c24c6-c60d-49cc-a057-94123601eeba,g:155ec3a3-79d5-4a25-a7e0-562ed3402740,d:efdf2fdf0cee42e79fa00bbc44d4c207--><html xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:sgry="http://www.surgerypartners.com/20201231" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgry-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN180L2ZyYWc6Mjk2ZjRlZTlhZjg3NGVmYmEwY2NhZDJmNWUzZDg2NmMvdGFibGU6ZDRjNDM4ZDNlYzVkNDVmY2JkMzc4NDVhOTkwY2NmMzkvdGFibGVyYW5nZTpkNGM0MzhkM2VjNWQ0NWZjYmQzNzg0NWE5OTBjY2YzOV80LTEtMS0xLTA_f8efc247-74ef-46f3-a0e9-d9d0fa165345">0001638833</ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN180L2ZyYWc6Mjk2ZjRlZTlhZjg3NGVmYmEwY2NhZDJmNWUzZDg2NmMvdGFibGU6ZDRjNDM4ZDNlYzVkNDVmY2JkMzc4NDVhOTkwY2NmMzkvdGFibGVyYW5nZTpkNGM0MzhkM2VjNWQ0NWZjYmQzNzg0NWE5OTBjY2YzOV85LTEtMS0xLTA_e3930639-6801-4ee3-a55d-1c8c4b1f9c81">2020</ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN180L2ZyYWc6Mjk2ZjRlZTlhZjg3NGVmYmEwY2NhZDJmNWUzZDg2NmMvdGFibGU6ZDRjNDM4ZDNlYzVkNDVmY2JkMzc4NDVhOTkwY2NmMzkvdGFibGVyYW5nZTpkNGM0MzhkM2VjNWQ0NWZjYmQzNzg0NWE5OTBjY2YzOV8xMC0xLTEtMS0w_191322f6-a838-4075-82b4-911fe3405b19">FY</ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN180L2ZyYWc6Mjk2ZjRlZTlhZjg3NGVmYmEwY2NhZDJmNWUzZDg2NmMvdGFibGU6ZDRjNDM4ZDNlYzVkNDVmY2JkMzc4NDVhOTkwY2NmMzkvdGFibGVyYW5nZTpkNGM0MzhkM2VjNWQ0NWZjYmQzNzg0NWE5OTBjY2YzOV8xMS0xLTEtMS0w_6d2f36ae-318f-4004-bbdc-169dfdcaed8b">False</ix:nonNumeric><ix:nonNumeric contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE4LTAtMS0xLTUzNzI_bdffc112-0257-4516-9c1f-1b9476bc5356">us-gaap:AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonFraction unitRef="physician_practice" contextRef="i9f21b36401084af9b89797997b0f33f6_D20200101-20201231" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODMyL2ZyYWc6M2VlZTMyMDEyNjNkNDRkZDgzZjMzYWM2NTljYTc4ODgvdGV4dHJlZ2lvbjozZWVlMzIwMTI2M2Q0NGRkODNmMzNhYzY1OWNhNzg4OF8yMTk5MDIzMjU1NTg3_11885956-b438-4123-9654-b4279331bc50">1</ix:nonFraction><ix:nonFraction unitRef="physician_practice" contextRef="i4ae1dcb070914de6b4ac251dfe871c7d_D20190101-20191231" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODMyL2ZyYWc6M2VlZTMyMDEyNjNkNDRkZDgzZjMzYWM2NTljYTc4ODgvdGV4dHJlZ2lvbjozZWVlMzIwMTI2M2Q0NGRkODNmMzNhYzY1OWNhNzg4OF8yMTk5MDIzMjU1NTg3_5f16a2c0-8a1f-4818-bd76-736413278ad1">1</ix:nonFraction><ix:nonFraction unitRef="optical_laboratory" contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231" decimals="INF" name="sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODMyL2ZyYWc6M2VlZTMyMDEyNjNkNDRkZDgzZjMzYWM2NTljYTc4ODgvdGV4dHJlZ2lvbjozZWVlMzIwMTI2M2Q0NGRkODNmMzNhYzY1OWNhNzg4OF8yNzQ4Nzc5MDY5NTE3_d9138148-15c0-4604-ad44-5c56f24b7219">1</ix:nonFraction><ix:nonNumeric contextRef="ib490a024fda045c39623460385f24d6d_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzMzNA_0c1bb596-84ab-46e0-9e07-1217a9251edc">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i3d46b8144fe4446782868e671eeca87f_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4MA_b602329f-ae4b-455f-ae04-0f191a8afe79">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="iffc0d8fbfdc542ba81423c554bc0a181_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2MA_33fd34e1-3ee5-447f-b7a8-7df209baa23f">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i0cd340aebd954a4884612b124a17d582_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5Mw_f789f954-9fee-479a-9ce3-41a85047306b">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="if5f27ae864964347a9304c5ef2222c1c_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNTk_bbc47750-6337-4405-89b2-99010957f9eb">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="id55b138001be441a9691661db6451a97_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a">us-gaap:LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="id55b138001be441a9691661db6451a97_I20201231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96">us-gaap:LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzg4L2ZyYWc6ZWVkNjVlNDNiNjY0NDAyNDlhN2YxYzEyOTg5OGJhZDkvdGFibGU6M2YwMjdlODgwNjgzNDk4NTk3M2E5NzJjYmY2ZGE1YzcvdGFibGVyYW5nZTozZjAyN2U4ODA2ODM0OTg1OTczYTk3MmNiZjZkYTVjN18yLTMtMS0xLTM2Nw_cdcfac35-2da8-4cd3-b311-03398c33e685">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="id55b138001be441a9691661db6451a97_I20201231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzg4L2ZyYWc6ZWVkNjVlNDNiNjY0NDAyNDlhN2YxYzEyOTg5OGJhZDkvdGFibGU6M2YwMjdlODgwNjgzNDk4NTk3M2E5NzJjYmY2ZGE1YzcvdGFibGVyYW5nZTozZjAyN2U4ODA2ODM0OTg1OTczYTk3MmNiZjZkYTVjN18yLTMtMS0xLTM2Nw_f789f8d7-2e18-4d1e-a87e-594879655160">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzg4L2ZyYWc6ZWVkNjVlNDNiNjY0NDAyNDlhN2YxYzEyOTg5OGJhZDkvdGFibGU6M2YwMjdlODgwNjgzNDk4NTk3M2E5NzJjYmY2ZGE1YzcvdGFibGVyYW5nZTozZjAyN2U4ODA2ODM0OTg1OTczYTk3MmNiZjZkYTVjN181LTMtMS0xLTQ0Ng_79fa4e9c-8029-485a-b67d-891f828e728f">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="id55b138001be441a9691661db6451a97_I20201231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzg4L2ZyYWc6ZWVkNjVlNDNiNjY0NDAyNDlhN2YxYzEyOTg5OGJhZDkvdGFibGU6M2YwMjdlODgwNjgzNDk4NTk3M2E5NzJjYmY2ZGE1YzcvdGFibGVyYW5nZTozZjAyN2U4ODA2ODM0OTg1OTczYTk3MmNiZjZkYTVjN181LTMtMS0xLTQ0Ng_a6f6d4b2-4c22-4648-9963-a062af536a48">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie26277c706b1409a8e1acda13f0eb374_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE0NjY_cd80199e-a025-45d6-ad9d-4f4ef62346f4">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgry-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibb7502bb866f48068b89dcf88b0dd9c7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia9b479934fbb4ecfa7a74bd97bccdd06_I20210303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id55b138001be441a9691661db6451a97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebd694edd2e84c559ed056b5007002ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i594520e2981546afb1cc70f2e2240d64_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9436eee8a582415faf17777a719e40aa_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4cfe65a0e734fc490c352616432aa34_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa882503424e4da0be7dc022a7146191_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2274a974182d4c01981835a4b40e9196_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8ef1c59a844626a0e801b7a033af22_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679f4a8d66c74b0bbb0c9afe9118ce6a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c8fd711c66341d38d95caf13c2cb675_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0014fa9a093345e0a96dd7ea4e8aa0cf_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1711e7a812034ce28d37fce9a82165eb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30805210d9e14b39939e153b9bd05398_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe757e1f73a54e7fa3eb2b75fd451837_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834d9736caee49309174d5e036c537c9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80894f3165b5496ca5111f55aa3835ee_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a50f5aedaa14987b3a169a2e743a7aa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d553aa54d740f48fcc1ab6b34d4095_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9f0a869b8843a6862016205567c15b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4b6a2e8a5d434dad534976125b83d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e8c64b0ba846c18f5a7a46fa045bc7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a23162dc89340049ff966ee6ce72f86_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if77a0a40975349a3b34383d5f0cb0c7d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1615052a3a7f484393a4b51a8b0cd4ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie56bc33ce06647288c4aef4b26242c11_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541eb4cc07d4416ab46cdea917e05d4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693318ba255342df98c96534cb3bdf86_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i975830e2f385428e80159f54d04d85df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if121998af9ae4288a4d53c8bf419dc1b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2303c6c0e9e483abccd08ac36c55d58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f4cb1d89ceb4b5380cabfddf941c7cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2369ebaa4684a78a2970d00fd9578f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7bc629529e4c048c9abfe722e66014_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebc6bef361c04164a50070ac5d583e49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d590096f6a4da5ae4f1dc1b45a84ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i5eda05d02ba64f78991a4f0b2af38f0b_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgry:SurgeryPartnersIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sgry:BainCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358a5e89179e41d0822a47803a3d6dac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgry:SurgeryPartnersIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sgry:BainCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>sgry:state</xbrli:measure></xbrli:unit><xbrli:unit id="surgical_facility"><xbrli:measure>sgry:surgical_facility</xbrli:measure></xbrli:unit><xbrli:context id="if91011ef54014758871d4c1d7f4f8be6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesAmbulatorySurgeryCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33440f4bb58f4fee905410e7e11b9a27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesSurgicalHospitalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="physician_practice"><xbrli:measure>sgry:physician_practice</xbrli:measure></xbrli:unit><xbrli:context id="i86b1a160332645c186bcb8e28fe6f17d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e7f2aea22094bddb8c6931fc0dea651_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i809eef37f4e54081a6dc49a891ecdaec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eab8ecdfcc74e9e855708a2c1ca417f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i119f3f636b3d41ad852c157ef3a54380_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e3eaeb718994330b5ba6da8d0809206_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911d67503a3e4528a30814a4348d8ea4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c30ac06941c4200b21b1e23272f2da0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aa2c1066f2b4f8c8f0f3388f465debe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162bdeb976434409ae1a1c6f77a718a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadab410bba6e4144a75e318b53880035_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd4886dd3f74966858590367b6f85d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d560570554a4fd1b7a05ce7bb03e9d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cb5f59640994a199093fe9c3ab2ac03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c0f5839140a4b41b51f5bd58cb54057_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa06470b17c4eb2b260df51cf4c128e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2bbed9c6534351953638dbdb3614f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e98bfd347534baf87731104e3ebb009_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1b7267569e4598a877a5bd1e7e60c0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb74e0812a1a443d8b8840c07f69e351_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i765813026e6747489932f2af5293073c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc2bea721a2d47a69444093571e4ee96_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie75ead2faa6f445cbe2c4cea920cf20c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f0752ff15148458214da6f9a47c887_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i281bab5aadc7405e927b61233cc41c4e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b3da5de5c04f86991cec578aae4497_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b4cc978af3f4a63b82fda4044e5fff5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9261ab18f79e429d8804ff5e25c2a493_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i825199532fc645f5b290bb16b440feda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbd90e3a784c4bef8f5691eca433c93c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd378e171d0488e9bd9affdec483b9a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3b0a3e3d1ca40ef8aa43b2e273dd745_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationOtherServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf8eaf96b18847fd812316b9aa3c3ea1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationOtherServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia042b57c0fae4f5ea23237a58e596e29_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationOtherServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb6553b4b74c4d84abce7d64bb6e0233_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf8d6a4513eb4b37bf1fdd0a3cd39717_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475a6b5170b94142b99badc78dfce138_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599771c495cc475cb14cd51b2c80b0ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ba3aeaa4184e578466ecc35d54af1e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id054af85841844e0a0510013723067b0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i142ee4c9bb7f48ac86443c88ccd89e60_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7005419b507e45a4aa93e70381643122_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db4acdb7fc34959956ed5d777c0c8aa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36320eddebd1443f9992f87dccb87372_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2540c42567484e9c8d3478cf6157e2d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab9c71919d94f0b8dd7b5473c520031_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if923233c958e4fd68b49484dc223744b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7250d04b81545d2b83ffebe4398b150_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b4b08c817e40b59ede6eeeb62709da_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i885eb9ec2ef944bca136520bc4460c09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c93236fd5e4fefa3dcd39e74f88113_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec00cab9d2244fb80d85733bd9a7509_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89029e5f88e44f1fae990a75d8ef24c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ea7f0bf38e48f6a9c4239b60ad72f6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab475b98e9148eeb2d8f43e3181a7bc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3172eb66c1954274b662b8b0387af2be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e2d986e12534bc0966c86c0cc1307aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e789cf2134b4a4dadeab6da7c134bbb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb93f590e80e4cedae1dcfd1b284ce87_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f4fb0674ba4d63b328c08bd2cd38d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4902e6aed24239a5e4d6ed4e5c823f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5d2f9dc0f01494986594870e8a27ffa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib051090172004935b836c83156fe9867_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd9ac1ba58bd4816b2c020ff0edcba26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icafafb71f58e407ab4cf51f081227241_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67253343d70443d9c7449f4a5c30664_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4daf007b63f4b438c7341c6ac37b460_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i559b03a82e914664a3d8b0edaabe4911_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f9c8cab4fb14810be18a40a5b9653b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7933eb55bb3143ffa2fd7f711c754dbf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i334aefa151714dc18f1b5f1cf16fe5f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0e51f9a61b4ac1bc4ea1f7ebbb64c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic75069bdec0e44eb9f28b52baa250e8a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa680d2bf8ab4a2d9fb8d803777a046f_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a946918c8b40eea1360771a870d93f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesNewMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia47d16d8651a47159a92c2d34a75506d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesExistingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if311991b251d46209bd73eff519dfe38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc2bd176b2b04f648164f8a60a3183bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesExistingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24702e29b0c7414e8f65fabb99f154f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e4786142704b339656b078b2112468_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f32ad0f9c64967bbb2cabcd332dc26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5a1e05804145ceab2d258e6b9b8d9d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="surgery_center"><xbrli:measure>sgry:surgery_center</xbrli:measure></xbrli:unit><xbrli:context id="i096eba00dd53417a97144cec06404675_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7dd0518ae1499292593c611baed1c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971b3ccc8c4c4158b9ebbc8fbe15c413_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="surgical_hospital"><xbrli:measure>sgry:surgical_hospital</xbrli:measure></xbrli:unit><xbrli:context id="i9f21b36401084af9b89797997b0f33f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:PhysicianPracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ae1dcb070914de6b4ac251dfe871c7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:PhysicianPracticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="optical_laboratory"><xbrli:measure>sgry:optical_laboratory</xbrli:measure></xbrli:unit><xbrli:context id="ic40107317bb949478adb6fc4f2480728_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba118baa03704512b22f936deffa8b05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib490a024fda045c39623460385f24d6d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a8169409c44abfadcd0a3bf2b8aedc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d46b8144fe4446782868e671eeca87f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3956d1c7040d40d2970ded51a67c32b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:FurnitureAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa40fcdd276343a8aed6a9a9a6a6ea6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ddb8219e714d378c98c211bb2cd34d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8c352ee9deb495eb58246bebe2e2e33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa5d9c2bf8a543b08549baa2240b44b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie020639241a94ada9a7368a42b91149c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d10b5c4c724186a5d9f3bb4e69a0a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if889bbc6323c4947b0bc16cfb5b88f95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d88e3845dc244d99f64392bd5e6a2d5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57cd5e7c106e4d9fb74e20bda4b999cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68828e4c55c440639deb9dee2ee8d14e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414e49c153824db4964a4427b5015209_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fdb52583c8b4bdd9a662cb6d4c8c12a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc0d8fbfdc542ba81423c554bc0a181_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:PhysicianIncomeGuaranteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1353b03ccc64693b38954fb5b09eaae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:PhysicianIncomeGuaranteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cd340aebd954a4884612b124a17d582_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f55624fc5d49db9e2be6b8db22e727_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i321bbd443b024763a2dbc89b24eaaa4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:ManagementRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f27ae864964347a9304c5ef2222c1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8425e9689bd4f9b9c04b4df8dcc5f4a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>sgry:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i83fa7ab9abbe4240abf5a9be8a23fd82_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb39a032ea34a87b804e96f67309730_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd41b7592e6496dae5a85b154e694ac_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4557e793265d4ca487ef329aeaae1ae3_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib321c333fae04579844d5ee99972bb0e_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca50bf762614029b46129e2456fd831_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4dce1c02884dedb36cc96503232a23_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9ee60353764f1f89b9af4f623bf105_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b51cb9aba5548ed93f4a31b4abdf654_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68f779024f44d59b01b47b4693ce33d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:ManagementRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76b5285d66914d4383e39ad0ba826fc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:ManagementRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba1731476d74ce2b3d217aad57dcc60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc383438e0c44af2bf287f3600874704_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38f34da757564475b695308801b42f1e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67bb1da722a94a38b17d3ec8f7e25de4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64394bce33e4e9ca4aca2ff0a3ab714_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1afaa2f8387439e98068fbf64e2ee04_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb34960793f34f629f106b22da0c737f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i817a7925476240d1a0297c22e048100c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i398bdf0cb33e4e9a95374ecf8c74bd27_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i673a6d4abfc04d07bc5da2e378ef3651_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2018IncrementalTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06dea18e47140059ff8bee1f65d492e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0832acb780465db2d59399c892b08c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298880778d4c4020a86c49df919d29b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65745a05a0cd456ab8a525d60910efd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85862ab6835e41eda58eb91f7b761382_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3f5b40bb954651a15a0509487a732e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia627d4a01c804d75933b140eb136c84a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e9ba12a1484646852fb69358ef6c43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">sgry:OneMonthLondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie114fdfc808045a391295f7885a63b41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cffedbc77074fe1a34b679e5841a01d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf5f1f86bf94962b6e3e0134fc3af0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f59e4d834d47dbb571b78b88198617_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie302bdf463064d918c23dd05f960895d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea8005193594087be6cd7ef7af8522d_I20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30095dd0fcb34c208f8bbc81fe378695_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i060e7eb7f3c84d6d94309114449b4f82_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia97d538681da4d98ae9a5301d88df53c_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">sgry:OneMonthLondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd68cd8cfddc4609b3d3f2f07babb578_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb199e263568416fa7ab39a1d69ed544_D20200422-20200422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-22</xbrli:startDate><xbrli:endDate>2020-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90553b5457f14a698b7cb8171b9a9315_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i568b49c59a4f4598aead50892e84c992_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd7045767554040a7d60f075ade6642_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0cdccdec4304478989201c4eb02dd07_D20170630-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe84b8f841949188f4220b606568120_I20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb43c983a45f4e8591fd3ed40d5f1536_D20190411-20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0919062a6a4f4909a1ae4a4a597169ee_D20190411-20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31650acf0ea42969dc4f705d51d36cf_D20190411-20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0635f303320f412186ec5ca19c6fe2f2_D20190411-20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ee0fbd7a0a46f594cc7b82247aa031_D20190411-20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic250d2ed04ae490aaaa2e78fd360cb53_D20190411-20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia64e7b3f55a140e2b8f74b0d1c22c37b_D20190411-20190411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">sgry:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-11</xbrli:startDate><xbrli:endDate>2019-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd4c7600c0b479ab4a28ccae5406b84_I20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option_to_renew"><xbrli:measure>sgry:option_to_renew</xbrli:measure></xbrli:unit><xbrli:context id="i50ba0a151834479a8473b3e13e71ff9c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">sgry:COVID19PandemicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bba07e3d9ed4c28b32eadb5928dc00a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7768b7591548fb890286a99b93de1b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc81a25e5bb4918abcbd07201bcc95f_D20170831-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-31</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i504a7a32d45c41d5b54fd670857c3477_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-31</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88337f9fbaa64e0ea242df6336604eda_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>sgry:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="i2c7fbb2ada8c40c981d5f09669df59ab_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="swap"><xbrli:measure>sgry:swap</xbrli:measure></xbrli:unit><xbrli:context id="ib481dfff988242d29c23918931366022_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36cc65a9e59d4da7ae3978ace772db56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50385fe9eb7447adb4a7a8c102372757_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047b904f4f4f4b5787db655ab1545242_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9c8ea68367495b9b437d93d0ca84d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe24d481eb644d19bca83b8dd928563_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72a24a82e274959946cf1d65a10b85f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26af377b8d9c4408a23b37c560fdc30e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb46091aec85404086cdd6773d8811e8_I20171215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a503d7300c4baaab4d78c7a78fe1ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0306c05aea4ff8908dcdbb29dc76e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ae2680c0a24c0f85638b06d6ff55bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10c51e09f2a46dd82c6116912a94c59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f2564128c34ff789c5d6d49d4f690e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sgry:InterestLimitationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0238428bd25e45529ad62844562813e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgry:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2828db13be9542a6b1c20843c59ad276_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e546cbd60bb4cb3b0bc3eb05ff08c90_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26277c706b1409a8e1acda13f0eb374_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038159bf343d4a9eaa27f787b51188c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7449dbb4efe040eeac8fd22c2a9264f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f57145632eb43a6ae9a59e0eb4f4180_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b10c28a8aa40f7a09f7a0424ba887c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i752e2e790a184e4ea39af03e843709ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc9c624583e425f9f3f383d5de093bc_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i347f272139b64fc897dd427a48e7af13_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f8b77cdfd93419e8d20d28aa5fff865_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7be8e78b15a040728e51f819890b13be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib77a4c3d6184412d9f09f4d2864124b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9be02e650974abdafe229970eab92a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c4f778361246b18c21e65a767306f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib26f364f72d64a0e823a7afe664f2323_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9657217604e94a48a864adfb783bc292_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f2f675e83142ada36ac4b6fab72299_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13a7bad162a4e20ba15bf84d71b699d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>sgry:installment</xbrli:measure></xbrli:unit><xbrli:context id="ibf62d3954751451e9588e5a61073849f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f71503bac9d41d4a56501b58e940ca8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe4cdae49d547e68aed4ebe2e458b2d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaab860223474d4faa76168a356ab862_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb3e91ef8ed486a975169f3a156bc61_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b51ef452dd4bca860d3742b03236b3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf7576735fbf445695c40b6c3a4332d2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c74e08e90e4514b53e1711e6d6c993_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65014b7959304f73b25e58fe57e3c32d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i689b53c3d93a499da0a1f5bd28ba963e_D20181216-20181216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-16</xbrli:startDate><xbrli:endDate>2018-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d2d66c878f4fb0a7b2c27692bcb2bf_D20181216-20181216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-16</xbrli:startDate><xbrli:endDate>2018-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774ec9394898484282082d77fdad2ddf_D20181216-20181216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-16</xbrli:startDate><xbrli:endDate>2018-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i729242ab1a2347118df4dba4c57f77f1_I20181216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibae4c0fc40e94a2db7579a9d625a90f3_D20181216-20181216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-16</xbrli:startDate><xbrli:endDate>2018-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9c47bc4b252439eb85adbb626c84a6e_I20181216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3da9fab6c3946a3bc42d096b6488712_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f863b1377d4c198f37e268eadcd88e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bdae67446eb4958aeff2fbff938b5ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafdcd1de1b344a998031d19f82faed75_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc3ee9a1e98470592066703d4aa997b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3474a6f91a7246d79ec08926d5336999_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b514b3c85dd48ff9fda4d7663a9cd66_D20210401-20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15035935d3e54ceba04f934c21488b65_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b6963e13f944e28b5413d6c9ff381b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">sgry:MateriallyMoreRestrictiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dea0a1d35084b82bbde452684959945_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">sgry:NotMateriallyMoreRestrictiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0570cd69811f45e1b5ff58850aabd565_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>sgry:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia8e40b357c844c71bed649d3cad09653_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a81da0560194155b4abbadf871ee362_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5878e06b7b984c2699576d1a46bb44f8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib03e505c471a4943901ca2907c0fa61e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie853ea8a85d94a4a8512ec67b36ff19c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ebaf38db0d469ebf56d6ca77dfe0d3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d2ddf0e9f54c259b2891a8c533060d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966ad612edb74fff9113dfbc6c476ba6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3ef67ea7a94f358e2956bacd5abd58_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad8b729655c4567bc34b3b7387d4214_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10a47a68bb1747c897f4f19e04584916_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ad5e2b8c5f43b0aa69ebc006430ab4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if35b1248a15b4a04a53222c87069bd54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe470e2b3fd645a5a04d06fd9d60eae6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018a6f0739764a949e8fe00e88704f6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6d10cceadc435bbc6d90570a26a639_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b0f35b18de46988ff6fbe8c8307369_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8880a4c46df641179425ee1784d1c48d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b34194b9c3e45b3861a805f0ab38022_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4027d5443cb745e1992a9fa9a7276711_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98564e51940c4e91a27b5a49261520cf_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgry:PublicStockOfferingFirmSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0fb1e697bf46f98f1f119b51d1217a_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596ba4d78eee424182ca76e6fe6f57f9_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9358b8a33748d69b07ec48689f9eee_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgry:PublicStockOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab383708d31447d6b0f9eb47c597c2e6_I20210127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638833</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-27</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6 id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5 id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08 id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08 id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5 id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8 id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTQtMS0xLTA_2f67ba76-2823-4860-b567-103790b87cf1 id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6 id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004" order="1"></ix:relationship></ix:resources></ix:header></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________________________________________________________</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDA0_7413e9e2-7ff6-49d3-a7e5-03ebf4de1821">10-K</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDg3_458ed25c-5691-4ddb-8db1-41adb5125fd8">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NTMy_ec16deea-63f9-44fa-aaf4-7b1f4ca61ef4"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NTMy_d37fb2e8-9f29-4a97-a1a6-72cb17c29a53">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDg4_8510ee04-f652-4047-a9f4-fca186c8190b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number:&#160; <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NTM0_b77e96af-0b1b-4f66-bd90-8c1973f1c372">001-37576</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV80MDI_ff4608a0-5933-4722-a24c-60bab7257ea3">Surgery Partners, Inc.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6YTJmZDIxYTU1MWJkNDAxZmEwNTJjOTM2MzA4YzZhMWEvdGFibGVyYW5nZTphMmZkMjFhNTUxYmQ0MDFmYTA1MmM5MzYzMDhjNmExYV8wLTAtMS0xLTEyNw_1a1ecadc-d988-466c-8e86-485b3884fc73">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6YTJmZDIxYTU1MWJkNDAxZmEwNTJjOTM2MzA4YzZhMWEvdGFibGVyYW5nZTphMmZkMjFhNTUxYmQ0MDFmYTA1MmM5MzYzMDhjNmExYV8wLTItMS0xLTEyNw_25466809-9b65-4c07-b68e-44fbe5312f6e">47-3620923</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDg5_4cc19115-d488-427f-a7e9-b7cb3b6307d0">310 Seven Springs Way, Suite&#160;500</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDkw_85a11040-91ef-445a-b227-de28cc24ea1e">Brentwood</ix:nonNumeric>, <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDA5_39d1e32b-f8f8-4f80-bb74-46d78d62d29a">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDEx_b28819b5-2e14-4c20-834f-402f5bc0feba">37027</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDU0_17567d74-a102-43e9-a4c7-9b5cc423bfaf">615</ix:nonNumeric>) <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDUy_e192d356-69c8-404b-8b3a-c439633a03ab">234-5900</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:33.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6NDEzNTIzNzhjODQyNDAzOGE2MjdjZDY3NzJhMTNjZGEvdGFibGVyYW5nZTo0MTM1MjM3OGM4NDI0MDM4YTYyN2NkNjc3MmExM2NkYV8xLTAtMS0xLTEzNw_01315365-0d86-4e39-8bf7-0c40f31b1f42">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6NDEzNTIzNzhjODQyNDAzOGE2MjdjZDY3NzJhMTNjZGEvdGFibGVyYW5nZTo0MTM1MjM3OGM4NDI0MDM4YTYyN2NkNjc3MmExM2NkYV8xLTItMS0xLTEzNw_7efa375a-a4a0-47a4-8756-d63eb0def3fc">SGRY</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6NDEzNTIzNzhjODQyNDAzOGE2MjdjZDY3NzJhMTNjZGEvdGFibGVyYW5nZTo0MTM1MjM3OGM4NDI0MDM4YTYyN2NkNjc3MmExM2NkYV8xLTQtMS0xLTEzNw_6b7d2358-14b5-41db-a8d0-eebb9c0c8530">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to section 12(g) of the Act: None</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDkx_389ba448-ffde-4471-8c91-609d5457f7d2">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDky_1dc60127-e134-4c6e-b6a4-0d11eb46b56a">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDkz_39e65af4-5613-47cc-817f-cc3fa8042fa7">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDk0_50be45fe-510a-4d68-8838-2232c326898e">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company (each as defined in Exchange Act Rule&#160;12b-2).&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:76.388%"><tr><td style="width:1.0%"></td><td style="width:25.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6ZGI2MjRhY2YwYzViNGYzODg1OTU5YzQzZTAzNDFmY2EvdGFibGVyYW5nZTpkYjYyNGFjZjBjNWI0ZjM4ODU5NTljNDNlMDM0MWZjYV8wLTItMS0xLTE2MS90ZXh0cmVnaW9uOjBhNThiZjZiYjhkNDQ5YTU5NjJkZWY4NTExZDNlODZiXzIxOTkwMjMyNTU2MTQ_cf89f455-c0a4-4a32-b5dc-7d4b49bd8e5d">Accelerated filer</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6ZGI2MjRhY2YwYzViNGYzODg1OTU5YzQzZTAzNDFmY2EvdGFibGVyYW5nZTpkYjYyNGFjZjBjNWI0ZjM4ODU5NTljNDNlMDM0MWZjYV8xLTAtMS0xLTE5MS90ZXh0cmVnaW9uOmZmMTIyMzkxOWU5ZDRkYzliNzdkNzc0ZWMwODU1YzA0XzIxOTkwMjMyNTU2MTQ_38f27cb9-b0ba-475a-8264-0de7efdabec2">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6ZGI2MjRhY2YwYzViNGYzODg1OTU5YzQzZTAzNDFmY2EvdGFibGVyYW5nZTpkYjYyNGFjZjBjNWI0ZjM4ODU5NTljNDNlMDM0MWZjYV8xLTItMS0xLTE4Ny90ZXh0cmVnaW9uOmZjNDhhMGIxOWE1ZjRiMGE5ODhhZWFjZTA5ZGU5Y2NjXzIxOTkwMjMyNTU2Mzk_2abfcf06-af37-42a7-8fcc-5349b3b6e5a2">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU5NjQ1_f074ee6c-3141-4bd9-83f4-da9107e2a2cb">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDk1_ee64c247-3a9b-4243-ac32-995d5cad928e">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s voting and non-voting common equity held by non-affiliates of the registrant based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2020, was $<ix:nonFraction unitRef="usd" contextRef="ibb7502bb866f48068b89dcf88b0dd9c7_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV84Nzk2MDkzMDI1MjM4_588ed86a-e786-4879-9547-589b9360054b">255.9</ix:nonFraction>&#160;million. As of March&#160;3, 2021, there were <ix:nonFraction unitRef="shares" contextRef="ia9b479934fbb4ecfa7a74bd97bccdd06_I20210303" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yNTk4_d2252f1c-abd0-4a4e-9aa6-68c154332bbf">59,859,614</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</span></div><div style="margin-bottom:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:174%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NTM1_6a22b6e9-bb28-4bde-8019-cdd9e6d62951" escape="true">Portions of the registrant's definitive proxy statement for the 2021 annual meeting of stockholders are incorporated by reference into Part III of this report.</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:11.567%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_13">PART I</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_19">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_22">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_25">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_28">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_31">38</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_34">PART II</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_37">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_40">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_40">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_43">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_43">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_73">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_73">Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_73">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_76">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_76">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_76">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_79">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_79">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_79">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_82">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_82">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_85">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_85">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_85">57</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_88">PART III</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_91">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_91">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_91">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_94">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_94">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_94">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_97">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_97">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_97">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_100">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_100">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_100">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_103">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_103">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_103">58</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_106">PART IV</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_109">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_109">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_109">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_112">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_112">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_112">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_205">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K (this "Annual Report") contains forward-looking statements based on our current expectations, estimates and assumptions about future events. All statements other than statements of current or historical fact contained in this report, including statements regarding our future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. The words "projections," "believe," "continue," "drive," "estimate," "expect," "intend," "may," "plan," "will," "could," "would" and similar expressions are generally intended to identify forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We believe that these risks and uncertainties include, but are not limited to, those described in the "Risk Factors" section of this Annual Report, which include but are not limited to the following: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the social and economic impact of the COVID-19 outbreak on our business; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on our business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to comply with current health care laws and regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations ("HMOs"), preferred provider organizations ("PPOs"), and other managed care organizations and employers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to contract with private insurance payors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">changes in our payor mix or surgical case mix;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the impact of payor controls designed to reduce the number of surgical procedures;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our efforts to integrate operations of acquired businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">shortages or quality control issues with surgery-related products, equipment and medical supplies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to attract and retain qualified health care professionals; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to enforce non-compete restrictions against our physicians;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to manage material liabilities whether known or unknown incurred as a result of acquiring surgical facilities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">economic and competitive conditions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the outcome of legal and regulatory proceedings that have been or may be brought against us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">payments we are required to make under the tax receivable agreement; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our indebtedness. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this Annual Report. We have based these forward-looking statements on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. They can be affected by known or unknown risks, uncertainties and assumptions, including, among other things, the risks, uncertainties and assumptions described in Item 1A. "Risk Factors."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any forward-looking statements and other information set forth in this Annual Report speak only as of the date made. Other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, press releases, investor presentations and our website.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_16"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners, Inc., a Delaware corporation, acting through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. Unless the context otherwise indicates, Surgery Partners, Inc. and its subsidiaries are referred to herein as "Surgery Partners," "we," "us," "our" or the "Company."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On August 31, 2017, (i) we completed the sale and issuance of 310,000 shares of our 10.00% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") to a fund advised by an affiliate of Bain Capital Private Equity LP ("Bain Capital"), at a cash purchase price of $1,000 per share (the "Preferred Private Placement"), and (ii) Bain Capital completed its purchase of 26,455,651 shares (the "Purchased Shares") of our common stock (the "Private Sale"). As a result, Bain Capital became our controlling stockholder, holding Series A Preferred Stock and Common Stock that collectively represented approximately 65.7% of the voting power of all classes of capital stock of the Company as of August 31, 2017. We refer to the Preferred Private Placement and the Private Sale collectively in this Annual Report as the "Transactions."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we owned or operated primarily in partnership with physicians, a portfolio of 127 surgical facilities in the United States ("U.S.") comprised of 110 ambulatory surgical centers ("ASCs") and 17 surgical hospitals ("surgical hospitals," and together with ASCs referred to as "surgical facilities" or "facilities") across 30 states, including a majority interest in 84 of the surgical facilities. During 2020, patient services provided in our surgical facilities generated approximately $1.8 billion in revenue. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our Growth Strategies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our differentiated operating model employs a multifaceted strategy to grow revenue, earnings and cash flow. We believe the following are key components to this strategy:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Deliver outstanding patient care and clinical outcomes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Continue to execute and expand upon our physician engagement strategy in attractive markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Become the partner of choice for physicians seeking to become or stay independent;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Drive organic growth at existing facilities through targeted physician recruitment, service line expansion and implementing our efficient operating model;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Seek partnership opportunities with payors to make health care more affordable for their members;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Seek partnership opportunities with health systems looking to develop and/or enhance their ambulatory surgery footprint to better meet the needs of the patients and medical staff;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Continue our disciplined acquisition strategy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Offer new services to provide a more comprehensive continuum of care; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Enhance operational efficiencies and productivity by delivering on integration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we believe favorable industry trends such as an aging population and advancements in medical technology will further drive growth. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Addressable Market</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on management estimates, we believe that the total U.S. surgical facility market represents approximately $90 billion in annual revenue, including approximately $55 billion of hospital outpatient department procedures and $35 billion of ambulatory surgical center procedures, and we believe that ambulatory surgical centers are capturing an increasing share of the total surgical procedure market. We estimate that as a result of this trend, total annual procedure volume is expected to grow over the next few years by approximately 2% in hospital outpatient departments and by approximately 6% in ambulatory surgery centers, while inpatient procedures will decline by approximately 2% during the same period. In addition, we believe that approximately $60 billion of inpatient surgical cases have the potential to move to outpatient surgery centers, which, together with procedures performed at hospital outpatient departments and ambulatory surgical centers, represents what we believe is a total addressable market of approximately $150 billion. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patient and Physician Satisfaction</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are leveraging our growth strategies to capture market share by providing high quality service. According to a 2019 survey of health and life safety tags, our ASCs averaged 25% fewer deficiencies compared with the total market, with 6.3 deficiencies at our ASCs compared to 8.4 in other ASCs. Similarly, our surgical hospitals averaged 48% fewer deficiencies per survey compared to all other hospitals surveyed, with 17.6 deficiencies for our surgical hospitals compared with 33.7 deficiencies at other hospitals according to a 2019 industry survey. In addition, 71% of our surgical hospitals in 2019 were rated five star in the CMS star rating, with the remaining 29% rated four star. This has resulted in an average patient net promoter score of 94, based on patient satisfaction surveys conducted from December </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2019 to May 2020. Our physicians similarly report strong satisfaction levels with Surgery Partners, with an average physician net promoter score of 81 based on a 2015 survey.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 update</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 global pandemic has significantly affected our facilities, employees, patients, communities, business operations and financial performance, as well as the U.S. economy and financial markets. Beginning mid-March 2020, the COVID-19 pandemic began to negatively affect our revenue and business operations, due in part to local, state and federal guidelines, as well as recommendations from major medical societies, requiring social distancing and self-quarantines in response to the COVID-19 pandemic. Surgical case volumes across most of our surgical facilities were significantly impacted in the second quarter of 2020. The impact of COVID-19 on our surgical facilities has varied based on the market in which the facility operates, the type of surgical facility and the procedures typically performed. Although we cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic, surgical case volumes improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our operating structure naturally enables some flexibility in the cost structure according to the volume of surgical procedures performed, including much of our cost of revenues. In addition to the natural variability of these costs, we and our partners in the surgical facilities have undertaken additional steps to preserve financial flexibility. Beginning in mid-March, and during the remainder of 2020, we took actions that included significantly reducing cash operating expenses and deferring non-essential expenditures at the height of the crisis. These measures were gradually reduced as surgical case volumes improved. For more information, please refer to Note 1. "Organization and Summary of Accounting Policies - COVID-19 Pandemic" to our audited consolidated financial statements for the year ended December 31, 2020 included elsewhere herein.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During 2020, we operated in three reporting segments: Surgical Facility Services, Ancillary Services and Optical Services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our Surgical Facility Services segment consisted of the operation of ASCs and surgical hospitals and includes our anesthesia services. Our surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology ("GI") and general surgery.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our Ancillary Services segment consisted of a diagnostic laboratory and multi-specialty physician practices, including physician practices owned and operated pursuant to long-term management service agreements. During the third quarter of 2020, we closed our diagnostic laboratory.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our Optical Services segment consisted of an optical products group purchasing organization, which was divested on December 31, 2020. Until we divested certain businesses in October 2018, this segment also included an optical laboratory that manufactured eyewear. Our Optical Services segment was not a material component of our total revenue, contributing less than 1% in each of 2020, 2019 and 2018.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Surgical Facility Services Segment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Surgical Facility Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we owned or operated primarily in partnership with physicians, 127 surgical facilities, including 110 ASCs and 17 licensed surgical hospitals. Our Surgical Facility Services segment contributed approximately 96% of our total revenue in 2020, and 95% of our total revenue in both 2019 and 2018. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our typical ASC is a free-standing facility that performs planned surgical procedures on an outpatient basis for patients not requiring hospitalization and for whom an overnight stay is not expected after surgery. Each center typically has one to four operating or procedure rooms with areas for reception, pre-operative care, recovery and administration. The staff of our ASCs generally includes a center administrator, registered nurses, operating room technicians, as well as other administrative staff.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our surgical hospitals are generally larger than our ASCs and include inpatient hospital rooms and, in certain cases, emergency departments. Our surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We operate both multi-specialty and single-specialty facilities. In multi-specialty facilities, a variety of surgical procedures are performed, including, among others, orthopedics and pain management, ophthalmology, GI and general surgery. We have diversified the mix of procedures performed at our facilities by strategically introducing select specialties that will complement existing services. In many cases, we keep certain facilities as single-specialty where it suits an individual facility or market demand.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our surgical facilities are generally located in close proximity to physicians&#8217; offices.&#160;We provide each of our surgical facilities with a full range of financial, marketing and operating services.&#160;For example, our regional managed care directors assist the local management team at each of our surgical facilities in developing relationships with private insurance payors and negotiating private insurance contracts.&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Surgical Facility Ownership Structure</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We own and operate our surgical facilities through partnerships or limited liability companies with physicians, physician groups and health care systems.&#160;One of our wholly-owned subsidiaries typically serves as the general partner or managing member of our surgical </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">facilities.&#160;We generally seek to own a majority interest in our surgical facilities or otherwise have sufficient control over the facilities in order to consolidate the financial results.&#160;In some instances, we will acquire ownership in a surgical facility with the prior owners retaining ownership, and, in some cases, we offer new ownership to other physicians or health care systems. We hold majority ownership in 84 of the 127 surgical facilities in which we own an interest.&#160;We provide intercompany loans to some of the surgical facilities which often are secured by a pledge of assets of the facility.&#160;We also provide day-to-day management services for a majority of our surgical facilities pursuant to a management agreement and receive a management fee that is typically equal to a percentage of the facility revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Strategic Relationships</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When attractive opportunities arise, we may develop, acquire or operate surgical facilities through strategic relationships with payors, health care systems, and other health care providers.&#160;We believe that forming such strategic relationships can enhance our ability to attract physicians and access favorable private insurance contracts for our surgical facilities in that market.&#160; </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The strategic relationships through which we own and operate surgical facilities are governed by partnership and operating agreements that are generally comparable to the partnership and operating agreements of the other surgical facilities in which we own an interest.&#160;The primary difference between the structure of these strategic relationships and the other surgical facilities in which we hold ownership is that, in these strategic relationships, a health care system holds ownership in the surgical facility in addition to physician investors. In each of these strategic relationships, we also have entered into a management agreement under which we provide day-to-day management services for a management fee equal to a percentage of the revenues of the surgical facility. The terms of those management agreements are comparable to the terms of our management agreements with other surgical facilities in which we own an interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sources of Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from our surgical facilities is earned from facility fees related to health care services performed in our surgical facilities and is included in our patient service revenues. The fee charged for surgical services varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, supplies, nursing staff and/or medications. Our fees do not typically include professional fees charged by the patient's surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are dependent upon government and private insurance sources of payment for the services we provide. The amounts that our surgical facilities receive in payment for their services may be adversely affected by market and cost factors as well as other factors over which we have no control, including Medicare, Medicaid and state regulations, cost containment and utilization decisions and reduced reimbursement schedules of private insurance payors.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the percentage of total patient service revenues for our consolidated surgical facilities by type of payor for the periods indicated:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private Insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We receive reimbursement from Medicare for surgical services based on three different payment systems depending on the site of service: hospital inpatient surgical services, hospital outpatient surgical services and outpatient surgical services generally provided in our ASCs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Medicare Reimbursement - Hospital Inpatient Services</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Seventeen of our surgical facilities are licensed as hospitals. Most inpatient services provided by hospitals are reimbursed by Medicare under the inpatient prospective payment system ("IPPS"). Under the IPPS, a hospital receives a fixed amount for inpatient hospital services based on each patient's final assigned Medicare-severity diagnosis related group ("MS-DRG"). Each MS-DRG is assigned a payment rate that is prospectively set by the Centers for Medicare and Medicaid Services ("CMS") using national average resources used per case for treating a patient with a particular diagnosis. This assignment also affects the prospectively determined capital rate paid with each MS-DRG. MS-DRG and capital payments are adjusted by a predetermined geographic adjustment factor assigned to the geographic area in which the hospital is located. The index used to adjust the MS-DRG rates, known as the "hospital market basket index," gives consideration to the inflation experienced by hospitals in purchasing goods and services.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 2, 2020, CMS published the IPPS final rule for federal fiscal year ("FFY") 2020, which began on October 2, 2020. Under the FFY 2020 final rule, rates for inpatient stays in hospitals paid under the IPPS that successfully report certain quality data under the Hospital Inpatient Quality Reporting ("IQR") Program and demonstrate meaningful use of certified electronic health record ("EHR") technology will be increased by 2.9%. Those hospitals that do not successfully report quality data under the IQR Program (but are </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">meaningful EHR users) may receive a payment rate increase of only 1.85%. In addition to the IQR Program, hospitals will be subject to payment adjustments under the Value Based Purchasing Program, Readmissions Reduction Program and Hospital Acquired Conditions Reduction Programs that have been implemented by the Department of Health and Human Services ("HHS").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Medicare Reimbursement - Hospital Outpatient Departments</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgical services that are provided in hospital outpatient departments ("HOPDs") generally are reimbursed by CMS using the Outpatient Prospective Payment System (the "OPPS"). The OPPS, established by the Secretary of HHS, determines payment amounts prospectively (generally the following calendar year) for various categories of medical services performed in HOPDs. On December 2, 2020, CMS published its OPPS final rule for 2021. The final rule provides for a payment rate increase of 2.4%. Hospitals that do not meet the reporting requirements of the Medicare Hospital Outpatient Quality Reporting Program will be subject to a 2.0% payment rate decrease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, as a result of legislative changes related to off-campus HOPDs, certain off-campus HOPDs that began billing under the OPPS (or underwent certain changes) on or after November 2, 2015 are no longer paid for most services under the OPPS. Instead, these facilities are paid under the Medicare Physician Fee Schedule ("MPFS"), which typically results in lower reimbursements. Services provided in a dedicated emergency department are still paid under the OPPS. This change has not significantly affected reimbursement to any of our HOPDs, but we cannot assure you that our HOPDs will not be impacted in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Medicare Reimbursement - ASCs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Payments under the Medicare program to ASCs are also made based on the OPPS. However, the payment received from CMS is a percentage of the payment to HOPDs. Reimbursement rates for ASCs are updated annually based on changes in the consumer price index offset by multifactor productivity adjustments. Based on the OPPS Final Rule, ASC reimbursement rates will increase by 2.4% for 2021. CMS has established the Ambulatory Surgical Center for Quality Reporting ("ASCQR") Program as a pay-for-reporting, quality data program. Our ASCs that participate in the ASCQR Program receive the full annual update to the ASC payment rate. Those ASCs that do not successfully report quality data under the ASCQR Program may receive a payment reduction.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Annual Cost Reports</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hospitals participating in Medicare and Medicaid programs, whether paid on a reasonable cost basis or under a prospective payment system, may be required to meet certain financial reporting requirements. Federal and, where applicable, state regulations require submission of annual cost reports identifying medical costs and expenses associated with the services provided by each hospital to Medicare beneficiaries and Medicaid recipients. Annual cost reports required under the Medicare and Medicaid programs are subject to routine governmental audits. These audits may result in adjustments to the amounts ultimately determined to be payable to us under these reimbursement programs. Finalization of these audits often takes several years. Providers may appeal any final determination made in connection with an audit. While ASCs are not currently subject to federal cost reporting requirements, it is possible that such requirements, which could be costly for us, will be implemented by CMS in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Ancillary Services Segment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Ancillary Services</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our portfolio of outpatient surgical facilities is complemented by a suite of ancillary services, which support our physicians in providing high quality and cost-efficient patient care. Our ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. The Company, physicians and patients benefit from these services through improved clinical efficiency and scheduling, and from incremental revenue associated with retaining fees for these services. Our Ancillary Services segment contributed approximately 3% of our total revenue in 2020, and 4% of our total revenue in both 2019 and 2018. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Until it was closed in the third quarter of 2020, we offered physicians toxicology testing services through our wholly-owned diagnostic laboratory based in Tampa, Florida.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We employ two models in connection with our network of multi-specialty physician practices. For example, in the state of Florida, where the law does not preclude a business corporation from employing physicians, we wholly-own and operate physician practices in several locations throughout Florida. In certain other states, we operate physician practices pursuant to long-term management service agreements with separate professional corporations that are wholly-owned by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sources of Revenue - Ancillary Services Segment</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fees charged for services in our Ancillary Services segment depend on a variety of factors, including the type of service provided, the location in which the service is provided and the provider of the service. Service fees are received from both government and private insurance payors. The amounts that we receive in payment for the provision of ancillary services may be adversely affected by market and cost factors as well as other factors over which we have no control, including Medicare, Medicaid and state regulations, cost containment and utilization decisions and reduced reimbursement schedules of private insurance payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Acquisition and Development Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisition Program. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to our corporate strategy, we continuously evaluate opportunities to expand our presence in the surgical facility market by making strategic acquisitions of existing surgical facilities and by developing new surgical facilities in cooperation with local physician partners and, when appropriate, health care systems and other strategic partners.&#160;We generally structure </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">our partnerships as two-way arrangements where either we are a majority owner partnered with physicians or we are a minority owner with buy-up rights.&#160;These buy-up rights give us the option to own a controlling interest at some point in the future.&#160;Alternatively, we may choose to pursue a strategic relationship with physicians and a health care system.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We employ a dedicated acquisition team with experience in health care services.&#160;Our team seeks to acquire surgical facilities that meet our criteria, including prominence and quality of physician partners, specialty mix, opportunities for growth, level of competition in the local market, level of private insurance penetration and our ability to access private insurance contracts. We carefully evaluate each of our acquisition opportunities through an extensive due diligence process to determine which facilities have the greatest potential for growth and profitability improvements under our operating structure.&#160;Our team may also identify opportunities to attract additional physicians to increase the acquired facility&#8217;s revenues and profitability.&#160; </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Development Program. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We develop surgical facilities in markets that we identify as having substantial interest by physicians and payors.&#160;We have experience in developing both single and multi-specialty surgical facilities.&#160;When we develop a new surgical facility, we generally provide all of the services necessary to complete the project.&#160;We offer in-house capabilities for structuring partnerships and financing facilities and work with architects and construction firms in the design and development of surgical facilities. Before and during the development phase of a new surgical facility, we analyze the competitive environment in the local market, review market data to identify appropriate services to provide, prepare and analyze financial forecasts, evaluate regulatory and licensing issues and assist in designing the surgical facility and identifying appropriate equipment to purchase or lease.&#160;After a surgical facility is developed, we typically provide general startup operational support, including information systems, equipment procurement and financing.&#160; </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Marketing</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We primarily direct our sales and marketing efforts at physicians who would utilize our surgical facilities.&#160;Marketing activities directed at physicians and other health care providers are coordinated locally by the individual surgical facility and are supplemented by dedicated corporate personnel.&#160;These activities generally emphasize the benefits offered by our surgical facilities compared to other facilities in the market, such as the proximity of our surgical facilities to physicians&#8217; offices, the ability to schedule consecutive cases without preemption by inpatient or emergency procedures, the efficient turnaround time between cases, our advanced surgical equipment and our simplified administrative procedures.&#160;Although the facility administrator is the primary point of contact, physicians who utilize our surgical facilities are important sources of recommendations to other physicians regarding the benefits of using our surgical facilities.&#160;Recruiting teams develop a target list of physicians, and we continually review our progress in successfully recruiting additional local physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also market our surgical facilities directly to private insurance payors.&#160;Payor marketing activities conducted by our corporate office management and facility administrators emphasize the high quality of care, cost advantages and convenience of our surgical facilities, and are focused on making each surgical facility an approved provider under local managed care plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In each market in which we operate a surgical facility, we compete with hospitals and operators of other surgical facilities to attract physicians and patients. We believe that the competitive factors that affect our surgical facilities&#8217; ability to compete for physicians are convenience of location of the surgical facilities, quality of care offered, convenience of scheduling, professionalism and cleanliness of facilities, access to capital and participation in private insurance programs. In addition, we believe the national prominence, scale and reputation of our company are instrumental in attracting physicians.&#160;We believe that our surgical facilities attract patients based upon our quality of care, the specialties and reputations of the physicians who operate in our surgical facilities, participation in managed care programs, ease of access and convenient scheduling and registration procedures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In developing or acquiring existing surgical facilities, we compete with other public and private surgical facility and hospital companies.&#160;Several large national companies own and/or manage surgical facilities, in some cases in connection with other lines of business with which we do not compete, including HCA&#160;Holdings, Inc., Envision Healthcare Corporation, Tenet Healthcare Corporation, Surgical Care Affiliates, Inc. and Optum, Inc. We also face competition from local hospitals, physicians and other providers who may compete with us in the ownership and operation of surgical facilities, as well as the trend of physicians choosing to perform procedures in an office-based setting rather than in a surgical facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Seasonality </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our revenue fluctuates based on the number of business days in each calendar quarter, because the majority of services provided by physicians in our surgical facilities consist of scheduled procedures and office visits that occur during business hours. In addition, revenue in the fourth quarter could also be impacted by an increased utilization of services due to annual deductibles which are not usually met until later in the year and also as patients utilize their health care benefits before they expire at year-end.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had approximately 10,800 employees, including approximately 1,700 part-time employees.&#160;None of our employees are represented by a collective bargaining agreement. We believe that we have a good relationship with our employees. We are subject to various state and federal laws that regulate wages, hours, benefits and other terms and conditions relating to employment. In some markets, nurse and medical support personnel availability has become a significant operating issue to healthcare providers. To </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">address this challenge, we have implemented several initiatives to improve engagement, retention, recruiting, compensation programs and productivity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our surgical facilities are staffed by licensed physicians. Our mission is to enhance patient quality of life through partnership. We generally do not enter into contracts with physicians who use our surgical facilities, other than partnership and operating agreements with physicians who own interests in our surgical facilities, agreements for anesthesiology services and medical director agreements. Most physicians are not employees of our surgical facilities and are not contractually required to use our facilities. Physicians who use our surgical facilities also use other facilities or hospitals and may choose to perform procedures in an office-based setting that might otherwise be performed at our surgical facilities. Our operations are dependent on the efforts, abilities and experience of our physicians and clinical personnel. We compete with other health care providers, primarily hospitals and other surgical facilities, in attracting physicians to utilize our surgical facilities, nurses and medical staff to support our surgical facilities, recruiting and retaining qualified management and support personnel responsible for the daily operations of each of our facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our surgical facilities, like most healthcare providers, have experienced rising labor costs. We may be required to continue to enhance wages and benefits to recruit and retain nurses and other medical support personnel or to hire more expensive temporary or contract personnel. As a result, our labor costs could continue to increase. We also depend on the available labor pool of semi-skilled and unskilled employees in each of the markets in which we operate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that our employees are vital contributors to our success, and we devote significant resources to recruit and retain our workforce. We strive to recruit and retain a diverse population of employees at all stages of their careers that are reflective of the communities we serve. We are committed to promoting an inclusive culture through diversity of thoughts and backgrounds, recognizing the value these experiences bring to our colleagues, physicians, patients and the communities in which we reside. Our workforce is comprised of approximately 81% female and 26% people of color. Our policies prohibit discrimination on the basis of race, sex, religion, color, national or ethnic origin, age, disability, sexual orientation, gender identity, gender expression, military service, pregnancy, physical or mental disabilities, genetic information, or any other class protected by applicable law in its administration of policies, programs or employment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have established, and continue to enhance and refine, a comprehensive set of practices for engagement, recruiting, managing and optimizing the human resources of our organization. In general, we seek to attract, develop and retain an engaged workforce and improve talent management processes accordingly. We offer a competitive range of compensation and benefit programs. In response to the COVID-19 pandemic, we implemented changes to address the safety and interests of our patients, employees, and medical staff, including the implementation of additional safety measures. Our code of conduct that promotes integrity, accountability and transparency, among other high ethical standards and a focus on employee welfare.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Environmental</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to various federal, state and local laws and regulations relating to the protection of the environment and human health and safety, including those governing the management and disposal of hazardous substances and wastes, the cleanup of contaminated sites and the maintenance of a safe workplace.&#160;Our operations include the use, generation and disposal of hazardous materials.&#160;We may, in the future, incur liability under environmental statutes and regulations with respect to contamination of sites we own or operate (including contamination caused by prior owners or operators of such sites, adjoining properties or other persons) and the off-site disposal of hazardous substances.&#160;We believe that we have been and are in substantial compliance with the terms of all applicable environmental laws and regulations and that we have no liabilities under environmental requirements that we would expect to have a material adverse effect on our business, results of operations or financial condition (including our capital expenditures, earnings and competitive position).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We maintain liability insurance in amounts that we believe are appropriate for our operations.&#160;Currently, we maintain professional, general and workers' compensation liability insurance in excess of self-insured retentions through third party commercial insurance carriers. We also maintain cyber insurance, business interruption insurance and property damage insurance.&#160;Coverage under certain of these policies is contingent upon the policy being in effect when a claim is made regardless of when the events which caused the claim occurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, physicians who provide professional services in our surgical facilities are required to maintain separate malpractice coverage with defined minimum coverage limits.&#160;While we believe that our insurance policies are adequate in amount and coverage for our operations, we make no assurances that the insurance coverage is sufficient to cover all future claims or will continue to be available in adequate amounts or at a reasonable cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Private Insurance Payors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Most private third-party payors reimburse us for services pursuant to written contracts. These contracts generally require that we offer discounts from our established charges. Some of our payments come from private insurance payors with which we do not have written contracts. In those situations, commonly known as "out-of-network" services, we generally charge the patients the same co-payment or other patient responsibility amounts that we would have charged had we had a contract with the private insurance payor. We also submit a claim for the services to the private insurance payor along with full disclosure that we have charged the patient an in-network patient responsibility amount.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our businesses are subject to federal, state and local laws dealing with issues such as occupational safety, employment, medical leave, insurance regulations, civil rights, discrimination, building codes and medical waste and other environmental issues. Federal, state and local governments are expanding the regulatory requirements on businesses like ours. The imposition of these regulatory requirements may have the effect of increasing operating costs and reducing the profitability of our operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Development in Response to COVID-19</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerous recent legislative and regulatory actions have been taken in an attempt to provide businesses, including health care providers, with relief from the negative impacts of the COVID-19 pandemic. The legislative and regulatory responses to the COVID-19 pandemic generally impact many of the statutes, regulations and policies summarized or discussed throughout this Annual Report.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">CARES Act and Other Stimulus Legislation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law to provide stimulus funding for the U.S. economy. The CARES Act is intended to provide over $2 trillion in stimulus benefits for the U.S. economy in order to offset the negative economic impact of the COVID-19 public health emergency. Among other things, the CARES Act includes support for small businesses, expands unemployment benefits, and provides $500 billion for loans, loan guarantees, and other investments for or in U.S. businesses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CARES Act contains a number of provisions that are intended to assist health care providers as they combat the effects of the COVID-19 public health emergency. The healthcare-specific provisions include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the temporary suspension of Medicare sequestration from May 1, 2020, to March 31, 2021;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an appropriation of $100 billion to the Public Health and Social Services Emergency Fund for a new program to reimburse, through grants or other mechanisms, eligible health care providers and other approved entities for COVID-19-related expenses or lost revenues;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the expansion of CMS&#8217; Accelerated and Advance Payment Program; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">waivers or temporary suspension of certain regulatory requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 27, 2020, the COVID-19 Economic Relief Bill (the &#8220;Bill&#8221;) was enacted, which among other significant matters, revised previous guidance on how grant funds distributed under the CARES Act may be utilized. These changes included greater clarity on the measurement of lost revenues eligible to be claimed against grant funds received through the CARES Act as well as how funds can be allocated among consolidated facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HHS&#8217; interpretation of the underlying terms and conditions of grant funds received through the CARES Act, the Bill and other governmental assistance programs, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in our inability to recognize certain payments, changes in the estimate of amounts recognized, or the derecognition of amounts previously recognized, including the amount estimated and included in our consolidated statement of operations for the year ended December 31, 2020 provided herein. Such changes may be material.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continue to closely monitor legislative actions and regulatory guidance at the federal, state and local levels with respect to the CARES Act as other governmental assistance might become available to us. For more information, please refer to Note 1. "Organization and Summary of Accounting Policies - COVID-19 Pandemic" to our audited consolidated financial statements for the year ended December 31, 2020 included elsewhere herein.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Waivers or Temporary Suspension of Certain Regulatory Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the financial and other relief that has been provided by the federal government through the CARES Act and other legislation that has been passed by Congress, CMS and many state governments have also issued a number of waivers and temporary suspensions of health care facility licensure, certification, and reimbursement requirements in order to provide hospitals, ambulatory surgery centers, physicians, and other health care providers with increased flexibility to meet the challenges presented by the COVID-19 public health emergency. For example, CMS has temporarily waived the enforcement of certain requirements of the Medicare conditions of participation and implemented a "hospitals without walls" program that would enable hospitals to treat patients in temporary locations and enable ASCs to temporarily enroll in Medicare as hospitals. CMS has also temporarily waived many provisions of the Stark law, including those provisions of the Stark law that prohibit our hospitals with physician ownership from expanding capacity. Many states have also suspended the enforcement of certain regulatory requirements to ensure that health care providers have sufficient capacity to treat COVID-19 patients. These regulatory changes are temporary, and we anticipate substantially all requirements will be reinstated in all material respects at the conclusion of the public health emergency.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Certificates of Need, Licensure and Accreditation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures for the construction of new health care facilities, the addition of beds or new health care services or the acquisition of existing health care facilities may be reviewable by state regulators under statutory programs that are sometimes referred to as certificate of need laws. States with certificate of need laws place limits on the construction and acquisition of health care facilities and the expansion of existing facilities and services. In these states, approvals, generally known as certificates of need, are required for capital expenditures exceeding certain preset monetary thresholds for the development, acquisition and/or expansion of certain facilities or services, including, in certain of these states, surgical facilities. Certificate of need laws are being challenged in many states across the country and any future changes could have positive and negative impacts on our business. We currently operate in 20 states that have certificate of need laws. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our surgical facilities also are subject to state licensing requirements for medical providers. Our ASCs have licenses to operate as required in the states in which they operate and must meet all applicable requirements for ASCs. In addition, even though our surgical facilities that are licensed as hospitals primarily provide surgical services, they must meet all applicable requirements for general hospital licensure. To assure continued compliance with these regulations, governmental and other authorities periodically inspect our surgical facilities. The failure to comply with these regulations could result in the suspension or revocation of a facility&#8217;s license. In addition, based on the specific operations of our surgical facilities, some of these facilities maintain a pharmacy license, a controlled substance registration, a clinical laboratory certification waiver, and environmental protection permits for biohazards and/or radioactive materials, as required by applicable law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the majority of our facilities were accredited by either The Joint Commission or the Accreditation Association for Ambulatory Health Care, two of the major national organizations that establish standards relating to the physical plant, administration, quality of patient care and operation of medical staffs of various types of health care facilities. The effect of accreditation by these organizations is to exempt the facilities from routine surveys by state agencies to determine compliance with CMS requirements. These accredited facilities are subject to periodic surveys by the accrediting organization to ensure that they are in compliance with the applicable standards. Many private insurance health plans require our facilities to be accredited by one or both of these organizations in order to be participating providers. Failure to maintain accreditation would cause a facility to become subject to state survey agency oversight and potentially subject to increased scrutiny by CMS, and could result in a loss of payment from private insurance health plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Affordable Care Act Repeal Efforts </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Initiatives to repeal or modify the Patient Protection and Affordable Care Act (the "Affordable Care Act") have been persistent over the past several years. As of December 31, 2020, legislative efforts to repeal and replace the Affordable Care Act in full have not been successful. However, as a result of the enactment of the Tax and Jobs Act of 2017, the tax penalty associated with the so-called "individual mandate," which requires most individuals to obtain qualifying health insurance coverage or pay a tax penalty, was reduced to zero starting in 2019. The effective repeal of the individual mandate tax penalty and any other future repeal or replacement of the Affordable Care Act may have significant impact on the reimbursement for health care services generally, and may cause more individuals to become uninsured, rendering them unable to afford our health care services. The Affordable Care Act also remains subject to various lawsuits challenging its enforcement and constitutionality. The U.S. Supreme Court recently agreed to hear a case that seeks to invalidate the Affordable Care Act, but it will not issue an opinion until 2021. Accordingly, there can be no assurance that the adoption of any future federal or state health care reform legislation, or any ruling by a court with respect to the Affordable Care Act, will not have a negative financial impact on the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Medicare and Medicaid Private Contractor Audits </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CMS has implemented a number of programs that use private contractors that contract with CMS to identify overpayments and underpayments and other potential sources of billing fraud. These contractors, known as Recovery Audit Contractors ("RACs") and Zone Program Integrity Contractors ("ZPICs") conduct both post-payment and pre-payment review of claims submitted by Medicare providers. In addition, CMS employs Medicaid Integrity Contractors ("MICs") to perform post-payment audits of Medicaid claims and identify overpayments. Our facilities and providers periodically receive letters from auditors such as RACs and ZPICs requesting repayment of alleged overpayments for services and incur expenses associated with responding to and appealing these determinations, as well as the costs of repaying any overpayments. Moreover, in recent years, the increase in Medicare payment appeals has created a backlog such that resolving appeals often takes multiple years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although all other repayments requested to date as a result of RAC, MIC and ZPIC audits have not been material to our Company, we are unable to quantify the aggregate financial impact of these audits on our facilities given the pending appeals and uncertainty about the extent of future audits. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Medicare and Medicaid Participation </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of our revenue is expected to continue to be received from third-party payors, including federal and state programs, such as Medicare and Medicaid, and private insurance payors. To participate in the Medicare program and receive Medicare payment, our surgical facilities must comply with regulations promulgated by HHS. Among other things, these regulations, known as "conditions for coverage" or "conditions of participation," impose numerous requirements on our facilities, their equipment, their personnel and their standards of medical care, as well as compliance with all applicable state and local laws and regulations. In 2007, CMS issued a policy memorandum (the "2007 CMS Policy Memorandum") that reaffirmed its prior interpretation of its conditions of participation that all </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">hospitals (other than critical access hospitals) participating in the Medicare program are required to provide basic emergency care interventions regardless of whether or not the hospital maintains an emergency department. Our facilities licensed as hospitals are required to meet this requirement to maintain their participating provider status in the Medicare program. Our hospitals that do not have an emergency room, maintain a protocol for the transfer of patients requiring emergency treatment. While we believe such protocols satisfy CMS requirements, CMS could interpret such protocols to be inconsistent with the 2007 CMS Policy Memorandum, which could jeopardize each facility's participation in the Medicare program. Our surgical facilities must also satisfy the conditions of participation to be eligible to participate in the various state Medicaid programs. The requirements for certification under Medicare and Medicaid are subject to change and, in order to remain qualified for these programs, we may have to make changes from time to time in our facilities, equipment, personnel or services. Although we intend to continue to participate in these reimbursement programs, we cannot ensure that our surgical facilities will continue to qualify for participation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Affordable Care Act and its associated regulations require a hospital to provide written disclosure of physician ownership interests to the hospital&#8217;s patients and on the hospital&#8217;s website and in any advertising, along with annual reports to the government detailing such interests. Additionally, hospitals that do not have 24/7 physician coverage are required to inform patients of this fact and receive signed acknowledgment from the patients of the disclosure. A hospital&#8217;s provider agreement may be terminated if it fails to provide the required notices. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Utilization Review </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal law contains numerous provisions designed to ensure that services rendered by hospitals to Medicare and Medicaid patients meet professionally recognized standards, are medically necessary and that claims for reimbursement are properly filed. These provisions include a requirement that a sampling of admissions of Medicare and Medicaid patients must be reviewed by quality improvement organizations, which review the appropriateness of patient admissions and discharges, the quality of care provided, the validity of MS-DRG classifications and the appropriateness of cases of extraordinary length of stay or cost. Quality improvement organizations may deny payment for services provided or assess fines and also have the authority to recommend to HHS that a provider which is in substantial noncompliance with the standards of the quality improvement organization be excluded from participation in the Medicare program. Utilization review is also a requirement of most non-governmental managed care organizations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Federal Anti-Kickback Statute and Medicare Fraud and Abuse Laws </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Social Security Act of 1935 includes provisions addressing false statements, illegal remuneration and other instances of fraud and abuse in federal health care programs.&#160;These provisions include the statute commonly known as the federal Anti-Kickback statute (the "Anti-Kickback Statute").&#160;The Anti-Kickback Statute prohibits providers and others from, among other things, soliciting, receiving, offering or paying, directly or indirectly, any remuneration in return for either making a referral for, or ordering or arranging for, or recommending the order of, any item or service covered by a federal health care program, including, but not limited to, the Medicare and Medicaid programs.&#160;Violations of the Anti-Kickback Statute are criminal offenses punishable by imprisonment and fines of up to $25,000 for each violation.&#160;Civil violations are punishable by fines of up to $50,000 for each violation, as well as damages of up to three times the total amount of remuneration received from the government for health care claims. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because physician-owners of our surgical facilities are in a position to generate referrals to the facilities, the distribution of available cash to those investors could come under scrutiny under the Anti-Kickback Statute.&#160;Some courts have held that the Anti-Kickback Statute is violated if one purpose (as opposed to a primary or the sole purpose) of a payment to a provider is to induce referrals. Further, Section&#160;6402(f)(2) of the Affordable Care Act amends the Anti-Kickback Statute by adding a provision to clarify that a person need not have actual knowledge of such section or specific intent to commit a violation of the Anti-Kickback Statute. Because none of these cases involved a joint venture such as those owning and operating our surgical facilities, it is not clear how a court would apply these holdings to our activities.&#160;It is clear, however, that a physician&#8217;s investment income from a surgical facility may not vary with the number of his or her referrals to the surgical facility. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under regulations issued by the Office of the Inspector General of HHS (the "OIG"), certain categories of activities are deemed not to violate the Anti-Kickback Statute (commonly referred to as the safe harbors).&#160;According to the preamble to these safe harbor regulations, the failure of a particular business arrangement to comply with the regulations does not determine whether the arrangement violates the Anti-Kickback Statute.&#160;The safe harbor regulations outline standards that, if complied with, protect conduct that might otherwise be deemed in violation of the Anti-Kickback Statute.&#160;When a transaction or relationship does not fit within a safe harbor, it does not mean that an Anti-Kickback Statute violation has occurred; rather, it means that the facts and circumstances as well as the intent of the parties related to a specific transaction or relationship must be examined to determine whether or not any illegal conduct has occurred. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe the ownership and operations of our surgical facilities do not fit wholly within any of the safe harbors, but we attempt to structure our ASCs to fit as closely as possible within the safe harbor designed to protect distributions to physician-investors in ASCs who directly refer patients to the ASC and personally perform the procedures at the center as an extension of their practice (the "ASC Safe Harbor").&#160;The ASC Safe Harbor protects four categories of investors, including ASCs owned by (1)&#160;general surgeons, (2)&#160;single-specialty </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">physicians, (3)&#160;multi-specialty physicians and (4)&#160;hospital/physician joint ventures, provided that certain requirements are satisfied.&#160;These requirements include the following: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The ASC must be certified to participate in the Medicare program, and its operating and recovery room space must be dedicated exclusively to the center and not a part of a hospital (although such space may be leased from a hospital if such lease meets the requirements of the safe harbor for space rental). </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Each investor must be either (a)&#160;a physician who derived at least one-third of his or her medical practice income for the previous fiscal year or 12-month period from performing procedures on the list of Medicare-covered procedures for ASCs, (b)&#160;a hospital, or (c)&#160;a person or entity not in a position to make or influence referrals to the center, nor to provide items or services to the center, nor employed by the center or any investor. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Unless all physician-investors are members of a single specialty, each physician-investor must perform at least one-third of his or her procedures at the ASC each year. This requirement is in addition to the requirement that the physician-investor has derived at least one-third of his or her medical practice income for the past year from performing procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Physician-investors must have fully informed their referred patients of the physician&#8217;s investment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The terms on which an investment interest is offered to an investor are not related to the previous or expected volume of referrals, services furnished or the amount of business otherwise generated from that investor to the entity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Neither the ASC nor any other investor nor any person acting on their behalf may loan funds to or guarantee a loan for an investor if the investor uses any part of such loan to obtain the investment interest. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The amount of payment to an investor in return for the investment interest is directly proportional to the amount of the capital investment (including the fair market value of any pre-operational services rendered) of that investor. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">All physician-investors, any hospital-investor and the center agree to treat patients receiving benefits or assistance under a federal health care program in a non-discriminatory manner. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">All ancillary services performed at the ASC for beneficiaries of federal health care programs must be directly and integrally related to primary procedures performed at the center and may not be billed separately. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">No hospital-investor may include on its cost report or any claim for payment from a federal health care program any costs associated with the ASC. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The ASC may not use equipment owned by or services provided by a hospital-investor unless such equipment is leased in accordance with a lease that complies with the Anti-Kickback Statute equipment rental safe harbor and such services are provided in accordance with a contract that complies with the Anti-Kickback Statute personal services and management contract safe harbor. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">No hospital-investor may be in a position to make or influence referrals directly or indirectly to any other investor or the center. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that the ownership and operations of our surgical facilities will not fully satisfy the ASC Safe Harbor requirements for investment interests in ASCs because, among other things, we or one of our subsidiaries will generally be an investor in and provide management services to each ASC.&#160;While we believe our ASCs would nonetheless be found to be compliant with the Anti-Kickback Statute, we cannot assure you that the OIG would view our activities favorably even though we strive to achieve compliance with the remaining elements of this safe harbor. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, although we expect each physician-investor to utilize the ASCs as an extension of his or her practice and ask each physician-investor to certify this practice, we cannot assure you that all physician-investors will derive at least one-third of their medical practice income from performing Medicare-covered ASC procedures, perform one-third of their procedures at the centers or inform their referred patients of their investment interests.&#160;Interests in our ASC joint ventures are purchased at what we believe to be fair market value.&#160;Investors who purchase at a later time generally pay more for a given percentage interest than founding investors.&#160;The result is that while all investors are paid distributions in accordance with their ownership interests, for ASCs where there are later purchases, we cannot meet the safe harbor requirement that return on investment is directly proportional to the amount of capital investment.&#160;The OIG has on several occasions reviewed investments relating to ASCs, and in Advisory Opinion No.&#160;07-05 (June 19, 2007), raised concerns that (a)&#160;purchases of interests from physicians might yield gains on investment rather than capital infusion to the ASCs, (b)&#160;such purchases could be meant to reward or influence the selling physicians&#8217; referrals to the ASC or the hospital, and (c)&#160;such returns might not be directly proportional to the amount of capital invested.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In OIG Advisory Opinion No.&#160;09-09 (July&#160;29, 2009), the OIG concluded that an arrangement involving an ASC joint venture between a hospital and physicians involving the combination of their two ASCs into a single, larger ASC presented minimal risk of fraud or abuse, despite the fact that it did not fit within any applicable Anti-Kickback safe harbors.&#160;Additionally, the OIG stated that fair market value should be determined based only on the tangible assets of each ASC since the physician investors are referral sources for the ASC. The OIG stated that a cash flow-based valuation of the business contributed by the physician investors potentially would include the value of the physician investors&#8217; referrals over the time that their ASC was in existence prior to the merger with the hospital&#8217;s ASC. The OIG went </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">on to note that a valuation involving intangible assets would not necessarily result in a violation of the Anti-Kickback Statute, but would require a review of all the facts and circumstances. It is not clear whether the OIG is concerned about using a cash flow-based valuation in most health care transactions involving referral sources, or just transactions where the parties&#8217; contributions would be valued differently for contributing the same assets if only one party&#8217;s contribution is valued as a going concern based on cash flow. Also, the OIG appears to be focused on historical cash flow rather than a projected, discounted cash flow, which is a commonly used valuation methodology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our hospital investments do not fit wholly within the safe harbor for investments in small entities because more than 40.0% of the investment interests are held by investors who are either in a position to refer to the hospital or who provide services to the hospital and more than 40.0% of the hospital&#8217;s gross revenue last year were derived from referrals generated by investors. However, we believe we comply with the remaining elements of the safe harbor. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the physician ownership in our surgical facilities, other financial relationships of ours with potential referral sources could potentially be scrutinized under the Anti-Kickback Statute. We have entered into management agreements to manage the majority of our surgical facilities and physician practices. Most of these agreements call for our subsidiary to be paid a percentage of revenue-based management fee. Although there is a safe harbor for personal services and management contracts (the "Personal Services and Management Safe Harbor"), the Personal Services and Management Safe Harbor requires, among other things, that the amount of the aggregate compensation paid to the manager over the term of the agreement be set in advance. Because our management fees are generally based on a percentage of revenue, our management agreements do not typically meet this requirement. We do, however, believe that our management arrangements satisfy the other requirements of the Personal Services and Management Safe Harbor for personal services and management contracts. The OIG has taken the position in several advisory opinions that percentage-based management agreements are not protected by a safe harbor, and consequently, may violate the Anti-Kickback Statute. We have implemented formal compliance programs designed to safeguard against overbilling and believe that our management agreements comply with the requirements of the Anti-Kickback Statute. However, we cannot assure you that the OIG would find our compliance programs to be adequate or that our management agreements would be found to comply with the Anti-Kickback Statute. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of our ASCs have entered into arrangements for professional services, including arrangements for anesthesia services. In a Special Advisory Bulletin issued in April 2003, the OIG focused on "questionable" contractual arrangements where a health care provider in one line of business (the "Owner") expands into a related health care business by contracting with an existing provider of a related item or service (the "Manager/Supplier") to provide the new item or service to the Owner&#8217;s existing patient population, including federal health care program patients (so called "suspect Contractual Joint Ventures"). The Manager/Supplier not only manages the new line of business, but may also supply it with inventory, employees, space, billing, and other services. In other words, the Owner contracts out substantially the entire operation of the related line of business to the Manager/Supplier-otherwise a potential competitor-receiving in return the profits of the business as remuneration for its referrals. Through an Advisory Opinion, the OIG extended this suspect contractual joint venture analysis to arrangements between anesthesiologists and physician owners of ASCs. In Advisory Opinion No. 12-06 (May 25, 2012), the OIG concluded that certain proposed arrangements between anesthesia groups and physician-owned ASCs could result in prohibited remuneration under the federal Anti-Kickback Statute. We believe our arrangements for anesthesia services are distinguishable from those described in Advisory Opinion 12-06 (May 25, 2012) and are in compliance with the requirements of the federal Anti-Kickback Statute. However, we cannot assure you that regulatory authorities would agree with that position. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also may guarantee a surgical facility&#8217;s third-party debt financing and certain lease obligations as part of our obligations under a management agreement. Physician investors are generally not required to enter into similar guarantees.&#160;The OIG might take the position that the failure of the physician investors to enter into similar guarantees represents a special benefit to the physician investors given to induce patient referrals and that such failure constitutes a violation of the Anti-Kickback Statute. We believe that the management fees (and in some cases guarantee fees) are adequate compensation to us for the credit risk associated with the guarantees and that the failure of the physician investors to enter into similar guarantees does not create a material risk of violating the Anti-Kickback Statute. However, the OIG has not issued any guidance in this regard. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The OIG is authorized to issue advisory opinions regarding the interpretation and applicability of the Anti-Kickback Statute, including whether an activity constitutes grounds for the imposition of civil or criminal sanctions. We have not, however, sought such an opinion regarding any of our arrangements. If it were determined that our activities, or those of our surgical facilities or hospitals, violate the Anti-Kickback Statute, we, our subsidiaries, our officers, our directors and each surgical facility and hospital investor could be subject, individually, to substantial monetary liability, prison sentences and/or exclusion from participation in any health care program funded in whole or in part by the U.S. government, including Medicare, Medicaid, TRICARE or state health care programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Evolving interpretations of current, or the adoption of new, federal or state laws or regulations, such as the Eliminating Kickbacks in Recovery Act (discussed below), could affect many of our arrangements. Law enforcement authorities, including the OIG, the courts and Congress, are increasing their scrutiny of arrangements between health care providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to exchange remuneration for patient care referrals or opportunities. Investigators have also demonstrated a willingness to look behind the formalities of a business transaction to determine the underlying purposes of payments between health care providers and potential referral sources. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On November 20, 2020, CMS and the OIG issued final rules that modify the federal physician self-referral law, or Stark Law, regulations and the federal anti-kickback and civil monetary penalty for beneficiary inducement statutes and regulations. The intent of the final rules is to reduce over-burdensome and unnecessary regulatory barriers to value-based compensation models and accelerate the transformation of the health care system into one that better promotes the coordination of care among providers. Among other things, the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">final rules create new anti-kickback and beneficiary inducement statute safe harbors and Stark Law exceptions for certain value based arrangements and arrangements that involve the donation of cybersecurity technology. In addition, the final rules provide additional guidance on several key compliance requirements, including fair market value and commercial reasonableness, that must be met in order for physicians and health care providers to comply with the Stark Law. We cannot yet predict the impact that the final rules will have on our surgery centers and hospitals. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Eliminating Kickbacks in Recovery Act</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to the Anti-Kickback Statute, the U.S. recently enacted a new law known as the Eliminating Kickbacks in Recovery Act (the "EKRA"). The EKRA is contained within the broader Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (the "SUPPORT Act"). The EKRA creates a new federal crime for knowingly and willfully: (1) soliciting or receiving any remuneration in return for referring a patient to a recovery home, clinical treatment facility, or laboratory; or (2) paying or offering any remuneration to induce such a referral or in exchange for an individual using the services of a recovery home, clinical treatment facility, or laboratory. Each conviction under the EKRA is punishable by up to $200,000 in monetary damages, imprisonment for up to ten (10) years, or both.&#160;Unlike the Anti-Kickback Statute, the EKRA is not limited to services reimbursable under a government health care program. While the SUPPORT Act targets substance abuse disorder prevention and recovery, the scope of EKRA is not limited to substance abuse drug testing (only one service line of a multitude provided by labs), and therefore it appears to prohibit payment for any patient referral to any laboratory for any service, unless an exception applies. While the EKRA does contain certain exceptions similar to the Anti-Kickback Statute Safe Harbors, those exceptions are more narrow than the Anti-Kickback Statute Safe Harbors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Federal Physician Self-Referral Law </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Stark Law prohibits certain self-referrals for health care services. The Stark Law prohibits a practitioner, including a physician, dentist or podiatrist, from referring patients to an entity with which the practitioner or a member of his or her immediate family has a "financial relationship" for the provision of certain "designated health services" that are paid for in whole or in part by Medicare or Medicaid unless an exception applies. "Designated health services" include inpatient and outpatient hospital services, clinical laboratory services and radiology services. The term "financial relationship" is broadly defined and includes most types of ownership and compensation relationships. The Stark Law also prohibits the entity from seeking payment from Medicare or Medicaid for services that are rendered through a prohibited referral.&#160;If an entity is paid for services provided through a prohibited referral, it may be required to refund the payments. Violations of the Stark Law may also result in the imposition of damages equal to three times the amount improperly claimed and civil monetary penalties of up to $15,000 per prohibited claim and $100,000 per prohibited circumvention scheme and exclusion from participation in the Medicare and Medicaid programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notably, "designated health services" does not include surgical services that are provided in an ASC. Furthermore, Stark Law regulations specifically define the term "designated health services" to not include services that are reimbursed by Medicare as part of a composite rate, such as services that are provided in an ASC. However, if designated health services are provided by an ASC and separately billed, referrals to the ASC by a physician-investor would be prohibited by the Stark Law. Because our facilities that are licensed as ASCs do not have independent laboratories and do not provide designated health services apart from surgical services, we do not believe referrals to these facilities by physician-investors are prohibited. If legislation or regulations are implemented that prohibit physicians from referring patients to surgical facilities in which the physician has a beneficial interest, our business and financial results could be materially adversely affected. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Stark Law currently includes the Whole Hospital Exception, which applies to physician ownership of a hospital, provided such ownership is in the whole hospital and the physician is authorized to perform services at the hospital. We believe that physician investments in our facilities licensed as hospitals meet this requirement. However, certain changes to the Whole Hospital Exception were made by the Affordable Care Act including: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a prohibition on hospitals from having any physician ownership unless the hospital already had physician ownership and a Medicare provider agreement in effect as of December 31, 2010; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a limitation on the percentage of total physician ownership or investment interests in the hospital or entity whose assets include the hospital to the percentage of physician ownership or investment as of March&#160;23, 2010; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a prohibition from expanding the number of beds, operating rooms, and procedure rooms for which it is licensed after March&#160;23, 2010, unless the hospital obtains an exception from the Secretary of the Department of Health &amp; Human Services (the "Secretary"); </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a requirement that return on investment be proportionate to the investment by each investor; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restrictions on preferential treatment of physician versus non-physician investors; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a requirement for written disclosures of physician ownership interests to the hospital&#8217;s patients and on the hospital&#8217;s website and in any advertising, along with annual reports to the government detailing such interests; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a prohibition on the hospital or other investors from providing financing to physician investors; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a requirement that any hospital that does not have 24/7 physician coverage inform patients of this fact and receive signed acknowledgments from the patients of the disclosure; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a prohibition on "grandfathered" status for any physician owned hospital that converted from an ASC to a hospital on or after March&#160;23, 2010. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We cannot predict whether other proposed amendments to the Whole Hospital Exception will be included in any future legislation, including a repeal of the Affordable Care Act, or if Congress will adopt any similar provisions that would prohibit or otherwise restrict physicians from holding ownership interests in hospitals. Any such changes could have an adverse effect on our financial condition and results of operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2010, CMS issued a "self-referral disclosure protocol" for hospitals and other providers that wish to self-disclose potential violations of the Stark Law to CMS and to attempt to resolve those potential violations and any related overpayment liabilities at levels below the maximum penalties and amounts set forth in the statute.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the physician ownership in our surgical facilities, we have other financial relationships with potential referral sources that potentially could be scrutinized under the Stark Law. We have entered into personal service agreements, such as medical director agreements, with physicians at our surgical hospitals and physician owners within our physician practices may make referrals for certain designated health services within their physician practices. We believe that our agreements with referral sources satisfy the requirements of the personal service arrangements exception and that our physician practices satisfy the physician services and in-office ancillary services exceptions to the Stark Law and have implemented formal compliance programs designed to ensure continued compliance. However, we cannot assure you that the OIG or CMS would find our compliance programs to be adequate or that our agreements with referral sources would be found to comply with the Stark Law. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Other Fraud and Abuse Laws </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Medicare Patient and Program Protection Act of 1987, as amended by the Health Insurance Portability and Accountability Act of 1996, ("HIPAA"), and the Balanced Budget Act of 1997, impose civil monetary penalties and exclusion from state and federal health care programs on providers who commit violations of fraud and abuse laws.&#160;HIPAA authorizes the Secretary, and in some cases requires the Secretary, to exclude individuals and entities that the Secretary determines have "committed an act" in violation of applicable fraud and abuse laws or improperly filed claims in violation of such laws from participating in any federal health care program.&#160;HIPAA also expanded the Secretary&#8217;s authority to exclude a person involved in fraudulent activity from participating in a program providing health benefits, whether directly or indirectly, in whole or in part, by the U.S. government. Additionally, under HIPAA, individuals who hold a direct or indirect ownership or controlling interest in an entity that is found to violate these laws may also be excluded from Medicare and Medicaid and other federal and state health care programs if the individual knew or should have known, or acted with deliberate ignorance or reckless disregard of, the truth or falsity of the information of the activity leading to the conviction or exclusion of the entity, or where the individual is an officer or managing employee of such entity.&#160;This standard does not require that specific intent to defraud be proven by OIG.&#160;Under HIPAA it is also a crime to defraud any commercial health care benefit program. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Privacy and Security Requirements </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to HIPAA, including the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act"), which was enacted as part of The American Recovery and Reinvestment Act of 2009. The HITECH Act strengthened the requirements and significantly increased the penalties for violations of the HIPAA privacy and security regulations. In 2013, HHS issued the HIPAA Omnibus Rule, which became effective on March&#160;26, 2013. The HIPAA Omnibus Rule requires us to notify patients of any unauthorized access, acquisition, or disclosure of their unsecured protected health information in all situations except those in which we can demonstrate that there is a low probability that the protected health information has been compromised. We have the burden of demonstrating through a risk assessment that a breach of protected health information has not occurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The HIPAA privacy standards apply to individually identifiable information held or disclosed by a covered entity in any form, whether communicated electronically, on paper or orally. These standards impose extensive administrative requirements on us. These standards require our compliance with rules governing the use and disclosure of this health information. They create rights for patients in their health information, such as the right to amend their health information, and they require us to impose these rules, by contract, on any business associate to whom we disclose such information in order to perform functions on our behalf. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The HIPAA security standards require us to establish and maintain reasonable and appropriate administrative, technical and physical safeguards to ensure the integrity, confidentiality and the availability of electronic protected health and related financial information. Although the security standards do not reference or advocate a specific technology, and covered health care providers, plans and clearinghouses have the flexibility to choose their own technical solutions, the security standards have required us to implement significant new systems, business procedures and training programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Violations of the HIPAA privacy and security regulations may result in civil and criminal penalties. The HITECH Act strengthened the requirements of the HIPAA privacy and security regulations and significantly increased the penalties for violations by introducing a tiered penalty system, with penalties of up to $50,000 per violation with a maximum civil penalty of $1.5 million in a calendar year for violations of the same requirement. However, a single breach incident can result in violations of multiple requirements, resulting in possible penalties well in excess of $1.5 million. Under the HITECH Act, HHS is required to conduct periodic compliance audits of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">covered entities and their business associates. The HITECH Act and the HIPAA Omnibus Rule also extend the application of certain provisions of the security and privacy regulations to business associates and subjects business associates to civil and criminal penalties for violation of the regulations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The HITECH Act authorizes State Attorneys General to bring civil actions seeking either an injunction or damages in response to violations of HIPAA privacy and security regulations or the new data breach law that affects the privacy of their state residents. We expect vigorous enforcement of the HITECH Act&#8217;s requirements by HHS and State Attorneys General. HHS has allocated increased funding towards HIPAA enforcement activity and such enforcement activity has seen a marked increase over recent years. We cannot predict whether our surgical facilities will be able to comply with the final rules and the financial impact to our surgical facilities in implementing the requirements under the final rules when they take effect, or whether our surgical hospitals will be selected for an audit, or the results of such an audit. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our facilities also remain subject to any state laws that relate to privacy or the reporting of data breaches that are more restrictive than the regulations issued under HIPAA and the requirements of the HITECH Act. For example, various state laws and regulations may require us to notify affected individuals in the event of a data breach involving certain personal information, such as social security numbers, dates of birth and credit card information. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">HIPAA Administrative Simplification Requirements </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The HIPAA transaction regulations were issued to encourage electronic commerce in the health care industry. These regulations include standards that health care providers must follow when electronically transmitting certain health care transactions, such as health care claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Emergency Medical Treatment and Active Labor Act </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our hospitals are subject to the Emergency Medical Treatment and Active Labor Act ("EMTALA"). This federal law requires any hospital that participates in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital&#8217;s emergency department for treatment and, if the patient is suffering from an emergency medical condition, to either stabilize that condition or make an appropriate transfer of the patient to a facility that can handle the condition. The obligation to screen and stabilize emergency medical conditions or transfer exists regardless of a patient&#8217;s ability to pay for treatment. Off-campus facilities such as surgery centers that lack emergency departments or otherwise do not treat emergency medical conditions generally are not subject to EMTALA. They must, however, have policies in place that explain how the location should proceed in an emergency situation, such as transferring the patient to the closest hospital with an emergency department. There are severe penalties under EMTALA if a hospital fails to screen or appropriately stabilize or transfer a patient or if the hospital delays appropriate treatment in order to first inquire about the patient&#8217;s ability to pay, including civil monetary penalties and exclusion from participation in the government health care programs. In addition, an injured patient, the patient&#8217;s family or a medical facility that suffers a financial loss as a direct result of another hospital&#8217;s violation of the law can bring a civil suit against that other hospital. CMS has actively enforced EMTALA and has indicated that it will continue to do so in the future. We believe that our surgical hospitals comply with EMTALA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">State Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Many of the states in which our surgical facilities operate have adopted statutes and/or regulations that prohibit the payment of kickbacks or any type of remuneration in exchange for patient referrals and that prohibit health care providers from, in certain circumstances, referring a patient to a health care facility in which the provider has an ownership or investment interest.&#160;While these statutes generally mirror the federal Anti-Kickback Statute and Stark Law, they vary widely in their scope and application.&#160;Some are specifically limited to health care services that are paid for in whole or in part by the Medicaid program; others apply to all health care services regardless of payor; and others apply only to state-defined designated services, which may differ from the designated health services under the Stark Law.&#160;In addition, many states have adopted statutes that mirror the False Claims Act and that prohibit the filing of a false or fraudulent claim with a state governmental agency.&#160;We intend to comply with all applicable state health care laws, rules&#160;and regulations.&#160;However, these laws, rules&#160;and regulations have typically been the subject of limited judicial and regulatory interpretation.&#160;As a result, we cannot assure you that our surgical facilities will not be investigated or scrutinized by the governmental authorities empowered to do so or, if challenged, that their activities would be found to be lawful.&#160;A determination of non-compliance with the applicable state health care laws, rules, and regulations could subject our surgical facilities to civil and criminal penalties and could have a material adverse effect on our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are also subject to various state insurance statutes and regulations that prohibit us from submitting inaccurate, incorrect or misleading claims.&#160;Many state insurance laws and regulations are broadly worded and could be implicated, for example, if our surgical facilities were to adjust an out-of-network co-payment or other patient responsibility amounts without fully disclosing the adjustment on the claim submitted to the payor.&#160;While some of our surgical facilities adjust the out-of-network costs of patient co-payment and deductible amounts to reflect in-network co-payment costs when providing services to patients whose health insurance is covered by a payor with which the surgical facilities are not contracted, our policy is to fully disclose adjustments in the claims submitted to the payors. We believe that our surgical facilities are in compliance with all applicable state insurance laws and regulations regarding the submission of claims.&#160;We cannot assure you, however, that none of our surgical facilities&#8217; insurance claims will ever be challenged.&#160;If we were found to be in violation of a state&#8217;s insurance laws or regulations, we could be forced to discontinue the violative practice, which could have an adverse effect on our financial position and results of operations, and we could be subject to fines and criminal penalties. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Fee Splitting; Corporate Practice of Medicine </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The laws of many states prohibit physicians from splitting fees with non-physicians (i.e., sharing in a percentage of professional fees), prohibit non-physician entities (such as us) from practicing medicine and exercising control over or employing physicians and prohibit referrals to facilities in which physicians have a financial interest. The existence, interpretation and enforcement of these laws vary significantly from state to state. In light of these restrictions, in certain states we facilitate the provision of physician services by maintaining long-term management services agreements through our subsidiaries with affiliated professional contractors, which employ or contract with physicians and other health care professionals to provide physician professional services. Under these arrangements, our subsidiaries perform only non-medical administrative services, do not represent that they offer medical services and do not exercise influence or control over the practice of medicine by the physicians employed by the affiliated professional contractors. Although we believe that the fees we receive from affiliated professional contractors have been structured in a manner that is compliant with applicable fee-splitting laws, it is possible that a government regulator could interpret such fee arrangements to be in violation of certain fee-splitting laws. Future interpretations of, or changes in, these laws might require structural and organizational modifications of our existing relationships, and we cannot assure you that we would be able to appropriately modify such relationships. In addition, statutes in some states could restrict our expansion into those states. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Clinical Laboratory Regulation </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our clinical laboratories are subject to federal oversight under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") which extends federal oversight to virtually all clinical laboratories by requiring that they be certified by the federal government or by a federally-approved accreditation agency. CLIA requires that all clinical laboratories meet quality assurance, quality control and personnel standards. Laboratories also must undergo proficiency testing and are subject to inspections. Standards for testing under CLIA are based on the complexity of the tests performed by the laboratory, with tests classified as "high complexity," "moderate complexity," or "waived." Laboratories performing high complexity testing are required to meet more stringent requirements than moderate complexity laboratories. Laboratories performing only waived tests, which are tests determined by the Food and Drug Administration to have a low potential for error and requiring little oversight, may apply for a certificate of waiver exempting them from most of the requirements of CLIA. Our operations also subject to state and local laboratory regulation. CLIA provides that a state may adopt laboratory regulations different from or more stringent than those under federal law, and a number of states have implemented their own laboratory regulatory requirements. State laws may require that laboratory personnel meet certain qualifications, specify certain quality controls, or require maintenance of certain records. We believe that we are in material compliance with all applicable laboratory requirements, but no assurances can be given that our laboratories will pass all future licensure or certification inspections.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Compliance Program </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have in place and continue to enhance a company-wide compliance program that focuses on all areas of regulatory compliance including billing, reimbursement, cost reporting practices and contractual arrangements with referral sources. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This regulatory compliance program is intended to help ensure that high standards of conduct are maintained in the operation of our business and that policies and procedures are implemented so that employees act in compliance with applicable laws, regulations and company policies. Under the regulatory compliance program, every employee and certain contractors involved in patient care, and coding and billing, receive initial and periodic legal compliance and ethics training. In addition, we regularly monitor our ongoing compliance efforts and develop and implement policies and procedures designed to foster compliance with the law. The program also includes a mechanism for employees to report, without fear of retaliation, any suspected legal or ethical violations to their supervisors, designated compliance officers in our facilities, our compliance hotline or directly to our corporate compliance office. We believe our compliance program is consistent with standard industry practices. However, we cannot provide any assurances that our compliance program will detect all violations of law or protect against qui tam suits or government enforcement actions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Where You Can Find More Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We make available on or through the "Investors-SEC Filings" page of our website at www.surgerypartners.com, free of charge, copies of reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and amendments to those reports (along with certain other Company filings with the SEC), as soon as reasonably practicable after electronically filing such material with, or furnishing it to, the SEC. The information found on, or otherwise accessible through, our website is not incorporated by reference into, nor does it form a part of, this Annual Report or any other document that we file with the SEC.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Annual Report and our other filings with the SEC, before making an investment decision regarding our common stock.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 and Other Potential Pandemic Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">The COVID-19 global pandemic continues to significantly affect our operations, business and financial condition, and our liquidity could continue to be negatively impacted further if the U.S. economy remains unstable for a significant amount of time or it takes an extended period for patient volumes at our facilities to recover to pre-COVID-19 pandemic levels.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Business and Operational Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We depend on payments from third-party payors, including government health care programs and private insurance organizations. If these payments are reduced or eliminated, our revenue and profitability could be materially and adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we are unable to negotiate and enter into favorable contracts or maintain satisfactory relationships and renew existing contracts on favorable terms with private insurance payors, our revenue and profitability may decrease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Significant changes in our payor mix or surgical case mix resulting from fluctuations in the types of cases performed at our facilities could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our ability to provide medical services at our facilities would be impaired and our revenue reduced if we are not able to maintain good relationships with affiliated physicians who utilize our surgical facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Physician treatment methodologies and governmental or private insurance controls designed to reduce the number of surgical procedures may reduce our revenue and profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our growth strategy depends in part on our ability to integrate operations of acquired surgical facilities, attract new physician partners, and to acquire and develop additional surgical facilities on favorable terms. If we are unable to achieve any of these goals, our future growth could be limited and our operating results could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Shortages of surgery-related products, equipment and medical supplies and quality control issues with such products, equipment and medical supplies could disrupt our operations and adversely affect our case volume, surgical case mix and profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We face competition from other health care facilities and providers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Competition for physicians and clinical personnel, including nurses, shortages of qualified personnel or other factors could increase our labor costs and adversely affect our revenue, profitability and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If any of our existing health care facilities lose their accreditation status or any of our new facilities fail to receive accreditation, such facilities could become ineligible to receive reimbursement under Medicare or Medicaid or other third-party payors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Growth of patient receivables or deterioration in the ability to collect on these accounts, due to changes in economic conditions or otherwise, could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we are unable to integrate and operate our information systems effectively or implement new systems and processes, our operations could be disrupted.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Financial and Accounting Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We have a history of net losses and may not achieve or sustain profitability in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, expose us to interest rate risk to the extent of our variable rate debt and prevent us from meeting our obligations under our outstanding indebtedness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">To service our indebtedness, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control, and any failure to meet our debt service obligations may adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Despite our current indebtedness levels, we and our subsidiaries may still be able to incur more debt, which could further exacerbate the risks associated with our leverage. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We make significant loans to, and are generally liable for debts and other obligations of, the partnerships and limited liability companies that own and operate some of our surgical facilities.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We entered into a tax receivable agreement that will require us to make payments to the pre-IPO owners of Surgery Center Holdings, LLC (the "Pre-IPO Owners"), which amounts are expected to be material.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity and Data Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Cybersecurity attacks or intrusions could adversely impact our businesses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Legal and Regulatory Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we fail to comply with or otherwise incur liabilities under the numerous federal and state laws and regulations relating to the operation of our facilities, we could incur significant penalties or other costs or be required to make significant changes to our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our surgical facilities do not satisfy the requirements for any of the safe harbors under the federal Anti-Kickback Statute. If a federal or state agency asserts a different position or enacts new laws in this regard, we could be subject to criminal and civil penalties, loss of licenses and exclusion from governmental programs, which may result in a substantial loss of revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we fail to comply with physician self-referral laws as they are currently interpreted or may be interpreted in the future, or if other legislative restrictions are issued, we could incur substantial monetary penalties and a significant loss of revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Federal law restricts the ability of our surgical hospitals to expand surgical capacity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Companies within the health care industry, including us, continue to be the subject of federal and state audits and investigations, including actions for false and other improper claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If we become subject to large malpractice or other legal claims, we could be required to pay significant damages, which may not be covered by insurance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Failure to comply with Medicare&#8217;s conditions for coverage and conditions of participation may result in loss of program payment or other governmental sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our facilities could face decreased Medicare payments if they fail to report and meet various quality metrics.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">If antitrust enforcement authorities conclude that our market share in any particular market is too concentrated, that our or our health system partners&#8217; commercial payor contract negotiating practices are illegal, or that we otherwise violate antitrust laws, we could be subject to enforcement actions that could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Governance Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We are a "controlled company" within the meaning of Nasdaq rules and, therefore, we qualify for, and currently rely on, exemptions from certain corporate governance requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our controlling stockholder has significant influence over us, including control over decisions that require the approval of stockholders, which could limit our stockholders&#8217; ability to influence the outcome of key transactions, including a change of control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Provisions in the certificate of designation governing our preferred stock and in our charter documents and Delaware law may deter takeover efforts that could be beneficial to stockholder value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Our amended and restated certificate of incorporation designates courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to risks and uncertainties that could cause our actual financial condition, results of operations, business and prospects to differ materially from those described in the forward-looking statements contained in this report or in our other filings with the SEC. Some of these risks and uncertainties are discussed below. If any of the following risks, or other risks and uncertainties, actually occurred, our business, financial condition and operating results could suffer.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19 and Other Potential Pandemic Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The COVID-19 global pandemic continues to significantly affect our operations, business and financial condition, and our liquidity could continue to be negatively impacted further if the U.S. economy remains unstable for a significant amount of time or it takes an extended period for patient volumes at our facilities to recover to pre-COVID-19 pandemic levels.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic has significantly affected our facilities, employees, patients, communities, business operations and financial performance, as well as the U.S. economy and financial markets. The COVID-19 crisis is still rapidly evolving and much of its impact remains unknown and difficult to predict; however, it has adversely affected our business operations since March, has materially impacted our financial performance for the remainder of 2020, and potentially could negatively impact our financial performance in 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continue to take or support measures to try to slow the spread and minimize the impact of the virus on our business. Beginning mid-March, the COVID-19 pandemic began to negatively affect our net revenue and business operations. Due in part to local, state and federal guidelines as well as recommendations from major medical societies regarding social distancing and self-quarantines in response to the COVID-19 pandemic, we cancelled or postponed a substantial percentage of the elective procedures scheduled at our facilities and reduced operating hours at a significant number of our facilities. As a result, our facilities experienced significantly lower surgical case volume, which was more significant at the beginning of the second quarter and has improved gradually as states re-opened and allowed for non-emergent procedures. The impact of the COVID-19 pandemic on our surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures that are typically performed. It is difficult to predict the duration of this lower surgical case volume and, while governmental restrictions are continuing to ease in certain areas of the U.S., other areas are experiencing a surge in COVID-19 cases and may impose, re-impose or consider the imposition of additional restrictions in response. We cannot predict the timing of the potential recapture of cancelled or postponed procedures, if any.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even after taking into account actions that we are taking intended to increase financial flexibility, the volume reductions we have experienced have resulted in materially lower revenue and material decreases in income from operations during 2020, and may potentially continue to do so for subsequent quarters. We cannot predict if or when utilization may return to pre-pandemic levels. Additionally, some of our actions to increase liquidity could result in increased expenses, reduced employee morale, labor unrest and work stoppages or other workforce disruptions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We experienced, and in the future could experience, supply chain disruptions, including shortages and delays, and could experience significant price increases, in equipment, pharmaceuticals and medical supplies, particularly personal protective equipment or PPE. Staffing, equipment, and pharmaceutical and medical supplies shortages may also impact our ability to serve patients at our facilities.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Broad economic factors resulting from the current COVID-19 pandemic, including increasing unemployment rates and reduced consumer spending, could also negatively affect our payor mix, increase the relative proportion of lower margin services we provide and reduce patient volumes, as well as diminish our ability to collect outstanding receivables. Business closings and layoffs in the areas in which we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients and other payors to pay for services as rendered. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations, requiring an increased level of working capital. If general economic conditions continue to deteriorate or remain uncertain or diminished for an extended period of time, our liquidity and ability to repay our outstanding debt may be harmed.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our results and financial condition may be further adversely affected by future federal or state laws, regulations, orders, or other governmental or regulatory actions addressing the current COVID-19 pandemic or the U.S. health care system, which, if adopted, could result in direct or indirect restrictions to our business, financial condition, results of operations and cash flow.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The foregoing and other continued disruptions to our business as a result of the COVID-19 pandemic (including the potential resurgences of COVID-19 in jurisdictions currently engaged in reopening) have had and are likely to continue to have a material adverse effect on our business and could have a material adverse effect on our results of operations, financial condition, cash flows and our ability to service our indebtedness. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finally, although we have received grants and accelerated payments under the CARES Act, we are reviewing and may seek any additional available benefits in the future under the CARES Act, the COVID-19 Economic Relief Bill (together, the &#8220;Relief Bills&#8221;) or other existing or any future legislation passed that could benefit us. We cannot predict the manner in which such future benefits will be allocated or administered, and we cannot assure you that we will be able to access such benefits in a timely manner or at all. Certain of the programs we seek to access under the Relief Bills have not previously been administered on the present scale or at all. Government or third party program administrators may be unable to cope with the volume of applications in the near term. There can be no assurance that the implementation or interpretation of the provisions of the Relief Bills or other legislation will not change in ways that affect our funding or eligibility to participate, or that changes to the terms of such programs will not result in government recoupment of funds that were initially released to us as grants. Additionally, accessing these programs and our response to the COVID-19 pandemic have required our management team to devote extensive resources and is likely to continue to do so in the near future, which may negatively affect our ability to implement our business plan and respond to opportunities.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, currently there is limited guidance available regarding the accounting treatment of funds that have been received by us and our facilities under the CARES Act. This lack of guidance requires us to apply professional judgement and make certain estimates and assumptions with respect to the presentation, amount and timing of our recognition of grant funds received under the CARES Act. For example, HHS published updated guidance in September 2020 regarding how we should apply grant funds, which required us to make </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">certain changes to our estimation procedures for the recognition of grant funds during the three months ended September 30, 2020. Subsequently, in December 2020, the COVID-19 Economic Relief Bill was signed into law, which required us to make further changes to our estimation procedures for the recognition of grant funds again during the three months ended December 31, 2020. We continue to monitor regulatory guidance published by HHS related to the required attestation guidance, which may require us to make additional changes to our estimation procedures for the recognition of grant funds in 2021.</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">A pandemic, epidemic or outbreak of a contagious disease in the markets in which we operate or that otherwise impacts our facilities could adversely impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If a pandemic, epidemic or outbreak of an infectious disease, including the recent outbreak of respiratory illness caused by a novel coronavirus known as COVID-19, or other public health crisis were to affect the areas in which we operate, our business, including our revenue, profitability and cash flows, could be adversely affected.&#160;If any of our facilities were involved, or perceived to be involved, in treating patients with a highly contagious disease, or there was an outbreak of a highly contagious disease in areas in which our surgical centers are located, our patients might cancel or defer elective procedures or otherwise avoid medical treatment.&#160;This could result in reduced patient volumes and operating revenues, potentially over an extended period. Further, a pandemic, epidemic or outbreak of an infectious disease might adversely impact our business by causing temporary shutdowns of our facilities or diversion of patients or by causing staffing shortages in our facilities.&#160;We may be unable to locate replacement supplies, and ongoing delays could require us to reduce procedure volume or cause temporary shutdowns of our facilities. Although we have disaster plans in place and operate pursuant to infectious disease protocols, the extent to which COVID-19 or other public health crisis will impact our business is difficult to predict and will depend on many factors beyond our control, including the speed of contagion, the development and implementation of effective preventative measures and possible treatments, the scope of governmental and other restrictions on travel and other activity, and public reactions to these factors.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Business and Operational Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We depend on payments from third-party payors, including government health care programs and private insurance organizations. If these payments are reduced or eliminated, our revenue and profitability could be materially and adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We depend upon private and governmental third-party sources of payment for the services provided by physicians in our physician network and to patients in our surgical facilities, including surgical hospitals. We derived approximately 39% in both 2020 and 2019 and 38% in 2018, of our revenue from government payors, including Medicare and Medicaid programs. The amounts that we receive from the Medicare and Medicaid programs for our services are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating payments or reimbursements, among other things; refinements to the Medicare Ambulatory Surgery Center payment system and refinements made by CMS to Medicare&#8217;s reimbursement policies; requirements for utilization review; and federal and state funding restrictions; any of which could materially adversely affect payments we receive from these government programs, as well as affect the timing of payments to our facilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the past several years, health care payors, such as federal and state governments, insurance companies and employers, have undertaken initiatives to revise payment methodologies and monitor health care costs. As part of their efforts to contain health care costs, payors increasingly are demanding discounted fee structures or the assumption by health care providers of all or a portion of the financial risk relating to paying for care provided, often in exchange for exclusive or preferred participation in their benefit plans. We expect efforts to impose greater discounts and more stringent cost controls by government and other payors to continue, thereby reducing the payments we receive for our services. Similarly, private third-party payors may be successful in negotiating reduced reimbursement schedules with our facilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixed fee schedules, capitation payment arrangements, exclusion from participation in or inability to reach agreements with private insurance organizations, reduction or elimination of payments or an increase in the payments at a rate that is less than the increase in our costs, or other factors affecting payments for health care services over which we have no control could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we are unable to negotiate and enter into favorable contracts or maintain satisfactory relationships and renew existing contracts on favorable terms with private insurance payors, our revenue and profitability may decrease. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments from private insurance payors, including state workers&#8217; compensation programs and managed care organizations, represented approximately 54% in both 2020 and 2019 and 55% in 2018, of our patient service revenue. Most of these payments came from private insurance payors with which our facilities have contracts. Managed care companies such as HMOs and PPOs, which offer prepaid and discounted medical service packages, represent a growing segment of private insurance payors. If we fail to enter into favorable contracts or maintain satisfactory relationships with private insurance organizations, our revenue may decrease. Our competitive position has been, and will continue to be, affected by initiatives undertaken during the past several years by major purchasers of health care services, including insurance companies and employers, to revise payment methods and monitor health care expenditures in an effort to contain health care costs. For instance, private insurance payors may lower reimbursement rates in response to increased obligations on payors imposed by the Affordable Care Act or future reductions in Medicare reimbursement rates. Further, private insurance payors may narrow their provider networks in response to the need to negotiate lower reimbursement rates with providers. If we are unable to maintain strong relationships with these payors, we may not be able to participate in these narrow provider networks. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Some of our payments from private insurance payors come from payors with which our facilities or subsidiaries do not have a contract. If we provide services to a patient that does not use a private insurance payor with which we have contracted, commonly known as "out-of-network" services, we generally charge the patient the same co-payment or other patient responsibility amounts that we would have charged had our facilities had a contract with the payor. In accordance with insurance laws and regulations, we submit a claim for the services to the payor along with full disclosure that our surgical facility has charged the patient an in-network patient responsibility amount. Historically, it was typical for those private insurance payors who do not have contracts with our surgical facilities to pay our claims at higher than comparable contracted rates. However, in recent years we have observed an increase in private insurance payors adopting out-of-network fee schedules that are more comparable to our contracted rates or to take other steps to discourage their enrollees from seeking treatment at out-of-network surgical facilities. If the proportion of our services subject to out-of-network fee schedules increases, we may experience a decrease in volume at our ASCs or other facilities due to fewer referrals of out-of-network patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, payments from workers&#8217; compensation payors represented approximately 6% of our patient service revenue in both 2020 and 2019, and approximately 5% of our patient service revenues in 2018. A majority of states have implemented workers&#8217; compensation provider fee schedules. In some cases, the fee schedule rates contain lower rates than the rates our surgical facilities have historically been paid for the same services. If states reduce the amounts paid to providers under the workers&#8217; compensation fee schedules, it could have an adverse impact on our operating results. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant changes in our payor mix or surgical case mix resulting from fluctuations in the types of cases performed at our facilities could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our results may change from period to period due to fluctuations in payor mix or case mix or other factors relating to the type of cases performed at our facilities. Payor mix refers to the relative share of total cases provided to patients with no insurance, private insurance, Medicare coverage and Medicaid coverage. Since, generally speaking, we receive relatively higher payment rates from private insurers than Medicare, Medicaid and other government-funded programs, a significant shift in our payor mix toward a higher percentage of Medicare and Medicaid cases, which could occur for reasons beyond our control, could have an adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Case mix refers to the relative share of total cases performed by specialty, such as GI, general surgery, ophthalmology, orthopedic and pain management. Generally speaking, certain types of our cases, such as orthopedic cases, generate relatively higher revenue than other types of cases, such as pain management and GI cases. Therefore, a significant shift in our case mix toward a higher percentage of lower revenue cases, which could occur for reasons beyond our control, could result in a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our case volume and surgical case mix may be adversely affected by patients&#8217; unwillingness to pay for procedures in our facilities. Higher numbers of unemployed individuals generally translates into more individuals without health care insurance to help pay for procedures, thereby increasing the potential for persons to elect not to have procedures performed. Even procedures normally thought to be non-elective may be delayed or may not be performed if the patient cannot afford the procedure due to a lack of insurance or money to pay their portion of our facilities&#8217; fee. It is difficult to predict the degree to which our business will continue to be impacted by economic conditions in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As we operate in multiple markets, each with a different competitive landscape, shifts within our payor mix or case mix may not be uniform across all of our affiliated facilities. Rather, these shifts may be concentrated within certain markets due to local competitive factors. Therefore, the results of our individual affiliated facilities, including facilities that are material to our results, may be volatile, which could result in a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our ability to provide medical services at our facilities would be impaired and our revenue reduced if we are not able to maintain good relationships with affiliated physicians who utilize our surgical facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our business depends, among other things, upon the efforts and success of affiliated physicians who provide medical services at our surgical facilities and the strength of our relationships with these physicians. We generally do not enter into contracts with physicians who use our surgical facilities, other than partnership and operating agreements with physicians who own interests in our surgical facilities, agreements for anesthesiology services and medical director agreements. Most physicians are not employees of our surgical facilities and are not contractually required to use our facilities. Physicians who use our surgical facilities also use other facilities or hospitals and may choose to perform procedures in an office-based setting that might otherwise be performed at our surgical facilities. In recent years, pain management and gastrointestinal procedures have been performed increasingly in an office-based setting because of potential cost savings or better access for patients and physicians. Although physicians who own interests in our surgical facilities are subject to agreements restricting ownership of competing facilities, these agreements may not restrict procedures performed in a physician office or in other unrelated facilities. Also, these agreements restricting ownership of competing facilities are difficult to enforce, and we may be unsuccessful in preventing physicians who own interests in our surgical facilities from acquiring interests in competing facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The financial success of our facilities is in part dependent upon the volume of procedures performed by the physicians who use our facilities, which can be affected by the economy, health care reform efforts, increases in patient co-payments and deductibles and other factors outside our or their control. The physicians who use our surgical facilities may choose not to accept patients who pay for services through certain third-party payors, which could reduce our revenue. From time to time, we may have disputes with physicians who use our surgical facilities and/or own interests in our surgical facilities or our Company. Our revenue and profitability could be significantly </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">reduced if we lost our relationship with one or more key physicians or groups of physicians, or if such key physician or group of physicians reduce their use of any of our surgical facilities. In addition, any damage to the reputation of a key physician or group of physicians or the failure of these physicians to provide quality medical care or adhere to professional guidelines at our surgical facilities could damage our reputation, subject us to liability and significantly reduce our revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Physician treatment methodologies and governmental or private insurance controls designed to reduce the number of surgical procedures may reduce our revenue and profitability. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Controls imposed by Medicare, Medicaid and private insurance payors designed to reduce surgical and other procedure volumes, in some instances referred to as "utilization review," could adversely affect our facilities. Although we are unable to predict the effect these changes will have on our operations, significant limits on the scope of services reimbursed and on reimbursement rates and fees may reduce our revenue and profitability. Additionally, trends in physician treatment protocols and private insurance plan design, such as plans that shift increased costs and accountability for care to patients, could reduce our surgical and other procedure volumes in favor of lower intensity and lower cost treatment methodologies, each of which could, in turn, have a material adverse effect on our business, prospects, results of operations and financial condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our growth strategy depends in part on our ability to integrate operations of acquired surgical facilities, attract new physician partners, and to acquire and develop additional surgical facilities on favorable terms. If we are unable to achieve any of these goals, our future growth could be limited and our operating results could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that an important component of our financial performance and growth is our ability to provide physicians who use our surgical facilities with the opportunity to purchase ownership interests in our facilities. We may not be successful in attracting new physician investment in our surgical facilities, and that failure could result in a reduction in the quality, efficiency and profitability of our facilities. Based on competitive factors and market conditions, physicians may be able to negotiate relatively higher levels of equity ownership in our facilities, consequently limiting or reducing our share of the profits from these facilities. In addition, physician ownership in our facilities is subject to certain regulatory restrictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, our growth strategy includes the acquisition and development of existing surgical facilities and the development of new surgical facilities jointly with local physicians and, in some cases, health care systems and other strategic partners. We are currently evaluating potential acquisitions and development projects and expect to continue to evaluate acquisitions and development projects in the foreseeable future. If we are unable to successfully execute on this strategy in the future, our future growth could be limited. We may be unable to identify suitable acquisition and development opportunities, or to complete acquisitions and new projects in a timely manner and on favorable terms. Further, the businesses or assets we acquire in the future may not ultimately produce returns that justify our related investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our acquisition and development activities, require substantial capital resources, and we may need to obtain additional capital or financing, from time to time, to fund these activities. Historically, we have funded acquisition and development activities through our credit facilities. As a result, we may take actions to fund future acquisitions and development activities that could have a material adverse effect on our business, prospects, results of operations and financial condition, including incurring substantial debt with certain restrictive terms. Further, sufficient capital or financing may not be available to us on satisfactory terms, if at all. In addition, our ability to acquire and develop additional surgical facilities may be limited by state certificate of need programs, licensure requirements, antitrust laws, and other regulatory restrictions on expansion. We also face significant competition from local, regional and national health systems and other owners of surgical facilities in pursuing attractive acquisition candidates. The limited number of surgical facilities we develop typically incur losses in their early months of operation (more so in the case of surgical hospitals) and, until their case loads grow, they generally experience lower total revenue and operating margins than established surgical facilities, and we expect this trend to continue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we are not successful in integrating the operations and personnel of newly acquired surgical facilities in a timely and efficient manner, then the potential benefits of the transaction may not be realized and our operations and earnings could be materially adversely impacted. If we experience the loss of key personnel or if the effort devoted to the integration of acquired facilities diverts significant management or other resources from other operational activities, our operations could be impaired. Additionally, in some acquisitions, we may have to renegotiate, or risk losing, one or more of the facility&#8217;s private insurance contracts. We may also be unable to immediately collect the accounts receivable of an acquired facility while we align the payors&#8217; payment systems and accounts with our own systems. Finally, certain transactions can require licensure changes which, in turn, result in disruptions in payment for services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, although we conduct extensive due diligence prior to the acquisition of surgical facilities and seek indemnification from prospective sellers covering unknown or contingent liabilities, we may acquire facilities with unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations for which we do not have sufficient insurance or indemnification rights. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our rapid growth has placed, and will continue to place, increased demands on our management, operational and financial information systems and other resources. Furthermore, expansions into new geographic markets and services may require us to comply with new and unfamiliar legal and regulatory requirements, which could impose substantial obligations on us and our management, cause us to expend additional time and resources, and increase our exposure to penalties or fines for non-compliance with such requirements. To accommodate our past and anticipated future growth, and to compete effectively, we will need to continue to improve our management, operational and financial information systems and to expand, train, manage and motivate our workforce. Our personnel, systems, procedures or controls </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may not be adequate to support our operations in the future. Further, focusing our financial resources and management attention on the expansion of our operations may negatively impact our financial results. Any failure to improve our management, operational and financial information systems, or to expand, train, manage or motivate our workforce, could reduce or prevent our growth.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shortages of surgery-related products, equipment and medical supplies and quality control issues with such products, equipment and medical supplies could disrupt our operations and adversely affect our case volume, surgical case mix and profitability. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our operations depend significantly upon our ability to obtain sufficient surgery-related products, drugs, equipment and medical supplies from suppliers on a timely and cost-effective basis. If we are unable to obtain such necessary products, or if we fail to properly manage existing inventory levels, the surgical facilities may be unable to perform certain surgeries, which could adversely affect case volume or result in a negative shift in surgical case mix. In addition, as a result of shortages, we could suffer, among other things, operational disruptions, disruptions in cash flows, increased costs and reductions in profitability. At times, supply shortages have occurred in our industry, and such shortages may be expected to recur from time to time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Medical supplies and services can also be subject to supplier product quality control incidents and recalls. In addition to contributing to materials shortages, product quality can affect patient care and safety. Material quality control incidents have occurred in the past and may occur again in the future, for reasons beyond our control, and such incidents can negatively impact case volume, product costs and our reputation. In addition, we may have to incur costs to resolve quality control incidents related to medical supplies and services regardless of whether they were caused by us. Our inability to obtain the necessary amount and quality of surgery-related products, equipment and medical supplies due to a quality control incident or recall could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We face competition from other health care facilities and providers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care business is highly competitive and each of the individual geographic areas in which we operate has a different competitive landscape. In each of our markets we compete with other health care providers for patients and in contracting with private insurance payors. In addition, because the number of physicians available to utilize and invest in our facilities is finite, we face intense competition from other surgery centers, hospitals, health systems and other health care providers in recruiting physicians to utilize and invest in our facilities. We are in competition with other surgery centers, hospitals and health care systems in the communities we serve to attract patients and provide them with the care they need.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are also unaffiliated hospitals in each market in which we operate. These hospitals have established relationships with physicians and payors. In addition, other companies either currently are in the same or similar business of developing, acquiring and operating surgical facilities or may decide to enter our business. Many of these companies have greater resources than we do, including financial, marketing, staff and capital resources. We also may compete with some of these companies for entry into strategic relationships with health care systems and health care professionals. In addition, many physician groups develop surgical facilities without a corporate partner. In recent years, more physicians are choosing to perform procedures, including pain management and gastrointestinal procedures, in an office-based setting rather than in a surgical facility. If we are unable to compete effectively with any of these entities or groups, we may be unable to implement our business strategies successfully and our financial position and results of operations could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Competition for physicians and clinical personnel, including nurses, shortages of qualified personnel or other factors could increase our labor costs and adversely affect our revenue, profitability and cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our operations are dependent on the efforts, abilities and experience of our physicians and clinical personnel. We compete with other health care providers, primarily hospitals and other surgical facilities, in attracting physicians to utilize our surgical facilities, nurses and medical staff to support our surgical facilities, recruiting and retaining qualified management and support personnel responsible for the daily operations of each of our facilities and in contracting with private insurance payors in each of our markets. In some markets, the lack of availability of clinical personnel, such as nurses, has become a significant operating issue facing all health care providers. This shortage may require us to continue to enhance wages and benefits to recruit and retain qualified personnel or to contract for more expensive temporary personnel. For the year-ended December&#160;31, 2020, our salary and benefit expenses represented approximately 30% of our revenue. We also depend on the available labor pool of semi-skilled and unskilled workers in each of the markets in which we operate. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If our labor costs increase, we may not be able to raise rates to offset these increased costs. Because a significant percentage of our revenue consists of fixed, prospective payments, our ability to pass along increased labor costs is limited. In particular, if labor costs rise at an annual rate greater than our net annual consumer price index basket update from Medicare, our results of operations and cash flows will likely be adversely affected. Any union activity at our facilities that may occur in the future could contribute to increased labor costs. Certain proposed changes in federal labor laws and the National Labor Relations Board&#8217;s modification of its election procedures could increase the likelihood of employee unionization attempts. Although none of our employees are currently represented by a collective bargaining agreement, to the extent a significant portion of our employee base unionizes, it is possible our labor costs could increase materially. Our failure to recruit and retain qualified management and medical personnel, or to control our labor costs, could have a material adverse effect on our business, prospects, results of operations and financial condition. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Some jurisdictions preclude us from entering into non-compete agreements with our physicians, and other non-compete agreements and restrictive covenants applicable to certain physicians and other clinical employees may not be enforceable. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have contracts with physicians and other health professionals in many states. Some of our physician services contracts, as well as many of our physician services contracts with hospitals, include provisions preventing these physicians and other health professionals from competing with us both during and after the term of our contract with them. The law governing non-compete agreements and other forms of restrictive covenants varies from state to state. Some jurisdictions prohibit us from entering into non-compete agreements with our professional staff. Other states are reluctant to strictly enforce non-compete agreements and restrictive covenants against physicians and other health care professionals. Therefore, there can be no assurance that our non-compete agreements related to employed or otherwise contracted physicians and other health professionals will be enforceable if challenged in certain states. In such event, we would be unable to prevent former employed or otherwise contracted physicians and other health professionals from competing with us, potentially resulting in the loss of some of our hospital contracts and other business. Additionally, certain facilities have the right to employ or engage our providers after the termination or expiration of our contract with those facilities and cause us not to enforce our non-compete provisions related to those providers. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our surgical facilities are sensitive to regulatory, economic and other conditions in the states where they are located. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our revenue is particularly sensitive to regulatory, economic and other conditions in the states of Georgia and Texas. As of December&#160;31, 2020, we owned and operated nine consolidated surgical facilities in Texas and six consolidated surgical facilities in Georgia. The Texas facilities represented approximately 14% of our revenue in fiscal 2020 and the Georgia facilities represented approximately 11% of our revenue in fiscal 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we own and operate three consolidated surgical facilities in Idaho, representing approximately 25% of our revenue during fiscal 2020. These surgical facilities also provide ancillary services, including physician practices, radiation oncology and anesthesia services. If there were an adverse regulatory, economic or other development in any of the states in which we have a higher concentration of facilities, including Idaho, our case volumes could decline in such states or there could be other unanticipated adverse impacts on our business in those states, which could have a material adverse effect on our business, prospects, results of operations and financial condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If any of our existing health care facilities lose their accreditation status or any of our new facilities fail to receive accreditation, such facilities could become ineligible to receive reimbursement under Medicare or Medicaid or other third-party payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The construction and operation of health care facilities are subject to extensive federal, state and local regulation relating to, among other things, the adequacy of medical care, equipment, personnel, operating policies and procedures, fire prevention, rate-setting and compliance with building codes and environmental protection. Additionally, such facilities are subject to periodic inspection by government authorities and accreditation organizations to assure their continued compliance with these various standards. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All of our facilities are deemed certified, meaning that they are accredited, properly licensed under the relevant state laws and regulations and certified under the Medicare program or are in the process of applying for such accreditation, licensing or certification. The effect of maintaining certified facilities is to allow such facilities to participate in the Medicare and Medicaid programs. We believe that all of our facilities are in material compliance with applicable federal, state, local and other relevant accreditation and certification regulations and standards. However, should any of our health care facilities lose their deemed certified status and thereby lose certification under the Medicare or Medicaid programs, such facilities would be unable to receive reimbursement from either or both of those programs, and possibly from other third-party payors, and our business could be materially adversely affected. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certain of our partnership and operating agreements contain provisions giving rights to our partners and other members that may be adverse to our interests. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the agreements governing the limited partnerships ("LPs"), general partnerships ("GPs") and limited liability companies ("LLCs") through which we own and operate our facilities contain provisions that give our partners or other members rights that may, in certain circumstances, be adverse to our interests. These rights include, but are not limited to, rights to purchase our interest in the partnership or LLC, rights to require us to purchase the interests of our partners or other members, or rights requiring the consent of our partners and other members prior to our transferring our ownership interest in a facility or prior to a change in control of us or certain of our subsidiaries. With respect to these purchase rights, the agreements generally include a specified formula or methodology to determine the applicable purchase price, which may or may not reflect fair market value. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, many of our partnership and operating agreements contain restrictions on actions that we can take, even though we may be the general partner or the managing member. Examples of these restrictions include the rights of our partners and other members to approve the sale of substantially all of the assets of the partnership or LLC, to dissolve the partnership or LLC, to appoint a new or additional general partner or managing member and to amend the partnership or operating agreements. Many of our agreements also restrict our ability in certain instances to compete with our existing facilities or with our partners. Where we hold only a limited partner or a non-managing member interest, the general partner or managing member may take certain actions without our consent, although we typically have certain protective rights to approve major decisions such as the sale of substantially all of the assets of the entity, dissolution of the partnership or LLC and the amendment of the partnership or operating agreement. These management and governance rights held by our partners and other members limit and restrict our ability to make unilateral decisions about the management and operation of the facilities without the approval of our partners and other members. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We may have a special legal responsibility to the holders of ownership interests in the entities through which we own our facilities, which may conflict with, and prevent us from acting solely in, our own best interests or the interests of our stockholders. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We generally hold our ownership interests in facilities through LPs, GPs, LLCs or limited liability partnerships ("LLPs") in which we maintain an ownership interest along with physicians and, in some cases, both physicians and health systems. As general partner and manager of most of these entities, we may have a fiduciary duty, to manage these entities in the best interests of the other owners. We also have a duty to operate our business for the benefit of our stockholders. As a result, we may encounter conflicts between our responsibility to the other owners and our responsibility to our stockholders. For example, we have entered into some management agreements to provide management services to our surgical facilities in exchange for a fee. Disputes may arise as to the nature of the services to be provided or the amount of the fee to be paid. In these cases, we may be obligated to exercise reasonable, good faith judgment to resolve the disputes and may not be free to act solely in our own best interests or the stockholders best interest. Disputes may also arise between us and our physician investors with respect to a particular business decision or regarding the interpretation of the provisions of the applicable partnership or limited liability company agreement. We seek to avoid these disputes but have not implemented any measures to resolve these conflicts if they arise. If we are unable to resolve a dispute on terms favorable or satisfactory to us, it could have a material adverse effect on our business, prospects, results of operations and financial condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Growth of patient receivables or deterioration in the ability to collect on these accounts, due to changes in economic conditions or otherwise, could have a material adverse effect on our business, prospects, results of operations and financial condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The current practice of providing medical services in advance of payment or, in many cases, prior to assessment of ability to pay for such services, may have significant negative impact on our revenue and cash flow. We bill numerous and varied payors, such as self-pay patients, private insurance payors and Medicare and Medicaid. These different payors typically have different billing requirements that must be satisfied prior to receiving payment for services rendered. Reimbursement is typically conditioned on our documenting medical necessity and correctly applying diagnosis codes. Incorrect or incomplete documentation and billing information could result in non-payment for services rendered. The primary collection risks with respect to our patient receivables relate to patient accounts for which the primary third-party payor has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and co-payments) remain outstanding. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional factors that could complicate our billing include: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">disputes between payors as to which party is responsible for payment; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">failure of information systems and processes to submit and collect claims in a timely manner; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">variation in coverage for similar services among various payors; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the difficulty of adherence to specific compliance requirements, diagnosis coding and other procedures mandated by various payors; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">failure to obtain proper physician credentialing and documentation in order to bill various payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the difficulty in assessing future trends, including the effects of changes in economic conditions, an increase in the amount of patient receivables or a deterioration in the collectability of these receivables could have a material adverse effect on our business, prospects, results of operations and financial condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we are unable to integrate and operate our information systems effectively or implement new systems and processes, our operations could be disrupted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our operations depend significantly on effective information systems, which require continual maintenance, upgrading and enhancement to meet our operational needs. Any system failure or integration delay that causes an interruption in service or availability of our systems could adversely affect operations or delay the collection of revenue. Moreover, we use the development and implementation of sophisticated and specialized technology to improve our profitability, and our acquired surgical centers and hospitals will require frequent transitions and integration of various information systems. If we are unable to properly integrate other information systems or expand our current information systems it may have an adverse effect on our ability to obtain new business, retain existing business and maintain or increase our profit margins and we could suffer, among other things, operational disruptions, disruptions in cash flows and increases in administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial and Accounting Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We have a history of net losses and may not achieve or sustain profitability in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We had net losses attributable to Surgery Partners, Inc. of $116.1 million, $74.8 million and $205.7 million, in 2020, 2019 and 2018, respectively. We cannot assure you that our revenue will grow or that we will achieve or maintain profitability in the future. Growth of our revenue may slow or revenue may decline and expenses may increase for a number of possible reasons, including reduced demand for our services, regulatory shifts and other risks and uncertainties. Our ability to achieve profitability will be affected by the other risks and uncertainties described in this section and in "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations," included elsewhere in this Annual Report. All of these factors could contribute to future net losses and, if we are unable to meet these risks </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and challenges as we encounter them, our business may suffer. If we are not able to achieve, sustain or increase profitability, our business will be adversely affected and our stock price may decline. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our leverage could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry, expose us to interest rate risk to the extent of our variable rate debt and prevent us from meeting our obligations under our outstanding indebtedness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we and our subsidiaries had approximately $2.9 billion aggregate principal amount of indebtedness outstanding, which includes approximately $1.5 billion principal amount of senior secured term loans (the "Term Loan") outstanding, $370.0 million senior unsecured notes due 2025 (the "2025 Unsecured Notes") and $545.0 million senior unsecured notes due 2027 (the "2027 Unsecured Notes"). As of December&#160;31, 2020, we had no outstanding borrowings under our $120.0 million senior secured revolving credit facility (the "Revolver" and, together with the Term Loan, the "Senior Secured Credit Facilities" and, together with the 2025 Unsecured Notes and the 2027 Unsecured Notes, the "Senior Indebtedness"). After giving effect to the $7.5 million principal amount of outstanding letters of credit issued under our Revolver, we had $112.5 million of unused commitments available to be borrowed under the Revolver. In addition to the Senior Indebtedness, our aggregate principal amount of indebtedness outstanding includes approximately $418.7 million of notes payable and finance lease obligations primarily related to property and equipment for operations. Our level of indebtedness increases the risk that we may be unable to generate cash sufficient to pay amounts due in respect of our indebtedness. In addition, subject to applicable restrictions under our Senior Indebtedness, we may incur significant additional indebtedness, which may be secured, from time to time, which could have important consequences, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">making it more difficult for us to satisfy our obligations with respect to our indebtedness;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">making us more vulnerable to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">requiring us to dedicate a substantial portion of our cash flow to making payments on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate purposes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">limiting our flexibility in reacting to competitive and other changes in our industry and economic conditions generally; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">limiting our ability to raise additional capital for working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy or other general corporate purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">To service our indebtedness, we will require a significant amount of cash. Our ability to generate cash depends on many factors beyond our control, and any failure to meet our debt service obligations may adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our ability to pay or to refinance our indebtedness and to fund working capital needs and planned capital expenditures will depend upon our future operating performance and our ability to generate cash, which, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory, business and other factors that are beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If our business does not generate sufficient cash flow or if future borrowings are not available to us in an amount sufficient to enable us to pay our indebtedness or to fund our other liquidity needs, we may need to refinance all or a portion of our indebtedness on or before the maturity thereof, sell assets, reduce or delay capital investments or seek to raise additional capital, any of which could have a material adverse effect on our operations. In addition, we may not be able to affect any of these actions, if necessary, on commercially-reasonable terms or at all. Our history of net losses may impair our ability to service our indebtedness or repay outstanding amounts when they become due. In addition, our ability to restructure or refinance our indebtedness will depend on the condition of the capital markets and our financial condition at such time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, and also might include incurring additional fees in connection with refinancing, which could further restrict our business operations. The terms of existing or future debt instruments may limit or prevent us from taking any of these actions. In addition, any failure to make scheduled payments of interest and principal on our outstanding indebtedness would likely result in a reduction of our credit rating, which could harm our ability to incur additional indebtedness on commercially-reasonable terms or at all. Our inability to generate sufficient cash flow to satisfy our debt service obligations, or to refinance or restructure our obligations on commercially reasonable terms or at all, may adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restrictive covenants in our debt instruments may adversely affect us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Senior Indebtedness imposes significant operating and financial restrictions and limit the ability of us and our restricted subsidiaries to, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">incur additional indebtedness and guarantee indebtedness;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">pay dividends or make other distributions in respect of, or repurchase or redeem, capital stock;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">prepay, redeem or repurchase certain debt;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">make loans and investments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">sell or otherwise dispose of assets;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">sell stock of our subsidiaries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">incur liens;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">enter into transactions with affiliates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">enter into agreements restricting certain of our subsidiaries&#8217; ability to pay dividends; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">consolidate, merge or sell all or substantially all of our assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these and other covenants and restrictions, we are and will be limited in how we conduct our business, and we may be unable to raise additional capital to compete effectively or to take advantage of new business opportunities. In addition, we may be required to maintain specified financial maintenance ratios and satisfy other financial condition tests in connection with the Senior Indebtedness. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that we will be able to maintain compliance with these covenants in the future and, if we fail to do so, that we will be able to obtain waivers from the lenders and/or amend the covenants. Our failure to comply with the restrictive covenants described above as well as others contained in our future debt instruments from time to time could result in an event of default, which, if not cured or waived, could result in our being required to repay these borrowings before their maturity. If we are forced to refinance these borrowings on less favorable terms, our results of operations and financial condition could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We cannot assure you that our business will generate sufficient cash flow from operations, that currently anticipated revenue growth and operating improvements will be realized or that future borrowings will be available to us under the Term Loan and Revolver in amounts sufficient to enable us to pay our indebtedness, or to fund our other liquidity needs. If we are unable to meet our debt service obligations or fund our other liquidity needs, we could attempt to restructure or refinance our indebtedness or seek additional equity capital. We cannot assure you that we will be able to accomplish those actions on satisfactory terms, if at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Despite our current indebtedness levels, we and our subsidiaries may still be able to incur more debt, which could further exacerbate the risks associated with our leverage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and our subsidiaries may be able to incur additional indebtedness in the future, including secured indebtedness. Although the credit agreement governing the Senior Secured Credit Facilities and the indentures governing each of the 2025 Unsecured Notes and 2027 Unsecured Notes, respectively, contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of significant qualifications and exceptions, and the indebtedness incurred in compliance with these restrictions could be substantial. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, as of December&#160;31, 2020 we had approximately $112.5 million available for additional borrowings under the Revolver (after giving effect to the $7.5 million aggregate principal amount of outstanding letters of credit issued under our Revolver at such time). If new debt is added to our or our subsidiaries&#8217; current debt levels, the related risks that we face would be increased.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We are a holding company with no operations of our own.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are a holding company, and our ability to service our debt is dependent upon the earnings from the business conducted by our subsidiaries that operate the surgical facilities. The effect of this structure is that we depend on the earnings of our subsidiaries, and the distribution or payment to us of a portion of these earnings to meet our obligations, including those under the Term Loans and Revolving Facility and any of our other debt obligations. The distributions of those earnings, advances or other distributions of funds by these entities to us, all of which are contingent upon our subsidiaries&#8217; earnings, are subject to various business considerations. In addition, distributions by our subsidiaries could be subject to statutory restrictions, including state laws requiring that such subsidiaries be solvent, or contractual restrictions. Some of our subsidiaries may become subject to agreements that restrict the sale of assets and significantly restrict or prohibit the payment of dividends or the making of distributions, loans or other payments to stockholders, partners or members.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We make significant loans to, and are generally liable for debts and other obligations of, the partnerships and limited liability companies that own and operate some of our surgical facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We own and operate our surgical facilities through limited partnerships and limited liability companies. Local physicians, physician groups and health care systems also own an interest many of these partnerships and limited liability companies. In the partnerships in which we are the general partner, we are liable for 100% of the debts and other obligations of the partnership, even if we do not own all of the partnership interests. For some of our surgical facilities, indebtedness at the partnership level is funded through intercompany loans that we provide. At December&#160;31, 2020, our intercompany loans totaled $38.6&#160;million. Through these loans we may have a security interest in the partnership&#8217;s or limited liability company&#8217;s assets, depending upon the terms thereof in each instance. However, our financial condition and results of operations would be materially adversely affected if our surgical facilities are unable to repay these intercompany loans, or such loans are challenged under certain health care laws. Additionally, at December&#160;31, 2020, our global intercompany note, which we use to transfer debt balances between our subsidiaries, had a zero balance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although most of our intercompany loans are secured by the assets of the partnership or limited liability company, the physicians and physician groups that own an interest in these partnerships and limited liability companies generally do not guarantee a pro rata amount of this debt or the other obligations of these partnerships and limited liability companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, we may guarantee our pro-rata share of the third-party debts and other obligations of our non-wholly owned non-consolidated partnerships and limited liability companies in which we own an interest in an amount proportionate to our pro rata share of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the equity interests issued by such entity. In such instances, the physicians and/or physician groups typically also guarantee their pro-rata share of such indebtedness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our variable rate indebtedness subjects us to interest rate risk, which could cause our indebtedness service obligations to increase significantly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities are at variable rates of interest and expose us to interest rate risk. If interest rates increase, our debt service obligations on variable rate indebtedness would increase even though the amount borrowed remained the same, and our net income and cash flows, including cash available for servicing our indebtedness, would correspondingly decrease. We periodically enter into interest rate swap agreements to manage our exposure to these fluctuations. Our interest rate swap agreements involve the exchange of fixed and variable rate interest payments between two parties, based on common notional principal amounts and maturity dates. The notional amounts of the swap agreements represent balances used to calculate the exchange of cash flows and are not our assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) the London Interbank Offered Rate ("LIBOR") plus a margin ranging from 3.00% to 3.25% per annum, depending on the Company&#8217;s first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.50% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than 2.00% per annum)) plus a margin ranging from 2.00% to 2.25% per annum. In addition, the Company is required to pay a commitment fee of 0.50% per annum in respect of unused commitments under the Revolver. The 2020 incremental term loans bear interest at a rate per annum equal to (x) LIBOR plus a margin of 8.00% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate, (iii) one-month LIBOR plus 1.00% per annum and (iv) 2.00% per annum) plus a margin of 7.00% per annum. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Discontinuation, reform or replacement of LIBOR may adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The credit agreement governing the Senior Secured Credit Facilities permits interest on borrowings to be calculated based on LIBOR. LIBOR and certain other interest "benchmarks" may be subject to regulatory guidance and/or reform that could cause interest rates under our current or future debt agreements to perform differently than in the past or cause other unanticipated consequences. The United Kingdom&#8217;s Financial Conduct Authority, which regulates LIBOR, has announced that it intends to phase out LIBOR by June 2023. If the phase out occurs as planned, the interest rate applicable to our variable rate debt may be calculated based on an alternative, comparable or successor rate which may have a material adverse impact on the cost of the variable rate portion of our indebtedness. The timing and result of the phase out of LIBOR are unclear, and efforts of industry groups to develop a suitable successor are not guaranteed to result in a viable or widely adopted replacement for LIBOR. If LIBOR becomes unavailable before a suitable replacement is widely adopted, it could have a material adverse impact on the availability of variable rate financing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we also had interest rate swap agreements based on LIBOR. If LIBOR becomes unavailable, it is unclear how payments under those agreements would be calculated. Relevant industry groups are seeking to create a standard protocol addressing the expected discontinuation of LIBOR, but there can be no assurance that such a protocol will be developed or implemented with respect to our swap agreements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had U.S. federal net operating loss ("NOL") carryforwards of approximately $615.7 million and state NOL carryforwards of approximately $678.9 million, which may be limited annually due to certain change in ownership provisions of Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"). In addition, as a result of the Symbion acquisition, approximately $179 million in NOL carryforwards are subject to an annual Section 382 base limitation of $4.9 million, and, as a result of the Novamed acquisition, approximately $17 million in NOL carryforwards are subject to an annual Section 382 base limitation of $4.9 million. As a result of our acquisition of NSH Holdco, Inc. ("NSH") on August 31, 2017, approximately $20.5 million in NOL carryforwards are subject to an annual Section 382 base limitation of $2.8 million. Further, the sale of H.I.G. Surgery Centers, LLC's ("H.I.G.") shares to Bain Capital in connection with the Transactions resulted in an ownership change as defined in Section 382. As a result, we will not be able to use our pre-ownership-change NOLs in excess of the limitation imposed by Section 382. These limitations, when combined with amounts allowable due to net unrecognized built in gains, are not expected to impact the realization of the deferred tax assets associated with these NOLs. $516.2 million of our federal NOL carryforwards will begin to expire in 2026 and will completely expire in 2037. The remaining federal NOL carryforwards, which were generated subsequent to 2017, do not expire. Our state NOL carryforwards will begin to expire in 2021 and will completely expire in 2040. Future ownership changes may subject our NOL carryforwards to further annual limitations, which could restrict our ability to use them to offset our taxable income in periods following the ownership changes. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We entered into a tax receivable agreement that will require us to make payments to the pre-IPO owners of Surgery Center Holdings, LLC (the "Pre-IPO Owners"), which amounts are expected to be material. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 30, 2015, Surgery Partners, Inc. became the direct parent and sole member of Surgery Center Holdings, LLC (the "Reorganization"). We indirectly acquired favorable tax attributes in connection with the Reorganization. These tax attributes would not be available to us in the absence of the consummation of the Reorganization. As part of the Reorganization, we entered into a tax receivable agreement with the Pre-IPO Owners. In connection with the Transactions completed in in August 2017, we entered into an agreement to amend the tax receivable agreement (as amended, the "TRA"), which became effective on August 31, 2017. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant the TRA, we agreed to make annual payments to H.I.G. in its capacity as the stockholders representative on behalf of the other pre-Reorganization stockholders pursuant to a fixed payment schedule. The final payment is scheduled to be made in 2024. The amounts payable under the TRA are calculated to equal the product of (i) an annual base amount and (ii) the sum of (x) the maximum corporate federal income tax rate for the applicable year and (y) three percent. The amounts payable under the TRA are related to our projected realized tax savings over the next five years and are not dependent on our actual tax savings over the next five years. The calculations of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that we are unable to make payments under the TRA, such payments will be deferred and will accrue interest at a rate of LIBOR plus 500 basis points until paid. If the terms of credit agreements and other debt documents cause us to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid. We estimate that the total remaining amounts payable under the TRA as of December&#160;31, 2020 may be as high as $43.2 million, but the ultimate amounts payable are likely to vary if there are further changes in law as to the income tax rates applicable to domestic corporations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our stock price could be volatile, and, as a result, our stockholders may not be able to resell their shares at or above the price paid for them.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Since our initial public offering, the price of our common stock as reported on The Nasdaq Global Select Market has ranged from a low of $4.00 on March 18, 2020 to a high of $42.87 on February 2, 2021. The price of our common stock could be subject to fluctuations in response to a number of factors, including those described elsewhere in this report and others such as:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">variations in our operating performance and the performance of our competitors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">actual or anticipated fluctuations in our quarterly or annual operating results;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">publication of research reports by securities analysts about us or our competitors or our industry;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">announcements by us, our competitors or our vendors of significant contracts, acquisitions, joint marketing relationships, joint ventures or capital commitments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the passage of legislation or other regulatory developments affecting us or our industry;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our limited public float;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">speculation in the press or investment community;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">changes in accounting principles;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">terrorist acts, acts of war or periods of widespread civil unrest;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">natural disasters and other calamities; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">changes in general market and economic conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities class action litigation is often initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation. For example, see Part I, Item 3. Legal Proceedings - Stockholder Litigation.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cybersecurity and Data Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cybersecurity attacks or intrusions could adversely impact our businesses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We, independently and through third-party vendors, collect and store on our networks and devices sensitive information, including intellectual property, proprietary business information and personally identifiable information of our patients and employees. Information security risks have generally increased in recent years because of threats from malicious persons and groups, new vulnerabilities, the proliferation of new technologies and the increased sophistication and activities of perpetrators of cyber-attacks. A failure in or breach of our operational or information security systems as a result of cyber-attacks or information security breaches could disrupt our business, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">result in the loss, disclosure or misuse of confidential or proprietary information, damage our reputation, increase our costs or lead to fines and financial losses. As a result, cybersecurity and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data and networks from attack, damage or unauthorized access remain a priority for us. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and our third-party vendors have been and likely will continue to be subject to attempted cybersecurity attacks. While there has been no material impact on our business or operations from these attempted attacks. There can be no assurance that we or our third-party vendors will not be subject to cybersecurity incidents that bypass our security measures, impact the integrity, availability or privacy of personal health information or other data subject to privacy laws or disrupt our information systems, devices or business, including our ability to provide various health care services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The market for cybersecurity insurance is relatively new and coverage available for cybersecurity events may evolve as the industry matures. While we maintain insurance relating to cybersecurity events, such insurance is subject to a number of exclusions and may be insufficient to offset any losses, costs or damage we experience. As cyber threats continue to evolve, we will be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HIPAA as well as numerous other federal and state laws and regulations, govern the collection, dissemination, use, privacy, security, confidentiality, integrity and availability of personally identifiable information ("PII"), including protected health information ("PHI") by covered entities such as us. Ongoing implementation of administrative, physical and technical safeguards, maintenance of policies and procedures governing use and disclosure of PHI, and oversight of compliance with HIPAA requirements involves significant time, effort and expense. While we undertake substantial efforts to secure the PHI we maintain, use and disclose in electronic form, a cyber-attack or other intrusion that bypasses our information security systems causing an information security breach, loss of protected health information or other data subject to privacy laws or a material disruption of our operational systems could result in a material adverse impact on our business, along with potentially substantial fines and penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HIPAA also requires our surgical facilities to use standard transaction code sets and identifiers for certain standardized health care transactions, including billing and other claim transactions. We have undertaken significant efforts involving substantial time and expense to implement these requirements, and we anticipate that continual time and expense will be required to submit standardized transactions and to ensure that any newly acquired facilities can submit HIPAA-compliant transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HIPAA requires covered entities to report breaches of unsecured protected health information to affected individuals without unreasonable delay and in no case later than 60 days after the discovery of the breach by the covered entity or its agents. Notification must also be made to HHS and, in certain situations involving large breaches, to the media. The HIPAA rules created a presumption that all non-permitted uses or disclosures of unsecured protected health information are breaches. HIPAA imposes mandatory civil and criminal penalties for violations of its requirements ranging up to $50,000 per violation, with a maximum civil penalty of $1.5 million in a calendar year for violations of the same requirement. However, a single breach incident can result in violations of multiple requirements, resulting in possible penalties well in excess of $1.5 million. In addition, the HITECH Act authorized state attorneys general to bring civil actions seeking either an injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HIPAA also authorizes state attorneys general to bring civil actions seeking either an injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA&#8217;s requirements, its standards have been used as a basis for the duty of care in state civil suits, such as those for negligence or recklessness in the handling of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities such as us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, many states in which we operate may impose laws that are more protective of the privacy and security of PII than HIPAA. Where these state laws are more protective than HIPAA, we have to comply with their stricter provisions. Only some of these state laws impose fines and penalties upon violators, but some may afford private rights of action to individuals who believe their PII has been misused. California&#8217;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. Both state and federal laws are subject to modification or enhancement of privacy protection at any time. Our facilities will continue to remain subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These statutes vary and could impose additional requirements on us and more severe penalties for disclosures of confidential health information. New health information standards could have a significant effect on the manner in which we do business, and the cost of complying with new standards could be significant. We may not remain in compliance with the diverse privacy requirements in all of the jurisdictions in which we do business. If we fail to comply with HIPAA or similar state laws, we could incur substantial civil monetary or criminal penalties.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal and Regulatory Risks </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to comply with or otherwise incur liabilities under the numerous federal and state laws and regulations relating to the operation of our facilities, we could incur significant penalties or other costs or be required to make significant changes to our operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care industry is heavily regulated and we are subject to many laws and regulations at the federal, state and local government levels in the markets in which we operate. These laws and regulations require that our facilities meet various licensing, accreditation, certification and other requirements, including, but not limited to, those relating to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">ownership and control of our facilities; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">operating policies and procedures; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">qualification, training and supervision of medical and support persons; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">pricing of, billing for and coding of services and properly handling overpayments, debt collection practices and the submission of false statements or claims; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the necessity, appropriateness and adequacy of medical care, equipment, personnel, operating policies and procedures; maintenance and preservation of medical records; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">financial arrangements between referral sources and our facilities; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the protection of privacy, including patient and credit card information; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">screening, stabilization and transfer of individuals who have emergency medical conditions and provision of emergency services; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">antitrust; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">building codes; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">workplace health and safety; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">licensure, certification and accreditation; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">fee-splitting and the corporate practice of medicine; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">handling of medication; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">confidentiality, data breach, identity theft and maintenance and protection of health-related and other personal information and medical records; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">environmental protection, health and safety. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we fail to comply with applicable laws and regulations, we could subject ourselves to administrative, civil or criminal penalties, cease and desist orders, forfeiture of amounts owed and recoupment of amounts paid to us by governmental or commercial payors, loss of licenses necessary to operate and disqualification from Medicare, Medicaid and other government-sponsored health care programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Many of these laws and regulations have not been fully interpreted by regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. Different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or require us to make changes in our operations, facilities, equipment, personnel, services, capital expenditure programs or operating expenses to comply with the evolving rules. Any enforcement action against us, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A number of initiatives have been proposed during the past several years to reform various aspects of the health care system in the U.S. In the future, different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses. In addition, some of the governmental and regulatory bodies that regulate us are considering or may in the future consider enhanced or new regulatory requirements. These authorities may also seek to exercise their supervisory or enforcement authority in new or more robust ways. All of these possibilities, if they occurred, could detrimentally affect the way we conduct our business and manage our capital, either of which, in turn, could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We cannot predict the effect that health care reform and other changes in government programs may have on our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Affordable Care Act has changed and continues to change how health care services are covered, delivered and reimbursed through, among other things, expanded coverage of uninsured individuals, reduced growth in Medicare program spending and the establishment and expansion of programs tying reimbursement to quality and clinical integration. The Affordable Care Act also reforms certain aspects of health insurance, quality of care and fraud and abuse enforcement. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Substantial uncertainty remains regarding the net effect of the Affordable Care Act on our business because the long-term impact of a number of factors, including the following, remains unclear:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the responses of individuals, businesses and other market participants to the evolving choices and obligations under the Affordable Care Act;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the states&#8217; decisions whether to implement the Medicaid expansion provisions of the Affordable Care Act, and under what terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the effect of value-based purchasing and other quality programs established under the Affordable Care Act;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the scope and nature of changes to Medicare reimbursement methods and programs, including accountable care organizations, bundled payment programs and other coordinated care models;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the financial sustainability of the Health Insurance Marketplace, which may be impacted by whether a sufficient number of payors participate;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">our ability to participate in health insurance plans offered through the Health Insurance Marketplaces and the terms of our participation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the net effect of reductions in federal health care program spending under the Affordable Care Act; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the resolution of new and ongoing legislative and legal challenges to the Affordable Care Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of the enactment of the Tax and Jobs Act of 2017, the tax penalty for failure to comply with the "individual mandate" was reduced to zero as of calendar year 2019, effectively repealing the mandate itself. The reduction to zero of the individual mandate tax penalty and any other future repeal or replacement of the Affordable Care Act or any component thereof may have significant impact on the reimbursement for health care services generally, and may cause more individuals to become uninsured, rendering them unable to afford health care services offered by the Company. In addition to proposed legislative changes to the Affordable Care Act, there remains ongoing litigation seeking to repeal the Affordable Care Act in whole or in part. The U.S. Supreme Court recently agreed to hear a case that seeks to invalidate the Affordable Care Act, but it will not issue an opinion until 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Initiatives to repeal the Affordable Care Act, in whole or in part, and to offer amendments or supplements to modify its provisions have been persistent and increased as a result of the 2016 election; however, the results of the 2020 election substantially reduce the likelihood of any successful attempt to repeal the law within the next two years.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of the many variables involved, we are unable to predict the net effect of the Affordable Care Act and other associated changes within the health care industry on us or our operations. Depending on how the Affordable Care Act continues to be interpreted, implemented or changed, it could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If laws governing the corporate practice of medicine or fee-splitting change, we may be required to restructure some of our relationships, which may result in a significant loss of revenue and divert other resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The laws of various states in which we operate or may operate in the future do not permit business corporations to practice medicine, to exercise control over or employ physicians who practice medicine or to engage in various business practices, such as fee-splitting with physicians (i.e., sharing in a percentage of professional fees). The interpretation and enforcement of these laws vary significantly from state to state. We provide management services to a network of physicians. If our arrangements with this network were deemed to violate state corporate practice of medicine, fee-splitting or similar laws, or if new laws are enacted rendering our arrangements illegal, we may be subject to civil and/or criminal penalties and could be required to restructure or terminate these arrangements, any of which may result in a significant loss of revenue and divert management and business resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If regulations change, we may be obligated to purchase some or all of the ownership of our physician partners or renegotiate some of our partnership and operating agreements with our physician partners and management agreements with surgical facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Upon the occurrence of various fundamental regulatory changes or changes in the interpretation of existing regulations, we may be obligated to purchase all of the ownership of the physician investors in most of the partnerships or limited liability companies that own and operate our surgical facilities and/or hospitals. The purchase price that we would be required to pay for the ownership is specified in our partnership agreements and is typically based on either a multiple of the surgical facility&#8217;s EBITDA, as defined in our partnership and operating agreements with these surgical facilities and hospitals, or the fair market value of the ownership as determined by a third-party appraisal. The physician investors in some of our surgical facilities and hospitals can require us to purchase their interests in exchange for cash or shares of our common stock if these regulatory changes occur. In addition, some of our partnership agreements with our physician partners and management agreements with surgical facilities and hospitals require us to attempt to renegotiate the agreements upon the occurrence of various fundamental regulatory changes or changes in the interpretation of existing regulations and provide for termination of the agreements if renegotiations are not successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory changes that could create purchase or renegotiation obligations include changes that:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">make illegal the referral of Medicare or other patients to our surgical facilities and hospitals by physician investors;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">create a substantial likelihood that cash distributions to physician investors from the partnerships or LLCs through which we operate our surgical facilities and hospitals would be illegal;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">make illegal the ownership by the physician investors of interests in the partnerships or LLCs through which we own and operate our surgical facilities and hospitals; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">require us to reduce the aggregate percentage of physician investor ownership in our hospitals.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We do not control whether or when any of these regulatory events might occur. In the event we are required to purchase all of the physicians&#8217; ownership, our existing capital resources would not be sufficient for us to meet this obligation. These obligations and the possible termination of our partnership and management agreements would have a material adverse effect on our financial condition and results of operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our surgical facilities do not satisfy the requirements for any of the safe harbors under the federal Anti-Kickback Statute. If a federal or state agency asserts a different position or enacts new laws in this regard, we could be subject to criminal and civil penalties, loss of licenses and exclusion from governmental programs, which may result in a substantial loss of revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Anti-Kickback Statute prohibits the offer, payment, solicitation or receipt of any form of remuneration in return for referrals for items or services payable by Medicare, Medicaid, or any other federally funded health care program. Our exclusion from participation in all federally funded health care programs as a result of a violation of the Anti-Kickback Statute would have a material adverse effect on our business, prospects, results of operations and financial condition. In addition, many of the states in which we operate have also adopted laws, similar to the Anti-Kickback Statute, that prohibit payments to physicians in exchange for referrals, some of which apply regardless of the source of payment for care. These statutes typically impose criminal and civil penalties, including the loss of a license to do business in the state.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The "Investment Interest" safe harbor and the "Personal Services and Management Contracts" safe harbor apply to business arrangements similar to those used in connection with our surgical facilities. However, the structure of the partnerships and limited liability companies operating our surgery centers and surgical hospitals, as well as our various business arrangements involving physician group practices, do not satisfy all of the requirements of either safe harbor. We have entered into management agreements to manage the majority of our surgical facilities.&#160;Most of these agreements call for our subsidiary to be paid a percentage-based management fee. Because our management fees are generally based on a percentage of revenue, our management agreements do not typically meet the Personal Services and Management Contracts safe harbor.&#160;We have implemented formal compliance programs designed to safeguard against overbilling and believe that our management agreements comply with the requirements of the Anti-Kickback Statute.&#160;However, we cannot assure you that the OIG would find our compliance programs to be adequate or that our management agreements would be found to comply with the Anti-Kickback Statute.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The surgery center safe harbor protects four types of investment arrangements: (1) surgeon owned surgery centers; (2) single specialty surgery centers; (3) multi-specialty surgery centers; and (4) hospital/physician surgery centers. In addition to the physician investor, the categories permit an "unrelated" investor, who is a person or entity that is not in a position to provide items or services related to the surgery center or its investors. Our business arrangements with our surgical facilities typically consist of one of our subsidiaries being an investor in each partnership or limited liability company that owns the facility, in addition to providing management and other services to the facility. Therefore, our business arrangements with our surgery centers, surgical hospitals and physician groups do not qualify for the expanded safe harbor protection from government review or prosecution under the Anti-Kickback Statute. However, we believe that we are in compliance with the requirements of the Anti-Kickback Statute.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We employ dedicated marketing personnel whose job functions include the recruitment of physicians to perform surgery at our facilities. These employees are paid a base salary plus a productivity bonus. We believe our employment arrangements with these employees are consistent with a safe harbor provision designed to protect payments made to employees. However, a government agency or private party may assert a contrary position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also enter into lease agreements with physicians from time to time for the rental of space for our surgical facilities. We seek to structure these lease agreements so that they are in compliance with the Anti-Kickback Statute safe harbor provision regarding real estate leases. However, a government agency or private party may assert a contrary position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If any of our business arrangements with physicians or sales and marketing personnel were alleged or deemed to violate the Anti-Kickback Statute or similar laws, or if new federal or state laws were enacted rendering these arrangements illegal, it could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">In addition to the physician ownership in our surgical facilities, other financial relationships of ours with potential referral sources could potentially be scrutinized under the Anti-Kickback Statute.&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of our ASCs have entered into arrangements for professional services, including arrangements for anesthesia services.&#160;The OIG scrutinizes certain arrangements it deems to be &#8220;suspect Contractual Joint Ventures,&#8221; including arrangements between anesthesiologists and physician owners of ASCs.&#160;We believe our arrangements for anesthesia services are distinguishable from those described in Advisory Opinion 12-06 (May&#160;25, 2012) and are in compliance with the requirements of the federal Anti-Kickback Statute.&#160;However, we cannot assure you that regulatory authorities would agree with that position.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Eliminating Kickbacks in Recovery Act may affect our financial relationships with referral sources utilizing our clinical laboratories</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the Anti-Kickback Statute, the U.S. recently enacted a new law known as the Eliminating Kickbacks in Recovery Act, or the EKRA, discussed in greater detail above. While the EKRA does contain certain exceptions similar to the Anti-Kickback Statute Safe Harbors, those exceptions are more narrow than the Anti-Kickback Statute Safe Harbors. As a result, the operations at our clinical laboratories may be impacted by the EKRA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we fail to comply with physician self-referral laws as they are currently interpreted or may be interpreted in the future, or if other legislative restrictions are issued, we could incur substantial monetary penalties and a significant loss of revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Stark Law prohibits certain self-referrals for health care services unless an exception applies. Under the current Stark Law and related regulations, services provided at an ASC are not covered by the statute, even if those services include imaging, laboratory services or other Stark designated health services, provided that (i) the ASC does not bill for these services separately, or (ii) if the center is permitted to bill separately for these services, they are specifically exempted from Stark Law prohibitions. These are generally radiology and other imaging services integral to performance of surgical procedures that meet certain requirements and certain outpatient prescription drugs. Services provided at our facilities licensed as hospitals are covered by the Stark Law. We attempt to structure our relationship with physicians who refer to our hospitals to meet an exception to the Stark Law where required, but the regulations implementing the exceptions are detailed and complex, and we cannot guarantee that every relationship complies fully with the Stark Law. We also believe that certain services provided by our managed physician network are covered by the Stark Law, but referrals for those services are exempt from the Stark Law under its "in-office ancillary services exception," among others.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Violations of these self-referral laws may result in substantial civil or criminal penalties, including treble damages for amounts improperly claimed, civil monetary penalties of up to $15,000 per prohibited service billed, up to $100,000 per prohibited circumvention scheme and exclusion from participation in the Medicare and Medicaid and other federal and state health care programs. Violations of the Stark Law will also create liability under the federal False Claims Act. Exclusion of our ASCs or hospitals from these programs through judicial or agency interpretation of existing laws or additional legislative restrictions on physician ownership or investments in health care entities could result in a significant loss of reimbursement revenue. We cannot provide assurances that CMS will not undertake other rulemaking to address additional revisions to or interpretations of the Stark Law regulations. If future rules modify the provisions of the Stark Law regulations that are applicable to our business, our revenue and profitability could be materially adversely affected and could require us to modify our relationships with our physician and health care system partners.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Federal law restricts the ability of our surgical hospitals to expand surgical capacity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Affordable Care Act dramatically curtailed the Whole Hospital Exception and prohibits physician ownership in hospitals that did not have a Medicare provider agreement by December 31, 2010. As a result, the law effectively prevents the formation of new physician-owned hospitals that participate in Medicare and Medicaid after December 31, 2010. Each of our surgical hospitals had a Medicare provider agreement in place prior to December 31, 2010 and is therefore able to continue operating with the ownership structure that was in place prior to December 30, 2010. However, the Affordable Care Act prohibits "grandfathered" hospitals from increasing their percentage of physician ownership, and it limits to a certain extent their ability to grow, because it prohibits such hospitals from increasing the aggregate number of inpatient beds, operating rooms and procedure rooms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Companies within the health care industry, including us, continue to be the subject of federal and state audits and investigations, including actions for false and other improper claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state government agencies, as well as commercial payors, have increased their auditing and administrative, civil and criminal enforcement efforts as part of numerous ongoing investigations of health care organizations. These audits and investigations relate to a wide variety of topics, including the following: cost reporting and billing practices; quality of care; financial reporting; financial relationships with referral sources; and medical necessity of services provided. In addition, the OIG and the U.S. Department of Justice ("DOJ") have, from time to time, undertaken national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. In its 2013 Work Plan, the OIG stated its intention to review the safety and quality of care for Medicare beneficiaries having surgeries and procedures in ASCs and hospital outpatient departments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The federal government may impose criminal, civil and administrative penalties on any person or entity that files a false claim for payment from the Medicare or Medicaid programs and other federal and state health care programs. Claims filed with private insurers can also lead to criminal and civil penalties, including, but not limited to, penalties relating to violations of federal mail and wire fraud statutes, as well as penalties under the anti-fraud provisions of the HIPAA. While the criminal statutes are generally reserved for instances of fraudulent intent, the federal government is applying its criminal, civil and administrative penalty statutes in an ever-expanding range of circumstances, including claiming payment for unnecessary services if the claimant merely should have known the services were unnecessary and claiming payment for low-quality services if the claimant should have known that the care was substandard. In addition, a violation of the Stark Law or the Anti-Kickback Statute can result in liability under the federal False Claims Act (the "FCA").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Over the past several years, the federal government has investigated an increasing number of health care providers for potential FCA violations, which, among other things, prohibits a person from knowingly presenting, or causing to be presented, a false or fraudulent claim to the federal government. The statute defines "knowingly" to include not only actual knowledge of a claim&#8217;s falsity, but also reckless disregard for or intentional ignorance of the truth or falsity of a claim. Violators of the FCA are subject to severe financial penalties, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">including treble damages and per claim penalties in excess of $10,000. Because our facilities perform hundreds or thousands of similar procedures each year for which they are paid by Medicare, and since the statute of limitations for such claims extends for six years under normal circumstances (and possibly as long as ten years in the event of failure to discover material facts), a repetitive billing error or cost reporting error could result in significant, material repayments and civil or criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Moreover, another trend impacting health care providers is the increased use of the FCA, particularly by individuals who bring actions under that law. Under the "qui tam," or whistleblower, provisions of the FCA, private parties may bring actions on behalf of the federal government. If the government intervenes and prevails in the action, the defendant may be required to pay three times the actual damages sustained by the government, plus mandatory civil monetary penalties of between $11,665 and $23,351 for each false claim submitted to the government. These private parties, often referred to as relators, are entitled to share in any amounts recovered by the government through trial or settlement. Both direct enforcement activity by the government and whistleblower lawsuits under the FCA have increased significantly in recent years; thus, the risk that we will have to defend a false claims action, pay significant fines or be excluded from the Medicare and Medicaid programs has increased.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the Fraud Enforcement and Recovery Act of 2009 ("FERA") further expanded the scope of the FCA to create liability for knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government and FERA, along with statutory provisions found in the Acts, created federal False Claims Act liability for the knowing failure to report and return an overpayment within 60 days of the identification of the overpayment or, in certain cases, the date by which a corresponding cost report is due, whichever is later. Governmental authorities have and may continue to challenge or scrutinize our operations. An allegation or determination that we have violated the law could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HIPAA also created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $11,665 for each wrongful act. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil False Claims Act, which can impose additional penalties associated with the wrongful act. Although this prohibition applies only to federal health care program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payors may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent our patient assistance programs or other discount policies are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To enforce compliance with the federal laws, the DOJ has increased its scrutiny of interactions between health care companies and health care providers, which has led to a number of investigations, prosecutions, convictions and settlements in the health care industry. Dealing with investigations can be time and resource consuming and can divert management&#8217;s attention from the business. In addition, settlements with the DOJ or other law enforcement agencies have forced health care providers to agree to additional compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are also subject to various state laws and regulations, as well as contractual provisions with commercial payors that prohibit us from submitting inaccurate, incorrect or misleading claims. We cannot be sure that none of our surgical facilities&#8217; claims will ever be challenged. If we were found to be in violation of a state&#8217;s laws or regulations, or of a commercial payor contract, we could be forced to discontinue the violative practice and be subject to recoupment actions, fines and criminal penalties, which could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All payors are increasingly conducting post-payment audits. For example, CMS has implemented the RAC program, involving Medicare claims audits nationwide, and employs MICs to perform post-payment audits of Medicaid claims and identify overpayments. In addition to RACs and MICs, the state Medicaid agencies and other contractors have increased their review activities. We are regularly subject to these external audits and we also perform both internal and third-party audits and monitoring.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although all other repayments requested to date as a result of RAC, MIC and ZPIC audits have not been material to our Company, we are unable to quantify the suspended payments and aggregate financial impact of these audits on our facilities given the pending appeals and uncertainty about the extent of future audits and whether the underlying conduct could be considered systemic. As such, the resolution of these audits could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 23, 2017, the Company received a series of civil investigative demands ("CIDs") from the federal government under the FCA for documents and information dating back to January 1, 2010 relating to the medical necessity of certain drug tests conducted by the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company&#8217;s physicians and submitted to laboratories owned and operated by the Company. In addition, the Company was informed by CMS that payments to its diagnostic laboratory, Logan Laboratories, were suspended for a period of time, pending further investigations by CMS. CMS lifted the suspension as of December 18, 2019. On January 23, 2020, the U.S. District Court for the Middle District of Florida unsealed the Complaint in the case of Cho et al. ex rel. United States v. Surgery Partners et al., which we understand to be related to the investigation that gave rise to the CIDs. On April 14, 2020, the Company entered into a settlement agreement (the "Settlement Agreement") with the United States of America, acting through the DOJ. Under the terms of the Settlement Agreement, the Company still owes payment of $30.7&#160;million plus accrued interest as of April 1, 2021. For additional information, please refer to Note 14. "Commitments and Contingencies" to our audited financial statements included elsewhere in the report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We may become involved in litigation which could negatively impact the value of our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time-to-time we are involved in lawsuits, claims, audits and investigations, including those arising out of services provided, personal injury claims, professional liability claims, billing and marketing practices, employment disputes and contractual claims. We may become subject to future lawsuits, claims, audits and investigations that could result in substantial costs and divert our attention and resources and adversely affect our business condition. In addition, since our current growth strategy includes acquisitions, among other things, we may become exposed to legal claims for the activities of an acquired business prior to our acquisition of such business. These lawsuits, claims, audits or investigations, regardless of their merit or outcome, may also adversely affect our reputation and ability to expand our business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, from time to time we have received, and expect to continue to receive, correspondence from former employees terminated by us who threaten to bring claims against us alleging that we have violated one or more labor and employment regulations. In certain instances former employees have brought claims against us and we expect that we will encounter similar actions against us in the future. An adverse outcome in any such litigation could require us to pay contractual damages, compensatory damages, punitive damages, attorneys&#8217; fees and costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If we become subject to large malpractice or other legal claims, we could be required to pay significant damages, which may not be covered by insurance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In recent years, physicians, hospitals and other health care providers have become subject to an increasing number of legal actions alleging malpractice, product liability or related legal theories. Many of these actions involve large monetary claims and significant defense costs. We also owe certain defense and indemnity obligations to our officers and directors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our insurance coverage may not cover all claims against us, or insurance coverage may not continue to be available at a cost allowing us to maintain adequate levels of insurance. If one or more successful claims against us were not covered by or exceeded the coverage of our insurance, our financial condition and results of operations could be adversely affected. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay damages or defense costs in connection with a claim that is outside the scope or limits of coverage of any applicable insurance coverage, including claims related to adverse patient events, contractual disputes, professional and general liability, and directors&#8217; and officers&#8217; duties. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, market rates for insurance premiums and deductibles have been steadily increasing. Our earnings and cash flows could be materially and adversely affected by any of the following: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the collapse or insolvency of our insurance carriers; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">further increases in premiums and deductibles; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; or </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an inability to obtain one or more types of insurance on acceptable terms, if at all. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Failure to comply with Medicare&#8217;s conditions for coverage and conditions of participation may result in loss of program payment or other governmental sanctions. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To participate in and receive payment from the Medicare program, our facilities must comply with regulations promulgated by CMS. These regulations, known as "conditions for coverage" for ASCs and "conditions of participation" for hospitals, set forth specific requirements with respect to, among other things, the facility&#8217;s physical plant, equipment, personnel and standards of medical care. All of our surgery centers and surgical hospitals are certified to participate in the Medicare program. As such, these facilities are subject to on-site, unannounced surveys by state survey agencies working on behalf of CMS, which may lead to deficiency citations requiring remedy with appropriate action plans. Failure to comply with Medicare&#8217;s conditions for coverage or conditions of participation may result in loss of payment or other governmental sanctions, including termination from participation in the Medicare program. We have established ongoing quality assurance activities to monitor our facilities&#8217; compliance with these conditions and respond to surveys, but we cannot be sure that our facilities are or will always remain in full compliance with the requirements. In addition, pending a determination regarding our compliance with these conditions, payment to us may be suspended and we may be required to devote significant time, effort and expense to demonstrate satisfactory compliance.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our facilities could face decreased Medicare payments if they fail to report and meet various quality metrics.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Medicare program presently requires hospitals and ASCs to report performance data on a variety of quality metrics. Facilities that fail to report are penalized with reduced Medicare payments. Additionally, payments to hospitals are adjusted based on the hospital&#8217;s performance on these quality measures. A substantial portion of hospital payment is at risk depending on its individual performance relative to benchmarks and other hospitals&#8217; performance. There is a substantial risk that our Medicare payments could be reduced if our hospitals fail to perform adequately on these measures. Additionally, there is a risk that Medicare payments could be reduced if our facilities (hospitals and ASCs) fail to adequate report data as required by CMS. ASC payments are not yet adjusted based on performance against quality measures, but there is a substantial risk that Congress may soon link ASC Medicare payments to actual performance, in addition to reporting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the public performance data becomes a primary factor in determining where patients choose to receive care, and if competing hospitals and ASCs have better results than our facilities on those measures, our patient volumes could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">State efforts to regulate the construction, acquisition or expansion of health care facilities could prevent us from acquiring additional surgical facilities, renovating our existing facilities or expanding the breadth of services we offer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some states require prior approval for the construction, acquisition or expansion of health care facilities or expansion of the services the facilities offer. In giving approval, these states consider the need for additional or expanded health care facilities or services, as well as the financial resources and operational experience of the potential new owners of existing health care facilities. In many of the states in which we currently operate, certificates of need must be obtained for capital expenditures exceeding a prescribed amount, changes in capacity or services offered and various other matters. The remaining states in which we now or may in the future operate may adopt similar legislation. Our costs of obtaining a certificate of need could be significant, and we cannot assure you that we will be able to obtain the certificates of need or other required approvals for additional or expanded surgical facilities or services in the future. In addition, at the time we acquire a surgical facility, we may agree to replace or expand the acquired facility. If we are unable to obtain required approvals, we may not be able to acquire additional surgical facilities, expand health care services we provide at these facilities or replace or expand acquired facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">If antitrust enforcement authorities conclude that our market share in any particular market is too concentrated, that our or our health system partners&#8217; commercial payor contract negotiating practices are illegal, or that we other violate antitrust laws, we could be subject to enforcement actions that could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The federal government and most states have enacted antitrust laws that prohibit certain types of conduct deemed to be anti-competitive. These laws prohibit price fixing, concerted refusal to deal, market monopolization, price discrimination, tying arrangements, acquisitions of competitors and other practices that have, or may have, an adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties. Antitrust enforcement in the health care industry is currently a priority of the Federal Trade Commission (the "FTC"). We believe we are in compliance with federal and state antitrust laws, but courts or regulatory authorities may reach a determination in the future that could have a material adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governance Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">We are a "controlled company" within the meaning of Nasdaq rules and, therefore, we qualify for, and currently rely on, exemptions from certain corporate governance requirements. Our stockholders do not have the same protections afforded to stockholders of companies that are subject to such requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Bain Capital controlled a majority of the voting power of our outstanding common stock. As a result, we are a "controlled company" within the meaning of the corporate governance standards of Nasdaq. Under these rules, a company of which more than a majority of the voting power is held by an individual, group or another company is a "controlled company" and may elect not to comply with certain corporate governance requirements including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">the requirement that a majority of the board of directors consist of independent directors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">the requirement that we have a nominating/corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">the requirement that we have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have availed ourselves of certain of these exemptions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For example, we did not have a majority of independent directors for the entire period covered by this report (and may, in the future, have less than a majority of independent directors) and we do not have a nominating and corporate governance committee. Accordingly, our stockholders will not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There can be no assurance as to the period of time during which we will remain a "controlled company".</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our controlling stockholder has significant influence over us, including control over decisions that require the approval of stockholders, which could limit our stockholders&#8217; ability to influence the outcome of key transactions, including a change of control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of the date of this filing we were controlled by Bain Capital, which beneficially owned approximately 60% of our outstanding common stock. For as long as Bain Capital continues to control a majority of the voting power of our common stock, it will be able to direct the election of all of the members of our board of directors and could exercise a controlling influence over our business and affairs, including any determinations with respect to mergers or other business combinations, the acquisition or disposition of assets, the incurrence of indebtedness, the issuance of any additional common stock or other equity securities, the repurchase or redemption of common stock and the payment of dividends. Similarly, Bain Capital will have the power to determine matters submitted to a vote of our stockholders without the consent of our other stockholders, will have the power to prevent a change in our control and could take other actions that might be favorable to it. Even if Bain Capital ceases to beneficially own a majority of the voting power of our common stock, it will continue to be able to strongly influence or effectively control our decisions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provisions in the certificate of designation governing our preferred stock and in our charter documents and Delaware law may deter takeover efforts that could be beneficial to stockholder value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our certificate of incorporation and by-laws, the certificate of designation governing our preferred stock and Delaware law contain provisions that could make it harder for a third party to acquire us, even if doing so might be beneficial to our stockholders. The provisions in our organizational documents include a classified board of directors and limitations on actions by our stockholders. In addition, our board of directors has the right to issue additional preferred stock without stockholder approval that could be used to dilute a potential hostile acquiror. Our certificate of incorporation also imposes some restrictions on mergers and other business combinations between us and any holder of 15.0% or more of our outstanding common stock other than affiliates of Bain Capital. Finally, our 10% Series A Convertible Perpetual Participating Preferred Stock accrues conversion value for each quarter it is outstanding and is subject, under certain circumstances, to a redemption premium, which could significantly increase the cost to a potential acquirer of buying all of the outstanding securities of the Company. As a result of these features, our stockholders may lose their ability to sell their stock for a price in excess of the prevailing market price, and efforts by stockholders to change the direction or management of the Company may be unsuccessful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation (the "Certificate of Incorporation") provides that, subject to certain exceptions and to the fullest extent permitted by applicable law, the Court of Chancery of the State of Delaware (the "Court of Chancery") will be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware, our Certificate of Incorporation or our amended and restated bylaws or (iv) any other action asserting a claim against us that is governed by the internal affairs doctrine (each, a "Covered Proceeding"). In addition, the Certificate of Incorporation states that this exclusive forum provision does not apply to actions in which the Court of Chancery concludes that an indispensable party is not subject to the jurisdiction of the Delaware courts and can be subject to the jurisdiction of another court within the U.S. Our Certificate of Incorporation also provides that if any action, the subject matter of which is a Covered Proceeding, is filed in a court other than the specified Delaware courts without the approval of our board of directors (each, a "Foreign Action"), the claiming party will be deemed to have consented to (i) the personal jurisdiction of the specified Delaware courts in connection with any action brought in any such courts to enforce the exclusive forum provision described above and (ii) having service of process made upon such claiming party in any such enforcement action by service upon such claiming party&#8217;s counsel in the Foreign Action as agent for such claiming party. It is our current view that in some circumstances, such as in respect of actions arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Court of Chancery may decline to exercise jurisdiction over such actions. Under such circumstances, our Certificate of Incorporation holds that such actions may properly be filed in a court other than the Court of Chancery. Any person or entity purchasing or otherwise acquiring any interest in shares of our stock shall be deemed to have notice of and to have consented to these provisions in our Certificate of Incorporation. These provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_25"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Brentwood, Tennessee, where we currently lease approximately 85,000 square feet of office space pursuant to an agreement with an initial term expiring December 31, 2027. Our surgical facilities typically are located on real estate leased by the partnership or limited liability company that operates the facility.&#160;Most of our ASC facilities range in size from 8,000 to 12,000 square feet, and are specifically tailored to meet the needs of physician-partners and their specialties. Of our 127 surgical facilities, 123 utilize leased real property. These leases generally have initial terms of ten years, but range from 2 to 15 years.&#160;Most of the leases contain options to extend the lease period for up to ten additional years. We generally guarantee the lease obligations of the partnerships and limited liability companies that own our surgical facilities. We expect to be able to renew or replace a substantial majority of these leases on substantially similar terms as they come due. We believe these spaces are sufficient and adequate for our needs at this time.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_28"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.  On December 4, 2017, a purported Company stockholder filed an action in the Delaware Court of Chancery (the "Delaware Action"). That action is captioned Klein v. H.I.G. Capital, L.L.C., et al., C.A. No. 2017-0862. The plaintiff in the Delaware Action asserted claims against (i) certain current and former members of the Company&#8217;s Board of Directors (together, the "Directors"); (ii) H.I.G. Capital, LLC and certain of its affiliates (collectively, the "H.I.G. Parties"); and (iii) Bain Capital Private Equity, L.P. and certain of its affiliates (collectively, "Bain Capital" and, together with the Directors and the H.I.G. Parties, the "Defendants"). The plaintiff asserted derivative claims on behalf of the Company, which is a nominal defendant in the Delaware Action, as well as putatively direct claims on behalf of a purported class of Company stockholders. The plaintiff in the Delaware Action asserted that the Defendants breached their fiduciary duties in connection with the transactions in which (i) the Company acquired National Surgical Healthcare; (ii) Bain Capital acquired preferred equity in the Company; and (iii) Bain Capital acquired H.I.G.'s equity stake in the Company, and that, in the alternative, Bain Capital aided and abetted those purported breaches. The plaintiff also asserted an unjust enrichment claim against Bain Capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 2, 2018, the Defendants moved to dismiss the plaintiff&#8217;s complaint. On December 19, 2018, the Court of Chancery issued a decision on that motion. Following that decision, all of the Directors have been dismissed from the Delaware Action. The Court did not dismiss the plaintiff&#8217;s breach of fiduciary duty claim against the H.I.G. Parties or the aiding and abetting claim asserted against Bain Capital. However, the Court dismissed the plaintiff&#8217;s breach of fiduciary duty and unjust enrichment claims against Bain Capital. In addition, the Court dismissed all of the plaintiff&#8217;s claims that were asserted on behalf of a putative class of Company stockholders. Accordingly, all of the plaintiff&#8217;s remaining claims in the Delaware Action are asserted derivatively on the Company&#8217;s behalf. The plaintiff has continued to pursue those derivative claims, and the parties to the Delaware Action are engaged in discovery.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Litigation.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, we are, from time to time, subject to claims and suits, or threats of claims or suits, relating to our business, including claims for damages for personal injuries, breach of management contracts and employment related claims. In certain of these actions, plaintiffs request payment for damages, including punitive damages, which may not be covered by insurance or may otherwise have a material adverse effect on our business or results of operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 14. "Commitments and Contingencies" for additional information.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_31"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_37"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Market Information for Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our common stock trades under the symbol "SGRY" on the Nasdaq Global Select Market.&#160;</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stockholders</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;3, 2021, there were 132 holders of record of our common stock.&#160;The actual number of common stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.&#160;This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have never declared or paid a cash dividend on our common stock, and have no current plans to declare or pay any cash dividends for the foreseeable future.&#160;Any decision to declare and pay dividends in the future will be made at the discretion of our Board of Directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our Board of Directors may deem relevant. In addition, our ability to pay dividends may be limited by covenants of our existing and future outstanding indebtedness we or our subsidiaries incur, including our credit facility. Additionally, because we are a holding company, we would depend on distributions from our subsidiaries to fund any potential dividends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following graph compares the cumulative total shareholder return on our common stock with the cumulative total returns of the Nasdaq Composite Index and the Dow Jones U.S. Health Care Providers Index. The graph begins on December 31, 2015, and the comparison assumes $100 was invested in our common stock and in each of the indices on such date and assumes the reinvestment of dividends, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><img src="sgry-20201231_g1.jpg" alt="sgry-20201231_g1.jpg" style="height:342px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"/></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12/31/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12/31/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nasdaq Composite Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dow Jones U.S. Health Care Providers Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This graph is furnished and not filed with the SEC, is not soliciting material under the Exchange Act and shall not be incorporated by reference into any such filings, irrespective of any general incorporation contained in such filing. The stock performance shown on the graph represents historical stock performance and is not necessarily indicative of future stock price performance.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recent Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 15, 2017, our Board of Directors authorized a share repurchase program of up to $50.0 million of our issued and outstanding common stock from time to time. The timing and size of repurchases will be determined based on market conditions and other factors. The authorization does not obligate us to repurchase any shares and we may repurchase shares of common stock at any time without prior notice. The share repurchases will be made in accordance with applicable securities laws in open market or privately negotiated transactions. The authorization does not have a specified expiration date, and the share repurchase program may be suspended, recommenced or discontinued at any time or from time to time without prior notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents information related to our repurchases of common stock for the periods indicated:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:47.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Number of Shares Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions, except per share amounts)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 1, 2020 to October 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 1, 2020 to November 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2020 to December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or vesting of stock awards. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6. Selected Financial Data</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_43"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties.&#160;For additional information regarding certain of the risks and uncertainties that affect our business and the industry in which we operate, please see Item 1A. "Risk Factors" and Item 9A. "Controls and Procedures" found elsewhere in this report.&#160;Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries. Unless the context implies otherwise, the term "affiliates" means direct and indirect subsidiaries of Surgery Partners, Inc., and partnerships and joint ventures in which such subsidiaries are partners. The terms "facilities" or "hospitals" refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term "employees" refers to employees of affiliates of Surgery Partners, Inc.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_46"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we owned or operated, primarily in partnership with physicians, a portfolio of 127 surgical facilities comprised of 110 ASCs and 17 surgical hospitals across 30 states.&#160;We owned a majority interest in 84 of the surgical facilities and consolidated 107 of these facilities for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenues for 2020 increased 1.6% to&#160;$1.9 billion&#160;from&#160;$1.8 billion&#160;in 2019. Same-facility revenues for 2020 decreased 1.1% from 2019, with a 14.1% increase in revenue per case and a 13.3% decrease in same-facility cases. The decrease in same-facility cases is attributable to the impacts of the COVID-19 pandemic that the Company began experiencing in mid-March, and extending into the fourth quarter. Same-facility revenue per case growth was driven by a favorable surgical case mix as we experienced a faster recovery of higher acuity cases as states began to re-open and allow for non-emergent procedures. For 2020, the net loss attributable to common stockholders was&#160;$155.6 million&#160;compared to $110.5 million&#160;for 2019. Additionally, for 2020, Adjusted EBITDA decreased 0.8% to&#160;$256.6 million&#160;compared to&#160;$258.6 million&#160;for 2019. A reconciliation of non-GAAP financial measures appears below under "Certain Non-GAAP Measures."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continue to focus on improving our same-facility performance, selectively acquiring established facilities and developing new facilities. During the year ended December&#160;31, 2020, we acquired a controlling interest in three surgical facilities, including a surgical hospital, a controlling interest in five surgical facilities in existing markets, that were merged into existing facilities and a physician practice for total aggregate consideration of $120.1&#160;million, including cash consideration of $104.6&#160;million, net of cash acquired, non-cash consideration of $8.7 million and contingent consideration of $0.7 million. The non-cash consideration consisted of non-controlling interests in the Company's existing surgical facilities. The cash consideration was funded through cash from operations, proceeds from our recent divestitures and other available resources. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During 2020, we sold our interests in three surgery centers, one of which was previously accounted for as an equity method investment, sold certain assets related to our anesthesia business, certain imaging assets and our optical products purchasing organization for combined net cash proceeds of $59.0&#160;million. Additionally, we closed our diagnostic laboratory in 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We&#160;had cash and cash equivalents of&#160;$317.9 million&#160;and&#160;$112.5 million of borrowing capacity under our revolving credit facility at December&#160;31, 2020. Operating cash flows were $246.9 million in 2020, an increase of $117.4 million compared to the prior year, primarily attributable to Medicare accelerated payments and other funds received under the CARES Act as well as actions taken to significantly reduce operating expenses and defer non-essential capital expenditures at the height of the crisis. Net operating cash inflows, including operating cash flows less distributions to non-controlling interests, were&#160;$137.3 million for 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 global pandemic has significantly affected our facilities, employees, patients, communities, business operations and financial performance, as well as the U.S. economy and financial markets. The COVID-19 pandemic materially impacted our financial performance for the year ending December 31, 2020. The length and severity of the pandemic continues to be difficult to predict and is dependent on factors beyond our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continue to take or support measures to try to slow the spread and minimize the impact of the virus. Beginning mid-March, the COVID-19 pandemic began to negatively affect our net revenue and business operations. Due in part to local, state and federal guidelines as well as recommendations from major medical societies regarding social distancing and self-quarantines in response to the COVID-19 pandemic, we cancelled or postponed a substantial percentage of the elective procedures scheduled at our facilities and reduced operating hours at a significant number of our facilities. As a result, surgical case volumes across most of our surgical facilities were significantly impacted in the second quarter of 2020. The impact of the COVID-19 pandemic on our surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures typically performed. Although we cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic, surgical case volumes improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our operating structure naturally enables some flexibility in the cost structure according to the volume of surgical procedures performed, including much of its cost of revenues. In addition to the natural variability of these costs, the Company and its partners in the surgical facilities have undertaken additional steps to preserve financial flexibility. Beginning in mid-March, and into the second and third quarters, we took actions that included significantly reducing cash operating expenses and deferring non-essential expenditures at the height of the crisis. These measures were gradually reduced as surgical case volumes improved. On April 22, 2020, we entered into a second incremental term loan amendment providing for an incremental borrowing of $120.0 million, and on July 30, 2020, we issued an additional $115.0 million aggregate principal amount of 10.000% senior unsecured notes due 2027. See Note 5. "Long-Term Debt" to our consolidated financial statements included elsewhere in this report for a further discussion of the second incremental term loan amendment and the senior unsecured notes. Additionally, as a result of the CARES Act and other governmental assistance programs, during the year ended December 31, 2020, the Company received approximately $59&#160;million in direct grant funding and approximately $120 million in accelerated Medicare payments, each of which is described in more detail in Note 1. &#8220;Organization and Summary of Accounting Polices - COVID-19 Pandemic&#8221; to our consolidated financial statements included elsewhere in this report. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Even after taking into account our actions intended to increase financial flexibility (including actions that management estimates have lowered cash operating expenses), the volume reductions resulted in materially higher losses and material decreases in Adjusted EBITDA during 2020, and may potentially continue to do so for subsequent quarters. We cannot predict if or when utilization may return to pre-pandemic levels.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is continuing to monitor legislative actions at federal and state levels, including the impact of the CARES Act and other governmental assistance that might be available.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, please see "Capital Resources" and "Summary" under the heading "Liquidity and Capital Resources" below for more information about the impact of the COVID-19 pandemic on the Company.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_49"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our Surgical Facility Services and Ancillary Services segments. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest and management services we provide to physician practices for which we are not required to provide capital or additional assets.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes revenues by service type as a percentage of total revenues: </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical services revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Payor Mix</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities that we consolidate for financial reporting purposes: </span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance payors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay payors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payors </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Surgical Case Mix</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the percentage of cases in each specialty performed at the surgical facilities that we consolidate for financial reporting purposes:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthopedics and pain management</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ophthalmology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gastrointestinal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our business is comprised of three segments: (1) Surgical Facility Services, (2) Ancillary Services and (3) Optical Services. On December 31, 2020, we sold the remaining assets of the Optical Services segment. For more information about the components of each segment, please see Part I, Item 1. Business--Operations included elsewhere in this Annual Report. "All other" primarily consists of the Company's corporate general and administrative functions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,793.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,748.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,771.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Adjusted EBITDA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash purchases of property and equipment, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment, net </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">For a reconciliation of Adjusted EBITDA to income before income taxes as reflected in the audited consolidated statements of operations see "Certain Non-GAAP Measures" below.</span></div><div style="margin-bottom:14pt;margin-top:14pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,962.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,580.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,413.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,018.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_55"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In preparing our consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles ("GAAP"), we must use estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures and the reported amounts of revenue and expenses.&#160;In general, our estimates are based on historical experience and various other assumptions we believe are reasonable under the circumstances.&#160;We evaluate our estimates on an ongoing basis and make changes to the estimates and related disclosures as experience develops or new information becomes known. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We consider our critical accounting policies to be those that involve significant judgments and uncertainties, and may potentially result in materially different results under different assumptions and conditions. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our patient service revenues are derived primarily from surgical procedures performed at our ASCs and surgical hospitals, patient visits to physician practices, anesthesia services provided to patients, pharmacy services and diagnostic screens ordered by our physicians. The fees for such services are billed either to the patient or a third-party payor, including Medicare and Medicaid. We recognize patient service revenues, net of contractual allowances, which we estimate based on existing contracts or the historical trend of our cash collections and contractual write-offs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to its sale on December 31, 2020, our optical products purchasing organization negotiated volume buying discounts with optical product manufacturers. The buying discounts and any handling charges billed to the members of the purchasing organization represented the revenues recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other service revenues consist of management and administrative service fees derived from non-consolidated surgical facilities that we account for under the equity method, management of surgical facilities in which we do not own an interest and management services we provide to physician networks for which we are not required to provide capital or additional assets.&#160;The fees we derive from these management arrangements are based on a predetermined percentage of the revenues of each surgical facility and physician network.&#160;We recognize other service revenues in the period in which services are rendered. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our patient service revenues and other receivables from third-party payors are recorded net of estimated implicit price concessions which are estimated based on the historical trend of our surgical hospitals&#8217; cash collections and contractual write-offs, and for our surgical facilities in general, established fee schedules, relationships with payors and procedure statistics.&#160;While changes in estimated reimbursement from third-party payors remain a possibility, we expect that any such changes would be minimal and, therefore, would not have a material effect on our financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account.&#160;The operating systems used to manage our patient accounts provide for an aging schedule in 30-day increments, by payor, physician and patient.&#160;We analyze accounts receivable at each of our surgical facilities to ensure the proper collection and aged category.&#160;The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts.&#160;Collection efforts include direct contact with insurance carriers or patients, written correspondence and the use of legal or collection agency assistance, as required. Our days sales outstanding was 69 days for the year ended December&#160;31, 2020 and 64 days for the year ended December&#160;31, 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We recognize that final reimbursement of outstanding accounts receivable is subject to final approval by each third-party payor.&#160;However, because we have contracts with our third-party payors and we verify the insurance coverage of the patient before services are rendered, the amounts that are pending approval from third-party payors are minimal.&#160;Amounts are classified outside of self-pay if we have an agreement with the third-party payor or we have verified a patient&#8217;s coverage prior to services rendered.&#160;It is our policy to collect co-payments and deductibles prior to providing services, where possible.&#160;It is also our policy to verify a patient&#8217;s insurance 72&#160;hours prior to the patient&#8217;s procedure.&#160;Because our services are primarily non-emergency, our surgical facilities have the ability to control these procedures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We use the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. If a NOL and/or interest limitation ("163(j)") carryforward exists, we make a determination as to whether that NOL and/or 163(j) carryforward will be utilized in the future. A valuation allowance will be established for certain NOL and 163(j) carryforwards and other deferred tax assets where their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets is based upon estimates and assumptions related to our ability to generate sufficient future taxable income in certain tax jurisdictions. If these estimates and related assumptions change in the future, we will be required to adjust our deferred tax valuation allowances. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had unused federal NOL carryforwards of approximately $615.7 million. Such losses expire in various amounts at varying times beginning in 2026. Unless they expire, these NOL carryforwards may be used to offset future taxable income and thereby reduce our income taxes otherwise payable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We recorded a valuation allowance against our deferred tax assets at December&#160;31, 2020 and 2019 totaling $91.1 million and $77.9 million, respectively. The valuation allowance has been established for certain deferred tax assets for which we believe it is more likely than not that the tax benefits will not be realized, which are primarily Section 163(j) interest carryforwards, certain state net operating losses and capital loss carryforwards. If our expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, we may need to adjust the valuation allowance, for all or a portion of our deferred tax assets. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code of 1986 ("Section 382"), as amended (the "Code") imposes an annual limit on the ability of a corporation that undergoes an "ownership change" to use its NOLs to reduce its tax liability. An "ownership change" is generally defined as any change in ownership of more than 50.0% of a corporation&#8217;s "stock" by its "5-percent shareholders" (as defined in Section 382) over a rolling three-year period based upon each of those shareholder&#8217;s lowest percentage of stock owned during such period. As a result of the Symbion acquisition in 2014, approximately $179 million in NOL carryforwards are subject to an annual Section 382 base limitation of $4.9 million, and, as a result of the NovaMed acquisition in 2011, approximately $17 million in NOL carryforwards are subject to an annual Section 382 base limitation of $4.9 million. As a result of the acquisition of NSH, approximately $20.5 million in NOL carryforwards are subject to an annual Section 382 base limitation of $2.8 million. The Private Sale resulted in an ownership change as defined in Section 382. As a result, approximately $485.9 million in NOL carryforwards are subject to an annual Section 382 base limitation of $14.2 million. At this time, we do not believe this limitation, when combined with amounts allowable due to net unrecognized built in gains, will affect our ability to use any NOLs before they expire. However, no such assurances can be provided. If our ability to utilize our NOLs to offset taxable income generated in the future is subject to this limitation, it could have an adverse effect on our business, prospects, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level, which is defined as one level below an operating segment, on an annual basis or sooner if the indicators of impairment arise. Our judgments regarding the existence of impairment indicators are based on market conditions and operational performance of each reporting unit. During 2020, the Company had identified three reporting units, which include the following: 1) Surgical Facilities, 2) Ancillary Services, and 3) Alliance, which is a component of the Optical Services operating segment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. A detailed evaluation of potential impairment indicators was performed, which specifically considered the volatility observed in the prices of the Company&#8217;s outstanding debt securities and common stock, as well as the decline in surgical case volumes following the emergence of the COVID-19 pandemic, all of which improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On the basis of available evidence as of August 31, 2020, we identified indicators of impairment related to the Ancillary Services and Alliance reporting units, including the impacts of the COVID-19 pandemic and the closure of our diagnostic laboratory. No indicators of impairment were identified for the Surgical Facilities reporting unit. Based on the impairment indicators noted, we performed an impairment analysis for the Ancillary Services and Alliance reporting units as of August 31, 2020. As of the August 31, 2020 valuation, the carrying value for both the Ancillary Services and Alliance reporting units exceeded the fair value, resulting in non-cash impairment charges of $28.6 million and $4.9 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of October 1, 2020, prior to its annual impairment testing, the Company's three reporting units with allocated goodwill were as follows: 1) Surgical Facilities - $3.3 billion, 2) Ancillary Services - no remaining goodwill after the August 31 impairment discussed above, and 3) Alliance - $4.2 million.&#160;As of the October 1, 2020 valuation, the fair value for the Surgical Facilities reporting unit was substantially in excess of its carrying value, and there were no additional indicators of impairment related to the other reporting units.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsequent to the date of our annual impairment test, the Company considered its operating results for the fourth quarter of 2020, macroeconomic, industry and market conditions, and other market indicators including its market capitalization. Based on its evaluation of all such factors, the Company concluded that an event had not occurred or circumstances had not changed that would more likely than not reduce the fair value of its reporting units below their carrying values. On December 31, 2020, the Company disposed of the Alliance reporting unit with the sale of its optical products purchasing organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, as a result of its impairment testing, the Company recorded non-cash impairment charges of $2.5&#160;million related to the Alliance reporting unit. During the year ended December 31, 2018, as a result of its impairment testing, the Company recorded non-cash impairment charges of $60.7&#160;million and $13.7&#160;million related to the Ancillary Services and Alliance reporting units, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 4. "Goodwill and Intangible Assets" to the consolidated financial statements elsewhere in this Annual Report for additional disclosure related to goodwill.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize certain results from the statements of operations for the periods indicated (dollars in millions):</span></div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,771.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,407.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,361.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction and integration costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,677.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,595.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,693.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(147.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:  Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December 31, 2020 Compared to Year Ended December 31, 2019 </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Overview.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During 2020, our revenues increased 1.6% to $1.9 billion from $1.8 billion in 2019. We incurred net loss attributable to Surgery Partners, Inc. in 2020 of $116.1 million, compared to net loss of $74.8 million in 2019, primarily attributable to the impairment charges taken during 2020 and the continued impact of the COVID-19 pandemic on surgical case volumes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues for 2020 and 2019 were as follows (dollars in millions):</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.045%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,803.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other service revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues increased 1.8% to $1.84 billion in 2020 compared to $1.80 billion in 2019. The increase in patient service revenues was primarily attributable to a de novo hospital completed in 2019 and acquisitions completed in 2020 and 2019. Same-facility revenues for 2020 decreased 1.1% from 2019, with a 14.1% increase in same-facility revenue per case, and a 13.3% decrease in the same-facility case volume primarily due to the impacts of the COVID-19 pandemic. Same-facility revenue per case growth was driven by a favorable surgical case mix as higher acuity cases were some of the first to recover when elective procedures returned in the second quarter of 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenues.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenues were $1.5 billion in 2020 compared to $1.4 billion in 2019. The increase in costs was primarily attributable to a de novo hospital completed in 2019, acquisitions completed in 2020 and 2019 and an increase in supply costs associated with higher acuity surgical case volumes. As a percentage of revenues, cost of revenues was 79.6% and 76.9% for 2020 and 2019, respectively. The increase as a percentage of revenues is primarily the result of the decreased revenues in 2020 driven by the decline in surgical case volume that began in mid-March due to the COVID-19 pandemic.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  General and administrative expenses were $97.1 million and $88.6 million in 2020 and 2019, respectively. As a percentage of revenues, general and administrative expenses were 5.2% in 2020 compared to 4.8% in 2019. The increase as a percentage of revenues is primarily the result of the decreased revenues driven by the decline in surgical case volume that began in mid-March due to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization was $94.8 million and $76.5 million in 2020 and 2019, respectively. The increase is primarily due to increased capital investments and integration of a de novo hospital completed in 2019 as well as acquisitions completed in 2020 and 2019. As a percentage of revenues, depreciation and amortization expenses were 5.1% in 2020 and 4.2% in 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Equity Investments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from equity investments was $10.8 million and $10.2 million in 2020 and 2019, respectively. As a percentage of revenues, income from equity investments was 0.6% for both 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Loss (gain) on Disposals and Deconsolidations, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  The net loss on disposals and deconsolidations was $5.7 million in 2020, including a $2.5 million net gain on the sale of three surgical facilities, certain assets related to its anesthesia business, certain imaging assets, its optical products purchasing organization and the closure of a diagnostic laboratory and $8.2 million primarily related to disposals of other long-lived assets. The net gain on disposals and deconsolidations was $4.4 million in 2019, including a $10.9 million gain on the sale of previously owned real property associated with one of our non-consolidated surgical facility equity method investments, offset by a loss of $6.5 million of disposals of other long-lived assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Transaction and Integration Costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  We incurred $23.2 million of transaction and integration costs in 2020 compared to $19.0 million in 2019. The increase primarily relates to costs for ongoing development initiatives, divestitures completed in 2020 and the integration of acquisitions we completed in 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Impairment Charges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  In 2020 we recorded non-cash impairment charges of $28.6 million and $4.9 million for goodwill assigned to the Ancillary Services and Alliance reporting units, respectively. See Note 4. "Goodwill and Intangibles" to our consolidated financial statements included elsewhere in this report for further discussion. In 2019 we recorded non-cash impairment charges of $2.5&#160;million for goodwill assigned to the Alliance reporting unit and $5.4 million related to a management rights agreement intangible asset. The impairment of the management rights agreement is related to our 2019 acquisition of a clinic that we previously managed. As a result of the transaction, we determined the management rights agreement related to the acquired clinic no longer provided a future benefit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Grant Funds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  We recognized $46.2 million in grant funds in 2020. The funds were received based on relief available to eligible health care providers under the provisions of the CARES Act, which is described in further detail above in the section titled "Impact of COVID-19&#8221; and in Note 1. &#8220;Organization and Summary of Accounting Polices - COVID-19 Pandemic&#8221; to our consolidated financial statements included elsewhere in this report. There were no grant funds received in 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Loss on Debt Extinguishment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  In 2019, we incurred a debt extinguishment loss of $11.7 million in connection with issuance of the 2027 Unsecured Notes, effective April 11, 2019. The loss includes the redemption premium paid to redeem the 2021 Unsecured Notes partially offset by the write-off of the unamortized fair value premium as of the redemption date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Litigation Settlement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  We incurred a loss in the amount of $1.2 million and $0.2 million in 2020 and 2019, respectively, related to the potential resolution of the government investigation discussed in Note 14. "Commitments and Contingencies" to our consolidated financial statements included elsewhere in this report. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense, Net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  Interest expense, net, was $201.8 million in 2020 compared to $178.9 million in 2019. The increase primarily relates to the issuance of the 2027 Unsecured Notes effective April 11, 2019, the 2020 Incremental Term Loans, which were fully drawn on April 22, 2020, the issuance of additional 2027 Unsecured Notes in the amount of $115.0 million effective July 30, 2020 as well as interest on the Revolver during the period it was fully drawn. As a percentage of revenues, interest expense, net was 10.8% in 2020 compared to 9.8% in 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Tax (Benefit) Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; The income tax benefit was $20.1 million and income tax expense was $9.5 million in 2020 and 2019, respectively. The effective tax rate was 106.9% for 2020 compared to 17.4% in 2019.&#160;New reconciling items in the 2020 effective tax rate include (i) the release of federal and state valuation allowances on the Company&#8217;s Internal Revenue Code Section 163(j) interest carryforwards as a result of the increase in deductible interest expense allowed under the CARES Act; (ii) the release of federal and state valuation allowances on the Company&#8217;s deferred tax assets related to debt financing costs as a result of the finalization of the Internal Revenue Code Section 163(j) interest regulations, for which the deductions of such debt financing costs that are incurred in years 2021 and forward are not considered interest expense for income tax purposes; and (iii) the Settlement Agreement, as discussed in Note 14. "Commitments and Contingencies" to our consolidated financial statements included elsewhere in this Annual Report, which provided that a portion of the final settlement amount was "restitution" for income tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Income Attributable to Non-Controlling Interests. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Net income attributable to non-controlling interests was $117.4 million and $119.9 million in 2020 and 2019, respectively. As a percentage of revenues, net income attributable to non-controlling interests was 6.3% in the 2020 period and 6.5% for the 2019 period.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December 31, 2019 Compared to Year Ended December 31, 2018</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our discussion regarding the comparison of the year ended December&#160;31, 2019 compared to the year ended December 31, 2018 was previously disclosed beginning on page 46 in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed on March 13, 2020, under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - Results of Operations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December 31, 2019 Compared to Year Ended December 31, 2018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">" and is hereby incorporated herein by reference.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_61"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary source of our operating cash flow is the collection of accounts receivable from federal and state agencies (under the Medicare and Medicaid programs), private insurance companies and individuals. Cash flow provided by operating activities was $246.9 million and $129.5 million in 2020 and 2019, respectively. The increase in operating cash flow in 2020 is primarily attributable to Medicare accelerated payments and other funds received under the CARES Act, discussed further below under the heading "Capital Resources," as well as actions taken to significantly reduce operating expenses and defer non-essential capital expenditures at the height of the crisis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities in 2020 was $88.4 million, which included $42.9 million related to purchases of property and equipment. We paid $104.6 million, in cash for acquisitions (net of cash acquired), which included a controlling interest in three surgical facilities, including a surgical hospital, a controlling interest in five surgical facilities in existing markets, that were merged into existing facilities and a physician practice. Additionally, we received cash proceeds of $58.5 million related to the sale of interests in three surgery centers, certain assets related to our anesthesia business, certain imaging assets and an optical products purchasing organization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities in 2019 was $85.2 million, which included $73.6 million related to purchases of property and equipment. We paid $13.8 million, in cash for acquisitions (net of cash acquired), which primarily included a surgical facility, a clinic that was merged into an existing facility and a physician practice. Further, we paid $15.2 million in cash for a non-controlling interest in four surgical facilities accounted for as equity method investments and we received cash proceeds of $17.6 million related to the sale of previously owned real property associated with one of our non-consolidated equity method investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities in 2020 was $66.7 million. During the year, we made distributions to non-controlling interest holders of $109.6 million and payments related to ownership transactions with consolidated affiliates of $27.4 million. Further, we made repayments on our long-term debt of $216.3 million, which was offset by borrowings of $429.4 million. In connection with the 2020 Incremental Term Loans, which were fully drawn on April 22, 2020, and the issuance of additional 2027 Unsecured Notes in the amount of $115.0 million effective July 30, 2020, we paid debt issuance costs of $8.5 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in financing activities in 2019 was $135.9 million. During this period, we made distributions to non-controlling interest holders of $121.2 million and payments related to ownership transactions with consolidated affiliates of $3.2 million. Further, we made repayments on our long-term debt of $490.8 million, which was offset by borrowings of $506.9 million. In connection with the issuance of the 2027 Unsecured Notes and redemption of the then existing 2021 Unsecured Notes, we paid debt issuance costs of $8.9 million and paid a redemption premium of $17.8 million.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discussion of the operating, investing and financing activities for the year ended December&#160;31, 2018 was previously disclosed beginning on page 47 in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed on March 13, 2020, under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources" and is hereby incorporated herein by reference.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the carrying value of our total indebtedness, including finance leases, was $2.857 billion, which includes unamortized fair value discount of $3.7 million and unamortized deferred financing costs of $16.3 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Term Loan and Revolving Credit Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had term loan borrowings with a carrying value of $1.539 billion, consisting of outstanding aggregate principal of $1.543 billion and unamortized fair value discount of $3.7 million (the "Term Loan"). The Term Loan matures on August 31, 2024 The Term Loan amortizes in equal quarterly installments of 0.25% of the aggregate original principal amount of the Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have a revolving credit facility providing for revolving borrowings of up to $120.0 million (the "Revolver" and, together with the Term Loan, the "Senior Secured Credit Facilities"). The Revolver will mature on August 31, 2022. As of December&#160;31, 2020, our availability on the Revolver was $112.5 million (including outstanding letters of credit of $7.5 million). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 27, 2021, the Company entered into an amendment to the Senior Secured Credit Facilities, which amended and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">supplemented the credit agreement to provide for an extension of the maturity date of the Revolver to February 1, 2026 and an increase in the outstanding commitments under the Revolver in an amount equal to $50.0&#160;million. The maturity extension and the additional commitments became operative on February 1, 2021. See Note 11. "Subsequent Events" to our consolidated financial statements included elsewhere in this Annual Report for a further discussion of the amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. Subject to certain conditions and requirements set forth in the credit agreement, we may request one or more additional incremental term loan facilities or one or more increases in the commitments on the Revolver.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin ranging from 3.00% to 3.25% per annum, depending on our first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than 2.00% per annum)) plus a margin ranging from 2.00% to 2.25% per annum. In addition, we are required to pay a commitment fee of 0.50% per annum in respect of unused commitments on the Revolver.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April 22, 2020, we entered into a second incremental term loan amendment, which amended and supplemented the existing credit agreement, to provide for an incremental borrowing of $120.0 million. The incremental amounts were fully drawn on April 22, 2020, and are included in the term loan borrowings discussed above. The incremental term loans bear interest at a rate per annum equal to (x) LIBOR plus a margin of 8.00% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate, (iii) one-month LIBOR plus 1.00% per annum and (iv) 2.00% per annum) plus a margin of 7.00% per annum. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April 16, 2020, we entered into a third amendment to our credit agreement, which amended and supplemented financial covenants applicable to the Revolver under the credit agreement. Pursuant to the third amendment, the Company's requirement to comply with a maximum consolidated total net leverage ratio was waived for the remainder of 2020. Additionally, for the first three quarters of 2021, the third amendment provides for an alternative calculation for the maximum consolidated total net leverage ratio where the trailing four quarter basis may be negatively impacted by the impacts of the COVID-19 pandemic. The third amendment became effective concurrently with the funding of the incremental term loans on April 22, 2020, discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have $545.0 million aggregate principal amount of senior unsecured notes due April 15, 2027 (the "2027 Unsecured Notes"). The 2027 Unsecured Notes bear interest at the rate of 10.000% per year, payable semi-annually on April 15 and October 15 of each year. See Note 5. "Long-Term Debt" to our consolidated financial statements included elsewhere in this report for a further discussion of the senior unsecured notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 30, 2020, we completed the issuance and sale of $115.0&#160;million in aggregate principal amount of senior unsecured notes due 2027 at 100.75% of the principal amount. The notes were issued as part of the same series as the existing 2027 Unsecured Notes originally issued in April 2019, and have the same terms. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have $370.0 million aggregate principal amount of senior unsecured notes due July 1, 2025 outstanding (the "2025 Unsecured Notes"). The 2025 Unsecured Notes bear interest at the rate of 6.750% per year, payable semi-annually on January 1 and July 1 of each year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and certain of our subsidiaries have other debt consisting of outstanding bank indebtedness of $137.5 million, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made, and right-of-use finance lease obligations of $281.2 million for which we are liable to various vendors for several property and equipment leases classified as finance leases.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to cash flows from operations, available cash and capacity on our Revolver, other sources of capital include funds we have received under the CARES Act as well as continued access to the capital markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted in Note 1. "Organization and Summary of Accounting Policies" to our consolidated financial statements included elsewhere in this report, as of December 31, 2020, we received relief via the CARES Act, including approximately $59&#160;million in direct grant payments and approximately $120&#160;million of accelerated payments pursuant to the Medicare Accelerated and Advance Payment Program. The direct grant payments are not required to be repaid, subject to certain terms and conditions, while payments received under the Medicare Accelerated and Advance Payment Program are required to be repaid. As of December 31, 2020, approximately $95&#160;million of accelerated payments are reflected as a component of Medicare accelerated payments and deferred governmental grants in the consolidated balance sheets while the remaining payments are included within other long-term liabilities. Based on the repayment terms, we expect recoupment of these funds to begin in 2021 under the repayment framework more specifically described in Note 1. "Organization and Summary of Accounting Policies."</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Additionally, the CARES Act permitted the deferral of payment of the social security payroll tax between March 27, 2020 and December 31, 2020, with half of the deferred amount due December 2021 and the other half due December 2022. As of December 31, 2020, we have deferred approximately $16.9&#160;million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that deferral of the social security payroll tax match, which we began doing in April 2020, along with the funds received under the CARES Act as noted above, have positively impacted our cash flows from operations during 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 pandemic has resulted in, and may continue to result in, significant disruptions of financial and capital markets, which could reduce our ability to access capital and negatively affect our liquidity in the future. Additionally, while we have received grants and accelerated payments under the CARES Act and other government assistance programs and may receive additional amounts in the future, there is no assurance regarding the extent to which anticipated negative impacts arising from the COVID-19 pandemic will be offset by amounts and benefits received under the CARES Act or future legislation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although we have seen continued improvement in surgical case volumes as states begin to re-open and allow for non-emergent procedures, broad economic factors resulting from the current COVID-19 pandemic, including increased unemployment rates and reduced consumer spending, could negatively affect our payor mix, increase the relative proportion of lower margin services we provide and reduce patient volumes, as well as diminish our ability to collect outstanding receivables. Business closings and layoffs in the areas in which we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of payors to pay for services as rendered. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations, requiring an increased level of working capital. If general economic conditions continue to deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on our current level of operations, we believe cash flow from operations, available cash, available capacity on our Revolver, the incremental term loan borrowings and issuance of new notes discussed above, funds we have received under the CARES Act, funds we may receive in the future and continued access to capital markets, together with the cost cutting steps taken in response to the impact of the COVID-19 pandemic, as discussed in Item 1A. "Risk Factors" elsewhere in this report, will be adequate to meet our short-term (i.e., 12 months) and long-term (beyond 12 months) liquidity needs.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_64"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certain Non-GAAP Measures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted EBITDA is not a measurement of financial performance under GAAP, and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with GAAP. The items excluded from this non-GAAP metric are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When we use the term "Adjusted EBITDA," we are referring to (loss) income before income taxes, adjusted for net income attributable to non-controlling interests, depreciation and amortization, net interest expense, equity-based compensation expense, transaction, integration and acquisition costs, impairment charges, net loss (gain) on disposals and deconsolidations, litigation settlements and other litigation costs, reserve adjustments, contingent acquisition compensation expense, gain on escrow release, loss on debt extinguishment and tax receivable agreement expense. When we use &#8220;Adjusted EBITDA excluding grant funds,&#8221; we are referring to Adjusted EBITDA less the impact of grant funds. We use Adjusted EBITDA and Adjusted EBITDA excluding grant funds as measures of financial performance. Adjusted EBITDA and Adjusted EBITDA excluding grant funds are key measures used by our management to assess operating performance, make business decisions and allocate resources.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles Adjusted EBITDA and Adjusted EBITDA excluding grant funds to (loss) income before income taxes, the most directly comparable GAAP financial measure (in millions and unaudited):</span></div><div style="margin-bottom:14pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated Statements of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Plus (minus):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement and other litigation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent acquisition compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on escrow release </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Impact of grant funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA excluding grant funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">For the year ended December 31, 2020, this amount includes transaction and integration costs of $23.2 million, of which $6.6&#160;million were acquisition related costs, and includes start-up costs related to a de novo surgical hospital of $15.0 million. For the year ended December 31, 2019, this amount includes transaction and integration costs of $19.0 million, and further includes other acquisition costs and start-up costs related to a de novo surgical hospital of $17.1 million. For the year ended December 31, 2018, this amount includes transaction and integration costs of $31.7 million, and further includes other acquisition costs of $2.3 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes litigation settlement costs of $1.2 million, $0.2 million and $46.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. This amount also includes other litigation costs of $5.2 million and $4.4 million for the years ended December 31, 2020 and 2019, respectively, with no comparable costs in 2018.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount represents adjustments to revenue in order to apply consistent policies to businesses acquired by Surgery Partners in prior periods.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Included in other income in the consolidated statement of operations for the year ended December 31, 2020, with no comparable gain in 2019 and 2018.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Represents the impact of grant funds recognized, net of amounts attributable to non-controlling interests.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We use Credit Agreement EBITDA as a measure of liquidity and to determine our compliance under certain covenants pursuant to our credit facilities. Credit Agreement EBITDA is determined on a trailing twelve-month basis. We have included it because we believe that it provides investors with additional information about our ability to incur and service debt and make capital expenditures. Credit Agreement EBITDA is not a measurement of liquidity under GAAP, and should not be considered in isolation or as a substitute for any other measure calculated in accordance with GAAP. The items excluded from Credit Agreement EBITDA are significant components in understanding and evaluating our liquidity. Our calculation of Credit Agreement EBITDA may not be comparable to similarly titled measures reported by other companies.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When we use the term "Credit Agreement EBITDA," we are referring to Adjusted EBITDA, as defined above, further adjusted for acquisitions and synergies. These adjustments do not relate to our historical financial performance and instead relate to estimates compiled by management and calculated in conformance with the definition of "Consolidated EBITDA" used in the credit agreements governing our credit facilities.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table reconciles Credit Agreement EBITDA to cash flows from operating activities, the most directly comparable GAAP financial measure (in millions and unaudited):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">246.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Plus (minus):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from equity investments, net of distributions received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare accelerated payments and deferred governmental grants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement and other litigation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on escrow release</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and synergies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit Agreement EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Represents impact of acquisitions as if each acquisition had occurred on January 1, 2020. Further this includes revenue synergies from other business initiatives, de novo facilities and an adjustment for the effects of adopting the new lease accounting standard, as defined in the credit agreement governing the Senior Secured Credit Facilities.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_1850"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Contractual Obligations and Commercial Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contractual obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">by period as of December&#160;31, 2020 (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4-5 years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 5 years</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt obligations, including interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,760.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">439.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,041.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,045.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease obligations, including interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,330.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,264.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Included in long-term debt obligations are principal and interest owed on our outstanding debt obligations. These amounts exclude our unamortized fair value adjustments related non-cash amortization for the Term Loan. These obligations are explained further in Note 5. "Long-Term Debt" to our consolidated financial statements included elsewhere in this Annual Report. We used the applicable annual interest rate as of December 31, 2020 of 4.25%, based on LIBOR plus the applicable margin, for our $1.4&#160;billion outstanding Term Loan to estimate interest payments on this variable rate debt instrument.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This reflects our future operating lease payments. We enter into operating leases in the normal course of business. Substantially all of our operating lease agreements have fixed payment terms based on the passage of time. Some lease agreements provide us with the option to renew the lease. Our future operating lease obligations would change if we exercised these renewal options and if we entered into additional operating lease agreements. These obligations are explained further in Note 6. "Leases" to our consolidated financial statements included elsewhere in this Annual Report. Operating lease obligations do not include common area maintenance, insurance or tax payments for which we are also obligated to pay.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This reflects payments made pursuant to the terms of the TRA, as described further in "Critical Accounting Policies and Tax Receivable Agreement."</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_70"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inflation and changing prices have not significantly affected our operating results or the markets in which we operate.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Please refer to Note 1. "Organization and Summary of Accounting Policies - Recent Accounting Pronouncements" to our consolidated financial statements included elsewhere in this Annual Report for a discussion of the impact of the adoption of recently issued accounting standards and accounting standards not yet adopted.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.&#160;We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage our exposures to changes in interest rates.&#160;Additionally, we periodically enter into interest rate swap agreements to manage our exposure to interest rate fluctuations. Our interest rate swap agreements involve the exchange of fixed and variable rate interest payments between two parties, based on common notional principal amounts and maturity dates. The notional amounts of the swap agreements represent balances used to calculate the exchange of cash flows and are not our assets or liabilities. Our credit risk related to these agreements is considered low because the swap agreements are with creditworthy financial institutions. The interest payments under these agreements are settled on a net basis. These derivatives have been recognized in the financial statements at their respective fair values. Changes in the fair value of these derivatives, which are designated as cash flow hedges, are included in other comprehensive income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our variable rate debt instruments are primarily indexed to the prime rate or LIBOR.&#160;Interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements.&#160;Based on our indebtedness and the effect of our interest rate swap agreements at December&#160;31, 2020, a 100 basis point interest rate change would impact our net earnings and cash flow by approximately $3.5&#160;million annually. Although there can be no assurances that interest rates will not change significantly, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2021 based on our indebtedness at December&#160;31, 2020.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_76"></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information with respect to this Item is contained in our consolidated financial statements beginning on Page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_115">F-1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of this Annual Report.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_79"></div><div style="margin-bottom:5pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_82"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures and Limitations on the Effectiveness of Controls</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">An evaluation was performed under the supervision and with the participation of our management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report. Based on the evaluation of our disclosure controls and procedures conducted as of December&#160;31, 2020, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate "internal control over financial reporting" (as such term is defined in Rule 13a-15(f)) under the Exchange Act) for the Company. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions and disposition of assets; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; providing reasonable assurance that receipts and expenditures are made only in accordance with management and board authorizations; and providing reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with GAAP. Because of the inherent limitations in any internal control, no matter how well designed, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2020. The assessment was based on criteria established in the framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, issued by the Committee of Sponsoring Organizations of the Treadway Commission.&#160;Based on that evaluation, management, including the Chief Executive Officer and Chief Financial Officer, determined that our internal control over financial reporting was effective as of December&#160;31, 2020. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deloitte &amp; Touche LLP, the Company's independent registered public accounting firm, has issued an attestation report on the effectiveness of our internal control over financial reporting as of December&#160;31, 2020. Their attestation report is included below in this Item 9A.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d&#8209;15(d) of the Exchange Act that occurred during the quarter ended&#160;December&#160;31, 2020&#160;that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Surgery Partners, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have audited the internal control over financial reporting of Surgery Partners, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2020, of the Company and our report dated March 10, 2021, expressed an unqualified opinion on those financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nashville, Tennessee<br/>March 10, 2021</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART III</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information called for by Item 10 is incorporated herein by reference to the definitive Proxy Statement of the Company relating to the 2021 Annual Meeting of Stockholders (the "Definitive Proxy Statement"), which the Company intends to file within 120 days after the close of its fiscal year ended December&#160;31, 2020. </span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information called for by Item 11 is incorporated herein by reference to the Definitive Proxy Statement referenced above in Item 10.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information called for by Item 12 is incorporated herein by reference to the Definitive Proxy Statement referenced above in Item 10.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information called for by Item 13 is incorporated herein by reference to the Definitive Proxy Statement referenced above in Item 10.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information called for by Item 14 is incorporated herein by reference to the Definitive Proxy Statement referenced above in Item 10.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_106"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART IV</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_109"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 15.  Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Financial Statements, Financial Statement Schedules and Exhibits</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1) Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:40.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements and Notes thereto are set forth starting on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_115">F-1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2) Financial Statement Schedules</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:40.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All financial schedules have been omitted either because they are not applicable or because the required information is provided in our Consolidated Financial Statements and Notes thereto, starting on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_115">F-1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of this Annual Report on Form 10-K. </span></div><div style="margin-bottom:5pt;margin-top:9pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3) Exhibits:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000119312517166717/d368189dex21.htm">Agreement and Plan of Merger by and among Surgery Partners, Inc., SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH, L.P., dated as of May 9, 2017 (incorporated herein by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed May 11, 2017).*</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917044503/a17-15150_5ex2d1.htm">Letter Amendment to Merger Agreement, by and among Surgery Partners, Inc., SP Merger Sub, Inc., NSH Holdco, Inc. and IPC / NSH, L.P., dated as of July 7, 2017 (incorporated herein by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed July 11, 2017).*</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917066046/a17-25100_1ex3d1.htm">Amended and Restated Certificate of Incorporation of Surgery Partners, Inc., dated October 30, 2017 (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed November 3, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917055001/a17-21150_1ex3d3.htm">Certificate of Designations, Preferences, Rights and Limitations of the 10.00% Series A Convertible Perpetual Participating Preferred Stock of Surgery Partners, Inc., dated August 31, 2017 (incorporated herein by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K filed September 1, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917055001/a17-21150_1ex3d2.htm">Amended and Restated Bylaws of Surgery Partners, Inc., dated August 31, 2017 (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed September 1, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000012/ye2019exhibit41.htm">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000012/ye2019exhibit41.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000012/ye2019exhibit41.htm">incorporated herein by reference to Exhibit 4.1 to the Company's Annu</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000012/ye2019exhibit41.htm">al Report on Form 10-K filed March 5, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000012/ye2019exhibit41.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000012/ye2019exhibit41.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917043866/a17-15150_4ex4d1.htm">Indenture, dated June 30, 2017, among SP Finco, LLC and Wilmington Trust, National Association, as Trustee (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed July 6, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917055001/a17-21150_1ex4d2.htm">First Supplemental Indenture, by and among Surgery Center Holdings, Inc., Wilmington Trust, National Association, as Trustee, and certain other parties thereto, dated August 31, 2017 (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed September 1, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465919020942/a19-8229_1ex4d1.htm">Indenture by and among Surgery Center Holdings, Inc., the guarantors from time to time party thereto and Wilmington Trust, National Association, dated April 11, 2019 (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed April 12, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465920088487/tm2026192d1_ex4-1.htm">Second Supplemental Indenture, dated July 30, 2020, among Surgery Center Holdings, Inc., the guarantors party thereto and Wilmington Trust, National Association, as Trustee (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed July 31, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000119312516521890/d141152dex101.htm">First Lien Incremental Term Loan Amendment and Consent, dated as of March 24, 2016, by and among SP Holdco I, Inc., Surgery Center (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed March 30, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883316000049/exhibit101amendmentno4tocr.htm">Amendment No. 4 to Credit Agreement, dated as of September 26, 2016, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., Jefferies Finance LLC and the other guarantors and lenders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed September 27, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883316000019/exhibit1021highwoodslease.htm">Office Lease Agreement dated November 17, 2015 between Highwoods Realty Limited Partnership and Surgery Partners, Inc. (incorporated herein by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed March 11, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883316000055/exhibit101firstamendmentto.htm">First Amendment to Lease Agreement, dated August 29, 2016, between Highwood Realty Limited Partnership and Surgery Partners, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed November 10, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883317000020/exhibit101highlandsleasese.htm">Second Amendment to Lease Agreement, dated April 26, 2017, between Highwoods Realty Limited Partnership and Surgery Partners, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 10, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917055001/a17-21150_1ex10d1.htm">Amended and Restated Registration Rights Agreement by and among Surgery Partners, Inc., certain stockholders of Surgery Partners, Inc. and certain other parties thereto, dated August 31, 2017 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed September 1, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917055001/a17-21150_1ex10d2.htm">Credit Agreement, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., Jefferies Finance LLC and the other guarantors and lenders party thereto, dated August 31, 2017 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed September 1, 2017).*</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883319000006/ye2018exhibit103.htm">Incremental Term Loan Amendment, dated as of October 23, 2018 with Jefferies, SP Holdco I, Inc., Surgery Center Holdings, Inc. and certain other parties thereto (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K filed March 15, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000038/a202004228-kexhibit102.htm">Second Incremental Term Loan Amendment, dated as of April 22, 2020, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., Jefferies Finance LLC and the other guarantors and lenders party thereto (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed April 22, 2020).</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465919016991/a19-6738_2ex10d1.htm#Exhibit10_1_091307">Amendment to the Credit Agreement, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., Jefferies Finance LLC and the other guarantors and lenders party thereto, dated March 25, 2019 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 25, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000038/a202004228-kexhibit101.htm">Third Amendment to the Credit Agreement, dated as of April 16, 2020, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc., Jefferies Finance LLC and the other lenders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed April 22, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1012.htm">Fifth amendment to credit agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1012.htm">, dated as of January 27, 2021, by and among SP Holdco I, Inc., Surgery Center Holdings, Inc. Jefferies Finance LLC and the other guarantors and lenders party thereto.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883315000007/exhibit101taxreceivableagr.htm">Tax Receivable Agreement, dated as of September 30, 2015, among Surgery Partners, Inc., H.I.G. Surgery Centers, LLC and certain other stockholders party thereto (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed November 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000119312517166717/d368189dex103.htm">Amendment No. 1 to Income Tax Receivable Agreement, by and between Surgery Partners, Inc. and H.I.G. Surgery Centers, LLC (in its capacity as the Stockholders Representative), dated May 9, 2017 (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed May 11, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883318000004/exhibit1011trawaiveragreem.htm">Form of TRA Waiver and Assignment Agreement (incorporated herein by reference to Exhibit 10.11 to the Company's Annual Report on Form 10-K filed March 16, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000119312515318621/d898342dex1014.htm">Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.14 to Amendment No. 1 to the Company's Registration Statement on Form S-1, filed September 14, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm">Surgery Partners, Inc. 2015 Omnibus Incentive Plan, as amended and restated effective January 1, 2020 (incorporated herein by reference as</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm">E</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm">xhib</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm">it 10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm">to the Company's Quarterly Report on Form 10-Q</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit102.htm">filed August 5, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000058/a2020q2exhibit101.htm">Surgery Partners, Inc. Cash Incentive Plan, as amended and restated effective January 1, 2020 (incorporated herein by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed August 5, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000119312515323822/d898342dex1017.htm">Symbion, Inc. Supplemental Executive Retirement Plan, Effective May 1, 2005 (incorporated herein by reference to Exhibit 10.17 to the Company's Registration Statement on Form S-1, Amended, filed September 21, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883315000007/exhibit105formofoptionaward.htm">Form of Non-Statutory Stock Option Agreement under the 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883315000007/exhibit106formofdirectorop.htm">Form of Non-Employee Director Non-Statutory Stock Option Agreement under the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883315000007/exhibit107formofrestricted.htm">Form of Restricted Stock Agreement under the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed November 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000119312516505204/d162226dex991.htm">Form of Restricted Stock Award Agreement under the 2015 Surgery Partners, Inc. Omnibus Incentive Plan (incorporated herein by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K filed March 15, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.24 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000119312516641575/d212841dex101.htm">Form of Performance Stock Unit Award Agreement under the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed July 5, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.25 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883317000010/exhibit101non-employeersaa.htm">Form of Non-Employee Director Restricted Stock Award Agreement under the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed April 3, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.26 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465918074124/a18-41943_1ex10d1.htm">Form of Stock-Settled Stock Appreciation Right Agreement under the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed December 20, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883317000012/a20170417exhibit101baldock.htm">Amended and Restated Employment Agreement, dated April 13, 2017, by and between Surgery Partners, Inc., Symbion, Inc. and Jennifer Baldock (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed April 17, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465917056338/a17-21454_1ex10d1.htm">Employment Agreement, dated September 7, 2017, between Surgery Partners, Inc. and Cliff Adlerz (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed September 8, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465918001309/a18-2233_1ex10d1.htm">Employment Agreement, dated January 4, 2018, between Surgery Partners, Inc., Surgery Partners, LLC and Wayne DeVeydt (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed January 8, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.30 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000002/a20200113ex101employmentag.htm">Amendment No. 1 to Employment Agreement by and between Surgery Partners, Inc., Surgery Partners, LLC and Wayne DeVeydt, dated January 13, 2020 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 13, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000110465918016704/a18-8067_1ex10d1.htm">Employment Agreement, dated March 9, 2018, by and between Surgery Partners, Inc. and Thomas F. Cowhey (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 12, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883319000002/a2019212ex101employmentagr.htm">Employment Agreement, dated February 11, 2019, by and between Surgery Partners, Inc., Surgery Partners, LLC and J. Eric Evans (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed February 12, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000002/a20200113ex102employmentag.htm">Amendment No. 1 to Employment Agreement by and between Surgery Partners, Inc., Surgery Partners, LLC and J. Eric Evans, dated January 13, 2020 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on January 13, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883319000038/a2019q1exhibit104ggemploym.htm">Employment Agreement by and between Symbion, Inc. and George M. Goodwin, dated June 13, 2014 (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1035.htm">Employment Agreement, dated June 13, 2014, by and between Symbion, Inc. and Anthony W. Taparo, as amended by that certain First Amendment to Employment Agreement dated July 31, 2016, and that certain Second Amendment to Employment Agreement dated August 7, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1036.htm">Employment Agreement, dated November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1036.htm">12</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1036.htm">, 2019, by and between Surgery Partners, Inc. and Brad</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1036.htm">ley R.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1036.htm"> Owens.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.37 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1037.htm">Employment Agreement, dated June 30, 2019, by and between Surgery Partners, Inc. and Laura</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1037.htm"> L.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit1037.htm"> Brocklehurst.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1638833/000163883320000043/a2020q1exhibit104.htm">Settlement Agreement regarding Logan Laboratories, LLC and Tampa Pain Relieve Centers, Inc., dated April 14, 2020 (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 11, 2020).</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit211.htm">List of Subsidiaries of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit231.htm">Consent of Independent Registered Public Accounting Firm (Deloitte).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ye2020exhibit321.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline XBRL (included in Exhibit 101).</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) Management Contract or Compensatory Plan or Arrangement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160; Schedules and/or Exhibits have been omitted pursuant to Item 601(b)(2)&#160;of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule or exhibit to the SEC upon request.</span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_112"></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 16.  Form 10-K Summary</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.787%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_118">Report</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_118"> of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_118">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_121">Consolidated Balance Sheets - December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_121">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_121"> and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_121">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_127">Consolidated Statements of Operations - for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_127">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_127">, 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_127">9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_127"> and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_127">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_130">Consolidated Statements of Comprehensive Income (Loss) - for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_130">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_130">, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_130">19</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_130"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_130">and 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_130">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_133">Consolidated Statements of Stockholders' Equity - for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_133">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_133">, 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_133">9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_133"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_133"> 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_133">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_136">Consolidated Statements of Cash Flows - for the years ended December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_136">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_136">, 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_136">9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_136"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_136"> 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_136">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_139">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">F-<a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_139">9</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Surgery Partners, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Surgery Partners, Inc. and subsidiaries (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 10, 2021, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change in Accounting Principle</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As discussed in Note 1 to the financial statements, the Company has adopted Accounting Standards Codification Topic 842, &#8220;Leases&#8221;, using the modified retrospective adoption method on January 1, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable &#8212; Refer to Note 1 to the financial statements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable are recorded net of estimated implicit price concessions at both surgical hospitals and ambulatory surgical centers. At surgical hospitals, the estimation process is based on historical trend of cash collections and contractual write-offs. The inputs used to determine the estimated implicit price concessions are based on objective data. Management&#8217;s determination of the estimate is complex and involves their assessment of the appropriateness and relevancy of the inputs and methodology to record accounts receivable at the net realizable value.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">We identified surgical hospitals accounts receivable as a critical audit matter because of the significant estimates management makes to determine the implicit price concession. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the methodology and application of the Company&#8217;s estimated implicit price concessions for the surgical hospitals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our audit procedures related to the Company&#8217;s estimated implicit price concessions for surgical hospitals include the following, among others:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We tested the effectiveness of controls over accounts receivable, including management&#8217;s controls over the review of the implicit price concessions and the verification of the accuracy and completeness of the data used in the assessment.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We evaluated management&#8217;s methodology and related assumptions, including cash collections, used in recording implicit price concessions, by comparing actual results to management&#8217;s historical estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We tested the underlying data related to the recognition of patient level charges and the subsequent activities, including cash collections and contractual write-offs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We tested the mathematical accuracy of the estimates applied to period-end accounts receivable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">We considered industry, economic, and company factors to determine the appropriateness of the net realizable value of accounts receivable.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nashville, Tennessee<br/>March 10, 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2018.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_121"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Dollars in millions, except per share amounts)</span></div></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzQtMi0xLTEtMA_fdbdccd8-2542-4060-8da6-9d3bdca872c8">317.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzQtNC0xLTEtMA_788a7d75-107b-4e71-becc-2424fb55f171">92.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzUtMi0xLTEtMA_699a30a8-9ce9-49fc-a8e2-ed218c664ca4">382.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzUtNC0xLTEtMA_46396158-d990-488d-a43b-3d5b604a2cc0">326.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzYtMi0xLTEtMA_5ddaf29e-fa37-498f-b62a-3613c058c729">56.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzYtNC0xLTEtMA_cf6d3690-4c6d-43b2-a799-afacb6d240b5">46.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzctMi0xLTEtMA_f7f66c55-d309-4bef-9440-f869b41771ed">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzctNC0xLTEtMA_83fb52fb-4fdf-45ce-aa62-bdd1ff87d212">17.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzgtMi0xLTEtMA_9aff132d-431c-4fe4-8bfe-5cfb23783145">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzgtNC0xLTEtMA_9beb5646-b99c-459f-adf7-eeca99129547">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzktMi0xLTEtMA_8fa0002c-fedd-4436-8e71-4e1b6cc2eebb">801.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzktNC0xLTEtMA_2d622bdb-680a-49eb-9f08-d6e29d490a62">525.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEwLTItMS0xLTA_c9ba1164-905c-4665-8cf5-bce60d8b938b">544.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEwLTQtMS0xLTA_330a2761-12a4-445d-bcbe-788c2b45a4c0">523.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzExLTItMS0xLTQ4NTI_6249dc5b-4db7-4963-a034-cf82f0a1cd8a">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzExLTQtMS0xLTQ4NTI_d34e675f-dfe1-41d9-8289-b7c8ea5555d1">47.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEyLTItMS0xLTA_bf0f3dd9-3635-411e-84ac-03c00231b29e">3,468.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEyLTQtMS0xLTA_7a68b1a6-3f54-4fe4-8ccb-662866a6898a">3,402.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in and advances to affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEzLTItMS0xLTA_4cdc0e71-a0df-4bbe-9112-25777f3f30a1">90.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEzLTQtMS0xLTA_4c7fa028-e7b9-47d6-ba1f-0b924a1f8fb3">93.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEzLTItMS0xLTMxNTU_1bf7fa5c-5ea9-47c6-aa5e-2e868fdbe7e3">310.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEzLTQtMS0xLTMxNTg_3f478364-70ef-4364-ae27-fbb92cea270d">297.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE0LTItMS0xLTA_798becec-112d-4d2c-b7e1-f0f077d00855">124.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE0LTQtMS0xLTA_7379c0b8-13be-46f7-b3ac-e314672cf01c">98.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE1LTItMS0xLTA_e3fbb22b-867c-48e1-8167-6f6a182c4f36">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE1LTQtMS0xLTA_9430f8e0-b4b8-4cc6-b709-835ed183a406">30.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE2LTItMS0xLTA_693363fb-7649-4779-a3b9-60a0483d7803">5,413.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE2LTQtMS0xLTA_c31eb2b4-c844-4db0-b7ad-6d8af512257d">5,018.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIwLTItMS0xLTA_713f40bb-f28e-4557-af98-71d3eba1c0cb">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIwLTQtMS0xLTA_2cd101b9-db30-4a47-bb86-65716d10aaa1">96.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIxLTItMS0xLTA_3bdf1578-6b73-4966-add0-1e26174f880b">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIxLTQtMS0xLTA_dcbedfad-a780-4f92-8a51-e9a9833a67a9">54.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare accelerated payments and deferred governmental grants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIyLTItMS0xLTMxNjM_4456cbf3-ca54-42ed-bf88-91001b08661c">109.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:zerodash" name="sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIyLTQtMS0xLTMxNjY_21f3366e-1c3f-47f5-ba95-6d9ab6daa66c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIyLTItMS0xLTA_6f3f8deb-f2d7-4da8-9ab9-dd11ed060148">217.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIyLTQtMS0xLTA_cb45a5ae-8798-4c6b-b26c-c1c9452db089">191.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIzLTItMS0xLTA_8a1cd895-2b3d-4691-8ecb-51c869d83cd7">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIzLTQtMS0xLTA_eef14053-a5fc-4311-9f71-e49989af451d">56.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI0LTItMS0xLTA_38de1d9b-c1ab-42fb-a75d-97aafcddc783">556.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI0LTQtMS0xLTA_77dba14c-0c40-4f98-9b83-4850cbefb70c">398.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, less current maturities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI1LTItMS0xLTA_f0e5ce02-86bf-4716-8c60-17ca247b248b">2,792.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI1LTQtMS0xLTA_2acd264f-03f5-433f-9d24-0ca53edd7739">2,524.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI3LTItMS0xLTMxNzE_22004b87-d7fa-4c22-b9e4-fbaadaa94231">300.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI3LTQtMS0xLTMxNzQ_92622221-e0ed-420d-9813-faa32569f748">283.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI2LTItMS0xLTA_2e79fe4e-7b6e-497e-870c-eed4f5e10ba7">139.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI2LTQtMS0xLTA_e8bbb0af-c108-48b9-beeb-44f7687260d5">113.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI4LTItMS0xLTA_b526b08f-3cbe-40ce-85cb-970e10beac3e">306.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI4LTQtMS0xLTA_27530487-3952-4c6d-93e0-fd2b0c5aa52c">321.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redeemable preferred stock - Series A; shares authorized, issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_2a55f59e-1218-4527-96e3-1fa412208010"><ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_2f337272-bbd9-4ba0-8070-cbf55e55f4d0"><ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_5ff032f2-8e88-457e-863e-b245b2d6f74a"><ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_bccb22e7-d929-4fe5-a2e2-58be6778a3fc"><ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_d309bf1b-9734-46e1-b232-9a630d5ea147"><ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_f31dc134-a12d-4f1e-b9ce-fa126eff273b">310,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>; redemption value - $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzE1_4308eb32-207b-4826-b2e0-57a3374e743d">434.5</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzI0_74d39bbf-69e0-44d8-bf17-dcd696cbde33">395.0</ix:nonFraction>, respectively </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTItMS0xLTA_1bfdbd97-a2fb-435c-a090-a5b3f5e45f40">434.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTQtMS0xLTA_6ccfdd15-fb4f-4f66-bae5-4073eb3085dc">395.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1NjYy_478f70a6-5550-40d4-ac65-08b8f00369a0"><ix:nonFraction unitRef="usdPerShare" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1NjYy_5efbd72e-e1c5-4f10-8a59-5e0ec93260a4">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njc1_b764141a-e244-4237-a236-df89b094e1e6"><ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njc1_d4b25b13-5042-43d0-9df5-af17d242d0cb">20,000,000</ix:nonFraction></ix:nonFraction>; shares issued or outstanding - <ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njgy_55c5c300-822e-401f-b9e6-5d467b842b52"><ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njgy_772069d2-cf1c-4647-9343-9a05af781227"><ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njgy_f0cbdb9e-f249-470f-a573-7ccb6b1734e4"><ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njgy_f80f3b56-6498-486a-92c8-92749e064bce">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTItMS0xLTA_0e1d694a-1586-4e1a-bf36-3acaec6e0c5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTQtMS0xLTA_22ec924c-cd89-4630-9ae0-3eeb88ca2c4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1Njk2_09c9c318-db21-4449-b728-df0154b709d2"><ix:nonFraction unitRef="usdPerShare" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1Njk2_f7480a73-8b07-468b-b82b-8d222cd1d289">0.01</ix:nonFraction></ix:nonFraction> par value; shares authorized - <ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzEw_b50247d9-945e-421e-bd3a-aa764c508d23"><ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzEw_fe330f8f-4757-4598-9660-2673d2359368">300,000,000</ix:nonFraction></ix:nonFraction>; shares issued and outstanding - <ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzIz_108c39e1-406c-4908-be04-0f03892578ee"><ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzIz_13ca947f-dc0e-497f-a67b-7f3f234fbf1f">50,461,706</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzM2_8b0b8c97-3110-471e-913a-cecbdb627b26"><ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzM2_906f3d79-da66-4b40-94f3-1710c2f97791">49,298,940</ix:nonFraction></ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTItMS0xLTA_f52dc9b9-d0c1-4ef1-a6c0-9126c08d3bfb">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTQtMS0xLTA_28d5c6e4-7ee9-4d40-a00e-f5db77d92d98">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM3LTItMS0xLTk1ODQ_27516f73-e537-4e39-8b65-2408ac62d469">607.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM3LTQtMS0xLTk1ODQ_b58f985c-3d97-4722-8f6f-85270559b51e">662.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM4LTItMS0xLTk1ODQ_3f003a64-aad8-4273-a6dd-846c0176caa2">61.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM4LTQtMS0xLTk1ODQ_add67725-5df1-49a9-a1ac-5c0b6dc65dac">50.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM2LTItMS0xLTA_b61ae8bc-2da8-4b29-a06a-f7bad67efb96">431.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM2LTQtMS0xLTA_ef4447cb-30f0-4078-a143-7d6d280c314c">315.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Surgery Partners, Inc. stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM3LTItMS0xLTA_9ac1e76b-dbba-4817-80a7-43e2cad4510e">115.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM3LTQtMS0xLTA_62f15ccf-b758-48c9-9d09-4b63d25af9f3">296.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-controlling interests&#8212;non-redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM4LTItMS0xLTA_aa98e3fc-0b15-4f0b-93ec-fb176025b2b8">766.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM4LTQtMS0xLTA_41471970-f8a0-4863-a637-b721ab8d3b6f">686.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM5LTItMS0xLTA_b719a53a-1bd0-4cb5-b576-575d8e9e77d0">882.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM5LTQtMS0xLTA_9d6d5492-eb0b-4a9a-9bbc-3327f95b4198">983.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzQwLTItMS0xLTA_8195f093-355e-40d0-bb3b-e20d546f241b">5,413.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzQwLTQtMS0xLTA_490a75c4-7ec9-40c1-90b5-b2fc546b6b07">5,018.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_127"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Dollars in millions, except per share amounts; shares in thousands)</span></div></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzQtMi0xLTEtMA_f6c94a83-11e4-4524-9073-d22fa2fe31ed">1,860.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzQtNC0xLTEtMA_6b1cc5e3-ba1a-4863-a2b7-eece50e04eed">1,831.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzQtNi0xLTEtMA_59f3752b-f8df-4133-811e-81570abf2964">1,771.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzYtMi0xLTEtMA_b64fe9b2-ad3b-4270-8459-6d609e9e2db3">550.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzYtNC0xLTEtMA_671c0650-6899-4063-b11c-a92f9ee31283">550.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzYtNi0xLTEtMA_e71a18f0-3fe2-41b8-8d19-0514f98e8655">534.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzctMi0xLTEtMA_faaf0dca-f003-4f09-8fa1-f6ed4d891942">538.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzctNC0xLTEtMA_aad69b0b-1ca6-483a-8341-fbf21891abff">507.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzctNi0xLTEtMA_52b9ca4c-972b-455a-89f4-770e2927dbe2">490.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Professional and medical fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzgtMi0xLTEtMA_dbe51bbf-aaf0-4399-87cd-ea1a63a7a786">191.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzgtNC0xLTEtMA_4de7bd67-df0b-4938-97ef-112916ff563b">154.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:ProfessionalFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzgtNi0xLTEtMA_cc9dd5e4-2486-432f-9c11-a113fb4ad2f5">145.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:OperatingAndFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzktMi0xLTEtMA_7d3ae762-9e7e-44af-a2c4-1eb61eb2fe8d">87.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:OperatingAndFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzktNC0xLTEtMA_49753009-c9f9-42e6-a3aa-641e8002281c">85.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:OperatingAndFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzktNi0xLTEtMA_2d9afecd-a4e5-4b0d-8b2d-f968b12936ce">86.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEwLTItMS0xLTA_0df79c46-057e-4834-94c8-447b286db7d8">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEwLTQtMS0xLTA_8eb53d03-e595-4bea-8c73-ea7bc17fb798">109.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEwLTYtMS0xLTA_aa3d1e0f-30dd-4afc-a7c9-ec8027e3a247">104.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzExLTItMS0xLTA_73823f3b-2a6e-4d8a-a739-2758391235c8">1,480.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzExLTQtMS0xLTA_ebd5d501-dd4e-47df-9f4a-0f639fa5e3db">1,407.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzExLTYtMS0xLTA_e400c0af-1559-4694-b9d5-1df261d97e74">1,361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEyLTItMS0xLTA_5fed4d9c-f51d-4f52-9bf1-78380f48aaf7">97.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEyLTQtMS0xLTA_d1e152b6-cd2d-43e5-9fdd-aa6ccf4aab94">88.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEyLTYtMS0xLTA_c990da7c-ae92-4bcb-a88b-f940df16137c">93.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEzLTItMS0xLTA_8ab6b417-2c07-4fe7-9ce8-79291b1ecff3">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEzLTQtMS0xLTA_e31f8eda-8790-4aef-b3ac-a75207016ac3">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEzLTYtMS0xLTA_2792f037-e601-4580-b293-97f83c7d5874">67.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE1LTItMS0xLTA_afa9f058-3c0c-4a5a-967f-1c02b462a7ed">10.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE1LTQtMS0xLTA_934d77dd-1714-4bee-8373-4c9d3212e7da">10.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE1LTYtMS0xLTA_61793cfd-5beb-41b0-b082-5516cbdf3372">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE2LTItMS0xLTA_09efc25b-ae45-458e-a674-7fcdae0dfdd6">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE2LTQtMS0xLTA_19953f1c-2b67-4036-820a-0d830443e61a">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE2LTYtMS0xLTA_f7042255-1312-4dc1-ac43-cfb80caa5140">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction and integration costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE3LTItMS0xLTA_06b54f47-c1f9-40ec-8d53-2d2543618540">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE3LTQtMS0xLTA_3e5ee7ef-9653-4814-b6d8-f03796ac3d3a">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE3LTYtMS0xLTA_fbc37e04-8bea-4e07-abae-5e91842948d9">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTItMS0xLTA_b4ed3ed5-eda2-41da-b0e6-011756edd215">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTQtMS0xLTA_bf423b14-6b7f-4bda-b7f8-50cbbe34759f">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTYtMS0xLTA_6787279a-2006-461f-af36-df6c9987496e">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:GrantRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTItMS0xLTMxODg_cb9a80e4-3975-4268-9618-ae3bd3b5132d">46.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="sgry:GrantRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTQtMS0xLTMxOTI_229fbcef-69af-44aa-b3f0-d1e9b21bdfba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="sgry:GrantRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTYtMS0xLTMxOTU_1a66c031-d030-4978-bb85-a54147cbddb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE5LTItMS0xLTA_6e7d31ec-885d-44f5-a56b-61100717cf9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE5LTQtMS0xLTA_3d703722-639d-4dee-a39b-d9b4255173f3">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE5LTYtMS0xLTA_e01fef9e-104b-4e25-82ee-069650f58ac7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIwLTItMS0xLTA_ec370b5e-2c66-4597-8121-e8f3781ad0fe">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIwLTQtMS0xLTA_a4bf2f66-b5b7-4f06-aa6f-3d24b7cf9e40">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIwLTYtMS0xLTA_be86ceba-aa0a-4410-87f9-6bf656f192a6">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNonrecurringIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIyLTItMS0xLTA_e711d129-0cac-4ab5-b0a3-c06c8c29624e">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherNonrecurringIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIyLTQtMS0xLTA_fa55b1af-93a6-47d4-b4c5-63c6256fa490">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherNonrecurringIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIyLTYtMS0xLTA_249a6c10-b770-4456-9ea5-3d0335dcad77">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIzLTItMS0xLTA_6408a5f4-75d4-4591-86ac-03a5c2f7d4a0">1,677.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIzLTQtMS0xLTA_77a2a262-8102-43e8-92eb-40d5cf34e2a5">1,595.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIzLTYtMS0xLTA_479d7c6b-2c7f-4eaf-89bc-c102171f8c36">1,693.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI0LTItMS0xLTA_80956f18-b28e-4379-886b-16e7f8a0727c">183.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI0LTQtMS0xLTA_b4bc8efe-cbce-4e21-90a7-d88fcfbf24bd">235.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI0LTYtMS0xLTA_9e06bed7-69dd-43b2-8f17-9266803dac63">77.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax receivable agreement expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI2LTItMS0xLTA_f0971c3d-a267-47f5-8480-b516e9edb66a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:OtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI2LTQtMS0xLTA_84363e6d-e652-4c02-b821-88676f89a833">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI2LTYtMS0xLTA_934fe096-5cca-443b-aa21-849ac16b2674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI3LTItMS0xLTA_4c6d2b5c-0fcd-41dc-a1eb-b825f7fb5a8d">201.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI3LTQtMS0xLTA_ea8c9e7b-3f4b-4fbe-909f-37257cf584d5">178.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI3LTYtMS0xLTA_0e427d26-d8b4-4b1d-bd15-80b655ff3e9d">147.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI4LTItMS0xLTA_c73bab2a-e123-4d07-8939-79f3e45740f4">18.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI4LTQtMS0xLTA_22beae06-6914-4850-ba34-b76319ae3604">54.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI4LTYtMS0xLTA_c0c892cd-1387-4681-84e0-72555e53765c">69.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI5LTItMS0xLTA_44ad3797-4b12-4190-b935-acabac31825e">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI5LTQtMS0xLTA_06ae5004-3118-4151-bb91-a99e2faee8a2">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI5LTYtMS0xLTA_feb54d46-5a53-4714-808b-193fa655df64">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMwLTItMS0xLTA_9182245b-3416-4da8-977b-5092c97207c9">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMwLTQtMS0xLTA_44e43cc4-4535-427d-915e-ee58d4363fa8">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMwLTYtMS0xLTA_81785881-161b-4db6-9d81-5f0ba7866117">95.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:  Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMxLTItMS0xLTA_c2d36fc3-7fd1-4ed2-a81c-039ff107a3d7">117.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMxLTQtMS0xLTA_66160a04-bd61-446b-8c99-22757da74129">119.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMxLTYtMS0xLTA_7ff030ee-f648-4ca9-9fbc-bcd29f93f07d">110.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMyLTItMS0xLTA_055925de-4410-4a3e-bf1f-e87dfae0cfa3">116.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMyLTQtMS0xLTA_a0b4331e-3023-4616-bcb5-6e9b32869427">74.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMyLTYtMS0xLTA_09e1932b-0da0-40ee-b27c-54d5ea50b7b9">205.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Amounts attributable to participating securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMzLTItMS0xLTA_ac695952-8022-494d-bc30-f0a2fab1eada">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMzLTQtMS0xLTA_9391b07c-3e03-46c6-89cc-f1e7d40db403">35.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMzLTYtMS0xLTA_f6e6b236-fb72-49cc-850c-5b0ab38fd371">32.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM0LTItMS0xLTA_fdf5fd62-c543-4c87-bc89-c66cc5ac19dc">155.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM0LTQtMS0xLTA_5643af29-80ea-4677-81f1-3ea7c0cd0e26">110.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM0LTYtMS0xLTA_53dd1103-4609-4c30-bc76-02900eeb0942">238.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders - basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e">3.19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTQtMS0xLTA_2f67ba76-2823-4860-b567-103790b87cf1">2.29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6">4.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8">48,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5">48,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08">48,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004" footnoteRole="http://www.xbrl.org/2003/role/footnote">The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in those periods.</ix:footnote></span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_130"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Dollars in millions)</span></div></div><div style="margin-bottom:17pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzQtMi0xLTEtMA_1fc48395-5381-4769-b057-1baef9a989f4">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzQtNC0xLTEtMA_095dcf04-16c4-4d65-bff9-b907c7fca045">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzQtNi0xLTEtMA_9b9d4c9d-3198-4172-9aff-afcbef69e4a8">95.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzYtMi0xLTEtMA_bf293690-2f0a-44cd-8f29-7e39ccf07020">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzYtNC0xLTEtMA_82c80a82-576d-4503-85d0-ddef8badcaf0">28.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzYtNi0xLTEtMA_807b6ffc-48c1-4460-a9b4-1812ea39e780">22.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzctMi0xLTEtMA_c1a9fb97-8f93-4ed7-b6b8-ab0600dc7bcf">9.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzctNC0xLTEtMA_941a797d-6f9a-4626-aab9-99b2011c007b">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzctNi0xLTEtMA_c0458f92-b211-4bfd-9bcf-2dc11d78158f">118.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:  Comprehensive income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzgtMi0xLTEtMA_a057cb8a-814f-4f04-9b12-5273b7fdf932">117.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzgtNC0xLTEtMA_f44cd513-1178-432c-a0f5-618dd57c95c6">119.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzgtNi0xLTEtMA_fe7ce39d-0465-47b9-b502-3af60b333652">110.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzktMi0xLTEtMA_0caccb88-8ff9-46c2-b04f-1df6a4eb107f">126.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzktNC0xLTEtMA_1ac5edfb-def7-4a0b-af46-49ac3cde63e9">103.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzktNi0xLTEtMA_17516292-82bb-4653-a106-a84dfdce44fa">228.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_133"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Dollars in millions; shares in thousands)</span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.312%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.227%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional <br/>Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Interests&#8212;  <br/>Non-Redeemable</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance as of December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i594520e2981546afb1cc70f2e2240d64_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItMS0xLTEtNTA1Mg_0d4ce962-9b44-4ec7-9d78-58faa6f2935d">48,687</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i594520e2981546afb1cc70f2e2240d64_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItMy0xLTEtNTA1Mg_b518d90d-9b95-4134-a5e3-88d98ffc8bb1">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9436eee8a582415faf17777a719e40aa_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItNS0xLTEtNTA1Mg_d250d23c-b3ab-4d71-a58a-333293a8e1fd">695.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4cfe65a0e734fc490c352616432aa34_I20171231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItOS0xLTEtNTA1Mg_fafee9ef-93d5-474b-b671-d7b7fa4dcd26">41.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa882503424e4da0be7dc022a7146191_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItMTEtMS0xLTUwNTI_8c1724de-5042-45a8-938c-f71290a70703">681.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2274a974182d4c01981835a4b40e9196_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItMTMtMS0xLTUwNTI_ad6fa1a3-69c5-46fc-8317-414d344ca054">1,336.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe8ef1c59a844626a0e801b7a033af22_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzMtOS0xLTEtNTA1Mg_6f27b832-2d6d-4a1f-8712-a25b63c48a02">205.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzMtMTEtMS0xLTUwNTI_ada4c5aa-61ef-451b-8d49-cd117deaf597">75.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzMtMTMtMS0xLTUwNTI_387679c7-92d5-4c21-a74c-4245e3e4b2cb">130.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i679f4a8d66c74b0bbb0c9afe9118ce6a_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzQtMS0xLTEtNTA1Mg_b7874a83-fdac-4c83-977e-73548419f574">339</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzQtNS0xLTEtNTA1Mg_6de89811-5bcd-40bc-8cb9-7099c245f63d">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzQtMTMtMS0xLTUwNTI_38125001-0160-456c-9fb4-4d70bc0feba0">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Preferred dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzUtNS0xLTEtNTA1Mg_fc6152ce-9dc0-4a79-9153-d5e2718ca1f4">32.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzUtMTMtMS0xLTUwNTI_89a77d7b-73a7-4222-96e4-8b41ed8451a0">32.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c8fd711c66341d38d95caf13c2cb675_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzYtNy0xLTEtNTA1Mg_52821dac-c21d-4751-9792-e342cfdfc502">22.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzYtMTMtMS0xLTUwNTI_ff264228-432a-4b92-9e7f-6f80ab6fa4ef">22.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repurchase of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i679f4a8d66c74b0bbb0c9afe9118ce6a_D20180101-20181231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzctMS0xLTEtNTA1Mg_91560452-3265-4b43-9eb2-2b40ed998ae8">157</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzctNS0xLTEtNTA1Mg_32edad8c-6902-4539-aa38-389e5b805b9b">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzctMTMtMS0xLTUwNTI_2d57e8e6-320a-4868-abce-ad29d849cdfd">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzgtNS0xLTEtNTA1Mg_652102cd-2fb9-4f69-a7bb-db350e64f47c">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzgtMTEtMS0xLTUwNTI_571f6a33-b00e-4e57-8b64-571e5eced1b4">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzgtMTMtMS0xLTUwNTI_de6c805e-8d8a-4db6-ac01-f812cab98b68">20.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions to non-controlling interests&#8212;non-redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzktMTEtMS0xLTUwNTI_3c215dad-028a-4609-9bd9-a823284e51f4">78.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzktMTMtMS0xLTUwNTI_21943323-b952-45e1-92d2-81af3f6252fb">78.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEwLTExLTEtMS01MDUy_c58ffacd-2378-4b78-8e77-ad695c67a519">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEwLTEzLTEtMS01MDUy_a443a735-034c-421c-b50b-dd8a814cda00">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0014fa9a093345e0a96dd7ea4e8aa0cf_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTEtMS0xLTUwNTI_673893bc-a4de-439c-afee-ab189c3ee1d8">48,869</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0014fa9a093345e0a96dd7ea4e8aa0cf_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTMtMS0xLTUwNTI_c634999b-1aad-4f36-87aa-841fd76499b4">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1711e7a812034ce28d37fce9a82165eb_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTUtMS0xLTUwNTI_51bf6d97-710c-4851-acd8-eef45172bba8">673.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30805210d9e14b39939e153b9bd05398_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTctMS0xLTUwNTI_81d26e2d-084a-4ae2-94ad-419f33443bb2">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe757e1f73a54e7fa3eb2b75fd451837_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTktMS0xLTUwNTI_27c1d565-e0b6-43dc-bc8b-7e1a5180030a">247.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i834d9736caee49309174d5e036c537c9_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTExLTEtMS01MDUy_988fd1fc-c18d-4a61-ba28-dc233a470010">694.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTEzLTEtMS01MDUy_1a1e4e60-1668-44f7-8bf9-e5f6703022b2">1,098.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a50f5aedaa14987b3a169a2e743a7aa_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEyLTktMS0xLTUwNTI_6f87ac60-2d9c-49d9-b5c7-1f9d085a20c4">74.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEyLTExLTEtMS01MDUy_842d15e3-0b44-44fa-8cda-7a1a3448ec62">80.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEyLTEzLTEtMS01MDUy_88e402b0-96f0-4847-8ecc-2d09cf287062">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1d553aa54d740f48fcc1ab6b34d4095_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEzLTEtMS0xLTUwNTI_0efb3689-c01c-41d8-b32e-3a8a74cea5d6">430</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9f0a869b8843a6862016205567c15b_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEzLTUtMS0xLTUwNTI_8faddb2d-cc8d-4709-be1d-9b452d78facc">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEzLTEzLTEtMS01MDUy_e8b4753c-c15f-4ad0-a819-7d2ef0886631">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Preferred dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d9f0a869b8843a6862016205567c15b_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE0LTUtMS0xLTUwNTI_c8189f10-f3c9-4a59-a47b-7dee47ed6b4d">35.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE0LTEzLTEtMS01MDUy_b1400dab-3127-499e-97dd-68c6713b9db3">35.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a4b6a2e8a5d434dad534976125b83d9_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE1LTctMS0xLTUwNTI_7656f176-6959-48a6-9cee-6eafba980433">28.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE1LTEzLTEtMS01MDUy_cb95b341-fa6b-419a-99d1-61b12f24ca66">28.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9f0a869b8843a6862016205567c15b_D20190101-20191231" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE2LTUtMS0xLTUwNTI_bf0e8a14-37a4-4670-8da2-d2149c42c705">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE2LTExLTEtMS01MDUy_e0292d76-a39c-4cba-814e-000174157515">7.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE2LTEzLTEtMS01MDUy_0027df6c-da0f-4155-aca6-8770d079a7f0">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions to non-controlling interests&#8212;non-redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE3LTExLTEtMS01MDUy_d7f91806-c26e-4214-82cc-f31f6d10d9ce">81.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE3LTEzLTEtMS01MDUy_6c526d77-a19f-477d-a1c4-fd0e5c94206d">81.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE4LTAtMS0xLTUzNzI_bdffc112-0257-4516-9c1f-1b9476bc5356">Impact of adoption of ASC 842</span></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36e8c64b0ba846c18f5a7a46fa045bc7_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE4LTktMS0xLTUwNTI_e286801e-07a8-46cc-bc26-e2f3c61ad854">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a23162dc89340049ff966ee6ce72f86_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE4LTEzLTEtMS01MDUy_bf44215d-0ba0-4227-aa15-7de698b00684">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE5LTExLTEtMS01MDUy_9bb7c19a-6f86-4f7a-9b0d-89c873b46085">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE5LTEzLTEtMS01MDUy_346564cf-dcd5-436b-bd71-81712366a3b6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if77a0a40975349a3b34383d5f0cb0c7d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTEtMS0xLTUwNTI_79fb4c7b-d3e4-4ce1-9344-418a29678c08">49,299</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if77a0a40975349a3b34383d5f0cb0c7d_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTMtMS0xLTUwNTI_ba08b795-9262-4a40-883f-278b4c37c14c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1615052a3a7f484393a4b51a8b0cd4ea_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTUtMS0xLTUwNTI_5929cc83-152e-4d21-bb8b-c33b7d81b5aa">662.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie56bc33ce06647288c4aef4b26242c11_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTctMS0xLTUwNTI_3e7068c0-0fcf-414d-b5ba-15787e81d568">50.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i541eb4cc07d4416ab46cdea917e05d4e_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTktMS0xLTUwNTI_c50bd0a2-4d24-4005-92af-da3213695137">315.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693318ba255342df98c96534cb3bdf86_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTExLTEtMS01MDUy_52f5c31a-df99-4456-b29c-d240c8eec470">686.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTEzLTEtMS01MDUy_d96fc79a-f2e4-4c7e-aa24-b324f7d906e1">983.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i975830e2f385428e80159f54d04d85df_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIxLTktMS0xLTUwNTI_abaaa519-d340-4b26-b328-783255ca69e8">116.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIxLTExLTEtMS01MDUy_bf8f7b9e-9a85-4e4d-8ea2-63648bb5ee92">85.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIxLTEzLTEtMS01MDUy_80e3aff3-9f1a-438b-8c40-a557223bcb3a">30.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if121998af9ae4288a4d53c8bf419dc1b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIyLTEtMS0xLTUwNjI_41919656-0b12-4eea-a5d3-7353ef85780b">1,163</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIyLTUtMS0xLTUwNjI_ec19d502-9d18-4318-83f1-2ffa1ff6cf01">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIyLTEzLTEtMS01MDYy_f84239b7-19ae-465c-a615-7b016a6c9afe">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Preferred dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIzLTUtMS0xLTUwNjI_eab94498-9354-481e-9f34-819fae366021">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIzLTEzLTEtMS01MDYy_5d24746d-5ff4-4fcb-818f-070b4d75c747">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2303c6c0e9e483abccd08ac36c55d58_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI0LTctMS0xLTUwNjI_b0a8179e-72a4-4d08-be44-a07f825229cd">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI0LTEzLTEtMS01MDYy_36f53b30-f42d-47cd-bd97-d832ab381b73">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231" decimals="-5" sign="-" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI1LTUtMS0xLTUwNjI_f1546c9a-9d09-40ca-ac32-0719b5557c00">27.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI1LTExLTEtMS01MDYy_9b9a7548-7c5c-4059-8572-221e68123b7d">67.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI1LTEzLTEtMS01MDYy_d7f02bd4-a4b3-49b4-b1af-005cac1a6113">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Distributions to non-controlling interests&#8212;non-redeemable holders</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI2LTExLTEtMS01MDYy_74863fbb-723e-4fd6-a873-17525d0af8d4">73.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI2LTEzLTEtMS01MDYy_a010629a-b231-436c-a543-96da60811433">73.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI3LTExLTEtMS01MDYy_55181449-d799-4c7f-8b6c-dbb937d6abf1">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI3LTEzLTEtMS01MDYy_c913fbe7-135d-4a20-8257-b12cf6dc9475">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 12.25pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3f4cb1d89ceb4b5380cabfddf941c7cb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTEtMS0xLTUwNjI_5ddb52f4-1134-4288-bd28-057ccbb26ace">50,462</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f4cb1d89ceb4b5380cabfddf941c7cb_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTMtMS0xLTUwNjI_a3ece06b-7dce-442c-81df-f5b9d5eaa56a">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2369ebaa4684a78a2970d00fd9578f8_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTUtMS0xLTUwNjI_482edb64-a476-408d-975a-1eff5f62892f">607.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b7bc629529e4c048c9abfe722e66014_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTctMS0xLTUwNjI_8776762d-9753-46c1-b4a8-9f1d777e6768">61.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc6bef361c04164a50070ac5d583e49_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTktMS0xLTUwNjI_65c173c9-142c-4275-a4d1-5e783fa67e17">431.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47d590096f6a4da5ae4f1dc1b45a84ef_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTExLTEtMS01MDYy_dfd6995e-703d-4b65-bd1e-c1bdabcfd831">766.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTEzLTEtMS01MDYy_0ff8f5a3-e403-433b-a8ba-0a5da43b5a8e">882.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_136"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Dollars in millions)</span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUtMi0xLTEtMA_1fc48395-5381-4769-b057-1baef9a989f4">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUtNC0xLTEtMA_69b5e31c-f241-4136-b278-48a65a4746be">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUtNi0xLTEtMA_3e1fa605-f957-47d2-a0b8-cb0c8dafca9d">95.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzctMi0xLTEtMA_0e0403a9-e309-4574-a24c-b826d3b79bce">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzctNC0xLTEtMA_650b6ee5-d553-43b7-96f0-6fe42eb72421">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzctNi0xLTEtMA_091fb16d-31f8-40f2-836f-797a2a1edc26">67.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense (income), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="sgry:NoncashInterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzgtMi0xLTEtMA_462f4335-f1cc-42c1-bc0d-8976e40a5a4b">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="sgry:NoncashInterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzgtNC0xLTEtMA_0e899d41-b4f2-4229-8f6e-79aeef89d5c1">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:NoncashInterestIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzgtNi0xLTEtMA_3ae01acc-96fe-4e4b-9e3f-d09214f4879e">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzktMi0xLTEtMA_06786725-4a0b-46db-a278-051a36b1ddfe">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzktNC0xLTEtMA_25b9af30-3b0c-4850-a087-17164e3b3281">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzktNi0xLTEtMA_cf2175a1-27e1-4489-832b-b855f83fcb30">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTItMS0xLTA_6804929c-6a49-4bd2-866a-f6110820cb3d">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTQtMS0xLTA_8d86bf8f-11d1-4a7e-bb3b-84b7586e81a0">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTYtMS0xLTA_64e39c3d-dcb3-454e-9a10-9b9da02a246e">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTItMS0xLTczMjI_a6fc733a-c407-4176-9e6d-0e98b315e33e">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTQtMS0xLTczMjI_41cc7bfc-5166-4b10-85e1-a3f26264ede3">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTYtMS0xLTczMjI_b9577171-ae34-4c75-b95d-489f059adcab">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTItMS0xLTczMzU_c9fbcf76-007e-4425-9364-94b6e300f181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTQtMS0xLTczMzU_f291ebb9-132d-4b8f-ac7d-284c83433f89">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTYtMS0xLTczMzU_97d8f1c3-64e4-46fa-9535-372a7e849002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTItMS0xLTA_472a49b7-d9de-4971-9b2e-4421e2891199">21.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTQtMS0xLTA_e3f85344-4f55-4be8-8032-91d9139fb6b4">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTYtMS0xLTA_347dcd78-7dc5-4688-b876-85bd401676ee">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from equity investments, net of distributions received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEyLTItMS0xLTA_4c71b7c0-e5ac-435d-a7d9-4c13c9130b5e">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEyLTQtMS0xLTA_8dc63a87-df0e-4061-805a-5b98bc1d3d8e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEyLTYtMS0xLTA_d2691354-eef9-4572-bd03-f2c095d889f9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzE0LTItMS0xLTA_85dc7a93-9d98-4c1c-95d5-95dc544b0c92">39.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzE0LTQtMS0xLTA_6c86945f-5332-43b6-b8a4-7717a97fdf6a">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzE0LTYtMS0xLTA_92c14d97-5559-4f69-81f4-4570137c0f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTItMS0xLTA_b75723f0-9ee3-48bf-ad4f-681f2a4843a1">46.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTQtMS0xLTA_0e8d9db4-6625-40d4-9cff-de4d7bbaa421">23.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTYtMS0xLTA_978acf7c-73d9-4d5c-8b34-6c41ccc4ba8e">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare accelerated payments and deferred governmental grants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTItMS0xLTQ4MDE_fd2174cd-a92b-4ba4-9e02-884ce5946b25">135.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTQtMS0xLTQ4MDE_fc7d4ed4-41ed-4e7a-bac8-0c2f6e0b2b6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTYtMS0xLTQ4MDE_a27e8514-da29-4f1c-b897-c6b37cae5914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIyLTItMS0xLTA_b30fc032-d306-4976-bbfc-81a157cc1e2a">12.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIyLTQtMS0xLTA_cf194c9a-10dd-4c3d-94aa-4d31e6d32dfb">45.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIyLTYtMS0xLTA_a4943409-9e22-43bc-83a0-5b88992e2634">56.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIzLTItMS0xLTA_29b0b8c9-18c3-4970-935b-f4ea894fd533">246.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIzLTQtMS0xLTA_7f90ff15-0f9d-41de-8edd-bdbc2ccef512">129.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIzLTYtMS0xLTA_a8b5e5b3-f8d8-4a17-ac6b-67e3e62c1bf6">144.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI2LTItMS0xLTA_a6f6c498-16a3-4d78-8c55-0fc67fa32944">42.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI2LTQtMS0xLTA_e9f88b6f-e892-4bfc-aee0-51a1497313c8">73.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI2LTYtMS0xLTA_7c4cb4a6-eb70-428f-8cf8-9d500707bc7b">39.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for acquisitions, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI3LTItMS0xLTA_81bafc76-cf61-440f-bd59-f6ac356acb97">104.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI3LTQtMS0xLTA_bec668cf-07f8-4afd-a76a-fcdba1fc7186">13.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI3LTYtMS0xLTA_aaca4239-a1d8-4ade-880f-e8eab5abacd2">106.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposals of facilities and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI0LTItMS0xLTczNTQ_9ef9a8f6-1a73-4635-b67c-c0e93fd1a8a5">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI0LTQtMS0xLTczNTQ_272ae68f-1e22-48d8-a68c-0a0d695ca001">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI0LTYtMS0xLTczNTQ_6e089bde-6f59-49b0-83c5-4cd1aa03c491">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI4LTItMS0xLTA_aff0a349-702b-422b-b40c-73b5d35edcdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI4LTQtMS0xLTA_472cd8c5-2f01-4f5f-bc06-518da9053346">15.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI4LTYtMS0xLTA_3ad68ec8-b747-488c-980c-45e4774ce8cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMwLTItMS0xLTA_3e828592-9701-434b-978b-80066a68f1ff">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMwLTQtMS0xLTA_c6541385-f4d3-402b-9ca6-1093f6e45f90">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMwLTYtMS0xLTA_0659b51e-902b-48f0-9a52-cfc235765e82">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMxLTItMS0xLTA_59e9abc5-9869-4578-91a8-2dcedc181e0b">88.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMxLTQtMS0xLTA_a800e5b3-c54c-47a9-990b-6b2acc302ff8">85.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMxLTYtMS0xLTA_16c99910-9ad0-4fc4-af19-2cd129138cbe">128.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments on long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM0LTItMS0xLTA_38edc134-c894-4234-bf4d-7d906a16cf64">216.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM0LTQtMS0xLTA_2ef0fd32-2937-4436-8af1-cd9c19a135c9">490.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM0LTYtMS0xLTA_62012cbd-c66e-4007-b09b-4e2db137caab">157.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM1LTItMS0xLTA_3fb696af-6d90-4f9d-9efb-d254e067e950">429.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM1LTQtMS0xLTA_8af9187a-99ae-49b2-b418-835b4223b58a">506.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM1LTYtMS0xLTA_75ae66f6-ba33-4213-8c7d-ca0306448820">282.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM2LTItMS0xLTA_395f746b-c9de-4078-9879-991c291c5121">8.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM2LTQtMS0xLTA_7eddee57-edd7-4d02-9b1b-a0308bfc3ea8">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM2LTYtMS0xLTA_8750d5d4-4bb0-4385-af6e-5b8ca1e4c2e1">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of premium on debt extinguishment </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="sgry:DebtInstrumentPrepaymentPenaltyAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM3LTItMS0xLTA_d08c1c9f-3d8c-448f-95df-49db440185ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:DebtInstrumentPrepaymentPenaltyAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM3LTQtMS0xLTA_814072cc-12e6-4f20-82e8-b43e6aa11119">17.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="sgry:DebtInstrumentPrepaymentPenaltyAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM3LTYtMS0xLTA_eb18c137-aebe-4039-8bbf-7fc843dc3cd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions to non-controlling interest holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM4LTItMS0xLTA_a50865c8-d4eb-4ba7-9eb3-d7d2d93544db">109.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM4LTQtMS0xLTA_36f9bc42-292c-40eb-a4ac-e6f590c008cd">121.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsOfDividendsMinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM4LTYtMS0xLTA_2dc25a38-7e76-4ca3-83b3-4411192ac4a7">109.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments related to ownership transactions with non-controlling interest holders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM5LTItMS0xLTA_70a4a11a-1a24-40a1-ba6a-8c3d35ff099d">27.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM5LTQtMS0xLTA_74ed2f51-1fcc-46e5-bff5-cbd37c50307f">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM5LTYtMS0xLTA_243c9443-bac3-47d1-b2b6-80a363396e1f">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of preferred dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQyLTItMS0xLTA_1d9a4410-a22b-4ef0-9c03-0af174c59937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQyLTQtMS0xLTA_76d11ec3-0564-4428-8de7-af05bd7a31e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQyLTYtMS0xLTA_dd4dc34a-b44c-4358-ac13-0b1c773ff0da">7.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQzLTItMS0xLTA_b8f98e0f-23b8-4fa7-a942-b849cfc7cec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQzLTQtMS0xLTA_57039389-7b9c-4483-8a7f-f4129234a4be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQzLTYtMS0xLTA_ad8dccf6-d67f-4ae3-b56d-8f715d789a96">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ0LTItMS0xLTA_fce06f3e-ab42-4c00-851e-adb7cca5bb76">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ0LTQtMS0xLTA_85f7df78-9d9c-4c83-95e9-b5f2d86f7dcf">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ0LTYtMS0xLTA_9c8dfc1d-dcd6-402c-80fe-a218d996681e">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ1LTItMS0xLTA_7f10e2da-3822-4eff-9837-158b42a0e042">66.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ1LTQtMS0xLTA_1827670d-d57e-448f-aec8-c224375e30b8">135.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ1LTYtMS0xLTA_c2facc7a-83cb-4a4b-956f-f09d9436ff45">6.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ2LTItMS0xLTA_93771de4-3b70-4861-a742-b01f23195870">225.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ2LTQtMS0xLTA_eb2aed0f-1b4c-4671-aac5-743ae76e21f1">91.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ2LTYtMS0xLTA_66562aac-2034-4faf-b196-e05e8d2a2935">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ3LTItMS0xLTA_15d83d67-9aa0-487e-b109-a18bdc4bd46c">93.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ3LTQtMS0xLTA_124281fa-a91e-4e92-b2d1-a2d6d0c31bfe">184.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2274a974182d4c01981835a4b40e9196_I20171231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ3LTYtMS0xLTA_0d7f5022-bebc-4f18-bbdd-19ba57429b76">175.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ4LTItMS0xLTA_e74ed614-2d60-407d-b990-da6aad818d0c">318.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ4LTQtMS0xLTA_07414187-ec22-4f56-afa0-2770ecfe129f">93.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ4LTYtMS0xLTA_674f25f5-925d-40c8-91b7-75853cec7586">184.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid, net of interest income received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUxLTItMS0xLTA_fcc710bd-0326-4cb8-8c57-a4e9f4cbe895">203.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUxLTQtMS0xLTA_9e6f2bd7-0497-4396-94ba-5c9bad842b74">180.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUxLTYtMS0xLTA_22b85790-6b1d-461b-b74e-34d67781d59d">145.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUyLTItMS0xLTA_bb6bdf44-89de-4d92-af53-37bbd70c18d6">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUyLTQtMS0xLTA_b36ab849-c619-491f-ab5c-12e459d125db">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUyLTYtMS0xLTA_2735582c-c855-41a8-9108-385fa7d58504">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUzLTItMS0xLTA_61463d33-0880-4e77-8deb-4d094c4765b7">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUzLTQtMS0xLTA_b75cc2d3-ca19-44e7-ac4d-90803db8f2a4">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUzLTYtMS0xLTA_a8916ef1-f477-409e-a179-f547ac21b452">61.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See notes to consolidated financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span><br/></span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_142"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NDk2_ae418b2b-8c05-490b-9081-c8015a81df3b" continuedAt="if215b8cd509e4d6d9a60880322541ad5" escape="true">Organization and Summary of Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if215b8cd509e4d6d9a60880322541ad5" continuedAt="ia059f129e5f145b5bfd3fe1c85df765e"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners, Inc.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Delaware corporation (together with its subsidiaries, the "Company"), was formed April 2, 2015. On August 31, 2017, a fund advised by an affiliate of Bain Capital Private Equity LP ("Bain Capital") became the controlling stockholder of the Company, holding Series A Preferred Stock (as defined in Note 7. "Redeemable Preferred Stock") and common stock that collectively represented approximately <ix:nonFraction unitRef="number" contextRef="i5eda05d02ba64f78991a4f0b2af38f0b_I20170831" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzU4NA_d7adf618-0f20-49e4-98f8-ae7df3c5347e">65.7</ix:nonFraction>% of the voting power of all classes of capital stock of the Company as of August 31, 2017. As of December 31, 2020, Bain Capital held approximately <ix:nonFraction unitRef="number" contextRef="i358a5e89179e41d0822a47803a3d6dac_I20201231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE3MDI3NTA_bc13eff5-c818-4f28-9680-88762a5216bc">67.0</ix:nonFraction>% of the voting power of all classes of capital stock of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company owned and operated a national network of surgical facilities and ancillary services in <ix:nonFraction unitRef="state" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzc2NA_0bda4872-0ccb-4b28-85de-54ad3dbc0277">30</ix:nonFraction> states.&#160;The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management.&#160;The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company owned or operated a portfolio of <ix:nonFraction unitRef="surgical_facility" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE0Mzk_f349c869-4876-4b57-8081-ac4b8597ebfc">127</ix:nonFraction> surgical facilities, comprised of <ix:nonFraction unitRef="surgical_facility" contextRef="if91011ef54014758871d4c1d7f4f8be6_I20201231" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE0NzY_6173d8dc-6ceb-4d8b-910f-5dfb1174f733">110</ix:nonFraction> ASCs and <ix:nonFraction unitRef="surgical_facility" contextRef="i33440f4bb58f4fee905410e7e11b9a27_I20201231" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE0ODg_18b7e471-9e66-488d-a1be-a8759dce5014">17</ix:nonFraction> surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in <ix:nonFraction unitRef="surgical_facility" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE2OTk_201a187a-ce10-4e2b-b260-3ad2aeb06a03">84</ix:nonFraction> of the surgical facilities and consolidated <ix:nonFraction unitRef="surgical_facility" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" name="sgry:NumberOfSurgicalFacilitiesOwnedConsolidated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE3NDY_2a908c87-7d11-42a0-a18d-5c8766d7acf3">107</ix:nonFraction> of the facilities for financial reporting purposes.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTYy_935d772e-6fab-4489-85b1-a7c35cd78e2f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTQz_1a558ccb-050b-4785-94d0-aac000d0b478" escape="true">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 global pandemic has significantly affected the Company's facilities, employees, patients, communities, business operations and financial performance, as well as the U.S. economy and financial markets. Beginning mid-March, the COVID-19 pandemic began to negatively affect the Company's net revenue and business operations. Due in part to local, state and federal guidelines, as well as recommendations from major medical societies, requiring social distancing and self-quarantines in response to the COVID-19 pandemic, surgical case volumes across most of the Company's surgical facilities were significantly impacted in the second quarter of 2020. The impact of COVID-19 on the Company's surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures that are typically performed. Although the Company cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic, surgical case volumes improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. The Company's operating structure naturally enables some flexibility in the cost structure according to the volume of surgical procedures performed, including much of its cost of revenues. In addition to the natural variability of these costs, the Company and its partners in the surgical facilities have undertaken additional steps to preserve financial flexibility. Beginning in mid-March, and for the remainder of 2020, the Company took actions that included significantly reducing cash operating expenses and deferring non-essential expenditures at the height of the crisis. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CARES Act</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law to provide stimulus funding for the U.S. economy. As part of the CARES Act, the U.S. government initially announced that it would offer $100&#160;billion of relief to eligible health care providers. On April 7, 2020, Centers for Medicare and Medicaid Services ("CMS") officials indicated they would distribute $30&#160;billion of direct grants to hospitals, ASCs and other health care providers based on how much they bill Medicare. Payments received from these grants are not required to be repaid provided the recipients attest to and comply with certain terms and conditions, including limitations on balance billing and not using funds received from the grants to reimburse expenses or losses that other sources are obligated to reimburse. The Company received approximately $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="sgry:ProceedsFromGovernmentAssistance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE2Njg4MDI_8fbfc951-419d-4e26-9d3a-e65e4e78ef7f">59</ix:nonFraction>&#160;million of the grant funds distributed under the CARES Act and other governmental assistance programs during the year ended December&#160;31, 2020. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company&#8217;s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the COVID-19 Economic Relief Bill, enacted on December 27, 2020, and all frequently </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="ia059f129e5f145b5bfd3fe1c85df765e" continuedAt="i0546c6d7774b4b72960855c1afb3c146"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">asked questions and other interpretive guidance issued by HHS, including the Post-Payment Notice of Reporting Requirements issued on January 15, 2021 (the &#8220;January 15, 2021 Notice&#8221;) and frequently asked questions issued by HHS on January 28, 2021 which clarified previously issued guidance, as well as expenses incurred attributable to COVID-19 and the Company&#8217;s results of operations during such period as compared to the Company&#8217;s budget. Such guidance, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to COVID-19 that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. As a result, the Company estimates approximately $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgry:GrantRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE2Njk2MTE_cb9a80e4-3975-4268-9618-ae3bd3b5132d">46.2</ix:nonFraction> million of grant funds received qualified for recognition as a reduction in operating expenses under the caption Grant funds in the consolidated statements of operations for the year ended December&#160;31, 2020. While the January 15, 2021 Notice and frequently asked questions issued by HHS on January 28, 2021 indicate that targeted distribution payments may be allocated or transferred to subsidiaries, distinct conditions exist for such allocations or transfers. There are significant uncertainties as to the meaning and interpretation of conditions specific to the allocation or transfer of targeted distribution payments such that, as of December 31, 2020, the Company is not reasonably assured that it can or will choose to comply with such conditions in order to allocate or transfer targeted distribution payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amounts received, but not recognized as a reduction to operating expenses as of December&#160;31, 2020, are reflected as a component of Medicare accelerated payments and deferred governmental grants in the consolidated balance sheets as of December&#160;31, 2020, and such unrecognized amounts may be recognized as a reduction in operating expenses in future periods if the underlying conditions for recognition are met. HHS&#8217; interpretation of the underlying terms and conditions of grant funds received through the CARES Act and other governmental assistance programs, including auditing and reporting requirements, may evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in the Company&#8217;s inability to recognize certain payments, changes in the estimate of amounts recognized, or the derecognition of amounts previously recognized, which may be material.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a way to increase cash flow to Medicare providers impacted by the COVID-19 pandemic, the CARES Act expanded the Medicare Accelerated and Advance Payment Program, which allows for most providers and suppliers, including the Company&#8217;s surgical hospitals and ASCs to request an advance payment of anticipated Medicare revenues. ASCs could request up to 100% of the Medicare Fee-for-Service payment amount for a three-month period. Hospitals could request up to 100% of the payment amount for a six-month period, with certain critical access hospitals able to request up to 125% of the payment for a six-month period. Under the current terms of the program, all providers will have 29 months from the date of their first program payment to repay the full amount of the accelerated or advance payments they have received. The revised terms extend the period before repayment begins from 210 days to one year from the date that payment under the program was received. Once the repayment period begins, the offset will be limited to 25% of new claims during the first 11 months of repayment and 50% of new claims during the final 6 months. The revised program terms also lower the interest rate on outstanding amounts due at the end of the repayment period from 10% to 4%.The Company received approximately $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="sgry:CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE2NzUyMTQ_47111b57-ff58-45b2-a95a-c57bf4539030">120</ix:nonFraction>&#160;million of accelerated payments during the year ended December&#160;31, 2020. These accelerated payments received were deferred. The current portion was approximately $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzExNTQ0ODcyMTYxOTAy_0565138b-f493-43c5-bd50-53a24e6c03eb">95</ix:nonFraction>&#160;million and is included as a component of Medicare accelerated payments and deferred governmental grants in the consolidated balance sheets as of December&#160;31, 2020. The long-term portion is included as a component of other long-term liabilities in the consolidate balance sheets. The Company does not expect to receive additional Medicare accelerated payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CARES Act also provides for the deferral of the Company's portion of social security payroll taxes for the remainder of 2020. Under the CARES Act, half of the deferred amount will have to be paid in each of December 2021 and December 2022. The Company began deferring the social security payroll tax match in April 2020. As of December&#160;31, 2020, the Company has deferred approximately $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgry:DeferredEmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE2OTc1MDI_466e0ce9-63e0-436b-8040-2368a4208892">16.9</ix:nonFraction>&#160;million. The current portion is included as a component of accrued payroll and benefits and the long term portion is included as a component of other long-term liabilities in the consolidated balance sheets as of December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is continuing to closely monitor legislative actions and regulatory guidance at the federal, state and local levels with respect to the CARES Act as other governmental assistance might become available to the Company.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjI1_03490ab7-a9d4-4916-99a9-094bc73e4b66" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of Accounting Standards Codification 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company has the power to direct the activities that most significantly impact a variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. At December&#160;31, 2020, the variable interest entities include <ix:nonFraction unitRef="surgical_facility" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:VariableInterestEntityNumberOfFacilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQxMTg_f5982ea6-b2a9-41be-8d28-c3ebb2a201e5">four</ix:nonFraction> surgical facilities and <ix:nonFraction unitRef="physician_practice" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:VariableInterestEntityNumberOfFacilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQxNzA_baa3e2d7-257e-4a77-a4ff-eb77e40049f2">three</ix:nonFraction> physician practices.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying consolidated balance sheets as of December&#160;31, 2020 and 2019, were $<ix:nonFraction unitRef="usd" contextRef="i86b1a160332645c186bcb8e28fe6f17d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQzNjM_003c3c87-a061-45fa-a736-e1390175ddd3">27.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8e7f2aea22094bddb8c6931fc0dea651_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQzNzA_fa4f6969-9d16-4ce8-a8cf-84c65c60fb04">36.2</ix:nonFraction> million, respectively, and the total liabilities of the consolidated VIEs were $<ix:nonFraction unitRef="usd" contextRef="i86b1a160332645c186bcb8e28fe6f17d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQ0NDQ_e7a88f98-648b-42c7-9d0d-e8ed64a2a899">21.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8e7f2aea22094bddb8c6931fc0dea651_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQ0NTE_4680ee4d-06c1-445a-ac27-b471d458350b">25.2</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NDY4_07c2a53a-a5cd-4ffa-b822-70e30eaea18b" continuedAt="i392f80c19572487a823ee92f5c5a8994" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i0546c6d7774b4b72960855c1afb3c146" continuedAt="i3ccabf64f3ce4731b6b5f9265300dd6d"><ix:continuation id="i392f80c19572487a823ee92f5c5a8994" continuedAt="ic290597a873947ef8378a508bb2ceadf"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div></ix:continuation><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTcz_a73a45d3-5cf6-455f-8b45-cedaf4889248" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:13pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809eef37f4e54081a6dc49a891ecdaec_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzQtMi0xLTEtMA_e8c9714f-360a-49c0-bfd0-7b809f4f727f">1,539.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eab8ecdfcc74e9e855708a2c1ca417f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzQtNC0xLTEtMA_29c91457-0ae2-45d5-b710-41165803e22c">1,434.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119f3f636b3d41ad852c157ef3a54380_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzQtNi0xLTEtMA_689e3ed2-7f7e-4b73-aed9-a9bb6701cc98">1,533.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3eaeb718994330b5ba6da8d0809206_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzQtOC0xLTEtMA_e3c0eb03-179c-4454-a282-b3fe83b3c034">1,434.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i911d67503a3e4528a30814a4348d8ea4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtMC0xLTEtNjA2L3RleHRyZWdpb246MmE4MzEyOTc0N2U2NDNhZmFiNjZkYmMyNDgyZGVjMjFfMjE5OTAyMzI1NTYwMA_10631964-487f-4b80-b7cc-92b2e6df91a0">6.750</ix:nonFraction>% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c30ac06941c4200b21b1e23272f2da0_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtMi0xLTEtMA_6f38fcaf-74c2-48ab-af46-3a19a43968d3">370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa2c1066f2b4f8c8f0f3388f465debe_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtNC0xLTEtMA_81814612-7df3-4ec5-9db4-652971c7a12b">370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162bdeb976434409ae1a1c6f77a718a1_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtNi0xLTEtMA_cdf8567f-62a6-4f49-8f7f-881b8bd548e5">376.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadab410bba6e4144a75e318b53880035_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtOC0xLTEtMA_73edb8ef-4563-40cc-a870-9d4f52de63e7">368.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7bd4886dd3f74966858590367b6f85d9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctMC0xLTEtNjEwL3RleHRyZWdpb246NzkxNjcyYTEzYWVmNDQ5M2I5YWVmZGQzM2UxYjcxZTFfMjE5OTAyMzI1NTYwMg_3ee4bf56-e937-42e9-9b86-388f3b53dd24">10.000</ix:nonFraction>% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d560570554a4fd1b7a05ce7bb03e9d4_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctMi0xLTEtMA_c5c02240-d35c-4353-a504-208425de3d42">545.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cb5f59640994a199093fe9c3ab2ac03_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctNC0xLTEtMA_6ff35b74-57b2-48ef-af9b-18af62dd793a">430.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0f5839140a4b41b51f5bd58cb54057_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctNi0xLTEtMA_f50b5cc4-fed3-4bd6-8c78-21d0c299253e">596.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa06470b17c4eb2b260df51cf4c128e_I20191231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctOC0xLTEtMA_ebc71b28-eec6-4c9f-86bb-1313b6c47887">471.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ic290597a873947ef8378a508bb2ceadf" continuedAt="i3339637671cb49798f60e540cebc5008">The fair values in the table above were based on a Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values under Level 3 calculations.</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has entered into certain interest rate swap agreements (see Note 8. "Derivatives and Hedging Activity"). At December&#160;31, 2020 and 2019, the fair value of these derivative instruments was $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzYxOTI_1351bedf-8358-44a1-9046-4fd72f1996d7">61.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzYxOTk_5c98eee4-e548-4da6-aba4-4d3c974f5d8f">50.7</ix:nonFraction> million, respectively, and was included in other long-term liabilities in the consolidated balance sheets. <ix:continuation id="i3339637671cb49798f60e540cebc5008">The fair value of these derivative financial instruments was based on a quoted market price, or a Level 2 input.</ix:continuation></span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjU1_38e06d3e-43e1-46a6-b2b2-5a562bae0565" continuedAt="i359c29d114654bc98b5b51a702ab45ce" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which our obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjA3_e6e2f630-03a8-4961-b833-face5b946ce2" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d2bbed9c6534351953638dbdb3614f3_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzQtMi0xLTEtMA_cce94c4a-94d3-4b0d-91f6-f819d8709f0a">95.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e98bfd347534baf87731104e3ebb009_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzQtNC0xLTEtMA_1ce8cfdf-8bcf-4390-b44d-3bc34aab78ba">94.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb1b7267569e4598a877a5bd1e7e60c0_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzQtNi0xLTEtMA_211c974c-35ec-4224-993b-9eb48591f338">93.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb74e0812a1a443d8b8840c07f69e351_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzUtMi0xLTEtMA_6d54f26d-f9df-4dde-b229-9b21421840fa">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i765813026e6747489932f2af5293073c_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzUtNC0xLTEtMA_02c60e42-f54c-4502-9137-966f6b4e29c0">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc2bea721a2d47a69444093571e4ee96_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzUtNi0xLTEtMA_0d57a67a-bc5f-449e-8199-99b3aee3c899">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie75ead2faa6f445cbe2c4cea920cf20c_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzYtMi0xLTEtMA_4e744893-c904-4ad1-9fae-368096952a89">98.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6f0752ff15148458214da6f9a47c887_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzYtNC0xLTEtMA_36d111b8-a8f7-4724-8161-1b847e2c6f75">98.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i281bab5aadc7405e927b61233cc41c4e_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzYtNi0xLTEtMA_01c7de88-28bf-4859-8285-f0a218df9527">98.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical services revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37b3da5de5c04f86991cec578aae4497_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzgtMi0xLTEtMA_0ff6c8bd-e06c-4d74-8575-71a87ef6dafe">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b4cc978af3f4a63b82fda4044e5fff5_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzgtNC0xLTEtMA_fd38b97b-a8a9-4d0b-8bb8-0fe85d1478da">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9261ab18f79e429d8804ff5e25c2a493_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzgtNi0xLTEtMA_d3564993-40fe-42e7-8171-661cf1e11f1e">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i825199532fc645f5b290bb16b440feda_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzktMi0xLTEtMA_179ea919-ed76-405a-825b-b6d0c79bb776">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibbd90e3a784c4bef8f5691eca433c93c_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzktNC0xLTEtMA_df119ce4-d18a-47e9-a26f-07bab4511b22">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4bd378e171d0488e9bd9affdec483b9a_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzktNi0xLTEtMA_8994c5a3-374d-4e64-b133-d3d84a742a6a">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie3b0a3e3d1ca40ef8aa43b2e273dd745_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzEwLTItMS0xLTA_2a374648-9e33-4899-b803-9448cdbd60a3">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf8eaf96b18847fd812316b9aa3c3ea1_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzEwLTQtMS0xLTA_015dd251-d939-44fd-b9f7-918adbbbd5c6">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia042b57c0fae4f5ea23237a58e596e29_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzEwLTYtMS0xLTA_ce49e806-35c8-40ba-a9da-2011fe4d6515">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb6553b4b74c4d84abce7d64bb6e0233_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzExLTItMS0xLTA_9073a37d-a3b0-424e-a2a0-69ec8964e1fc">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf8d6a4513eb4b37bf1fdd0a3cd39717_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzExLTQtMS0xLTA_313cbf15-c201-4d8a-92d8-2953c31f843d">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i475a6b5170b94142b99badc78dfce138_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzExLTYtMS0xLTA_c78a7976-592f-4309-b501-562bd02f93ff">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"><ix:continuation id="i359c29d114654bc98b5b51a702ab45ce" continuedAt="i38a589128e8b4e689162e97a63371434"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160; This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications.&#160;The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. </span></ix:continuation></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i3ccabf64f3ce4731b6b5f9265300dd6d" continuedAt="idef221b9ba624b549600a85565c25350"><ix:continuation id="i38a589128e8b4e689162e97a63371434"><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments, discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Optical service revenues consist of handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. The Company satisfies the performance obligation and recognizes revenue when the orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company sold its optical products purchasing organization on December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div></ix:continuation><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTI4_584efc16-5e67-4dc3-a30a-8ebcdbc621cc" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599771c495cc475cb14cd51b2c80b0ff_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtMi0xLTEtMA_a97d973f-39e5-478e-8860-fa90cd66de93">989.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7ba3aeaa4184e578466ecc35d54af1e_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtNC0xLTEtMA_a1258ffa-5d1b-4365-97e5-b832c6ff85ef">53.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id054af85841844e0a0510013723067b0_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtNi0xLTEtMA_24a7982d-bc23-4093-af8b-01cb1bb1283a">970.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i142ee4c9bb7f48ac86443c88ccd89e60_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtOC0xLTEtMA_d081a98b-7f80-46d3-8ecc-a32207015bc4">53.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7005419b507e45a4aa93e70381643122_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtMTAtMS0xLTA_578e172d-6ea9-46e1-a375-4fc9cced6559">948.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8db4acdb7fc34959956ed5d777c0c8aa_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtMTItMS0xLTA_5edf1195-4ae6-4db0-8577-95fc8f00a38c">54.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36320eddebd1443f9992f87dccb87372_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtMi0xLTEtMA_6664e5c0-4616-4e79-a6d4-833f5ed6aaf1">708.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2540c42567484e9c8d3478cf6157e2d0_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtNC0xLTEtMA_a5c9dc61-0a66-4a23-ae30-87b10332caee">38.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab9c71919d94f0b8dd7b5473c520031_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtNi0xLTEtMA_dba4a023-ed6c-4254-adcf-0cdbdc2b3e8d">701.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if923233c958e4fd68b49484dc223744b_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtOC0xLTEtMA_28ec1506-d38a-4c00-b0ba-cbc52c006e14">38.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7250d04b81545d2b83ffebe4398b150_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtMTAtMS0xLTA_ab48bc68-0eac-4082-adfe-b2be764ab982">653.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8b4b08c817e40b59ede6eeeb62709da_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtMTItMS0xLTA_8818308e-015c-45c1-b2ec-04a752bfd99a">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i885eb9ec2ef944bca136520bc4460c09_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctMi0xLTEtMA_ec303060-f417-43cd-9163-4f56f746c5c4">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94c93236fd5e4fefa3dcd39e74f88113_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctNC0xLTEtMA_3a48f07a-2f4f-40f8-8d6a-19066b7c12e3">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec00cab9d2244fb80d85733bd9a7509_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctNi0xLTEtMA_e6bb2214-ac78-40de-957a-25bc27dad9bd">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89029e5f88e44f1fae990a75d8ef24c0_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctOC0xLTEtMA_3a8cf016-232c-4279-91db-0364659039ad">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ea7f0bf38e48f6a9c4239b60ad72f6_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctMTAtMS0xLTA_987e3537-cd04-471c-96d0-88361df6ab8d">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaab475b98e9148eeb2d8f43e3181a7bc_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctMTItMS0xLTA_285200f4-2e67-4777-b1d7-08e56b6c996a">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3172eb66c1954274b662b8b0387af2be_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtMi0xLTEtMA_e4df3cfe-b96d-4a23-b42d-f8e56dac42dc">79.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e2d986e12534bc0966c86c0cc1307aa_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtNC0xLTEtMA_76427e24-90cf-4852-b7cb-4b0f112de2e0">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e789cf2134b4a4dadeab6da7c134bbb_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtNi0xLTEtMA_bb9d426d-6237-4baa-9c2d-077589494c73">84.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb93f590e80e4cedae1dcfd1b284ce87_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtOC0xLTEtMA_8f06e387-ba5c-47ef-8a88-4b764943e270">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f4fb0674ba4d63b328c08bd2cd38d0_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtMTAtMS0xLTA_2f2517e5-6132-4c80-86c3-e755e91efb44">84.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd4902e6aed24239a5e4d6ed4e5c823f_D20180101-20181231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtMTItMS0xLTA_62454f8d-306e-4cca-8d5f-c7d833655def">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d2f9dc0f01494986594870e8a27ffa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktMi0xLTEtMA_61d9c5d3-8292-4a90-819f-4c955c08b9ca">1,836.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib051090172004935b836c83156fe9867_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktNC0xLTEtMA_57c1c687-dd67-494f-988f-0852b87cff0a">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9ac1ba58bd4816b2c020ff0edcba26_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktNi0xLTEtMA_26388c8e-d6d8-4a7c-971b-b009945d62bb">1,803.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icafafb71f58e407ab4cf51f081227241_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktOC0xLTEtMA_ccfc4ea0-f3be-4bf1-ad3b-b9dcc5715a8b">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67253343d70443d9c7449f4a5c30664_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktMTAtMS0xLTA_82c16fb1-7825-42d4-af00-20f33c3d92a5">1,737.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4daf007b63f4b438c7341c6ac37b460_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktMTItMS0xLTA_5f45b81b-89dd-4c05-aa13-cca6da5bb549">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559b03a82e914664a3d8b0edaabe4911_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzExLTItMS0xLTA_5c9cba49-5951-4817-a249-060ce2821889">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9c8cab4fb14810be18a40a5b9653b9_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzExLTYtMS0xLTA_f6ffd940-1ff0-4cd5-8c53-457057a40645">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7933eb55bb3143ffa2fd7f711c754dbf_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzExLTEwLTEtMS0w_7820e60a-9675-4ddd-8bda-a47527b70529">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334aefa151714dc18f1b5f1cf16fe5f8_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEyLTItMS0xLTA_911bd2d0-ee14-4043-9549-81db03a55ace">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0e51f9a61b4ac1bc4ea1f7ebbb64c3_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEyLTYtMS0xLTA_382c7dba-ef46-4bc6-93a0-453a486cd92c">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic75069bdec0e44eb9f28b52baa250e8a_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEyLTEwLTEtMS0w_5ca07c90-3c73-4e04-a136-88a4c211b322">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEzLTItMS0xLTA_a7aeb5f3-f81b-465c-8a54-31b5aeffc803">1,860.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEzLTYtMS0xLTA_e163de87-72b8-4a1c-ba67-9111c8286ee0">1,831.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEzLTEwLTEtMS0w_6df5ef9f-ec78-4f78-b0ff-f5cb7ad64c8d">1,771.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTM5_b81bd1ca-c2cd-42b0-ad7c-dee366e87c28" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash reported within the consolidated statement of cash flows includes $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEzODE4_1f155b0f-57d1-4932-8e25-135e0cbb5042"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEzODE4_80464201-5418-4984-bd19-379134304d95">0.3</ix:nonFraction></ix:nonFraction> million of restricted investments, which are reflected in other long-term assets in the consolidated balance sheet at both December&#160;31, 2020 and 2019. These restricted investments represent restricted cash held in accordance with the provisions of a long-term operating lease agreement held as security for performance under the Company's covenants and obligations within the agreement through January 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NDc3_796364ff-d9d3-4354-9bd2-2dc5c605a2c6" continuedAt="ie6298b0c83d54698bc110a3a7f17e98a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="idef221b9ba624b549600a85565c25350" continuedAt="iecde572fac5d49b3976a341295d25f06"><ix:continuation id="ie6298b0c83d54698bc110a3a7f17e98a"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to its sale on December 31, 2020, the receivables related to the Company's optical products purchasing organization were recognized separately from patient accounts receivable and included in other current assets in the consolidated balance sheets. Such receivables were $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgry:OpticalProductsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE3MzYy_1745b432-d73b-4653-8104-74d94a226ee2">8.6</ix:nonFraction> million at December 31, 2019. </span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjIz_b97bf7c6-e1b2-4690-8725-3cef8a99030a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets, Goodwill and Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value.&#160;The cash flow projection and fair value represents management&#8217;s best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation.&#160;For discussion on impairment for goodwill and indefinite-lived intangible assets, refer to Note 4. "Goodwill and Intangible Assets."</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:SelfInsuranceReservePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTIw_e19e8605-8990-41bf-b02c-a58abcd5c6ef" continuedAt="i2287be372e2341cc8a9346791f5c74a4" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Professional and General and Workers' Compensation Insurance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional liability insurance coverage is on a claims-made basis and the general liability insurance is on an occurrence basis. The Company also maintains workers' compensation insurance, subject to a self-insured retention.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i2287be372e2341cc8a9346791f5c74a4">The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers' compensation claims which relate to (i)&#160;claims made during the policy period, which are offset by insurance recoveries and (ii)&#160;an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTgw_f775597f-0236-4c87-9b8e-c6dd8717153c" continuedAt="ia4e0863a629a45e2bd3557e8b97ac8e8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value.&#160;The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzIxOTkwMjMyODUyMTM_e53b44fc-f2cd-4a27-8f07-0461008024f6" continuedAt="i6eca4da0a77147368c27c7317e138a3c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Unconsolidated Affiliates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless the investments are a result of the Company losing control of a previously controlled entity, but still retaining a non-controlling interest. Transactions that result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="iecde572fac5d49b3976a341295d25f06" continuedAt="ifaf7cb4d2db344c881b73dced204b651"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i6eca4da0a77147368c27c7317e138a3c">which include unobservable data, to measure the fair value of the retained non-controlling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in and advances to affiliates in the accompanying consolidated balance sheets. The Company&#8217;s share of the profits and losses from these investments is reported in income from equity investments in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary.</ix:continuation></span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTYx_28eece6a-2c7e-4f97-86da-17aa1b4927e5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-Controlling Interests &#8212; Redeemable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjUy_f58c97f8-2a99-4950-93c9-ab9f2d28029e" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to the non-controlling interests&#8212;redeemable for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzMtMi0xLTEtMA_bd11be4e-1c4d-4638-978d-c9d42eb1f827">321.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzMtNC0xLTEtMA_d3263f15-6ae6-4eff-a8f7-81237a205041">326.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzQtMi0xLTEtMA_8bd64f1e-ca86-44e5-b503-38614a2a3c68">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzQtNC0xLTEtMA_07c3a5b1-549c-49c4-8822-2008a7a4ca44">39.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzUtMi0xLTEtMA_65fb4c9a-517b-4e43-82a7-82cd3e3f49c4">9.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzUtNC0xLTEtMA_7d2c578d-cecd-4f12-8f3c-58576c941ea3">4.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest &#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzYtMi0xLTEtMA_81ed0db7-31b7-431e-904b-070f2ffbef89">36.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzYtNC0xLTEtMA_e682cae8-3d9e-4c8b-8b3b-8844cea8be46">40.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzgtMi0xLTEtMA_af26d15a-2af6-45e5-a3e6-1afa9e8af7d4">306.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzgtNC0xLTEtMA_bd11be4e-1c4d-4638-978d-c9d42eb1f827">321.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjE0_dc4dbe47-edd2-4e76-b4ad-6531f23f5dc0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTIx_b3bbbf90-34d7-45b7-afdf-b451c7045b21" continuedAt="i726e403d71ed40a8ae5fc91b2b5b86d5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-04 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future London Interbank Offered Rate ("LIBOR") indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="ifaf7cb4d2db344c881b73dced204b651"><ix:continuation id="i726e403d71ed40a8ae5fc91b2b5b86d5"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (&#8220;CECL&#8221;) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, which is primarily applicable to accounts receivable for the Company. This ASU was effective for the Company on January 1, 2020. The adoption of this ASU did not have a material impact on its consolidated financial position and results of operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, "Leases" (the "Lease Accounting Standard"). The Company adopted the Lease Accounting Standard effective January 1, 2019, using a modified retrospective transition approach. The most prominent of the changes resulting from this ASU is the recognition of right-of-use assets and lease liabilities by lessees for those leases classified as operating leases. The Company&#8217;s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. Upon adoption of the Lease Accounting Standard, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ifa680d2bf8ab4a2d9fb8d803777a046f_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzExNTQ0ODcyMTYzODYz_17856664-8c3e-453b-877e-0d1191a0138c"><ix:nonFraction unitRef="usd" contextRef="ifa680d2bf8ab4a2d9fb8d803777a046f_I20190101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzExNTQ0ODcyMTYzODYz_7e4eeeea-a339-4a36-94fd-c87c49e2d1fb">294.0</ix:nonFraction></ix:nonFraction>&#160;million of operating lease liabilities and right-of-use assets on January 1, 2019. The cumulative effect of the accounting change recognized upon adoption was $<ix:nonFraction unitRef="usd" contextRef="i36e8c64b0ba846c18f5a7a46fa045bc7_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzExNTQ0ODcyMTYzODky_dcb80bf2-d8b8-423d-bb1f-7dadf58a014d">6.1</ix:nonFraction>&#160;million reflected as an adjustment to retained deficit in our consolidated balance sheets.</span></div></ix:continuation></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_148"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzYzOTA_8e1c6d96-fa7d-4b44-a39e-0e4a2912d276" continuedAt="i55553ee98b39421193178a4cb8e9f18c" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="sgry:BusinessCombinationsAndDisposalsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzYzOTY_3cdde42f-ec95-49a9-805c-c6b958ff09ab" continuedAt="i247f0e0357ac41db9685122482d99b67" escape="true">Acquisitions and Disposals</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i247f0e0357ac41db9685122482d99b67" continuedAt="i451faec7dc4d4c43996d64d2515fbc1a"><ix:continuation id="i55553ee98b39421193178a4cb8e9f18c"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for business combinations in accordance with the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer can be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any non-controlling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Any goodwill recognized is determined as the excess of the fair value of the consideration conveyed plus the fair value of any non-controlling interests in the acquisition over the fair value of the net assets acquired. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquired assets and assumed liabilities typically include, but are not limited to, fixed assets, intangible assets and right-of-use leases. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. Fair value attributable to non-controlling interests is based on a Level 3 computation using significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of non-controlling interests, primarily from acquisitions of surgical facilities. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. Fair value attributable to the property and equipment acquired is based on Level 3 computations using key inputs such as cost trend data and comparable asset sales. Fair value attributable to the intangible assets acquired is based on Level 3 computations using key inputs such as the Company's internally-prepared financial projections. Fair values assigned to acquired working capital are based on carrying amounts reported by the acquiree at the date of acquisition, which approximate their fair values.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company acquired a controlling interest in <ix:nonFraction unitRef="surgical_facility" contextRef="if5a946918c8b40eea1360771a870d93f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyODQ4MjY_9e535a78-baf0-4ee3-b8f2-3b70abd4018b">three</ix:nonFraction> surgical facilities, including a surgical hospital, a controlling interest in <ix:nonFraction unitRef="surgical_facility" contextRef="ia47d16d8651a47159a92c2d34a75506d_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyODQ4MzY_11859b8c-e699-4bc2-8910-22d8835b0993">five</ix:nonFraction> surgical facilities in existing markets, that were merged into existing facilities and a physician practice for total aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE1OTY2_04f99852-e21b-41ce-84af-2a2fbcdc6d66">120.1</ix:nonFraction>&#160;million, including cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzEwOTk1MTE2NTc4MTk_40484a8b-7858-4de8-b7a7-dd245d1d653c">104.6</ix:nonFraction>&#160;million, net of cash acquired, non-cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE2MDM2_e03aaf2d-7515-4449-80c6-80c8c81c878c">8.7</ix:nonFraction> million and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE2MDUz_3e420eee-5f7d-479c-a4d2-2f2d71734887">0.7</ix:nonFraction> million. The non-cash consideration consisted of non-controlling interests in the Company's existing surgical facilities. The cash consideration was funded through cash from operations, proceeds from its recent divestitures and other available resources. The total consideration was allocated to the assets acquired and liabilities assumed based upon the respective acquisition date fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, the Company acquired a controlling interest in <ix:nonFraction unitRef="surgical_facility" contextRef="icc2bd176b2b04f648164f8a60a3183bc_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyNjYxMTg_4130f50c-5187-4b19-83b9-6f68cb3fde1a">one</ix:nonFraction> surgical facility, a clinic that was merged into an existing facility and a physician practice for total aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="i24702e29b0c7414e8f65fabb99f154f6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTEyNzE1_17c41828-c16b-40e3-91cd-4b51fa50a2c7">26.7</ix:nonFraction>&#160;million, including cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ia0e4786142704b339656b078b2112468_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzg3OTYwOTMwMjkzMDA_792146cc-0cc7-460b-a810-adb02a658f6a">20.1</ix:nonFraction>&#160;million, net of cash acquired. The remainder of the consideration related to the forgiveness of certain amounts due to the Company from the acquired clinic. During 2020, the Company made a working capital settlement payment resulting in additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgry:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE0NjEx_e62529d7-ee67-4b8e-843b-00c92709da8f">0.8</ix:nonFraction>&#160;million related to the clinic acquisition. The additional consideration is reflected in the table below. During the year ended December&#160;31, 2020, no other significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2019.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i451faec7dc4d4c43996d64d2515fbc1a"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzYzODA_17eae498-651d-43b6-a17f-99cb7c666a7f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preliminary or final amounts recognized for each major class of assets acquired and liabilities assumed for acquisitions completed during the years ended December 31, 2020 and 2019, including post acquisition date adjustments, are as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzItMi0xLTEtMA_04f99852-e21b-41ce-84af-2a2fbcdc6d66">120.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e4786142704b339656b078b2112468_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzItNC0xLTEtMA_c1f7ba4c-56c7-4530-81da-da78463c7f8b">27.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzMtMi0xLTEtMA_9b5158c2-04e7-4d07-a61f-2008ab4a15ee">57.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzMtNC0xLTEtMA_92945aa0-b220-4732-a59e-883065573f28">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzQtMi0xLTEtMA_da1ab933-a198-4ee0-b871-bcf0f49614fc">177.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzQtNC0xLTEtMA_b8f78411-735c-46ef-ad3a-14db630459d1">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzYtMi0xLTEtMA_c63a48d5-a451-4e80-9356-47a87cc26765">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzYtNC0xLTEtMA_9c05f736-be29-4154-93e7-c2b385523cef">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzctMi0xLTEtMA_256ed066-9f8a-427d-a28c-c6eb66096de9">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzctNC0xLTEtMA_787e0de5-563a-4881-8f05-4df33a514b81">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzgtMi0xLTEtMA_81d3132d-dbe5-4cd5-837f-b0e2a00b1deb">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzgtNC0xLTEtMA_0162d0b4-f7cb-410f-8fcf-d4d343a31773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzktMi0xLTEtMA_15c5f1cf-2587-482a-9013-23216430d771">153.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzktNC0xLTEtMA_6a31b2d4-6743-4794-a218-bbbb00cddf1f">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="sgry:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEwLTItMS0xLTQyMTQ_a3d4d0e8-8f1f-4562-b075-ff055ef6eb5f">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="sgry:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEwLTQtMS0xLTQyMTc_62429e16-3b44-434a-9499-13e052a9bf4b">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEwLTItMS0xLTA_621613f7-fda6-4f32-b460-63aa948600fd">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEwLTQtMS0xLTA_28c5985d-af80-482e-8b60-4e6bbb1c28fc">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzExLTItMS0xLTA_a244acbd-5eef-4be7-baf8-6b7ab98efc17">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzExLTQtMS0xLTA_7e324e22-eaa2-4e46-bef4-7c4586cc07f9">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEyLTItMS0xLTA_f0d34af0-12eb-4895-9ba1-1bf96688da8a">40.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEyLTQtMS0xLTA_3bac56b0-08ec-4ca1-84eb-8c31fc422bec">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzE0LTItMS0xLTQyMjM_ee8f4abe-5e07-40e2-a8ef-fcb54be1f452">14.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzE0LTQtMS0xLTQyMzE_003db365-bec1-4b17-9c98-1a4682ccc1f8">28.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if311991b251d46209bd73eff519dfe38_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzE0LTItMS0xLTA_bf178cbf-b2b4-4550-af5b-53eb3b0651f8">177.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzE0LTQtMS0xLTA_362613f0-4d02-468e-9dcf-2117fee9fbae">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">In connection with the clinic acquisition in 2019, the Company acquired the remaining non-controlling interests in one of its existing consolidated surgical facilities. As such, $<ix:nonFraction unitRef="usd" contextRef="i31f32ad0f9c64967bbb2cabcd332dc26_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzQwMzk_5f4880bd-1204-433c-9332-9119cadad0a4">6.3</ix:nonFraction> million of the cash consideration for the clinic acquisition was classified as a financing activity and presented in payments related to ownership transactions with non-controlling interest holders in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The assets acquired in 2019 includes the fair value of a non-controlling investment held by the acquired clinic in one of the Company's consolidated surgical facilities of $<ix:nonFraction unitRef="usd" contextRef="ied5a1e05804145ceab2d258e6b9b8d9d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzQ0NTA_eb68121f-bea6-4fe4-9eef-abcdf73679ca">8.8</ix:nonFraction> million. This investment asset was subsequently eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values assigned to certain assets acquired and liabilities assumed by the Company in 2020 have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. The goodwill acquired in connection with the 2020 acquisitions was allocated to the Company's Surgical Facility Services reportable segment. The results of operations of the 2020 acquisitions are included in the Company&#8217;s results of operations beginning on the dates of acquisition, and were not considered significant for the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, the Company acquired non-controlling interests, primarily in <ix:nonFraction unitRef="surgical_facility" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTExMTUy_618ed89c-ce88-4d61-b661-3ddb146cc400">four</ix:nonFraction> surgical facilities, for a cash investment of $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTExMjAy_472cd8c5-2f01-4f5f-bc06-518da9053346">15.2</ix:nonFraction> million. The non-controlling interests were accounted for as equity method investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Disposals</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company sold its interests in <ix:nonFraction unitRef="surgery_center" contextRef="i096eba00dd53417a97144cec06404675_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE5Njcy_c28d6d6d-1265-49f1-9896-20948378636e">three</ix:nonFraction> surgery centers, one of which was previously accounted for as an equity method investment, sold certain assets related to its anesthesia business, certain imaging assets and its optical products purchasing organization for combined net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i096eba00dd53417a97144cec06404675_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE5NjU4_a738acaa-8eb5-4a4c-978f-64a3f706ed87">58.5</ix:nonFraction>&#160;million, and recognized a net pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="i096eba00dd53417a97144cec06404675_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE5NzAx_660130fd-88e7-48e1-8b50-54b8f93dfdfd">5.2</ix:nonFraction>&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December&#160;31, 2020. Additionally, the Company closed its diagnostic laboratory and recognized a net pre-tax loss of $<ix:nonFraction unitRef="usd" contextRef="i4b7dd0518ae1499292593c611baed1c9_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTIwMTQ0_68e97248-452b-4ed3-82a2-7f3b8320b85a">3.5</ix:nonFraction>&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, the Company disposed of previously owned real property associated with one of its existing non-consolidated surgical facilities. In connection with the sale, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i971b3ccc8c4c4158b9ebbc8fbe15c413_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzg3OTYwOTMwMzE3Mjk_c5f93ff2-81f8-4097-9bc0-7eaa71a08128">10.9</ix:nonFraction>&#160;million pretax gain included in loss (gain) on disposals and deconsolidations, net in the accompanying consolidated statements of operations. The sale did not impact the Company's investment in the surgical facility, which continues to be accounted for as an equity method investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, the Company disposed of <ix:nonFraction unitRef="surgery_center" contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyODQ4NDg_fb5446de-768c-4435-937d-356d2c4b6da5">four</ix:nonFraction> surgery centers, <ix:nonFraction unitRef="surgical_hospital" contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyODQ4NTc_7f000783-d0d6-4ade-9646-a5831579db11">two</ix:nonFraction> surgical hospitals and its optical laboratory for net cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTIwODg2_2273ed03-e4aa-4bf9-bf06-ba38ce84b03f">18.7</ix:nonFraction>&#160;million, and recognized a net pretax loss of $<ix:nonFraction unitRef="usd" contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTIwOTAx_110ca711-a21a-4b09-a65a-3ba37c263265">21.2</ix:nonFraction>&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December 31, 2018. The non-cash loss was primarily a result of the write-off of the net assets of the facility (net of proceeds received) and was primarily driven by the write-off of the associated goodwill.</span></div></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_151"></div><div style="margin-bottom:5pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIzNzc_37954539-da2a-46f7-bc51-ff605883d361" continuedAt="i5c9737b52b914ae3a500205f21d12c8c" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIzODU_f999c852-8977-4580-9a88-de61f1f30316" continuedAt="i516edf88712c4a8fb26920f7e2d27706" escape="true">Property and Equipment</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i5c9737b52b914ae3a500205f21d12c8c" continuedAt="if4c1bf9cb59644b2bc7f990ab3effa92"><ix:continuation id="i516edf88712c4a8fb26920f7e2d27706" continuedAt="i9bebd514938e43f0a559af97f5708c4a">Property and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally <ix:nonNumeric contextRef="ic40107317bb949478adb6fc4f2480728_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzI3OA_a258a109-27cd-4237-96a6-0f59b50a639e">20</ix:nonNumeric> to <ix:nonNumeric contextRef="iba118baa03704512b22f936deffa8b05_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzI4NA_f676aa54-6b09-4ca3-a188-80a0d06268c1">40</ix:nonNumeric> years for buildings </ix:continuation></ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="if4c1bf9cb59644b2bc7f990ab3effa92" continuedAt="i6a894b4c5b3f4b9c8b15301edc6a44bd"><ix:continuation id="i9bebd514938e43f0a559af97f5708c4a"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and building improvements, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzMzNA_0c1bb596-84ab-46e0-9e07-1217a9251edc">three</span> to <ix:nonNumeric contextRef="i76a8169409c44abfadcd0a3bf2b8aedc_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM0MA_54d7c923-1f6d-4905-9569-67f19a36be18">five years</ix:nonNumeric> for computers and software and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4MA_b602329f-ae4b-455f-ae04-0f191a8afe79">five</span> to <ix:nonNumeric contextRef="i3956d1c7040d40d2970ded51a67c32b3_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4Ng_c7e9251d-6d51-4f04-9783-64097f07af92">seven years</ix:nonNumeric> for furniture and equipment.&#160;Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also leases certain facilities and equipment under finance leases. Assets held under finance leases are stated at the present value of lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset.</span></div></ix:continuation><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIzODM_002d656d-15df-4139-b560-f4799cff81ec" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of property and equipment follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa40fcdd276343a8aed6a9a9a6a6ea6c_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzMtMi0xLTEtMA_929b0b49-965a-440b-bea5-4691ab49d2cf">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ddb8219e714d378c98c211bb2cd34d_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzMtNC0xLTEtMA_3b5408a5-73e7-4f20-9b9c-86d415694d6c">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c352ee9deb495eb58246bebe2e2e33_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzQtMi0xLTEtMA_0b073985-740d-49d5-b1de-25b1d9867640">109.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5d9c2bf8a543b08549baa2240b44b6_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzQtNC0xLTEtMA_09087b23-eaeb-4bb1-a729-81b5a7e35a5e">106.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie020639241a94ada9a7368a42b91149c_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzUtMi0xLTEtMA_7460c3c0-85a5-427a-8a7c-6fd1c4473a06">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d10b5c4c724186a5d9f3bb4e69a0a1_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzUtNC0xLTEtMA_e6a40f53-30ec-4d3a-921f-4202d6541da4">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if889bbc6323c4947b0bc16cfb5b88f95_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzYtMi0xLTEtMA_dd10b615-3415-4109-b09d-98c8cfa3a8a0">80.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d88e3845dc244d99f64392bd5e6a2d5_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzYtNC0xLTEtMA_f21357a8-408b-4dda-ae72-3b497b85318d">59.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57cd5e7c106e4d9fb74e20bda4b999cb_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzctMi0xLTEtMA_aa1ece93-d64e-44a3-bb00-c181bbdb3a6b">196.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68828e4c55c440639deb9dee2ee8d14e_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzctNC0xLTEtMA_1c6b09c3-6baa-4245-a23b-f96ca8e50e87">148.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use finance lease asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzgtMi0xLTEtMA_de64cfdd-8f2b-4c38-92a6-214028313b36">298.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzgtNC0xLTEtMA_f5379f86-074f-41f8-92dc-a149b57b40fc">259.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414e49c153824db4964a4427b5015209_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzktMi0xLTEtMA_9a19fdf1-7291-4f93-8c14-0316fc4bf7e3">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdb52583c8b4bdd9a662cb6d4c8c12a_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzktNC0xLTEtMA_94c047e9-777f-42bc-a610-635ebef0c3cc">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzEwLTItMS0xLTA_f477b396-4209-4e16-b281-575ac29b069c">733.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzEwLTQtMS0xLTA_2c2ddf60-da76-4907-8790-c13c2eb64aee">634.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:  Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzExLTItMS0xLTA_2a953972-b48d-492f-be0f-a9898f8d8a36">189.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzExLTQtMS0xLTA_1f5ffc57-f277-4310-a126-06b59eba9989">110.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzEyLTItMS0xLTA_d1722888-ae40-41e2-9988-00e5b11f7bd5">544.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzEyLTQtMS0xLTA_adfe9fce-419f-42de-88a3-4f4aff0defd9">523.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i6a894b4c5b3f4b9c8b15301edc6a44bd">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIxOTg_36a89c15-4256-45ee-b00b-0f552d04fa65">90.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIyMDU_5542d39a-68ad-4d8f-9f16-7685bd3c7cd8">71.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzg3OTYwOTMwMjQ2Mjc_c5c49696-2439-4e17-8964-81af70ed45da">62.5</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</ix:continuation> </span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_154"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NTM_d67f70b5-99c8-43ac-900b-5b22e765bcc5" continuedAt="ib18abf860e4646e6b823dd9383d9700b" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2Njg_cbe404dc-5fb3-4ef2-be0a-e180e6120254" continuedAt="i8f715185348e4cdb9ee8501addf5c793" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ib18abf860e4646e6b823dd9383d9700b" continuedAt="ib258098d9548430ca3de20885873a32f"><ix:continuation id="i8f715185348e4cdb9ee8501addf5c793" continuedAt="i18334139ddbc4244b37515c65afd7f23"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located, Medicare licenses and certain management rights agreements. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management rights agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2MA_33fd34e1-3ee5-447f-b7a8-7df209baa23f">three</span> to <ix:nonNumeric contextRef="ie1353b03ccc64693b38954fb5b09eaae_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2Ng_5224f0e4-3dba-4590-98d3-e811f79fd9db">four years</ix:nonNumeric>. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5Mw_f789f954-9fee-479a-9ce3-41a85047306b">two</span> to <ix:nonNumeric contextRef="i56f55624fc5d49db9e2be6b8db22e727_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5OQ_8841f0a6-9aa5-474a-a065-4b9f39b5bb95">five years</ix:nonNumeric> for non-compete agreements and <ix:nonNumeric contextRef="i321bbd443b024763a2dbc89b24eaaa4e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEwMzM_26b1405b-15a8-41f0-9cd9-91ef04d7a706">15</ix:nonNumeric> years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the consolidated statements of operations over the estimated lives of the relationships, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNTk_bbc47750-6337-4405-89b2-99010957f9eb">three</span> to <ix:nonNumeric contextRef="if8425e9689bd4f9b9c04b4df8dcc5f4a_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNjU_dbd0938e-4e88-4ea9-91af-1ab2677f635d">ten years</ix:nonNumeric>.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. During 2020, the Company identified <ix:nonFraction unitRef="reporting_unit" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzExNTQ0ODcyMTA3MDAz_68a94d95-c134-4ba5-af27-d6027766e45e">three</ix:nonFraction> reporting units, which include the following: 1) Surgical Facilities, 2) Ancillary Services, and 3) Alliance, which is a component of the Optical Services operating segment. A detailed evaluation of potential impairment indicators was performed, which specifically considered the volatility observed in the prices of the Company&#8217;s outstanding debt securities and common stock, as well as the decline in surgical case volumes following the emergence of the COVID-19 pandemic, all of which improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company compares the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. To determine the fair value of the reporting units, the Company obtained valuations at the reporting unit level prepared by third-party valuation specialists which typically utilizes a combination of the income and market approaches. The discounted cash flow model is projected based on a year-by-year assessment that considers historical results, estimated market conditions, internal projections, and relevant publicly available statistics. Determining fair value requires the exercise of significant judgment, including assumptions about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows. The significant judgments are typically based upon Level 3 inputs, generally defined as unobservable inputs representing the Company's own assumptions. The cash flows employed in the discounted cash flow analysis are based on the Company's most recent budgets and business plans aligned with provided guidance and, when applicable, various growth rates are assumed for years beyond the current business plan period. Discount rate assumptions are based on an assessment of the risk inherent in the future cash flows of the respective reporting units. The variables within the discount rate, many of which are outside of the Company's control, provide the best estimate of all assumptions applied within the discounted cash flow model. There can be no assurance that operations will achieve the future cash flows reflected in the projections. In determining the fair value under the market approaches, the analysis includes a control premium, which was based on observable market data and a review of selected </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i18334139ddbc4244b37515c65afd7f23" continuedAt="i8bc260f180444bfc97a8f6ed5294e301"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ib258098d9548430ca3de20885873a32f">transactions of companies that operate in the Company's sector. While the Company believes that all assumptions utilized in the testing were appropriate, they may not reflect actual outcomes that could occur. Specific factors that could negatively impact the assumptions used include changes to the discount and growth rates and a change in the equity and enterprise premiums being realized in the market.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On the basis of available evidence as of August 31, 2020, the Company identified indicators of impairment related to its Ancillary Services and Alliance reporting units, including the impacts of the COVID-19 pandemic, the closure of its diagnostic laboratory (as discussed in Note 2. "Acquisitions and Disposals") and its strategic decision to sell its optical products purchasing organization. No indicators of impairment were identified for the Company's Surgical Facilities reporting unit. Based on the impairment indicators noted, the Company performed an impairment analysis for the Ancillary Services and Alliance reporting units as of August 31, 2020. As of the September 30, 2020 valuation, carrying value for both the Ancillary Services and Alliance reporting units exceeded the fair value, resulting in non-cash impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i83fa7ab9abbe4240abf5a9be8a23fd82_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzExNTQ0ODcyMTA0NDQ1_1614bde3-b266-4e0e-b6bb-92ca79cb70ef">28.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1fb39a032ea34a87b804e96f67309730_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzExNTQ0ODcyMTA0NDYw_07d50b24-a4fb-4ccf-aae2-69d8dd58f0ed">4.9</ix:nonFraction>&#160;million, respectively. The fair values as of August 31, 2020 were determined using the adjusted book value for the Ancillary Services reporting unit and the discounted cash flow model for the Alliance reporting unit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of October 1, 2020, prior to its annual impairment testing, the Company's <ix:nonFraction unitRef="reporting_unit" contextRef="idbd41b7592e6496dae5a85b154e694ac_D20201001-20201001" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzQxNDI_1ad2742b-6702-439a-9b67-a9a0791e820c">three</ix:nonFraction> reporting units with allocated goodwill were as follows: 1) Surgical Facilities - $<ix:nonFraction unitRef="usd" contextRef="i4557e793265d4ca487ef329aeaae1ae3_I20201001" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzQyMjI_0543a655-a955-4c11-92f6-af994879dbb8">3.3</ix:nonFraction> billion, 2) Ancillary Services - <ix:nonFraction unitRef="usd" contextRef="ib321c333fae04579844d5ee99972bb0e_I20201001" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzIxOTkwMjMyNzA0MDU_e51aef98-37d1-45e8-95d7-42fd231e5c88">no</ix:nonFraction> remaining goodwill after the August 31 impairment discussed above, and 3) Alliance - $<ix:nonFraction unitRef="usd" contextRef="i1ca50bf762614029b46129e2456fd831_I20201001" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzExNTQ0ODcyMTA1NjA4_4ffd02ce-add1-4c48-a89a-8675b3563e31">4.2</ix:nonFraction> million.&#160;As of the October 1, 2020 valuation, the fair value for the Surgical Facilities reporting unit was substantially in excess of its carrying value, and there were no additional indicators of impairment related to the other reporting units. The fair value of the Surgical Facilities reporting unit as of October 1, 2020 was determined using the income and market approach as discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsequent to the date of our annual impairment test, the Company considered its operating results for the fourth quarter of 2020, macroeconomic, industry and market conditions, and other market indicators including its market capitalization. Based on its evaluation of all such factors, the Company concluded that an event had not occurred or circumstances had not changed that would more likely than not reduce the fair value of its reporting units below their carrying values. On December 31, 2020, the Company disposed of the Alliance reporting unit with the sale of its optical products purchasing organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, as a result of its impairment testing, the Company recorded non-cash impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i1e4dce1c02884dedb36cc96503232a23_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzIxOTkwMjMyNzA0MTQ_2fb8997d-699f-4edc-b4d4-08e4452e347f">2.5</ix:nonFraction>&#160;million related to the Alliance reporting unit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, as a result of its impairment testing, the Company recorded non-cash impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i5a9ee60353764f1f89b9af4f623bf105_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzIxOTkwMjMyNzA0Mjg_eeff8fe9-8b2b-4a01-8d7c-e3612b62278c">60.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8b51cb9aba5548ed93f4a31b4abdf654_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzIxOTkwMjMyNzA0NDM_12b4d76d-afb1-457e-952b-d2def0a99e55">13.7</ix:nonFraction>&#160;million related to the Ancillary Services and Alliance reporting units, respectively.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NzA_f44ec3c4-33c0-440c-b155-6b454281ae56" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the changes in the carrying amount of goodwill follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.232%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzMtMi0xLTEtMA_7ec51a2a-cadf-41af-b509-2fbb79174c71">3,402.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzMtNC0xLTEtMA_f3604626-b47a-48f4-8470-4566aa5fabc5">3,382.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzQtMi0xLTEtMA_4a5efcbb-f26a-4ec5-b30c-1a8f285763b5">154.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzQtNC0xLTEtMA_8b6d6766-2592-476f-9bd9-5181984b6acd">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals and deconsolidations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzUtMi0xLTEtMA_f178f0e3-e439-4e63-8263-0634b7ceca2e">55.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzUtNC0xLTEtMA_5281ed5b-eb9d-4444-a7ed-827ba554cc12">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzYtMi0xLTEtMA_1a1cfb8d-3a36-4760-9dd2-fa45f90d2f90">33.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzYtNC0xLTEtMA_d3c862cd-d88a-47c2-8b3e-136bc63dd26b">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzctMi0xLTEtMA_b76b3dea-ebff-46db-85fd-a7d51eeb246d">3,468.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzctNC0xLTEtMA_7ec51a2a-cadf-41af-b509-2fbb79174c71">3,402.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the Company's acquisitions and disposals for the years ended December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2019 is included in Note 2. "Acquisitions and Disposals." </span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NTk_3e4133c7-1c31-43e3-8e50-bd686eaade00" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NjA_bc99dd2e-d0da-40eb-9d0f-8dd6191c851f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the components of intangible assets follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management rights agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68f779024f44d59b01b47b4693ce33d_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtMi0xLTEtMA_f2b18c4e-4d3e-48ca-91b7-00f61285e4b7">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if68f779024f44d59b01b47b4693ce33d_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtNC0xLTEtMA_a40519b6-6e29-4256-af78-d72b136b4db4">10.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68f779024f44d59b01b47b4693ce33d_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtNi0xLTEtMA_cff37bd8-6eae-4812-acd9-d014dba0a07b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b5285d66914d4383e39ad0ba826fc6_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtOC0xLTEtMA_8f03a52a-962e-46a1-92ec-5469f1e5039e">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76b5285d66914d4383e39ad0ba826fc6_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtMTAtMS0xLTA_5bea3692-49d2-49de-a63b-d6991862515a">7.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b5285d66914d4383e39ad0ba826fc6_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtMTItMS0xLTA_22581a99-a69e-435a-96a6-7215b32ad6a2">23.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba1731476d74ce2b3d217aad57dcc60_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtMi0xLTEtMA_e28b50f5-a978-4012-b529-92ab816a8af4">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ba1731476d74ce2b3d217aad57dcc60_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtNC0xLTEtMA_6e287f82-82b7-4a38-9709-9a4868e46e4b">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba1731476d74ce2b3d217aad57dcc60_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtNi0xLTEtMA_6f69c2a0-ceda-432d-97f8-8dc41abda702">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc383438e0c44af2bf287f3600874704_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtOC0xLTEtMA_364ae78a-2688-4fda-9a2d-e5ec88a68620">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc383438e0c44af2bf287f3600874704_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtMTAtMS0xLTA_e0c8cfa4-a6f4-4453-b141-2cba08af7026">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc383438e0c44af2bf287f3600874704_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtMTItMS0xLTA_92a567fe-6e5a-4bbc-bb4f-a5d85bc5c0c8">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtMi0xLTEtMA_1e37d9ca-3984-4d4c-a753-137e535d4903">44.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtNC0xLTEtMA_a55613a6-05f4-4850-951e-04fb7df1ad6c">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtNi0xLTEtMA_ad5844d1-73cf-4543-a078-1aef3164113a">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtOC0xLTEtMA_8d1fe9c6-4ed7-4589-a491-2ce48aa68a86">39.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtMTAtMS0xLTA_c275e6c6-e6dd-4337-a1e6-f6319db562a1">11.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtMTItMS0xLTA_74370582-5a6e-4804-818d-aaeb215146f7">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzctMi0xLTEtMA_914c3fe9-e8be-42c6-b65e-605529ebfbef">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzctNi0xLTEtMA_0813d802-70b2-4a92-97b0-943042109f0d">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzctOC0xLTEtMA_caf6dfad-adf0-43e2-a1d6-32d6b8de6e2a">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzctMTItMS0xLTA_4debafa8-f85e-4145-a0e9-f6ad3bfec694">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtMi0xLTEtMA_61f71ec6-00f7-48d1-bed4-536c3160bfc3">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtNC0xLTEtMA_468ca8b1-12ec-4850-9854-af94664b5385">16.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtNi0xLTEtMA_665885e9-503d-4f2f-bca6-21d5beaf68c3">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtOC0xLTEtMA_e993becc-e6ad-41cd-a265-da35e633a5ab">59.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtMTAtMS0xLTA_deeba344-a1f1-447f-a858-f268f6730897">11.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtMTItMS0xLTA_46a59c92-c20f-4d5c-9693-d37275960c26">47.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i8bc260f180444bfc97a8f6ed5294e301"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company acquired a clinic that was previously managed by the Company. As a result of the transaction, the Company determined the management rights agreement related to the acquired clinic no longer provided a future benefit. As such, the Company recorded non-cash impairment charges of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzYxNjQ_94b2c3fc-48ae-4045-b3ce-0d35435cca08">5.4</ix:nonFraction> million, which was included as a component of impairment charges on the accompanying consolidated statement of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzYzMjk_cb046c43-7c13-4730-aec3-7fbe0d15357f">4.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzYzMzY_bf43a727-2157-44ec-95cd-314d98c43a74">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzg3OTYwOTMwMzI4MDI_e6515cdd-0ef5-4867-8b14-7ad6e27d2b88">4.9</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NjM_8e33af6f-59c9-4c6f-af8e-44d405cc05ae" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzAtMi0xLTEtMA_dd75362c-638e-4420-b61a-026c2053580d">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzEtMi0xLTEtMA_5cfa48a6-4844-4b47-942d-0e2950d06b67">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzItMi0xLTEtMA_701250bd-cc0a-4ecb-a8fd-1c08fc660943">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzMtMi0xLTEtMA_474992db-43f9-43c5-96d1-725a54c11052">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzQtMi0xLTEtMA_59302904-32ed-490b-a70b-8c6e1a23f577">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzUtMi0xLTEtMA_e6a59f68-65b6-4ccf-99aa-fe254f7a607d">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzYtMi0xLTEtMA_e8737f01-d727-4948-8026-cd3dbdbd0b52">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_157"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEzMjQ1_a86bdc2c-f1b0-4c7c-9124-7823b1a1184c" continuedAt="ied24f6a331324da895252af2b0bad4bc" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="ied24f6a331324da895252af2b0bad4bc" continuedAt="i2ce699b515444f35ade467426501141a"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEzMjUz_1bb075fc-bce4-443c-bdae-c879ab5f4599" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzMtMi0xLTEtMA_947f15f8-f4ae-4131-8f50-48e2c14ed259">1,539.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f34da757564475b695308801b42f1e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzMtNC0xLTEtMA_3083982e-f56c-425e-b0f6-56fd5c4e55b6">1,434.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured revolving credit facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bb1da722a94a38b17d3ec8f7e25de4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzQtMi0xLTEtMA_0b9e3f8e-83a2-4ca3-8ad1-9dbbad696034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64394bce33e4e9ca4aca2ff0a3ab714_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzQtNC0xLTEtMA_4926dca2-5d95-496c-8c61-6fd6b4ff02ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i911d67503a3e4528a30814a4348d8ea4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzYtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzQ5MDc3MTI0NjQzZmI5YzAxMmE2ZTA2MjMyZjU2XzIxOTkwMjMyNTU2MDA_10631964-487f-4b80-b7cc-92b2e6df91a0">6.750</ix:nonFraction>% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911d67503a3e4528a30814a4348d8ea4_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzYtMi0xLTEtMA_9866987b-ed9f-4dbe-bf61-3d7cab00c1db">370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1afaa2f8387439e98068fbf64e2ee04_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzYtNC0xLTEtMA_3ddd243e-57d4-4eee-a8d8-2ca3378c0bc7">370.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7bd4886dd3f74966858590367b6f85d9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzctMC0xLTEtMC90ZXh0cmVnaW9uOjkyYjVmYjU5ZmUzZDQ3YTk5YWQyMTMyN2NhOWE0YjBkXzIxOTkwMjMyNTU2MDI_3ee4bf56-e937-42e9-9b86-388f3b53dd24">10.000</ix:nonFraction>% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd4886dd3f74966858590367b6f85d9_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzctMi0xLTEtMA_15c3ef0e-ce5a-4a81-89f8-bc735f92a8be">545.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb34960793f34f629f106b22da0c737f_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzctNC0xLTEtMA_e0af11dd-d25a-41ca-bc70-9f6657cffe11">430.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i817a7925476240d1a0297c22e048100c_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzgtMi0xLTEtMA_c721d328-a570-4800-aa2a-3b947cf27872">137.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i398bdf0cb33e4e9a95374ecf8c74bd27_I20191231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzgtNC0xLTEtMA_016138f2-d1bd-49e0-9167-4dbc35343acf">104.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzktMi0xLTEtMA_5150068a-2a6c-478b-a78f-fa88dafc4b90">281.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzktNC0xLTEtMA_5e1221ce-b2a8-4ea1-87cd-bb212f340156">253.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEwLTItMS0xLTA_0728ec3b-2974-4600-81e4-e675759e61f9">16.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEwLTQtMS0xLTA_f27cd0fa-fd90-4e1e-820b-346a960e8a4d">10.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzExLTItMS0xLTA_12bfe99e-3ed5-443e-9654-cb60c7dc4310">2,856.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzExLTQtMS0xLTA_625b28ff-7b6b-4b35-8c8c-598ea06ec0fb">2,580.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEyLTItMS0xLTA_8a1cd895-2b3d-4691-8ecb-51c869d83cd7">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEyLTQtMS0xLTA_f0e5ecb5-bc60-4112-9e29-b0adea7fe82a">56.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEzLTItMS0xLTA_e20f1e44-38e8-43c2-b7db-1e5d9edf4112">2,792.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEzLTQtMS0xLTA_36becdf2-0f1c-4fa2-a497-ed9952005aee">2,524.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $<ix:nonFraction unitRef="usd" contextRef="ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEyMg_f4fdd4dd-8aa8-40c4-a3c3-1131058e17e9">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i38f34da757564475b695308801b42f1e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEyOQ_5c78611a-4f6a-44d3-a5e0-c690f0bdaa79">4.6</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has a credit agreement (the "Credit Agreement") providing for a $<ix:nonFraction unitRef="usd" contextRef="ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwOTk1MTE2NjE5Mjc_a6bd9051-2e04-4eec-9584-b953f6985643">1.29</ix:nonFraction>&#160;billion senior secured term loan (the "Term Loan"), a $<ix:nonFraction unitRef="usd" contextRef="i673a6d4abfc04d07bc5da2e378ef3651_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwOTk1MTE2NjIwODk_86f29af7-4ac5-4a18-8f11-8d068f2c92a8">180.0</ix:nonFraction>&#160;million senior secured incremental term loan (the "2018 Incremental Term Loan"), a $<ix:nonFraction unitRef="usd" contextRef="ie06dea18e47140059ff8bee1f65d492e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwOTk1MTE2NjIwNzM_7ed67a14-ba17-4580-b319-8b1270b907c8">120.0</ix:nonFraction>&#160;million senior secured incremental term loan (the "2020 Incremental Term Loan") and a $<ix:nonFraction unitRef="usd" contextRef="i8e0832acb780465db2d59399c892b08c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEyNjc_f17e44e4-7ec8-4e4d-80eb-e54b0c63902a">120.0</ix:nonFraction> million senior secured revolving credit facility (the "Revolver" and, together with the Term Loan, the 2018 Incremental Term Loan and the 2020 Incremental Term Loan, the &#8220;Senior Secured Credit Facilities"). The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. Subject to certain conditions and requirements set forth in the Credit Agreement, the Company may request one or more additional incremental term loan facilities or one or more increases in the commitments under the Revolver. On March 18, 2020, the Company drew down its available capacity under its Revolver, as a precautionary measure in order to increase liquidity and preserve financial flexibility in light of current uncertainty resulting from the COVID-19 pandemic. During the second quarter, the Company fully repaid the outstanding balance. As of both December 31, 2020 and 2019, the Company had <ix:nonFraction unitRef="usd" contextRef="i298880778d4c4020a86c49df919d29b2_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyNzQ1ODg_305d0b2c-45d1-4f6b-98bf-44e0fbfecb4b"><ix:nonFraction unitRef="usd" contextRef="i8e0832acb780465db2d59399c892b08c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyNzQ1ODg_dc5bb822-4b91-455f-9697-f8cde487fbcf">no</ix:nonFraction></ix:nonFraction> outstanding borrowing on the Revolver. As of December&#160;31, 2020, the Company's availability on the Revolver was $<ix:nonFraction unitRef="usd" contextRef="i8e0832acb780465db2d59399c892b08c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxNzM_34c4d129-c16d-46eb-ba74-923f18aa95ff">112.5</ix:nonFraction> million (including outstanding letters of credit of $<ix:nonFraction unitRef="usd" contextRef="i65745a05a0cd456ab8a525d60910efd0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIyMjA_2a20d88a-15df-4968-8238-4617cc9a979d">7.5</ix:nonFraction> million).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Term Loan will mature on August 31, 2024 and the Revolver will mature on August 31, 2022. The Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="i85862ab6835e41eda58eb91f7b761382_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI0MzY_528b2b2f-3119-43fa-a6b1-ed22298bcf2f">3.00</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="icb3f5b40bb954651a15a0509487a732e_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI0NDI_c42a9983-5427-4fe6-85ea-97c1bd2009f3">3.25</ix:nonFraction>% per annum, depending on the Company's first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) <ix:nonFraction unitRef="number" contextRef="ia627d4a01c804d75933b140eb136c84a_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI1OTg_d8f6d577-b60b-4e1c-856b-ce30c35a11af">0.5</ix:nonFraction>% per annum above the federal funds effective rate and (iii) one-month LIBOR plus <ix:nonFraction unitRef="number" contextRef="ib2e9ba12a1484646852fb69358ef6c43_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI2ODE_c3176d84-80fd-4ad9-8e08-8b9b231bc5c4">1.00</ix:nonFraction>% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than <ix:nonFraction unitRef="number" contextRef="ie114fdfc808045a391295f7885a63b41_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI3ODA_2e31e156-d91e-4557-b9d1-a6846a9186a2">2.00</ix:nonFraction>% per annum)) plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="i4cffedbc77074fe1a34b679e5841a01d_D20200101-20201231" decimals="INF" name="sgry:DebtInstrumentMarginInAdditionToBaseRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI4MjI_e65c12a8-7cd9-4039-ae7c-a2aafd547309">2.00</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ifdf5f1f86bf94962b6e3e0134fc3af0a_D20200101-20201231" decimals="INF" name="sgry:DebtInstrumentMarginInAdditionToBaseRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI4Mjg_3cf977a8-b173-42f0-81d5-4d64a6816871">2.25</ix:nonFraction>% per annum. In addition, the Company is required to pay a commitment fee of <ix:nonFraction unitRef="number" contextRef="i04f59e4d834d47dbb571b78b88198617_D20200101-20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI5MDY_159d614a-0fcd-4b97-b1b0-9b12a3ed7fd5">0.50</ix:nonFraction>% per annum in respect of unused commitments under the Revolver.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i2ce699b515444f35ade467426501141a" continuedAt="i3e42c48265004f4cbb428735ea7dc96e"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Term Loan amortizes in equal quarterly installments of <ix:nonFraction unitRef="number" contextRef="ie302bdf463064d918c23dd05f960895d_D20200101-20201231" decimals="INF" name="sgry:DebtInstrumentQuarterlyMaturityInstallments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzMwMzE_623c2564-13d4-4181-b715-a7ace29f1134">0.25</ix:nonFraction>% of the aggregate original principal amount of the Term Loan. The Term Loan is subject to mandatory prepayments based on excess cash flow for the applicable fiscal year that will depend on the first lien net leverage ratio as of the last day of the applicable fiscal year, as well as upon the occurrence of certain other events, as described in the Credit Agreement. There were no excess cash flow payments required as of December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April 22, 2020, the Company entered into a second incremental term loan amendment, which further amended and supplemented the Credit Agreement to provide for a $<ix:nonFraction unitRef="usd" contextRef="iaea8005193594087be6cd7ef7af8522d_I20200422" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1NjI_654f1cc6-8526-42ec-a226-6d25222f1f76">120.0</ix:nonFraction>&#160;million senior secured incremental term loan. The 2020 Incremental Term Loans were fully drawn on April 22, 2020 and bear interest at a rate per annum equal to (x) LIBOR plus a margin of <ix:nonFraction unitRef="number" contextRef="i30095dd0fcb34c208f8bbc81fe378695_D20200422-20200422" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1Nzg_3432655e-5897-4349-ba14-94e69dc063ae">8.00</ix:nonFraction>% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) <ix:nonFraction unitRef="number" contextRef="i060e7eb7f3c84d6d94309114449b4f82_D20200422-20200422" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1MzU_0be2bde2-99f1-4a10-b23f-138a3c4dd25f">0.5</ix:nonFraction>% per annum above the federal funds effective rate, (iii) one-month LIBOR plus <ix:nonFraction unitRef="number" contextRef="ia97d538681da4d98ae9a5301d88df53c_D20200422-20200422" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1NDE_06d3478c-fcae-4691-b5d6-31539aa421a4">1.00</ix:nonFraction>% per annum and (iv) <ix:nonFraction unitRef="number" contextRef="ibd68cd8cfddc4609b3d3f2f07babb578_D20200422-20200422" decimals="INF" name="sgry:DebtInstrumentAlternateBaseRateFloor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1NDg_d83f16ba-2683-4a0e-93bb-3b8d388cd436">2.00</ix:nonFraction>% per annum) plus a margin of <ix:nonFraction unitRef="number" contextRef="idb199e263568416fa7ab39a1d69ed544_D20200422-20200422" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1NTU_974e5d65-c080-4fd4-88bb-f10939b9b7bf">7.00</ix:nonFraction>% per annum. The 2020 Incremental Term Loans were incurred as a separate tranche of term loans under the Credit Agreement, and are subject to maturity, amortization and mandatory prepayment provisions consistent with the existing terms loans outstanding under the Credit Agreement. Voluntary prepayments of the 2020 Incremental Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except LIBOR breakage costs and a make-whole and call premium, as applicable, in the case of certain prepayments or events within a specified period of time after April 22, 2020, as set forth in the second incremental term loan amendment).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to the Revolver, the Company is required to comply with a maximum consolidated total net leverage ratio of <ix:nonFraction unitRef="number" contextRef="i04f59e4d834d47dbb571b78b88198617_D20200101-20201231" decimals="INF" name="sgry:DebtInstrumentNetLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzM1Nzk_9f828e51-9e06-45ae-8fd4-2fc8396cf980">9.50</ix:nonFraction>:1.00, which covenant will be tested quarterly on a trailing four quarter basis only if, as of the last day of the applicable fiscal quarter the Revolver is drawn in an aggregate amount greater than <ix:nonFraction unitRef="number" contextRef="i04f59e4d834d47dbb571b78b88198617_D20200101-20201231" decimals="INF" name="sgry:DebtInstrumentTotalCommitmentThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzM3Nzg_5d55eb5f-040a-4664-855a-db94846895ba">35</ix:nonFraction>% of the total commitments under the Revolver. Such financial maintenance covenant is subject to an equity cure. The Credit Agreement includes customary negative covenants restricting or limiting the ability of the Company and its restricted subsidiaries, to, among other things, sell assets, alter its business, engage in mergers, acquisitions and other business combinations, declare dividends or redeem or repurchase equity interests, incur additional indebtedness or guarantees, make loans and investments, incur liens, enter into transactions with affiliates, prepay certain junior debt, and modify or waive certain material agreements and organizational documents, in each case, subject to customary and other agreed upon exceptions. The Credit Agreement also contains customary affirmative covenants and events of default. On April 16, 2020, the Company entered into a third amendment to Credit Agreement governing the Revolver, which amended and supplemented financial covenants applicable to the Revolver. Pursuant to the third amendment, the Company's requirement to comply with a maximum consolidated total net leverage ratio was waived for the remainder of 2020. Additionally, for the first three quarters of 2021, the third amendment provides for an alternative calculation for the maximum consolidated total net leverage ratio where the trailing four quarter basis may be negatively impacted by the impacts of the COVID-19 pandemic. The third amendment became effective concurrently with the funding of the 2020 Incremental Term Loans on April 22, 2020, and are discussed in more detail above. As of December&#160;31, 2020, the Company was in compliance with the covenants contained in the Credit Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities are guaranteed, on a joint and several basis, by SP Holdco I, Inc. and each of Surgery Center Holdings, Inc.'s current and future wholly-owned domestic restricted subsidiaries (subject to certain exceptions) (the "Subsidiary Guarantors") and are secured by a first priority security interest in substantially all of Surgery Center Holdings, Inc.'s, SP Holdco I, Inc.'s and the Subsidiary Guarantors&#8217; assets (subject to certain exceptions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the 2020 Incremental Term Loans borrowings, the Company recorded debt issuance costs and discount of $<ix:nonFraction unitRef="usd" contextRef="iaea8005193594087be6cd7ef7af8522d_I20200422" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1ODc_d3b11e1f-e1c0-4590-9fc4-4d563fb71b4f">6.5</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzY0NTI_44b69b8c-2574-4928-81c4-c027b4be3808">6.750</ix:nonFraction>% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective June 30, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzY1NDU_bcb21d10-bef7-49de-9214-7d6a521fcdd9">370.0</ix:nonFraction> million in gross proceeds of senior unsecured notes due July 1, 2025 (the "2025 Unsecured Notes"). The 2025 Unsecured Notes bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzY2OTM_cf847182-3f94-4ae9-ba71-43020197cd11">6.750</ix:nonFraction>% per year, payable semi-annually on January 1 and July 1 of each year. The 2025 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly-owned restricted subsidiaries that guarantees the Senior Secured Credit Facilities (subject to certain exceptions).</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:DebtInstrumentRedemptionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEzMjQ3_a42cdaea-a789-4372-92e7-69698b936866" continuedAt="i384527e5dd4e4400a4472e19c830b7f6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2020 to June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90553b5457f14a698b7cb8171b9a9315_D20170630-20170630" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTpmNzMzMmFlNDI0MTQ0OGM0YTUzYmVmODdjNzQ2NTdmYS90YWJsZXJhbmdlOmY3MzMyYWU0MjQxNDQ4YzRhNTNiZWY4N2M3NDY1N2ZhXzAtMS0xLTEtMA_48c7b45d-366b-411c-a231-7bb27775f496">103.375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2021 to June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i568b49c59a4f4598aead50892e84c992_D20170630-20170630" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTpmNzMzMmFlNDI0MTQ0OGM0YTUzYmVmODdjNzQ2NTdmYS90YWJsZXJhbmdlOmY3MzMyYWU0MjQxNDQ4YzRhNTNiZWY4N2M3NDY1N2ZhXzEtMS0xLTEtMA_071de52a-36ab-43ab-8f8a-cf4acebd60ed">101.688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2022 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dd7045767554040a7d60f075ade6642_D20170630-20170630" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTpmNzMzMmFlNDI0MTQ0OGM0YTUzYmVmODdjNzQ2NTdmYS90YWJsZXJhbmdlOmY3MzMyYWU0MjQxNDQ4YzRhNTNiZWY4N2M3NDY1N2ZhXzItMS0xLTEtMA_166827b1-101b-414c-8e95-bab4cfa73481">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If Surgery Center Holdings, Inc. experiences a change in control under certain circumstances, it must offer to purchase the 2025 Unsecured Notes at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="ie0cdccdec4304478989201c4eb02dd07_D20170630-20170630" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzg0NTQ_261dd60a-1732-4fb6-87f6-dda78f2abfab">101.000</ix:nonFraction>% of the principal amount, plus accrued and unpaid interest, if any, up to, but excluding, the date of repurchase.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2025 Unsecured Notes contain customary affirmative and negative covenants, which, among other things, limit the Company&#8217;s ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i3e42c48265004f4cbb428735ea7dc96e"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9fe84b8f841949188f4220b606568120_I20190411" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzkxNTk_86372cb9-aa8c-4c32-a5b1-c607ba0021f6">10.000</ix:nonFraction>% Senior Unsecured Notes due 2027</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective April 11, 2019, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i9fe84b8f841949188f4220b606568120_I20190411" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzkzMDA_88ea0bcc-4d3d-48bf-bbe0-8c36b93e75e4">430.0</ix:nonFraction> million in an aggregate principal amount of senior unsecured notes due April 15, 2027 (the "2027 Unsecured Notes"). The 2027 Unsecured Notes bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="i9fe84b8f841949188f4220b606568120_I20190411" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzkzNzc_bf7b33e2-1fad-4d72-accf-83701a5ab85d">10.000</ix:nonFraction>% per annum, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2019. The 2027 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly-owned restricted subsidiaries that guarantees the Senior Secured Credit Facilities (subject to certain exceptions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may redeem up to <ix:nonFraction unitRef="number" contextRef="idb43c983a45f4e8591fd3ed40d5f1536_D20190411-20190411" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzk4NDg_de8d912e-ba0d-47bb-ae29-656037ab4874">40</ix:nonFraction>% of the aggregate principal amount of the 2027 Unsecured Notes at any time prior to April 15, 2022, with the net cash proceeds of certain equity issuances at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i0919062a6a4f4909a1ae4a4a597169ee_D20190411-20190411" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwMDM2_f209b820-0868-40bc-a1cd-895f76d35108">110.000</ix:nonFraction>% of the principal amount of notes to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may redeem the 2027 Unsecured Notes, in whole or in part, at any time prior to April 15, 2022, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="ib31650acf0ea42969dc4f705d51d36cf_D20190411-20190411" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwMzAy_f4c90e2e-1dcf-4842-b125-98c4a5394569">100</ix:nonFraction>% of the principal amount of notes to be redeemed plus the applicable premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. <ix:continuation id="i384527e5dd4e4400a4472e19c830b7f6" continuedAt="iedae9047f37749c59dda2840e069fcc7">The Company may redeem the 2027 Unsecured Notes, in whole or in part, at any time on or after April 15, 2022, at the redemption prices set forth below (expressed as a percentage of the principal amount of notes to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:</ix:continuation></span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><ix:continuation id="iedae9047f37749c59dda2840e069fcc7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2022 to April 14, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0635f303320f412186ec5ca19c6fe2f2_D20190411-20190411" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZToyMmM4MzU3YjU5OWU0ZjZhYjllZDczMmU1YTdkODdhMS90YWJsZXJhbmdlOjIyYzgzNTdiNTk5ZTRmNmFiOWVkNzMyZTVhN2Q4N2ExXzAtMS0xLTEtMA_92824a0e-83af-480c-b8a6-fdbd6bfe3be0">105.000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2023 to April 14, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9ee0fbd7a0a46f594cc7b82247aa031_D20190411-20190411" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZToyMmM4MzU3YjU5OWU0ZjZhYjllZDczMmU1YTdkODdhMS90YWJsZXJhbmdlOjIyYzgzNTdiNTk5ZTRmNmFiOWVkNzMyZTVhN2Q4N2ExXzEtMS0xLTEtMA_8ce41a90-01a6-4ac1-9733-a0764bd61c9f">102.500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2024 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic250d2ed04ae490aaaa2e78fd360cb53_D20190411-20190411" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZToyMmM4MzU3YjU5OWU0ZjZhYjllZDczMmU1YTdkODdhMS90YWJsZXJhbmdlOjIyYzgzNTdiNTk5ZTRmNmFiOWVkNzMyZTVhN2Q4N2ExXzItMS0xLTEtMA_1e7d185e-aaac-4d24-9e68-760fad028fc2">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If Surgery Center Holdings, Inc. experiences a change of control under certain circumstances, it must offer to purchase the 2027 Unsecured Notes at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="ia64e7b3f55a140e2b8f74b0d1c22c37b_D20190411-20190411" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwOTU5_f6589ed7-c33f-465b-95fb-fdd5f007ce79">101.000</ix:nonFraction>% of the aggregate principal amount of notes, plus accrued and unpaid interest, if any, up to, but excluding, the date of repurchase.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The indenture governing the 2027 Unsecured Notes contains customary affirmative and negative covenants, which, among other things, limit the Company&#8217;s ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 30, 2020, the Company completed the issuance and sale of $<ix:nonFraction unitRef="usd" contextRef="i8cd4c7600c0b479ab4a28ccae5406b84_I20200730" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk2MDE_7c7a15e4-3c11-4572-aad4-fb8afc349a7f">115.0</ix:nonFraction>&#160;million in aggregate principal amount of senior unsecured notes due 2027 at <ix:nonFraction unitRef="number" contextRef="i8cd4c7600c0b479ab4a28ccae5406b84_I20200730" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk2MTc_180ea730-5c01-4e5b-8cfe-5300b086abc9">100.75</ix:nonFraction>% of the principal amount. The notes were issued as part of the same series as the existing 2027 Unsecured Notes originally issued in April 2019, and have the same terms. In connection with the notes issuance, the Company recorded debt issuance costs, net of issuance premium of $<ix:nonFraction unitRef="usd" contextRef="i8cd4c7600c0b479ab4a28ccae5406b84_I20200730" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk2MjY_8bf03f73-6fbd-4ada-999a-1e0164f232b7">1.0</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s subsidiaries have outstanding indebtedness under notes payable and other secured loans, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made, and right-of-use finance lease obligations for which the Company is liable to various vendors for several property and equipment leases classified as finance leases.&#160;The various bank indebtedness agreements contain covenants to maintain certain financial ratios and also restrict encumbrance of assets, creation of indebtedness, investing activities and payment of distributions. At December&#160;31, 2020, the Company was in compliance with its covenants contained in the credit agreements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Maturities</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEzMjYz_ec30028d-f8b6-486a-95e3-b2c71dd2e0e9" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of maturities for the Company's long-term debt, excluding unamortized debt issuance costs and the unamortized fair value discount discussed above, for the next five years and thereafter as of December&#160;31, 2020 follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzAtMi0xLTEtMA_c3cff4dc-ddb2-48ed-8948-657b13d4e96e">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzEtMi0xLTEtMA_7e8b94fa-d14f-4ffe-8f4b-613c90b772ca">57.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzItMi0xLTEtMA_b920ee74-d908-4ea3-9bdd-772e67fc4308">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzMtMi0xLTEtMA_09992f29-2f65-4922-8414-b9aefb545e9a">1,519.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzQtMi0xLTEtMA_42e82552-b189-4fde-9b73-5a45b63a9a77">396.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzUtMi0xLTEtMA_b196b400-1f60-44c5-aa5b-a6fb59a74fcf">785.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzYtMi0xLTEtMA_d8384c72-5bde-4bec-aa80-f051d625125e">2,876.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_160"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3ODg_19c355ae-9388-4cfc-a747-b88efd44b8ac" continuedAt="i930742ae2f514c3a8fdd744127f4eac6" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3ODk_9d25213e-bd8b-4fc0-a0d0-bef672f2f45f" continuedAt="i9abf4c37c048440bb4d7ebec2ba285bb" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3OTQ_3d4e86ca-e1b5-4780-a4b9-4e0a429035ff" continuedAt="i83b0a3323f4e499eae951e242e3ab969" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i930742ae2f514c3a8fdd744127f4eac6" continuedAt="i72cef2a4f95b4cafa08d3ddb21c81573"><ix:continuation id="i9abf4c37c048440bb4d7ebec2ba285bb" continuedAt="ibf99743873014ab99636a69d5ad71fc0"><ix:continuation id="i83b0a3323f4e499eae951e242e3ab969" continuedAt="i27e21217c8744b8f8649848911fed2dd">The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the right to use the underlying assets for the lease term and the lease liabilities represent the obligation to make lease payments arising from the leases. Right-of-use assets and liabilities are recognized at commencement date based on the present value of future lease payments over the lease term, which includes </ix:continuation></ix:continuation></ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="ibf99743873014ab99636a69d5ad71fc0" continuedAt="i6aec95ff7f374729bf2338d9556be863"><ix:continuation id="i27e21217c8744b8f8649848911fed2dd" continuedAt="i622d0efaffb34750bb132bfb49ac5da3"><ix:continuation id="i72cef2a4f95b4cafa08d3ddb21c81573"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">only payments that are fixed and determinable at the time of commencement. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company's incremental borrowing rate is used. The Company calculates its incremental borrowing rate on a periodic basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company applies its incremental borrowing rate using a portfolio approach. The right-of-use asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The Company's finance leases also include certain land, buildings and improvements as discussed in Note 3. "Property and Equipment." Real estate lease agreements typically have initial terms of <ix:nonNumeric contextRef="id55b138001be441a9691661db6451a97_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LessorOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzI4Nzc_8435f182-3725-4254-8527-37032f4a41b3">ten years</ix:nonNumeric> and may include <ix:nonFraction unitRef="option_to_renew" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzI4OTY_0ff76f1b-83fd-42f6-ade1-1d9b727061b3">one</ix:nonFraction> or more options to renew. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of the Company's medical equipment leases have a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life. The Company's lease agreements do not contain any material residual value guarantees, restrictions or covenants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company's lease agreements require the Company to pay common area maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Certain lease agreements also include escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. These variable components of lease payments are expensed as incurred and are not included in the determination of the right-of-use asset or lease liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the COVID-19 pandemic, the Company received concessions for certain of its leases primarily consisting of deferral of rental payments. The Company has elected to account for these COVID-19 related concessions as though the enforceable rights and obligations for those concessions are explicit within the underlying contract. The Company accounts for the deferred rentals as a component of other current liabilities within the consolidated balance sheets. In a few instances the Company modified the terms of the lease in exchange for lease concessions. These modifications resulted in an increase to the Company's right-of-use operating lease assets and liabilities of $<ix:nonFraction unitRef="usd" contextRef="i50ba0a151834479a8473b3e13e71ff9c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzExNTQ0ODcyMTAyMzA1_1d6c7ad1-2e88-469a-a795-c620a7774b40">27.4</ix:nonFraction>&#160;million during the year ended December 31, 2020.</span></div></ix:continuation><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="sgry:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3OTE_8f497709-45ac-4c74-b9a4-815cb0d9c91a" continuedAt="if0dc5cbcf63e48d198b89cfc31347328" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets at December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzMtNC0xLTEtNDM2OA_f67406b6-b5a5-442b-8997-2904a931124c">310.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzMtNC0xLTEtMA_49b8fc3c-64f4-40d8-b89e-e6e03adab6d9">297.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzQtNC0xLTEtNDM3Nw_febe3414-bd03-4544-9614-8294c79aa4b4">258.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzQtNC0xLTEtMA_62a2d12d-7f15-4020-a8ab-85d66082cc49">237.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:LeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzUtNC0xLTEtNDQ3MA_8976456f-c2bf-4483-b0c1-049d24cce49e">568.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:LeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzUtNC0xLTEtMA_24d55e22-21c3-4c19-85ad-1c4dc768de36">534.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktNC0xLTEtNDM4MA_4855e2b7-0cfe-4b62-ae58-d25b9448cedf">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktNC0xLTEtMA_4060ad39-7d17-41fc-9964-5b89b164c95b">37.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzEwLTQtMS0xLTQzODM_b3539d8f-8f73-4439-bc10-42b3a71931c3">300.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzEwLTQtMS0xLTA_79f48df9-cc7b-4540-b6a9-31bf02f0ff30">283.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzExLTQtMS0xLTQ0NzA_d05a26c1-331a-4c1a-a277-9714de88ed70">340.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzExLTQtMS0xLTA_8ea3d330-aa65-404a-8cca-33f0aba491db">320.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzEzLTQtMS0xLTQzODY_ee7835ff-1ec0-4921-952c-f22bfb6ab3da">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzEzLTQtMS0xLTA_f33d261c-059d-4739-a004-a34db966a19f">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTQtMS0xLTQzODk_e2b71dff-da64-4aa2-8892-d059624959fe">262.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTQtMS0xLTA_020bc89e-2268-4c67-b620-43108bcf1263">237.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE1LTQtMS0xLTQ0NzA_93347cf0-5080-4bbe-a567-f8e546e783b5">281.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE1LTQtMS0xLTA_7bce66a5-ab33-46c0-af4e-740b9c0ae251">253.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE2LTQtMS0xLTQ0NzA_e83a04b6-b5c2-4d57-99e5-552dc19dfe83">621.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:LeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE2LTQtMS0xLTA_44420f5b-de10-466c-8919-9b02650eb876">573.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i6aec95ff7f374729bf2338d9556be863"><ix:continuation id="i622d0efaffb34750bb132bfb49ac5da3"><ix:continuation id="if0dc5cbcf63e48d198b89cfc31347328"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the weighted-average lease terms and discount rates at December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55b138001be441a9691661db6451a97_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzMtMi0xLTEtNDQwNw_64049f8c-5621-4335-9b00-b74364f2b841">8.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id55b138001be441a9691661db6451a97_I20201231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzMtNC0xLTEtNDQxMg_e2df15fb-b722-4f5e-a724-a9018fcd197e">15.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzItMi0xLTEtMA_c2470074-4182-4d0d-9ae7-1c3ba33d9855">8.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzItNC0xLTEtMA_65d2d17c-c3d9-4e5e-b49d-5df22e1c516f">16.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weight average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzQtMi0xLTEtNDQxNQ_2d6aaced-74b9-44c1-9a1c-c4d98bab97da">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzQtNC0xLTEtNDQxOA_74555f9a-3c56-4e58-a549-03a175d68073">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzMtMi0xLTEtMA_292543e7-8410-43a8-aa26-5b62025f4129">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzMtNC0xLTEtMA_887f46fc-9fa5-42ed-b60e-091d8bc99deb">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3ODE_ca877249-84c9-4484-8906-6b73918c0f8f" continuedAt="i77aaad4e366f4ac6a8a09c7686720278" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense and their classification in the consolidated statement of operations for the years ended December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzItMi0xLTEtNDM5Mg_258a65c8-6831-4bcd-93ba-22056dfd0c7e">74.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzItMi0xLTEtMA_177406d1-bdd4-4949-aff9-cf01acf44b29">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzQtMi0xLTEtNDM5Ng_f477b842-3014-4577-852a-83e3d95be233">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzQtMi0xLTEtMA_2d29e20a-5339-4368-95d7-712be15d0a73">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzUtMi0xLTEtNDM5OQ_d8aa2ffa-c33a-44f3-a50f-e336ad17f5c0">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzUtMi0xLTEtMA_b825fc09-489a-4bac-85e6-027983d44abf">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzYtMi0xLTEtNDQ3Mw_1b19ff35-11c2-40eb-a6a3-4799fb6d5bbf">48.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzYtMi0xLTEtMA_c82002cb-07f0-4f77-894c-a64edaa1e229">35.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:VariableAndShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzctMi0xLTEtNDQwMg_3bd49ed5-05fe-428b-9342-94da587f9c87">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:VariableAndShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzctMi0xLTEtMA_5e36c34d-5beb-4489-95b2-a9ad8a209a13">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzgtMi0xLTEtNDQ3Mw_339f32a8-678f-4213-a7a0-7cb04387d114">139.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzgtMi0xLTEtMA_8d596e42-9c63-4915-8900-0a56fe862425">118.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company incurred lease costs of $<ix:nonFraction unitRef="usd" contextRef="i9bba07e3d9ed4c28b32eadb5928dc00a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzEwOTk1MTE2MzgxMjc_c370842c-778c-4b23-87bc-7a35610dfb02">22.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2e7768b7591548fb890286a99b93de1b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzQ2NjM_05ad45c5-2162-4d8f-93dd-a84ce2028346">20.6</ix:nonFraction> million, respectively, under operating lease agreements with physician investors who are related parties. During the years ended December&#160;31, 2020 and 2019, the Company paid rent of $<ix:nonFraction unitRef="usd" contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgry:FinanceLeasePrincipalAndInterestPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzIxOTkwMjMyNjQwMTI_f2c17f55-ea14-4030-a28f-2053c5f83354">6.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgry:FinanceLeasePrincipalAndInterestPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzQ4MDA_294fb858-5407-4eb4-8cac-0e4b8875367e">6.7</ix:nonFraction> million, respectively, under a finance lease agreement with a lessor who is a related party. One of the Company's surgical facilities has a non-controlling ownership interest in the lessor. Payments are allocated to principal adjustments of the finance lease liability and interest expense.</span></div><ix:continuation id="i77aaad4e366f4ac6a8a09c7686720278"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for the years ended December&#160;31, 2020 and 2019 (dollars in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzMtMi0xLTEtNDQyMQ_4b58416e-24d8-420c-a3c4-df489e6037ef">68.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzMtMi0xLTEtMA_61ba262b-821a-44b5-ab9e-a45d790114b6">67.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzQtMi0xLTEtNDQyMQ_f60679de-685c-4676-9deb-0bf4387f4c61">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzQtMi0xLTEtMA_d6d610fa-d1e0-4aa0-9b6d-61f817abada3">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzUtMi0xLTEtNDQyMQ_519220f2-f5e6-4dca-8986-b81312e89227">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzUtMi0xLTEtMA_3f2bb668-c733-468f-b0d5-92afd1db8d5d">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzgtMi0xLTEtNDQyNg_92257a70-40b6-4547-af68-1a2fb2123050">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzgtMi0xLTEtMA_53a70dbe-8ec5-409f-b54f-9c7f1275faed">56.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzktMi0xLTEtNDQyNg_f1e2d582-3645-4b81-b40a-aa002eb50ae4">47.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzktMi0xLTEtMA_6f593c0f-087a-4ab4-a0d2-194aaeb88278">133.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3ODY_7fbbebf0-ccf2-44e4-b0f4-0e196915b982" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3OTI_12c82171-0b4f-4f70-a88b-fccd8b0dc8bb" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzItMi0xLTEtMA_dce43d93-bed0-48f7-ad79-ca3b1f202945">70.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzItNC0xLTEtMA_0b7cae71-fb66-4825-be62-ffa00905ae15">43.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzMtMi0xLTEtMA_0b352335-5435-4458-bc03-e74e8d226343">66.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzMtNC0xLTEtMA_0b47a2ef-2c59-47a6-9510-8310442c88c6">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzQtMi0xLTEtMA_5d7eec3c-ed59-465c-936c-842cae5a8473">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzQtNC0xLTEtMA_f85cbb5c-322a-4887-93b7-f107d17bd611">37.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzUtMi0xLTEtMA_1a54c043-2f8c-44ff-a5a8-8bf1676e7a19">58.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzUtNC0xLTEtMA_dc31133d-efd2-40f2-82f0-1e3d1d6a0454">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzYtMi0xLTEtMA_3d0c423e-fa27-4cd0-8a92-b15433ec6750">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzYtNC0xLTEtMA_ea64f53b-06dd-4930-a05c-c5267d902b0d">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzctMi0xLTEtMA_1a0fd311-bae3-4586-aa35-525ace2ac186">219.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzctNC0xLTEtMA_c23c056e-7257-4f49-8dbc-30ad6782ca6b">381.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzgtMi0xLTEtMA_9e8b8981-0ba0-496b-961c-e4e13cb6a25a">526.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzgtNC0xLTEtMA_93e0b689-8d08-41e6-8d50-06f4f83e7e37">565.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzktMi0xLTEtMA_67e37774-033d-498e-9e77-8af8c730f6c0">186.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzktNC0xLTEtMA_d0de5ed7-9da3-4d85-bcc4-f6f0e2a5dbf7">284.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzEwLTItMS0xLTA_0a7beb2c-2c45-4bb1-bbc8-a4d48462f2af">340.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzEwLTQtMS0xLTA_b20b504e-880b-4c15-8932-a7860883ed3a">281.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_163"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="sgry:RedeemablePreferredStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQzODM_ce5cca4c-7f61-4e04-8d44-c72136d0e6fd" continuedAt="i15ae818bb782406eb9d6b0bb56b6da24" escape="true">Redeemable Preferred Stock</ix:nonNumeric></span></div><ix:continuation id="i15ae818bb782406eb9d6b0bb56b6da24"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On August 31, 2017, the Company completed the sale issuance of <ix:nonFraction unitRef="shares" contextRef="i6fc81a25e5bb4918abcbd07201bcc95f_D20170831-20170831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzExMw_5f66e228-5524-40b6-b29e-db99d9a0427e">310,000</ix:nonFraction> shares of the Company's preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i504a7a32d45c41d5b54fd670857c3477_I20170831" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzE2Nw_d88348d7-1d24-447a-9af1-0744c6a42ade">0.01</ix:nonFraction> per share, designated as <ix:nonFraction unitRef="number" contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzE5NQ_8c391593-d07a-4a85-aa46-c2d65a3b9b68">10.00</ix:nonFraction>% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") to Bain Capital at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i504a7a32d45c41d5b54fd670857c3477_I20170831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzMzMQ_79d2b220-842f-44ce-9289-536bc5bb6e9b">1,000</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i6fc81a25e5bb4918abcbd07201bcc95f_D20170831-20170831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzM3OQ_114db57c-fc02-4239-90bd-9dd5d777f975">310.0</ix:nonFraction> million (the "Preferred Private Placement").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accrued value of the Series A Preferred Stock is convertible into shares of common stock at a price per share of common stock equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i88337f9fbaa64e0ea242df6336604eda_I20170831" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzU1OA_99d5cf2a-8908-4b89-9eb3-1a75cdeb2e70">19.00</ix:nonFraction>, subject to certain adjustments as provided in the Certificate of Designations, Preferences, Rights and Limitations of the <ix:nonFraction unitRef="number" contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzY4NA_a89fd3d9-5929-4366-84be-373c51b969e9">10.00</ix:nonFraction>% Series A Convertible Perpetual Participating Preferred Stock of Surgery Partners, Inc. (the "Series A Certificate of Designation"), at any time at the option of the holder. In addition, the Company may require the conversion of all, but not less than all, of the Series A Preferred Stock pursuant to the terms and conditions of the Series A Certificate of Designation, after the second anniversary of the date of issuance, if the volume weighted average closing price of the Common Stock for any <ix:nonFraction unitRef="trading_day" contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831" decimals="INF" name="sgry:TemporaryEquityThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzExODM_648e9f6e-47c2-4afb-ab0f-a76d7c6c34b2">20</ix:nonFraction> out of <ix:nonFraction unitRef="trading_day" contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831" decimals="INF" name="sgry:TemporaryEquityThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzExOTM_e5fcaac3-98d3-4699-a74e-6b6a6fa437d2">30</ix:nonFraction> consecutive trading days prior to such date, equals or exceeds $<ix:nonFraction unitRef="usdPerShare" contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831" decimals="INF" name="sgry:TemporaryEquityThresholdSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzEyNTk_69aacab6-02b5-49d3-8fa4-890e71eab18e">42.00</ix:nonFraction> per share. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot redeem the Series A Preferred Stock prior to the fifth anniversary of its issuance and thereafter, may redeem all, but not less than all, of the Series A Preferred Stock for cash pursuant to and subject to the terms and conditions of the Series A Certificate of Designation. The holders of Series A Preferred Stock may cause the Company to redeem the Series A Preferred Stock upon the occurrence of certain change of control transactions of the Company or the common stock ceasing to be listed or quoted on a trading market. The Company adjusts the carrying amount of the Series A Preferred Stock to equal the redemption value at the end of each reporting period as if it were also the redemption date. Changes in the redemption value are recognized immediately as they occur. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Series A Preferred Stock ranks senior to the common stock and any other capital stock of the Company with respect to dividends, redemption and any other rights upon the liquidation, dissolution or winding up of the Company, and the holders thereof are entitled to vote with the holders of common stock, together as a single class, on all matters submitted to a vote of the Company&#8217;s stockholders. In addition to participating in any dividends that may be declared with respect to the common stock on an as-converted basis, each share of Series A Preferred Stock accrues dividends daily at a dividend rate of <ix:nonFraction unitRef="number" contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzI2ODM_6184fd9a-1fe4-4374-8aee-d8697af233ff">10.00</ix:nonFraction>%, compounding quarterly, and in any given quarter, subject to certain conditions, the Board of Directors of the Company may declare a cash dividend in an amount up to <ix:nonFraction unitRef="number" contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831" decimals="INF" name="sgry:TemporaryEquityMaximumCashDividendDeclarable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzI4NTI_2ce289c8-d224-45e8-bb0c-68332aefc6f7">50</ix:nonFraction>% of the amount of the dividend that has accrued and accumulated during such quarter through the end of such quarter, and the amount of any quarterly dividend paid in cash shall not compound on the applicable date and shall not be included in the accrued value of the Series A Preferred Stock. In the event of the Company&#8217;s liquidation, dissolution or winding-up (whether voluntary of involuntary), holders of Series A Preferred Stock will be entitled to receive out of the assets of the Company available for distribution to shareholders, after satisfaction of any liabilities and obligations to creditors of the Company, with respect to each Series A Preferred Share, an amount equal to the greater of (i) $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c7fbb2ada8c40c981d5f09669df59ab_I20170831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzM1NjE_e14e0ee7-9215-492e-aed3-08ee89662b07">1,000.00</ix:nonFraction> per share, plus dividends compounded to date, plus dividends accrued but not yet compounded and (ii) the amount that a holder of one share of common stock would receive, assuming the Series A Preferred Stock had converted into shares of common stock.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:TemporaryEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQzODQ_7f8c9a96-a34d-43ed-bfb6-7a781ad98d88" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to the redeemable preferred stock for the years ended December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzMtMi0xLTEtMA_12bac0d2-6d67-4826-88cb-475b3d4622b4">395.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="-5" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzMtNC0xLTEtMA_0c137abb-602e-4955-9d3e-668b1997a35f">359.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends accrued (there were <ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquityDividendsAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NmQ4YWYzZGRjZTRjMDI4MDYxYWM0ZjcwYmU5NDA0XzIxOTkwMjMyNTU2MTU_8e8e6700-498b-4fdb-bec7-0bf85e508a2e"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquityDividendsAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NmQ4YWYzZGRjZTRjMDI4MDYxYWM0ZjcwYmU5NDA0XzIxOTkwMjMyNTU2MTU_a36c8026-2d8b-48b2-9d0d-b5470e8330f8">no</ix:nonFraction></ix:nonFraction> cash dividends declared)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:TemporaryEquityAccretionOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzQtMi0xLTEtMA_5fb70306-f49e-4ab2-8dfb-305bf5480d1d">39.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:TemporaryEquityAccretionOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzQtNC0xLTEtMA_0e12aca1-5776-4b77-a979-ddf462ff83c3">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzYtMi0xLTEtMA_642b948a-29b1-471e-9bdf-27b24c5e2f6e">434.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzYtNC0xLTEtMA_24a78f09-059c-426a-8f5c-f8f472f1d5a0">395.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQxOTU_25a5bfa3-3b18-46b6-955e-e11834e0ffe1"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQxOTU_ce237bf2-e4d2-4ccd-abc5-23092d484674">no</ix:nonFraction></ix:nonFraction> unpaid cash dividends declared at December&#160;31, 2020 and 2019. The aggregate and per share amounts of unpaid cumulative preferred dividends as of December&#160;31, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAmountOfPreferredDividendsInArrears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQzNDM_e6ebe175-e723-455a-a198-8d00d0228201">109.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usdPerShare" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="2" name="us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQzNTA_51345a47-39d1-43df-9fed-c7822ed5c4e2">351.54</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAmountOfPreferredDividendsInArrears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4Xzg3OTYwOTMwMjY5MDE_f072f75f-ba56-470e-bbd0-7147d97bf89e">69.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="2" name="us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4Xzg3OTYwOTMwMjY4OTI_cba889ec-e12c-4aac-9c46-3ceb6b5cf584">224.09</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_166"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.  <ix:continuation id="ia4e0863a629a45e2bd3557e8b97ac8e8" continuedAt="i36e866055c364d9d8d967076fbfce8af"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzE4ODU_29076c50-8790-4a07-966f-f9e234bd3c17" continuedAt="i0b99ef808e2a4c10b9b1ab0e1d1342fa" escape="true">Derivatives and Hedging Activities</ix:nonNumeric></ix:continuation></span></div><ix:continuation id="i0b99ef808e2a4c10b9b1ab0e1d1342fa" continuedAt="iafc0b934d9a24c82aaa1b91665c1eb0f"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i36e866055c364d9d8d967076fbfce8af" continuedAt="i243fab56670644808f0f2e0aa47d2825">The Company&#8217;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. During 2020 and 2019, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.  </ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i243fab56670644808f0f2e0aa47d2825">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#8217;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt.</ix:continuation> Over the next 12 months, the Company estimates that $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzExMDQ_3fae3942-25b7-4a93-a259-477c67f27e30">21.8</ix:nonFraction> million will be reclassified as an increase to interest expense.  </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="iafc0b934d9a24c82aaa1b91665c1eb0f"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company had <ix:nonFraction unitRef="swap" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzExOTI_09928fcf-4f97-497f-b21a-87e6569d664c"><ix:nonFraction unitRef="swap" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzExOTI_b2beb31c-f840-4cdc-a2b0-8e870775e58b">four</ix:nonFraction></ix:nonFraction> interest rate swaps with a current notional amount of $<ix:nonFraction unitRef="usd" contextRef="ib481dfff988242d29c23918931366022_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzEyNDk_2c9f79e6-bfe9-4ec1-9352-9a49549a0e3f"><ix:nonFraction unitRef="usd" contextRef="i36cc65a9e59d4da7ae3978ace772db56_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzEyNDk_6bfd9d24-3361-4d13-adcf-385b88d64b04">1.2</ix:nonFraction></ix:nonFraction> billion and a termination date of November&#160;30, 2023. The derivatives are recorded at fair value (see Note 1. "Organization and Summary of Accounting Policies") and classified as a long-term liability included in other long-term liabilities in the consolidated balance sheets as of December&#160;31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzE4ODE_9c610241-7b62-45a0-ac75-5cb77c8396f2" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps on the Company's accumulated OCI and statement of operations (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzUtMi0xLTEtMA_a6b5cc42-966d-42f2-9a4c-dff3f2972b2f">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzUtNC0xLTEtMA_2db1e075-cdef-4958-bd8b-fe0097ad3dfd">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzUtNi0xLTEtMA_01e50761-ae79-43e5-b641-c1d3481890e2">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss reclassified from accumulated OCI to interest expense (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzYtMi0xLTEtMA_3f4de486-a44b-49ec-aa61-b983e6469ace">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzYtNC0xLTEtMA_7277e74a-0ea3-4fbc-ba67-0d440da72ab1">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzYtNi0xLTEtMA_f1ec32f6-95a9-4d90-a5a8-2603dfbd8a48">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_169"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIzNTg_aa83b2cb-7d94-4045-a9fb-1895e64a5946" continuedAt="i14de1206fe714bb2818eebd5ed34aad1" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIzNTk_73116707-032d-4ef9-97ad-0940b2a5f594" continuedAt="idef429d3aadf4a2798ae454cc59acbbb" escape="true">Earnings Per Share</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="idef429d3aadf4a2798ae454cc59acbbb"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i14de1206fe714bb2818eebd5ed34aad1">Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The Company computes basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings.</ix:continuation> </span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIzNjI_77d57227-85bc-4120-9f2c-eee3917fa8b6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): </span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzUtMi0xLTEtMA_055925de-4410-4a3e-bf1f-e87dfae0cfa3">116.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzUtNC0xLTEtMA_a0b4331e-3023-4616-bcb5-6e9b32869427">74.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzUtNi0xLTEtMA_09e1932b-0da0-40ee-b27c-54d5ea50b7b9">205.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amounts allocated to participating securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzYtMi0xLTEtMA_39dd7928-7ae3-4612-ba21-9f51dcaa751f">39.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzYtNC0xLTEtMA_67de81ca-9851-444c-8d5c-d5935601042d">35.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzYtNi0xLTEtMA_437e83d1-dd7f-4b44-b3cd-8e02751b055c">32.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzgtMi0xLTEtMA_7458f22d-cf5e-4f33-a2e4-ba383039e769">155.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzgtNC0xLTEtMA_6def45d1-dd42-4005-9993-7ebae8f3bd96">110.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzgtNi0xLTEtMA_53d53854-a885-4943-b697-8fd85f8dca3c">238.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8">48,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5">48,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08">48,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e">3.19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTQtMS0xLTA_e2601a14-aa10-4c9d-904f-cfe5a64cd0de">2.29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6">4.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50385fe9eb7447adb4a7a8c102372757_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE2LTItMS0xLTA_066d89dc-7deb-46d8-aea9-9f071403910c">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i047b904f4f4f4b5787db655ab1545242_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE2LTQtMS0xLTA_3684892e-2840-4977-9294-31de41c7cb96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe9c8ea68367495b9b437d93d0ca84d0_D20180101-20181231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE2LTYtMS0xLTA_3d8a3294-8ea0-4c63-a0e0-321e6b90bc74">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fe24d481eb644d19bca83b8dd928563_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE3LTItMS0xLTA_c8ad6fa7-d9a7-4fc2-b2ce-983d0e57280f">981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie72a24a82e274959946cf1d65a10b85f_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE3LTQtMS0xLTA_2d5934dc-3121-4c38-a184-24c4017b14ea">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26af377b8d9c4408a23b37c560fdc30e_D20180101-20181231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE3LTYtMS0xLTA_94ad6ff9-51d1-4467-b0d9-2d93876f2580">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes dividends accrued during all periods for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in each of those periods.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Transactions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 15, 2017, the Company's Board of Directors authorized a share repurchase program of up to $<ix:nonFraction unitRef="usd" contextRef="icb46091aec85404086cdd6773d8811e8_I20171215" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzEzMjM_8531078d-092c-48d1-bcd9-9c9579830ba9">50.0</ix:nonFraction> million of the Company's issued and outstanding common stock from time to time. The timing and size of repurchases will be determined based on market conditions and other factors. The authorization does not obligate the repurchase of any shares and the Company may repurchase shares of common stock at any time without prior notice. The share repurchases will be made in accordance with applicable securities laws in open market or privately negotiated transactions. The authorization does not have a specified expiration date, and the share repurchase program may be suspended, recommenced or discontinued at any time or from time to time without prior notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIxNDc_b5290ac7-8a9f-449a-abfb-8c762cae85c9">156,818</ix:nonFraction> shares of its common stock at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIyMDA_4d7bc6cb-4f29-4b23-89ba-0e84a8a8820d">12.64</ix:nonFraction> per share through market purchases. At December 31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIyNzc_1fe308e5-f6e9-485c-825b-3aad62e4740e">46.0</ix:nonFraction> million of repurchase authorization available under the December 2017 authorization.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_172"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.&#160; <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMTU_0ec5d68b-5fff-4ae3-b5a1-8f0d69ddfa39" continuedAt="ica2132535b4d462ca1ea5b376d463e04" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ica2132535b4d462ca1ea5b376d463e04" continuedAt="i2c4950c7ab804b3daea2a5fbe45ef482"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMjQ_03399799-498e-4aef-b6aa-8a0831d42a9a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes.&#160;Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160;Any change in tax rates that could impact deferred tax assets or liabilities are recognized in the same period the change occurs. If a net operating loss ("NOL") and/or interest limitation ("163(j)") carryforward exists, the Company makes a determination as to whether that NOL and/or 163(j) carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss and interest limitation carryforwards when their recoverability is deemed to be uncertain.&#160;The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions.&#160;If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2017 or state income tax examinations for years prior to 2016.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made income tax payments of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzIxODI_38b180a3-6d63-40be-bfaa-ec616557a5ea">1.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzIxODk_b36ab849-c619-491f-ab5c-12e459d125db">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzEwOTk1MTE2MzYxNzk_2735582c-c855-41a8-9108-385fa7d58504">2.2</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMjM_e79a7a53-2e4d-4b62-ac77-45f7d77c0e8a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense is comprised of the following (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzUtMi0xLTEtMA_aaf4b0d2-38da-45ff-8783-a6cd92e56864">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzUtNC0xLTEtMA_abc57da0-025e-48b7-a50c-5a6f66b2a51f">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzUtNi0xLTEtMA_92a1a61c-9036-4013-9dd2-bdcba91d4a2f">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzYtMi0xLTEtMA_6c519132-10b4-4eb4-9a65-bed0476784b8">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzYtNC0xLTEtMA_b5f21c0b-1ba5-40e0-87e9-ba2f1f9fa2ef">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzYtNi0xLTEtMA_dc312acc-7d2e-4404-bbe4-21e499ffa836">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzgtMi0xLTEtMA_388b2205-5257-4a98-8090-ebb7a7ad73b7">22.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzgtNC0xLTEtMA_7b9efef6-27ea-411d-8008-7578d9ee4a1c">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzgtNi0xLTEtMA_4f100bce-87f0-43e8-8d32-ad4164f7d2ca">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzktMi0xLTEtMA_7dd88d1e-62d8-4ff9-b81e-197d99ae9d2f">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzktNC0xLTEtMA_2c63cfd7-7f39-48c4-8c97-cca8f254a872">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzktNi0xLTEtMA_fee77219-c557-41aa-9ba7-658a9c5a7c6c">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzEwLTItMS0xLTA_8e167c39-25a7-4fa1-9273-dcb7c00c5f8e">20.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzEwLTQtMS0xLTA_1fef0a65-5826-4f2e-a9cc-386afe9db636">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzEwLTYtMS0xLTA_0c9c365f-d98f-45cc-9ab9-7ef58f3b13c5">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i2c4950c7ab804b3daea2a5fbe45ef482" continuedAt="i6b3dfa72f016433c9b689886b49f2b05"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMjc_d6b2ea48-6365-4f25-8d3e-42659141b12d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax (benefit) expense computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 21% (2020, 2019 and 2018) follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax (benefit) expense at U.S.federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzQtMi0xLTEtMA_65dc051f-9abc-4730-859d-d4d99e8c438d">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzQtNC0xLTEtMA_5fbbece1-f3dd-4728-be82-3041bfe7a56c">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzQtNi0xLTEtMA_f61d83ad-263d-40c6-baef-3d7ac4bc17ec">14.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of U.S. federal tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzUtMi0xLTEtMA_6da8b076-fb6d-4c56-9ad9-8fd1d09403af">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzUtNC0xLTEtMA_3b5e5d5b-efdf-49cb-85f6-5dd40f602949">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzUtNi0xLTEtMA_153a7722-c1d6-46d3-87b0-28daa9a7931d">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzYtMi0xLTEtMA_795e0efc-0a9a-415c-8aba-5bfcd9aa9a15">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzYtNC0xLTEtMA_00460fe3-6066-4803-a00f-e5c2a827724c">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzYtNi0xLTEtMA_7cc3254d-d49d-41f5-ad57-c848e67ef93c">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzctMi0xLTEtMA_2c4d794a-e610-4a09-8e92-380a7d71294d">24.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzctNC0xLTEtMA_98d7a745-a6f6-4668-85fd-586535313795">25.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzctNi0xLTEtMA_25326b73-662e-472e-9235-3380c296e120">23.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in measurement of uncertain tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzgtMi0xLTEtMA_4f824fc9-3b03-48be-a6f2-ef749a648422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzgtNC0xLTEtMA_e6424c2e-bb28-48cd-814e-0e2813400094">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzgtNi0xLTEtMA_65f9be12-471f-4c7c-80be-86e11069fec9">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzktMi0xLTEtMA_0a4ccb49-e67a-422c-b0cb-3d64bc435ff5">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzktNC0xLTEtMA_ea51b35f-8832-46af-b04d-657e2416f5c8">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzktNi0xLTEtMA_c3cd822f-2e8a-4381-8591-d2f693122131">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differences related to divested facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="sgry:EffectiveIncomeTaxReconciliationDivestitureAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEwLTItMS0xLTA_1942bfa8-9339-4973-9b4f-5bd7438bb9a7">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:EffectiveIncomeTaxReconciliationDivestitureAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEwLTQtMS0xLTA_e4b61f9f-d177-44a6-8c54-0aac91ac92f1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:EffectiveIncomeTaxReconciliationDivestitureAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEwLTYtMS0xLTA_f5dba668-e45d-444a-aec5-6bf32fe46235">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax return reconciling differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEyLTItMS0xLTA_44fa1729-a7fe-4421-bd5a-4e2f5376d052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEyLTQtMS0xLTA_938cbb3c-414a-42d4-aa5b-f47f174e44de">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEyLTYtMS0xLTA_7fa31cdd-843e-4837-bcae-82a8eb91944e">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEzLTItMS0xLTA_4f316039-0cd8-4906-a517-6e6fea442d67">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEzLTQtMS0xLTA_a1703fe5-d84e-4a32-a6c7-aa2fb6874106">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEzLTYtMS0xLTA_09361920-6813-46df-b395-25031646633d">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Receivable Agreement liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE0LTItMS0xLTA_6d174b78-6607-4172-9e6d-465fcad7a717">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE0LTQtMS0xLTA_71093117-f32d-4232-bc0b-9996993cecb5">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE0LTYtMS0xLTA_5b019b51-d787-4c84-b245-fb4e8d3eefaf">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE1LTItMS0xLTA_3739722c-3d47-4ae6-a313-cf8b80f2ad84">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE1LTQtMS0xLTA_1ef6a402-e671-43b5-a5fb-2466c7f12645">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE1LTYtMS0xLTA_f92a4187-4117-43a2-8b04-3a04f7dd92ce">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE2LTItMS0xLTA_bdec0665-fccb-4e7c-9aab-f5d96e828a63">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE2LTQtMS0xLTA_1793d35a-333c-4d14-86f3-52d3a9fd05e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE2LTYtMS0xLTA_19cc89b0-3652-4ded-a6df-dd828c8cf5a5">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE3LTItMS0xLTA_43cd5d79-b0fc-43d9-86ec-fe7b66db3c11">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE3LTQtMS0xLTA_41d8c704-a5ab-4a42-a912-3ded063ddc3c">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE3LTYtMS0xLTA_7b24fb40-8237-407e-94d6-b267dcd68804">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE4LTItMS0xLTA_eae6664a-7e52-4887-92b1-6ad9b0d5269e">20.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE4LTQtMS0xLTA_8489eca9-3817-48c6-a521-20e7ab75831d">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE4LTYtMS0xLTA_935a04f3-731d-4521-990c-070e48167f18">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMTk_8b8b4866-56f0-45f8-8a8a-62ba5d5f053b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of temporary differences and the approximate tax effects that give rise to the Company&#8217;s net deferred tax asset are as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical malpractice liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzQtMi0xLTEtMA_c227d350-a461-4286-a679-bb19a1299195">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzQtNC0xLTEtMA_3085d2ad-4d62-4438-af6d-d8bb54782421">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and incentive compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzUtMi0xLTEtMA_7e564963-32a3-42c0-87bf-fa9a97af936a">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzUtNC0xLTEtMA_4a7f0c72-4da4-422b-add1-4d3cb2cf7aa8">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzYtMi0xLTEtMA_52e8da45-0008-47a1-bd65-2bf7d0f894d9">164.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzYtNC0xLTEtMA_c7415a44-49bc-4520-a16b-9bdecad66bcf">143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for bad debts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzctMi0xLTEtMA_8b4720be-1767-4463-b65e-deefdd261e23">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzctNC0xLTEtMA_f856a16c-b19b-4afd-a9a0-d9f27a3520e4">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzgtMi0xLTEtMA_bb806fcf-f70f-4b6c-baae-c59914f24fa4">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzgtNC0xLTEtMA_546c5c98-fd42-4de1-981e-a2fbd2d11ae0">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEwLTItMS0xLTA_9ae0ea57-7fa9-46fc-8ed2-5beee0e5e598">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEwLTQtMS0xLTA_416a5e58-0397-44b2-b366-ef5491d9ac15">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzExLTItMS0xLTA_6f55693b-1936-489a-ad55-d0132a33b245">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzExLTQtMS0xLTA_f434a66d-2f5b-4fa4-9413-bb00637ee448">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 163(j) interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEyLTItMS0xLTA_9b948f63-d7d9-439e-b52b-fa476fa7084f">69.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEyLTQtMS0xLTA_e3ccd1b6-0548-470b-862a-e02d38a7a88f">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsHedgingTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEzLTItMS0xLTA_0c16481e-1845-48da-8727-16170c3b8844">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsHedgingTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEzLTQtMS0xLTA_3f9e910a-2e4c-4e72-b9d6-c6c426e66bee">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TRA liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:DeferredTaxAssetTaxReceivableAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE0LTItMS0xLTA_840f83ac-8620-4968-8ff9-8b1730e56647">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:DeferredTaxAssetTaxReceivableAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE0LTQtMS0xLTA_2b47c435-4c5c-46c2-9aed-d3994df62c17">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:DeferredTaxAssetsRightOfUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE1LTItMS0xLTA_d6882f5f-29db-4b78-b9ee-039b459122d7">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:DeferredTaxAssetsRightOfUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE1LTQtMS0xLTA_5ff997f1-772c-4e30-bc49-501425f0e626">52.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Affiliate indebtedness receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:zerodash" name="sgry:DeferredTaxAssetsAffiliateIndebtednessReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE2LTItMS0xLTA_2ed46b7f-d019-4931-909b-dedddbb938ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:DeferredTaxAssetsAffiliateIndebtednessReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE2LTQtMS0xLTA_19a9b40f-d666-4127-8c78-faa977c85e86">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other deferred assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE3LTItMS0xLTA_fb16a73e-76b4-4969-9204-360ef781afcd">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE3LTQtMS0xLTA_b3b50e8c-1bdf-47b9-b5be-0a397cd53a9a">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE4LTItMS0xLTA_d4a150cc-f620-4cd8-a4a1-f6eff679ecf5">339.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE4LTQtMS0xLTA_d34a5473-e57a-4c97-908c-0697a8ff354f">299.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE5LTItMS0xLTA_d461c2e8-0fe2-4bc7-a706-11df9e1fcf5c">91.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE5LTQtMS0xLTA_60741c12-74f7-4101-b14b-1387edf6a44e">77.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIwLTItMS0xLTA_d11b51ec-5b5d-4c4f-9986-d91d160e3724">248.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIwLTQtMS0xLTA_8c15fb40-0c3d-4aec-bc26-619941b59c64">221.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation on property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIyLTItMS0xLTA_f518a4b0-97f8-4229-a5e7-e75f4c94bb03">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIyLTQtMS0xLTA_151b515f-9d67-4057-96d0-8a7dfbdf0003">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basis differences of partnerships and joint ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIzLTItMS0xLTA_812a0033-c7b6-48f7-8a31-3117c2d23d6a">73.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIzLTQtMS0xLTA_7ac348b1-9191-4f45-83a9-77db5e8ce33f">67.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI0LTItMS0xLTA_66733615-716d-4b41-834c-2007a75a680d">47.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI0LTQtMS0xLTA_d9918e9a-9409-43ac-ac75-58102231a01c">51.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI1LTItMS0xLTA_5feeaad3-35a3-49d2-8f28-24ccc653b9fa">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI1LTQtMS0xLTA_fcc5bd8c-fe5b-41bc-b365-9bf9ffb1ee44">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI2LTItMS0xLTA_e7865a29-93c7-4ca1-b72a-dff50ce47863">123.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI2LTQtMS0xLTA_4e09b5d8-af1f-48bd-addb-1175883de2a8">122.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI3LTItMS0xLTA_fc261d97-1098-4167-ab2f-37f06bdf4193">124.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI3LTQtMS0xLTA_e88c4287-cec9-4176-b409-711b93b23903">98.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i6b3dfa72f016433c9b689886b49f2b05"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had federal NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ib4a503d7300c4baaab4d78c7a78fe1ab_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzI5NTY_87936e26-2c24-4a66-b850-028cfe918cb9">615.7</ix:nonFraction> million as of December&#160;31, 2020, of which $<ix:nonFraction unitRef="usd" contextRef="ib4a503d7300c4baaab4d78c7a78fe1ab_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzI5Nzg_a43cfc79-d132-4a71-a193-2bd8d52b2b6e">516.2</ix:nonFraction> million expire between 2026 and 2037. The remaining federal NOL carryforwards, which were generated subsequent to 2017, do not expire. The Company had state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i4f0306c05aea4ff8908dcdbb29dc76e5_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzMxNDc_b90a0149-e347-43e6-a495-73b78e456257">678.9</ix:nonFraction> million as of December&#160;31, 2020, which expire between 2021 and 2040.&#160;The Company had capital loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ic8ae2680c0a24c0f85638b06d6ff55bc_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzMyMzg_99685221-5122-4fe2-bbfa-7d481b23ae15">6.2</ix:nonFraction> million as of December&#160;31, 2020, which expire between 2021 and 2023. The Company had federal and state credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ib10c51e09f2a46dd82c6116912a94c59_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzMzNDE_f4b6523a-a132-426a-86ef-72632773f05a">0.7</ix:nonFraction> million as of December&#160;31, 2020. The federal credits do not expire, and the state credits expire between 2021 and 2031. The Company had IRC Section 163(j) interest limitation carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ie5f2564128c34ff789c5d6d49d4f690e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzM1MDk_533510c1-d34d-46ab-a1aa-d7b5df3da200">278.4</ix:nonFraction> million as of December&#160;31, 2020, which do not expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recorded a valuation allowance against deferred tax assets at December&#160;31, 2020 and 2019 totaling $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzM2NTU_578a6c21-441b-40a2-91d4-2c63b337986c">91.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzM2NjI_41b70139-fbc1-4747-9a34-19f1c9d29fcf">77.9</ix:nonFraction> million, respectively, which represents an increase of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzM3MTI_43d7e95b-bd11-4cba-9704-e42cef45c205">13.2</ix:nonFraction> million. The valuation allowance continues to be provided for certain deferred tax assets for which the Company believes it is more likely than not that the tax benefits will not be realized, which are primarily Section 163(j) interest carryforwards, certain state NOLs and capital loss carryforwards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has evaluated the realizability of its deferred tax assets based on sources of positive and negative evidence, and determined that it is more likely than not that the NOL carryforwards will be realized. The determination was made based upon projections of future book and taxable income. If the Company's expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, the Company may need to adjust the valuation allowance, for all or a portion of its deferred tax assets. The Company's income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in its valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on the Company's future earnings. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in the increase in the valuation allowance for the year ended December&#160;31, 2020 was an increase of approximately $<ix:nonFraction unitRef="usd" contextRef="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgry:NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzUwNjM_bd73fd5d-d949-4d86-bf56-07210fa8903b">2.8</ix:nonFraction> million that was recorded to additional-paid-in-capital as the result of the tax effect of the interest rate swap liability. Approximately $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzUxOTc_1cd81297-fd8b-49bf-b2e9-fbd0322a7826">16.8</ix:nonFraction> million of the valuation allowance as of December&#160;31, 2020 is recorded against deferred tax assets that, if subsequently recognized, will be credited directly to contributed capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMTM_dd1dad27-205b-4c19-a556-cfb5f416c794" continuedAt="i6cefbf1a963a4039ac14a2b55f906ecf" escape="true">A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><ix:continuation id="i6cefbf1a963a4039ac14a2b55f906ecf"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzMtMi0xLTEtMA_4103f5f3-0329-407a-87d0-f5b35cfb3bf6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzMtNC0xLTEtMA_56773342-7d2f-411e-8e0f-24e3785d77fc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzYtMi0xLTEtMA_6eb74cca-4846-4a01-9910-696d217c7e02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzYtNC0xLTEtMA_cf2a302a-18b9-4fe8-b9d9-aab0426738ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzgtMi0xLTEtMA_c7d25403-44dc-4e15-a869-f4e0f724835b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzgtNC0xLTEtMA_0ae63c64-06e6-4ffa-849d-28a91b9a2148">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions in its provision for income taxes in the consolidated statements of operations. For both years ended December&#160;31, 2020 and 2019, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzg3OTYwOTMwMzExMzA_1f299f1f-c54b-451d-aa9a-f0ba9ddba865"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzg3OTYwOTMwMzExMzA_d0066df8-6f76-41b4-95a5-4f732fdb5097">0.1</ix:nonFraction></ix:nonFraction> million each of accrued interest and penalties related to uncertain tax positions. The total amount of accrued liabilities related to uncertain tax positions that would affect the Company's effective tax rate, if recognized, is $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzEwOTk1MTE2Mzc1MDk_81860c7b-3f9d-4158-943b-8ba7f4b9efe7"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzEwOTk1MTE2Mzc1MDk_ecec97a6-396e-4811-81c6-82599679ae92">0.1</ix:nonFraction></ix:nonFraction> million as of both December&#160;31, 2020 and 2019. The reserves are included in long-term taxes payable in the consolidated balance sheet as of December&#160;31, 2020.</span></div></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_175"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11.&#160; <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzg1_dff4375c-b279-49a5-86cd-241fb26900f9" continuedAt="icea2740cfc104f6da48257a906ddfce8" escape="true"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzg4_64c581e7-0592-46b1-9e21-0663a78a4cdb" continuedAt="i60c690aa2233491e847ee7fd1b0d8921" escape="true">Equity-Based Compensation</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="icea2740cfc104f6da48257a906ddfce8" continuedAt="i74f392bece8b4014b86ac5ffd9a291cf"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i60c690aa2233491e847ee7fd1b0d8921">Transactions in which the Company receives employee and non-employee services in exchange for the Company&#8217;s equity instruments or liabilities that are based on the fair value of the Company&#8217;s equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. The Company&#8217;s policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Surgery Partners, Inc. 2015 Omnibus Incentive Plan, as amended and restated effective January 1, 2020 ("2015 Omnibus Incentive Plan") from which all equity-based awards will be granted. Under this plan, the Company can grant stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of its common stock. As of December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i0238428bd25e45529ad62844562813e6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg5MQ_23593c36-7a0e-43dc-87ce-09d830e5c886">8,315,700</ix:nonFraction> shares were authorized to be granted under the 2015 Omnibus Incentive Plan and <ix:nonFraction unitRef="shares" contextRef="i0238428bd25e45529ad62844562813e6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzk3Mw_ce86ce1a-b183-4f72-945f-6a164f2a6f66">5,285,421</ix:nonFraction> were available for future equity grants. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted and Performance Share-Based Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company granted <ix:nonFraction unitRef="shares" contextRef="i2828db13be9542a6b1c20843c59ad276_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExMDI_fb28e4e4-cc1b-4474-8300-bbf69c9900b8">1,077,367</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8e546cbd60bb4cb3b0bc3eb05ff08c90_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExMDk_e41d7550-5a2b-408b-9eef-a08d6b9d6e7f">556,450</ix:nonFraction> restricted stock awards ("RSAs") to certain officers, employees and non-employee directors in accordance with the 2015 Omnibus Incentive Plan, respectively. Vesting and payment of these RSAs are generally subject to continuing service of the employee or non-employee director over the ratable vesting periods beginning one year from the date of grant to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE0NjY_cd80199e-a025-45d6-ad9d-4f4ef62346f4">three</span> or <ix:nonNumeric contextRef="i038159bf343d4a9eaa27f787b51188c8_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE0NzI_4478a404-3978-479e-bf0c-6077db576d6c">five years</ix:nonNumeric> after the date of grant. The fair values of these RSAs were determined based on the closing price of the Company&#8217;s common stock on the trading date immediately prior to the grant date.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i74f392bece8b4014b86ac5ffd9a291cf" continuedAt="i5a6653a8ff2944c58be1e797ca0ef062"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company granted <ix:nonFraction unitRef="shares" contextRef="i7449dbb4efe040eeac8fd22c2a9264f9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE3MjA_e370487e-468a-49a3-92c1-dcef514edd20">854,367</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0f57145632eb43a6ae9a59e0eb4f4180_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE3Mjc_53ef9bae-06eb-42cc-8608-033f50dc4862">389,972</ix:nonFraction> performance-based restricted stock units ("PSUs") subject to the achievement of a combination of performance conditions, respectively. In addition to the achievement of the performance conditions, these PSUs are generally subject to the continuing service of the employee over the ratable vesting period from the earned date continuing for <ix:nonNumeric contextRef="i7449dbb4efe040eeac8fd22c2a9264f9_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIwNzA_764f9bd5-3108-45eb-b208-a2c11a7e857f">two years</ix:nonNumeric>. For these PSUs, the number of shares payable at the end of the performance periods ranges from <ix:nonFraction unitRef="number" contextRef="i90b10c28a8aa40f7a09f7a0424ba887c_D20200101-20201231" decimals="INF" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTM_baa87770-8624-4175-82af-5f46403e63ae">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i752e2e790a184e4ea39af03e843709ff_D20200101-20201231" decimals="INF" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTk_7d68e1e4-c4d9-4d53-882a-cd22ae4f14cb">150</ix:nonFraction>% of the targeted units based on the Company&#8217;s actual performance and/or market conditions results as compared to the targets. These PSUs are not considered outstanding until earned. During the years ended December&#160;31, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i7449dbb4efe040eeac8fd22c2a9264f9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="sgry:ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzI0MTY_427d5144-ecd1-4c82-ac81-181a3fdb0495">309,692</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0f57145632eb43a6ae9a59e0eb4f4180_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="sgry:ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzEwOTk1MTE2Mzk3OTM_2d31126f-4447-4141-9c38-a94e8604d424">245,301</ix:nonFraction> of the PSUs previously granted were deemed to have been earned, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Performance Share-Based Activity</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzg2_7ff8e3db-f7f2-4f29-bf84-10d846595a01" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of non-vested restricted share-based activity for the years ended December&#160;31, 2020, 2019, and 2018 follows:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unvested Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafc9c624583e425f9f3f383d5de093bc_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE1LTItMS0xLTA_bebf623a-79a3-4dd8-82da-54f22022856c">574,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafc9c624583e425f9f3f383d5de093bc_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE1LTQtMS0xLTA_63b04cae-7af8-4dc2-854a-eded67012371">15.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE2LTItMS0xLTA_7aacc241-414e-488b-8959-53a2716e0be1">519,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE2LTQtMS0xLTA_3a586cf4-49f9-4541-aa98-80a81bc96b1d">16.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE3LTItMS0xLTA_acec45bf-86bb-4e73-be02-0438339de477">180,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE3LTQtMS0xLTA_b33c0c76-8400-4049-bcbc-9433c2c59147">15.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE4LTItMS0xLTA_1f013660-1c3e-4fbf-ac8d-f6a230fa51b7">210,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE4LTQtMS0xLTA_0bade3bb-51c3-41a1-bb2b-447515f28aad">16.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f8b77cdfd93419e8d20d28aa5fff865_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE5LTItMS0xLTA_6924226b-20e0-4848-a8dd-f9a4fb0c29a6">703,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f8b77cdfd93419e8d20d28aa5fff865_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE5LTQtMS0xLTA_199004fe-79ab-4cae-a8f1-78d4e5a96bf0">16.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIwLTItMS0xLTA_d9e410d4-5dd7-4757-865d-553858904523">801,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIwLTQtMS0xLTA_e37a2373-c3cb-43bb-957d-a091d4d2d753">12.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIxLTItMS0xLTA_da9ec113-0f2b-4a42-bb61-166bc7bf204d">272,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIxLTQtMS0xLTA_4e80b4bd-2b05-49d9-a660-22278ad6da35">12.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIyLTItMS0xLTA_d209eec7-1031-42cb-9e99-90776087f338">456,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIyLTQtMS0xLTA_5ceeb89e-282f-47a4-a83a-271ca1c53eaf">16.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib77a4c3d6184412d9f09f4d2864124b1_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIzLTItMS0xLTA_a23c104a-21eb-4f59-a464-60db4c50fa50">775,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib77a4c3d6184412d9f09f4d2864124b1_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIzLTQtMS0xLTA_935f0fd3-f281-48a7-9ad0-4cd71bae6159">13.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEwLTItMS0xLTE0Nzg_0071e0a5-f4a5-4db3-bec6-003880208baf">1,387,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEwLTQtMS0xLTE0ODI_2cc7cdb6-ac4b-450c-8d06-6a5cbd87e056">6.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzExLTItMS0xLTE0Nzg_ea5484d7-a6fc-413f-8810-e03524d9ab89">162,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzExLTQtMS0xLTE0ODI_d1fe492f-19c0-40e4-955b-bb4ca9afdef2">13.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEyLTItMS0xLTE0Nzg_3fe42d50-8ece-4957-84d8-4b9080c71ac3">552,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEyLTQtMS0xLTE0ODI_78168f37-4e0b-4d77-9da6-8d003847bb0a">12.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56c4f778361246b18c21e65a767306f6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEzLTItMS0xLTE3NjQ_e2b6e212-ece4-461a-9989-2f3f6e22f332">1,447,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56c4f778361246b18c21e65a767306f6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEzLTQtMS0xLTE0ODI_1de1ae18-c053-429b-b22b-1209c21572cb">9.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="ib26f364f72d64a0e823a7afe664f2323_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzU0MjI_603fbb4c-ae6e-459e-90d2-6edfef77ddfd">2,256,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9657217604e94a48a864adfb783bc292_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzEwOTk1MTE2NDA0MjQ_08c30384-9946-4e9b-a8e9-b84744029a29">700,000</ix:nonFraction> stock options during the years ended December&#160;31, 2019 and 2018, respectively. <ix:nonFraction unitRef="shares" contextRef="i88f2f675e83142ada36ac4b6fab72299_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTkwMjMyNjg1NjE_703ce278-e358-42ae-a89d-f163b8844d83">No</ix:nonFraction> stock options were granted during the year ended December&#160;31, 2020. Options to purchase shares are granted with an exercise price equal to the fair market value of the Company&#8217;s common stock on the day of grant, based on the closing price of the Company&#8217;s common stock on the trading date immediately prior to the grant date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The stock options granted during the year ended December&#160;31, 2019 are subject to the following performance and vesting criteria: (i) one-third (<ix:nonFraction unitRef="number" contextRef="if13a7bad162a4e20ba15bf84d71b699d_D20190101-20191231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYwMjc_703702c8-9f8b-4db8-8902-141ecaac6889">33.3</ix:nonFraction>%) of the award will vest in <ix:nonFraction unitRef="installment" contextRef="if13a7bad162a4e20ba15bf84d71b699d_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYwNTc_0d7b5169-7968-40af-a855-050b3fb6bda7">three</ix:nonFraction> equal annual installments on each of the first three anniversaries of December 31, 2019, (ii) one-third (<ix:nonFraction unitRef="number" contextRef="ibf62d3954751451e9588e5a61073849f_D20190101-20191231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYxNjU_e6f64b91-2502-4181-b79a-7595b9a00e97">33.3</ix:nonFraction>%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3f71503bac9d41d4a56501b58e940ca8_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYzNTY_1beedcd6-3d54-43e6-9a49-92440c698cf0">25.00</ix:nonFraction> over a period of thirty (<ix:nonFraction unitRef="trading_day" contextRef="ibf62d3954751451e9588e5a61073849f_D20190101-20191231" decimals="INF" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYzODQ_a6668a01-4566-4166-84be-8a8667be0a14">30</ix:nonFraction>) consecutive trading days, and (iii) one-third (<ix:nonFraction unitRef="number" contextRef="ifbe4cdae49d547e68aed4ebe2e458b2d_D20190101-20191231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY0MzU_1c0933a5-6b8a-4733-87e3-d77406498a5a">33.3</ix:nonFraction>%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $<ix:nonFraction unitRef="usdPerShare" contextRef="icaab860223474d4faa76168a356ab862_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY2MjY_839682aa-c643-42b2-b9ce-f024de568cb7">35.00</ix:nonFraction> over a period of thirty (<ix:nonFraction unitRef="trading_day" contextRef="ifbe4cdae49d547e68aed4ebe2e458b2d_D20190101-20191231" decimals="INF" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY2NTQ_fe9af6b8-b66d-44d9-bb5c-590a3cdbdd3b">30</ix:nonFraction>) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The stock options granted during the year ended December&#160;31, 2018 are subject to the following performance and vesting criteria: (i) fifty percent (<ix:nonFraction unitRef="number" contextRef="i4fb3e91ef8ed486a975169f3a156bc61_D20180101-20181231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY5MzY_164a3e95-bd16-48bd-955e-8d95d0865ad4">50</ix:nonFraction>%) of the stock option awards will vest in <ix:nonFraction unitRef="installment" contextRef="i4fb3e91ef8ed486a975169f3a156bc61_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY5ODA_ab4a7763-5373-4bca-a833-0f81d6391d16">five</ix:nonFraction> equal annual installments on each of the first five anniversaries of the date of grant, (ii) twenty-five percent (<ix:nonFraction unitRef="number" contextRef="i52b51ef452dd4bca860d3742b03236b3_D20180101-20181231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzcwOTc_180edcd3-8262-4139-943a-131370023ac1">25</ix:nonFraction>%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $<ix:nonFraction unitRef="usdPerShare" contextRef="idf7576735fbf445695c40b6c3a4332d2_I20181231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzcyODg_25b82f50-ee4b-49f7-bcb4-318d7efb687b">25.00</ix:nonFraction> over a period of sixty (<ix:nonFraction unitRef="trading_day" contextRef="i52b51ef452dd4bca860d3742b03236b3_D20180101-20181231" decimals="INF" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzczMTU_53b2bc62-7383-4e06-8fe9-2eac2bff9394">60</ix:nonFraction>) consecutive trading days, and (iii) twenty-five percent (<ix:nonFraction unitRef="number" contextRef="i9657217604e94a48a864adfb783bc292_D20180101-20181231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzczNzY_ddcb334d-fdc4-44e5-9fd0-2172c787a303">25</ix:nonFraction>%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5c74e08e90e4514b53e1711e6d6c993_I20181231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzc1Njc_12e1aa6c-7ea5-40ff-8a88-5dc4e38f550a">35.00</ix:nonFraction> over a period of sixty (<ix:nonFraction unitRef="trading_day" contextRef="i65014b7959304f73b25e58fe57e3c32d_D20180101-20181231" decimals="INF" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzc1OTQ_50ed3eea-3e40-44b7-9f72-61db3bca9bc7">60</ix:nonFraction>) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 16, 2018, the Company cancelled <ix:nonFraction unitRef="shares" contextRef="i689b53c3d93a499da0a1f5bd28ba963e_D20181216-20181216" decimals="-3" format="ixt:numdotdecimal" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzc3ODc_d6f17997-ab64-4aec-9ef4-16b6331cb160">200,000</ix:nonFraction> stock options and replaced them with <ix:nonFraction unitRef="shares" contextRef="i689b53c3d93a499da0a1f5bd28ba963e_D20181216-20181216" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzEwOTk1MTE2NDA2MTA_992b00f6-b880-4110-bd0b-7223cd7560a6">200,000</ix:nonFraction> stock-settled stock appreciation right awards (the "SAR Awards"). These were the only SAR Awards granted as of December&#160;31, 2020. The SAR Awards had a base price equal to the exercise price of the cancelled stock options. Fifty percent (<ix:nonFraction unitRef="number" contextRef="i08d2d66c878f4fb0a7b2c27692bcb2bf_D20181216-20181216" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzgwNTI_a4166ad8-914c-442c-91cf-b3323abedc90">50</ix:nonFraction>%) of the SAR Awards will vest in <ix:nonFraction unitRef="installment" contextRef="i08d2d66c878f4fb0a7b2c27692bcb2bf_D20181216-20181216" decimals="INF" format="ixt-sec:numwordsen" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzgwODc_8ddeb773-2106-45dc-b7ac-d0d6dec182a3">five</ix:nonFraction> equal annual installments on each of the first five anniversaries of the date of grant, generally subject to continued employment on each vesting date. Twenty-five percent (<ix:nonFraction unitRef="number" contextRef="i774ec9394898484282082d77fdad2ddf_D20181216-20181216" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzgyNjM_f68f3363-f8f0-4729-9205-f0c5cbb8b48c">25</ix:nonFraction>%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $<ix:nonFraction unitRef="usdPerShare" contextRef="i729242ab1a2347118df4dba4c57f77f1_I20181216" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg0NTQ_f3042bb5-3e5d-4de1-886b-faa774b6a204">25.00</ix:nonFraction> over a period of sixty (<ix:nonFraction unitRef="trading_day" contextRef="i774ec9394898484282082d77fdad2ddf_D20181216-20181216" decimals="INF" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg0ODE_8e07f596-89b3-4721-baa8-2d3e5c1ac0dc">60</ix:nonFraction>) consecutive trading days, and twenty-five percent (<ix:nonFraction unitRef="number" contextRef="ibae4c0fc40e94a2db7579a9d625a90f3_D20181216-20181216" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg1MzY_18ff5d3b-80cb-4e47-9076-53549b1b3efe">25</ix:nonFraction>%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic9c47bc4b252439eb85adbb626c84a6e_I20181216" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg3Mjc_7efeff65-8c00-4076-bba2-957645c7d086">35.00</ix:nonFraction> over a period of sixty (<ix:nonFraction unitRef="trading_day" contextRef="ibae4c0fc40e94a2db7579a9d625a90f3_D20181216-20181216" decimals="INF" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg3NTQ_5001ee29-d04a-43ee-9792-613a42fd293a">60</ix:nonFraction>) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i5a6653a8ff2944c58be1e797ca0ef062" continuedAt="i9cd83a4ade7947e782e1a2964fb6d514"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Option/SAR Valuation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In applying the Monte Carlo simulation model to value both the stock options and SAR Awards, the Company used the following assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642; &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; The risk-free interest rate is used as a component of the fair value of stock options to take into account the time value of money.&#160;For the risk-free interest rate, the Company uses the implied yield on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life, in years, of the options granted. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; Volatility, for the purpose of share-based compensation, is a measurement of the amount that a share price has fluctuated.&#160;Expected volatility involves reviewing historical volatility and determining what, if any, change the share price will have in the future. The Company used historical stock price information of certain peer group companies for a period of time equal to the expected option life period to determine estimated volatility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642; &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Expected life, in years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; A clear distinction is made between the expected life of an option and the contractual term of the option.&#160;The expected life of an option is considered the amount of time, in years, that an option is expected to be outstanding before it is exercised.&#160;Whereas, the contractual term of the stock option is the term an option is valid before it expires. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642; &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; Since issuing dividends will affect the fair value of a stock option, GAAP requires companies to estimate future dividend yields or payments.&#160;The Company has not historically issued dividends and does not intend to issue dividends in the future. As a result, the Company does not apply a dividend yield component to its valuation. </span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzg3_5c7f7ae8-2a9f-4052-9630-6dcb8f452212" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the assumptions used by the Company to estimate the fair value of stock options and SAR Awards granted during the years ended December&#160;31, 2019 and 2018. <ix:nonFraction unitRef="shares" contextRef="i88f2f675e83142ada36ac4b6fab72299_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTkwMjMyNjg1NzA_684d8212-8b1c-4f67-bf1c-586836c62c82"><ix:nonFraction unitRef="shares" contextRef="ie3da9fab6c3946a3bc42d096b6488712_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTkwMjMyNjg1NzA_bbd497ce-d9ee-4cc3-9934-0e29c4f34098">No</ix:nonFraction></ix:nonFraction> stock options or SAR Awards were granted during the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzItNC0xLTEtMA_90bf6f49-6a20-49fd-953a-3c5a942658f8">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzItNC0xLTEtNzc5NC90ZXh0cmVnaW9uOjhjMTVhODEyMmFiYTQ4ZDc5ZTBlMmZjYzlmM2EwZDBlXzExNTQ0ODcyMDkxNjY0_d3112804-ae25-4952-957f-d2be433b0561">60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzItNC0xLTEtNzc5NC90ZXh0cmVnaW9uOjhjMTVhODEyMmFiYTQ4ZDc5ZTBlMmZjYzlmM2EwZDBlXzExNTQ0ODcyMDkxNjcw_fea5fe16-4ab2-4b2d-8021-e7254ce95770">65</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzMtNC0xLTEtMC90ZXh0cmVnaW9uOmVkMjI1NTg2YWVlNzQzZTQ5ZjJkN2JkZWUwMjA4MWY5XzIxOTkwMjMyNTU1NzQ_86e2d996-ced0-42b0-9983-84aa65e08e21">2.30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzMtNC0xLTEtMC90ZXh0cmVnaW9uOmVkMjI1NTg2YWVlNzQzZTQ5ZjJkN2JkZWUwMjA4MWY5XzIxOTkwMjMyNTU1ODI_fd732266-57aa-4c40-9507-a4ba3e6e5d29">2.40</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzMtNC0xLTEtNzc4OS90ZXh0cmVnaW9uOjEzYmZiM2JiYTQzMDQ1NmU5MjZiNGNlY2NkM2M3ZjQ2XzExNTQ0ODcyMDkxNjYw_844e7c3c-0d0c-49ab-b17d-9ba1b75e64a2">2.50</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzMtNC0xLTEtNzc4OS90ZXh0cmVnaW9uOjEzYmZiM2JiYTQzMDQ1NmU5MjZiNGNlY2NkM2M3ZjQ2XzExNTQ0ODcyMDkxNjY0_bdbcd9d8-bca3-4db2-bd00-74120586ad91">2.90</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzQtNC0xLTEtMA_52e44118-1f1b-4ec6-9c2f-f164f65baab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzQtNC0xLTEtNzgyMQ_0d2a20f4-d16c-48f8-935b-e55628ad2d83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzUtNC0xLTEtMA_7d0f4eaa-103b-45a3-adc8-4c6f43deb286">4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzUtNC0xLTEtNzgyMQ_10159458-64ba-4218-88eb-0c5c0f323720">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i32f863b1377d4c198f37e268eadcd88e_I20191231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzYtNC0xLTEtMC90ZXh0cmVnaW9uOjYyYTVjZjlhNGE2MTQ1NGNhOTcwOGU1YWQwYjAxZGM3XzIxOTkwMjMyNTU1NzQ_3e2f16da-3be3-4ec2-9449-67941fabc4fb">4.83</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i7bdae67446eb4958aeff2fbff938b5ca_I20191231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzYtNC0xLTEtMC90ZXh0cmVnaW9uOjYyYTVjZjlhNGE2MTQ1NGNhOTcwOGU1YWQwYjAxZGM3XzIxOTkwMjMyNTU1ODI_0d3c10bd-df16-4af2-99a2-b47a02cbb0b0">6.41</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iafdcd1de1b344a998031d19f82faed75_I20181231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzYtNC0xLTEtNzc4OS90ZXh0cmVnaW9uOmE2YTkyNDk2ZjRmZTQ4YWNhM2QwNjQxMzZmNmU1YTA4XzExNTQ0ODcyMDkxNjYw_1cd89e69-74b2-4893-ab93-7e138f39b762">8.48</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i0bc3ee9a1e98470592066703d4aa997b_I20181231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzYtNC0xLTEtNzc4OS90ZXh0cmVnaW9uOmE2YTkyNDk2ZjRmZTQ4YWNhM2QwNjQxMzZmNmU1YTA4XzExNTQ0ODcyMDkxNjY0_5679ee49-f837-47db-b072-061107f92336">9.44</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of options is amortized to expense on a straight-line basis over the options&#8217; vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Option and Stock Appreciation Rights Activity </span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzk1_d3c15759-72e1-4b9f-9004-27143d95bb89" continuedAt="i86fd1c9c08714e85832f7d68397777c8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of stock option and SAR Award activity for the years ended December&#160;31, 2020, 2019, and 2018 follows: </span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.363%"><tr><td style="width:1.0%"></td><td style="width:64.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options/SARs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2274a974182d4c01981835a4b40e9196_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE1LTItMS0xLTA_24f1babc-2bf6-43cb-9602-804a81edc327">12,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2274a974182d4c01981835a4b40e9196_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE1LTQtMS0xLTA_9d0d9745-4d72-421c-84fd-513bbeecec1c">20.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3474a6f91a7246d79ec08926d5336999_D20170101-20171231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE1LTYtMS0xLTA_8e9547e0-cac8-4d44-a004-e4589f24b650">1.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE2LTItMS0xLTA_c8fd2fd3-1571-4c68-8cdf-0053ad68a85e">700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE2LTQtMS0xLTA_e2465f0d-7ef6-46ef-a853-4a0f46eb6daa">12.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" format="ixt-sec:duryear" name="sgry:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE2LTYtMS0xLTA_5bf2814f-4e50-4ee0-9856-5ab7a237fe54">10.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE3LTItMS0xLTA_7f3f13cf-4a6b-4d74-a5c4-69c90ee9a4b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE4LTItMS0xLTA_3e87c315-b0ad-441b-a500-cb55df2f893e">200,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE4LTQtMS0xLTA_f43c45b6-72fa-46f0-b9bd-9e8975ece691">12.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" format="ixt-sec:duryear" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE4LTYtMS0xLTA_a0da0321-8ddc-46c2-9cba-0d594c2735ff">10.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE5LTItMS0xLTA_191e5daf-03b2-425d-83ab-dca417be4d4f">512,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE5LTQtMS0xLTA_a52019ec-bd87-4244-a831-85dfa2ac52ef">13.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE5LTYtMS0xLTA_3445bbce-de39-4f24-bde0-401167fd5634">9.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIwLTItMS0xLTA_06340386-ad52-4a46-907f-7f6dc96a767f">2,256,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIwLTQtMS0xLTA_793da21a-f815-448d-89a6-db81fea6578b">13.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" format="ixt-sec:duryear" name="sgry:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIwLTYtMS0xLTA_739945b1-7065-4a67-9887-7eefd15c15f5">9.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIxLTItMS0xLTA_6f95671b-1e74-4d82-93a3-fc364f20eb99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIyLTItMS0xLTA_19993c2a-efc8-4b3a-8b32-a11ea1a36859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIzLTItMS0xLTA_1fcf1e77-b137-49c5-a808-f2af6b1522f9">2,769,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIzLTQtMS0xLTA_8c18166f-7177-4973-b7f1-b100ea201fe0">13.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIzLTYtMS0xLTA_3d4d0968-73b9-48b6-bfd1-5e5d9a3dd339">9.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEwLTItMS0xLTE1NDE_6f13366b-4d01-4c84-96d0-c5668bf337ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzExLTItMS0xLTE1NDE_7f0a563b-5156-4984-a3f5-5425f4f9cdd8">4,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzExLTQtMS0xLTE1Mzc_1f05b84a-7ca4-4c4f-8ba6-ccf823c3e64b">20.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:duryear" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzExLTYtMS0xLTE1MzM_ab4150d5-1415-4dc9-a2b6-55879548a62c">5.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEyLTItMS0xLTE1NDE_d55eab49-ecc6-4fd7-91f6-0b50229a9a5a">4,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEyLTQtMS0xLTE1Mzc_e8b62a6b-4614-4a5f-8b37-fa48f4cb9649">19.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:duryear" name="sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEyLTYtMS0xLTE1MzM_0e94da33-06f3-42f0-aa3a-da16a5f8b396">4.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEzLTItMS0xLTE3Njc_4be5598a-295e-4467-a154-7a92b7544893">2,760,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEzLTQtMS0xLTE1Mzc_c9fc60d4-54a8-4e9e-a766-e5fb9139461b">12.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEzLTYtMS0xLTE1MzM_1ea0075a-e0c3-4671-84ec-c0f6d4270840">8.0</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i86fd1c9c08714e85832f7d68397777c8" continuedAt="i33171964fc3a4ed19269d7390426c8ad">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i33171964fc3a4ed19269d7390426c8ad"> Of the outstanding stock options, <ix:nonFraction unitRef="shares" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExMTEx_cc51e774-8157-4016-9f1e-5401bb6707b3">585,119</ix:nonFraction> were exercisable as of December&#160;31, 2020.</ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i9cd83a4ade7947e782e1a2964fb6d514"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other information pertaining to equity-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2020, unrecognized compensation cost related to unvested shares was approximately $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExMjg0_0ec99f00-90bd-4b3c-b583-6e2d01bf4515">20.2</ix:nonFraction> million. Unrecognized compensation cost will be expensed annually based on the number of shares that vest during the year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records equity-based compensation expense to recognize the fair value of the restricted shares that vest and stock options granted. The Company recorded equity-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNjA0_d602acdd-199a-4bd7-82c2-61cb241ba40f">13.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNjEx_fd143d01-a6e8-4510-b1ed-14aacbc87cb3">10.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzEwOTk1MTE2NDA3NjU_99f14ae7-7edf-46e8-b538-4e1746ccf5a5">9.3</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019, and 2018, respectively.</span></div></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_181"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12.&#160; <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5Xzk4Ng_af3e2a53-6316-4312-987c-f0e412788331" continuedAt="i004d6ea373f643a4a6f8a64fb7eca726" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i004d6ea373f643a4a6f8a64fb7eca726"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Surgery Partners 401(k) Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners 401(k) Plan is a defined contribution plan whereby certain employees who have completed at least one month of service, including at least one hour of service during that period of time, are eligible to participate. Employees may enroll in the plan immediately upon completion of the minimum service requirement. The Surgery Partners 401(k) Plan allows eligible employees to make contributions of varying percentages or flat dollar amounts of their annual compensation, up to the maximum allowable amounts by the Internal Revenue Service ("IRS"). Eligible employees may or may not receive a match by the Company of their contributions. Employer contributions vest incrementally over a period of <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:durwordsen" name="sgry:DefinedContributionPlanVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5Xzc3Nw_55127c85-7c3e-4de1-91df-649dbf91bc47">five years</ix:nonNumeric>. The Company's contributions were $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5XzgyMA_0c2a8644-a958-45ef-bcca-283915b1415d">7.2</ix:nonFraction> million for the year ended December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5XzEwOTk1MTE2Mjg3NzQ_52e83af2-5687-43a2-84a2-15e259c28d47"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5XzEwOTk1MTE2Mjg3NzQ_a5699223-8c29-4a26-a0ea-20b53252e457">7.6</ix:nonFraction></ix:nonFraction> million for each of the years ended December&#160;31, 2019 and 2018.</span></div></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_187"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90ZXh0cmVnaW9uOmY3ZWI4NzgzNWVlZTQ0MWQ4OTgwYzU3ZTY3Nzc2OTAxXzE2NTM_f758530d-cc7f-47bb-8ca1-9a8c95c82788" continuedAt="i921c431a7f40471bba72b9e1517acbe1" escape="true">Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i921c431a7f40471bba72b9e1517acbe1" continuedAt="i3627ccceb4714a3a967ef803234a8b99"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90ZXh0cmVnaW9uOmY3ZWI4NzgzNWVlZTQ0MWQ4OTgwYzU3ZTY3Nzc2OTAxXzE2NjI_ec82295d-f085-41d4-a2e1-53fd0e6b3887" continuedAt="icc957d3be3634eb5a91ac397cb08adef" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzMtMi0xLTEtNzU1NQ_6f053652-0f49-4fde-bc7a-0520827ba5a5">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzMtNC0xLTEtNzU1NQ_9c04e67a-d8a1-48f2-9596-4dde2bd841d0">37.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzQtMi0xLTEtNzU2OQ_20a0da21-755d-4a0d-8b4d-c3bb2edb7619">32.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzQtNC0xLTEtNzU2OQ_c19f05ec-cbc5-4d21-a147-b846ab4bd1ec">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzMtMi0xLTEtMA_96c5c147-fb17-47a9-b6c2-b3ca101c13c8">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzMtNC0xLTEtMA_46162e5b-e558-4a0d-a946-33baa93cb5a3">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:TaxReceivableAgreementLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzYtMi0xLTEtMTAwNDc_cc61c3d0-de11-43ed-a246-9960203ab984">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:TaxReceivableAgreementLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzYtNC0xLTEtMTAwNDc_a7056a74-c93d-4cac-95c7-41db2b59cac3">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="srt:PayablesToCustomers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzQtMi0xLTEtMA_8a54c197-2bbe-4006-81b3-0295c9ab172f">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="srt:PayablesToCustomers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzQtNC0xLTEtMA_3f1650d2-165e-4957-9c39-a30bfc341ba8">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="sgry:CostReportLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzgtMi0xLTEtMTAwNTA_ce834203-605f-441d-be3b-df1e58c5bea6">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="sgry:CostReportLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzgtNC0xLTEtMTAwNTA_61594ad5-f7d1-4baa-8b00-9b0763af3c44">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzctMi0xLTEtMA_6e186001-25bd-4021-aec8-1ec6a02e2a2d">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzctNC0xLTEtMA_9af674aa-9e03-4c12-b97e-af75d399bf23">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzgtMi0xLTEtMA_191a21d8-33f7-46ac-9460-b0e660f6fb04">217.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzgtNC0xLTEtMA_9f926459-14c9-452f-bccf-551064936fe3">191.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;margin-top:5pt;padding-left:13.5pt;text-indent:-13.5pt"><ix:continuation id="i3627ccceb4714a3a967ef803234a8b99"><ix:continuation id="icc957d3be3634eb5a91ac397cb08adef"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">See Note 14. "Commitments and Contingencies" for further discussion.</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_190"></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEyNDgz_c5f8f85d-f1e7-4a56-9eef-d8fd66ad76d2" continuedAt="ibac423a51ead44b28caaf388cbc4427a" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ibac423a51ead44b28caaf388cbc4427a" continuedAt="i25c1ecdc13584e439ec0a1a148c08cb5"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Professional, General and Workers' Compensation Liability Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions, through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of December&#160;31, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SelfInsuranceReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMDg_b7ebd81d-e5e5-4999-87bd-02390ba092e0">21.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SelfInsuranceReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMTU_a37bee53-2594-47cd-ac43-a92c8c7fece6">19.4</ix:nonFraction> million, respectively. Expected insurance recoveries of $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EstimatedInsuranceRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwODc_0367dda7-91eb-4321-bf09-e298538d1a59">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EstimatedInsuranceRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwOTQ_cf46e7c1-be7f-4202-9a3c-d4050a9e028a">12.1</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively, are included as a component of other current assets and other long-term assets in the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i25c1ecdc13584e439ec0a1a148c08cb5" continuedAt="i248e15526b21413c854c62b532048b3a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Government Settlement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April 14, 2020, Logan Laboratories, LLC ("Logan Labs"), a toxicology laboratory based in Tampa, Florida, that provides urine testing services and Tampa Pain Relief Centers, Inc. ("Tampa Pain" and, together with Logan Labs, the "Companies"), a pain management medical practice based in Tampa, Florida, both indirect wholly-owned subsidiaries of the Company, entered into a settlement agreement (the "Settlement Agreement") with the United States of America, acting through the United States Department of Justice (&#8220;DOJ&#8221;) and on behalf of the Office of Inspector General of the Department of Health and Human Services ("OIG"), the Defense Health Agency, acting on behalf of the TRICARE Program, the Office of Personnel Management, as the administrator of the Federal Employees Health Benefits Program, the Office of Workers Compensation Programs of the United States Department of Labor, which administers federal workers compensation claims for federal employees, including the United States Postal Service, and the United States Department of Veterans Affairs (collectively, the "U.S. Parties") and certain other parties to resolve the pending DOJ investigation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Settlement Agreement, the Companies still owe payment of $<ix:nonFraction unitRef="usd" contextRef="i7b514b3c85dd48ff9fda4d7663a9cd66_D20210401-20210401" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwOTk1MTE2NDkxNjE_f9612c7d-7f30-45bc-a725-1265aa42a1b5">30.7</ix:nonFraction>&#160;million plus accrued interest on April 1, 2021. The Company previously recorded a litigation-related charge of $<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwOTk1MTE2NDkxNzY_52fe4610-0875-4fe1-86a2-457e73260f12">46.0</ix:nonFraction>&#160;million relating to an anticipated resolution of the DOJ investigation on the consolidated statements of operations for the year ended December 31, 2018. For the year ended December 31, 2020, the Company recorded an additional litigation-related charge of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwOTk1MTE2NDkxOTM_71c2c84b-b37d-4867-b091-a5087d9fc03b">1.2</ix:nonFraction>&#160;million relating to the resolution of the Covered Conduct on the consolidated statement of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Acquired Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the Stark Law, the Anti-Kickback Statute, the FCA, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Potential Physician Investor Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 9, 2017, the Company entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September&#160;30, 2015 (as amended, the "TRA"), by and between the Company, and the other parties referred to therein, which amendment became effective on August 31, 2017. Pursuant to the amendment to the TRA, the Company agreed to make payments to H.I.G., the Company's former controlling shareholder, in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus <ix:nonFraction unitRef="number" contextRef="i15035935d3e54ceba04f934c21488b65_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzIxOTkwMjMyODM0NjA_347aad8e-1d36-43ec-b7d7-bc1d836e6c4f">three</ix:nonFraction> percent. The amounts payable under the TRA are related to the Company&#8217;s projected realized tax savings over the next <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" format="ixt-sec:durwordsen" name="sgry:CollaborativeTaxAgreementProjectedTaxSavingsTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzIxOTkwMjMyODM0NDQ_32d091b3-3b69-49f4-8c87-229e2006e8ea">five years</ix:nonNumeric> and are not dependent on the Company&#8217;s actual tax savings over such period. The calculation of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that the Company is unable to make payments under the TRA, such payments will be deferred and will accrue interest at a rate of LIBOR plus&#160;<ix:nonFraction unitRef="number" contextRef="ia7b6963e13f944e28b5413d6c9ff381b_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzgyOTQ_7ecfe030-6d3a-4f89-b3f5-fb406a603dab">500</ix:nonFraction> basis points until paid. If the terms of credit agreements and other debt documents cause the Company to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus <ix:nonFraction unitRef="number" contextRef="i8dea0a1d35084b82bbde452684959945_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzg2MjA_aa875d65-6243-45a9-bef8-025405f9bebb">300</ix:nonFraction> basis points until paid.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assuming the Company's tax rate is <ix:nonFraction unitRef="number" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzk2OTc_c1000423-a83d-4fe7-94dd-aff07cf4afc3">24</ix:nonFraction>%, calculated as the maximum corporate federal tax rate plus <ix:nonFraction unitRef="number" contextRef="i0570cd69811f45e1b5ff58850aabd565_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgry:CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzk3NTk_df4bb87f-48d2-49a1-8aa1-cdd342f8884f">three</ix:nonFraction> percent, throughout the remaining term of the TRA, the Company estimates the total remaining amounts payable under the TRA was approximately $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzk5MDM_70316bb8-5609-42f0-9869-ec72e5e2d910">43.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzk5MTA_06263d90-2a91-470c-bbc8-88f9b2abc1cc">60.1</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. The carrying value of the liability under the TRA, reflecting a discount, was $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMDQz_0d898a97-e1d8-4f2d-b1c0-59f0ad490d5c">37.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMDUw_62f1cd24-c961-40a1-9590-f04573e93532">48.7</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. The current portion of the liability was $<ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgry:DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMTI1_4d8d4ea6-29e3-43b3-ba6e-c9286840c866">21.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgry:DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMTMy_32668fce-692e-4fb9-a930-3db0088987a2">16.9</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively, and is included as a component of other current liabilities in the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i248e15526b21413c854c62b532048b3a">consolidated balance sheets. The long-term portion is included as a component of other long-term liabilities in the consolidate balance sheets.</ix:continuation> </span></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_196"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIyNDM_709f8174-6ba3-426c-89a2-b0027f04e22c" continuedAt="i8bf07e8197ff40a9a5b9ce055e579596" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="i8bf07e8197ff40a9a5b9ce055e579596" continuedAt="i830941646e57499ba7c420d937a7b17c"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company operates in&#160;<ix:nonFraction unitRef="segment" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzUxMDI_1b9da445-709d-4e6a-b72c-7f93a277119e">three</ix:nonFraction>&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities, the operation of ancillary services and the operation of optical services. The Surgical Facility Services segment consists of the operation of ASCs and surgical hospitals and includes anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices and a diagnostic laboratory, which was closed during the third quarter of 2020. The Optical Services segment consists of an optical products group purchasing organization, which was sold on December 31, 2020, as discussed in Note 2. "Acquisitions and Disposals." "All other" primarily consists of the Company's corporate general and administrative functions.</span></div><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIyMzI_3025d1c0-4772-4a6a-9f8f-f97501299421" continuedAt="i7d8e0b0532eb4ed2b6906e8de3f4f795" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e40b357c844c71bed649d3cad09653_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzQtMi0xLTEtMA_500c59fd-9e6c-4127-a5e4-45c950170f32">1,793.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a81da0560194155b4abbadf871ee362_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzQtNC0xLTEtMA_e9ae9bf4-3587-46e5-becf-14bce3670ee1">1,748.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5878e06b7b984c2699576d1a46bb44f8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzQtNi0xLTEtMA_f6324bbf-f7d6-41a8-a8d1-5fcaceed853f">1,682.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03e505c471a4943901ca2907c0fa61e_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzUtMi0xLTEtMA_6dd797c6-208c-4b35-b886-76f26207ce9d">63.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie853ea8a85d94a4a8512ec67b36ff19c_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzUtNC0xLTEtMA_c038fffc-0756-426f-9378-ccfb20dc0917">79.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ebaf38db0d469ebf56d6ca77dfe0d3_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzUtNi0xLTEtMA_73bf697e-c971-46db-b774-ea8eef049383">79.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d2ddf0e9f54c259b2891a8c533060d_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzYtMi0xLTEtMA_144cc41c-37fc-4509-a563-ea924e4490b4">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966ad612edb74fff9113dfbc6c476ba6_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzYtNC0xLTEtMA_526e87e7-6a6d-44b8-94b0-84faf2032953">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3ef67ea7a94f358e2956bacd5abd58_D20180101-20181231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzYtNi0xLTEtMA_781170a6-8e67-485f-8c17-24a32f7fc48d">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzctMi0xLTEtMA_38019a2b-805e-4d9d-8ba6-8aeb7e3c8cf7">1,860.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzctNC0xLTEtMA_bb4b1515-9e95-4151-aeee-9f982328c786">1,831.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzctNi0xLTEtMA_b2084cc1-3889-4302-a288-a0099d16d998">1,771.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e40b357c844c71bed649d3cad09653_D20200101-20201231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEwLTItMS0xLTA_aad237cc-f24d-4e06-881b-372337392436">339.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a81da0560194155b4abbadf871ee362_D20190101-20191231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEwLTQtMS0xLTA_44cecea8-7366-4bb5-8ea5-7f7fc7cb7096">328.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5878e06b7b984c2699576d1a46bb44f8_D20180101-20181231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEwLTYtMS0xLTA_4f5565d1-6ad7-46e2-9d73-e953984a715b">309.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib03e505c471a4943901ca2907c0fa61e_D20200101-20201231" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzExLTItMS0xLTA_504111c3-a20f-491e-8549-8f1122d2d115">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie853ea8a85d94a4a8512ec67b36ff19c_D20190101-20191231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzExLTQtMS0xLTA_c9901d6a-0383-4a02-87fd-fc6cba48ae8c">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ebaf38db0d469ebf56d6ca77dfe0d3_D20180101-20181231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzExLTYtMS0xLTA_c09c0baa-a9a1-4c1b-8f6d-db2c458f6eb2">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d2ddf0e9f54c259b2891a8c533060d_D20200101-20201231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEyLTItMS0xLTA_522b516d-3f85-4f71-8f77-94754dfcf8f0">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966ad612edb74fff9113dfbc6c476ba6_D20190101-20191231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEyLTQtMS0xLTA_856250b1-f867-4464-a13f-731998d4ad10">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3ef67ea7a94f358e2956bacd5abd58_D20180101-20181231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEyLTYtMS0xLTA_863c5435-901c-4934-94dd-08ede6869a11">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad8b729655c4567bc34b3b7387d4214_D20200101-20201231" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEzLTItMS0xLTA_d6c1c33d-b67f-45b0-8576-6403c3a05d0d">80.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10a47a68bb1747c897f4f19e04584916_D20190101-20191231" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEzLTQtMS0xLTA_fdd00de8-e230-4bb8-b342-9077fe44db29">74.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59ad5e2b8c5f43b0aa69ebc006430ab4_D20180101-20181231" decimals="-5" sign="-" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEzLTYtMS0xLTA_cac5bced-67d1-42da-8a72-aa14094245f6">80.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE0LTItMS0xLTA_c850116b-0286-4c17-89a0-c60553db2281">256.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE0LTQtMS0xLTA_62182fdc-1144-48bc-b06c-74f7305aaafd">258.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE0LTYtMS0xLTA_01ae1b58-ed6b-48ff-96e8-5ebe8419bf9c">234.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE2LTItMS0xLTQ5ODI_9f4c369c-1ced-4dad-8c54-6ab15234040d">18.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE2LTQtMS0xLTQ5ODI_1228c62d-57a3-47f0-a01f-ed248e209488">54.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE2LTYtMS0xLTQ5ODI_e4381e4b-ba5e-42d2-89fe-0c1ebe371214">69.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE4LTItMS0xLTQ5ODU_0219765b-eb49-45d0-9864-066fca8d103a">117.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE4LTQtMS0xLTQ5ODU_471a8122-9f2f-4c0e-9831-bca490e96cc9">119.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE4LTYtMS0xLTQ5ODU_973f57ae-66b7-4bf8-b1a0-1523a41503eb">110.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE5LTItMS0xLTQ5ODc_b6e0bb7f-b6a6-4e84-a795-05ed8033bac8">94.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE5LTQtMS0xLTQ5ODc_f45a0775-73c1-4f5f-8017-f14c6b258a93">76.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE5LTYtMS0xLTQ5ODc_f34afec3-1848-463f-9698-937c6f554a89">67.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIwLTItMS0xLTQ5ODk_5267c68e-ec6e-4d36-9cae-174419606461">201.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIwLTQtMS0xLTQ5ODk_983f4b5b-f92d-4ad7-80a9-63f0b04154ce">178.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIwLTYtMS0xLTQ5ODk_9ed9d1a3-45f6-4fe3-94c3-c04b20aee9ed">147.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIxLTItMS0xLTQ5OTE_dc62cd6f-827c-4bdb-bfcf-b77692d601e7">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIxLTQtMS0xLTQ5OTE_66ef3f91-47d8-4044-8558-012ef8c8ece3">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIxLTYtMS0xLTQ5OTE_33f4f285-04a2-4301-93c4-65dc15e8e9aa">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIyLTItMS0xLTQ5OTU_79cce3d0-b44c-4c3a-b53b-451a5680649d">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIyLTQtMS0xLTQ5OTU_ecc55be7-4c09-4d5b-81c3-70ed49a7b51c">36.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIyLTYtMS0xLTQ5OTU_3749747f-bebf-4928-bc4b-82d54500f5e0">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIzLTItMS0xLTQ5OTM_3a1011ed-4141-44b0-a9c0-36c25dd4eb80">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIzLTQtMS0xLTQ5OTM_16c2b4e5-abfb-47f7-a1fe-497bdd54b529">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIzLTYtMS0xLTQ5OTM_3ca920ec-ff5d-4010-b295-b4da54fedd6b">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI0LTItMS0xLTQ5OTg_585e7bb3-4256-4f0f-b919-bdcef9356349">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI0LTQtMS0xLTQ5OTg_045be707-adf0-4f32-b2f3-e7029b6823e5">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="sgry:GainLossOnDispositionOfAssetsAndDeconsolidation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI0LTYtMS0xLTQ5OTg_1d5b749c-6295-4946-a240-5145d025ee70">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement and other litigation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" name="sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI1LTItMS0xLTUwMDA_bcf0818c-14b2-441b-9430-0b3621cdc2da">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI1LTQtMS0xLTUwMDA_68947b05-42a1-479a-a669-2a50e13eaad1">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" name="sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI1LTYtMS0xLTUwMDA_ef6de306-295b-417f-873a-4058aa5ee660">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTItMS0xLTUwNDg_5e1e8fd9-f222-4a66-b2f1-a7b782e27b6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTQtMS0xLTUwNDg_253a87c9-6de0-44ea-bbe0-63f6e8f49ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTYtMS0xLTUwNDg_813a1088-642b-4bf1-a4ee-ad8ac673ab5d">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent acquisition compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="sgry:BusinessCombinationContingentAcquisitionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTItMS0xLTUwNzI_9df55cd4-8bcd-4e59-9220-a5523bca0cdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="sgry:BusinessCombinationContingentAcquisitionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTQtMS0xLTUwNzI_ce84966d-eb47-42db-a2b6-1800a762fc3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:BusinessCombinationContingentAcquisitionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTYtMS0xLTUwNzI_c2971d5d-6080-46cc-b99c-8bce670d9285">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on escrow release </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:BusinessCombinationGainLossOnAcquisitionEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTItMS0xLTUwMDI_b7356062-b4c5-4bbc-aa72-cbc9a2c12401">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="sgry:BusinessCombinationGainLossOnAcquisitionEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTQtMS0xLTUwMDI_7f9e3a5b-d5b7-4759-8f1a-6746043535e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="sgry:BusinessCombinationGainLossOnAcquisitionEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTYtMS0xLTUwMDI_6ab8b4c9-c620-4e16-9db2-165e954d2980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTItMS0xLTUwMDQ_e37e5b7a-875d-4c76-a32a-a526beda03a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTQtMS0xLTUwMDQ_6c2843bc-4eed-4ab4-8dcb-8312f224a94e">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTYtMS0xLTUwMDQ_381a213e-9f44-4fc5-aad0-b193515c2ba3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="sgry:TaxReceivableAgreementExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI4LTItMS0xLTUwMDY_71baf6b9-e7fa-42b3-928f-36a1fc509b44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:TaxReceivableAgreementExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI4LTQtMS0xLTUwMDY_24a713ca-ade8-43c3-8968-2afe4b7103b1">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="sgry:TaxReceivableAgreementExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI4LTYtMS0xLTUwMDY_1b78756c-cd6e-4bd7-9a7f-9f1014576c35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI5LTItMS0xLTUwMDg_9d9ab873-5ec0-469d-b33c-d22a8bba39e3">256.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI5LTQtMS0xLTUwMDg_8a1f1c44-ef01-415d-89af-9d02683ef30a">258.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI5LTYtMS0xLTUwMDg_dc794037-8ed1-4611-a2a3-05692eacebe6">234.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">For the year ended December 31, 2020, this amount includes transaction and integration costs of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5MzYy_1212cf46-8376-49b9-a3a5-94a1ff3dbc32">23.2</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5NzEx_d6d38573-b372-4155-85ce-b255e13f5cbf">6.6</ix:nonFraction>&#160;million were acquisition related costs, and includes start-up costs related to a de novo surgical hospital of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgry:StartUpActivitiesStartUpCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5NDg5_c75c0b8f-c6bc-4b01-a6ae-5b7a2a0722c9">15.0</ix:nonFraction> million. For the year ended December 31, 2019, this amount includes transaction and integration costs of $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5NTkw_38de6336-d33a-4b07-930c-a00bdf558b2b">19.0</ix:nonFraction> million, and includes other acquisition costs and start-up costs related to a de novo surgical hospital of $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="sgry:StartUpActivitiesStartUpCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5NzAx_a8831085-d1f0-4584-aede-8309155748c3">17.1</ix:nonFraction> million. For the year ended December 31, 2018, this amount includes transaction and integration costs of $<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzA4ODM_21e95c6b-24c1-4972-95d6-7c3f92e80167">31.7</ix:nonFraction> million, and includes other acquisition costs of $<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzE1NjU_51437415-65ed-41a2-8dae-0e444ec56945">2.3</ix:nonFraction> million.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SURGERY PARTNERS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</span></div></div><ix:continuation id="i830941646e57499ba7c420d937a7b17c"><ix:continuation id="i7d8e0b0532eb4ed2b6906e8de3f4f795"><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes litigation settlement costs of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIwOTA_fcae2df5-795b-4bc1-8ac7-1e62639aa54c">1.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIwOTM_e7586ce7-e17e-4d8b-b2df-a5359a8046e4">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIwOTY_c1f6c201-153b-4f1c-9c0e-85ce26891d11">46.0</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively. This amount further includes other litigation costs of $<ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIyNDM_2e0e75e4-7051-4d3c-95a8-d6e9b3c2a7c5">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIyNDY_8344ca1b-a5b7-4752-8eea-3a67b0ce530c">4.4</ix:nonFraction> million for the years ended December 31, 2020 and 2019, respectively, with <ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LitigationSettlementExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIxOTkwMjMyNjA5NTI_343e4ab5-17ac-4fff-8a6e-3d0fd1541aae">no</ix:nonFraction> comparable costs in 2018.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount represents adjustments to revenue in order to apply consistent policies to businesses acquired by Surgery Partners in prior periods.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Included in other income in the consolidated statement of operations for the year ended December 31, 2020, with no comparable gain in 2019 and 2018.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIyNDA_6a249a3b-ee7a-44a7-a8ae-1786f2fe8f41" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if35b1248a15b4a04a53222c87069bd54_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzMtMi0xLTEtMA_5f45dc57-6038-45bb-9eed-4472a337a09d">4,962.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe470e2b3fd645a5a04d06fd9d60eae6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzMtNC0xLTEtMA_c027f81b-c315-42c7-80f1-ac507cef2099">4,580.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018a6f0739764a949e8fe00e88704f6d_I20201231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzQtMi0xLTEtMA_bbcbedec-0d40-407b-9aba-2f7cb70316cf">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6d10cceadc435bbc6d90570a26a639_I20191231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzQtNC0xLTEtMA_23736fd1-c338-4188-a30f-11746d1034cd">69.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b0f35b18de46988ff6fbe8c8307369_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzUtMi0xLTEtMA_4aaae996-c5d4-45f8-982a-771d9d9b9e77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8880a4c46df641179425ee1784d1c48d_I20191231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzUtNC0xLTEtMA_e3181a28-4972-4ca6-97c9-d0bfeee96185">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b34194b9c3e45b3861a805f0ab38022_I20201231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzYtMi0xLTEtMA_33e96d62-61a7-4723-be75-2511838b4faa">415.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4027d5443cb745e1992a9fa9a7276711_I20191231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzYtNC0xLTEtMA_b9c18b62-c0f2-4a75-8b52-cd0a36d8e861">351.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55b138001be441a9691661db6451a97_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzctMi0xLTEtMA_c4a100d0-dd5a-4919-a37a-811aa181f3b9">5,413.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzctNC0xLTEtMA_aef47faf-c0b2-4599-911f-f438ebf9d989">5,018.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:14pt;margin-top:11pt"><ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIyNDY_5f20e688-b638-45cb-b614-ea1a14ac7adb" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e40b357c844c71bed649d3cad09653_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzQtMi0xLTEtMA_d27cae7b-cf10-48cf-95ee-cba80c4dbc48">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a81da0560194155b4abbadf871ee362_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzQtNC0xLTEtMA_9dc41a5f-4b46-4308-a1ea-7b991bf16276">65.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5878e06b7b984c2699576d1a46bb44f8_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzQtNi0xLTEtMA_ba8ec43a-6103-49a8-8cad-ec4de791f00b">34.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03e505c471a4943901ca2907c0fa61e_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzUtMi0xLTEtMA_7fc5411e-26e2-4111-a841-7f3eb616a7bc">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie853ea8a85d94a4a8512ec67b36ff19c_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzUtNC0xLTEtMA_e21dfedd-ee12-42de-aa85-d5285a3beea9">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ebaf38db0d469ebf56d6ca77dfe0d3_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzUtNi0xLTEtMA_ea172abf-626c-4ae1-b81f-ea59221e2b4a">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad8b729655c4567bc34b3b7387d4214_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzctMi0xLTEtMA_c5fb1718-d5f7-4d65-9282-8fceab1e4766">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10a47a68bb1747c897f4f19e04584916_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzctNC0xLTEtMA_03f487d0-1d5a-45da-b0ca-0a13859af0fc">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ad5e2b8c5f43b0aa69ebc006430ab4_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzctNi0xLTEtMA_9a387ee2-304a-4b7b-b855-f32aab12c725">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzgtMi0xLTEtMA_aaaed521-d3ab-4eda-8513-06f94029fc4e">42.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzgtNC0xLTEtMA_d7cacfd6-edf4-4ddd-85d5-7d6f7af278b7">73.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzgtNi0xLTEtMA_ac222d8f-9669-4923-ac91-47d8ce014457">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_202"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16.  <ix:nonNumeric contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMDg_f1bda1de-7a65-439c-a0f0-3b32c11ad7bc" continuedAt="if9250b39d42f459ca11f45fce9bd930e" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="if9250b39d42f459ca11f45fce9bd930e"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 27, 2021, the Company entered into an underwriting agreement relating to a public offering of <ix:nonFraction unitRef="shares" contextRef="i98564e51940c4e91a27b5a49261520cf_D20210201-20210201" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMTA_c279961f-51af-40f5-9b7d-cc82d5fa600f">7,500,000</ix:nonFraction> shares (the &#8220;Firm Shares&#8221;) of the Company&#8217;s common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa0fb1e697bf46f98f1f119b51d1217a_I20210201" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMjE_f3915ae8-0645-4519-ae1a-3fe1c237ccda">0.01</ix:nonFraction> par value per share, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa0fb1e697bf46f98f1f119b51d1217a_I20210201" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMjg_799e3e3a-10a7-42b2-b1c9-9e0889f3c422">30.25</ix:nonFraction> per share. In addition, the Company granted the underwriters an option to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="i596ba4d78eee424182ca76e6fe6f57f9_D20210201-20210201" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMzY_0d7071f2-a525-4c2d-a7bb-77a9d001dc0b">1,125,000</ix:nonFraction> shares of common stock at the same price per share as the Firm Shares. On February 1, 2021, the Company completed the public offering pursuant to which the Company sold <ix:nonFraction unitRef="shares" contextRef="ibf9358b8a33748d69b07ec48689f9eee_D20210201-20210201" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwNDc_ba394e86-88d7-4e25-8a11-ac6c52203638">8,625,000</ix:nonFraction> shares of common stock, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ibf9358b8a33748d69b07ec48689f9eee_D20210201-20210201" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwNTg_32a78c68-50af-441e-b416-794c1487371f">249.2</ix:nonFraction>&#160;million, net of underwriting discounts and commissions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 27, 2021, the Company entered into an amendment to the credit agreement governing the Revolver, dated as of January 27, 2021 (the &#8220;Amendment&#8221;), which amended and supplemented the credit agreement, dated as of August 31, 2017, to provide for an extension of the maturity date of the Revolver to February 1, 2026 and an increase in the outstanding commitments under the Revolver in an amount equal to $<ix:nonFraction unitRef="usd" contextRef="iab383708d31447d6b0f9eb47c597c2e6_I20210127" decimals="INF" format="ixt:numdotdecimal" name="sgry:LineOfCreditFacilityMaximumBorrowingCapacityIncrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwNzQ_2a8d910f-1446-4d56-8b6a-2d378c5c1ef5">50.0</ix:nonFraction>&#160;million. The maturity extension and the additional commitments became operative on February 1, 2021, upon satisfaction by the Borrower of certain conditions precedent set forth in the Amendment, including the closing of the offering of the Firm Shares.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><div id="iefdf2fdf0cee42e79fa00bbc44d4c207_205"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline" href="#iefdf2fdf0cee42e79fa00bbc44d4c207_7">Table of Contents</a></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:17pt;margin-top:5pt;padding-left:180pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SURGERY PARTNERS,&#160;INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ J. Eric Evans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">J. Eric Evans</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date: March&#160;10, 2021 </span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SIGNATURES</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Executive Officer, Director<br/> (Principal Executive Officer)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ J. Eric Evans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J. Eric Evans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Thomas F. Cowhey</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas F. Cowhey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Executive Chairman of the Board</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Wayne S. DeVeydt</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wayne S. DeVeydt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ T. Devin O'Reilly</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">T. Devin O'Reilly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Teresa DeLuca</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teresa DeLuca</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ John A. Deane</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">John A. Deane</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Brent Turner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brent Turner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Andrew Kaplan</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Andrew Kaplan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 10, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Clifford G. Adlerz</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clifford G. Adlerz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>ye2020exhibit1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icb41ce3323ec46d3b1200e5d69a1be11_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Execution Version</font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.12</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FIFTH AMENDMENT TO CREDIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This FIFTH AMENDMENT TO CREDIT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), dated as of January 27, 2021, by and among Surgery Center Holdings, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), SP Holdco I, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the other Guarantors party hereto, each 2021 New Revolving Lender (as defined below) party hereto, Jefferies Finance LLC, as administrative agent for the Lenders (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and as collateral agent for the Secured Parties (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or, as Administrative Agent or Collateral Agent, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Jefferies Finance LLC, as an Issuing Bank, and KKR Corporate Lending LLC, as an Issuing Bank.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">W I T N E S S E T H&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Borrower, Holdings, Guarantors, Lenders and Agent, among others, are parties to that certain Credit Agreement, dated as of August 31, 2017, as amended pursuant to that certain Incremental Term Loan Amendment, dated as of October 23, 2018, among the Borrower, Holdings, the other Guarantors party thereto, the Agent and the Lenders party thereto, that certain Incremental Revolving Loan Amendment, dated as of March 25, 2019, among the Borrower, Holdings, the other Guarantors party thereto, the Agent and the Lenders party thereto, that certain Third Amendment to Credit Agreement, dated as of April 16, 2020, among the Borrower, Holdings, the Agent and the Lenders party thereto, that certain Second Incremental Term Loan Amendment, dated as of April 22, 2020, among the Borrower, Holdings, the other Guarantors party thereto, the Agent and the Lenders party thereto, and as the same may be further amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;&#59; the Credit Agreement, as amended pursuant to this Amendment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amended Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, pursuant to the Credit Agreement, the Revolving Lenders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Revolving Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) thereunder previously provided Revolving Commitments (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Revolving Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and the Revolving Loans made thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the Borrower&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, pursuant to, and in accordance with, Section 2.21(b) of the Credit Agreement, (i) the Borrower has made a Revolving Extension Offer to each Existing Revolving Lender in an amount equal to such Existing Revolving Lender&#8217;s Existing Revolving Commitments, (ii) each Existing Revolving Lender as of the Effective Date (as defined below) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Extending Revolving Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), whose name is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto under the heading &#8220;Extending Revolving Lender&#8221;, has accepted the Revolving Extension Offer and hereby agrees to provide an Extended Revolving Commitment in an aggregate principal amount equal to its Existing Revolving Commitment as of the Effective Date (which, for the avoidance of doubt, is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Extended Revolving Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and the loans made pursuant thereto, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Extended Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), effective as of the Extension Effective Time, which 2021 Extended Revolving Commitments shall have the terms set forth herein and in the Amended Credit Agreement and (iii) each Extending Revolving Lender and the Administrative Agent have agreed, upon the terms and subject to the conditions set forth herein, that each Extending Revolving Lender will provide its respective 2021 Extended Revolving Commitments to the Borrower at the Extension Effective Time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (i) the Borrower has requested that each Lender party hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Incremental Revolving Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and, together with the Extending Revolving Lenders, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 New Revolving </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#124;US-DOCS&#92;120853984.6&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) whose name is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto under the heading &#8220;2021 Incremental Revolving Lender&#8221; provide a Revolving Commitment Increase, to become effective immediately after the Extension Effective Time on the date of the Extension Effective Time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Extension Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), under Section 2.19 of the Credit Agreement to the 2021 Extended Revolving Commitments in an aggregate principal amount equal to the amount set forth opposite such 2021 Incremental Revolving Lender&#8217;s name on Schedule 2.01 hereto under the heading &#8220;2021 Incremental Revolving Commitment&#8221; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Incremental Revolving Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and, together with the 2021 Extended Revolving Commitments, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 New Revolving Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), effective as of the Fourth Incremental Amendment Time (as defined below), which 2021 Incremental Revolving Commitments shall have the terms set forth herein and in the Amended Credit Agreement and (ii) each 2021 Incremental Revolving Lender and the Administrative Agent have agreed, upon the terms and subject to the conditions set forth herein, that each 2021 Incremental Revolving Lender will provide its respective 2021 Incremental Revolving Commitments to the Borrower as of the Fourth Incremental Amendment Time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (a) Section 2 of this Amendment constitutes an Extension Amendment under and as defined in Section 2.21 of the Credit Agreement and (b) Section 3 of this Amendment constitutes an Incremental Amendment under and as defined in Section 2.19 of the Credit Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Agent and the 2021 New Revolving Lenders are willing, on the terms and subject to the conditions set forth below, to enter into the extensions, increases, amendments, modifications and agreements set forth in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of the premises and the mutual agreements herein contained and other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless otherwise defined herein, capitalized terms used herein shall have the respective meanings ascribed thereto in the Amended Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Extension Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to the satisfaction of the conditions precedent set forth in Section 6 below, the Borrower, the Guarantors, each of the Extending Revolving Lenders and Agent hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Each Extending Revolving Lender agrees, severally and not jointly, to provide to the Borrower its 2021 Extended Revolving Commitments as &#8220;Extended Revolving Commitments&#8221; under and as defined in the Amended Credit Agreement, commencing as of the Extension Effective Time in an amount equal to such Extending Revolving Lender&#8217;s 2021 Extended Revolving Commitments as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto, and to make 2021 Extended Revolving Loans to the Borrower under the Amended Credit Agreement, in each case, from time to time, on any Business Day during the period from the Extension Effective Time until the earlier of the Revolving Maturity Date and the termination of the 2021 Extended Revolving Commitments of such Extending Revolving Lender in accordance with the terms of the Amended Credit Agreement, in an aggregate principal amount not to exceed at any time outstanding the amount of such Extending Revolving Lender&#8217;s 2021 Extended Revolving Commitments.  The 2021 Extended Revolving Commitments shall constitute &#8220;Revolving Commitments&#8221; for all purposes under the Amended Credit Agreement, and the 2021 Extended Revolving Loans shall constitute &#8220;Revolving Loans&#8221; for all purposes under the Amended Credit Agreement.  For the avoidance of doubt, immediately following the effectiveness of the 2021 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Extended Revolving Commitments at the Extension Effective Time, the Existing Revolving Commitments of each Extending Revolving Lender shall automatically be terminated in full.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each Extending Revolving Lender hereby severally agrees that its Existing Revolving Loans shall be converted into 2021 Extended Revolving Loans (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Converted Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at the Extension Effective Time, and each such Converted Revolving Loan shall be deemed to have been extended as a 2021 Extended Revolving Loan at the Extension Effective Time.  All Converted Revolving Loans shall constitute the same Revolving Borrowing. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Each Letter of Credit issued under the Credit Agreement and the Existing Revolving Commitments as of immediately prior to the Extension Effective Time shall be deemed to be issued under the Amended Credit Agreement and the 2021 Extended Revolving Commitments upon the Extension Effective Time, and the LC Exposure of each Extending Revolving Lender shall be based on such Extending Revolving Lender&#8217;s Pro Rata Share of the aggregate LC Exposure (after giving effect to the Extension Effective Time).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Subject to satisfaction of the Extension Conditions, the definition of &#8220;Revolving Maturity Date&#8221; as set forth in Section 1.01 of the Credit Agreement is hereby amended and restated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revolving Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (i) with respect to the Revolving Commitments and the Revolving Loans, February 1, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Extended Revolving Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Revolving Maturity Date with respect to the Revolving Commitments and Revolving Loans shall be August 31, 2024 if, on or prior to August 31, 2024, the Term Loans with a maturity date earlier than the Extended Revolving Maturity Date have not either been (x) repaid in full, (y) replaced or refinanced with Indebtedness permitted hereunder (including, without limitation, pursuant to Section 2.20 or 2.21 of this Agreement) having a maturity date not earlier than the Extended Revolving Maturity Date or (z) otherwise amended or modified to have a maturity date not earlier than the Extended Revolving Maturity Date, (ii) with respect to any tranche of Extended Revolving Loans or Extended Revolving Commitments (in each case, other than the 2021 Extended Revolving Commitments (as defined in the Fifth Amendment) and the 2021 Extended Revolving Loans (as defined in the Fifth Amendment)), the final maturity date as specified in the applicable Extension Amendment and (iii) with respect to any tranche of Other Revolving Loans or Other Revolving Commitments, the final maturity date as specified in the applicable Refinancing Amendment&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, if any such day is not a Business Day, the applicable Revolving Maturity Date shall be the Business Day immediately succeeding such day.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Subject to satisfaction of the Extension Conditions, Section 1.01 of the Credit Agreement is hereby amended by adding the following defined term in correct alphabetical order&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fifth Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Fifth Amendment to Credit Agreement, dated as of January 27, 2021, by and among the Borrower, the Guarantors, the 2021 New Revolving Lenders (as defined therein) and the Administrative Agent, the Collateral Agent and the Issuing Banks.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">The obligations of each Extending Revolving Lender to provide the 2021 Extended Revolving Commitments to the Borrower pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not become </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">effective until the date on which each of the following conditions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Extension Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is first satisfied (the time of such satisfaction being the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Extension Effective Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (provided that the Extension Effective Time shall not be deemed to occur, and no Extending Revolving Lender shall be obligated or deemed to provide the 2021 Extended Revolving Commitments, if the Extension Conditions are not satisfied on or prior to the date that is 30 calendar days after the date hereof)&#58;</font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">the Administrative Agent shall have received a certificate executed by a Responsible Officer of the Borrower, certifying that, as of the Extension Effective Date, after giving effect to both the 2021 Extended Revolving Commitments and the 2021 Incremental Revolving Commitments contemplated hereby, (x) each of the representations and warranties made by the Loan Parties set forth in this Amendment, in Article 5 of the Credit Agreement and in all other Loan Documents are true and correct in all material respects on and as of the Extension Effective Date with the same effect as though made on and as of the Extension Effective Date, except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties are true and correct in all material respects as of such earlier date&#59; provided, that any such representation and warranty that is qualified by &#8220;materiality,&#8221; &#8220;material adverse effect&#8221; or similar language is true and correct in all respects (after giving effect to any such qualification therein) on and as of such earlier date with the same effect as though made on and as of the Extension Effective Date or such earlier date, as applicable, and (y) no Default or Event of Default exists or would result from the incurrence of the 2021 Extended Revolving Commitments and&#47;or the 2021 Incremental Revolving Commitments contemplated by this Amendment&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.36pt">Holdings and the Borrower shall have paid on or prior to the Extension Effective Time to the Administrative Agent and the 2021 New Revolving Lenders, as applicable, all expenses payable to them in connection with this Amendment (whether incurred before or after the Effective Date), in each case, to the extent invoiced at least two Business Days prior to the Extension Effective Time (except as otherwise reasonably agreed by the Borrower)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.03pt">the Administrative Agent shall have received, on behalf of itself, the Collateral Agent and the 2021 New Revolving Lenders, an opinion of (x) Ropes &#38; Gray LLP, counsel for the Loan Parties and (y) each local counsel for the Loan Parties listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4.02(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to this Amendment (or other local counsel reasonably acceptable to the Administrative Agent), in each case, with respect to the Amendment and dated on or after the Effective Date and on or prior to the Extension Effective Time and addressed to the Administrative Agent, the Collateral Agent and the 2021 New Revolving Lenders and in customary form and substance (it being understood that, without limitation, any such opinions in form and substance consistent with the corresponding opinions provided in connection with the Second Incremental Amendment shall be deemed to be in customary form and substance)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.69pt">the Administrative Agent shall have received (x) a certificate as to the good standing of each Loan Party as of a recent date, (y) a certificate of a Responsible Officer of each Loan Party dated on the Extension Effective Date certifying (A) that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">attached thereto is a copy of the certificate or articles of incorporation or organization or certificate of formation, including all amendments thereto, of each Loan Party, certified as of a recent date by the Secretary of State of the state of its organization, or, in the alternative, certifying that such certificate or articles of incorporation or organization or certificate of formation has not been amended since delivery thereof to the Administrative Agent on the Closing Date, the First Incremental Amendment Date, the Second Incremental Amendment Date or the Third Incremental Amendment Date, as applicable, (B) that attached thereto is a true and complete copy of the by-laws or operating (or limited liability company) agreement of such Loan Party as in effect on the Extension Effective Time (or that the by-laws or operating (or limited liability company) agreement of such Loan Party has not been amended or otherwise modified since the delivery of such documents to the Administrative Agent on the Closing Date, the First Incremental Amendment Date, the Second Incremental Amendment Date or the Third Incremental Amendment Date, as applicable), (C) that attached thereto is a true and complete copy of resolutions duly adopted by the board of directors (or equivalent governing body) of such Loan Party authorizing or ratifying the execution, delivery and performance of the Amendment and, in the case of the Borrower, the borrowings and&#47;or incurrence of the 2021 New Revolving Commitments and the Revolving Loans contemplated thereby, and that such resolutions have not been modified, rescinded or amended and are in full force and effect and (D) as to the incumbency and specimen signature of each officer executing any Loan Document or any other document delivered in connection herewith on behalf of such Loan Party and (z) a certificate of another officer as to the incumbency and specimen signature of the Secretary or Assistant Secretary executing the certificate pursuant to clause (y) above, in each case under this clause (iv), unless otherwise agreed by the Administrative Agent&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Administrative Agent shall have received Notes executed by the Borrower in favor of each 2021 New Revolving Lender that has requested a Note at least three Business Days in advance of the Extension Effective Time&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.69pt">the Administrative Agent shall have received a solvency certificate, substantially in the form set forth in Exhibit H to the Credit Agreement, from the chief financial officer, chief operating officer or other officer with similar responsibilities of the Borrower, dated as of the</font><font style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Extension Effective Date and giving effect to the 2021 New Revolving Commitments and any Revolving Loans made pursuant to the 2021 New Revolving Commitments as of the Extension Effective Date&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:15.36pt">the Administrative Agent shall have received all documentation and other information about the Borrower and the Guarantors required under applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including the USA PATRIOT Act, that has been reasonably requested in writing at least three days prior to the Extension Effective Time&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.03pt">Parent shall have issued common stock pursuant to that certain Underwriting Agreement, dated as of the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Specified Equity Offering </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Underwriting Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), among Parent, J.P. Morgan Securities LLC and Jefferies LLC (without giving effect to any over-allotment option thereunder) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Specified Equity Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (it being understood that the net cash proceeds of such Specified Equity Offering pursuant to the Specified Equity Offering Underwriting Agreement shall have been contributed to the Borrower)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.69pt">any LC Participation Fees, any interest with respect to any Existing Revolving Loans, and any Commitment Fees with respect to any Existing Revolving Commitments, in each case, that have accrued and are owing to the Existing Revolving Lenders (in each case, even if not yet due and payable at such time) as of the calendar day prior to the Extension Effective Time shall have been paid to the Administrative Agent on behalf of the Existing Revolving Lenders&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, without limitation, the Extension Effective Time shall be deemed to be the date that the certificate set forth in clause (i) above is delivered to the Administrative Agent if as of the date such certificate is delivered each of the Extension Conditions (other than clause (i) above) has been satisfied.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">This Amendment shall constitute a Revolving Extension Offer to all Lenders holding Existing Revolving Commitments (as of immediately prior to this Amendment) pursuant to Section 2.21(b) of the Credit Agreement, and, for the avoidance of doubt, shall satisfy all such notice and offer requirements set forth in Section 2.21(b) and 2.21(e) of the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Incremental Revolving Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to the satisfaction of the conditions precedent set forth in Section 6 below, the Borrower, the Guarantors, the 2021 Incremental Revolving Lenders and Agent hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Borrower is requesting 2021 Incremental Revolving Commitments in the aggregate principal amount of $50,000,000 from the 2021 Incremental Revolving Lenders pursuant to, and on the terms set forth in, Section 2.19 of the Credit Agreement, effective as of the Fourth Incremental Amendment Time.  The full principal amount of such 2021 Incremental Revolving Commitments are being incurred in reliance on clause (i)(y)(A) of the first proviso of Section 2.19(a) under the Credit Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each 2021 Incremental Revolving Lender agrees, severally and not jointly, to provide to the Borrower its 2021 Incremental Revolving Commitments as a Revolving Commitment Increase under the Amended Credit Agreement commencing as of the Fourth Incremental Amendment Time in an amount equal to such 2021 Incremental Revolving Lender&#8217;s 2021 Incremental Revolving Commitments as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto, and to make Revolving Loans to the Borrower under the Amended Credit Agreement, in each case, at any time and from time to time on and after the Fourth Incremental Amendment Time until the earlier of the Revolving Maturity Date and the termination of the Revolving Commitment of such 2021 Incremental Revolving Lender in accordance with the terms of the Amended Credit Agreement, in an aggregate principal amount at any time outstanding not to exceed such 2021 Incremental Revolving Lender&#8217;s 2021 Incremental Revolving Commitment.  With effect from and after the Fourth Incremental Amendment Time, after giving effect to the Revolving Commitment Increase pursuant to the 2021 Incremental Revolving Commitments, (x) each Extending Revolving Lender that has Revolving Exposure under the 2021 Extended Revolving Commitments with respect to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021 Extended Revolving Loans that are outstanding under its 2021 Extended Revolving Commitments as of the Fourth Incremental Amendment Time, shall assign to each 2021 Incremental Revolving Lender, and each 2021 Incremental Revolving Lender shall purchase from such Extending Revolving Lender, at the principal amount thereof, such interests in the 2021 Extended Revolving Loans outstanding as of the Fourth Incremental Amendment Time as shall be necessary in order that, after giving effect to all such assignments and purchases under this clause (x), and taking into account all Credit Extensions of Revolving Loans made as of the Fourth Incremental Amendment Time, such 2021 Extended Revolving Loans will be held by Extending Revolving Lenders and 2021 Incremental Revolving Lenders having a 2021 Incremental Revolving Commitment ratably in accordance with their Revolving Commitments after giving effect to the Revolving Commitment Increase pursuant to the 2021 Incremental Revolving Commitments and (y) the LC Exposure of each Revolving Lender shall be based on such Revolving Lender&#8217;s Pro Rata Share (determined after giving effect to the Revolving Commitment Increase pursuant to the 2021 Incremental Revolving Commitments) of the aggregate LC Exposure.  The Administrative Agent and each Issuing Bank hereby consents to each 2021 Incremental Revolving Lender to the extent required pursuant to Section 2.19 and&#47;or Section 10.04 under the Credit Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The obligations of each 2021 Incremental Revolving Lender to provide the 2021 Incremental Revolving Commitments to the Borrower pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall become effective on the Extension Effective Date immediately after the Extension Effective Time occurs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fourth Incremental Amendment Condition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and the time of such satisfaction being the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fourth Incremental Amendment Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, without limitation, the Fourth Incremental Amendment Time shall be deemed to be the date that the certificate set forth in Section 2(f)(i) above is delivered to the Administrative Agent if as of the date such certificate is delivered each of the conditions set forth in Section 2(f) above (other than Section 2(f)(i) above) has been satisfied.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Subject to satisfaction of the Fourth Incremental Amendment Condition, the Revolving Commitments of the Extending Revolving Lenders and the 2021 Incremental Revolving Commitments shall be deemed to be, and treated as, part of a single Class of Revolving Commitments (and any Revolving Loans made pursuant to the 2021 Extended Revolving Commitments and the 2021 Incremental Revolving Commitments shall be deemed to be, and treated as, part of a single Class of Revolving Loans).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Subject to satisfaction of the Fourth Incremental Amendment Condition, the definition of &#8220;Revolving Commitment&#8221; under Section 1.01 of the Credit Agreement (as amended pursuant to the Extension Amendment set forth in Section 2 above) is hereby amended and restated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revolving Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Lender, the commitment, if any, of such Lender to make Revolving Loans hereunder up to the amount set forth on Schedule 2.01 under the caption &#8220;Revolving Loan Commitment&#8221; or in the Assignment and Acceptance or Refinancing Amendment pursuant to which such Lender assumed its Revolving Commitment, as applicable, as the same may be (a) reduced from time to time pursuant to Section 2.09 and (b) reduced or increased from time to time pursuant to (i) assignments by or to such Lender pursuant to an Assignment and Acceptance, (ii) a Refinancing Amendment, (iii) an Extension Amendment or (iv) an Incremental Amendment. The aggregate principal amount of the Lenders&#8217; Revolving Commitments </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;immediately prior to the Fourth Incremental Amendment Time was $120,000,000 and (y) as of the Fourth Incremental Amendment Time was $170,000,000 (immediately after giving effect to the 2021 Incremental Revolving Commitments).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">Subject to satisfaction of the Fourth Incremental Amendment Condition, Section 1.01 of the Credit Agreement (as amended pursuant to the Extension Amendment set forth in Section 2 above) is hereby further amended by (x) adding the following defined terms in correct alphabetical order&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021 Incremental Revolving Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Fifth Amendment.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth Incremental Amendment Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Fifth Amendment.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and (y) by adding the following sentence to the end of the definition of &#8220;Class&#8221; therein&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding any provision herein to the contrary, from and after the Fourth Incremental Amendment Time, the 2021 Extended Revolving Commitments (as defined in the Fifth Amendment) and the 2021 Incremental Revolving Commitments shall be deemed to be, and treated as, part of a single Class of Revolving Commitments (and any Revolving Loans made pursuant to the 2021 Extended Revolving Commitments and the 2021 Incremental Revolving Commitments shall be deemed to be, and treated as, part of a single Class of Revolving Loans).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Subject to satisfaction of the Fourth Incremental Amendment Condition, for the avoidance of doubt, (i) the loans made pursuant to the 2021 Incremental Revolving Commitments shall be deemed to be &#8220;Loans&#8221; and &#8220;Revolving Loans&#8221;, (ii) each 2021 Incremental Revolving Lender shall be deemed to be a &#8220;Lender&#8221; and a &#8220;Revolving Lender&#8221; and (iii) the 2021 Incremental Revolving Commitments shall be deemed to be a &#8220;Incremental Revolving Commitment&#8221;, a &#8220;Revolving Commitment Increase&#8221; and a &#8220;Revolving Commitment&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">For the avoidance of doubt, subject to satisfaction of the Fourth Incremental Amendment Condition, the 2021 Incremental Revolving Commitments, and the Revolving Loans made in connection therewith, shall have the same terms as the 2021 Extended Revolving Commitments and 2021 Extended Revolving Loans, as applicable, and shall bear interest and Commitment Fees, as applicable, as provided for in the Amended Credit Agreement with respect to Revolving Loans and Revolving Commitments, respectively.  The parties hereto hereby agree that, notwithstanding anything in the Amended Credit Agreement to the contrary, the Administrative Agent is hereby authorized to take all actions as it may reasonably deem to be necessary to ensure that (a) the 2021 Extended Revolving Commitments constitute Extended Revolving Commitments and Revolving Commitments and (b) the 2021 Incremental Revolving Commitments constitute a Revolving Commitment Increase to the 2021 Extended Revolving Commitments.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">This Amendment shall constitute notice to the Administrative Agent by the Borrower requesting the 2021 Incremental Revolving Commitments pursuant to Section 2.19(a) of the Credit Agreement, and, for the avoidance of doubt, shall satisfy such notice requirement set forth in Section 2.19(a) of the Credit Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Joinder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each 2021 Incremental Revolving Lender acknowledges and agrees that, effective as of the Effective Date, such 2021 Incremental Revolving Lender commits to provide its 2021 Incremental Revolving Commitment from and after the Fourth Incremental Amendment Time, as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto on the terms set forth herein and in the Amended Credit Agreement and subject to the conditions set forth herein and, from and after the Fourth Incremental Amendment Time, shall be a &#8220;Revolving Lender&#8221; and &#8220;Lender&#8221; under, and for all purposes of, the Amended Credit Agreement and the other Loan Documents and shall be subject to and bound by the terms thereof (and shall perform all the obligations of and shall have all the rights of a Lender thereunder).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In order to induce the other parties hereto to enter into this Amendment in the manner provided herein, each of Holdings, the Borrower and each Guarantor represents and warrants to the other parties hereto&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">immediately prior to giving effect to this Amendment, on and as of the date hereof, each of the representations and warranties set forth in Article 5 of the Credit Agreement and in each other Loan Document are true and correct in all material respects on and as of the date hereof with the same effect as though made on and as of the date hereof, except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties are true and correct in all material respects as of such earlier date (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that any such representation and warranty that is qualified by &#8220;materiality,&#8221; &#8220;material adverse effect&#8221; or similar language is true and correct in all respects (after giving effect to any such qualification therein) on and as of such earlier date with the same effect as though made on and as of the date hereof or such earlier date, as applicable)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">on and as of the Extension Effective Time and the Fourth Incremental Amendment Time, each of the representations and warranties set forth in Article 5 of the Amended Credit Agreement and in each other Loan Document shall be true and correct in all material respects with the same effect as though made on and as of the Extension Effective Time and the Fourth Incremental Amendment Time, except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that any such representation and warranty that is qualified by &#8220;materiality,&#8221; &#8220;material adverse effect&#8221; or similar language is true and correct in all respects (after giving effect to any such qualification therein) on and as of such earlier date with the same effect as though made on and as of the Extension Effective Time and the Fourth Incremental Amendment Time or such earlier date, as applicable)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">as of the date hereof and immediately after giving effect to this Amendment, no Default or Event of Default has occurred and is continuing&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">as of the Extension Effective Time and the Fourth Incremental Amendment Time, no Default or Event of Default shall have occurred and be continuing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Condition to Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The effectiveness of this Amendment is subject solely to the condition that the Administrative Agent shall have received counterparts of this Amendment duly executed by Holdings, the Borrower, each Subsidiary Guarantor, the Administrative Agent, the Collateral Agent, each Issuing Bank and each 2021 New Revolving Lender (which collectively constitute all of the Revolving Lenders under the Credit Agreement) (the time at which such condition is so satisfied is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The Borrower and each Guarantor hereby confirm that, as of the date hereof and as of the Extension Effective Time and the Fourth Incremental Amendment Time, as applicable, each Loan Document to which it is a party or otherwise bound and all Collateral encumbered thereby will continue to guarantee or secure, as the case may be, to the fullest extent possible in accordance with the Loan Documents the payment and performance of all Obligations and Secured Obligations under each of the Loan Documents to which it is a party (in each case as such terms are defined in the applicable Loan Document).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">The Borrower and each Guarantor acknowledge and agree that, as of the date hereof and as of the Extension Effective Time and the Fourth Incremental Amendment Time, as applicable, any of the Loan Documents to which it is a party or otherwise bound shall continue in full force and effect and that all of its obligations thereunder shall be valid and enforceable and shall not be impaired or limited by the execution or effectiveness of this Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">Each of the Borrower and each Guarantor hereby acknowledges that it has reviewed the terms and provisions of this Amendment and consents to the amendment of the Credit Agreement effected pursuant to this Amendment and acknowledges and agrees that, effective as of the Extension Effective Time and the Fourth Incremental Amendment Time, as applicable, each 2021 New Revolving Lender (and any assignee thereof) is a &#8220;Lender&#8221; and a &#8220;Secured Party&#8221; for all purposes under the Loan Documents to which the Borrower or such Guarantor is a party.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each Guarantor acknowledges and agrees that (i) notwithstanding the conditions to effectiveness set forth in this Amendment, such Guarantor is not required by the terms of the Credit Agreement or any other Loan Document to consent to the amendments to the Credit Agreement effected pursuant to this Amendment and (ii) nothing in the Credit Agreement, this Amendment or any other Loan Document shall be deemed to require the consent of such Guarantor to any future amendments to the Credit Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The parties hereto agree and acknowledge that, for all purposes under the Credit Agreement and the other Loan Documents, this Amendment constitutes (a) an Extension Amendment contemplated by Section 2.21 of the Credit Agreement and (b) an Incremental Amendment contemplated by Section 2.19 of the Credit Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">Each of the Borrower and each Guarantor hereby (i) acknowledges and agrees that all of its obligations under the Guarantees set out in the Amended Credit Agreement and any other guaranties in the Loan Documents to which it is a party are reaffirmed and remain in full force and effect on a continuous basis, (ii) reaffirms each Lien granted by each Loan Party to the Collateral Agent for the benefit of the Secured Parties and reaffirms the Guarantees made pursuant to the Amended Credit Agreement, (iii) acknowledges and agrees that the grants of security interests by and the Guarantees of the Loan Parties contained in the Amended Credit Agreement and the other Collateral Documents are, and shall remain, in full force and effect after giving effect to this Amendment, and (iv) agrees that, effective as of the Extension Effective Time and the Fourth Incremental Amendment Time, as applicable, the Obligations include, among other things and without limitation, the prompt and complete payment and performance by the Borrower when due and payable (whether at the stated maturity, by acceleration or otherwise) of principal and interest on, the Revolving Loans made pursuant to the 2021 New Revolving </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commitments under the Amended Credit Agreement. Nothing contained in this Amendment shall be construed as substitution or novation of the obligations outstanding under the Credit Agreement or the other Loan Documents, which shall remain in full force and effect, except to any extent modified hereby.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">GOVERNING LAW AND WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">THIS AMENDMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AMENDMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW PRINCIPLES THAT WOULD APPLY THE LAWS OF ANOTHER JURISDICTION.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AMENDMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE).  EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AMENDMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8(B).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Amendment may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  Delivery of an executed counterpart of a signature page to this Amendment by facsimile or other electronic imaging transmission shall be as effective as delivery of a manually executed counterpart of this Amendment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Reference to and Limited Effect on the Credit Agreement and the Other Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">On and after the Effective Date, (x) each reference in the Credit Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221;, &#8220;herein&#8221; or words of like import referring to the Credit Agreement, and (B) each reference in the other Loan Documents to the &#8220;Credit Agreement&#8221;, &#8220;thereunder&#8221;, &#8220;thereof&#8221;, &#8220;therein&#8221; or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement after giving effect to this Amendment (but, (I) with respect to the items expressly stated herein to be subject to the satisfaction of the Extension Conditions, subject to the satisfaction of such Extension Conditions and (II) with respect to the items expressly stated herein to be subject to the satisfaction of the Fourth Incremental Amendment Condition, subject to the satisfaction of such Fourth Incremental Amendment Condition).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Except as specifically amended by this Amendment, the Credit Agreement and each of the other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">The execution, delivery and performance of this Amendment shall not constitute a waiver of any provision of, or operate as a waiver of any right, power or remedy of the Agent or Lender under, the Credit Agreement or any of the other Loan Documents.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">Each of Holdings, the Borrower and each other Guarantor hereby (i) ratifies, confirms and reaffirms its liabilities, its payment and performance obligations (contingent or otherwise) and its agreements under the Credit Agreement and the other Loan Documents and (ii) acknowledges, ratifies and confirms that such liabilities, obligations and agreements constitute valid and existing Obligations under the Credit Agreement, in each case, to the extent Holdings, the Borrower or such Guarantor, as applicable, is a party thereto. In addition, each of Holdings, the Borrower and each Guarantor hereby ratifies, confirms and reaffirms (i) the liens and security interests granted, created and perfected under the Collateral Documents and any other Loan Documents and (ii) that each of the Collateral Documents to which it is a party remain in full force and effect notwithstanding the effectiveness of this Amendment.  Without limiting the generality of the foregoing, each of Holdings, the Borrower and each other Guarantor further agrees (A) that any reference to &#8220;Obligations&#8221; contained in any Collateral Documents shall include, without limitation, the &#8220;Obligations&#8221; as such term is defined in the Credit Agreement (as amended by this Amendment from and after the Extension Effective Time and the Fourth Incremental Amendment Time, as applicable) and (B) that the related guarantees and grants of security contained in such Collateral Documents shall include and extend to such Obligations. This Amendment shall not constitute a modification of the Credit Agreement, except as specified under Sections 2 and 3 hereto, or a course of dealing with Agent or any Lender at variance with the Credit Agreement such as to require further notice by Agent or any Lender to require strict compliance with the terms of the Credit Agreement and the other Loan Documents in the future, except as expressly set forth herein. This Amendment contains the entire agreement among Holdings, the Borrower, the other Guarantors, and the 2021 New Revolving Lenders contemplated by this Amendment. Neither Holdings nor the Borrower nor any other Guarantor has any knowledge of any challenge to Agent&#8217;s or any Lender&#8217;s claims arising under the Loan Documents or the effectiveness of the Loan Documents.  Agent and Lenders reserve all rights, privileges and remedies under the Loan Documents. Nothing in this Amendment is intended, or shall be construed, to constitute a novation or an accord and satisfaction of any of the Obligations or to modify, affect or impair the perfection, priority or continuation of the security interests in, security titles to or other Liens on any Collateral for the Obligations.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">This Amendment is a Loan Document (as defined in the Amended Credit Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower and Holdings agree, jointly and severally, to pay on demand all reasonable out-of-pocket costs and expenses incurred by the Agent and the 2021 New Revolving Lenders in connection with the preparation, negotiation and execution of this Amendment (whether incurred before or after the Effective Date), including, without limitation, all Attorney Costs of Agent, in each case, to the extent required under Section 10.05 of the Credit Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding the foregoing and anything to the contrary in any Loan Document, this Amendment (and the 2021 New Revolving Commitments) shall not be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">assignable by the 2021 New Revolving Lenders prior to the Fourth Incremental Amendment Time without the prior written consent of the Borrower (such consent not to be unreasonably withheld or delayed) and any purported assignment without such consent shall be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event any one or more of the provisions contained in this Amendment should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction).  The parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Section headings used herein are for convenience of reference only, are not part of this Amendment and shall not affect the construction of, or to be taken into consideration in interpreting, this Amendment.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature pages follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="icb41ce3323ec46d3b1200e5d69a1be11_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their respective proper and duly authorized officers as of the day and year first written above.</font></div><div><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY CENTER HOLDINGS, INC., </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Borrower</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer B. Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Jennifer B. Baldock</font></div><div style="margin-bottom:24pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Vice President and Secretary</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SP HOLDCO I, INC., </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Holdings</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer B. Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Jennifer B. Baldock</font></div><div style="margin-bottom:24pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Vice President and Secretary</font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SUBSIDIARY GUARANTORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMBULATORY RESOURCE CENTRES INVESTMENT COMPANY, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMBULATORY RESOURCE CENTRES OF WASHINGTON, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMBULATORY RESOURCE CENTRES OF WILMINGTON, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ANESTHESIOLOGY PROFESSIONAL SERVICES, INC.</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">APS OF HAMMOND, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">APS OF JONESBORO, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARC DEVELOPMENT, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARC FINANCIAL SERVICES, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">COMMUNITY HOSPITAL HOLDING COMPANY, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">COMMUNITY HOSPITAL MANAGEMENT COMPANY, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HAMMOND ANESTHESIA SERVICES, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IDAHO FALLS COMMUNITY HOSPITAL, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JENKINS COUNTY HOSPITAL, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JONESBORO ANESTHESIA SERVICES, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LOGAN LABORATORIES, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NATIONAL SURGICAL HOSPITALS, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NEOSPINE SURGERY OF PUYALLUP, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NEOSPINE SURGERY, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED ACQUISITION COMPANY, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED MANAGEMENT OF KANSAS CITY, LLC </font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED MANAGEMENT SERVICES, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED OF BETHLEHEM, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED OF LAREDO, INC.</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED OF LEBANON, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED OF SAN ANTONIO, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED OF TEXAS, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED OF WISCONSIN, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOVAMED, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH CALIFORNIA, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH CONNECTICUT, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH DURHAM, INC.</font></div><div style="padding-left:162pt"><font><br></font></div><div style="padding-left:162pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer B. Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Jennifer B. Baldock</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Vice President and Secretary</font></div><div style="padding-left:207pt;text-indent:-27pt"><font><br></font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><div id="icb41ce3323ec46d3b1200e5d69a1be11_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH EL PASO INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH EL PASO SPECIALTY HOSPITAL, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH GEORGIA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH LOUISIANA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH MANAGEMENT OF ARIZONA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH MANAGEMENT OF CALIFORNIA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH MESA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH MICHIGAN, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH NORTH IDAHO, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH SAN ANTONIO SURGICAL HOSPITAL, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH TEXAS, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NSH WISCONSIN, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PSC DEVELOPMENT COMPANY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PSC OPERATING COMPANY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">QUAHOG HOLDING COMPANY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RIVERSIDE BILLING AND MANAGEMENT COMPANY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RIVERSIDE SPINE &#38; PAIN PHYSICIANS, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SARC&#47;ASHEVILLE, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SARC&#47;FT. MYERS, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SARC&#47;GEORGIA, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SARC&#47;KENT, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SARC&#47;LARGO ENDOSCOPY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SARC&#47;LARGO, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SARC&#47;PROVIDENCE, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SARC&#47;ST. CHARLES, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCREVEN COUNTY FAMILY HEALTH CENTER, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCREVEN COUNTY HOSPITAL, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SGRY HOLDINGS, LP</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SGRY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBI DOCS, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBI GREAT FALLS, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBI HAVERTOWN, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBI IDAHO, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBI LHH, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBI PORTSMOUTH, LLC </font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBI STLWSC, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBIMS BIRMINGHAM, LLC</font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer B. Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Jennifer B. Baldock</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Vice President and Secretary</font></div><div style="padding-left:198pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:198pt;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><div id="icb41ce3323ec46d3b1200e5d69a1be11_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBIMS DURANGO, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBIMS FLORIDA I, LLC </font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBIMS KIRKWOOD, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBIMS STEUBENVILLE, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBIMS WICHITA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBISS BEVERLY HILLS, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBISS CHESTERFIELD, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBISS ENCINO, LLC </font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SMBISS IRVINE, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SP LOUISIANA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SP MANAGEMENT SERVICES, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SP NORTH DAKOTA, LLC</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SP PRACTICE MANAGEMENT, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY CENTER OF PENNSYLVANIA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS ACQUISITION COMPANY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF CORAL GABLES, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF LAKE MARY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF LAKE WORTH, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF MERRITT ISLAND, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF MILLENIA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF PARK PLACE, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF SARASOTA, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF WEST KENDALL, L.L.C.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS OF WESTCHASE, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SURGERY PARTNERS, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SYMBION AMBULATORY RESOURCE CENTRES, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SYMBIONARC SUPPORT SERVICES, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SYMBION HOLDINGS, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TAMPA PAIN RELIEF CENTER, INC.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TEXARKANA SURGERY CENTER GP, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THE CENTER FOR SPECIAL SURGERY, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">UNIPHY HEALTHCARE OF JOHNSON CITY VI, LLC</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">VASC, LLC </font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">VILLAGE SURGICENTER, LLC</font></div><div style="padding-left:153pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer B. Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Jennifer B. Baldock</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Vice President and Secretary</font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GREAT FALLS CLINIC, LLP</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GREAT FALLS CLINIC SURGERY CENTER, L.L.C.</font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MONTANA HEALTH PARTNERS, LLC</font></div><div style="padding-left:153pt"><font><br></font></div><div style="padding-left:153pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer B. Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Jennifer B. Baldock</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Vice President and Secretary</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CMSC, LLC   </font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer B. Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Jennifer B. Baldock</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Vice President and Secretary</font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:157.5pt"><font><br></font></div><div style="padding-left:153pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><div id="icb41ce3323ec46d3b1200e5d69a1be11_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JEFFERIES FINANCE LLC,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Administrative Agent, Collateral Agent, 2021 New Revolving Lender and an Issuing Bank</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Paul Chisholm&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;  Paul Chisholm</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;  Managing Director</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">KKR CORPORATE LENDING LLC, </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a 2021 New Revolving Lender and an Issuing Bank</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; John Knox&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;  John Knox</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;  CFO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MACQUARIE CAPITAL FUNDING LLC, </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a 2021 New Revolving Lender</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ayesha Farooqi&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;  Ayesha Farooqi</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;  Authorized Signatory</font></div><div style="padding-left:216pt;padding-right:18pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Lisa Grushkin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;  Lisa Grushkin</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;  Authorized Signatory</font></div><div style="padding-left:216pt;padding-right:18pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MADISON PARK FUNDING XL, LTD., </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a 2021 New Revolving Lender</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; Credit Suisse Asset Management, LLC, as portfolio manager</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Thomas Flannery&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;  Thomas Flannery</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;  Authorized Signatory</font></div><div style="padding-left:216pt;padding-right:18pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MADISON PARK FUNDING XVII, LTD., </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a 2021 New Revolving Lender</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; Credit Suisse Asset Management, LLC, as portfolio manager</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Thomas Flannery&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;  Thomas Flannery</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;  Authorized Signatory</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BARCLAYS BANK PLC, </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a 2021 New Revolving Lender</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ronnie Glenn&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;  Ronnie Glenn</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;  Director</font></div><div style="padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:252pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JPMORGAN CHASE BANK, N.A., </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a 2021 New Revolving Lender</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Dawn Lee Lum&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;  Dawn Lee Lum</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;  Executive Director</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Fifth Amendment&#93;</font></div></div></div><div id="icb41ce3323ec46d3b1200e5d69a1be11_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 2.01</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Extended Revolving Commitments</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Extending Revolving Lender</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Existing Revolving Commitment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jefferies Finance LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$56,250,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">KKR Corporate Lending LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$33,750,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Macquarie Capital Funding LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$15,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Madison Park Funding XL, LTD.</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$8,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Madison Park Funding XVII, LTD.</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$7,000,000</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">$120,000,000</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Incremental Revolving Commitments</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021 Incremental Revolving Lender</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021 Incremental Revolving Commitment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Barclays Bank PLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$25,000,000</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JPMorgan Chase Bank, N.A.</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$25,000,000</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">$50,000,000</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icb41ce3323ec46d3b1200e5d69a1be11_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Execution Version</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 4.02(d)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Local Counsel Opinions</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:31.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">State</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Counsel Information</font></div><div style="text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Florida</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">McDermott Will &#38; Emery LLP <br>333 Avenue of the Americas, Suite 4500<br>Miami, FL 33131-4336</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tennessee</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Waller Lansden Dortch &#38; Davis, LLP </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">511 Union Street, Suite 2700</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PO Box 198966</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nashville, TN 37219-8966</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Texas</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">McGuire, Craddock &#38; Strother, P.C.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">500 N. Akard Street, Suite 2200</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dallas, TX 75201</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">North Carolina</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Carruthers &#38; Roth, P.A.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Post Office Box 540</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">235 North Edgeworth Street</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Greensboro, NC 27401</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Montana</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gordon Rees Scully Mansukhani, LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">201 W. Main Street, Suite 101</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Missoula, MT 59802</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>3
<FILENAME>ye2020exhibit1035.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ide1cffbe45d84d96bf80bbfc8e25f9d3_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.35</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECOND AMENDMENT TO EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is hereby entered into on August 7, 2019. by and between Surgery Partners. Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Symbion, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Symbion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, and together with Parent, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Anthony W. Taparo (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;The Company and the Executive entered into that certain Employment Agreement dated June&#160;13, 2017. as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;The Company and the Executive desire to amend certain provisions of the Agreement pursuant to the terms and conditions set forth herein.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Section 2(a) of the Agreement is amended by deleting the first sentence of such provision in its entirety and replacing it with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;During the Employment Period, Executive shall serve as Group President and Chief Growth Officer of Parent reporting to the CEO or COO.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Section 3(a) of the Agreement is amended by deleting the first sentence of such provision and re&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;During the Employment Period, Executive&#8217;s Base Salary shall be $400,000 per annum (which annual base salary, as modified from time to time in accordance with this Section 3, shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), payable by the Company in regular installments in accordance with the Company&#8217;s general payroll practices, less taxes and other applicable withholdings.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Executive expressly acknowledges and agrees that he shall not be entitled, and hereby waives his right (if any), to resign his employment with the Company for &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; pursuant to Section 4(b) of the Agreement in connection with any change to Executive&#8217;s core functional role and responsibilities as a result of the changes made in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">This Amendment may be executed in counterparts and by means of a facsimile machine or PDF, each of which shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">This Amendment shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflicts of law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Except as set forth herein, the Agreement shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SURGERY PARTNERS, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer Baldock&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jennifer Baldock</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Executive VP and Chief Legal Officer</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SYMBION, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer Baldock&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Jennifer Baldock</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive VP and Chief Legal Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accepted and Agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony W. Taparo&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Anthony W. Taparo</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">August 7, 2019&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="ide1cffbe45d84d96bf80bbfc8e25f9d3_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is hereby entered into on July&#160;31, 2016 by and between Surgery Partners, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Surgery Partners</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Symbion, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Symbion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, and together with Surgery Partners, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Anthony W. Taparo (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Symbion and the Executive entered into that certain Employment Agreement dated ____________, 2014, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;The Company and the Executive desire to amend certain provisions of the Agreement pursuant to the terms and conditions set forth herein .</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing and the mutual agreements contained herein , and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Effective as of the date first mentioned above, the Agreement is hereby amended by deleting Section 4(g)(iii) in its entirety and replacing it with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Compensation after Termination.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;If the Employment Period has commenced and is terminated (1)&#160;by the Company without Cause, (2)&#160;by Executive for Good Reason or (3)&#160;this Agreement is not renewed by the Company or is allowed to expire by the Company, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitle d to receive as severance compensation the following (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; )&#58; (A)&#160;an amount equal to the sum of Executive&#8217;s then-current annual Base Salary, payable in regular installments beginning within 30 days following the Termination Date in accordance with the Company&#8217;s general payroll practices for salaried employees&#59; (B)&#160;continuation of the welfare benefits described in Section 3(b) for 12 months (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the extent permissible under the terms of the relevant benefit plans at no cost to Executive&#59; (C)&#160;the Bonus payable to Executive within 2 and 1&#47;2 months after the end of the applicable year&#59; (D)&#160;with respect to the portion of each restricted stock award held by Executive as of date on which the Employment Period is terminated that is subject to time-based vesting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Time-Based RSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), accelerated vesting of the Time-Based RSA to the vesting event next following the date on which the Employment Period is terminated&#59; and (E)&#160;with respect to the portion of each performance stock unit award held by the Executive as of the date on which the Employment Period is terminated that has been converted into &#8220;earned shares&#8221; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Earned PS Us</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), accelerated vesting of the Earned PSUs to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the vesting event next following the date on which the Employment Period is terminated. For purposes of this Section 4(g), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an amount equal to Executive&#8217;s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof. For the avoidance of doubt, the unvested portion of any restricted stock awards and performance share unit awards held by Executive as of the date on which the Employment Period ends (after giving effect to the acceleration provisions set forth in subsections (D)&#160;and (E)&#160;herein and the terms and conditions of the applicable award agreements and the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time)) shall be forfeited and of no further force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">This Amendment may be executed in counterparts and by means of a facsimile machine or PDF, each of which shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">This Amendment shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflicts of law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Except as set forth herein, the Agreement shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature  Page Follows&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="ide1cffbe45d84d96bf80bbfc8e25f9d3_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SURGERY PARTNERS, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Michael T. Doyle&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Michael T. Doyle</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SYMBION, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Michael T. Doyle&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Michael T. Doyle</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accepted and Agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony W. Taparo&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Anthony W. Taparo</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">August 5, 2016&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="ide1cffbe45d84d96bf80bbfc8e25f9d3_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made as of June 13, 2014, between Symbion, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Anthony W. Taparo (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, simultaneously with the execution of this Agreement, Surgery Center Holdings, LLC, a Delaware limited liability company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), SH Acquisition Corp. a Delaware corporation and a wholly-owned subsidiary of the Parent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Sub</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and Symbion Holdings Corporation, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Symbion Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), are entering into that certain Agreement and Plan of Merger (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Merger Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) pursuant to which, among other things, Merger Sub shall merge with and into Symbion Holdings, whereupon the separate existence of the Merger Sub shall cease, and Symbion Holdings shall be the surviving corporation and shall become a wholly-owned subsidiary of Parent following such merger&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company is wholly owned by Symbion Holdings&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, as a condition to the execution of the Merger Agreement, the parties hereto are entering into this Agreement pursuant to which, contingent upon the closing of the transactions contemplated by the Merger Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company will employ Executive on the terms and conditions contained in this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the covenants and agreements contained in this Agreement are contingent upon, and subject to, the occurrence of the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall employ Executive, and Executive hereby accepts employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on the date of the Closing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and ending on the five (5) year anniversary of the Commencement Date&#59; provided, however, that the term of this Agreement shall automatically be extended for one additional year on the fifth anniversary of the Commencement Date and each anniversary thereafter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) unless either party gives thirty (30) days&#8217; notice of non-renewal. The parties hereto acknowledge and agree that the covenants, agreements and obligations of the parties hereto are contingent upon, and subject to, the occurrence of the Closing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, Executive shall serve as the Group President of the Parent reporting to the CEO or COO. Executive shall have such responsibilities, duties and authorities, and will render such services for the Company and its Subsidiaries or Affiliates as the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (or any designated officer of the Board or the Company or Parent), may from time to time direct. Executive will devote his best efforts, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">energies and abilities and his full business time, skill and attention to the business and affairs of the Company and its Subsidiaries, and shall perform his duties and responsibilities to the best of his ability, in a diligent, trustworthy, businesslike and efficient manner for the purpose of advancing the businesses of Company and its Subsidiaries. Executive acknowledges that his duties and responsibilities will require his full time business efforts and agrees that during the Employment Period he will not engage in any other business activity or have any business pursuits that interferes with Executive&#8217;s duties and responsibilities under this Agreement or are competitive with the businesses of the Company. Notwithstanding the foregoing, Executive shall be permitted to devote a reasonable amount of time and effort to (i)&#160;providing service to, or serving on governing boards of, civic and charitable organizations, and (ii)&#160;personally investing and managing personal and family investments in real estate and in any corporation, partnership or other entity&#59; but in each case, only to the extent that any of the activities described in clauses (i) or (ii), individually or as a whole, do not (A)&#160;require or involve the active participation of Executive in the management of any corporation, partnership or other entity or interfere with the execution of Executive&#8217;s duties hereunder, or (B)&#160;otherwise violate any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of this Agreement, (i)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any corporation or other entity of which either (a)&#160;the securities or other ownership interests having the voting power to elect a majority of the board of directors or other governing body are, at the time of determination, owned by the Company, Symbian Holdings or Parent, directly or through one or more subsidiaries or (b)&#160;to which the Company, Symbian Holdings or Parent, or any of their Affiliates provide management services to, and (ii)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of an entity means any other person or entity, directly or indirectly controlling, controlled by or under common control with an entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, Executive&#8217;s base salary shall be $275,000.00 per annum (which annual base salary, as modified from time to time in accordance with this Section 3, shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), payable by the Company in regular installments in accordance with the Company&#8217;s general payroll practices, less taxes and other applicable withholdings. The Board or any designated officer shall perform an annual review of Executive&#8217;s Base Salary based on Executive&#8217;s performance of his duties and the Company&#8217;s other compensation policies&#59; provided that any modification in the Base Salary shall require approval of the Board or its Compensation Committee, which may give or withhold such approval in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In addition, during the Employment Period, Executive shall be entitled to participate in all of the Company&#8217;s benefit programs for which employees of the Company are generally eligible, subject to the eligibility and participation requirements thereof, including, but not limited to, the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">medical, dental, vision, life and disability insurance, as is generally provided to other employees of the Company&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">eligibility for vacation time in accordance with the policies of the Company as are in effect as of the Commencement Date&#59; provided, however, that Executive shall not have less than 20 days of vacation time per calendar year&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">participation in the management equity plan of Parent, pursuant to which Executive shall be granted 150,000 Class B Units of Parent, which Class B Units will be subject to customary vesting, buyback and other provisions and restrictions as set forth in the applicable award agreement and Parent&#8217;s LLC Agreement. Copies of both the applicable award agreement and Parent&#8217;s LLC Agreement have been provided to Executive prior to the date of this Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">participation in the existing Symbion, Inc. supplemental Executive Retirement Plan, or its equivalent or a successor plan, with a minimum of a two percent (2%) match for Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, the Company shall reimburse Executive for all reasonable out-of-pocket expenses incurred by his in the course of performing his duties and responsibilities under this Agreement which are consistent with the Company&#8217;s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company&#8217;s requirements with respect to reporting and documentation of such expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In addition to the Base Salary, Executive will be eligible to receive an annual bonus of fifty percent (50%) of the Base Salary upon the achievement of certain performance targets to be defined by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">All amounts payable to Executive hereunder shall be subject to all required withholdings by the Company. If additional guidance is issued under, or modifications are made to, Section 409A of the Internal Revenue Code or any other law affecting payments to be made under the Agreement, the Executive agrees that the Company may take such reasonable actions and adopt such reasonable amendments as the Company believes are necessary to ensure continued compliance with the Internal Revenue Code, including Section 409A thereof. However, the Company does not hereby or otherwise represent or warrant that any payments hereunder are or will be in compliance with Section 409A, and Executive shall be responsible for obtaining his own tax advice with regard to such matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination By Executive or the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Employment Period (i)&#160;shall terminate upon Executive&#8217;s resignation with Good Reason (as defined below) or without Good Reason, death or Incapacity (as defined below) or (ii)&#160;may be terminated by the Company at any time for Cause (as defined below) or without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean without the written consent of Executive&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">without the express written consent of Executive, a material diminution of his position, duties, responsibilities, and status with the Company as in effect as of the Commencement Date or a material reduction of Executive&#8217;s resources as in effect on the Commencement Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">a reduction in Executive&#8217;s Base Salary or annual bonus percentage&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a material reduction in the level of benefits available or awarded to Executive, other than any reduction in connection with a Company-wide reduction applicable generally to similarly situated executive officers of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">during the first twelve (12) months of this Agreement or within twelve (12) months of any Change in Control (as defined herein), a material increase in Executive&#8217;s core functional responsibilities with a corresponding material change in Executive&#8217;s core functional role without a corresponding increase in compensation, provided, however, the addition of additional facilities or territories to Executive&#8217;s oversight responsibilities or other ordinary course growth of the Parent or Company shall not be a material increase in Executive&#8217;s core functional responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a relocation by the Company of Executive&#8217;s primary employment location to a location which is more than 50 miles from Executive&#8217;s primary employment location on the date hereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">a material breach by the Company of the terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">but only if (x)&#160;Executive notifies the Company in writing within 60 days after the initial existence or occurrence of any of these conditions which notice describes in reasonable detail the basis for Executive&#8217;s belief that Good Reason exists and that the Executive intends to resign for Good Reason and the Company, within 15 days after receipt of such notice, either fails to cure the condition or delivers a written notice to Executive that the Company intends not to cure such condition and (y)&#160;Executive actually resigns prior to 15 days after the earlier to occur of either the end of such 15-day cure period or delivery of such written notice by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein shall mean that Executive is unable to perform, with or without reasonable accommodation, by reason of physical or mental incapacity, the essential duties, responsibilities and functions of his or his position. A medical examination by a physician selected by the Company to whom the Executive or his duly appointed guardian, if any, has no reasonable objection shall determine, according to the facts then available, whether and when Incapacity has occurred. Such determination shall not be arbitrary or unreasonable, and shall be final and binding on the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein means the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a material breach by Executive of any of the terms and conditions of this Agreement&#59; provided that, if curable, Executive shall have a reasonable period of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">time (which in no event shall exceed 45 days) during which to cure such material breach following the date on which Executive receives the Company&#8217;s written notice of such material breach&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Executive&#8217;s reporting to work (A)&#160;intoxicated (other than Executive&#8217;s reasonable use of alcohol in connection with business entertainment, provided, that such use of alcohol does not cause the Company, Parent or any of their Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm) or (B)&#160;under the influence of illegal drugs&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">Executive&#8217;s use of illegal drugs (whether or not at the workplace) or other conduct causing the Company, Parent or any of their Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company, Parent or any of their Subsidiaries or Affiliates&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">chronic absenteeism, which shall be deemed to have occurred if Executive has at least ten absences unrelated to paid time off, disability or illness in any ten week period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Executive&#8217;s material failure or willful refusal to substantially perform his duties, responsibilities and functions&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">Executive&#8217;s failure to comply with any of the Company&#8217;s, Parent&#8217;s or any of their Subsidiaries&#8217; written guidelines or procedures promulgated by the Company, Parent or any such Subsidiary and furnished to Executive, including, without limitation, any guidelines or procedures relating to marketing or community relations&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">Executive has committed an act or acts constituting a felony or any other act or omission involving theft, dishonesty or fraud against the Company, Parent or any of their Subsidiaries or any of their respective customers or suppliers or other business relationships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be deemed to have occurred at such time as&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Upon the closing of a reorganization, merger, share exchange or consolidation, other than a reorganization, merger, share exchange or consolidation with respect to which those persons who were the beneficial owners, immediately prior to such reorganization, merger, share exchange or consolidation, of outstanding securities of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Parent or the Company ordinarily having the right to vote in the election of directors own, immediately after the closing of such transaction, own more than 51% of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Upon approval by the Parent or the Company stockholders or members of a complete liquidation and dissolution of the Parent or the Company or the sale or other disposition of all or substantially all of the assets of the Parent or the Company other than to a Subsidiary or Affiliate&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided, however, that a sale, in a firm commitment underwritten public offering led by a nationally recognized underwriting firm pursuant to an effective registration statement under the Securities Act of 1933, as amended, or any successor federal statute, of units of the Parent (or common stock of an entity into which the units of the Parent convert) shall not be a Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive has the right to terminate his employment under this Agreement at any time, for any or no reason, but only after giving the Company (i)&#160;thirty (30) days prior written notice with respect to any termination without Good Reason or (ii)&#160;the number of days prior written notice set forth in the last sentence of Section 4(b) with respect to any termination with Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Compensation After Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">If the Employment Period has commenced and is terminated pursuant to Executive&#8217;s resignation without Good Reason, death or Incapacity, Executive shall only be entitled to receive his Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company, Parent or their Subsidiaries, except as may be required by applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">If the Employment Period has commenced and is terminated by the Company for Cause, Executive shall only be entitled to his Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company, Parent or their Subsidiaries, except as may be required by applicable law. In addition, in such event, Executive shall automatically forfeit any rights to any unvested Units owned by Executive in Parent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">If the Employment Period has commenced and is terminated (1)&#160;by the Company without Cause, (2)&#160;by Executive for Good Reason or (3)&#160;this Agreement is not renewed by the Company or allowed to expire by the Company, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitled to receive as severance compensation the following (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58; (A)&#160;an amount equal to the sum of Executive&#8217;s then-current annual Base Salary, payable in regular installments beginning within 30 days following the Termination Date in accordance with the Company&#8217;s general payroll practices for salaried employees&#59; (B)&#160;continuation of the welfare benefits described in Section 3(b) for twelve (12) months (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the extent permissible under the terms of the relevant benefit plans at no cost to Executive and (C)&#160;the Bonus payable to the Executive within 2 and l&#47;2 months after the end of the applicable year. For purposes of this Section 4(g), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an amount equal to the Executive&#8217;s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">If, within twelve (12) months following a Change in Control, either (A)&#160;the Company terminates the employment of Executive hereunder without Cause under Section 4(a) above, or (B)&#160;Executive terminates his employment for Good Reason under Section 4(e) above, then, in lieu of any other compensation that may be specified in this Agreement, the Company will pay Executive the Severance Pay. The Company will make any payment due under this clause (iv) in a single lump-sum payment not later than 30 days after termination. If any payment obligation under this Section 4(g) arises, no compensation received from other employment (or otherwise) will reduce the Company&#8217;s obligation to make the payment(s) described in this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding Section 4(g)(iii), Executive&#8217;s right to receive Severance Pay hereunder is conditioned upon&#58; (A)&#160;Executive executing, and not revoking, a written separation agreement and general release of all claims against the Parent, Company, their Subsidiaries and Affiliates and their respective managers, directors, officers, shareholders, members, representatives, agents, attorneys, predecessors, successors and assigns (other than a claim for the severance payments described in Section 4(g)(iii) and (iv) and Executive&#8217;s rights to future distributions and payments related to the continued ownership of any equity securities in Parent that Executive will continue to own after such termination), in form and substance acceptable to the Company, which shall among other things, contain a general release by Executive of all claims arising out of his employment and termination of employment by the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) within 30 days of Executive&#8217;s Termination Date&#59; and (B)&#160;Executive&#8217;s material compliance with all of his obligations which survive termination of this Agreement. The Severance Pay is intended to be in lieu of all other payments to which Executive might otherwise be entitled in respect of his termination without Cause, resignation with Good Reason or this Agreement is not renewed or allowed to expire by the Company. The Company, Parent and their Subsidiaries and Affiliates shall have no further obligations hereunder or otherwise with respect to Executive&#8217;s employment from and after the date of termination of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the Company, Parent and their Subsidiaries and Affiliates shall continue to have all other rights available hereunder (including without limitation, all rights hereunder at law or in equity).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Except as otherwise expressly provided herein, all of Executive&#8217;s rights to salary, bonuses, benefits and other compensation hereunder which might otherwise accrue or become payable after the termination of the Employment Period shall cease upon such termination, other than those expressly required under applicable law (such as COBRA). All amounts payable to Executive as severance hereunder shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subject to all required withholdings by the Company (including, but not limited to, Section 409A of the Internal Revenue Code).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company may offset any amount Executive owes it or Parent or their Subsidiaries or Affiliates against any amount they or their Subsidiaries or Affiliates owes Executive hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Other than in the performance of his duties hereunder, during the Restrictive Period (as defined below) and thereafter, Executive shall keep secret and retain in strictest confidence, and shall not, without the prior written consent of the Company, furnish, make available or disclose to any third party or use for the benefit of herself or any third party, any Confidential Information. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any information relating to the business or affairs of the Company, Parent any of their Subsidiaries or Affiliates or the Business, including but not limited to any technical or non-technical data, formulae, compilations, programs, devices, methods, techniques, designs, processes, procedures, improvements, models, manuals, financial data, acquisition strategies and information, information relating to operating procedures and marketing strategies, and any other proprietary information used by the Company, Parent or any of their Subsidiaries or Affiliates in connection with the Business, irrespective of its form&#59; provided, however, that Confidential Information shall not include any information which is in the public domain or becomes known in the industry, in each case through no wrongful act on the part of Executive. Executive acknowledges that the Confidential Information is vital, sensitive, confidential and proprietary to the Company, Parent and their Subsidiaries and Affiliates. Executive will immediately notify the Company of any unauthorized possession, use, disclosure, copying, removal or destruction, or attempt thereof, of any Confidential Information by anyone of which Executive becomes aware and of all details thereof. Executive shall take all reasonably appropriate steps to safeguard Confidential Information and to protect it against disclosure, misuse, espionage, loss and theft. Executive shall deliver to the Company at the termination or expiration of the Employment Period, or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, computers, printouts and software and other documents and data (and copies thereof) embodying or relating to the Confidential Information, Inventions and Discoveries (as defined below) or the business of the Company, Parent or any of their Subsidiaries or Affiliates which he may then possess or have under his control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein means the business of owning, operating, developing and&#47;or managing, or providing management or administrative services to, (a) ambulatory surgery centers anywhere in the United States or (b) physician-owned surgical hospitals within a fifty (50) mile radius of any hospital that is owned, operated, developed or managed by Parent or any Affiliate of Parent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive understands and agrees that all inventions, discoveries, ideas, improvements, whether patentable, copyrightable or not, pertaining to the Business or relating to the Company&#8217;s, Parent&#8217;s or any of their Subsidiaries&#8217; or Affiliates&#8217; actual or demonstrably anticipated research, development or inventions (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">result from any work performed by Executive solely or jointly with others for the Company, Parent or any of their Subsidiaries or Affiliates which Executive, solely or jointly with others, conceives, develops, or reduces to practice during the course of Executive&#8217;s employment with the Company, Parent or any of their Subsidiaries, are the sole and exclusive property of the Company. Executive will promptly disclose all such matters to the Company and will assist the Company in obtaining legal protection for Inventions and Discoveries. Executive hereby agrees on behalf of herself, his executors, legal representatives and assignees that he will assign, transfer and convey to the Company, its successors and assigns the Inventions and Discoveries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">THE COMPANY AND EXECUTIVE ACKNOWLEDGE AND AGREE THAT SECTION 6(a) SHALL NOT APPLY TO AN INVENTION OF EXECUTIVE FOR WHICH NO EQUIPMENT, SUPPLIES, FACILITY OR TRADE SECRET INFORMATION OF THE COMPANY, PARENT OR ANY OF THEIR SUBSIDIARIES WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON EXECUTIVE&#8217;S OWN TIME, UNLESS (A)&#160;THE INVENTION RELATED (I)&#160;TO THE BUSINESS OF THE COMPANY, PARENT OR ANY OF THEIR SUBSIDIARIES OR AFFILIATES OR (II)&#160;TO THE COMPANY&#8217;S OR ANY OF ITS SUBSIDIARIES&#8217; OR AFFILIATES&#8217; ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT, OR (B)&#160;THE INVENTION RESULTS FROM ANY WORK PERFORMED BY EXECUTIVE FOR THE COMPANY, PARENT OR ANY OF THEIR SUBSIDIARIES OR AFFILIATES. EXECUTIVE AND THE COMPANY FURTHER ACKNOWLEDGE AND AGREE THAT SECTION 6(a) SHALL NOT APPLY TO ANY INVENTIONS OR WORK PRODUCT DEVELOPED OR VESTED BY EXECUTIVE PRIOR TO THE EFFECTIVE DATE, A COMPLETE AND ACCURATE LIST OF WHICH IS SET FORTH ON SCHEDULE 6(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">EXECUTIVE ACKNOWLEDGES THAT HE HAS READ THIS SECTION 6 AND FULLY UNDERSTANDS THE LIMITATIONS WHICH IT IMPOSES UPON HIS AND HAS RECEIVED A DUPLICATE COPY OF THIS AGREEMENT FOR HIS RECORDS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive acknowledges that in the course of his employment with the Company, Parent or any of their Subsidiaries or Affiliates, or their predecessors or successors, he has been or will be given access to and has or will become familiar with their trade secrets and with other Confidential Information and that his services have been and shall be of special, unique and extraordinary value to the Company, Parent and their Subsidiaries or Affiliates. Therefore, and in further consideration of the compensation to be paid to Executive hereunder and in connection with his employment and the profit interests in Parent issued to Executive under that certain Executive Securities Agreement, dated as of the date hereof, and to protect the Company&#8217;s and its Subsidiaries&#8217; and Affiliates&#8217; Confidential Information, business interests and goodwill&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive hereby agrees that for a period commencing on the date hereof and ending on the Termination Date, and thereafter, through the period ending on the first anniversary of the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), he shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co-partner or in any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other individual or representative capacity, own, operate, manage, control, engage in, invest in or participate in any manner in, act as a consultant or advisor to, render services for (alone or in association with any person, firm, corporation or entity), or otherwise assist any person or entity (other than the Parent and its Subsidiaries) that engages in or owns, invests in, operates, manages or controls any venture or enterprise that directly or indirectly engages or is actively developing or attempting to develop in any element of the Business anywhere within a 50-mile radius of the Nashville metropolitan area or within a 50-mile radius of any area (or in the event such area is a major city, the metropolitan area relating to such city) in which the Parent, the Company or any of their Subsidiaries on the Termination Date actively engages or is actively developing or attempting to develop in any element of the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, that nothing contained herein shall be construed to prevent Executive from investing in the stock of any competing corporation listed on a national securities exchange or traded in the over-the-counter market, but only if Executive is not involved in the business of said corporation and if Executive and his associates (as such term is defined in Regulation 14(A) promulgated under the Securities Exchange Act of 1934, as in effect on the date hereof), collectively, do not own more than an aggregate of 3% of the stock of such corporation.  With respect to the Territory, Executive specifically acknowledges that the Parent and its Subsidiaries intend to expand the Business into and throughout the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Interference with Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Without limiting the generality of the provisions of Section 7(a) hereof, Executive hereby agrees that, for a period commencing on the date hereof and ending on the Termination Date, and thereafter, through the period ending on the second anniversary of the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Solicit Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), he will not, directly or indirectly, as employee, agent, consultant, stockholder, director, partner or in any other individual or representative capacity, (i)&#160;solicit or encourage, or participate in any business which solicits or encourages (A)&#160;any person, firm, corporation or other entity which has executed, or proposes to execute, a management services agreement or other services agreement with the Company, Parent or any of their Subsidiaries at any time during the term of this Agreement, or from any successor in interest to any such person, firm, corporation or other entity, for the purpose of securing business or contracts related to any element of the Business, or (b)&#160;any present customer or patient of the Company, Parent or any of their Subsidiaries or any of their Affiliated Practices to terminate or otherwise alter his, his or its relationship with the Company, Parent or any of their Subsidiaries or such Affiliated Practice&#59; provided, however, that nothing contained herein shall be construed to prohibit or restrict Executive from soliciting business from any such parties on behalf of the Company, Parent or any of their Subsidiaries in performance of his duties as an employee of the Company required under and as specifically contemplated by Section 2 above or (ii)&#160;divert, entice away, solicit or encourage, or attempt to divert, entice away, solicit or encourage, any physician who utilizes or has invested in an Affiliated Practice to become an owner, investor or user of another practice or facility that is not an Affiliated Practice or approach any such physician for any of the foregoing purposes or authorize or assist in the taking of any such action by any third party. In addition, at all times from and after the Termination Date, Executive shall not contact or communicate in any manner with any of the Company&#8217;s, the Parent&#8217;s or any of their Subsidiaries&#8217; or Affiliates&#8217; suppliers or vendors, or any other third party providing services to the Company, Parent or any of their Subsidiaries, regarding the Parent, the Company, any of their Subsidiaries or any Company- or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any such Subsidiary-related matter (which suppliers, vendors or third party service providers will include, without limitation, any third party with whom the Company, the Parent or any of their Subsidiaries was, during the term of Executive&#8217;s employment with the Parent, the Company or any of their Subsidiaries, contemplating engaging, or negotiating with, for the future provision of products or services).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Other than in the performance of his duties hereunder, during the Non-Solicit Restrictive Period, Executive shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co-partner or in any other individual or representative capacity, employ, recruit or solicit for employment or engagement, any person who is employed or engaged by the Parent, the Company or any of their Subsidiaries or any of its Affiliated Practices during the Non Solicit Restrictive Period, or otherwise seek to influence or alter any such person&#8217;s relationship with any of the Affiliated Practices, the Parent, the Company or any of their Subsidiaries&#59; provided, however that responses to a general solicitation (such as an internet or newspaper solicitation) that are not targeted towards any particular person shall not be deemed to be a violation of the restrictions set forth in this Section 7(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include any practice or facility (i)&#160;in which the Parent, Company or any of their Subsidiaries has an ownership interest or (ii)&#160;that is managed by or receives other services from the Parent, the Company or any of their Subsidiaries in connection with any element of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Blue Pencil</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any court of competent jurisdiction shall at any time deem the term of this Agreement or any particular Restrictive Covenant (as defined below) too lengthy or the Territory too extensive, the other provisions of this Section 7 shall nevertheless stand, the Restrictive Period herein shall be deemed to be the longest period permissible by law under the circumstances and the Territory herein shall be deemed to comprise the largest territory permissible by law under the circumstances. The court in each case shall reduce the time period and&#47;or Territory to permissible duration or size.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Covenant Not to Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Restrictive Period and thereafter, Executive shall not disparage, denigrate or derogate in any way, directly or indirectly, the Parent, the Company, any of their Subsidiaries or Affiliates, or any of its or their respective agents, officers, directors, employees, parent, subsidiaries, affiliates, Affiliated Practices, affiliated doctors (including any physicians who utilize or have invested in any Affiliated Practice), representatives, attorneys, executors, administrators, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Protected Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), nor shall Executive disparage, denigrate or derogate in any way, directly or indirectly, his experience with any Protected Party, or any actions or decisions made by any Protected Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive acknowledges and agrees that the covenants set forth in this Section 7 and the preceding Sections 5 and 6 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are reasonable and necessary for the protection of the business interests of the Company, Parent and their Subsidiaries and Affiliates, that irreparable injury may result to the Company, Parent and their Subsidiaries and Affiliates if Executive breaches any of the terms of said Restrictive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Covenants, and that in the event of Executive&#8217;s actual or threatened breach of any such Restrictive Covenants, the Company, Parent and their Subsidiaries and Affiliates will have no adequate remedy at law. Executive accordingly agrees that in the event of any actual or threatened breach by his of any of the Restrictive Covenants, the Company, Parent and their Subsidiaries and Affiliates shall be entitled to immediate temporary injunctive and other equitable relief subject to hearing as soon thereafter as possible. Nothing contained herein shall be construed as prohibiting the Company, Parent or any of their Subsidiaries or Affiliates from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove. In addition and supplementary to other rights and remedies existing in its (or their) favor, in the event of the material breach by Executive of any of the provisions of this Section 7, the Company or Parent (and&#47;or their Subsidiaries or Affiliates) shall be entitled to require the Executive to account for and pay over to the Company or Parent (and&#47;or their Subsidiaries or Affiliates) all compensation, profits, moneys, accruals, increments or other benefits actually derived from or received as a result of any transactions constituting a breach of the covenants contained in this Agreement which may require Executive to repay any severance. In addition, in the event of an alleged breach or violation by Executive of this Section 7, the restricted periods set forth in this Section 7 shall be tolled until such breach or violation has been duly cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Executive understands that the foregoing restrictions may limit his ability to earn a livelihood in a business similar to the business of the Company, Parent and their Subsidiaries or Affiliates, but he nevertheless believes that he has received and will receive sufficient consideration and other benefits as an executive of the Company and as otherwise provided hereunder to clearly justify such restrictions which, in any event (given his education, skills and ability), the Executive does not believe would prevent his from otherwise earning a living. Executive acknowledges that the Restrictive Covenants are reasonable and that he has reviewed the provisions of this Agreement with his legal counsel. The Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such employer with a copy of such restrictions, prior to the commencement of that employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Executive&#8217;s Representations and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive hereby represents and warrants to the Company that (i)&#160;the execution, delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which he is bound, (ii)&#160;Executive is not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity which will survive the Closing and (iii)&#160;upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the covenants, agreements and obligations contained herein shall be contingent upon, and subject to, the occurrence of the Closing. Executive hereby acknowledges and represents that he has consulted with independent legal counsel regarding his rights and obligations under this Agreement and that he fully understands the terms and conditions contained herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During the Employment Period and thereafter, Executive shall cooperate with the Company, Parent and their Subsidiaries and Affiliates in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are or may come into Executive&#8217;s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments). In the event the Company requires Executive&#8217;s cooperation in accordance with this Section 8(b), the Company shall reimburse Executive for reasonable travel expenses (including, without limitation, travel expenses, lodging and meals, and reasonable attorneys&#8217; fees upon submission of receipts).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sections 4 through 22 shall survive and continue in full force in accordance with their terms notwithstanding the expiration or termination of the Employment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice provided for in this Agreement must be in writing and must be either (i)&#160;personally delivered, (ii)&#160;mailed by registered or certified first class mail, prepaid with return receipt requested or (iii)&#160;sent by a recognized overnight courier service, to the recipient at the address below indicated&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices to the Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58; </font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58;</font></div><div style="margin-bottom:0.12pt;padding-left:288pt;text-indent:-1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58;</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-indent:-180pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">with a copy to (which shall not constitute notice to Executive)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:0.12pt;padding-left:288pt;text-indent:-1.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">McKenzie Laird, PLLC </font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4015 Hillsboro Pike</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Suite 222</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nashville, Tennessee 37215 </font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Robert H. Laird, Jr.</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58; (615) 916-3223 </font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; rlaird&#64;mckenzielaird.com</font></div><div style="margin-bottom:12pt;padding-left:288pt;text-indent:-180pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c&#47;o H.I.G. Middle Market, LLC</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1450 Brickell Avenue, 31st Floor </font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Miami, Florida 33131</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Chris Laitala and Matt Lozow </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58; (305) 379-2322</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; (305) 381-4157</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; claitala&#64;higcapital.com and &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mlozow&#64;higcapital.com</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-indent:-180pt"><font><br></font></div><div style="margin-bottom:0.12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">with copies to (which shall not constitute notice to the Company)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">McDermott Will &#38; Emery LLP </font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">227 West Monroe Street </font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chicago, Illinois 60606-5096 </font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; Brooks B. Gruemmer</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58; 312-984-7594</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; 312-984-7700</font></div><div style="margin-bottom:0.12pt;padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; bgruemmer&#64;mwe.com</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or such other address or to the attention of such other person or entity as the recipient party shall have specified by prior written notice to the sending party. Any notice under this Agreement will be deemed to have been given (a)&#160;on the date such notice is personally delivered, (b)&#160;three (3) days after the date of mailing if sent by certified or registered mail, or (c)&#160;one (1) day after the date such notice is delivered to the overnight courier service if sent by overnight courier.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, those documents expressly referred to herein and other documents of even date herewith, embody the complete agreement and understanding among Executive and the Company and its Subsidiaries and, as of the Effective Date, shall supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way. Upon the Commencement Date, Executive will no longer be a participant in Symbion Inc. Executive Change in Control Severance Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Executive hereby releases the Company and its Subsidiaries and waives any claims or rights that he may have under the Plan or any other prior or existing agreement or understanding he may have with the Parent, the Company or any of their Subsidiaries, Affiliates or predecessors, including, but not limited to, any claim for severance or other benefits. To the extent that any inconsistency exists between this Agreement and the LLC Agreement, the language of this Agreement shall supersede.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in separate counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together constitute one and the same agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company or Parent and their respective successors and permitted assigns. Executive may not assign any of his rights or obligations hereunder without the prior written consent of the Company. The Company may (a)&#160;assign any or all of its respective rights and interests hereunder to Parent or one or more Subsidiaries or Affiliates of Parent or the Company, (b)&#160;designate one or more Subsidiaries or Affiliates of Parent or Company to perform its obligations hereunder (in any or all of which cases the  Company nonetheless shall remain responsible for the performance of all of its obligations hereunder), (c)&#160;assign its rights hereunder in connection with the sale of all or a substantial part of the business or assets of the Company or Parent or one of their Subsidiaries (whether by merger, sale of stock or assets, recapitalization or otherwise) and (d)&#160;merge any of the Subsidiaries or Affiliates with or into the Company (or vice versa)&#59; provided, however, that the foregoing actions may provide Executive with Good Reason to terminate this Agreement. The rights of the Company hereunder are enforceable by Parent or the Company Subsidiaries or Affiliates, which are the intended third party beneficiaries hereof and no other third party beneficiary is so otherwise intended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Delivery by Facsimile or PDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or PDF, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute original forms thereof and deliver them to the other party. No party hereto shall raise the use of a facsimile machine or PDF to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile machine or PDF as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Income Tax Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive and the Company acknowledge that it is the intention of the Company to deduct all cash amounts paid under this Agreement as ordinary and necessary business expenses for income tax purposes. Executive agrees and represents that he will treat all such non-reimbursable amounts as ordinary income for income tax purposes, and should he report such amounts as other than ordinary income for income tax purposes, he will indemnify and hold the Company harmless from and against any and all taxes, penalties, interest, costs and expenses, including reasonable attorneys&#8217; and accounting fees and costs, which are incurred by Company directly or indirectly as a result thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflict of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT. THE PARTIES HERETO ALSO WAIVE ANY BOND OR SURETY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE OTHER PARTY. THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. THE COMPANY AND EXECUTIVE FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH THEIR RESPECTIVE LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES THEIR RESPECTIVE JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTION CONTEMPLATED HEREBY. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">THE COMPANY AND EXECUTIVE HEREBY CONSENT TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE STATE IN WHICH EXECUTIVE RESIDES AND IRREVOCABLY AGREE THAT SUBJECT TO THE COMPANY&#8217;S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE LITIGATED IN SUCH COURTS. EXECUTIVE ACCEPTS FOR HERSELF AND IN CONNECTION WITH HIS PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding Section 20(a), the parties intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 5 through 7 upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold such covenants wholly or partially invalid or unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any provision of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the maximum extent permitted by law, this Agreement shall be interpreted in such a manner that the payments to Executive under this Agreement are either exempt from, or comply with, Section 409A of the Internal Revenue Code and the regulations and other interpretive guidance issued thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including without limitation any such regulations or other guidance that may be issued after the Commencement Date. For purposes of Section 409A, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; as defined in Section 409A as of Executive&#8217;s termination of employment, then, to the extent any payment under this Agreement resulting from Executive&#8217;s termination of employment constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A) and to the extent required by Section 409A, no payments due under this Agreement as a result of Executive&#8217;s termination of employment may be made until the earlier of (a)&#160;the first day following the sixth month anniversary of Executive&#8217;s date of termination and (b)&#160;Executive&#8217;s date of death&#59; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum as soon as reasonably practicable following the sixth month anniversary of Executive&#8217;s date of termination.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><div id="ide1cffbe45d84d96bf80bbfc8e25f9d3_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SYMBION, INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Richard E. Francis, Jr.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Richard E. Francis, Jr.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Its&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Anthony W. Taparo&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Anthony W. Taparo</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="ide1cffbe45d84d96bf80bbfc8e25f9d3_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 6(b)</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior Inventions</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>4
<FILENAME>ye2020exhibit1036.htm
<DESCRIPTION>EX-10.36
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i843915dfa4a2429a9ab7029fe7ed0d8c_1"></div><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.36</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is hereby entered into effective as of November&#160;12, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), between Surgery Partners, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Brad Owens (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall employ Executive, and Executive hereby accepts continued employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on December&#160;2, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and ending on the Termination Date, as provided for in Section 4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, Executive shall serve as the Group President. Executive shall have such responsibilities, duties and authorities, and will render such services for the Company and its Subsidiaries or Affiliates as the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may from time to time direct. Executive will devote his best efforts, energies and abilities and his full business time, skill and attention to the business and affairs of the Company and its Subsidiaries, and shall perform his duties and responsibilities to the best of his ability, in a diligent, trustworthy, businesslike and efficient manner for the purpose of advancing the businesses of Company and its Subsidiaries. Executive acknowledges that his duties and responsibilities will require his full time business efforts and agrees that during the Employment Period he will not engage in any other business activity or have any business pursuits that interfere with Executive &#8216;s duties and responsibilities under this Agreement or are competitive with the businesses of the Company. Notwithstanding the foregoing, Executive shall be permitted to devote a reasonable amount of time and effort to (i)&#160;providing service to, or serving on governing boards of, civic and charitable organizations, and (ii)&#160;personally investing and managing personal and family investments in real estate and in any corporation, partnership or other entity&#59; but in each case, only to the extent that any of the activities described in clauses (i) or (ii), individually or as a whole, do not (A)&#160;require or involve the active participation of Executive in the management of any corporation, partnership or other entity or interfere with the execution of Executive&#8217;s duties hereunder, or (B)&#160;otherwise violate any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of this Agreement, (i)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any corporation or other entity (A)&#160;of which the securities or other ownership interests having the voting power to elect a majority of the board of directors or other governing body are, at the time of determination, owned by the Company, directly or through one or more subsidiaries or (B)&#160;to which the Company or any of its Affiliates provide management services, and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of an entity means any other person or entity, directly or indirectly controlling, controlled by or under common control with an entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, Executive&#8217;s base salary shall be $365,000 per annum, payable by the Company in regular installments in accordance with the Company&#8217;s general payroll practices , less taxes and other applicable withholdings, and subject to review and adjustment from time to time by the Board or the Compensation Committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in either case, in its discretion (as modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In addition, during the Employment Period, Executive shall be entitled to participate in all of the Company&#8217;s benefit programs for which employees of the Company are generally eligible, subject to the eligibility and participation requirements thereof, including, but not limited to, the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">medical, dental, vision, life and disability insurance, as is generally provided to other employees of the Company&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">eligibility for vacation time in accordance with the policies of the Company as from time to time in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, the Company shall reimburse Executive for all reasonable out-of-pocket expenses incurred by his in the course of performing his duties and responsibilities under this Agreement which are consistent with the Company&#8217;s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company&#8217;s requirements with respect to reporting and documentation of such expenses. Executive&#8217;s right to payment or reimbursement for business expenses hereunder will be subject to the following additional rules&#58; (i)&#160;no reimbursement of any expense shall affect Executive&#8217;s right to reimbursement of any other expense in any other taxable year&#59; (ii)&#160;the amount of expenses eligible for payment or reimbursement during any calendar year will not affect the expenses eligible for payment or reimbursement in any other taxable year&#59; (iii)&#160;payment or reimbursement will be made not later than December&#160;31 of the calendar year following the calendar year in which the expense was incurred or paid, and (iv)&#160;the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In addition to the Base Salary, Executive will be eligible to receive an annual bonus of fifty percent (50%) of the Base Salary, with the actual amount of any such bonus being determined by the Board or the Committee, in either case, in its discretion, based on the achievement of performance goals established annually by the Board or the Committee, as applicable. Any annual bonus payable under this Section 3(d) will be paid no later than March&#160;31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> following the close of the year for which the bonus is earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive shall be eligible to participate in the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on terms and conditions set forth therein and in the relevant award agreement unless specifically stated otherwise in this Agreement, and will starting in 2020, be eligible for annual equity grants under the Equity Plan, in an annual target amount of $325,000, subject to approval of the Board (or an authorized committee thereof), in such forms as determined by the Board or its designee in its discretion.</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">All amounts payable to Executive hereunder shall be subject to all required withholdings by the Company. If additional guidance is issued under, or modification s are made to, Section 409A of the Internal Revenue Code of the Internal Revenue Code and the regulations and other interpretive guidance issued thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or any other law affecting payments to be made under this Agreement, Executive agrees that the Company may take such reasonable actions and adopt such reasonable amendments as the Company believes are necessary to ensure continued compliance with the Internal Revenue Code, including Section 409A. However, the Company does not hereby or otherwise represent or warrant that any payments hereunder are or will be in compliance with Section 409A, and Executive shall be responsible for obtaining his own tax advice with regard to such matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination by Executive or the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Employment Period (i)&#160;shall terminate upon Executive&#8217;s resignation with Good Reason (as defined below) or without Good Reason, death or Incapacity (as defined below) or (ii)&#160;may be terminated by the Company at any time for Cause (as defined below) or without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean without the written consent of Executive&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">without the express written consent of Executive, a material diminution of his position, duties, responsibilities, and status with the Company as in effect as of the Commencement Date or a material reduction of Executive&#8217;s resources as in effect on the Commencement Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">a material reduction in Executive&#8217;s Base Salary or annual bonus target percentage&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a material reduction in the level of benefits available or awarded to Executive, other than any reduction in connection with a Company-wide reduction applicable generally to similarly situated executive officers of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">within twelve months of a Change in Control (as defined herein), a material increase in Executive&#8217;s core functional responsibilities with a corresponding material change in Executive&#8217;s core functional role without a corresponding increase in compensation, provided, however, the addition of additional facilities or territories to Executive&#8217;s oversight responsibilities or other ordinary course growth of the Company or any of its Subsidiaries or Affiliates shall not be a material increase in Executive&#8217;s core functional responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a relocation by the Company of Executive&#8217;s primary employment location to a location which is more than 50 miles from Executive&#8217;s primary employment location on the date hereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">a material breach by the Company of the terms of this Agreement&#59;</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">but only if (x)&#160;Executive notifies the Company in writing within 90 days after the initial existence or occurrence of any of these conditions which notice describes in reasonable detail the basis for Executive&#8217;s belief that Good Reason exists and that Executive intends to resign for Good Reason and the Company, within 30 days after receipt of such notice, either fails to cure the condition or delivers a written notice to Executive that the Company intends not to cure such condition and (y)&#160;Executive actually resigns prior to 15 days after the earlier to occur of either the end of such 30-day cure period or delivery of such written notice by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein shall mean that Executive is unable to perform, with or without reasonable accommodation, by reason of physical or mental incapacity, the essential duties, responsibilities and functions of his position. A medical examination by a physician selected by the Company to whom Executive or his duly appointed guardian, if any, has no reasonable objection shall determine , according to the facts then available, whether and when Incapacity has occurred. Such determination shall not be arbitrary or unreasonable, and shall be final and binding on the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein means the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a material breach by Executive of any of the terms and conditions of this Agreement&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such material breach following the date on which Executive receives the Company&#8217;s written notice of such material breach&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Executive&#8217;s reporting to work (A)&#160;intoxicated (other than Executive &#8216;s reasonable use of alcohol in connection with business entertainment, provided, that such use of alcohol does not cause the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm) or (B)&#160;under the influence of illegal drugs&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">Executive&#8217;s use of illegal drugs (whether or not at the workplace) or other conduct causing the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company or any of its Subsidiaries or Affiliates &#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">chronic absenteeism, which shall be deemed to have occurred if Executive has at least ten absences unrelated to paid time off, disability or illness in any ten week period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Executive&#8217;s material failure or willful refusal to substantially perform his duties, responsibilities and functions&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">Executive&#8217;s failure to comply with any of the Company&#8217;s or any of its Subsidiaries&#8217; written guidelines or procedures promulgated by the Company or any such Subsidiary and furnished to Executive, including, without limitation, any guidelines or procedures relating to marketing or community relations&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59; or </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">Executive has committed an act or acts constituting a felony or any other act or omission involving theft, dishonesty or fraud against the Company or any of its Subsidiaries or any of their respective customers or suppliers or other business relationships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be deemed to have occurred upon any of the following events, provided that, to the extent required by Section 409A, such events would also qualify as a &#8220;change in control event&#8221; under Treas. Reg. &#167;&#160;1.409A-3(i)(5)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Upon the closing of a reorganization, merger, share exchange or consolidation, other than a reorganization, merger, share exchange or consolidation with respect to which those persons who were the beneficial owners , immediately prior to such reorganization, merger, share exchange or consolidation, of outstanding securities of the Company ordinarily having the right to vote in the election of directors own, immediately after the closing of such transaction, more than 51% of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Upon approval by the stockholders of a complete liquidation and dissolution of the Company or the sale or other disposition of all or substantially all of the assets of the Company other than to a Subsidiary or Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive has the right to terminate his employment under this Agreement at any time, for any or no reason, but only after giving the Company (i)&#160;30 days prior written notice with respect to any termination without Good Reason or (ii)&#160;the number of days prior written notice set forth in the last sentence of Section 4(b) with respect to any termination with Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Compensation after Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">If the Employment Period is terminated pursuant to Executive&#8217;s resignation without Good Reason, death or Incapacity, Executive shall only be entitled to receive his Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">If the Employment Period is terminated by the Company for Cause, Executive shall only be entitled to his Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law. In addition , in such event, Executive shall automatically forfeit any rights to any unvested equity owned by Executive in the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">If the Employment Period is terminated by the Company without Cause or by Executive for Good Reason, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitled to receive as severance compensation the following (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58; (A)&#160;an amount equal to twelve (12) months of Executive&#8217;s then-current annual Base Salary, payable in regular installments beginning within 30 days following the Termination Date in accordance with the Company&#8217;s general payroll practices for salaried employees &#59; (B)&#160;continuation of the welfare benefits described in Section 3(b) for twelve (12) months to the extent permissible under the terms of the relevant benefit plans at the same cost to Executive as if Executive were an active employee of the Company&#59; (C)&#160;the Bonus payable to Executive within 3 months after the end of the applicable year (to the extent not previously paid), paid in a lump sum at the time that bonuses are regularly paid to employees&#59; (D)&#160;with respect to the portion of each restricted stock award held by Executive as of date on which the Employment Period is terminated that is subject to time-based vesting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Time-Based RSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), accelerated vesting of the TimeBased RSA to the vesting event next following the date on which the Employment Period is terminated&#59; and (E)&#160;with respect to the portion of each performance stock unit award held by the Executive as of the date on which the Employment Period is terminated that has been converted into &#8220;earned shares &#8220; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Earned PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), accelerated vesting of the Earned PSUs to the vesting event next following the date on which the Employment Period is terminated. For purposes of this Section 4(g), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an amount equal to Executive&#8217;s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof. For the avoidance of doubt, the unvested portion of any restricted stock awards and performance share unit awards held by Executive as of the date on which the Employment Period ends (after giving effect to the acceleration provisions set forth in subsections (D) and (E) herein and the terms and conditions of the applicable award agreements and the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time)) shall be forfeited and of no further force and effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">If, within 12 months following a Change in Control, either (A)&#160;the Company terminates the employment of Executive hereunder without Cause under Section 4(a) above, or (B)&#160;Executive terminates his employment for Good Reason under Section 4(b) above, then, in lieu of any other compensation that may be specified in this Agreement, the Company will pay Executive the Severance Pay in a single lump-sum payment not later than 30 days after termination. If any payment obligation under this Section 4(g) arises, no compensation received from other employment (or otherwise) will reduce the Company&#8217;s obligation to make the payment(s) described in this paragraph.</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding Sections 4(g)(iii) or (iv), Executive&#8217;s right to receive Severance Pay hereunder is conditioned upon&#58; (A)&#160;Executive executing, and not revoking, a written separation agreement and general release of all claims against the Company, its Subsidiaries and Affiliates and their respective managers, directors, officers, shareholders, members, representatives, agents, attorneys, predecessors, successors and assigns (other than a claim for the severance payments described in Section 4(g)(iii) or (iv) and Executive&#8217;s rights to future distributions and payments related to the continued ownership of any equity securities in the Company that Executive will continue to own after such termination), in form and substance acceptable to the Company, which shall among other things, contain a general release by Executive of all claims arising out of her employment and termination of employment by the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) within 30 days of Executive&#8217;s Termination Date&#59; and (B)&#160;Executive&#8217;s material compliance with all of his obligations which survive termination of this Agreement. The Severance Pay is intended to be in lieu of all other payments to which Executive might otherwise be entitled in respect of his termination without Cause or resignation with Good Reason. The Company and its Subsidiaries and Affiliates shall have no further obligations hereunder or otherwise with respect to Executive&#8217;s employment from and after the date of termination of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the Company and its Subsidiaries and Affiliates shall continue to have all other rights available hereunder (including without limitation, all rights hereunder at law or in equity).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Except as otherwise expressly provided herein, all of Executive&#8217;s rights to salary, bonuses, benefits and other compensation hereunder which might otherwise accrue or become payable after the termination of the Employment Period shall cease upon such termination , other than those expressly required under applicable law (such as COBRA). All amounts payable to Executive as severance hereunder shall be subject to all required withholdings by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company may offset any amount Executive owes the Company or its Subsidiaries or Affiliates against any amount they or their Subsidiaries or Affiliates owe Executive hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Other than in the performance of his duties hereunder, during the Restrictive Period (as defined below) and thereafter, Executive shall keep secret and retain in strictest confidence, and shall not, without the prior written consent of the Company, furnish, make available or disclose to any third party or use for the benefit of himself or any third party, any Confidential Information. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any information relating to the business or affairs of the Company or any of its Subsidiaries or Affiliates or the Business, including but not limited to any technical or non-technical data, formulae, compilations, programs, devices , methods, techniques, designs, processes, procedures, improvements, models, manuals, financial data, acquisition strategies and information, information relating to operating procedures and marketing strategies, and any other proprietary information used by the Company or any of its Subsidiaries or Affiliates in connection with the Business, irrespective of its form&#59; provided, however, that Confidential </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information shall not include any information which is in the public domain or becomes known in the industry, in each case through no wrongful  act on the part of Executive. Executive acknowledges that the Confidential Information is vital, sensitive, confidential and proprietary to the Company and its Subsidiaries and Affiliates. Executive will immediately notify the Company of any unauthorized possession, use, disclosure, copying, removal or destruction, or attempt thereof, of any Confidential Information by anyone of which Executive becomes aware and of all details thereof. Executive shall take all reasonably appropriate steps to safeguard Confidential Information and to protect it against disclosure, misuse, espionage , loss and theft. Executive shall deliver to the Company at the termination or expiration of the Employment Period , or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, computers, printouts and software and other documents and data (and copies thereof) embodying or relating to the Confidential Information, Inventions and Discoveries (as defined below) or the business of the Company or any of its Subsidiaries or Affiliates which Executive may then possess or have under his control. Nothing in this Agreement limits, restricts or in any other way affects Executive&#8217;s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity, or requires Executive to provide notice to the Company of the same. Executive cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (l)&#160;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspended violation of law, or (2)&#160;in a compliant or other document filed under seal in a lawsuit or other proceeding. Notwithstanding this immunity from liability, Executive may be held liable if Executive unlawfully accesses trade secrets by unauthorized means.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein means the business of owning, operating, developing and&#47;or managing, or providing management or administrative services to, (a) ambulatory surgery centers anywhere in the United States or (b) physician-owned surgical hospitals within a 50 mile radius of any hospital that is owned, operated, developed or managed by the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive understands and agrees that all inventions, discoveries , ideas , improvements, whether patentable, copyrightable or not, pertaining to the Business or relating to Company&#8217;s or any of its Subsidiaries&#8217; or Affiliates&#8217; actual or demonstrably anticipated research, development or inventions (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that result from any work performed by Executive solely or jointly with others for the Company or any of its Subsidiaries or Affiliates which Executive, solely or jointly with others, conceives, develops, or reduces to practice during the course of Executive&#8217;s employment with the Company or any of its Subsidiaries, are the sole and exclusive property of the Company. Executive will promptly disclose all such matters to the Company and will assist the Company in obtaining legal protection for Inventions and Discoveries. Executive hereby agrees on behalf of himself, his executors, legal representatives and assignees that he will assign, transfer and convey to the Company, its successors and assigns the Inventions and Discoveries.</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">THE COMPANY AND EXECUTIVE ACKNOWLEDGE AND AGREE THAT SECTION 6(a) SHALL NOT APPLY TO AN INVENTION OF EXECUTIVE FOR WHICH NO EQUIPMENT, SUPPLIES, FACILITY OR TRADE SECRET INFORMATION OF THE COMPANY OR ANY OF ITS SUBSIDIARIES WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON EXECUTIVE&#8217;S OWN TIME, UNLESS (A) THE INVENTION RELATED (I) TO THE BUSINESS OF THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES OR (II) TO THE COMPANY&#8217;S OR ANY OF ITS SUBSIDIARIES&#8217; OR AFFILIATES&#8217; ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT, OR (B) THE INVENTION RESULTS FROM ANY WORK PERFORMED BY EXECUTIVE FOR THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">EXECUTIVE ACKNOWLEDGES THAT HE HAS READ THIS SECTION 6 AND FULLY UNDERSTANDS THE LIMITATIONS WHICH IT IMPOSES UPON HIM AND HAS RECEIVED A DUPLICATE COPY OF THIS AGREEMENT FOR HIS RECORDS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive acknowledges that in the course of his employment with the Company or any of its Subsidiaries or Affiliates, or their predecessors or successors, he has been and will be given access to and has and will become familiar with their trade secrets and with other Confidential Information and that his services have been and shall be of special, unique and extraordinary value to the Company and its Subsidiaries or Affiliates. Therefore, and in further consideration of the compensation to be paid to Executive hereunder and in connection with his employment, and to protect the Company&#8217;s and its Subsidiaries&#8217; and Affiliates&#8217; Confidential Information, business interests and goodwill&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive hereby agrees that for a period commencing on the date hereof and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), he shall not, directly or indirectly, as employee, agent, consultant, stockholder, director , co-partner or in any other individual or representative capacity, own, operate, manage, control, engage in, invest in or participate in any manner in, act as a consultant or advisor to, render services for (alone or in association with any person, firm, corporation or entity), or otherwise assist any person or entity (other than the Company and its Subsidiaries) that engages in or owns, invests in, operates, manages or controls any venture or enterprise that directly or indirectly engages or is actively developing or attempting to develop in any element of the Business anywhere within a 50-mile radius of the Nashville, Tennessee metropolitan area or within a 50-mile radius of any area (or in the event such area is a major city, the metropolitan area relating to such city) in which the Company or any of its Subsidiaries on the Termination Date actively engages or is actively developing or attempting to develop in any element of the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, that nothing contained herein shall be construed to prevent Executive from investing in the stock of any competing corporation listed on a national securities exchange or traded in the over-the-counter market, but only if Executive is not involved in the business of said corporation and if Executive and his associates (as such term is defined in Regulation 14(A) promulgated under the Securities Exchange Act of 1934, as in effect on the date hereof), collectively, do not own more than an aggregate of 3% of the stock of such corporation. With respect to the </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Territory, Executive specifically acknowledges that the Company and its Subsidiaries intend to expand the Business into and throughout the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Interference with Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Without limiting the generality of the provisions of Section 7(a) hereof, Executive hereby agrees that, for a period commencing on the Commencement Date and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Solicit Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), he will not, directly or indirectly, as employee, agent, consultant, stockholder, director, partner or in any other individual or representative capacity, (i)&#160;solicit or encourage, or participate in any business which solicits or encourages (A)&#160;any person, firm, corporation or other entity which has executed, or proposes to execute, a management services agreement or other services agreement with the Company or any of its Subsidiaries at any time during the term of this Agreement , or any successor in interest to any such person, firm, corporation or other entity, for the purpose of securing business or contracts related to any element of the Business, or (B)&#160;any present customer or patient of the Company or any of its Subsidiaries or any of their Affiliated Practices to terminate or otherwise alter his, her or its relationship with the Company or any of its Subsidiaries or such Affiliated Practice&#59; provided, however, that nothing contained herein shall be construed to prohibit or restrict Executive from soliciting business from any such parties on behalf of the Company or any of its Subsidiaries in performance of his duties as an employee of the Company required under and as specifically contemplated by Section 2 above or (ii)&#160;divert, entice away, solicit or encourage, or attempt to divert, entice away, solicit or encourage, any physician who utilizes or has invested in an Affiliated Practice to become an owner, investor or user of another practice or facility that is not an Affiliated Practice or approach any such physician for any of the foregoing purposes or authorize or assist in the taking of any such action by any third party. In addition, at all times from and after the Termination Date, Executive shall not contact or communicate in any manner with any of Company&#8217;s, or any of its Subsidiaries&#8217; or Affiliates&#8217; suppliers or vendors, or any other third party providing services to the Company or any of its Subsidiaries, regarding the Company or any of its Subsidiaries or any Company- or any such Subsidiary-related matter (which suppliers, vendors or third party service providers will include, without limitation, any third party with whom the Company or any of its Subsidiaries was, during the term of Executive&#8217;s employment with the Company or any of its Subsidiaries, contemplating engaging, or negotiating with, for the future provision of products or services).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Other than in the performance of his duties hereunder, during the Non-Solicit Restrictive Period, Executive shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co-partner or in any other individual or representative capacity, employ, recruit or solicit for employment or engagement, any person who is employed or engaged by the Company or any of its Subsidiaries or any of its Affiliated Practices during the Non-Solicit Restrictive Period, or otherwise seek to influence or alter any such person&#8217;s relationship with any of the Affiliated Practices, the Company or any of its Subsidiaries&#59; provided, however that responses to a general solicitation (such as an internet or newspaper solicitation) that are not targeted towards any particular person shall not be deemed to be a violation of the restrictions set forth in this Section 7(c).</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include any practice or facility (i)&#160;in which the Company or any of its Subsidiaries has an ownership interest or (ii)&#160;that is managed by or receives other services from the Company or any of its Subsidiaries in connection with any element of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Blue Pencil</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any court of competent jurisdiction shall at any time deem the term of this Agreement or any particular Restrictive Covenant (as defined below) too lengthy or the Territory too extensive, the other provisions of this Section 7 shall nevertheless stand, the Restrictive Period herein shall be deemed to be the longest period permissible by law under the circumstances and the Territory herein shall be deemed to comprise the largest territory permissible by law under the circumstances. The court in each case shall reduce the time period and&#47;or Territory to permissible duration or size.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Covenant Not to Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Restrictive Period and thereafter, Executive shall not disparage, denigrate or derogate in any way, directly or indirectly, the Company any of its Subsidiaries or Affiliates, or any of its or their respective agents, officers, directors, employees, parent, subsidiaries, affiliates, Affiliated Practices, affiliated doctors (including any physicians who utilize or have invested in any Affiliated Practice), representatives, attorneys, executors, administrators, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Protected Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), nor shall Executive disparage, denigrate or derogate in any way, directly or indirectly, his experience with any Protected Party, or any actions or decisions made by any Protected Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive acknowledges and agrees that the covenants set forth in this Section 7 and the preceding Sections 5 and 6 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are reasonable and necessary for the protection of the business interests of the Company and its Subsidiaries and Affiliates, that irreparable injury may result to the Company and its Subsidiaries and Affiliates if Executive breaches any of the terms of said Restrictive Covenants, and that in the event of Executive&#8217;s actual or threatened breach of any such Restrictive Covenants, the Company and its Subsidiaries and Affiliates will have no adequate remedy at law. Executive accordingly agrees that in the event of any actual or threatened breach by him of any of the Restrictive Covenants, the Company and its Subsidiaries and Affiliates shall be entitled to immediate temporary injunctive and other equitable relief subject to hearing as soon thereafter as possible. Nothing contained herein shall be construed as prohibiting the Company or any of its Subsidiaries or Affiliates from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove. In addition and supplementary to other rights and remedies existing in its (or their) favor, in the event of the material breach by Executive of any of the provisions of this Section 7, the Company (and&#47;or its Subsidiaries or Affiliates) shall be entitled to require Executive to account for and pay over to the Company (and&#47;or its Subsidiaries or Affiliates) all compensation, profits, moneys, accruals, increments or other benefits actually derived from or received as a result of any transactions constituting a breach of the covenants contained in this Agreement which may require Executive to repay any severance. In addition, in the event of an alleged breach or violation by Executive of this Section 7, the restricted periods set forth in this Section 7 shall be tolled until such breach or violation has been duly cured.</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Executive understands that the foregoing restrictions may limit his ability to earn a livelihood in a business similar to the business of the Company and its Subsidiaries or Affiliates, but he nevertheless believes that he has received and will receive sufficient consideration and other benefits as an executive of the Company and as otherwise provided hereunder to clearly justify such restrictions which, in any event (given his education, skills and ability), Executive does not believe would prevent him from otherwise earning a living. Executive acknowledges that the Restrictive Covenants are reasonable and that he has reviewed the provisions of this Agreement with his legal counsel. Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such employer with a copy of such restrictions, prior to the commencement of that employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Executive &#8216;s Representations and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive hereby represents and warrants to the Company that (i)&#160;the execution , delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which he is bound, (ii)&#160;Executive is not a party to or bound by any employment agreement, noncompete agreement or confidentiality agreement with any other person or entity and (iii)&#160;upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms. Executive hereby acknowledges and represents that he has consulted with independent legal counsel regarding his rights and obligations under this Agreement and that he fully understands the terms and conditions contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During the Employment Period and thereafter, Executive shall cooperate with the Company and its Subsidiaries and Affiliates in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are in or may come into Executive&#8217;s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments). In the event the Company requires Executive&#8217;s cooperation in accordance with this Section 8(b), the Company shall reimburse Executive for reasonable travel expenses (including, without limitation, travel expenses, lodging and meals , and reasonable attorneys&#8217; fees upon submission of receipts).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sections 4 through 22 shall survive and continue in full force in accordance with their terms notwithstanding the expiration or termination of the Employment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to Executive at his last known address on the books of the Company or, in the case </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Company, to it at its principal place of business, attention of the Chief Executive Officer, or to such other address as either party may specify by notice to the other actually received.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, those documents expressly referred to herein and other documents of even date herewith, embody the complete agreement and understanding among Executive and the Company and its Subsidiaries and, as of the Effective Date, shall supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way, including, for the avoidance of doubt, the Former Employment Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in separate counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together constitute one and the same agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company and its successors and permitted assigns. Executive may not assign any of his rights or obligations hereunder without the prior written consent of the Company. The Company may (a)&#160;assign any or all of its respective rights and interests hereunder to one or more Subsidiaries or Affiliates of the Company, (b)&#160;designate one or more Subsidiaries or Affiliates of the Company to perform its obligations hereunder (in any or all of which cases the Company nonetheless shall remain responsible for the performance of all of its obligations hereunder), (c)&#160;assign its rights hereunder in connection with the sale of all or a substantial part of the business or assets of the Company or one of its Subsidiaries (whether by merger, sale of stock or assets, recapitalization or otherwise) and (d)&#160;merge any of the Subsidiaries or Affiliates with or into the Company (or vice versa). The rights of the Company hereunder are enforceable by the Company or its Subsidiaries or Affiliates, which are the intended third party beneficiaries hereof and no other third party beneficiary is so otherwise intended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Delivery by Facsimile or PDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or PDF, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute original forms thereof </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and deliver them to the other party. No party hereto shall raise the use of a facsimile machine or PDF to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile machine or PDF as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Income Tax Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive and the Company acknowledge that it is the intention of the Company to deduct all cash amounts paid under this Agreement as ordinary and necessary business expense s for income tax purposes. Executive agrees and represents that he will treat all such non-reimbursable amounts as ordinary income for income tax purposes, and should he report such amounts as other than ordinary income for income tax purposes, he will indemnify and hold the Company harmless from and against any and all taxes, penalties, interest, costs and expenses, including reasonable attorneys&#8217; and accounting fees and costs, which are incurred by Company directly or indirectly as a result thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflict of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT. THE PARTIES HERETO ALSO WAIVE ANY BOND OR SURE TY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE OTHER PARTY. THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. THE COMPANY AND EXECUTIVE FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH THEIR RESPECTIVE LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES THEIR RESPECTIVE JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE , MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTION CONTEMPLATED HEREBY. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">THE COMPANY AND EXECUTIVE HEREBY CONSENT TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE STATE IN WHICH EXECUTIVE RESIDES AND IRREVOCABLY AGREE THAT SUBJECT TO THE COMPANY&#8217;S ELECTION, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RELATING TO THIS AGREEMENT SHALL BE LITIGATED IN SUCH COURTS. EXECUTIVE ACCEPTS FOR HIMSELF AND IN CONNECTION WITH HIS PROPERTIES, GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding Section 20(a), the parties intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 5 through 7 upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold such covenants wholly or partially invalid or unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent co tenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any provision of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the maximum extent permitted by law, this Agreement shall be interpreted in such a manner that the payments to Executive under this Agreement are either exempt from, or comply with, Section 409A, including without limitation any such regulations or other guidance that may be issued after the date hereof. For purposes of Section 409A, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; as defined below, as of Executive&#8217;s termination of employment, then, to the extent any payment under this Agreement resulting from Executive&#8217;s termination of employment constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A) and to the extent required by Section 409A, no payments due under this Agreement as a result of Executive&#8217;s termination of employment may be made until the earlier of (a) the first day following the six-month anniversary of Executive&#8217;s date of termination and (b) Executive&#8217;s date of death&#59; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum as soon as reasonably practicable following the sixth month anniversary of Executive&#8217;s date of termination. For purposes of this Agreement, all references to &#8220;termination of employment&#8221; and correlative phrases shall be construed to require a &#8220;separation from service&#8221; (as defined in Treas. Reg. &#167;1.409A-l(h) after giving effect to the presumptions contained therein), and the term &#8220;specified employee&#8221; means an individual determined by the Company to be a specified employee under Treas. Reg. &#167;409A-l(i).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="i843915dfa4a2429a9ab7029fe7ed0d8c_4"></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SURGERY PARTNERS, INC.</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jennifer Baldock</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Executive Vice President and Chief Legal Officer</font></div><div style="padding-left:180pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accepted and Agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Brad Owens&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Brad Owens</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">November 12, 2019&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Employment Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>5
<FILENAME>ye2020exhibit1037.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i574072b8d1454581b8e38548c4c5b212_1"></div><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.37</font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is hereby entered into effective as of June&#160;30, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), between Surgery Partners, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Laura Brocklehurst (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall employ Executive, and Executive hereby accepts continued employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on June&#160;30, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and ending on the Termination Date, as provided for in Section 4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Position and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, Executive shall serve as the Senior Vice President and Chief Human Resources Officer. Executive shall have such responsibilities, duties and authorities, and will render such services for the Company and its Subsidiaries or Affiliates as the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may from time to time direct. Executive will devote her best efforts, energies and abilities and her full business time, skill and attention to the business and affairs of the Company and its Subsidiaries, and shall perform her duties and responsibilities to the best of her ability, in a diligent, trustworthy, businesslike and efficient manner for the purpose of advancing the businesses of Company and its Subsidiaries. Executive acknowledges that her duties and responsibilities will require her full time business efforts and agrees that during the Employment Period she will not engage in any other business activity or have any business pursuits that interfere with Executive &#8216;s duties and responsibilities under this Agreement or are competitive with the businesses of the Company. Notwithstanding the foregoing, Executive shall be permitted to devote a reasonable amount of time and effort to (i)&#160;providing service to, or serving on governing boards of, civic and charitable organizations, and (ii)&#160;personally investing and managing personal and family investments in real estate and in any corporation, partnership or other entity&#59; but in each case, only to the extent that any of the activities described in clauses (i) or (ii), individually or as a whole, do not (A)&#160;require or involve the active participation of Executive in the management of any corporation, partnership or other entity or interfere with the execution of Executive&#8217;s duties hereunder, or (B)&#160;otherwise violate any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For purposes of this Agreement, (i)&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any corporation or other entity (A)&#160;of which the securities or other ownership interests having the voting power to elect a majority of the board of directors or other governing body are, at the time of determination, owned by the Company, directly or through one or more subsidiaries or (B)&#160;to which the Company or any of its Affiliates provide management services, and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of an entity means any other person or entity, directly or indirectly controlling, controlled by or under common control with an entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, Executive&#8217;s base salary shall be $270,000 per annum, payable by the Company in regular installments in accordance with the Company&#8217; s general payroll practices , less taxes and other applicable withholdings, and subject to review and adjustment from time to time by the Board or the Compensation Committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in either case, in its discretion (as modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In addition, during the Employment Period, Executive shall be entitled to participate in all of the Company&#8217; s benefit programs for which employees of the Company are generally eligible, subject to the eligibility and participation requirements thereof, including, but not limited to, the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">medical, dental, vision, life and disability insurance, as is generally provided to other employees of the Company&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">eligibility for vacation time in accordance with the policies of the Company as from time to time in effect&#59; provided, however, that Executive shall not have less than 20 days of vacation time per calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During the Employment Period, the Company shall reimburse Executive for all reasonable out-of-pocket expenses incurred by her in the course of performing her duties and responsibilities under this Agreement which are consistent with the Company&#8217; s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company&#8217;s requirements with respect to reporting and documentation of such expenses. Executive&#8217;s right to payment or reimbursement for business expenses hereunder will be subject to the following additional rules&#58; (i)&#160;no reimbursement of any expense shall affect Executive&#8217;s right to reimbursement of any other expense in any other taxable year&#59; (ii)&#160;the amount of expenses eligible for payment or reimbursement during any calendar year will not affect the expenses eligible for payment or reimbursement in any other taxable year&#59; (iii)&#160;payment or reimbursement will be made not later than December&#160;31 of the calendar year following the calendar year in which the expense was incurred or paid, and (iv)&#160;the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In addition to the Base Salary, Executive will be eligible to receive an annual bonus of forty percent (40%) of the Base Salary, with the actual amount of any such bonus being determined by the Board or the Committee, in either case, in its discretion, based on the achievement of performance goals established annually by the Board or the Committee, as applicable. Any annual bonus payable under this Section 3(d) will be paid no later than March&#160;31st following the close of the year for which the bonus is earned.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive shall be eligible to participate in the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on terms and conditions set forth therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">All amounts payable to Executive hereunder shall be subject to all required withholdings by the Company. If additional guidance is issued under, or modification s are made to, Section 409A of the Internal Revenue Code of the Internal Revenue Code and the </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">regulations and other interpretive guidance issued thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or any other law affecting payments to be made under this Agreement, Executive agrees that the Company may take such reasonable actions and adopt such reasonable amendments as the Company believes are necessary to ensure continued compliance with the Internal Revenue Code, including Section 409A. However, the Company does not hereby or otherwise represent or warrant that any payments hereunder are or will be in compliance with Section 409A, and Executive shall be responsible for obtaining her own tax advice with regard to such matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination by Executive or the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Employment Period (i)&#160;shall terminate upon Executive&#8217;s resignation with Good Reason (as defined below) or without Good Reason, death or Incapacity (as defined below) or (ii)&#160;may be terminated by the Company at any time for Cause (as defined below) or without Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean without the written consent of Executive&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">without the express written consent of Executive, a material diminution of her position, duties, responsibilities, and status with the Company as in effect as of the Commencement Date or a material reduction of Executive&#8217;s resources as in effect on the Commencement Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">a material reduction in Executive&#8217;s Base Salary or annual bonus target percentage&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">a material reduction in the level of benefits available or awarded to Executive, other than any reduction in connection with a Company-wide reduction applicable generally to similarly situated executive officers of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">within twelve months of a Change in Control (as defined herein), a material increase in Executive&#8217;s core functional responsibilities with a corresponding material change in Executive&#8217;s core functional role without a corresponding increase in compensation, provided, however, the addition of additional facilities or territories to Executive&#8217;s oversight responsibilities or other ordinary course growth of the Company or any of its Subsidiaries or Affiliates shall not be a material increase in Executive&#8217;s core functional responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">a relocation by the Company of Executive&#8217;s primary employment location to a location which is more than 50 miles from Executive&#8217;s primary employment location on the date hereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">a material breach by the Company of the terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">but only if (x)&#160;Executive notifies the Company in writing within 90 days after the initial existence or occurrence of any of these conditions which notice describes in reasonable detail the basis for Executive&#8217;s belief that Good Reason exists and that Executive intends to resign for Good Reason and the Company, within 30 days after receipt of such notice, either fails to cure </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the condition or delivers a written notice to Executive that the Company intends not to cure such condition and (y)&#160;Executive actually resigns prior to 15 days after the earlier to occur of either the end of such 30-day cure period or delivery of such written notice by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Incapacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein shall mean that Executive is unable to perform, with or without reasonable accommodation, by reason of physical or mental incapacity, the essential duties, responsibilities and functions of her position. A medical examination by a physician selected by the Company to whom Executive or her duly appointed guardian, if any, has no reasonable objection shall determine , according to the facts then available, whether and when Incapacity has occurred. Such determination shall not be arbitrary or unreasonable, and shall be final and binding on the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein means the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">a material breach by Executive of any of the terms and conditions of this Agreement&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such material breach following the date on which Executive receives the Company&#8217;s written notice of such material breach&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Executive&#8217;s reporting to work (A)&#160;intoxicated (other than Executive &#8216;s reasonable use of alcohol in connection with business entertainment, provided, that such use of alcohol does not cause the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm) or (B)&#160;under the influence of illegal drugs&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">Executive&#8217;s use of illegal drugs (whether or not at the workplace) or other conduct causing the Company or any of its Subsidiaries or Affiliates substantial public disgrace or disrepute or economic harm&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">breach of fiduciary duty, gross negligence or willful misconduct with respect to the Company or any of its Subsidiaries or Affiliates &#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">chronic absenteeism, which shall be deemed to have occurred if Executive has at least ten absences unrelated to paid time off, disability or illness in any ten week period&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Executive&#8217;s material failure or willful refusal to substantially perform her duties, responsibilities and functions&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217; s written notice of such failure&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">Executive&#8217;s failure to comply with any of the Company&#8217;s or any of its Subsidiaries &#8216; written guidelines or procedures promulgated by the Company or any </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such Subsidiary and furnished to Executive, including, without limitation, any guidelines or procedures relating to marketing or community relations&#59; provided that, if curable, Executive shall have a reasonable period of time (which in no event shall exceed 45 days) during which to cure such failure following the date on which Executive receives the Company&#8217;s written notice of such failure&#59; or </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">Executive has committed an act or acts constituting a felony or any other act or omission involving theft, dishonesty or fraud against the Company or any of its Subsidiaries or any of their respective customers or suppliers or other business relationships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">A &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be deemed to have occurred upon any of the following events, provided that, to the extent required by Section 409A, such events would also qualify as a &#8220;change in control event&#8221; under Treas. Reg. &#167;&#160;1.409A-3(i)(5)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Upon the closing of a reorganization, merger, share exchange or consolidation, other than a reorganization, merger, share exchange or consolidation with respect to which those persons who were the beneficial owners , immediately prior to such reorganization, merger, share exchange or consolidation, of outstanding securities of the Company ordinarily having the right to vote in the election of directors own, immediately after the closing of such transaction, more than 51% of the outstanding securities of the resulting corporation ordinarily having the right to vote in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Upon approval by the stockholders of a complete liquidation and dissolution of the Company or the sale or other disposition of all or substantially all of the assets of the Company other than to a Subsidiary or Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive has the right to terminate her employment under this Agreement at any time, for any or no reason, but only after giving the Company (i)&#160;30 days prior written notice with respect to any termination without Good Reason or (ii)&#160;the number of days prior written notice set forth in the last sentence of Section 4(b) with respect to any termination with Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Compensation after Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">If the Employment Period is terminated pursuant to Executive&#8217; s resignation without Good Reason, death or Incapacity, Executive shall only be entitled to receive her Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">If the Employment Period is terminated by the Company for Cause, Executive shall only be entitled to her Base Salary through the date of termination and shall not be entitled to any other salary, bonus, compensation or benefits from the Company or its Subsidiaries, except as may be required by applicable law. In addition , in </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such event, Executive shall automatically forfeit any rights to any unvested equity owned by Executive in the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">If the Employment Period is terminated by the Company without Cause or by Executive for Good Reason, then subject to the conditions described in Section 4(g)(v) below, Executive shall be entitled to receive as severance compensation the following (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58; (A)&#160;an amount equal to twelve (12) months of Executive&#8217;s then-current annual Base Salary, payable in regular installments beginning within 30 days following the Termination Date in accordance with the Company&#8217;s general payroll practices for salaried employees &#59; (B)&#160;continuation of the welfare benefits described in Section 3(b) for twelve (12) months to the extent permissible under the terms of the relevant benefit plans at the same cost to Executive as if Executive were an active employee of the Company&#59; (C)&#160;the Bonus payable to Executive within 3 months after the end of the applicable year (to the extent not previously paid), paid in a lump sum at the time that bonuses are regularly paid to employees&#59; (D)&#160;with respect to the portion of each restricted stock award held by Executive as of date on which the Employment Period is terminated that is subject to time-based vesting (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Time-Based RSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; ), accelerated vesting of the TimeBased RSA to the vesting event next following the date on which the Employment Period is terminated&#59; and (E)&#160;with respect to the portion of each performance stock unit award held by the Executive as of the date on which the Employment Period is terminated that has been converted into &#8220;earned shares &#8220; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Earned PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), accelerated vesting of the Earned PSUs to the vesting event next following the date on which the Employment Period is terminated. For purposes of this Section 4(g), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean an amount equal to Executive&#8217;s then-current annual Base Salary, multiplied by the percentage contained in Section 3(d) hereof. For the avoidance of doubt, the unvested portion of any restricted stock awards and performance share unit awards held by Executive as of the date on which the Employment Period ends (after giving effect to the acceleration provisions set forth in subsections (D) and (E) herein and the terms and conditions of the applicable award agreements and the Surgery Partners, Inc. 2015 Omnibus Incentive Plan (as amended from time to time)) shall be forfeited and of no further force and effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">If, within 90 days prior to or 12 months following a Change in Control, either (A)&#160;the Company terminates the employment of Executive hereunder without Cause under Section 4(a) above, or (B)&#160;Executive terminates her employment for Good Reason under Section 4(b) above, then, in lieu of any other compensation that may be specified in this Agreement, the Company will pay Executive the Severance Pay in a single lump-sum payment not later than 30 days after termination. If any payment obligation under this Section 4(g) arises, no compensation received from other employment (or otherwise) will reduce the Company&#8217; s obligation to make the payment(s) described in this paragraph.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding Sections 4(g)(iii) or (iv), Executive&#8217;s right to receive Severance Pay hereunder is conditioned upon&#58; (A)&#160;Executive executing, and not revoking, a written separation agreement and general release of all claims against the </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company, its Subsidiaries and Affiliates and their respective managers, directors, officers, shareholders, members, representatives, agents, attorneys, predecessors, successors and assigns (other than a claim for the severance payments described in Section 4(g)(iii) or (iv) and Executive&#8217; s rights to future distributions and payments related to the continued ownership of any equity securities in the Company that Executive will continue to own after such termination), in form and substance acceptable to the Company, which shall among other things, contain a general release by Executive of all claims arising out of her employment and termination of employment by the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) within 30 days of Executive&#8217; s Termination Date&#59; and (B)&#160;Executive&#8217;s material compliance with all of her obligations which survive termination of this Agreement. The Severance Pay is intended to be in lieu of all other payments to which Executive might otherwise be entitled in respect of her termination without Cause or resignation with Good Reason. The Company and its Subsidiaries and Affiliates shall have no further obligations hereunder or otherwise with respect to Executive &#8216;s employment from and after the date of termination of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the Company and its Subsidiaries and Affiliates shall continue to have all other rights available hereunder (including without limitation, all rights hereunder at law or in equity).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Except as otherwise expressly provided herein, all of Executive&#8217;s rights to salary, bonuses, benefits and other compensation hereunder which might otherwise accrue or become payable after the termination of the Employment Period shall cease upon such termination , other than those expressly required under applicable law (such as COBRA). All amounts payable to Executive as severance hereunder shall be subject to all required withholdings by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Company may offset any amount Executive owes the Company or its Subsidiaries or Affiliates against any amount they or their Subsidiaries or Affiliates owe Executive hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Other than in the performance of her duties hereunder, during the Restrictive Period (as defined below) and thereafter, Executive shall keep secret and retain in strictest confidence, and shall not, without the prior written consent of the Company, furnish, make available or disclose to any third party or use for the benefit of herself or any third party, any Confidential Information. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any information relating to the business or affairs of the Company or any of its Subsidiaries or Affiliates or the Business, including but not limited to any technical or non-technical data, formulae, compilations, programs, devices , methods, techniques, designs, processes, procedures, improvements, models, manuals, financial data, acquisition strategies and information, information relating to operating procedures and marketing strategies, and any other proprietary information used by the Company or any of its Subsidiaries or Affiliates in connection with the Business, irrespective of its form&#59; provided, however, that Confidential Information shall not include any information which is in the public domain or becomes known in the industry, in each case through no wrongful  act on the part of Executive. Executive acknowledges that the Confidential Information is vital, sensitive, confidential and proprietary to </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Company and its Subsidiaries and Affiliates. Executive will immediately notify the Company of any unauthorized possession, use, disclosure, copying, removal or destruction, or attempt thereof, of any Confidential Information by anyone of which Executive becomes aware and of all details thereof. Executive shall take all reasonably appropriate steps to safeguard Confidential Information and to protect it against disclosure, misuse, espionage , loss and theft. Executive shall deliver to the Company at the termination or expiration of the Employment Period , or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, computers, printouts and software and other documents and data (and copies thereof) embodying or relating to the Confidential Information, Inventions and Discoveries (as defined below) or the business of the Company or any of its Subsidiaries or Affiliates which Executive may then possess or have under her control. Nothing in this Agreement limits, restricts or in any other way affects Executive&#8217; s communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity, or requires Executive to provide notice to the Company of the same. Executive cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (l)&#160;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspended violation of law, or (2)&#160;in a compliant or other document filed under seal in a lawsuit or other proceeding. Notwithstanding this immunity from liability, Executive may be held liable if Executive unlawfully accesses trade secrets by unauthorized means.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as used herein means the business of owning, operating, developing and&#47;or managing, or providing management or administrative services to, (a) ambulatory surgery centers anywhere in the United States or (b) physician-owned surgical hospitals within a 50 mile radius of any hospital that is owned, operated, developed or managed by the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive understands and agrees that all inventions, discoveries , ideas , improvements, whether patentable, copyrightable or not, pertaining to the Business or relating to Company&#8217;s or any of its Subsidiaries &#8216; or Affiliates&#8217; actual or demonstrably anticipated research, development or inventions (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Inventions and Discoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that result from any work performed by Executive solely or jointly with others for the Company or any of its Subsidiaries or Affiliates which Executive, solely or jointly with others, conceives, develops, or reduces to practice during the course of Executive&#8217;s employment with the Company or any of its Subsidiaries, are the sole and exclusive property of the Company. Executive will promptly disclose all such matters to the Company and will assist the Company in obtaining legal protection for Inventions and Discoveries. Executive hereby agrees on behalf of herself, her executors, legal representatives and assignees that she will assign, transfer and convey to the Company, its successors and assigns the Inventions and Discoveries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">THE COMPANY AND EXECUTIVE ACKNOWLEDGE AND AGREE THAT SECTION 6(a) SHALL NOT APPLY TO AN INVENTION OF EXECUTIVE FOR WHICH NO EQUIPMENT, SUPPLIES, FACILITY OR TRADE SECRET INFORMATION </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OF THE COMPANY OR ANY OF ITS SUBSIDIARIES WAS USED AND WHICH WAS DEVELOPED ENTIRELY ON EXECUTIVE&#8217;S OWN TIME, UNLESS (A) THE INVENTION RELATED (I) TO THE BUSINESS OF THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES OR (II) TO THE COMPANY&#8217; S OR ANY OF ITS SUBSIDIARIES &#8216; OR AFFILIATES&#8217; ACTUAL OR DEMONSTRABLY ANTICIPATED RESEARCH OR DEVELOPMENT, OR (B) THE INVENTION RESULTS FROM ANY WORK PERFORMED BY EXECUTIVE FOR THE COMPANY OR ANY OF ITS SUBSIDIARIES OR AFFILIATES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">EXECUTIVE ACKNOWLEDGES THAT SHE HAS READ THIS SECTION 6 AND FULLY UNDERSTANDS THE LIMITATIONS WHICH IT IMPOSES UPON HER AND HAS RECEIVED A DUPLICATE COPY OF THIS AGREEMENT FOR HER RECORDS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive acknowledges that in the course of her employment with the Company or any of its Subsidiaries or Affiliates, or their predecessors or successors, she has been and will be given access to and has and will become familiar with their trade secrets and with other Confidential Information and that her services have been and shall be of special, unique and extraordinary value to the Company and its Subsidiaries or Affiliates. Therefore, and in further consideration of the compensation to be paid to Executive hereunder and in connection with her employment, and to protect the Company&#8217; s and its Subsidiaries&#8217; and Affiliates&#8217; Confidential Information, business interests and goodwill&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive hereby agrees that for a period commencing on the date hereof and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), she shall not, directly or indirectly, as employee, agent, consultant, stockholder, director , co-partner or in any other individual or representative capacity, own, operate, manage, control, engage in, invest in or participate in any manner in, act as a consultant or advisor to, render services for (alone or in association with any person, firm, corporation or entity), or otherwise assist any person or entity (other than the Company and its Subsidiaries) that engages in or owns, invests in, operates, manages or controls any venture or enterprise that directly or indirectly engages or is actively developing or attempting to develop in any element of the Business anywhere within a 50-mile radius of the Nashville, Tennessee metropolitan area or within a 50-mile radius of any area (or in the event such area is a major city, the metropolitan area relating to such city) in which the Company or any of its Subsidiaries on the Termination Date actively engages or is actively developing or attempting to develop in any element of the Business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, that nothing contained herein shall be construed to prevent Executive from investing in the stock of any competing corporation listed on a national securities exchange or traded in the over-the-counter market, but only if Executive is not involved in the business of said corporation and if Executive and her associates (as such term is defined in Regulation l4(A) promulgated under the Securities Exchange Act of 1934, as in effect on the date hereof), collectively, do not own more than an aggregate of 3% of the stock of such corporation. With respect to the Territory, Executive specifically acknowledges that the Company and its Subsidiaries intend to expand the Business into and throughout the United States.</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Interference with Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Without limiting the generality of the provisions of Section 7(a) hereof, Executive hereby agrees that, for a period commencing on the Commencement Date and ending on the Termination Date, and thereafter, through the period ending twelve (12) months after the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Solicit Restrictive Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), she will not, directly or indirectly, as employee, agent, consultant, stockholder, director, partner or in any other individual or representative capacity, (i)&#160;solicit or encourage, or participate in any business which solicits or encourages (A)&#160;any person, firm, corporation or other entity which has executed, or proposes to execute, a management services agreement or other services agreement with the Company or any of its Subsidiaries at any time during the term of this Agreement , or any successor in interest to any such person, firm, corporation or other entity, for the purpose of securing business or contracts related to any element of the Business, or (B)&#160;any present customer or patient of the Company or any of its Subsidiaries or any of their Affiliated Practices to terminate or otherwise alter his, her or its relationship with the Company or any of its Subsidiaries or such Affiliated Practice&#59; provided, however, that nothing contained herein shall be construed to prohibit or restrict Executive from soliciting business from any such parties on behalf of the Company or any of its Subsidiaries in performance of her duties as an employee of the Company required under and as specifically contemplated by Section 2 above or (ii)&#160;divert, entice away, solicit or encourage, or attempt to divert, entice away, solicit or encourage, any physician who utilizes or has invested in an Affiliated Practice to become an owner, investor or user of another practice or facility that is not an Affiliated Practice or approach any such physician for any of the foregoing purposes or authorize or assist in the taking of any such action by any third party. In addition, at all times from and after the Termination Date, Executive shall not contact or communicate in any manner with any of Company&#8217;s, or any of its Subsidiaries &#8216; or Affiliates&#8217; suppliers or vendors, or any other third party providing services to the Company or any of its Subsidiaries, regarding the Company or any of its Subsidiaries or any Company- or any such Subsidiary-related matter (which suppliers, vendors or third party service providers will include, without limitation, any third party with whom the Company or any of its Subsidiaries was, during the term of Executive&#8217;s employment with the Company or any of its Subsidiaries, contemplating engaging, or negotiating with, for the future provision of products or services).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Other than in the performance of her duties hereunder, during the Non-Solicit Restrictive Period, Executive shall not, directly or indirectly, as employee, agent, consultant, stockholder, director, co-partner or in any other individual or representative capacity, employ, recruit or solicit for employment or engagement, any person who is employed or engaged by the Company or any of its Subsidiaries or any of its Affiliated Practices during the Non-Solicit Restrictive Period, or otherwise seek to influence or alter any such person&#8217;s relationship with any of the Affiliated Practices, the Company or any of its Subsidiaries&#59; provided, however that responses to a general solicitation (such as an internet or newspaper solicitation) that are not targeted towards any particular person shall not be deemed to be a violation of the restrictions set forth in this Section 7(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include any practice or facility (i)&#160;in which the Company or any of its Subsidiaries has an ownership interest or (ii)&#160;that is managed by or receives other services from the Company or any of its Subsidiaries in connection with any element of the Business.</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Blue Pencil</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any court of competent jurisdiction shall at any time deem the term of this Agreement or any particular Restrictive Covenant (as defined below) too lengthy or the Territory too extensive, the other provisions of this Section 7 shall nevertheless stand, the Restrictive Period herein shall be deemed to be the longest period permissible by law under the circumstances and the Territory herein shall be deemed to comprise the largest territory permissible by law under the circumstances. The court in each case shall reduce the time period and&#47;or Territory to permissible duration or size.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Covenant Not to Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Restrictive Period and thereafter, Executive shall not disparage, denigrate or derogate in any way, directly or indirectly, the Company any of its Subsidiaries or Affiliates, or any of its or their respective agents, officers, directors, employees, parent, subsidiaries, affiliates, Affiliated Practices, affiliated doctors (including any physicians who utilize or have invested in any Affiliated Practice), representatives, attorneys, executors, administrators, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Protected Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), nor shall Executive disparage, denigrate or derogate in any way, directly or indirectly, her experience with any Protected Party, or any actions or decisions made by any Protected Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive acknowledges and agrees that the covenants set forth in this Section 7 and the preceding Sections 5 and 6 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are reasonable and necessary for the protection of the business interests of the Company and its Subsidiaries and Affiliates, that irreparable injury may result to the Company and its Subsidiaries and Affiliates if Executive breaches any of the terms of said Restrictive Covenants , and that in the event of Executive&#8217;s actual or threatened breach of any such Restrictive Covenants, the Company and its Subsidiaries and Affiliates will have no adequate remedy at law. Executive accordingly agrees that in the event of any actual or threatened breach by her of any of the Restrictive Covenants , the Company and its Subsidiaries and Affiliates shall be entitled to immediate temporary injunctive and other equitable relief subject to hearing as soon thereafter as possible. Nothing contained herein shall be construed as prohibiting the Company or any of its Subsidiaries or Affiliates from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of any damages which it is able to prove. In addition and supplementary to other rights and remedies existing in its (or their) favor, in the event of the material breach by Executive of any of the provisions of this Section 7, the Company (and&#47;or its Subsidiaries or Affiliates) shall be entitled to require Executive to account for and pay over to the Company (and&#47;or its Subsidiaries or Affiliates) all compensation, profits, moneys, accruals, increments or other benefits actually derived from or received as a result of any transactions constituting a breach of the covenants contained in this Agreement which may require Executive to repay any severance. In addition, in the event of an alleged breach or violation by Executive of this Section 7, the restricted periods set forth in this Section 7 shall be tolled until such breach or violation has been duly cured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Executive understands that the foregoing restrictions may limit her ability to earn a livelihood in a business similar to the business of the Company and its Subsidiaries or Affiliates, but she nevertheless believes that she has received and will receive sufficient consideration and other benefits as an executive of the Company and as otherwise provided </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">hereunder to clearly justify such restrictions which, in any event (given her education, skills and ability), Executive does not believe would prevent her from otherwise earning a living. Executive acknowledges that the Restrictive Covenants are reasonable and that she has reviewed the provisions of this Agreement with her legal counsel. Executive shall inform any prospective or future employer of any and all restrictions contained in this Agreement and provide such employer with a copy of such restrictions, prior to the commencement of that employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Executive &#8216;s Representations and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive hereby represents and warrants to the Company that (i)&#160;the execution , delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Executive is a party or by which she is bound, (ii)&#160;Executive is not a party to or bound by any employment agreement, noncompete agreement or confidentiality agreement with any other person or entity and (iii)&#160;upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive, enforceable in accordance with its terms. Executive hereby acknowledges and represents that she has consulted with independent legal counsel regarding her rights and obligations under this Agreement and that she fully understands the terms and conditions contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During the Employment Period and thereafter, Executive shall cooperate with the Company and its Subsidiaries and Affiliates in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are in or may come into Executive&#8217; s possession, all at times and on schedules that are reasonably consistent with Executive&#8217;s other permitted activities and commitments). In the event the Company requires Executive&#8217;s cooperation in accordance with this Section 8(b), the Company shall reimburse Executive for reasonable travel expenses (including, without limitation, travel expenses, lodging and meals , and reasonable attorneys&#8217; fees upon submission of receipts).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Sections 4 through 22 shall survive and continue in full force in accordance with their terms notwithstanding the expiration or termination of the Employment Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notices provided for in this Agreement shall be in writing and shall be effective when delivered in person or deposited in the United States mail, postage prepaid, and addressed to Executive at her last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Chief Executive Officer, or to such other address as either party may specify by notice to the other actually received.</font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Complete Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, those documents expressly referred to herein and other documents of even date herewith, embody the complete agreement and understanding among Executive and the Company and its Subsidiaries and, as of the Effective Date, shall supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way, including, for the avoidance of doubt, the Former Employment Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Strict Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The language used in this Agreement will be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in separate counterparts (including by facsimile or PDF signature pages), each of which is deemed to be an original and all of which taken together constitute one and the same agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company and its successors and permitted assigns. Executive may not assign any of her rights or obligations hereunder without the prior written consent of the Company. The Company may (a)&#160;assign any or all of its respective rights and interests hereunder to one or more Subsidiaries or Affiliates of the Company, (b)&#160;designate one or more Subsidiaries or Affiliates of the Company to perform its obligations hereunder (in any or all of which cases the Company nonetheless shall remain responsible for the performance of all of its obligations hereunder), (c)&#160;assign its rights hereunder in connection with the sale of all or a substantial part of the business or assets of the Company or one of its Subsidiaries (whether by merger, sale of stock or assets, recapitalization or otherwise) and (d)&#160;merge any of the Subsidiaries or Affiliates with or into the Company (or vice versa). The rights of the Company hereunder are enforceable by the Company or its Subsidiaries or Affiliates, which are the intended third party beneficiaries hereof and no other third party beneficiary is so otherwise intended .</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Delivery by Facsimile or PDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or PDF, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute original forms thereof and deliver them to the other party. No party hereto shall raise the use of a facsimile machine or PDF to deliver a signature or the fact that any signature or agreement or instrument was </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">transmitted or communicated through the use of a facsimile machine or PDF as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Income Tax Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive and the Company acknowledge that it is the intention of the Company to deduct all cash amounts paid under this Agreement as ordinary and necessary business expense s for income tax purposes. Executive agrees and represents that she will treat all such non-reimbursable amounts as ordinary income for income tax purposes, and should she report such amounts as other than ordinary income for income tax purposes, she will indemnify and hold the Company harmless from and against any and all taxes, penalties, interest, costs and expenses, including reasonable attorneys&#8217; and accounting fees and costs, which are incurred by Company directly or indirectly as a result thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the laws of the state in which Executive resides, without giving effect to provisions thereof regarding conflict of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. THE PARTIES HERETO HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT. THE PARTIES HERETO ALSO WAIVE ANY BOND OR SURE TY OR SECURITY UPON SUCH BOND WHICH MIGHT, BUT FOR THIS WAIVER, BE REQUIRED OF THE OTHER PARTY. THE PARTIES HERETO ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT AND THAT EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. THE COMPANY AND EXECUTIVE FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH THEIR RESPECTIVE LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES THEIR RESPECTIVE JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE , MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTION CONTEMPLATED HEREBY. IN THE EVENT OF LITIGATION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT .</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">THE COMPANY AND EXECUTIVE HEREBY CONSENT TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED WITHIN THE STATE IN WHICH EXECUTIVE RESIDES AND IRREVOCABLY AGREE THAT SUBJECT TO THE COMPANY&#8217; S ELECT IO N, ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE LITIGATED IN SUCH COURTS. EXECUTIVE ACCEPTS FOR HERSELF AND IN CONNECTION WITH her PROPERTIES, </font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GENERALLY AND UNCONDITIONALLY, THE NONEXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WA IVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY AGREES TO BE BOUND BY ANY JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding Section 20(a), the parties intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 5 through 7 upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold such covenants wholly or partially invalid or unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties that such determination not bar or in any way affect the Company&#8217;s right to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent co tenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any provision of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the maximum extent permitted by law, this Agreement shall be interpreted in such a manner that the payments to Executive under this Agreement are either exempt from, or comply with, Section 409A, including without limitation any such regulations or other guidance that may be issued after the date hereof. For purposes of Section 409A, each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; as defined below, as of Executive&#8217;s termination of employment, then, to the extent any payment under this Agreement resulting from Executive&#8217;s termination of employment constitutes deferred compensation (after taking into account any applicable exemptions from Section 409A) and to the extent required by Section 409A, no payments due under this Agreement as a result of Executive&#8217;s termination of employment may be made until the earlier of (a) the first day following the six-month anniversary of Executive&#8217;s date of termination and (b) Executive&#8217;s date of death&#59; provided, however, that any payments delayed during this six-month period shall be paid in the aggregate in a lump sum as soon as reasonably practicable following the sixth month anniversary of Executive&#8217;s date of termination. For purposes of this Agreement, all references to &#8220;termination of employment&#8221; and correlative phrases shall be construed to require a &#8220;separation from service&#8221; (as defined in Treas. Reg. &#167;I .409A-l(h) after giving effect to the presumptions contained therein), and the term &#8220;specified employee&#8221; means an individual determined by the Company to be a specified employee under Treas. Reg. &#167;409A-l(i).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div><font><br></font></div><div style="height:67pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="i574072b8d1454581b8e38548c4c5b212_4"></div><hr style="page-break-after:always"><div style="min-height:75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SURGERY PARTNERS, INC.</font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font><br></font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer Baldock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jennifer Baldock</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Executive Vice President and Chief Legal Officer</font></div><div style="padding-left:180pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accepted and Agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Laura Brocklehurst&#160;&#160;&#160;&#160;   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Laura Brocklehurst</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">July 30, 2019&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Employment Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>ye2020exhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i708d9a823fc54688bb9e72e0b431c33a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Surgery Partners, Inc.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Entity Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Doing Business As</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advanced Pain Institute Treatment Center, LLC</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advanced Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nebraska</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A&#38;S Management, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Afshin Gerayli, MD</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pain Specialists of Orange County</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AllCare Holdco PC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambulatory Resource Centres Investment Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambulatory Resource Centres of Washington, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ambulatory Resource Centres of Wilmington, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anderson &#38; Shapiro Eye Surgeons, S.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anesthesiology Professional Services, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animas Surgical Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">APS of Hammond, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">APS of Jonesboro, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARC Development, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARC Financial Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARC Kentucky, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARC Kentucky&#47;Louisville, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARC of Bellingham, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARC of Georgia, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premier Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Armenia Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC Gamma Partners, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">West Kendall Surgical Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baton Rouge Anesthesia Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bayside Endoscopy Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhode Island</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BBH Holdings of Idaho Falls, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Birmingham Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Blue Ridge Surgical Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Boulder Spine Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimally Invasive Spine Institute</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazos Valley Physicians Alliance</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazos Valley Physicians Organization MSO, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bristol Spine Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Renaissance Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cache Valley Specialty Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utah</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canyon Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cape Coral Ambulatory Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cape Coral Anesthesia Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiac Cath Lab of Idaho Falls, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Eagle Rock Outpatient Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CBSH, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CBSH Physicians Organization</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CC Pocatello, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCIF, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chesterfield Spine Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">St. Louis Spine and Orthopedic Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CMSC, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Montana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coastal Bend Medical Park, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coastal Bend Surgery Center, Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coastal Pain Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cold Springs Medical Surgical Group, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collier Anesthesia Pain, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Community Care Channing Way, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Community Care Rexburg, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Community Care West Side, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Community Hospital Holding Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Community Hospital Management Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consultants in Pain Medicine, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crescent View Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cypress Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware Outpatient Center for Surgery, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dupont Holdco PC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kentucky</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">El Paso Specialty Hospital, Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">El Paso Specialty Physicians Group</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eyes on Stark Surgery Center, LLC </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vista Surgical Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fairfield Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Connecticut</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gainesville Eye Physicians, P.A.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gold Coast Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gulf Coast Surgical Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grand Teton Surgical Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Great Falls Clinic Surgery Center, L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Montana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hammond Anesthesia Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Haverford Management Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Heart Hospital of BK, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bakersfield Heart Hospital</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho Falls ASC, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho Falls Community Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Honolulu Sports and Spine Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IFSC Acquisition, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interventional Spine Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPM Surgery Centers, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SpinalCARE Surgicenter</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jacksonville Beach Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jacksonville Beach Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jenkins County Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jonesboro Anesthesia Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arkansas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kent, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhode Island</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lafayette Surgical Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lake Mary Surgery Center, L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">La Peer Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Largo Endoscopy Center, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tampa Bay Regional Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Largo Surgery, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">West Bay Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Laser and Outpatient Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Logan Laboratories, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lubbock Heart Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lubbock Heart &#38; Surgical Hospital</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Center Endoscopy, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Midwest Uncuts, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Iowa</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Midwest Labs</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Millenia Surgery Center, L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimally Invasive Surgical and Neuroscience Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mission Hills Surgicenter, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mission Hills Pain Treatment Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Montana Health Partners, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Montana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mountain View Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MV Oncology, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MV Pocatello ENT, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH Anesthesia, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eagle Rock Anesthesia</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH BMC, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH Endoscopy, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH Idaho Falls Oncology, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH Parkway, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH PC Specialists, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH PIC, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH PMHS, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH NWSH, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH SNF Holding, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MVH Surgical Specialists, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Surgical Hospitals, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoSpine Puyallup Spine Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Microsurgical Spine Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoSpine Surgery of Puyallup, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoSpine Surgery, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina Specialty Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Dakota Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Idaho Day Surgery, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Northwest Ambulatory Surgery Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bellingham Ambulatory Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Acquisition Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premier Vision Buying Group</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Buyers Edge</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Alliance</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Eye Surgery Center of North County, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Woodcrest Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Eye Surgery Center of Overland Park, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Management of Kansas City, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Missouri</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Management Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed of Bethlehem, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed of Laredo, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed of Lebanon, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed of San Antonio, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed of Texas, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed of Wisconsin, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Baton Rouge, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interventional Pain Management Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Chattanooga, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Chicago-Northshore, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Eye Surgery Center &#8211; Northshore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Cleveland, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Surgery Center of Cleveland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Colorado Springs, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Ambulatory Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Denver, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colorado Outpatient Eye Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Jonesboro, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eye Surgery Center of Arkansas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Madison, Limited Partnership</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Nashua, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nashua Eye Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Oak Lawn, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Center for Reconstructive Surgery</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Orlando, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Downtown Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of San Antonio, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">American Surgery Centers of South Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Sandusky, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center of Sandusky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of St. Peters, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">St. Peters Ambulatory Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Tyler, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Cataract Center of East Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Warrensburg, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center of Warrensburg</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eye Surgery Center of Warrensburg</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed Surgery Center of Whittier, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Center for Outpatient Surgery</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NovaMed, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH California, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Connecticut, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Connecticut</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Durham, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH El Paso Specialty Hospital, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH El Paso, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Georgia, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Logan, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utah</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Louisiana, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Management of Arizona, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arizona</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Management of California, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Mesa, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arizona</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Michigan, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH North Idaho, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Idaho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH San Antonio Surgical Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Texas, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSH Wisconsin, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oak Leaf Surgical Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wisconsin</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ocean State Endoscopy Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhode Island</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orange City Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthopedic Surgery Center of Asheville, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthopedic Surgery Center of Asheville, Limited</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthopedic &#38; Spine Surgical Hospital of South Texas, LP</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Park Place Surgery Center, L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Permian Basin Surgical Care Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Physicians Medical Center, L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Physicians Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lee Island Coast Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PMCROS, L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portsmouth, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSC Development Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSC Operating Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSHS Alpha Partners, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lake Worth Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSHS Beta Partners, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Gables Surgical Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quahog Holding Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quantum Enterprises, PLLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colorado</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Riverside Billing &#38; Management Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Riverside Spine &#38; Pain Physicians, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Riverside Surgical Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SAM Holdco PC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Santa Barbara ASC Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sarasota Ambulatory Surgery Center, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARC&#47;Asheville, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARC&#47;Ft. Myers, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARC&#47;Georgia, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARC&#47;Kent, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARC&#47;Largo Endoscopy, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARC&#47;Largo, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARC&#47;Providence, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARC&#47;St. Charles, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SCA Holdco PC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SCNA Holdco PC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Screven County Family Health Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Screven County Hospital, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sequoia Surgical Center Holding Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sequoia Surgical Center, LP</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sequoia Surgical Pavilion, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SGRY, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SGRY Holdings, LP</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Skyway Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBI DOCS, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBI Great Falls, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBI Havertown, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBI Idaho, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBI LHH, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBI Portsmouth, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBI STLWSC, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBIMS Birmingham, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBIMS Durango, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBIMS Florida I, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBIMS Kirkwood, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBIMS Steubenville, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBIMS Wichita, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBISS Beverly Hills, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBISS Chesterfield, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBISS Encino, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBISS Irvine, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMBISS Thousand Oaks, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Sound Neurosurgery, PLLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP California Management, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP Gainesville Management, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP Holdco I, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP Louisiana, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Louisiana</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP Management Services, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SymbionARC Management Services</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners Management Services, Inc.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SGRY SP Management Services, Inc.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SGRY Surgery Partners Management Services, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP Maury County, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP North Dakota, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP Physician Management, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SP Practice Management, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Space Coast Surgery Center LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Surgical Center of Beverly Hills, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Surgical Center of Encino, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Surgical Center of Encino, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Surgical Center of Irvine, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Surgical Center of Irvine, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specialty Surgical Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">St. Louis Women&#8217;s Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">St. Louis Women's Multispecialty Surgery Center</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">St. Raphael's Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">STSSH Physicians Organization</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center of Fremont, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center of Kalamazoo, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center of Lebanon, LP</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Physicians Surgical Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center of Pennsylvania, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Center Partners, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Timberlake Surgery Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners Acquisition Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of Coral Gables, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of Lake Mary, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of Lake Worth, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of Merritt Island, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of Millenia, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of Park Place, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of Sarasota, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of West Kendall, L.L.C.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners of Westchase, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgery Partners, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SGRY SP, LLC</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Symbion Ambulatory Resource Centres, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Symbion Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SymbionARC Support Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tampa Pain Relief Center, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Central Florida Pain Relief Centers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Orthopedic Partners</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Pain Institute - Melbourne</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Pain Institute - Merritt Island</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Pain Institute - Palm Bay</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florinda Pain Institute - Pineda</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Pain Institute - Titusville</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Pain Institute - Viera</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Pain Relief Centers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida Spine Sports and Rehabilitation Center</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jacksonville Pain Relief Center</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kaizen Orthopedics</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Village Urgent Care</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orlando Pain Relief Center</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pain Institute Of Tampa</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pain Management of Brandon</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pain Medicine Institute</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palm Beach Pain Relief Center</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rehabilitation Medical Group</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sarasota Pain Relief Center - Bee Ridge</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sarasota Pain Relief Center - Bradenton</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sarasota Pain Relief Center - CPCS</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sarasota Pain Relief Center - Downtown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sarasota Pain Relief Center - PMC</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sarasota Pain Relief Center - Venice</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sarasota Pain Relief Center</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Florida Pain Relief Center - Boynton Beach</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Florida Pain Relief Center</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tampa Pain Relief Center - Himes</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tattnall Hospital Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texarkana Surgery Center GP, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texarkana Surgery Center, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas Physician Group</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austin Wound Care and Hyperbaric Center</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Center for Special Surgery, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Center for Specialized Surgery, LP</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Surgery Center of Ocala, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tracy Surgery Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UniPhy Healthcare of Johnson City VI, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United ASC Holding Company, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valley Ambulatory Surgery Center, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valley Surgical Center, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VASC, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">West Bloomfield Surgery Center LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Westchase Surgery Center, Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wilmington Surgery Center, L.P.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ye2020exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i53a1bb78f60041448c29d87dcffd5443_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 23.1 </font></div><div style="margin-top:9pt;text-align:right"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in Registration Statement Nos. 333-207298 and 333-233223 on Form S-8 and Registration Statement Nos. 333-235664 and 333-252399 on Form S-3 of our reports dated March 10, 2021, relating to the financial statements of Surgery Partners, Inc. and subsidiaries (the &#8220;Company&#8221;) and the effectiveness of the Company's internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 10, 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>ye2020exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ibf18c11f54a44ea8909192b5980559ba_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, J. Eric Evans, certify that&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Surgery Partners, Inc.&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:13pt;margin-top:5pt;padding-left:180pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  March&#160;10, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>ye2020exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9cd2063e465e4398b221de7d95364270_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="padding-left:18pt;text-align:right;text-indent:-18pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Thomas F. Cowhey, certify that&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Surgery Partners, Inc.&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:13.5pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:20.25pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:13pt;margin-top:5pt;padding-left:180pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  Thomas F. Cowhey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas F. Cowhey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  March&#160;10, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>ye2020exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia2052c44ed29453e83ec46017622217e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the Annual Report of Surgery Partners, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein. </font></div><div style="margin-bottom:13pt;margin-top:5pt;padding-left:180pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J. Eric Evans</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  March&#160;10, 2021 </font></div><div style="margin-bottom:13pt;margin-top:5pt;padding-left:180pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:304.50pt"><tr><td style="width:1.0pt"></td><td style="width:22.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;  Thomas F. Cowhey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas F. Cowhey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;  March&#160;10, 2021</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>sgry-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:934c24c6-c60d-49cc-a057-94123601eeba,g:155ec3a3-79d5-4a25-a7e0-562ed3402740-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgry="http://www.surgerypartners.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.surgerypartners.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgry-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.surgerypartners.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.surgerypartners.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPolicies" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesPolicies" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesTables" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesOrganizationDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails">
        <link:definition>2404401 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesCARESACTDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails">
        <link:definition>2405402 - Disclosure - Organization and Summary of Accounting Policies - CARES ACT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails">
        <link:definition>2406403 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails">
        <link:definition>2407404 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails">
        <link:definition>2408405 - Disclosure - Organization and Summary of Accounting Policies - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails">
        <link:definition>2409406 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails">
        <link:definition>2410407 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2411408 - Disclosure - Organization and Summary of Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails">
        <link:definition>2412409 - Disclosure - Organization and Summary of Accounting Policies - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails">
        <link:definition>2413410 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails" roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails">
        <link:definition>2414411 - Disclosure - Organization and Summary of Accounting Policies - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposals" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposals">
        <link:definition>2115102 - Disclosure - Acquisitions and Disposals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsTables" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables">
        <link:definition>2316302 - Disclosure - Acquisitions and Disposals (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsAcquisitionsDetails" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails">
        <link:definition>2417412 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2418413 - Disclosure - Acquisitions and Disposals - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDisposalsDisposalsDetails" roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails">
        <link:definition>2419414 - Disclosure - Acquisitions and Disposals - Disposals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.surgerypartners.com/role/PropertyandEquipment">
        <link:definition>2120103 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentTables">
        <link:definition>2321303 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetails" roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails">
        <link:definition>2422415 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyandEquipmentDetails" roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails">
        <link:definition>2423416 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssets">
        <link:definition>2124104 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2325304 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails">
        <link:definition>2426417 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails" roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails">
        <link:definition>2427418 - Disclosure - Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails" roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails">
        <link:definition>2428419 - Disclosure - Goodwill and Intangible Assets - Summary of Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails" roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails">
        <link:definition>2429420 - Disclosure - Goodwill and Intangible Assets - Future Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.surgerypartners.com/role/LongTermDebt">
        <link:definition>2130105 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.surgerypartners.com/role/LongTermDebtTables">
        <link:definition>2331305 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofLongTermDebtDetails" roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails">
        <link:definition>2432421 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofLongTermDebtDetails_1" roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails_1">
        <link:definition>2432421 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails">
        <link:definition>2433422 - Disclosure - Long-Term Debt - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt6750SeniorUnsecuredNotesdue2025Details" roleURI="http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details">
        <link:definition>2434423 - Disclosure - Long-Term Debt - 6.750% Senior Unsecured Notes due 2025 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt10000SeniorUnsecuredNotesdue2027Details" roleURI="http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details">
        <link:definition>2435424 - Disclosure - Long-Term Debt - 10.000% Senior Unsecured Notes due 2027 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails" roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails">
        <link:definition>2436425 - Disclosure - Long-Term Debt - Summary of Scheduled Maturities of Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.surgerypartners.com/role/Leases">
        <link:definition>2137106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.surgerypartners.com/role/LeasesTables">
        <link:definition>2338306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" roleURI="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails">
        <link:definition>2439426 - Disclosure - Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseExpenseandCashFlowInformationDetails" roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails">
        <link:definition>2440427 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>2441428 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>2441428 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemablePreferredStock" roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStock">
        <link:definition>2142107 - Disclosure - Redeemable Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemablePreferredStockTables" roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStockTables">
        <link:definition>2343307 - Disclosure - Redeemable Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemablePreferredStockAdditionalInformationDetails" roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails">
        <link:definition>2444429 - Disclosure - Redeemable Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivities" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivities">
        <link:definition>2145108 - Disclosure - Derivatives and Hedging Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesTables" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables">
        <link:definition>2346308 - Disclosure - Derivatives and Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativesandHedgingActivitiesDetails" roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails">
        <link:definition>2447430 - Disclosure - Derivatives and Hedging Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.surgerypartners.com/role/EarningsPerShare">
        <link:definition>2148109 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.surgerypartners.com/role/EarningsPerShareTables">
        <link:definition>2349309 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.surgerypartners.com/role/EarningsPerShareDetails">
        <link:definition>2450431 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.surgerypartners.com/role/IncomeTaxes">
        <link:definition>2151110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.surgerypartners.com/role/IncomeTaxesTables">
        <link:definition>2352310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2453432 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitExpenseDetails" roleURI="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails">
        <link:definition>2454433 - Disclosure - Income Taxes - Income Tax (Benefit) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxRateReconciliationDetails" roleURI="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails">
        <link:definition>2455434 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails" roleURI="http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails">
        <link:definition>2456435 - Disclosure - Income Taxes - Approx. Tax Effects of Temporary Differences, Deferred Tax Asset and Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>2457436 - Disclosure - Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation" roleURI="http://www.surgerypartners.com/role/EquityBasedCompensation">
        <link:definition>2158111 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationTables" roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationTables">
        <link:definition>2359311 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationAdditionalInformationDetails" roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails">
        <link:definition>2460437 - Disclosure - Equity-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails" roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails">
        <link:definition>2461438 - Disclosure - Equity-Based Compensation - Summary of Restricted and Performance Share-Based Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationFairValueAssumptionsDetails" roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails">
        <link:definition>2462439 - Disclosure - Equity-Based Compensation - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationSummaryofOptionsActivityDetails" roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails">
        <link:definition>2463440 - Disclosure - Equity-Based Compensation - Summary of Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.surgerypartners.com/role/EmployeeBenefitPlans">
        <link:definition>2164112 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails">
        <link:definition>2465441 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilities" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilities">
        <link:definition>2166113 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilitiesTables" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables">
        <link:definition>2367312 - Disclosure - Other Current Liabilities - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails">
        <link:definition>2468442 - Disclosure - Other Current Liabilities - Schedule of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.surgerypartners.com/role/CommitmentsandContingencies">
        <link:definition>2169114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2470443 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.surgerypartners.com/role/SegmentReporting">
        <link:definition>2171115 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.surgerypartners.com/role/SegmentReportingTables">
        <link:definition>2372313 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" roleURI="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails">
        <link:definition>2473444 - Disclosure - Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails">
        <link:definition>2474445 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.surgerypartners.com/role/SubsequentEvents">
        <link:definition>2175116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails">
        <link:definition>2476446 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" abstract="false" name="DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" abstract="false" name="NumberOfSurgicalFacilitiesOwnedMajorityInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_SurgicalFacilitiesExistingMarketsMember" abstract="true" name="SurgicalFacilitiesExistingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestRollForward" abstract="true" name="RedeemableNoncontrollingInterestRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" abstract="false" name="LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_AllianceMember" abstract="true" name="AllianceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_HealthcareOrganizationPatientServiceMember" abstract="true" name="HealthcareOrganizationPatientServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" abstract="false" name="DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_A2017TermLoanMaturing2024Member" abstract="true" name="A2017TermLoanMaturing2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_COVID19PandemicMember" abstract="true" name="COVID19PandemicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock" abstract="false" name="BusinessCombinationsAndDisposalsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgry_DebtInstrumentNetLeverageRatio" abstract="false" name="DebtInstrumentNetLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="sgry_FacilitiesAmbulatorySurgeryCentersMember" abstract="true" name="FacilitiesAmbulatorySurgeryCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_DisposalGroupThreeMember" abstract="true" name="DisposalGroupThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_TemporaryEquityThresholdSharePrice" abstract="false" name="TemporaryEquityThresholdSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="sgry_SurgicalFacilityMember" abstract="true" name="SurgicalFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_OpticalProductsReceivable" abstract="false" name="OpticalProductsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DebtInstrumentPrepaymentPenaltyAmount" abstract="false" name="DebtInstrumentPrepaymentPenaltyAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_EffectiveIncomeTaxReconciliationDivestitureAmount" abstract="false" name="EffectiveIncomeTaxReconciliationDivestitureAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_TemporaryEquityMaximumCashDividendDeclarable" abstract="false" name="TemporaryEquityMaximumCashDividendDeclarable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" abstract="false" name="NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgry_PrivateInsuranceMember" abstract="true" name="PrivateInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_SurgicalFacilitiesNewMarketMember" abstract="true" name="SurgicalFacilitiesNewMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgry_SeniorUnsecuredNotesDue2027Member" abstract="true" name="SeniorUnsecuredNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_A2015OmnibusIncentivePlanMember" abstract="true" name="A2015OmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" abstract="false" name="MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DeferredTaxAssetsRightOfUse" abstract="false" name="DeferredTaxAssetsRightOfUse" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_RedeemablePreferredStockTextBlock" abstract="false" name="RedeemablePreferredStockTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgry_BusinessCombinationsAndDisposalsAbstract" abstract="true" name="BusinessCombinationsAndDisposalsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_FacilitiesSurgicalHospitalsMember" abstract="true" name="FacilitiesSurgicalHospitalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_FurnitureAndEquipmentMember" abstract="true" name="FurnitureAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_OperatingAndFinanceLeaseExpense" abstract="false" name="OperatingAndFinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DebtInstrumentRedemptionPeriodSixMember" abstract="true" name="DebtInstrumentRedemptionPeriodSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_GovernmentRevenueMember" abstract="true" name="GovernmentRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_BainCapitalMember" abstract="true" name="BainCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_VariableAndShortTermLeaseCost" abstract="false" name="VariableAndShortTermLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_BusinessCombinationGainLossOnAcquisitionEscrow" abstract="false" name="BusinessCombinationGainLossOnAcquisitionEscrow" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DebtInstrumentTotalCommitmentThreshold" abstract="false" name="DebtInstrumentTotalCommitmentThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgry_DeferredEmployeeRelatedLiabilitiesCurrent" abstract="false" name="DeferredEmployeeRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" abstract="false" name="GainLossOnDispositionOfAssetsAndDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_PublicStockOfferingFirmSharesMember" abstract="true" name="PublicStockOfferingFirmSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_CostReportLiabilitiesCurrent" abstract="false" name="CostReportLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" abstract="false" name="NumberOfSurgicalFacilitiesOwnedConsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" abstract="false" name="EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_EmployeeStockOptionsAndStockAppreciationRightsMember" abstract="true" name="EmployeeStockOptionsAndStockAppreciationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" abstract="false" name="DeferredIncomeTaxLiabilitiesNetOfDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_A2018IncrementalTermLoanMember" abstract="true" name="A2018IncrementalTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_SeniorUnsecuredNotesDue2025Member" abstract="true" name="SeniorUnsecuredNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_PhysicianPracticeMember" abstract="true" name="PhysicianPracticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_HealthcareOrganizationOtherServiceMember" abstract="true" name="HealthcareOrganizationOtherServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="EarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_OpticalServicesMember" abstract="true" name="OpticalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_NumberOfSurgicalFacilitiesOwned" abstract="false" name="NumberOfSurgicalFacilitiesOwned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_DebtInstrumentQuarterlyMaturityInstallments" abstract="false" name="DebtInstrumentQuarterlyMaturityInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgry_ProceedsFromGovernmentAssistance" abstract="false" name="ProceedsFromGovernmentAssistance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" abstract="false" name="NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" abstract="false" name="GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DebtInstrumentMarginInAdditionToBaseRate" abstract="false" name="DebtInstrumentMarginInAdditionToBaseRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgry_A2020IncrementalLoansMember" abstract="true" name="A2020IncrementalLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_NotMateriallyMoreRestrictiveMember" abstract="true" name="NotMateriallyMoreRestrictiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_DebtInstrumentAlternateBaseRateFloor" abstract="false" name="DebtInstrumentAlternateBaseRateFloor" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" abstract="false" name="IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_SurgicalFacilityAndPhysicianPracticeMember" abstract="true" name="SurgicalFacilityAndPhysicianPracticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_InterestLimitationMember" abstract="true" name="InterestLimitationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_BusinessCombinationContingentAcquisitionExpense" abstract="false" name="BusinessCombinationContingentAcquisitionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_NotesPayableAndSecuredLoansMember" abstract="true" name="NotesPayableAndSecuredLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_DisposalGroupOneMember" abstract="true" name="DisposalGroupOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityIncrease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_VariableInterestEntityNumberOfFacilities" abstract="false" name="VariableInterestEntityNumberOfFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" abstract="false" name="DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_MateriallyMoreRestrictiveMember" abstract="true" name="MateriallyMoreRestrictiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgry_PhysicianIncomeGuaranteesMember" abstract="true" name="PhysicianIncomeGuaranteesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_AncillaryServicesMember" abstract="true" name="AncillaryServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" abstract="false" name="ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgry_SelfPayRevenueMember" abstract="true" name="SelfPayRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_DefinedContributionPlanVestingPeriod" abstract="false" name="DefinedContributionPlanVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgry_SurgicalFacilityServicesMember" abstract="true" name="SurgicalFacilityServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_OtherServicesMember" abstract="true" name="OtherServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_MedicalEquipmentMember" abstract="true" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable" abstract="false" name="DeferredTaxAssetsAffiliateIndebtednessReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_TaxReceivableAgreementExpenseBenefit" abstract="false" name="TaxReceivableAgreementExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" abstract="false" name="GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_TemporaryEquityThresholdTradingDays" abstract="false" name="TemporaryEquityThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_StartUpActivitiesStartUpCosts" abstract="false" name="StartUpActivitiesStartUpCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_TemporaryEquityThresholdConsecutiveTradingDays" abstract="false" name="TemporaryEquityThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgry_FinanceLeaseCost1Abstract" abstract="true" name="FinanceLeaseCost1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" abstract="false" name="BusinessCombinationIntegrationRelatedCostsAndMergerCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_TaxReceivableAgreementLiabilityCurrent" abstract="false" name="TaxReceivableAgreementLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_FinanceLeasePrincipalAndInterestPayments" abstract="false" name="FinanceLeasePrincipalAndInterestPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_ManagementRightsMember" abstract="true" name="ManagementRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_SurgeryPartnersIncMember" abstract="true" name="SurgeryPartnersIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract" abstract="true" name="RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" abstract="false" name="BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_OtherPatientServiceRevenueSourcesMember" abstract="true" name="OtherPatientServiceRevenueSourcesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_GrantRevenue" abstract="false" name="GrantRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" abstract="false" name="RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" abstract="false" name="CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" abstract="false" name="CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgry_DisposalGroupTwoMember" abstract="true" name="DisposalGroupTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" abstract="false" name="CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" abstract="false" name="RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" abstract="false" name="CollaborativeTaxAgreementProjectedTaxSavingsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgry_RestrictedStockAndPerformanceSharesMember" abstract="true" name="RestrictedStockAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" abstract="false" name="UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_A2017SeniorSecuredCreditFacilityMember" abstract="true" name="A2017SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_DeferredTaxAssetTaxReceivableAgreement" abstract="false" name="DeferredTaxAssetTaxReceivableAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_OneMonthLondonInterbankOfferedRateLIBORMember" abstract="true" name="OneMonthLondonInterbankOfferedRateLIBORMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgry_NoncashInterestIncomeExpenseNet" abstract="false" name="NoncashInterestIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgry_DisposalGroupFourMember" abstract="true" name="DisposalGroupFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>sgry-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:934c24c6-c60d-49cc-a057-94123601eeba,g:155ec3a3-79d5-4a25-a7e0-562ed3402740-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Cover" xlink:type="simple" xlink:href="sgry-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5ae3cd4d-0b49-4b2f-a2f5-230b2e535c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8c59835-532a-4372-830f-8bb833b8d6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5ae3cd4d-0b49-4b2f-a2f5-230b2e535c85" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8c59835-532a-4372-830f-8bb833b8d6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6fae93de-6b0a-4cc3-af04-f4623894ebad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5ae3cd4d-0b49-4b2f-a2f5-230b2e535c85" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6fae93de-6b0a-4cc3-af04-f4623894ebad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9f63800c-19f9-4095-bf16-1e039fe33831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5ae3cd4d-0b49-4b2f-a2f5-230b2e535c85" xlink:to="loc_us-gaap_InventoryNet_9f63800c-19f9-4095-bf16-1e039fe33831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_a8b55623-25d1-4910-ba8a-5800ba774270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5ae3cd4d-0b49-4b2f-a2f5-230b2e535c85" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_a8b55623-25d1-4910-ba8a-5800ba774270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b553a672-355f-429d-9cea-dddce41bbc71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5ae3cd4d-0b49-4b2f-a2f5-230b2e535c85" xlink:to="loc_us-gaap_OtherAssetsCurrent_b553a672-355f-429d-9cea-dddce41bbc71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aded02b-0941-4b67-a132-67c800c0b811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06e48631-1f88-4f97-92a9-e2d5ddede7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aded02b-0941-4b67-a132-67c800c0b811" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06e48631-1f88-4f97-92a9-e2d5ddede7d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7375c712-fd10-4bd0-b0e9-58472781a2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aded02b-0941-4b67-a132-67c800c0b811" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7375c712-fd10-4bd0-b0e9-58472781a2a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8483c3e1-f7f7-4b42-81c2-ae8ed71900b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aded02b-0941-4b67-a132-67c800c0b811" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8483c3e1-f7f7-4b42-81c2-ae8ed71900b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2fa57e19-e0bb-4cd1-9eed-496ea6af2786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aded02b-0941-4b67-a132-67c800c0b811" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2fa57e19-e0bb-4cd1-9eed-496ea6af2786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_97f7c633-6c68-4d58-87e4-66e14bf7b81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aded02b-0941-4b67-a132-67c800c0b811" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_97f7c633-6c68-4d58-87e4-66e14bf7b81a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_02dfa50a-9546-418f-9288-3fb1704168da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aded02b-0941-4b67-a132-67c800c0b811" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_02dfa50a-9546-418f-9288-3fb1704168da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8ddf1da8-d5ad-494d-82db-2c8130bf8b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6aded02b-0941-4b67-a132-67c800c0b811" xlink:to="loc_us-gaap_LiabilitiesCurrent_8ddf1da8-d5ad-494d-82db-2c8130bf8b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_896b76a6-55c7-4811-b486-846424f14e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_896b76a6-55c7-4811-b486-846424f14e92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fa655093-e523-4ea5-b88b-17dec8c4592b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:to="loc_us-gaap_AssetsCurrent_fa655093-e523-4ea5-b88b-17dec8c4592b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2caf6e6c-00ab-434c-9218-186259fafb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:to="loc_us-gaap_Goodwill_2caf6e6c-00ab-434c-9218-186259fafb05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45ab4717-d825-47c6-a49d-68f92caae584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_45ab4717-d825-47c6-a49d-68f92caae584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_005cfe2d-1452-412a-b83e-3168987a2295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_005cfe2d-1452-412a-b83e-3168987a2295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_521c86ab-7526-45e4-9f77-df1f1a68601f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_521c86ab-7526-45e4-9f77-df1f1a68601f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_84a20914-b8b6-4ebe-aafc-d23efc1f6356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_84a20914-b8b6-4ebe-aafc-d23efc1f6356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c3cc0b25-f945-410f-9553-4c4e137d1a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7cd509f3-f924-491e-a1c8-463303d5a001" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c3cc0b25-f945-410f-9553-4c4e137d1a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d74e13cf-4377-4ed5-8226-7b1ba66059e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d0212c99-3969-4be1-947c-4455db58fbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d74e13cf-4377-4ed5-8226-7b1ba66059e4" xlink:to="loc_us-gaap_StockholdersEquity_d0212c99-3969-4be1-947c-4455db58fbfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_13fb4ce4-3fa4-4041-a31b-c2a320fda356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d74e13cf-4377-4ed5-8226-7b1ba66059e4" xlink:to="loc_us-gaap_MinorityInterest_13fb4ce4-3fa4-4041-a31b-c2a320fda356" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8abeffec-f194-49d3-86ec-ff38c0ca773d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae38ef07-7e4a-46ef-a106-662ca4190300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8abeffec-f194-49d3-86ec-ff38c0ca773d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae38ef07-7e4a-46ef-a106-662ca4190300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_558074a8-0596-4b2a-b211-1cd61d420d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8abeffec-f194-49d3-86ec-ff38c0ca773d" xlink:to="loc_us-gaap_CommonStockValueOutstanding_558074a8-0596-4b2a-b211-1cd61d420d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b0d05bb8-9e78-4917-824a-035616231024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8abeffec-f194-49d3-86ec-ff38c0ca773d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b0d05bb8-9e78-4917-824a-035616231024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4bbd3f9b-dc6c-4cf4-9881-42a901834b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8abeffec-f194-49d3-86ec-ff38c0ca773d" xlink:to="loc_us-gaap_PreferredStockValue_4bbd3f9b-dc6c-4cf4-9881-42a901834b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_375d4434-81a6-421c-8138-8f7b355477e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8abeffec-f194-49d3-86ec-ff38c0ca773d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_375d4434-81a6-421c-8138-8f7b355477e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b6df5491-a4ce-4d0d-a7ed-ebd4d4a7a17c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2107fcb6-1530-4abb-9b6d-256643b31d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6df5491-a4ce-4d0d-a7ed-ebd4d4a7a17c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2107fcb6-1530-4abb-9b6d-256643b31d5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8ec9bb45-dfb7-43a1-8f43-b9e6eb2ddca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6df5491-a4ce-4d0d-a7ed-ebd4d4a7a17c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8ec9bb45-dfb7-43a1-8f43-b9e6eb2ddca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_cd11d8a0-3dc3-432c-b3a0-bb62fe584eec" xlink:href="sgry-20201231.xsd#sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6df5491-a4ce-4d0d-a7ed-ebd4d4a7a17c" xlink:to="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_cd11d8a0-3dc3-432c-b3a0-bb62fe584eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0a665170-c09a-42f6-abf4-105972ccfb5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6df5491-a4ce-4d0d-a7ed-ebd4d4a7a17c" xlink:to="loc_us-gaap_AccountsPayableCurrent_0a665170-c09a-42f6-abf4-105972ccfb5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e5657b0e-dc6b-4472-9e72-23cb956d2c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b6df5491-a4ce-4d0d-a7ed-ebd4d4a7a17c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e5657b0e-dc6b-4472-9e72-23cb956d2c99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0c4061a1-4b8a-421e-b74c-1e16cf10b0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_449e528d-0a63-4372-a225-39a06d37a12d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0c4061a1-4b8a-421e-b74c-1e16cf10b0c3" xlink:to="loc_us-gaap_ProfitLoss_449e528d-0a63-4372-a225-39a06d37a12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c5cf1712-813b-4a30-90c8-353ba6103313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0c4061a1-4b8a-421e-b74c-1e16cf10b0c3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c5cf1712-813b-4a30-90c8-353ba6103313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_96a62de5-8799-4581-9175-067d72bda32b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_96cdcee8-222e-4623-8a5e-6319b2f4ae3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_96a62de5-8799-4581-9175-067d72bda32b" xlink:to="loc_us-gaap_LaborAndRelatedExpense_96cdcee8-222e-4623-8a5e-6319b2f4ae3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_11c0b1e0-7674-4e48-96d1-350e8b70c9d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_96a62de5-8799-4581-9175-067d72bda32b" xlink:to="loc_us-gaap_SuppliesExpense_11c0b1e0-7674-4e48-96d1-350e8b70c9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_d13dfe00-7006-47b0-ac1b-3a1b14ac2d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_96a62de5-8799-4581-9175-067d72bda32b" xlink:to="loc_us-gaap_ProfessionalFees_d13dfe00-7006-47b0-ac1b-3a1b14ac2d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_4a31417c-51e0-408b-b6e1-61f6ada456b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_96a62de5-8799-4581-9175-067d72bda32b" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_4a31417c-51e0-408b-b6e1-61f6ada456b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense_93c56025-d3c3-4c25-a776-2c39f291b9b7" xlink:href="sgry-20201231.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_96a62de5-8799-4581-9175-067d72bda32b" xlink:to="loc_sgry_OperatingAndFinanceLeaseExpense_93c56025-d3c3-4c25-a776-2c39f291b9b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c4e33d42-e7c6-443e-a492-b245cb44ec24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_624a4efe-e7dd-4bb0-b90d-9662fcd16756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c4e33d42-e7c6-443e-a492-b245cb44ec24" xlink:to="loc_us-gaap_OperatingExpenses_624a4efe-e7dd-4bb0-b90d-9662fcd16756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4760bdd4-2704-4128-acf4-9e5911bfa3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c4e33d42-e7c6-443e-a492-b245cb44ec24" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4760bdd4-2704-4128-acf4-9e5911bfa3d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b45eda4d-e531-4483-aa02-14fe0ad47581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8670e02e-56a0-47b1-99ac-9c27e7f4e6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b45eda4d-e531-4483-aa02-14fe0ad47581" xlink:to="loc_us-gaap_OperatingIncomeLoss_8670e02e-56a0-47b1-99ac-9c27e7f4e6f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_795e3ab3-f716-4bdd-bf6b-5f8c8c7300de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b45eda4d-e531-4483-aa02-14fe0ad47581" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_795e3ab3-f716-4bdd-bf6b-5f8c8c7300de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_44b61d5f-9221-4f9d-81bd-2fc7062a30a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b45eda4d-e531-4483-aa02-14fe0ad47581" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_44b61d5f-9221-4f9d-81bd-2fc7062a30a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7d3528f1-d421-4049-b3d8-eb060efdd060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d50989e0-b3c9-4f95-ad58-920dc6c9a9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7d3528f1-d421-4049-b3d8-eb060efdd060" xlink:to="loc_us-gaap_NetIncomeLoss_d50989e0-b3c9-4f95-ad58-920dc6c9a9e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_aad5337e-b661-40c7-b5cd-e269413b8db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7d3528f1-d421-4049-b3d8-eb060efdd060" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_aad5337e-b661-40c7-b5cd-e269413b8db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f217426a-f775-41d6-8e2e-840abaaf5239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_98995355-e351-4742-ad13-858d8e22c110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_f217426a-f775-41d6-8e2e-840abaaf5239" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_98995355-e351-4742-ad13-858d8e22c110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1fe81cdc-da65-4ff4-9b0b-0e2f2cfd8440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_f217426a-f775-41d6-8e2e-840abaaf5239" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1fe81cdc-da65-4ff4-9b0b-0e2f2cfd8440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4f71e168-8f2c-4baf-9d23-fc99db4f2ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_AssetImpairmentCharges_4f71e168-8f2c-4baf-9d23-fc99db4f2ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_7f424d03-56a0-4c55-8f5e-a6d82edc3fe4" xlink:href="sgry-20201231.xsd#sgry_GrantRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_sgry_GrantRevenue_7f424d03-56a0-4c55-8f5e-a6d82edc3fe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_1da53044-bbd3-4915-9608-7215d0490d89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_1da53044-bbd3-4915-9608-7215d0490d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_0eb70eca-f715-4d02-bd82-7220e0b0c374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_0eb70eca-f715-4d02-bd82-7220e0b0c374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_99287351-27d2-4de3-9182-037c52a6cece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_99287351-27d2-4de3-9182-037c52a6cece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2fd281bb-f36f-4569-aa6b-3ddfde00e315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2fd281bb-f36f-4569-aa6b-3ddfde00e315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6f286019-7c1a-4cc8-8f5b-bb7569f83c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6f286019-7c1a-4cc8-8f5b-bb7569f83c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_fbb2dbd9-4388-4efb-90d8-d1d5b8e7032b" xlink:href="sgry-20201231.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_fbb2dbd9-4388-4efb-90d8-d1d5b8e7032b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_f3924f80-2f55-4265-83eb-52edc0bd1b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_f3924f80-2f55-4265-83eb-52edc0bd1b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dad3712a-1c4d-47eb-b5c2-6b0990a0b79d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dad3712a-1c4d-47eb-b5c2-6b0990a0b79d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3d7c82b4-9e71-4ed8-bee3-5e878ea635b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0fbf0d2-8900-4cd8-bfa5-64436c27a053" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3d7c82b4-9e71-4ed8-bee3-5e878ea635b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3da9f2d0-fb66-413a-b4fc-f93e7b320143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d23bb803-1ff1-47f4-a378-9fe009771ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3da9f2d0-fb66-413a-b4fc-f93e7b320143" xlink:to="loc_us-gaap_ProfitLoss_d23bb803-1ff1-47f4-a378-9fe009771ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3f8a1597-273c-4828-97f8-48b37bfeec5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3da9f2d0-fb66-413a-b4fc-f93e7b320143" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3f8a1597-273c-4828-97f8-48b37bfeec5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b7c5d07b-ce17-4775-80cd-93457a2ea23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e95a1ea7-a87c-4eb9-a43b-7ca52dc0a16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b7c5d07b-ce17-4775-80cd-93457a2ea23f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e95a1ea7-a87c-4eb9-a43b-7ca52dc0a16d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ae90d5ae-c090-4dc7-9ee2-37d2aebd41d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b7c5d07b-ce17-4775-80cd-93457a2ea23f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ae90d5ae-c090-4dc7-9ee2-37d2aebd41d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_143f1e96-dd7f-498b-ac8f-45f03d3698d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efb3d09f-6b90-4444-9168-4bb68b565603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_143f1e96-dd7f-498b-ac8f-45f03d3698d9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_efb3d09f-6b90-4444-9168-4bb68b565603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d4cdeb26-fbe2-4467-a22d-e1a08f528afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_143f1e96-dd7f-498b-ac8f-45f03d3698d9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d4cdeb26-fbe2-4467-a22d-e1a08f528afc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_1193ffb7-cdd6-4bc4-8faa-c25f7c422e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_143f1e96-dd7f-498b-ac8f-45f03d3698d9" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_1193ffb7-cdd6-4bc4-8faa-c25f7c422e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_52840ab5-13a2-46c1-b8cf-2103ffad6abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_143f1e96-dd7f-498b-ac8f-45f03d3698d9" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_52840ab5-13a2-46c1-b8cf-2103ffad6abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_083ed652-22f2-416b-8e6a-a9bf79404f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_143f1e96-dd7f-498b-ac8f-45f03d3698d9" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_083ed652-22f2-416b-8e6a-a9bf79404f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7a5bea95-b969-4db3-b3ce-ca1196383518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7a5bea95-b969-4db3-b3ce-ca1196383518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2f042343-f49d-450e-ae02-9843f339f2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2f042343-f49d-450e-ae02-9843f339f2e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8d22bb69-dfe6-473e-a7a1-8de935505970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_ShareBasedCompensation_8d22bb69-dfe6-473e-a7a1-8de935505970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bc9aee8e-e700-4c9b-aa00-ac07a347366b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_ProfitLoss_bc9aee8e-e700-4c9b-aa00-ac07a347366b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_c3b7900b-a9c8-4203-8092-3a29188d950b" xlink:href="sgry-20201231.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_c3b7900b-a9c8-4203-8092-3a29188d950b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_804d7e6b-f949-4d3a-9993-0e864b9c2406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_OperatingLeaseExpense_804d7e6b-f949-4d3a-9993-0e864b9c2406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3d0cb03e-9ca1-40fd-9768-082a700cc54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_AssetImpairmentCharges_3d0cb03e-9ca1-40fd-9768-082a700cc54e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_e619b90b-17a9-4146-880f-9455189a1cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_e619b90b-17a9-4146-880f-9455189a1cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_536b4e28-4ce9-4559-b654-5b63885d67de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_536b4e28-4ce9-4559-b654-5b63885d67de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet_231658f3-1661-47bc-9e4a-e3b1b8e42db0" xlink:href="sgry-20201231.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_sgry_NoncashInterestIncomeExpenseNet_231658f3-1661-47bc-9e4a-e3b1b8e42db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_2a984faa-8fd8-48c0-bfdf-134b78a33977" xlink:href="sgry-20201231.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_2a984faa-8fd8-48c0-bfdf-134b78a33977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_de26b2ad-816c-4163-babe-a292f9fc5f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_de26b2ad-816c-4163-babe-a292f9fc5f80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b6ce4cee-f3b6-4dcf-ba41-d14b49c865db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1e3d7b78-02fa-4c7c-af19-6661cbc08725" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_b6ce4cee-f3b6-4dcf-ba41-d14b49c865db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7080669-16d4-4580-b5c4-8bd537e069ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6579c07-33c1-4b60-a8bd-645b839fda35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7080669-16d4-4580-b5c4-8bd537e069ba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6579c07-33c1-4b60-a8bd-645b839fda35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7114ee4-8424-434d-8cc0-cbb22dd6c814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7080669-16d4-4580-b5c4-8bd537e069ba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d7114ee4-8424-434d-8cc0-cbb22dd6c814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07b38a8-046b-4ba1-834b-34b91464ecca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7080669-16d4-4580-b5c4-8bd537e069ba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07b38a8-046b-4ba1-834b-34b91464ecca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_eb59880f-0ada-4257-a31f-82c808fe033d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_eb59880f-0ada-4257-a31f-82c808fe033d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_de0c9d7a-4a1c-4a2f-821f-e9a289d55cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_de0c9d7a-4a1c-4a2f-821f-e9a289d55cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentPrepaymentPenaltyAmount_22398254-ae76-4b50-bb38-8e62ddab3bb2" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentPrepaymentPenaltyAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_sgry_DebtInstrumentPrepaymentPenaltyAmount_22398254-ae76-4b50-bb38-8e62ddab3bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ecc033a9-8473-4122-8083-2a1ac21eb15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ecc033a9-8473-4122-8083-2a1ac21eb15b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d32dfa58-7806-4fbc-9ff3-eeee383ade98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d32dfa58-7806-4fbc-9ff3-eeee383ade98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_11d173f5-2673-4535-bbd5-aafc5dae6271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_11d173f5-2673-4535-bbd5-aafc5dae6271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_99cd692a-816f-4f2c-82fb-da750d720b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_99cd692a-816f-4f2c-82fb-da750d720b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4c758249-5eeb-4c69-8371-43ea1409b4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4c758249-5eeb-4c69-8371-43ea1409b4a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ccb622b9-af80-4aaf-ad99-9f2b28f2d4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8908cf10-eefd-4d06-a0aa-9e78250dbc3a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ccb622b9-af80-4aaf-ad99-9f2b28f2d4e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesCARESACTDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposals"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_9dd1d222-bf96-45ac-8cd9-6139c52a43a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_9dd1d222-bf96-45ac-8cd9-6139c52a43a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_da88d871-2277-4df5-bb60-5b4d8206fbe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_da88d871-2277-4df5-bb60-5b4d8206fbe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_4cc3b204-48b5-4c36-bb8d-22d709b05f88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_4cc3b204-48b5-4c36-bb8d-22d709b05f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b769e704-5829-47fa-8dda-318691cbae87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_us-gaap_Goodwill_b769e704-5829-47fa-8dda-318691cbae87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_4bd164a8-e240-4966-b0c3-75a09ebd9335" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_4bd164a8-e240-4966-b0c3-75a09ebd9335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_80881af4-98ef-4b2a-996c-98cacfefd964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_80881af4-98ef-4b2a-996c-98cacfefd964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4b18fa45-3b93-4514-90d8-f97626745094" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_4b18fa45-3b93-4514-90d8-f97626745094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a1108c60-0a90-4e0f-a173-718a35f93b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a1108c60-0a90-4e0f-a173-718a35f93b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_e22eec1d-23f9-4517-b093-d1f198e16048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_58e22410-2e1e-4d2d-9b1c-1b306c93dcd6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_e22eec1d-23f9-4517-b093-d1f198e16048" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsDisposalsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b901985e-7ed6-4f3c-9dc6-3c7132df3c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_05a22b00-94f8-4366-b00e-a3a9e2907ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b901985e-7ed6-4f3c-9dc6-3c7132df3c23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_05a22b00-94f8-4366-b00e-a3a9e2907ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_dd51e1af-25e1-499f-85dc-a5e142336077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b901985e-7ed6-4f3c-9dc6-3c7132df3c23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_dd51e1af-25e1-499f-85dc-a5e142336077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_853614b1-ba22-43d2-ab56-6384bd1c9803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0c9554cb-51f2-4fcd-a967-58e87e937ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_853614b1-ba22-43d2-ab56-6384bd1c9803" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0c9554cb-51f2-4fcd-a967-58e87e937ed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_800eebc7-bca8-410e-9943-64555a1adfdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_853614b1-ba22-43d2-ab56-6384bd1c9803" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_800eebc7-bca8-410e-9943-64555a1adfdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7f0db20c-5613-4a7a-82b7-343d6ee44c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_434290b2-e89e-4533-8cad-a501d8fef2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7f0db20c-5613-4a7a-82b7-343d6ee44c11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_434290b2-e89e-4533-8cad-a501d8fef2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9cc651dc-7f64-4753-b90e-816bfa4c227b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7f0db20c-5613-4a7a-82b7-343d6ee44c11" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9cc651dc-7f64-4753-b90e-816bfa4c227b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b8206474-0a60-4a5c-9075-04edafd07164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23d70b9c-6a73-49ac-8ba3-d31312a391ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b8206474-0a60-4a5c-9075-04edafd07164" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23d70b9c-6a73-49ac-8ba3-d31312a391ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c5848c81-c600-464c-bd5e-3ad6deec99fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b8206474-0a60-4a5c-9075-04edafd07164" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c5848c81-c600-464c-bd5e-3ad6deec99fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1eaa6a47-2b5f-409d-a935-2e2f996e0cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3229e205-b883-440e-9372-79f12a149f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1eaa6a47-2b5f-409d-a935-2e2f996e0cbf" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3229e205-b883-440e-9372-79f12a149f07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eccee38b-3876-4745-a130-45766e414de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1eaa6a47-2b5f-409d-a935-2e2f996e0cbf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_eccee38b-3876-4745-a130-45766e414de2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_be108e52-68a6-48c1-bcc7-d4e566234c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_03fb2a3b-ffa3-4f13-95d7-36ce71754ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_be108e52-68a6-48c1-bcc7-d4e566234c8f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_03fb2a3b-ffa3-4f13-95d7-36ce71754ed2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4e4fc250-60c3-4554-b003-2ceb7c599151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_be108e52-68a6-48c1-bcc7-d4e566234c8f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4e4fc250-60c3-4554-b003-2ceb7c599151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_303b9132-58ce-40cb-960b-414f3c0f4135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_be108e52-68a6-48c1-bcc7-d4e566234c8f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_303b9132-58ce-40cb-960b-414f3c0f4135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ade928f9-e18d-4160-bcbd-3fd4002c09fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_be108e52-68a6-48c1-bcc7-d4e566234c8f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ade928f9-e18d-4160-bcbd-3fd4002c09fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_35b62665-4664-4cbd-b332-00fd5a09b3a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_be108e52-68a6-48c1-bcc7-d4e566234c8f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_35b62665-4664-4cbd-b332-00fd5a09b3a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_450e52da-91ff-45f6-8b4f-94f2430334c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_be108e52-68a6-48c1-bcc7-d4e566234c8f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_450e52da-91ff-45f6-8b4f-94f2430334c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_2af5a6e5-0044-4561-a851-b6ffd19a6d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3366783f-15be-452c-b05c-d7bd084c7905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_2af5a6e5-0044-4561-a851-b6ffd19a6d19" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3366783f-15be-452c-b05c-d7bd084c7905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f1b0a028-9dfd-45c5-be38-c5519827a3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_2af5a6e5-0044-4561-a851-b6ffd19a6d19" xlink:to="loc_us-gaap_FinanceLeaseLiability_f1b0a028-9dfd-45c5-be38-c5519827a3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_98a0a98a-4afc-432c-ab48-afd50d2b8b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_2af5a6e5-0044-4561-a851-b6ffd19a6d19" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_98a0a98a-4afc-432c-ab48-afd50d2b8b28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails_1" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSummaryofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_0e742d08-078c-45fc-8ffa-618454c75683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e2d84db5-c33c-4ba9-9ce1-3ce76f382868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_0e742d08-078c-45fc-8ffa-618454c75683" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e2d84db5-c33c-4ba9-9ce1-3ce76f382868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1af22e71-a18d-4a38-95d9-7f300f0acda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_0e742d08-078c-45fc-8ffa-618454c75683" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1af22e71-a18d-4a38-95d9-7f300f0acda3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSeniorSecuredCreditFacilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt6750SeniorUnsecuredNotesdue2025Details"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt10000SeniorUnsecuredNotesdue2027Details"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b96a3761-dceb-43b3-8afb-08b8994851e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fd2faae9-d50b-4a6a-ad1e-845ceb581ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b96a3761-dceb-43b3-8afb-08b8994851e1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fd2faae9-d50b-4a6a-ad1e-845ceb581ea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_26f946f1-8ef8-46ea-9b61-a105237a386e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b96a3761-dceb-43b3-8afb-08b8994851e1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_26f946f1-8ef8-46ea-9b61-a105237a386e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e05f9ba8-5c2c-4ea7-b503-975247925007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b96a3761-dceb-43b3-8afb-08b8994851e1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e05f9ba8-5c2c-4ea7-b503-975247925007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0ffdb06c-71d1-4a0b-95be-483cd4efd8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b96a3761-dceb-43b3-8afb-08b8994851e1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0ffdb06c-71d1-4a0b-95be-483cd4efd8b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a3acb47e-d398-4234-9fee-f5c39df6c52c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b96a3761-dceb-43b3-8afb-08b8994851e1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a3acb47e-d398-4234-9fee-f5c39df6c52c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_63021278-e0bc-4a0b-b817-009625fe1e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b96a3761-dceb-43b3-8afb-08b8994851e1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_63021278-e0bc-4a0b-b817-009625fe1e91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Leases" xlink:type="simple" xlink:href="sgry-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_9cdbb4ac-36b9-4789-959e-8c8b635c897b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_4b3880fe-7b51-466f-afe1-069d6824756c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_9cdbb4ac-36b9-4789-959e-8c8b635c897b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_4b3880fe-7b51-466f-afe1-069d6824756c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1bea890e-580a-4676-bf6b-607852010dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_9cdbb4ac-36b9-4789-959e-8c8b635c897b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1bea890e-580a-4676-bf6b-607852010dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset_01251420-511c-4961-92fb-cfc1643e918f" xlink:href="sgry-20201231.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5448e2c9-7366-4405-81df-ea01df61dac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseRightOfUseAsset_01251420-511c-4961-92fb-cfc1643e918f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5448e2c9-7366-4405-81df-ea01df61dac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_0fa370df-0e39-4931-93c4-e2515434f919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseRightOfUseAsset_01251420-511c-4961-92fb-cfc1643e918f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_0fa370df-0e39-4931-93c4-e2515434f919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability_3afec71d-c018-44a2-8f94-2443e5674405" xlink:href="sgry-20201231.xsd#sgry_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a3f87cae-0623-46e0-8486-cce1d273ec96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseLiability_3afec71d-c018-44a2-8f94-2443e5674405" xlink:to="loc_us-gaap_OperatingLeaseLiability_a3f87cae-0623-46e0-8486-cce1d273ec96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d52d3300-fe8b-4ef9-be4b-e9f16fa23aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_LeaseLiability_3afec71d-c018-44a2-8f94-2443e5674405" xlink:to="loc_us-gaap_FinanceLeaseLiability_d52d3300-fe8b-4ef9-be4b-e9f16fa23aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1fb3c9eb-09e7-457c-a173-e2f163d87ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_78e5fef9-02f3-467a-8cdb-9d26015387ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_1fb3c9eb-09e7-457c-a173-e2f163d87ea7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_78e5fef9-02f3-467a-8cdb-9d26015387ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da619d2d-3e6a-4f75-a9b6-2bbbd884a08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_1fb3c9eb-09e7-457c-a173-e2f163d87ea7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_da619d2d-3e6a-4f75-a9b6-2bbbd884a08c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesLeaseExpenseandCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_40ae26e8-b86f-46c1-88ac-131bdbe1fd34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d8178b4c-afac-4a81-ba41-3b47ba134345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_40ae26e8-b86f-46c1-88ac-131bdbe1fd34" xlink:to="loc_us-gaap_OperatingLeaseCost_d8178b4c-afac-4a81-ba41-3b47ba134345" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_7c3e06e9-8185-4a00-a4a3-3bb72bc64b3e" xlink:href="sgry-20201231.xsd#sgry_FinanceLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_40ae26e8-b86f-46c1-88ac-131bdbe1fd34" xlink:to="loc_sgry_FinanceLeaseCost_7c3e06e9-8185-4a00-a4a3-3bb72bc64b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost_28efcf6f-6abf-4517-9a6b-c5e283f21915" xlink:href="sgry-20201231.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_40ae26e8-b86f-46c1-88ac-131bdbe1fd34" xlink:to="loc_sgry_VariableAndShortTermLeaseCost_28efcf6f-6abf-4517-9a6b-c5e283f21915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_c6a084f9-9a3d-47fb-80dc-20bfcf9f5a26" xlink:href="sgry-20201231.xsd#sgry_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_634b562d-f7ba-4ec0-ad10-78cfe17d66a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_FinanceLeaseCost_c6a084f9-9a3d-47fb-80dc-20bfcf9f5a26" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_634b562d-f7ba-4ec0-ad10-78cfe17d66a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_f20d5405-11e2-44d7-9d11-6d8fc25e434d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgry_FinanceLeaseCost_c6a084f9-9a3d-47fb-80dc-20bfcf9f5a26" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_f20d5405-11e2-44d7-9d11-6d8fc25e434d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c2a64cd-6a67-4142-b419-41a966278ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_62b358f1-6ef5-40f6-8a39-5d05c9b49d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c2a64cd-6a67-4142-b419-41a966278ad1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_62b358f1-6ef5-40f6-8a39-5d05c9b49d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a21cb37b-6b6b-4008-be5b-90b8b8dd8e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c2a64cd-6a67-4142-b419-41a966278ad1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a21cb37b-6b6b-4008-be5b-90b8b8dd8e05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0b74ebe6-23e4-4f74-86ec-c192e5d58da6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c2a64cd-6a67-4142-b419-41a966278ad1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0b74ebe6-23e4-4f74-86ec-c192e5d58da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16e9592b-aa67-424d-ae19-d915b13759c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c2a64cd-6a67-4142-b419-41a966278ad1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16e9592b-aa67-424d-ae19-d915b13759c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_562d9bf5-20d0-443f-be23-657b3eba5f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c2a64cd-6a67-4142-b419-41a966278ad1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_562d9bf5-20d0-443f-be23-657b3eba5f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_72cf2637-5a29-46cd-a7b2-554e038fa023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c2a64cd-6a67-4142-b419-41a966278ad1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_72cf2637-5a29-46cd-a7b2-554e038fa023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3b835eb1-21f7-4916-a391-09f996e7e62a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_655e2647-94b9-4d81-abce-060aa819e4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3b835eb1-21f7-4916-a391-09f996e7e62a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_655e2647-94b9-4d81-abce-060aa819e4f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3ce9f0b2-af5f-453d-8c44-625a74e16e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3b835eb1-21f7-4916-a391-09f996e7e62a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_3ce9f0b2-af5f-453d-8c44-625a74e16e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_aa87ef6f-f756-4d0a-9aca-e8f42162f476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3b835eb1-21f7-4916-a391-09f996e7e62a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_aa87ef6f-f756-4d0a-9aca-e8f42162f476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_72880acd-481a-4e30-90ba-47253236581b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3b835eb1-21f7-4916-a391-09f996e7e62a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_72880acd-481a-4e30-90ba-47253236581b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8c6e9852-87d2-42ef-bfae-8ace428c85f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3b835eb1-21f7-4916-a391-09f996e7e62a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8c6e9852-87d2-42ef-bfae-8ace428c85f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_e0229a8d-0dff-46ed-be34-9808c88677ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3b835eb1-21f7-4916-a391-09f996e7e62a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_e0229a8d-0dff-46ed-be34-9808c88677ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_aa636d0d-87a5-4f47-9c4b-96a11aa78e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_da73fcb6-7c2d-4fa3-9fb9-2bf3ec0d071e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_aa636d0d-87a5-4f47-9c4b-96a11aa78e0e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_da73fcb6-7c2d-4fa3-9fb9-2bf3ec0d071e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_ba991173-181b-41c7-9d7a-8b4e42dd3984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_aa636d0d-87a5-4f47-9c4b-96a11aa78e0e" xlink:to="loc_us-gaap_FinanceLeaseLiability_ba991173-181b-41c7-9d7a-8b4e42dd3984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e5eb573-8de4-4c13-b674-8ce0b257f07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_76c0f135-21b5-4c1a-a214-5cb52944e215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e5eb573-8de4-4c13-b674-8ce0b257f07f" xlink:to="loc_us-gaap_OperatingLeaseLiability_76c0f135-21b5-4c1a-a214-5cb52944e215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b7091a0d-fc41-4ff5-93e9-38cc881cff34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e5eb573-8de4-4c13-b674-8ce0b257f07f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b7091a0d-fc41-4ff5-93e9-38cc881cff34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStock" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStock"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStockTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStockTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStockAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivities"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivitiesTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivitiesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShare"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_577436a3-b619-4be6-8634-9acfb47c914c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_afea67ee-2861-40ca-93f5-7003af94a2cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_577436a3-b619-4be6-8634-9acfb47c914c" xlink:to="loc_us-gaap_NetIncomeLoss_afea67ee-2861-40ca-93f5-7003af94a2cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_960213e0-6eff-4380-9e5f-b10c64226146" xlink:href="sgry-20201231.xsd#sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_577436a3-b619-4be6-8634-9acfb47c914c" xlink:to="loc_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_960213e0-6eff-4380-9e5f-b10c64226146" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesIncomeTaxBenefitExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e514fa30-0501-4f12-a1eb-69db7ac594b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7c55cc66-1f3f-4a47-920a-81339b2b16ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e514fa30-0501-4f12-a1eb-69db7ac594b9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7c55cc66-1f3f-4a47-920a-81339b2b16ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a2219614-d271-4090-9635-7fb902ad3da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e514fa30-0501-4f12-a1eb-69db7ac594b9" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a2219614-d271-4090-9635-7fb902ad3da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_cfccb6e6-b5d6-4993-a75b-6b8e76b6e5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e514fa30-0501-4f12-a1eb-69db7ac594b9" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_cfccb6e6-b5d6-4993-a75b-6b8e76b6e5ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_012de905-879e-42a1-9ecb-f9aef2af838a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e514fa30-0501-4f12-a1eb-69db7ac594b9" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_012de905-879e-42a1-9ecb-f9aef2af838a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c3de6f05-1e6e-43b7-aebd-49ffbea30d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c3de6f05-1e6e-43b7-aebd-49ffbea30d72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_df1411d8-5add-48d6-913d-ec237d04fb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_df1411d8-5add-48d6-913d-ec237d04fb01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3e3094a4-3f1c-449d-86f6-c9c9b44331c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3e3094a4-3f1c-449d-86f6-c9c9b44331c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_fc06c95c-f8c2-41c8-bc6f-6a35bb2d77b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_fc06c95c-f8c2-41c8-bc6f-6a35bb2d77b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_dd01c7d9-647d-4281-9e19-5be9839fe5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_dd01c7d9-647d-4281-9e19-5be9839fe5e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_08019485-316b-4bdf-aef3-1ddc41819fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_08019485-316b-4bdf-aef3-1ddc41819fc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_974f1099-d763-4e91-a1f9-3839475d22db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_974f1099-d763-4e91-a1f9-3839475d22db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_96215aef-db15-4fa3-8ca1-495d712b04e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_96215aef-db15-4fa3-8ca1-495d712b04e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount_6b7a0bfb-ef52-4941-97fd-839c3fd23aac" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount_6b7a0bfb-ef52-4941-97fd-839c3fd23aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1a32aaf8-0105-4907-912a-fcf9bd6e9894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1a32aaf8-0105-4907-912a-fcf9bd6e9894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount_94f965ba-2b95-4270-baac-647bf1a91afd" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxReconciliationDivestitureAmount"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount_94f965ba-2b95-4270-baac-647bf1a91afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_683e891b-d024-4884-9cd3-209543e74b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_683e891b-d024-4884-9cd3-209543e74b4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount_f7bfee13-ad5f-4673-9383-3b16f470e129" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_9cfa03fd-7db5-4eb0-8824-9b813d213a63" xlink:to="loc_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount_f7bfee13-ad5f-4673-9383-3b16f470e129" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1e8414af-d4e4-449b-aec6-e4ae7aeca8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_184f7a25-99b6-42ab-b8b1-183fa92479f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e8414af-d4e4-449b-aec6-e4ae7aeca8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_184f7a25-99b6-42ab-b8b1-183fa92479f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2578184d-1827-47a4-b639-89a644e72429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1e8414af-d4e4-449b-aec6-e4ae7aeca8f6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2578184d-1827-47a4-b639-89a644e72429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_f9ada66f-1336-4ac8-9115-4cba312fb2da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_f9ada66f-1336-4ac8-9115-4cba312fb2da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation_c212f716-7b30-4e93-967e-00429a6bcc43" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation_c212f716-7b30-4e93-967e-00429a6bcc43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_cfb338c8-7eb6-473d-a4f8-a6495e6e343a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_cfb338c8-7eb6-473d-a4f8-a6495e6e343a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2a2e25bc-1faf-4db4-b412-05eb9c4de32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2a2e25bc-1faf-4db4-b412-05eb9c4de32d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_f50d0ff9-df4c-4842-827e-d7d682c729aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_f50d0ff9-df4c-4842-827e-d7d682c729aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets_4c1fd74f-8f0a-4187-b456-59b8808c6681" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets_4c1fd74f-8f0a-4187-b456-59b8808c6681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts_776e93ee-2655-41c3-9b1f-2a3cd4cbe97e" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts_776e93ee-2655-41c3-9b1f-2a3cd4cbe97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation_d7ff49d4-0da8-478c-b2d4-9f7ada8aaec1" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation_d7ff49d4-0da8-478c-b2d4-9f7ada8aaec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsHedgingTransactions_58064839-80aa-4ef4-9653-b892b221eb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsHedgingTransactions"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_us-gaap_DeferredTaxAssetsHedgingTransactions_58064839-80aa-4ef4-9653-b892b221eb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetTaxReceivableAgreement_df3c2cea-9bff-4b52-bc9c-016ae9b8b90a" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetTaxReceivableAgreement"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_sgry_DeferredTaxAssetTaxReceivableAgreement_df3c2cea-9bff-4b52-bc9c-016ae9b8b90a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsRightOfUse_6608c834-dc53-4069-94d3-f4e8615dafec" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsRightOfUse"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_sgry_DeferredTaxAssetsRightOfUse_6608c834-dc53-4069-94d3-f4e8615dafec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable_ebfe9419-3c4e-4e41-8f6a-d72f88f3bec0" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable_ebfe9419-3c4e-4e41-8f6a-d72f88f3bec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_79755065-e04f-46de-b834-5c1ff7b81450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_247e7e3f-2e25-4b14-99d7-883d271fed5e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_79755065-e04f-46de-b834-5c1ff7b81450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_17b799e5-bf32-4e19-b5ca-f97dcfbd70e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d593b074-99d8-4c16-a952-3ea1ffc1bbb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_17b799e5-bf32-4e19-b5ca-f97dcfbd70e9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d593b074-99d8-4c16-a952-3ea1ffc1bbb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_046437b9-cd68-4b6e-a402-8ded6a3668af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_17b799e5-bf32-4e19-b5ca-f97dcfbd70e9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_046437b9-cd68-4b6e-a402-8ded6a3668af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_93049e86-72c6-4e07-ba77-2ca90f900df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8ad42113-4d76-414d-846a-4ec87e486452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_93049e86-72c6-4e07-ba77-2ca90f900df3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8ad42113-4d76-414d-846a-4ec87e486452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures_5006d7ce-2742-4c7c-8c84-cb8a25b6b90e" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_93049e86-72c6-4e07-ba77-2ca90f900df3" xlink:to="loc_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures_5006d7ce-2742-4c7c-8c84-cb8a25b6b90e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_24550a37-c134-4be6-a3b0-88a7a58f4159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_93049e86-72c6-4e07-ba77-2ca90f900df3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_24550a37-c134-4be6-a3b0-88a7a58f4159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a8cc4705-c272-4196-ad2a-f2914a6cba94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_93049e86-72c6-4e07-ba77-2ca90f900df3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a8cc4705-c272-4196-ad2a-f2914a6cba94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationSummaryofOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="sgry-20201231.xsd#EmployeeBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EmployeeBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EmployeeBenefitPlansDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilities"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_eb36539b-501b-48c7-8aeb-09d47e308da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent_f98c8d33-5b56-4c67-9ab0-c37517c38ed8" xlink:href="sgry-20201231.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eb36539b-501b-48c7-8aeb-09d47e308da7" xlink:to="loc_sgry_CostReportLiabilitiesCurrent_f98c8d33-5b56-4c67-9ab0-c37517c38ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers_8734fbe1-98a7-4cdc-8e94-de45f123f050" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PayablesToCustomers"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eb36539b-501b-48c7-8aeb-09d47e308da7" xlink:to="loc_srt_PayablesToCustomers_8734fbe1-98a7-4cdc-8e94-de45f123f050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementLiabilityCurrent_1199a957-afb0-4b24-b83d-d4a3570b6fc5" xlink:href="sgry-20201231.xsd#sgry_TaxReceivableAgreementLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eb36539b-501b-48c7-8aeb-09d47e308da7" xlink:to="loc_sgry_TaxReceivableAgreementLiabilityCurrent_1199a957-afb0-4b24-b83d-d4a3570b6fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c6ada56-9a8f-492a-ab1c-704d57cd93f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eb36539b-501b-48c7-8aeb-09d47e308da7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c6ada56-9a8f-492a-ab1c-704d57cd93f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ca5039fc-d127-4295-8287-bce6af606446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eb36539b-501b-48c7-8aeb-09d47e308da7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ca5039fc-d127-4295-8287-bce6af606446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_ac8609df-f252-4420-ab5e-110e2c35787b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eb36539b-501b-48c7-8aeb-09d47e308da7" xlink:to="loc_us-gaap_LitigationReserveCurrent_ac8609df-f252-4420-ab5e-110e2c35787b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_d953e3cf-e8a3-40de-b793-5777ffe3288a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_eb36539b-501b-48c7-8aeb-09d47e308da7" xlink:to="loc_us-gaap_InterestPayableCurrent_d953e3cf-e8a3-40de-b793-5777ffe3288a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgry-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReporting"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingTables"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgry-20201231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>sgry-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:934c24c6-c60d-49cc-a057-94123601eeba,g:155ec3a3-79d5-4a25-a7e0-562ed3402740-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Cover" xlink:type="simple" xlink:href="sgry-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/Cover" xlink:type="extended" id="i8a526fe52004447c8d35c1c3aecf13b5_Cover"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i4970bbb84a7d4ce2bf8d9a0e96582f5b_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ie6015cd943624b9aaa037b4d39020c02_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i9150ec3e2e93402bae39707cba4de509_ConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended" id="if84c096a723948ca95bdaa824667e4cf_ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i0a5057dff1e64302a8373183a8236a9c_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ebc01e26-21fe-46e5-bd04-ab500fb5ec6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ebc01e26-21fe-46e5-bd04-ab500fb5ec6e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d70dbbfa-7aaf-4900-b23f-560d4f89afc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d70dbbfa-7aaf-4900-b23f-560d4f89afc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f415a48-1ad1-4ada-b7af-edfd7885a1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f415a48-1ad1-4ada-b7af-edfd7885a1f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_7f144e80-921c-480e-a332-5cbe6a187017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_7f144e80-921c-480e-a332-5cbe6a187017" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b54f65c4-ac48-417d-a4bd-a92590c5fcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b54f65c4-ac48-417d-a4bd-a92590c5fcfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_90e01084-6bf9-4697-acc6-6bde52c698f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_90e01084-6bf9-4697-acc6-6bde52c698f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_dc5775e9-b7f4-4497-976c-41f85f74f73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_dc5775e9-b7f4-4497-976c-41f85f74f73a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56d2cedd-c56d-422e-a2ee-c300ed103adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56d2cedd-c56d-422e-a2ee-c300ed103adb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_9b14014a-783c-43ed-a0d5-46b2cd2ac63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_9b14014a-783c-43ed-a0d5-46b2cd2ac63c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_934e5270-43d6-4ef3-8a04-06358306d279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_934e5270-43d6-4ef3-8a04-06358306d279" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_cc3a93d9-1b96-434a-90ec-f831d5cc825c" xlink:href="sgry-20201231.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_cc3a93d9-1b96-434a-90ec-f831d5cc825c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e59f337d-8908-4c54-842a-929eb20cc469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e59f337d-8908-4c54-842a-929eb20cc469" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_171be85d-f6b1-48bd-b3da-1cd34cdd192e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockholdersEquityOther_171be85d-f6b1-48bd-b3da-1cd34cdd192e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39a50d85-2b49-4cca-9d49-6856671e15d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e37a9179-1fb6-47ca-9660-fd8bb0173be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_23c76c1d-8374-4eae-866b-fed3cedf5bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ebc01e26-21fe-46e5-bd04-ab500fb5ec6e" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_23c76c1d-8374-4eae-866b-fed3cedf5bab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ebc01e26-21fe-46e5-bd04-ab500fb5ec6e" xlink:to="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7" xlink:to="loc_us-gaap_EquityComponentDomain_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7" xlink:to="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e59d9105-41d8-4440-8cbb-3820f20911e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_CommonStockMember_e59d9105-41d8-4440-8cbb-3820f20911e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_01cded40-7f1b-4079-8534-a275ea095e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_01cded40-7f1b-4079-8534-a275ea095e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6b643f06-9179-4a1e-b5b1-51a7ba84c362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6b643f06-9179-4a1e-b5b1-51a7ba84c362" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_929d6c18-e526-4472-b9f5-7d3331688ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_RetainedEarningsMember_929d6c18-e526-4472-b9f5-7d3331688ae5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_dd2d1d29-c26c-4643-937e-71e540dafb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_dd2d1d29-c26c-4643-937e-71e540dafb21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ea9d036a-0db4-44da-a2a3-8a0b9f549251" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ea9d036a-0db4-44da-a2a3-8a0b9f549251" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ea9d036a-0db4-44da-a2a3-8a0b9f549251_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ea9d036a-0db4-44da-a2a3-8a0b9f549251" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ea9d036a-0db4-44da-a2a3-8a0b9f549251_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b383e51b-2962-40b0-bb1a-71e699f54144" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ea9d036a-0db4-44da-a2a3-8a0b9f549251" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b383e51b-2962-40b0-bb1a-71e699f54144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b12316ab-5c88-4856-ab59-7a0bd90b7f42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b383e51b-2962-40b0-bb1a-71e699f54144" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b12316ab-5c88-4856-ab59-7a0bd90b7f42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i17d2a6d95ff9405cad0f38f05cbbb289_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="extended" id="i4c97c21ba6d742ecb29b8532939d4646_OrganizationandSummaryofAccountingPolicies"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="extended" id="i399dc98830a24b049527d6f2744a864b_OrganizationandSummaryofAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="extended" id="i38c911dcc4b740058a432e596efc37b9_OrganizationandSummaryofAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="extended" id="i9ce4b313045142478e0b31c26efacbaa_OrganizationandSummaryofAccountingPoliciesOrganizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_a83c6ae1-a32e-4d8d-bd57-12a195bb00af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_a83c6ae1-a32e-4d8d-bd57-12a195bb00af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_85e2c136-e5a6-4a47-ad69-dfda9407f20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_85e2c136-e5a6-4a47-ad69-dfda9407f20e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned_c0eb86b0-e93d-404d-9d7a-1eb9f0afa71d" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwned_c0eb86b0-e93d-404d-9d7a-1eb9f0afa71d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_37b0342a-5a4d-4e9c-bd02-b3e5815ccfc7" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_37b0342a-5a4d-4e9c-bd02-b3e5815ccfc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_0563791a-c3a5-4d29-ab0a-96e87d7a686b" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_0563791a-c3a5-4d29-ab0a-96e87d7a686b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e649ac98-12ed-4fe6-ba7d-fd034997aa93" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:to="loc_dei_LegalEntityAxis_e649ac98-12ed-4fe6-ba7d-fd034997aa93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e649ac98-12ed-4fe6-ba7d-fd034997aa93_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e649ac98-12ed-4fe6-ba7d-fd034997aa93" xlink:to="loc_dei_EntityDomain_e649ac98-12ed-4fe6-ba7d-fd034997aa93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a9ea24e0-8ab1-424c-929b-c8d99eac7e16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e649ac98-12ed-4fe6-ba7d-fd034997aa93" xlink:to="loc_dei_EntityDomain_a9ea24e0-8ab1-424c-929b-c8d99eac7e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BainCapitalMember_fe7bfcfc-e383-4d70-a6f6-4bf23b6e5d3e" xlink:href="sgry-20201231.xsd#sgry_BainCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a9ea24e0-8ab1-424c-929b-c8d99eac7e16" xlink:to="loc_sgry_BainCapitalMember_fe7bfcfc-e383-4d70-a6f6-4bf23b6e5d3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c321086f-ff14-42f2-9362-4fb29db195f6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:to="loc_srt_OwnershipAxis_c321086f-ff14-42f2-9362-4fb29db195f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c321086f-ff14-42f2-9362-4fb29db195f6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_c321086f-ff14-42f2-9362-4fb29db195f6" xlink:to="loc_srt_OwnershipDomain_c321086f-ff14-42f2-9362-4fb29db195f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d6a963e4-6899-4765-8f18-f021905730a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_c321086f-ff14-42f2-9362-4fb29db195f6" xlink:to="loc_srt_OwnershipDomain_d6a963e4-6899-4765-8f18-f021905730a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgeryPartnersIncMember_a5f2d7d0-9e21-4f97-83d2-d15517d54ec6" xlink:href="sgry-20201231.xsd#sgry_SurgeryPartnersIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_d6a963e4-6899-4765-8f18-f021905730a9" xlink:to="loc_sgry_SurgeryPartnersIncMember_a5f2d7d0-9e21-4f97-83d2-d15517d54ec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d83d3429-86b6-4d6c-928d-b41e06779d34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:to="loc_srt_ProductOrServiceAxis_d83d3429-86b6-4d6c-928d-b41e06779d34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d83d3429-86b6-4d6c-928d-b41e06779d34_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d83d3429-86b6-4d6c-928d-b41e06779d34" xlink:to="loc_srt_ProductsAndServicesDomain_d83d3429-86b6-4d6c-928d-b41e06779d34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6478d044-64db-44ee-9abc-fec13b9e366a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d83d3429-86b6-4d6c-928d-b41e06779d34" xlink:to="loc_srt_ProductsAndServicesDomain_6478d044-64db-44ee-9abc-fec13b9e366a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_4929d547-83c1-47b1-b5ce-945f244d0ffd" xlink:href="sgry-20201231.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6478d044-64db-44ee-9abc-fec13b9e366a" xlink:to="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_4929d547-83c1-47b1-b5ce-945f244d0ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember_4a271bfa-01ff-404a-b0c4-9a6527f36bb5" xlink:href="sgry-20201231.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6478d044-64db-44ee-9abc-fec13b9e366a" xlink:to="loc_sgry_FacilitiesSurgicalHospitalsMember_4a271bfa-01ff-404a-b0c4-9a6527f36bb5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesCARESACTDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails" xlink:type="extended" id="i2d12a33790b5480e96280fa145d58551_OrganizationandSummaryofAccountingPoliciesCARESACTDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended" id="if650534edd01465c8265e642396ac3a5_OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities_68332382-d75c-4c1b-9bc6-41046af9db01" xlink:href="sgry-20201231.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:to="loc_sgry_VariableInterestEntityNumberOfFacilities_68332382-d75c-4c1b-9bc6-41046af9db01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_204cbf7a-bcdf-4b4d-9265-ddf742983e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:to="loc_us-gaap_Assets_204cbf7a-bcdf-4b4d-9265-ddf742983e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_68c436d3-9b03-4b6f-946a-3e7e816be618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:to="loc_us-gaap_Liabilities_68c436d3-9b03-4b6f-946a-3e7e816be618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_57c140f2-b2fb-46bf-b477-6c514aa8c22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_57c140f2-b2fb-46bf-b477-6c514aa8c22c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7678f8a6-6d40-4d89-9c1c-592d681c0502" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_57c140f2-b2fb-46bf-b477-6c514aa8c22c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7678f8a6-6d40-4d89-9c1c-592d681c0502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7678f8a6-6d40-4d89-9c1c-592d681c0502_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7678f8a6-6d40-4d89-9c1c-592d681c0502" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7678f8a6-6d40-4d89-9c1c-592d681c0502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_79db10c7-f82c-4834-9b45-4e7f09cbacd6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7678f8a6-6d40-4d89-9c1c-592d681c0502" xlink:to="loc_srt_ConsolidatedEntitiesDomain_79db10c7-f82c-4834-9b45-4e7f09cbacd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_baf0ce54-572f-4a7a-8e68-ea9bcb7a37a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_79db10c7-f82c-4834-9b45-4e7f09cbacd6" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_baf0ce54-572f-4a7a-8e68-ea9bcb7a37a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="iae83fff6aa9d471f902de0a94d4dce64_OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7974602b-5d4b-4f4c-8d60-ac3f4b60f11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ed9c46ac-0eb7-40d6-9e82-c7902e9e7ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7974602b-5d4b-4f4c-8d60-ac3f4b60f11e" xlink:to="loc_us-gaap_LongTermDebt_ed9c46ac-0eb7-40d6-9e82-c7902e9e7ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_388f6dc2-26d2-44fa-ab4e-31a269709c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7974602b-5d4b-4f4c-8d60-ac3f4b60f11e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_388f6dc2-26d2-44fa-ab4e-31a269709c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7974602b-5d4b-4f4c-8d60-ac3f4b60f11e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d3c86f3-6a96-4da8-8637-17d49f759318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d3c86f3-6a96-4da8-8637-17d49f759318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d3c86f3-6a96-4da8-8637-17d49f759318_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d3c86f3-6a96-4da8-8637-17d49f759318" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d3c86f3-6a96-4da8-8637-17d49f759318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d3c86f3-6a96-4da8-8637-17d49f759318" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_34b74470-174c-4f3e-bb2d-f6ba37139ae0" xlink:href="sgry-20201231.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_34b74470-174c-4f3e-bb2d-f6ba37139ae0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_87293f13-fdaa-415c-95ef-6d685f0e44be" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_87293f13-fdaa-415c-95ef-6d685f0e44be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_0dfc9ed4-50dc-407a-871a-45e5a8a2b6ec" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_0dfc9ed4-50dc-407a-871a-45e5a8a2b6ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ff744a09-514a-469b-abe2-95f318b7f999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ff744a09-514a-469b-abe2-95f318b7f999" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff744a09-514a-469b-abe2-95f318b7f999_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff744a09-514a-469b-abe2-95f318b7f999" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff744a09-514a-469b-abe2-95f318b7f999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8a9171d3-b737-4815-b128-9509f10c30cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff744a09-514a-469b-abe2-95f318b7f999" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8a9171d3-b737-4815-b128-9509f10c30cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a55a7dc5-9677-4487-a56e-af83db532806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8a9171d3-b737-4815-b128-9509f10c30cd" xlink:to="loc_us-gaap_SecuredDebtMember_a55a7dc5-9677-4487-a56e-af83db532806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5d8c5963-e99b-47ad-a7e8-3c7016d27dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8a9171d3-b737-4815-b128-9509f10c30cd" xlink:to="loc_us-gaap_SeniorNotesMember_5d8c5963-e99b-47ad-a7e8-3c7016d27dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9b51c2a4-ad79-482e-b801-14fe1819df2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9b51c2a4-ad79-482e-b801-14fe1819df2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9b51c2a4-ad79-482e-b801-14fe1819df2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9b51c2a4-ad79-482e-b801-14fe1819df2a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9b51c2a4-ad79-482e-b801-14fe1819df2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_af963438-dc5d-4901-8127-d634f196371a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9b51c2a4-ad79-482e-b801-14fe1819df2a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_af963438-dc5d-4901-8127-d634f196371a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e36c982-4ca6-4343-a7a6-a155bad5c1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_af963438-dc5d-4901-8127-d634f196371a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e36c982-4ca6-4343-a7a6-a155bad5c1a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dda4f1d4-a364-4d45-9a6b-b141defa8f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e36c982-4ca6-4343-a7a6-a155bad5c1a6" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dda4f1d4-a364-4d45-9a6b-b141defa8f2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b97bc984-e2dc-4bca-8327-c885510369e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e36c982-4ca6-4343-a7a6-a155bad5c1a6" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b97bc984-e2dc-4bca-8327-c885510369e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128096c3-4014-444a-b8cc-cbf47b8c8e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128096c3-4014-444a-b8cc-cbf47b8c8e18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_128096c3-4014-444a-b8cc-cbf47b8c8e18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128096c3-4014-444a-b8cc-cbf47b8c8e18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_128096c3-4014-444a-b8cc-cbf47b8c8e18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8949fb1-5485-4670-8f23-f630851e0e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128096c3-4014-444a-b8cc-cbf47b8c8e18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8949fb1-5485-4670-8f23-f630851e0e83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e22ecc3c-c364-421d-8e94-09f54e4e7c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8949fb1-5485-4670-8f23-f630851e0e83" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e22ecc3c-c364-421d-8e94-09f54e4e7c00" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="ibdf03c079baa4767bb1040d337400eef_OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="extended" id="i22274e2b08614317bd2345ede1d51412_OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aff415fc-d160-4d35-87ef-99d39cc78021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b15a2c08-7e92-49e2-b4be-33fb0fa3da8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aff415fc-d160-4d35-87ef-99d39cc78021" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b15a2c08-7e92-49e2-b4be-33fb0fa3da8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aff415fc-d160-4d35-87ef-99d39cc78021" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_94b41091-3689-443f-b062-c02a45b4d420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_94b41091-3689-443f-b062-c02a45b4d420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_94b41091-3689-443f-b062-c02a45b4d420_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_94b41091-3689-443f-b062-c02a45b4d420" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_94b41091-3689-443f-b062-c02a45b4d420_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_97e23d4e-80a3-4968-ae8e-512a4534c781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_94b41091-3689-443f-b062-c02a45b4d420" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_97e23d4e-80a3-4968-ae8e-512a4534c781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_b43b68b5-9598-49ae-b651-281e93a41749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_97e23d4e-80a3-4968-ae8e-512a4534c781" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_b43b68b5-9598-49ae-b651-281e93a41749" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_970e790f-21de-4e0d-8529-1f76167f271e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_970e790f-21de-4e0d-8529-1f76167f271e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_970e790f-21de-4e0d-8529-1f76167f271e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_970e790f-21de-4e0d-8529-1f76167f271e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_970e790f-21de-4e0d-8529-1f76167f271e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8067443f-2486-4f83-ad6e-04da02baf933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_970e790f-21de-4e0d-8529-1f76167f271e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8067443f-2486-4f83-ad6e-04da02baf933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f37568e6-4ab0-4259-ba2c-b7b383d0d19f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8067443f-2486-4f83-ad6e-04da02baf933" xlink:to="loc_us-gaap_SalesRevenueNetMember_f37568e6-4ab0-4259-ba2c-b7b383d0d19f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0ef47a6f-ca46-4522-94dd-9199b0e7ed26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:to="loc_srt_ProductOrServiceAxis_0ef47a6f-ca46-4522-94dd-9199b0e7ed26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ef47a6f-ca46-4522-94dd-9199b0e7ed26_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0ef47a6f-ca46-4522-94dd-9199b0e7ed26" xlink:to="loc_srt_ProductsAndServicesDomain_0ef47a6f-ca46-4522-94dd-9199b0e7ed26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5daac4c-f790-4f14-877e-22f53e75d189" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0ef47a6f-ca46-4522-94dd-9199b0e7ed26" xlink:to="loc_srt_ProductsAndServicesDomain_c5daac4c-f790-4f14-877e-22f53e75d189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_2e9f220f-3251-4236-8cc9-caa79d911841" xlink:href="sgry-20201231.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5daac4c-f790-4f14-877e-22f53e75d189" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_2e9f220f-3251-4236-8cc9-caa79d911841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_d9e68f50-daeb-460c-b92e-644981d4ddb5" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2e9f220f-3251-4236-8cc9-caa79d911841" xlink:to="loc_sgry_SurgicalFacilityServicesMember_d9e68f50-daeb-460c-b92e-644981d4ddb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_5b784230-080b-4bc4-a05c-fae40245359a" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2e9f220f-3251-4236-8cc9-caa79d911841" xlink:to="loc_sgry_AncillaryServicesMember_5b784230-080b-4bc4-a05c-fae40245359a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationOtherServiceMember_354884b4-6d3f-477b-ab45-c4b37caa591d" xlink:href="sgry-20201231.xsd#sgry_HealthcareOrganizationOtherServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5daac4c-f790-4f14-877e-22f53e75d189" xlink:to="loc_sgry_HealthcareOrganizationOtherServiceMember_354884b4-6d3f-477b-ab45-c4b37caa591d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember_cc3d72a0-542b-4ab2-85f0-51d73857f44e" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationOtherServiceMember_354884b4-6d3f-477b-ab45-c4b37caa591d" xlink:to="loc_sgry_OpticalServicesMember_cc3d72a0-542b-4ab2-85f0-51d73857f44e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_47743767-72bd-4ac0-bbad-06327039b4c7" xlink:href="sgry-20201231.xsd#sgry_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationOtherServiceMember_354884b4-6d3f-477b-ab45-c4b37caa591d" xlink:to="loc_sgry_OtherServicesMember_47743767-72bd-4ac0-bbad-06327039b4c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="extended" id="id27c1fd5cf0f40e6b33466dc7c6fb4a7_OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cd6fa3b5-e9f7-4f4f-ae22-f315584107a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4fba583b-54fe-4323-b57e-44c7f7d23c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cd6fa3b5-e9f7-4f4f-ae22-f315584107a0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4fba583b-54fe-4323-b57e-44c7f7d23c6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2fdc823a-938f-4170-8e5e-cb60d75f62dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cd6fa3b5-e9f7-4f4f-ae22-f315584107a0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2fdc823a-938f-4170-8e5e-cb60d75f62dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cd6fa3b5-e9f7-4f4f-ae22-f315584107a0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7db2699b-72a1-477a-86d1-16eba0b94818" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:to="loc_srt_ProductOrServiceAxis_7db2699b-72a1-477a-86d1-16eba0b94818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7db2699b-72a1-477a-86d1-16eba0b94818_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7db2699b-72a1-477a-86d1-16eba0b94818" xlink:to="loc_srt_ProductsAndServicesDomain_7db2699b-72a1-477a-86d1-16eba0b94818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7db2699b-72a1-477a-86d1-16eba0b94818" xlink:to="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:href="sgry-20201231.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember_03608f68-0ee4-4a0b-a251-759cbf725dac" xlink:href="sgry-20201231.xsd#sgry_PrivateInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:to="loc_sgry_PrivateInsuranceMember_03608f68-0ee4-4a0b-a251-759cbf725dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GovernmentRevenueMember_a5187875-cf36-4afb-8e05-9c45daa9cf49" xlink:href="sgry-20201231.xsd#sgry_GovernmentRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:to="loc_sgry_GovernmentRevenueMember_a5187875-cf36-4afb-8e05-9c45daa9cf49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember_4ed419ce-2785-4ee3-bb6d-700b43c64fe9" xlink:href="sgry-20201231.xsd#sgry_SelfPayRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:to="loc_sgry_SelfPayRevenueMember_4ed419ce-2785-4ee3-bb6d-700b43c64fe9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember_5ba08611-2e92-4888-bd82-399e162ad673" xlink:href="sgry-20201231.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:to="loc_sgry_OtherPatientServiceRevenueSourcesMember_5ba08611-2e92-4888-bd82-399e162ad673" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember_0e2e36d5-5438-4a53-9d0f-893d160042b5" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:to="loc_sgry_OpticalServicesMember_0e2e36d5-5438-4a53-9d0f-893d160042b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_457264b8-b08e-4465-b1f4-1d703c2610a1" xlink:href="sgry-20201231.xsd#sgry_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:to="loc_sgry_OtherServicesMember_457264b8-b08e-4465-b1f4-1d703c2610a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6fee9595-9b66-4202-83d4-d65d44b99024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6fee9595-9b66-4202-83d4-d65d44b99024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6fee9595-9b66-4202-83d4-d65d44b99024_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6fee9595-9b66-4202-83d4-d65d44b99024" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6fee9595-9b66-4202-83d4-d65d44b99024_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_78d368c5-a708-4184-b3b5-3e60684f2436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6fee9595-9b66-4202-83d4-d65d44b99024" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_78d368c5-a708-4184-b3b5-3e60684f2436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a303758d-949d-4d0f-9f3c-9de63f196964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_78d368c5-a708-4184-b3b5-3e60684f2436" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a303758d-949d-4d0f-9f3c-9de63f196964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_062e82ac-1633-4d15-9878-537becc3bfb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_062e82ac-1633-4d15-9878-537becc3bfb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_062e82ac-1633-4d15-9878-537becc3bfb2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_062e82ac-1633-4d15-9878-537becc3bfb2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_062e82ac-1633-4d15-9878-537becc3bfb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8269da6f-b9de-4d8a-b513-9ae026c3650a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_062e82ac-1633-4d15-9878-537becc3bfb2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8269da6f-b9de-4d8a-b513-9ae026c3650a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_798797f7-a63c-47ce-9d64-075bb0ac67a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8269da6f-b9de-4d8a-b513-9ae026c3650a" xlink:to="loc_us-gaap_SalesRevenueNetMember_798797f7-a63c-47ce-9d64-075bb0ac67a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="if6c092416143435aaa3d502fa8401fb5_OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails" xlink:type="extended" id="i1037cb3f87844b9a9596168e4ecdb82b_OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="extended" id="i4dea4b31b4254dcdad385a2bd2226bdf_OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" id="id7adcebed33147daabbd9acc7e1b5da2_OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_baacc28d-7eea-4de0-9062-46740a0cc640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:to="loc_us-gaap_OperatingLeaseLiability_baacc28d-7eea-4de0-9062-46740a0cc640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c6531d9-61b5-4b1f-85e0-ac86f8bad6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c6531d9-61b5-4b1f-85e0-ac86f8bad6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_040ea733-6065-48ce-b087-b060b9f29a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_040ea733-6065-48ce-b087-b060b9f29a2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5" xlink:to="loc_us-gaap_EquityComponentDomain_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_946bf139-d8f7-4482-b787-ab11ba08c2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5" xlink:to="loc_us-gaap_EquityComponentDomain_946bf139-d8f7-4482-b787-ab11ba08c2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f0c4b724-0be1-4326-8d3a-587774391a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_946bf139-d8f7-4482-b787-ab11ba08c2fe" xlink:to="loc_us-gaap_RetainedEarningsMember_f0c4b724-0be1-4326-8d3a-587774391a52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_387a2257-1727-4715-8140-9fedcb70a209" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_387a2257-1727-4715-8140-9fedcb70a209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_387a2257-1727-4715-8140-9fedcb70a209_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_387a2257-1727-4715-8140-9fedcb70a209" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_387a2257-1727-4715-8140-9fedcb70a209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1ea98012-1346-4ae0-9687-a5a579e26ae7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_387a2257-1727-4715-8140-9fedcb70a209" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1ea98012-1346-4ae0-9687-a5a579e26ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_573582cf-1aea-4eac-b1d5-9bbc101f2a0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1ea98012-1346-4ae0-9687-a5a579e26ae7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_573582cf-1aea-4eac-b1d5-9bbc101f2a0f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposals"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="extended" id="i2e4ba9897acb416ca5f185533f4b0062_AcquisitionsandDisposals"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables" xlink:type="extended" id="ie9a3908b714f4e9c93742b607172314f_AcquisitionsandDisposalsTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="extended" id="i73d2a30f944f4fac82783e5a5aa1311a_AcquisitionsandDisposalsAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_e640367b-aff7-47de-8742-07ebfd2071d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_e640367b-aff7-47de-8742-07ebfd2071d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d933c29-31aa-49bf-9bfe-5b6f47fcda06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d933c29-31aa-49bf-9bfe-5b6f47fcda06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f4bfa86-8376-4498-a0ff-69fc78cb2d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f4bfa86-8376-4498-a0ff-69fc78cb2d3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_14af2114-b026-432e-8876-42e9f5b56c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_14af2114-b026-432e-8876-42e9f5b56c1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b62b1c21-375d-4a2d-8690-8f1d4b853ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b62b1c21-375d-4a2d-8690-8f1d4b853ee0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments_81c45bd4-9b4e-431e-80b8-5f6b004185fe" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments_81c45bd4-9b4e-431e-80b8-5f6b004185fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired_774b5678-cfd5-4d27-83e2-e7f85b5f7096" xlink:href="sgry-20201231.xsd#sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired_774b5678-cfd5-4d27-83e2-e7f85b5f7096" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e268a54f-1eda-46af-8de7-976ce1d29cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e268a54f-1eda-46af-8de7-976ce1d29cc4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bd92bc3b-501b-4683-af80-7f0830f0ae8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bd92bc3b-501b-4683-af80-7f0830f0ae8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd92bc3b-501b-4683-af80-7f0830f0ae8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bd92bc3b-501b-4683-af80-7f0830f0ae8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bd92bc3b-501b-4683-af80-7f0830f0ae8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19846d40-a496-42d3-8754-504a2bacb79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bd92bc3b-501b-4683-af80-7f0830f0ae8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19846d40-a496-42d3-8754-504a2bacb79e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityAndPhysicianPracticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19846d40-a496-42d3-8754-504a2bacb79e" xlink:to="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesNewMarketMember_19f61d81-e045-464e-b3dc-29d692afb7a8" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilitiesNewMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:to="loc_sgry_SurgicalFacilitiesNewMarketMember_19f61d81-e045-464e-b3dc-29d692afb7a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember_cb94a57c-73dd-4e9e-8a7f-96a0a8484912" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:to="loc_sgry_SurgicalFacilitiesExistingMarketsMember_cb94a57c-73dd-4e9e-8a7f-96a0a8484912" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PhysicianPracticeMember_6404ce85-0375-430f-894e-e26397291107" xlink:href="sgry-20201231.xsd#sgry_PhysicianPracticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:to="loc_sgry_PhysicianPracticeMember_6404ce85-0375-430f-894e-e26397291107" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f43ab81b-485b-41b9-810f-d7a7f33acbd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:to="loc_srt_RestatementAxis_f43ab81b-485b-41b9-810f-d7a7f33acbd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f43ab81b-485b-41b9-810f-d7a7f33acbd5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_f43ab81b-485b-41b9-810f-d7a7f33acbd5" xlink:to="loc_srt_RestatementDomain_f43ab81b-485b-41b9-810f-d7a7f33acbd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_10a06efc-420f-45a6-bd13-0e541bd33acc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_f43ab81b-485b-41b9-810f-d7a7f33acbd5" xlink:to="loc_srt_RestatementDomain_10a06efc-420f-45a6-bd13-0e541bd33acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_271e80f9-1862-4fab-a28c-935ed7c847ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_10a06efc-420f-45a6-bd13-0e541bd33acc" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_271e80f9-1862-4fab-a28c-935ed7c847ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="if2c851fdf6954c5c8bdeb1e43f321518_AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_768d8703-c498-4bb4-aec8-2f79ff7fd88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_768d8703-c498-4bb4-aec8-2f79ff7fd88c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_953d55d5-989b-4d24-bc25-913ca8d7d31e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_953d55d5-989b-4d24-bc25-913ca8d7d31e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_d8f2e7af-02e6-4ca9-b6f5-fdda0ff910e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_d8f2e7af-02e6-4ca9-b6f5-fdda0ff910e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_aac85a2e-38e7-49d6-b9a4-b4ea11f90bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_aac85a2e-38e7-49d6-b9a4-b4ea11f90bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_441acec9-26de-4443-8aef-8b88cae4e718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_441acec9-26de-4443-8aef-8b88cae4e718" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cde9d51d-0482-4829-9762-e156098fe668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cde9d51d-0482-4829-9762-e156098fe668" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05968d71-fff5-49d4-8849-2c8cedf67813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_Goodwill_05968d71-fff5-49d4-8849-2c8cedf67813" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_413bc9bb-7c57-4526-b59b-bff2b0f9cccb" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_413bc9bb-7c57-4526-b59b-bff2b0f9cccb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_6a1196ef-a7e2-451f-a72a-9448b525fbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_6a1196ef-a7e2-451f-a72a-9448b525fbf6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_d7c3438e-db23-4251-907d-efc8e48003fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_d7c3438e-db23-4251-907d-efc8e48003fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9f54a889-59ca-47f3-9c6d-f1808e351fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9f54a889-59ca-47f3-9c6d-f1808e351fd2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_5ae70a73-5489-4542-9294-03fe95de8f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_5ae70a73-5489-4542-9294-03fe95de8f2e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9e1af46f-7315-40d4-9392-b2b134ae58b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9e1af46f-7315-40d4-9392-b2b134ae58b1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_4c66a225-63f8-4a4d-acf6-2abdd4a896cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_4c66a225-63f8-4a4d-acf6-2abdd4a896cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d694830-0dea-4fd8-a3a7-f323789365e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d694830-0dea-4fd8-a3a7-f323789365e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bbfbd7aa-18a9-4d0a-930c-9816824729de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d694830-0dea-4fd8-a3a7-f323789365e9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bbfbd7aa-18a9-4d0a-930c-9816824729de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbfbd7aa-18a9-4d0a-930c-9816824729de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bbfbd7aa-18a9-4d0a-930c-9816824729de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bbfbd7aa-18a9-4d0a-930c-9816824729de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e4788c0-fb50-429d-b422-78bb3ca6a477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bbfbd7aa-18a9-4d0a-930c-9816824729de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e4788c0-fb50-429d-b422-78bb3ca6a477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_074011a3-9251-46a1-a4b6-fda9e32cd767" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityAndPhysicianPracticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e4788c0-fb50-429d-b422-78bb3ca6a477" xlink:to="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_074011a3-9251-46a1-a4b6-fda9e32cd767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityMember_e41ee9c2-baa2-4112-b4a3-c9468d806e0e" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_074011a3-9251-46a1-a4b6-fda9e32cd767" xlink:to="loc_sgry_SurgicalFacilityMember_e41ee9c2-baa2-4112-b4a3-c9468d806e0e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsDisposalsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails" xlink:type="extended" id="i8f41d62b658c436782d6ea1cb0d92c0a_AcquisitionsandDisposalsDisposalsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed_23fc4b5c-b7a7-43f3-b271-6b4ff543f30a" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:to="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed_23fc4b5c-b7a7-43f3-b271-6b4ff543f30a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_13e02d1b-363b-4214-87b2-1600ac0fe357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_13e02d1b-363b-4214-87b2-1600ac0fe357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_07c138f3-316d-4421-81f7-0d4602c8ccb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_07c138f3-316d-4421-81f7-0d4602c8ccb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_da87ea40-9623-4420-addc-9c02820ef220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_da87ea40-9623-4420-addc-9c02820ef220" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d8311373-80fa-43f8-a2d7-f1d3027147a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_da87ea40-9623-4420-addc-9c02820ef220" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d8311373-80fa-43f8-a2d7-f1d3027147a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d8311373-80fa-43f8-a2d7-f1d3027147a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d8311373-80fa-43f8-a2d7-f1d3027147a3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d8311373-80fa-43f8-a2d7-f1d3027147a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d8311373-80fa-43f8-a2d7-f1d3027147a3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupOneMember_9c26ed41-7a20-4296-8087-70f1931fbf67" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:to="loc_sgry_DisposalGroupOneMember_9c26ed41-7a20-4296-8087-70f1931fbf67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupTwoMember_71c8aabb-cc5e-487e-91d5-310b3fe14df8" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:to="loc_sgry_DisposalGroupTwoMember_71c8aabb-cc5e-487e-91d5-310b3fe14df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupThreeMember_e94329e0-a00d-4bd8-9cb3-a1102abc4069" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:to="loc_sgry_DisposalGroupThreeMember_e94329e0-a00d-4bd8-9cb3-a1102abc4069" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupFourMember_366a84f5-9132-428b-a4d3-8bde6135e427" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:to="loc_sgry_DisposalGroupFourMember_366a84f5-9132-428b-a4d3-8bde6135e427" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipment" xlink:type="extended" id="i6321102a7d2e439dbc807bca01dfe4e0_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentTables" xlink:type="extended" id="i1ef3356b2e7b4d249dbde74506a53901_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended" id="i6c7da7130bae426e877a55094d466577_PropertyandEquipmentAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6c89987b-a7fb-4402-bf4f-1e316585af46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6a15c0f5-aa15-4129-9a55-30808a57aab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6c89987b-a7fb-4402-bf4f-1e316585af46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6a15c0f5-aa15-4129-9a55-30808a57aab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0b0a82b1-aa26-43f1-b45c-aa284ba1d89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6c89987b-a7fb-4402-bf4f-1e316585af46" xlink:to="loc_us-gaap_Depreciation_0b0a82b1-aa26-43f1-b45c-aa284ba1d89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6c89987b-a7fb-4402-bf4f-1e316585af46" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f820d84-8919-4c90-943f-4d09876143b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f820d84-8919-4c90-943f-4d09876143b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f820d84-8919-4c90-943f-4d09876143b5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f820d84-8919-4c90-943f-4d09876143b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3f820d84-8919-4c90-943f-4d09876143b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f820d84-8919-4c90-943f-4d09876143b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_baab4627-94a1-4b2a-afd9-3961c7b80868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_baab4627-94a1-4b2a-afd9-3961c7b80868" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_9f0ad756-f984-4fd4-915c-024e8cd1cd4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:to="loc_us-gaap_ComputerEquipmentMember_9f0ad756-f984-4fd4-915c-024e8cd1cd4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FurnitureAndEquipmentMember_125fcc7a-d3b6-4873-82cf-ed106f52a8ac" xlink:href="sgry-20201231.xsd#sgry_FurnitureAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:to="loc_sgry_FurnitureAndEquipmentMember_125fcc7a-d3b6-4873-82cf-ed106f52a8ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_59b1af37-9702-4736-a861-dfde478661a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:to="loc_srt_RangeAxis_59b1af37-9702-4736-a861-dfde478661a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_59b1af37-9702-4736-a861-dfde478661a1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_59b1af37-9702-4736-a861-dfde478661a1" xlink:to="loc_srt_RangeMember_59b1af37-9702-4736-a861-dfde478661a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92700c41-3ca2-431e-9f0f-de0083ce30dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_59b1af37-9702-4736-a861-dfde478661a1" xlink:to="loc_srt_RangeMember_92700c41-3ca2-431e-9f0f-de0083ce30dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7852b819-0077-4b26-a5e8-6e68560359b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92700c41-3ca2-431e-9f0f-de0083ce30dd" xlink:to="loc_srt_MinimumMember_7852b819-0077-4b26-a5e8-6e68560359b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f056d8bc-ba16-4b1e-adfa-926da10e8d2c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92700c41-3ca2-431e-9f0f-de0083ce30dd" xlink:to="loc_srt_MaximumMember_f056d8bc-ba16-4b1e-adfa-926da10e8d2c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended" id="ia15d8ea907c54c04b3e7a4688d1b115a_PropertyandEquipmentSummaryofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b078c632-019d-4b55-9c19-df3821f0c61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b078c632-019d-4b55-9c19-df3821f0c61c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_f4992036-a021-400d-9a93-490d6f14cfda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_f4992036-a021-400d-9a93-490d6f14cfda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_d5b1f205-4ba7-48cf-8777-b4f318e812a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_d5b1f205-4ba7-48cf-8777-b4f318e812a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_415474fe-333b-422a-98d7-28dcea2d8170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_415474fe-333b-422a-98d7-28dcea2d8170" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5af68d2b-8b71-42dd-8626-ef27924942d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5af68d2b-8b71-42dd-8626-ef27924942d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a936a0b-23fa-4d36-aae2-058adf6f2713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a936a0b-23fa-4d36-aae2-058adf6f2713" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a22b7724-f9ae-4bd7-941c-561206b6a790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a936a0b-23fa-4d36-aae2-058adf6f2713" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a22b7724-f9ae-4bd7-941c-561206b6a790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a22b7724-f9ae-4bd7-941c-561206b6a790_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a22b7724-f9ae-4bd7-941c-561206b6a790" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a22b7724-f9ae-4bd7-941c-561206b6a790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a22b7724-f9ae-4bd7-941c-561206b6a790" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_a142b072-495a-40fd-8e4d-bc6fedd2916b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_us-gaap_LandMember_a142b072-495a-40fd-8e4d-bc6fedd2916b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_2c0ba4c4-f93b-4f7e-b7a4-ae40a096432c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_2c0ba4c4-f93b-4f7e-b7a4-ae40a096432c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FurnitureAndEquipmentMember_081bb032-4c8b-4374-9932-1c462f5f2eeb" xlink:href="sgry-20201231.xsd#sgry_FurnitureAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_sgry_FurnitureAndEquipmentMember_081bb032-4c8b-4374-9932-1c462f5f2eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_857f81a6-83a0-47d8-bb13-8314bab1bafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_us-gaap_ComputerEquipmentMember_857f81a6-83a0-47d8-bb13-8314bab1bafa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicalEquipmentMember_50aad415-909c-4a3f-8097-b4c7a9b140d7" xlink:href="sgry-20201231.xsd#sgry_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_sgry_MedicalEquipmentMember_50aad415-909c-4a3f-8097-b4c7a9b140d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ba317cc5-ebfc-45e9-a704-41688b737f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_us-gaap_ConstructionInProgressMember_ba317cc5-ebfc-45e9-a704-41688b737f20" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssets" xlink:type="extended" id="i3f80496200d44cec8e43636b1fda3921_GoodwillandIntangibleAssets"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended" id="ia2a7a89fc37948cda74d60ff979c02eb_GoodwillandIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended" id="i48c1933ec0e1499aa961e528a4d7b690_GoodwillandIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_29ab5690-ed11-4f0a-aaa5-311096b6d974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_29ab5690-ed11-4f0a-aaa5-311096b6d974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_26da5c72-0f72-4ddd-a725-60782363633a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_NumberOfReportingUnits_26da5c72-0f72-4ddd-a725-60782363633a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_735d9fe1-d561-416c-8897-b58c8d270ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_735d9fe1-d561-416c-8897-b58c8d270ed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_78cd61b1-dc27-4a29-9713-013172313dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_Goodwill_78cd61b1-dc27-4a29-9713-013172313dc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f52c87a4-61c8-4731-b5d4-d748970a6f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f52c87a4-61c8-4731-b5d4-d748970a6f8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_dd2bb774-93f7-48cd-afaf-7028847e01ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:to="loc_us-gaap_ReportingUnitAxis_dd2bb774-93f7-48cd-afaf-7028847e01ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_dd2bb774-93f7-48cd-afaf-7028847e01ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_dd2bb774-93f7-48cd-afaf-7028847e01ac" xlink:to="loc_us-gaap_ReportingUnitDomain_dd2bb774-93f7-48cd-afaf-7028847e01ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_dd2bb774-93f7-48cd-afaf-7028847e01ac" xlink:to="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_e6816bb6-e959-4f8e-aefc-9554afe41610" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:to="loc_sgry_SurgicalFacilityServicesMember_e6816bb6-e959-4f8e-aefc-9554afe41610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_6ffdd225-efef-44ad-b0b6-c8125152384a" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:to="loc_sgry_AncillaryServicesMember_6ffdd225-efef-44ad-b0b6-c8125152384a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AllianceMember_af3d9e82-e4cc-4772-8517-dfdc3c684523" xlink:href="sgry-20201231.xsd#sgry_AllianceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:to="loc_sgry_AllianceMember_af3d9e82-e4cc-4772-8517-dfdc3c684523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85e01ef5-2ffe-46de-975f-fded1eaceff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85e01ef5-2ffe-46de-975f-fded1eaceff6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85e01ef5-2ffe-46de-975f-fded1eaceff6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85e01ef5-2ffe-46de-975f-fded1eaceff6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_85e01ef5-2ffe-46de-975f-fded1eaceff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85e01ef5-2ffe-46de-975f-fded1eaceff6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PhysicianIncomeGuaranteesMember_21927d9c-7de5-40bc-a3e4-c91aca25187d" xlink:href="sgry-20201231.xsd#sgry_PhysicianIncomeGuaranteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:to="loc_sgry_PhysicianIncomeGuaranteesMember_21927d9c-7de5-40bc-a3e4-c91aca25187d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_87ffb88f-c44e-4df3-8a71-4a91ab212465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_87ffb88f-c44e-4df3-8a71-4a91ab212465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ManagementRightsMember_15c28061-f5df-43de-902d-db672f2b3ca9" xlink:href="sgry-20201231.xsd#sgry_ManagementRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:to="loc_sgry_ManagementRightsMember_15c28061-f5df-43de-902d-db672f2b3ca9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_68a0bfea-30a1-4f22-8fc4-5f55a967c663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:to="loc_us-gaap_CustomerRelationshipsMember_68a0bfea-30a1-4f22-8fc4-5f55a967c663" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89db6f33-8595-4eea-b517-1072e4d67d37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:to="loc_srt_RangeAxis_89db6f33-8595-4eea-b517-1072e4d67d37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_89db6f33-8595-4eea-b517-1072e4d67d37_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_89db6f33-8595-4eea-b517-1072e4d67d37" xlink:to="loc_srt_RangeMember_89db6f33-8595-4eea-b517-1072e4d67d37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cf7a7d5-c702-423c-baeb-61f19699b4b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_89db6f33-8595-4eea-b517-1072e4d67d37" xlink:to="loc_srt_RangeMember_4cf7a7d5-c702-423c-baeb-61f19699b4b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ec407a81-19d8-4dbb-96d6-f725c3b9ea9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4cf7a7d5-c702-423c-baeb-61f19699b4b8" xlink:to="loc_srt_MinimumMember_ec407a81-19d8-4dbb-96d6-f725c3b9ea9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3fa4dab0-c460-49e3-97b1-466cf5a1e19d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4cf7a7d5-c702-423c-baeb-61f19699b4b8" xlink:to="loc_srt_MaximumMember_3fa4dab0-c460-49e3-97b1-466cf5a1e19d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails" xlink:type="extended" id="i2175d95f33b34d2383410ad65d148bff_GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails" xlink:type="extended" id="i84efb555e1f2480f8e5d50a475144ad8_GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f77f1d49-c878-47a5-be25-73c6382af8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f77f1d49-c878-47a5-be25-73c6382af8dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ba4c1cfb-cace-4e02-965c-173c4addd272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ba4c1cfb-cace-4e02-965c-173c4addd272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0cd4420b-d0fe-48a8-818d-cb5da15266b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0cd4420b-d0fe-48a8-818d-cb5da15266b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4268eef4-3c7b-4222-baa8-e7553e9e3198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4268eef4-3c7b-4222-baa8-e7553e9e3198" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c78340dc-b1e5-482d-abb7-273f99c208d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c78340dc-b1e5-482d-abb7-273f99c208d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9d19062-99bb-4372-8164-69bdefd623e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9d19062-99bb-4372-8164-69bdefd623e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ba96b6cc-b8fb-4be2-842b-dc80b704e146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ba96b6cc-b8fb-4be2-842b-dc80b704e146" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70a4dc08-6cf2-489f-bdd5-cbde01467602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ba96b6cc-b8fb-4be2-842b-dc80b704e146" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70a4dc08-6cf2-489f-bdd5-cbde01467602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70a4dc08-6cf2-489f-bdd5-cbde01467602_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70a4dc08-6cf2-489f-bdd5-cbde01467602" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70a4dc08-6cf2-489f-bdd5-cbde01467602_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ce5a073-50db-4952-ba08-c60ecbafb759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70a4dc08-6cf2-489f-bdd5-cbde01467602" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ce5a073-50db-4952-ba08-c60ecbafb759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ManagementRightsMember_e1385857-2dd0-4728-bc80-68630faf4b0a" xlink:href="sgry-20201231.xsd#sgry_ManagementRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ce5a073-50db-4952-ba08-c60ecbafb759" xlink:to="loc_sgry_ManagementRightsMember_e1385857-2dd0-4728-bc80-68630faf4b0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_2fcdbaf1-b539-4b18-8448-a3cb4bd18f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ce5a073-50db-4952-ba08-c60ecbafb759" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_2fcdbaf1-b539-4b18-8448-a3cb4bd18f24" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended" id="i798597fb6a6f4db0b2e842746398134f_GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="extended" id="i84fa215a5ded4cdbbbb90f88041524c0_LongTermDebt"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="extended" id="i5541b2a7ba1b40dc9aec50c14deefe6a_LongTermDebtTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails" xlink:type="extended" id="i587f62a157f1441b907b9b55500361af_LongTermDebtSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_65d30e7a-93f8-41d3-9804-e23bb526dbf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_65d30e7a-93f8-41d3-9804-e23bb526dbf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_88a83604-679f-4ab9-859e-0d9a62dec88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_FinanceLeaseLiability_88a83604-679f-4ab9-859e-0d9a62dec88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_962acf35-515a-44d9-950c-93bf31f559d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_962acf35-515a-44d9-950c-93bf31f559d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_83f74132-db68-472e-a88d-40032c482629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_83f74132-db68-472e-a88d-40032c482629" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_3fbf9fd2-ba24-45ac-8f8e-871dc90c2de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_3fbf9fd2-ba24-45ac-8f8e-871dc90c2de1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f4901abd-1ea1-4a0b-a81b-7e9af67d48e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f4901abd-1ea1-4a0b-a81b-7e9af67d48e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_092a81ee-bf02-484c-9033-a906e1ff0af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_092a81ee-bf02-484c-9033-a906e1ff0af2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_023b62d6-0510-41d3-8368-5690d52dc4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_023b62d6-0510-41d3-8368-5690d52dc4f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3531bc37-6013-4447-8230-40f64fa5c17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:to="loc_us-gaap_DebtInstrumentAxis_3531bc37-6013-4447-8230-40f64fa5c17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3531bc37-6013-4447-8230-40f64fa5c17e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3531bc37-6013-4447-8230-40f64fa5c17e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3531bc37-6013-4447-8230-40f64fa5c17e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3531bc37-6013-4447-8230-40f64fa5c17e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_1fa718bf-268c-4f57-a91d-83779e99f1bc" xlink:href="sgry-20201231.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_1fa718bf-268c-4f57-a91d-83779e99f1bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_142908f6-cef3-48e2-a34a-a95f2ae97998" xlink:href="sgry-20201231.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_142908f6-cef3-48e2-a34a-a95f2ae97998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_282f04f6-99bb-4374-a6bb-60ae32ad96c0" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_282f04f6-99bb-4374-a6bb-60ae32ad96c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_acfc5a69-ae88-43b5-97e0-0e163403f33c" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_acfc5a69-ae88-43b5-97e0-0e163403f33c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_69d6d71a-5415-4133-8100-9c5e6ac55342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_69d6d71a-5415-4133-8100-9c5e6ac55342" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_69d6d71a-5415-4133-8100-9c5e6ac55342_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69d6d71a-5415-4133-8100-9c5e6ac55342" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_69d6d71a-5415-4133-8100-9c5e6ac55342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69d6d71a-5415-4133-8100-9c5e6ac55342" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_067ccb3a-f477-4bdf-b272-bd0ab1b7cd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:to="loc_us-gaap_SecuredDebtMember_067ccb3a-f477-4bdf-b272-bd0ab1b7cd6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_57a062c2-b9d5-406c-bf7b-f5d40f0d963b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:to="loc_us-gaap_SeniorNotesMember_57a062c2-b9d5-406c-bf7b-f5d40f0d963b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember_636ee599-5204-49cf-b5bd-7448f2514960" xlink:href="sgry-20201231.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:to="loc_sgry_NotesPayableAndSecuredLoansMember_636ee599-5204-49cf-b5bd-7448f2514960" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="i0d6a34a705874e029fb87e6a9b1e1908_LongTermDebtSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e56b24de-c0ef-4a00-a191-d508f3b58ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e56b24de-c0ef-4a00-a191-d508f3b58ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_d7644462-cf6c-4b77-8314-d26c1fe36a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_LineOfCredit_d7644462-cf6c-4b77-8314-d26c1fe36a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_61e139f8-ba8b-4d4b-94fc-b562b6fdd18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_61e139f8-ba8b-4d4b-94fc-b562b6fdd18b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_da33e8dc-ab61-4b11-8e6b-3824c2649db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_da33e8dc-ab61-4b11-8e6b-3824c2649db7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentMarginInAdditionToBaseRate_e55a6903-1365-4338-a20f-f1713b191ae8" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentMarginInAdditionToBaseRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentMarginInAdditionToBaseRate_e55a6903-1365-4338-a20f-f1713b191ae8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_ba1b2f0e-85e7-4fbf-8f3c-83cb814dce92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_ba1b2f0e-85e7-4fbf-8f3c-83cb814dce92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentQuarterlyMaturityInstallments_2a58f9fe-f6ce-479e-b1be-95365d095c1f" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentQuarterlyMaturityInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentQuarterlyMaturityInstallments_2a58f9fe-f6ce-479e-b1be-95365d095c1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9b2993bc-8313-4d71-a3e4-260ad34be30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9b2993bc-8313-4d71-a3e4-260ad34be30c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentAlternateBaseRateFloor_205512c5-cf7c-45aa-a80a-46151539e552" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentAlternateBaseRateFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentAlternateBaseRateFloor_205512c5-cf7c-45aa-a80a-46151539e552" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentNetLeverageRatio_97d69a32-b650-4f17-8e75-87b7cedcaf5e" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentNetLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentNetLeverageRatio_97d69a32-b650-4f17-8e75-87b7cedcaf5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentTotalCommitmentThreshold_330d8849-08ec-433e-ac66-f8c538218b76" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentTotalCommitmentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentTotalCommitmentThreshold_330d8849-08ec-433e-ac66-f8c538218b76" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eeb4e12-4342-46c7-9852-00e70a0e8733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eeb4e12-4342-46c7-9852-00e70a0e8733" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8a333b5b-14db-4bbb-9d23-9a03925261d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_srt_RangeAxis_8a333b5b-14db-4bbb-9d23-9a03925261d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a333b5b-14db-4bbb-9d23-9a03925261d1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8a333b5b-14db-4bbb-9d23-9a03925261d1" xlink:to="loc_srt_RangeMember_8a333b5b-14db-4bbb-9d23-9a03925261d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a5909d9-7433-44ec-a92a-4cf08c76903e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8a333b5b-14db-4bbb-9d23-9a03925261d1" xlink:to="loc_srt_RangeMember_1a5909d9-7433-44ec-a92a-4cf08c76903e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c45c951f-72f4-4c96-9405-6ba78f21ba7a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1a5909d9-7433-44ec-a92a-4cf08c76903e" xlink:to="loc_srt_MinimumMember_c45c951f-72f4-4c96-9405-6ba78f21ba7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_01641763-a53c-4989-a2e4-a69678abca0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1a5909d9-7433-44ec-a92a-4cf08c76903e" xlink:to="loc_srt_MaximumMember_01641763-a53c-4989-a2e4-a69678abca0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ffa10824-1b0e-4360-9746-41cef5561c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_VariableRateAxis_ffa10824-1b0e-4360-9746-41cef5561c34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ffa10824-1b0e-4360-9746-41cef5561c34_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_ffa10824-1b0e-4360-9746-41cef5561c34" xlink:to="loc_us-gaap_VariableRateDomain_ffa10824-1b0e-4360-9746-41cef5561c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_ffa10824-1b0e-4360-9746-41cef5561c34" xlink:to="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f55abaf7-d6a4-4973-8c04-70c40e48d328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f55abaf7-d6a4-4973-8c04-70c40e48d328" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_7ae9dc7b-e8f1-42b7-b0ff-4dbc4f3e46a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_7ae9dc7b-e8f1-42b7-b0ff-4dbc4f3e46a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OneMonthLondonInterbankOfferedRateLIBORMember_ca462c73-47aa-4e93-ae16-84056a89988c" xlink:href="sgry-20201231.xsd#sgry_OneMonthLondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:to="loc_sgry_OneMonthLondonInterbankOfferedRateLIBORMember_ca462c73-47aa-4e93-ae16-84056a89988c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_dd08cb77-b8fc-44ed-8b15-bee13dd632a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:to="loc_us-gaap_BaseRateMember_dd08cb77-b8fc-44ed-8b15-bee13dd632a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_274ed1e7-f314-4a58-b205-449cdaa3e95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_274ed1e7-f314-4a58-b205-449cdaa3e95a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_274ed1e7-f314-4a58-b205-449cdaa3e95a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_274ed1e7-f314-4a58-b205-449cdaa3e95a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_274ed1e7-f314-4a58-b205-449cdaa3e95a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_274ed1e7-f314-4a58-b205-449cdaa3e95a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_0c3d01b5-23b5-4234-87d4-0a6c3be0d023" xlink:href="sgry-20201231.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_0c3d01b5-23b5-4234-87d4-0a6c3be0d023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_c5e22a23-670d-47d4-b875-ff8962a4c80f" xlink:href="sgry-20201231.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_c5e22a23-670d-47d4-b875-ff8962a4c80f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2018IncrementalTermLoanMember_3344df7f-d56a-46a5-94f5-12abd29e55bd" xlink:href="sgry-20201231.xsd#sgry_A2018IncrementalTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:to="loc_sgry_A2018IncrementalTermLoanMember_3344df7f-d56a-46a5-94f5-12abd29e55bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2020IncrementalLoansMember_257ae333-f7af-43d1-bc17-76d4dde1f210" xlink:href="sgry-20201231.xsd#sgry_A2020IncrementalLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:to="loc_sgry_A2020IncrementalLoansMember_257ae333-f7af-43d1-bc17-76d4dde1f210" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b76ff3a2-61b3-4fa9-b81d-8f901109f26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b76ff3a2-61b3-4fa9-b81d-8f901109f26b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b76ff3a2-61b3-4fa9-b81d-8f901109f26b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b76ff3a2-61b3-4fa9-b81d-8f901109f26b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b76ff3a2-61b3-4fa9-b81d-8f901109f26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ebf44236-f4c2-4ef3-874e-436ade717486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b76ff3a2-61b3-4fa9-b81d-8f901109f26b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ebf44236-f4c2-4ef3-874e-436ade717486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_51092cbd-3d8a-43d8-8d64-c1d67538a72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ebf44236-f4c2-4ef3-874e-436ade717486" xlink:to="loc_us-gaap_SecuredDebtMember_51092cbd-3d8a-43d8-8d64-c1d67538a72a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_23dabcfb-d190-4040-9eab-7e3cc78f1845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_CreditFacilityAxis_23dabcfb-d190-4040-9eab-7e3cc78f1845" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_23dabcfb-d190-4040-9eab-7e3cc78f1845_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_23dabcfb-d190-4040-9eab-7e3cc78f1845" xlink:to="loc_us-gaap_CreditFacilityDomain_23dabcfb-d190-4040-9eab-7e3cc78f1845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6354e33f-e834-4296-9bf0-f845819903d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_23dabcfb-d190-4040-9eab-7e3cc78f1845" xlink:to="loc_us-gaap_CreditFacilityDomain_6354e33f-e834-4296-9bf0-f845819903d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_86ecec8b-0897-4bd6-b36e-ac146d619c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_6354e33f-e834-4296-9bf0-f845819903d8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_86ecec8b-0897-4bd6-b36e-ac146d619c4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_89506a71-5b71-484b-87dd-c61ec92b27ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_6354e33f-e834-4296-9bf0-f845819903d8" xlink:to="loc_us-gaap_LetterOfCreditMember_89506a71-5b71-484b-87dd-c61ec92b27ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt6750SeniorUnsecuredNotesdue2025Details"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details" xlink:type="extended" id="ie5ea043988584bad8003cfda055cd019_LongTermDebt6750SeniorUnsecuredNotesdue2025Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13d2a488-5b7a-462b-96fe-ad7e18328d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13d2a488-5b7a-462b-96fe-ad7e18328d62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_49ac70d2-77d4-4224-b806-26d0f6036781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_49ac70d2-77d4-4224-b806-26d0f6036781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3330ad7b-cbdf-456b-807c-8fbe0423b37d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3330ad7b-cbdf-456b-807c-8fbe0423b37d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:to="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_811fc86d-9396-4adb-b4c8-26b072a7e224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_811fc86d-9396-4adb-b4c8-26b072a7e224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_84df6eb9-c4be-4d84-a431-d402fec52234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_811fc86d-9396-4adb-b4c8-26b072a7e224" xlink:to="loc_us-gaap_SeniorNotesMember_84df6eb9-c4be-4d84-a431-d402fec52234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_76bffb6f-25c1-4963-ad70-8d9805a4f502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:to="loc_us-gaap_DebtInstrumentAxis_76bffb6f-25c1-4963-ad70-8d9805a4f502" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_76bffb6f-25c1-4963-ad70-8d9805a4f502_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_76bffb6f-25c1-4963-ad70-8d9805a4f502" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_76bffb6f-25c1-4963-ad70-8d9805a4f502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65a3c6fb-394c-4670-bce5-0480edbe06bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_76bffb6f-25c1-4963-ad70-8d9805a4f502" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65a3c6fb-394c-4670-bce5-0480edbe06bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_d3ec229e-1351-4686-a93b-b33678cae19f" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65a3c6fb-394c-4670-bce5-0480edbe06bf" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_d3ec229e-1351-4686-a93b-b33678cae19f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c275acd6-87d9-4f32-a9dd-c28c7b63012e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c275acd6-87d9-4f32-a9dd-c28c7b63012e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c275acd6-87d9-4f32-a9dd-c28c7b63012e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c275acd6-87d9-4f32-a9dd-c28c7b63012e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c275acd6-87d9-4f32-a9dd-c28c7b63012e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c275acd6-87d9-4f32-a9dd-c28c7b63012e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_81f5a3e9-475a-4bbb-9a9f-c27140206e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_81f5a3e9-475a-4bbb-9a9f-c27140206e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_0854a5e4-1bd0-4731-8953-107baf9885c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_0854a5e4-1bd0-4731-8953-107baf9885c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_57b6029f-0ed3-487d-9f26-5fc5bd00afee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_57b6029f-0ed3-487d-9f26-5fc5bd00afee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3a8e6309-ee47-4fc2-84e7-9ad19931e7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3a8e6309-ee47-4fc2-84e7-9ad19931e7d8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt10000SeniorUnsecuredNotesdue2027Details"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details" xlink:type="extended" id="i70241ca77dd24e09b97d74825c05a58c_LongTermDebt10000SeniorUnsecuredNotesdue2027Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_96823670-e361-425f-98fc-cb62fca61423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_96823670-e361-425f-98fc-cb62fca61423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a8a0a5a8-288a-4e2f-b386-319a0c2bcc92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a8a0a5a8-288a-4e2f-b386-319a0c2bcc92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e553af7f-c21d-47bf-96b9-877476d4b766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e553af7f-c21d-47bf-96b9-877476d4b766" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3df2a622-2b40-4cb2-adab-7b0a8d4c650f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3df2a622-2b40-4cb2-adab-7b0a8d4c650f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_12db6b6c-fb3a-42c3-abb8-02f6aedc6485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_12db6b6c-fb3a-42c3-abb8-02f6aedc6485" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d99ed368-d36c-4950-a128-0cbd75e58ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d99ed368-d36c-4950-a128-0cbd75e58ff3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c661b7a8-0f69-4693-aa47-1d94174f6ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c661b7a8-0f69-4693-aa47-1d94174f6ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_65bc6197-0ea2-43ae-8167-a4f0045063e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c661b7a8-0f69-4693-aa47-1d94174f6ea7" xlink:to="loc_us-gaap_SeniorNotesMember_65bc6197-0ea2-43ae-8167-a4f0045063e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9335e6cc-9b26-4728-b803-ab3380a2eadb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:to="loc_us-gaap_DebtInstrumentAxis_9335e6cc-9b26-4728-b803-ab3380a2eadb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9335e6cc-9b26-4728-b803-ab3380a2eadb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9335e6cc-9b26-4728-b803-ab3380a2eadb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9335e6cc-9b26-4728-b803-ab3380a2eadb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6bb033c-3775-463d-9b5e-f3d97135fa67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9335e6cc-9b26-4728-b803-ab3380a2eadb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6bb033c-3775-463d-9b5e-f3d97135fa67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_15e6e1fb-65ad-48c3-8b01-b8a56e0358f9" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6bb033c-3775-463d-9b5e-f3d97135fa67" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_15e6e1fb-65ad-48c3-8b01-b8a56e0358f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_008f755e-38a6-452e-a6a8-7a53b70c923e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_008f755e-38a6-452e-a6a8-7a53b70c923e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_008f755e-38a6-452e-a6a8-7a53b70c923e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_008f755e-38a6-452e-a6a8-7a53b70c923e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_008f755e-38a6-452e-a6a8-7a53b70c923e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_008f755e-38a6-452e-a6a8-7a53b70c923e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b45482d7-f14a-47fe-8d43-514975665b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b45482d7-f14a-47fe-8d43-514975665b05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ea988795-05be-4e44-aa5b-721d62886742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ea988795-05be-4e44-aa5b-721d62886742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_0c53c406-ae7c-4a64-b9af-e6d637fb59c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_0c53c406-ae7c-4a64-b9af-e6d637fb59c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_1d7ecbaf-25f2-41c8-ba6b-c5ad1643b54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_1d7ecbaf-25f2-41c8-ba6b-c5ad1643b54e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_e07c27fe-f31e-4d28-9d40-1607f9fea91c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_e07c27fe-f31e-4d28-9d40-1607f9fea91c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentRedemptionPeriodSixMember_9947e6bf-b1da-4343-88f4-9f7bf1be95df" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentRedemptionPeriodSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_sgry_DebtInstrumentRedemptionPeriodSixMember_9947e6bf-b1da-4343-88f4-9f7bf1be95df" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails" xlink:type="extended" id="i0f671260bba1409ab72e8cdad261b36e_LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Leases" xlink:type="simple" xlink:href="sgry-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/Leases" xlink:type="extended" id="i6d78e0361e5c4ea0ac2bafd543b60af7_Leases"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LeasesTables" xlink:type="extended" id="i992e5d6803964c0ba373091e64845c95_LeasesTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="extended" id="iff1b95e54ea845f891f30cd6c47e4484_LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_9463fa85-9572-4dbd-b0e8-75de1b7be8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cc8dee20-a35a-411c-be6f-35c10304d4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_9463fa85-9572-4dbd-b0e8-75de1b7be8c2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cc8dee20-a35a-411c-be6f-35c10304d4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_dd0b2c74-6ffd-4bb8-8e1f-96bcabc8d9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_9463fa85-9572-4dbd-b0e8-75de1b7be8c2" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_dd0b2c74-6ffd-4bb8-8e1f-96bcabc8d9c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_f3b690ca-1caf-4a28-8c07-6d50624cc88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_dd0b2c74-6ffd-4bb8-8e1f-96bcabc8d9c9" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_f3b690ca-1caf-4a28-8c07-6d50624cc88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_f3b690ca-1caf-4a28-8c07-6d50624cc88f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_f3b690ca-1caf-4a28-8c07-6d50624cc88f" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_f3b690ca-1caf-4a28-8c07-6d50624cc88f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_8e619691-d29b-4b9d-a562-1d04183d0a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_f3b690ca-1caf-4a28-8c07-6d50624cc88f" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_8e619691-d29b-4b9d-a562-1d04183d0a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_COVID19PandemicMember_47a38339-9079-4b58-a27e-5c816097e977" xlink:href="sgry-20201231.xsd#sgry_COVID19PandemicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_8e619691-d29b-4b9d-a562-1d04183d0a21" xlink:to="loc_sgry_COVID19PandemicMember_47a38339-9079-4b58-a27e-5c816097e977" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesLeaseExpenseandCashFlowInformationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="extended" id="i90d2d772a7174aaca70a9d4aeb3c9a8a_LeasesLeaseExpenseandCashFlowInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1266c6a7-eafa-46d5-abcf-364517ba4b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_us-gaap_OperatingLeaseCost_1266c6a7-eafa-46d5-abcf-364517ba4b31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:href="sgry-20201231.xsd#sgry_FinanceLeaseCost1Abstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d01c2e1f-04e1-4801-a330-1669ab2318e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d01c2e1f-04e1-4801-a330-1669ab2318e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_871eee89-79d9-43fc-8236-9c2748cd2bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_871eee89-79d9-43fc-8236-9c2748cd2bd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_22616807-a2f9-4543-80f1-12493bdca143" xlink:href="sgry-20201231.xsd#sgry_FinanceLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:to="loc_sgry_FinanceLeaseCost_22616807-a2f9-4543-80f1-12493bdca143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost_04e439ab-08f0-41d4-b7d8-f6f8b5d5e6c1" xlink:href="sgry-20201231.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_sgry_VariableAndShortTermLeaseCost_04e439ab-08f0-41d4-b7d8-f6f8b5d5e6c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8440e5dd-441e-494e-ab6e-e1c3872bc034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_us-gaap_LeaseCost_8440e5dd-441e-494e-ab6e-e1c3872bc034" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5aafb76a-d1df-40d7-bd39-df9af9f10cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeasePrincipalAndInterestPayments_bf87cc40-c2e6-4ab0-9920-e476a409da17" xlink:href="sgry-20201231.xsd#sgry_FinanceLeasePrincipalAndInterestPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_sgry_FinanceLeasePrincipalAndInterestPayments_bf87cc40-c2e6-4ab0-9920-e476a409da17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_63305f10-a553-408c-9fbc-d6144c3c40f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_63305f10-a553-408c-9fbc-d6144c3c40f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_63305f10-a553-408c-9fbc-d6144c3c40f2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_63305f10-a553-408c-9fbc-d6144c3c40f2" xlink:to="loc_us-gaap_RelatedPartyDomain_63305f10-a553-408c-9fbc-d6144c3c40f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e8df538e-bc5e-4937-baa7-1ccc89467c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_63305f10-a553-408c-9fbc-d6144c3c40f2" xlink:to="loc_us-gaap_RelatedPartyDomain_e8df538e-bc5e-4937-baa7-1ccc89467c53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_6a3c62be-0739-48b7-b2f5-c8184f19e8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e8df538e-bc5e-4937-baa7-1ccc89467c53" xlink:to="loc_us-gaap_InvestorMember_6a3c62be-0739-48b7-b2f5-c8184f19e8a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_76bf729f-e9bb-4a67-b3e0-eadecfe432d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_76bf729f-e9bb-4a67-b3e0-eadecfe432d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76bf729f-e9bb-4a67-b3e0-eadecfe432d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76bf729f-e9bb-4a67-b3e0-eadecfe432d6" xlink:to="loc_us-gaap_EquityComponentDomain_76bf729f-e9bb-4a67-b3e0-eadecfe432d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a25755e1-79ef-4fd3-8e6d-d88c607060e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76bf729f-e9bb-4a67-b3e0-eadecfe432d6" xlink:to="loc_us-gaap_EquityComponentDomain_a25755e1-79ef-4fd3-8e6d-d88c607060e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1e121829-303b-4dc6-aa98-c36da9679141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a25755e1-79ef-4fd3-8e6d-d88c607060e9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1e121829-303b-4dc6-aa98-c36da9679141" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" id="i4f6b91517c904644839efebc179ccb03_LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStock" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStock"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStock" xlink:type="extended" id="i5479f2984b824bb28ab374290df337d7_RedeemablePreferredStock"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStockTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStockTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStockTables" xlink:type="extended" id="ie4501e92380c4ec789b2dd42359aff46_RedeemablePreferredStockTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStockAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails" xlink:type="extended" id="iafa0f944cadc451aab672c5278adaaaf_RedeemablePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_861ebb15-d79f-4f96-b6dc-53c42bde152a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_861ebb15-d79f-4f96-b6dc-53c42bde152a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8c330f6b-56c7-4210-aa58-fabbf911baac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8c330f6b-56c7-4210-aa58-fabbf911baac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_9412ecb7-4661-4654-ba90-5e71d3e43733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_9412ecb7-4661-4654-ba90-5e71d3e43733" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1671218d-4d35-4ee8-ae81-7ac91f0d6408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1671218d-4d35-4ee8-ae81-7ac91f0d6408" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c45a3c2f-699c-4ad6-9896-3314f2354a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c45a3c2f-699c-4ad6-9896-3314f2354a52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_69d47462-6754-473c-a60d-434cc35fb89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_SharePrice_69d47462-6754-473c-a60d-434cc35fb89f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdTradingDays_503052fc-632a-4da9-a0b6-f8474788ddd6" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_sgry_TemporaryEquityThresholdTradingDays_503052fc-632a-4da9-a0b6-f8474788ddd6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdConsecutiveTradingDays_b3028749-34b3-4ef7-b173-89b9572378e4" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_sgry_TemporaryEquityThresholdConsecutiveTradingDays_b3028749-34b3-4ef7-b173-89b9572378e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdSharePrice_bfce7ebe-1bbf-496d-8b59-c728cc9b964b" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_sgry_TemporaryEquityThresholdSharePrice_bfce7ebe-1bbf-496d-8b59-c728cc9b964b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityMaximumCashDividendDeclarable_24e694cd-5d7f-495d-91c6-f98fcec40f49" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityMaximumCashDividendDeclarable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_sgry_TemporaryEquityMaximumCashDividendDeclarable_24e694cd-5d7f-495d-91c6-f98fcec40f49" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_49619dd5-8243-46a9-a7d0-3b0630c020ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_49619dd5-8243-46a9-a7d0-3b0630c020ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_495eb85f-0b8e-46bb-97c8-e0baafd2dac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_495eb85f-0b8e-46bb-97c8-e0baafd2dac1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_ecc03683-55f8-4da5-99c1-b6499e740ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_ecc03683-55f8-4da5-99c1-b6499e740ab3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_f647dca5-1272-40ea-9dc7-ad8df54e9b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_f647dca5-1272-40ea-9dc7-ad8df54e9b2e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6505cdc-5fd2-4fba-884b-fbffee776f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6505cdc-5fd2-4fba-884b-fbffee776f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b6505cdc-5fd2-4fba-884b-fbffee776f37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6505cdc-5fd2-4fba-884b-fbffee776f37" xlink:to="loc_us-gaap_RelatedPartyDomain_b6505cdc-5fd2-4fba-884b-fbffee776f37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8706d6c2-f5f8-4b46-815e-04bc67331953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6505cdc-5fd2-4fba-884b-fbffee776f37" xlink:to="loc_us-gaap_RelatedPartyDomain_8706d6c2-f5f8-4b46-815e-04bc67331953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember_b9e219e6-bbc5-4d0d-b968-148e8c90aefc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8706d6c2-f5f8-4b46-815e-04bc67331953" xlink:to="loc_us-gaap_MajorityShareholderMember_b9e219e6-bbc5-4d0d-b968-148e8c90aefc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1c3dc495-8529-4e2e-9d78-426718c855a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1c3dc495-8529-4e2e-9d78-426718c855a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1c3dc495-8529-4e2e-9d78-426718c855a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c3dc495-8529-4e2e-9d78-426718c855a3" xlink:to="loc_us-gaap_ClassOfStockDomain_1c3dc495-8529-4e2e-9d78-426718c855a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_678d8b7f-ebdb-44b2-8e69-14aa9619397c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c3dc495-8529-4e2e-9d78-426718c855a3" xlink:to="loc_us-gaap_ClassOfStockDomain_678d8b7f-ebdb-44b2-8e69-14aa9619397c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_eb235e44-821b-41d8-99a7-99f846392322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_678d8b7f-ebdb-44b2-8e69-14aa9619397c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_eb235e44-821b-41d8-99a7-99f846392322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6e17bc24-c35c-4e55-958a-bee848189499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6e17bc24-c35c-4e55-958a-bee848189499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6e17bc24-c35c-4e55-958a-bee848189499_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6e17bc24-c35c-4e55-958a-bee848189499" xlink:to="loc_us-gaap_EquityComponentDomain_6e17bc24-c35c-4e55-958a-bee848189499_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a067359-89c3-45ab-abb2-2a386012300b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6e17bc24-c35c-4e55-958a-bee848189499" xlink:to="loc_us-gaap_EquityComponentDomain_2a067359-89c3-45ab-abb2-2a386012300b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_90a32f96-92a8-4e41-9339-70be0189ce88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a067359-89c3-45ab-abb2-2a386012300b" xlink:to="loc_us-gaap_CommonStockMember_90a32f96-92a8-4e41-9339-70be0189ce88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivities"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="extended" id="ifdb6d4a858954b64a7f85aa97f14eedc_DerivativesandHedgingActivities"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivitiesTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="extended" id="i8f5d4efd7db64d78b594602424920597_DerivativesandHedgingActivitiesTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails" xlink:type="extended" id="i83542c0b11b445b3a1f16365c49b0fad_DerivativesandHedgingActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_1e580674-c8b6-4803-a28b-9b7cf0da7f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_1e580674-c8b6-4803-a28b-9b7cf0da7f5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_fe4aebac-b713-41a2-a32b-96bb1944b647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_fe4aebac-b713-41a2-a32b-96bb1944b647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ffdb9435-e191-429d-a35c-31223dd47d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ffdb9435-e191-429d-a35c-31223dd47d00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3c463797-0764-4483-afb3-9f25387bed09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3c463797-0764-4483-afb3-9f25387bed09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss_80a51449-1408-43a1-857f-89fbf805dbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss_80a51449-1408-43a1-857f-89fbf805dbd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_383bc15e-e619-4a2e-8f9f-a393b142ed1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_383bc15e-e619-4a2e-8f9f-a393b142ed1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_184d41fa-69d3-4ebe-949c-77d2fb2bb142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_184d41fa-69d3-4ebe-949c-77d2fb2bb142" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e9444993-a46f-4ccb-a819-664e8b33b38e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_DerivativeTable_e9444993-a46f-4ccb-a819-664e8b33b38e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4eda9cab-1406-46e0-afbe-7f5e76455ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e9444993-a46f-4ccb-a819-664e8b33b38e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4eda9cab-1406-46e0-afbe-7f5e76455ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4eda9cab-1406-46e0-afbe-7f5e76455ac6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4eda9cab-1406-46e0-afbe-7f5e76455ac6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4eda9cab-1406-46e0-afbe-7f5e76455ac6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_29f87ef4-cfbe-4f9b-921e-ac124388ca7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4eda9cab-1406-46e0-afbe-7f5e76455ac6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_29f87ef4-cfbe-4f9b-921e-ac124388ca7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_bae95366-41fe-4c89-98a6-c2deba0124e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_29f87ef4-cfbe-4f9b-921e-ac124388ca7a" xlink:to="loc_us-gaap_InterestRateSwapMember_bae95366-41fe-4c89-98a6-c2deba0124e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShare"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="extended" id="ifc2e4207b4fd4778bc92d6039e30ebb4_EarningsPerShare"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="extended" id="ib81216badc4146bda2354d7363fdfd90_EarningsPerShareTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareDetails" xlink:type="extended" id="i9e1fd16c717042348369a61efe61124c_EarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:to="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c91354b-2bfe-43f8-b15f-f1f4bb5f6416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:to="loc_us-gaap_NetIncomeLoss_5c91354b-2bfe-43f8-b15f-f1f4bb5f6416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_b2524443-58bf-4b1b-8377-72341c6e5bfa" xlink:href="sgry-20201231.xsd#sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:to="loc_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_b2524443-58bf-4b1b-8377-72341c6e5bfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_83453489-c056-43cf-9bd2-93b321d477b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_83453489-c056-43cf-9bd2-93b321d477b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ff30410-1fac-4bdc-8809-86388ab3a46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ff30410-1fac-4bdc-8809-86388ab3a46e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_215ba980-79a2-4767-9e26-5a378f673a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ff30410-1fac-4bdc-8809-86388ab3a46e" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_215ba980-79a2-4767-9e26-5a378f673a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_86c2eaec-9886-424c-8492-089f4a7f5312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ff30410-1fac-4bdc-8809-86388ab3a46e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_86c2eaec-9886-424c-8492-089f4a7f5312" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5eb595c-bfa2-4c96-9237-8c6cc86403a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5eb595c-bfa2-4c96-9237-8c6cc86403a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_eab3f1b5-bdcc-42e6-8cab-335755b88654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_eab3f1b5-bdcc-42e6-8cab-335755b88654" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_eab3f1b5-bdcc-42e6-8cab-335755b88654" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_12af3336-7a89-41a1-b721-4cc6e44d5c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_12af3336-7a89-41a1-b721-4cc6e44d5c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ed282697-089d-4734-9d25-293c982b63a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_12af3336-7a89-41a1-b721-4cc6e44d5c69" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ed282697-089d-4734-9d25-293c982b63a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_425c3242-d0e9-4737-a6a7-786ae33b689f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_12af3336-7a89-41a1-b721-4cc6e44d5c69" xlink:to="loc_us-gaap_RestrictedStockMember_425c3242-d0e9-4737-a6a7-786ae33b689f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxes" xlink:type="extended" id="i671f6381631c44e6b5c9e2bb2c5e32f3_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesTables" xlink:type="extended" id="ic9ca14fff0374c5c8c21af300a8e0001_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i402a924fad504a61829f58a515038437_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_df8f195c-d678-47cc-a798-50f947acaf22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_df8f195c-d678-47cc-a798-50f947acaf22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ce76184e-c54a-4f0a-b516-8217b6bda577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ce76184e-c54a-4f0a-b516-8217b6bda577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e33ff3c0-c31e-44ee-a047-87ee700cbe41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e33ff3c0-c31e-44ee-a047-87ee700cbe41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0e1b0215-1173-4c6c-b133-bdba80db0560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0e1b0215-1173-4c6c-b133-bdba80db0560" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c2ef57c0-ee4d-4b2e-9e7d-f8c45b01bd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c2ef57c0-ee4d-4b2e-9e7d-f8c45b01bd6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_31e2737f-2cca-416e-a9bf-a58dd93ead6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_31e2737f-2cca-416e-a9bf-a58dd93ead6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax_b767219d-b535-4aab-89ae-ea5760c80c94" xlink:href="sgry-20201231.xsd#sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax_b767219d-b535-4aab-89ae-ea5760c80c94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_6e0023b1-ae51-4db1-9c8d-539d0dcc7d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_6e0023b1-ae51-4db1-9c8d-539d0dcc7d9c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7f242a07-f32f-4491-ae8d-539014e1a28a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7f242a07-f32f-4491-ae8d-539014e1a28a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9a56f330-b658-4f91-a0d0-2233a40b9e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9a56f330-b658-4f91-a0d0-2233a40b9e01" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c802d625-f859-401e-80b5-f73a90726585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c802d625-f859-401e-80b5-f73a90726585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c802d625-f859-401e-80b5-f73a90726585_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c802d625-f859-401e-80b5-f73a90726585" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c802d625-f859-401e-80b5-f73a90726585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e5f816c6-fa3d-46fd-bd6d-65fd142c593e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c802d625-f859-401e-80b5-f73a90726585" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e5f816c6-fa3d-46fd-bd6d-65fd142c593e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_284c2ada-9158-492e-a6a4-7f83a1cdcd5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5f816c6-fa3d-46fd-bd6d-65fd142c593e" xlink:to="loc_us-gaap_DomesticCountryMember_284c2ada-9158-492e-a6a4-7f83a1cdcd5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a7b84c72-9152-4682-9770-8bc35acea006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5f816c6-fa3d-46fd-bd6d-65fd142c593e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a7b84c72-9152-4682-9770-8bc35acea006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_0e55576f-374e-4469-aef8-f01c30e02bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_0e55576f-374e-4469-aef8-f01c30e02bf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0e55576f-374e-4469-aef8-f01c30e02bf9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_0e55576f-374e-4469-aef8-f01c30e02bf9" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0e55576f-374e-4469-aef8-f01c30e02bf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_0e55576f-374e-4469-aef8-f01c30e02bf9" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_41fe4f94-98a3-44c4-85c8-94a8740e8727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_41fe4f94-98a3-44c4-85c8-94a8740e8727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember_994d7962-2c9a-4137-bd17-ef67ea006d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:to="loc_us-gaap_GeneralBusinessMember_994d7962-2c9a-4137-bd17-ef67ea006d63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestLimitationMember_aab126eb-5b98-460a-9b03-17623bea7e9c" xlink:href="sgry-20201231.xsd#sgry_InterestLimitationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:to="loc_sgry_InterestLimitationMember_aab126eb-5b98-460a-9b03-17623bea7e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f430b487-796f-4ebd-af65-7203146467c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f430b487-796f-4ebd-af65-7203146467c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f430b487-796f-4ebd-af65-7203146467c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f430b487-796f-4ebd-af65-7203146467c2" xlink:to="loc_us-gaap_EquityComponentDomain_f430b487-796f-4ebd-af65-7203146467c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_50ee7ba4-7b85-4f06-a83d-ef79babacae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f430b487-796f-4ebd-af65-7203146467c2" xlink:to="loc_us-gaap_EquityComponentDomain_50ee7ba4-7b85-4f06-a83d-ef79babacae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f57bf168-05d9-4dc2-bd16-56e6981ba4be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_50ee7ba4-7b85-4f06-a83d-ef79babacae0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f57bf168-05d9-4dc2-bd16-56e6981ba4be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesIncomeTaxBenefitExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails" xlink:type="extended" id="i9dc8dd59cfbb44159dbe04a3570a8375_IncomeTaxesIncomeTaxBenefitExpenseDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesIncomeTaxRateReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="extended" id="if4f8c7fdaea3450c9e6ef3e363d40221_IncomeTaxesIncomeTaxRateReconciliationDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails" xlink:type="extended" id="i4a74615cf0504359a03623db4de68378_IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i377af7602b7d480db4d271d734a6163b_IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensation" xlink:type="extended" id="ie441d6e24995407288f8fd53cd5aadad_EquityBasedCompensation"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationTables" xlink:type="extended" id="if2aa0021a26240189cdb024ab2c89d24_EquityBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i0e0d69a01a3d4f2e934bbbfc1f978674_EquityBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635a33d9-f5b2-4d71-9c41-afdf44ab1b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635a33d9-f5b2-4d71-9c41-afdf44ab1b7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91e739c9-7133-46c2-bb8a-237d53a242d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91e739c9-7133-46c2-bb8a-237d53a242d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6f93422-f2ad-4670-b7b0-9c29d729fddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6f93422-f2ad-4670-b7b0-9c29d729fddb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_efeae1fc-c0dd-4f86-ace6-20d56f7771f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_efeae1fc-c0dd-4f86-ace6-20d56f7771f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod_55374dd5-5a38-4e82-b94f-964f6cd1c4df" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod_55374dd5-5a38-4e82-b94f-964f6cd1c4df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod_a146f003-f22a-4dfb-a243-b3d0f05f7ad2" xlink:href="sgry-20201231.xsd#sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod_a146f003-f22a-4dfb-a243-b3d0f05f7ad2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5e91457f-8248-4a73-ad88-75ea7cb63255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5e91457f-8248-4a73-ad88-75ea7cb63255" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c146b7db-c7d3-4ff1-b0ab-d5e20ec1badc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c146b7db-c7d3-4ff1-b0ab-d5e20ec1badc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_aeb6c968-a983-460d-acaa-a9f390fe80ad" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_aeb6c968-a983-460d-acaa-a9f390fe80ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_99216c44-8d68-4b1e-a66d-f649fd7b9067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_SharePrice_99216c44-8d68-4b1e-a66d-f649fd7b9067" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_7e01d4df-daa4-4f7b-b94d-493e40c32438" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_7e01d4df-daa4-4f7b-b94d-493e40c32438" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_4115f4f7-e8f2-444a-aa1b-339613cea68a" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_4115f4f7-e8f2-444a-aa1b-339613cea68a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8082d39c-6831-4003-96f4-164b69af1d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8082d39c-6831-4003-96f4-164b69af1d47" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_935968c2-9c7b-440a-8dd7-1630acff4825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_935968c2-9c7b-440a-8dd7-1630acff4825" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_us-gaap_PlanNameAxis_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3" xlink:to="loc_us-gaap_PlanNameDomain_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_86026675-5ef1-432f-aee6-2bbdab587c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3" xlink:to="loc_us-gaap_PlanNameDomain_86026675-5ef1-432f-aee6-2bbdab587c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2015OmnibusIncentivePlanMember_2eb38a0f-0661-47bd-9690-dc8cd9a16e57" xlink:href="sgry-20201231.xsd#sgry_A2015OmnibusIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_86026675-5ef1-432f-aee6-2bbdab587c4e" xlink:to="loc_sgry_A2015OmnibusIncentivePlanMember_2eb38a0f-0661-47bd-9690-dc8cd9a16e57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6c8d80c6-2ebe-49d7-a55e-012345d11210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_srt_RangeAxis_6c8d80c6-2ebe-49d7-a55e-012345d11210" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c8d80c6-2ebe-49d7-a55e-012345d11210_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6c8d80c6-2ebe-49d7-a55e-012345d11210" xlink:to="loc_srt_RangeMember_6c8d80c6-2ebe-49d7-a55e-012345d11210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72bb2b5e-671b-483b-8980-99f6176b5281" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6c8d80c6-2ebe-49d7-a55e-012345d11210" xlink:to="loc_srt_RangeMember_72bb2b5e-671b-483b-8980-99f6176b5281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_42c00fcf-c30d-4dfb-8583-bc9ca28f43a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_72bb2b5e-671b-483b-8980-99f6176b5281" xlink:to="loc_srt_MinimumMember_42c00fcf-c30d-4dfb-8583-bc9ca28f43a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b553b848-3165-4b2a-9aad-7443a31a3eff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_72bb2b5e-671b-483b-8980-99f6176b5281" xlink:to="loc_srt_MaximumMember_b553b848-3165-4b2a-9aad-7443a31a3eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bdbafea4-7baa-444f-8b62-ab8ad1639cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_us-gaap_AwardTypeAxis_bdbafea4-7baa-444f-8b62-ab8ad1639cd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdbafea4-7baa-444f-8b62-ab8ad1639cd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bdbafea4-7baa-444f-8b62-ab8ad1639cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bdbafea4-7baa-444f-8b62-ab8ad1639cd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bdbafea4-7baa-444f-8b62-ab8ad1639cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4c6fd165-38f9-4e45-b893-6170de4f51cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4c6fd165-38f9-4e45-b893-6170de4f51cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ba6b7c26-088e-4935-9780-218bd39c52fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:to="loc_us-gaap_PerformanceSharesMember_ba6b7c26-088e-4935-9780-218bd39c52fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_60fbcf75-4309-4e79-bb68-fc264e21f953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_60fbcf75-4309-4e79-bb68-fc264e21f953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_86539051-5e81-4f85-9060-3b2de843ceaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_86539051-5e81-4f85-9060-3b2de843ceaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0571102e-f430-4df5-bc5b-d5702c6de84e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_us-gaap_VestingAxis_0571102e-f430-4df5-bc5b-d5702c6de84e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0571102e-f430-4df5-bc5b-d5702c6de84e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_0571102e-f430-4df5-bc5b-d5702c6de84e" xlink:to="loc_us-gaap_VestingDomain_0571102e-f430-4df5-bc5b-d5702c6de84e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_0571102e-f430-4df5-bc5b-d5702c6de84e" xlink:to="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fcae2c01-3af8-4dec-91d4-6f6a4bc6af6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fcae2c01-3af8-4dec-91d4-6f6a4bc6af6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2f43b16f-1bcd-46f0-bcc3-bb64c5d89c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2f43b16f-1bcd-46f0-bcc3-bb64c5d89c76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2b3b75b5-1509-4fab-98b9-dbfe93c36630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2b3b75b5-1509-4fab-98b9-dbfe93c36630" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails" xlink:type="extended" id="i6dab63c52c424b5a87df9071724017c9_EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_066db5d2-2d29-4d76-a40b-937d016d5359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_066db5d2-2d29-4d76-a40b-937d016d5359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a46dcf0-0472-4138-adb9-2761aa9bc5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a46dcf0-0472-4138-adb9-2761aa9bc5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a2edd95-fabd-498a-8ea9-a992757184f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a2edd95-fabd-498a-8ea9-a992757184f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94bbc1d4-a2ef-4ea6-9fe9-7a5f2f6d548e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94bbc1d4-a2ef-4ea6-9fe9-7a5f2f6d548e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d6761794-be32-4042-a5f8-b95c899ff401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d6761794-be32-4042-a5f8-b95c899ff401" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e6f4565b-c49d-49ef-8dc5-87d7b1a871ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_066db5d2-2d29-4d76-a40b-937d016d5359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a02698b1-0e4c-4385-9bd1-91599b1d079d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a02698b1-0e4c-4385-9bd1-91599b1d079d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66d33b1b-65bf-41ac-9b6e-76429c8aeec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66d33b1b-65bf-41ac-9b6e-76429c8aeec4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_94a87f8a-a44d-47d5-9700-fe59bdef7387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_94a87f8a-a44d-47d5-9700-fe59bdef7387" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_43414c1e-7d94-48fb-ae99-4849b951166f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_43414c1e-7d94-48fb-ae99-4849b951166f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_20518d58-13eb-411e-90e7-f50103affb41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575d26c7-ba73-4a57-a06d-ab9bf67ae97b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_066db5d2-2d29-4d76-a40b-937d016d5359" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575d26c7-ba73-4a57-a06d-ab9bf67ae97b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_659d381f-fe1d-442a-9a7b-81b5e4ab8793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575d26c7-ba73-4a57-a06d-ab9bf67ae97b" xlink:to="loc_us-gaap_AwardTypeAxis_659d381f-fe1d-442a-9a7b-81b5e4ab8793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_659d381f-fe1d-442a-9a7b-81b5e4ab8793_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_659d381f-fe1d-442a-9a7b-81b5e4ab8793" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_659d381f-fe1d-442a-9a7b-81b5e4ab8793_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_972f2951-d4e7-490e-aa84-8bf082bcf698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_659d381f-fe1d-442a-9a7b-81b5e4ab8793" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_972f2951-d4e7-490e-aa84-8bf082bcf698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RestrictedStockAndPerformanceSharesMember_c37c3462-3a23-4c1a-bc7c-7bcdb61ede96" xlink:href="sgry-20201231.xsd#sgry_RestrictedStockAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_972f2951-d4e7-490e-aa84-8bf082bcf698" xlink:to="loc_sgry_RestrictedStockAndPerformanceSharesMember_c37c3462-3a23-4c1a-bc7c-7bcdb61ede96" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails" xlink:type="extended" id="i63c4d060944d4e8fb4015f57c9024a56_EquityBasedCompensationFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4157e20a-21b3-4d23-af42-88be538d1f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_166c1d72-c759-4fc5-ba10-e9af7a39663f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4157e20a-21b3-4d23-af42-88be538d1f5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_166c1d72-c759-4fc5-ba10-e9af7a39663f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4157e20a-21b3-4d23-af42-88be538d1f5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_46bab2e6-64b5-4449-a4d8-04b1617d3ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_46bab2e6-64b5-4449-a4d8-04b1617d3ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_41497c9c-c094-4793-915b-d63b07fcd57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_41497c9c-c094-4793-915b-d63b07fcd57d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_90f8ee76-4a3f-486f-ade2-26585d29edd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_90f8ee76-4a3f-486f-ade2-26585d29edd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_481f2f22-d224-4275-a907-e5a4d0643d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_481f2f22-d224-4275-a907-e5a4d0643d63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8c647b99-1db4-46b0-bbb5-1e3cc59f1624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8c647b99-1db4-46b0-bbb5-1e3cc59f1624" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c9dc7cc2-757c-4b43-8c09-0473049e2d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c9dc7cc2-757c-4b43-8c09-0473049e2d0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_767692b7-5dd1-4e77-a663-5e54ee471d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_767692b7-5dd1-4e77-a663-5e54ee471d31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_fdf7fb7a-7fe2-4c3f-8f4a-bb8230370923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_SharePrice_fdf7fb7a-7fe2-4c3f-8f4a-bb8230370923" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4157e20a-21b3-4d23-af42-88be538d1f5d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b4d71292-db5f-44b7-8654-5b18e412b0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:to="loc_us-gaap_AwardTypeAxis_b4d71292-db5f-44b7-8654-5b18e412b0d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4d71292-db5f-44b7-8654-5b18e412b0d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b4d71292-db5f-44b7-8654-5b18e412b0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4d71292-db5f-44b7-8654-5b18e412b0d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a074f21e-623b-4baf-83ea-e68a9abce703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b4d71292-db5f-44b7-8654-5b18e412b0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a074f21e-623b-4baf-83ea-e68a9abce703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_64160936-8c65-4312-9632-5cf04367b881" xlink:href="sgry-20201231.xsd#sgry_EmployeeStockOptionsAndStockAppreciationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a074f21e-623b-4baf-83ea-e68a9abce703" xlink:to="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_64160936-8c65-4312-9632-5cf04367b881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_226a8ffa-6ddc-4cae-ab4c-ab5ccc8b6ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_64160936-8c65-4312-9632-5cf04367b881" xlink:to="loc_us-gaap_EmployeeStockOptionMember_226a8ffa-6ddc-4cae-ab4c-ab5ccc8b6ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_1a3a8b1d-654f-4f76-bbc8-b7a4f163c663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_64160936-8c65-4312-9632-5cf04367b881" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_1a3a8b1d-654f-4f76-bbc8-b7a4f163c663" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d781423-622c-48d3-9f37-28ca83bc5041" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:to="loc_srt_RangeAxis_8d781423-622c-48d3-9f37-28ca83bc5041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d781423-622c-48d3-9f37-28ca83bc5041_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8d781423-622c-48d3-9f37-28ca83bc5041" xlink:to="loc_srt_RangeMember_8d781423-622c-48d3-9f37-28ca83bc5041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56fc79fa-b316-4a9a-9640-057f099968bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8d781423-622c-48d3-9f37-28ca83bc5041" xlink:to="loc_srt_RangeMember_56fc79fa-b316-4a9a-9640-057f099968bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7e8cfb1d-b9af-4470-91e7-6580127d5c68" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56fc79fa-b316-4a9a-9640-057f099968bf" xlink:to="loc_srt_MinimumMember_7e8cfb1d-b9af-4470-91e7-6580127d5c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ed3af610-54a3-47bb-b744-5b5d474dce6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56fc79fa-b316-4a9a-9640-057f099968bf" xlink:to="loc_srt_MaximumMember_ed3af610-54a3-47bb-b744-5b5d474dce6a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationSummaryofOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails" xlink:type="extended" id="i8835e6de54bc4592bf9bba02e9ed9869_EquityBasedCompensationSummaryofOptionsActivityDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="sgry-20201231.xsd#EmployeeBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EmployeeBenefitPlans" xlink:type="extended" id="i7d594f2aa01e4c0c8337b5b49685c3c3_EmployeeBenefitPlans"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" id="i1cc1d81dd70d4fb7aaeddddc7bffbafd_EmployeeBenefitPlansDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilities"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="extended" id="i5517e707ef4e4911897fafc2842be3c5_OtherCurrentLiabilities"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="extended" id="i579250e01ab24105babccf56ed5ac2ab_OtherCurrentLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended" id="icfaa0b7ffb2a4ebc8497695357ec6d9c_OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgry-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="extended" id="i39abdea3d4db427a83cc71c628ac8f35_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i1550fd50d0104fdea18cd445854af68f_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_25910c58-9950-4625-85d8-aebacf373be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_SelfInsuranceReserve_25910c58-9950-4625-85d8-aebacf373be7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_b003d844-7077-4388-a7bf-c54b7d84b2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_b003d844-7077-4388-a7bf-c54b7d84b2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7a93d692-3e07-4209-a43a-55bb1f593305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7a93d692-3e07-4209-a43a-55bb1f593305" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b12b57db-1b51-48cf-926b-405d6fcdd361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b12b57db-1b51-48cf-926b-405d6fcdd361" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c2228ff3-64ba-427b-a5ad-4ee8fb7807c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c2228ff3-64ba-427b-a5ad-4ee8fb7807c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_e7bf692f-be40-4742-ac6c-72b70823aaf9" xlink:href="sgry-20201231.xsd#sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_e7bf692f-be40-4742-ac6c-72b70823aaf9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9f4912a0-47bc-49ee-9c59-561694623300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9f4912a0-47bc-49ee-9c59-561694623300" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_d45cc845-f701-4b77-b341-b776a68867e6" xlink:href="sgry-20201231.xsd#sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_d45cc845-f701-4b77-b341-b776a68867e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_0c72b036-af13-4981-a5cc-89603a5321e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_0c72b036-af13-4981-a5cc-89603a5321e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_477b27a2-ec25-4b92-93c1-4c3475318872" xlink:href="sgry-20201231.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_477b27a2-ec25-4b92-93c1-4c3475318872" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent_74d0a836-82a1-47b0-924b-5114bf6a4803" xlink:href="sgry-20201231.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent_74d0a836-82a1-47b0-924b-5114bf6a4803" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_a7e3eb89-1262-43fe-8a62-5eb4c6426603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_a7e3eb89-1262-43fe-8a62-5eb4c6426603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_a7e3eb89-1262-43fe-8a62-5eb4c6426603_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_a7e3eb89-1262-43fe-8a62-5eb4c6426603" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_a7e3eb89-1262-43fe-8a62-5eb4c6426603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_488e1f2c-4da7-4d4a-9b8a-e944a2d86d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_a7e3eb89-1262-43fe-8a62-5eb4c6426603" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_488e1f2c-4da7-4d4a-9b8a-e944a2d86d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MateriallyMoreRestrictiveMember_02a9a699-0c5a-4c41-94f3-ea08f3968afc" xlink:href="sgry-20201231.xsd#sgry_MateriallyMoreRestrictiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_488e1f2c-4da7-4d4a-9b8a-e944a2d86d98" xlink:to="loc_sgry_MateriallyMoreRestrictiveMember_02a9a699-0c5a-4c41-94f3-ea08f3968afc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotMateriallyMoreRestrictiveMember_8647fc18-349c-4761-b3d2-87d136c2c2d7" xlink:href="sgry-20201231.xsd#sgry_NotMateriallyMoreRestrictiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_488e1f2c-4da7-4d4a-9b8a-e944a2d86d98" xlink:to="loc_sgry_NotMateriallyMoreRestrictiveMember_8647fc18-349c-4761-b3d2-87d136c2c2d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ef3d8ece-fcb5-44c6-b026-c11872d727b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:to="loc_us-gaap_VariableRateAxis_ef3d8ece-fcb5-44c6-b026-c11872d727b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ef3d8ece-fcb5-44c6-b026-c11872d727b0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_ef3d8ece-fcb5-44c6-b026-c11872d727b0" xlink:to="loc_us-gaap_VariableRateDomain_ef3d8ece-fcb5-44c6-b026-c11872d727b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_19a2cd2c-feec-4f36-8216-32b1351e01df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_ef3d8ece-fcb5-44c6-b026-c11872d727b0" xlink:to="loc_us-gaap_VariableRateDomain_19a2cd2c-feec-4f36-8216-32b1351e01df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d29830a0-3901-4456-8498-1dd8c434ca06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_19a2cd2c-feec-4f36-8216-32b1351e01df" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d29830a0-3901-4456-8498-1dd8c434ca06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_461d0aa9-d856-4e2d-b372-ba33fed63194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_19a2cd2c-feec-4f36-8216-32b1351e01df" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_461d0aa9-d856-4e2d-b372-ba33fed63194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:to="loc_srt_StatementScenarioAxis_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972" xlink:to="loc_srt_ScenarioUnspecifiedDomain_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7b95484a-88cf-4031-8a95-d3b6a9350a66" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7b95484a-88cf-4031-8a95-d3b6a9350a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a0b95c56-552d-4324-9700-7bab9c3c4945" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7b95484a-88cf-4031-8a95-d3b6a9350a66" xlink:to="loc_srt_ScenarioForecastMember_a0b95c56-552d-4324-9700-7bab9c3c4945" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReporting"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="extended" id="i7d3f072b16cc44fd935be043e76f6a11_SegmentReporting"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingTables"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="extended" id="i83ac5d93b4c8491195e1239125df8c65_SegmentReportingTables"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="extended" id="i5df5a101db9c405187e4f522b34f0769_SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_10572ea8-d7e2-4884-9b75-171c99f3c827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_10572ea8-d7e2-4884-9b75-171c99f3c827" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_f96dea13-c39a-4f40-a565-1b121acbf864" xlink:href="sgry-20201231.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:to="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_f96dea13-c39a-4f40-a565-1b121acbf864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_592aa038-0355-423a-b4f8-b4135a5a3d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_592aa038-0355-423a-b4f8-b4135a5a3d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4b937fc2-f769-413d-8cea-223ef8663152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4b937fc2-f769-413d-8cea-223ef8663152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7f08ba47-a59b-42a5-93df-f7ad0170cb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7f08ba47-a59b-42a5-93df-f7ad0170cb9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fd643e82-912d-42a9-b4ed-12a5f356d802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fd643e82-912d-42a9-b4ed-12a5f356d802" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5e469d02-b11d-468a-adbd-1d3dc63c23f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_ShareBasedCompensation_5e469d02-b11d-468a-adbd-1d3dc63c23f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_c8bcca10-9205-49ea-b636-69052a4a28ab" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_c8bcca10-9205-49ea-b636-69052a4a28ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b6a96741-7194-4f5f-b7f2-242cfa9e86e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_AssetImpairmentCharges_b6a96741-7194-4f5f-b7f2-242cfa9e86e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_2eceba64-5f3c-4c72-85ad-9a0f177874da" xlink:href="sgry-20201231.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_2eceba64-5f3c-4c72-85ad-9a0f177874da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_f5ef9127-9708-44bf-ad53-43367117c366" xlink:href="sgry-20201231.xsd#sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_f5ef9127-9708-44bf-ad53-43367117c366" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c669d582-72fc-4ccc-958d-6d3a448fa69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c669d582-72fc-4ccc-958d-6d3a448fa69a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationContingentAcquisitionExpense_2bb3d415-83dd-44e6-ab77-f5f59d9e8c2c" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationContingentAcquisitionExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_BusinessCombinationContingentAcquisitionExpense_2bb3d415-83dd-44e6-ab77-f5f59d9e8c2c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationGainLossOnAcquisitionEscrow_f6780e94-aae5-4113-a35f-2c41aec3c15d" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationGainLossOnAcquisitionEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_BusinessCombinationGainLossOnAcquisitionEscrow_f6780e94-aae5-4113-a35f-2c41aec3c15d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9aba3f31-26ce-4e14-87c3-61c7161ff45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9aba3f31-26ce-4e14-87c3-61c7161ff45f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementExpenseBenefit_e498fe0e-ae51-42ca-a777-2e4426fbf92e" xlink:href="sgry-20201231.xsd#sgry_TaxReceivableAgreementExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_TaxReceivableAgreementExpenseBenefit_e498fe0e-ae51-42ca-a777-2e4426fbf92e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_da7c56f3-670c-43a5-bb44-31c8530d3821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_da7c56f3-670c-43a5-bb44-31c8530d3821" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b96796f1-47d6-4046-8c10-d4aa14ba93ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b96796f1-47d6-4046-8c10-d4aa14ba93ef" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_StartUpActivitiesStartUpCosts_01339349-95cf-4223-851d-b9e1f628a01b" xlink:href="sgry-20201231.xsd#sgry_StartUpActivitiesStartUpCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_StartUpActivitiesStartUpCosts_01339349-95cf-4223-851d-b9e1f628a01b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_a24e8cae-1d59-4dbd-8432-ec0f8b498e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_a24e8cae-1d59-4dbd-8432-ec0f8b498e6b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_35daafa1-fa35-4fbd-be11-091c4a67264c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_LitigationSettlementExpense_35daafa1-fa35-4fbd-be11-091c4a67264c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c16b4673-aca4-416c-9d30-2b80811b97af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c16b4673-aca4-416c-9d30-2b80811b97af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c16b4673-aca4-416c-9d30-2b80811b97af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c16b4673-aca4-416c-9d30-2b80811b97af" xlink:to="loc_us-gaap_SegmentDomain_c16b4673-aca4-416c-9d30-2b80811b97af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c16b4673-aca4-416c-9d30-2b80811b97af" xlink:to="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_d79970b3-1479-4a7b-a0f9-c95ff39f181d" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:to="loc_sgry_SurgicalFacilityServicesMember_d79970b3-1479-4a7b-a0f9-c95ff39f181d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_28abceb5-9053-41f5-80a6-8f7665d03a0b" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:to="loc_sgry_AncillaryServicesMember_28abceb5-9053-41f5-80a6-8f7665d03a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember_ae122719-96bd-4965-b88b-241b9f0c9741" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:to="loc_sgry_OpticalServicesMember_ae122719-96bd-4965-b88b-241b9f0c9741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:to="loc_srt_ConsolidationItemsAxis_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726" xlink:to="loc_srt_ConsolidationItemsDomain_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8957b172-e1f9-438f-9c8c-7edfeec838f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726" xlink:to="loc_srt_ConsolidationItemsDomain_8957b172-e1f9-438f-9c8c-7edfeec838f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_830ecd0b-6efd-4915-b429-c39b00e9bce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8957b172-e1f9-438f-9c8c-7edfeec838f4" xlink:to="loc_us-gaap_OperatingSegmentsMember_830ecd0b-6efd-4915-b429-c39b00e9bce9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_64e0d2e8-2b15-4e32-bc1c-b69c80d0027f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_8957b172-e1f9-438f-9c8c-7edfeec838f4" xlink:to="loc_us-gaap_CorporateNonSegmentMember_64e0d2e8-2b15-4e32-bc1c-b69c80d0027f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="extended" id="i17a770969fe045188dfa1cd900956a52_SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_24fb48c1-9337-4193-a5b3-6a10cef31e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_61083179-6f69-4b81-87be-34a24c944810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24fb48c1-9337-4193-a5b3-6a10cef31e50" xlink:to="loc_us-gaap_Assets_61083179-6f69-4b81-87be-34a24c944810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ad8af17-51e5-4962-98a2-a545ccb3bdbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24fb48c1-9337-4193-a5b3-6a10cef31e50" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ad8af17-51e5-4962-98a2-a545ccb3bdbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24fb48c1-9337-4193-a5b3-6a10cef31e50" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0d5825e5-be55-4003-8aa6-21d8bd53a9a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:to="loc_srt_ConsolidationItemsAxis_0d5825e5-be55-4003-8aa6-21d8bd53a9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0d5825e5-be55-4003-8aa6-21d8bd53a9a3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_0d5825e5-be55-4003-8aa6-21d8bd53a9a3" xlink:to="loc_srt_ConsolidationItemsDomain_0d5825e5-be55-4003-8aa6-21d8bd53a9a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_55a46ec6-4517-4d91-986a-0e852d6f684a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_0d5825e5-be55-4003-8aa6-21d8bd53a9a3" xlink:to="loc_srt_ConsolidationItemsDomain_55a46ec6-4517-4d91-986a-0e852d6f684a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_73a15a6d-fcb1-47fb-b028-1c84ba9dadbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_55a46ec6-4517-4d91-986a-0e852d6f684a" xlink:to="loc_us-gaap_OperatingSegmentsMember_73a15a6d-fcb1-47fb-b028-1c84ba9dadbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_be83d22e-3b6d-4675-adbd-c60cda2ebc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_55a46ec6-4517-4d91-986a-0e852d6f684a" xlink:to="loc_us-gaap_CorporateNonSegmentMember_be83d22e-3b6d-4675-adbd-c60cda2ebc4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f8970200-ebba-4530-af95-94abfb5c5674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f8970200-ebba-4530-af95-94abfb5c5674" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f8970200-ebba-4530-af95-94abfb5c5674_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f8970200-ebba-4530-af95-94abfb5c5674" xlink:to="loc_us-gaap_SegmentDomain_f8970200-ebba-4530-af95-94abfb5c5674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f8970200-ebba-4530-af95-94abfb5c5674" xlink:to="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_6b2dc5a0-5697-468c-9dae-7b3a19e2ab06" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:to="loc_sgry_SurgicalFacilityServicesMember_6b2dc5a0-5697-468c-9dae-7b3a19e2ab06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_6490e791-fd9e-4d2b-bbfa-b52b231f95dc" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:to="loc_sgry_AncillaryServicesMember_6490e791-fd9e-4d2b-bbfa-b52b231f95dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember_dca72184-9dc4-4fc3-8b1a-d61786fdaa45" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:to="loc_sgry_OpticalServicesMember_dca72184-9dc4-4fc3-8b1a-d61786fdaa45" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgry-20201231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="extended" id="i0703fa94c39e423d98619ea362538ae4_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="extended" id="ie4a3feea065e478eaefe79737438055d_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_705a2d95-abee-419e-9d20-c6f2fe37ebcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_705a2d95-abee-419e-9d20-c6f2fe37ebcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23731f68-4f92-4854-bfaa-45a0af60b746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23731f68-4f92-4854-bfaa-45a0af60b746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1178edef-e174-4fb8-ab80-9747225e54f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1178edef-e174-4fb8-ab80-9747225e54f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_08c8a583-90ae-47f4-a552-bc405170095d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_08c8a583-90ae-47f4-a552-bc405170095d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease_77e9a398-78f1-408f-8282-2209b44587cb" xlink:href="sgry-20201231.xsd#sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease_77e9a398-78f1-408f-8282-2209b44587cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_78435cfe-13c9-4b00-9618-4a8cbb1abe82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_78435cfe-13c9-4b00-9618-4a8cbb1abe82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_78435cfe-13c9-4b00-9618-4a8cbb1abe82_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_78435cfe-13c9-4b00-9618-4a8cbb1abe82" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_78435cfe-13c9-4b00-9618-4a8cbb1abe82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2738d885-8a1d-4a61-ab38-6334466d23d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_78435cfe-13c9-4b00-9618-4a8cbb1abe82" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2738d885-8a1d-4a61-ab38-6334466d23d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8a27a99d-ef27-410b-ba21-425a62ab0319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2738d885-8a1d-4a61-ab38-6334466d23d9" xlink:to="loc_us-gaap_SubsequentEventMember_8a27a99d-ef27-410b-ba21-425a62ab0319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_04c587ad-894f-4770-ae75-4ed324b7a534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_04c587ad-894f-4770-ae75-4ed324b7a534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PublicStockOfferingMember_d590ea5a-ab61-47d4-8dfa-2ef267897e8c" xlink:href="sgry-20201231.xsd#sgry_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_04c587ad-894f-4770-ae75-4ed324b7a534" xlink:to="loc_sgry_PublicStockOfferingMember_d590ea5a-ab61-47d4-8dfa-2ef267897e8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PublicStockOfferingFirmSharesMember_5b991978-aae7-446d-a13b-1c0d832a13d2" xlink:href="sgry-20201231.xsd#sgry_PublicStockOfferingFirmSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_PublicStockOfferingMember_d590ea5a-ab61-47d4-8dfa-2ef267897e8c" xlink:to="loc_sgry_PublicStockOfferingFirmSharesMember_5b991978-aae7-446d-a13b-1c0d832a13d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_600b2589-1ca8-409c-b9bb-f2b941c1a42d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgry_PublicStockOfferingMember_d590ea5a-ab61-47d4-8dfa-2ef267897e8c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_600b2589-1ca8-409c-b9bb-f2b941c1a42d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_CreditFacilityAxis_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e" xlink:to="loc_us-gaap_CreditFacilityDomain_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_138c8c3c-34a1-4d94-b0da-4529bc0464ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e" xlink:to="loc_us-gaap_CreditFacilityDomain_138c8c3c-34a1-4d94-b0da-4529bc0464ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4e0d4fdd-b0a4-4aed-acbf-85ba126a011a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_138c8c3c-34a1-4d94-b0da-4529bc0464ef" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4e0d4fdd-b0a4-4aed-acbf-85ba126a011a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_790bc43b-e9c2-4591-926a-5921e427bbb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_DebtInstrumentAxis_790bc43b-e9c2-4591-926a-5921e427bbb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_790bc43b-e9c2-4591-926a-5921e427bbb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_790bc43b-e9c2-4591-926a-5921e427bbb7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_790bc43b-e9c2-4591-926a-5921e427bbb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a8a9739b-7814-4077-b6b1-42abb1cb964a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_790bc43b-e9c2-4591-926a-5921e427bbb7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a8a9739b-7814-4077-b6b1-42abb1cb964a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_bb05b610-9bd5-4b67-bb4b-45d48dc11e6f" xlink:href="sgry-20201231.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8a9739b-7814-4077-b6b1-42abb1cb964a" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_bb05b610-9bd5-4b67-bb4b-45d48dc11e6f" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>sgry-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:934c24c6-c60d-49cc-a057-94123601eeba,g:155ec3a3-79d5-4a25-a7e0-562ed3402740-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd7c9ed7-e7fe-4818-9f9d-54d0f6a1c6e9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted during period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33e4981e-1fd0-4834-8795-ce1d1ede97fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted/Earned (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_584096dd-50b2-4f2a-8c86-2b461fb44df5_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6f5c1c65-7f95-4692-9f00-e28e83f24972_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_f5b07c2a-ca06-45f0-b8fc-8940a630fc28_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_dfafb2de-f1d8-4ecd-bc67-f1ba3e2897e4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_3813be2e-a244-4c50-910b-bb354038ce44_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated insurance recoveries</link:label>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:to="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_bf3e20d2-a496-46b8-aae7-d5fec0253344_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and General and Workers' Compensation Insurance</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:to="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_e8dc127f-8a7a-425e-8396-dd9dcb24d921_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in effective tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a0ecf3f3-0336-453c-acfb-cde4b275191d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2b11fb87-41df-4014-9a56-8ae84d473af1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_abadbd07-8a2f-4a89-a599-897e4c19d2fb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate acquisition date fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81de4c8f-05f8-4c14-916f-fac1f09a73ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_89ecddad-0c57-4fa5-a8ce-8ee8afdb6373_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interests&#8212;non-redeemable holders</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_33ffc4c9-7987-4f56-aac4-6263dc88fb70_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of leased assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_e5a17bd9-1cfb-46bf-8650-841ae97e38a1_terseLabel_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest Taxes Depreciation And Amortization</link:label>
    <link:label id="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest Taxes Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="sgry-20201231.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_0408f57b-476e-44b9-a46d-a8efc1f1846c_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_TemporaryEquityThresholdTradingDays_efa93b52-8b9c-4499-908b-e5fb29f9b20a_terseLabel_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading days</link:label>
    <link:label id="lab_sgry_TemporaryEquityThresholdTradingDays_label_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Threshold Trading Days</link:label>
    <link:label id="lab_sgry_TemporaryEquityThresholdTradingDays_documentation_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdTradingDays" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_TemporaryEquityThresholdTradingDays" xlink:to="lab_sgry_TemporaryEquityThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0a1c39dc-af87-4fb6-96ca-349391c0a244_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DebtInstrumentPrepaymentPenaltyAmount_bbab184e-205f-4716-971a-494f249ecbd6_negatedTerseLabel_en-US" xlink:label="lab_sgry_DebtInstrumentPrepaymentPenaltyAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of premium on debt extinguishment</link:label>
    <link:label id="lab_sgry_DebtInstrumentPrepaymentPenaltyAmount_label_en-US" xlink:label="lab_sgry_DebtInstrumentPrepaymentPenaltyAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty Amount</link:label>
    <link:label id="lab_sgry_DebtInstrumentPrepaymentPenaltyAmount_documentation_en-US" xlink:label="lab_sgry_DebtInstrumentPrepaymentPenaltyAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentPrepaymentPenaltyAmount" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentPrepaymentPenaltyAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DebtInstrumentPrepaymentPenaltyAmount" xlink:to="lab_sgry_DebtInstrumentPrepaymentPenaltyAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_eeac678a-bb93-4631-9ed9-753e93c73e6c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use finance lease asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_cff9f1c1-562a-4601-b15a-710f86614e64_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_18241349-3c49-4cc9-9524-a291c555d044_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_244f71cd-61f8-46f3-83f4-0a5c78563974_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59a78a2d-fd89-4a18-8721-0a3ceee4199a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f0968a57-28bd-4f11-8733-15b44914c9ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_52027a2b-d474-40d6-8a50-a7b77c639f6c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_03719f12-ac7d-4086-b844-b6dcf61deeb0_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2b9fb03a-0e0e-4cba-9c83-b29a08ad5dab_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_e8bf4957-c11c-47dd-aa21-2c8fab7688f2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f4e5b820-38b2-4ec8-9bd4-df522247679a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_991e0a87-e1dc-46a2-b346-e6dc0bc56a18_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_dd832666-3607-4414-bf03-91ce65027008_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_97d0b858-4812-40f7-bcbb-c934bbabe2b9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_dc4437a0-60f0-4e6b-89ea-39b4b050c569_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SAR Awards</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_571fcb63-55bd-4d8a-bc47-cb75754d39c9_terseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and disposal of shares of non-controlling interests, net&#8212;redeemable</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Increase (Decrease) From Redemptions Or Purchase Of Interests</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:href="sgry-20201231.xsd#sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:to="lab_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5e35f20e-c696-41c3-82a6-e41eb1d0aa1e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_74fc204d-8adb-4847-bd1e-7f51199dd4d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_c6df1e0a-2835-4c50-a379-f8e208efc5b3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DebtInstrumentRedemptionPeriodSixMember_5f924225-8124-4984-9879-f92edbece060_terseLabel_en-US" xlink:label="lab_sgry_DebtInstrumentRedemptionPeriodSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Six</link:label>
    <link:label id="lab_sgry_DebtInstrumentRedemptionPeriodSixMember_label_en-US" xlink:label="lab_sgry_DebtInstrumentRedemptionPeriodSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Six [Member]</link:label>
    <link:label id="lab_sgry_DebtInstrumentRedemptionPeriodSixMember_documentation_en-US" xlink:label="lab_sgry_DebtInstrumentRedemptionPeriodSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentRedemptionPeriodSixMember" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentRedemptionPeriodSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DebtInstrumentRedemptionPeriodSixMember" xlink:to="lab_sgry_DebtInstrumentRedemptionPeriodSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_b836bde4-a6bc-40fa-8970-7840b9b28c3b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a50b733a-5c56-46e8-9884-4c37c32efbc6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_1f3baff1-97dc-4d4c-b8a8-5e0ed5693b64_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0dd51d35-b06d-432f-b6b8-83686f3ad125_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9b6b408-8d14-40d0-af5a-5a0d44efdd73_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4608076-1d75-406c-b95e-46cdaca9bce9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_97bcc38e-decf-4083-aa38-7fa83e77bde5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7f6228e8-4edd-433d-b438-4cb4e7a17268_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_2b2e1b4b-b870-4972-9fc2-3cca7a14c798_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts attributable to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_a0742042-cae4-421f-8b55-e6553c215613_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, less current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_100139dc-3d1b-4efc-9225-20a67e6dc43b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupTwoMember_21cdcb90-bee1-4837-a098-639d4297e5c3_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Laboratory</link:label>
    <link:label id="lab_sgry_DisposalGroupTwoMember_label_en-US" xlink:label="lab_sgry_DisposalGroupTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Two [Member]</link:label>
    <link:label id="lab_sgry_DisposalGroupTwoMember_documentation_en-US" xlink:label="lab_sgry_DisposalGroupTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupTwoMember" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupTwoMember" xlink:to="lab_sgry_DisposalGroupTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_831ab741-a1e3-409d-ad16-55196170a742_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b4892612-1a58-47ad-8f72-5c480a015aef_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_037cbd7b-8ccd-49c8-94f0-da3d436821a7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_32349360-cb84-41f0-8335-810bfa437619_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value; shares authorized - 20,000,000; shares issued or outstanding - none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_a7d7a60b-1423-453b-b875-b04a1b025aa6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_49a346a5-3215-4596-ae7b-6601c610401a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c7151526-59c9-4370-b21c-6dd57f84af68_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_f0ec9f56-2952-44f0-b090-df4e4e52c744_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_72d89ded-ed9c-4dff-9146-a6b0cd79527c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_945aeec2-c45a-4f2e-856b-45871a21a36f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_feaa61e8-46ed-4791-93a3-f06144940102_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned, majority interest</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Facilities Owned, Majority Interest</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned, Majority Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_358cb11a-be2e-4241-87f4-dc480560dc9b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5adb95dd-e0ef-4e63-8ee6-4bc1295affac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation_aea09b9d-bca9-4d94-8f3c-fffb7806264f_terseLabel_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 163(j) interest</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation_label_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Interest Limitation</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation_documentation_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Interest Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" xlink:to="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_1e6509fa-7aa8-4d63-bd13-d1dd88579364_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by service type as a percentage of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_dd17174b-89a1-49c6-8556-c4ae97f9a9a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_57c0523b-f7d3-46b9-90c7-d687a5b0d730_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e49b8b94-efca-4df1-b049-bbf6bb21c26c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_79de5baf-3301-421b-a226-8fa7cfaa7800_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fc4041b3-4a84-4029-b43d-d45c1b21676f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_aebde05d-a070-415e-9b76-ff9e3f2e58f3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_c6d47dcd-42ad-4d1e-9ce9-45fac8ff34e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss reclassified from accumulated OCI to interest expense (effective portion)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DebtInstrumentTotalCommitmentThreshold_39ae268d-06b9-456b-b9c9-397a4542f99c_terseLabel_en-US" xlink:label="lab_sgry_DebtInstrumentTotalCommitmentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment threshold</link:label>
    <link:label id="lab_sgry_DebtInstrumentTotalCommitmentThreshold_label_en-US" xlink:label="lab_sgry_DebtInstrumentTotalCommitmentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Total Commitment Threshold</link:label>
    <link:label id="lab_sgry_DebtInstrumentTotalCommitmentThreshold_documentation_en-US" xlink:label="lab_sgry_DebtInstrumentTotalCommitmentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Total Commitment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentTotalCommitmentThreshold" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentTotalCommitmentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DebtInstrumentTotalCommitmentThreshold" xlink:to="lab_sgry_DebtInstrumentTotalCommitmentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_15d8cbe3-00cf-401a-88bf-5d29031bc848_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_1a8eed76-0fad-430c-bcfe-75bd6abf799b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_StartUpActivitiesStartUpCosts_882e53f1-3202-47d6-8396-316618304a19_terseLabel_en-US" xlink:label="lab_sgry_StartUpActivitiesStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-up costs related to de novo surgical hospital</link:label>
    <link:label id="lab_sgry_StartUpActivitiesStartUpCosts_label_en-US" xlink:label="lab_sgry_StartUpActivitiesStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-Up Activities, Start-Up Costs</link:label>
    <link:label id="lab_sgry_StartUpActivitiesStartUpCosts_documentation_en-US" xlink:label="lab_sgry_StartUpActivitiesStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-Up Activities, Start-Up Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_StartUpActivitiesStartUpCosts" xlink:href="sgry-20201231.xsd#sgry_StartUpActivitiesStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_StartUpActivitiesStartUpCosts" xlink:to="lab_sgry_StartUpActivitiesStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1c79095b-c83a-4c57-9e5b-27744af0b447_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6dcb2af-a4dd-4f23-b358-d5b217eeee2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_f4475b37-caaf-4ec6-bc1d-3d915d2127e1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew_aa459d87-d116-413c-a4b2-9fc9bf33e244_terseLabel_en-US" xlink:label="lab_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew operating leases</link:label>
    <link:label id="lab_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew_label_en-US" xlink:label="lab_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Number Of Options To Renew</link:label>
    <link:label id="lab_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Number Of Options To Renew</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" xlink:href="sgry-20201231.xsd#sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" xlink:to="lab_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8a9f65af-0a55-45d2-b564-35091c603b27_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_e226f52b-f36b-42b4-80b2-4f66f1b4be51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7a20959d-3423-4fda-a6a5-76912a41321b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3c86897d-45ba-4d60-8e12-9b1bde950933_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b557f4a7-6e1a-46bf-95ed-ace3cbe48a75_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_bc3267bf-4f5b-4c26-9221-bb25b2ea6449_terseLabel_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured revolving credit facility</link:label>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_sgry_A2017SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Senior Secured Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:href="sgry-20201231.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:to="lab_sgry_A2017SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bbcceb19-5ad2-450f-af50-d6918f2cb872_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized under plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_b8a5450f-b91b-4db3-8cc5-92e29fe25411_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_c7c67dfc-ed09-48fb-82a9-10e37919e963_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_148760f0-e149-4cc8-85f0-ffeddb4ad8b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a0ea10ae-4927-4b3d-ac0f-c4bdf25088d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grant (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_f834bc71-3c9e-4d98-9289-50539d10a4e4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative preferred dividends</link:label>
    <link:label id="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_label_en-US" xlink:label="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Amount of Preferred Dividends in Arrears</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:to="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_3d6e724a-b688-4e10-80f7-1f39681c6b06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interest holders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_2f9bafb3-1dfb-403b-be95-a01bce0de847_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction, integration and acquisition costs</link:label>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_label_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs, And Merger Costs</link:label>
    <link:label id="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs, And Merger Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:to="lab_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_69d54dce-825d-4722-84a7-a84799e4fd45_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_70a9da47-41cd-4a09-b33d-b95829822f02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_a1263744-6269-4d03-a0ed-974dc4cd96e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Unconsolidated Affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a8d75e6b-3603-41fc-b817-e37f4f37680e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_8467a086-c992-4d5d-b302-36585e96def6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0bddd1bd-ed82-4dcf-ab80-0dd72fef0174_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Adjusted EBITDA:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_93286262-95a3-4ec5-ad45-f5f8eed4edf3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_c19ff965-b3f9-45bb-905c-d4e657052cd5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_436d9a2d-98a1-46bb-840f-cc68f18bd1ee_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsHedgingTransactions_4fc874c4-e17d-4350-a764-2425d38fddbb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsHedgingTransactions_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Hedging Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsHedgingTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:to="lab_us-gaap_DeferredTaxAssetsHedgingTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_037a9b0a-c3e6-4586-add2-7169bcbef178_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5798ebb9-7711-4e53-bfbb-7ff6c0bf0e22_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_cef2906d-4bdb-47a3-ab23-b4e75fd4b1bb_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93773dc8-8f75-483f-945c-f55865501ea7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain_bdf5c4da-1abc-41e4-bc25-07a6f441eabb_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2da3c042-b7df-41a6-96d0-0cd7d3c6a1ec_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Expense and Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_afa4c34b-0ba2-4327-b9fb-eeabc06d058f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d5906cb6-70e0-4983-a7bb-58ccd98c3063_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_77a1986d-b7af-4159-a887-c0b1d332c917_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_a06dc5fc-f08e-4754-8c9c-bcab32cb9ee2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_5afef9af-adb8-4b0c-98dd-e256ef40be1a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a28245ba-a597-4751-ab2a-e58896835a1b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_07f689d3-4074-4afc-8431-ce8f53d36a38_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_81b37339-6629-47e1-a863-7a8e789f4a80_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_TaxReceivableAgreementExpenseBenefit_ed504a46-fd75-423b-bd68-9c3eb06704e8_terseLabel_en-US" xlink:label="lab_sgry_TaxReceivableAgreementExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement expense</link:label>
    <link:label id="lab_sgry_TaxReceivableAgreementExpenseBenefit_label_en-US" xlink:label="lab_sgry_TaxReceivableAgreementExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Expense (Benefit)</link:label>
    <link:label id="lab_sgry_TaxReceivableAgreementExpenseBenefit_documentation_en-US" xlink:label="lab_sgry_TaxReceivableAgreementExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementExpenseBenefit" xlink:href="sgry-20201231.xsd#sgry_TaxReceivableAgreementExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_TaxReceivableAgreementExpenseBenefit" xlink:to="lab_sgry_TaxReceivableAgreementExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c36fe2ed-9504-4c16-99bc-59dd847f1132_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of the period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cc18c20e-981d-4094-97c7-a0117d20fc70_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of the period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments_a39bf0d9-28e4-49a7-ad50-e32b483b9b2a_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash consideration from working capital settlement payment</link:label>
    <link:label id="lab_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments_label_en-US" xlink:label="lab_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Working Capital Adjustments</link:label>
    <link:label id="lab_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Working Capital Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" xlink:to="lab_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_6c4ce704-5e93-4712-b112-3f43c537da92_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_206fb40a-7ebe-43e2-a7b6-ae0341c01261_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_012f3740-e20a-4fe3-9fb7-be406510d892_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gain (loss)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_de70378c-1b40-42e3-81c6-e5dbe85e585a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d2d43c56-6f79-4eef-ae18-385ef88dd1b7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable_5bfee226-028f-4cf6-be79-55e6587c2aff_terseLabel_en-US" xlink:label="lab_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate indebtedness receivable</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable_label_en-US" xlink:label="lab_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Affiliate Indebtedness Receivable</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable_documentation_en-US" xlink:label="lab_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Affiliate Indebtedness Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable" xlink:to="lab_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount_ec52416b-1423-4293-8f31-39a58380fea8_terseLabel_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Differences related to divested facilities</link:label>
    <link:label id="lab_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount_label_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Divestiture, Amount</link:label>
    <link:label id="lab_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount_documentation_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Divestiture, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxReconciliationDivestitureAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount" xlink:to="lab_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_15097d70-9313-4347-8273-5c6df5817a65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_5f6bec89-3191-42c4-8d76-86e9b197d0e7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_59bdc767-bb42-4ea1-8586-faed5801ebd8_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted invested assets included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1124b5f0-65e1-4e4b-b377-13b783966167_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_97101955-efa4-4594-bcd4-94bd920e68cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e1d77635-a430-4852-b9b7-15b2f71162ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_62d34c59-c17a-41cf-ad43-fe8ecf76837d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationContingentAcquisitionExpense_fa66cd1d-c34c-48d6-8d0b-bde0c408842a_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationContingentAcquisitionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent acquisition compensation expense</link:label>
    <link:label id="lab_sgry_BusinessCombinationContingentAcquisitionExpense_label_en-US" xlink:label="lab_sgry_BusinessCombinationContingentAcquisitionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Acquisition Expense</link:label>
    <link:label id="lab_sgry_BusinessCombinationContingentAcquisitionExpense_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationContingentAcquisitionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Acquisition Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationContingentAcquisitionExpense" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationContingentAcquisitionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationContingentAcquisitionExpense" xlink:to="lab_sgry_BusinessCombinationContingentAcquisitionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_564b9e56-ab2a-4ee9-8c46-5941fcd32330_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rollforward of Non-Controlling Interests - Redeemable</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b0777d4-46ef-446f-bc1f-0d5a6353f667_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_a6403182-fb7b-48a7-b9de-8370c5845f22_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3b38953f-8473-4d7a-81f5-6a2f8ee61ae8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_22ed8483-bfff-4ed9-96c7-376e11df2d2d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PayablesToCustomers_fae56ac6-fcb0-492e-8df1-d74353da901e_terseLabel_en-US" xlink:label="lab_srt_PayablesToCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due to patients and payors</link:label>
    <link:label id="lab_srt_PayablesToCustomers_label_en-US" xlink:label="lab_srt_PayablesToCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker-Dealer, Payable to Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PayablesToCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PayablesToCustomers" xlink:to="lab_srt_PayablesToCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8b0193be-fe3f-400f-b7fc-008b7e9bca39_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_18a02550-d663-4d5a-8607-78c5f782a378_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_5c0a6d15-3556-48e7-9613-646ef724559a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5cc0ee1e-b7eb-4697-97b1-536f00d26590_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d059592e-6cc5-40fe-a34f-bb39bb741c2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a247a6e4-459e-4c21-b981-e06790ebacc0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, stockholders' equity (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6e0d98ee-56bb-4e66-9747-c362936af469_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, stockholders' equity (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8ef38f6f-126d-4599-8627-3227892315cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_37b46a51-f9fd-47a0-87a8-5c0056fbb789_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_309e993a-fa57-4c25-a47c-367bc9471d31_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_a8f33f9b-4400-4c94-a5fd-ebaf4066d70b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction and integration costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7beb659-13fe-4fce-8aa6-6045a3ef31a5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_04ae3e59-0ed7-42b5-90df-f215bf6fe74c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c1169c66-4a73-48e3-bdc0-f0f11035abbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d81cae8f-b308-4c40-81f4-4f28d0d73e7c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash consideration, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e25ccf2d-37ff-4348-a2c5-7cc535813525_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ff188e8b-8bed-41de-9bd1-e2f23146e4b5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, excluding right-of-use finance lease asset, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_01983454-634b-47b9-a256-c4e2bfb86a94_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f5e1e581-0cb5-4d09-9c5a-22f2ed441dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Information by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0d60957a-7809-414e-9a97-0b9043238400_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss_5eb4f73b-aeab-466f-9a41-817e6ce25d98_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recognized in OCI (effective portion)</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Interest Rate Cash Flow Hedges, Pretax, Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_e42fdf1e-ca23-450d-99cb-3d378b86f9a5_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Shares Granted to Underwriters</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2cf2d3c0-0705-438d-9a3a-4ec950929d78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_709505e5-1800-4868-9f71-d02a61ce02ff_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e685a4e6-437a-4087-80ac-d46451a8131a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_8a341739-0961-4092-9923-7e0a6a11a0f0_terseLabel_en-US" xlink:label="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated payments</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_label_en-US" xlink:label="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_documentation_en-US" xlink:label="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:href="sgry-20201231.xsd#sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:to="lab_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_bc29d690-56d4-4fc9-a3f9-bfd460edd80d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_57241544-e107-402c-9aa4-b0314041bc37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs and discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c69bc373-c235-40ed-97f3-7a60ad09adad_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs and discount, net of issuance premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6083e756-db2a-4447-a3e6-fddfa4ab9e68_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5b8b2e8d-8639-425c-b171-7e4de8290cbc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_8783f4e9-760a-4ecd-8aa6-d22d85915b6c_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a3b3207c-8e42-47b1-9252-eaef5e8baff3_negatedTerseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to non-controlling interest &#8212;redeemable holders</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="sgry-20201231.xsd#sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_2e8fd20d-66de-46cb-8561-7877d6ad5d0a_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_cdf42271-e538-4001-af7f-f3123ba8fd73_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for bad debts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2d5d2d6e-e7c6-415e-bf49-9537a02771b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d70810d6-f3d9-4d1a-963f-bf36098b781d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_6142d699-c0eb-4b0b-a562-3c8f6b787501_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_fd1362ba-36e7-4c2d-9964-661e4e605ec6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_c0e23775-5741-4183-9585-a5055c4d52d3_terseLabel_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities included in VIE</link:label>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_label_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number Of Facilities</link:label>
    <link:label id="lab_sgry_VariableInterestEntityNumberOfFacilities_documentation_en-US" xlink:label="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities" xlink:href="sgry-20201231.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_VariableInterestEntityNumberOfFacilities" xlink:to="lab_sgry_VariableInterestEntityNumberOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ae6b46f1-5935-4f83-9f81-db9d9282c7a4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_faa8fca3-7a40-4289-88cd-e8761a47cb7f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_1b5646fa-8182-49ed-91b7-0f87075cec0e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ece79c7c-7efc-402e-b4c6-240f7a7e3545_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from equity investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_b54eff25-c68a-4f78-a935-3ca331a500ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_d65b872a-ddb7-47cc-b5d2-78d604498eb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:to="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_62a1eb3e-ff86-47ba-9ccb-0e778fe111a9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_1fee211d-6e37-4c45-a24e-ae3e6340ac4e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b6caaf57-f8c9-4103-b2da-d03e48db6eba_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including post acquisition adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0d02b099-dde8-4b3f-92ef-293daeb01391_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, and equipment useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_838ff666-20cd-481f-81a7-94a06a2b1930_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_e88ece71-1f92-490c-8851-59e8e007ec65_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned, consolidated</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Surgical Facilities Owned, Consolidated</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned, Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_088ac712-b71c-4761-96ab-9477b92f99f8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NotMateriallyMoreRestrictiveMember_d71bafff-d120-423f-bcb2-3a4a9d0ad858_terseLabel_en-US" xlink:label="lab_sgry_NotMateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Materially More Restrictive</link:label>
    <link:label id="lab_sgry_NotMateriallyMoreRestrictiveMember_label_en-US" xlink:label="lab_sgry_NotMateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Materially More Restrictive [Member]</link:label>
    <link:label id="lab_sgry_NotMateriallyMoreRestrictiveMember_documentation_en-US" xlink:label="lab_sgry_NotMateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Materially More Restrictive [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotMateriallyMoreRestrictiveMember" xlink:href="sgry-20201231.xsd#sgry_NotMateriallyMoreRestrictiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NotMateriallyMoreRestrictiveMember" xlink:to="lab_sgry_NotMateriallyMoreRestrictiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_ee7dab14-cc0e-4b30-93be-fcb05868ccfa_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_TemporaryEquityThresholdConsecutiveTradingDays_1e0d84af-eee4-410b-8344-92011367d21e_terseLabel_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days</link:label>
    <link:label id="lab_sgry_TemporaryEquityThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_sgry_TemporaryEquityThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdConsecutiveTradingDays" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_TemporaryEquityThresholdConsecutiveTradingDays" xlink:to="lab_sgry_TemporaryEquityThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0641f11c-9734-42be-ad86-86782a1a01ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_d8165d02-8430-4a1a-a17f-d3874959e9e3_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_f5f5f0c3-7ff7-41ce-90a6-31182f19d6b8_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a875fa9e-a35f-4f43-a0c8-c5b15cedb57e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_abddf739-1766-4c79-a6da-476608b82b49_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_cbc26466-8faa-4d1f-8d41-09574a9fbd2e_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupOneMember_16de751c-654f-46ac-a37b-ddef9db68705_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery Centers, Certain Assets Related to Anesthesia Business, Certain Imaging ASsets and Optical Products Purchasing Organization</link:label>
    <link:label id="lab_sgry_DisposalGroupOneMember_label_en-US" xlink:label="lab_sgry_DisposalGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group One [Member]</link:label>
    <link:label id="lab_sgry_DisposalGroupOneMember_documentation_en-US" xlink:label="lab_sgry_DisposalGroupOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupOneMember" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupOneMember" xlink:to="lab_sgry_DisposalGroupOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_bd44d627-a050-4854-bc8c-a7e809eb383e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_fb38ab25-8c32-4467-8af6-bc827e38c20d_terseLabel_en-US" xlink:label="lab_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options and Stock Appreciation Rights</link:label>
    <link:label id="lab_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_label_en-US" xlink:label="lab_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options And Stock Appreciation Rights [Member]</link:label>
    <link:label id="lab_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_documentation_en-US" xlink:label="lab_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options And Stock Appreciation Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:href="sgry-20201231.xsd#sgry_EmployeeStockOptionsAndStockAppreciationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:to="lab_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e989f125-7244-4909-8094-d7c03e7bf6d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_dab91c01-4e23-44f9-a4e4-f749ba4bdda4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_87c71e05-28d8-454a-846a-4df00c32e13d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_f36c6343-b05c-43d3-bb66-bfdf02022828_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted and Performance Share-Based Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OpticalProductsReceivable_866e299a-937f-4723-82dd-d2d5cf6ed666_verboseLabel_en-US" xlink:label="lab_sgry_OpticalProductsReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optical products receivable</link:label>
    <link:label id="lab_sgry_OpticalProductsReceivable_label_en-US" xlink:label="lab_sgry_OpticalProductsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optical Products Receivable</link:label>
    <link:label id="lab_sgry_OpticalProductsReceivable_documentation_en-US" xlink:label="lab_sgry_OpticalProductsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optical Products Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalProductsReceivable" xlink:href="sgry-20201231.xsd#sgry_OpticalProductsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OpticalProductsReceivable" xlink:to="lab_sgry_OpticalProductsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_f847cd27-f40c-4c78-bbcd-d5ceea4f1543_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_34675eb9-c6f3-4c74-b827-d0e63b2d45e5_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of adoption of ASC 842</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_900b43ab-87e2-40e5-b7ca-11ed95c72cf7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_821098dd-f3b5-452c-bf45-428df01faab5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_d2a2a3ab-6438-4104-b3d9-ff3262b37dcf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_510e3e90-e37c-4140-924c-90bce6ded90a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PhysicianIncomeGuaranteesMember_b6ec0157-0abd-4f32-af17-f5191466adcf_terseLabel_en-US" xlink:label="lab_sgry_PhysicianIncomeGuaranteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician income guarantees</link:label>
    <link:label id="lab_sgry_PhysicianIncomeGuaranteesMember_label_en-US" xlink:label="lab_sgry_PhysicianIncomeGuaranteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Income Guarantees [Member]</link:label>
    <link:label id="lab_sgry_PhysicianIncomeGuaranteesMember_documentation_en-US" xlink:label="lab_sgry_PhysicianIncomeGuaranteesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Income Guarantees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PhysicianIncomeGuaranteesMember" xlink:href="sgry-20201231.xsd#sgry_PhysicianIncomeGuaranteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PhysicianIncomeGuaranteesMember" xlink:to="lab_sgry_PhysicianIncomeGuaranteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ProceedsFromGovernmentAssistance_7eb67dd6-ffd6-445b-a64b-0017b5a5cb56_terseLabel_en-US" xlink:label="lab_sgry_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from grants received</link:label>
    <link:label id="lab_sgry_ProceedsFromGovernmentAssistance_label_en-US" xlink:label="lab_sgry_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Government Assistance</link:label>
    <link:label id="lab_sgry_ProceedsFromGovernmentAssistance_documentation_en-US" xlink:label="lab_sgry_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Government Assistance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProceedsFromGovernmentAssistance" xlink:href="sgry-20201231.xsd#sgry_ProceedsFromGovernmentAssistance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ProceedsFromGovernmentAssistance" xlink:to="lab_sgry_ProceedsFromGovernmentAssistance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_f230c8ea-acdc-4c52-ad70-3672efb1003c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_c7f300f1-5d51-43e8-8d14-9e7d4c12806d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_6e70c50a-05e7-4a4f-ae1d-0dba2df170cc_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Revenue and Operating Income</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_847f4388-d3ac-4d2a-b9d1-adfe806df0f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_c05419b8-6f6a-43fc-98e3-5bc0fe568827_terseLabel_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:to="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f796bfe8-f4cb-4cff-a36b-c4ac53d042c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_04e7b24c-130f-4a31-a287-4a7db56b8ca2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SelfPayRevenueMember_dc4f9e4b-a4ea-498a-9af6-cac3a1d33b7e_terseLabel_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-pay</link:label>
    <link:label id="lab_sgry_SelfPayRevenueMember_label_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay Revenue [Member]</link:label>
    <link:label id="lab_sgry_SelfPayRevenueMember_documentation_en-US" xlink:label="lab_sgry_SelfPayRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember" xlink:href="sgry-20201231.xsd#sgry_SelfPayRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SelfPayRevenueMember" xlink:to="lab_sgry_SelfPayRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_82f2ad9b-1f55-4302-ad7e-40586d1d4a8c_terseLabel_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_label_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patient Service Revenue Sources [Member]</link:label>
    <link:label id="lab_sgry_OtherPatientServiceRevenueSourcesMember_documentation_en-US" xlink:label="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patient Service Revenue Sources [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember" xlink:href="sgry-20201231.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OtherPatientServiceRevenueSourcesMember" xlink:to="lab_sgry_OtherPatientServiceRevenueSourcesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_MateriallyMoreRestrictiveMember_d750e68d-cf69-4ac2-8e0b-3a0bd780d766_terseLabel_en-US" xlink:label="lab_sgry_MateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materially More Restrictive</link:label>
    <link:label id="lab_sgry_MateriallyMoreRestrictiveMember_label_en-US" xlink:label="lab_sgry_MateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materially More Restrictive [Member]</link:label>
    <link:label id="lab_sgry_MateriallyMoreRestrictiveMember_documentation_en-US" xlink:label="lab_sgry_MateriallyMoreRestrictiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materially More Restrictive [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MateriallyMoreRestrictiveMember" xlink:href="sgry-20201231.xsd#sgry_MateriallyMoreRestrictiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_MateriallyMoreRestrictiveMember" xlink:to="lab_sgry_MateriallyMoreRestrictiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_3f0f6961-547d-411d-8373-7a010f28a06e_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a7e2fee2-46bf-44b7-8560-35f65fe5a40e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d8facb79-fb0d-41fa-9c73-d219160a4d2f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_1810eb05-b1c4-475a-aa53-70dede02c089_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e6b47b03-e230-4571-ba34-ac6b4dfb7362_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_6a6af717-1828-431a-9ddc-c8d48c93e916_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement expense</link:label>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherTaxExpenseBenefit" xlink:to="lab_us-gaap_OtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b097aa4d-d5ea-41a2-811b-33a9f3fbdc09_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4accde9b-909f-4b67-a53c-a6c55685f821_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_fea516ba-ffab-47a3-8f97-0b0875076800_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_5b4439aa-3d92-4f12-b640-fc141cd17441_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services</link:label>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilityServicesMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilityServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilityServicesMember" xlink:to="lab_sgry_SurgicalFacilityServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock_0b38ce7d-d7eb-4f07-899e-87a69ef390c4_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Disposals</link:label>
    <link:label id="lab_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock_label_en-US" xlink:label="lab_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations And Disposals Disclosure [Text Block]</link:label>
    <link:label id="lab_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations And Disposals Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:to="lab_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e620ee0b-2246-4a15-87a6-6600235a823f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1305327e-5617-4627-810d-8972ae518594_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original balance of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_281e217d-0ff8-4c1e-a55d-93c67c6512a6_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face value of debt issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_42ccde3d-2239-43c9-ace6-0c4e43e346e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred dividends</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_88d56408-14cf-4315-b088-6f86b18d59e8_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_6eee0874-41f3-4eb1-8c03-3a11f9a4b0fa_terseLabel_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.750% senior unsecured notes due 2025</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_label_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2025 [Member]</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2025Member_documentation_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SeniorUnsecuredNotesDue2025Member" xlink:to="lab_sgry_SeniorUnsecuredNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_df0c9493-ac2b-417e-ae03-f5015ef18dae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_69232c79-5d78-41ee-a393-2c69292f2f4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_09816c96-4fee-461b-a156-6875cc35d7a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_283879eb-73bd-4c24-9de7-18b77f300087_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_18518edf-96cf-451d-b822-0ccd82965c7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_938b7dfb-9a42-4ec6-8735-fab0096fc267_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_1f5db464-cef2-4c24-b3fb-05ee7815e440_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0dff4ffb-dee6-48e1-9109-82af5771e15f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_c9354931-7211-45e2-a040-02b0409a5175_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_379a10dc-b9c2-48c4-a0fa-561f1c79d804_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_6124b605-c214-413d-8918-75b2ae0b22f1_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation_65386ebb-fe03-406d-9f40-b2be3c58eb13_terseLabel_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued vacation and incentive compensation</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation_label_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences and Incentive Compensation</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation_documentation_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences and Incentive Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" xlink:to="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f5486da3-509d-4f7c-96b3-f855b8d756be_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_a4e55bd0-8c50-4a66-a6d9-eb967297c994_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Five</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_788feb8e-b85c-4c6d-8d85-469be90935a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9a430aaa-be96-4f35-b5d3-4a10e7918ad2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_f66e8e08-7238-461b-9129-65a319cc2ded_negatedTerseLabel_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense (income), net</link:label>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_label_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Income (Expense), Net</link:label>
    <link:label id="lab_sgry_NoncashInterestIncomeExpenseNet_documentation_en-US" xlink:label="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet" xlink:href="sgry-20201231.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NoncashInterestIncomeExpenseNet" xlink:to="lab_sgry_NoncashInterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent_71dce773-6bf7-4c22-859c-75f786a16a89_terseLabel_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated payments, current portion</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent_label_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments, Current</link:label>
    <link:label id="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent_documentation_en-US" xlink:label="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments, Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" xlink:href="sgry-20201231.xsd#sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" xlink:to="lab_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_58651312-129d-46a4-b690-1080a8c580d5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_a7669add-642f-422a-a05e-e2a02d143e48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_ad39e1cd-02c3-4cd1-bbcb-6d127762e69a_terseLabel_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers</link:label>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_label_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers [Member]</link:label>
    <link:label id="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember_documentation_en-US" xlink:label="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Ambulatory Surgery Centers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:href="sgry-20201231.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:to="lab_sgry_FacilitiesAmbulatorySurgeryCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_5650a8bb-67c8-4bf6-af7d-9c92e18291fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of preferred dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_e7096a92-226e-4213-9b1f-0de3da7a7a12_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_689248ab-c11e-4aac-a3c5-a1d7353a935f_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_c66f7003-a531-4c15-bf1f-729d33c62044_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb302935-2100-438e-a449-80ddc0fe7882_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_002e18da-3203-450d-b180-7f8abf098cde_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_eb6b23a5-9e31-4117-829e-b513c2de5396_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GovernmentRevenueMember_0b232710-0dd4-43fc-81d2-e80451a27b29_terseLabel_en-US" xlink:label="lab_sgry_GovernmentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_sgry_GovernmentRevenueMember_label_en-US" xlink:label="lab_sgry_GovernmentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Revenue [Member]</link:label>
    <link:label id="lab_sgry_GovernmentRevenueMember_documentation_en-US" xlink:label="lab_sgry_GovernmentRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GovernmentRevenueMember" xlink:href="sgry-20201231.xsd#sgry_GovernmentRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GovernmentRevenueMember" xlink:to="lab_sgry_GovernmentRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d5d6c391-0379-484a-8b05-e85eeb68baf0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_c32c48ac-e7e3-49c3-a478-01b9a55a2b17_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale price to public (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_589ad904-8aac-4a69-add7-9db91d520274_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_809ca713-d196-4b56-adb0-3d541470cff3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in measurement of uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_37cedc35-896c-4c24-afe1-a69bc4b7c2ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3e45134a-133f-4f0b-8431-2e5ec414aa1b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_58fd82eb-fb86-4dac-b687-5af21c54de7f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_764eb613-02a4-41f3-b2bc-bb8982c3394a_terseLabel_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured term loan</link:label>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_eaa97323-8a7d-4f37-b34b-5b47394aa7c6_verboseLabel_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured term loan</link:label>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_label_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loan, Maturing 2024 [Member]</link:label>
    <link:label id="lab_sgry_A2017TermLoanMaturing2024Member_documentation_en-US" xlink:label="lab_sgry_A2017TermLoanMaturing2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loan, Maturing 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member" xlink:href="sgry-20201231.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2017TermLoanMaturing2024Member" xlink:to="lab_sgry_A2017TermLoanMaturing2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c7b11328-10fe-43f7-a1da-d9d9a7771c41_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3dcf86eb-f73f-47b3-8715-9e56ad2fd565_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_965697ec-14c9-4687-8898-afe104a4c3ca_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c290a07b-a890-4d83-834d-015add91db6c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_da601a7a-039c-47db-bdb4-dabaeea70772_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_fdb212a5-4627-4f3d-84cb-4d3e8cdad4be_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_15eb6144-dc3a-44c8-9a25-64f31381e318_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of debt principal redeemable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_83257cc1-d186-4b35-ba3a-3d9885fcc793_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_95c6f8d1-b91f-4c01-8384-fd5ec773d2e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_eb28b26b-a65c-4cbd-865a-4431df5e8f70_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable preferred stock - Series A; shares authorized, issued and outstanding - 310,000; redemption value - $434.5 and $395.0, respectively</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_7f8a91cf-fe48-4cbc-bb6e-8437d8976b34_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c50b31c8-1f19-4079-8034-c7a8809b04a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c4485b2c-32ac-4225-82e6-2420fdb39410_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Surgery Partners, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_08feca11-c583-4ff6-b213-6904a4694e7d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aggregate consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_f4b54b3d-ed95-47f4-a992-3eb2245f3771_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0be15743-841d-4501-abdc-c4a48641a61f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_579e3e5e-ef5f-4cba-989e-6007c64b8a97_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_07cef193-1b13-418a-9fda-f235ec4c4c91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_710c10e9-f0df-4233-bdf7-927623691308_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_b9eb6154-8525-438d-8664-001dd887497e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Interest Rate Swaps</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest Rate Derivatives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fadb3447-1983-434b-8f71-be8708514953_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilitiesNewMarketMember_0b2ec9b1-0a58-40bf-9ebd-19638374115e_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilitiesNewMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Including Surgical Hospital</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesNewMarketMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilitiesNewMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, New Market [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesNewMarketMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilitiesNewMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, New Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesNewMarketMember" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilitiesNewMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilitiesNewMarketMember" xlink:to="lab_sgry_SurgicalFacilitiesNewMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OpticalServicesMember_f0296b21-7eb2-4ad9-bddc-70b645a2a04b_terseLabel_en-US" xlink:label="lab_sgry_OpticalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optical Services</link:label>
    <link:label id="lab_sgry_OpticalServicesMember_label_en-US" xlink:label="lab_sgry_OpticalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optical Services [Member]</link:label>
    <link:label id="lab_sgry_OpticalServicesMember_documentation_en-US" xlink:label="lab_sgry_OpticalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optical Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OpticalServicesMember" xlink:to="lab_sgry_OpticalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PublicStockOfferingFirmSharesMember_0badd798-c795-47ee-bcff-6e82c45c2d0b_terseLabel_en-US" xlink:label="lab_sgry_PublicStockOfferingFirmSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Firm Shares</link:label>
    <link:label id="lab_sgry_PublicStockOfferingFirmSharesMember_label_en-US" xlink:label="lab_sgry_PublicStockOfferingFirmSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering, Firm Shares [Member]</link:label>
    <link:label id="lab_sgry_PublicStockOfferingFirmSharesMember_documentation_en-US" xlink:label="lab_sgry_PublicStockOfferingFirmSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering, Firm Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PublicStockOfferingFirmSharesMember" xlink:href="sgry-20201231.xsd#sgry_PublicStockOfferingFirmSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PublicStockOfferingFirmSharesMember" xlink:to="lab_sgry_PublicStockOfferingFirmSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e38ae78d-c3f9-45d3-98cf-1842c30e2ba1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_679101d5-34d2-4262-ad0f-764ff75d9399_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_68872c2c-5025-4e44-9423-3395079259ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_4a1f5c72-df50-4b66-9235-d5d5acaa678b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f0875b0d-6ccf-48b9-90e0-addb7b324b20_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_58e6b864-f8d4-442e-91d4-821a296920c5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_bc68708d-9eb8-491b-909c-49036191456d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9836def6-a7a0-4c6c-86b2-4a57c74e6c7e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_a325dfa2-b565-4be8-8d57-b685954409e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0b21866e-dfce-42a4-ab08-a2b33352fd72_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_71f699a8-9d36-4ae0-b79c-32db65ebdff1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_5fb33cdb-2e1a-40b9-9b8b-7f7e62c789e0_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_834d26e0-9309-4b85-a929-179acadbdd2a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f099afde-32b0-470a-ae8b-472a7328e6d8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_9de84662-31d1-445c-8af1-6cffdd98196e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps held</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8e4ce479-7de0-4953-a37e-f7b1a17802dd_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_e8ea3a6b-9f44-47c8-b490-823be36121c0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f296690b-e251-4ad2-84a7-b640c5cc4c22_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2d12d2d3-0e3d-4328-8871-fb6ad6aad8e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_AllianceMember_8ee3356d-946a-4362-984e-cb1cfb0b66b8_terseLabel_en-US" xlink:label="lab_sgry_AllianceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance</link:label>
    <link:label id="lab_sgry_AllianceMember_label_en-US" xlink:label="lab_sgry_AllianceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance [Member]</link:label>
    <link:label id="lab_sgry_AllianceMember_documentation_en-US" xlink:label="lab_sgry_AllianceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AllianceMember" xlink:href="sgry-20201231.xsd#sgry_AllianceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_AllianceMember" xlink:to="lab_sgry_AllianceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_be6d5ac1-c471-456b-b3ef-f2dccd36ee26_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_4751cee9-80ef-4b46-ad8d-6afc3761d84d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d8eb2896-d7da-42bc-a6d8-3af2809267a8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_d11862bd-8208-44bb-b53b-836c20945f6f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of non-controlling interests</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_d20e2a2e-44b0-45f3-84b6-4d59303eef38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash consideration</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3aa1b258-5572-4dde-8312-2a8f0d230e3c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ec38b589-a480-4723-946e-12eb674518c9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_073a9aa1-e2eb-4981-b91e-204c3e90fd30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_431dc362-5e70-4a79-99a3-a18067a68452_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation-related charge</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_996b496e-08e6-4b36-b34b-e46e1947a495_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term of operating leases</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_974fb50d-4bdf-404d-b4d6-fcc82df6d3c2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_65bb31c0-ff2f-461c-8351-14497ec79951_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ce845405-0743-42e2-8fef-4cea7c966e17_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5d5b71a0-de2a-49c9-800d-03fcc87b1f8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4ea57d7b-70b0-4484-b96b-1f57e9091763_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6727d55f-d618-4af2-a8ee-d02aab064d2e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_a5a86396-280c-41f3-aea2-54dc2a4ac61e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_9ccdb63d-8929-41f9-8e08-9f80dd93adcd_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_509d7450-2cc3-4dd4-91e2-e85cdabed83a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contribution expense</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_16ce1c74-fab5-4331-b823-39c77926e8d2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate, finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_93d039db-3379-49bf-ae6b-c12ca2d5dbab_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_9920172b-be25-410c-882a-cf9c1435179f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_5cd2fd88-7642-489d-89a9-55ad64c08d88_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DebtInstrumentAlternateBaseRateFloor_ce4832fa-53a1-4066-8a60-e44be555a473_terseLabel_en-US" xlink:label="lab_sgry_DebtInstrumentAlternateBaseRateFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate base rate, floor</link:label>
    <link:label id="lab_sgry_DebtInstrumentAlternateBaseRateFloor_label_en-US" xlink:label="lab_sgry_DebtInstrumentAlternateBaseRateFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Base Rate, Floor</link:label>
    <link:label id="lab_sgry_DebtInstrumentAlternateBaseRateFloor_documentation_en-US" xlink:label="lab_sgry_DebtInstrumentAlternateBaseRateFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Base Rate, Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentAlternateBaseRateFloor" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentAlternateBaseRateFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DebtInstrumentAlternateBaseRateFloor" xlink:to="lab_sgry_DebtInstrumentAlternateBaseRateFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_920d4148-5ae4-4cbe-9f2d-9072e2194fa6_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_69705285-3f81-45dd-97ce-3159cdb9ffe6_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_e44501f2-7d9f-4aa6-b3ba-d353f7aae298_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemablePreferredStockTextBlock_4cd420de-fcda-43a7-8457-57357330a62c_terseLabel_en-US" xlink:label="lab_sgry_RedeemablePreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Stock</link:label>
    <link:label id="lab_sgry_RedeemablePreferredStockTextBlock_label_en-US" xlink:label="lab_sgry_RedeemablePreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Stock [Text Block]</link:label>
    <link:label id="lab_sgry_RedeemablePreferredStockTextBlock_documentation_en-US" xlink:label="lab_sgry_RedeemablePreferredStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Preferred Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemablePreferredStockTextBlock" xlink:href="sgry-20201231.xsd#sgry_RedeemablePreferredStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemablePreferredStockTextBlock" xlink:to="lab_sgry_RedeemablePreferredStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_40ddff12-7d3d-47ba-9eda-105a4a6a7cf6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative preferred dividends (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_label_en-US" xlink:label="lab_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:to="lab_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4e88d659-bab3-4970-8602-81739f7b9bc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_TemporaryEquityMaximumCashDividendDeclarable_b8854ece-bc09-4be8-b370-3c22262cfe49_terseLabel_en-US" xlink:label="lab_sgry_TemporaryEquityMaximumCashDividendDeclarable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum cash dividend declarable</link:label>
    <link:label id="lab_sgry_TemporaryEquityMaximumCashDividendDeclarable_label_en-US" xlink:label="lab_sgry_TemporaryEquityMaximumCashDividendDeclarable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Maximum Cash Dividend Declarable</link:label>
    <link:label id="lab_sgry_TemporaryEquityMaximumCashDividendDeclarable_documentation_en-US" xlink:label="lab_sgry_TemporaryEquityMaximumCashDividendDeclarable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Maximum Cash Dividend Declarable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityMaximumCashDividendDeclarable" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityMaximumCashDividendDeclarable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_TemporaryEquityMaximumCashDividendDeclarable" xlink:to="lab_sgry_TemporaryEquityMaximumCashDividendDeclarable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_f4d8ca10-54fb-4707-a416-184f53a4bf11_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease assets</link:label>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" xlink:to="lab_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_584ade95-8b38-4b3f-8727-c3981570e7fe_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2018IncrementalTermLoanMember_473a984f-cf84-4a3d-b410-3f103ad57029_terseLabel_en-US" xlink:label="lab_sgry_A2018IncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incremental Term Loan</link:label>
    <link:label id="lab_sgry_A2018IncrementalTermLoanMember_label_en-US" xlink:label="lab_sgry_A2018IncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incremental Term Loan [Member]</link:label>
    <link:label id="lab_sgry_A2018IncrementalTermLoanMember_documentation_en-US" xlink:label="lab_sgry_A2018IncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Incremental Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2018IncrementalTermLoanMember" xlink:href="sgry-20201231.xsd#sgry_A2018IncrementalTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2018IncrementalTermLoanMember" xlink:to="lab_sgry_A2018IncrementalTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax_e5caea4d-6d78-47c0-ab7a-146118709451_terseLabel_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional-paid-in-capital increase, due to tax effect of disposals of shares of noncontrolling interests</link:label>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax_label_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest, Acquisitions and Disposals of Interests held by Non-Controlling Interest Holders, Tax</link:label>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax_documentation_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest, Acquisitions and Disposals of Interests held by Non-Controlling Interest Holders, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" xlink:href="sgry-20201231.xsd#sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" xlink:to="lab_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e87ad233-3783-4cbf-8ba1-231795bf0989_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c3a73dd1-69b1-4e1e-a60a-cef0bb07278c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_3404b3be-ebac-4fb1-871d-90ee1b845acc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_959ee30d-2264-47c4-82e5-49a7043cff9d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c6a9bd5e-093f-443e-9b2b-3bfb8aca9ff1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_011c1c58-e825-447c-9096-e96443ae45f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FinanceLeaseCost_a8c8ad44-31e9-44df-9c06-fed7cb23f5be_totalLabel_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease costs</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost_label_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost_documentation_en-US" xlink:label="lab_sgry_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost" xlink:href="sgry-20201231.xsd#sgry_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FinanceLeaseCost" xlink:to="lab_sgry_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2f6bf00f-5df1-4144-9097-fb11e991ff52_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_40fafd82-c46d-4864-ac1e-3b3b8ecc99bc_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1a9143eb-6d79-46d0-975b-4c7f629eb763_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c20f9b6b-7971-45a9-9c74-52103b41147a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ea637f27-c433-4a5f-9c01-a259c635e966_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, net of interest income received</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_247513e2-a1d6-425f-8f96-8462b61c7b51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4c3070ca-6671-4d49-b78b-31179489ebaa_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e5c68f67-a0ce-4ff3-b2c6-646a1c1b2ed7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_837376e5-954b-4e34-93f3-61cdebf056ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_71827b9f-57c0-4d3b-98b9-b15c7768dc4f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to retained deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a6ce27e7-c0a0-46fa-b37b-6299db68ff06_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0663fa76-f666-4a9a-b190-3aa0b2331df7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8767b9b9-27be-4baf-89bb-0810a516c1ef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_a27c03ca-0080-424e-b830-91e9038538b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8a1f0531-28d7-472a-b3fa-4cd97376ae9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract_093ff309-6c76-4675-91c3-b5827119d8a5_terseLabel_en-US" xlink:label="lab_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</link:label>
    <link:label id="lab_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract_label_en-US" xlink:label="lab_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:label id="lab_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract_documentation_en-US" xlink:label="lab_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract" xlink:href="sgry-20201231.xsd#sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lab_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4dec6310-6f19-47e5-8f9d-826f1a165a94_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_f4fe21e9-b16f-4fa2-849c-93b7a4af7990_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7639a0ca-cc07-49e1-9b14-7fb950460b8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_4bbfea61-9900-41b6-9bb2-b188676d181d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_9da309e1-0235-42b3-be29-c140d62075d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_b9d6633d-0af7-42e9-a3d4-9175941c7007_terseLabel_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected tax savings period</link:label>
    <link:label id="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_label_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Tax Agreement, Projected Tax Savings, Term</link:label>
    <link:label id="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_documentation_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Tax Agreement, Projected Tax Savings, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:href="sgry-20201231.xsd#sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:to="lab_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod_b3a1e064-442a-419b-a2e4-7d8699fa6282_terseLabel_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable at end of period</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod_label_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payable At End Of Performance Period</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod_documentation_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payable At End Of Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" xlink:to="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f2be0ead-8920-4af2-9e49-57a2ee5b9a8f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_00c873d5-655a-4aa8-ab03-9a1ff5da72d2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3dcaf541-e174-4b28-8de4-d5509e3700bf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_ecddb3f1-88c0-4e80-8ac0-648005048325_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_50d829b6-e553-4a3e-a208-41577f168732_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_79e4b89e-c9a5-4b61-be91-7142cd4fd035_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e24d50a8-3e9c-453f-9b12-f167c119a21f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3d6116b1-1b9a-45c6-b8dc-ed2dc3bd76b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period Four</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_f4c99c90-20fa-4265-8c57-31725c6aaf9d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_419bfbb2-7ebe-4429-a003-3db193fa87d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b6e43e86-f3fc-49a4-acd0-69d941abcf42_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_95432a63-dd92-4fa0-9e9d-b58ea319f71b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenues</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_802f3d23-c879-4b41-8c76-7d1631c5c242_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Effective Swap Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5b422529-48ac-4779-a5d4-f8b7da8068f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_5dd638a7-1368-4ad3-a07e-e852d7de65fa_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests&#8212; Non-Redeemable</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_28bbb9aa-d395-43d6-9d33-e5c1a38264ba_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DefinedContributionPlanVestingPeriod_00303c4d-7097-4d2c-9c3e-e42476420b8a_terseLabel_en-US" xlink:label="lab_sgry_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_sgry_DefinedContributionPlanVestingPeriod_label_en-US" xlink:label="lab_sgry_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Vesting Period</link:label>
    <link:label id="lab_sgry_DefinedContributionPlanVestingPeriod_documentation_en-US" xlink:label="lab_sgry_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DefinedContributionPlanVestingPeriod" xlink:href="sgry-20201231.xsd#sgry_DefinedContributionPlanVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DefinedContributionPlanVestingPeriod" xlink:to="lab_sgry_DefinedContributionPlanVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d308571a-c236-4ef7-8b70-7c161787fd52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DebtInstrumentNetLeverageRatio_210f9793-f72f-4868-a2a8-8c80165f6025_terseLabel_en-US" xlink:label="lab_sgry_DebtInstrumentNetLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net leverage ratio</link:label>
    <link:label id="lab_sgry_DebtInstrumentNetLeverageRatio_label_en-US" xlink:label="lab_sgry_DebtInstrumentNetLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Net Leverage Ratio</link:label>
    <link:label id="lab_sgry_DebtInstrumentNetLeverageRatio_documentation_en-US" xlink:label="lab_sgry_DebtInstrumentNetLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Net Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentNetLeverageRatio" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentNetLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DebtInstrumentNetLeverageRatio" xlink:to="lab_sgry_DebtInstrumentNetLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3b6d7c9d-5f0b-4abf-99db-511d0b810692_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_ec0a2f04-a6d0-469a-8dbc-36cc81286da0_terseLabel_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable and short-term lease costs</link:label>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_label_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable And Short-Term Lease, Cost</link:label>
    <link:label id="lab_sgry_VariableAndShortTermLeaseCost_documentation_en-US" xlink:label="lab_sgry_VariableAndShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable And Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost" xlink:href="sgry-20201231.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_VariableAndShortTermLeaseCost" xlink:to="lab_sgry_VariableAndShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2015OmnibusIncentivePlanMember_9f354081-9fe3-4919-8a70-3372b4af47cd_terseLabel_en-US" xlink:label="lab_sgry_A2015OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Omnibus Incentive Plan</link:label>
    <link:label id="lab_sgry_A2015OmnibusIncentivePlanMember_label_en-US" xlink:label="lab_sgry_A2015OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
    <link:label id="lab_sgry_A2015OmnibusIncentivePlanMember_documentation_en-US" xlink:label="lab_sgry_A2015OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2015OmnibusIncentivePlanMember" xlink:href="sgry-20201231.xsd#sgry_A2015OmnibusIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2015OmnibusIncentivePlanMember" xlink:to="lab_sgry_A2015OmnibusIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75de959b-5587-4e44-a7b7-156bff9663e2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_598c760c-3986-4be8-b1af-1a07be55d533_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends accrued (there were no cash dividends declared)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_55666d23-ca9c-4993-9cb8-831ffdb54baa_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationGainLossOnAcquisitionEscrow_a70802de-5117-4077-908e-86a621b6e4fc_negatedTerseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationGainLossOnAcquisitionEscrow" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on escrow release</link:label>
    <link:label id="lab_sgry_BusinessCombinationGainLossOnAcquisitionEscrow_label_en-US" xlink:label="lab_sgry_BusinessCombinationGainLossOnAcquisitionEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Gain (Loss) On Acquisition Escrow</link:label>
    <link:label id="lab_sgry_BusinessCombinationGainLossOnAcquisitionEscrow_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationGainLossOnAcquisitionEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Gain (Loss) On Acquisition Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationGainLossOnAcquisitionEscrow" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationGainLossOnAcquisitionEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationGainLossOnAcquisitionEscrow" xlink:to="lab_sgry_BusinessCombinationGainLossOnAcquisitionEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_804449a4-0773-40e6-be80-2bb997c3d2d1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_dc71740c-a48f-4c09-8625-3a4a8913f97e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_e7db43f4-ed5d-4304-8b4b-6a384df8e3e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax return reconciling differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_02d4e79c-c3af-4405-b48b-67ff08aaf6d6_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_01debd49-a1e1-4af3-9d1e-a39d34897f9f_terseLabel_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of annual installments</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_label_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_documentation_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_a1ec4da5-4064-4924-a4a5-98b7f84517fc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Disposals</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f73e5d05-a278-40b2-85a5-d67ad113eaba_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_dfb67504-6b86-4c7c-b882-d11692e16a66_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_deb19cc9-998a-47eb-8e71-c9e0a4d66ab6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and rights granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10d6354c-7e6a-4210-b6a0-ced8854d1989_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_3def92a8-a83d-47f7-b9f2-a19e26347112_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductInformationLineItems_84c14aa6-4f17-4230-9629-17ccbee2016f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_57236226-6276-45de-a8e7-e46d1bdf53b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_bd6db776-4c0f-44ba-a9fa-553ef93d27c7_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f51e8143-3978-4054-87ac-001f86ea91c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_846ec881-7c12-4ef0-98da-5d01ff6dff3e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FurnitureAndEquipmentMember_813a8a5c-fef6-49a1-9bb2-0fa48c9c535a_terseLabel_en-US" xlink:label="lab_sgry_FurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_sgry_FurnitureAndEquipmentMember_label_en-US" xlink:label="lab_sgry_FurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Equipment [Member]</link:label>
    <link:label id="lab_sgry_FurnitureAndEquipmentMember_documentation_en-US" xlink:label="lab_sgry_FurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FurnitureAndEquipmentMember" xlink:href="sgry-20201231.xsd#sgry_FurnitureAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FurnitureAndEquipmentMember" xlink:to="lab_sgry_FurnitureAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_fa4e89aa-e139-4cce-a4e7-97ce8899ba51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_da2da430-3b64-4e39-8090-f641d5bef264_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_25547591-2ac8-4f1c-942a-3b41ed941278_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e7f9fdf4-3dd9-4bb6-82c9-5a33c63625a9_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_2a1b7609-112b-4e02-b6c7-5f8085384749_terseLabel_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of liability, net of discount</link:label>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_label_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net Of Discount</link:label>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_documentation_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net Of Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:href="sgry-20201231.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:to="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_e1edb39f-2fef-49d8-8c93-f893b55943f5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_A2020IncrementalLoansMember_232219fe-d0c7-46ce-98e7-6c5eea0eb15a_terseLabel_en-US" xlink:label="lab_sgry_A2020IncrementalLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 incremental term loans</link:label>
    <link:label id="lab_sgry_A2020IncrementalLoansMember_label_en-US" xlink:label="lab_sgry_A2020IncrementalLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Incremental Loans [Member]</link:label>
    <link:label id="lab_sgry_A2020IncrementalLoansMember_documentation_en-US" xlink:label="lab_sgry_A2020IncrementalLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Incremental Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2020IncrementalLoansMember" xlink:href="sgry-20201231.xsd#sgry_A2020IncrementalLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_A2020IncrementalLoansMember" xlink:to="lab_sgry_A2020IncrementalLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7a39b083-da02-4772-ae11-1f46f3397101_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_5d81c9a8-9d96-4800-bbc2-9034d938b23e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_681bc84e-d575-4297-8ff2-e749a869f75a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets, Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_cf73f214-fc5d-4421-9426-6101d8c84767_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional, general and workers' compensation insurance reserve</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserve" xlink:to="lab_us-gaap_SelfInsuranceReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LeaseLiability_f6a069f4-8500-412d-97a3-bdca2475bc22_totalLabel_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_sgry_LeaseLiability_label_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_sgry_LeaseLiability_documentation_en-US" xlink:label="lab_sgry_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability" xlink:href="sgry-20201231.xsd#sgry_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LeaseLiability" xlink:to="lab_sgry_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_c649404e-5cf9-47c3-b052-a824e03388b3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7ed76ae1-6244-43a4-8bd0-58e88e0359e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_83c0622e-c42d-4f66-aa24-4e0c244a6b92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_d7f75751-0553-4917-b1f5-8381645794b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c8cd278c-2144-4862-8f24-8b04b2720fff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_832c9ebb-ccf1-49d9-bf64-09623ed5e0ee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_41af2405-ddb7-4311-a777-8eddaf9f7ee8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f0d53431-406f-4ae1-9c5d-811a928f0c97_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_530933fa-10c9-46b8-81d7-781670783f74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax (benefit) expense at U.S.federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8efb5d57-7aa0-4e86-a865-a8a9b50ed943_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts_1439a43a-b194-4b66-916f-36ff75fac2fd_terseLabel_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts_label_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Deferred Financing Costs</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts_documentation_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Deferred Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" xlink:to="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0e8987b0-248b-4b86-803b-f61231d0b8a4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_a22b83b7-0c2f-4f0a-969d-0d67ce52a60d_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_67301e88-3274-4d71-a395-644d02ef1d25_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f0899996-2453-41d0-a0d5-dcea3c961fd3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0e0e9475-87ca-49c0-958d-56e92ffb663a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_00b09c53-4314-47b7-92f6-fac99cee6ff2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0e4031b2-d1bc-4c15-91d1-27b62cb38109_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized fair value discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_562d13e6-28f9-4691-9053-8a370a961de0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_266695a7-1327-460e-8389-175faf8abca1_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_bd56d500-1627-4dea-a6d2-9cdddf7e5bd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation on property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_d3eae02e-06c3-4bb7-8b04-32cd1555ce6f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Source</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PrivateInsuranceMember_05c733a6-e2c0-4acb-a08e-aa508519b11b_terseLabel_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private insurance</link:label>
    <link:label id="lab_sgry_PrivateInsuranceMember_label_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Insurance [Member]</link:label>
    <link:label id="lab_sgry_PrivateInsuranceMember_documentation_en-US" xlink:label="lab_sgry_PrivateInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember" xlink:href="sgry-20201231.xsd#sgry_PrivateInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PrivateInsuranceMember" xlink:to="lab_sgry_PrivateInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_eec089cc-4257-4954-80eb-e6ada7161d9b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_dcc82d65-5fb2-4ce1-8cb7-164926ce5526_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_94ecd1ee-42de-4af2-8718-7b54da215bd6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_09bced91-caf7-458d-93d4-ce975114e945_terseLabel_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable and other secured loans</link:label>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_label_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Secured Loans [Member]</link:label>
    <link:label id="lab_sgry_NotesPayableAndSecuredLoansMember_documentation_en-US" xlink:label="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable and Secured Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember" xlink:href="sgry-20201231.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NotesPayableAndSecuredLoansMember" xlink:to="lab_sgry_NotesPayableAndSecuredLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount_dcbe56b8-518e-49b9-b159-3b15d58d3b4e_terseLabel_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount_label_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Litigation Settlement, Amount</link:label>
    <link:label id="lab_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount_documentation_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Litigation Settlement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" xlink:to="lab_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgeryPartnersIncMember_e3dffa20-0b6d-4ac6-b4ea-44ed18809501_terseLabel_en-US" xlink:label="lab_sgry_SurgeryPartnersIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery Partners, Inc</link:label>
    <link:label id="lab_sgry_SurgeryPartnersIncMember_label_en-US" xlink:label="lab_sgry_SurgeryPartnersIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery Partners, Inc [Member]</link:label>
    <link:label id="lab_sgry_SurgeryPartnersIncMember_documentation_en-US" xlink:label="lab_sgry_SurgeryPartnersIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery Partners, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgeryPartnersIncMember" xlink:href="sgry-20201231.xsd#sgry_SurgeryPartnersIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgeryPartnersIncMember" xlink:to="lab_sgry_SurgeryPartnersIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_efe7666b-355b-4a8a-8fea-a0bd5501eef3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_4cff1e02-23ea-4632-a647-1aaa77bee650_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_a3122dcf-3391-4ef1-930e-da8066875f99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equity investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_db9a90c5-05cf-4c7d-870b-cfe830b51aa4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash investment for purchase of equity investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_faee6963-bf81-4999-9048-134f1fb4b2de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding options, exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0c4fe362-1d3b-4fe4-b621-762605dea240_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OneMonthLondonInterbankOfferedRateLIBORMember_e68bce48-fcd2-4bda-b7d9-8808affac5da_terseLabel_en-US" xlink:label="lab_sgry_OneMonthLondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Month LIBOR</link:label>
    <link:label id="lab_sgry_OneMonthLondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_sgry_OneMonthLondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Month London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:label id="lab_sgry_OneMonthLondonInterbankOfferedRateLIBORMember_documentation_en-US" xlink:label="lab_sgry_OneMonthLondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Month London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OneMonthLondonInterbankOfferedRateLIBORMember" xlink:href="sgry-20201231.xsd#sgry_OneMonthLondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OneMonthLondonInterbankOfferedRateLIBORMember" xlink:to="lab_sgry_OneMonthLondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6ffa5b32-7909-49c4-958f-f3cfde7e7fc4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_49742d37-42d3-478a-865b-504379f7d5aa_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_a8036d0b-bcd2-4a9c-baac-fa0329679312_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_e28eea1a-74b6-4103-a865-7ed36038aecd_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5379b60c-8f1e-4b05-a2a7-af370e3087c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_COVID19PandemicMember_5593032c-d201-4586-94fa-9c9346972efb_terseLabel_en-US" xlink:label="lab_sgry_COVID19PandemicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Pandemic</link:label>
    <link:label id="lab_sgry_COVID19PandemicMember_label_en-US" xlink:label="lab_sgry_COVID19PandemicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Pandemic [Member]</link:label>
    <link:label id="lab_sgry_COVID19PandemicMember_documentation_en-US" xlink:label="lab_sgry_COVID19PandemicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Pandemic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_COVID19PandemicMember" xlink:href="sgry-20201231.xsd#sgry_COVID19PandemicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_COVID19PandemicMember" xlink:to="lab_sgry_COVID19PandemicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_5548a0d9-bcb2-425e-a55a-9fccb9a4b33d_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_6416f35a-8834-4a68-b0b2-bc66342373c4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_fa9446de-12b6-4d0d-bcd0-0fcfc92b2311_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_bad33903-3618-4f21-8c1b-45dbd1c1f774_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_b58ee9b0-5294-4c75-87f5-a1fb7d596edf_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d5d9e979-7bb3-4d9e-9658-251216a09f48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GrantRevenue_6876b717-4a61-43e9-85ba-c5937284ceed_negatedTerseLabel_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funds</link:label>
    <link:label id="lab_sgry_GrantRevenue_be7376a6-dacc-4594-825c-72e3553a3ce2_terseLabel_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funds</link:label>
    <link:label id="lab_sgry_GrantRevenue_label_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:label id="lab_sgry_GrantRevenue_documentation_en-US" xlink:label="lab_sgry_GrantRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue" xlink:href="sgry-20201231.xsd#sgry_GrantRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GrantRevenue" xlink:to="lab_sgry_GrantRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_43754e1a-64b0-43ac-93f1-c86212fb2b60_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_32615857-2ccd-49ea-9ce5-b6a9fab54f71_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_e5d5c038-e42d-4291-bdc1-a23b014d0aec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DebtInstrumentQuarterlyMaturityInstallments_01ad2716-9065-4476-ada0-a1822d73932e_terseLabel_en-US" xlink:label="lab_sgry_DebtInstrumentQuarterlyMaturityInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly installment of original principal</link:label>
    <link:label id="lab_sgry_DebtInstrumentQuarterlyMaturityInstallments_label_en-US" xlink:label="lab_sgry_DebtInstrumentQuarterlyMaturityInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Maturity Installments</link:label>
    <link:label id="lab_sgry_DebtInstrumentQuarterlyMaturityInstallments_documentation_en-US" xlink:label="lab_sgry_DebtInstrumentQuarterlyMaturityInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Quarterly Maturity Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentQuarterlyMaturityInstallments" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentQuarterlyMaturityInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DebtInstrumentQuarterlyMaturityInstallments" xlink:to="lab_sgry_DebtInstrumentQuarterlyMaturityInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_f0c30944-696c-4a77-a7e2-5d0594ef27f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap agreement</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_826c05a0-c038-4023-bd1d-466b0de32c48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_bd9f73df-28f8-4b65-99e5-f2d475c2d3ed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders - basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_19b5da32-4d1f-4245-ae65-3769fef923d4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount_21b8cc62-f3ae-4b68-b077-6afd5991f0bb_terseLabel_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement liability</link:label>
    <link:label id="lab_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount_label_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Receivable Agreement, Amount</link:label>
    <link:label id="lab_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount_documentation_en-US" xlink:label="lab_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Receivable Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" xlink:to="lab_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_70521109-6359-4ea8-a54b-d73cb1f3de64_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1e7c0886-47b3-40bc-8782-62e41eaade5b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d5d43cd0-4d2d-4906-8723-f62d5ba3abc2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2099a3c1-7961-463e-81df-cca12d5aa0b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_3bf43e93-0ab0-47d3-83a9-2074b8dfe134_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DebtInstrumentMarginInAdditionToBaseRate_7dcd8d11-9e20-4eeb-88f0-fc6b119cb4ae_terseLabel_en-US" xlink:label="lab_sgry_DebtInstrumentMarginInAdditionToBaseRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, margin in addition to base rate</link:label>
    <link:label id="lab_sgry_DebtInstrumentMarginInAdditionToBaseRate_label_en-US" xlink:label="lab_sgry_DebtInstrumentMarginInAdditionToBaseRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Margin In Addition To Base Rate</link:label>
    <link:label id="lab_sgry_DebtInstrumentMarginInAdditionToBaseRate_documentation_en-US" xlink:label="lab_sgry_DebtInstrumentMarginInAdditionToBaseRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Margin In Addition To Base Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentMarginInAdditionToBaseRate" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentMarginInAdditionToBaseRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DebtInstrumentMarginInAdditionToBaseRate" xlink:to="lab_sgry_DebtInstrumentMarginInAdditionToBaseRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_42e900a6-37e3-4935-94e1-a18838ad06aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Numerator and Denominator of Basic and Diluted EPS</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_012224cd-31c8-43bf-a07b-94a47a567964_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed_5efbe75e-0b58-4507-a5f9-eef06807fe70_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interests sold</link:label>
    <link:label id="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed_label_en-US" xlink:label="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Number Of Interests Disposed</link:label>
    <link:label id="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed_documentation_en-US" xlink:label="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Number Of Interests Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" xlink:to="lab_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a1437a08-00a0-423e-bffb-2827b1220b38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_2a6153e7-008d-4d08-a40e-52c872949614_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c631667-d98a-41af-8ff9-8cdace797098_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_cf54b360-f822-4e5a-9fe5-8ab27a01dc47_terseLabel_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals</link:label>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_label_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals [Member]</link:label>
    <link:label id="lab_sgry_FacilitiesSurgicalHospitalsMember_documentation_en-US" xlink:label="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities, Surgical Hospitals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember" xlink:href="sgry-20201231.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FacilitiesSurgicalHospitalsMember" xlink:to="lab_sgry_FacilitiesSurgicalHospitalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_51eb7938-240a-4d85-886f-a0ca7348c7b7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_01c4ffb3-2444-4039-9616-0cb0492470bb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_c41aa09c-b426-4708-acd2-7912a33638a5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other litigation costs</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_TaxReceivableAgreementLiabilityCurrent_d144cd3d-35b6-48dc-a15e-2bb99a7e8296_terseLabel_en-US" xlink:label="lab_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement liability</link:label>
    <link:label id="lab_sgry_TaxReceivableAgreementLiabilityCurrent_label_en-US" xlink:label="lab_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability, Current</link:label>
    <link:label id="lab_sgry_TaxReceivableAgreementLiabilityCurrent_documentation_en-US" xlink:label="lab_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:href="sgry-20201231.xsd#sgry_TaxReceivableAgreementLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:to="lab_sgry_TaxReceivableAgreementLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_65875dd4-c087-4348-a795-b80a373c0a9a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_80e9a2ec-679a-4b41-a698-c4ad2836097a_negatedTerseLabel_en-US" xlink:label="lab_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amounts allocated to participating securities</link:label>
    <link:label id="lab_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_label_en-US" xlink:label="lab_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Including Dividends Accrued</link:label>
    <link:label id="lab_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_documentation_en-US" xlink:label="lab_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Including Dividends Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" xlink:href="sgry-20201231.xsd#sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" xlink:to="lab_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5e01620f-cbdf-4b36-a8d8-673b9eee525d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_62092b59-86b1-42c2-80e6-bc5b7c83cefe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1ca16fc8-d74d-4173-a5c8-1049849a1da8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Components of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_11e87c18-b966-465a-9cdb-930840d8dd9b_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9127d642-b79d-467f-99a6-0a78809421ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a057c836-8858-475c-8c8c-fbee2c60d094_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_6eba363f-3e3e-48f7-af71-dee5697b2fdd_terseLabel_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10.000% senior unsecured notes due 2027</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_label_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes, Due 2027 [Member]</link:label>
    <link:label id="lab_sgry_SeniorUnsecuredNotesDue2027Member_documentation_en-US" xlink:label="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes, Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SeniorUnsecuredNotesDue2027Member" xlink:to="lab_sgry_SeniorUnsecuredNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2290d295-a83b-40ce-97e1-c2da320041c3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3f36f9ba-25bd-4ada-8b64-22a6dacd87ef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets_1b7b2e53-d37f-4e06-a653-ace969d82041_terseLabel_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Amortization Of Intangible Assets</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets_documentation_en-US" xlink:label="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Amortization Of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" xlink:to="lab_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorityShareholderMember_6f22c644-0935-4cc2-b217-3064e928ff3b_terseLabel_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Majority Shareholder</link:label>
    <link:label id="lab_us-gaap_MajorityShareholderMember_label_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Majority Shareholder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorityShareholderMember" xlink:to="lab_us-gaap_MajorityShareholderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease_1c877788-f047-4dc6-8d10-9201ee32947a_terseLabel_en-US" xlink:label="lab_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in outstanding commitments</link:label>
    <link:label id="lab_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease_label_en-US" xlink:label="lab_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Increase</link:label>
    <link:label id="lab_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease_documentation_en-US" xlink:label="lab_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease" xlink:href="sgry-20201231.xsd#sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease" xlink:to="lab_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_ce217590-1589-4ba8-81b8-bebb3142e37e_terseLabel_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease costs:</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_label_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost1 [Abstract]</link:label>
    <link:label id="lab_sgry_FinanceLeaseCost1Abstract_documentation_en-US" xlink:label="lab_sgry_FinanceLeaseCost1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost1 [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost1Abstract" xlink:href="sgry-20201231.xsd#sgry_FinanceLeaseCost1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FinanceLeaseCost1Abstract" xlink:to="lab_sgry_FinanceLeaseCost1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_25ffc242-345a-42b6-921f-cf5cc205bcf5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupThreeMember_359d0c9f-88e4-4fcf-83c3-13dc352d8660_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Owned Real Property Associated with Existing Non-Consolidated Surgical Facility</link:label>
    <link:label id="lab_sgry_DisposalGroupThreeMember_label_en-US" xlink:label="lab_sgry_DisposalGroupThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Three [Member]</link:label>
    <link:label id="lab_sgry_DisposalGroupThreeMember_documentation_en-US" xlink:label="lab_sgry_DisposalGroupThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupThreeMember" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupThreeMember" xlink:to="lab_sgry_DisposalGroupThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_a92890a6-0e55-4614-af8d-ba3e2b3c2b1c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased, average price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_810f4be4-d28f-4843-a1c9-5b5b4058686e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_6259fbdc-bd98-42f4-85a5-bf336467aaf3_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5890a707-5623-4e77-825b-d8db99e34b90_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_d26877d0-b814-4f3d-8614-b440c98cfa42_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_HealthcareOrganizationOtherServiceMember_16a80757-6ad2-4c8c-950a-aa4a1f08f6ab_terseLabel_en-US" xlink:label="lab_sgry_HealthcareOrganizationOtherServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other service revenues</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationOtherServiceMember_label_en-US" xlink:label="lab_sgry_HealthcareOrganizationOtherServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Organization, Other Service [Member]</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationOtherServiceMember_documentation_en-US" xlink:label="lab_sgry_HealthcareOrganizationOtherServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Organization, Other Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationOtherServiceMember" xlink:href="sgry-20201231.xsd#sgry_HealthcareOrganizationOtherServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_HealthcareOrganizationOtherServiceMember" xlink:to="lab_sgry_HealthcareOrganizationOtherServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4bf6539c-2c3d-4ef7-a460-9e6acc178c90_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_560f5f96-5beb-4330-ada8-1aa39caf833e_negatedLabel_en-US" xlink:label="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlements and other litigation costs</link:label>
    <link:label id="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_label_en-US" xlink:label="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement And Other Litigation Costs</link:label>
    <link:label id="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_documentation_en-US" xlink:label="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement And Other Litigation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:href="sgry-20201231.xsd#sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:to="lab_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2c286af0-e6cf-45bd-9eba-43bb8ff54a68_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0b25326a-a2f0-4627-aaa3-39b3b9e7ca55_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_af3a5fda-005f-4076-8445-6090cdee1045_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash outflows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_55ecc29b-78a4-4742-85bf-49c27a57120b_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_FinanceLeasePrincipalAndInterestPayments_2fc1afaf-688a-4dee-b082-32dc9982f5d4_terseLabel_en-US" xlink:label="lab_sgry_FinanceLeasePrincipalAndInterestPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent paid under finance lease agreement, allocated to principal and interest</link:label>
    <link:label id="lab_sgry_FinanceLeasePrincipalAndInterestPayments_label_en-US" xlink:label="lab_sgry_FinanceLeasePrincipalAndInterestPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal And Interest Payments</link:label>
    <link:label id="lab_sgry_FinanceLeasePrincipalAndInterestPayments_documentation_en-US" xlink:label="lab_sgry_FinanceLeasePrincipalAndInterestPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal And Interest Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeasePrincipalAndInterestPayments" xlink:href="sgry-20201231.xsd#sgry_FinanceLeasePrincipalAndInterestPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_FinanceLeasePrincipalAndInterestPayments" xlink:to="lab_sgry_FinanceLeasePrincipalAndInterestPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5485aee8-6b19-4f12-8b0d-fb3bce2ea614_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_aad3aa3c-a4d7-4aff-810a-ca581f586072_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2652c68c-dd1e-4828-a91f-8d25cd69d26c_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_62bd3a2e-1f89-481e-b92b-9d9a6f94bb23_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_f26a25fd-44a5-4295-9bc3-67f77e80e75b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_67e0f899-57e2-4012-a8a6-3e2c00765405_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9afd2897-8c04-4776-9bf4-1ea81522a3f2_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a9527586-2972-464b-b203-347d99a84605_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_1bdc571b-4fb9-437e-8431-8614580aa956_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e91a119c-6b03-4df7-9816-30b181f2bdf3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8c7ee1b8-10fe-4182-91a0-291246ee262b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax (Benefit) Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_376449db-a779-45e9-887b-aed81936550b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_6efe5a22-1664-41f7-93f6-9b57df9105b0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposals of facilities and other assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock_eafc1e50-3abb-465b-b18a-379388e08789_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Redemption Percentages</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:to="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_cddf7556-1a4d-4ec0-b371-23a9ff7cf95e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity Related to Redeemable Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_ab7b4a23-05fc-43c9-aeee-16915f48b915_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a16b5f80-be3d-4772-84ca-ebe18f4bfc85_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilityMember_81b0fdf1-ed70-4eba-90e3-9e272a18d42d_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility</link:label>
    <link:label id="lab_sgry_SurgicalFacilityMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilityMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityMember" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilityMember" xlink:to="lab_sgry_SurgicalFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e5b02955-b30a-49b7-a768-9d179e1768a9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_71de65ef-2bb8-4f3b-a688-cbf8adb47269_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_58f3c446-1d8a-4e74-859f-b9768762a2c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recognized in OCI (effective portion)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations_b9d2c15f-ffed-464b-97c6-b9aabf12aad8_negatedTerseLabel_en-US" xlink:label="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals and deconsolidations</link:label>
    <link:label id="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations_label_en-US" xlink:label="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written Off Related To Sale Of Business Unit And Deconsolidations</link:label>
    <link:label id="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations_documentation_en-US" xlink:label="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written Off Related To Sale Of Business Unit And Deconsolidations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" xlink:href="sgry-20201231.xsd#sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" xlink:to="lab_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5cb4c168-f634-42e9-b3c8-0d3db009e92a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_07b37cbe-c8ab-4bc2-9567-396bd73b6800_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_cf1883ef-22ec-41c7-a6a4-3a9e451c61eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_93d1e0a0-8467-45d2-bde1-44a27f9644aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PhysicianPracticeMember_bce875d2-5fe2-4438-8160-6c7183f3518d_terseLabel_en-US" xlink:label="lab_sgry_PhysicianPracticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Practice</link:label>
    <link:label id="lab_sgry_PhysicianPracticeMember_label_en-US" xlink:label="lab_sgry_PhysicianPracticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Practice [Member]</link:label>
    <link:label id="lab_sgry_PhysicianPracticeMember_documentation_en-US" xlink:label="lab_sgry_PhysicianPracticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Practice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PhysicianPracticeMember" xlink:href="sgry-20201231.xsd#sgry_PhysicianPracticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PhysicianPracticeMember" xlink:to="lab_sgry_PhysicianPracticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_59ec00fd-6c8c-4340-9cea-646a2002a25d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of U.S. federal tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9165cd81-3be7-4519-9349-a581cbe684fa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_540dab4e-c513-4772-92e5-660e9b1c9a7b_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_76f0f537-cb9d-4990-9d35-614f785ed635_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_fcd08621-309d-448e-97b0-7196cf429d6d_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_4b6c99b4-1dd4-4b7a-85a4-b1d87abf369f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_6b3098a7-c57d-418c-9b6b-ce4cf6abeef4_terseLabel_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled (shares)</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_label_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cancelled In Period</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_documentation_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cancelled In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:to="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_46671bc4-43f2-4e40-8ede-9ceecc70e00e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_ddc2d799-9362-4697-9c80-0acd065f047e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_TemporaryEquityThresholdSharePrice_65057766-6a61-466b-b3b1-a0134c80528f_terseLabel_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold share price (in USD per share)</link:label>
    <link:label id="lab_sgry_TemporaryEquityThresholdSharePrice_label_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Threshold Share Price</link:label>
    <link:label id="lab_sgry_TemporaryEquityThresholdSharePrice_documentation_en-US" xlink:label="lab_sgry_TemporaryEquityThresholdSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Threshold Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdSharePrice" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_TemporaryEquityThresholdSharePrice" xlink:to="lab_sgry_TemporaryEquityThresholdSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_75cc8822-982d-4956-bbeb-df8626766309_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_81b44628-0a2a-4840-9c0a-54dd473e7fa4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4b1d8ea3-d890-4ffc-a5e1-e42af3629609_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0c2a2776-4fdc-4bf5-8e3c-71c74ef900f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ebeb411c-9dde-4ba9-bd07-26672e51bf86_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_b7bf3164-0a7d-423c-aade-05dc15783887_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_f36c96ee-279b-4a0a-aa50-0554d2be96c0_terseLabel_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_label_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Expense</link:label>
    <link:label id="lab_sgry_OperatingAndFinanceLeaseExpense_documentation_en-US" xlink:label="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense" xlink:href="sgry-20201231.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OperatingAndFinanceLeaseExpense" xlink:to="lab_sgry_OperatingAndFinanceLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8d302071-0eab-44a4-9c58-5b9c0a5bd68c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a70ed9a5-770a-48c3-80ec-359bcdd745f6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_45cd35a9-d89c-4732-846b-457aee4d510d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_675e7416-3ef8-4de7-af8e-069ee0d50fef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_eb174bbf-cb4d-4162-be8a-6ac7143997a9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_41e39da7-41b9-4345-a8d6-8ddc61b951c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_1be677af-e82a-494c-b691-784f4880335d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss reclassified from accumulated OCI to interest expense (effective portion)</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:to="lab_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3a35b9ec-70ea-4739-b655-7347733cf88f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_309d535b-eed2-43ca-b29a-3b08af14835f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fe9c781b-d4e2-4a1d-a132-f41e5c9bfffd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_afddd04d-aa60-4bb9-8192-e2b7c1ce5020_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_a48378b2-dd34-4210-bc7c-08e696e7294d_negatedLabel_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposals and deconsolidations, net</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_60c54044-251d-41c6-a033-4cfd1b471d65_negatedTerseLabel_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposals and deconsolidations, net</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_label_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets And Deconsolidation</link:label>
    <link:label id="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_documentation_en-US" xlink:label="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition of Assets And Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:href="sgry-20201231.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:to="lab_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_91cf39fc-837f-4a6b-b031-72823991bbd7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8e216cc7-af81-4576-b5c6-7c059d8377b6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_OtherServicesMember_ada45470-6425-4f8c-86ce-2306769411d0_verboseLabel_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sgry_OtherServicesMember_label_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:label id="lab_sgry_OtherServicesMember_documentation_en-US" xlink:label="lab_sgry_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember" xlink:href="sgry-20201231.xsd#sgry_OtherServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_OtherServicesMember" xlink:to="lab_sgry_OtherServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_289bf295-93a1-4b82-9ae2-1d2bd99481a6_terseLabel_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Right-of-use Assets and Liabilities Related to Leases</link:label>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="sgry-20201231.xsd#sgry_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_sgry_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_701ddb4d-a99d-42c0-bca8-2923cc968fa8_terseLabel_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests - Redeemable [Roll Forward]</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_label_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_sgry_RedeemableNoncontrollingInterestRollForward_documentation_en-US" xlink:label="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestRollForward" xlink:href="sgry-20201231.xsd#sgry_RedeemableNoncontrollingInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward" xlink:to="lab_sgry_RedeemableNoncontrollingInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_78585665-6532-4c98-b595-cb5a9060bd4e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c7ed551c-c0c3-4758-a03e-06c3188df943_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6fd4958f-d821-478f-848c-ed14c9373cda_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_2c415ee4-ab1c-4349-a4e1-b1a1783dc385_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_ce428714-a1b3-4dd7-b90e-6e538dd808de_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources for Patient Service Revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_43b703bb-c842-4a0b-87eb-a9236bd0714f_terseLabel_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days, threshold</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:to="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_2ab7154a-f50f-45d4-ab7e-8bfa498e703b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6ee38abf-198b-4f1f-9257-548ad71ea3ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_d2533305-8101-4792-b0ad-fab52a000ed9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_b2fd1949-a5f4-48c1-afba-2e4de6294697_terseLabel_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare accelerated payments and deferred governmental grants</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_label_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</link:label>
    <link:label id="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_documentation_en-US" xlink:label="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:href="sgry-20201231.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:to="lab_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f479788a-4e85-4e4e-b18d-3fc608245a77_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_89a8fc25-5988-40a8-91bf-c834bb71bf26_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DisposalGroupFourMember_e8f961c1-e262-490d-901b-9a9ef07e68a1_terseLabel_en-US" xlink:label="lab_sgry_DisposalGroupFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery Centers, Surgical Hospitals, and Optical Laboratory</link:label>
    <link:label id="lab_sgry_DisposalGroupFourMember_label_en-US" xlink:label="lab_sgry_DisposalGroupFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Four [Member]</link:label>
    <link:label id="lab_sgry_DisposalGroupFourMember_documentation_en-US" xlink:label="lab_sgry_DisposalGroupFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupFourMember" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DisposalGroupFourMember" xlink:to="lab_sgry_DisposalGroupFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_40a3ab97-15fa-4db3-b2bb-0b77f464b049_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAndNoncurrent_0a5463e1-30e9-49f8-a479-3487902ddb55_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amounts payable under TRA</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_05fa8f76-ebd7-439c-a845-79f048e935b3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_9914875f-9dc4-4b29-90b8-0a4b7730b4e6_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_eb77ac6d-ba64-4e99-af06-cbd377a207c1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_386b0174-d046-4c75-84ef-a41d5df74595_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_15881717-32bb-46ab-81d0-c0a728d70d67_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_MedicalEquipmentMember_01b084e7-152b-467b-951b-4579c967e81d_terseLabel_en-US" xlink:label="lab_sgry_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_sgry_MedicalEquipmentMember_label_en-US" xlink:label="lab_sgry_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_sgry_MedicalEquipmentMember_documentation_en-US" xlink:label="lab_sgry_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicalEquipmentMember" xlink:href="sgry-20201231.xsd#sgry_MedicalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_MedicalEquipmentMember" xlink:to="lab_sgry_MedicalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c25590e5-fd5f-4071-820d-ac92abe4ef5e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_13665412-1e87-4799-8bae-b1fc0774637c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative activity</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_68e3b1f1-6d09-4d76-b798-6194d553d833_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c1a16bd0-378b-45ef-b7bb-93a9ae5eccd6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_343dd19d-4e28-48df-aa26-5b4f98c7709e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_acc6ab57-0e30-4de3-8d96-4d7edf5b1e78_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b3077f0c-eb99-41cd-a37b-1d3f6b1d9b31_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralBusinessMember_94eb4ecb-3d7b-47de-a07f-3d2a7c319c2e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Business Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_GeneralBusinessMember_label_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralBusinessMember" xlink:to="lab_us-gaap_GeneralBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_c57c5f23-4491-4405-9744-11068cb0d22f_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredTaxAssetsRightOfUse_23db8cc5-24b9-4a5d-aa5e-ada49a527cbf_terseLabel_en-US" xlink:label="lab_sgry_DeferredTaxAssetsRightOfUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsRightOfUse_label_en-US" xlink:label="lab_sgry_DeferredTaxAssetsRightOfUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Right Of Use</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetsRightOfUse_documentation_en-US" xlink:label="lab_sgry_DeferredTaxAssetsRightOfUse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Right Of Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsRightOfUse" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsRightOfUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredTaxAssetsRightOfUse" xlink:to="lab_sgry_DeferredTaxAssetsRightOfUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_bf016369-8637-4ce3-a1c7-ece3727e5d90_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical malpractice liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_07ed5bbf-72fe-49cc-81bc-fee55bb10579_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e77b5de5-319a-44a6-ba5c-59eb706bf1b9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ef9859e0-1e28-433c-a9c6-f2ab15e9ddd9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_611cfe1b-77fa-45b0-8293-de644b15d226_terseLabel_en-US" xlink:label="lab_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:href="sgry-20201231.xsd#sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="lab_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b24ec7d8-8c24-46c1-baf1-ba29352cfcbe_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2f225553-5eff-4dbc-8bed-d4ae06cc5910_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_34313173-1efa-479f-bbe6-f5462c7cf0a9_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_269d65cf-cc58-4176-b745-94145c8928aa_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment under settlement agreement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_627147d1-36d6-4e4f-83b5-bccd2601776e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6f651852-4ff4-46d7-931a-7703721589c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_a2ecb630-9d94-402d-80ff-cce191c7a089_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_4cd36f04-18e6-4354-82f8-79c0b6565175_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_16a44837-c09f-484c-95a2-36f12b85054f_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_6edb2bba-cd8e-4801-82cd-06d0a470c6c4_totalLabel_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leased assets</link:label>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_sgry_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_sgry_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset" xlink:href="sgry-20201231.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_LeaseRightOfUseAsset" xlink:to="lab_sgry_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_1dfdccbe-721a-485d-b6f1-acb0d628fa79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount estimated to be reclassified as a reduction to interest expense over next 12 months</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4edb8e1d-58df-4a00-94f9-2cc8053e2c3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_3d2980d9-f1c1-4324-895c-15f4f64e8898_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_18cc929b-e3b1-43cd-b2fc-0a9999332047_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a9f108f9-946e-4cae-8676-85f6978fc460_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e289a2d6-79a8-4704-b74b-db05692915bb_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_f7e66432-09fb-4e0a-bf34-6aa0c58b9478_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interest held</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5d64a2c6-ae54-46dc-9bdf-f4db9104eb73_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deferred assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_PublicStockOfferingMember_eb592100-6853-4379-a25b-02d80bccfc12_terseLabel_en-US" xlink:label="lab_sgry_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_sgry_PublicStockOfferingMember_label_en-US" xlink:label="lab_sgry_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_sgry_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_sgry_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PublicStockOfferingMember" xlink:href="sgry-20201231.xsd#sgry_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_PublicStockOfferingMember" xlink:to="lab_sgry_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_85169ffa-6a18-47ba-a975-586c91f68721_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_5a9756ef-d495-45ff-8c61-cb08da3ffebd_terseLabel_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities owned</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_label_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned</link:label>
    <link:label id="lab_sgry_NumberOfSurgicalFacilitiesOwned_documentation_en-US" xlink:label="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Surgical Facilities Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NumberOfSurgicalFacilitiesOwned" xlink:to="lab_sgry_NumberOfSurgicalFacilitiesOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_f79e71c1-208b-417a-a4f8-92b8a8cd1d3b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_6cb0c649-9b37-4a68-a5e9-eae26df3965d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_6dbc8735-d873-4d85-9c02-ea10b0942d68_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from equity investments, net of distributions received</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_aa1a4f31-35ab-4470-b500-ff0af1b3a542_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ee234442-43ca-4d6a-ad1c-f8f03527d5a1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_b3c29927-79db-401c-abac-f1052a992bc2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_38e4ded3-af94-41d3-bc8f-896b83631cc4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9e7e3eaa-4bdd-4240-afae-8d42ff00e978_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_47d186d2-211f-4e0f-ac4b-6cea1ba3eeaa_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ManagementRightsMember_a6f8a6f2-2b49-4ddd-92e5-c01e74a2120e_terseLabel_en-US" xlink:label="lab_sgry_ManagementRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management rights agreements</link:label>
    <link:label id="lab_sgry_ManagementRightsMember_label_en-US" xlink:label="lab_sgry_ManagementRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Rights [Member]</link:label>
    <link:label id="lab_sgry_ManagementRightsMember_documentation_en-US" xlink:label="lab_sgry_ManagementRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ManagementRightsMember" xlink:href="sgry-20201231.xsd#sgry_ManagementRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ManagementRightsMember" xlink:to="lab_sgry_ManagementRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_AncillaryServicesMember_1ac29b98-bbad-4afc-9c69-8081fc168fa8_terseLabel_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services</link:label>
    <link:label id="lab_sgry_AncillaryServicesMember_label_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services [Member]</link:label>
    <link:label id="lab_sgry_AncillaryServicesMember_documentation_en-US" xlink:label="lab_sgry_AncillaryServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_AncillaryServicesMember" xlink:to="lab_sgry_AncillaryServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_78be7d44-a185-4f92-8646-0e61dc8d52c9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_0d58f330-8830-407f-9309-8fb6813df104_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures_f56b14e2-54e0-4ec2-aaef-249de88153cd_negatedTerseLabel_en-US" xlink:label="lab_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis differences of partnerships and joint ventures</link:label>
    <link:label id="lab_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures_label_en-US" xlink:label="lab_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Basis Differences of Partnerships and Joint Ventures</link:label>
    <link:label id="lab_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures_documentation_en-US" xlink:label="lab_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Basis Differences of Partnerships and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" xlink:to="lab_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_c80b7cf1-48cb-4cce-ac13-e109f409ce91_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_977a27fe-d89b-41fc-b219-ea69dc79ef50_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_63589c1d-af51-4504-9a28-d4bfca8daaff_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2fd0302b-5762-4c43-9624-6941f3ae0f77_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_069dcea7-39df-4952-8da9-3dccd27daac9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cb3337d2-2380-4a41-a52a-47cd3bc1897a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired_16aa1ea5-8e11-48ca-a8ea-25e344794e2a_terseLabel_en-US" xlink:label="lab_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of surgical facilities acquired</link:label>
    <link:label id="lab_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired_label_en-US" xlink:label="lab_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Number Of Noncontrolling Interests Acquired</link:label>
    <link:label id="lab_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired_documentation_en-US" xlink:label="lab_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Number Of Noncontrolling Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" xlink:href="sgry-20201231.xsd#sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" xlink:to="lab_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_4f2aa22d-0534-4852-936f-9e3858a31dc1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 50,461,706 and 49,298,940, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_d70163da-1460-456a-bb01-d4046e773fb1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance that if recognized, would credit directly to contributed capital</link:label>
    <link:label id="lab_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_label_en-US" xlink:label="lab_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Taxes, Business Combination, Valuation Allowance, Allocated to Contributed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" xlink:to="lab_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_eeb058a3-a62f-43bd-a49c-693fbddfb0a5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_236b78d5-887b-444e-b49d-3b8525736463_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0d4f7efd-3b15-4bf7-97d8-f31217fd9273_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e3967cb7-63c9-49c7-b824-90ef4c356059_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d30099eb-685a-4b3f-a4f1-988a36b3ab50_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a9406963-a6d7-4594-b9bd-129372de2c1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d4a7bd17-f008-499d-b8b3-be35567f32bc_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_InterestLimitationMember_ef597e68-77e0-4d72-a09c-c959a21b7ce5_terseLabel_en-US" xlink:label="lab_sgry_InterestLimitationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Limitation</link:label>
    <link:label id="lab_sgry_InterestLimitationMember_label_en-US" xlink:label="lab_sgry_InterestLimitationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Limitation [Member]</link:label>
    <link:label id="lab_sgry_InterestLimitationMember_documentation_en-US" xlink:label="lab_sgry_InterestLimitationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Limitation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestLimitationMember" xlink:href="sgry-20201231.xsd#sgry_InterestLimitationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_InterestLimitationMember" xlink:to="lab_sgry_InterestLimitationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e5bcbf47-5ef7-4d4c-9c51-0974bda21b96_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ec61ed7a-11fb-4626-b25a-49810d89543b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_a228ea59-50e7-4438-b2d1-23e86d6219df_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional and medical fees</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_e5b550f1-2e1c-48ba-81de-69c55cdc3e0c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ac98df45-06c1-4240-83c9-66db79baeaf2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6d2faaaa-f096-4eaf-b2d1-ce9e71f6a082_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_5ce0a907-ec74-4b0b-b32c-845c54458881_terseLabel_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost report liabilities</link:label>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_label_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Report Liabilities, Current</link:label>
    <link:label id="lab_sgry_CostReportLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sgry_CostReportLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Report Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent" xlink:href="sgry-20201231.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CostReportLiabilitiesCurrent" xlink:to="lab_sgry_CostReportLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_ed67ae81-138a-4395-815e-04277011ef10_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests&#8212;non-redeemable</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f84b14cf-fb4f-4299-b64d-8e0dbfbd8d01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted/Earned (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6dd686f6-f572-448a-a7cf-4ffbc337d3d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_7d003c2f-67f2-4fda-8e8f-de728b5d0b0c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_31a6d0ef-560b-4c7d-b141-3a93b19998c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BainCapitalMember_62b33b5d-9e12-4569-a8be-9ac3e6500769_terseLabel_en-US" xlink:label="lab_sgry_BainCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bain Capital</link:label>
    <link:label id="lab_sgry_BainCapitalMember_label_en-US" xlink:label="lab_sgry_BainCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bain Capital [Member]</link:label>
    <link:label id="lab_sgry_BainCapitalMember_documentation_en-US" xlink:label="lab_sgry_BainCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bain Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BainCapitalMember" xlink:href="sgry-20201231.xsd#sgry_BainCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BainCapitalMember" xlink:to="lab_sgry_BainCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_d2a3daeb-1f3a-425b-b8b9-d520381a9a14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other deferred liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f133abcd-6b73-48c8-bcff-0ccba2bcafce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_59aaf655-f44b-4b1b-bf95-a1e1b9f43e11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e6a7f5f5-77c8-4e29-af3e-5631991ca52c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_cd59eaa0-e9dc-400f-8bd4-ad82f4b71a2b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_754f50bf-bd6b-4001-b773-6d0718a241f2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_16e2e2e5-5be6-41d2-ab78-e05311da2d14_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business entities acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c57700e-ed40-4683-ad1d-fe18be28031e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ff5542c1-9033-46df-9359-ee108899fb7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_5ca2bf11-4d7c-4fae-ad3c-cc1daea705d4_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6ad376d1-4ff4-4d41-aa65-0883ce887bb5_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues by Service Type</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5eb33966-88c4-4c1b-8901-441191ff8229_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_dd6d09e0-ca7b-411a-8157-de457a039bb7_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate acquisition date fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4ddeb15c-3104-4866-a1fd-a4c1435eca0b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9ed7e544-b9af-40c1-adcd-4978c08e970a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_0db805fe-91eb-49f2-ab53-9cac6e37df6d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term, finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_68209767-4852-4174-ad2f-e71fd2d9f16f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ad0ec791-dc3f-4ab9-b391-028742505e49_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1ee91110-5e5f-44fa-a48d-3e638a81baf3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_313eef8a-ed77-441d-83e6-07c389b4c787_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilitiesExistingMarketsMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facilities, Existing Markets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:to="lab_sgry_SurgicalFacilitiesExistingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b447832c-d520-4d8a-99f9-4be904dca421_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_19bd3be0-059e-4667-97c9-5396c68d6fba_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_e230bdf6-3288-49e9-b46d-bc9afea06f44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_53921807-d750-4a58-80f5-0f7c25496e8c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0f956e1c-ecac-4c25-b4b7-56d32e6c6f31_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5cd908e6-0b96-4e44-9409-248586351b6c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_faab0541-72fa-413a-889a-704d6eba67e1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Surgery Partners, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_91e49a98-e8f3-4e9b-8363-76aca130014c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_eb2df243-0cd7-44bf-8978-4ffae4d206cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_5db098c1-17fb-4f1d-9866-fa4e14fb864e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to ownership transactions with non-controlling interest holders</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_5a4bb4f1-b957-4deb-835f-b1a40e7c4fb1_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4203773c-7750-4789-a6d0-96c6b5fe51c7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_15b1c24a-5efd-4c86-a509-96f52188ea23_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_d92df0e2-e0d4-44e8-a413-000051622790_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_fbedf5c2-1f16-45de-bb3a-f5e041392a8d_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_7d5fb85d-9fe8-4d15-9f52-9ee685686d02_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod_7253730e-33e6-46d6-a9a2-e043cb49f3ce_terseLabel_en-US" xlink:label="lab_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted units granted, earned during period (shares)</link:label>
    <link:label id="lab_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod_label_en-US" xlink:label="lab_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Earned In Period</link:label>
    <link:label id="lab_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod_documentation_en-US" xlink:label="lab_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Earned In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" xlink:href="sgry-20201231.xsd#sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" xlink:to="lab_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_c25b24e1-ba41-49d2-b4bf-b022e924e387_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve adjustments</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ed1b05f6-c24d-4404-9830-b051b4c2ef3c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_21edfcf0-594f-4670-829f-fca455305a93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options/SARs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_c45c8b2e-7e6c-4806-81c2-99c18dbcd68d_terseLabel_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition and disposal of shares of non-controlling interests, net</link:label>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_label_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</link:label>
    <link:label id="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_documentation_en-US" xlink:label="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:href="sgry-20201231.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:to="lab_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_bb22b441-0515-48a5-9ba1-d6ec6356c3f1_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpense_b8139219-7ae1-470e-96c1-f2fdadd560fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonrecurringIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonrecurring (Income) Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncomeExpense" xlink:to="lab_us-gaap_OtherNonrecurringIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_fd40ea72-9551-484a-9e0f-b469eed15301_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_44396fc1-1fe2-4053-b9ab-d37c3ff9911a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b3aef804-b6cf-4bcc-a021-eea98d329605_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent_13427474-bd62-492d-a144-f73bab6f1bc3_terseLabel_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, current</link:label>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent_label_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net Of Discount, Current</link:label>
    <link:label id="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent_documentation_en-US" xlink:label="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net Of Discount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" xlink:href="sgry-20201231.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" xlink:to="lab_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c6196a73-70a2-4dab-850d-d4d0df07e353_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_13758fc6-40de-444d-bce2-c422f44c677f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to non-controlling interests&#8212;redeemable</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_863d0390-3711-4dce-909e-8364cf8f43bb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_813371a9-0bc6-4a27-a453-234c7a12f638_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_ef9af1a8-ada3-4fae-8ec0-e99244088337_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividends, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b48a2403-bb2c-4486-b73f-41d7d902ff0e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_43ef9edc-0756-40a3-9b98-ac2f0339726d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend rate</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ff558ddf-8ea1-4e7a-be2a-b74b10186849_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_6edbaff5-e806-4d1c-add0-e9be49a67f56_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance on debt</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7b47da54-e41b-4840-ad09-73e825c62b0b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_7d35dac7-6a58-4446-91eb-72202c8b2ab6_terseLabel_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeited, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Options, Forfeited, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="lab_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_RestrictedStockAndPerformanceSharesMember_63a14d01-2dd4-4766-b787-161d8064ed51_terseLabel_en-US" xlink:label="lab_sgry_RestrictedStockAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted and Performance Shares</link:label>
    <link:label id="lab_sgry_RestrictedStockAndPerformanceSharesMember_label_en-US" xlink:label="lab_sgry_RestrictedStockAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Performance Shares [Member]</link:label>
    <link:label id="lab_sgry_RestrictedStockAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_sgry_RestrictedStockAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Performance Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RestrictedStockAndPerformanceSharesMember" xlink:href="sgry-20201231.xsd#sgry_RestrictedStockAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_RestrictedStockAndPerformanceSharesMember" xlink:to="lab_sgry_RestrictedStockAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_a2ffeb10-aefe-4711-b32e-759d8d42b3a6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredTaxAssetTaxReceivableAgreement_8501ff6a-76cf-4a57-8731-522c73443aa8_terseLabel_en-US" xlink:label="lab_sgry_DeferredTaxAssetTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRA liability</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetTaxReceivableAgreement_label_en-US" xlink:label="lab_sgry_DeferredTaxAssetTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Receivable Agreement</link:label>
    <link:label id="lab_sgry_DeferredTaxAssetTaxReceivableAgreement_documentation_en-US" xlink:label="lab_sgry_DeferredTaxAssetTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Receivable Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetTaxReceivableAgreement" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetTaxReceivableAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredTaxAssetTaxReceivableAgreement" xlink:to="lab_sgry_DeferredTaxAssetTaxReceivableAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_a62e573f-75ca-4598-9b89-a9c209590a97_terseLabel_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient service revenues</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_label_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Organization, Patient Service [Member]</link:label>
    <link:label id="lab_sgry_HealthcareOrganizationPatientServiceMember_documentation_en-US" xlink:label="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Organization, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember" xlink:href="sgry-20201231.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember" xlink:to="lab_sgry_HealthcareOrganizationPatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_42633316-174c-4d12-a1f4-b48d30541282_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_103c4968-9579-4e68-9034-ddde5122d5ec_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_daaa180c-9f89-433f-a5af-ab80f7a8d52f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_36475691-0f4f-441a-83e6-b3830d3daffa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_8598fa26-94bd-4774-8df8-939d7c44e48f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and advances to affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4bab35ee-bf79-4c86-9a77-a97f9d0b2879_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_40b8109b-0244-425a-94f4-b8eab75097aa_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_a0a925df-8f48-4995-8d9f-2564ed0c2ff8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_fe8432a4-9238-4539-b9a4-bfd70bc9aa73_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_32d05632-21be-487e-8ef0-cd4e1484b551_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9376db1e-3948-4585-830f-fae3f3e4567a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f5a8abec-2d05-4664-906c-4ca2ab365fa5_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_ae85204c-35a8-49e1-9030-5690906651be_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared but unpaid</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7f77d088-ded1-4014-8b20-52a6a73f0e5f_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in right-of-use operating lease assets and liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3024bda5-ac3a-4726-9c6f-db23385daee0_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_0fc5559c-2b75-4f09-99bd-dace401eddad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_86b138af-7452-4962-a7e9-22b3d0b4e5ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b6896dac-ad55-4122-b6a6-44ae26ff39e5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b4915a9-c1ff-408f-9d1c-fa71e88308df_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34936f9e-4363-4c5f-8612-2695390d0bf4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e5775c44-02ed-4a52-8663-59dce46f0860_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b1a8bfee-55a8-4625-aebd-682adf9537b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Scheduled Maturities of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_55b1ad36-a7e4-4a5d-bdd5-f536703f2c0e_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_179bcaa8-e68d-4327-96e5-881a237793ac_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2d79de0c-8dcf-4eeb-8645-b79f0de6d6d0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_75aa3f98-cf47-4788-a5ec-9a163193ce8f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_842ce358-38c7-499c-b1d5-a2ec37dcba65_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_21dcd403-593e-4e76-ace3-481321063291_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_250a9f97-24e7-4e75-99fa-fbb4ab2d1fb5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Scheduled Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_b51ae9d3-e2c1-4f39-8314-bec7f0501424_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_dff771d7-72bd-4717-ba1b-9402e4326cc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_8af8fd66-aa13-46be-87de-ddbdbce23334_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_62b04891-0658-4379-bbd0-3d486e176307_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Components of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e3f28c47-8e0d-44d9-9e6f-344cbb96db26_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1a4fdaf0-23e7-46fe-aa5c-8b04e398adc1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_215066c0-04ef-4413-aa40-9bf6a38fae6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_1256c3ef-dc8f-4045-a3fc-3415a550347a_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c04e79bc-cae5-43d5-ac22-b94d337495de_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9e578859-92e4-4c23-b5b0-ea4adeab23d3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5fb8b13-acf2-46e6-81be-e78c4a815e20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e352c765-7a5f-4458-ad87-dd2b05c0fb31_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_SurgicalFacilityAndPhysicianPracticeMember_4c1912a9-e9cd-4004-a0e0-57e83fe38f8f_terseLabel_en-US" xlink:label="lab_sgry_SurgicalFacilityAndPhysicianPracticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility and Physician Practice</link:label>
    <link:label id="lab_sgry_SurgicalFacilityAndPhysicianPracticeMember_label_en-US" xlink:label="lab_sgry_SurgicalFacilityAndPhysicianPracticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility And Physician Practice [Member]</link:label>
    <link:label id="lab_sgry_SurgicalFacilityAndPhysicianPracticeMember_documentation_en-US" xlink:label="lab_sgry_SurgicalFacilityAndPhysicianPracticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Facility And Physician Practice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityAndPhysicianPracticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember" xlink:to="lab_sgry_SurgicalFacilityAndPhysicianPracticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_18827557-5113-472a-b3b5-3b4bb5dcee67_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_650162b8-0c36-4bae-b0d4-a480e57bd45e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_64f8adbe-609f-44e0-86d1-d6827b8d3ed4_terseLabel_en-US" xlink:label="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare accelerated payments and deferred governmental grants</link:label>
    <link:label id="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_label_en-US" xlink:label="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Accelerated Payments And Deferred Governmental Grants, Current</link:label>
    <link:label id="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_documentation_en-US" xlink:label="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Accelerated Payments And Deferred Governmental Grants, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:href="sgry-20201231.xsd#sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:to="lab_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_7495a5cb-53a8-403c-9517-53d16cb24a23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8448519e-ecf1-4a80-b082-fa79a9c80f8d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_53346a47-c561-4add-bf0d-d8232b4970e3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ef0db13-ab17-4578-8542-22a2eb604717_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9b1a4973-463f-4684-bbc4-135af57cbd7b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bac58d9-1cfa-4a95-853e-7a3969b5433f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_aa5473aa-d827-4842-ab22-939edec52bcd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_259d6870-821f-4be1-9da3-c1381bc674b0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_bf8e38be-03b9-4613-8d70-f914aa24e784_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2dae0cd9-f43e-4a32-abea-b85e2d20d129_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_e1b6b310-e9ad-420b-978b-34510d890c45_terseLabel_en-US" xlink:label="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred accrued payroll and benefits</link:label>
    <link:label id="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Employee-related Liabilities, Current</link:label>
    <link:label id="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:href="sgry-20201231.xsd#sgry_DeferredEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_sgry_DeferredEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_5d90439b-4e83-4efc-aa38-ef8be3d7e3d9_terseLabel_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest accrued on payment under Tax Receivable Agreement, basis spread on variable rate</link:label>
    <link:label id="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_label_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate</link:label>
    <link:label id="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_documentation_en-US" xlink:label="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:href="sgry-20201231.xsd#sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:to="lab_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_2d91f8bd-9692-46a5-b5ce-5608ce2d9e2f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities:</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_87064e34-734a-4448-aeb2-0d74efa6dd15_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests&#8212;redeemable</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2fb12891-3743-4190-95e5-b66b12bd14bc_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest, beginning balance</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9faf5123-f478-4c75-8452-0594f9012df1_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest, ending balance</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4e504b33-3193-4945-937f-7de919211bc4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_805a0aa3-530f-4fe8-8354-e33d6faaa2de_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_2eca46cd-bf07-43f8-af3b-ffae084ef2ef_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems" xlink:to="lab_us-gaap_GuaranteeObligationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgry_BusinessCombinationsAndDisposalsAbstract_a21538d1-8d4e-4ebb-a41d-24c18283f2b3_terseLabel_en-US" xlink:label="lab_sgry_BusinessCombinationsAndDisposalsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations And Disposals [Abstract]</link:label>
    <link:label id="lab_sgry_BusinessCombinationsAndDisposalsAbstract_label_en-US" xlink:label="lab_sgry_BusinessCombinationsAndDisposalsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations And Disposals [Abstract]</link:label>
    <link:label id="lab_sgry_BusinessCombinationsAndDisposalsAbstract_documentation_en-US" xlink:label="lab_sgry_BusinessCombinationsAndDisposalsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations And Disposals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationsAndDisposalsAbstract" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationsAndDisposalsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgry_BusinessCombinationsAndDisposalsAbstract" xlink:to="lab_sgry_BusinessCombinationsAndDisposalsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_95f2eeae-9bce-4e2d-8463-022c91453f2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_438f1a86-78ff-484d-b2ed-1662c7b25770_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9b91e477-6025-4ca4-881d-efe7c754321c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue_39a7c672-b7fa-4b03-b17d-81319f912a83_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable preferred stock, redemption value</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Preferred, Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>sgry-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:934c24c6-c60d-49cc-a057-94123601eeba,g:155ec3a3-79d5-4a25-a7e0-562ed3402740-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Cover" xlink:type="simple" xlink:href="sgry-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_68ea5430-e908-455c-bc3e-1efdd6138fb9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_DocumentType_68ea5430-e908-455c-bc3e-1efdd6138fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ad8a7d92-7624-4065-84c6-bf50d36b9026" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_DocumentAnnualReport_ad8a7d92-7624-4065-84c6-bf50d36b9026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e291909a-acb5-44b2-81ae-ac1be110f90b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_DocumentPeriodEndDate_e291909a-acb5-44b2-81ae-ac1be110f90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e8055e5d-8053-40b2-b79b-5cfbdd2769cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_CurrentFiscalYearEndDate_e8055e5d-8053-40b2-b79b-5cfbdd2769cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_35bda89f-f089-46d3-9932-84f3ba575ed3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_DocumentTransitionReport_35bda89f-f089-46d3-9932-84f3ba575ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_711184b3-30ee-4c57-8f1b-beb6c236d0bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityFileNumber_711184b3-30ee-4c57-8f1b-beb6c236d0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e4be0a02-0e5e-41e6-8769-13e59e07bc64" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityRegistrantName_e4be0a02-0e5e-41e6-8769-13e59e07bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_30a54d77-f943-470e-ade9-1640413a930f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_30a54d77-f943-470e-ade9-1640413a930f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_eb39a26c-8507-4dea-989d-41c0fb8d2fb6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityTaxIdentificationNumber_eb39a26c-8507-4dea-989d-41c0fb8d2fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bc8636e5-f1c1-44bc-a495-3e407e428123" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityAddressAddressLine1_bc8636e5-f1c1-44bc-a495-3e407e428123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_50ba5383-958f-4974-a2ce-4e2573e60ee2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityAddressCityOrTown_50ba5383-958f-4974-a2ce-4e2573e60ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_12b9aa00-d126-4395-8283-421e566e8ad0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityAddressStateOrProvince_12b9aa00-d126-4395-8283-421e566e8ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2e4ab27e-1adb-483c-8d34-ffcc437f5997" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityAddressPostalZipCode_2e4ab27e-1adb-483c-8d34-ffcc437f5997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e69c479a-062c-4659-9e20-e82bfa289dd5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_CityAreaCode_e69c479a-062c-4659-9e20-e82bfa289dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_31c2231a-facc-4d0e-a5fe-5343c5f6aa50" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_LocalPhoneNumber_31c2231a-facc-4d0e-a5fe-5343c5f6aa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6aadb5bf-2c69-4ab3-b25a-0d69462d61ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_Security12bTitle_6aadb5bf-2c69-4ab3-b25a-0d69462d61ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_67705d70-390d-4c20-a1d8-0d3cdef9b194" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_TradingSymbol_67705d70-390d-4c20-a1d8-0d3cdef9b194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6d494e51-5157-419f-b0f5-96721f905271" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_SecurityExchangeName_6d494e51-5157-419f-b0f5-96721f905271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_473b3db6-7168-4e44-92cd-dfa73d3fd778" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_473b3db6-7168-4e44-92cd-dfa73d3fd778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_2518003d-2e15-44ce-acd4-a62685256a79" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityVoluntaryFilers_2518003d-2e15-44ce-acd4-a62685256a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a7f0a8cc-4d8d-46b8-921b-a7d2a2d13c5a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityCurrentReportingStatus_a7f0a8cc-4d8d-46b8-921b-a7d2a2d13c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5e16ad24-1388-4712-992d-5af359731fdd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityInteractiveDataCurrent_5e16ad24-1388-4712-992d-5af359731fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b730e9ba-6f32-48f0-a239-af8e434ff46e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityFilerCategory_b730e9ba-6f32-48f0-a239-af8e434ff46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f8330ab2-60ae-415e-9883-626eee8da322" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntitySmallBusiness_f8330ab2-60ae-415e-9883-626eee8da322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ebb1e74d-fc1a-4b54-b902-85d05804d8f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityEmergingGrowthCompany_ebb1e74d-fc1a-4b54-b902-85d05804d8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_3d17033d-35cf-496c-96a8-7ac1dee81b98" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_3d17033d-35cf-496c-96a8-7ac1dee81b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2702dc72-c97a-4a35-8bf3-c1e90b3d94e0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityShellCompany_2702dc72-c97a-4a35-8bf3-c1e90b3d94e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_5cb32ab2-6b9c-4058-8940-ceb0661b49b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityPublicFloat_5cb32ab2-6b9c-4058-8940-ceb0661b49b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d06ed7ff-09fd-46bb-b4d5-a394f2fd747d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d06ed7ff-09fd-46bb-b4d5-a394f2fd747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e0bcf230-55e3-4990-9f6d-b3f13363c45a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e0bcf230-55e3-4990-9f6d-b3f13363c45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d1440b35-dc98-41a0-9d54-4c4fc4b0472d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_EntityCentralIndexKey_d1440b35-dc98-41a0-9d54-4c4fc4b0472d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_54c4d60b-d1fc-4f8f-b8c0-14afb91dcab7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_DocumentFiscalYearFocus_54c4d60b-d1fc-4f8f-b8c0-14afb91dcab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_18c02b20-be50-47b2-9294-bf7db106dda0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_18c02b20-be50-47b2-9294-bf7db106dda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e7129ac3-56e3-42a3-9638-68e02c78437c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b8b3b3a-3dd6-4a2f-a047-c1e37236536b" xlink:to="loc_dei_AmendmentFlag_e7129ac3-56e3-42a3-9638-68e02c78437c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c0d3aa51-3a47-4f30-8b30-cafc222142cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0d3aa51-3a47-4f30-8b30-cafc222142cf" xlink:to="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7675b337-ead2-4f20-a90d-cef8e5557c89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7675b337-ead2-4f20-a90d-cef8e5557c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e58f25c6-acf0-467b-9d19-ddcacccb3b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7675b337-ead2-4f20-a90d-cef8e5557c89" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e58f25c6-acf0-467b-9d19-ddcacccb3b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_11b1134e-3b14-47c2-91f3-9041a332818f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7675b337-ead2-4f20-a90d-cef8e5557c89" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_11b1134e-3b14-47c2-91f3-9041a332818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bdc0dd4e-9ba2-4fb6-a743-0d79fdd10044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7675b337-ead2-4f20-a90d-cef8e5557c89" xlink:to="loc_us-gaap_InventoryNet_bdc0dd4e-9ba2-4fb6-a743-0d79fdd10044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4c672501-313a-4ae2-bfb8-9025ac58d1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7675b337-ead2-4f20-a90d-cef8e5557c89" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4c672501-313a-4ae2-bfb8-9025ac58d1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0cb086f0-6567-4bc2-9111-b3cf314ba87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7675b337-ead2-4f20-a90d-cef8e5557c89" xlink:to="loc_us-gaap_OtherAssetsCurrent_0cb086f0-6567-4bc2-9111-b3cf314ba87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f6b7bc89-2600-4a7f-b309-cc181fd5886f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7675b337-ead2-4f20-a90d-cef8e5557c89" xlink:to="loc_us-gaap_AssetsCurrent_f6b7bc89-2600-4a7f-b309-cc181fd5886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4bec0b30-d0f9-440e-a4e2-5ab82f2c1d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4bec0b30-d0f9-440e-a4e2-5ab82f2c1d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4d296cfa-7994-473d-90d7-6558f00e8899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4d296cfa-7994-473d-90d7-6558f00e8899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_602bf9a3-8178-4fc6-baf8-d1b7a3a60d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_Goodwill_602bf9a3-8178-4fc6-baf8-d1b7a3a60d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_98b08048-4ad8-4425-b62f-58f2b664620a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_98b08048-4ad8-4425-b62f-58f2b664620a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_120a1d43-a15a-4378-9575-2f850a93a53e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_120a1d43-a15a-4378-9575-2f850a93a53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8d8ff063-1fa1-4df7-a133-7c44e0ef5724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8d8ff063-1fa1-4df7-a133-7c44e0ef5724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_08fc95ae-2f5c-408e-945e-bf5cbfe85387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_08fc95ae-2f5c-408e-945e-bf5cbfe85387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0599afde-3f80-4167-849a-dc2cbb0120a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8115f072-e63c-4650-bab9-6f5cd33ca1e6" xlink:to="loc_us-gaap_Assets_0599afde-3f80-4167-849a-dc2cbb0120a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c0d3aa51-3a47-4f30-8b30-cafc222142cf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_83d03be8-e6dd-44e5-9ea2-2191c88bae35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_83d03be8-e6dd-44e5-9ea2-2191c88bae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5807a006-9baf-4a0c-ace8-5a575acf4ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d03be8-e6dd-44e5-9ea2-2191c88bae35" xlink:to="loc_us-gaap_AccountsPayableCurrent_5807a006-9baf-4a0c-ace8-5a575acf4ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e21d7da4-94c6-4a73-a5ef-ab61477662b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d03be8-e6dd-44e5-9ea2-2191c88bae35" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e21d7da4-94c6-4a73-a5ef-ab61477662b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_769d71f7-37c3-412a-839b-848496cafbea" xlink:href="sgry-20201231.xsd#sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d03be8-e6dd-44e5-9ea2-2191c88bae35" xlink:to="loc_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent_769d71f7-37c3-412a-839b-848496cafbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8621d388-5089-45e9-b8b9-ec7c7b2fd502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d03be8-e6dd-44e5-9ea2-2191c88bae35" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8621d388-5089-45e9-b8b9-ec7c7b2fd502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e0437972-cf56-4f6b-bf5d-adc77e6e9d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d03be8-e6dd-44e5-9ea2-2191c88bae35" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e0437972-cf56-4f6b-bf5d-adc77e6e9d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_505c0a9a-884c-4566-8a4c-ab8fb286f7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83d03be8-e6dd-44e5-9ea2-2191c88bae35" xlink:to="loc_us-gaap_LiabilitiesCurrent_505c0a9a-884c-4566-8a4c-ab8fb286f7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1177c528-330a-4f1b-b15f-375ba5f008ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_1177c528-330a-4f1b-b15f-375ba5f008ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bac02daf-889d-4918-952d-fa62f5a97b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bac02daf-889d-4918-952d-fa62f5a97b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_23e0dd04-df70-4f12-8203-f2dbf025531f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_23e0dd04-df70-4f12-8203-f2dbf025531f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3c4e9684-db1b-49db-9b00-c6d43cca6a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3c4e9684-db1b-49db-9b00-c6d43cca6a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5f7cb05d-e973-4df7-9ae8-ab3cc3196da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5f7cb05d-e973-4df7-9ae8-ab3cc3196da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6659cc9d-3f06-4e3e-afb3-eb6972036705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:to="loc_us-gaap_PreferredStockValue_6659cc9d-3f06-4e3e-afb3-eb6972036705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_5f92b42e-7c56-40c9-af17-324255eaf317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:to="loc_us-gaap_CommonStockValueOutstanding_5f92b42e-7c56-40c9-af17-324255eaf317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9dd9c309-b37d-49f0-a1c9-b05ba51b0195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9dd9c309-b37d-49f0-a1c9-b05ba51b0195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7eccd5c2-934b-4968-9834-503d463f4eba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7eccd5c2-934b-4968-9834-503d463f4eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d4019af7-6d91-45db-b54d-cb7528a3f739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d4019af7-6d91-45db-b54d-cb7528a3f739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_723d8b05-12dc-4dd6-941c-81d0c4fa2cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:to="loc_us-gaap_StockholdersEquity_723d8b05-12dc-4dd6-941c-81d0c4fa2cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_86f2d69c-0422-4c75-92fd-a2ea95548f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:to="loc_us-gaap_MinorityInterest_86f2d69c-0422-4c75-92fd-a2ea95548f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_556a8ea4-3940-42ff-9dc7-e200d6bdaf25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5a87e8ec-c86c-4aab-a324-61b852755590" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_556a8ea4-3940-42ff-9dc7-e200d6bdaf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3899f0d0-08fc-4d61-a852-6cfedd5eb624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2d8e33b8-3db5-4b88-987f-025927e3b95f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3899f0d0-08fc-4d61-a852-6cfedd5eb624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_a4244f2a-7f05-4038-a087-0e5ccd2aa955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_a4244f2a-7f05-4038-a087-0e5ccd2aa955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_067627ee-4b35-41d4-8ed4-76f12b470f04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_067627ee-4b35-41d4-8ed4-76f12b470f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_992ff06c-d544-4fae-9bc7-3d6f437892ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_992ff06c-d544-4fae-9bc7-3d6f437892ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue_716681f6-a2ae-438b-9c2f-fa4aa7987688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue_716681f6-a2ae-438b-9c2f-fa4aa7987688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bca47695-f0e8-43f4-b2fb-eb105a739578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bca47695-f0e8-43f4-b2fb-eb105a739578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8b6c1ef4-32c3-48f8-adec-cd9e3af73ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8b6c1ef4-32c3-48f8-adec-cd9e3af73ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ea7ea007-0f58-4747-8db8-8ecfd9f58c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ea7ea007-0f58-4747-8db8-8ecfd9f58c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0498abf9-248b-40e2-98d0-8d6d835d9528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0498abf9-248b-40e2-98d0-8d6d835d9528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e6d8bff-b821-4ed3-83fd-ee73d870e545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5e6d8bff-b821-4ed3-83fd-ee73d870e545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_175d0c41-cf99-4a27-8f89-f769566cd15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_175d0c41-cf99-4a27-8f89-f769566cd15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b0785d51-e13e-4d25-888b-c4ef02ebb5f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_CommonStockSharesIssued_b0785d51-e13e-4d25-888b-c4ef02ebb5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8cb281c6-acfa-45a7-b8ef-c5394332722e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f900d9c3-a87a-4866-8434-fc1f68512b16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8cb281c6-acfa-45a7-b8ef-c5394332722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_05f249dd-ccfe-4fe6-b744-f1237d30edcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_05f249dd-ccfe-4fe6-b744-f1237d30edcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_c213c266-2b2d-491f-bb0c-103508725b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_LaborAndRelatedExpense_c213c266-2b2d-491f-bb0c-103508725b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_58441843-bbca-4aa0-a30a-c349349500ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_SuppliesExpense_58441843-bbca-4aa0-a30a-c349349500ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_d1389cc4-83ea-4dd4-b38c-6846d0fba7cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_ProfessionalFees_d1389cc4-83ea-4dd4-b38c-6846d0fba7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OperatingAndFinanceLeaseExpense_649daceb-4574-4be7-bceb-816de2e485aa" xlink:href="sgry-20201231.xsd#sgry_OperatingAndFinanceLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_sgry_OperatingAndFinanceLeaseExpense_649daceb-4574-4be7-bceb-816de2e485aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_975e019e-7daa-4f0d-873f-1485335f3b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_975e019e-7daa-4f0d-873f-1485335f3b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_05d425e4-db43-41e3-887b-3c45afe05f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_05d425e4-db43-41e3-887b-3c45afe05f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9a76926d-f736-46f9-af21-626d49b6287c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9a76926d-f736-46f9-af21-626d49b6287c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bf83389b-ad7c-4d34-af44-220fb18e6ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bf83389b-ad7c-4d34-af44-220fb18e6ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_eed4c19c-d81c-4c46-9176-dd300645d005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_eed4c19c-d81c-4c46-9176-dd300645d005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_ab2cd96c-7dc6-470a-a909-09d7ecb1c272" xlink:href="sgry-20201231.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_ab2cd96c-7dc6-470a-a909-09d7ecb1c272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_95d15c36-96ad-498d-b2fa-15ad714ea76c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_95d15c36-96ad-498d-b2fa-15ad714ea76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_86803fca-4d7d-4d49-a56e-bfed5cd41d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_AssetImpairmentCharges_86803fca-4d7d-4d49-a56e-bfed5cd41d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_1d0e2c09-160f-4986-bd6a-e6529b87b089" xlink:href="sgry-20201231.xsd#sgry_GrantRevenue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_sgry_GrantRevenue_1d0e2c09-160f-4986-bd6a-e6529b87b089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a5fe49ee-373b-403e-9708-8fddb7bb0632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a5fe49ee-373b-403e-9708-8fddb7bb0632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_8e89328b-e0d9-4a54-8471-e5c6ca232d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_8e89328b-e0d9-4a54-8471-e5c6ca232d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonrecurringIncomeExpense_3f00719c-31ef-4490-9269-73b15e926f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonrecurringIncomeExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_OtherNonrecurringIncomeExpense_3f00719c-31ef-4490-9269-73b15e926f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e7cc68bd-134c-44a1-8903-d735da407fae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6295adbf-8a4d-40c7-8bd4-a0560d834d63" xlink:to="loc_us-gaap_OperatingExpenses_e7cc68bd-134c-44a1-8903-d735da407fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_309e278b-0a1d-4b1a-af66-47ed38f029b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_OperatingIncomeLoss_309e278b-0a1d-4b1a-af66-47ed38f029b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_5a7f71d8-359d-4dd5-92ca-a077a442c5e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_5a7f71d8-359d-4dd5-92ca-a077a442c5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_91584e81-80e3-4972-91b7-af6518bb7fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_91584e81-80e3-4972-91b7-af6518bb7fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2760a754-4781-4e94-bb7d-ecf87cbd1646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2760a754-4781-4e94-bb7d-ecf87cbd1646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3cdc90f-e667-4573-8a04-27e90e0c8217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f3cdc90f-e667-4573-8a04-27e90e0c8217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1f34e4cc-c840-4ab1-a858-7a7e0e4b271c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_ProfitLoss_1f34e4cc-c840-4ab1-a858-7a7e0e4b271c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6b85b723-7eb8-43a7-a789-91876f774676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6b85b723-7eb8-43a7-a789-91876f774676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fae02270-9dc4-480a-b0ff-d6dc83276843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_NetIncomeLoss_fae02270-9dc4-480a-b0ff-d6dc83276843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_dcc64d59-7bc2-45ad-8a97-62fb5b267864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_dcc64d59-7bc2-45ad-8a97-62fb5b267864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_eb70896a-ba73-4062-ba47-f0557aa3e0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_eb70896a-ba73-4062-ba47-f0557aa3e0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9f64cfe8-e9be-45d1-947a-d97269e324f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9f64cfe8-e9be-45d1-947a-d97269e324f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ba4efba1-c7cd-4bcb-b909-72e96d15c509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6d23c853-cbeb-49f5-9453-19b30bd869c8" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ba4efba1-c7cd-4bcb-b909-72e96d15c509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3559badc-83b9-4652-8036-7f669da7535d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69010d76-af7a-4fb0-8a59-67d7dabe3aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3559badc-83b9-4652-8036-7f669da7535d" xlink:to="loc_us-gaap_ProfitLoss_69010d76-af7a-4fb0-8a59-67d7dabe3aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_77bd18b0-7d72-45f6-a752-f95095ba567b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3559badc-83b9-4652-8036-7f669da7535d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_77bd18b0-7d72-45f6-a752-f95095ba567b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2c074d4b-6457-4585-91ce-3b8fa7e9ae50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_77bd18b0-7d72-45f6-a752-f95095ba567b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2c074d4b-6457-4585-91ce-3b8fa7e9ae50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_551b8ab5-553b-4e3d-a9e5-fc98caa764b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3559badc-83b9-4652-8036-7f669da7535d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_551b8ab5-553b-4e3d-a9e5-fc98caa764b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b70e4503-6e36-4f73-a466-d7faf120cf34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3559badc-83b9-4652-8036-7f669da7535d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b70e4503-6e36-4f73-a466-d7faf120cf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7574fde9-712e-46de-8785-5225ee57274c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3559badc-83b9-4652-8036-7f669da7535d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7574fde9-712e-46de-8785-5225ee57274c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e00f0719-49aa-4b32-8c3e-c2f4497f1624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e00f0719-49aa-4b32-8c3e-c2f4497f1624" xlink:to="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c214db8b-14ea-4bb6-8a7b-1fe494dc31f7" xlink:to="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e59d9105-41d8-4440-8cbb-3820f20911e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_CommonStockMember_e59d9105-41d8-4440-8cbb-3820f20911e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_01cded40-7f1b-4079-8534-a275ea095e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_01cded40-7f1b-4079-8534-a275ea095e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6b643f06-9179-4a1e-b5b1-51a7ba84c362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6b643f06-9179-4a1e-b5b1-51a7ba84c362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_929d6c18-e526-4472-b9f5-7d3331688ae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_RetainedEarningsMember_929d6c18-e526-4472-b9f5-7d3331688ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_dd2d1d29-c26c-4643-937e-71e540dafb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1f429ec-fcbd-49e1-be16-c3ddbc7e148d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_dd2d1d29-c26c-4643-937e-71e540dafb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ea9d036a-0db4-44da-a2a3-8a0b9f549251" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ea9d036a-0db4-44da-a2a3-8a0b9f549251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b383e51b-2962-40b0-bb1a-71e699f54144" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ea9d036a-0db4-44da-a2a3-8a0b9f549251" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b383e51b-2962-40b0-bb1a-71e699f54144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b12316ab-5c88-4856-ab59-7a0bd90b7f42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b383e51b-2962-40b0-bb1a-71e699f54144" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b12316ab-5c88-4856-ab59-7a0bd90b7f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ebc01e26-21fe-46e5-bd04-ab500fb5ec6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09a7af52-91a8-4cc3-a7f6-24ac21ce1c32" xlink:to="loc_us-gaap_StatementLineItems_ebc01e26-21fe-46e5-bd04-ab500fb5ec6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ebc01e26-21fe-46e5-bd04-ab500fb5ec6e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d70dbbfa-7aaf-4900-b23f-560d4f89afc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d70dbbfa-7aaf-4900-b23f-560d4f89afc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f415a48-1ad1-4ada-b7af-edfd7885a1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f415a48-1ad1-4ada-b7af-edfd7885a1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_7f144e80-921c-480e-a332-5cbe6a187017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_7f144e80-921c-480e-a332-5cbe6a187017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b54f65c4-ac48-417d-a4bd-a92590c5fcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b54f65c4-ac48-417d-a4bd-a92590c5fcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_90e01084-6bf9-4697-acc6-6bde52c698f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_90e01084-6bf9-4697-acc6-6bde52c698f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_dc5775e9-b7f4-4497-976c-41f85f74f73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_dc5775e9-b7f4-4497-976c-41f85f74f73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56d2cedd-c56d-422e-a2ee-c300ed103adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56d2cedd-c56d-422e-a2ee-c300ed103adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_9b14014a-783c-43ed-a0d5-46b2cd2ac63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_9b14014a-783c-43ed-a0d5-46b2cd2ac63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_934e5270-43d6-4ef3-8a04-06358306d279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_934e5270-43d6-4ef3-8a04-06358306d279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_cc3a93d9-1b96-434a-90ec-f831d5cc825c" xlink:href="sgry-20201231.xsd#sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet_cc3a93d9-1b96-434a-90ec-f831d5cc825c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e59f337d-8908-4c54-842a-929eb20cc469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e59f337d-8908-4c54-842a-929eb20cc469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_171be85d-f6b1-48bd-b3da-1cd34cdd192e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockholdersEquityOther_171be85d-f6b1-48bd-b3da-1cd34cdd192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39a50d85-2b49-4cca-9d49-6856671e15d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_39a50d85-2b49-4cca-9d49-6856671e15d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e37a9179-1fb6-47ca-9660-fd8bb0173be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0768519e-2382-425d-bf5d-f4da1f0aea6e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e37a9179-1fb6-47ca-9660-fd8bb0173be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_23c76c1d-8374-4eae-866b-fed3cedf5bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ebc01e26-21fe-46e5-bd04-ab500fb5ec6e" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_23c76c1d-8374-4eae-866b-fed3cedf5bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgry-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b3952553-fec5-46c5-870c-5159ca24c9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_258e13f3-e709-43c0-be54-cd0ef4d9fa79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b3952553-fec5-46c5-870c-5159ca24c9cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_258e13f3-e709-43c0-be54-cd0ef4d9fa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_582a5420-0a5c-477a-966e-1250f00d3062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_258e13f3-e709-43c0-be54-cd0ef4d9fa79" xlink:to="loc_us-gaap_ProfitLoss_582a5420-0a5c-477a-966e-1250f00d3062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_258e13f3-e709-43c0-be54-cd0ef4d9fa79" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_be15f3cb-0289-48ad-9304-d21180d73a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_be15f3cb-0289-48ad-9304-d21180d73a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NoncashInterestIncomeExpenseNet_468393bc-862c-47f5-87c2-dd8a1cfa9db9" xlink:href="sgry-20201231.xsd#sgry_NoncashInterestIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_sgry_NoncashInterestIncomeExpenseNet_468393bc-862c-47f5-87c2-dd8a1cfa9db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a5ee866e-aff9-4bb0-a9f6-e19470014fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_us-gaap_ShareBasedCompensation_a5ee866e-aff9-4bb0-a9f6-e19470014fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_192eb2e0-53dc-4c30-8cb5-0f480f7cac8d" xlink:href="sgry-20201231.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_192eb2e0-53dc-4c30-8cb5-0f480f7cac8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ebc7f5df-375c-4537-8cd7-54c7214bfe00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_us-gaap_AssetImpairmentCharges_ebc7f5df-375c-4537-8cd7-54c7214bfe00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2b51c0f8-3b21-424f-8d69-29198f0ed312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2b51c0f8-3b21-424f-8d69-29198f0ed312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e4b07cbd-a67f-427a-819c-4a5306e0aabf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e4b07cbd-a67f-427a-819c-4a5306e0aabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_63ffef9a-8f60-4065-a795-1713c96404e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_63ffef9a-8f60-4065-a795-1713c96404e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_b8ed1937-5306-4c72-8ae9-93e6f9f4a503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_us-gaap_OperatingLeaseExpense_b8ed1937-5306-4c72-8ae9-93e6f9f4a503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0fcfad6d-fe46-4af7-957d-f14a5dfa7a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59cbb579-1a37-4b24-a2b5-ebe6198d8a0d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0fcfad6d-fe46-4af7-957d-f14a5dfa7a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fad5be98-29f2-4cb4-895e-993371fdaaa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0fcfad6d-fe46-4af7-957d-f14a5dfa7a30" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fad5be98-29f2-4cb4-895e-993371fdaaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_7cf96fe4-fb55-486b-b624-3b9560becf17" xlink:href="sgry-20201231.xsd#sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0fcfad6d-fe46-4af7-957d-f14a5dfa7a30" xlink:to="loc_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants_7cf96fe4-fb55-486b-b624-3b9560becf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d87c313f-8eae-4f91-9e01-7d365659d2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0fcfad6d-fe46-4af7-957d-f14a5dfa7a30" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_d87c313f-8eae-4f91-9e01-7d365659d2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39239a43-8030-44c9-9eea-eca11c8b93e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_258e13f3-e709-43c0-be54-cd0ef4d9fa79" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39239a43-8030-44c9-9eea-eca11c8b93e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f24a5cc-4afb-45ec-a125-562a5d10a703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b3952553-fec5-46c5-870c-5159ca24c9cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f24a5cc-4afb-45ec-a125-562a5d10a703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_52e44817-e75a-46cc-907b-f70752c6d2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f24a5cc-4afb-45ec-a125-562a5d10a703" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_52e44817-e75a-46cc-907b-f70752c6d2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7a459d86-af17-444e-82ff-293aa2d762fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f24a5cc-4afb-45ec-a125-562a5d10a703" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7a459d86-af17-444e-82ff-293aa2d762fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_113f90a2-a164-4090-a532-6d5ff87a3ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f24a5cc-4afb-45ec-a125-562a5d10a703" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_113f90a2-a164-4090-a532-6d5ff87a3ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_a2663e69-38c9-4b3a-aa01-9eba713c5951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f24a5cc-4afb-45ec-a125-562a5d10a703" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_a2663e69-38c9-4b3a-aa01-9eba713c5951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2851acef-7c24-4561-9fb0-b8c1e3cd22ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f24a5cc-4afb-45ec-a125-562a5d10a703" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2851acef-7c24-4561-9fb0-b8c1e3cd22ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f0211c0-ae07-4011-8cb2-b1fb2e0ed300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9f24a5cc-4afb-45ec-a125-562a5d10a703" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f0211c0-ae07-4011-8cb2-b1fb2e0ed300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b3952553-fec5-46c5-870c-5159ca24c9cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c5aab449-0d2b-4ec3-8b39-d28949c3bd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c5aab449-0d2b-4ec3-8b39-d28949c3bd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b696b915-85ae-4dd1-ae27-46f2fed50549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b696b915-85ae-4dd1-ae27-46f2fed50549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a79d0566-64ce-4133-8e37-cca8c25e3cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a79d0566-64ce-4133-8e37-cca8c25e3cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentPrepaymentPenaltyAmount_8f8e6971-f3cd-4583-a763-52f00e242968" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentPrepaymentPenaltyAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_sgry_DebtInstrumentPrepaymentPenaltyAmount_8f8e6971-f3cd-4583-a763-52f00e242968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_59318dbb-07c2-4ca3-a053-f6d5cb43e85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_59318dbb-07c2-4ca3-a053-f6d5cb43e85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_c73d0f93-dc7d-446f-9264-8836d248f35d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_c73d0f93-dc7d-446f-9264-8836d248f35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_7032c7cb-761c-48b0-8068-4a5019035b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_7032c7cb-761c-48b0-8068-4a5019035b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7bb521f4-2234-4555-8059-01b0a316a08d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7bb521f4-2234-4555-8059-01b0a316a08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2049647f-63ac-4655-827b-f090a046eeee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2049647f-63ac-4655-827b-f090a046eeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcab54ca-c164-47e4-a229-87e27ca7f207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97c7177b-cbd0-474f-871a-705a2b7d4edd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bcab54ca-c164-47e4-a229-87e27ca7f207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_89d82a75-758f-46fa-be3d-328082be16a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b3952553-fec5-46c5-870c-5159ca24c9cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_89d82a75-758f-46fa-be3d-328082be16a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_556bc4d0-3bb4-487f-9ae3-dc24ca99b77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b3952553-fec5-46c5-870c-5159ca24c9cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_556bc4d0-3bb4-487f-9ae3-dc24ca99b77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9f4dc58-1a64-4445-af79-9a2806bcb1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b3952553-fec5-46c5-870c-5159ca24c9cb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9f4dc58-1a64-4445-af79-9a2806bcb1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9bc6791-2661-427b-b7d7-6f1d984e48e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b3952553-fec5-46c5-870c-5159ca24c9cb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9bc6791-2661-427b-b7d7-6f1d984e48e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_344bf951-701a-4bcb-a45e-f601e040a133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9bc6791-2661-427b-b7d7-6f1d984e48e0" xlink:to="loc_us-gaap_InterestPaidNet_344bf951-701a-4bcb-a45e-f601e040a133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_a81eb0bf-6a7a-4290-8119-6a01ad309cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9bc6791-2661-427b-b7d7-6f1d984e48e0" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_a81eb0bf-6a7a-4290-8119-6a01ad309cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_6af68bb7-6f3d-47a5-b63e-80b74d8b1bce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9bc6791-2661-427b-b7d7-6f1d984e48e0" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_6af68bb7-6f3d-47a5-b63e-80b74d8b1bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d84ca201-2a72-4785-81ff-dda74b9662b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_48fa2b38-5c25-4576-a3f0-3b4b39123690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d84ca201-2a72-4785-81ff-dda74b9662b0" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_48fa2b38-5c25-4576-a3f0-3b4b39123690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86dfb718-2f92-4bf7-b642-32c4ea605b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_86dfb718-2f92-4bf7-b642-32c4ea605b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d92a1162-1600-4d5e-9e3c-c490de15a726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d92a1162-1600-4d5e-9e3c-c490de15a726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_7b203bbe-e790-4abb-80ef-741844002545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_7b203bbe-e790-4abb-80ef-741844002545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5903d0e1-3cd5-4d98-9e68-4a8fc04712c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5903d0e1-3cd5-4d98-9e68-4a8fc04712c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5d8f1653-342a-42d3-9e39-7f742605ba4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5d8f1653-342a-42d3-9e39-7f742605ba4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_492c29de-7964-4f02-88a2-219a258dc626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_492c29de-7964-4f02-88a2-219a258dc626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_d368b0b4-4c75-489a-bb45-290911df40f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_d368b0b4-4c75-489a-bb45-290911df40f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_3da57da0-6af2-4063-b82f-8f28c92c7356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_3da57da0-6af2-4063-b82f-8f28c92c7356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_56091c5a-876e-4d53-9925-cdbea1c880d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_56091c5a-876e-4d53-9925-cdbea1c880d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_4411b13a-25ee-4150-9cdb-1985396ba44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_4411b13a-25ee-4150-9cdb-1985396ba44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_78674af2-1db1-4bc5-b1b1-4701f7b57701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_78674af2-1db1-4bc5-b1b1-4701f7b57701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_797f8000-6f72-4dc5-b349-4d47873248f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_797f8000-6f72-4dc5-b349-4d47873248f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_061071ec-4801-4573-992b-431d6cd0fbc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_061071ec-4801-4573-992b-431d6cd0fbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b1d3177e-400f-4eb7-bfe1-c411ae33a109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b1d3177e-400f-4eb7-bfe1-c411ae33a109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_3a29ce34-0003-498f-b585-6df5a4bad0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_3a29ce34-0003-498f-b585-6df5a4bad0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_afc23d49-344d-4fc3-b0b2-f0f75c7b61e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_afc23d49-344d-4fc3-b0b2-f0f75c7b61e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_65613cb1-c361-4f7b-b156-17f62d6ebb45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_65613cb1-c361-4f7b-b156-17f62d6ebb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_7151ef3e-fbea-474c-b8a0-a117a76a4aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_7151ef3e-fbea-474c-b8a0-a117a76a4aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_32897bcb-30af-45ad-9394-af8132fddd29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_32897bcb-30af-45ad-9394-af8132fddd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8baa7559-34b9-4690-9389-35efc3b9e4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_8baa7559-34b9-4690-9389-35efc3b9e4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_e80b7c2d-2493-4436-ab74-fa483e2b9ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4115d5eb-3e7a-4062-a489-af57c05088de" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_e80b7c2d-2493-4436-ab74-fa483e2b9ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d98ae394-e079-4dad-916c-4ab7706de80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_785ebb22-5014-4ac4-93fa-39b2ef360d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d98ae394-e079-4dad-916c-4ab7706de80b" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_785ebb22-5014-4ac4-93fa-39b2ef360d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_682a866a-9eaa-4571-82a0-aa3bec0276a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d98ae394-e079-4dad-916c-4ab7706de80b" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_682a866a-9eaa-4571-82a0-aa3bec0276a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8d94d6a8-4be4-40eb-81c9-0e2a9590bceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d98ae394-e079-4dad-916c-4ab7706de80b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8d94d6a8-4be4-40eb-81c9-0e2a9590bceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_15c2dc28-0cd7-4b1a-9fe9-87cd13935dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d98ae394-e079-4dad-916c-4ab7706de80b" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_15c2dc28-0cd7-4b1a-9fe9-87cd13935dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9b02458-50ec-4040-a7b3-2ecdf2c03cc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9b02458-50ec-4040-a7b3-2ecdf2c03cc5" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e649ac98-12ed-4fe6-ba7d-fd034997aa93" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:to="loc_dei_LegalEntityAxis_e649ac98-12ed-4fe6-ba7d-fd034997aa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a9ea24e0-8ab1-424c-929b-c8d99eac7e16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e649ac98-12ed-4fe6-ba7d-fd034997aa93" xlink:to="loc_dei_EntityDomain_a9ea24e0-8ab1-424c-929b-c8d99eac7e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BainCapitalMember_fe7bfcfc-e383-4d70-a6f6-4bf23b6e5d3e" xlink:href="sgry-20201231.xsd#sgry_BainCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a9ea24e0-8ab1-424c-929b-c8d99eac7e16" xlink:to="loc_sgry_BainCapitalMember_fe7bfcfc-e383-4d70-a6f6-4bf23b6e5d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c321086f-ff14-42f2-9362-4fb29db195f6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:to="loc_srt_OwnershipAxis_c321086f-ff14-42f2-9362-4fb29db195f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d6a963e4-6899-4765-8f18-f021905730a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_c321086f-ff14-42f2-9362-4fb29db195f6" xlink:to="loc_srt_OwnershipDomain_d6a963e4-6899-4765-8f18-f021905730a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgeryPartnersIncMember_a5f2d7d0-9e21-4f97-83d2-d15517d54ec6" xlink:href="sgry-20201231.xsd#sgry_SurgeryPartnersIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_d6a963e4-6899-4765-8f18-f021905730a9" xlink:to="loc_sgry_SurgeryPartnersIncMember_a5f2d7d0-9e21-4f97-83d2-d15517d54ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d83d3429-86b6-4d6c-928d-b41e06779d34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:to="loc_srt_ProductOrServiceAxis_d83d3429-86b6-4d6c-928d-b41e06779d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6478d044-64db-44ee-9abc-fec13b9e366a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d83d3429-86b6-4d6c-928d-b41e06779d34" xlink:to="loc_srt_ProductsAndServicesDomain_6478d044-64db-44ee-9abc-fec13b9e366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_4929d547-83c1-47b1-b5ce-945f244d0ffd" xlink:href="sgry-20201231.xsd#sgry_FacilitiesAmbulatorySurgeryCentersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6478d044-64db-44ee-9abc-fec13b9e366a" xlink:to="loc_sgry_FacilitiesAmbulatorySurgeryCentersMember_4929d547-83c1-47b1-b5ce-945f244d0ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FacilitiesSurgicalHospitalsMember_4a271bfa-01ff-404a-b0c4-9a6527f36bb5" xlink:href="sgry-20201231.xsd#sgry_FacilitiesSurgicalHospitalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6478d044-64db-44ee-9abc-fec13b9e366a" xlink:to="loc_sgry_FacilitiesSurgicalHospitalsMember_4a271bfa-01ff-404a-b0c4-9a6527f36bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_04d163c3-0176-487f-aca4-fbef0cad94ff" xlink:to="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_a83c6ae1-a32e-4d8d-bd57-12a195bb00af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_a83c6ae1-a32e-4d8d-bd57-12a195bb00af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_85e2c136-e5a6-4a47-ad69-dfda9407f20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_85e2c136-e5a6-4a47-ad69-dfda9407f20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwned_c0eb86b0-e93d-404d-9d7a-1eb9f0afa71d" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwned_c0eb86b0-e93d-404d-9d7a-1eb9f0afa71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_37b0342a-5a4d-4e9c-bd02-b3e5815ccfc7" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest_37b0342a-5a4d-4e9c-bd02-b3e5815ccfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_0563791a-c3a5-4d29-ab0a-96e87d7a686b" xlink:href="sgry-20201231.xsd#sgry_NumberOfSurgicalFacilitiesOwnedConsolidated"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_fecd77da-ddd8-4342-8950-6f6039194e04" xlink:to="loc_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated_0563791a-c3a5-4d29-ab0a-96e87d7a686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesCARESACTDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07e7d519-8691-4e6c-8ada-477816317b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ProceedsFromGovernmentAssistance_6aab06c4-c34a-4ec8-b719-aaea10220f71" xlink:href="sgry-20201231.xsd#sgry_ProceedsFromGovernmentAssistance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07e7d519-8691-4e6c-8ada-477816317b43" xlink:to="loc_sgry_ProceedsFromGovernmentAssistance_6aab06c4-c34a-4ec8-b719-aaea10220f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GrantRevenue_761857b0-4d2c-4c20-aae7-2baff16372f9" xlink:href="sgry-20201231.xsd#sgry_GrantRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07e7d519-8691-4e6c-8ada-477816317b43" xlink:to="loc_sgry_GrantRevenue_761857b0-4d2c-4c20-aae7-2baff16372f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_d0f4052a-e57e-4ab7-b519-3e32222ae104" xlink:href="sgry-20201231.xsd#sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07e7d519-8691-4e6c-8ada-477816317b43" xlink:to="loc_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments_d0f4052a-e57e-4ab7-b519-3e32222ae104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent_ff542202-09b4-43c7-9121-ddaeec21826f" xlink:href="sgry-20201231.xsd#sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07e7d519-8691-4e6c-8ada-477816317b43" xlink:to="loc_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent_ff542202-09b4-43c7-9121-ddaeec21826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_e29fff75-1394-4849-9d8e-f11da1f84b8d" xlink:href="sgry-20201231.xsd#sgry_DeferredEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07e7d519-8691-4e6c-8ada-477816317b43" xlink:to="loc_sgry_DeferredEmployeeRelatedLiabilitiesCurrent_e29fff75-1394-4849-9d8e-f11da1f84b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_157fb067-df82-4d58-b9a4-072fbdd803b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_57c140f2-b2fb-46bf-b477-6c514aa8c22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_157fb067-df82-4d58-b9a4-072fbdd803b5" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_57c140f2-b2fb-46bf-b477-6c514aa8c22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7678f8a6-6d40-4d89-9c1c-592d681c0502" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_57c140f2-b2fb-46bf-b477-6c514aa8c22c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7678f8a6-6d40-4d89-9c1c-592d681c0502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_79db10c7-f82c-4834-9b45-4e7f09cbacd6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7678f8a6-6d40-4d89-9c1c-592d681c0502" xlink:to="loc_srt_ConsolidatedEntitiesDomain_79db10c7-f82c-4834-9b45-4e7f09cbacd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_baf0ce54-572f-4a7a-8e68-ea9bcb7a37a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_79db10c7-f82c-4834-9b45-4e7f09cbacd6" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_baf0ce54-572f-4a7a-8e68-ea9bcb7a37a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_57c140f2-b2fb-46bf-b477-6c514aa8c22c" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableInterestEntityNumberOfFacilities_68332382-d75c-4c1b-9bc6-41046af9db01" xlink:href="sgry-20201231.xsd#sgry_VariableInterestEntityNumberOfFacilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:to="loc_sgry_VariableInterestEntityNumberOfFacilities_68332382-d75c-4c1b-9bc6-41046af9db01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_204cbf7a-bcdf-4b4d-9265-ddf742983e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:to="loc_us-gaap_Assets_204cbf7a-bcdf-4b4d-9265-ddf742983e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_68c436d3-9b03-4b6f-946a-3e7e816be618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a8bd1c88-b728-46db-a340-ec99a3181f4d" xlink:to="loc_us-gaap_Liabilities_68c436d3-9b03-4b6f-946a-3e7e816be618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3abac331-8aa3-4473-a56e-c350fb66c5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3abac331-8aa3-4473-a56e-c350fb66c5ae" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d3c86f3-6a96-4da8-8637-17d49f759318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d3c86f3-6a96-4da8-8637-17d49f759318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d3c86f3-6a96-4da8-8637-17d49f759318" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_34b74470-174c-4f3e-bb2d-f6ba37139ae0" xlink:href="sgry-20201231.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_34b74470-174c-4f3e-bb2d-f6ba37139ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_87293f13-fdaa-415c-95ef-6d685f0e44be" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_87293f13-fdaa-415c-95ef-6d685f0e44be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_0dfc9ed4-50dc-407a-871a-45e5a8a2b6ec" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b34d9a1a-ac5d-4d27-abd3-f18c088c1c76" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_0dfc9ed4-50dc-407a-871a-45e5a8a2b6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ff744a09-514a-469b-abe2-95f318b7f999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ff744a09-514a-469b-abe2-95f318b7f999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8a9171d3-b737-4815-b128-9509f10c30cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ff744a09-514a-469b-abe2-95f318b7f999" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8a9171d3-b737-4815-b128-9509f10c30cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a55a7dc5-9677-4487-a56e-af83db532806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8a9171d3-b737-4815-b128-9509f10c30cd" xlink:to="loc_us-gaap_SecuredDebtMember_a55a7dc5-9677-4487-a56e-af83db532806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5d8c5963-e99b-47ad-a7e8-3c7016d27dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8a9171d3-b737-4815-b128-9509f10c30cd" xlink:to="loc_us-gaap_SeniorNotesMember_5d8c5963-e99b-47ad-a7e8-3c7016d27dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9b51c2a4-ad79-482e-b801-14fe1819df2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9b51c2a4-ad79-482e-b801-14fe1819df2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_af963438-dc5d-4901-8127-d634f196371a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9b51c2a4-ad79-482e-b801-14fe1819df2a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_af963438-dc5d-4901-8127-d634f196371a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e36c982-4ca6-4343-a7a6-a155bad5c1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_af963438-dc5d-4901-8127-d634f196371a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e36c982-4ca6-4343-a7a6-a155bad5c1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dda4f1d4-a364-4d45-9a6b-b141defa8f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e36c982-4ca6-4343-a7a6-a155bad5c1a6" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dda4f1d4-a364-4d45-9a6b-b141defa8f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b97bc984-e2dc-4bca-8327-c885510369e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_0e36c982-4ca6-4343-a7a6-a155bad5c1a6" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b97bc984-e2dc-4bca-8327-c885510369e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128096c3-4014-444a-b8cc-cbf47b8c8e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128096c3-4014-444a-b8cc-cbf47b8c8e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8949fb1-5485-4670-8f23-f630851e0e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_128096c3-4014-444a-b8cc-cbf47b8c8e18" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8949fb1-5485-4670-8f23-f630851e0e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e22ecc3c-c364-421d-8e94-09f54e4e7c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8949fb1-5485-4670-8f23-f630851e0e83" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e22ecc3c-c364-421d-8e94-09f54e4e7c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7974602b-5d4b-4f4c-8d60-ac3f4b60f11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_33b71dc7-d3f0-45e7-a2b2-1a3309fa898a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7974602b-5d4b-4f4c-8d60-ac3f4b60f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ed9c46ac-0eb7-40d6-9e82-c7902e9e7ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7974602b-5d4b-4f4c-8d60-ac3f4b60f11e" xlink:to="loc_us-gaap_LongTermDebt_ed9c46ac-0eb7-40d6-9e82-c7902e9e7ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_388f6dc2-26d2-44fa-ab4e-31a269709c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7974602b-5d4b-4f4c-8d60-ac3f4b60f11e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_388f6dc2-26d2-44fa-ab4e-31a269709c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_022795f1-e43d-497b-8950-cdad65e8ad65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f27e9f67-ef0f-4c00-8d07-45deab05c10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_022795f1-e43d-497b-8950-cdad65e8ad65" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f27e9f67-ef0f-4c00-8d07-45deab05c10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_79f5dd89-1704-4c4b-8c9f-699cadd97aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_79f5dd89-1704-4c4b-8c9f-699cadd97aaf" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_94b41091-3689-443f-b062-c02a45b4d420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_94b41091-3689-443f-b062-c02a45b4d420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_97e23d4e-80a3-4968-ae8e-512a4534c781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_94b41091-3689-443f-b062-c02a45b4d420" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_97e23d4e-80a3-4968-ae8e-512a4534c781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_b43b68b5-9598-49ae-b651-281e93a41749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_97e23d4e-80a3-4968-ae8e-512a4534c781" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_b43b68b5-9598-49ae-b651-281e93a41749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_970e790f-21de-4e0d-8529-1f76167f271e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_970e790f-21de-4e0d-8529-1f76167f271e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8067443f-2486-4f83-ad6e-04da02baf933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_970e790f-21de-4e0d-8529-1f76167f271e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8067443f-2486-4f83-ad6e-04da02baf933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f37568e6-4ab0-4259-ba2c-b7b383d0d19f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8067443f-2486-4f83-ad6e-04da02baf933" xlink:to="loc_us-gaap_SalesRevenueNetMember_f37568e6-4ab0-4259-ba2c-b7b383d0d19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0ef47a6f-ca46-4522-94dd-9199b0e7ed26" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:to="loc_srt_ProductOrServiceAxis_0ef47a6f-ca46-4522-94dd-9199b0e7ed26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5daac4c-f790-4f14-877e-22f53e75d189" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0ef47a6f-ca46-4522-94dd-9199b0e7ed26" xlink:to="loc_srt_ProductsAndServicesDomain_c5daac4c-f790-4f14-877e-22f53e75d189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_2e9f220f-3251-4236-8cc9-caa79d911841" xlink:href="sgry-20201231.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5daac4c-f790-4f14-877e-22f53e75d189" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_2e9f220f-3251-4236-8cc9-caa79d911841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_d9e68f50-daeb-460c-b92e-644981d4ddb5" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2e9f220f-3251-4236-8cc9-caa79d911841" xlink:to="loc_sgry_SurgicalFacilityServicesMember_d9e68f50-daeb-460c-b92e-644981d4ddb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_5b784230-080b-4bc4-a05c-fae40245359a" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2e9f220f-3251-4236-8cc9-caa79d911841" xlink:to="loc_sgry_AncillaryServicesMember_5b784230-080b-4bc4-a05c-fae40245359a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationOtherServiceMember_354884b4-6d3f-477b-ab45-c4b37caa591d" xlink:href="sgry-20201231.xsd#sgry_HealthcareOrganizationOtherServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5daac4c-f790-4f14-877e-22f53e75d189" xlink:to="loc_sgry_HealthcareOrganizationOtherServiceMember_354884b4-6d3f-477b-ab45-c4b37caa591d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember_cc3d72a0-542b-4ab2-85f0-51d73857f44e" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationOtherServiceMember_354884b4-6d3f-477b-ab45-c4b37caa591d" xlink:to="loc_sgry_OpticalServicesMember_cc3d72a0-542b-4ab2-85f0-51d73857f44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_47743767-72bd-4ac0-bbad-06327039b4c7" xlink:href="sgry-20201231.xsd#sgry_OtherServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationOtherServiceMember_354884b4-6d3f-477b-ab45-c4b37caa591d" xlink:to="loc_sgry_OtherServicesMember_47743767-72bd-4ac0-bbad-06327039b4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aff415fc-d160-4d35-87ef-99d39cc78021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_617071b3-cb82-45dd-b08e-1c58f7e981fc" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aff415fc-d160-4d35-87ef-99d39cc78021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b15a2c08-7e92-49e2-b4be-33fb0fa3da8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aff415fc-d160-4d35-87ef-99d39cc78021" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b15a2c08-7e92-49e2-b4be-33fb0fa3da8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e4686ef-fde0-442a-8fd3-008429c48083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e4686ef-fde0-442a-8fd3-008429c48083" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7db2699b-72a1-477a-86d1-16eba0b94818" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:to="loc_srt_ProductOrServiceAxis_7db2699b-72a1-477a-86d1-16eba0b94818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7db2699b-72a1-477a-86d1-16eba0b94818" xlink:to="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:href="sgry-20201231.xsd#sgry_HealthcareOrganizationPatientServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:to="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PrivateInsuranceMember_03608f68-0ee4-4a0b-a251-759cbf725dac" xlink:href="sgry-20201231.xsd#sgry_PrivateInsuranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:to="loc_sgry_PrivateInsuranceMember_03608f68-0ee4-4a0b-a251-759cbf725dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GovernmentRevenueMember_a5187875-cf36-4afb-8e05-9c45daa9cf49" xlink:href="sgry-20201231.xsd#sgry_GovernmentRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:to="loc_sgry_GovernmentRevenueMember_a5187875-cf36-4afb-8e05-9c45daa9cf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SelfPayRevenueMember_4ed419ce-2785-4ee3-bb6d-700b43c64fe9" xlink:href="sgry-20201231.xsd#sgry_SelfPayRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:to="loc_sgry_SelfPayRevenueMember_4ed419ce-2785-4ee3-bb6d-700b43c64fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherPatientServiceRevenueSourcesMember_5ba08611-2e92-4888-bd82-399e162ad673" xlink:href="sgry-20201231.xsd#sgry_OtherPatientServiceRevenueSourcesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_HealthcareOrganizationPatientServiceMember_2ca6f74e-fb40-4658-962b-b46934f4f9f6" xlink:to="loc_sgry_OtherPatientServiceRevenueSourcesMember_5ba08611-2e92-4888-bd82-399e162ad673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember_0e2e36d5-5438-4a53-9d0f-893d160042b5" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:to="loc_sgry_OpticalServicesMember_0e2e36d5-5438-4a53-9d0f-893d160042b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OtherServicesMember_457264b8-b08e-4465-b1f4-1d703c2610a1" xlink:href="sgry-20201231.xsd#sgry_OtherServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0634c62-de4e-4f3c-ba33-6c6a15a2163d" xlink:to="loc_sgry_OtherServicesMember_457264b8-b08e-4465-b1f4-1d703c2610a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6fee9595-9b66-4202-83d4-d65d44b99024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6fee9595-9b66-4202-83d4-d65d44b99024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_78d368c5-a708-4184-b3b5-3e60684f2436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6fee9595-9b66-4202-83d4-d65d44b99024" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_78d368c5-a708-4184-b3b5-3e60684f2436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a303758d-949d-4d0f-9f3c-9de63f196964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_78d368c5-a708-4184-b3b5-3e60684f2436" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a303758d-949d-4d0f-9f3c-9de63f196964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_062e82ac-1633-4d15-9878-537becc3bfb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_062e82ac-1633-4d15-9878-537becc3bfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8269da6f-b9de-4d8a-b513-9ae026c3650a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_062e82ac-1633-4d15-9878-537becc3bfb2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8269da6f-b9de-4d8a-b513-9ae026c3650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_798797f7-a63c-47ce-9d64-075bb0ac67a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8269da6f-b9de-4d8a-b513-9ae026c3650a" xlink:to="loc_us-gaap_SalesRevenueNetMember_798797f7-a63c-47ce-9d64-075bb0ac67a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cd6fa3b5-e9f7-4f4f-ae22-f315584107a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7f6a8b99-4271-4ff5-aeb4-73a3d287092e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_cd6fa3b5-e9f7-4f4f-ae22-f315584107a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4fba583b-54fe-4323-b57e-44c7f7d23c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cd6fa3b5-e9f7-4f4f-ae22-f315584107a0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4fba583b-54fe-4323-b57e-44c7f7d23c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2fdc823a-938f-4170-8e5e-cb60d75f62dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cd6fa3b5-e9f7-4f4f-ae22-f315584107a0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2fdc823a-938f-4170-8e5e-cb60d75f62dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4cc24f1-6946-4daa-8307-3cc3b008418f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c6d364de-c4f4-418e-bd6d-4e4a9a857fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4cc24f1-6946-4daa-8307-3cc3b008418f" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c6d364de-c4f4-418e-bd6d-4e4a9a857fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41c6c581-aa02-4980-928d-26e965f3c513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalProductsReceivable_c6341483-0d4f-4cb7-a979-d24f545348bd" xlink:href="sgry-20201231.xsd#sgry_OpticalProductsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41c6c581-aa02-4980-928d-26e965f3c513" xlink:to="loc_sgry_OpticalProductsReceivable_c6341483-0d4f-4cb7-a979-d24f545348bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce0747e0-8d54-49c3-ab01-bef05edc6d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestRollForward_99e1672a-5f19-4d26-ba0f-b72db6f294e1" xlink:href="sgry-20201231.xsd#sgry_RedeemableNoncontrollingInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce0747e0-8d54-49c3-ab01-bef05edc6d1f" xlink:to="loc_sgry_RedeemableNoncontrollingInterestRollForward_99e1672a-5f19-4d26-ba0f-b72db6f294e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_56ccfa1b-ec40-4dfa-ba70-7c2ff101ef82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_99e1672a-5f19-4d26-ba0f-b72db6f294e1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_56ccfa1b-ec40-4dfa-ba70-7c2ff101ef82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_fd78a227-86fb-4e76-8509-c8430754e987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_99e1672a-5f19-4d26-ba0f-b72db6f294e1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_fd78a227-86fb-4e76-8509-c8430754e987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_521b4424-c736-4542-97f9-3d9273d8b583" xlink:href="sgry-20201231.xsd#sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_99e1672a-5f19-4d26-ba0f-b72db6f294e1" xlink:to="loc_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests_521b4424-c736-4542-97f9-3d9273d8b583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c01612da-ef69-4376-aef3-b62d707a2054" xlink:href="sgry-20201231.xsd#sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_99e1672a-5f19-4d26-ba0f-b72db6f294e1" xlink:to="loc_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c01612da-ef69-4376-aef3-b62d707a2054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2e66536b-1706-4323-81b8-9823b4e376c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RedeemableNoncontrollingInterestRollForward_99e1672a-5f19-4d26-ba0f-b72db6f294e1" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2e66536b-1706-4323-81b8-9823b4e376c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a1abfa0-6193-4b86-8ce3-7be39113df74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a1abfa0-6193-4b86-8ce3-7be39113df74" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_946bf139-d8f7-4482-b787-ab11ba08c2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e33abd3-45ec-42e3-8b9f-9865b0c8abb5" xlink:to="loc_us-gaap_EquityComponentDomain_946bf139-d8f7-4482-b787-ab11ba08c2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f0c4b724-0be1-4326-8d3a-587774391a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_946bf139-d8f7-4482-b787-ab11ba08c2fe" xlink:to="loc_us-gaap_RetainedEarningsMember_f0c4b724-0be1-4326-8d3a-587774391a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_387a2257-1727-4715-8140-9fedcb70a209" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_387a2257-1727-4715-8140-9fedcb70a209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1ea98012-1346-4ae0-9687-a5a579e26ae7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_387a2257-1727-4715-8140-9fedcb70a209" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1ea98012-1346-4ae0-9687-a5a579e26ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_573582cf-1aea-4eac-b1d5-9bbc101f2a0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_1ea98012-1346-4ae0-9687-a5a579e26ae7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_573582cf-1aea-4eac-b1d5-9bbc101f2a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2227daa9-6056-4cc9-9631-8948f6687e5d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_baacc28d-7eea-4de0-9062-46740a0cc640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:to="loc_us-gaap_OperatingLeaseLiability_baacc28d-7eea-4de0-9062-46740a0cc640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c6531d9-61b5-4b1f-85e0-ac86f8bad6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2c6531d9-61b5-4b1f-85e0-ac86f8bad6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_040ea733-6065-48ce-b087-b060b9f29a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1e141dd0-3f61-41e2-a7bf-7470c980ee42" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_040ea733-6065-48ce-b087-b060b9f29a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposals"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationsAndDisposalsAbstract_6096f72e-38a8-46f3-ab08-c1925e41ff44" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationsAndDisposalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock_a506c4eb-f975-4921-870c-cef003c87149" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_BusinessCombinationsAndDisposalsAbstract_6096f72e-38a8-46f3-ab08-c1925e41ff44" xlink:to="loc_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock_a506c4eb-f975-4921-870c-cef003c87149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationsAndDisposalsAbstract_64881818-1576-4a96-afef-afd63705890b" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationsAndDisposalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e381ba3a-addd-487c-9d9f-c3c01c5a1beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_BusinessCombinationsAndDisposalsAbstract_64881818-1576-4a96-afef-afd63705890b" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e381ba3a-addd-487c-9d9f-c3c01c5a1beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationsAndDisposalsAbstract_c05002e5-4314-4925-a573-955ea45cdb8b" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationsAndDisposalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_BusinessCombinationsAndDisposalsAbstract_c05002e5-4314-4925-a573-955ea45cdb8b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bd92bc3b-501b-4683-af80-7f0830f0ae8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bd92bc3b-501b-4683-af80-7f0830f0ae8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19846d40-a496-42d3-8754-504a2bacb79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bd92bc3b-501b-4683-af80-7f0830f0ae8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19846d40-a496-42d3-8754-504a2bacb79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityAndPhysicianPracticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19846d40-a496-42d3-8754-504a2bacb79e" xlink:to="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesNewMarketMember_19f61d81-e045-464e-b3dc-29d692afb7a8" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilitiesNewMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:to="loc_sgry_SurgicalFacilitiesNewMarketMember_19f61d81-e045-464e-b3dc-29d692afb7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilitiesExistingMarketsMember_cb94a57c-73dd-4e9e-8a7f-96a0a8484912" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilitiesExistingMarketsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:to="loc_sgry_SurgicalFacilitiesExistingMarketsMember_cb94a57c-73dd-4e9e-8a7f-96a0a8484912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PhysicianPracticeMember_6404ce85-0375-430f-894e-e26397291107" xlink:href="sgry-20201231.xsd#sgry_PhysicianPracticeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_37c223d2-196c-47cb-b5f5-9de4d9f2ab23" xlink:to="loc_sgry_PhysicianPracticeMember_6404ce85-0375-430f-894e-e26397291107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f43ab81b-485b-41b9-810f-d7a7f33acbd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:to="loc_srt_RestatementAxis_f43ab81b-485b-41b9-810f-d7a7f33acbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_10a06efc-420f-45a6-bd13-0e541bd33acc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_f43ab81b-485b-41b9-810f-d7a7f33acbd5" xlink:to="loc_srt_RestatementDomain_10a06efc-420f-45a6-bd13-0e541bd33acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_271e80f9-1862-4fab-a28c-935ed7c847ab" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_10a06efc-420f-45a6-bd13-0e541bd33acc" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_271e80f9-1862-4fab-a28c-935ed7c847ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1695cfb-d95f-45e1-abaf-cc2d6fab7aa8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_e640367b-aff7-47de-8742-07ebfd2071d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_e640367b-aff7-47de-8742-07ebfd2071d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d933c29-31aa-49bf-9bfe-5b6f47fcda06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d933c29-31aa-49bf-9bfe-5b6f47fcda06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f4bfa86-8376-4498-a0ff-69fc78cb2d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f4bfa86-8376-4498-a0ff-69fc78cb2d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_14af2114-b026-432e-8876-42e9f5b56c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_14af2114-b026-432e-8876-42e9f5b56c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b62b1c21-375d-4a2d-8690-8f1d4b853ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b62b1c21-375d-4a2d-8690-8f1d4b853ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments_81c45bd4-9b4e-431e-80b8-5f6b004185fe" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments_81c45bd4-9b4e-431e-80b8-5f6b004185fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired_774b5678-cfd5-4d27-83e2-e7f85b5f7096" xlink:href="sgry-20201231.xsd#sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired_774b5678-cfd5-4d27-83e2-e7f85b5f7096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e268a54f-1eda-46af-8de7-976ce1d29cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8e92403-3f0e-48ca-aa34-a75be547be9f" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e268a54f-1eda-46af-8de7-976ce1d29cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationsAndDisposalsAbstract_cae87ae6-d235-409b-a737-8edf7c3791e7" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationsAndDisposalsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d694830-0dea-4fd8-a3a7-f323789365e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_BusinessCombinationsAndDisposalsAbstract_cae87ae6-d235-409b-a737-8edf7c3791e7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d694830-0dea-4fd8-a3a7-f323789365e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bbfbd7aa-18a9-4d0a-930c-9816824729de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d694830-0dea-4fd8-a3a7-f323789365e9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bbfbd7aa-18a9-4d0a-930c-9816824729de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e4788c0-fb50-429d-b422-78bb3ca6a477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bbfbd7aa-18a9-4d0a-930c-9816824729de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e4788c0-fb50-429d-b422-78bb3ca6a477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_074011a3-9251-46a1-a4b6-fda9e32cd767" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityAndPhysicianPracticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e4788c0-fb50-429d-b422-78bb3ca6a477" xlink:to="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_074011a3-9251-46a1-a4b6-fda9e32cd767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityMember_e41ee9c2-baa2-4112-b4a3-c9468d806e0e" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_SurgicalFacilityAndPhysicianPracticeMember_074011a3-9251-46a1-a4b6-fda9e32cd767" xlink:to="loc_sgry_SurgicalFacilityMember_e41ee9c2-baa2-4112-b4a3-c9468d806e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d694830-0dea-4fd8-a3a7-f323789365e9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_768d8703-c498-4bb4-aec8-2f79ff7fd88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_768d8703-c498-4bb4-aec8-2f79ff7fd88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_953d55d5-989b-4d24-bc25-913ca8d7d31e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_953d55d5-989b-4d24-bc25-913ca8d7d31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_d8f2e7af-02e6-4ca9-b6f5-fdda0ff910e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_d8f2e7af-02e6-4ca9-b6f5-fdda0ff910e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_aac85a2e-38e7-49d6-b9a4-b4ea11f90bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_aac85a2e-38e7-49d6-b9a4-b4ea11f90bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_441acec9-26de-4443-8aef-8b88cae4e718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_441acec9-26de-4443-8aef-8b88cae4e718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cde9d51d-0482-4829-9762-e156098fe668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cde9d51d-0482-4829-9762-e156098fe668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05968d71-fff5-49d4-8849-2c8cedf67813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_Goodwill_05968d71-fff5-49d4-8849-2c8cedf67813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_413bc9bb-7c57-4526-b59b-bff2b0f9cccb" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset_413bc9bb-7c57-4526-b59b-bff2b0f9cccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_6a1196ef-a7e2-451f-a72a-9448b525fbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_6a1196ef-a7e2-451f-a72a-9448b525fbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_d7c3438e-db23-4251-907d-efc8e48003fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_d7c3438e-db23-4251-907d-efc8e48003fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9f54a889-59ca-47f3-9c6d-f1808e351fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_9f54a889-59ca-47f3-9c6d-f1808e351fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_5ae70a73-5489-4542-9294-03fe95de8f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_5ae70a73-5489-4542-9294-03fe95de8f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9e1af46f-7315-40d4-9392-b2b134ae58b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_8e99f8af-2397-4eb8-9f1c-84a39d027ea4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9e1af46f-7315-40d4-9392-b2b134ae58b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_4c66a225-63f8-4a4d-acf6-2abdd4a896cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31620fb6-0098-435e-a386-a69e05fa048a" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_4c66a225-63f8-4a4d-acf6-2abdd4a896cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#AcquisitionsandDisposalsDisposalsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_a51676e8-310d-405c-aec4-a5fa3ffe446e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_da87ea40-9623-4420-addc-9c02820ef220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_a51676e8-310d-405c-aec4-a5fa3ffe446e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_da87ea40-9623-4420-addc-9c02820ef220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d8311373-80fa-43f8-a2d7-f1d3027147a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_da87ea40-9623-4420-addc-9c02820ef220" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d8311373-80fa-43f8-a2d7-f1d3027147a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d8311373-80fa-43f8-a2d7-f1d3027147a3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupOneMember_9c26ed41-7a20-4296-8087-70f1931fbf67" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:to="loc_sgry_DisposalGroupOneMember_9c26ed41-7a20-4296-8087-70f1931fbf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupTwoMember_71c8aabb-cc5e-487e-91d5-310b3fe14df8" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:to="loc_sgry_DisposalGroupTwoMember_71c8aabb-cc5e-487e-91d5-310b3fe14df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupThreeMember_e94329e0-a00d-4bd8-9cb3-a1102abc4069" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:to="loc_sgry_DisposalGroupThreeMember_e94329e0-a00d-4bd8-9cb3-a1102abc4069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupFourMember_366a84f5-9132-428b-a4d3-8bde6135e427" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7337f167-b104-4528-b671-41f968f6e878" xlink:to="loc_sgry_DisposalGroupFourMember_366a84f5-9132-428b-a4d3-8bde6135e427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_da87ea40-9623-4420-addc-9c02820ef220" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed_23fc4b5c-b7a7-43f3-b271-6b4ff543f30a" xlink:href="sgry-20201231.xsd#sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:to="loc_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed_23fc4b5c-b7a7-43f3-b271-6b4ff543f30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_13e02d1b-363b-4214-87b2-1600ac0fe357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_13e02d1b-363b-4214-87b2-1600ac0fe357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_07c138f3-316d-4421-81f7-0d4602c8ccb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f9faa3cc-976a-4dd6-880b-6aeca176f4c8" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_07c138f3-316d-4421-81f7-0d4602c8ccb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fbc28c17-5525-471a-bd59-0b113b8dad1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f5eb9a13-1f51-4a0e-baf2-2acfd45df154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fbc28c17-5525-471a-bd59-0b113b8dad1c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f5eb9a13-1f51-4a0e-baf2-2acfd45df154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e55b3dc6-adcd-4207-b256-84fe93146fdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_272c0cdc-95bd-485f-9674-8c39e2836180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e55b3dc6-adcd-4207-b256-84fe93146fdb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_272c0cdc-95bd-485f-9674-8c39e2836180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c3e530ab-b19e-4532-82d2-90a433c105a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c3e530ab-b19e-4532-82d2-90a433c105a6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f820d84-8919-4c90-943f-4d09876143b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f820d84-8919-4c90-943f-4d09876143b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3f820d84-8919-4c90-943f-4d09876143b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_baab4627-94a1-4b2a-afd9-3961c7b80868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_baab4627-94a1-4b2a-afd9-3961c7b80868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_9f0ad756-f984-4fd4-915c-024e8cd1cd4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:to="loc_us-gaap_ComputerEquipmentMember_9f0ad756-f984-4fd4-915c-024e8cd1cd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FurnitureAndEquipmentMember_125fcc7a-d3b6-4873-82cf-ed106f52a8ac" xlink:href="sgry-20201231.xsd#sgry_FurnitureAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e105676d-50e0-40b6-8108-d323cd14fd13" xlink:to="loc_sgry_FurnitureAndEquipmentMember_125fcc7a-d3b6-4873-82cf-ed106f52a8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_59b1af37-9702-4736-a861-dfde478661a1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:to="loc_srt_RangeAxis_59b1af37-9702-4736-a861-dfde478661a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92700c41-3ca2-431e-9f0f-de0083ce30dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_59b1af37-9702-4736-a861-dfde478661a1" xlink:to="loc_srt_RangeMember_92700c41-3ca2-431e-9f0f-de0083ce30dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7852b819-0077-4b26-a5e8-6e68560359b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92700c41-3ca2-431e-9f0f-de0083ce30dd" xlink:to="loc_srt_MinimumMember_7852b819-0077-4b26-a5e8-6e68560359b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f056d8bc-ba16-4b1e-adfa-926da10e8d2c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92700c41-3ca2-431e-9f0f-de0083ce30dd" xlink:to="loc_srt_MaximumMember_f056d8bc-ba16-4b1e-adfa-926da10e8d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6c89987b-a7fb-4402-bf4f-1e316585af46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2d4dea05-6af8-4893-a224-1936afc73645" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6c89987b-a7fb-4402-bf4f-1e316585af46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6a15c0f5-aa15-4129-9a55-30808a57aab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6c89987b-a7fb-4402-bf4f-1e316585af46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6a15c0f5-aa15-4129-9a55-30808a57aab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0b0a82b1-aa26-43f1-b45c-aa284ba1d89e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6c89987b-a7fb-4402-bf4f-1e316585af46" xlink:to="loc_us-gaap_Depreciation_0b0a82b1-aa26-43f1-b45c-aa284ba1d89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86e99bcf-359e-4ae8-9f5c-68c1224533e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a936a0b-23fa-4d36-aae2-058adf6f2713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86e99bcf-359e-4ae8-9f5c-68c1224533e4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a936a0b-23fa-4d36-aae2-058adf6f2713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a22b7724-f9ae-4bd7-941c-561206b6a790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a936a0b-23fa-4d36-aae2-058adf6f2713" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a22b7724-f9ae-4bd7-941c-561206b6a790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a22b7724-f9ae-4bd7-941c-561206b6a790" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_a142b072-495a-40fd-8e4d-bc6fedd2916b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_us-gaap_LandMember_a142b072-495a-40fd-8e4d-bc6fedd2916b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_2c0ba4c4-f93b-4f7e-b7a4-ae40a096432c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_2c0ba4c4-f93b-4f7e-b7a4-ae40a096432c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FurnitureAndEquipmentMember_081bb032-4c8b-4374-9932-1c462f5f2eeb" xlink:href="sgry-20201231.xsd#sgry_FurnitureAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_sgry_FurnitureAndEquipmentMember_081bb032-4c8b-4374-9932-1c462f5f2eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_857f81a6-83a0-47d8-bb13-8314bab1bafa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_us-gaap_ComputerEquipmentMember_857f81a6-83a0-47d8-bb13-8314bab1bafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MedicalEquipmentMember_50aad415-909c-4a3f-8097-b4c7a9b140d7" xlink:href="sgry-20201231.xsd#sgry_MedicalEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_sgry_MedicalEquipmentMember_50aad415-909c-4a3f-8097-b4c7a9b140d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ba317cc5-ebfc-45e9-a704-41688b737f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca15c411-7275-4fbe-a1d7-7f1eff39dd3f" xlink:to="loc_us-gaap_ConstructionInProgressMember_ba317cc5-ebfc-45e9-a704-41688b737f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a936a0b-23fa-4d36-aae2-058adf6f2713" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b078c632-019d-4b55-9c19-df3821f0c61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b078c632-019d-4b55-9c19-df3821f0c61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_f4992036-a021-400d-9a93-490d6f14cfda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_f4992036-a021-400d-9a93-490d6f14cfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_d5b1f205-4ba7-48cf-8777-b4f318e812a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_d5b1f205-4ba7-48cf-8777-b4f318e812a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_415474fe-333b-422a-98d7-28dcea2d8170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_415474fe-333b-422a-98d7-28dcea2d8170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5af68d2b-8b71-42dd-8626-ef27924942d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_edd203b2-9a96-4814-9edf-b3ba8ea0c58a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5af68d2b-8b71-42dd-8626-ef27924942d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1cc9a4d9-97e0-49f3-8886-1a758f6c92ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0f52b7a2-52c5-4ca3-8958-bf6ac8b32c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1cc9a4d9-97e0-49f3-8886-1a758f6c92ab" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0f52b7a2-52c5-4ca3-8958-bf6ac8b32c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e7b880f-5664-4d93-9a49-5554de797686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_ac3bd5e1-bff3-4203-baca-715d378e3eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e7b880f-5664-4d93-9a49-5554de797686" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_ac3bd5e1-bff3-4203-baca-715d378e3eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8a41bc39-8ab8-41a2-9000-b3e9eb97f1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e7b880f-5664-4d93-9a49-5554de797686" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_8a41bc39-8ab8-41a2-9000-b3e9eb97f1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_220e5dc8-934f-4c1a-b63d-207e331ff50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e7b880f-5664-4d93-9a49-5554de797686" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_220e5dc8-934f-4c1a-b63d-207e331ff50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_9532a0c5-441f-4368-a58b-a684ed574835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e7b880f-5664-4d93-9a49-5554de797686" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_9532a0c5-441f-4368-a58b-a684ed574835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b098537d-5cda-4e85-b572-66a20082ec68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b098537d-5cda-4e85-b572-66a20082ec68" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_dd2bb774-93f7-48cd-afaf-7028847e01ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:to="loc_us-gaap_ReportingUnitAxis_dd2bb774-93f7-48cd-afaf-7028847e01ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_dd2bb774-93f7-48cd-afaf-7028847e01ac" xlink:to="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_e6816bb6-e959-4f8e-aefc-9554afe41610" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:to="loc_sgry_SurgicalFacilityServicesMember_e6816bb6-e959-4f8e-aefc-9554afe41610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_6ffdd225-efef-44ad-b0b6-c8125152384a" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:to="loc_sgry_AncillaryServicesMember_6ffdd225-efef-44ad-b0b6-c8125152384a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AllianceMember_af3d9e82-e4cc-4772-8517-dfdc3c684523" xlink:href="sgry-20201231.xsd#sgry_AllianceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_08c226c9-6a04-4984-8ae5-1a15a2ecd862" xlink:to="loc_sgry_AllianceMember_af3d9e82-e4cc-4772-8517-dfdc3c684523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85e01ef5-2ffe-46de-975f-fded1eaceff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85e01ef5-2ffe-46de-975f-fded1eaceff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85e01ef5-2ffe-46de-975f-fded1eaceff6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PhysicianIncomeGuaranteesMember_21927d9c-7de5-40bc-a3e4-c91aca25187d" xlink:href="sgry-20201231.xsd#sgry_PhysicianIncomeGuaranteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:to="loc_sgry_PhysicianIncomeGuaranteesMember_21927d9c-7de5-40bc-a3e4-c91aca25187d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_87ffb88f-c44e-4df3-8a71-4a91ab212465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_87ffb88f-c44e-4df3-8a71-4a91ab212465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ManagementRightsMember_15c28061-f5df-43de-902d-db672f2b3ca9" xlink:href="sgry-20201231.xsd#sgry_ManagementRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:to="loc_sgry_ManagementRightsMember_15c28061-f5df-43de-902d-db672f2b3ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_68a0bfea-30a1-4f22-8fc4-5f55a967c663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2268e7aa-fbc4-4b29-9b10-92a697cd1eff" xlink:to="loc_us-gaap_CustomerRelationshipsMember_68a0bfea-30a1-4f22-8fc4-5f55a967c663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_89db6f33-8595-4eea-b517-1072e4d67d37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:to="loc_srt_RangeAxis_89db6f33-8595-4eea-b517-1072e4d67d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cf7a7d5-c702-423c-baeb-61f19699b4b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_89db6f33-8595-4eea-b517-1072e4d67d37" xlink:to="loc_srt_RangeMember_4cf7a7d5-c702-423c-baeb-61f19699b4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ec407a81-19d8-4dbb-96d6-f725c3b9ea9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4cf7a7d5-c702-423c-baeb-61f19699b4b8" xlink:to="loc_srt_MinimumMember_ec407a81-19d8-4dbb-96d6-f725c3b9ea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3fa4dab0-c460-49e3-97b1-466cf5a1e19d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4cf7a7d5-c702-423c-baeb-61f19699b4b8" xlink:to="loc_srt_MaximumMember_3fa4dab0-c460-49e3-97b1-466cf5a1e19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_faba8b3e-db65-4ab4-87e8-f6270b83f11e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_29ab5690-ed11-4f0a-aaa5-311096b6d974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_29ab5690-ed11-4f0a-aaa5-311096b6d974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_26da5c72-0f72-4ddd-a725-60782363633a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_NumberOfReportingUnits_26da5c72-0f72-4ddd-a725-60782363633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_735d9fe1-d561-416c-8897-b58c8d270ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_735d9fe1-d561-416c-8897-b58c8d270ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_78cd61b1-dc27-4a29-9713-013172313dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_Goodwill_78cd61b1-dc27-4a29-9713-013172313dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f52c87a4-61c8-4731-b5d4-d748970a6f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c8deaa97-57ba-44b8-aaa6-ae436dc59549" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f52c87a4-61c8-4731-b5d4-d748970a6f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_53d0824d-90a7-4919-91f5-fac2e8087237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_a27cb6aa-3f12-4bb0-8fcf-af28c304f442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_53d0824d-90a7-4919-91f5-fac2e8087237" xlink:to="loc_us-gaap_GoodwillRollForward_a27cb6aa-3f12-4bb0-8fcf-af28c304f442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_03bbd3ab-2e7c-47f1-8343-f82a2c3c93f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a27cb6aa-3f12-4bb0-8fcf-af28c304f442" xlink:to="loc_us-gaap_Goodwill_03bbd3ab-2e7c-47f1-8343-f82a2c3c93f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_9d432971-0546-486d-8ce3-c41a37884a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a27cb6aa-3f12-4bb0-8fcf-af28c304f442" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_9d432971-0546-486d-8ce3-c41a37884a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations_9f1f6277-9b8f-4e76-ba67-800f9f406337" xlink:href="sgry-20201231.xsd#sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a27cb6aa-3f12-4bb0-8fcf-af28c304f442" xlink:to="loc_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations_9f1f6277-9b8f-4e76-ba67-800f9f406337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_833b9fba-b556-41da-9a29-667a4aa17ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a27cb6aa-3f12-4bb0-8fcf-af28c304f442" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_833b9fba-b556-41da-9a29-667a4aa17ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2032d959-4f9e-4b5d-9d15-c3c956193eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a27cb6aa-3f12-4bb0-8fcf-af28c304f442" xlink:to="loc_us-gaap_Goodwill_2032d959-4f9e-4b5d-9d15-c3c956193eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21ffe9a6-0134-4048-bf0d-1d0174c94a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ba96b6cc-b8fb-4be2-842b-dc80b704e146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21ffe9a6-0134-4048-bf0d-1d0174c94a54" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ba96b6cc-b8fb-4be2-842b-dc80b704e146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70a4dc08-6cf2-489f-bdd5-cbde01467602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ba96b6cc-b8fb-4be2-842b-dc80b704e146" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70a4dc08-6cf2-489f-bdd5-cbde01467602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ce5a073-50db-4952-ba08-c60ecbafb759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70a4dc08-6cf2-489f-bdd5-cbde01467602" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ce5a073-50db-4952-ba08-c60ecbafb759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ManagementRightsMember_e1385857-2dd0-4728-bc80-68630faf4b0a" xlink:href="sgry-20201231.xsd#sgry_ManagementRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ce5a073-50db-4952-ba08-c60ecbafb759" xlink:to="loc_sgry_ManagementRightsMember_e1385857-2dd0-4728-bc80-68630faf4b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_2fcdbaf1-b539-4b18-8448-a3cb4bd18f24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ce5a073-50db-4952-ba08-c60ecbafb759" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_2fcdbaf1-b539-4b18-8448-a3cb4bd18f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ba96b6cc-b8fb-4be2-842b-dc80b704e146" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f77f1d49-c878-47a5-be25-73c6382af8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f77f1d49-c878-47a5-be25-73c6382af8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ba4c1cfb-cace-4e02-965c-173c4addd272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ba4c1cfb-cace-4e02-965c-173c4addd272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0cd4420b-d0fe-48a8-818d-cb5da15266b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0cd4420b-d0fe-48a8-818d-cb5da15266b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4268eef4-3c7b-4222-baa8-e7553e9e3198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4268eef4-3c7b-4222-baa8-e7553e9e3198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c78340dc-b1e5-482d-abb7-273f99c208d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c78340dc-b1e5-482d-abb7-273f99c208d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9d19062-99bb-4372-8164-69bdefd623e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9930c00a-8f86-42c9-9490-8b5c1e7e1334" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9d19062-99bb-4372-8164-69bdefd623e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf868a2-e021-40d8-9bf3-c1512481a702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_da3f1210-2ea7-4440-af45-9ad952cee7e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf868a2-e021-40d8-9bf3-c1512481a702" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_da3f1210-2ea7-4440-af45-9ad952cee7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a9fe33d6-47c6-4eb3-8df0-8b5f1d25f199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf868a2-e021-40d8-9bf3-c1512481a702" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a9fe33d6-47c6-4eb3-8df0-8b5f1d25f199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b39f47f8-181c-4043-a084-1fd969c0d570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf868a2-e021-40d8-9bf3-c1512481a702" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b39f47f8-181c-4043-a084-1fd969c0d570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_14c35597-cba1-43a8-9aea-d12abf27dcea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf868a2-e021-40d8-9bf3-c1512481a702" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_14c35597-cba1-43a8-9aea-d12abf27dcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_dc85dce2-11ab-4409-b3cb-94b4b7208fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf868a2-e021-40d8-9bf3-c1512481a702" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_dc85dce2-11ab-4409-b3cb-94b4b7208fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8028d99e-93e8-444f-9a98-07d5da6d8a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf868a2-e021-40d8-9bf3-c1512481a702" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8028d99e-93e8-444f-9a98-07d5da6d8a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_beff7267-56e0-4a71-a2d4-17d183f10ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf868a2-e021-40d8-9bf3-c1512481a702" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_beff7267-56e0-4a71-a2d4-17d183f10ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_59c527cf-79e4-4184-862b-965d923aa9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_dff7e196-8371-43f5-8a16-644c7a8fbe12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_59c527cf-79e4-4184-862b-965d923aa9af" xlink:to="loc_us-gaap_LongTermDebtTextBlock_dff7e196-8371-43f5-8a16-644c7a8fbe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_da240db1-a0c3-4bae-bad2-fa281f7624f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0c8e2057-9889-468b-9006-08e6a7ef034f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_da240db1-a0c3-4bae-bad2-fa281f7624f4" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_0c8e2057-9889-468b-9006-08e6a7ef034f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock_1715abdf-86d1-457e-bd90-01896024e08d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_da240db1-a0c3-4bae-bad2-fa281f7624f4" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock_1715abdf-86d1-457e-bd90-01896024e08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c29ed299-44e8-484f-9ce1-72c32c57cd2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_da240db1-a0c3-4bae-bad2-fa281f7624f4" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c29ed299-44e8-484f-9ce1-72c32c57cd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_142bab8e-03ba-46e4-9f0f-5f4aae5fcb97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_142bab8e-03ba-46e4-9f0f-5f4aae5fcb97" xlink:to="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3531bc37-6013-4447-8230-40f64fa5c17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:to="loc_us-gaap_DebtInstrumentAxis_3531bc37-6013-4447-8230-40f64fa5c17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3531bc37-6013-4447-8230-40f64fa5c17e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_1fa718bf-268c-4f57-a91d-83779e99f1bc" xlink:href="sgry-20201231.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_1fa718bf-268c-4f57-a91d-83779e99f1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_142908f6-cef3-48e2-a34a-a95f2ae97998" xlink:href="sgry-20201231.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_142908f6-cef3-48e2-a34a-a95f2ae97998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_282f04f6-99bb-4374-a6bb-60ae32ad96c0" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_282f04f6-99bb-4374-a6bb-60ae32ad96c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_acfc5a69-ae88-43b5-97e0-0e163403f33c" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b42a3a2-af67-4ba9-a48a-9e06fc7e469e" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_acfc5a69-ae88-43b5-97e0-0e163403f33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_69d6d71a-5415-4133-8100-9c5e6ac55342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_69d6d71a-5415-4133-8100-9c5e6ac55342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_69d6d71a-5415-4133-8100-9c5e6ac55342" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_067ccb3a-f477-4bdf-b272-bd0ab1b7cd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:to="loc_us-gaap_SecuredDebtMember_067ccb3a-f477-4bdf-b272-bd0ab1b7cd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_57a062c2-b9d5-406c-bf7b-f5d40f0d963b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:to="loc_us-gaap_SeniorNotesMember_57a062c2-b9d5-406c-bf7b-f5d40f0d963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotesPayableAndSecuredLoansMember_636ee599-5204-49cf-b5bd-7448f2514960" xlink:href="sgry-20201231.xsd#sgry_NotesPayableAndSecuredLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b98a781a-ae49-403b-9727-dbe613afd2ea" xlink:to="loc_sgry_NotesPayableAndSecuredLoansMember_636ee599-5204-49cf-b5bd-7448f2514960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b05ea35-d8f6-480d-85c7-fea6f0a927bb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_65d30e7a-93f8-41d3-9804-e23bb526dbf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_65d30e7a-93f8-41d3-9804-e23bb526dbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_88a83604-679f-4ab9-859e-0d9a62dec88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_FinanceLeaseLiability_88a83604-679f-4ab9-859e-0d9a62dec88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_962acf35-515a-44d9-950c-93bf31f559d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_962acf35-515a-44d9-950c-93bf31f559d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_83f74132-db68-472e-a88d-40032c482629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_83f74132-db68-472e-a88d-40032c482629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_3fbf9fd2-ba24-45ac-8f8e-871dc90c2de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_3fbf9fd2-ba24-45ac-8f8e-871dc90c2de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f4901abd-1ea1-4a0b-a81b-7e9af67d48e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_f4901abd-1ea1-4a0b-a81b-7e9af67d48e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_092a81ee-bf02-484c-9033-a906e1ff0af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_092a81ee-bf02-484c-9033-a906e1ff0af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_023b62d6-0510-41d3-8368-5690d52dc4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0a48fcb2-e56d-42d6-8614-4ee3ce916426" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_023b62d6-0510-41d3-8368-5690d52dc4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails_1" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSummaryofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_83e1add6-bdc4-413f-9bfa-614f4b8b0506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_83e1add6-bdc4-413f-9bfa-614f4b8b0506" xlink:to="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8a333b5b-14db-4bbb-9d23-9a03925261d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_srt_RangeAxis_8a333b5b-14db-4bbb-9d23-9a03925261d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a5909d9-7433-44ec-a92a-4cf08c76903e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8a333b5b-14db-4bbb-9d23-9a03925261d1" xlink:to="loc_srt_RangeMember_1a5909d9-7433-44ec-a92a-4cf08c76903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c45c951f-72f4-4c96-9405-6ba78f21ba7a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1a5909d9-7433-44ec-a92a-4cf08c76903e" xlink:to="loc_srt_MinimumMember_c45c951f-72f4-4c96-9405-6ba78f21ba7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_01641763-a53c-4989-a2e4-a69678abca0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1a5909d9-7433-44ec-a92a-4cf08c76903e" xlink:to="loc_srt_MaximumMember_01641763-a53c-4989-a2e4-a69678abca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ffa10824-1b0e-4360-9746-41cef5561c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_VariableRateAxis_ffa10824-1b0e-4360-9746-41cef5561c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_ffa10824-1b0e-4360-9746-41cef5561c34" xlink:to="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f55abaf7-d6a4-4973-8c04-70c40e48d328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_f55abaf7-d6a4-4973-8c04-70c40e48d328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_7ae9dc7b-e8f1-42b7-b0ff-4dbc4f3e46a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_7ae9dc7b-e8f1-42b7-b0ff-4dbc4f3e46a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OneMonthLondonInterbankOfferedRateLIBORMember_ca462c73-47aa-4e93-ae16-84056a89988c" xlink:href="sgry-20201231.xsd#sgry_OneMonthLondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:to="loc_sgry_OneMonthLondonInterbankOfferedRateLIBORMember_ca462c73-47aa-4e93-ae16-84056a89988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_dd08cb77-b8fc-44ed-8b15-bee13dd632a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_5cacc238-1dbf-4005-973c-f79d5a0b9093" xlink:to="loc_us-gaap_BaseRateMember_dd08cb77-b8fc-44ed-8b15-bee13dd632a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_274ed1e7-f314-4a58-b205-449cdaa3e95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_DebtInstrumentAxis_274ed1e7-f314-4a58-b205-449cdaa3e95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_274ed1e7-f314-4a58-b205-449cdaa3e95a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017TermLoanMaturing2024Member_0c3d01b5-23b5-4234-87d4-0a6c3be0d023" xlink:href="sgry-20201231.xsd#sgry_A2017TermLoanMaturing2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:to="loc_sgry_A2017TermLoanMaturing2024Member_0c3d01b5-23b5-4234-87d4-0a6c3be0d023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_c5e22a23-670d-47d4-b875-ff8962a4c80f" xlink:href="sgry-20201231.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_c5e22a23-670d-47d4-b875-ff8962a4c80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2018IncrementalTermLoanMember_3344df7f-d56a-46a5-94f5-12abd29e55bd" xlink:href="sgry-20201231.xsd#sgry_A2018IncrementalTermLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:to="loc_sgry_A2018IncrementalTermLoanMember_3344df7f-d56a-46a5-94f5-12abd29e55bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2020IncrementalLoansMember_257ae333-f7af-43d1-bc17-76d4dde1f210" xlink:href="sgry-20201231.xsd#sgry_A2020IncrementalLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4dd6554c-89e2-454c-9a70-6d67a0aa8dc8" xlink:to="loc_sgry_A2020IncrementalLoansMember_257ae333-f7af-43d1-bc17-76d4dde1f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b76ff3a2-61b3-4fa9-b81d-8f901109f26b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b76ff3a2-61b3-4fa9-b81d-8f901109f26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ebf44236-f4c2-4ef3-874e-436ade717486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b76ff3a2-61b3-4fa9-b81d-8f901109f26b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ebf44236-f4c2-4ef3-874e-436ade717486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_51092cbd-3d8a-43d8-8d64-c1d67538a72a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ebf44236-f4c2-4ef3-874e-436ade717486" xlink:to="loc_us-gaap_SecuredDebtMember_51092cbd-3d8a-43d8-8d64-c1d67538a72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_23dabcfb-d190-4040-9eab-7e3cc78f1845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_CreditFacilityAxis_23dabcfb-d190-4040-9eab-7e3cc78f1845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6354e33f-e834-4296-9bf0-f845819903d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_23dabcfb-d190-4040-9eab-7e3cc78f1845" xlink:to="loc_us-gaap_CreditFacilityDomain_6354e33f-e834-4296-9bf0-f845819903d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_86ecec8b-0897-4bd6-b36e-ac146d619c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_6354e33f-e834-4296-9bf0-f845819903d8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_86ecec8b-0897-4bd6-b36e-ac146d619c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_89506a71-5b71-484b-87dd-c61ec92b27ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_6354e33f-e834-4296-9bf0-f845819903d8" xlink:to="loc_us-gaap_LetterOfCreditMember_89506a71-5b71-484b-87dd-c61ec92b27ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41e9bff2-5ed0-45a2-8868-9f97f26c21c0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e56b24de-c0ef-4a00-a191-d508f3b58ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e56b24de-c0ef-4a00-a191-d508f3b58ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_d7644462-cf6c-4b77-8314-d26c1fe36a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_LineOfCredit_d7644462-cf6c-4b77-8314-d26c1fe36a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_61e139f8-ba8b-4d4b-94fc-b562b6fdd18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_61e139f8-ba8b-4d4b-94fc-b562b6fdd18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_da33e8dc-ab61-4b11-8e6b-3824c2649db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_da33e8dc-ab61-4b11-8e6b-3824c2649db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentMarginInAdditionToBaseRate_e55a6903-1365-4338-a20f-f1713b191ae8" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentMarginInAdditionToBaseRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentMarginInAdditionToBaseRate_e55a6903-1365-4338-a20f-f1713b191ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_ba1b2f0e-85e7-4fbf-8f3c-83cb814dce92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_ba1b2f0e-85e7-4fbf-8f3c-83cb814dce92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentQuarterlyMaturityInstallments_2a58f9fe-f6ce-479e-b1be-95365d095c1f" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentQuarterlyMaturityInstallments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentQuarterlyMaturityInstallments_2a58f9fe-f6ce-479e-b1be-95365d095c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9b2993bc-8313-4d71-a3e4-260ad34be30c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9b2993bc-8313-4d71-a3e4-260ad34be30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentAlternateBaseRateFloor_205512c5-cf7c-45aa-a80a-46151539e552" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentAlternateBaseRateFloor"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentAlternateBaseRateFloor_205512c5-cf7c-45aa-a80a-46151539e552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentNetLeverageRatio_97d69a32-b650-4f17-8e75-87b7cedcaf5e" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentNetLeverageRatio"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentNetLeverageRatio_97d69a32-b650-4f17-8e75-87b7cedcaf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentTotalCommitmentThreshold_330d8849-08ec-433e-ac66-f8c538218b76" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentTotalCommitmentThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_sgry_DebtInstrumentTotalCommitmentThreshold_330d8849-08ec-433e-ac66-f8c538218b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eeb4e12-4342-46c7-9852-00e70a0e8733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_faf6f11f-7be0-47da-9dce-878cd2174347" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0eeb4e12-4342-46c7-9852-00e70a0e8733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt6750SeniorUnsecuredNotesdue2025Details"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6cf7b46-f2d4-4094-b1d6-8dd9d0ea3fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6cf7b46-f2d4-4094-b1d6-8dd9d0ea3fdf" xlink:to="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_811fc86d-9396-4adb-b4c8-26b072a7e224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_828f0384-9ec2-40d3-85eb-f6ae2f7a8b01" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_811fc86d-9396-4adb-b4c8-26b072a7e224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_84df6eb9-c4be-4d84-a431-d402fec52234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_811fc86d-9396-4adb-b4c8-26b072a7e224" xlink:to="loc_us-gaap_SeniorNotesMember_84df6eb9-c4be-4d84-a431-d402fec52234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_76bffb6f-25c1-4963-ad70-8d9805a4f502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:to="loc_us-gaap_DebtInstrumentAxis_76bffb6f-25c1-4963-ad70-8d9805a4f502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65a3c6fb-394c-4670-bce5-0480edbe06bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_76bffb6f-25c1-4963-ad70-8d9805a4f502" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65a3c6fb-394c-4670-bce5-0480edbe06bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2025Member_d3ec229e-1351-4686-a93b-b33678cae19f" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65a3c6fb-394c-4670-bce5-0480edbe06bf" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2025Member_d3ec229e-1351-4686-a93b-b33678cae19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c275acd6-87d9-4f32-a9dd-c28c7b63012e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c275acd6-87d9-4f32-a9dd-c28c7b63012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c275acd6-87d9-4f32-a9dd-c28c7b63012e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_81f5a3e9-475a-4bbb-9a9f-c27140206e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_81f5a3e9-475a-4bbb-9a9f-c27140206e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_0854a5e4-1bd0-4731-8953-107baf9885c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_0854a5e4-1bd0-4731-8953-107baf9885c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_57b6029f-0ed3-487d-9f26-5fc5bd00afee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_57b6029f-0ed3-487d-9f26-5fc5bd00afee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3a8e6309-ee47-4fc2-84e7-9ad19931e7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_164a6db8-5caf-4f59-8bc1-f1ab0602b76d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_3a8e6309-ee47-4fc2-84e7-9ad19931e7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_57a8c3ec-2bfb-4576-ab8c-933b9dc53fc5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13d2a488-5b7a-462b-96fe-ad7e18328d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13d2a488-5b7a-462b-96fe-ad7e18328d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_49ac70d2-77d4-4224-b806-26d0f6036781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_49ac70d2-77d4-4224-b806-26d0f6036781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3330ad7b-cbdf-456b-807c-8fbe0423b37d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7f9740e-6ac1-4d80-8c17-b867afd62ece" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3330ad7b-cbdf-456b-807c-8fbe0423b37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebt10000SeniorUnsecuredNotesdue2027Details"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_04599461-3840-40bf-93b1-f2b49a2d35fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_04599461-3840-40bf-93b1-f2b49a2d35fc" xlink:to="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c661b7a8-0f69-4693-aa47-1d94174f6ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_27b09d15-ac5b-4880-8f8d-53ca2a9e98aa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c661b7a8-0f69-4693-aa47-1d94174f6ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_65bc6197-0ea2-43ae-8167-a4f0045063e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c661b7a8-0f69-4693-aa47-1d94174f6ea7" xlink:to="loc_us-gaap_SeniorNotesMember_65bc6197-0ea2-43ae-8167-a4f0045063e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9335e6cc-9b26-4728-b803-ab3380a2eadb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:to="loc_us-gaap_DebtInstrumentAxis_9335e6cc-9b26-4728-b803-ab3380a2eadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a6bb033c-3775-463d-9b5e-f3d97135fa67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9335e6cc-9b26-4728-b803-ab3380a2eadb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a6bb033c-3775-463d-9b5e-f3d97135fa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SeniorUnsecuredNotesDue2027Member_15e6e1fb-65ad-48c3-8b01-b8a56e0358f9" xlink:href="sgry-20201231.xsd#sgry_SeniorUnsecuredNotesDue2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a6bb033c-3775-463d-9b5e-f3d97135fa67" xlink:to="loc_sgry_SeniorUnsecuredNotesDue2027Member_15e6e1fb-65ad-48c3-8b01-b8a56e0358f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_008f755e-38a6-452e-a6a8-7a53b70c923e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_008f755e-38a6-452e-a6a8-7a53b70c923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_008f755e-38a6-452e-a6a8-7a53b70c923e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b45482d7-f14a-47fe-8d43-514975665b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b45482d7-f14a-47fe-8d43-514975665b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ea988795-05be-4e44-aa5b-721d62886742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ea988795-05be-4e44-aa5b-721d62886742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_0c53c406-ae7c-4a64-b9af-e6d637fb59c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_0c53c406-ae7c-4a64-b9af-e6d637fb59c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_1d7ecbaf-25f2-41c8-ba6b-c5ad1643b54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_1d7ecbaf-25f2-41c8-ba6b-c5ad1643b54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_e07c27fe-f31e-4d28-9d40-1607f9fea91c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFiveMember_e07c27fe-f31e-4d28-9d40-1607f9fea91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DebtInstrumentRedemptionPeriodSixMember_9947e6bf-b1da-4343-88f4-9f7bf1be95df" xlink:href="sgry-20201231.xsd#sgry_DebtInstrumentRedemptionPeriodSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_1c2467bc-3e09-4ff1-837f-70c8c7c22501" xlink:to="loc_sgry_DebtInstrumentRedemptionPeriodSixMember_9947e6bf-b1da-4343-88f4-9f7bf1be95df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_efa3fcca-4e1f-49c7-87a3-fa8eae9ed9ef" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_96823670-e361-425f-98fc-cb62fca61423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_96823670-e361-425f-98fc-cb62fca61423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a8a0a5a8-288a-4e2f-b386-319a0c2bcc92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a8a0a5a8-288a-4e2f-b386-319a0c2bcc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e553af7f-c21d-47bf-96b9-877476d4b766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e553af7f-c21d-47bf-96b9-877476d4b766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3df2a622-2b40-4cb2-adab-7b0a8d4c650f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3df2a622-2b40-4cb2-adab-7b0a8d4c650f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_12db6b6c-fb3a-42c3-abb8-02f6aedc6485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_12db6b6c-fb3a-42c3-abb8-02f6aedc6485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d99ed368-d36c-4950-a128-0cbd75e58ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ac5cd14-e167-46e5-b185-b5fd84dd2969" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d99ed368-d36c-4950-a128-0cbd75e58ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_837c5e29-8536-4cc2-9223-ef80fc0d817c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5cb15d42-eee1-44b1-b880-bcd818ee2c91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_837c5e29-8536-4cc2-9223-ef80fc0d817c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5cb15d42-eee1-44b1-b880-bcd818ee2c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_262f9032-1b9f-4cd1-ab5d-ddcc7a003e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_837c5e29-8536-4cc2-9223-ef80fc0d817c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_262f9032-1b9f-4cd1-ab5d-ddcc7a003e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4031e61a-d8e3-4454-89bb-00768effe0bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_837c5e29-8536-4cc2-9223-ef80fc0d817c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4031e61a-d8e3-4454-89bb-00768effe0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_18dd088a-bd3a-470b-9fd0-4862a55cad60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_837c5e29-8536-4cc2-9223-ef80fc0d817c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_18dd088a-bd3a-470b-9fd0-4862a55cad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ebbb2aa2-eb9a-48e9-9c27-26651321e7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_837c5e29-8536-4cc2-9223-ef80fc0d817c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ebbb2aa2-eb9a-48e9-9c27-26651321e7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_cf9536ef-43ba-42a3-8faf-9f5019a2c023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_837c5e29-8536-4cc2-9223-ef80fc0d817c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_cf9536ef-43ba-42a3-8faf-9f5019a2c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1fb8cee5-1645-4d84-9e7f-12aa475c21a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_837c5e29-8536-4cc2-9223-ef80fc0d817c" xlink:to="loc_us-gaap_LongTermDebt_1fb8cee5-1645-4d84-9e7f-12aa475c21a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/Leases" xlink:type="simple" xlink:href="sgry-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0bc568bb-fe4b-4936-90a9-0b88b6ae058c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_a41f635b-a6ce-40bc-ba79-bf1e11510bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0bc568bb-fe4b-4936-90a9-0b88b6ae058c" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_a41f635b-a6ce-40bc-ba79-bf1e11510bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ff1b227c-acbe-41c3-bef4-1d0bf31b0a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0bc568bb-fe4b-4936-90a9-0b88b6ae058c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ff1b227c-acbe-41c3-bef4-1d0bf31b0a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2bb89365-e493-4c7c-ac5a-e1ac9703d988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_620ef180-8aa9-44d5-b5e0-571a44971471" xlink:href="sgry-20201231.xsd#sgry_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2bb89365-e493-4c7c-ac5a-e1ac9703d988" xlink:to="loc_sgry_AssetsAndLiabilitiesLesseeTableTextBlock_620ef180-8aa9-44d5-b5e0-571a44971471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_bd91909b-7285-416d-aee2-8166a12a7795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2bb89365-e493-4c7c-ac5a-e1ac9703d988" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_bd91909b-7285-416d-aee2-8166a12a7795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c24cec5e-1cc2-4605-b5a3-134c22c85612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2bb89365-e493-4c7c-ac5a-e1ac9703d988" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c24cec5e-1cc2-4605-b5a3-134c22c85612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_26a50320-0b6f-4286-9eb3-36d11992ec9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2bb89365-e493-4c7c-ac5a-e1ac9703d988" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_26a50320-0b6f-4286-9eb3-36d11992ec9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_e7f89ad4-cb9f-4576-91b8-aee455f6cf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_e7f89ad4-cb9f-4576-91b8-aee455f6cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew_7f719d2a-4cb6-4f86-9a0c-f1f9292ba3f6" xlink:href="sgry-20201231.xsd#sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew_7f719d2a-4cb6-4f86-9a0c-f1f9292ba3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_dd0b2c74-6ffd-4bb8-8e1f-96bcabc8d9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_dd0b2c74-6ffd-4bb8-8e1f-96bcabc8d9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_f3b690ca-1caf-4a28-8c07-6d50624cc88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_dd0b2c74-6ffd-4bb8-8e1f-96bcabc8d9c9" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_f3b690ca-1caf-4a28-8c07-6d50624cc88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_8e619691-d29b-4b9d-a562-1d04183d0a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_f3b690ca-1caf-4a28-8c07-6d50624cc88f" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_8e619691-d29b-4b9d-a562-1d04183d0a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_COVID19PandemicMember_47a38339-9079-4b58-a27e-5c816097e977" xlink:href="sgry-20201231.xsd#sgry_COVID19PandemicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_8e619691-d29b-4b9d-a562-1d04183d0a21" xlink:to="loc_sgry_COVID19PandemicMember_47a38339-9079-4b58-a27e-5c816097e977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_9463fa85-9572-4dbd-b0e8-75de1b7be8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_dd0b2c74-6ffd-4bb8-8e1f-96bcabc8d9c9" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_9463fa85-9572-4dbd-b0e8-75de1b7be8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cc8dee20-a35a-411c-be6f-35c10304d4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_9463fa85-9572-4dbd-b0e8-75de1b7be8c2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cc8dee20-a35a-411c-be6f-35c10304d4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d117bb48-3dad-452d-807e-c7bff51605d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_us-gaap_AssetsAbstract_d117bb48-3dad-452d-807e-c7bff51605d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_66c64fe3-4945-459d-8eb1-4a7452b0247b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d117bb48-3dad-452d-807e-c7bff51605d6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_66c64fe3-4945-459d-8eb1-4a7452b0247b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_2a850a83-8a32-4f16-be72-3ef48749f556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d117bb48-3dad-452d-807e-c7bff51605d6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_2a850a83-8a32-4f16-be72-3ef48749f556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_ae72d3c9-e051-4a8a-9209-cd9a3b0c619b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d117bb48-3dad-452d-807e-c7bff51605d6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_ae72d3c9-e051-4a8a-9209-cd9a3b0c619b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseRightOfUseAsset_2f0891ab-75cd-4edc-9917-b413570fe4f8" xlink:href="sgry-20201231.xsd#sgry_LeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d117bb48-3dad-452d-807e-c7bff51605d6" xlink:to="loc_sgry_LeaseRightOfUseAsset_2f0891ab-75cd-4edc-9917-b413570fe4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_2654f1ce-21c0-4ea2-a2ec-7ddab01d69b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_us-gaap_LiabilitiesAbstract_2654f1ce-21c0-4ea2-a2ec-7ddab01d69b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_aada7852-7d9c-4bd5-8170-b0580bc1c145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2654f1ce-21c0-4ea2-a2ec-7ddab01d69b5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_aada7852-7d9c-4bd5-8170-b0580bc1c145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b50561d1-7047-4364-a61e-31b5aeae0883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_aada7852-7d9c-4bd5-8170-b0580bc1c145" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b50561d1-7047-4364-a61e-31b5aeae0883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d75931c-c5ff-40a0-8a42-7ec6c212a16a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_aada7852-7d9c-4bd5-8170-b0580bc1c145" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d75931c-c5ff-40a0-8a42-7ec6c212a16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8aa0678f-cac9-43c4-87bc-7410e90607ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_aada7852-7d9c-4bd5-8170-b0580bc1c145" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8aa0678f-cac9-43c4-87bc-7410e90607ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_00ac1991-7faa-4b9a-99b3-ff7b0c47d80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_aada7852-7d9c-4bd5-8170-b0580bc1c145" xlink:to="loc_us-gaap_OperatingLeaseLiability_00ac1991-7faa-4b9a-99b3-ff7b0c47d80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_7eaa5f53-6920-467e-b8cc-c3f7a805c2f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2654f1ce-21c0-4ea2-a2ec-7ddab01d69b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_7eaa5f53-6920-467e-b8cc-c3f7a805c2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_fde72558-1ca1-46c9-985a-00c88898bd6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_7eaa5f53-6920-467e-b8cc-c3f7a805c2f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_fde72558-1ca1-46c9-985a-00c88898bd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_aa9b35ce-c91e-4d09-81ae-528d2c60a397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_7eaa5f53-6920-467e-b8cc-c3f7a805c2f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_aa9b35ce-c91e-4d09-81ae-528d2c60a397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9500edd5-cd55-41ee-8f1e-313990acaf66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_7eaa5f53-6920-467e-b8cc-c3f7a805c2f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9500edd5-cd55-41ee-8f1e-313990acaf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0af56964-3087-428b-a382-fc01fd01d427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_7eaa5f53-6920-467e-b8cc-c3f7a805c2f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0af56964-3087-428b-a382-fc01fd01d427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_3269d05b-d913-4f14-aa25-06272bfb1212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_7eaa5f53-6920-467e-b8cc-c3f7a805c2f2" xlink:to="loc_us-gaap_FinanceLeaseLiability_3269d05b-d913-4f14-aa25-06272bfb1212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LeaseLiability_73a75aab-601c-4f5f-9047-0e633fd5569f" xlink:href="sgry-20201231.xsd#sgry_LeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_sgry_LeaseLiability_73a75aab-601c-4f5f-9047-0e633fd5569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5bba5c30-03c7-4d36-a0f8-25c61ee09967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5bba5c30-03c7-4d36-a0f8-25c61ee09967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c5c67197-3107-4045-b77e-eea01db94f98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c5c67197-3107-4045-b77e-eea01db94f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_291522e7-8c9c-41ba-9a18-cb921071260f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_291522e7-8c9c-41ba-9a18-cb921071260f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_d7c33c26-f7c5-4c6f-aefd-5af393c19e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a336268-f1fb-49d5-a5ea-8ae2368de1fb" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_d7c33c26-f7c5-4c6f-aefd-5af393c19e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesLeaseExpenseandCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3e68972f-da08-47e0-bd01-24eaad9663c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e68972f-da08-47e0-bd01-24eaad9663c4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_63305f10-a553-408c-9fbc-d6144c3c40f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_63305f10-a553-408c-9fbc-d6144c3c40f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e8df538e-bc5e-4937-baa7-1ccc89467c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_63305f10-a553-408c-9fbc-d6144c3c40f2" xlink:to="loc_us-gaap_RelatedPartyDomain_e8df538e-bc5e-4937-baa7-1ccc89467c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_6a3c62be-0739-48b7-b2f5-c8184f19e8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e8df538e-bc5e-4937-baa7-1ccc89467c53" xlink:to="loc_us-gaap_InvestorMember_6a3c62be-0739-48b7-b2f5-c8184f19e8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_76bf729f-e9bb-4a67-b3e0-eadecfe432d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_76bf729f-e9bb-4a67-b3e0-eadecfe432d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a25755e1-79ef-4fd3-8e6d-d88c607060e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76bf729f-e9bb-4a67-b3e0-eadecfe432d6" xlink:to="loc_us-gaap_EquityComponentDomain_a25755e1-79ef-4fd3-8e6d-d88c607060e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1e121829-303b-4dc6-aa98-c36da9679141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a25755e1-79ef-4fd3-8e6d-d88c607060e9" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1e121829-303b-4dc6-aa98-c36da9679141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4382282e-8048-4564-9ee8-93a3a025a9fa" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1266c6a7-eafa-46d5-abcf-364517ba4b31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_us-gaap_OperatingLeaseCost_1266c6a7-eafa-46d5-abcf-364517ba4b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:href="sgry-20201231.xsd#sgry_FinanceLeaseCost1Abstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d01c2e1f-04e1-4801-a330-1669ab2318e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d01c2e1f-04e1-4801-a330-1669ab2318e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_871eee89-79d9-43fc-8236-9c2748cd2bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_871eee89-79d9-43fc-8236-9c2748cd2bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeaseCost_22616807-a2f9-4543-80f1-12493bdca143" xlink:href="sgry-20201231.xsd#sgry_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_FinanceLeaseCost1Abstract_5be3757e-39e9-4bb7-944e-61114a260e94" xlink:to="loc_sgry_FinanceLeaseCost_22616807-a2f9-4543-80f1-12493bdca143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_VariableAndShortTermLeaseCost_04e439ab-08f0-41d4-b7d8-f6f8b5d5e6c1" xlink:href="sgry-20201231.xsd#sgry_VariableAndShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_sgry_VariableAndShortTermLeaseCost_04e439ab-08f0-41d4-b7d8-f6f8b5d5e6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8440e5dd-441e-494e-ab6e-e1c3872bc034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_us-gaap_LeaseCost_8440e5dd-441e-494e-ab6e-e1c3872bc034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5aafb76a-d1df-40d7-bd39-df9af9f10cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_FinanceLeasePrincipalAndInterestPayments_bf87cc40-c2e6-4ab0-9920-e476a409da17" xlink:href="sgry-20201231.xsd#sgry_FinanceLeasePrincipalAndInterestPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b984376a-dedf-4829-8f95-82c7c09bb61c" xlink:to="loc_sgry_FinanceLeasePrincipalAndInterestPayments_bf87cc40-c2e6-4ab0-9920-e476a409da17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8ef3e0c0-a71e-461b-8100-3b7467aafc88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e68972f-da08-47e0-bd01-24eaad9663c4" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8ef3e0c0-a71e-461b-8100-3b7467aafc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e5a159e7-352c-4f5d-803a-8d2eb9bde3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8ef3e0c0-a71e-461b-8100-3b7467aafc88" xlink:to="loc_us-gaap_OperatingLeasePayments_e5a159e7-352c-4f5d-803a-8d2eb9bde3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_7c34e588-2e48-4c62-a650-5594a259d200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8ef3e0c0-a71e-461b-8100-3b7467aafc88" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_7c34e588-2e48-4c62-a650-5594a259d200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_20f84f27-5ac7-402f-b184-f733bf932f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8ef3e0c0-a71e-461b-8100-3b7467aafc88" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_20f84f27-5ac7-402f-b184-f733bf932f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract_f5d5c995-860a-49a8-a95b-d3794d1e906c" xlink:href="sgry-20201231.xsd#sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e68972f-da08-47e0-bd01-24eaad9663c4" xlink:to="loc_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract_f5d5c995-860a-49a8-a95b-d3794d1e906c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c800dfe8-fe93-45d8-b567-4d9f937b7cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract_f5d5c995-860a-49a8-a95b-d3794d1e906c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c800dfe8-fe93-45d8-b567-4d9f937b7cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6e8b60c3-86f0-4cc4-bf97-dd395f0864d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract_f5d5c995-860a-49a8-a95b-d3794d1e906c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_6e8b60c3-86f0-4cc4-bf97-dd395f0864d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_646de77c-c80e-4041-8c19-fb06c1d89d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_646de77c-c80e-4041-8c19-fb06c1d89d2f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6420936c-7d11-452d-80c9-5573ef36e9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6420936c-7d11-452d-80c9-5573ef36e9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2bcfc6e6-dedd-4c3a-bc59-b0cc8ac1f49f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2bcfc6e6-dedd-4c3a-bc59-b0cc8ac1f49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_777f2aaf-2b04-4910-a68c-a3ef9bc07fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_777f2aaf-2b04-4910-a68c-a3ef9bc07fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fe5b0b86-a6c4-4e5a-92d3-bb0dd7911a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fe5b0b86-a6c4-4e5a-92d3-bb0dd7911a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e65dc512-6639-4772-bb44-c1e02f2e7245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e65dc512-6639-4772-bb44-c1e02f2e7245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7bfd6ebf-65cd-40d0-8d8d-99e56e5a6c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7bfd6ebf-65cd-40d0-8d8d-99e56e5a6c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13b87ea6-c0f5-4392-9dc0-70f71843f00e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13b87ea6-c0f5-4392-9dc0-70f71843f00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3156d31b-5f70-4045-ad20-330b86c07243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3156d31b-5f70-4045-ad20-330b86c07243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3959b817-c307-410c-bbb5-127940095aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8b736082-8fcd-434b-828c-d6336d07258b" xlink:to="loc_us-gaap_OperatingLeaseLiability_3959b817-c307-410c-bbb5-127940095aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_646de77c-c80e-4041-8c19-fb06c1d89d2f" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_eb9a8aea-4331-4053-947c-07a59ed0f51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_eb9a8aea-4331-4053-947c-07a59ed0f51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0729b082-7ab0-45df-97ae-0bca54fa48d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0729b082-7ab0-45df-97ae-0bca54fa48d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_246573ab-151e-4318-ae78-36dd271180cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_246573ab-151e-4318-ae78-36dd271180cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a6b1aab6-d379-4e8f-b01e-4a8924b2c7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a6b1aab6-d379-4e8f-b01e-4a8924b2c7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8e712a66-adde-492e-b443-185279215730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8e712a66-adde-492e-b443-185279215730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_9ddbfae9-f494-4d9c-b5bf-8ad641e3d475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_9ddbfae9-f494-4d9c-b5bf-8ad641e3d475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_07a5fb18-0684-4af6-857e-c66ea0906e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_07a5fb18-0684-4af6-857e-c66ea0906e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c5e78202-e713-4201-a5dd-5c87ada06d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c5e78202-e713-4201-a5dd-5c87ada06d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f1f1e559-f237-4f7e-a94f-8f46d3840f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_111d4154-5ada-489c-82e6-0dc55e8e3605" xlink:to="loc_us-gaap_FinanceLeaseLiability_f1f1e559-f237-4f7e-a94f-8f46d3840f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="sgry-20201231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStock" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStock"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_1292f425-986f-4a35-880b-f43252e05091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RedeemablePreferredStockTextBlock_ec0a4408-2d92-4ef7-b291-3aaf50630c47" xlink:href="sgry-20201231.xsd#sgry_RedeemablePreferredStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_1292f425-986f-4a35-880b-f43252e05091" xlink:to="loc_sgry_RedeemablePreferredStockTextBlock_ec0a4408-2d92-4ef7-b291-3aaf50630c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStockTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStockTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_0e6ad0df-33f3-415e-8bb8-168637b18132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_8d12151e-bef5-4131-8afa-e576db94d6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_0e6ad0df-33f3-415e-8bb8-168637b18132" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_8d12151e-bef5-4131-8afa-e576db94d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#RedeemablePreferredStockAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_3e33e224-17f2-43da-9ad8-b091203d42bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_3e33e224-17f2-43da-9ad8-b091203d42bb" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6505cdc-5fd2-4fba-884b-fbffee776f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6505cdc-5fd2-4fba-884b-fbffee776f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8706d6c2-f5f8-4b46-815e-04bc67331953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6505cdc-5fd2-4fba-884b-fbffee776f37" xlink:to="loc_us-gaap_RelatedPartyDomain_8706d6c2-f5f8-4b46-815e-04bc67331953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorityShareholderMember_b9e219e6-bbc5-4d0d-b968-148e8c90aefc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorityShareholderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8706d6c2-f5f8-4b46-815e-04bc67331953" xlink:to="loc_us-gaap_MajorityShareholderMember_b9e219e6-bbc5-4d0d-b968-148e8c90aefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1c3dc495-8529-4e2e-9d78-426718c855a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1c3dc495-8529-4e2e-9d78-426718c855a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_678d8b7f-ebdb-44b2-8e69-14aa9619397c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c3dc495-8529-4e2e-9d78-426718c855a3" xlink:to="loc_us-gaap_ClassOfStockDomain_678d8b7f-ebdb-44b2-8e69-14aa9619397c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_eb235e44-821b-41d8-99a7-99f846392322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_678d8b7f-ebdb-44b2-8e69-14aa9619397c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_eb235e44-821b-41d8-99a7-99f846392322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6e17bc24-c35c-4e55-958a-bee848189499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6e17bc24-c35c-4e55-958a-bee848189499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a067359-89c3-45ab-abb2-2a386012300b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6e17bc24-c35c-4e55-958a-bee848189499" xlink:to="loc_us-gaap_EquityComponentDomain_2a067359-89c3-45ab-abb2-2a386012300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_90a32f96-92a8-4e41-9339-70be0189ce88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a067359-89c3-45ab-abb2-2a386012300b" xlink:to="loc_us-gaap_CommonStockMember_90a32f96-92a8-4e41-9339-70be0189ce88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_0ede8187-25bb-4425-a9f3-02d514c4a481" xlink:to="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_861ebb15-d79f-4f96-b6dc-53c42bde152a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_861ebb15-d79f-4f96-b6dc-53c42bde152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8c330f6b-56c7-4210-aa58-fabbf911baac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8c330f6b-56c7-4210-aa58-fabbf911baac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_9412ecb7-4661-4654-ba90-5e71d3e43733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_9412ecb7-4661-4654-ba90-5e71d3e43733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1671218d-4d35-4ee8-ae81-7ac91f0d6408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1671218d-4d35-4ee8-ae81-7ac91f0d6408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c45a3c2f-699c-4ad6-9896-3314f2354a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c45a3c2f-699c-4ad6-9896-3314f2354a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_69d47462-6754-473c-a60d-434cc35fb89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_SharePrice_69d47462-6754-473c-a60d-434cc35fb89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdTradingDays_503052fc-632a-4da9-a0b6-f8474788ddd6" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_sgry_TemporaryEquityThresholdTradingDays_503052fc-632a-4da9-a0b6-f8474788ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdConsecutiveTradingDays_b3028749-34b3-4ef7-b173-89b9572378e4" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_sgry_TemporaryEquityThresholdConsecutiveTradingDays_b3028749-34b3-4ef7-b173-89b9572378e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityThresholdSharePrice_bfce7ebe-1bbf-496d-8b59-c728cc9b964b" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityThresholdSharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_sgry_TemporaryEquityThresholdSharePrice_bfce7ebe-1bbf-496d-8b59-c728cc9b964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TemporaryEquityMaximumCashDividendDeclarable_24e694cd-5d7f-495d-91c6-f98fcec40f49" xlink:href="sgry-20201231.xsd#sgry_TemporaryEquityMaximumCashDividendDeclarable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_sgry_TemporaryEquityMaximumCashDividendDeclarable_24e694cd-5d7f-495d-91c6-f98fcec40f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_49619dd5-8243-46a9-a7d0-3b0630c020ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_49619dd5-8243-46a9-a7d0-3b0630c020ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_495eb85f-0b8e-46bb-97c8-e0baafd2dac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_495eb85f-0b8e-46bb-97c8-e0baafd2dac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_ecc03683-55f8-4da5-99c1-b6499e740ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_ecc03683-55f8-4da5-99c1-b6499e740ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_f647dca5-1272-40ea-9dc7-ad8df54e9b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_4b9fe404-6d59-426d-805e-df0a3f85d473" xlink:to="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_f647dca5-1272-40ea-9dc7-ad8df54e9b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9327e199-251f-4805-8dc9-021dac52c569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_3e33e224-17f2-43da-9ad8-b091203d42bb" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9327e199-251f-4805-8dc9-021dac52c569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0c1b7256-55dd-4abe-87f9-f76331b59143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9327e199-251f-4805-8dc9-021dac52c569" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0c1b7256-55dd-4abe-87f9-f76331b59143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_4f1c4722-4fc0-497e-9c30-5ae355d41883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9327e199-251f-4805-8dc9-021dac52c569" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_4f1c4722-4fc0-497e-9c30-5ae355d41883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_b3d753cb-9b3b-439e-ad03-1e40ad43bc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9327e199-251f-4805-8dc9-021dac52c569" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_b3d753cb-9b3b-439e-ad03-1e40ad43bc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4eac13e3-58ee-4d8c-96c7-35a619025bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_9327e199-251f-4805-8dc9-021dac52c569" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4eac13e3-58ee-4d8c-96c7-35a619025bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivities"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_224fb40c-a815-4f13-9f71-56d87265569a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_85bc3c71-93a5-4c11-8085-5d59e2e95d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_224fb40c-a815-4f13-9f71-56d87265569a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_85bc3c71-93a5-4c11-8085-5d59e2e95d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5dbf45c-0d42-4157-8665-fab5a8a53375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_1893264e-5caa-4e84-8fd2-08c345eb2f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e5dbf45c-0d42-4157-8665-fab5a8a53375" xlink:to="loc_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock_1893264e-5caa-4e84-8fd2-08c345eb2f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#DerivativesandHedgingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_29ea3f02-51ad-44b8-a40a-5beaf3352c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e9444993-a46f-4ccb-a819-664e8b33b38e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_29ea3f02-51ad-44b8-a40a-5beaf3352c3d" xlink:to="loc_us-gaap_DerivativeTable_e9444993-a46f-4ccb-a819-664e8b33b38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4eda9cab-1406-46e0-afbe-7f5e76455ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e9444993-a46f-4ccb-a819-664e8b33b38e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4eda9cab-1406-46e0-afbe-7f5e76455ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_29f87ef4-cfbe-4f9b-921e-ac124388ca7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4eda9cab-1406-46e0-afbe-7f5e76455ac6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_29f87ef4-cfbe-4f9b-921e-ac124388ca7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_bae95366-41fe-4c89-98a6-c2deba0124e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_29f87ef4-cfbe-4f9b-921e-ac124388ca7a" xlink:to="loc_us-gaap_InterestRateSwapMember_bae95366-41fe-4c89-98a6-c2deba0124e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e9444993-a46f-4ccb-a819-664e8b33b38e" xlink:to="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_1e580674-c8b6-4803-a28b-9b7cf0da7f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_1e580674-c8b6-4803-a28b-9b7cf0da7f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_fe4aebac-b713-41a2-a32b-96bb1944b647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_fe4aebac-b713-41a2-a32b-96bb1944b647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ffdb9435-e191-429d-a35c-31223dd47d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ffdb9435-e191-429d-a35c-31223dd47d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3c463797-0764-4483-afb3-9f25387bed09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_3c463797-0764-4483-afb3-9f25387bed09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss_80a51449-1408-43a1-857f-89fbf805dbd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss_80a51449-1408-43a1-857f-89fbf805dbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_383bc15e-e619-4a2e-8f9f-a393b142ed1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_383bc15e-e619-4a2e-8f9f-a393b142ed1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_184d41fa-69d3-4ebe-949c-77d2fb2bb142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8b4f0ad7-c64b-40f9-9933-c2a7bc6c4a52" xlink:to="loc_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion_184d41fa-69d3-4ebe-949c-77d2fb2bb142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_40cd0635-fdd9-451d-96e5-8137dc5603f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d4df9f2f-5f1f-4e9a-a071-e9cdbbc83122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_40cd0635-fdd9-451d-96e5-8137dc5603f4" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d4df9f2f-5f1f-4e9a-a071-e9cdbbc83122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f5049310-0f89-412f-9e07-d39d799190c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4c690fc4-3a79-4763-b8c5-85edfb6b854c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f5049310-0f89-412f-9e07-d39d799190c7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4c690fc4-3a79-4763-b8c5-85edfb6b854c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fbeb3366-cf16-4b5f-844c-175d02d3f109" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_eab3f1b5-bdcc-42e6-8cab-335755b88654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fbeb3366-cf16-4b5f-844c-175d02d3f109" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_eab3f1b5-bdcc-42e6-8cab-335755b88654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_eab3f1b5-bdcc-42e6-8cab-335755b88654" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_12af3336-7a89-41a1-b721-4cc6e44d5c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f064eb9c-4f1a-44e9-8a4a-e53cabaff8c0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_12af3336-7a89-41a1-b721-4cc6e44d5c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ed282697-089d-4734-9d25-293c982b63a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_12af3336-7a89-41a1-b721-4cc6e44d5c69" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ed282697-089d-4734-9d25-293c982b63a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_425c3242-d0e9-4737-a6a7-786ae33b689f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_12af3336-7a89-41a1-b721-4cc6e44d5c69" xlink:to="loc_us-gaap_RestrictedStockMember_425c3242-d0e9-4737-a6a7-786ae33b689f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_eab3f1b5-bdcc-42e6-8cab-335755b88654" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:to="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c91354b-2bfe-43f8-b15f-f1f4bb5f6416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:to="loc_us-gaap_NetIncomeLoss_5c91354b-2bfe-43f8-b15f-f1f4bb5f6416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_b2524443-58bf-4b1b-8377-72341c6e5bfa" xlink:href="sgry-20201231.xsd#sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:to="loc_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued_b2524443-58bf-4b1b-8377-72341c6e5bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_83453489-c056-43cf-9bd2-93b321d477b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_e1032677-a6df-4414-821a-7f9d00a6ebd5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_83453489-c056-43cf-9bd2-93b321d477b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ff30410-1fac-4bdc-8809-86388ab3a46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ff30410-1fac-4bdc-8809-86388ab3a46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_215ba980-79a2-4767-9e26-5a378f673a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ff30410-1fac-4bdc-8809-86388ab3a46e" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_215ba980-79a2-4767-9e26-5a378f673a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_86c2eaec-9886-424c-8492-089f4a7f5312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ff30410-1fac-4bdc-8809-86388ab3a46e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_86c2eaec-9886-424c-8492-089f4a7f5312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5eb595c-bfa2-4c96-9237-8c6cc86403a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d7c845f-ded3-416c-8ad9-95a7eb370dac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5eb595c-bfa2-4c96-9237-8c6cc86403a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d2264f80-07da-4779-9c8e-aa7a329f4eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fbeb3366-cf16-4b5f-844c-175d02d3f109" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d2264f80-07da-4779-9c8e-aa7a329f4eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_9fb174a1-8112-4a71-8375-2fb91e8856d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fbeb3366-cf16-4b5f-844c-175d02d3f109" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_9fb174a1-8112-4a71-8375-2fb91e8856d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_74f6664f-8e84-45e6-99e5-56a352a11331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fbeb3366-cf16-4b5f-844c-175d02d3f109" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_74f6664f-8e84-45e6-99e5-56a352a11331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_85e73d18-2527-4f3a-90e6-d348b4aa4ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fbeb3366-cf16-4b5f-844c-175d02d3f109" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_85e73d18-2527-4f3a-90e6-d348b4aa4ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b97a7cc7-2200-4dfc-8f75-c17ed261a08c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_821aa9ba-26d7-4052-bee1-fec5cac790ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b97a7cc7-2200-4dfc-8f75-c17ed261a08c" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_821aa9ba-26d7-4052-bee1-fec5cac790ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_64f348ec-d03d-462f-a37c-5356c87ac6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_03bb2946-f5cb-4320-bd16-53208e1aa72e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64f348ec-d03d-462f-a37c-5356c87ac6cc" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_03bb2946-f5cb-4320-bd16-53208e1aa72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5819e55b-4971-4ff8-9f24-4cad1448b538" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64f348ec-d03d-462f-a37c-5356c87ac6cc" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5819e55b-4971-4ff8-9f24-4cad1448b538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_61aff237-7255-49ca-ad37-9c1dbf67aa2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64f348ec-d03d-462f-a37c-5356c87ac6cc" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_61aff237-7255-49ca-ad37-9c1dbf67aa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_20ff8f48-8fcb-4b44-8801-b979bd21fbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64f348ec-d03d-462f-a37c-5356c87ac6cc" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_20ff8f48-8fcb-4b44-8801-b979bd21fbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_20541c48-6bf1-48d8-85ea-98010e1bd490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_20541c48-6bf1-48d8-85ea-98010e1bd490" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c802d625-f859-401e-80b5-f73a90726585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c802d625-f859-401e-80b5-f73a90726585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e5f816c6-fa3d-46fd-bd6d-65fd142c593e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c802d625-f859-401e-80b5-f73a90726585" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e5f816c6-fa3d-46fd-bd6d-65fd142c593e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_284c2ada-9158-492e-a6a4-7f83a1cdcd5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5f816c6-fa3d-46fd-bd6d-65fd142c593e" xlink:to="loc_us-gaap_DomesticCountryMember_284c2ada-9158-492e-a6a4-7f83a1cdcd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a7b84c72-9152-4682-9770-8bc35acea006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5f816c6-fa3d-46fd-bd6d-65fd142c593e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a7b84c72-9152-4682-9770-8bc35acea006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_0e55576f-374e-4469-aef8-f01c30e02bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_0e55576f-374e-4469-aef8-f01c30e02bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_0e55576f-374e-4469-aef8-f01c30e02bf9" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_41fe4f94-98a3-44c4-85c8-94a8740e8727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_41fe4f94-98a3-44c4-85c8-94a8740e8727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember_994d7962-2c9a-4137-bd17-ef67ea006d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:to="loc_us-gaap_GeneralBusinessMember_994d7962-2c9a-4137-bd17-ef67ea006d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_InterestLimitationMember_aab126eb-5b98-460a-9b03-17623bea7e9c" xlink:href="sgry-20201231.xsd#sgry_InterestLimitationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2556442f-4c32-4b8d-8a8b-18df112dde4d" xlink:to="loc_sgry_InterestLimitationMember_aab126eb-5b98-460a-9b03-17623bea7e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f430b487-796f-4ebd-af65-7203146467c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f430b487-796f-4ebd-af65-7203146467c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_50ee7ba4-7b85-4f06-a83d-ef79babacae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f430b487-796f-4ebd-af65-7203146467c2" xlink:to="loc_us-gaap_EquityComponentDomain_50ee7ba4-7b85-4f06-a83d-ef79babacae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f57bf168-05d9-4dc2-bd16-56e6981ba4be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_50ee7ba4-7b85-4f06-a83d-ef79babacae0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f57bf168-05d9-4dc2-bd16-56e6981ba4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_77972f39-f479-49eb-8e54-7b4383a16151" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_df8f195c-d678-47cc-a798-50f947acaf22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_df8f195c-d678-47cc-a798-50f947acaf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ce76184e-c54a-4f0a-b516-8217b6bda577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ce76184e-c54a-4f0a-b516-8217b6bda577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e33ff3c0-c31e-44ee-a047-87ee700cbe41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_e33ff3c0-c31e-44ee-a047-87ee700cbe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0e1b0215-1173-4c6c-b133-bdba80db0560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0e1b0215-1173-4c6c-b133-bdba80db0560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c2ef57c0-ee4d-4b2e-9e7d-f8c45b01bd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c2ef57c0-ee4d-4b2e-9e7d-f8c45b01bd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_31e2737f-2cca-416e-a9bf-a58dd93ead6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_31e2737f-2cca-416e-a9bf-a58dd93ead6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax_b767219d-b535-4aab-89ae-ea5760c80c94" xlink:href="sgry-20201231.xsd#sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax_b767219d-b535-4aab-89ae-ea5760c80c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_6e0023b1-ae51-4db1-9c8d-539d0dcc7d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital_6e0023b1-ae51-4db1-9c8d-539d0dcc7d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7f242a07-f32f-4491-ae8d-539014e1a28a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7f242a07-f32f-4491-ae8d-539014e1a28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9a56f330-b658-4f91-a0d0-2233a40b9e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c56b6ebb-611d-49ca-a4d9-b937afddea7d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9a56f330-b658-4f91-a0d0-2233a40b9e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesIncomeTaxBenefitExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bcae8561-7d27-434c-974e-eb50b98c9bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4327f1d8-7fdb-46a3-a97d-36bc19c9517c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bcae8561-7d27-434c-974e-eb50b98c9bbe" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4327f1d8-7fdb-46a3-a97d-36bc19c9517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a3cb766e-8a96-43d1-ad88-182a5c974197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4327f1d8-7fdb-46a3-a97d-36bc19c9517c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a3cb766e-8a96-43d1-ad88-182a5c974197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2399137b-18a9-479f-a883-899fa51083c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4327f1d8-7fdb-46a3-a97d-36bc19c9517c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2399137b-18a9-479f-a883-899fa51083c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cf6dd5a2-c0de-465f-886b-68e0eefb2afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bcae8561-7d27-434c-974e-eb50b98c9bbe" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cf6dd5a2-c0de-465f-886b-68e0eefb2afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5939f3b2-aa64-48eb-b6e7-e8a4db1439d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cf6dd5a2-c0de-465f-886b-68e0eefb2afb" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5939f3b2-aa64-48eb-b6e7-e8a4db1439d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4de50612-10ca-49aa-a4f7-c35f185477e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_cf6dd5a2-c0de-465f-886b-68e0eefb2afb" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4de50612-10ca-49aa-a4f7-c35f185477e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09935b1a-6eca-46b7-ae6c-503efbb5654a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bcae8561-7d27-434c-974e-eb50b98c9bbe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_09935b1a-6eca-46b7-ae6c-503efbb5654a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_51d016d0-ea8b-4a4b-95ea-5786ef4ac311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_51d016d0-ea8b-4a4b-95ea-5786ef4ac311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2be67525-cbae-47b4-9682-c88056f249d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2be67525-cbae-47b4-9682-c88056f249d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_539c4f59-01bc-40a2-aff3-63305a37d76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_539c4f59-01bc-40a2-aff3-63305a37d76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_6d8068fd-0526-4545-9749-fb4aca23473d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_6d8068fd-0526-4545-9749-fb4aca23473d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_332f8100-f733-4465-be1e-35cbeba14613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_332f8100-f733-4465-be1e-35cbeba14613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_fbe6cb33-53a3-4402-94e7-47e781a2a56d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_fbe6cb33-53a3-4402-94e7-47e781a2a56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount_34d9ca8b-81f5-42d3-83fd-cf150b362f8f" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxReconciliationDivestitureAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount_34d9ca8b-81f5-42d3-83fd-cf150b362f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_98f0ac8d-f099-46b5-9306-7dbe63dfc0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_98f0ac8d-f099-46b5-9306-7dbe63dfc0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_da8c07eb-1dee-4db7-b8b5-e5696a84ad5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_da8c07eb-1dee-4db7-b8b5-e5696a84ad5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount_09bf336d-9119-4651-ab38-d0396dc1d5b4" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount_09bf336d-9119-4651-ab38-d0396dc1d5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_08835379-4359-4be1-98b4-0f042e1784f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_08835379-4359-4be1-98b4-0f042e1784f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount_b1c0b06c-d1d0-4c32-9df5-e4574960dfac" xlink:href="sgry-20201231.xsd#sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount_b1c0b06c-d1d0-4c32-9df5-e4574960dfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_287c17ad-b37b-4300-924c-ad026a8e7fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_287c17ad-b37b-4300-924c-ad026a8e7fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea5d64f4-31de-4df2-b61a-9819fbd75e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d3c0891-4911-47fb-82e3-d38aea2d9067" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ea5d64f4-31de-4df2-b61a-9819fbd75e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7187968d-40cd-43bd-9ccb-b1b663f3082a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7187968d-40cd-43bd-9ccb-b1b663f3082a" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_9aba94c9-a179-4817-b173-06f6923166d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_9aba94c9-a179-4817-b173-06f6923166d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation_d26496ae-f5e5-487a-8b47-40018d8bcc7c" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation_d26496ae-f5e5-487a-8b47-40018d8bcc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b9e49e1a-dad9-4b2f-98fd-4194833b485a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b9e49e1a-dad9-4b2f-98fd-4194833b485a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_f18cad43-d896-40e6-a247-6fe384f6c5d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_f18cad43-d896-40e6-a247-6fe384f6c5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_3c7a5e06-475c-481f-a5bb-ab072b35ce72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_3c7a5e06-475c-481f-a5bb-ab072b35ce72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets_f630b440-edef-4377-9f3c-da05e0d25450" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets_f630b440-edef-4377-9f3c-da05e0d25450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts_e9a4aa8a-8bcb-4ac6-9808-5d055e57fc66" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts_e9a4aa8a-8bcb-4ac6-9808-5d055e57fc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation_b5f07683-1adf-495b-84e6-1740ced7a6aa" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation_b5f07683-1adf-495b-84e6-1740ced7a6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsHedgingTransactions_29487853-bd65-4942-9acd-e13d8c07162a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsHedgingTransactions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsHedgingTransactions_29487853-bd65-4942-9acd-e13d8c07162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetTaxReceivableAgreement_8e3b632d-0d3e-4154-b128-7485a347503b" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetTaxReceivableAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_sgry_DeferredTaxAssetTaxReceivableAgreement_8e3b632d-0d3e-4154-b128-7485a347503b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsRightOfUse_f9144f0a-4968-40f4-a69e-b753cbe56604" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsRightOfUse"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_sgry_DeferredTaxAssetsRightOfUse_f9144f0a-4968-40f4-a69e-b753cbe56604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable_9fb4043e-2be7-4b93-a64b-a5960a961234" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable_9fb4043e-2be7-4b93-a64b-a5960a961234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_25bed578-f855-458d-a763-6c31e5e420ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_25bed578-f855-458d-a763-6c31e5e420ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a67b4ddb-b2af-4d4b-a139-a860851d8351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a67b4ddb-b2af-4d4b-a139-a860851d8351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2840c1e3-d9d8-48a5-be40-28475d03d266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2840c1e3-d9d8-48a5-be40-28475d03d266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5461ab27-1b7b-4da5-8b59-f36594fb6328" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_51432823-bc25-4fa8-bcaf-5c316bc1d5e9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5461ab27-1b7b-4da5-8b59-f36594fb6328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_84ad1d5c-118b-4a70-b9ab-a137679d3bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7187968d-40cd-43bd-9ccb-b1b663f3082a" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_84ad1d5c-118b-4a70-b9ab-a137679d3bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e5ba13c4-1876-4c66-bd1b-231590814f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_84ad1d5c-118b-4a70-b9ab-a137679d3bc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e5ba13c4-1876-4c66-bd1b-231590814f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures_b7a95999-ea1e-4f25-9114-de05332afaa9" xlink:href="sgry-20201231.xsd#sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_84ad1d5c-118b-4a70-b9ab-a137679d3bc6" xlink:to="loc_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures_b7a95999-ea1e-4f25-9114-de05332afaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_182273fa-273d-48d2-b7d4-a13926946b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_84ad1d5c-118b-4a70-b9ab-a137679d3bc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_182273fa-273d-48d2-b7d4-a13926946b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_7e88c8c1-3fc4-41bf-a392-9a959e377417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_84ad1d5c-118b-4a70-b9ab-a137679d3bc6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_7e88c8c1-3fc4-41bf-a392-9a959e377417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ef87f754-4277-40b0-8768-fde81622bf1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_84ad1d5c-118b-4a70-b9ab-a137679d3bc6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ef87f754-4277-40b0-8768-fde81622bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_05ea86c4-5ce0-460d-8fd1-2ea63f3acbde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7187968d-40cd-43bd-9ccb-b1b663f3082a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_05ea86c4-5ce0-460d-8fd1-2ea63f3acbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f26b303b-ec8b-4fcc-b950-11fa0397e2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ab202d02-ba7b-4738-a9a6-04eff9594eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f26b303b-ec8b-4fcc-b950-11fa0397e2ad" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ab202d02-ba7b-4738-a9a6-04eff9594eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f7058600-0aef-4b69-b9ac-8e179edf7536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ab202d02-ba7b-4738-a9a6-04eff9594eed" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f7058600-0aef-4b69-b9ac-8e179edf7536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_003e894d-b788-4b20-b2d2-409e457409d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ab202d02-ba7b-4738-a9a6-04eff9594eed" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_003e894d-b788-4b20-b2d2-409e457409d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4c5e63a7-3b8d-4f2f-a5d1-a1e91992b060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ab202d02-ba7b-4738-a9a6-04eff9594eed" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4c5e63a7-3b8d-4f2f-a5d1-a1e91992b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75b88c75-c443-478d-9982-0aff9d6f04fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_413a018c-5419-4e85-9346-448d36e543ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_75b88c75-c443-478d-9982-0aff9d6f04fa" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_413a018c-5419-4e85-9346-448d36e543ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9bcbac6-4a29-4257-86d1-afd7df98887b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_6638e3c8-d151-4cb0-a6c7-7741e3394b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9bcbac6-4a29-4257-86d1-afd7df98887b" xlink:to="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_6638e3c8-d151-4cb0-a6c7-7741e3394b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01865991-6c0f-4a23-bd99-8bc9c6e8683b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9bcbac6-4a29-4257-86d1-afd7df98887b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01865991-6c0f-4a23-bd99-8bc9c6e8683b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92008fe3-3f3f-49f5-9c27-08b2f6eff454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9bcbac6-4a29-4257-86d1-afd7df98887b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92008fe3-3f3f-49f5-9c27-08b2f6eff454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a082567-deac-4863-b69e-289b88be43e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a082567-deac-4863-b69e-289b88be43e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_us-gaap_PlanNameAxis_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_86026675-5ef1-432f-aee6-2bbdab587c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_22d899b9-9f8a-4fb6-bdd3-d1216d5731b3" xlink:to="loc_us-gaap_PlanNameDomain_86026675-5ef1-432f-aee6-2bbdab587c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2015OmnibusIncentivePlanMember_2eb38a0f-0661-47bd-9690-dc8cd9a16e57" xlink:href="sgry-20201231.xsd#sgry_A2015OmnibusIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_86026675-5ef1-432f-aee6-2bbdab587c4e" xlink:to="loc_sgry_A2015OmnibusIncentivePlanMember_2eb38a0f-0661-47bd-9690-dc8cd9a16e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6c8d80c6-2ebe-49d7-a55e-012345d11210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_srt_RangeAxis_6c8d80c6-2ebe-49d7-a55e-012345d11210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72bb2b5e-671b-483b-8980-99f6176b5281" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6c8d80c6-2ebe-49d7-a55e-012345d11210" xlink:to="loc_srt_RangeMember_72bb2b5e-671b-483b-8980-99f6176b5281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_42c00fcf-c30d-4dfb-8583-bc9ca28f43a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_72bb2b5e-671b-483b-8980-99f6176b5281" xlink:to="loc_srt_MinimumMember_42c00fcf-c30d-4dfb-8583-bc9ca28f43a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b553b848-3165-4b2a-9aad-7443a31a3eff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_72bb2b5e-671b-483b-8980-99f6176b5281" xlink:to="loc_srt_MaximumMember_b553b848-3165-4b2a-9aad-7443a31a3eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bdbafea4-7baa-444f-8b62-ab8ad1639cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_us-gaap_AwardTypeAxis_bdbafea4-7baa-444f-8b62-ab8ad1639cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bdbafea4-7baa-444f-8b62-ab8ad1639cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4c6fd165-38f9-4e45-b893-6170de4f51cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4c6fd165-38f9-4e45-b893-6170de4f51cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ba6b7c26-088e-4935-9780-218bd39c52fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:to="loc_us-gaap_PerformanceSharesMember_ba6b7c26-088e-4935-9780-218bd39c52fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_60fbcf75-4309-4e79-bb68-fc264e21f953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_60fbcf75-4309-4e79-bb68-fc264e21f953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_86539051-5e81-4f85-9060-3b2de843ceaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a8b3fe-337c-40b8-bb58-c71476b9e62e" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_86539051-5e81-4f85-9060-3b2de843ceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0571102e-f430-4df5-bc5b-d5702c6de84e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_us-gaap_VestingAxis_0571102e-f430-4df5-bc5b-d5702c6de84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_0571102e-f430-4df5-bc5b-d5702c6de84e" xlink:to="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fcae2c01-3af8-4dec-91d4-6f6a4bc6af6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fcae2c01-3af8-4dec-91d4-6f6a4bc6af6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2f43b16f-1bcd-46f0-bcc3-bb64c5d89c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2f43b16f-1bcd-46f0-bcc3-bb64c5d89c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2b3b75b5-1509-4fab-98b9-dbfe93c36630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_44209b87-ed68-4774-b8b3-8c1ee14aae40" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2b3b75b5-1509-4fab-98b9-dbfe93c36630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c0a1068d-2643-4570-b7c1-fbe58962252b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635a33d9-f5b2-4d71-9c41-afdf44ab1b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_635a33d9-f5b2-4d71-9c41-afdf44ab1b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91e739c9-7133-46c2-bb8a-237d53a242d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_91e739c9-7133-46c2-bb8a-237d53a242d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6f93422-f2ad-4670-b7b0-9c29d729fddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6f93422-f2ad-4670-b7b0-9c29d729fddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_efeae1fc-c0dd-4f86-ace6-20d56f7771f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_efeae1fc-c0dd-4f86-ace6-20d56f7771f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod_55374dd5-5a38-4e82-b94f-964f6cd1c4df" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod_55374dd5-5a38-4e82-b94f-964f6cd1c4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod_a146f003-f22a-4dfb-a243-b3d0f05f7ad2" xlink:href="sgry-20201231.xsd#sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod_a146f003-f22a-4dfb-a243-b3d0f05f7ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5e91457f-8248-4a73-ad88-75ea7cb63255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5e91457f-8248-4a73-ad88-75ea7cb63255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c146b7db-c7d3-4ff1-b0ab-d5e20ec1badc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c146b7db-c7d3-4ff1-b0ab-d5e20ec1badc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_aeb6c968-a983-460d-acaa-a9f390fe80ad" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_aeb6c968-a983-460d-acaa-a9f390fe80ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_99216c44-8d68-4b1e-a66d-f649fd7b9067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_SharePrice_99216c44-8d68-4b1e-a66d-f649fd7b9067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_7e01d4df-daa4-4f7b-b94d-493e40c32438" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays_7e01d4df-daa4-4f7b-b94d-493e40c32438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_4115f4f7-e8f2-444a-aa1b-339613cea68a" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_4115f4f7-e8f2-444a-aa1b-339613cea68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8082d39c-6831-4003-96f4-164b69af1d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8082d39c-6831-4003-96f4-164b69af1d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_935968c2-9c7b-440a-8dd7-1630acff4825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_183b9bac-a0b1-4708-929c-6f0d21b31844" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_935968c2-9c7b-440a-8dd7-1630acff4825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f415d4c2-c7a9-4ebf-81bd-536de851d0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575d26c7-ba73-4a57-a06d-ab9bf67ae97b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f415d4c2-c7a9-4ebf-81bd-536de851d0ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575d26c7-ba73-4a57-a06d-ab9bf67ae97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_659d381f-fe1d-442a-9a7b-81b5e4ab8793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575d26c7-ba73-4a57-a06d-ab9bf67ae97b" xlink:to="loc_us-gaap_AwardTypeAxis_659d381f-fe1d-442a-9a7b-81b5e4ab8793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_972f2951-d4e7-490e-aa84-8bf082bcf698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_659d381f-fe1d-442a-9a7b-81b5e4ab8793" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_972f2951-d4e7-490e-aa84-8bf082bcf698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_RestrictedStockAndPerformanceSharesMember_c37c3462-3a23-4c1a-bc7c-7bcdb61ede96" xlink:href="sgry-20201231.xsd#sgry_RestrictedStockAndPerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_972f2951-d4e7-490e-aa84-8bf082bcf698" xlink:to="loc_sgry_RestrictedStockAndPerformanceSharesMember_c37c3462-3a23-4c1a-bc7c-7bcdb61ede96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_066db5d2-2d29-4d76-a40b-937d016d5359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_575d26c7-ba73-4a57-a06d-ab9bf67ae97b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_066db5d2-2d29-4d76-a40b-937d016d5359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_066db5d2-2d29-4d76-a40b-937d016d5359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a46dcf0-0472-4138-adb9-2761aa9bc5c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a46dcf0-0472-4138-adb9-2761aa9bc5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a2edd95-fabd-498a-8ea9-a992757184f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a2edd95-fabd-498a-8ea9-a992757184f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94bbc1d4-a2ef-4ea6-9fe9-7a5f2f6d548e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_94bbc1d4-a2ef-4ea6-9fe9-7a5f2f6d548e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d6761794-be32-4042-a5f8-b95c899ff401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d6761794-be32-4042-a5f8-b95c899ff401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e6f4565b-c49d-49ef-8dc5-87d7b1a871ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6389fb6c-d4c5-4803-805e-9439cfc12ffb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e6f4565b-c49d-49ef-8dc5-87d7b1a871ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_066db5d2-2d29-4d76-a40b-937d016d5359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a02698b1-0e4c-4385-9bd1-91599b1d079d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a02698b1-0e4c-4385-9bd1-91599b1d079d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66d33b1b-65bf-41ac-9b6e-76429c8aeec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66d33b1b-65bf-41ac-9b6e-76429c8aeec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_94a87f8a-a44d-47d5-9700-fe59bdef7387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_94a87f8a-a44d-47d5-9700-fe59bdef7387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_43414c1e-7d94-48fb-ae99-4849b951166f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_43414c1e-7d94-48fb-ae99-4849b951166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_20518d58-13eb-411e-90e7-f50103affb41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43c36816-0a6c-42e6-898e-356be164be14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_20518d58-13eb-411e-90e7-f50103affb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f8ddfa5-68e5-4069-8702-65713e25991a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f8ddfa5-68e5-4069-8702-65713e25991a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b4d71292-db5f-44b7-8654-5b18e412b0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:to="loc_us-gaap_AwardTypeAxis_b4d71292-db5f-44b7-8654-5b18e412b0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a074f21e-623b-4baf-83ea-e68a9abce703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b4d71292-db5f-44b7-8654-5b18e412b0d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a074f21e-623b-4baf-83ea-e68a9abce703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_64160936-8c65-4312-9632-5cf04367b881" xlink:href="sgry-20201231.xsd#sgry_EmployeeStockOptionsAndStockAppreciationRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a074f21e-623b-4baf-83ea-e68a9abce703" xlink:to="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_64160936-8c65-4312-9632-5cf04367b881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_226a8ffa-6ddc-4cae-ab4c-ab5ccc8b6ec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_64160936-8c65-4312-9632-5cf04367b881" xlink:to="loc_us-gaap_EmployeeStockOptionMember_226a8ffa-6ddc-4cae-ab4c-ab5ccc8b6ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_1a3a8b1d-654f-4f76-bbc8-b7a4f163c663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_EmployeeStockOptionsAndStockAppreciationRightsMember_64160936-8c65-4312-9632-5cf04367b881" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_1a3a8b1d-654f-4f76-bbc8-b7a4f163c663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d781423-622c-48d3-9f37-28ca83bc5041" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:to="loc_srt_RangeAxis_8d781423-622c-48d3-9f37-28ca83bc5041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56fc79fa-b316-4a9a-9640-057f099968bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8d781423-622c-48d3-9f37-28ca83bc5041" xlink:to="loc_srt_RangeMember_56fc79fa-b316-4a9a-9640-057f099968bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7e8cfb1d-b9af-4470-91e7-6580127d5c68" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56fc79fa-b316-4a9a-9640-057f099968bf" xlink:to="loc_srt_MinimumMember_7e8cfb1d-b9af-4470-91e7-6580127d5c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ed3af610-54a3-47bb-b744-5b5d474dce6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56fc79fa-b316-4a9a-9640-057f099968bf" xlink:to="loc_srt_MaximumMember_ed3af610-54a3-47bb-b744-5b5d474dce6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4157e20a-21b3-4d23-af42-88be538d1f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34fe2ace-ab44-41d7-85ac-2b313d12c83b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4157e20a-21b3-4d23-af42-88be538d1f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_166c1d72-c759-4fc5-ba10-e9af7a39663f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4157e20a-21b3-4d23-af42-88be538d1f5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_166c1d72-c759-4fc5-ba10-e9af7a39663f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4157e20a-21b3-4d23-af42-88be538d1f5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_46bab2e6-64b5-4449-a4d8-04b1617d3ef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_46bab2e6-64b5-4449-a4d8-04b1617d3ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_41497c9c-c094-4793-915b-d63b07fcd57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_41497c9c-c094-4793-915b-d63b07fcd57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_90f8ee76-4a3f-486f-ade2-26585d29edd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_90f8ee76-4a3f-486f-ade2-26585d29edd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_481f2f22-d224-4275-a907-e5a4d0643d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_481f2f22-d224-4275-a907-e5a4d0643d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8c647b99-1db4-46b0-bbb5-1e3cc59f1624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8c647b99-1db4-46b0-bbb5-1e3cc59f1624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c9dc7cc2-757c-4b43-8c09-0473049e2d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c9dc7cc2-757c-4b43-8c09-0473049e2d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_767692b7-5dd1-4e77-a663-5e54ee471d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_767692b7-5dd1-4e77-a663-5e54ee471d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_fdf7fb7a-7fe2-4c3f-8f4a-bb8230370923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ee9aca75-5868-45ab-8eff-06c92630eea0" xlink:to="loc_us-gaap_SharePrice_fdf7fb7a-7fe2-4c3f-8f4a-bb8230370923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EquityBasedCompensationSummaryofOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4e11900-d98f-4d30-95eb-d299e439ff84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45d8a008-9cee-460c-983c-4ab20adb8038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4e11900-d98f-4d30-95eb-d299e439ff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45d8a008-9cee-460c-983c-4ab20adb8038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b14bf024-543f-4e02-b9de-9462a45ea199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45d8a008-9cee-460c-983c-4ab20adb8038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b14bf024-543f-4e02-b9de-9462a45ea199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d16a7a9d-9df9-44db-9ee0-9802bed82088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45d8a008-9cee-460c-983c-4ab20adb8038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d16a7a9d-9df9-44db-9ee0-9802bed82088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_289aae6b-fbf8-4a3f-9997-fe882efd5154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45d8a008-9cee-460c-983c-4ab20adb8038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_289aae6b-fbf8-4a3f-9997-fe882efd5154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43fcdbab-8341-4137-a411-ce8de72dd8da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45d8a008-9cee-460c-983c-4ab20adb8038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_43fcdbab-8341-4137-a411-ce8de72dd8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5712a1b-ed7d-45e2-b965-d4005c30c652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_45d8a008-9cee-460c-983c-4ab20adb8038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5712a1b-ed7d-45e2-b965-d4005c30c652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_672ea78b-36bd-4846-b8c2-7f8de075d97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4e11900-d98f-4d30-95eb-d299e439ff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_672ea78b-36bd-4846-b8c2-7f8de075d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c200fee7-c12b-4d89-9e10-ba3ee4dd3273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_672ea78b-36bd-4846-b8c2-7f8de075d97d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c200fee7-c12b-4d89-9e10-ba3ee4dd3273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_488225ad-9da5-4d7e-8086-0a8bafaa12f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_672ea78b-36bd-4846-b8c2-7f8de075d97d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_488225ad-9da5-4d7e-8086-0a8bafaa12f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_46c71d52-bad1-492f-bc10-8df2f8d7db92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_672ea78b-36bd-4846-b8c2-7f8de075d97d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_46c71d52-bad1-492f-bc10-8df2f8d7db92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6c57aeb5-fab5-4855-9437-2aedb1e85090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_672ea78b-36bd-4846-b8c2-7f8de075d97d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6c57aeb5-fab5-4855-9437-2aedb1e85090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec8e2c56-af9d-47ec-adf3-2de81748243b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_672ea78b-36bd-4846-b8c2-7f8de075d97d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec8e2c56-af9d-47ec-adf3-2de81748243b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd1f779-7b98-4e19-a5e9-56bb8948db64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4e11900-d98f-4d30-95eb-d299e439ff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd1f779-7b98-4e19-a5e9-56bb8948db64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a024bc37-9701-478c-aa64-6706cf9081c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd1f779-7b98-4e19-a5e9-56bb8948db64" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a024bc37-9701-478c-aa64-6706cf9081c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_bb12fe7a-b767-4a18-ac38-0d9ba98371ad" xlink:href="sgry-20201231.xsd#sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd1f779-7b98-4e19-a5e9-56bb8948db64" xlink:to="loc_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_bb12fe7a-b767-4a18-ac38-0d9ba98371ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_0926261b-d96f-46dc-914b-2a1e9c3413be" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd1f779-7b98-4e19-a5e9-56bb8948db64" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_0926261b-d96f-46dc-914b-2a1e9c3413be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_a461c369-f785-4c92-8855-82d4a0e00278" xlink:href="sgry-20201231.xsd#sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0dd1f779-7b98-4e19-a5e9-56bb8948db64" xlink:to="loc_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_a461c369-f785-4c92-8855-82d4a0e00278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_55dcb88a-1bc5-4384-95cf-b7f2b19c30f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4e11900-d98f-4d30-95eb-d299e439ff84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_55dcb88a-1bc5-4384-95cf-b7f2b19c30f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="sgry-20201231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0243b04e-2530-4377-bd32-da2ea633a32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_49b9d815-dad3-4554-997e-d06f0c77b392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0243b04e-2530-4377-bd32-da2ea633a32d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_49b9d815-dad3-4554-997e-d06f0c77b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_898f0eb6-d609-446f-a6ae-020f136f3ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DefinedContributionPlanVestingPeriod_06f5df8b-63b9-4ce3-8281-1f4c4fed865b" xlink:href="sgry-20201231.xsd#sgry_DefinedContributionPlanVestingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_898f0eb6-d609-446f-a6ae-020f136f3ed6" xlink:to="loc_sgry_DefinedContributionPlanVestingPeriod_06f5df8b-63b9-4ce3-8281-1f4c4fed865b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_86db86de-08e1-468e-a311-c0c1ee6c0d67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_898f0eb6-d609-446f-a6ae-020f136f3ed6" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_86db86de-08e1-468e-a311-c0c1ee6c0d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_9058a0a7-f9e8-4eae-a680-e0d8cb66eda2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_4a711dc4-c1e0-4171-bdb6-69fc023e5668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_9058a0a7-f9e8-4eae-a680-e0d8cb66eda2" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_4a711dc4-c1e0-4171-bdb6-69fc023e5668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ebd52182-5950-4ec4-9e7b-cc0b94106d89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_3b6df4a1-e9f8-44e4-a94f-d463d84079a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_ebd52182-5950-4ec4-9e7b-cc0b94106d89" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_3b6df4a1-e9f8-44e4-a94f-d463d84079a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b87654aa-7830-4b3d-8a6d-2893c3f65e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b87654aa-7830-4b3d-8a6d-2893c3f65e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_75ff6111-bd0d-4e1c-abad-a6e3739afd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:to="loc_us-gaap_LitigationReserveCurrent_75ff6111-bd0d-4e1c-abad-a6e3739afd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_2e052da5-8279-4dd8-85e4-dfc14a2ba8ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:to="loc_us-gaap_InterestPayableCurrent_2e052da5-8279-4dd8-85e4-dfc14a2ba8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementLiabilityCurrent_b2cd9dca-b1de-4248-8363-5c9d49596c57" xlink:href="sgry-20201231.xsd#sgry_TaxReceivableAgreementLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:to="loc_sgry_TaxReceivableAgreementLiabilityCurrent_b2cd9dca-b1de-4248-8363-5c9d49596c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PayablesToCustomers_0cba2a5d-5a9e-4583-90ae-23bad790ca0b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_PayablesToCustomers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:to="loc_srt_PayablesToCustomers_0cba2a5d-5a9e-4583-90ae-23bad790ca0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CostReportLiabilitiesCurrent_063a0cb8-546e-4424-8ea7-8a5e593feaee" xlink:href="sgry-20201231.xsd#sgry_CostReportLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:to="loc_sgry_CostReportLiabilitiesCurrent_063a0cb8-546e-4424-8ea7-8a5e593feaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_39387da6-72a9-45a1-8b9e-96470657d4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_39387da6-72a9-45a1-8b9e-96470657d4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_508b3af9-c663-48e5-88e5-b98f2c5f0532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a332077f-932f-49a0-ba55-fdc0e6f1458f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_508b3af9-c663-48e5-88e5-b98f2c5f0532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgry-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4ce4e64a-9d63-4858-8834-937a90529ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85ec79a6-641a-4dec-bc03-c4f5427c52a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4ce4e64a-9d63-4858-8834-937a90529ff0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85ec79a6-641a-4dec-bc03-c4f5427c52a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e830569-f5d1-4e93-b907-218c8b80dbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e830569-f5d1-4e93-b907-218c8b80dbd9" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_a7e3eb89-1262-43fe-8a62-5eb4c6426603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_a7e3eb89-1262-43fe-8a62-5eb4c6426603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_488e1f2c-4da7-4d4a-9b8a-e944a2d86d98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyByNatureAxis_a7e3eb89-1262-43fe-8a62-5eb4c6426603" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_488e1f2c-4da7-4d4a-9b8a-e944a2d86d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_MateriallyMoreRestrictiveMember_02a9a699-0c5a-4c41-94f3-ea08f3968afc" xlink:href="sgry-20201231.xsd#sgry_MateriallyMoreRestrictiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_488e1f2c-4da7-4d4a-9b8a-e944a2d86d98" xlink:to="loc_sgry_MateriallyMoreRestrictiveMember_02a9a699-0c5a-4c41-94f3-ea08f3968afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_NotMateriallyMoreRestrictiveMember_8647fc18-349c-4761-b3d2-87d136c2c2d7" xlink:href="sgry-20201231.xsd#sgry_NotMateriallyMoreRestrictiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyNatureDomain_488e1f2c-4da7-4d4a-9b8a-e944a2d86d98" xlink:to="loc_sgry_NotMateriallyMoreRestrictiveMember_8647fc18-349c-4761-b3d2-87d136c2c2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ef3d8ece-fcb5-44c6-b026-c11872d727b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:to="loc_us-gaap_VariableRateAxis_ef3d8ece-fcb5-44c6-b026-c11872d727b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_19a2cd2c-feec-4f36-8216-32b1351e01df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_ef3d8ece-fcb5-44c6-b026-c11872d727b0" xlink:to="loc_us-gaap_VariableRateDomain_19a2cd2c-feec-4f36-8216-32b1351e01df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d29830a0-3901-4456-8498-1dd8c434ca06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_19a2cd2c-feec-4f36-8216-32b1351e01df" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d29830a0-3901-4456-8498-1dd8c434ca06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_461d0aa9-d856-4e2d-b372-ba33fed63194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_19a2cd2c-feec-4f36-8216-32b1351e01df" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_461d0aa9-d856-4e2d-b372-ba33fed63194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:to="loc_srt_StatementScenarioAxis_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7b95484a-88cf-4031-8a95-d3b6a9350a66" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_28d2a2b9-37f2-40a1-8c5d-2e5d25fac972" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7b95484a-88cf-4031-8a95-d3b6a9350a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a0b95c56-552d-4324-9700-7bab9c3c4945" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7b95484a-88cf-4031-8a95-d3b6a9350a66" xlink:to="loc_srt_ScenarioForecastMember_a0b95c56-552d-4324-9700-7bab9c3c4945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_c4a9640d-045c-4125-aa14-ff941b126b4a" xlink:to="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_25910c58-9950-4625-85d8-aebacf373be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_SelfInsuranceReserve_25910c58-9950-4625-85d8-aebacf373be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_b003d844-7077-4388-a7bf-c54b7d84b2df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_b003d844-7077-4388-a7bf-c54b7d84b2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7a93d692-3e07-4209-a43a-55bb1f593305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7a93d692-3e07-4209-a43a-55bb1f593305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b12b57db-1b51-48cf-926b-405d6fcdd361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b12b57db-1b51-48cf-926b-405d6fcdd361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c2228ff3-64ba-427b-a5ad-4ee8fb7807c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c2228ff3-64ba-427b-a5ad-4ee8fb7807c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_e7bf692f-be40-4742-ac6c-72b70823aaf9" xlink:href="sgry-20201231.xsd#sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm_e7bf692f-be40-4742-ac6c-72b70823aaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9f4912a0-47bc-49ee-9c59-561694623300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9f4912a0-47bc-49ee-9c59-561694623300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_d45cc845-f701-4b77-b341-b776a68867e6" xlink:href="sgry-20201231.xsd#sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate_d45cc845-f701-4b77-b341-b776a68867e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_0c72b036-af13-4981-a5cc-89603a5321e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_us-gaap_TaxesPayableCurrentAndNoncurrent_0c72b036-af13-4981-a5cc-89603a5321e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_477b27a2-ec25-4b92-93c1-4c3475318872" xlink:href="sgry-20201231.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount_477b27a2-ec25-4b92-93c1-4c3475318872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent_74d0a836-82a1-47b0-924b-5114bf6a4803" xlink:href="sgry-20201231.xsd#sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_69b0b48d-0169-4403-9e64-af93baecbf89" xlink:to="loc_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent_74d0a836-82a1-47b0-924b-5114bf6a4803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b8a4e9fa-41d4-4c08-a8b4-b72139945b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_42517fae-1cad-410f-a736-34d59aee1e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b8a4e9fa-41d4-4c08-a8b4-b72139945b9f" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_42517fae-1cad-410f-a736-34d59aee1e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5166bc57-ab5b-43d0-885e-4044e090f039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_410ee3ff-4417-46c2-a175-8ae4a3c2d6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5166bc57-ab5b-43d0-885e-4044e090f039" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_410ee3ff-4417-46c2-a175-8ae4a3c2d6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_d0bf9ebd-cf55-4e18-ae08-667579ef2438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5166bc57-ab5b-43d0-885e-4044e090f039" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_d0bf9ebd-cf55-4e18-ae08-667579ef2438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_dc06ac82-4a83-45c6-97e7-354f7a8bc762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5166bc57-ab5b-43d0-885e-4044e090f039" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_dc06ac82-4a83-45c6-97e7-354f7a8bc762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bb3df29a-88ef-4204-a086-f0da8a7c8ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_426f16e8-ff9e-4b5b-88bd-9cf7310aedca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bb3df29a-88ef-4204-a086-f0da8a7c8ed4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_426f16e8-ff9e-4b5b-88bd-9cf7310aedca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bb3df29a-88ef-4204-a086-f0da8a7c8ed4" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c16b4673-aca4-416c-9d30-2b80811b97af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c16b4673-aca4-416c-9d30-2b80811b97af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c16b4673-aca4-416c-9d30-2b80811b97af" xlink:to="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_d79970b3-1479-4a7b-a0f9-c95ff39f181d" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:to="loc_sgry_SurgicalFacilityServicesMember_d79970b3-1479-4a7b-a0f9-c95ff39f181d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_28abceb5-9053-41f5-80a6-8f7665d03a0b" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:to="loc_sgry_AncillaryServicesMember_28abceb5-9053-41f5-80a6-8f7665d03a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember_ae122719-96bd-4965-b88b-241b9f0c9741" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33d9b653-4bfb-4429-8c75-335401866b3e" xlink:to="loc_sgry_OpticalServicesMember_ae122719-96bd-4965-b88b-241b9f0c9741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:to="loc_srt_ConsolidationItemsAxis_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8957b172-e1f9-438f-9c8c-7edfeec838f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_d3e8b5c6-1bd1-495b-8a6b-db61ecde4726" xlink:to="loc_srt_ConsolidationItemsDomain_8957b172-e1f9-438f-9c8c-7edfeec838f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_830ecd0b-6efd-4915-b429-c39b00e9bce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8957b172-e1f9-438f-9c8c-7edfeec838f4" xlink:to="loc_us-gaap_OperatingSegmentsMember_830ecd0b-6efd-4915-b429-c39b00e9bce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_64e0d2e8-2b15-4e32-bc1c-b69c80d0027f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_8957b172-e1f9-438f-9c8c-7edfeec838f4" xlink:to="loc_us-gaap_CorporateNonSegmentMember_64e0d2e8-2b15-4e32-bc1c-b69c80d0027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_92956d06-e8f9-45cc-b6b9-473cb5a4615c" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_10572ea8-d7e2-4884-9b75-171c99f3c827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_10572ea8-d7e2-4884-9b75-171c99f3c827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_f96dea13-c39a-4f40-a565-1b121acbf864" xlink:href="sgry-20201231.xsd#sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:to="loc_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization_f96dea13-c39a-4f40-a565-1b121acbf864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_03151bf2-7ab6-4a86-93ee-42ec902058d2" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_592aa038-0355-423a-b4f8-b4135a5a3d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_592aa038-0355-423a-b4f8-b4135a5a3d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4b937fc2-f769-413d-8cea-223ef8663152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4b937fc2-f769-413d-8cea-223ef8663152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7f08ba47-a59b-42a5-93df-f7ad0170cb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7f08ba47-a59b-42a5-93df-f7ad0170cb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fd643e82-912d-42a9-b4ed-12a5f356d802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fd643e82-912d-42a9-b4ed-12a5f356d802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5e469d02-b11d-468a-adbd-1d3dc63c23f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_ShareBasedCompensation_5e469d02-b11d-468a-adbd-1d3dc63c23f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_c8bcca10-9205-49ea-b636-69052a4a28ab" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts_c8bcca10-9205-49ea-b636-69052a4a28ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b6a96741-7194-4f5f-b7f2-242cfa9e86e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_AssetImpairmentCharges_b6a96741-7194-4f5f-b7f2-242cfa9e86e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_2eceba64-5f3c-4c72-85ad-9a0f177874da" xlink:href="sgry-20201231.xsd#sgry_GainLossOnDispositionOfAssetsAndDeconsolidation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation_2eceba64-5f3c-4c72-85ad-9a0f177874da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_f5ef9127-9708-44bf-ad53-43367117c366" xlink:href="sgry-20201231.xsd#sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts_f5ef9127-9708-44bf-ad53-43367117c366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c669d582-72fc-4ccc-958d-6d3a448fa69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_c669d582-72fc-4ccc-958d-6d3a448fa69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationContingentAcquisitionExpense_2bb3d415-83dd-44e6-ab77-f5f59d9e8c2c" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationContingentAcquisitionExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_BusinessCombinationContingentAcquisitionExpense_2bb3d415-83dd-44e6-ab77-f5f59d9e8c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_BusinessCombinationGainLossOnAcquisitionEscrow_f6780e94-aae5-4113-a35f-2c41aec3c15d" xlink:href="sgry-20201231.xsd#sgry_BusinessCombinationGainLossOnAcquisitionEscrow"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_BusinessCombinationGainLossOnAcquisitionEscrow_f6780e94-aae5-4113-a35f-2c41aec3c15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9aba3f31-26ce-4e14-87c3-61c7161ff45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9aba3f31-26ce-4e14-87c3-61c7161ff45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_TaxReceivableAgreementExpenseBenefit_e498fe0e-ae51-42ca-a777-2e4426fbf92e" xlink:href="sgry-20201231.xsd#sgry_TaxReceivableAgreementExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_TaxReceivableAgreementExpenseBenefit_e498fe0e-ae51-42ca-a777-2e4426fbf92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_da7c56f3-670c-43a5-bb44-31c8530d3821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_da7c56f3-670c-43a5-bb44-31c8530d3821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b96796f1-47d6-4046-8c10-d4aa14ba93ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b96796f1-47d6-4046-8c10-d4aa14ba93ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_StartUpActivitiesStartUpCosts_01339349-95cf-4223-851d-b9e1f628a01b" xlink:href="sgry-20201231.xsd#sgry_StartUpActivitiesStartUpCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_sgry_StartUpActivitiesStartUpCosts_01339349-95cf-4223-851d-b9e1f628a01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_a24e8cae-1d59-4dbd-8432-ec0f8b498e6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_a24e8cae-1d59-4dbd-8432-ec0f8b498e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_35daafa1-fa35-4fbd-be11-091c4a67264c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_0572f2b0-f7e2-47cd-bd43-6e311b0689bc" xlink:to="loc_us-gaap_LitigationSettlementExpense_35daafa1-fa35-4fbd-be11-091c4a67264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fc7d70f8-3ae5-4090-86a1-8b1353d79b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fc7d70f8-3ae5-4090-86a1-8b1353d79b1f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_0d5825e5-be55-4003-8aa6-21d8bd53a9a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:to="loc_srt_ConsolidationItemsAxis_0d5825e5-be55-4003-8aa6-21d8bd53a9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_55a46ec6-4517-4d91-986a-0e852d6f684a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_0d5825e5-be55-4003-8aa6-21d8bd53a9a3" xlink:to="loc_srt_ConsolidationItemsDomain_55a46ec6-4517-4d91-986a-0e852d6f684a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_73a15a6d-fcb1-47fb-b028-1c84ba9dadbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_55a46ec6-4517-4d91-986a-0e852d6f684a" xlink:to="loc_us-gaap_OperatingSegmentsMember_73a15a6d-fcb1-47fb-b028-1c84ba9dadbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_be83d22e-3b6d-4675-adbd-c60cda2ebc4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_55a46ec6-4517-4d91-986a-0e852d6f684a" xlink:to="loc_us-gaap_CorporateNonSegmentMember_be83d22e-3b6d-4675-adbd-c60cda2ebc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f8970200-ebba-4530-af95-94abfb5c5674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f8970200-ebba-4530-af95-94abfb5c5674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f8970200-ebba-4530-af95-94abfb5c5674" xlink:to="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_SurgicalFacilityServicesMember_6b2dc5a0-5697-468c-9dae-7b3a19e2ab06" xlink:href="sgry-20201231.xsd#sgry_SurgicalFacilityServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:to="loc_sgry_SurgicalFacilityServicesMember_6b2dc5a0-5697-468c-9dae-7b3a19e2ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_AncillaryServicesMember_6490e791-fd9e-4d2b-bbfa-b52b231f95dc" xlink:href="sgry-20201231.xsd#sgry_AncillaryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:to="loc_sgry_AncillaryServicesMember_6490e791-fd9e-4d2b-bbfa-b52b231f95dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_OpticalServicesMember_dca72184-9dc4-4fc3-8b1a-d61786fdaa45" xlink:href="sgry-20201231.xsd#sgry_OpticalServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c8cb4c22-a1d2-4e94-a075-b2b2468f651d" xlink:to="loc_sgry_OpticalServicesMember_dca72184-9dc4-4fc3-8b1a-d61786fdaa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_24fb48c1-9337-4193-a5b3-6a10cef31e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_cb7adb72-5d65-4905-81d3-67a8a7d5358c" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_24fb48c1-9337-4193-a5b3-6a10cef31e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_61083179-6f69-4b81-87be-34a24c944810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24fb48c1-9337-4193-a5b3-6a10cef31e50" xlink:to="loc_us-gaap_Assets_61083179-6f69-4b81-87be-34a24c944810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ad8af17-51e5-4962-98a2-a545ccb3bdbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_24fb48c1-9337-4193-a5b3-6a10cef31e50" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ad8af17-51e5-4962-98a2-a545ccb3bdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgry-20201231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_98adef3d-eaa3-4a63-bd2a-1b895f98508b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c5438da9-133e-4062-83e6-7de5a2caa2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_98adef3d-eaa3-4a63-bd2a-1b895f98508b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c5438da9-133e-4062-83e6-7de5a2caa2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgry-20201231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.surgerypartners.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_77bb51a3-799e-475f-9062-6b191790699f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_77bb51a3-799e-475f-9062-6b191790699f" xlink:to="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_78435cfe-13c9-4b00-9618-4a8cbb1abe82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_78435cfe-13c9-4b00-9618-4a8cbb1abe82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2738d885-8a1d-4a61-ab38-6334466d23d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_78435cfe-13c9-4b00-9618-4a8cbb1abe82" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2738d885-8a1d-4a61-ab38-6334466d23d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8a27a99d-ef27-410b-ba21-425a62ab0319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2738d885-8a1d-4a61-ab38-6334466d23d9" xlink:to="loc_us-gaap_SubsequentEventMember_8a27a99d-ef27-410b-ba21-425a62ab0319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_04c587ad-894f-4770-ae75-4ed324b7a534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3e2d56ba-99cc-4be9-ae54-dcae8435bfbf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_04c587ad-894f-4770-ae75-4ed324b7a534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PublicStockOfferingMember_d590ea5a-ab61-47d4-8dfa-2ef267897e8c" xlink:href="sgry-20201231.xsd#sgry_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_04c587ad-894f-4770-ae75-4ed324b7a534" xlink:to="loc_sgry_PublicStockOfferingMember_d590ea5a-ab61-47d4-8dfa-2ef267897e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_PublicStockOfferingFirmSharesMember_5b991978-aae7-446d-a13b-1c0d832a13d2" xlink:href="sgry-20201231.xsd#sgry_PublicStockOfferingFirmSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_PublicStockOfferingMember_d590ea5a-ab61-47d4-8dfa-2ef267897e8c" xlink:to="loc_sgry_PublicStockOfferingFirmSharesMember_5b991978-aae7-446d-a13b-1c0d832a13d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_600b2589-1ca8-409c-b9bb-f2b941c1a42d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgry_PublicStockOfferingMember_d590ea5a-ab61-47d4-8dfa-2ef267897e8c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_600b2589-1ca8-409c-b9bb-f2b941c1a42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_CreditFacilityAxis_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_138c8c3c-34a1-4d94-b0da-4529bc0464ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_6d49bdb6-ee26-4f1a-88b5-66c8e6db537e" xlink:to="loc_us-gaap_CreditFacilityDomain_138c8c3c-34a1-4d94-b0da-4529bc0464ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4e0d4fdd-b0a4-4aed-acbf-85ba126a011a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_138c8c3c-34a1-4d94-b0da-4529bc0464ef" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4e0d4fdd-b0a4-4aed-acbf-85ba126a011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_790bc43b-e9c2-4591-926a-5921e427bbb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_DebtInstrumentAxis_790bc43b-e9c2-4591-926a-5921e427bbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a8a9739b-7814-4077-b6b1-42abb1cb964a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_790bc43b-e9c2-4591-926a-5921e427bbb7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a8a9739b-7814-4077-b6b1-42abb1cb964a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_A2017SeniorSecuredCreditFacilityMember_bb05b610-9bd5-4b67-bb4b-45d48dc11e6f" xlink:href="sgry-20201231.xsd#sgry_A2017SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a8a9739b-7814-4077-b6b1-42abb1cb964a" xlink:to="loc_sgry_A2017SeniorSecuredCreditFacilityMember_bb05b610-9bd5-4b67-bb4b-45d48dc11e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_7b41213f-fa23-4e44-a9d4-5d48b28377ee" xlink:to="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_705a2d95-abee-419e-9d20-c6f2fe37ebcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_705a2d95-abee-419e-9d20-c6f2fe37ebcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23731f68-4f92-4854-bfaa-45a0af60b746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23731f68-4f92-4854-bfaa-45a0af60b746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1178edef-e174-4fb8-ab80-9747225e54f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1178edef-e174-4fb8-ab80-9747225e54f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_08c8a583-90ae-47f4-a552-bc405170095d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_08c8a583-90ae-47f4-a552-bc405170095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease_77e9a398-78f1-408f-8282-2209b44587cb" xlink:href="sgry-20201231.xsd#sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7ac8bae3-c501-4410-a4a0-c1f585d5f3f8" xlink:to="loc_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease_77e9a398-78f1-408f-8282-2209b44587cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>sgry-20201231_g1.jpg
<TEXT>
begin 644 sgry-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YO;VYA;BP@
M1&%N:65L    !9 #  (    4   0J) $  (    4   0O)*1  (    #.#<
M )*2  (    #.#<  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C$Z,#(Z,3@@,3 Z,C<Z,S0 ,C R,3HP
M,CHQ." Q,#HR-SHS-    $X ;P!O &X 80!N "P ( !$ &$ ;@!I &4 ;
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 'G [P# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% ".I:-E5BA((#+C*^XSQ7FVD_##6(?%^H>(=8\3
MBXU I)'87EM9I'(A>&*,R2*<H6 B "A=IY/&0J^E44 <-'\-_P"T9-<N?%VJ
MC4[S6=.73));2V^RK%  ?NJ7?YRS%BQ..@  ZT6^$TE]I^H'7-=%UJMQ;VD%
MM>P6?DK;"V.^)O++MN)?EOF&1P-O6O1Z* .>\*>%W\/MJMW?7J7VI:M>&ZNI
MXX#"F=JHJ(A9B%"J.K$Y)YZ =#110!S?PX_Y)9X4_P"P+9_^B$KI*YOX<?\
M)+/"G_8%L_\ T0E=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '-_#C_DEGA3_L"V?_HA*Z2N;^''
M_)+/"G_8%L__ $0E=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '-_#C_ ))9X4_[ MG_ .B$KI*Y
MOX<?\DL\*?\ 8%L__1"5TE !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%,F$AMY! 564J=A8<!L<9KP?X437TOB;Q#X=\
M6ZKXBTGQ3=*PF5KA7CF(BB#2Q,P91(HP1MP CJ!D*-H![W17COA#7]0U34O&
ML7@.YU'6='T^P%O8SWM\\_VC40K9,<TK'Y3\N>0HX( #<X]QKFK^%O#LWA?4
MI-1M/$\MOIR3WW]N3WPDBFF$4LB>8<0R9WC"#C((8X!H ]ZHKAOA]>W*Z]XN
MT&6YNKJUTC4D6TDNYWFD6.2%7*&1R68!BV-Q) .,X KJ=6UJUT6*.2\BOI%D
M;:HL[">Z(/N(D8@>YQ0!E_#C_DEGA3_L"V?_ *(2NDKB_A7K5KJ'P[\.V<$5
M\DMKH]HLC3V$\,;$1*/DD= KCW4G(YZ5VE !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !113)9H[>%YIY%BBC4L[NP"J!U))Z"@!]<[XX\3#POX9EN8-CZC<.
MMKIT#MCSKF0[8U^F3D^P-7$U:>^O;1=(M5NM,N8#*VJ+<)Y:@@[0BC)<D@>B
M@'.2>*P=5^'<FKRZ1=7'BC5DU#2GEECNU2 EGD !.UHRJX P  ,9/?F@#*\
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M*?\ 8%L__1"5TE<W\./^26>%/^P+9_\ HA*Z2@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC+'CFNPU;6K718HY+R*^D61MJBSL)[H@^XB1B![G% &7\./^26>%/^P+9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MREB!C)VD9^G2@">>^M+61([FZAA>1@J+)(%+$\  'J:IZOXBT[0VB6_:X+S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLK5O
M%&AZ%,D&KZK:VL\B[T@>0>8ZYQE4'S$9XX% &K163I/B*WUFY>.SL]12)4W?
M:+JQDMT;D# \P*2><],>]5[Z3Q;->2Q:9;Z-:6RG$=S<S2SNX]3$JH!_WV:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)HVG6UD)B&E,,84R$=V/5C[G-:&,=* *$.I27FC&^LK&X\PJQCMKI# [$$@
MAONYQW[&LGS/&]X?EM]"TE?5Y9;UOR"Q ?F:Z6B@"AJ.FRZGI\=L^H75FX96
MDEL6$3/@<C)#$*?8Y]ZSK7P/H%O>17<EG)>W4+B2.?4+F2Z='!R&4R,VT@C@
MC&*Z"B@ HHHH **J3ZMIUKJ-O87-_;0WEUGR+=Y5$DN 2=JDY/ /3TK._M?5
M-3TQIM"TIH)O."+_ &QNMP4QS(%4,Q] K!"?;N ;E9][K=G8S6T4AFEDNI#'
M$MO \W((#$[ =H&>2< 5&VCR7-]<37^H7%Q;3P& V&%6!0P 8\#<2<'DL<9.
M,5<L-/L]+LH[/3;6&TMHAA(8(PB+SG@#CK0!GN=<O_[0MQ'#I,0(2TO$E$\K
M<_,YC*[5XZ99NO([5+!X?L4NK2]O(_M^HVD(ACOKE5:4#!RPP JL<G)4#.?2
MM.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** $=%DC9)%#HP(96&01Z&N8\-_#
MKPYX3U:ZU'1;22.:XX023O(MNA5 4B#$[%/EJ>/0#[H4#J** ,:/PEH<5OJ\
M T^-H=:E:;4(Y&9UG=E"DD,3C@#@8%4[;X>^&+72K[3ETUIK>_B6&X-S<RSR
M,B#"*))&+J%ZJ%(VGD8/-=+10!G:)H&G>';.2VTF!XTFF:>9Y)GFDED;&7>1
MR68X &23P .@%:-%% '-_#C_ ))9X4_[ MG_ .B$KI*YOX<?\DL\*?\ 8%L_
M_1"5TE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12.ZQH7D8*JC)8G
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M MG_ .B$KI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAD,U_8MK-RQ!-QK$K7K@C^[YA(7_ ("!VKJ:* $1%C1410JJ,*H& !Z4M%%
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M6=K'C3PSX>O5L]=U_3M.N602"&YN4C8J20#@GID'\JYWX?&0^-/B!Y>/L?\
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M8(@ID. .W0<9P.,DGJ23K44 5[73[*QDN)+*T@MWNI/-G:*((97QC<Q ^8X
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M_IS3_P#/=;94D'T=0&'YU7_X0BT@_P"07JVN:<>PBU.651]$F+J/H!BNEHH
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M!K,'AWPYJ&LW<<DD%A;/<2)$ 6954D@9(&>*-6\0:1H2*VL:C;6>_P#U:2R
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MV6;\2:U" RE6 ((P0>]+10!#]CMO^?>+_O@5*B+&H6-0JCH%& *6B@ HHHH
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MX_O$UO9(?X=+TY5=?^!S-("??8/I72T4 <U_P@>DW'.LS:AK)[C4+V22,_\
M;($1_P#CM;6GZ5I^DV_D:586UE#_ ,\[:%8U_)0!5NB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH CAMX;?S/L\,<7F.9'V*%W,>K''4GUJ2BB@
M HHHH YOX<?\DL\*?]@6S_\ 1"5TE<W\./\ DEGA3_L"V?\ Z(2NDH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ,8Z4444 <%%I_C/0O$_B&YT72
MM'O[/5;U+J-[G49('3$$<94J(6'6,GKWJ;3-,\5ZA\0+'7/$6GZ786UEI]Q;
M*MG?/<,[2O$V<-$F /+/YUV]% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-_#C_ ))9
MX4_[ MG_ .B$KI*YOX<?\DL\*?\ 8%L__1"5TE !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <W\./^
M26>%/^P+9_\ HA*Z2N;^''_)+/"G_8%L_P#T0E=)0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7O[ZUTO3[B^U"=
M+>UMHVEFED.%10,DFN9TGXH>%=8T/4=5AOWM[?379+E;F!XY%'F-&K!"-S!V
M4A0 23\N P*C3\96>F:AX*U>TU]ITTV:T=;E[>-GD1,<LH56)(Z]#TZ$5\^:
M%J6KR^"=3TU;Y=<\.Z)KD%\-2CC *QC4)#+OP?F!51.<\JKY)VXP ?1NB:]I
MWB&Q>ZTF=I8XYF@E62%XI(I%.&1T<!E8<<$ X(/0BM&O/_ADXO\ 6/&>L6DJ
MSZ9?ZSFSGC(:.8)$B,Z,.&7<",CCY378:M#K$T48T*^L;.0-^\:\LGN0P] %
MECP??)H R_AQ_P DL\*?]@6S_P#1"5TE<SX4T#7_  [H=EI-SK.FWEI86D5K
M;F/2Y(I-L:A06)G8$X'8#FMSR[__ )^;;_P';_XN@"U157R[_P#Y^;;_ ,!V
M_P#BZ/+O_P#GYMO_  ';_P"+H M455\N_P#^?FV_\!V_^+H\N_\ ^?FV_P#
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M5(6 (!(!)P/>JWEW_P#S\VW_ (#M_P#%U'+:WTLD+FZMP8GWC%NW/RE?[_\
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MCR[_ /Y^;;_P';_XN@"U157R[_\ Y^;;_P !V_\ BZ/+O_\ GYMO_ =O_BZ
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MCR[_ /Y^;;_P';_XN@"U157R[_\ Y^;;_P !V_\ BZ/+O_\ GYMO_ =O_BZ
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M^])C2)  +C<Y(9/G'J!0![ #E01W]1BBH;0SM8P&\4+<&-3*JG(#8Y'YU-0
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MZ%HUKX>\/V.CZ<@2VL8$@C &,A1C)]SU)[DF@"_1110 4444 %%%% !1110
M4444 %%%% !7-_\ "PO"ITW4]0CUF&6TTN<6]U-$K.JRG&$7 .\G<!A,\\=:
MW+^QM]4TVYL+Z/S;:ZA>&:/<5W(P*L,CD9!/(KQ[0O$>D?#*Q^).IFS2*RL-
M86.VL[=1&&8PH$C7 PH)[XX&3S0!Z?:>+]$O-'U#4XKMH[;3 YO1<6\D,EL%
M7>=\;J'7Y>>1R.1FJA^(7AA=8BTQM2(N9&A3FVE\M'E7=&CR;=B.PZ*Q#'CC
MFO)M!5]3^'.LWFH:WINI^(/&NJVEM?1:?<)*EG'*ZH(B%)P5B$AY[#'.TD]9
M\4->TVXGT_2].N/MFN:9JEI+%X?D0QB]8N-K8P&=4&YPR-L!7Y]P&* .];Q/
MHR^*$\.?VA$VKO ;C[(N698QCEL#"]1@$@GMFL^[^(7AJSD$<E]-+,9Y[<0V
MUE//(7A.)<)&A8JIX+8VY[UQFH:?I'A;X[V-]9VD-HDFBZA?7DBCYI7,BN[L
MQY/?Z#@8 Q6'K7C>Z\$_"7PYHNGRVMMXE\3PM<"XNY%AAL_/8RRRNS< @R$#
M/?GG&" >GWWQ"\+:=!9SW.K(T-Y;_:HI((I)E$.0OFN44B-,L!N? SGG@U?U
MSQ1HOAN*UDUO48;07DRP6X;+-,[$ !5&2>HR<8'4X%>#WMAIOA'1]3TVWU*&
M_M+_ ,$BPTJ\BD#I?W ED$D<)!.YB\H.Q23@]\5UOQ'\-VEIX)\,:E?6<;:W
M;W.E63W3C+JJR@E1Z99FSCKQG.!@ [^_\>>&],UXZ->ZCY=ZKQ1R 02-'"\N
M?+624*4C9L<!F!(P>XKHJ\"\:NL?C[Q&@A5-0DU/2GM=".0-;5<#SSGYFV?-
MS&54&+YPW->^T %%%% !1110 4444 %%%% !1110 4444 9NO^(=)\+Z/+JN
MOWT5C90_>ED)Y/8 #EB>P )-9VJ>/O#>C7*6]_?R+(UL+MO*M9I1#"3@22%$
M(C7W? X/I7/?&[1--U#X8ZQJ5]917%YI]C-]DED&?)+E-Q4= ?E'/4<XZG/)
M_%#QK]HL=)^'.FZG8Z5-JUC&VIZGJ$RQQ6EJ5P5&X@,[ 'C/3C^+<H!ZYJ7B
M71](D@34;^*#[1;RW,;-DJ8HE#2.6 P% 9>2>XQ5?1/&>@^(8+F;3+X[;6-9
M9Q<P26S1QLNY9"LJJ=A&2&Q@X//!KF-*ET^U\<75U;RF;2?#/ARWMH98E,[,
M)29&*[ 2W[N&(_*#G=[UE^'8M$\9_$#Q.D0@\2Z!J5I9W$^H.VY5E20M'9_+
MA2J@!MN-WS$2%L@  [FV\;^';SPT_B"TU-)M*6?[/]I2-R&D\P1@ 8RV7( (
M!!SQQ3+3QYX<O=:_LJVOV>Y-P]JKFVE6%YD&6C68KY;. #\H8G@\<&O+?!*)
M<^%O#.@PHBQW'BR[N'0+PL5M))-T]-ZQ#\:2[\5V_P 3/C!;V$6L6&G:+X9N
MF-M#-=)'<ZG?@,JE%)W;5)XP.>>N[Y0#U?1_&F@:]J<FGZ3?^?<(KN 89$65
M4?8S1NRA95#<%D+ ''K3E\9>'6U+5+ :M;_:-'A$^H#=\MLG/+M]T$;3D9R.
MXKR3X;9N]?\ A]8VIQ<^'M)OXM7@ ^:T<NJ".0?PL64D \D#/2KD7A3P]8^-
MO'OA]+<Z;HI\.6R2BSC+.B_O-S@ %G?OT))ZYH ]2T#Q7H_B83?V/<R.\(1I
M(I[>2WD57&4?9(JMM8=&Q@X.#P:V*\D^&K3ZK\2;W5K;6[;7M-M] M;$ZA9V
MI@B>7>SA,%V^<(06&1@O@A>!7K= !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP<KSP36C0 45G6>O:;J&N:EH]I<^9?Z6(C>0^6P\KS5+)R1@Y )X)QWQ6C0
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MCQ/XD\2R>,=3B_ME-+O0FG-H:SZC<PK(' +%+2&)Q=;Y"Z-G)4 ?= S7OU%
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M,+?5K7)=8P& W.<GA<L"0,*2"/1_#_BF'4FL=,U(?9/$,FE0ZC=Z>8W'D!\
MC)&.'RN,YXZ5T%% 'ENJ:?<ZC^TD8K/5[S2G7PDC&:S2%F8?;&^4^;&XQSG@
M \=:\VTG5=2TS1-*M+G4FL]%DNM6,EU-JLNF))<K,=N^>%&.[;N98\!6.>N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>sgry-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgry="http://www.surgerypartners.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgry-20201231.xsd" xlink:type="simple"/>
    <context id="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb7502bb866f48068b89dcf88b0dd9c7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia9b479934fbb4ecfa7a74bd97bccdd06_I20210303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2021-03-03</instant>
        </period>
    </context>
    <context id="id55b138001be441a9691661db6451a97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebd694edd2e84c559ed056b5007002ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i594520e2981546afb1cc70f2e2240d64_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9436eee8a582415faf17777a719e40aa_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib4cfe65a0e734fc490c352616432aa34_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ifa882503424e4da0be7dc022a7146191_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i2274a974182d4c01981835a4b40e9196_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ibe8ef1c59a844626a0e801b7a033af22_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i679f4a8d66c74b0bbb0c9afe9118ce6a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0c8fd711c66341d38d95caf13c2cb675_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0014fa9a093345e0a96dd7ea4e8aa0cf_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1711e7a812034ce28d37fce9a82165eb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i30805210d9e14b39939e153b9bd05398_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibe757e1f73a54e7fa3eb2b75fd451837_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i834d9736caee49309174d5e036c537c9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i80894f3165b5496ca5111f55aa3835ee_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9a50f5aedaa14987b3a169a2e743a7aa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic1d553aa54d740f48fcc1ab6b34d4095_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d9f0a869b8843a6862016205567c15b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a4b6a2e8a5d434dad534976125b83d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36e8c64b0ba846c18f5a7a46fa045bc7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4a23162dc89340049ff966ee6ce72f86_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if77a0a40975349a3b34383d5f0cb0c7d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1615052a3a7f484393a4b51a8b0cd4ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie56bc33ce06647288c4aef4b26242c11_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i541eb4cc07d4416ab46cdea917e05d4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i693318ba255342df98c96534cb3bdf86_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i975830e2f385428e80159f54d04d85df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if121998af9ae4288a4d53c8bf419dc1b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2303c6c0e9e483abccd08ac36c55d58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f4cb1d89ceb4b5380cabfddf941c7cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2369ebaa4684a78a2970d00fd9578f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b7bc629529e4c048c9abfe722e66014_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebc6bef361c04164a50070ac5d583e49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47d590096f6a4da5ae4f1dc1b45a84ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5eda05d02ba64f78991a4f0b2af38f0b_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgry:SurgeryPartnersIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sgry:BainCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i358a5e89179e41d0822a47803a3d6dac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgry:SurgeryPartnersIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sgry:BainCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if91011ef54014758871d4c1d7f4f8be6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesAmbulatorySurgeryCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33440f4bb58f4fee905410e7e11b9a27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:FacilitiesSurgicalHospitalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86b1a160332645c186bcb8e28fe6f17d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e7f2aea22094bddb8c6931fc0dea651_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i809eef37f4e54081a6dc49a891ecdaec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9eab8ecdfcc74e9e855708a2c1ca417f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i119f3f636b3d41ad852c157ef3a54380_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e3eaeb718994330b5ba6da8d0809206_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i911d67503a3e4528a30814a4348d8ea4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c30ac06941c4200b21b1e23272f2da0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0aa2c1066f2b4f8c8f0f3388f465debe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i162bdeb976434409ae1a1c6f77a718a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iadab410bba6e4144a75e318b53880035_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7bd4886dd3f74966858590367b6f85d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d560570554a4fd1b7a05ce7bb03e9d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4cb5f59640994a199093fe9c3ab2ac03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c0f5839140a4b41b51f5bd58cb54057_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5aa06470b17c4eb2b260df51cf4c128e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d2bbed9c6534351953638dbdb3614f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e98bfd347534baf87731104e3ebb009_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb1b7267569e4598a877a5bd1e7e60c0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idb74e0812a1a443d8b8840c07f69e351_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i765813026e6747489932f2af5293073c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc2bea721a2d47a69444093571e4ee96_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie75ead2faa6f445cbe2c4cea920cf20c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6f0752ff15148458214da6f9a47c887_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i281bab5aadc7405e927b61233cc41c4e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i37b3da5de5c04f86991cec578aae4497_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b4cc978af3f4a63b82fda4044e5fff5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9261ab18f79e429d8804ff5e25c2a493_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i825199532fc645f5b290bb16b440feda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibbd90e3a784c4bef8f5691eca433c93c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4bd378e171d0488e9bd9affdec483b9a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie3b0a3e3d1ca40ef8aa43b2e273dd745_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationOtherServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf8eaf96b18847fd812316b9aa3c3ea1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationOtherServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia042b57c0fae4f5ea23237a58e596e29_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationOtherServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibb6553b4b74c4d84abce7d64bb6e0233_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf8d6a4513eb4b37bf1fdd0a3cd39717_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i475a6b5170b94142b99badc78dfce138_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i599771c495cc475cb14cd51b2c80b0ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7ba3aeaa4184e578466ecc35d54af1e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id054af85841844e0a0510013723067b0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i142ee4c9bb7f48ac86443c88ccd89e60_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7005419b507e45a4aa93e70381643122_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8db4acdb7fc34959956ed5d777c0c8aa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:PrivateInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i36320eddebd1443f9992f87dccb87372_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2540c42567484e9c8d3478cf6157e2d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ab9c71919d94f0b8dd7b5473c520031_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if923233c958e4fd68b49484dc223744b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if7250d04b81545d2b83ffebe4398b150_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie8b4b08c817e40b59ede6eeeb62709da_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:GovernmentRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i885eb9ec2ef944bca136520bc4460c09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94c93236fd5e4fefa3dcd39e74f88113_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ec00cab9d2244fb80d85733bd9a7509_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89029e5f88e44f1fae990a75d8ef24c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i69ea7f0bf38e48f6a9c4239b60ad72f6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaab475b98e9148eeb2d8f43e3181a7bc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:SelfPayRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3172eb66c1954274b662b8b0387af2be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e2d986e12534bc0966c86c0cc1307aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e789cf2134b4a4dadeab6da7c134bbb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb93f590e80e4cedae1dcfd1b284ce87_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2f4fb0674ba4d63b328c08bd2cd38d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifd4902e6aed24239a5e4d6ed4e5c823f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherPatientServiceRevenueSourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia5d2f9dc0f01494986594870e8a27ffa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib051090172004935b836c83156fe9867_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd9ac1ba58bd4816b2c020ff0edcba26_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icafafb71f58e407ab4cf51f081227241_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia67253343d70443d9c7449f4a5c30664_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia4daf007b63f4b438c7341c6ac37b460_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:HealthcareOrganizationPatientServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i559b03a82e914664a3d8b0edaabe4911_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f9c8cab4fb14810be18a40a5b9653b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7933eb55bb3143ffa2fd7f711c754dbf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i334aefa151714dc18f1b5f1cf16fe5f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e0e51f9a61b4ac1bc4ea1f7ebbb64c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic75069bdec0e44eb9f28b52baa250e8a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgry:OtherServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifa680d2bf8ab4a2d9fb8d803777a046f_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="if5a946918c8b40eea1360771a870d93f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesNewMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia47d16d8651a47159a92c2d34a75506d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesExistingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if311991b251d46209bd73eff519dfe38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc2bd176b2b04f648164f8a60a3183bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilitiesExistingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24702e29b0c7414e8f65fabb99f154f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia0e4786142704b339656b078b2112468_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityAndPhysicianPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31f32ad0f9c64967bbb2cabcd332dc26_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ied5a1e05804145ceab2d258e6b9b8d9d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:SurgicalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i096eba00dd53417a97144cec06404675_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b7dd0518ae1499292593c611baed1c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i971b3ccc8c4c4158b9ebbc8fbe15c413_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">sgry:DisposalGroupFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9f21b36401084af9b89797997b0f33f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:PhysicianPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ae1dcb070914de6b4ac251dfe871c7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgry:PhysicianPracticeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic40107317bb949478adb6fc4f2480728_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba118baa03704512b22f936deffa8b05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib490a024fda045c39623460385f24d6d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76a8169409c44abfadcd0a3bf2b8aedc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d46b8144fe4446782868e671eeca87f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3956d1c7040d40d2970ded51a67c32b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa40fcdd276343a8aed6a9a9a6a6ea6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14ddb8219e714d378c98c211bb2cd34d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8c352ee9deb495eb58246bebe2e2e33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa5d9c2bf8a543b08549baa2240b44b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie020639241a94ada9a7368a42b91149c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85d10b5c4c724186a5d9f3bb4e69a0a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if889bbc6323c4947b0bc16cfb5b88f95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d88e3845dc244d99f64392bd5e6a2d5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i57cd5e7c106e4d9fb74e20bda4b999cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68828e4c55c440639deb9dee2ee8d14e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgry:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i414e49c153824db4964a4427b5015209_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fdb52583c8b4bdd9a662cb6d4c8c12a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffc0d8fbfdc542ba81423c554bc0a181_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:PhysicianIncomeGuaranteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie1353b03ccc64693b38954fb5b09eaae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:PhysicianIncomeGuaranteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cd340aebd954a4884612b124a17d582_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56f55624fc5d49db9e2be6b8db22e727_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i321bbd443b024763a2dbc89b24eaaa4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:ManagementRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5f27ae864964347a9304c5ef2222c1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8425e9689bd4f9b9c04b4df8dcc5f4a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83fa7ab9abbe4240abf5a9be8a23fd82_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1fb39a032ea34a87b804e96f67309730_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idbd41b7592e6496dae5a85b154e694ac_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i4557e793265d4ca487ef329aeaae1ae3_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="ib321c333fae04579844d5ee99972bb0e_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i1ca50bf762614029b46129e2456fd831_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i1e4dce1c02884dedb36cc96503232a23_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5a9ee60353764f1f89b9af4f623bf105_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8b51cb9aba5548ed93f4a31b4abdf654_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">sgry:AllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if68f779024f44d59b01b47b4693ce33d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:ManagementRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76b5285d66914d4383e39ad0ba826fc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sgry:ManagementRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ba1731476d74ce2b3d217aad57dcc60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc383438e0c44af2bf287f3600874704_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38f34da757564475b695308801b42f1e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67bb1da722a94a38b17d3ec8f7e25de4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic64394bce33e4e9ca4aca2ff0a3ab714_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1afaa2f8387439e98068fbf64e2ee04_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb34960793f34f629f106b22da0c737f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i817a7925476240d1a0297c22e048100c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i398bdf0cb33e4e9a95374ecf8c74bd27_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sgry:NotesPayableAndSecuredLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i673a6d4abfc04d07bc5da2e378ef3651_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2018IncrementalTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie06dea18e47140059ff8bee1f65d492e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e0832acb780465db2d59399c892b08c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i298880778d4c4020a86c49df919d29b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65745a05a0cd456ab8a525d60910efd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85862ab6835e41eda58eb91f7b761382_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb3f5b40bb954651a15a0509487a732e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia627d4a01c804d75933b140eb136c84a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2e9ba12a1484646852fb69358ef6c43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">sgry:OneMonthLondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie114fdfc808045a391295f7885a63b41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4cffedbc77074fe1a34b679e5841a01d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifdf5f1f86bf94962b6e3e0134fc3af0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04f59e4d834d47dbb571b78b88198617_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie302bdf463064d918c23dd05f960895d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017TermLoanMaturing2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaea8005193594087be6cd7ef7af8522d_I20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-22</instant>
        </period>
    </context>
    <context id="i30095dd0fcb34c208f8bbc81fe378695_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="i060e7eb7f3c84d6d94309114449b4f82_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="ia97d538681da4d98ae9a5301d88df53c_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">sgry:OneMonthLondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="ibd68cd8cfddc4609b3d3f2f07babb578_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="idb199e263568416fa7ab39a1d69ed544_D20200422-20200422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2020IncrementalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-22</startDate>
            <endDate>2020-04-22</endDate>
        </period>
    </context>
    <context id="i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i90553b5457f14a698b7cb8171b9a9315_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i568b49c59a4f4598aead50892e84c992_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i3dd7045767554040a7d60f075ade6642_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="ie0cdccdec4304478989201c4eb02dd07_D20170630-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="i9fe84b8f841949188f4220b606568120_I20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-11</instant>
        </period>
    </context>
    <context id="idb43c983a45f4e8591fd3ed40d5f1536_D20190411-20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-04-11</endDate>
        </period>
    </context>
    <context id="i0919062a6a4f4909a1ae4a4a597169ee_D20190411-20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-04-11</endDate>
        </period>
    </context>
    <context id="ib31650acf0ea42969dc4f705d51d36cf_D20190411-20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-04-11</endDate>
        </period>
    </context>
    <context id="i0635f303320f412186ec5ca19c6fe2f2_D20190411-20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-04-11</endDate>
        </period>
    </context>
    <context id="if9ee0fbd7a0a46f594cc7b82247aa031_D20190411-20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-04-11</endDate>
        </period>
    </context>
    <context id="ic250d2ed04ae490aaaa2e78fd360cb53_D20190411-20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-04-11</endDate>
        </period>
    </context>
    <context id="ia64e7b3f55a140e2b8f74b0d1c22c37b_D20190411-20190411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">sgry:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-11</startDate>
            <endDate>2019-04-11</endDate>
        </period>
    </context>
    <context id="i8cd4c7600c0b479ab4a28ccae5406b84_I20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:SeniorUnsecuredNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-30</instant>
        </period>
    </context>
    <context id="i50ba0a151834479a8473b3e13e71ff9c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">sgry:COVID19PandemicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bba07e3d9ed4c28b32eadb5928dc00a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e7768b7591548fb890286a99b93de1b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6fc81a25e5bb4918abcbd07201bcc95f_D20170831-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-31</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i504a7a32d45c41d5b54fd670857c3477_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-31</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i88337f9fbaa64e0ea242df6336604eda_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i2c7fbb2ada8c40c981d5f09669df59ab_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ib481dfff988242d29c23918931366022_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i36cc65a9e59d4da7ae3978ace772db56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50385fe9eb7447adb4a7a8c102372757_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i047b904f4f4f4b5787db655ab1545242_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe9c8ea68367495b9b437d93d0ca84d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9fe24d481eb644d19bca83b8dd928563_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie72a24a82e274959946cf1d65a10b85f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i26af377b8d9c4408a23b37c560fdc30e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icb46091aec85404086cdd6773d8811e8_I20171215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <instant>2017-12-15</instant>
        </period>
    </context>
    <context id="ib4a503d7300c4baaab4d78c7a78fe1ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f0306c05aea4ff8908dcdbb29dc76e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8ae2680c0a24c0f85638b06d6ff55bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib10c51e09f2a46dd82c6116912a94c59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5f2564128c34ff789c5d6d49d4f690e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sgry:InterestLimitationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0238428bd25e45529ad62844562813e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgry:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2828db13be9542a6b1c20843c59ad276_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e546cbd60bb4cb3b0bc3eb05ff08c90_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie26277c706b1409a8e1acda13f0eb374_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i038159bf343d4a9eaa27f787b51188c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7449dbb4efe040eeac8fd22c2a9264f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f57145632eb43a6ae9a59e0eb4f4180_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i90b10c28a8aa40f7a09f7a0424ba887c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i752e2e790a184e4ea39af03e843709ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafc9c624583e425f9f3f383d5de093bc_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i347f272139b64fc897dd427a48e7af13_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5f8b77cdfd93419e8d20d28aa5fff865_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7be8e78b15a040728e51f819890b13be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib77a4c3d6184412d9f09f4d2864124b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9be02e650974abdafe229970eab92a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56c4f778361246b18c21e65a767306f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:RestrictedStockAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib26f364f72d64a0e823a7afe664f2323_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9657217604e94a48a864adfb783bc292_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i88f2f675e83142ada36ac4b6fab72299_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if13a7bad162a4e20ba15bf84d71b699d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibf62d3954751451e9588e5a61073849f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f71503bac9d41d4a56501b58e940ca8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifbe4cdae49d547e68aed4ebe2e458b2d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icaab860223474d4faa76168a356ab862_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4fb3e91ef8ed486a975169f3a156bc61_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i52b51ef452dd4bca860d3742b03236b3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idf7576735fbf445695c40b6c3a4332d2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia5c74e08e90e4514b53e1711e6d6c993_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i65014b7959304f73b25e58fe57e3c32d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i689b53c3d93a499da0a1f5bd28ba963e_D20181216-20181216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-16</startDate>
            <endDate>2018-12-16</endDate>
        </period>
    </context>
    <context id="i08d2d66c878f4fb0a7b2c27692bcb2bf_D20181216-20181216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-16</startDate>
            <endDate>2018-12-16</endDate>
        </period>
    </context>
    <context id="i774ec9394898484282082d77fdad2ddf_D20181216-20181216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-16</startDate>
            <endDate>2018-12-16</endDate>
        </period>
    </context>
    <context id="i729242ab1a2347118df4dba4c57f77f1_I20181216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-16</instant>
        </period>
    </context>
    <context id="ibae4c0fc40e94a2db7579a9d625a90f3_D20181216-20181216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-16</startDate>
            <endDate>2018-12-16</endDate>
        </period>
    </context>
    <context id="ic9c47bc4b252439eb85adbb626c84a6e_I20181216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-16</instant>
        </period>
    </context>
    <context id="ie3da9fab6c3946a3bc42d096b6488712_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i32f863b1377d4c198f37e268eadcd88e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7bdae67446eb4958aeff2fbff938b5ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafdcd1de1b344a998031d19f82faed75_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0bc3ee9a1e98470592066703d4aa997b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sgry:EmployeeStockOptionsAndStockAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3474a6f91a7246d79ec08926d5336999_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i7b514b3c85dd48ff9fda4d7663a9cd66_D20210401-20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="i15035935d3e54ceba04f934c21488b65_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7b6963e13f944e28b5413d6c9ff381b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">sgry:MateriallyMoreRestrictiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dea0a1d35084b82bbde452684959945_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">sgry:NotMateriallyMoreRestrictiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0570cd69811f45e1b5ff58850aabd565_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8e40b357c844c71bed649d3cad09653_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a81da0560194155b4abbadf871ee362_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5878e06b7b984c2699576d1a46bb44f8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib03e505c471a4943901ca2907c0fa61e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie853ea8a85d94a4a8512ec67b36ff19c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77ebaf38db0d469ebf56d6ca77dfe0d3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib8d2ddf0e9f54c259b2891a8c533060d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i966ad612edb74fff9113dfbc6c476ba6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c3ef67ea7a94f358e2956bacd5abd58_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0ad8b729655c4567bc34b3b7387d4214_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10a47a68bb1747c897f4f19e04584916_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i59ad5e2b8c5f43b0aa69ebc006430ab4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if35b1248a15b4a04a53222c87069bd54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe470e2b3fd645a5a04d06fd9d60eae6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:SurgicalFacilityServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i018a6f0739764a949e8fe00e88704f6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d6d10cceadc435bbc6d90570a26a639_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:AncillaryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51b0f35b18de46988ff6fbe8c8307369_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8880a4c46df641179425ee1784d1c48d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sgry:OpticalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b34194b9c3e45b3861a805f0ab38022_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4027d5443cb745e1992a9fa9a7276711_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i98564e51940c4e91a27b5a49261520cf_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgry:PublicStockOfferingFirmSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="iaa0fb1e697bf46f98f1f119b51d1217a_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i596ba4d78eee424182ca76e6fe6f57f9_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="ibf9358b8a33748d69b07ec48689f9eee_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgry:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="iab383708d31447d6b0f9eb47c597c2e6_I20210127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638833</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sgry:A2017SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-27</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="state">
        <measure>sgry:state</measure>
    </unit>
    <unit id="surgical_facility">
        <measure>sgry:surgical_facility</measure>
    </unit>
    <unit id="physician_practice">
        <measure>sgry:physician_practice</measure>
    </unit>
    <unit id="surgery_center">
        <measure>sgry:surgery_center</measure>
    </unit>
    <unit id="surgical_hospital">
        <measure>sgry:surgical_hospital</measure>
    </unit>
    <unit id="optical_laboratory">
        <measure>sgry:optical_laboratory</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>sgry:reporting_unit</measure>
    </unit>
    <unit id="option_to_renew">
        <measure>sgry:option_to_renew</measure>
    </unit>
    <unit id="trading_day">
        <measure>sgry:trading_day</measure>
    </unit>
    <unit id="swap">
        <measure>sgry:swap</measure>
    </unit>
    <unit id="installment">
        <measure>sgry:installment</measure>
    </unit>
    <unit id="segment">
        <measure>sgry:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN180L2ZyYWc6Mjk2ZjRlZTlhZjg3NGVmYmEwY2NhZDJmNWUzZDg2NmMvdGFibGU6ZDRjNDM4ZDNlYzVkNDVmY2JkMzc4NDVhOTkwY2NmMzkvdGFibGVyYW5nZTpkNGM0MzhkM2VjNWQ0NWZjYmQzNzg0NWE5OTBjY2YzOV80LTEtMS0xLTA_f8efc247-74ef-46f3-a0e9-d9d0fa165345">0001638833</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN180L2ZyYWc6Mjk2ZjRlZTlhZjg3NGVmYmEwY2NhZDJmNWUzZDg2NmMvdGFibGU6ZDRjNDM4ZDNlYzVkNDVmY2JkMzc4NDVhOTkwY2NmMzkvdGFibGVyYW5nZTpkNGM0MzhkM2VjNWQ0NWZjYmQzNzg0NWE5OTBjY2YzOV85LTEtMS0xLTA_e3930639-6801-4ee3-a55d-1c8c4b1f9c81">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN180L2ZyYWc6Mjk2ZjRlZTlhZjg3NGVmYmEwY2NhZDJmNWUzZDg2NmMvdGFibGU6ZDRjNDM4ZDNlYzVkNDVmY2JkMzc4NDVhOTkwY2NmMzkvdGFibGVyYW5nZTpkNGM0MzhkM2VjNWQ0NWZjYmQzNzg0NWE5OTBjY2YzOV8xMC0xLTEtMS0w_191322f6-a838-4075-82b4-911fe3405b19">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN180L2ZyYWc6Mjk2ZjRlZTlhZjg3NGVmYmEwY2NhZDJmNWUzZDg2NmMvdGFibGU6ZDRjNDM4ZDNlYzVkNDVmY2JkMzc4NDVhOTkwY2NmMzkvdGFibGVyYW5nZTpkNGM0MzhkM2VjNWQ0NWZjYmQzNzg0NWE5OTBjY2YzOV8xMS0xLTEtMS0w_6d2f36ae-318f-4004-bbdc-169dfdcaed8b">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE4LTAtMS0xLTUzNzI_bdffc112-0257-4516-9c1f-1b9476bc5356">us-gaap:AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i9f21b36401084af9b89797997b0f33f6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODMyL2ZyYWc6M2VlZTMyMDEyNjNkNDRkZDgzZjMzYWM2NTljYTc4ODgvdGV4dHJlZ2lvbjozZWVlMzIwMTI2M2Q0NGRkODNmMzNhYzY1OWNhNzg4OF8yMTk5MDIzMjU1NTg3_11885956-b438-4123-9654-b4279331bc50"
      unitRef="physician_practice">1</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i4ae1dcb070914de6b4ac251dfe871c7d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODMyL2ZyYWc6M2VlZTMyMDEyNjNkNDRkZDgzZjMzYWM2NTljYTc4ODgvdGV4dHJlZ2lvbjozZWVlMzIwMTI2M2Q0NGRkODNmMzNhYzY1OWNhNzg4OF8yMTk5MDIzMjU1NTg3_5f16a2c0-8a1f-4818-bd76-736413278ad1"
      unitRef="physician_practice">1</us-gaap:NumberOfBusinessesAcquired>
    <sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed
      contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODMyL2ZyYWc6M2VlZTMyMDEyNjNkNDRkZDgzZjMzYWM2NTljYTc4ODgvdGV4dHJlZ2lvbjozZWVlMzIwMTI2M2Q0NGRkODNmMzNhYzY1OWNhNzg4OF8yNzQ4Nzc5MDY5NTE3_d9138148-15c0-4604-ad44-5c56f24b7219"
      unitRef="optical_laboratory">1</sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib490a024fda045c39623460385f24d6d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzMzNA_0c1bb596-84ab-46e0-9e07-1217a9251edc">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3d46b8144fe4446782868e671eeca87f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4MA_b602329f-ae4b-455f-ae04-0f191a8afe79">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iffc0d8fbfdc542ba81423c554bc0a181_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2MA_33fd34e1-3ee5-447f-b7a8-7df209baa23f">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0cd340aebd954a4884612b124a17d582_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5Mw_f789f954-9fee-479a-9ce3-41a85047306b">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if5f27ae864964347a9304c5ef2222c1c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNTk_bbc47750-6337-4405-89b2-99010957f9eb">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a">us-gaap:LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96">us-gaap:LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzg4L2ZyYWc6ZWVkNjVlNDNiNjY0NDAyNDlhN2YxYzEyOTg5OGJhZDkvdGFibGU6M2YwMjdlODgwNjgzNDk4NTk3M2E5NzJjYmY2ZGE1YzcvdGFibGVyYW5nZTozZjAyN2U4ODA2ODM0OTg1OTczYTk3MmNiZjZkYTVjN18yLTMtMS0xLTM2Nw_cdcfac35-2da8-4cd3-b311-03398c33e685">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzg4L2ZyYWc6ZWVkNjVlNDNiNjY0NDAyNDlhN2YxYzEyOTg5OGJhZDkvdGFibGU6M2YwMjdlODgwNjgzNDk4NTk3M2E5NzJjYmY2ZGE1YzcvdGFibGVyYW5nZTozZjAyN2U4ODA2ODM0OTg1OTczYTk3MmNiZjZkYTVjN18yLTMtMS0xLTM2Nw_f789f8d7-2e18-4d1e-a87e-594879655160">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzg4L2ZyYWc6ZWVkNjVlNDNiNjY0NDAyNDlhN2YxYzEyOTg5OGJhZDkvdGFibGU6M2YwMjdlODgwNjgzNDk4NTk3M2E5NzJjYmY2ZGE1YzcvdGFibGVyYW5nZTozZjAyN2U4ODA2ODM0OTg1OTczYTk3MmNiZjZkYTVjN181LTMtMS0xLTQ0Ng_79fa4e9c-8029-485a-b67d-891f828e728f">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzg4L2ZyYWc6ZWVkNjVlNDNiNjY0NDAyNDlhN2YxYzEyOTg5OGJhZDkvdGFibGU6M2YwMjdlODgwNjgzNDk4NTk3M2E5NzJjYmY2ZGE1YzcvdGFibGVyYW5nZTozZjAyN2U4ODA2ODM0OTg1OTczYTk3MmNiZjZkYTVjN181LTMtMS0xLTQ0Ng_a6f6d4b2-4c22-4648-9963-a062af536a48">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie26277c706b1409a8e1acda13f0eb374_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE0NjY_cd80199e-a025-45d6-ad9d-4f4ef62346f4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDA0_7413e9e2-7ff6-49d3-a7e5-03ebf4de1821">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDg3_458ed25c-5691-4ddb-8db1-41adb5125fd8">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NTMy_ec16deea-63f9-44fa-aaf4-7b1f4ca61ef4">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NTMy_d37fb2e8-9f29-4a97-a1a6-72cb17c29a53">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDg4_8510ee04-f652-4047-a9f4-fca186c8190b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NTM0_b77e96af-0b1b-4f66-bd90-8c1973f1c372">001-37576</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV80MDI_ff4608a0-5933-4722-a24c-60bab7257ea3">Surgery Partners, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6YTJmZDIxYTU1MWJkNDAxZmEwNTJjOTM2MzA4YzZhMWEvdGFibGVyYW5nZTphMmZkMjFhNTUxYmQ0MDFmYTA1MmM5MzYzMDhjNmExYV8wLTAtMS0xLTEyNw_1a1ecadc-d988-466c-8e86-485b3884fc73">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6YTJmZDIxYTU1MWJkNDAxZmEwNTJjOTM2MzA4YzZhMWEvdGFibGVyYW5nZTphMmZkMjFhNTUxYmQ0MDFmYTA1MmM5MzYzMDhjNmExYV8wLTItMS0xLTEyNw_25466809-9b65-4c07-b68e-44fbe5312f6e">47-3620923</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDg5_4cc19115-d488-427f-a7e9-b7cb3b6307d0">310 Seven Springs Way, Suite&#160;500</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDkw_85a11040-91ef-445a-b227-de28cc24ea1e">Brentwood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDA5_39d1e32b-f8f8-4f80-bb74-46d78d62d29a">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDEx_b28819b5-2e14-4c20-834f-402f5bc0feba">37027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDU0_17567d74-a102-43e9-a4c7-9b5cc423bfaf">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDUy_e192d356-69c8-404b-8b3a-c439633a03ab">234-5900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6NDEzNTIzNzhjODQyNDAzOGE2MjdjZDY3NzJhMTNjZGEvdGFibGVyYW5nZTo0MTM1MjM3OGM4NDI0MDM4YTYyN2NkNjc3MmExM2NkYV8xLTAtMS0xLTEzNw_01315365-0d86-4e39-8bf7-0c40f31b1f42">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6NDEzNTIzNzhjODQyNDAzOGE2MjdjZDY3NzJhMTNjZGEvdGFibGVyYW5nZTo0MTM1MjM3OGM4NDI0MDM4YTYyN2NkNjc3MmExM2NkYV8xLTItMS0xLTEzNw_7efa375a-a4a0-47a4-8756-d63eb0def3fc">SGRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6NDEzNTIzNzhjODQyNDAzOGE2MjdjZDY3NzJhMTNjZGEvdGFibGVyYW5nZTo0MTM1MjM3OGM4NDI0MDM4YTYyN2NkNjc3MmExM2NkYV8xLTQtMS0xLTEzNw_6b7d2358-14b5-41db-a8d0-eebb9c0c8530">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDkx_389ba448-ffde-4471-8c91-609d5457f7d2">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDky_1dc60127-e134-4c6e-b6a4-0d11eb46b56a">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDkz_39e65af4-5613-47cc-817f-cc3fa8042fa7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDk0_50be45fe-510a-4d68-8838-2232c326898e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6ZGI2MjRhY2YwYzViNGYzODg1OTU5YzQzZTAzNDFmY2EvdGFibGVyYW5nZTpkYjYyNGFjZjBjNWI0ZjM4ODU5NTljNDNlMDM0MWZjYV8wLTItMS0xLTE2MS90ZXh0cmVnaW9uOjBhNThiZjZiYjhkNDQ5YTU5NjJkZWY4NTExZDNlODZiXzIxOTkwMjMyNTU2MTQ_cf89f455-c0a4-4a32-b5dc-7d4b49bd8e5d">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6ZGI2MjRhY2YwYzViNGYzODg1OTU5YzQzZTAzNDFmY2EvdGFibGVyYW5nZTpkYjYyNGFjZjBjNWI0ZjM4ODU5NTljNDNlMDM0MWZjYV8xLTAtMS0xLTE5MS90ZXh0cmVnaW9uOmZmMTIyMzkxOWU5ZDRkYzliNzdkNzc0ZWMwODU1YzA0XzIxOTkwMjMyNTU2MTQ_38f27cb9-b0ba-475a-8264-0de7efdabec2">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGFibGU6ZGI2MjRhY2YwYzViNGYzODg1OTU5YzQzZTAzNDFmY2EvdGFibGVyYW5nZTpkYjYyNGFjZjBjNWI0ZjM4ODU5NTljNDNlMDM0MWZjYV8xLTItMS0xLTE4Ny90ZXh0cmVnaW9uOmZjNDhhMGIxOWE1ZjRiMGE5ODhhZWFjZTA5ZGU5Y2NjXzIxOTkwMjMyNTU2Mzk_2abfcf06-af37-42a7-8fcc-5349b3b6e5a2">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU5NjQ1_f074ee6c-3141-4bd9-83f4-da9107e2a2cb">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NDk1_ee64c247-3a9b-4243-ac32-995d5cad928e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ibb7502bb866f48068b89dcf88b0dd9c7_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV84Nzk2MDkzMDI1MjM4_588ed86a-e786-4879-9547-589b9360054b"
      unitRef="usd">255900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia9b479934fbb4ecfa7a74bd97bccdd06_I20210303"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yNTk4_d2252f1c-abd0-4a4e-9aa6-68c154332bbf"
      unitRef="shares">59859614</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xL2ZyYWc6NTM0NjEyM2MzOTdmNGQ5NmJiZTQwOTQ0MGRmNjk0ZTEvdGV4dHJlZ2lvbjo1MzQ2MTIzYzM5N2Y0ZDk2YmJlNDA5NDQwZGY2OTRlMV8yMTk5MDIzMjU4NTM1_6a22b6e9-bb28-4bde-8019-cdd9e6d62951">Portions of the registrant's definitive proxy statement for the 2021 annual meeting of stockholders are incorporated by reference into Part III of this report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzQtMi0xLTEtMA_fdbdccd8-2542-4060-8da6-9d3bdca872c8"
      unitRef="usd">317900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzQtNC0xLTEtMA_788a7d75-107b-4e71-becc-2424fb55f171"
      unitRef="usd">92700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzUtMi0xLTEtMA_699a30a8-9ce9-49fc-a8e2-ed218c664ca4"
      unitRef="usd">382200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzUtNC0xLTEtMA_46396158-d990-488d-a43b-3d5b604a2cc0"
      unitRef="usd">326900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzYtMi0xLTEtMA_5ddaf29e-fa37-498f-b62a-3613c058c729"
      unitRef="usd">56400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzYtNC0xLTEtMA_cf6d3690-4c6d-43b2-a799-afacb6d240b5"
      unitRef="usd">46300000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzctMi0xLTEtMA_f7f66c55-d309-4bef-9440-f869b41771ed"
      unitRef="usd">17600000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzctNC0xLTEtMA_83fb52fb-4fdf-45ce-aa62-bdd1ff87d212"
      unitRef="usd">17800000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzgtMi0xLTEtMA_9aff132d-431c-4fe4-8bfe-5cfb23783145"
      unitRef="usd">27400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzgtNC0xLTEtMA_9beb5646-b99c-459f-adf7-eeca99129547"
      unitRef="usd">41800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzktMi0xLTEtMA_8fa0002c-fedd-4436-8e71-4e1b6cc2eebb"
      unitRef="usd">801500000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzktNC0xLTEtMA_2d622bdb-680a-49eb-9f08-d6e29d490a62"
      unitRef="usd">525500000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEwLTItMS0xLTA_c9ba1164-905c-4665-8cf5-bce60d8b938b"
      unitRef="usd">544600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEwLTQtMS0xLTA_330a2761-12a4-445d-bcbe-788c2b45a4c0"
      unitRef="usd">523300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzExLTItMS0xLTQ4NTI_6249dc5b-4db7-4963-a034-cf82f0a1cd8a"
      unitRef="usd">46900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzExLTQtMS0xLTQ4NTI_d34e675f-dfe1-41d9-8289-b7c8ea5555d1"
      unitRef="usd">47300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEyLTItMS0xLTA_bf0f3dd9-3635-411e-84ac-03c00231b29e"
      unitRef="usd">3468000000.0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEyLTQtMS0xLTA_7a68b1a6-3f54-4fe4-8ccb-662866a6898a"
      unitRef="usd">3402400000</us-gaap:Goodwill>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEzLTItMS0xLTA_4cdc0e71-a0df-4bbe-9112-25777f3f30a1"
      unitRef="usd">90300000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEzLTQtMS0xLTA_4c7fa028-e7b9-47d6-ba1f-0b924a1f8fb3"
      unitRef="usd">93200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEzLTItMS0xLTMxNTU_1bf7fa5c-5ea9-47c6-aa5e-2e868fdbe7e3"
      unitRef="usd">310100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzEzLTQtMS0xLTMxNTg_3f478364-70ef-4364-ae27-fbb92cea270d"
      unitRef="usd">297700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE0LTItMS0xLTA_798becec-112d-4d2c-b7e1-f0f077d00855"
      unitRef="usd">124800000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE0LTQtMS0xLTA_7379c0b8-13be-46f7-b3ac-e314672cf01c"
      unitRef="usd">98700000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE1LTItMS0xLTA_e3fbb22b-867c-48e1-8167-6f6a182c4f36"
      unitRef="usd">27000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE1LTQtMS0xLTA_9430f8e0-b4b8-4cc6-b709-835ed183a406"
      unitRef="usd">30800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE2LTItMS0xLTA_693363fb-7649-4779-a3b9-60a0483d7803"
      unitRef="usd">5413200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzE2LTQtMS0xLTA_c31eb2b4-c844-4db0-b7ad-6d8af512257d"
      unitRef="usd">5018900000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIwLTItMS0xLTA_713f40bb-f28e-4557-af98-71d3eba1c0cb"
      unitRef="usd">100200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIwLTQtMS0xLTA_2cd101b9-db30-4a47-bb86-65716d10aaa1"
      unitRef="usd">96700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIxLTItMS0xLTA_3bdf1578-6b73-4966-add0-1e26174f880b"
      unitRef="usd">65400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIxLTQtMS0xLTA_dcbedfad-a780-4f92-8a51-e9a9833a67a9"
      unitRef="usd">54200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIyLTItMS0xLTMxNjM_4456cbf3-ca54-42ed-bf88-91001b08661c"
      unitRef="usd">109800000</sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent>
    <sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIyLTQtMS0xLTMxNjY_21f3366e-1c3f-47f5-ba95-6d9ab6daa66c"
      unitRef="usd">0</sgry:MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIyLTItMS0xLTA_6f3f8deb-f2d7-4da8-9ab9-dd11ed060148"
      unitRef="usd">217000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIyLTQtMS0xLTA_cb45a5ae-8798-4c6b-b26c-c1c9452db089"
      unitRef="usd">191200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIzLTItMS0xLTA_8a1cd895-2b3d-4691-8ecb-51c869d83cd7"
      unitRef="usd">64400000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzIzLTQtMS0xLTA_eef14053-a5fc-4311-9f71-e49989af451d"
      unitRef="usd">56000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI0LTItMS0xLTA_38de1d9b-c1ab-42fb-a75d-97aafcddc783"
      unitRef="usd">556800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI0LTQtMS0xLTA_77dba14c-0c40-4f98-9b83-4850cbefb70c"
      unitRef="usd">398100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI1LTItMS0xLTA_f0e5ce02-86bf-4716-8c60-17ca247b248b"
      unitRef="usd">2792400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI1LTQtMS0xLTA_2acd264f-03f5-433f-9d24-0ca53edd7739"
      unitRef="usd">2524700000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI3LTItMS0xLTMxNzE_22004b87-d7fa-4c22-b9e4-fbaadaa94231"
      unitRef="usd">300900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI3LTQtMS0xLTMxNzQ_92622221-e0ed-420d-9813-faa32569f748"
      unitRef="usd">283100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI2LTItMS0xLTA_2e79fe4e-7b6e-497e-870c-eed4f5e10ba7"
      unitRef="usd">139700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI2LTQtMS0xLTA_e8bbb0af-c108-48b9-beeb-44f7687260d5"
      unitRef="usd">113600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI4LTItMS0xLTA_b526b08f-3cbe-40ce-85cb-970e10beac3e"
      unitRef="usd">306800000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI4LTQtMS0xLTA_27530487-3952-4c6d-93e0-fd2b0c5aa52c"
      unitRef="usd">321000000.0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_2a55f59e-1218-4527-96e3-1fa412208010"
      unitRef="shares">310000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_2f337272-bbd9-4ba0-8070-cbf55e55f4d0"
      unitRef="shares">310000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_5ff032f2-8e88-457e-863e-b245b2d6f74a"
      unitRef="shares">310000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_bccb22e7-d929-4fe5-a2e2-58be6778a3fc"
      unitRef="shares">310000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_d309bf1b-9734-46e1-b232-9a630d5ea147"
      unitRef="shares">310000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzA2_f31dc134-a12d-4f1e-b9ce-fa126eff273b"
      unitRef="shares">310000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzE1_4308eb32-207b-4826-b2e0-57a3374e743d"
      unitRef="usd">434500000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ODNhNzBlOTA5MTA0N2YzOWQwMzRkMGJkMGJlOGI0MV8yMTk5MDIzMjU1NzI0_74d39bbf-69e0-44d8-bf17-dcd696cbde33"
      unitRef="usd">395000000.0</us-gaap:RedeemableNoncontrollingInterestEquityPreferredRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTItMS0xLTA_1bfdbd97-a2fb-435c-a090-a5b3f5e45f40"
      unitRef="usd">434500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzI5LTQtMS0xLTA_6ccfdd15-fb4f-4f66-bae5-4073eb3085dc"
      unitRef="usd">395000000.0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1NjYy_478f70a6-5550-40d4-ac65-08b8f00369a0"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1NjYy_5efbd72e-e1c5-4f10-8a59-5e0ec93260a4"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njc1_b764141a-e244-4237-a236-df89b094e1e6"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njc1_d4b25b13-5042-43d0-9df5-af17d242d0cb"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njgy_55c5c300-822e-401f-b9e6-5d467b842b52"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njgy_772069d2-cf1c-4647-9343-9a05af781227"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njgy_f0cbdb9e-f249-470f-a573-7ccb6b1734e4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjpiNmQzMmJmMTFlNDQ0NmMxYTYyMmY4MzI5MGI2ZDczN18yMTk5MDIzMjU1Njgy_f80f3b56-6498-486a-92c8-92749e064bce"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTItMS0xLTA_0e1d694a-1586-4e1a-bf36-3acaec6e0c5e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMyLTQtMS0xLTA_22ec924c-cd89-4630-9ae0-3eeb88ca2c4a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1Njk2_09c9c318-db21-4449-b728-df0154b709d2"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1Njk2_f7480a73-8b07-468b-b82b-8d222cd1d289"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzEw_b50247d9-945e-421e-bd3a-aa764c508d23"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzEw_fe330f8f-4757-4598-9660-2673d2359368"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzIz_108c39e1-406c-4908-be04-0f03892578ee"
      unitRef="shares">50461706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzIz_13ca947f-dc0e-497f-a67b-7f3f234fbf1f"
      unitRef="shares">50461706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzM2_8b0b8c97-3110-471e-913a-cecbdb627b26"
      unitRef="shares">49298940</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTAtMS0xLTAvdGV4dHJlZ2lvbjo4OGFlYTJjZDA2YWU0N2M1ODQ2ZTM0ZjRjMDM3NGJiZV8yMTk5MDIzMjU1NzM2_906f3d79-da66-4b40-94f3-1710c2f97791"
      unitRef="shares">49298940</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTItMS0xLTA_f52dc9b9-d0c1-4ef1-a6c0-9126c08d3bfb"
      unitRef="usd">500000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzMzLTQtMS0xLTA_28d5c6e4-7ee9-4d40-a00e-f5db77d92d98"
      unitRef="usd">500000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM3LTItMS0xLTk1ODQ_27516f73-e537-4e39-8b65-2408ac62d469"
      unitRef="usd">607900000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM3LTQtMS0xLTk1ODQ_b58f985c-3d97-4722-8f6f-85270559b51e"
      unitRef="usd">662700000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM4LTItMS0xLTk1ODQ_3f003a64-aad8-4273-a6dd-846c0176caa2"
      unitRef="usd">-61000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM4LTQtMS0xLTk1ODQ_add67725-5df1-49a9-a1ac-5c0b6dc65dac"
      unitRef="usd">-50700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM2LTItMS0xLTA_b61ae8bc-2da8-4b29-a06a-f7bad67efb96"
      unitRef="usd">-431800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM2LTQtMS0xLTA_ef4447cb-30f0-4078-a143-7d6d280c314c"
      unitRef="usd">-315700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM3LTItMS0xLTA_9ac1e76b-dbba-4817-80a7-43e2cad4510e"
      unitRef="usd">115600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM3LTQtMS0xLTA_62f15ccf-b758-48c9-9d09-4b63d25af9f3"
      unitRef="usd">296800000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM4LTItMS0xLTA_aa98e3fc-0b15-4f0b-93ec-fb176025b2b8"
      unitRef="usd">766500000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM4LTQtMS0xLTA_41471970-f8a0-4863-a637-b721ab8d3b6f"
      unitRef="usd">686600000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM5LTItMS0xLTA_b719a53a-1bd0-4cb5-b576-575d8e9e77d0"
      unitRef="usd">882100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzM5LTQtMS0xLTA_9d6d5492-eb0b-4a9a-9bbc-3327f95b4198"
      unitRef="usd">983400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzQwLTItMS0xLTA_8195f093-355e-40d0-bb3b-e20d546f241b"
      unitRef="usd">5413200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjEvZnJhZzo1ZTVjNDQ0NDgwMjk0NjMwYTc4MTQ4YWNjNDAxMzdkNC90YWJsZTowMDg5MTYzNjg0ZWQ0YzgwYTI0NjRiNzM1MDFmOTYzMC90YWJsZXJhbmdlOjAwODkxNjM2ODRlZDRjODBhMjQ2NGI3MzUwMWY5NjMwXzQwLTQtMS0xLTA_490a75c4-7ec9-40c1-90b5-b2fc546b6b07"
      unitRef="usd">5018900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzQtMi0xLTEtMA_f6c94a83-11e4-4524-9073-d22fa2fe31ed"
      unitRef="usd">1860100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzQtNC0xLTEtMA_6b1cc5e3-ba1a-4863-a2b7-eece50e04eed"
      unitRef="usd">1831400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzQtNi0xLTEtMA_59f3752b-f8df-4133-811e-81570abf2964"
      unitRef="usd">1771500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzYtMi0xLTEtMA_b64fe9b2-ad3b-4270-8459-6d609e9e2db3"
      unitRef="usd">550300000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzYtNC0xLTEtMA_671c0650-6899-4063-b11c-a92f9ee31283"
      unitRef="usd">550000000.0</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzYtNi0xLTEtMA_e71a18f0-3fe2-41b8-8d19-0514f98e8655"
      unitRef="usd">534700000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:SuppliesExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzctMi0xLTEtMA_faaf0dca-f003-4f09-8fa1-f6ed4d891942"
      unitRef="usd">538400000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzctNC0xLTEtMA_aad69b0b-1ca6-483a-8341-fbf21891abff"
      unitRef="usd">507900000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzctNi0xLTEtMA_52b9ca4c-972b-455a-89f4-770e2927dbe2"
      unitRef="usd">490300000</us-gaap:SuppliesExpense>
    <us-gaap:ProfessionalFees
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzgtMi0xLTEtMA_dbe51bbf-aaf0-4399-87cd-ea1a63a7a786"
      unitRef="usd">191400000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzgtNC0xLTEtMA_4de7bd67-df0b-4938-97ef-112916ff563b"
      unitRef="usd">154800000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzgtNi0xLTEtMA_cc9dd5e4-2486-432f-9c11-a113fb4ad2f5"
      unitRef="usd">145500000</us-gaap:ProfessionalFees>
    <sgry:OperatingAndFinanceLeaseExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzktMi0xLTEtMA_7d3ae762-9e7e-44af-a2c4-1eb61eb2fe8d"
      unitRef="usd">87400000</sgry:OperatingAndFinanceLeaseExpense>
    <sgry:OperatingAndFinanceLeaseExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzktNC0xLTEtMA_49753009-c9f9-42e6-a3aa-641e8002281c"
      unitRef="usd">85600000</sgry:OperatingAndFinanceLeaseExpense>
    <sgry:OperatingAndFinanceLeaseExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzktNi0xLTEtMA_2d9afecd-a4e5-4b0d-8b2d-f968b12936ce"
      unitRef="usd">86700000</sgry:OperatingAndFinanceLeaseExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEwLTItMS0xLTA_0df79c46-057e-4834-94c8-447b286db7d8"
      unitRef="usd">112800000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEwLTQtMS0xLTA_8eb53d03-e595-4bea-8c73-ea7bc17fb798"
      unitRef="usd">109300000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEwLTYtMS0xLTA_aa3d1e0f-30dd-4afc-a7c9-ec8027e3a247"
      unitRef="usd">104200000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzExLTItMS0xLTA_73823f3b-2a6e-4d8a-a739-2758391235c8"
      unitRef="usd">1480300000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzExLTQtMS0xLTA_ebd5d501-dd4e-47df-9f4a-0f639fa5e3db"
      unitRef="usd">1407600000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzExLTYtMS0xLTA_e400c0af-1559-4694-b9d5-1df261d97e74"
      unitRef="usd">1361400000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEyLTItMS0xLTA_5fed4d9c-f51d-4f52-9bf1-78380f48aaf7"
      unitRef="usd">97100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEyLTQtMS0xLTA_d1e152b6-cd2d-43e5-9fdd-aa6ccf4aab94"
      unitRef="usd">88600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEyLTYtMS0xLTA_c990da7c-ae92-4bcb-a88b-f940df16137c"
      unitRef="usd">93600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEzLTItMS0xLTA_8ab6b417-2c07-4fe7-9ce8-79291b1ecff3"
      unitRef="usd">94800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEzLTQtMS0xLTA_e31f8eda-8790-4aef-b3ac-a75207016ac3"
      unitRef="usd">76500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzEzLTYtMS0xLTA_2792f037-e601-4580-b293-97f83c7d5874"
      unitRef="usd">67400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE1LTItMS0xLTA_afa9f058-3c0c-4a5a-967f-1c02b462a7ed"
      unitRef="usd">10800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE1LTQtMS0xLTA_934d77dd-1714-4bee-8373-4c9d3212e7da"
      unitRef="usd">10200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE1LTYtMS0xLTA_61793cfd-5beb-41b0-b082-5516cbdf3372"
      unitRef="usd">8900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE2LTItMS0xLTA_09efc25b-ae45-458e-a674-7fcdae0dfdd6"
      unitRef="usd">-5700000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE2LTQtMS0xLTA_19953f1c-2b67-4036-820a-0d830443e61a"
      unitRef="usd">4400000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE2LTYtMS0xLTA_f7042255-1312-4dc1-ac43-cfb80caa5140"
      unitRef="usd">-31800000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE3LTItMS0xLTA_06b54f47-c1f9-40ec-8d53-2d2543618540"
      unitRef="usd">23200000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE3LTQtMS0xLTA_3e5ee7ef-9653-4814-b6d8-f03796ac3d3a"
      unitRef="usd">19000000.0</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE3LTYtMS0xLTA_fbc37e04-8bea-4e07-abae-5e91842948d9"
      unitRef="usd">31700000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTItMS0xLTA_b4ed3ed5-eda2-41da-b0e6-011756edd215"
      unitRef="usd">33500000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTQtMS0xLTA_bf423b14-6b7f-4bda-b7f8-50cbbe34759f"
      unitRef="usd">7900000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTYtMS0xLTA_6787279a-2006-461f-af36-df6c9987496e"
      unitRef="usd">74400000</us-gaap:AssetImpairmentCharges>
    <sgry:GrantRevenue
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTItMS0xLTMxODg_cb9a80e4-3975-4268-9618-ae3bd3b5132d"
      unitRef="usd">46200000</sgry:GrantRevenue>
    <sgry:GrantRevenue
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTQtMS0xLTMxOTI_229fbcef-69af-44aa-b3f0-d1e9b21bdfba"
      unitRef="usd">0</sgry:GrantRevenue>
    <sgry:GrantRevenue
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE4LTYtMS0xLTMxOTU_1a66c031-d030-4978-bb85-a54147cbddb1"
      unitRef="usd">0</sgry:GrantRevenue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE5LTItMS0xLTA_6e7d31ec-885d-44f5-a56b-61100717cf9b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE5LTQtMS0xLTA_3d703722-639d-4dee-a39b-d9b4255173f3"
      unitRef="usd">-11700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzE5LTYtMS0xLTA_e01fef9e-104b-4e25-82ee-069650f58ac7"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIwLTItMS0xLTA_ec370b5e-2c66-4597-8121-e8f3781ad0fe"
      unitRef="usd">-1200000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIwLTQtMS0xLTA_a4bf2f66-b5b7-4f06-aa6f-3d24b7cf9e40"
      unitRef="usd">-200000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIwLTYtMS0xLTA_be86ceba-aa0a-4410-87f9-6bf656f192a6"
      unitRef="usd">-46000000.0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OtherNonrecurringIncomeExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIyLTItMS0xLTA_e711d129-0cac-4ab5-b0a3-c06c8c29624e"
      unitRef="usd">-1700000</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:OtherNonrecurringIncomeExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIyLTQtMS0xLTA_fa55b1af-93a6-47d4-b4c5-63c6256fa490"
      unitRef="usd">-1400000</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:OtherNonrecurringIncomeExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIyLTYtMS0xLTA_249a6c10-b770-4456-9ea5-3d0335dcad77"
      unitRef="usd">-3700000</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIzLTItMS0xLTA_6408a5f4-75d4-4591-86ac-03a5c2f7d4a0"
      unitRef="usd">1677100000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIzLTQtMS0xLTA_77a2a262-8102-43e8-92eb-40d5cf34e2a5"
      unitRef="usd">1595500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzIzLTYtMS0xLTA_479d7c6b-2c7f-4eaf-89bc-c102171f8c36"
      unitRef="usd">1693700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI0LTItMS0xLTA_80956f18-b28e-4379-886b-16e7f8a0727c"
      unitRef="usd">183000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI0LTQtMS0xLTA_b4bc8efe-cbce-4e21-90a7-d88fcfbf24bd"
      unitRef="usd">235900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI0LTYtMS0xLTA_9e06bed7-69dd-43b2-8f17-9266803dac63"
      unitRef="usd">77800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI2LTItMS0xLTA_f0971c3d-a267-47f5-8480-b516e9edb66a"
      unitRef="usd">0</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI2LTQtMS0xLTA_84363e6d-e652-4c02-b821-88676f89a833"
      unitRef="usd">2400000</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI2LTYtMS0xLTA_934fe096-5cca-443b-aa21-849ac16b2674"
      unitRef="usd">0</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI3LTItMS0xLTA_4c6d2b5c-0fcd-41dc-a1eb-b825f7fb5a8d"
      unitRef="usd">-201800000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI3LTQtMS0xLTA_ea8c9e7b-3f4b-4fbe-909f-37257cf584d5"
      unitRef="usd">-178900000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI3LTYtMS0xLTA_0e427d26-d8b4-4b1d-bd15-80b655ff3e9d"
      unitRef="usd">-147000000.0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI4LTItMS0xLTA_c73bab2a-e123-4d07-8939-79f3e45740f4"
      unitRef="usd">-18800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI4LTQtMS0xLTA_22beae06-6914-4850-ba34-b76319ae3604"
      unitRef="usd">54600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI4LTYtMS0xLTA_c0c892cd-1387-4681-84e0-72555e53765c"
      unitRef="usd">-69200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI5LTItMS0xLTA_44ad3797-4b12-4190-b935-acabac31825e"
      unitRef="usd">-20100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI5LTQtMS0xLTA_06ae5004-3118-4151-bb91-a99e2faee8a2"
      unitRef="usd">9500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzI5LTYtMS0xLTA_feb54d46-5a53-4714-808b-193fa655df64"
      unitRef="usd">26400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMwLTItMS0xLTA_9182245b-3416-4da8-977b-5092c97207c9"
      unitRef="usd">1300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMwLTQtMS0xLTA_44e43cc4-4535-427d-915e-ee58d4363fa8"
      unitRef="usd">45100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMwLTYtMS0xLTA_81785881-161b-4db6-9d81-5f0ba7866117"
      unitRef="usd">-95600000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMxLTItMS0xLTA_c2d36fc3-7fd1-4ed2-a81c-039ff107a3d7"
      unitRef="usd">117400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMxLTQtMS0xLTA_66160a04-bd61-446b-8c99-22757da74129"
      unitRef="usd">119900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMxLTYtMS0xLTA_7ff030ee-f648-4ca9-9fbc-bcd29f93f07d"
      unitRef="usd">110100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMyLTItMS0xLTA_055925de-4410-4a3e-bf1f-e87dfae0cfa3"
      unitRef="usd">-116100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMyLTQtMS0xLTA_a0b4331e-3023-4616-bcb5-6e9b32869427"
      unitRef="usd">-74800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMyLTYtMS0xLTA_09e1932b-0da0-40ee-b27c-54d5ea50b7b9"
      unitRef="usd">-205700000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMzLTItMS0xLTA_ac695952-8022-494d-bc30-f0a2fab1eada"
      unitRef="usd">39500000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMzLTQtMS0xLTA_9391b07c-3e03-46c6-89cc-f1e7d40db403"
      unitRef="usd">35700000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzMzLTYtMS0xLTA_f6e6b236-fb72-49cc-850c-5b0ab38fd371"
      unitRef="usd">32400000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM0LTItMS0xLTA_fdf5fd62-c543-4c87-bc89-c66cc5ac19dc"
      unitRef="usd">-155600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM0LTQtMS0xLTA_5643af29-80ea-4677-81f1-3ea7c0cd0e26"
      unitRef="usd">-110500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM0LTYtMS0xLTA_53dd1103-4609-4c30-bc76-02900eeb0942"
      unitRef="usd">-238100000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e"
      unitRef="usdPerShare">-3.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTQtMS0xLTA_2f67ba76-2823-4860-b567-103790b87cf1"
      unitRef="usdPerShare">-2.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6"
      unitRef="usdPerShare">-4.96</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8"
      unitRef="shares">48776000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5"
      unitRef="shares">48280000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08"
      unitRef="shares">48028000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzQtMi0xLTEtMA_1fc48395-5381-4769-b057-1baef9a989f4"
      unitRef="usd">1300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzQtNC0xLTEtMA_095dcf04-16c4-4d65-bff9-b907c7fca045"
      unitRef="usd">45100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzQtNi0xLTEtMA_9b9d4c9d-3198-4172-9aff-afcbef69e4a8"
      unitRef="usd">-95600000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzYtMi0xLTEtMA_bf293690-2f0a-44cd-8f29-7e39ccf07020"
      unitRef="usd">-10300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzYtNC0xLTEtMA_82c80a82-576d-4503-85d0-ddef8badcaf0"
      unitRef="usd">-28300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzYtNi0xLTEtMA_807b6ffc-48c1-4460-a9b4-1812ea39e780"
      unitRef="usd">-22400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzctMi0xLTEtMA_c1a9fb97-8f93-4ed7-b6b8-ab0600dc7bcf"
      unitRef="usd">-9000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzctNC0xLTEtMA_941a797d-6f9a-4626-aab9-99b2011c007b"
      unitRef="usd">16800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzctNi0xLTEtMA_c0458f92-b211-4bfd-9bcf-2dc11d78158f"
      unitRef="usd">-118000000.0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzgtMi0xLTEtMA_a057cb8a-814f-4f04-9b12-5273b7fdf932"
      unitRef="usd">117400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzgtNC0xLTEtMA_f44cd513-1178-432c-a0f5-618dd57c95c6"
      unitRef="usd">119900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzgtNi0xLTEtMA_fe7ce39d-0465-47b9-b502-3af60b333652"
      unitRef="usd">110100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzktMi0xLTEtMA_0caccb88-8ff9-46c2-b04f-1df6a4eb107f"
      unitRef="usd">-126400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzktNC0xLTEtMA_1ac5edfb-def7-4a0b-af46-49ac3cde63e9"
      unitRef="usd">-103100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzAvZnJhZzowZDA1MmQ3ODFmZDQ0Y2Q5YTNmODllODEzMDNjNGI2OS90YWJsZToxNDI0OGEzYjc0YzM0NTFkOTJiOTI4M2Y0NjZlODZiOS90YWJsZXJhbmdlOjE0MjQ4YTNiNzRjMzQ1MWQ5MmI5MjgzZjQ2NmU4NmI5XzktNi0xLTEtMA_17516292-82bb-4653-a106-a84dfdce44fa"
      unitRef="usd">-228100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i594520e2981546afb1cc70f2e2240d64_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItMS0xLTEtNTA1Mg_0d4ce962-9b44-4ec7-9d78-58faa6f2935d"
      unitRef="shares">48687000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i594520e2981546afb1cc70f2e2240d64_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItMy0xLTEtNTA1Mg_b518d90d-9b95-4134-a5e3-88d98ffc8bb1"
      unitRef="usd">500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9436eee8a582415faf17777a719e40aa_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItNS0xLTEtNTA1Mg_d250d23c-b3ab-4d71-a58a-333293a8e1fd"
      unitRef="usd">695500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4cfe65a0e734fc490c352616432aa34_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItOS0xLTEtNTA1Mg_fafee9ef-93d5-474b-b671-d7b7fa4dcd26"
      unitRef="usd">-41300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa882503424e4da0be7dc022a7146191_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItMTEtMS0xLTUwNTI_8c1724de-5042-45a8-938c-f71290a70703"
      unitRef="usd">681900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2274a974182d4c01981835a4b40e9196_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzItMTMtMS0xLTUwNTI_ad6fa1a3-69c5-46fc-8317-414d344ca054"
      unitRef="usd">1336600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ibe8ef1c59a844626a0e801b7a033af22_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzMtOS0xLTEtNTA1Mg_6f27b832-2d6d-4a1f-8712-a25b63c48a02"
      unitRef="usd">-205700000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzMtMTEtMS0xLTUwNTI_ada4c5aa-61ef-451b-8d49-cd117deaf597"
      unitRef="usd">75500000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzMtMTMtMS0xLTUwNTI_387679c7-92d5-4c21-a74c-4245e3e4b2cb"
      unitRef="usd">-130200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i679f4a8d66c74b0bbb0c9afe9118ce6a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzQtMS0xLTEtNTA1Mg_b7874a83-fdac-4c83-977e-73548419f574"
      unitRef="shares">339000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzQtNS0xLTEtNTA1Mg_6de89811-5bcd-40bc-8cb9-7099c245f63d"
      unitRef="usd">8100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzQtMTMtMS0xLTUwNTI_38125001-0160-456c-9fb4-4d70bc0feba0"
      unitRef="usd">8100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzUtNS0xLTEtNTA1Mg_fc6152ce-9dc0-4a79-9153-d5e2718ca1f4"
      unitRef="usd">32400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzUtMTMtMS0xLTUwNTI_89a77d7b-73a7-4222-96e4-8b41ed8451a0"
      unitRef="usd">32400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0c8fd711c66341d38d95caf13c2cb675_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzYtNy0xLTEtNTA1Mg_52821dac-c21d-4751-9792-e342cfdfc502"
      unitRef="usd">-22400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzYtMTMtMS0xLTUwNTI_ff264228-432a-4b92-9e7f-6f80ab6fa4ef"
      unitRef="usd">-22400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i679f4a8d66c74b0bbb0c9afe9118ce6a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzctMS0xLTEtNTA1Mg_91560452-3265-4b43-9eb2-2b40ed998ae8"
      unitRef="shares">157000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzctNS0xLTEtNTA1Mg_32edad8c-6902-4539-aa38-389e5b805b9b"
      unitRef="usd">2000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzctMTMtMS0xLTUwNTI_2d57e8e6-320a-4868-abce-ad29d849cdfd"
      unitRef="usd">2000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i644c94a5596d498a9d5027fd5bfc7ea9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzgtNS0xLTEtNTA1Mg_652102cd-2fb9-4f69-a7bb-db350e64f47c"
      unitRef="usd">4300000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzgtMTEtMS0xLTUwNTI_571f6a33-b00e-4e57-8b64-571e5eced1b4"
      unitRef="usd">15800000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzgtMTMtMS0xLTUwNTI_de6c805e-8d8a-4db6-ac01-f812cab98b68"
      unitRef="usd">20100000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzktMTEtMS0xLTUwNTI_3c215dad-028a-4609-9bd9-a823284e51f4"
      unitRef="usd">78300000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzktMTMtMS0xLTUwNTI_21943323-b952-45e1-92d2-81af3f6252fb"
      unitRef="usd">78300000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i25e811c957d2426dbde770114dde4cf3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEwLTExLTEtMS01MDUy_c58ffacd-2378-4b78-8e77-ad695c67a519"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEwLTEzLTEtMS01MDUy_a443a735-034c-421c-b50b-dd8a814cda00"
      unitRef="usd">600000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0014fa9a093345e0a96dd7ea4e8aa0cf_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTEtMS0xLTUwNTI_673893bc-a4de-439c-afee-ab189c3ee1d8"
      unitRef="shares">48869000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0014fa9a093345e0a96dd7ea4e8aa0cf_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTMtMS0xLTUwNTI_c634999b-1aad-4f36-87aa-841fd76499b4"
      unitRef="usd">500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1711e7a812034ce28d37fce9a82165eb_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTUtMS0xLTUwNTI_51bf6d97-710c-4851-acd8-eef45172bba8"
      unitRef="usd">673500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30805210d9e14b39939e153b9bd05398_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTctMS0xLTUwNTI_81d26e2d-084a-4ae2-94ad-419f33443bb2"
      unitRef="usd">-22400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe757e1f73a54e7fa3eb2b75fd451837_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTktMS0xLTUwNTI_27c1d565-e0b6-43dc-bc8b-7e1a5180030a"
      unitRef="usd">-247000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i834d9736caee49309174d5e036c537c9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTExLTEtMS01MDUy_988fd1fc-c18d-4a61-ba28-dc233a470010"
      unitRef="usd">694300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzExLTEzLTEtMS01MDUy_1a1e4e60-1668-44f7-8bf9-e5f6703022b2"
      unitRef="usd">1098900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i9a50f5aedaa14987b3a169a2e743a7aa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEyLTktMS0xLTUwNTI_6f87ac60-2d9c-49d9-b5c7-1f9d085a20c4"
      unitRef="usd">-74800000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEyLTExLTEtMS01MDUy_842d15e3-0b44-44fa-8cda-7a1a3448ec62"
      unitRef="usd">80800000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEyLTEzLTEtMS01MDUy_88e402b0-96f0-4847-8ecc-2d09cf287062"
      unitRef="usd">6000000.0</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic1d553aa54d740f48fcc1ab6b34d4095_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEzLTEtMS0xLTUwNTI_0efb3689-c01c-41d8-b32e-3a8a74cea5d6"
      unitRef="shares">430000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6d9f0a869b8843a6862016205567c15b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEzLTUtMS0xLTUwNTI_8faddb2d-cc8d-4709-be1d-9b452d78facc"
      unitRef="usd">9200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzEzLTEzLTEtMS01MDUy_e8b4753c-c15f-4ad0-a819-7d2ef0886631"
      unitRef="usd">9200000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i6d9f0a869b8843a6862016205567c15b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE0LTUtMS0xLTUwNTI_c8189f10-f3c9-4a59-a47b-7dee47ed6b4d"
      unitRef="usd">35700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE0LTEzLTEtMS01MDUy_b1400dab-3127-499e-97dd-68c6713b9db3"
      unitRef="usd">35700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3a4b6a2e8a5d434dad534976125b83d9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE1LTctMS0xLTUwNTI_7656f176-6959-48a6-9cee-6eafba980433"
      unitRef="usd">-28300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE1LTEzLTEtMS01MDUy_cb95b341-fa6b-419a-99d1-61b12f24ca66"
      unitRef="usd">-28300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i6d9f0a869b8843a6862016205567c15b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE2LTUtMS0xLTUwNTI_bf0e8a14-37a4-4670-8da2-d2149c42c705"
      unitRef="usd">15700000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE2LTExLTEtMS01MDUy_e0292d76-a39c-4cba-814e-000174157515"
      unitRef="usd">-7400000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE2LTEzLTEtMS01MDUy_0027df6c-da0f-4155-aca6-8770d079a7f0"
      unitRef="usd">8300000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE3LTExLTEtMS01MDUy_d7f91806-c26e-4214-82cc-f31f6d10d9ce"
      unitRef="usd">81200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE3LTEzLTEtMS01MDUy_6c526d77-a19f-477d-a1c4-fd0e5c94206d"
      unitRef="usd">81200000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36e8c64b0ba846c18f5a7a46fa045bc7_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE4LTktMS0xLTUwNTI_e286801e-07a8-46cc-bc26-e2f3c61ad854"
      unitRef="usd">6100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a23162dc89340049ff966ee6ce72f86_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE4LTEzLTEtMS01MDUy_bf44215d-0ba0-4227-aa15-7de698b00684"
      unitRef="usd">6100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityOther
      contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE5LTExLTEtMS01MDUy_9bb7c19a-6f86-4f7a-9b0d-89c873b46085"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzE5LTEzLTEtMS01MDUy_346564cf-dcd5-436b-bd71-81712366a3b6"
      unitRef="usd">-100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if77a0a40975349a3b34383d5f0cb0c7d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTEtMS0xLTUwNTI_79fb4c7b-d3e4-4ce1-9344-418a29678c08"
      unitRef="shares">49299000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if77a0a40975349a3b34383d5f0cb0c7d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTMtMS0xLTUwNTI_ba08b795-9262-4a40-883f-278b4c37c14c"
      unitRef="usd">500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1615052a3a7f484393a4b51a8b0cd4ea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTUtMS0xLTUwNTI_5929cc83-152e-4d21-bb8b-c33b7d81b5aa"
      unitRef="usd">662700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie56bc33ce06647288c4aef4b26242c11_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTctMS0xLTUwNTI_3e7068c0-0fcf-414d-b5ba-15787e81d568"
      unitRef="usd">-50700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i541eb4cc07d4416ab46cdea917e05d4e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTktMS0xLTUwNTI_c50bd0a2-4d24-4005-92af-da3213695137"
      unitRef="usd">-315700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i693318ba255342df98c96534cb3bdf86_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTExLTEtMS01MDUy_52f5c31a-df99-4456-b29c-d240c8eec470"
      unitRef="usd">686600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIwLTEzLTEtMS01MDUy_d96fc79a-f2e4-4c7e-aa24-b324f7d906e1"
      unitRef="usd">983400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i975830e2f385428e80159f54d04d85df_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIxLTktMS0xLTUwNTI_abaaa519-d340-4b26-b328-783255ca69e8"
      unitRef="usd">-116100000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIxLTExLTEtMS01MDUy_bf8f7b9e-9a85-4e4d-8ea2-63648bb5ee92"
      unitRef="usd">85700000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIxLTEzLTEtMS01MDUy_80e3aff3-9f1a-438b-8c40-a557223bcb3a"
      unitRef="usd">-30400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if121998af9ae4288a4d53c8bf419dc1b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIyLTEtMS0xLTUwNjI_41919656-0b12-4eea-a5d3-7353ef85780b"
      unitRef="shares">1163000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIyLTUtMS0xLTUwNjI_ec19d502-9d18-4318-83f1-2ffa1ff6cf01"
      unitRef="usd">12400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIyLTEzLTEtMS01MDYy_f84239b7-19ae-465c-a615-7b016a6c9afe"
      unitRef="usd">12400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIzLTUtMS0xLTUwNjI_eab94498-9354-481e-9f34-819fae366021"
      unitRef="usd">39500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzIzLTEzLTEtMS01MDYy_5d24746d-5ff4-4fcb-818f-070b4d75c747"
      unitRef="usd">39500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib2303c6c0e9e483abccd08ac36c55d58_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI0LTctMS0xLTUwNjI_b0a8179e-72a4-4d08-be44-a07f825229cd"
      unitRef="usd">-10300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI0LTEzLTEtMS01MDYy_36f53b30-f42d-47cd-bd97-d832ab381b73"
      unitRef="usd">-10300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI1LTUtMS0xLTUwNjI_f1546c9a-9d09-40ca-ac32-0719b5557c00"
      unitRef="usd">-27700000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI1LTExLTEtMS01MDYy_9b9a7548-7c5c-4059-8572-221e68123b7d"
      unitRef="usd">67500000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI1LTEzLTEtMS01MDYy_d7f02bd4-a4b3-49b4-b1af-005cac1a6113"
      unitRef="usd">39800000</sgry:NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI2LTExLTEtMS01MDYy_74863fbb-723e-4fd6-a873-17525d0af8d4"
      unitRef="usd">73100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI2LTEzLTEtMS01MDYy_a010629a-b231-436c-a543-96da60811433"
      unitRef="usd">73100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther
      contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI3LTExLTEtMS01MDYy_55181449-d799-4c7f-8b6c-dbb937d6abf1"
      unitRef="usd">200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI3LTEzLTEtMS01MDYy_c913fbe7-135d-4a20-8257-b12cf6dc9475"
      unitRef="usd">200000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3f4cb1d89ceb4b5380cabfddf941c7cb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTEtMS0xLTUwNjI_5ddb52f4-1134-4288-bd28-057ccbb26ace"
      unitRef="shares">50462000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3f4cb1d89ceb4b5380cabfddf941c7cb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTMtMS0xLTUwNjI_a3ece06b-7dce-442c-81df-f5b9d5eaa56a"
      unitRef="usd">500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2369ebaa4684a78a2970d00fd9578f8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTUtMS0xLTUwNjI_482edb64-a476-408d-975a-1eff5f62892f"
      unitRef="usd">607900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b7bc629529e4c048c9abfe722e66014_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTctMS0xLTUwNjI_8776762d-9753-46c1-b4a8-9f1d777e6768"
      unitRef="usd">-61000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iebc6bef361c04164a50070ac5d583e49_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTktMS0xLTUwNjI_65c173c9-142c-4275-a4d1-5e783fa67e17"
      unitRef="usd">-431800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47d590096f6a4da5ae4f1dc1b45a84ef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTExLTEtMS01MDYy_dfd6995e-703d-4b65-bd1e-c1bdabcfd831"
      unitRef="usd">766500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzMvZnJhZzpkOWIxYTExNTI0MTc0ZWI1OWQxMjI5MTE1ZDNlYWJkNS90YWJsZTowNDk1YjlkOGJmYzg0ODFkOWMwZjIwM2ZiYmFmMmNiNS90YWJsZXJhbmdlOjA0OTViOWQ4YmZjODQ4MWQ5YzBmMjAzZmJiYWYyY2I1XzI4LTEzLTEtMS01MDYy_0ff8f5a3-e403-433b-a8ba-0a5da43b5a8e"
      unitRef="usd">882100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUtMi0xLTEtMA_1fc48395-5381-4769-b057-1baef9a989f4"
      unitRef="usd">1300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUtNC0xLTEtMA_69b5e31c-f241-4136-b278-48a65a4746be"
      unitRef="usd">45100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUtNi0xLTEtMA_3e1fa605-f957-47d2-a0b8-cb0c8dafca9d"
      unitRef="usd">-95600000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzctMi0xLTEtMA_0e0403a9-e309-4574-a24c-b826d3b79bce"
      unitRef="usd">94800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzctNC0xLTEtMA_650b6ee5-d553-43b7-96f0-6fe42eb72421"
      unitRef="usd">76500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzctNi0xLTEtMA_091fb16d-31f8-40f2-836f-797a2a1edc26"
      unitRef="usd">67400000</us-gaap:DepreciationDepletionAndAmortization>
    <sgry:NoncashInterestIncomeExpenseNet
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzgtMi0xLTEtMA_462f4335-f1cc-42c1-bc0d-8976e40a5a4b"
      unitRef="usd">-4500000</sgry:NoncashInterestIncomeExpenseNet>
    <sgry:NoncashInterestIncomeExpenseNet
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzgtNC0xLTEtMA_0e899d41-b4f2-4229-8f6e-79aeef89d5c1"
      unitRef="usd">-2500000</sgry:NoncashInterestIncomeExpenseNet>
    <sgry:NoncashInterestIncomeExpenseNet
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzgtNi0xLTEtMA_3ae01acc-96fe-4e4b-9e3f-d09214f4879e"
      unitRef="usd">1400000</sgry:NoncashInterestIncomeExpenseNet>
    <us-gaap:ShareBasedCompensation
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzktMi0xLTEtMA_06786725-4a0b-46db-a278-051a36b1ddfe"
      unitRef="usd">13200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzktNC0xLTEtMA_25b9af30-3b0c-4850-a087-17164e3b3281"
      unitRef="usd">10200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzktNi0xLTEtMA_cf2175a1-27e1-4489-832b-b855f83fcb30"
      unitRef="usd">9300000</us-gaap:ShareBasedCompensation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTItMS0xLTA_6804929c-6a49-4bd2-866a-f6110820cb3d"
      unitRef="usd">-5700000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTQtMS0xLTA_8d86bf8f-11d1-4a7e-bb3b-84b7586e81a0"
      unitRef="usd">4400000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTYtMS0xLTA_64e39c3d-dcb3-454e-9a10-9b9da02a246e"
      unitRef="usd">-31800000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTItMS0xLTczMjI_a6fc733a-c407-4176-9e6d-0e98b315e33e"
      unitRef="usd">33500000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTQtMS0xLTczMjI_41cc7bfc-5166-4b10-85e1-a3f26264ede3"
      unitRef="usd">7900000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEwLTYtMS0xLTczMjI_b9577171-ae34-4c75-b95d-489f059adcab"
      unitRef="usd">74400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTItMS0xLTczMzU_c9fbcf76-007e-4425-9364-94b6e300f181"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTQtMS0xLTczMzU_f291ebb9-132d-4b8f-ac7d-284c83433f89"
      unitRef="usd">-11700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTYtMS0xLTczMzU_97d8f1c3-64e4-46fa-9535-372a7e849002"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTItMS0xLTA_472a49b7-d9de-4971-9b2e-4421e2891199"
      unitRef="usd">-21900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTQtMS0xLTA_e3f85344-4f55-4be8-8032-91d9139fb6b4"
      unitRef="usd">8500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzExLTYtMS0xLTA_347dcd78-7dc5-4688-b876-85bd401676ee"
      unitRef="usd">25300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEyLTItMS0xLTA_4c71b7c0-e5ac-435d-a7d9-4c13c9130b5e"
      unitRef="usd">-500000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEyLTQtMS0xLTA_8dc63a87-df0e-4061-805a-5b98bc1d3d8e"
      unitRef="usd">-300000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzEyLTYtMS0xLTA_d2691354-eef9-4572-bd03-f2c095d889f9"
      unitRef="usd">-200000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:OperatingLeaseExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzE0LTItMS0xLTA_85dc7a93-9d98-4c1c-95d5-95dc544b0c92"
      unitRef="usd">39400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzE0LTQtMS0xLTA_6c86945f-5332-43b6-b8a4-7717a97fdf6a"
      unitRef="usd">40000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzE0LTYtMS0xLTA_92c14d97-5559-4f69-81f4-4570137c0f04"
      unitRef="usd">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTItMS0xLTA_b75723f0-9ee3-48bf-ad4f-681f2a4843a1"
      unitRef="usd">46600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTQtMS0xLTA_0e8d9db4-6625-40d4-9cff-de4d7bbaa421"
      unitRef="usd">23500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTYtMS0xLTA_978acf7c-73d9-4d5c-8b34-6c41ccc4ba8e"
      unitRef="usd">22800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTItMS0xLTQ4MDE_fd2174cd-a92b-4ba4-9e02-884ce5946b25"
      unitRef="usd">135200000</sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants>
    <sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTQtMS0xLTQ4MDE_fc7d4ed4-41ed-4e7a-bac8-0c2f6e0b2b6e"
      unitRef="usd">0</sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants>
    <sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIxLTYtMS0xLTQ4MDE_a27e8514-da29-4f1c-b897-c6b37cae5914"
      unitRef="usd">0</sgry:IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIyLTItMS0xLTA_b30fc032-d306-4976-bbfc-81a157cc1e2a"
      unitRef="usd">12700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIyLTQtMS0xLTA_cf194c9a-10dd-4c3d-94aa-4d31e6d32dfb"
      unitRef="usd">45300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIyLTYtMS0xLTA_a4943409-9e22-43bc-83a0-5b88992e2634"
      unitRef="usd">-56000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIzLTItMS0xLTA_29b0b8c9-18c3-4970-935b-f4ea894fd533"
      unitRef="usd">246900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIzLTQtMS0xLTA_7f90ff15-0f9d-41de-8edd-bdbc2ccef512"
      unitRef="usd">129500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzIzLTYtMS0xLTA_a8b5e5b3-f8d8-4a17-ac6b-67e3e62c1bf6"
      unitRef="usd">144600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI2LTItMS0xLTA_a6f6c498-16a3-4d78-8c55-0fc67fa32944"
      unitRef="usd">42900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI2LTQtMS0xLTA_e9f88b6f-e892-4bfc-aee0-51a1497313c8"
      unitRef="usd">73600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI2LTYtMS0xLTA_7c4cb4a6-eb70-428f-8cf8-9d500707bc7b"
      unitRef="usd">39800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI3LTItMS0xLTA_81bafc76-cf61-440f-bd59-f6ac356acb97"
      unitRef="usd">104600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI3LTQtMS0xLTA_bec668cf-07f8-4afd-a76a-fcdba1fc7186"
      unitRef="usd">13800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI3LTYtMS0xLTA_aaca4239-a1d8-4ade-880f-e8eab5abacd2"
      unitRef="usd">106800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI0LTItMS0xLTczNTQ_9ef9a8f6-1a73-4635-b67c-c0e93fd1a8a5"
      unitRef="usd">58500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI0LTQtMS0xLTczNTQ_272ae68f-1e22-48d8-a68c-0a0d695ca001"
      unitRef="usd">17600000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI0LTYtMS0xLTczNTQ_6e089bde-6f59-49b0-83c5-4cd1aa03c491"
      unitRef="usd">19200000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI4LTItMS0xLTA_aff0a349-702b-422b-b40c-73b5d35edcdf"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI4LTQtMS0xLTA_472cd8c5-2f01-4f5f-bc06-518da9053346"
      unitRef="usd">15200000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzI4LTYtMS0xLTA_3ad68ec8-b747-488c-980c-45e4774ce8cb"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMwLTItMS0xLTA_3e828592-9701-434b-978b-80066a68f1ff"
      unitRef="usd">-600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMwLTQtMS0xLTA_c6541385-f4d3-402b-9ca6-1093f6e45f90"
      unitRef="usd">200000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMwLTYtMS0xLTA_0659b51e-902b-48f0-9a52-cfc235765e82"
      unitRef="usd">1500000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMxLTItMS0xLTA_59e9abc5-9869-4578-91a8-2dcedc181e0b"
      unitRef="usd">-88400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMxLTQtMS0xLTA_a800e5b3-c54c-47a9-990b-6b2acc302ff8"
      unitRef="usd">-85200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzMxLTYtMS0xLTA_16c99910-9ad0-4fc4-af19-2cd129138cbe"
      unitRef="usd">-128900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM0LTItMS0xLTA_38edc134-c894-4234-bf4d-7d906a16cf64"
      unitRef="usd">216300000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM0LTQtMS0xLTA_2ef0fd32-2937-4436-8af1-cd9c19a135c9"
      unitRef="usd">490800000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM0LTYtMS0xLTA_62012cbd-c66e-4007-b09b-4e2db137caab"
      unitRef="usd">157600000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM1LTItMS0xLTA_3fb696af-6d90-4f9d-9efb-d254e067e950"
      unitRef="usd">429400000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM1LTQtMS0xLTA_8af9187a-99ae-49b2-b418-835b4223b58a"
      unitRef="usd">506900000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM1LTYtMS0xLTA_75ae66f6-ba33-4213-8c7d-ca0306448820"
      unitRef="usd">282700000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM2LTItMS0xLTA_395f746b-c9de-4078-9879-991c291c5121"
      unitRef="usd">8500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM2LTQtMS0xLTA_7eddee57-edd7-4d02-9b1b-a0308bfc3ea8"
      unitRef="usd">8900000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM2LTYtMS0xLTA_8750d5d4-4bb0-4385-af6e-5b8ca1e4c2e1"
      unitRef="usd">3000000.0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <sgry:DebtInstrumentPrepaymentPenaltyAmount
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM3LTItMS0xLTA_d08c1c9f-3d8c-448f-95df-49db440185ce"
      unitRef="usd">0</sgry:DebtInstrumentPrepaymentPenaltyAmount>
    <sgry:DebtInstrumentPrepaymentPenaltyAmount
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM3LTQtMS0xLTA_814072cc-12e6-4f20-82e8-b43e6aa11119"
      unitRef="usd">17800000</sgry:DebtInstrumentPrepaymentPenaltyAmount>
    <sgry:DebtInstrumentPrepaymentPenaltyAmount
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM3LTYtMS0xLTA_eb18c137-aebe-4039-8bbf-7fc843dc3cd0"
      unitRef="usd">0</sgry:DebtInstrumentPrepaymentPenaltyAmount>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM4LTItMS0xLTA_a50865c8-d4eb-4ba7-9eb3-d7d2d93544db"
      unitRef="usd">109600000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM4LTQtMS0xLTA_36f9bc42-292c-40eb-a4ac-e6f590c008cd"
      unitRef="usd">121200000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM4LTYtMS0xLTA_2dc25a38-7e76-4ca3-83b3-4411192ac4a7"
      unitRef="usd">109000000.0</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM5LTItMS0xLTA_70a4a11a-1a24-40a1-ba6a-8c3d35ff099d"
      unitRef="usd">27400000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM5LTQtMS0xLTA_74ed2f51-1fcc-46e5-bff5-cbd37c50307f"
      unitRef="usd">3200000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzM5LTYtMS0xLTA_243c9443-bac3-47d1-b2b6-80a363396e1f"
      unitRef="usd">2200000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQyLTItMS0xLTA_1d9a4410-a22b-4ef0-9c03-0af174c59937"
      unitRef="usd">0</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQyLTQtMS0xLTA_76d11ec3-0564-4428-8de7-af05bd7a31e1"
      unitRef="usd">0</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQyLTYtMS0xLTA_dd4dc34a-b44c-4358-ac13-0b1c773ff0da"
      unitRef="usd">7800000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQzLTItMS0xLTA_b8f98e0f-23b8-4fa7-a942-b849cfc7cec0"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQzLTQtMS0xLTA_57039389-7b9c-4483-8a7f-f4129234a4be"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQzLTYtMS0xLTA_ad8dccf6-d67f-4ae3-b56d-8f715d789a96"
      unitRef="usd">2000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ0LTItMS0xLTA_fce06f3e-ab42-4c00-851e-adb7cca5bb76"
      unitRef="usd">-900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ0LTQtMS0xLTA_85f7df78-9d9c-4c83-95e9-b5f2d86f7dcf"
      unitRef="usd">-900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ0LTYtMS0xLTA_9c8dfc1d-dcd6-402c-80fe-a218d996681e"
      unitRef="usd">-7400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ1LTItMS0xLTA_7f10e2da-3822-4eff-9837-158b42a0e042"
      unitRef="usd">66700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ1LTQtMS0xLTA_1827670d-d57e-448f-aec8-c224375e30b8"
      unitRef="usd">-135900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ1LTYtMS0xLTA_c2facc7a-83cb-4a4b-956f-f09d9436ff45"
      unitRef="usd">-6300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ2LTItMS0xLTA_93771de4-3b70-4861-a742-b01f23195870"
      unitRef="usd">225200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ2LTQtMS0xLTA_eb2aed0f-1b4c-4671-aac5-743ae76e21f1"
      unitRef="usd">-91600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ2LTYtMS0xLTA_66562aac-2034-4faf-b196-e05e8d2a2935"
      unitRef="usd">9400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ3LTItMS0xLTA_15d83d67-9aa0-487e-b109-a18bdc4bd46c"
      unitRef="usd">93000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ3LTQtMS0xLTA_124281fa-a91e-4e92-b2d1-a2d6d0c31bfe"
      unitRef="usd">184600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2274a974182d4c01981835a4b40e9196_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ3LTYtMS0xLTA_0d7f5022-bebc-4f18-bbdd-19ba57429b76"
      unitRef="usd">175200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ4LTItMS0xLTA_e74ed614-2d60-407d-b990-da6aad818d0c"
      unitRef="usd">318200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ4LTQtMS0xLTA_07414187-ec22-4f56-afa0-2770ecfe129f"
      unitRef="usd">93000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzQ4LTYtMS0xLTA_674f25f5-925d-40c8-91b7-75853cec7586"
      unitRef="usd">184600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUxLTItMS0xLTA_fcc710bd-0326-4cb8-8c57-a4e9f4cbe895"
      unitRef="usd">203600000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUxLTQtMS0xLTA_9e6f2bd7-0497-4396-94ba-5c9bad842b74"
      unitRef="usd">180300000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUxLTYtMS0xLTA_22b85790-6b1d-461b-b74e-34d67781d59d"
      unitRef="usd">145400000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUyLTItMS0xLTA_bb6bdf44-89de-4d92-af53-37bbd70c18d6"
      unitRef="usd">1700000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUyLTQtMS0xLTA_b36ab849-c619-491f-ab5c-12e459d125db"
      unitRef="usd">1600000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUyLTYtMS0xLTA_2735582c-c855-41a8-9108-385fa7d58504"
      unitRef="usd">2200000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUzLTItMS0xLTA_61463d33-0880-4e77-8deb-4d094c4765b7"
      unitRef="usd">27700000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUzLTQtMS0xLTA_b75cc2d3-ca19-44e7-ac4d-90803db8f2a4"
      unitRef="usd">30700000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMzYvZnJhZzphZjlkNzY0ZmI0Njc0NWRkOTMwZDliMmVhYTYyNGViYy90YWJsZTo1NmJiOTc4ZDIxMWM0MGYxYTVmMjFhYTI4NjlkMWI2MC90YWJsZXJhbmdlOjU2YmI5NzhkMjExYzQwZjFhNWYyMWFhMjg2OWQxYjYwXzUzLTYtMS0xLTA_a8916ef1-f477-409e-a179-f547ac21b452"
      unitRef="usd">61000000.0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NDk2_ae418b2b-8c05-490b-9081-c8015a81df3b">Organization and Summary of Accounting Policies&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Surgery Partners, Inc.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Delaware corporation (together with its subsidiaries, the "Company"), was formed April 2, 2015. On August 31, 2017, a fund advised by an affiliate of Bain Capital Private Equity LP ("Bain Capital") became the controlling stockholder of the Company, holding Series A Preferred Stock (as defined in Note 7. "Redeemable Preferred Stock") and common stock that collectively represented approximately 65.7% of the voting power of all classes of capital stock of the Company as of August 31, 2017. As of December 31, 2020, Bain Capital held approximately 67.0% of the voting power of all classes of capital stock of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company owned and operated a national network of surgical facilities and ancillary services in 30 states.&#160;The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management.&#160;The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company owned or operated a portfolio of 127 surgical facilities, comprised of 110 ASCs and 17 surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in 84 of the surgical facilities and consolidated 107 of the facilities for financial reporting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The COVID-19 global pandemic has significantly affected the Company's facilities, employees, patients, communities, business operations and financial performance, as well as the U.S. economy and financial markets. Beginning mid-March, the COVID-19 pandemic began to negatively affect the Company's net revenue and business operations. Due in part to local, state and federal guidelines, as well as recommendations from major medical societies, requiring social distancing and self-quarantines in response to the COVID-19 pandemic, surgical case volumes across most of the Company's surgical facilities were significantly impacted in the second quarter of 2020. The impact of COVID-19 on the Company's surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures that are typically performed. Although the Company cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic, surgical case volumes improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. The Company's operating structure naturally enables some flexibility in the cost structure according to the volume of surgical procedures performed, including much of its cost of revenues. In addition to the natural variability of these costs, the Company and its partners in the surgical facilities have undertaken additional steps to preserve financial flexibility. Beginning in mid-March, and for the remainder of 2020, the Company took actions that included significantly reducing cash operating expenses and deferring non-essential expenditures at the height of the crisis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CARES Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#x201c;CARES Act&#x201d;) was signed into law to provide stimulus funding for the U.S. economy. As part of the CARES Act, the U.S. government initially announced that it would offer $100&#160;billion of relief to eligible health care providers. On April 7, 2020, Centers for Medicare and Medicaid Services ("CMS") officials indicated they would distribute $30&#160;billion of direct grants to hospitals, ASCs and other health care providers based on how much they bill Medicare. Payments received from these grants are not required to be repaid provided the recipients attest to and comply with certain terms and conditions, including limitations on balance billing and not using funds received from the grants to reimburse expenses or losses that other sources are obligated to reimburse. The Company received approximately $59&#160;million of the grant funds distributed under the CARES Act and other governmental assistance programs during the year ended December&#160;31, 2020. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the COVID-19 Economic Relief Bill, enacted on December 27, 2020, and all frequently &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;asked questions and other interpretive guidance issued by HHS, including the Post-Payment Notice of Reporting Requirements issued on January 15, 2021 (the &#x201c;January 15, 2021 Notice&#x201d;) and frequently asked questions issued by HHS on January 28, 2021 which clarified previously issued guidance, as well as expenses incurred attributable to COVID-19 and the Company&#x2019;s results of operations during such period as compared to the Company&#x2019;s budget. Such guidance, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to COVID-19 that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. As a result, the Company estimates approximately $46.2 million of grant funds received qualified for recognition as a reduction in operating expenses under the caption Grant funds in the consolidated statements of operations for the year ended December&#160;31, 2020. While the January 15, 2021 Notice and frequently asked questions issued by HHS on January 28, 2021 indicate that targeted distribution payments may be allocated or transferred to subsidiaries, distinct conditions exist for such allocations or transfers. There are significant uncertainties as to the meaning and interpretation of conditions specific to the allocation or transfer of targeted distribution payments such that, as of December 31, 2020, the Company is not reasonably assured that it can or will choose to comply with such conditions in order to allocate or transfer targeted distribution payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Amounts received, but not recognized as a reduction to operating expenses as of December&#160;31, 2020, are reflected as a component of Medicare accelerated payments and deferred governmental grants in the consolidated balance sheets as of December&#160;31, 2020, and such unrecognized amounts may be recognized as a reduction in operating expenses in future periods if the underlying conditions for recognition are met. HHS&#x2019; interpretation of the underlying terms and conditions of grant funds received through the CARES Act and other governmental assistance programs, including auditing and reporting requirements, may evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in the Company&#x2019;s inability to recognize certain payments, changes in the estimate of amounts recognized, or the derecognition of amounts previously recognized, which may be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As a way to increase cash flow to Medicare providers impacted by the COVID-19 pandemic, the CARES Act expanded the Medicare Accelerated and Advance Payment Program, which allows for most providers and suppliers, including the Company&#x2019;s surgical hospitals and ASCs to request an advance payment of anticipated Medicare revenues. ASCs could request up to 100% of the Medicare Fee-for-Service payment amount for a three-month period. Hospitals could request up to 100% of the payment amount for a six-month period, with certain critical access hospitals able to request up to 125% of the payment for a six-month period. Under the current terms of the program, all providers will have 29 months from the date of their first program payment to repay the full amount of the accelerated or advance payments they have received. The revised terms extend the period before repayment begins from 210 days to one year from the date that payment under the program was received. Once the repayment period begins, the offset will be limited to 25% of new claims during the first 11 months of repayment and 50% of new claims during the final 6 months. The revised program terms also lower the interest rate on outstanding amounts due at the end of the repayment period from 10% to 4%.The Company received approximately $120&#160;million of accelerated payments during the year ended December&#160;31, 2020. These accelerated payments received were deferred. The current portion was approximately $95&#160;million and is included as a component of Medicare accelerated payments and deferred governmental grants in the consolidated balance sheets as of December&#160;31, 2020. The long-term portion is included as a component of other long-term liabilities in the consolidate balance sheets. The Company does not expect to receive additional Medicare accelerated payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The CARES Act also provides for the deferral of the Company's portion of social security payroll taxes for the remainder of 2020. Under the CARES Act, half of the deferred amount will have to be paid in each of December 2021 and December 2022. The Company began deferring the social security payroll tax match in April 2020. As of December&#160;31, 2020, the Company has deferred approximately $16.9&#160;million. The current portion is included as a component of accrued payroll and benefits and the long term portion is included as a component of other long-term liabilities in the consolidated balance sheets as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is continuing to closely monitor legislative actions and regulatory guidance at the federal, state and local levels with respect to the CARES Act as other governmental assistance might become available to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of Accounting Standards Codification 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company has the power to direct the activities that most significantly impact a variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. At December&#160;31, 2020, the variable interest entities include four surgical facilities and three physician practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying consolidated balance sheets as of December&#160;31, 2020 and 2019, were $27.7 million and $36.2 million, respectively, and the total liabilities of the consolidated VIEs were $21.1 million and $25.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the carrying amounts and fair values of the Company's long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,539.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,434.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,533.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,434.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;376.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;368.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values in the table above were based on a Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values under Level 3 calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has entered into certain interest rate swap agreements (see Note 8. "Derivatives and Hedging Activity"). At December&#160;31, 2020 and 2019, the fair value of these derivative instruments was $61.0 million and $50.7 million, respectively, and was included in other long-term liabilities in the consolidated balance sheets. The fair value of these derivative financial instruments was based on a quoted market price, or a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which our obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of revenues by service type as a percentage of total revenues follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical facilities revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient service revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160; This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications.&#160;The fee does not normally include professional fees charged by the patient&#x2019;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments, discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other service revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Optical service revenues consist of handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. The Company satisfies the performance obligation and recognizes revenue when the orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company sold its optical products purchasing organization on December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Private insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;970.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;948.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;708.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;701.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Self-pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,836.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,803.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,737.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,860.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,831.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,771.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash reported within the consolidated statement of cash flows includes $0.3 million of restricted investments, which are reflected in other long-term assets in the consolidated balance sheet at both December&#160;31, 2020 and 2019. These restricted investments represent restricted cash held in accordance with the provisions of a long-term operating lease agreement held as security for performance under the Company's covenants and obligations within the agreement through January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#x2019; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#x2019;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior to its sale on December 31, 2020, the receivables related to the Company's optical products purchasing organization were recognized separately from patient accounts receivable and included in other current assets in the consolidated balance sheets. Such receivables were $8.6 million at December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets, Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value.&#160;The cash flow projection and fair value represents management&#x2019;s best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation.&#160;For discussion on impairment for goodwill and indefinite-lived intangible assets, refer to Note 4. "Goodwill and Intangible Assets."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Professional and General and Workers' Compensation Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional liability insurance coverage is on a claims-made basis and the general liability insurance is on an occurrence basis. The Company also maintains workers' compensation insurance, subject to a self-insured retention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers' compensation claims which relate to (i)&#160;claims made during the policy period, which are offset by insurance recoveries and (ii)&#160;an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records all derivatives on the balance sheet at fair value.&#160;The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Investments in Unconsolidated Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless the investments are a result of the Company losing control of a previously controlled entity, but still retaining a non-controlling interest. Transactions that result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which include unobservable data, to measure the fair value of the retained non-controlling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in and advances to affiliates in the accompanying consolidated balance sheets. The Company&#x2019;s share of the profits and losses from these investments is reported in income from equity investments in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-Controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Controlling Interests &#x2014; Redeemable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#x2019; or physician minority members&#x2019;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;redeemable are reported outside of stockholders' equity in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to the non-controlling interests&#x2014;redeemable for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition and disposal of shares of non-controlling interests, net&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions to non-controlling interest &#x2014;redeemable holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-04 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future London Interbank Offered Rate ("LIBOR") indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (&#x201c;CECL&#x201d;) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, which is primarily applicable to accounts receivable for the Company. This ASU was effective for the Company on January 1, 2020. The adoption of this ASU did not have a material impact on its consolidated financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, "Leases" (the "Lease Accounting Standard"). The Company adopted the Lease Accounting Standard effective January 1, 2019, using a modified retrospective transition approach. The most prominent of the changes resulting from this ASU is the recognition of right-of-use assets and lease liabilities by lessees for those leases classified as operating leases. The Company&#x2019;s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. Upon adoption of the Lease Accounting Standard, the Company recorded $294.0&#160;million of operating lease liabilities and right-of-use assets on January 1, 2019. The cumulative effect of the accounting change recognized upon adoption was $6.1&#160;million reflected as an adjustment to retained deficit in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i5eda05d02ba64f78991a4f0b2af38f0b_I20170831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzU4NA_d7adf618-0f20-49e4-98f8-ae7df3c5347e"
      unitRef="number">0.657</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i358a5e89179e41d0822a47803a3d6dac_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE3MDI3NTA_bc13eff5-c818-4f28-9680-88762a5216bc"
      unitRef="number">0.670</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzc2NA_0bda4872-0ccb-4b28-85de-54ad3dbc0277"
      unitRef="state">30</us-gaap:NumberOfStatesInWhichEntityOperates>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE0Mzk_f349c869-4876-4b57-8081-ac4b8597ebfc"
      unitRef="surgical_facility">127</sgry:NumberOfSurgicalFacilitiesOwned>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="if91011ef54014758871d4c1d7f4f8be6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE0NzY_6173d8dc-6ceb-4d8b-910f-5dfb1174f733"
      unitRef="surgical_facility">110</sgry:NumberOfSurgicalFacilitiesOwned>
    <sgry:NumberOfSurgicalFacilitiesOwned
      contextRef="i33440f4bb58f4fee905410e7e11b9a27_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE0ODg_18b7e471-9e66-488d-a1be-a8759dce5014"
      unitRef="surgical_facility">17</sgry:NumberOfSurgicalFacilitiesOwned>
    <sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE2OTk_201a187a-ce10-4e2b-b260-3ad2aeb06a03"
      unitRef="surgical_facility">84</sgry:NumberOfSurgicalFacilitiesOwnedMajorityInterest>
    <sgry:NumberOfSurgicalFacilitiesOwnedConsolidated
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE3NDY_2a908c87-7d11-42a0-a18d-5c8766d7acf3"
      unitRef="surgical_facility">107</sgry:NumberOfSurgicalFacilitiesOwnedConsolidated>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTYy_935d772e-6fab-4489-85b1-a7c35cd78e2f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTQz_1a558ccb-050b-4785-94d0-aac000d0b478">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <sgry:ProceedsFromGovernmentAssistance
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE2Njg4MDI_8fbfc951-419d-4e26-9d3a-e65e4e78ef7f"
      unitRef="usd">59000000</sgry:ProceedsFromGovernmentAssistance>
    <sgry:GrantRevenue
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE2Njk2MTE_cb9a80e4-3975-4268-9618-ae3bd3b5132d"
      unitRef="usd">46200000</sgry:GrantRevenue>
    <sgry:CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE2NzUyMTQ_47111b57-ff58-45b2-a95a-c57bf4539030"
      unitRef="usd">120000000</sgry:CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments>
    <sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzExNTQ0ODcyMTYxOTAy_0565138b-f493-43c5-bd50-53a24e6c03eb"
      unitRef="usd">95000000</sgry:CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent>
    <sgry:DeferredEmployeeRelatedLiabilitiesCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEwOTk1MTE2OTc1MDI_466e0ce9-63e0-436b-8040-2368a4208892"
      unitRef="usd">16900000</sgry:DeferredEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjI1_03490ab7-a9d4-4916-99a9-094bc73e4b66">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of Accounting Standards Codification 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company has the power to direct the activities that most significantly impact a variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. At December&#160;31, 2020, the variable interest entities include four surgical facilities and three physician practices.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <sgry:VariableInterestEntityNumberOfFacilities
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQxMTg_f5982ea6-b2a9-41be-8d28-c3ebb2a201e5"
      unitRef="surgical_facility">4</sgry:VariableInterestEntityNumberOfFacilities>
    <sgry:VariableInterestEntityNumberOfFacilities
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQxNzA_baa3e2d7-257e-4a77-a4ff-eb77e40049f2"
      unitRef="physician_practice">3</sgry:VariableInterestEntityNumberOfFacilities>
    <us-gaap:Assets
      contextRef="i86b1a160332645c186bcb8e28fe6f17d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQzNjM_003c3c87-a061-45fa-a736-e1390175ddd3"
      unitRef="usd">27700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8e7f2aea22094bddb8c6931fc0dea651_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQzNzA_fa4f6969-9d16-4ce8-a8cf-84c65c60fb04"
      unitRef="usd">36200000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i86b1a160332645c186bcb8e28fe6f17d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQ0NDQ_e7a88f98-648b-42c7-9d0d-e8ed64a2a899"
      unitRef="usd">21100000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8e7f2aea22094bddb8c6931fc0dea651_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzQ0NTE_4680ee4d-06c1-445a-ac27-b471d458350b"
      unitRef="usd">25200000</us-gaap:Liabilities>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NDY4_07c2a53a-a5cd-4ffa-b822-70e30eaea18b">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt"&gt;Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.&lt;/span&gt;&lt;/div&gt;The fair values in the table above were based on a Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values under Level 3 calculations.The fair value of these derivative financial instruments was based on a quoted market price, or a Level 2 input.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTcz_a73a45d3-5cf6-455f-8b45-cedaf4889248">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the carrying amounts and fair values of the Company's long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.787%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,539.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,434.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,533.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,434.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;376.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;368.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;596.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i809eef37f4e54081a6dc49a891ecdaec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzQtMi0xLTEtMA_e8c9714f-360a-49c0-bfd0-7b809f4f727f"
      unitRef="usd">1539400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9eab8ecdfcc74e9e855708a2c1ca417f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzQtNC0xLTEtMA_29c91457-0ae2-45d5-b710-41165803e22c"
      unitRef="usd">1434100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i119f3f636b3d41ad852c157ef3a54380_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzQtNi0xLTEtMA_689e3ed2-7f7e-4b73-aed9-a9bb6701cc98"
      unitRef="usd">1533400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1e3eaeb718994330b5ba6da8d0809206_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzQtOC0xLTEtMA_e3c0eb03-179c-4454-a282-b3fe83b3c034"
      unitRef="usd">1434100000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i911d67503a3e4528a30814a4348d8ea4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtMC0xLTEtNjA2L3RleHRyZWdpb246MmE4MzEyOTc0N2U2NDNhZmFiNjZkYmMyNDgyZGVjMjFfMjE5OTAyMzI1NTYwMA_10631964-487f-4b80-b7cc-92b2e6df91a0"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8c30ac06941c4200b21b1e23272f2da0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtMi0xLTEtMA_6f38fcaf-74c2-48ab-af46-3a19a43968d3"
      unitRef="usd">370000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0aa2c1066f2b4f8c8f0f3388f465debe_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtNC0xLTEtMA_81814612-7df3-4ec5-9db4-652971c7a12b"
      unitRef="usd">370000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i162bdeb976434409ae1a1c6f77a718a1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtNi0xLTEtMA_cdf8567f-62a6-4f49-8f7f-881b8bd548e5"
      unitRef="usd">376000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iadab410bba6e4144a75e318b53880035_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzYtOC0xLTEtMA_73edb8ef-4563-40cc-a870-9d4f52de63e7"
      unitRef="usd">368200000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7bd4886dd3f74966858590367b6f85d9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctMC0xLTEtNjEwL3RleHRyZWdpb246NzkxNjcyYTEzYWVmNDQ5M2I5YWVmZGQzM2UxYjcxZTFfMjE5OTAyMzI1NTYwMg_3ee4bf56-e937-42e9-9b86-388f3b53dd24"
      unitRef="number">0.10000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5d560570554a4fd1b7a05ce7bb03e9d4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctMi0xLTEtMA_c5c02240-d35c-4353-a504-208425de3d42"
      unitRef="usd">545000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4cb5f59640994a199093fe9c3ab2ac03_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctNC0xLTEtMA_6ff35b74-57b2-48ef-af9b-18af62dd793a"
      unitRef="usd">430000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6c0f5839140a4b41b51f5bd58cb54057_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctNi0xLTEtMA_f50b5cc4-fed3-4bd6-8c78-21d0c299253e"
      unitRef="usd">596800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5aa06470b17c4eb2b260df51cf4c128e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo4N2I0ZTk0OTZhNmM0NzQyYmMwZTE4MDQ2ZTQ1YmJjNy90YWJsZXJhbmdlOjg3YjRlOTQ5NmE2YzQ3NDJiYzBlMTgwNDZlNDViYmM3XzctOC0xLTEtMA_ebc71b28-eec6-4c9f-86bb-1313b6c47887"
      unitRef="usd">471400000</us-gaap:LongTermDebt>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzYxOTI_1351bedf-8358-44a1-9046-4fd72f1996d7"
      unitRef="usd">61000000.0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzYxOTk_5c98eee4-e548-4da6-aba4-4d3c974f5d8f"
      unitRef="usd">50700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjU1_38e06d3e-43e1-46a6-b2b2-5a562bae0565">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which our obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient service revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160; This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications.&#160;The fee does not normally include professional fees charged by the patient&#x2019;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. &lt;/span&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments, discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other service revenues.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Optical service revenues consist of handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. The Company satisfies the performance obligation and recognizes revenue when the orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company sold its optical products purchasing organization on December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjA3_e6e2f630-03a8-4961-b833-face5b946ce2">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of revenues by service type as a percentage of total revenues follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical facilities revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5d2bbed9c6534351953638dbdb3614f3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzQtMi0xLTEtMA_cce94c4a-94d3-4b0d-91f6-f819d8709f0a"
      unitRef="number">0.953</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6e98bfd347534baf87731104e3ebb009_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzQtNC0xLTEtMA_1ce8cfdf-8bcf-4390-b44d-3bc34aab78ba"
      unitRef="number">0.941</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifb1b7267569e4598a877a5bd1e7e60c0_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzQtNi0xLTEtMA_211c974c-35ec-4224-993b-9eb48591f338"
      unitRef="number">0.936</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb74e0812a1a443d8b8840c07f69e351_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzUtMi0xLTEtMA_6d54f26d-f9df-4dde-b229-9b21421840fa"
      unitRef="number">0.034</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i765813026e6747489932f2af5293073c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzUtNC0xLTEtMA_02c60e42-f54c-4502-9137-966f6b4e29c0"
      unitRef="number">0.043</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc2bea721a2d47a69444093571e4ee96_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzUtNi0xLTEtMA_0d57a67a-bc5f-449e-8199-99b3aee3c899"
      unitRef="number">0.045</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie75ead2faa6f445cbe2c4cea920cf20c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzYtMi0xLTEtMA_4e744893-c904-4ad1-9fae-368096952a89"
      unitRef="number">0.987</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib6f0752ff15148458214da6f9a47c887_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzYtNC0xLTEtMA_36d111b8-a8f7-4724-8161-1b847e2c6f75"
      unitRef="number">0.984</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i281bab5aadc7405e927b61233cc41c4e_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzYtNi0xLTEtMA_01c7de88-28bf-4859-8285-f0a218df9527"
      unitRef="number">0.981</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i37b3da5de5c04f86991cec578aae4497_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzgtMi0xLTEtMA_0ff6c8bd-e06c-4d74-8575-71a87ef6dafe"
      unitRef="number">0.002</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6b4cc978af3f4a63b82fda4044e5fff5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzgtNC0xLTEtMA_fd38b97b-a8a9-4d0b-8bb8-0fe85d1478da"
      unitRef="number">0.002</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9261ab18f79e429d8804ff5e25c2a493_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzgtNi0xLTEtMA_d3564993-40fe-42e7-8171-661cf1e11f1e"
      unitRef="number">0.005</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i825199532fc645f5b290bb16b440feda_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzktMi0xLTEtMA_179ea919-ed76-405a-825b-b6d0c79bb776"
      unitRef="number">0.011</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibbd90e3a784c4bef8f5691eca433c93c_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzktNC0xLTEtMA_df119ce4-d18a-47e9-a26f-07bab4511b22"
      unitRef="number">0.014</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4bd378e171d0488e9bd9affdec483b9a_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzktNi0xLTEtMA_8994c5a3-374d-4e64-b133-d3d84a742a6a"
      unitRef="number">0.014</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie3b0a3e3d1ca40ef8aa43b2e273dd745_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzEwLTItMS0xLTA_2a374648-9e33-4899-b803-9448cdbd60a3"
      unitRef="number">0.013</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icf8eaf96b18847fd812316b9aa3c3ea1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzEwLTQtMS0xLTA_015dd251-d939-44fd-b9f7-918adbbbd5c6"
      unitRef="number">0.016</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia042b57c0fae4f5ea23237a58e596e29_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzEwLTYtMS0xLTA_ce49e806-35c8-40ba-a9da-2011fe4d6515"
      unitRef="number">0.019</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibb6553b4b74c4d84abce7d64bb6e0233_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzExLTItMS0xLTA_9073a37d-a3b0-424e-a2a0-69ec8964e1fc"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icf8d6a4513eb4b37bf1fdd0a3cd39717_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzExLTQtMS0xLTA_313cbf15-c201-4d8a-92d8-2953c31f843d"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i475a6b5170b94142b99badc78dfce138_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTpjZTU1ODkxOWVkYmQ0OWViYWEwNGRlZjczNDQxM2RhNS90YWJsZXJhbmdlOmNlNTU4OTE5ZWRiZDQ5ZWJhYTA0ZGVmNzM0NDEzZGE1XzExLTYtMS0xLTA_c78a7976-592f-4309-b501-562bd02f93ff"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTI4_584efc16-5e67-4dc3-a30a-8ebcdbc621cc">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Patient service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Private insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;970.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;948.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;708.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;701.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Self-pay&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total patient service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,836.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,803.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,737.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other service revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical service revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,860.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,831.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,771.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i599771c495cc475cb14cd51b2c80b0ff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtMi0xLTEtMA_a97d973f-39e5-478e-8860-fa90cd66de93"
      unitRef="usd">989900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if7ba3aeaa4184e578466ecc35d54af1e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtNC0xLTEtMA_a1258ffa-5d1b-4365-97e5-b832c6ff85ef"
      unitRef="number">0.539</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="id054af85841844e0a0510013723067b0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtNi0xLTEtMA_24a7982d-bc23-4093-af8b-01cb1bb1283a"
      unitRef="usd">970500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i142ee4c9bb7f48ac86443c88ccd89e60_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtOC0xLTEtMA_d081a98b-7f80-46d3-8ecc-a32207015bc4"
      unitRef="number">0.538</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7005419b507e45a4aa93e70381643122_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtMTAtMS0xLTA_578e172d-6ea9-46e1-a375-4fc9cced6559"
      unitRef="usd">948900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8db4acdb7fc34959956ed5d777c0c8aa_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzUtMTItMS0xLTA_5edf1195-4ae6-4db0-8577-95fc8f00a38c"
      unitRef="number">0.546</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i36320eddebd1443f9992f87dccb87372_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtMi0xLTEtMA_6664e5c0-4616-4e79-a6d4-833f5ed6aaf1"
      unitRef="usd">708500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2540c42567484e9c8d3478cf6157e2d0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtNC0xLTEtMA_a5c9dc61-0a66-4a23-ae30-87b10332caee"
      unitRef="number">0.386</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0ab9c71919d94f0b8dd7b5473c520031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtNi0xLTEtMA_dba4a023-ed6c-4254-adcf-0cdbdc2b3e8d"
      unitRef="usd">701900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if923233c958e4fd68b49484dc223744b_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtOC0xLTEtMA_28ec1506-d38a-4c00-b0ba-cbc52c006e14"
      unitRef="number">0.389</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if7250d04b81545d2b83ffebe4398b150_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtMTAtMS0xLTA_ab48bc68-0eac-4082-adfe-b2be764ab982"
      unitRef="usd">653300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie8b4b08c817e40b59ede6eeeb62709da_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzYtMTItMS0xLTA_8818308e-015c-45c1-b2ec-04a752bfd99a"
      unitRef="number">0.376</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i885eb9ec2ef944bca136520bc4460c09_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctMi0xLTEtMA_ec303060-f417-43cd-9163-4f56f746c5c4"
      unitRef="usd">58500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i94c93236fd5e4fefa3dcd39e74f88113_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctNC0xLTEtMA_3a48f07a-2f4f-40f8-8d6a-19066b7c12e3"
      unitRef="number">0.032</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1ec00cab9d2244fb80d85733bd9a7509_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctNi0xLTEtMA_e6bb2214-ac78-40de-957a-25bc27dad9bd"
      unitRef="usd">46100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i89029e5f88e44f1fae990a75d8ef24c0_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctOC0xLTEtMA_3a8cf016-232c-4279-91db-0364659039ad"
      unitRef="number">0.026</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i69ea7f0bf38e48f6a9c4239b60ad72f6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctMTAtMS0xLTA_987e3537-cd04-471c-96d0-88361df6ab8d"
      unitRef="usd">50000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaab475b98e9148eeb2d8f43e3181a7bc_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzctMTItMS0xLTA_285200f4-2e67-4777-b1d7-08e56b6c996a"
      unitRef="number">0.029</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3172eb66c1954274b662b8b0387af2be_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtMi0xLTEtMA_e4df3cfe-b96d-4a23-b42d-f8e56dac42dc"
      unitRef="usd">79200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8e2d986e12534bc0966c86c0cc1307aa_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtNC0xLTEtMA_76427e24-90cf-4852-b7cb-4b0f112de2e0"
      unitRef="number">0.043</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4e789cf2134b4a4dadeab6da7c134bbb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtNi0xLTEtMA_bb9d426d-6237-4baa-9c2d-077589494c73"
      unitRef="usd">84600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifb93f590e80e4cedae1dcfd1b284ce87_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtOC0xLTEtMA_8f06e387-ba5c-47ef-8a88-4b764943e270"
      unitRef="number">0.047</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if2f4fb0674ba4d63b328c08bd2cd38d0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtMTAtMS0xLTA_2f2517e5-6132-4c80-86c3-e755e91efb44"
      unitRef="usd">84800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifd4902e6aed24239a5e4d6ed4e5c823f_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzgtMTItMS0xLTA_62454f8d-306e-4cca-8d5f-c7d833655def"
      unitRef="number">0.049</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia5d2f9dc0f01494986594870e8a27ffa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktMi0xLTEtMA_61d9c5d3-8292-4a90-819f-4c955c08b9ca"
      unitRef="usd">1836100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib051090172004935b836c83156fe9867_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktNC0xLTEtMA_57c1c687-dd67-494f-988f-0852b87cff0a"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idd9ac1ba58bd4816b2c020ff0edcba26_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktNi0xLTEtMA_26388c8e-d6d8-4a7c-971b-b009945d62bb"
      unitRef="usd">1803100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icafafb71f58e407ab4cf51f081227241_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktOC0xLTEtMA_ccfc4ea0-f3be-4bf1-ad3b-b9dcc5715a8b"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia67253343d70443d9c7449f4a5c30664_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktMTAtMS0xLTA_82c16fb1-7825-42d4-af00-20f33c3d92a5"
      unitRef="usd">1737000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia4daf007b63f4b438c7341c6ac37b460_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzktMTItMS0xLTA_5f45b81b-89dd-4c05-aa13-cca6da5bb549"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i559b03a82e914664a3d8b0edaabe4911_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzExLTItMS0xLTA_5c9cba49-5951-4817-a249-060ce2821889"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6f9c8cab4fb14810be18a40a5b9653b9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzExLTYtMS0xLTA_f6ffd940-1ff0-4cd5-8c53-457057a40645"
      unitRef="usd">3800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7933eb55bb3143ffa2fd7f711c754dbf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzExLTEwLTEtMS0w_7820e60a-9675-4ddd-8bda-a47527b70529"
      unitRef="usd">9500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i334aefa151714dc18f1b5f1cf16fe5f8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEyLTItMS0xLTA_911bd2d0-ee14-4043-9549-81db03a55ace"
      unitRef="usd">21000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9e0e51f9a61b4ac1bc4ea1f7ebbb64c3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEyLTYtMS0xLTA_382c7dba-ef46-4bc6-93a0-453a486cd92c"
      unitRef="usd">24500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic75069bdec0e44eb9f28b52baa250e8a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEyLTEwLTEtMS0w_5ca07c90-3c73-4e04-a136-88a4c211b322"
      unitRef="usd">25000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEzLTItMS0xLTA_a7aeb5f3-f81b-465c-8a54-31b5aeffc803"
      unitRef="usd">1860100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEzLTYtMS0xLTA_e163de87-72b8-4a1c-ba67-9111c8286ee0"
      unitRef="usd">1831400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo2NTFhOGFiY2RhZjc0NGMxYTA0Nzk1NDE4YTFhOWZkZi90YWJsZXJhbmdlOjY1MWE4YWJjZGFmNzQ0YzFhMDQ3OTU0MThhMWE5ZmRmXzEzLTEwLTEtMS0w_6df5ef9f-ec78-4f78-b0ff-f5cb7ad64c8d"
      unitRef="usd">1771500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTM5_b81bd1ca-c2cd-42b0-ad7c-dee366e87c28">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash reported within the consolidated statement of cash flows includes $0.3 million of restricted investments, which are reflected in other long-term assets in the consolidated balance sheet at both December&#160;31, 2020 and 2019. These restricted investments represent restricted cash held in accordance with the provisions of a long-term operating lease agreement held as security for performance under the Company's covenants and obligations within the agreement through January 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEzODE4_1f155b0f-57d1-4932-8e25-135e0cbb5042"
      unitRef="usd">300000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzEzODE4_80464201-5418-4984-bd19-379134304d95"
      unitRef="usd">300000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NDc3_796364ff-d9d3-4354-9bd2-2dc5c605a2c6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#x2019; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#x2019;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <sgry:OpticalProductsReceivable
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzE3MzYy_1745b432-d73b-4653-8104-74d94a226ee2"
      unitRef="usd">8600000</sgry:OpticalProductsReceivable>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjIz_b97bf7c6-e1b2-4690-8725-3cef8a99030a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets, Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value.&#160;The cash flow projection and fair value represents management&#x2019;s best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation.&#160;For discussion on impairment for goodwill and indefinite-lived intangible assets, refer to Note 4. "Goodwill and Intangible Assets."&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:SelfInsuranceReservePolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTIw_e19e8605-8990-41bf-b02c-a58abcd5c6ef">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Professional and General and Workers' Compensation Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional liability insurance coverage is on a claims-made basis and the general liability insurance is on an occurrence basis. The Company also maintains workers' compensation insurance, subject to a self-insured retention.&lt;/span&gt;&lt;/div&gt;The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers' compensation claims which relate to (i)&#160;claims made during the policy period, which are offset by insurance recoveries and (ii)&#160;an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets.</us-gaap:SelfInsuranceReservePolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTgw_f775597f-0236-4c87-9b8e-c6dd8717153c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records all derivatives on the balance sheet at fair value.&#160;The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.&lt;/span&gt;&lt;/div&gt;Derivatives and Hedging ActivitiesThe Company&#x2019;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. During 2020 and 2019, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.  For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#x2019;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#x2019;s variable-rate debt.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzIxOTkwMjMyODUyMTM_e53b44fc-f2cd-4a27-8f07-0461008024f6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Investments in Unconsolidated Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless the investments are a result of the Company losing control of a previously controlled entity, but still retaining a non-controlling interest. Transactions that result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, &lt;/span&gt;&lt;/div&gt;which include unobservable data, to measure the fair value of the retained non-controlling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in and advances to affiliates in the accompanying consolidated balance sheets. The Company&#x2019;s share of the profits and losses from these investments is reported in income from equity investments in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTYx_28eece6a-2c7e-4f97-86da-17aa1b4927e5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-Controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Controlling Interests &#x2014; Redeemable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#x2019; or physician minority members&#x2019;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;redeemable are reported outside of stockholders' equity in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjUy_f58c97f8-2a99-4950-93c9-ab9f2d28029e">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of activity related to the non-controlling interests&#x2014;redeemable for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;326.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition and disposal of shares of non-controlling interests, net&#x2014;redeemable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Distributions to non-controlling interest &#x2014;redeemable holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;321.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzMtMi0xLTEtMA_bd11be4e-1c4d-4638-978d-c9d42eb1f827"
      unitRef="usd">321000000.0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzMtNC0xLTEtMA_d3263f15-6ae6-4eff-a8f7-81237a205041"
      unitRef="usd">326600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzQtMi0xLTEtMA_8bd64f1e-ca86-44e5-b503-38614a2a3c68"
      unitRef="usd">31700000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzQtNC0xLTEtMA_07c3a5b1-549c-49c4-8822-2008a7a4ca44"
      unitRef="usd">39100000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzUtMi0xLTEtMA_65fb4c9a-517b-4e43-82a7-82cd3e3f49c4"
      unitRef="usd">-9400000</sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests>
    <sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzUtNC0xLTEtMA_7d2c578d-cecd-4f12-8f3c-58576c941ea3"
      unitRef="usd">-4700000</sgry:RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests>
    <sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzYtMi0xLTEtMA_81ed0db7-31b7-431e-904b-070f2ffbef89"
      unitRef="usd">36500000</sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzYtNC0xLTEtMA_e682cae8-3d9e-4c8b-8b3b-8844cea8be46"
      unitRef="usd">40000000.0</sgry:RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzgtMi0xLTEtMA_af26d15a-2af6-45e5-a3e6-1afa9e8af7d4"
      unitRef="usd">306800000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90YWJsZTo5ZWZlNmVkOGYzMjU0ZGE4OWQ1OWIyNjZlZGZjMmI5OS90YWJsZXJhbmdlOjllZmU2ZWQ4ZjMyNTRkYTg5ZDU5YjI2NmVkZmMyYjk5XzgtNC0xLTEtMA_bd11be4e-1c4d-4638-978d-c9d42eb1f827"
      unitRef="usd">321000000.0</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NjE0_dc4dbe47-edd2-4e76-b4ad-6531f23f5dc0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzI5NTIx_b3bbbf90-34d7-45b7-afdf-b451c7045b21">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-04 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future London Interbank Offered Rate ("LIBOR") indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (&#x201c;CECL&#x201d;) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, which is primarily applicable to accounts receivable for the Company. This ASU was effective for the Company on January 1, 2020. The adoption of this ASU did not have a material impact on its consolidated financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU 2016-02, "Leases" (the "Lease Accounting Standard"). The Company adopted the Lease Accounting Standard effective January 1, 2019, using a modified retrospective transition approach. The most prominent of the changes resulting from this ASU is the recognition of right-of-use assets and lease liabilities by lessees for those leases classified as operating leases. The Company&#x2019;s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. Upon adoption of the Lease Accounting Standard, the Company recorded $294.0&#160;million of operating lease liabilities and right-of-use assets on January 1, 2019. The cumulative effect of the accounting change recognized upon adoption was $6.1&#160;million reflected as an adjustment to retained deficit in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifa680d2bf8ab4a2d9fb8d803777a046f_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzExNTQ0ODcyMTYzODYz_17856664-8c3e-453b-877e-0d1191a0138c"
      unitRef="usd">294000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ifa680d2bf8ab4a2d9fb8d803777a046f_I20190101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzExNTQ0ODcyMTYzODYz_7e4eeeea-a339-4a36-94fd-c87c49e2d1fb"
      unitRef="usd">294000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36e8c64b0ba846c18f5a7a46fa045bc7_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDIvZnJhZzo4OWJhMGQ4YWQxNjg0YmQzOGM3ZjA4Zjg5OWY1Y2VmZC90ZXh0cmVnaW9uOjg5YmEwZDhhZDE2ODRiZDM4YzdmMDhmODk5ZjVjZWZkXzExNTQ0ODcyMTYzODky_dcb80bf2-d8b8-423d-bb1f-7dadf58a014d"
      unitRef="usd">6100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzYzOTA_8e1c6d96-fa7d-4b44-a39e-0e4a2912d276">Acquisitions and Disposals&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company accounts for business combinations in accordance with the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer can be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any non-controlling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Any goodwill recognized is determined as the excess of the fair value of the consideration conveyed plus the fair value of any non-controlling interests in the acquisition over the fair value of the net assets acquired. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Acquired assets and assumed liabilities typically include, but are not limited to, fixed assets, intangible assets and right-of-use leases. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. Fair value attributable to non-controlling interests is based on a Level 3 computation using significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of non-controlling interests, primarily from acquisitions of surgical facilities. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. Fair value attributable to the property and equipment acquired is based on Level 3 computations using key inputs such as cost trend data and comparable asset sales. Fair value attributable to the intangible assets acquired is based on Level 3 computations using key inputs such as the Company's internally-prepared financial projections. Fair values assigned to acquired working capital are based on carrying amounts reported by the acquiree at the date of acquisition, which approximate their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <sgry:BusinessCombinationsAndDisposalsDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzYzOTY_3cdde42f-ec95-49a9-805c-c6b958ff09ab">Acquisitions and Disposals&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company accounts for business combinations in accordance with the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer can be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any non-controlling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Any goodwill recognized is determined as the excess of the fair value of the consideration conveyed plus the fair value of any non-controlling interests in the acquisition over the fair value of the net assets acquired. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Acquired assets and assumed liabilities typically include, but are not limited to, fixed assets, intangible assets and right-of-use leases. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. Fair value attributable to non-controlling interests is based on a Level 3 computation using significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of non-controlling interests, primarily from acquisitions of surgical facilities. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. Fair value attributable to the property and equipment acquired is based on Level 3 computations using key inputs such as cost trend data and comparable asset sales. Fair value attributable to the intangible assets acquired is based on Level 3 computations using key inputs such as the Company's internally-prepared financial projections. Fair values assigned to acquired working capital are based on carrying amounts reported by the acquiree at the date of acquisition, which approximate their fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company acquired a controlling interest in three surgical facilities, including a surgical hospital, a controlling interest in five surgical facilities in existing markets, that were merged into existing facilities and a physician practice for total aggregate consideration of $120.1&#160;million, including cash consideration of $104.6&#160;million, net of cash acquired, non-cash consideration of $8.7 million and contingent consideration of $0.7 million. The non-cash consideration consisted of non-controlling interests in the Company's existing surgical facilities. The cash consideration was funded through cash from operations, proceeds from its recent divestitures and other available resources. The total consideration was allocated to the assets acquired and liabilities assumed based upon the respective acquisition date fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2019, the Company acquired a controlling interest in one surgical facility, a clinic that was merged into an existing facility and a physician practice for total aggregate consideration of $26.7&#160;million, including cash consideration of $20.1&#160;million, net of cash acquired. The remainder of the consideration related to the forgiveness of certain amounts due to the Company from the acquired clinic. During 2020, the Company made a working capital settlement payment resulting in additional cash consideration of $0.8&#160;million related to the clinic acquisition. The additional consideration is reflected in the table below. During the year ended December&#160;31, 2020, no other significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preliminary or final amounts recognized for each major class of assets acquired and liabilities assumed for acquisitions completed during the years ended December 31, 2020 and 2019, including post acquisition date adjustments, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consideration transferred &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;In connection with the clinic acquisition in 2019, the Company acquired the remaining non-controlling interests in one of its existing consolidated surgical facilities. As such, $6.3 million of the cash consideration for the clinic acquisition was classified as a financing activity and presented in payments related to ownership transactions with non-controlling interest holders in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The assets acquired in 2019 includes the fair value of a non-controlling investment held by the acquired clinic in one of the Company's consolidated surgical facilities of $8.8 million. This investment asset was subsequently eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values assigned to certain assets acquired and liabilities assumed by the Company in 2020 have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. The goodwill acquired in connection with the 2020 acquisitions was allocated to the Company's Surgical Facility Services reportable segment. The results of operations of the 2020 acquisitions are included in the Company&#x2019;s results of operations beginning on the dates of acquisition, and were not considered significant for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2019, the Company acquired non-controlling interests, primarily in four surgical facilities, for a cash investment of $15.2 million. The non-controlling interests were accounted for as equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, the Company sold its interests in three surgery centers, one of which was previously accounted for as an equity method investment, sold certain assets related to its anesthesia business, certain imaging assets and its optical products purchasing organization for combined net cash proceeds of $58.5&#160;million, and recognized a net pre-tax gain of $5.2&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December&#160;31, 2020. Additionally, the Company closed its diagnostic laboratory and recognized a net pre-tax loss of $3.5&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2019, the Company disposed of previously owned real property associated with one of its existing non-consolidated surgical facilities. In connection with the sale, the Company recognized a $10.9&#160;million pretax gain included in loss (gain) on disposals and deconsolidations, net in the accompanying consolidated statements of operations. The sale did not impact the Company's investment in the surgical facility, which continues to be accounted for as an equity method investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2018, the Company disposed of four surgery centers, two surgical hospitals and its optical laboratory for net cash proceeds of $18.7&#160;million, and recognized a net pretax loss of $21.2&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December 31, 2018. The non-cash loss was primarily a result of the write-off of the net assets of the facility (net of proceeds received) and was primarily driven by the write-off of the associated goodwill.&lt;/span&gt;&lt;/div&gt;</sgry:BusinessCombinationsAndDisposalsDisclosureTextBlock>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="if5a946918c8b40eea1360771a870d93f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyODQ4MjY_9e535a78-baf0-4ee3-b8f2-3b70abd4018b"
      unitRef="surgical_facility">3</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="ia47d16d8651a47159a92c2d34a75506d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyODQ4MzY_11859b8c-e699-4bc2-8910-22d8835b0993"
      unitRef="surgical_facility">5</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE1OTY2_04f99852-e21b-41ce-84af-2a2fbcdc6d66"
      unitRef="usd">120100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzEwOTk1MTE2NTc4MTk_40484a8b-7858-4de8-b7a7-dd245d1d653c"
      unitRef="usd">104600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE2MDM2_e03aaf2d-7515-4449-80c6-80c8c81c878c"
      unitRef="usd">-8700000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE2MDUz_3e420eee-5f7d-479c-a4d2-2f2d71734887"
      unitRef="usd">700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="icc2bd176b2b04f648164f8a60a3183bc_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyNjYxMTg_4130f50c-5187-4b19-83b9-6f68cb3fde1a"
      unitRef="surgical_facility">1</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i24702e29b0c7414e8f65fabb99f154f6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTEyNzE1_17c41828-c16b-40e3-91cd-4b51fa50a2c7"
      unitRef="usd">26700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia0e4786142704b339656b078b2112468_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzg3OTYwOTMwMjkzMDA_792146cc-0cc7-460b-a810-adb02a658f6a"
      unitRef="usd">20100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <sgry:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments
      contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE0NjEx_e62529d7-ee67-4b8e-843b-00c92709da8f"
      unitRef="usd">800000</sgry:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzYzODA_17eae498-651d-43b6-a17f-99cb7c666a7f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preliminary or final amounts recognized for each major class of assets acquired and liabilities assumed for acquisitions completed during the years ended December 31, 2020 and 2019, including post acquisition date adjustments, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consideration transferred &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Aggregate acquisition date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;In connection with the clinic acquisition in 2019, the Company acquired the remaining non-controlling interests in one of its existing consolidated surgical facilities. As such, $6.3 million of the cash consideration for the clinic acquisition was classified as a financing activity and presented in payments related to ownership transactions with non-controlling interest holders in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The assets acquired in 2019 includes the fair value of a non-controlling investment held by the acquired clinic in one of the Company's consolidated surgical facilities of $8.8 million. This investment asset was subsequently eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i29814b7c755c407e8db38e069ea034b4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzItMi0xLTEtMA_04f99852-e21b-41ce-84af-2a2fbcdc6d66"
      unitRef="usd">120100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia0e4786142704b339656b078b2112468_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzItNC0xLTEtMA_c1f7ba4c-56c7-4530-81da-da78463c7f8b"
      unitRef="usd">27400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzMtMi0xLTEtMA_9b5158c2-04e7-4d07-a61f-2008ab4a15ee"
      unitRef="usd">57300000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzMtNC0xLTEtMA_92945aa0-b220-4732-a59e-883065573f28"
      unitRef="usd">8300000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzQtMi0xLTEtMA_da1ab933-a198-4ee0-b871-bcf0f49614fc"
      unitRef="usd">177400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzQtNC0xLTEtMA_b8f78411-735c-46ef-ad3a-14db630459d1"
      unitRef="usd">35700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzYtMi0xLTEtMA_c63a48d5-a451-4e80-9356-47a87cc26765"
      unitRef="usd">24300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzYtNC0xLTEtMA_9c05f736-be29-4154-93e7-c2b385523cef"
      unitRef="usd">5400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzctMi0xLTEtMA_256ed066-9f8a-427d-a28c-c6eb66096de9"
      unitRef="usd">50600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzctNC0xLTEtMA_787e0de5-563a-4881-8f05-4df33a514b81"
      unitRef="usd">1800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzgtMi0xLTEtMA_81d3132d-dbe5-4cd5-837f-b0e2a00b1deb"
      unitRef="usd">3600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzgtNC0xLTEtMA_0162d0b4-f7cb-410f-8fcf-d4d343a31773"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzktMi0xLTEtMA_15c5f1cf-2587-482a-9013-23216430d771"
      unitRef="usd">153700000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzktNC0xLTEtMA_6a31b2d4-6743-4794-a218-bbbb00cddf1f"
      unitRef="usd">23400000</us-gaap:Goodwill>
    <sgry:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEwLTItMS0xLTQyMTQ_a3d4d0e8-8f1f-4562-b075-ff055ef6eb5f"
      unitRef="usd">15400000</sgry:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset>
    <sgry:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEwLTQtMS0xLTQyMTc_62429e16-3b44-434a-9499-13e052a9bf4b"
      unitRef="usd">28800000</sgry:BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEwLTItMS0xLTA_621613f7-fda6-4f32-b460-63aa948600fd"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEwLTQtMS0xLTA_28c5985d-af80-482e-8b60-4e6bbb1c28fc"
      unitRef="usd">8900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzExLTItMS0xLTA_a244acbd-5eef-4be7-baf8-6b7ab98efc17"
      unitRef="usd">16400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzExLTQtMS0xLTA_7e324e22-eaa2-4e46-bef4-7c4586cc07f9"
      unitRef="usd">4200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEyLTItMS0xLTA_f0d34af0-12eb-4895-9ba1-1bf96688da8a"
      unitRef="usd">40000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzEyLTQtMS0xLTA_3bac56b0-08ec-4ca1-84eb-8c31fc422bec"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzE0LTItMS0xLTQyMjM_ee8f4abe-5e07-40e2-a8ef-fcb54be1f452"
      unitRef="usd">14000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzE0LTQtMS0xLTQyMzE_003db365-bec1-4b17-9c98-1a4682ccc1f8"
      unitRef="usd">28200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="if311991b251d46209bd73eff519dfe38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzE0LTItMS0xLTA_bf178cbf-b2b4-4550-af5b-53eb3b0651f8"
      unitRef="usd">177400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i3e82cf5176a74986b3d84617fbd5cb6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90YWJsZTpkNDVjYzg1ZWVhNGY0NWE4YWQzOGM2ZjE5NzUwMmU1MS90YWJsZXJhbmdlOmQ0NWNjODVlZWE0ZjQ1YThhZDM4YzZmMTk3NTAyZTUxXzE0LTQtMS0xLTA_362613f0-4d02-468e-9dcf-2117fee9fbae"
      unitRef="usd">35700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i31f32ad0f9c64967bbb2cabcd332dc26_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzQwMzk_5f4880bd-1204-433c-9332-9119cadad0a4"
      unitRef="usd">6300000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="ied5a1e05804145ceab2d258e6b9b8d9d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzQ0NTA_eb68121f-bea6-4fe4-9eef-abcdf73679ca"
      unitRef="usd">8800000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <sgry:EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTExMTUy_618ed89c-ce88-4d61-b661-3ddb146cc400"
      unitRef="surgical_facility">4</sgry:EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTExMjAy_472cd8c5-2f01-4f5f-bc06-518da9053346"
      unitRef="usd">15200000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed
      contextRef="i096eba00dd53417a97144cec06404675_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE5Njcy_c28d6d6d-1265-49f1-9896-20948378636e"
      unitRef="surgery_center">3</sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i096eba00dd53417a97144cec06404675_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE5NjU4_a738acaa-8eb5-4a4c-978f-64a3f706ed87"
      unitRef="usd">58500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i096eba00dd53417a97144cec06404675_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTE5NzAx_660130fd-88e7-48e1-8b50-54b8f93dfdfd"
      unitRef="usd">5200000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i4b7dd0518ae1499292593c611baed1c9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTIwMTQ0_68e97248-452b-4ed3-82a2-7f3b8320b85a"
      unitRef="usd">-3500000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i971b3ccc8c4c4158b9ebbc8fbe15c413_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzg3OTYwOTMwMzE3Mjk_c5f93ff2-81f8-4097-9bc0-7eaa71a08128"
      unitRef="usd">10900000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed
      contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyODQ4NDg_fb5446de-768c-4435-937d-356d2c4b6da5"
      unitRef="surgery_center">4</sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed>
    <sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed
      contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzIxOTkwMjMyODQ4NTc_7f000783-d0d6-4ade-9646-a5831579db11"
      unitRef="surgical_hospital">2</sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTIwODg2_2273ed03-e4aa-4bf9-bf06-ba38ce84b03f"
      unitRef="usd">18700000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="i948b3cec9a734dd897c2701e0783d3f9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNDgvZnJhZzo3OGM2ZDBmYzRjZTg0ZjZjYWQ1Y2I3NDc0NmQyNzdiYi90ZXh0cmVnaW9uOjc4YzZkMGZjNGNlODRmNmNhZDVjYjc0NzQ2ZDI3N2JiXzExNTQ0ODcyMTIwOTAx_110ca711-a21a-4b09-a65a-3ba37c263265"
      unitRef="usd">-21200000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIzNzc_37954539-da2a-46f7-bc51-ff605883d361">Property and EquipmentProperty and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally 20 to 40 years for buildings &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;and building improvements, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzMzNA_0c1bb596-84ab-46e0-9e07-1217a9251edc"&gt;three&lt;/span&gt; to five years for computers and software and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4MA_b602329f-ae4b-455f-ae04-0f191a8afe79"&gt;five&lt;/span&gt; to seven years for furniture and equipment.&#160;Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company also leases certain facilities and equipment under finance leases. Assets held under finance leases are stated at the present value of lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of property and equipment follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use finance lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;733.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:  Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(189.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(110.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;544.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;523.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense was $90.5 million, $71.9 million and $62.5 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIzODU_f999c852-8977-4580-9a88-de61f1f30316">Property and EquipmentProperty and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally 20 to 40 years for buildings &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;and building improvements, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzMzNA_0c1bb596-84ab-46e0-9e07-1217a9251edc"&gt;three&lt;/span&gt; to five years for computers and software and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4MA_b602329f-ae4b-455f-ae04-0f191a8afe79"&gt;five&lt;/span&gt; to seven years for furniture and equipment.&#160;Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company also leases certain facilities and equipment under finance leases. Assets held under finance leases are stated at the present value of lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic40107317bb949478adb6fc4f2480728_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzI3OA_a258a109-27cd-4237-96a6-0f59b50a639e">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iba118baa03704512b22f936deffa8b05_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzI4NA_f676aa54-6b09-4ca3-a188-80a0d06268c1">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i76a8169409c44abfadcd0a3bf2b8aedc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM0MA_54d7c923-1f6d-4905-9569-67f19a36be18">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3956d1c7040d40d2970ded51a67c32b3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4Ng_c7e9251d-6d51-4f04-9783-64097f07af92">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIzODM_002d656d-15df-4139-b560-f4799cff81ec">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of property and equipment follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use finance lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;733.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:  Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(189.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(110.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;544.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;523.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifa40fcdd276343a8aed6a9a9a6a6ea6c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzMtMi0xLTEtMA_929b0b49-965a-440b-bea5-4691ab49d2cf"
      unitRef="usd">11100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i14ddb8219e714d378c98c211bb2cd34d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzMtNC0xLTEtMA_3b5408a5-73e7-4f20-9b9c-86d415694d6c"
      unitRef="usd">11000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie8c352ee9deb495eb58246bebe2e2e33_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzQtMi0xLTEtMA_0b073985-740d-49d5-b1de-25b1d9867640"
      unitRef="usd">109700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaa5d9c2bf8a543b08549baa2240b44b6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzQtNC0xLTEtMA_09087b23-eaeb-4bb1-a729-81b5a7e35a5e"
      unitRef="usd">106600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie020639241a94ada9a7368a42b91149c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzUtMi0xLTEtMA_7460c3c0-85a5-427a-8a7c-6fd1c4473a06"
      unitRef="usd">20700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i85d10b5c4c724186a5d9f3bb4e69a0a1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzUtNC0xLTEtMA_e6a40f53-30ec-4d3a-921f-4202d6541da4"
      unitRef="usd">23100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if889bbc6323c4947b0bc16cfb5b88f95_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzYtMi0xLTEtMA_dd10b615-3415-4109-b09d-98c8cfa3a8a0"
      unitRef="usd">80800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9d88e3845dc244d99f64392bd5e6a2d5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzYtNC0xLTEtMA_f21357a8-408b-4dda-ae72-3b497b85318d"
      unitRef="usd">59800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i57cd5e7c106e4d9fb74e20bda4b999cb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzctMi0xLTEtMA_aa1ece93-d64e-44a3-bb00-c181bbdb3a6b"
      unitRef="usd">196800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i68828e4c55c440639deb9dee2ee8d14e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzctNC0xLTEtMA_1c6b09c3-6baa-4245-a23b-f96ca8e50e87"
      unitRef="usd">148300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzgtMi0xLTEtMA_de64cfdd-8f2b-4c38-92a6-214028313b36"
      unitRef="usd">298400000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzgtNC0xLTEtMA_f5379f86-074f-41f8-92dc-a149b57b40fc"
      unitRef="usd">259300000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i414e49c153824db4964a4427b5015209_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzktMi0xLTEtMA_9a19fdf1-7291-4f93-8c14-0316fc4bf7e3"
      unitRef="usd">16400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0fdb52583c8b4bdd9a662cb6d4c8c12a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzktNC0xLTEtMA_94c047e9-777f-42bc-a610-635ebef0c3cc"
      unitRef="usd">25900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzEwLTItMS0xLTA_f477b396-4209-4e16-b281-575ac29b069c"
      unitRef="usd">733900000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzEwLTQtMS0xLTA_2c2ddf60-da76-4907-8790-c13c2eb64aee"
      unitRef="usd">634000000.0</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzExLTItMS0xLTA_2a953972-b48d-492f-be0f-a9898f8d8a36"
      unitRef="usd">189300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzExLTQtMS0xLTA_1f5ffc57-f277-4310-a126-06b59eba9989"
      unitRef="usd">110700000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzEyLTItMS0xLTA_d1722888-ae40-41e2-9988-00e5b11f7bd5"
      unitRef="usd">544600000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90YWJsZTo5Y2E1MDdmNzlkMDQ0OTA2ODhkNzU5ODdkMGFlMjRiZi90YWJsZXJhbmdlOjljYTUwN2Y3OWQwNDQ5MDY4OGQ3NTk4N2QwYWUyNGJmXzEyLTQtMS0xLTA_adfe9fce-419f-42de-88a3-4f4aff0defd9"
      unitRef="usd">523300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Depreciation
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIxOTg_36a89c15-4256-45ee-b00b-0f552d04fa65"
      unitRef="usd">90500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzIyMDU_5542d39a-68ad-4d8f-9f16-7685bd3c7cd8"
      unitRef="usd">71900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzg3OTYwOTMwMjQ2Mjc_c5c49696-2439-4e17-8964-81af70ed45da"
      unitRef="usd">62500000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NTM_d67f70b5-99c8-43ac-900b-5b22e765bcc5">Goodwill and Intangible Assets&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located, Medicare licenses and certain management rights agreements. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management rights agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2MA_33fd34e1-3ee5-447f-b7a8-7df209baa23f"&gt;three&lt;/span&gt; to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5Mw_f789f954-9fee-479a-9ce3-41a85047306b"&gt;two&lt;/span&gt; to five years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the consolidated statements of operations over the estimated lives of the relationships, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNTk_bbc47750-6337-4405-89b2-99010957f9eb"&gt;three&lt;/span&gt; to ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. During 2020, the Company identified three reporting units, which include the following: 1) Surgical Facilities, 2) Ancillary Services, and 3) Alliance, which is a component of the Optical Services operating segment. A detailed evaluation of potential impairment indicators was performed, which specifically considered the volatility observed in the prices of the Company&#x2019;s outstanding debt securities and common stock, as well as the decline in surgical case volumes following the emergence of the COVID-19 pandemic, all of which improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company compares the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. To determine the fair value of the reporting units, the Company obtained valuations at the reporting unit level prepared by third-party valuation specialists which typically utilizes a combination of the income and market approaches. The discounted cash flow model is projected based on a year-by-year assessment that considers historical results, estimated market conditions, internal projections, and relevant publicly available statistics. Determining fair value requires the exercise of significant judgment, including assumptions about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows. The significant judgments are typically based upon Level 3 inputs, generally defined as unobservable inputs representing the Company's own assumptions. The cash flows employed in the discounted cash flow analysis are based on the Company's most recent budgets and business plans aligned with provided guidance and, when applicable, various growth rates are assumed for years beyond the current business plan period. Discount rate assumptions are based on an assessment of the risk inherent in the future cash flows of the respective reporting units. The variables within the discount rate, many of which are outside of the Company's control, provide the best estimate of all assumptions applied within the discounted cash flow model. There can be no assurance that operations will achieve the future cash flows reflected in the projections. In determining the fair value under the market approaches, the analysis includes a control premium, which was based on observable market data and a review of selected &lt;/span&gt;&lt;/div&gt;transactions of companies that operate in the Company's sector. While the Company believes that all assumptions utilized in the testing were appropriate, they may not reflect actual outcomes that could occur. Specific factors that could negatively impact the assumptions used include changes to the discount and growth rates and a change in the equity and enterprise premiums being realized in the market.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2Njg_cbe404dc-5fb3-4ef2-be0a-e180e6120254">Goodwill and Intangible Assets&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located, Medicare licenses and certain management rights agreements. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management rights agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2MA_33fd34e1-3ee5-447f-b7a8-7df209baa23f"&gt;three&lt;/span&gt; to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5Mw_f789f954-9fee-479a-9ce3-41a85047306b"&gt;two&lt;/span&gt; to five years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the consolidated statements of operations over the estimated lives of the relationships, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNTk_bbc47750-6337-4405-89b2-99010957f9eb"&gt;three&lt;/span&gt; to ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. During 2020, the Company identified three reporting units, which include the following: 1) Surgical Facilities, 2) Ancillary Services, and 3) Alliance, which is a component of the Optical Services operating segment. A detailed evaluation of potential impairment indicators was performed, which specifically considered the volatility observed in the prices of the Company&#x2019;s outstanding debt securities and common stock, as well as the decline in surgical case volumes following the emergence of the COVID-19 pandemic, all of which improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company compares the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. To determine the fair value of the reporting units, the Company obtained valuations at the reporting unit level prepared by third-party valuation specialists which typically utilizes a combination of the income and market approaches. The discounted cash flow model is projected based on a year-by-year assessment that considers historical results, estimated market conditions, internal projections, and relevant publicly available statistics. Determining fair value requires the exercise of significant judgment, including assumptions about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows. The significant judgments are typically based upon Level 3 inputs, generally defined as unobservable inputs representing the Company's own assumptions. The cash flows employed in the discounted cash flow analysis are based on the Company's most recent budgets and business plans aligned with provided guidance and, when applicable, various growth rates are assumed for years beyond the current business plan period. Discount rate assumptions are based on an assessment of the risk inherent in the future cash flows of the respective reporting units. The variables within the discount rate, many of which are outside of the Company's control, provide the best estimate of all assumptions applied within the discounted cash flow model. There can be no assurance that operations will achieve the future cash flows reflected in the projections. In determining the fair value under the market approaches, the analysis includes a control premium, which was based on observable market data and a review of selected &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;transactions of companies that operate in the Company's sector. While the Company believes that all assumptions utilized in the testing were appropriate, they may not reflect actual outcomes that could occur. Specific factors that could negatively impact the assumptions used include changes to the discount and growth rates and a change in the equity and enterprise premiums being realized in the market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On the basis of available evidence as of August 31, 2020, the Company identified indicators of impairment related to its Ancillary Services and Alliance reporting units, including the impacts of the COVID-19 pandemic, the closure of its diagnostic laboratory (as discussed in Note 2. "Acquisitions and Disposals") and its strategic decision to sell its optical products purchasing organization. No indicators of impairment were identified for the Company's Surgical Facilities reporting unit. Based on the impairment indicators noted, the Company performed an impairment analysis for the Ancillary Services and Alliance reporting units as of August 31, 2020. As of the September 30, 2020 valuation, carrying value for both the Ancillary Services and Alliance reporting units exceeded the fair value, resulting in non-cash impairment charges of $28.6&#160;million and $4.9&#160;million, respectively. The fair values as of August 31, 2020 were determined using the adjusted book value for the Ancillary Services reporting unit and the discounted cash flow model for the Alliance reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of October 1, 2020, prior to its annual impairment testing, the Company's three reporting units with allocated goodwill were as follows: 1) Surgical Facilities - $3.3 billion, 2) Ancillary Services - no remaining goodwill after the August 31 impairment discussed above, and 3) Alliance - $4.2 million.&#160;As of the October 1, 2020 valuation, the fair value for the Surgical Facilities reporting unit was substantially in excess of its carrying value, and there were no additional indicators of impairment related to the other reporting units. The fair value of the Surgical Facilities reporting unit as of October 1, 2020 was determined using the income and market approach as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subsequent to the date of our annual impairment test, the Company considered its operating results for the fourth quarter of 2020, macroeconomic, industry and market conditions, and other market indicators including its market capitalization. Based on its evaluation of all such factors, the Company concluded that an event had not occurred or circumstances had not changed that would more likely than not reduce the fair value of its reporting units below their carrying values. On December 31, 2020, the Company disposed of the Alliance reporting unit with the sale of its optical products purchasing organization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, as a result of its impairment testing, the Company recorded non-cash impairment charges of $2.5&#160;million related to the Alliance reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2018, as a result of its impairment testing, the Company recorded non-cash impairment charges of $60.7&#160;million and $13.7&#160;million related to the Ancillary Services and Alliance reporting units, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the changes in the carrying amount of goodwill follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,402.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,382.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions, including post acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Disposals and deconsolidations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,468.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,402.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the Company's acquisitions and disposals for the years ended December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2019 is included in Note 2. "Acquisitions and Disposals." &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the components of intangible assets follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management rights agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company acquired a clinic that was previously managed by the Company. As a result of the transaction, the Company determined the management rights agreement related to the acquired clinic no longer provided a future benefit. As such, the Company recorded non-cash impairment charges of $5.4 million, which was included as a component of impairment charges on the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense for intangible assets was $4.3 million, $4.6 million and $4.9 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie1353b03ccc64693b38954fb5b09eaae_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2Ng_5224f0e4-3dba-4590-98d3-e811f79fd9db">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i56f55624fc5d49db9e2be6b8db22e727_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5OQ_8841f0a6-9aa5-474a-a065-4b9f39b5bb95">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i321bbd443b024763a2dbc89b24eaaa4e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEwMzM_26b1405b-15a8-41f0-9cd9-91ef04d7a706">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if8425e9689bd4f9b9c04b4df8dcc5f4a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNjU_dbd0938e-4e88-4ea9-91af-1ab2677f635d">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:NumberOfReportingUnits
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzExNTQ0ODcyMTA3MDAz_68a94d95-c134-4ba5-af27-d6027766e45e"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i83fa7ab9abbe4240abf5a9be8a23fd82_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzExNTQ0ODcyMTA0NDQ1_1614bde3-b266-4e0e-b6bb-92ca79cb70ef"
      unitRef="usd">28600000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1fb39a032ea34a87b804e96f67309730_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzExNTQ0ODcyMTA0NDYw_07d50b24-a4fb-4ccf-aae2-69d8dd58f0ed"
      unitRef="usd">4900000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="idbd41b7592e6496dae5a85b154e694ac_D20201001-20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzQxNDI_1ad2742b-6702-439a-9b67-a9a0791e820c"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:Goodwill
      contextRef="i4557e793265d4ca487ef329aeaae1ae3_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzQyMjI_0543a655-a955-4c11-92f6-af994879dbb8"
      unitRef="usd">3300000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib321c333fae04579844d5ee99972bb0e_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzIxOTkwMjMyNzA0MDU_e51aef98-37d1-45e8-95d7-42fd231e5c88"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i1ca50bf762614029b46129e2456fd831_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzExNTQ0ODcyMTA1NjA4_4ffd02ce-add1-4c48-a89a-8675b3563e31"
      unitRef="usd">4200000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1e4dce1c02884dedb36cc96503232a23_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzIxOTkwMjMyNzA0MTQ_2fb8997d-699f-4edc-b4d4-08e4452e347f"
      unitRef="usd">2500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5a9ee60353764f1f89b9af4f623bf105_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzIxOTkwMjMyNzA0Mjg_eeff8fe9-8b2b-4a01-8d7c-e3612b62278c"
      unitRef="usd">60700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8b51cb9aba5548ed93f4a31b4abdf654_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzIxOTkwMjMyNzA0NDM_12b4d76d-afb1-457e-952b-d2def0a99e55"
      unitRef="usd">13700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NzA_f44ec3c4-33c0-440c-b155-6b454281ae56">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the changes in the carrying amount of goodwill follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,402.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,382.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions, including post acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Disposals and deconsolidations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,468.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,402.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzMtMi0xLTEtMA_7ec51a2a-cadf-41af-b509-2fbb79174c71"
      unitRef="usd">3402400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzMtNC0xLTEtMA_f3604626-b47a-48f4-8470-4566aa5fabc5"
      unitRef="usd">3382800000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzQtMi0xLTEtMA_4a5efcbb-f26a-4ec5-b30c-1a8f285763b5"
      unitRef="usd">154700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzQtNC0xLTEtMA_8b6d6766-2592-476f-9bd9-5181984b6acd"
      unitRef="usd">22300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzUtMi0xLTEtMA_f178f0e3-e439-4e63-8263-0634b7ceca2e"
      unitRef="usd">55600000</sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations>
    <sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzUtNC0xLTEtMA_5281ed5b-eb9d-4444-a7ed-827ba554cc12"
      unitRef="usd">200000</sgry:GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzYtMi0xLTEtMA_1a1cfb8d-3a36-4760-9dd2-fa45f90d2f90"
      unitRef="usd">33500000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzYtNC0xLTEtMA_d3c862cd-d88a-47c2-8b3e-136bc63dd26b"
      unitRef="usd">2500000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzctMi0xLTEtMA_b76b3dea-ebff-46db-85fd-a7d51eeb246d"
      unitRef="usd">3468000000.0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToyYzdhMjk5M2Y3MDI0YjczYjI5NWU3NTdlZWFiNjEwOC90YWJsZXJhbmdlOjJjN2EyOTkzZjcwMjRiNzNiMjk1ZTc1N2VlYWI2MTA4XzctNC0xLTEtMA_7ec51a2a-cadf-41af-b509-2fbb79174c71"
      unitRef="usd">3402400000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NTk_3e4133c7-1c31-43e3-8e50-bd686eaade00">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the components of intangible assets follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management rights agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NjA_bc99dd2e-d0da-40eb-9d0f-8dd6191c851f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of the components of intangible assets follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management rights agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if68f779024f44d59b01b47b4693ce33d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtMi0xLTEtMA_f2b18c4e-4d3e-48ca-91b7-00f61285e4b7"
      unitRef="usd">31100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if68f779024f44d59b01b47b4693ce33d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtNC0xLTEtMA_a40519b6-6e29-4256-af78-d72b136b4db4"
      unitRef="usd">10100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if68f779024f44d59b01b47b4693ce33d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtNi0xLTEtMA_cff37bd8-6eae-4812-acd9-d014dba0a07b"
      unitRef="usd">21000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i76b5285d66914d4383e39ad0ba826fc6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtOC0xLTEtMA_8f03a52a-962e-46a1-92ec-5469f1e5039e"
      unitRef="usd">31100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i76b5285d66914d4383e39ad0ba826fc6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtMTAtMS0xLTA_5bea3692-49d2-49de-a63b-d6991862515a"
      unitRef="usd">7300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i76b5285d66914d4383e39ad0ba826fc6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzQtMTItMS0xLTA_22581a99-a69e-435a-96a6-7215b32ad6a2"
      unitRef="usd">23800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5ba1731476d74ce2b3d217aad57dcc60_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtMi0xLTEtMA_e28b50f5-a978-4012-b529-92ab816a8af4"
      unitRef="usd">13600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5ba1731476d74ce2b3d217aad57dcc60_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtNC0xLTEtMA_6e287f82-82b7-4a38-9709-9a4868e46e4b"
      unitRef="usd">6500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5ba1731476d74ce2b3d217aad57dcc60_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtNi0xLTEtMA_6f69c2a0-ceda-432d-97f8-8dc41abda702"
      unitRef="usd">7100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icc383438e0c44af2bf287f3600874704_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtOC0xLTEtMA_364ae78a-2688-4fda-9a2d-e5ec88a68620"
      unitRef="usd">8800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icc383438e0c44af2bf287f3600874704_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtMTAtMS0xLTA_e0c8cfa4-a6f4-4453-b141-2cba08af7026"
      unitRef="usd">4500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icc383438e0c44af2bf287f3600874704_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzUtMTItMS0xLTA_92a567fe-6e5a-4bbc-bb4f-a5d85bc5c0c8"
      unitRef="usd">4300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtMi0xLTEtMA_1e37d9ca-3984-4d4c-a753-137e535d4903"
      unitRef="usd">44700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtNC0xLTEtMA_a55613a6-05f4-4850-951e-04fb7df1ad6c"
      unitRef="usd">16600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtNi0xLTEtMA_ad5844d1-73cf-4543-a078-1aef3164113a"
      unitRef="usd">28100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtOC0xLTEtMA_8d1fe9c6-4ed7-4589-a491-2ce48aa68a86"
      unitRef="usd">39900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtMTAtMS0xLTA_c275e6c6-e6dd-4337-a1e6-f6319db562a1"
      unitRef="usd">11800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzYtMTItMS0xLTA_74370582-5a6e-4804-818d-aaeb215146f7"
      unitRef="usd">28100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzctMi0xLTEtMA_914c3fe9-e8be-42c6-b65e-605529ebfbef"
      unitRef="usd">18800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzctNi0xLTEtMA_0813d802-70b2-4a92-97b0-943042109f0d"
      unitRef="usd">18800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzctOC0xLTEtMA_caf6dfad-adf0-43e2-a1d6-32d6b8de6e2a"
      unitRef="usd">19200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzctMTItMS0xLTA_4debafa8-f85e-4145-a0e9-f6ad3bfec694"
      unitRef="usd">19200000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtMi0xLTEtMA_61f71ec6-00f7-48d1-bed4-536c3160bfc3"
      unitRef="usd">63500000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtNC0xLTEtMA_468ca8b1-12ec-4850-9854-af94664b5385"
      unitRef="usd">16600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtNi0xLTEtMA_665885e9-503d-4f2f-bca6-21d5beaf68c3"
      unitRef="usd">46900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtOC0xLTEtMA_e993becc-e6ad-41cd-a265-da35e633a5ab"
      unitRef="usd">59100000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtMTAtMS0xLTA_deeba344-a1f1-447f-a858-f268f6730897"
      unitRef="usd">11800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZToxMDc1OTgxOTkyMjE0YWE1YmU3YzBmZDg3MWIyNjI1YS90YWJsZXJhbmdlOjEwNzU5ODE5OTIyMTRhYTViZTdjMGZkODcxYjI2MjVhXzgtMTItMS0xLTA_46a59c92-c20f-4d5c-9693-d37275960c26"
      unitRef="usd">47300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzYxNjQ_94b2c3fc-48ae-4045-b3ce-0d35435cca08"
      unitRef="usd">5400000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzYzMjk_cb046c43-7c13-4730-aec3-7fbe0d15357f"
      unitRef="usd">4300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzYzMzY_bf43a727-2157-44ec-95cd-314d98c43a74"
      unitRef="usd">4600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzg3OTYwOTMwMzI4MDI_e6515cdd-0ef5-4867-8b14-7ad6e27d2b88"
      unitRef="usd">4900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzY2NjM_8e33af6f-59c9-4c6f-af8e-44d405cc05ae">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzAtMi0xLTEtMA_dd75362c-638e-4420-b61a-026c2053580d"
      unitRef="usd">5700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzEtMi0xLTEtMA_5cfa48a6-4844-4b47-942d-0e2950d06b67"
      unitRef="usd">3800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzItMi0xLTEtMA_701250bd-cc0a-4ecb-a8fd-1c08fc660943"
      unitRef="usd">2900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzMtMi0xLTEtMA_474992db-43f9-43c5-96d1-725a54c11052"
      unitRef="usd">2500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzQtMi0xLTEtMA_59302904-32ed-490b-a70b-8c6e1a23f577"
      unitRef="usd">1900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzUtMi0xLTEtMA_e6a59f68-65b6-4ccf-99aa-fe254f7a607d"
      unitRef="usd">11300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90YWJsZTpmMjA1NTY4MjNhNWI0YzZmOGQyMTRiYjM2ZjRlYTlhYS90YWJsZXJhbmdlOmYyMDU1NjgyM2E1YjRjNmY4ZDIxNGJiMzZmNGVhOWFhXzYtMi0xLTEtMA_e8737f01-d727-4948-8026-cd3dbdbd0b52"
      unitRef="usd">28100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LongTermDebtTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEzMjQ1_a86bdc2c-f1b0-4c7c-9124-7823b1a1184c">Long-Term Debt&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,539.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,434.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Notes payable and other secured loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,856.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,792.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,524.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes unamortized fair value discount of $3.7 million and $4.6 million as of December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has a credit agreement (the "Credit Agreement") providing for a $1.29&#160;billion senior secured term loan (the "Term Loan"), a $180.0&#160;million senior secured incremental term loan (the "2018 Incremental Term Loan"), a $120.0&#160;million senior secured incremental term loan (the "2020 Incremental Term Loan") and a $120.0 million senior secured revolving credit facility (the "Revolver" and, together with the Term Loan, the 2018 Incremental Term Loan and the 2020 Incremental Term Loan, the &#x201c;Senior Secured Credit Facilities"). The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. Subject to certain conditions and requirements set forth in the Credit Agreement, the Company may request one or more additional incremental term loan facilities or one or more increases in the commitments under the Revolver. On March 18, 2020, the Company drew down its available capacity under its Revolver, as a precautionary measure in order to increase liquidity and preserve financial flexibility in light of current uncertainty resulting from the COVID-19 pandemic. During the second quarter, the Company fully repaid the outstanding balance. As of both December 31, 2020 and 2019, the Company had no outstanding borrowing on the Revolver. As of December&#160;31, 2020, the Company's availability on the Revolver was $112.5 million (including outstanding letters of credit of $7.5 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Term Loan will mature on August 31, 2024 and the Revolver will mature on August 31, 2022. The Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin ranging from 3.00% to 3.25% per annum, depending on the Company's first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than 2.00% per annum)) plus a margin ranging from 2.00% to 2.25% per annum. In addition, the Company is required to pay a commitment fee of 0.50% per annum in respect of unused commitments under the Revolver.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Term Loan amortizes in equal quarterly installments of 0.25% of the aggregate original principal amount of the Term Loan. The Term Loan is subject to mandatory prepayments based on excess cash flow for the applicable fiscal year that will depend on the first lien net leverage ratio as of the last day of the applicable fiscal year, as well as upon the occurrence of certain other events, as described in the Credit Agreement. There were no excess cash flow payments required as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On April 22, 2020, the Company entered into a second incremental term loan amendment, which further amended and supplemented the Credit Agreement to provide for a $120.0&#160;million senior secured incremental term loan. The 2020 Incremental Term Loans were fully drawn on April 22, 2020 and bear interest at a rate per annum equal to (x) LIBOR plus a margin of 8.00% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate, (iii) one-month LIBOR plus 1.00% per annum and (iv) 2.00% per annum) plus a margin of 7.00% per annum. The 2020 Incremental Term Loans were incurred as a separate tranche of term loans under the Credit Agreement, and are subject to maturity, amortization and mandatory prepayment provisions consistent with the existing terms loans outstanding under the Credit Agreement. Voluntary prepayments of the 2020 Incremental Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except LIBOR breakage costs and a make-whole and call premium, as applicable, in the case of certain prepayments or events within a specified period of time after April 22, 2020, as set forth in the second incremental term loan amendment).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;With respect to the Revolver, the Company is required to comply with a maximum consolidated total net leverage ratio of 9.50:1.00, which covenant will be tested quarterly on a trailing four quarter basis only if, as of the last day of the applicable fiscal quarter the Revolver is drawn in an aggregate amount greater than 35% of the total commitments under the Revolver. Such financial maintenance covenant is subject to an equity cure. The Credit Agreement includes customary negative covenants restricting or limiting the ability of the Company and its restricted subsidiaries, to, among other things, sell assets, alter its business, engage in mergers, acquisitions and other business combinations, declare dividends or redeem or repurchase equity interests, incur additional indebtedness or guarantees, make loans and investments, incur liens, enter into transactions with affiliates, prepay certain junior debt, and modify or waive certain material agreements and organizational documents, in each case, subject to customary and other agreed upon exceptions. The Credit Agreement also contains customary affirmative covenants and events of default. On April 16, 2020, the Company entered into a third amendment to Credit Agreement governing the Revolver, which amended and supplemented financial covenants applicable to the Revolver. Pursuant to the third amendment, the Company's requirement to comply with a maximum consolidated total net leverage ratio was waived for the remainder of 2020. Additionally, for the first three quarters of 2021, the third amendment provides for an alternative calculation for the maximum consolidated total net leverage ratio where the trailing four quarter basis may be negatively impacted by the impacts of the COVID-19 pandemic. The third amendment became effective concurrently with the funding of the 2020 Incremental Term Loans on April 22, 2020, and are discussed in more detail above. As of December&#160;31, 2020, the Company was in compliance with the covenants contained in the Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities are guaranteed, on a joint and several basis, by SP Holdco I, Inc. and each of Surgery Center Holdings, Inc.'s current and future wholly-owned domestic restricted subsidiaries (subject to certain exceptions) (the "Subsidiary Guarantors") and are secured by a first priority security interest in substantially all of Surgery Center Holdings, Inc.'s, SP Holdco I, Inc.'s and the Subsidiary Guarantors&#x2019; assets (subject to certain exceptions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with the 2020 Incremental Term Loans borrowings, the Company recorded debt issuance costs and discount of $6.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;6.750% Senior Unsecured Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effective June 30, 2017, the Company issued $370.0 million in gross proceeds of senior unsecured notes due July 1, 2025 (the "2025 Unsecured Notes"). The 2025 Unsecured Notes bear interest at the rate of 6.750% per year, payable semi-annually on January 1 and July 1 of each year. The 2025 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly-owned restricted subsidiaries that guarantees the Senior Secured Credit Facilities (subject to certain exceptions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2020 to June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103.375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2021 to June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If Surgery Center Holdings, Inc. experiences a change in control under certain circumstances, it must offer to purchase the 2025 Unsecured Notes at a purchase price equal to 101.000% of the principal amount, plus accrued and unpaid interest, if any, up to, but excluding, the date of repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The 2025 Unsecured Notes contain customary affirmative and negative covenants, which, among other things, limit the Company&#x2019;s ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;10.000% Senior Unsecured Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effective April 11, 2019, the Company issued $430.0 million in an aggregate principal amount of senior unsecured notes due April 15, 2027 (the "2027 Unsecured Notes"). The 2027 Unsecured Notes bear interest at the rate of 10.000% per annum, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2019. The 2027 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly-owned restricted subsidiaries that guarantees the Senior Secured Credit Facilities (subject to certain exceptions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company may redeem up to 40% of the aggregate principal amount of the 2027 Unsecured Notes at any time prior to April 15, 2022, with the net cash proceeds of certain equity issuances at a redemption price equal to 110.000% of the principal amount of notes to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company may redeem the 2027 Unsecured Notes, in whole or in part, at any time prior to April 15, 2022, at a redemption price equal to 100% of the principal amount of notes to be redeemed plus the applicable premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may redeem the 2027 Unsecured Notes, in whole or in part, at any time on or after April 15, 2022, at the redemption prices set forth below (expressed as a percentage of the principal amount of notes to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 15, 2022 to April 14, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 15, 2023 to April 14, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 15, 2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If Surgery Center Holdings, Inc. experiences a change of control under certain circumstances, it must offer to purchase the 2027 Unsecured Notes at a purchase price equal to 101.000% of the aggregate principal amount of notes, plus accrued and unpaid interest, if any, up to, but excluding, the date of repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The indenture governing the 2027 Unsecured Notes contains customary affirmative and negative covenants, which, among other things, limit the Company&#x2019;s ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On July 30, 2020, the Company completed the issuance and sale of $115.0&#160;million in aggregate principal amount of senior unsecured notes due 2027 at 100.75% of the principal amount. The notes were issued as part of the same series as the existing 2027 Unsecured Notes originally issued in April 2019, and have the same terms. In connection with the notes issuance, the Company recorded debt issuance costs, net of issuance premium of $1.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s subsidiaries have outstanding indebtedness under notes payable and other secured loans, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made, and right-of-use finance lease obligations for which the Company is liable to various vendors for several property and equipment leases classified as finance leases.&#160;The various bank indebtedness agreements contain covenants to maintain certain financial ratios and also restrict encumbrance of assets, creation of indebtedness, investing activities and payment of distributions. At December&#160;31, 2020, the Company was in compliance with its covenants contained in the credit agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of maturities for the Company's long-term debt, excluding unamortized debt issuance costs and the unamortized fair value discount discussed above, for the next five years and thereafter as of December&#160;31, 2020 follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,519.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,876.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEzMjUz_1bb075fc-bce4-443c-bdae-c879ab5f4599">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of long-term debt follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured term loan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,539.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,434.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Senior secured revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.750% senior unsecured notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;370.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.000% senior unsecured notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Notes payable and other secured loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,856.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,792.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,524.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes unamortized fair value discount of $3.7 million and $4.6 million as of December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzMtMi0xLTEtMA_947f15f8-f4ae-4131-8f50-48e2c14ed259"
      unitRef="usd">1539400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i38f34da757564475b695308801b42f1e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzMtNC0xLTEtMA_3083982e-f56c-425e-b0f6-56fd5c4e55b6"
      unitRef="usd">1434100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i67bb1da722a94a38b17d3ec8f7e25de4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzQtMi0xLTEtMA_0b9e3f8e-83a2-4ca3-8ad1-9dbbad696034"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic64394bce33e4e9ca4aca2ff0a3ab714_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzQtNC0xLTEtMA_4926dca2-5d95-496c-8c61-6fd6b4ff02ad"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i911d67503a3e4528a30814a4348d8ea4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzYtMC0xLTEtMC90ZXh0cmVnaW9uOmY3YzQ5MDc3MTI0NjQzZmI5YzAxMmE2ZTA2MjMyZjU2XzIxOTkwMjMyNTU2MDA_10631964-487f-4b80-b7cc-92b2e6df91a0"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i911d67503a3e4528a30814a4348d8ea4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzYtMi0xLTEtMA_9866987b-ed9f-4dbe-bf61-3d7cab00c1db"
      unitRef="usd">370000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia1afaa2f8387439e98068fbf64e2ee04_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzYtNC0xLTEtMA_3ddd243e-57d4-4eee-a8d8-2ca3378c0bc7"
      unitRef="usd">370000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7bd4886dd3f74966858590367b6f85d9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzctMC0xLTEtMC90ZXh0cmVnaW9uOjkyYjVmYjU5ZmUzZDQ3YTk5YWQyMTMyN2NhOWE0YjBkXzIxOTkwMjMyNTU2MDI_3ee4bf56-e937-42e9-9b86-388f3b53dd24"
      unitRef="number">0.10000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7bd4886dd3f74966858590367b6f85d9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzctMi0xLTEtMA_15c3ef0e-ce5a-4a81-89f8-bc735f92a8be"
      unitRef="usd">545000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb34960793f34f629f106b22da0c737f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzctNC0xLTEtMA_e0af11dd-d25a-41ca-bc70-9f6657cffe11"
      unitRef="usd">430000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i817a7925476240d1a0297c22e048100c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzgtMi0xLTEtMA_c721d328-a570-4800-aa2a-3b947cf27872"
      unitRef="usd">137500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i398bdf0cb33e4e9a95374ecf8c74bd27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzgtNC0xLTEtMA_016138f2-d1bd-49e0-9167-4dbc35343acf"
      unitRef="usd">104000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzktMi0xLTEtMA_5150068a-2a6c-478b-a78f-fa88dafc4b90"
      unitRef="usd">281200000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzktNC0xLTEtMA_5e1221ce-b2a8-4ea1-87cd-bb212f340156"
      unitRef="usd">253400000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEwLTItMS0xLTA_0728ec3b-2974-4600-81e4-e675759e61f9"
      unitRef="usd">16300000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEwLTQtMS0xLTA_f27cd0fa-fd90-4e1e-820b-346a960e8a4d"
      unitRef="usd">10800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzExLTItMS0xLTA_12bfe99e-3ed5-443e-9654-cb60c7dc4310"
      unitRef="usd">2856800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzExLTQtMS0xLTA_625b28ff-7b6b-4b35-8c8c-598ea06ec0fb"
      unitRef="usd">2580700000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEyLTItMS0xLTA_8a1cd895-2b3d-4691-8ecb-51c869d83cd7"
      unitRef="usd">64400000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEyLTQtMS0xLTA_f0e5ecb5-bc60-4112-9e29-b0adea7fe82a"
      unitRef="usd">56000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEzLTItMS0xLTA_e20f1e44-38e8-43c2-b7db-1e5d9edf4112"
      unitRef="usd">2792400000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTozZTY3YjM4MjZhYjY0YTNhOGNhNWRlNTkxNjcwMzgyNS90YWJsZXJhbmdlOjNlNjdiMzgyNmFiNjRhM2E4Y2E1ZGU1OTE2NzAzODI1XzEzLTQtMS0xLTA_36becdf2-0f1c-4fa2-a497-ed9952005aee"
      unitRef="usd">2524700000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEyMg_f4fdd4dd-8aa8-40c4-a3c3-1131058e17e9"
      unitRef="usd">3700000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i38f34da757564475b695308801b42f1e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEyOQ_5c78611a-4f6a-44d3-a5e0-c690f0bdaa79"
      unitRef="usd">4600000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwOTk1MTE2NjE5Mjc_a6bd9051-2e04-4eec-9584-b953f6985643"
      unitRef="usd">1290000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i673a6d4abfc04d07bc5da2e378ef3651_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwOTk1MTE2NjIwODk_86f29af7-4ac5-4a18-8f11-8d068f2c92a8"
      unitRef="usd">180000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie06dea18e47140059ff8bee1f65d492e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwOTk1MTE2NjIwNzM_7ed67a14-ba17-4580-b319-8b1270b907c8"
      unitRef="usd">120000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8e0832acb780465db2d59399c892b08c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEyNjc_f17e44e4-7ec8-4e4d-80eb-e54b0c63902a"
      unitRef="usd">120000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCredit
      contextRef="i298880778d4c4020a86c49df919d29b2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyNzQ1ODg_305d0b2c-45d1-4f6b-98bf-44e0fbfecb4b"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i8e0832acb780465db2d59399c892b08c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyNzQ1ODg_dc5bb822-4b91-455f-9697-f8cde487fbcf"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i8e0832acb780465db2d59399c892b08c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxNzM_34c4d129-c16d-46eb-ba74-923f18aa95ff"
      unitRef="usd">112500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i65745a05a0cd456ab8a525d60910efd0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIyMjA_2a20d88a-15df-4968-8238-4617cc9a979d"
      unitRef="usd">7500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i85862ab6835e41eda58eb91f7b761382_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI0MzY_528b2b2f-3119-43fa-a6b1-ed22298bcf2f"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icb3f5b40bb954651a15a0509487a732e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI0NDI_c42a9983-5427-4fe6-85ea-97c1bd2009f3"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia627d4a01c804d75933b140eb136c84a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI1OTg_d8f6d577-b60b-4e1c-856b-ce30c35a11af"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib2e9ba12a1484646852fb69358ef6c43_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI2ODE_c3176d84-80fd-4ad9-8e08-8b9b231bc5c4"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie114fdfc808045a391295f7885a63b41_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI3ODA_2e31e156-d91e-4557-b9d1-a6846a9186a2"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <sgry:DebtInstrumentMarginInAdditionToBaseRate
      contextRef="i4cffedbc77074fe1a34b679e5841a01d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI4MjI_e65c12a8-7cd9-4039-ae7c-a2aafd547309"
      unitRef="number">0.0200</sgry:DebtInstrumentMarginInAdditionToBaseRate>
    <sgry:DebtInstrumentMarginInAdditionToBaseRate
      contextRef="ifdf5f1f86bf94962b6e3e0134fc3af0a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI4Mjg_3cf977a8-b173-42f0-81d5-4d64a6816871"
      unitRef="number">0.0225</sgry:DebtInstrumentMarginInAdditionToBaseRate>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i04f59e4d834d47dbb571b78b88198617_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzI5MDY_159d614a-0fcd-4b97-b1b0-9b12a3ed7fd5"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <sgry:DebtInstrumentQuarterlyMaturityInstallments
      contextRef="ie302bdf463064d918c23dd05f960895d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzMwMzE_623c2564-13d4-4181-b715-a7ace29f1134"
      unitRef="number">0.0025</sgry:DebtInstrumentQuarterlyMaturityInstallments>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iaea8005193594087be6cd7ef7af8522d_I20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1NjI_654f1cc6-8526-42ec-a226-6d25222f1f76"
      unitRef="usd">120000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i30095dd0fcb34c208f8bbc81fe378695_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1Nzg_3432655e-5897-4349-ba14-94e69dc063ae"
      unitRef="number">0.0800</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i060e7eb7f3c84d6d94309114449b4f82_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1MzU_0be2bde2-99f1-4a10-b23f-138a3c4dd25f"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia97d538681da4d98ae9a5301d88df53c_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1NDE_06d3478c-fcae-4691-b5d6-31539aa421a4"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <sgry:DebtInstrumentAlternateBaseRateFloor
      contextRef="ibd68cd8cfddc4609b3d3f2f07babb578_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1NDg_d83f16ba-2683-4a0e-93bb-3b8d388cd436"
      unitRef="number">0.0200</sgry:DebtInstrumentAlternateBaseRateFloor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idb199e263568416fa7ab39a1d69ed544_D20200422-20200422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1NTU_974e5d65-c080-4fd4-88bb-f10939b9b7bf"
      unitRef="number">0.0700</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <sgry:DebtInstrumentNetLeverageRatio
      contextRef="i04f59e4d834d47dbb571b78b88198617_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzM1Nzk_9f828e51-9e06-45ae-8fd4-2fc8396cf980"
      unitRef="number">9.50</sgry:DebtInstrumentNetLeverageRatio>
    <sgry:DebtInstrumentTotalCommitmentThreshold
      contextRef="i04f59e4d834d47dbb571b78b88198617_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzM3Nzg_5d55eb5f-040a-4664-855a-db94846895ba"
      unitRef="number">0.35</sgry:DebtInstrumentTotalCommitmentThreshold>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="iaea8005193594087be6cd7ef7af8522d_I20200422"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk1ODc_d3b11e1f-e1c0-4590-9fc4-4d563fb71b4f"
      unitRef="usd">6500000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzY0NTI_44b69b8c-2574-4928-81c4-c027b4be3808"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzY1NDU_bcb21d10-bef7-49de-9214-7d6a521fcdd9"
      unitRef="usd">370000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzY2OTM_cf847182-3f94-4ae9-ba71-43020197cd11"
      unitRef="number">0.06750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEzMjQ3_a42cdaea-a789-4372-92e7-69698b936866">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2020 to June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103.375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2021 to June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company may redeem the 2027 Unsecured Notes, in whole or in part, at any time on or after April 15, 2022, at the redemption prices set forth below (expressed as a percentage of the principal amount of notes to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 15, 2022 to April 14, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 15, 2023 to April 14, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 15, 2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtInstrumentRedemptionTableTextBlock>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i90553b5457f14a698b7cb8171b9a9315_D20170630-20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTpmNzMzMmFlNDI0MTQ0OGM0YTUzYmVmODdjNzQ2NTdmYS90YWJsZXJhbmdlOmY3MzMyYWU0MjQxNDQ4YzRhNTNiZWY4N2M3NDY1N2ZhXzAtMS0xLTEtMA_48c7b45d-366b-411c-a231-7bb27775f496"
      unitRef="number">1.03375</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i568b49c59a4f4598aead50892e84c992_D20170630-20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTpmNzMzMmFlNDI0MTQ0OGM0YTUzYmVmODdjNzQ2NTdmYS90YWJsZXJhbmdlOmY3MzMyYWU0MjQxNDQ4YzRhNTNiZWY4N2M3NDY1N2ZhXzEtMS0xLTEtMA_071de52a-36ab-43ab-8f8a-cf4acebd60ed"
      unitRef="number">1.01688</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i3dd7045767554040a7d60f075ade6642_D20170630-20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTpmNzMzMmFlNDI0MTQ0OGM0YTUzYmVmODdjNzQ2NTdmYS90YWJsZXJhbmdlOmY3MzMyYWU0MjQxNDQ4YzRhNTNiZWY4N2M3NDY1N2ZhXzItMS0xLTEtMA_166827b1-101b-414c-8e95-bab4cfa73481"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie0cdccdec4304478989201c4eb02dd07_D20170630-20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzg0NTQ_261dd60a-1732-4fb6-87f6-dda78f2abfab"
      unitRef="number">1.01000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9fe84b8f841949188f4220b606568120_I20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzkxNTk_86372cb9-aa8c-4c32-a5b1-c607ba0021f6"
      unitRef="number">0.10000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9fe84b8f841949188f4220b606568120_I20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzkzMDA_88ea0bcc-4d3d-48bf-bbe0-8c36b93e75e4"
      unitRef="usd">430000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9fe84b8f841949188f4220b606568120_I20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzkzNzc_bf7b33e2-1fad-4d72-accf-83701a5ab85d"
      unitRef="number">0.10000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="idb43c983a45f4e8591fd3ed40d5f1536_D20190411-20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzk4NDg_de8d912e-ba0d-47bb-ae29-656037ab4874"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i0919062a6a4f4909a1ae4a4a597169ee_D20190411-20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwMDM2_f209b820-0868-40bc-a1cd-895f76d35108"
      unitRef="number">1.10000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ib31650acf0ea42969dc4f705d51d36cf_D20190411-20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwMzAy_f4c90e2e-1dcf-4842-b125-98c4a5394569"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i0635f303320f412186ec5ca19c6fe2f2_D20190411-20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZToyMmM4MzU3YjU5OWU0ZjZhYjllZDczMmU1YTdkODdhMS90YWJsZXJhbmdlOjIyYzgzNTdiNTk5ZTRmNmFiOWVkNzMyZTVhN2Q4N2ExXzAtMS0xLTEtMA_92824a0e-83af-480c-b8a6-fdbd6bfe3be0"
      unitRef="number">1.05000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="if9ee0fbd7a0a46f594cc7b82247aa031_D20190411-20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZToyMmM4MzU3YjU5OWU0ZjZhYjllZDczMmU1YTdkODdhMS90YWJsZXJhbmdlOjIyYzgzNTdiNTk5ZTRmNmFiOWVkNzMyZTVhN2Q4N2ExXzEtMS0xLTEtMA_8ce41a90-01a6-4ac1-9733-a0764bd61c9f"
      unitRef="number">1.02500</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ic250d2ed04ae490aaaa2e78fd360cb53_D20190411-20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZToyMmM4MzU3YjU5OWU0ZjZhYjllZDczMmU1YTdkODdhMS90YWJsZXJhbmdlOjIyYzgzNTdiNTk5ZTRmNmFiOWVkNzMyZTVhN2Q4N2ExXzItMS0xLTEtMA_1e7d185e-aaac-4d24-9e68-760fad028fc2"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ia64e7b3f55a140e2b8f74b0d1c22c37b_D20190411-20190411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEwOTU5_f6589ed7-c33f-465b-95fb-fdd5f007ce79"
      unitRef="number">1.01000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8cd4c7600c0b479ab4a28ccae5406b84_I20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk2MDE_7c7a15e4-3c11-4572-aad4-fb8afc349a7f"
      unitRef="usd">115000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8cd4c7600c0b479ab4a28ccae5406b84_I20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk2MTc_180ea730-5c01-4e5b-8cfe-5300b086abc9"
      unitRef="number">1.0075</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i8cd4c7600c0b479ab4a28ccae5406b84_I20200730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzIxOTkwMjMyODk2MjY_8bf03f73-6fbd-4ada-999a-1e0164f232b7"
      unitRef="usd">1000000.0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90ZXh0cmVnaW9uOjE5Y2RkYWJjMTRiMjRmOTE5MzE2ZTZhODkxZmM0OTRmXzEzMjYz_ec30028d-f8b6-486a-95e3-b2c71dd2e0e9">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of maturities for the Company's long-term debt, excluding unamortized debt issuance costs and the unamortized fair value discount discussed above, for the next five years and thereafter as of December&#160;31, 2020 follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,519.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;396.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,876.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzAtMi0xLTEtMA_c3cff4dc-ddb2-48ed-8948-657b13d4e96e"
      unitRef="usd">64400000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzEtMi0xLTEtMA_7e8b94fa-d14f-4ffe-8f4b-613c90b772ca"
      unitRef="usd">57100000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzItMi0xLTEtMA_b920ee74-d908-4ea3-9bdd-772e67fc4308"
      unitRef="usd">53400000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzMtMi0xLTEtMA_09992f29-2f65-4922-8414-b9aefb545e9a"
      unitRef="usd">1519700000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzQtMi0xLTEtMA_42e82552-b189-4fde-9b73-5a45b63a9a77"
      unitRef="usd">396700000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzUtMi0xLTEtMA_b196b400-1f60-44c5-aa5b-a6fb59a74fcf"
      unitRef="usd">785500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTcvZnJhZzoxOWNkZGFiYzE0YjI0ZjkxOTMxNmU2YTg5MWZjNDk0Zi90YWJsZTo2ZjFkYjUzZjc3ODc0NzJiOWQ3ZWFiOTAyZDRmZWJhOC90YWJsZXJhbmdlOjZmMWRiNTNmNzc4NzQ3MmI5ZDdlYWI5MDJkNGZlYmE4XzYtMi0xLTEtMA_d8384c72-5bde-4bec-aa80-f051d625125e"
      unitRef="usd">2876800000</us-gaap:LongTermDebt>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3ODg_19c355ae-9388-4cfc-a747-b88efd44b8ac">LeasesThe Company determines if an arrangement is a lease at inception. Right-of-use assets represent the right to use the underlying assets for the lease term and the lease liabilities represent the obligation to make lease payments arising from the leases. Right-of-use assets and liabilities are recognized at commencement date based on the present value of future lease payments over the lease term, which includes &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;only payments that are fixed and determinable at the time of commencement. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company's incremental borrowing rate is used. The Company calculates its incremental borrowing rate on a periodic basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company applies its incremental borrowing rate using a portfolio approach. The right-of-use asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The Company's finance leases also include certain land, buildings and improvements as discussed in Note 3. "Property and Equipment." Real estate lease agreements typically have initial terms of ten years and may include one or more options to renew. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of the Company's medical equipment leases have a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life. The Company's lease agreements do not contain any material residual value guarantees, restrictions or covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain of the Company's lease agreements require the Company to pay common area maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Certain lease agreements also include escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. These variable components of lease payments are expensed as incurred and are not included in the determination of the right-of-use asset or lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due to the COVID-19 pandemic, the Company received concessions for certain of its leases primarily consisting of deferral of rental payments. The Company has elected to account for these COVID-19 related concessions as though the enforceable rights and obligations for those concessions are explicit within the underlying contract. The Company accounts for the deferred rentals as a component of other current liabilities within the consolidated balance sheets. In a few instances the Company modified the terms of the lease in exchange for lease concessions. These modifications resulted in an increase to the Company's right-of-use operating lease assets and liabilities of $27.4&#160;million during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3ODk_9d25213e-bd8b-4fc0-a0d0-bef672f2f45f">LeasesThe Company determines if an arrangement is a lease at inception. Right-of-use assets represent the right to use the underlying assets for the lease term and the lease liabilities represent the obligation to make lease payments arising from the leases. Right-of-use assets and liabilities are recognized at commencement date based on the present value of future lease payments over the lease term, which includes &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;only payments that are fixed and determinable at the time of commencement. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company's incremental borrowing rate is used. The Company calculates its incremental borrowing rate on a periodic basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company applies its incremental borrowing rate using a portfolio approach. The right-of-use asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The Company's finance leases also include certain land, buildings and improvements as discussed in Note 3. "Property and Equipment." Real estate lease agreements typically have initial terms of ten years and may include one or more options to renew. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of the Company's medical equipment leases have a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life. The Company's lease agreements do not contain any material residual value guarantees, restrictions or covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain of the Company's lease agreements require the Company to pay common area maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Certain lease agreements also include escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. These variable components of lease payments are expensed as incurred and are not included in the determination of the right-of-use asset or lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due to the COVID-19 pandemic, the Company received concessions for certain of its leases primarily consisting of deferral of rental payments. The Company has elected to account for these COVID-19 related concessions as though the enforceable rights and obligations for those concessions are explicit within the underlying contract. The Company accounts for the deferred rentals as a component of other current liabilities within the consolidated balance sheets. In a few instances the Company modified the terms of the lease in exchange for lease concessions. These modifications resulted in an increase to the Company's right-of-use operating lease assets and liabilities of $27.4&#160;million during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets at December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;310.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;568.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;534.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;573.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the weighted-average lease terms and discount rates at December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weight average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense and their classification in the consolidated statement of operations for the years ended December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020 and 2019, the Company incurred lease costs of $22.8&#160;million and $20.6 million, respectively, under operating lease agreements with physician investors who are related parties. During the years ended December&#160;31, 2020 and 2019, the Company paid rent of $6.9&#160;million and $6.7 million, respectively, under a finance lease agreement with a lessor who is a related party. One of the Company's surgical facilities has a non-controlling ownership interest in the lessor. Payments are allocated to principal adjustments of the finance lease liability and interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information for the years ended December&#160;31, 2020 and 2019 (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;526.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;565.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(284.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3OTQ_3d4e86ca-e1b5-4780-a4b9-4e0a429035ff">LeasesThe Company determines if an arrangement is a lease at inception. Right-of-use assets represent the right to use the underlying assets for the lease term and the lease liabilities represent the obligation to make lease payments arising from the leases. Right-of-use assets and liabilities are recognized at commencement date based on the present value of future lease payments over the lease term, which includes &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;only payments that are fixed and determinable at the time of commencement. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company's incremental borrowing rate is used. The Company calculates its incremental borrowing rate on a periodic basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company applies its incremental borrowing rate using a portfolio approach. The right-of-use asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The Company's finance leases also include certain land, buildings and improvements as discussed in Note 3. "Property and Equipment." Real estate lease agreements typically have initial terms of ten years and may include one or more options to renew. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of the Company's medical equipment leases have a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life. The Company's lease agreements do not contain any material residual value guarantees, restrictions or covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Certain of the Company's lease agreements require the Company to pay common area maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Certain lease agreements also include escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. These variable components of lease payments are expensed as incurred and are not included in the determination of the right-of-use asset or lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due to the COVID-19 pandemic, the Company received concessions for certain of its leases primarily consisting of deferral of rental payments. The Company has elected to account for these COVID-19 related concessions as though the enforceable rights and obligations for those concessions are explicit within the underlying contract. The Company accounts for the deferred rentals as a component of other current liabilities within the consolidated balance sheets. In a few instances the Company modified the terms of the lease in exchange for lease concessions. These modifications resulted in an increase to the Company's right-of-use operating lease assets and liabilities of $27.4&#160;million during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets at December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;310.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;568.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;534.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;573.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the weighted-average lease terms and discount rates at December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weight average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense and their classification in the consolidated statement of operations for the years ended December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020 and 2019, the Company incurred lease costs of $22.8&#160;million and $20.6 million, respectively, under operating lease agreements with physician investors who are related parties. During the years ended December&#160;31, 2020 and 2019, the Company paid rent of $6.9&#160;million and $6.7 million, respectively, under a finance lease agreement with a lessor who is a related party. One of the Company's surgical facilities has a non-controlling ownership interest in the lessor. Payments are allocated to principal adjustments of the finance lease liability and interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information for the years ended December&#160;31, 2020 and 2019 (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;526.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;565.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(284.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzI4Nzc_8435f182-3725-4254-8527-37032f4a41b3">P10Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <sgry:LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzI4OTY_0ff76f1b-83fd-42f6-ade1-1d9b727061b3"
      unitRef="option_to_renew">1</sgry:LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i50ba0a151834479a8473b3e13e71ff9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzExNTQ0ODcyMTAyMzA1_1d6c7ad1-2e88-469a-a795-c620a7774b40"
      unitRef="usd">27400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <sgry:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3OTE_8f497709-45ac-4c74-b9a4-815cb0d9c91a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets at December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification in Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;310.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net of accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;568.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;534.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;300.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current maturities of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96"&gt;Long-term debt, less current maturities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;573.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the weighted-average lease terms and discount rates at December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weight average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgry:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzMtNC0xLTEtNDM2OA_f67406b6-b5a5-442b-8997-2904a931124c"
      unitRef="usd">310100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzMtNC0xLTEtMA_49b8fc3c-64f4-40d8-b89e-e6e03adab6d9"
      unitRef="usd">297700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzQtNC0xLTEtNDM3Nw_febe3414-bd03-4544-9614-8294c79aa4b4"
      unitRef="usd">258100000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzQtNC0xLTEtMA_62a2d12d-7f15-4020-a8ab-85d66082cc49"
      unitRef="usd">237100000</us-gaap:FinanceLeaseRightOfUseAsset>
    <sgry:LeaseRightOfUseAsset
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzUtNC0xLTEtNDQ3MA_8976456f-c2bf-4483-b0c1-049d24cce49e"
      unitRef="usd">568200000</sgry:LeaseRightOfUseAsset>
    <sgry:LeaseRightOfUseAsset
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzUtNC0xLTEtMA_24d55e22-21c3-4c19-85ad-1c4dc768de36"
      unitRef="usd">534800000</sgry:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktNC0xLTEtNDM4MA_4855e2b7-0cfe-4b62-ae58-d25b9448cedf"
      unitRef="usd">39200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktNC0xLTEtMA_4060ad39-7d17-41fc-9964-5b89b164c95b"
      unitRef="usd">37300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzEwLTQtMS0xLTQzODM_b3539d8f-8f73-4439-bc10-42b3a71931c3"
      unitRef="usd">300900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzEwLTQtMS0xLTA_79f48df9-cc7b-4540-b6a9-31bf02f0ff30"
      unitRef="usd">283100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzExLTQtMS0xLTQ0NzA_d05a26c1-331a-4c1a-a277-9714de88ed70"
      unitRef="usd">340100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzExLTQtMS0xLTA_8ea3d330-aa65-404a-8cca-33f0aba491db"
      unitRef="usd">320400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzEzLTQtMS0xLTQzODY_ee7835ff-1ec0-4921-952c-f22bfb6ab3da"
      unitRef="usd">18900000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzEzLTQtMS0xLTA_f33d261c-059d-4739-a004-a34db966a19f"
      unitRef="usd">15800000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTQtMS0xLTQzODk_e2b71dff-da64-4aa2-8892-d059624959fe"
      unitRef="usd">262300000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTQtMS0xLTA_020bc89e-2268-4c67-b620-43108bcf1263"
      unitRef="usd">237600000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE1LTQtMS0xLTQ0NzA_93347cf0-5080-4bbe-a567-f8e546e783b5"
      unitRef="usd">281200000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE1LTQtMS0xLTA_7bce66a5-ab33-46c0-af4e-740b9c0ae251"
      unitRef="usd">253400000</us-gaap:FinanceLeaseLiability>
    <sgry:LeaseLiability
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE2LTQtMS0xLTQ0NzA_e83a04b6-b5c2-4d57-99e5-552dc19dfe83"
      unitRef="usd">621300000</sgry:LeaseLiability>
    <sgry:LeaseLiability
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE2LTQtMS0xLTA_44420f5b-de10-466c-8919-9b02650eb876"
      unitRef="usd">573800000</sgry:LeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzMtMi0xLTEtNDQwNw_64049f8c-5621-4335-9b00-b74364f2b841">P8Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzMtNC0xLTEtNDQxMg_e2df15fb-b722-4f5e-a724-a9018fcd197e">P15Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzItMi0xLTEtMA_c2470074-4182-4d0d-9ae7-1c3ba33d9855">P8Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzItNC0xLTEtMA_65d2d17c-c3d9-4e5e-b49d-5df22e1c516f">P16Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzQtMi0xLTEtNDQxNQ_2d6aaced-74b9-44c1-9a1c-c4d98bab97da"
      unitRef="number">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzQtNC0xLTEtNDQxOA_74555f9a-3c56-4e58-a549-03a175d68073"
      unitRef="number">0.092</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzMtMi0xLTEtMA_292543e7-8410-43a8-aa26-5b62025f4129"
      unitRef="number">0.104</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTpiMTI5Yjk4MjIzODQ0NzI4OTQ2ZDNmOTYxZGY5OTkyYi90YWJsZXJhbmdlOmIxMjliOTgyMjM4NDQ3Mjg5NDZkM2Y5NjFkZjk5OTJiXzMtNC0xLTEtMA_887f46fc-9fa5-42ed-b60e-091d8bc99deb"
      unitRef="number">0.087</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3ODE_ca877249-84c9-4484-8906-6b73918c0f8f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the Company's lease expense and their classification in the consolidated statement of operations for the years ended December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable and short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents supplemental cash flow information for the years ended December&#160;31, 2020 and 2019 (dollars in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Financing cash outflows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzItMi0xLTEtNDM5Mg_258a65c8-6831-4bcd-93ba-22056dfd0c7e"
      unitRef="usd">74100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzItMi0xLTEtMA_177406d1-bdd4-4949-aff9-cf01acf44b29"
      unitRef="usd">70400000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzQtMi0xLTEtNDM5Ng_f477b842-3014-4577-852a-83e3d95be233"
      unitRef="usd">26200000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzQtMi0xLTEtMA_2d29e20a-5339-4368-95d7-712be15d0a73"
      unitRef="usd">22200000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzUtMi0xLTEtNDM5OQ_d8aa2ffa-c33a-44f3-a50f-e336ad17f5c0"
      unitRef="usd">22200000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzUtMi0xLTEtMA_b825fc09-489a-4bac-85e6-027983d44abf"
      unitRef="usd">13000000.0</us-gaap:FinanceLeaseInterestExpense>
    <sgry:FinanceLeaseCost
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzYtMi0xLTEtNDQ3Mw_1b19ff35-11c2-40eb-a6a3-4799fb6d5bbf"
      unitRef="usd">48400000</sgry:FinanceLeaseCost>
    <sgry:FinanceLeaseCost
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzYtMi0xLTEtMA_c82002cb-07f0-4f77-894c-a64edaa1e229"
      unitRef="usd">35200000</sgry:FinanceLeaseCost>
    <sgry:VariableAndShortTermLeaseCost
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzctMi0xLTEtNDQwMg_3bd49ed5-05fe-428b-9342-94da587f9c87"
      unitRef="usd">16900000</sgry:VariableAndShortTermLeaseCost>
    <sgry:VariableAndShortTermLeaseCost
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzctMi0xLTEtMA_5e36c34d-5beb-4489-95b2-a9ad8a209a13"
      unitRef="usd">13200000</sgry:VariableAndShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzgtMi0xLTEtNDQ3Mw_339f32a8-678f-4213-a7a0-7cb04387d114"
      unitRef="usd">139400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTowZTE5N2VhZjA0MGI0N2ViODgzYjkxMThiNWI2MDUwNy90YWJsZXJhbmdlOjBlMTk3ZWFmMDQwYjQ3ZWI4ODNiOTExOGI1YjYwNTA3XzgtMi0xLTEtMA_8d596e42-9c63-4915-8900-0a56fe862425"
      unitRef="usd">118800000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9bba07e3d9ed4c28b32eadb5928dc00a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzEwOTk1MTE2MzgxMjc_c370842c-778c-4b23-87bc-7a35610dfb02"
      unitRef="usd">22800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2e7768b7591548fb890286a99b93de1b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzQ2NjM_05ad45c5-2162-4d8f-93dd-a84ce2028346"
      unitRef="usd">20600000</us-gaap:OperatingLeaseCost>
    <sgry:FinanceLeasePrincipalAndInterestPayments
      contextRef="i127295e72ee24cf4a023cb3f61d6a361_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzIxOTkwMjMyNjQwMTI_f2c17f55-ea14-4030-a28f-2053c5f83354"
      unitRef="usd">6900000</sgry:FinanceLeasePrincipalAndInterestPayments>
    <sgry:FinanceLeasePrincipalAndInterestPayments
      contextRef="ifa4c553a8af448ba93fa86e1f713f1d0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzQ4MDA_294fb858-5407-4eb4-8cac-0e4b8875367e"
      unitRef="usd">6700000</sgry:FinanceLeasePrincipalAndInterestPayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzMtMi0xLTEtNDQyMQ_4b58416e-24d8-420c-a3c4-df489e6037ef"
      unitRef="usd">68100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzMtMi0xLTEtMA_61ba262b-821a-44b5-ab9e-a45d790114b6"
      unitRef="usd">67300000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzQtMi0xLTEtNDQyMQ_f60679de-685c-4676-9deb-0bf4387f4c61"
      unitRef="usd">20700000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzQtMi0xLTEtMA_d6d610fa-d1e0-4aa0-9b6d-61f817abada3"
      unitRef="usd">13000000.0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzUtMi0xLTEtNDQyMQ_519220f2-f5e6-4dca-8986-b81312e89227"
      unitRef="usd">18300000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzUtMi0xLTEtMA_3f2bb668-c733-468f-b0d5-92afd1db8d5d"
      unitRef="usd">13400000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzgtMi0xLTEtNDQyNg_92257a70-40b6-4547-af68-1a2fb2123050"
      unitRef="usd">62100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzgtMi0xLTEtMA_53a70dbe-8ec5-409f-b54f-9c7f1275faed"
      unitRef="usd">56200000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzktMi0xLTEtNDQyNg_f1e2d582-3645-4b81-b40a-aa002eb50ae4"
      unitRef="usd">47000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTo0MmUwZTFkNjQ0ZjM0ZDRmYjYyMmIxZmI3ZmI1N2YyMC90YWJsZXJhbmdlOjQyZTBlMWQ2NDRmMzRkNGZiNjIyYjFmYjdmYjU3ZjIwXzktMi0xLTEtMA_6f593c0f-087a-4ab4-a0d2-194aaeb88278"
      unitRef="usd">133300000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3ODY_7fbbebf0-ccf2-44e4-b0f4-0e196915b982">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;526.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;565.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(284.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90ZXh0cmVnaW9uOjM3ZTRhOTQ0NmRiYzQ1YTNiNTVkYWEyNWY5OGY5YWEyXzY3OTI_12c82171-0b4f-4f70-a88b-fccd8b0dc8bb">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;381.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;526.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;565.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(186.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(284.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzItMi0xLTEtMA_dce43d93-bed0-48f7-ad79-ca3b1f202945"
      unitRef="usd">70700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzItNC0xLTEtMA_0b7cae71-fb66-4825-be62-ffa00905ae15"
      unitRef="usd">43200000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzMtMi0xLTEtMA_0b352335-5435-4458-bc03-e74e8d226343"
      unitRef="usd">66100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzMtNC0xLTEtMA_0b47a2ef-2c59-47a6-9510-8310442c88c6"
      unitRef="usd">40700000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzQtMi0xLTEtMA_5d7eec3c-ed59-465c-936c-842cae5a8473"
      unitRef="usd">62100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzQtNC0xLTEtMA_f85cbb5c-322a-4887-93b7-f107d17bd611"
      unitRef="usd">37000000.0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzUtMi0xLTEtMA_1a54c043-2f8c-44ff-a5a8-8bf1676e7a19"
      unitRef="usd">58400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzUtNC0xLTEtMA_dc31133d-efd2-40f2-82f0-1e3d1d6a0454"
      unitRef="usd">32100000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzYtMi0xLTEtMA_3d0c423e-fa27-4cd0-8a92-b15433ec6750"
      unitRef="usd">50000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzYtNC0xLTEtMA_ea64f53b-06dd-4930-a05c-c5267d902b0d"
      unitRef="usd">30700000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzctMi0xLTEtMA_1a0fd311-bae3-4586-aa35-525ace2ac186"
      unitRef="usd">219100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzctNC0xLTEtMA_c23c056e-7257-4f49-8dbc-30ad6782ca6b"
      unitRef="usd">381900000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzgtMi0xLTEtMA_9e8b8981-0ba0-496b-961c-e4e13cb6a25a"
      unitRef="usd">526400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzgtNC0xLTEtMA_93e0b689-8d08-41e6-8d50-06f4f83e7e37"
      unitRef="usd">565600000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzktMi0xLTEtMA_67e37774-033d-498e-9e77-8af8c730f6c0"
      unitRef="usd">186300000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzktNC0xLTEtMA_d0de5ed7-9da3-4d85-bcc4-f6f0e2a5dbf7"
      unitRef="usd">284400000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzEwLTItMS0xLTA_0a7beb2c-2c45-4bb1-bbc8-a4d48462f2af"
      unitRef="usd">340100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZTozM2JiMjU0M2ZjOGQ0NmIwYTEyOWU0ZmQ3Y2FlNTI1MS90YWJsZXJhbmdlOjMzYmIyNTQzZmM4ZDQ2YjBhMTI5ZTRmZDdjYWU1MjUxXzEwLTQtMS0xLTA_b20b504e-880b-4c15-8932-a7860883ed3a"
      unitRef="usd">281200000</us-gaap:FinanceLeaseLiability>
    <sgry:RedeemablePreferredStockTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQzODM_ce5cca4c-7f61-4e04-8d44-c72136d0e6fd">Redeemable Preferred Stock&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On August 31, 2017, the Company completed the sale issuance of 310,000 shares of the Company's preferred stock, par value $0.01 per share, designated as 10.00% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") to Bain Capital at a purchase price of $1,000 per share for an aggregate purchase price of $310.0 million (the "Preferred Private Placement").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accrued value of the Series A Preferred Stock is convertible into shares of common stock at a price per share of common stock equal to $19.00, subject to certain adjustments as provided in the Certificate of Designations, Preferences, Rights and Limitations of the 10.00% Series A Convertible Perpetual Participating Preferred Stock of Surgery Partners, Inc. (the "Series A Certificate of Designation"), at any time at the option of the holder. In addition, the Company may require the conversion of all, but not less than all, of the Series A Preferred Stock pursuant to the terms and conditions of the Series A Certificate of Designation, after the second anniversary of the date of issuance, if the volume weighted average closing price of the Common Stock for any 20 out of 30 consecutive trading days prior to such date, equals or exceeds $42.00 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company cannot redeem the Series A Preferred Stock prior to the fifth anniversary of its issuance and thereafter, may redeem all, but not less than all, of the Series A Preferred Stock for cash pursuant to and subject to the terms and conditions of the Series A Certificate of Designation. The holders of Series A Preferred Stock may cause the Company to redeem the Series A Preferred Stock upon the occurrence of certain change of control transactions of the Company or the common stock ceasing to be listed or quoted on a trading market. The Company adjusts the carrying amount of the Series A Preferred Stock to equal the redemption value at the end of each reporting period as if it were also the redemption date. Changes in the redemption value are recognized immediately as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Series A Preferred Stock ranks senior to the common stock and any other capital stock of the Company with respect to dividends, redemption and any other rights upon the liquidation, dissolution or winding up of the Company, and the holders thereof are entitled to vote with the holders of common stock, together as a single class, on all matters submitted to a vote of the Company&#x2019;s stockholders. In addition to participating in any dividends that may be declared with respect to the common stock on an as-converted basis, each share of Series A Preferred Stock accrues dividends daily at a dividend rate of 10.00%, compounding quarterly, and in any given quarter, subject to certain conditions, the Board of Directors of the Company may declare a cash dividend in an amount up to 50% of the amount of the dividend that has accrued and accumulated during such quarter through the end of such quarter, and the amount of any quarterly dividend paid in cash shall not compound on the applicable date and shall not be included in the accrued value of the Series A Preferred Stock. In the event of the Company&#x2019;s liquidation, dissolution or winding-up (whether voluntary of involuntary), holders of Series A Preferred Stock will be entitled to receive out of the assets of the Company available for distribution to shareholders, after satisfaction of any liabilities and obligations to creditors of the Company, with respect to each Series A Preferred Share, an amount equal to the greater of (i) $1,000.00 per share, plus dividends compounded to date, plus dividends accrued but not yet compounded and (ii) the amount that a holder of one share of common stock would receive, assuming the Series A Preferred Stock had converted into shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to the redeemable preferred stock for the years ended December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;359.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividends accrued (there were no cash dividends declared)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There were no unpaid cash dividends declared at December&#160;31, 2020 and 2019. The aggregate and per share amounts of unpaid cumulative preferred dividends as of December&#160;31, 2020 and 2019 were $109.0 million and $351.54, and $69.5&#160;million and $224.09, respectively.&lt;/span&gt;&lt;/div&gt;</sgry:RedeemablePreferredStockTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6fc81a25e5bb4918abcbd07201bcc95f_D20170831-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzExMw_5f66e228-5524-40b6-b29e-db99d9a0427e"
      unitRef="shares">310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i504a7a32d45c41d5b54fd670857c3477_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzE2Nw_d88348d7-1d24-447a-9af1-0744c6a42ade"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzE5NQ_8c391593-d07a-4a85-aa46-c2d65a3b9b68"
      unitRef="number">0.1000</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i504a7a32d45c41d5b54fd670857c3477_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzMzMQ_79d2b220-842f-44ce-9289-536bc5bb6e9b"
      unitRef="usdPerShare">1000</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6fc81a25e5bb4918abcbd07201bcc95f_D20170831-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzM3OQ_114db57c-fc02-4239-90bd-9dd5d777f975"
      unitRef="usd">310000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="i88337f9fbaa64e0ea242df6336604eda_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzU1OA_99d5cf2a-8908-4b89-9eb3-1a75cdeb2e70"
      unitRef="usdPerShare">19.00</us-gaap:SharePrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzY4NA_a89fd3d9-5929-4366-84be-373c51b969e9"
      unitRef="number">0.1000</us-gaap:PreferredStockDividendRatePercentage>
    <sgry:TemporaryEquityThresholdTradingDays
      contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzExODM_648e9f6e-47c2-4afb-ab0f-a76d7c6c34b2"
      unitRef="trading_day">20</sgry:TemporaryEquityThresholdTradingDays>
    <sgry:TemporaryEquityThresholdConsecutiveTradingDays
      contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzExOTM_e5fcaac3-98d3-4699-a74e-6b6a6fa437d2"
      unitRef="trading_day">30</sgry:TemporaryEquityThresholdConsecutiveTradingDays>
    <sgry:TemporaryEquityThresholdSharePrice
      contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzEyNTk_69aacab6-02b5-49d3-8fa4-890e71eab18e"
      unitRef="usdPerShare">42.00</sgry:TemporaryEquityThresholdSharePrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzI2ODM_6184fd9a-1fe4-4374-8aee-d8697af233ff"
      unitRef="number">0.1000</us-gaap:PreferredStockDividendRatePercentage>
    <sgry:TemporaryEquityMaximumCashDividendDeclarable
      contextRef="ic745907b541c43319ff5638b1d98c0df_D20170831-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzI4NTI_2ce289c8-d224-45e8-bb0c-68332aefc6f7"
      unitRef="number">0.50</sgry:TemporaryEquityMaximumCashDividendDeclarable>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="i2c7fbb2ada8c40c981d5f09669df59ab_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzM1NjE_e14e0ee7-9215-492e-aed3-08ee89662b07"
      unitRef="usdPerShare">1000.00</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQzODQ_7f8c9a96-a34d-43ed-bfb6-7a781ad98d88">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of activity related to the redeemable preferred stock for the years ended December&#160;31, 2020 and 2019 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;359.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividends accrued (there were no cash dividends declared)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzMtMi0xLTEtMA_12bac0d2-6d67-4826-88cb-475b3d4622b4"
      unitRef="usd">395000000.0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzMtNC0xLTEtMA_0c137abb-602e-4955-9d3e-668b1997a35f"
      unitRef="usd">359300000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NmQ4YWYzZGRjZTRjMDI4MDYxYWM0ZjcwYmU5NDA0XzIxOTkwMjMyNTU2MTU_8e8e6700-498b-4fdb-bec7-0bf85e508a2e"
      unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzQtMC0xLTEtMC90ZXh0cmVnaW9uOmY0NmQ4YWYzZGRjZTRjMDI4MDYxYWM0ZjcwYmU5NDA0XzIxOTkwMjMyNTU2MTU_a36c8026-2d8b-48b2-9d0d-b5470e8330f8"
      unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzQtMi0xLTEtMA_5fb70306-f49e-4ab2-8dfb-305bf5480d1d"
      unitRef="usd">39500000</us-gaap:TemporaryEquityAccretionOfDividends>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzQtNC0xLTEtMA_0e12aca1-5776-4b77-a979-ddf462ff83c3"
      unitRef="usd">35700000</us-gaap:TemporaryEquityAccretionOfDividends>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzYtMi0xLTEtMA_642b948a-29b1-471e-9bdf-27b24c5e2f6e"
      unitRef="usd">434500000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90YWJsZTo5NzQyMzllZjc5MjQ0MWY1OWUxMTBlNzhmMTM3ZGFmNC90YWJsZXJhbmdlOjk3NDIzOWVmNzkyNDQxZjU5ZTExMGU3OGYxMzdkYWY0XzYtNC0xLTEtMA_24a78f09-059c-426a-8f5c-f8f472f1d5a0"
      unitRef="usd">395000000.0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQxOTU_25a5bfa3-3b18-46b6-955e-e11834e0ffe1"
      unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQxOTU_ce237bf2-e4d2-4ccd-abc5-23092d484674"
      unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQzNDM_e6ebe175-e723-455a-a198-8d00d0228201"
      unitRef="usd">109000000.0</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
    <us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4XzQzNTA_51345a47-39d1-43df-9fed-c7822ed5c4e2"
      unitRef="usdPerShare">351.54</us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears>
    <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4Xzg3OTYwOTMwMjY5MDE_f072f75f-ba56-470e-bbd0-7147d97bf89e"
      unitRef="usd">69500000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
    <us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjMvZnJhZzo1MDcxNzY5MDVjYjc0YTNkYmFkYTM0NmU5ZTkyYzhhOC90ZXh0cmVnaW9uOjUwNzE3NjkwNWNiNzRhM2RiYWRhMzQ2ZTllOTJjOGE4Xzg3OTYwOTMwMjY4OTI_cba889ec-e12c-4aac-9c46-3ceb6b5cf584"
      unitRef="usdPerShare">224.09</us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzE4ODU_29076c50-8790-4a07-966f-f9e234bd3c17">Derivatives and Hedging Activities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. During 2020 and 2019, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#x2019;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#x2019;s variable-rate debt. Over the next 12 months, the Company estimates that $21.8 million will be reclassified as an increase to interest expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company had four interest rate swaps with a current notional amount of $1.2 billion and a termination date of November&#160;30, 2023. The derivatives are recorded at fair value (see Note 1. "Organization and Summary of Accounting Policies") and classified as a long-term liability included in other long-term liabilities in the consolidated balance sheets as of December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax effect of the interest rate swaps on the Company's accumulated OCI and statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss recognized in OCI (effective portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss reclassified from accumulated OCI to interest expense (effective portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzExMDQ_3fae3942-25b7-4a93-a259-477c67f27e30"
      unitRef="usd">-21800000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzExOTI_09928fcf-4f97-497f-b21a-87e6569d664c"
      unitRef="swap">4</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzExOTI_b2beb31c-f840-4cdc-a2b0-8e870775e58b"
      unitRef="swap">4</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib481dfff988242d29c23918931366022_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzEyNDk_2c9f79e6-bfe9-4ec1-9352-9a49549a0e3f"
      unitRef="usd">1200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i36cc65a9e59d4da7ae3978ace772db56_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzEyNDk_6bfd9d24-3361-4d13-adcf-385b88d64b04"
      unitRef="usd">1200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90ZXh0cmVnaW9uOjBhYWY1NTg5ZTc4ODQzMDliNjFkNzVjY2YxMzkzZGFmXzE4ODE_9c610241-7b62-45a0-ac75-5cb77c8396f2">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table presents the pre-tax effect of the interest rate swaps on the Company's accumulated OCI and statement of operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives in cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss recognized in OCI (effective portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss reclassified from accumulated OCI to interest expense (effective portion)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzUtMi0xLTEtMA_a6b5cc42-966d-42f2-9a4c-dff3f2972b2f"
      unitRef="usd">30500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzUtNC0xLTEtMA_2db1e075-cdef-4958-bd8b-fe0097ad3dfd"
      unitRef="usd">35800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzUtNi0xLTEtMA_01e50761-ae79-43e5-b641-c1d3481890e2"
      unitRef="usd">23100000</us-gaap:UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzYtMi0xLTEtMA_3f4de486-a44b-49ec-aa61-b983e6469ace"
      unitRef="usd">20200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzYtNC0xLTEtMA_7277e74a-0ea3-4fbc-ba67-0d440da72ab1"
      unitRef="usd">7500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjYvZnJhZzowYWFmNTU4OWU3ODg0MzA5YjYxZDc1Y2NmMTM5M2RhZi90YWJsZTo4NmU0ZTc1OGJhODE0NzU5YWU0NzA3OGZkMmVmYjM5MS90YWJsZXJhbmdlOjg2ZTRlNzU4YmE4MTQ3NTlhZTQ3MDc4ZmQyZWZiMzkxXzYtNi0xLTEtMA_f1ec32f6-95a9-4d90-a5a8-2603dfbd8a48"
      unitRef="usd">600000</us-gaap:DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIzNTg_aa83b2cb-7d94-4045-a9fb-1895e64a5946">Earnings Per ShareBasic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The Company computes basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIzNTk_73116707-032d-4ef9-97ad-0940b2a5f594">Earnings Per Share&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The Company computes basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Surgery Partners, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Amounts allocated to participating securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(155.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(110.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(238.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- basic and diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes dividends accrued during all periods for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in each of those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Repurchase Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On December 15, 2017, the Company's Board of Directors authorized a share repurchase program of up to $50.0 million of the Company's issued and outstanding common stock from time to time. The timing and size of repurchases will be determined based on market conditions and other factors. The authorization does not obligate the repurchase of any shares and the Company may repurchase shares of common stock at any time without prior notice. The share repurchases will be made in accordance with applicable securities laws in open market or privately negotiated transactions. The authorization does not have a specified expiration date, and the share repurchase program may be suspended, recommenced or discontinued at any time or from time to time without prior notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2018, the Company repurchased 156,818 shares of its common stock at an average price of $12.64 per share through market purchases. At December 31, 2020, the Company had $46.0 million of repurchase authorization available under the December 2017 authorization.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIzNjI_77d57227-85bc-4120-9f2c-eee3917fa8b6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Surgery Partners, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Amounts allocated to participating securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(155.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(110.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(238.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding- basic and diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Includes dividends accrued during all periods for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in each of those periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzUtMi0xLTEtMA_055925de-4410-4a3e-bf1f-e87dfae0cfa3"
      unitRef="usd">-116100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzUtNC0xLTEtMA_a0b4331e-3023-4616-bcb5-6e9b32869427"
      unitRef="usd">-74800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzUtNi0xLTEtMA_09e1932b-0da0-40ee-b27c-54d5ea50b7b9"
      unitRef="usd">-205700000</us-gaap:NetIncomeLoss>
    <sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzYtMi0xLTEtMA_39dd7928-7ae3-4612-ba21-9f51dcaa751f"
      unitRef="usd">39500000</sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued>
    <sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzYtNC0xLTEtMA_67de81ca-9851-444c-8d5c-d5935601042d"
      unitRef="usd">35700000</sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued>
    <sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzYtNi0xLTEtMA_437e83d1-dd7f-4b44-b3cd-8e02751b055c"
      unitRef="usd">32400000</sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzgtMi0xLTEtMA_7458f22d-cf5e-4f33-a2e4-ba383039e769"
      unitRef="usd">-155600000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzgtNC0xLTEtMA_6def45d1-dd42-4005-9993-7ebae8f3bd96"
      unitRef="usd">-110500000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzgtNi0xLTEtMA_53d53854-a885-4943-b697-8fd85f8dca3c"
      unitRef="usd">-238100000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8"
      unitRef="shares">48776000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5"
      unitRef="shares">48280000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08"
      unitRef="shares">48028000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e"
      unitRef="usdPerShare">-3.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTQtMS0xLTA_e2601a14-aa10-4c9d-904f-cfe5a64cd0de"
      unitRef="usdPerShare">-2.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6"
      unitRef="usdPerShare">-4.96</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i50385fe9eb7447adb4a7a8c102372757_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE2LTItMS0xLTA_066d89dc-7deb-46d8-aea9-9f071403910c"
      unitRef="shares">712000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i047b904f4f4f4b5787db655ab1545242_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE2LTQtMS0xLTA_3684892e-2840-4977-9294-31de41c7cb96"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe9c8ea68367495b9b437d93d0ca84d0_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE2LTYtMS0xLTA_3d8a3294-8ea0-4c63-a0e0-321e6b90bc74"
      unitRef="shares">83000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9fe24d481eb644d19bca83b8dd928563_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE3LTItMS0xLTA_c8ad6fa7-d9a7-4fc2-b2ce-983d0e57280f"
      unitRef="shares">981000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie72a24a82e274959946cf1d65a10b85f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE3LTQtMS0xLTA_2d5934dc-3121-4c38-a184-24c4017b14ea"
      unitRef="shares">67000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i26af377b8d9c4408a23b37c560fdc30e_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzE3LTYtMS0xLTA_94ad6ff9-51d1-4467-b0d9-2d93876f2580"
      unitRef="shares">198000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="icb46091aec85404086cdd6773d8811e8_I20171215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzEzMjM_8531078d-092c-48d1-bcd9-9c9579830ba9"
      unitRef="usd">50000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIxNDc_b5290ac7-8a9f-449a-abfb-8c762cae85c9"
      unitRef="shares">156818</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIyMDA_4d7bc6cb-4f29-4b23-89ba-0e84a8a8820d"
      unitRef="usdPerShare">12.64</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90ZXh0cmVnaW9uOmU4MTQ5Mjg4NGI3YzQxMGY5MGMyNzU1ZWI2MTlkYTY5XzIyNzc_1fe308e5-f6e9-485c-825b-3aad62e4740e"
      unitRef="usd">46000000.0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMTU_0ec5d68b-5fff-4ae3-b5a1-8f0d69ddfa39">Income Taxes&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes.&#160;Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160;Any change in tax rates that could impact deferred tax assets or liabilities are recognized in the same period the change occurs. If a net operating loss ("NOL") and/or interest limitation ("163(j)") carryforward exists, the Company makes a determination as to whether that NOL and/or 163(j) carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss and interest limitation carryforwards when their recoverability is deemed to be uncertain.&#160;The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions.&#160;If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2017 or state income tax examinations for years prior to 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company made income tax payments of $1.7 million, $1.6 million and $2.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income tax (benefit) expense is comprised of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax (benefit) expense computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 21% (2020, 2019 and 2018) follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax (benefit) expense at U.S.federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax, net of U.S. federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in measurement of uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock option compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Differences related to divested facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax return reconciling differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax Receivable Agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The components of temporary differences and the approximate tax effects that give rise to the Company&#x2019;s net deferred tax asset are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical malpractice liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued vacation and incentive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Allowance for bad debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Section 163(j) interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;TRA liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right of use&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Affiliate indebtedness receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other deferred assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation on property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basis differences of partnerships and joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right of use&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other deferred liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(123.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(122.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company had federal NOL carryforwards of $615.7 million as of December&#160;31, 2020, of which $516.2 million expire between 2026 and 2037. The remaining federal NOL carryforwards, which were generated subsequent to 2017, do not expire. The Company had state NOL carryforwards of $678.9 million as of December&#160;31, 2020, which expire between 2021 and 2040.&#160;The Company had capital loss carryforwards of $6.2 million as of December&#160;31, 2020, which expire between 2021 and 2023. The Company had federal and state credit carryforwards of $0.7 million as of December&#160;31, 2020. The federal credits do not expire, and the state credits expire between 2021 and 2031. The Company had IRC Section 163(j) interest limitation carryforwards of $278.4 million as of December&#160;31, 2020, which do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has recorded a valuation allowance against deferred tax assets at December&#160;31, 2020 and 2019 totaling $91.1 million and $77.9 million, respectively, which represents an increase of $13.2 million. The valuation allowance continues to be provided for certain deferred tax assets for which the Company believes it is more likely than not that the tax benefits will not be realized, which are primarily Section 163(j) interest carryforwards, certain state NOLs and capital loss carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the realizability of its deferred tax assets based on sources of positive and negative evidence, and determined that it is more likely than not that the NOL carryforwards will be realized. The determination was made based upon projections of future book and taxable income. If the Company's expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, the Company may need to adjust the valuation allowance, for all or a portion of its deferred tax assets. The Company's income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in its valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on the Company's future earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Included in the increase in the valuation allowance for the year ended December&#160;31, 2020 was an increase of approximately $2.8 million that was recorded to additional-paid-in-capital as the result of the tax effect of the interest rate swap liability. Approximately $16.8 million of the valuation allowance as of December&#160;31, 2020 is recorded against deferred tax assets that, if subsequently recognized, will be credited directly to contributed capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to uncertain tax positions in its provision for income taxes in the consolidated statements of operations. For both years ended December&#160;31, 2020 and 2019, the Company had approximately $0.1 million each of accrued interest and penalties related to uncertain tax positions. The total amount of accrued liabilities related to uncertain tax positions that would affect the Company's effective tax rate, if recognized, is $0.1 million as of both December&#160;31, 2020 and 2019. The reserves are included in long-term taxes payable in the consolidated balance sheet as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMjQ_03399799-498e-4aef-b6aa-8a0831d42a9a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes.&#160;Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160;Any change in tax rates that could impact deferred tax assets or liabilities are recognized in the same period the change occurs. If a net operating loss ("NOL") and/or interest limitation ("163(j)") carryforward exists, the Company makes a determination as to whether that NOL and/or 163(j) carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss and interest limitation carryforwards when their recoverability is deemed to be uncertain.&#160;The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions.&#160;If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2017 or state income tax examinations for years prior to 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzIxODI_38b180a3-6d63-40be-bfaa-ec616557a5ea"
      unitRef="usd">1700000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzIxODk_b36ab849-c619-491f-ab5c-12e459d125db"
      unitRef="usd">1600000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzEwOTk1MTE2MzYxNzk_2735582c-c855-41a8-9108-385fa7d58504"
      unitRef="usd">2200000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMjM_e79a7a53-2e4d-4b62-ac77-45f7d77c0e8a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income tax (benefit) expense is comprised of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzUtMi0xLTEtMA_aaf4b0d2-38da-45ff-8783-a6cd92e56864"
      unitRef="usd">-200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzUtNC0xLTEtMA_abc57da0-025e-48b7-a50c-5a6f66b2a51f"
      unitRef="usd">-200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzUtNi0xLTEtMA_92a1a61c-9036-4013-9dd2-bdcba91d4a2f"
      unitRef="usd">-300000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzYtMi0xLTEtMA_6c519132-10b4-4eb4-9a65-bed0476784b8"
      unitRef="usd">1900000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzYtNC0xLTEtMA_b5f21c0b-1ba5-40e0-87e9-ba2f1f9fa2ef"
      unitRef="usd">1700000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzYtNi0xLTEtMA_dc312acc-7d2e-4404-bbe4-21e499ffa836"
      unitRef="usd">1500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzgtMi0xLTEtMA_388b2205-5257-4a98-8090-ebb7a7ad73b7"
      unitRef="usd">-22200000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzgtNC0xLTEtMA_7b9efef6-27ea-411d-8008-7578d9ee4a1c"
      unitRef="usd">3200000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzgtNi0xLTEtMA_4f100bce-87f0-43e8-8d32-ad4164f7d2ca"
      unitRef="usd">16500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzktMi0xLTEtMA_7dd88d1e-62d8-4ff9-b81e-197d99ae9d2f"
      unitRef="usd">400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzktNC0xLTEtMA_2c63cfd7-7f39-48c4-8c97-cca8f254a872"
      unitRef="usd">4800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzktNi0xLTEtMA_fee77219-c557-41aa-9ba7-658a9c5a7c6c"
      unitRef="usd">8700000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzEwLTItMS0xLTA_8e167c39-25a7-4fa1-9273-dcb7c00c5f8e"
      unitRef="usd">-20100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzEwLTQtMS0xLTA_1fef0a65-5826-4f2e-a9cc-386afe9db636"
      unitRef="usd">9500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo1MDk3ZGNlODkxZGM0MDA4YmY3NGJkYzY0YTM2NWU5Zi90YWJsZXJhbmdlOjUwOTdkY2U4OTFkYzQwMDhiZjc0YmRjNjRhMzY1ZTlmXzEwLTYtMS0xLTA_0c9c365f-d98f-45cc-9ab9-7ef58f3b13c5"
      unitRef="usd">26400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMjc_d6b2ea48-6365-4f25-8d3e-42659141b12d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax (benefit) expense computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 21% (2020, 2019 and 2018) follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax (benefit) expense at U.S.federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income tax, net of U.S. federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in measurement of uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock option compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Differences related to divested facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax return reconciling differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax Receivable Agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzQtMi0xLTEtMA_65dc051f-9abc-4730-859d-d4d99e8c438d"
      unitRef="usd">-4000000.0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzQtNC0xLTEtMA_5fbbece1-f3dd-4728-be82-3041bfe7a56c"
      unitRef="usd">11500000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzQtNi0xLTEtMA_f61d83ad-263d-40c6-baef-3d7ac4bc17ec"
      unitRef="usd">-14500000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzUtMi0xLTEtMA_6da8b076-fb6d-4c56-9ad9-8fd1d09403af"
      unitRef="usd">2400000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzUtNC0xLTEtMA_3b5e5d5b-efdf-49cb-85f6-5dd40f602949"
      unitRef="usd">5700000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzUtNi0xLTEtMA_153a7722-c1d6-46d3-87b0-28daa9a7931d"
      unitRef="usd">10000000.0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzYtMi0xLTEtMA_795e0efc-0a9a-415c-8aba-5bfcd9aa9a15"
      unitRef="usd">4100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzYtNC0xLTEtMA_00460fe3-6066-4803-a00f-e5c2a827724c"
      unitRef="usd">13600000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzYtNi0xLTEtMA_7cc3254d-d49d-41f5-ad57-c848e67ef93c"
      unitRef="usd">26900000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzctMi0xLTEtMA_2c4d794a-e610-4a09-8e92-380a7d71294d"
      unitRef="usd">24800000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzctNC0xLTEtMA_98d7a745-a6f6-4668-85fd-586535313795"
      unitRef="usd">25200000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzctNi0xLTEtMA_25326b73-662e-472e-9235-3380c296e120"
      unitRef="usd">23100000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzgtMi0xLTEtMA_4f824fc9-3b03-48be-a6f2-ef749a648422"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzgtNC0xLTEtMA_e6424c2e-bb28-48cd-814e-0e2813400094"
      unitRef="usd">-100000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzgtNi0xLTEtMA_65f9be12-471f-4c7c-80be-86e11069fec9"
      unitRef="usd">-100000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzktMi0xLTEtMA_0a4ccb49-e67a-422c-b0cb-3d64bc435ff5"
      unitRef="usd">1200000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzktNC0xLTEtMA_ea51b35f-8832-46af-b04d-657e2416f5c8"
      unitRef="usd">1300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzktNi0xLTEtMA_c3cd822f-2e8a-4381-8591-d2f693122131"
      unitRef="usd">500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sgry:EffectiveIncomeTaxReconciliationDivestitureAmount
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEwLTItMS0xLTA_1942bfa8-9339-4973-9b4f-5bd7438bb9a7"
      unitRef="usd">-700000</sgry:EffectiveIncomeTaxReconciliationDivestitureAmount>
    <sgry:EffectiveIncomeTaxReconciliationDivestitureAmount
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEwLTQtMS0xLTA_e4b61f9f-d177-44a6-8c54-0aac91ac92f1"
      unitRef="usd">100000</sgry:EffectiveIncomeTaxReconciliationDivestitureAmount>
    <sgry:EffectiveIncomeTaxReconciliationDivestitureAmount
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEwLTYtMS0xLTA_f5dba668-e45d-444a-aec5-6bf32fe46235"
      unitRef="usd">6000000.0</sgry:EffectiveIncomeTaxReconciliationDivestitureAmount>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEyLTItMS0xLTA_44fa1729-a7fe-4421-bd5a-4e2f5376d052"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEyLTQtMS0xLTA_938cbb3c-414a-42d4-aa5b-f47f174e44de"
      unitRef="usd">1100000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEyLTYtMS0xLTA_7fa31cdd-843e-4837-bcae-82a8eb91944e"
      unitRef="usd">1700000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEzLTItMS0xLTA_4f316039-0cd8-4906-a517-6e6fea442d67"
      unitRef="usd">-800000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEzLTQtMS0xLTA_a1703fe5-d84e-4a32-a6c7-aa2fb6874106"
      unitRef="usd">300000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzEzLTYtMS0xLTA_09361920-6813-46df-b395-25031646633d"
      unitRef="usd">500000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE0LTItMS0xLTA_6d174b78-6607-4172-9e6d-465fcad7a717"
      unitRef="usd">900000</sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount>
    <sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE0LTQtMS0xLTA_71093117-f32d-4232-bc0b-9996993cecb5"
      unitRef="usd">1600000</sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount>
    <sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE0LTYtMS0xLTA_5b019b51-d787-4c84-b245-fb4e8d3eefaf"
      unitRef="usd">900000</sgry:EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE1LTItMS0xLTA_3739722c-3d47-4ae6-a313-cf8b80f2ad84"
      unitRef="usd">4300000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE1LTQtMS0xLTA_1ef6a402-e671-43b5-a5fb-2466c7f12645"
      unitRef="usd">500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE1LTYtMS0xLTA_f92a4187-4117-43a2-8b04-3a04f7dd92ce"
      unitRef="usd">8900000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE2LTItMS0xLTA_bdec0665-fccb-4e7c-9aab-f5d96e828a63"
      unitRef="usd">-3700000</sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount>
    <sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE2LTQtMS0xLTA_1793d35a-333c-4d14-86f3-52d3a9fd05e2"
      unitRef="usd">0</sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount>
    <sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE2LTYtMS0xLTA_19cc89b0-3652-4ded-a6df-dd828c8cf5a5"
      unitRef="usd">8600000</sgry:EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE3LTItMS0xLTA_43cd5d79-b0fc-43d9-86ec-fe7b66db3c11"
      unitRef="usd">1000000.0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE3LTQtMS0xLTA_41d8c704-a5ab-4a42-a912-3ded063ddc3c"
      unitRef="usd">-900000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE3LTYtMS0xLTA_7b24fb40-8237-407e-94d6-b267dcd68804"
      unitRef="usd">100000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE4LTItMS0xLTA_eae6664a-7e52-4887-92b1-6ad9b0d5269e"
      unitRef="usd">-20100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE4LTQtMS0xLTA_8489eca9-3817-48c6-a521-20e7ab75831d"
      unitRef="usd">9500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpkOWU4NDIyMmFjYWE0NWVkODI5ZjZhZjFjOTk1MmU2YS90YWJsZXJhbmdlOmQ5ZTg0MjIyYWNhYTQ1ZWQ4MjlmNmFmMWM5OTUyZTZhXzE4LTYtMS0xLTA_935a04f3-731d-4521-990c-070e48167f18"
      unitRef="usd">26400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMTk_8b8b4866-56f0-45f8-8a8a-62ba5d5f053b">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The components of temporary differences and the approximate tax effects that give rise to the Company&#x2019;s net deferred tax asset are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical malpractice liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued vacation and incentive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Allowance for bad debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Section 163(j) interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest rate swap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;TRA liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right of use&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Affiliate indebtedness receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other deferred assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation on property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basis differences of partnerships and joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right of use&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(51.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other deferred liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(123.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(122.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzQtMi0xLTEtMA_c227d350-a461-4286-a679-bb19a1299195"
      unitRef="usd">4000000.0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzQtNC0xLTEtMA_3085d2ad-4d62-4438-af6d-d8bb54782421"
      unitRef="usd">3500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <sgry:DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzUtMi0xLTEtMA_7e564963-32a3-42c0-87bf-fa9a97af936a"
      unitRef="usd">3200000</sgry:DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation>
    <sgry:DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzUtNC0xLTEtMA_4a7f0c72-4da4-422b-add1-4d3cb2cf7aa8"
      unitRef="usd">2300000</sgry:DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzYtMi0xLTEtMA_52e8da45-0008-47a1-bd65-2bf7d0f894d9"
      unitRef="usd">164700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzYtNC0xLTEtMA_c7415a44-49bc-4520-a16b-9bdecad66bcf"
      unitRef="usd">143000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzctMi0xLTEtMA_8b4720be-1767-4463-b65e-deefdd261e23"
      unitRef="usd">2500000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzctNC0xLTEtMA_f856a16c-b19b-4afd-a9a0-d9f27a3520e4"
      unitRef="usd">2200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzgtMi0xLTEtMA_bb806fcf-f70f-4b6c-baae-c59914f24fa4"
      unitRef="usd">1700000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzgtNC0xLTEtMA_546c5c98-fd42-4de1-981e-a2fbd2d11ae0"
      unitRef="usd">2000000.0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <sgry:DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEwLTItMS0xLTA_9ae0ea57-7fa9-46fc-8ed2-5beee0e5e598"
      unitRef="usd">2200000</sgry:DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets>
    <sgry:DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEwLTQtMS0xLTA_416a5e58-0397-44b2-b366-ef5491d9ac15"
      unitRef="usd">300000</sgry:DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets>
    <sgry:DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzExLTItMS0xLTA_6f55693b-1936-489a-ad55-d0132a33b245"
      unitRef="usd">7900000</sgry:DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts>
    <sgry:DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzExLTQtMS0xLTA_f434a66d-2f5b-4fa4-9413-bb00637ee448"
      unitRef="usd">9500000</sgry:DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts>
    <sgry:DeferredTaxAssetsTaxDeferredExpenseInterestLimitation
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEyLTItMS0xLTA_9b948f63-d7d9-439e-b52b-fa476fa7084f"
      unitRef="usd">69800000</sgry:DeferredTaxAssetsTaxDeferredExpenseInterestLimitation>
    <sgry:DeferredTaxAssetsTaxDeferredExpenseInterestLimitation
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEyLTQtMS0xLTA_e3ccd1b6-0548-470b-862a-e02d38a7a88f"
      unitRef="usd">54700000</sgry:DeferredTaxAssetsTaxDeferredExpenseInterestLimitation>
    <us-gaap:DeferredTaxAssetsHedgingTransactions
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEzLTItMS0xLTA_0c16481e-1845-48da-8727-16170c3b8844"
      unitRef="usd">15800000</us-gaap:DeferredTaxAssetsHedgingTransactions>
    <us-gaap:DeferredTaxAssetsHedgingTransactions
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzEzLTQtMS0xLTA_3f9e910a-2e4c-4e72-b9d6-c6c426e66bee"
      unitRef="usd">12900000</us-gaap:DeferredTaxAssetsHedgingTransactions>
    <sgry:DeferredTaxAssetTaxReceivableAgreement
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE0LTItMS0xLTA_840f83ac-8620-4968-8ff9-8b1730e56647"
      unitRef="usd">1000000.0</sgry:DeferredTaxAssetTaxReceivableAgreement>
    <sgry:DeferredTaxAssetTaxReceivableAgreement
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE0LTQtMS0xLTA_2b47c435-4c5c-46c2-9aed-d3994df62c17"
      unitRef="usd">1200000</sgry:DeferredTaxAssetTaxReceivableAgreement>
    <sgry:DeferredTaxAssetsRightOfUse
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE1LTItMS0xLTA_d6882f5f-29db-4b78-b9ee-039b459122d7"
      unitRef="usd">50600000</sgry:DeferredTaxAssetsRightOfUse>
    <sgry:DeferredTaxAssetsRightOfUse
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE1LTQtMS0xLTA_5ff997f1-772c-4e30-bc49-501425f0e626"
      unitRef="usd">52100000</sgry:DeferredTaxAssetsRightOfUse>
    <sgry:DeferredTaxAssetsAffiliateIndebtednessReceivable
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE2LTItMS0xLTA_2ed46b7f-d019-4931-909b-dedddbb938ac"
      unitRef="usd">0</sgry:DeferredTaxAssetsAffiliateIndebtednessReceivable>
    <sgry:DeferredTaxAssetsAffiliateIndebtednessReceivable
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE2LTQtMS0xLTA_19a9b40f-d666-4127-8c78-faa977c85e86"
      unitRef="usd">6800000</sgry:DeferredTaxAssetsAffiliateIndebtednessReceivable>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE3LTItMS0xLTA_fb16a73e-76b4-4969-9204-360ef781afcd"
      unitRef="usd">16400000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE3LTQtMS0xLTA_b3b50e8c-1bdf-47b9-b5be-0a397cd53a9a"
      unitRef="usd">9000000.0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE4LTItMS0xLTA_d4a150cc-f620-4cd8-a4a1-f6eff679ecf5"
      unitRef="usd">339800000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE4LTQtMS0xLTA_d34a5473-e57a-4c97-908c-0697a8ff354f"
      unitRef="usd">299500000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE5LTItMS0xLTA_d461c2e8-0fe2-4bc7-a706-11df9e1fcf5c"
      unitRef="usd">91100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzE5LTQtMS0xLTA_60741c12-74f7-4101-b14b-1387edf6a44e"
      unitRef="usd">77900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIwLTItMS0xLTA_d11b51ec-5b5d-4c4f-9986-d91d160e3724"
      unitRef="usd">248700000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIwLTQtMS0xLTA_8c15fb40-0c3d-4aec-bc26-619941b59c64"
      unitRef="usd">221600000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIyLTItMS0xLTA_f518a4b0-97f8-4229-a5e7-e75f4c94bb03"
      unitRef="usd">1800000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIyLTQtMS0xLTA_151b515f-9d67-4057-96d0-8a7dfbdf0003"
      unitRef="usd">2800000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <sgry:DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIzLTItMS0xLTA_812a0033-c7b6-48f7-8a31-3117c2d23d6a"
      unitRef="usd">73600000</sgry:DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures>
    <sgry:DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzIzLTQtMS0xLTA_7ac348b1-9191-4f45-83a9-77db5e8ce33f"
      unitRef="usd">67500000</sgry:DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI0LTItMS0xLTA_66733615-716d-4b41-834c-2007a75a680d"
      unitRef="usd">47500000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI0LTQtMS0xLTA_d9918e9a-9409-43ac-ac75-58102231a01c"
      unitRef="usd">51500000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI1LTItMS0xLTA_5feeaad3-35a3-49d2-8f28-24ccc653b9fa"
      unitRef="usd">1000000.0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI1LTQtMS0xLTA_fcc5bd8c-fe5b-41bc-b365-9bf9ffb1ee44"
      unitRef="usd">1100000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI2LTItMS0xLTA_e7865a29-93c7-4ca1-b72a-dff50ce47863"
      unitRef="usd">123900000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI2LTQtMS0xLTA_4e09b5d8-af1f-48bd-addb-1175883de2a8"
      unitRef="usd">122900000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI3LTItMS0xLTA_fc261d97-1098-4167-ab2f-37f06bdf4193"
      unitRef="usd">124800000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTpmZjNmMWJhMGNjYjc0NWEyYTVkZjZmNTUzZDhlNzkwYi90YWJsZXJhbmdlOmZmM2YxYmEwY2NiNzQ1YTJhNWRmNmY1NTNkOGU3OTBiXzI3LTQtMS0xLTA_e88c4287-cec9-4176-b409-711b93b23903"
      unitRef="usd">98700000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib4a503d7300c4baaab4d78c7a78fe1ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzI5NTY_87936e26-2c24-4a66-b850-028cfe918cb9"
      unitRef="usd">615700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="ib4a503d7300c4baaab4d78c7a78fe1ab_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzI5Nzg_a43cfc79-d132-4a71-a193-2bd8d52b2b6e"
      unitRef="usd">516200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i4f0306c05aea4ff8908dcdbb29dc76e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzMxNDc_b90a0149-e347-43e6-a495-73b78e456257"
      unitRef="usd">678900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic8ae2680c0a24c0f85638b06d6ff55bc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzMyMzg_99685221-5122-4fe2-bbfa-7d481b23ae15"
      unitRef="usd">6200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ib10c51e09f2a46dd82c6116912a94c59_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzMzNDE_f4b6523a-a132-426a-86ef-72632773f05a"
      unitRef="usd">700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ie5f2564128c34ff789c5d6d49d4f690e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzM1MDk_533510c1-d34d-46ab-a1aa-d7b5df3da200"
      unitRef="usd">278400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzM2NTU_578a6c21-441b-40a2-91d4-2c63b337986c"
      unitRef="usd">91100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzM2NjI_41b70139-fbc1-4747-9a34-19f1c9d29fcf"
      unitRef="usd">77900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzM3MTI_43d7e95b-bd11-4cba-9704-e42cef45c205"
      unitRef="usd">13200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <sgry:NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax
      contextRef="i40edf829554a46aa94ff3aa07af2e2ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzUwNjM_bd73fd5d-d949-4d86-bf56-07210fa8903b"
      unitRef="usd">2800000</sgry:NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax>
    <us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzUxOTc_1cd81297-fd8b-49bf-b2e9-fbd0322a7826"
      unitRef="usd">16800000</us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzcyMTM_dd1dad27-205b-4c19-a556-cfb5f416c794">A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzMtMi0xLTEtMA_4103f5f3-0329-407a-87d0-f5b35cfb3bf6"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzMtNC0xLTEtMA_56773342-7d2f-411e-8e0f-24e3785d77fc"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzYtMi0xLTEtMA_6eb74cca-4846-4a01-9910-696d217c7e02"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzYtNC0xLTEtMA_cf2a302a-18b9-4fe8-b9d9-aab0426738ed"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzgtMi0xLTEtMA_c7d25403-44dc-4e15-a869-f4e0f724835b"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90YWJsZTo5NWI2NjIyN2U5ZjU0NmFkOTI0Y2M5MjZkN2FlZjIzYS90YWJsZXJhbmdlOjk1YjY2MjI3ZTlmNTQ2YWQ5MjRjYzkyNmQ3YWVmMjNhXzgtNC0xLTEtMA_0ae63c64-06e6-4ffa-849d-28a91b9a2148"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzg3OTYwOTMwMzExMzA_1f299f1f-c54b-451d-aa9a-f0ba9ddba865"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzg3OTYwOTMwMzExMzA_d0066df8-6f76-41b4-95a5-4f732fdb5097"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzEwOTk1MTE2Mzc1MDk_81860c7b-3f9d-4158-943b-8ba7f4b9efe7"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzIvZnJhZzphNmU4NzAzZjYyMGM0NDZmODc0YTU0MzY5YzcyZWIwMC90ZXh0cmVnaW9uOmE2ZTg3MDNmNjIwYzQ0NmY4NzRhNTQzNjljNzJlYjAwXzEwOTk1MTE2Mzc1MDk_ecec97a6-396e-4811-81c6-82599679ae92"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzg1_dff4375c-b279-49a5-86cd-241fb26900f9">Equity-Based Compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transactions in which the Company receives employee and non-employee services in exchange for the Company&#x2019;s equity instruments or liabilities that are based on the fair value of the Company&#x2019;s equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. The Company&#x2019;s policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Surgery Partners, Inc. 2015 Omnibus Incentive Plan, as amended and restated effective January 1, 2020 ("2015 Omnibus Incentive Plan") from which all equity-based awards will be granted. Under this plan, the Company can grant stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of its common stock. As of December&#160;31, 2020, 8,315,700 shares were authorized to be granted under the 2015 Omnibus Incentive Plan and 5,285,421 were available for future equity grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted and Performance Share-Based Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020 and 2019, the Company granted 1,077,367 and 556,450 restricted stock awards ("RSAs") to certain officers, employees and non-employee directors in accordance with the 2015 Omnibus Incentive Plan, respectively. Vesting and payment of these RSAs are generally subject to continuing service of the employee or non-employee director over the ratable vesting periods beginning one year from the date of grant to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE0NjY_cd80199e-a025-45d6-ad9d-4f4ef62346f4"&gt;three&lt;/span&gt; or five years after the date of grant. The fair values of these RSAs were determined based on the closing price of the Company&#x2019;s common stock on the trading date immediately prior to the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020 and 2019, the Company granted 854,367 and 389,972 performance-based restricted stock units ("PSUs") subject to the achievement of a combination of performance conditions, respectively. In addition to the achievement of the performance conditions, these PSUs are generally subject to the continuing service of the employee over the ratable vesting period from the earned date continuing for two years. For these PSUs, the number of shares payable at the end of the performance periods ranges from 0% to 150% of the targeted units based on the Company&#x2019;s actual performance and/or market conditions results as compared to the targets. These PSUs are not considered outstanding until earned. During the years ended December&#160;31, 2020 and 2019, 309,692 and 245,301 of the PSUs previously granted were deemed to have been earned, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted and Performance Share-Based Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of non-vested restricted share-based activity for the years ended December&#160;31, 2020, 2019, and 2018 follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unvested Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;574,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted/Earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;519,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(210,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;703,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted/Earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;801,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(272,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(456,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;775,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted/Earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,387,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(162,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(552,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,447,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Stock Appreciation Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company granted 2,256,500 and 700,000 stock options during the years ended December&#160;31, 2019 and 2018, respectively. No stock options were granted during the year ended December&#160;31, 2020. Options to purchase shares are granted with an exercise price equal to the fair market value of the Company&#x2019;s common stock on the day of grant, based on the closing price of the Company&#x2019;s common stock on the trading date immediately prior to the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The stock options granted during the year ended December&#160;31, 2019 are subject to the following performance and vesting criteria: (i) one-third (33.3%) of the award will vest in three equal annual installments on each of the first three anniversaries of December 31, 2019, (ii) one-third (33.3%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $25.00 over a period of thirty (30) consecutive trading days, and (iii) one-third (33.3%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $35.00 over a period of thirty (30) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The stock options granted during the year ended December&#160;31, 2018 are subject to the following performance and vesting criteria: (i) fifty percent (50%) of the stock option awards will vest in five equal annual installments on each of the first five anniversaries of the date of grant, (ii) twenty-five percent (25%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $25.00 over a period of sixty (60) consecutive trading days, and (iii) twenty-five percent (25%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $35.00 over a period of sixty (60) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On December 16, 2018, the Company cancelled 200,000 stock options and replaced them with 200,000 stock-settled stock appreciation right awards (the "SAR Awards"). These were the only SAR Awards granted as of December&#160;31, 2020. The SAR Awards had a base price equal to the exercise price of the cancelled stock options. Fifty percent (50%) of the SAR Awards will vest in five equal annual installments on each of the first five anniversaries of the date of grant, generally subject to continued employment on each vesting date. Twenty-five percent (25%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $25.00 over a period of sixty (60) consecutive trading days, and twenty-five percent (25%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $35.00 over a period of sixty (60) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Option/SAR Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In applying the Monte Carlo simulation model to value both the stock options and SAR Awards, the Company used the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&#160; The risk-free interest rate is used as a component of the fair value of stock options to take into account the time value of money.&#160;For the risk-free interest rate, the Company uses the implied yield on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life, in years, of the options granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&#160; Volatility, for the purpose of share-based compensation, is a measurement of the amount that a share price has fluctuated.&#160;Expected volatility involves reviewing historical volatility and determining what, if any, change the share price will have in the future. The Company used historical stock price information of certain peer group companies for a period of time equal to the expected option life period to determine estimated volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected life, in years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&#160; A clear distinction is made between the expected life of an option and the contractual term of the option.&#160;The expected life of an option is considered the amount of time, in years, that an option is expected to be outstanding before it is exercised.&#160;Whereas, the contractual term of the stock option is the term an option is valid before it expires. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x25aa; &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&#160; Since issuing dividends will affect the fair value of a stock option, GAAP requires companies to estimate future dividend yields or payments.&#160;The Company has not historically issued dividends and does not intend to issue dividends in the future. As a result, the Company does not apply a dividend yield component to its valuation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth the assumptions used by the Company to estimate the fair value of stock options and SAR Awards granted during the years ended December&#160;31, 2019 and 2018. No stock options or SAR Awards were granted during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60% - 65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.30% - 2.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.50% - 2.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.83 - $6.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$8.48 - $9.44&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimated fair value of options is amortized to expense on a straight-line basis over the options&#x2019; vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option and Stock Appreciation Rights Activity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of stock option and SAR Award activity for the years ended December&#160;31, 2020, 2019, and 2018 follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options/SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,256,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,769,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,760,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Of the outstanding stock options, 585,119 were exercisable as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other information pertaining to equity-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, unrecognized compensation cost related to unvested shares was approximately $20.2 million. Unrecognized compensation cost will be expensed annually based on the number of shares that vest during the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records equity-based compensation expense to recognize the fair value of the restricted shares that vest and stock options granted. The Company recorded equity-based compensation expense of $13.2 million, $10.2 million and $9.3 million for the years ended December&#160;31, 2020, 2019, and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzg4_64c581e7-0592-46b1-9e21-0663a78a4cdb">Equity-Based CompensationTransactions in which the Company receives employee and non-employee services in exchange for the Company&#x2019;s equity instruments or liabilities that are based on the fair value of the Company&#x2019;s equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. The Company&#x2019;s policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i0238428bd25e45529ad62844562813e6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg5MQ_23593c36-7a0e-43dc-87ce-09d830e5c886"
      unitRef="shares">8315700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0238428bd25e45529ad62844562813e6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzk3Mw_ce86ce1a-b183-4f72-945f-6a164f2a6f66"
      unitRef="shares">5285421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2828db13be9542a6b1c20843c59ad276_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExMDI_fb28e4e4-cc1b-4474-8300-bbf69c9900b8"
      unitRef="shares">1077367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8e546cbd60bb4cb3b0bc3eb05ff08c90_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExMDk_e41d7550-5a2b-408b-9eef-a08d6b9d6e7f"
      unitRef="shares">556450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i038159bf343d4a9eaa27f787b51188c8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE0NzI_4478a404-3978-479e-bf0c-6077db576d6c">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7449dbb4efe040eeac8fd22c2a9264f9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE3MjA_e370487e-468a-49a3-92c1-dcef514edd20"
      unitRef="shares">854367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0f57145632eb43a6ae9a59e0eb4f4180_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE3Mjc_53ef9bae-06eb-42cc-8608-033f50dc4862"
      unitRef="shares">389972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7449dbb4efe040eeac8fd22c2a9264f9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIwNzA_764f9bd5-3108-45eb-b208-a2c11a7e857f">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod
      contextRef="i90b10c28a8aa40f7a09f7a0424ba887c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTM_baa87770-8624-4175-82af-5f46403e63ae"
      unitRef="number">0</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod
      contextRef="i752e2e790a184e4ea39af03e843709ff_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTk_7d68e1e4-c4d9-4d53-882a-cd22ae4f14cb"
      unitRef="number">1.50</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod>
    <sgry:ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod
      contextRef="i7449dbb4efe040eeac8fd22c2a9264f9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzI0MTY_427d5144-ecd1-4c82-ac81-181a3fdb0495"
      unitRef="shares">309692</sgry:ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod>
    <sgry:ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod
      contextRef="i0f57145632eb43a6ae9a59e0eb4f4180_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzEwOTk1MTE2Mzk3OTM_2d31126f-4447-4141-9c38-a94e8604d424"
      unitRef="shares">245301</sgry:ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzg2_7ff8e3db-f7f2-4f29-bf84-10d846595a01">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of non-vested restricted share-based activity for the years ended December&#160;31, 2020, 2019, and 2018 follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unvested Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;574,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted/Earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;519,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(210,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;703,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted/Earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;801,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(272,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(456,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;775,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted/Earned&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,387,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(162,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(552,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,447,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iafc9c624583e425f9f3f383d5de093bc_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE1LTItMS0xLTA_bebf623a-79a3-4dd8-82da-54f22022856c"
      unitRef="shares">574456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iafc9c624583e425f9f3f383d5de093bc_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE1LTQtMS0xLTA_63b04cae-7af8-4dc2-854a-eded67012371"
      unitRef="usdPerShare">15.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE2LTItMS0xLTA_7aacc241-414e-488b-8959-53a2716e0be1"
      unitRef="shares">519605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE2LTQtMS0xLTA_3a586cf4-49f9-4541-aa98-80a81bc96b1d"
      unitRef="usdPerShare">16.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE3LTItMS0xLTA_acec45bf-86bb-4e73-be02-0438339de477"
      unitRef="shares">180719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE3LTQtMS0xLTA_b33c0c76-8400-4049-bcbc-9433c2c59147"
      unitRef="usdPerShare">15.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE4LTItMS0xLTA_1f013660-1c3e-4fbf-ac8d-f6a230fa51b7"
      unitRef="shares">210318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i347f272139b64fc897dd427a48e7af13_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE4LTQtMS0xLTA_0bade3bb-51c3-41a1-bb2b-447515f28aad"
      unitRef="usdPerShare">16.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5f8b77cdfd93419e8d20d28aa5fff865_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE5LTItMS0xLTA_6924226b-20e0-4848-a8dd-f9a4fb0c29a6"
      unitRef="shares">703024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5f8b77cdfd93419e8d20d28aa5fff865_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzE5LTQtMS0xLTA_199004fe-79ab-4cae-a8f1-78d4e5a96bf0"
      unitRef="usdPerShare">16.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIwLTItMS0xLTA_d9e410d4-5dd7-4757-865d-553858904523"
      unitRef="shares">801751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIwLTQtMS0xLTA_e37a2373-c3cb-43bb-957d-a091d4d2d753"
      unitRef="usdPerShare">12.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIxLTItMS0xLTA_da9ec113-0f2b-4a42-bb61-166bc7bf204d"
      unitRef="shares">272706</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIxLTQtMS0xLTA_4e80b4bd-2b05-49d9-a660-22278ad6da35"
      unitRef="usdPerShare">12.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIyLTItMS0xLTA_d209eec7-1031-42cb-9e99-90776087f338"
      unitRef="shares">456183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7be8e78b15a040728e51f819890b13be_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIyLTQtMS0xLTA_5ceeb89e-282f-47a4-a83a-271ca1c53eaf"
      unitRef="usdPerShare">16.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib77a4c3d6184412d9f09f4d2864124b1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIzLTItMS0xLTA_a23c104a-21eb-4f59-a464-60db4c50fa50"
      unitRef="shares">775886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib77a4c3d6184412d9f09f4d2864124b1_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzIzLTQtMS0xLTA_935f0fd3-f281-48a7-9ad0-4cd71bae6159"
      unitRef="usdPerShare">13.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEwLTItMS0xLTE0Nzg_0071e0a5-f4a5-4db3-bec6-003880208baf"
      unitRef="shares">1387059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEwLTQtMS0xLTE0ODI_2cc7cdb6-ac4b-450c-8d06-6a5cbd87e056"
      unitRef="usdPerShare">6.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzExLTItMS0xLTE0Nzg_ea5484d7-a6fc-413f-8810-e03524d9ab89"
      unitRef="shares">162635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzExLTQtMS0xLTE0ODI_d1fe492f-19c0-40e4-955b-bb4ca9afdef2"
      unitRef="usdPerShare">13.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEyLTItMS0xLTE0Nzg_3fe42d50-8ece-4957-84d8-4b9080c71ac3"
      unitRef="shares">552943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic9be02e650974abdafe229970eab92a3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEyLTQtMS0xLTE0ODI_78168f37-4e0b-4d77-9da6-8d003847bb0a"
      unitRef="usdPerShare">12.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i56c4f778361246b18c21e65a767306f6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEzLTItMS0xLTE3NjQ_e2b6e212-ece4-461a-9989-2f3f6e22f332"
      unitRef="shares">1447367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i56c4f778361246b18c21e65a767306f6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo5OWNkODQxNzFkYTA0YjI2OTExY2IyYTAzMmFmMDhiOS90YWJsZXJhbmdlOjk5Y2Q4NDE3MWRhMDRiMjY5MTFjYjJhMDMyYWYwOGI5XzEzLTQtMS0xLTE0ODI_1de1ae18-c053-429b-b22b-1209c21572cb"
      unitRef="usdPerShare">9.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib26f364f72d64a0e823a7afe664f2323_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzU0MjI_603fbb4c-ae6e-459e-90d2-6edfef77ddfd"
      unitRef="shares">2256500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9657217604e94a48a864adfb783bc292_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzEwOTk1MTE2NDA0MjQ_08c30384-9946-4e9b-a8e9-b84744029a29"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i88f2f675e83142ada36ac4b6fab72299_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTkwMjMyNjg1NjE_703ce278-e358-42ae-a89d-f163b8844d83"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="if13a7bad162a4e20ba15bf84d71b699d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYwMjc_703702c8-9f8b-4db8-8902-141ecaac6889"
      unitRef="number">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="if13a7bad162a4e20ba15bf84d71b699d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYwNTc_0d7b5169-7968-40af-a855-050b3fb6bda7"
      unitRef="installment">3</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ibf62d3954751451e9588e5a61073849f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYxNjU_e6f64b91-2502-4181-b79a-7595b9a00e97"
      unitRef="number">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharePrice
      contextRef="i3f71503bac9d41d4a56501b58e940ca8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYzNTY_1beedcd6-3d54-43e6-9a49-92440c698cf0"
      unitRef="usdPerShare">25.00</us-gaap:SharePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays
      contextRef="ibf62d3954751451e9588e5a61073849f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzYzODQ_a6668a01-4566-4166-84be-8a8667be0a14"
      unitRef="trading_day">30</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ifbe4cdae49d547e68aed4ebe2e458b2d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY0MzU_1c0933a5-6b8a-4733-87e3-d77406498a5a"
      unitRef="number">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharePrice
      contextRef="icaab860223474d4faa76168a356ab862_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY2MjY_839682aa-c643-42b2-b9ce-f024de568cb7"
      unitRef="usdPerShare">35.00</us-gaap:SharePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays
      contextRef="ifbe4cdae49d547e68aed4ebe2e458b2d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY2NTQ_fe9af6b8-b66d-44d9-bb5c-590a3cdbdd3b"
      unitRef="trading_day">30</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4fb3e91ef8ed486a975169f3a156bc61_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY5MzY_164a3e95-bd16-48bd-955e-8d95d0865ad4"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="i4fb3e91ef8ed486a975169f3a156bc61_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzY5ODA_ab4a7763-5373-4bca-a833-0f81d6391d16"
      unitRef="installment">5</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i52b51ef452dd4bca860d3742b03236b3_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzcwOTc_180edcd3-8262-4139-943a-131370023ac1"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharePrice
      contextRef="idf7576735fbf445695c40b6c3a4332d2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzcyODg_25b82f50-ee4b-49f7-bcb4-318d7efb687b"
      unitRef="usdPerShare">25.00</us-gaap:SharePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays
      contextRef="i52b51ef452dd4bca860d3742b03236b3_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzczMTU_53b2bc62-7383-4e06-8fe9-2eac2bff9394"
      unitRef="trading_day">60</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9657217604e94a48a864adfb783bc292_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzczNzY_ddcb334d-fdc4-44e5-9fd0-2172c787a303"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharePrice
      contextRef="ia5c74e08e90e4514b53e1711e6d6c993_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzc1Njc_12e1aa6c-7ea5-40ff-8a88-5dc4e38f550a"
      unitRef="usdPerShare">35.00</us-gaap:SharePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays
      contextRef="i65014b7959304f73b25e58fe57e3c32d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzc1OTQ_50ed3eea-3e40-44b7-9f72-61db3bca9bc7"
      unitRef="trading_day">60</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
      contextRef="i689b53c3d93a499da0a1f5bd28ba963e_D20181216-20181216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzc3ODc_d6f17997-ab64-4aec-9ef4-16b6331cb160"
      unitRef="shares">200000</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i689b53c3d93a499da0a1f5bd28ba963e_D20181216-20181216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzEwOTk1MTE2NDA2MTA_992b00f6-b880-4110-bd0b-7223cd7560a6"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i08d2d66c878f4fb0a7b2c27692bcb2bf_D20181216-20181216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzgwNTI_a4166ad8-914c-442c-91cf-b3323abedc90"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="i08d2d66c878f4fb0a7b2c27692bcb2bf_D20181216-20181216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzgwODc_8ddeb773-2106-45dc-b7ac-d0d6dec182a3"
      unitRef="installment">5</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i774ec9394898484282082d77fdad2ddf_D20181216-20181216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzgyNjM_f68f3363-f8f0-4729-9205-f0c5cbb8b48c"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharePrice
      contextRef="i729242ab1a2347118df4dba4c57f77f1_I20181216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg0NTQ_f3042bb5-3e5d-4de1-886b-faa774b6a204"
      unitRef="usdPerShare">25.00</us-gaap:SharePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays
      contextRef="i774ec9394898484282082d77fdad2ddf_D20181216-20181216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg0ODE_8e07f596-89b3-4721-baa8-2d3e5c1ac0dc"
      unitRef="trading_day">60</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ibae4c0fc40e94a2db7579a9d625a90f3_D20181216-20181216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg1MzY_18ff5d3b-80cb-4e47-9076-53549b1b3efe"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharePrice
      contextRef="ic9c47bc4b252439eb85adbb626c84a6e_I20181216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg3Mjc_7efeff65-8c00-4076-bba2-957645c7d086"
      unitRef="usdPerShare">35.00</us-gaap:SharePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays
      contextRef="ibae4c0fc40e94a2db7579a9d625a90f3_D20181216-20181216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzg3NTQ_5001ee29-d04a-43ee-9792-613a42fd293a"
      unitRef="trading_day">60</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzg3_5c7f7ae8-2a9f-4052-9630-6dcb8f452212">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table sets forth the assumptions used by the Company to estimate the fair value of stock options and SAR Awards granted during the years ended December&#160;31, 2019 and 2018. No stock options or SAR Awards were granted during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60% - 65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.30% - 2.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.50% - 2.90%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.83 - $6.41&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$8.48 - $9.44&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i88f2f675e83142ada36ac4b6fab72299_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTkwMjMyNjg1NzA_684d8212-8b1c-4f67-bf1c-586836c62c82"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie3da9fab6c3946a3bc42d096b6488712_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzIxOTkwMjMyNjg1NzA_bbd497ce-d9ee-4cc3-9934-0e29c4f34098"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzItNC0xLTEtMA_90bf6f49-6a20-49fd-953a-3c5a942658f8"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzItNC0xLTEtNzc5NC90ZXh0cmVnaW9uOjhjMTVhODEyMmFiYTQ4ZDc5ZTBlMmZjYzlmM2EwZDBlXzExNTQ0ODcyMDkxNjY0_d3112804-ae25-4952-957f-d2be433b0561"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzItNC0xLTEtNzc5NC90ZXh0cmVnaW9uOjhjMTVhODEyMmFiYTQ4ZDc5ZTBlMmZjYzlmM2EwZDBlXzExNTQ0ODcyMDkxNjcw_fea5fe16-4ab2-4b2d-8021-e7254ce95770"
      unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzMtNC0xLTEtMC90ZXh0cmVnaW9uOmVkMjI1NTg2YWVlNzQzZTQ5ZjJkN2JkZWUwMjA4MWY5XzIxOTkwMjMyNTU1NzQ_86e2d996-ced0-42b0-9983-84aa65e08e21"
      unitRef="number">0.0230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzMtNC0xLTEtMC90ZXh0cmVnaW9uOmVkMjI1NTg2YWVlNzQzZTQ5ZjJkN2JkZWUwMjA4MWY5XzIxOTkwMjMyNTU1ODI_fd732266-57aa-4c40-9507-a4ba3e6e5d29"
      unitRef="number">0.0240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzMtNC0xLTEtNzc4OS90ZXh0cmVnaW9uOjEzYmZiM2JiYTQzMDQ1NmU5MjZiNGNlY2NkM2M3ZjQ2XzExNTQ0ODcyMDkxNjYw_844e7c3c-0d0c-49ab-b17d-9ba1b75e64a2"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzMtNC0xLTEtNzc4OS90ZXh0cmVnaW9uOjEzYmZiM2JiYTQzMDQ1NmU5MjZiNGNlY2NkM2M3ZjQ2XzExNTQ0ODcyMDkxNjY0_bdbcd9d8-bca3-4db2-bd00-74120586ad91"
      unitRef="number">0.0290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzQtNC0xLTEtMA_52e44118-1f1b-4ec6-9c2f-f164f65baab2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzQtNC0xLTEtNzgyMQ_0d2a20f4-d16c-48f8-935b-e55628ad2d83"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzUtNC0xLTEtMA_7d0f4eaa-103b-45a3-adc8-4c6f43deb286">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i806af524ac2f4d36a0c477115bf7fca6_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzUtNC0xLTEtNzgyMQ_10159458-64ba-4218-88eb-0c5c0f323720">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="i32f863b1377d4c198f37e268eadcd88e_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzYtNC0xLTEtMC90ZXh0cmVnaW9uOjYyYTVjZjlhNGE2MTQ1NGNhOTcwOGU1YWQwYjAxZGM3XzIxOTkwMjMyNTU1NzQ_3e2f16da-3be3-4ec2-9449-67941fabc4fb"
      unitRef="usdPerShare">4.83</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i7bdae67446eb4958aeff2fbff938b5ca_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzYtNC0xLTEtMC90ZXh0cmVnaW9uOjYyYTVjZjlhNGE2MTQ1NGNhOTcwOGU1YWQwYjAxZGM3XzIxOTkwMjMyNTU1ODI_0d3c10bd-df16-4af2-99a2-b47a02cbb0b0"
      unitRef="usdPerShare">6.41</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="iafdcd1de1b344a998031d19f82faed75_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzYtNC0xLTEtNzc4OS90ZXh0cmVnaW9uOmE2YTkyNDk2ZjRmZTQ4YWNhM2QwNjQxMzZmNmU1YTA4XzExNTQ0ODcyMDkxNjYw_1cd89e69-74b2-4893-ab93-7e138f39b762"
      unitRef="usdPerShare">8.48</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i0bc3ee9a1e98470592066703d4aa997b_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTpjYWZhMjRkZjlmMTM0MjBiOGNiM2NkMjViYjA2MGVlNy90YWJsZXJhbmdlOmNhZmEyNGRmOWYxMzQyMGI4Y2IzY2QyNWJiMDYwZWU3XzYtNC0xLTEtNzc4OS90ZXh0cmVnaW9uOmE2YTkyNDk2ZjRmZTQ4YWNhM2QwNjQxMzZmNmU1YTA4XzExNTQ0ODcyMDkxNjY0_5679ee49-f837-47db-b072-061107f92336"
      unitRef="usdPerShare">9.44</us-gaap:SharePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNzk1_d3c15759-72e1-4b9f-9004-27143d95bb89">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of stock option and SAR Award activity for the years ended December&#160;31, 2020, 2019, and 2018 follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options/SARs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;512,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,256,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,769,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,760,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Of the outstanding stock options, 585,119 were exercisable as of December&#160;31, 2020.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2274a974182d4c01981835a4b40e9196_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE1LTItMS0xLTA_24f1babc-2bf6-43cb-9602-804a81edc327"
      unitRef="shares">12687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2274a974182d4c01981835a4b40e9196_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE1LTQtMS0xLTA_9d0d9745-4d72-421c-84fd-513bbeecec1c"
      unitRef="usdPerShare">20.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3474a6f91a7246d79ec08926d5336999_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE1LTYtMS0xLTA_8e9547e0-cac8-4d44-a004-e4589f24b650">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE2LTItMS0xLTA_c8fd2fd3-1571-4c68-8cdf-0053ad68a85e"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE2LTQtMS0xLTA_e2465f0d-7ef6-46ef-a853-4a0f46eb6daa"
      unitRef="usdPerShare">12.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <sgry:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE2LTYtMS0xLTA_5bf2814f-4e50-4ee0-9856-5ab7a237fe54">P10Y</sgry:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE3LTItMS0xLTA_7f3f13cf-4a6b-4d74-a5c4-69c90ee9a4b3"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE4LTItMS0xLTA_3e87c315-b0ad-441b-a500-cb55df2f893e"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE4LTQtMS0xLTA_f43c45b6-72fa-46f0-b9bd-9e8975ece691"
      unitRef="usdPerShare">12.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE4LTYtMS0xLTA_a0da0321-8ddc-46c2-9cba-0d594c2735ff">P10Y</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE5LTItMS0xLTA_191e5daf-03b2-425d-83ab-dca417be4d4f"
      unitRef="shares">512687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i80894f3165b5496ca5111f55aa3835ee_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE5LTQtMS0xLTA_a52019ec-bd87-4244-a831-85dfa2ac52ef"
      unitRef="usdPerShare">13.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzE5LTYtMS0xLTA_3445bbce-de39-4f24-bde0-401167fd5634">P9Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIwLTItMS0xLTA_06340386-ad52-4a46-907f-7f6dc96a767f"
      unitRef="shares">2256500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIwLTQtMS0xLTA_793da21a-f815-448d-89a6-db81fea6578b"
      unitRef="usdPerShare">13.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <sgry:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIwLTYtMS0xLTA_739945b1-7065-4a67-9887-7eefd15c15f5">P9Y2M12D</sgry:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIxLTItMS0xLTA_6f95671b-1e74-4d82-93a3-fc364f20eb99"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIyLTItMS0xLTA_19993c2a-efc8-4b3a-8b32-a11ea1a36859"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIzLTItMS0xLTA_1fcf1e77-b137-49c5-a808-f2af6b1522f9"
      unitRef="shares">2769187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIzLTQtMS0xLTA_8c18166f-7177-4973-b7f1-b100ea201fe0"
      unitRef="usdPerShare">13.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzIzLTYtMS0xLTA_3d4d0968-73b9-48b6-bfd1-5e5d9a3dd339">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEwLTItMS0xLTE1NDE_6f13366b-4d01-4c84-96d0-c5668bf337ba"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzExLTItMS0xLTE1NDE_7f0a563b-5156-4984-a3f5-5425f4f9cdd8"
      unitRef="shares">4199</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzExLTQtMS0xLTE1Mzc_1f05b84a-7ca4-4c4f-8ba6-ccf823c3e64b"
      unitRef="usdPerShare">20.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzExLTYtMS0xLTE1MzM_ab4150d5-1415-4dc9-a2b6-55879548a62c">P5Y9M18D</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEyLTItMS0xLTE1NDE_d55eab49-ecc6-4fd7-91f6-0b50229a9a5a"
      unitRef="shares">4473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEyLTQtMS0xLTE1Mzc_e8b62a6b-4614-4a5f-8b37-fa48f4cb9649"
      unitRef="usdPerShare">19.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEyLTYtMS0xLTE1MzM_0e94da33-06f3-42f0-aa3a-da16a5f8b396">P4Y9M18D</sgry:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEzLTItMS0xLTE3Njc_4be5598a-295e-4467-a154-7a92b7544893"
      unitRef="shares">2760515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEzLTQtMS0xLTE1Mzc_c9fc60d4-54a8-4e9e-a766-e5fb9139461b"
      unitRef="usdPerShare">12.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90YWJsZTo1M2RhZWM2MjRlYTg0YTQ1YTUwYzBhNjk2YTY1OWFkNC90YWJsZXJhbmdlOjUzZGFlYzYyNGVhODRhNDVhNTBjMGE2OTZhNjU5YWQ0XzEzLTYtMS0xLTE1MzM_1ea0075a-e0c3-4671-84ec-c0f6d4270840">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExMTEx_cc51e774-8157-4016-9f1e-5401bb6707b3"
      unitRef="shares">585119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExMjg0_0ec99f00-90bd-4b3c-b583-6e2d01bf4515"
      unitRef="usd">20200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNjA0_d602acdd-199a-4bd7-82c2-61cb241ba40f"
      unitRef="usd">13200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzExNjEx_fd143d01-a6e8-4510-b1ed-14aacbc87cb3"
      unitRef="usd">10200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzEwOTk1MTE2NDA3NjU_99f14ae7-7edf-46e8-b538-4e1746ccf5a5"
      unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5Xzk4Ng_af3e2a53-6316-4312-987c-f0e412788331">Employee Benefit Plans&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Surgery Partners 401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Surgery Partners 401(k) Plan is a defined contribution plan whereby certain employees who have completed at least one month of service, including at least one hour of service during that period of time, are eligible to participate. Employees may enroll in the plan immediately upon completion of the minimum service requirement. The Surgery Partners 401(k) Plan allows eligible employees to make contributions of varying percentages or flat dollar amounts of their annual compensation, up to the maximum allowable amounts by the Internal Revenue Service ("IRS"). Eligible employees may or may not receive a match by the Company of their contributions. Employer contributions vest incrementally over a period of five years. The Company's contributions were $7.2 million for the year ended December&#160;31, 2020 and $7.6 million for each of the years ended December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <sgry:DefinedContributionPlanVestingPeriod
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5Xzc3Nw_55127c85-7c3e-4de1-91df-649dbf91bc47">P5Y</sgry:DefinedContributionPlanVestingPeriod>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5XzgyMA_0c2a8644-a958-45ef-bcca-283915b1415d"
      unitRef="usd">7200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5XzEwOTk1MTE2Mjg3NzQ_52e83af2-5687-43a2-84a2-15e259c28d47"
      unitRef="usd">7600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODEvZnJhZzoyODZiY2VmMTBkMTE0YjdhYTA5NDk5MjI1NzY4ZTNhOS90ZXh0cmVnaW9uOjI4NmJjZWYxMGQxMTRiN2FhMDk0OTkyMjU3NjhlM2E5XzEwOTk1MTE2Mjg3NzQ_a5699223-8c29-4a26-a0ea-20b53252e457"
      unitRef="usd">7600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90ZXh0cmVnaW9uOmY3ZWI4NzgzNWVlZTQ0MWQ4OTgwYzU3ZTY3Nzc2OTAxXzE2NTM_f758530d-cc7f-47bb-8ca1-9a8c95c82788">Other Current Liabilities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of other current liabilities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued legal settlement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax receivable agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts due to patients and payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost report liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;See Note 14. "Commitments and Contingencies" for further discussion.&lt;/span&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90ZXh0cmVnaW9uOmY3ZWI4NzgzNWVlZTQ0MWQ4OTgwYzU3ZTY3Nzc2OTAxXzE2NjI_ec82295d-f085-41d4-a2e1-53fd0e6b3887">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A summary of other current liabilities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued legal settlement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax receivable agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts due to patients and payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost report liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;See Note 14. "Commitments and Contingencies" for further discussion.&lt;/span&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzMtMi0xLTEtNzU1NQ_6f053652-0f49-4fde-bc7a-0520827ba5a5"
      unitRef="usd">39200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzMtNC0xLTEtNzU1NQ_9c04e67a-d8a1-48f2-9596-4dde2bd841d0"
      unitRef="usd">37300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzQtMi0xLTEtNzU2OQ_20a0da21-755d-4a0d-8b4d-c3bb2edb7619"
      unitRef="usd">32200000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzQtNC0xLTEtNzU2OQ_c19f05ec-cbc5-4d21-a147-b846ab4bd1ec"
      unitRef="usd">35100000</us-gaap:LitigationReserveCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzMtMi0xLTEtMA_96c5c147-fb17-47a9-b6c2-b3ca101c13c8"
      unitRef="usd">24500000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzMtNC0xLTEtMA_46162e5b-e558-4a0d-a946-33baa93cb5a3"
      unitRef="usd">21800000</us-gaap:InterestPayableCurrent>
    <sgry:TaxReceivableAgreementLiabilityCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzYtMi0xLTEtMTAwNDc_cc61c3d0-de11-43ed-a246-9960203ab984"
      unitRef="usd">21200000</sgry:TaxReceivableAgreementLiabilityCurrent>
    <sgry:TaxReceivableAgreementLiabilityCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzYtNC0xLTEtMTAwNDc_a7056a74-c93d-4cac-95c7-41db2b59cac3"
      unitRef="usd">16900000</sgry:TaxReceivableAgreementLiabilityCurrent>
    <srt:PayablesToCustomers
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzQtMi0xLTEtMA_8a54c197-2bbe-4006-81b3-0295c9ab172f"
      unitRef="usd">20900000</srt:PayablesToCustomers>
    <srt:PayablesToCustomers
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzQtNC0xLTEtMA_3f1650d2-165e-4957-9c39-a30bfc341ba8"
      unitRef="usd">16500000</srt:PayablesToCustomers>
    <sgry:CostReportLiabilitiesCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzgtMi0xLTEtMTAwNTA_ce834203-605f-441d-be3b-df1e58c5bea6"
      unitRef="usd">16900000</sgry:CostReportLiabilitiesCurrent>
    <sgry:CostReportLiabilitiesCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzgtNC0xLTEtMTAwNTA_61594ad5-f7d1-4baa-8b00-9b0763af3c44"
      unitRef="usd">5600000</sgry:CostReportLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzctMi0xLTEtMA_6e186001-25bd-4021-aec8-1ec6a02e2a2d"
      unitRef="usd">62100000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzctNC0xLTEtMA_9af674aa-9e03-4c12-b97e-af75d399bf23"
      unitRef="usd">58000000.0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzgtMi0xLTEtMA_191a21d8-33f7-46ac-9460-b0e660f6fb04"
      unitRef="usd">217000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xODcvZnJhZzpmN2ViODc4MzVlZWU0NDFkODk4MGM1N2U2Nzc3NjkwMS90YWJsZTo4YmQzMzRjOGI0OTU0MmU4OGU3MjUwYzNmYmI1YjcxNi90YWJsZXJhbmdlOjhiZDMzNGM4YjQ5NTQyZTg4ZTcyNTBjM2ZiYjViNzE2XzgtNC0xLTEtMA_9f926459-14c9-452f-bccf-551064936fe3"
      unitRef="usd">191200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEyNDgz_c5f8f85d-f1e7-4a56-9eef-d8fd66ad76d2">Commitments and Contingencies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Professional, General and Workers' Compensation Liability Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions, through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of December&#160;31, 2020 and 2019 were $21.4 million and $19.4 million, respectively. Expected insurance recoveries of $10.5 million and $12.1 million as of December&#160;31, 2020 and 2019, respectively, are included as a component of other current assets and other long-term assets in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Laws and Regulations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On April 14, 2020, Logan Laboratories, LLC ("Logan Labs"), a toxicology laboratory based in Tampa, Florida, that provides urine testing services and Tampa Pain Relief Centers, Inc. ("Tampa Pain" and, together with Logan Labs, the "Companies"), a pain management medical practice based in Tampa, Florida, both indirect wholly-owned subsidiaries of the Company, entered into a settlement agreement (the "Settlement Agreement") with the United States of America, acting through the United States Department of Justice (&#x201c;DOJ&#x201d;) and on behalf of the Office of Inspector General of the Department of Health and Human Services ("OIG"), the Defense Health Agency, acting on behalf of the TRICARE Program, the Office of Personnel Management, as the administrator of the Federal Employees Health Benefits Program, the Office of Workers Compensation Programs of the United States Department of Labor, which administers federal workers compensation claims for federal employees, including the United States Postal Service, and the United States Department of Veterans Affairs (collectively, the "U.S. Parties") and certain other parties to resolve the pending DOJ investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the terms of the Settlement Agreement, the Companies still owe payment of $30.7&#160;million plus accrued interest on April 1, 2021. The Company previously recorded a litigation-related charge of $46.0&#160;million relating to an anticipated resolution of the DOJ investigation on the consolidated statements of operations for the year ended December 31, 2018. For the year ended December 31, 2020, the Company recorded an additional litigation-related charge of $1.2&#160;million relating to the resolution of the Covered Conduct on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the Stark Law, the Anti-Kickback Statute, the FCA, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Potential Physician Investor Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Receivable Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On May 9, 2017, the Company entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September&#160;30, 2015 (as amended, the "TRA"), by and between the Company, and the other parties referred to therein, which amendment became effective on August 31, 2017. Pursuant to the amendment to the TRA, the Company agreed to make payments to H.I.G., the Company's former controlling shareholder, in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus three percent. The amounts payable under the TRA are related to the Company&#x2019;s projected realized tax savings over the next five years and are not dependent on the Company&#x2019;s actual tax savings over such period. The calculation of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that the Company is unable to make payments under the TRA, such payments will be deferred and will accrue interest at a rate of LIBOR plus&#160;500 basis points until paid. If the terms of credit agreements and other debt documents cause the Company to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Assuming the Company's tax rate is 24%, calculated as the maximum corporate federal tax rate plus three percent, throughout the remaining term of the TRA, the Company estimates the total remaining amounts payable under the TRA was approximately $43.2 million and $60.1 million as of December&#160;31, 2020 and 2019, respectively. The carrying value of the liability under the TRA, reflecting a discount, was $37.0 million and $48.7 million as of December&#160;31, 2020 and 2019, respectively. The current portion of the liability was $21.2 million and $16.9 million as of December&#160;31, 2020 and 2019, respectively, and is included as a component of other current liabilities in the &lt;/span&gt;&lt;/div&gt;consolidated balance sheets. The long-term portion is included as a component of other long-term liabilities in the consolidate balance sheets.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SelfInsuranceReserve
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMDg_b7ebd81d-e5e5-4999-87bd-02390ba092e0"
      unitRef="usd">21400000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMTU_a37bee53-2594-47cd-ac43-a92c8c7fece6"
      unitRef="usd">19400000</us-gaap:SelfInsuranceReserve>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwODc_0367dda7-91eb-4321-bf09-e298538d1a59"
      unitRef="usd">10500000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwOTQ_cf46e7c1-be7f-4202-9a3c-d4050a9e028a"
      unitRef="usd">12100000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i7b514b3c85dd48ff9fda4d7663a9cd66_D20210401-20210401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwOTk1MTE2NDkxNjE_f9612c7d-7f30-45bc-a725-1265aa42a1b5"
      unitRef="usd">30700000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwOTk1MTE2NDkxNzY_52fe4610-0875-4fe1-86a2-457e73260f12"
      unitRef="usd">-46000000.0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwOTk1MTE2NDkxOTM_71c2c84b-b37d-4867-b091-a5087d9fc03b"
      unitRef="usd">-1200000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i15035935d3e54ceba04f934c21488b65_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzIxOTkwMjMyODM0NjA_347aad8e-1d36-43ec-b7d7-bc1d836e6c4f"
      unitRef="number">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <sgry:CollaborativeTaxAgreementProjectedTaxSavingsTerm
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzIxOTkwMjMyODM0NDQ_32d091b3-3b69-49f4-8c87-229e2006e8ea">P5Y</sgry:CollaborativeTaxAgreementProjectedTaxSavingsTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia7b6963e13f944e28b5413d6c9ff381b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzgyOTQ_7ecfe030-6d3a-4f89-b3f5-fb406a603dab"
      unitRef="number">0.0500</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8dea0a1d35084b82bbde452684959945_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzg2MjA_aa875d65-6243-45a9-bef8-025405f9bebb"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzk2OTc_c1000423-a83d-4fe7-94dd-aff07cf4afc3"
      unitRef="number">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <sgry:CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate
      contextRef="i0570cd69811f45e1b5ff58850aabd565_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzk3NTk_df4bb87f-48d2-49a1-8aa1-cdd342f8884f"
      unitRef="number">0.03</sgry:CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzk5MDM_70316bb8-5609-42f0-9869-ec72e5e2d910"
      unitRef="usd">43200000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0Xzk5MTA_06263d90-2a91-470c-bbc8-88f9b2abc1cc"
      unitRef="usd">60100000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMDQz_0d898a97-e1d8-4f2d-b1c0-59f0ad490d5c"
      unitRef="usd">37000000.0</sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount>
    <sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMDUw_62f1cd24-c961-40a1-9590-f04573e93532"
      unitRef="usd">48700000</sgry:DeferredIncomeTaxLiabilitiesNetOfDiscount>
    <sgry:DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMTI1_4d8d4ea6-29e3-43b3-ba6e-c9286840c866"
      unitRef="usd">21200000</sgry:DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent>
    <sgry:DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTAvZnJhZzphNTQ3ZDY2YjgyODM0NGJmYWRkMDcwZjI3NGE5ZWM3NC90ZXh0cmVnaW9uOmE1NDdkNjZiODI4MzQ0YmZhZGQwNzBmMjc0YTllYzc0XzEwMTMy_32668fce-692e-4fb9-a930-3db0088987a2"
      unitRef="usd">16900000</sgry:DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIyNDM_709f8174-6ba3-426c-89a2-b0027f04e22c">Segment Reporting&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company operates in&#160;three&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities, the operation of ancillary services and the operation of optical services. The Surgical Facility Services segment consists of the operation of ASCs and surgical hospitals and includes anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices and a diagnostic laboratory, which was closed during the third quarter of 2020. The Optical Services segment consists of an optical products group purchasing organization, which was sold on December 31, 2020, as discussed in Note 2. "Acquisitions and Disposals." "All other" primarily consists of the Company's corporate general and administrative functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present financial information for each reportable segment (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,793.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,748.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,682.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,860.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,831.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,771.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;328.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(80.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(80.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reconciliation of Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(110.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transaction, integration and acquisition costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss (gain) on disposals and deconsolidations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Litigation settlement and other litigation costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent acquisition compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain on escrow release &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax receivable agreement expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;For the year ended December 31, 2020, this amount includes transaction and integration costs of $23.2 million, of which $6.6&#160;million were acquisition related costs, and includes start-up costs related to a de novo surgical hospital of $15.0 million. For the year ended December 31, 2019, this amount includes transaction and integration costs of $19.0 million, and includes other acquisition costs and start-up costs related to a de novo surgical hospital of $17.1 million. For the year ended December 31, 2018, this amount includes transaction and integration costs of $31.7 million, and includes other acquisition costs of $2.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes litigation settlement costs of $1.2 million, $0.2 million and $46.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. This amount further includes other litigation costs of $5.2 million and $4.4 million for the years ended December 31, 2020 and 2019, respectively, with no comparable costs in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount represents adjustments to revenue in order to apply consistent policies to businesses acquired by Surgery Partners in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Included in other income in the consolidated statement of operations for the year ended December 31, 2020, with no comparable gain in 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,962.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,580.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,413.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,018.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash purchases of property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzUxMDI_1b9da445-709d-4e6a-b72c-7f93a277119e"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIyMzI_3025d1c0-4772-4a6a-9f8f-f97501299421">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables present financial information for each reportable segment (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;margin-top:11pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,793.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,748.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,682.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,860.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,831.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,771.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;339.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;328.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(80.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(80.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Reconciliation of Adjusted EBITDA:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(110.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Transaction, integration and acquisition costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss (gain) on disposals and deconsolidations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Litigation settlement and other litigation costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent acquisition compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain on escrow release &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax receivable agreement expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;For the year ended December 31, 2020, this amount includes transaction and integration costs of $23.2 million, of which $6.6&#160;million were acquisition related costs, and includes start-up costs related to a de novo surgical hospital of $15.0 million. For the year ended December 31, 2019, this amount includes transaction and integration costs of $19.0 million, and includes other acquisition costs and start-up costs related to a de novo surgical hospital of $17.1 million. For the year ended December 31, 2018, this amount includes transaction and integration costs of $31.7 million, and includes other acquisition costs of $2.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount includes litigation settlement costs of $1.2 million, $0.2 million and $46.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. This amount further includes other litigation costs of $5.2 million and $4.4 million for the years ended December 31, 2020 and 2019, respectively, with no comparable costs in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;This amount represents adjustments to revenue in order to apply consistent policies to businesses acquired by Surgery Partners in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt"&gt;Included in other income in the consolidated statement of operations for the year ended December 31, 2020, with no comparable gain in 2019 and 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia8e40b357c844c71bed649d3cad09653_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzQtMi0xLTEtMA_500c59fd-9e6c-4127-a5e4-45c950170f32"
      unitRef="usd">1793400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1a81da0560194155b4abbadf871ee362_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzQtNC0xLTEtMA_e9ae9bf4-3587-46e5-becf-14bce3670ee1"
      unitRef="usd">1748200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i5878e06b7b984c2699576d1a46bb44f8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzQtNi0xLTEtMA_f6324bbf-f7d6-41a8-a8d1-5fcaceed853f"
      unitRef="usd">1682400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib03e505c471a4943901ca2907c0fa61e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzUtMi0xLTEtMA_6dd797c6-208c-4b35-b886-76f26207ce9d"
      unitRef="usd">63600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie853ea8a85d94a4a8512ec67b36ff19c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzUtNC0xLTEtMA_c038fffc-0756-426f-9378-ccfb20dc0917"
      unitRef="usd">79400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i77ebaf38db0d469ebf56d6ca77dfe0d3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzUtNi0xLTEtMA_73bf697e-c971-46db-b774-ea8eef049383"
      unitRef="usd">79600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ib8d2ddf0e9f54c259b2891a8c533060d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzYtMi0xLTEtMA_144cc41c-37fc-4509-a563-ea924e4490b4"
      unitRef="usd">3100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i966ad612edb74fff9113dfbc6c476ba6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzYtNC0xLTEtMA_526e87e7-6a6d-44b8-94b0-84faf2032953"
      unitRef="usd">3800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6c3ef67ea7a94f358e2956bacd5abd58_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzYtNi0xLTEtMA_781170a6-8e67-485f-8c17-24a32f7fc48d"
      unitRef="usd">9500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzctMi0xLTEtMA_38019a2b-805e-4d9d-8ba6-8aeb7e3c8cf7"
      unitRef="usd">1860100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzctNC0xLTEtMA_bb4b1515-9e95-4151-aeee-9f982328c786"
      unitRef="usd">1831400000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzctNi0xLTEtMA_b2084cc1-3889-4302-a288-a0099d16d998"
      unitRef="usd">1771500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia8e40b357c844c71bed649d3cad09653_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEwLTItMS0xLTA_aad237cc-f24d-4e06-881b-372337392436"
      unitRef="usd">339300000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i1a81da0560194155b4abbadf871ee362_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEwLTQtMS0xLTA_44cecea8-7366-4bb5-8ea5-7f7fc7cb7096"
      unitRef="usd">328900000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i5878e06b7b984c2699576d1a46bb44f8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEwLTYtMS0xLTA_4f5565d1-6ad7-46e2-9d73-e953984a715b"
      unitRef="usd">309500000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ib03e505c471a4943901ca2907c0fa61e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzExLTItMS0xLTA_504111c3-a20f-491e-8549-8f1122d2d115"
      unitRef="usd">-3400000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ie853ea8a85d94a4a8512ec67b36ff19c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzExLTQtMS0xLTA_c9901d6a-0383-4a02-87fd-fc6cba48ae8c"
      unitRef="usd">2600000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i77ebaf38db0d469ebf56d6ca77dfe0d3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzExLTYtMS0xLTA_c09c0baa-a9a1-4c1b-8f6d-db2c458f6eb2"
      unitRef="usd">3000000.0</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ib8d2ddf0e9f54c259b2891a8c533060d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEyLTItMS0xLTA_522b516d-3f85-4f71-8f77-94754dfcf8f0"
      unitRef="usd">1400000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i966ad612edb74fff9113dfbc6c476ba6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEyLTQtMS0xLTA_856250b1-f867-4464-a13f-731998d4ad10"
      unitRef="usd">1400000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i6c3ef67ea7a94f358e2956bacd5abd58_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEyLTYtMS0xLTA_863c5435-901c-4934-94dd-08ede6869a11"
      unitRef="usd">2500000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i0ad8b729655c4567bc34b3b7387d4214_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEzLTItMS0xLTA_d6c1c33d-b67f-45b0-8576-6403c3a05d0d"
      unitRef="usd">-80700000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i10a47a68bb1747c897f4f19e04584916_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEzLTQtMS0xLTA_fdd00de8-e230-4bb8-b342-9077fe44db29"
      unitRef="usd">-74300000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i59ad5e2b8c5f43b0aa69ebc006430ab4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzEzLTYtMS0xLTA_cac5bced-67d1-42da-8a72-aa14094245f6"
      unitRef="usd">-80200000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE0LTItMS0xLTA_c850116b-0286-4c17-89a0-c60553db2281"
      unitRef="usd">256600000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE0LTQtMS0xLTA_62182fdc-1144-48bc-b06c-74f7305aaafd"
      unitRef="usd">258600000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE0LTYtMS0xLTA_01ae1b58-ed6b-48ff-96e8-5ebe8419bf9c"
      unitRef="usd">234800000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE2LTItMS0xLTQ5ODI_9f4c369c-1ced-4dad-8c54-6ab15234040d"
      unitRef="usd">-18800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE2LTQtMS0xLTQ5ODI_1228c62d-57a3-47f0-a01f-ed248e209488"
      unitRef="usd">54600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE2LTYtMS0xLTQ5ODI_e4381e4b-ba5e-42d2-89fe-0c1ebe371214"
      unitRef="usd">-69200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE4LTItMS0xLTQ5ODU_0219765b-eb49-45d0-9864-066fca8d103a"
      unitRef="usd">117400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE4LTQtMS0xLTQ5ODU_471a8122-9f2f-4c0e-9831-bca490e96cc9"
      unitRef="usd">119900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE4LTYtMS0xLTQ5ODU_973f57ae-66b7-4bf8-b1a0-1523a41503eb"
      unitRef="usd">110100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE5LTItMS0xLTQ5ODc_b6e0bb7f-b6a6-4e84-a795-05ed8033bac8"
      unitRef="usd">94800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE5LTQtMS0xLTQ5ODc_f45a0775-73c1-4f5f-8017-f14c6b258a93"
      unitRef="usd">76500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzE5LTYtMS0xLTQ5ODc_f34afec3-1848-463f-9698-937c6f554a89"
      unitRef="usd">67400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIwLTItMS0xLTQ5ODk_5267c68e-ec6e-4d36-9cae-174419606461"
      unitRef="usd">-201800000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIwLTQtMS0xLTQ5ODk_983f4b5b-f92d-4ad7-80a9-63f0b04154ce"
      unitRef="usd">-178900000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIwLTYtMS0xLTQ5ODk_9ed9d1a3-45f6-4fe3-94c3-c04b20aee9ed"
      unitRef="usd">-147000000.0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ShareBasedCompensation
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIxLTItMS0xLTQ5OTE_dc62cd6f-827c-4bdb-bfcf-b77692d601e7"
      unitRef="usd">13200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIxLTQtMS0xLTQ5OTE_66ef3f91-47d8-4044-8558-012ef8c8ece3"
      unitRef="usd">10200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIxLTYtMS0xLTQ5OTE_33f4f285-04a2-4301-93c4-65dc15e8e9aa"
      unitRef="usd">9300000</us-gaap:ShareBasedCompensation>
    <sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIyLTItMS0xLTQ5OTU_79cce3d0-b44c-4c3a-b53b-451a5680649d"
      unitRef="usd">38200000</sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts>
    <sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIyLTQtMS0xLTQ5OTU_ecc55be7-4c09-4d5b-81c3-70ed49a7b51c"
      unitRef="usd">36100000</sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts>
    <sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIyLTYtMS0xLTQ5OTU_3749747f-bebf-4928-bc4b-82d54500f5e0"
      unitRef="usd">34000000.0</sgry:BusinessCombinationIntegrationRelatedCostsAndMergerCosts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIzLTItMS0xLTQ5OTM_3a1011ed-4141-44b0-a9c0-36c25dd4eb80"
      unitRef="usd">33500000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIzLTQtMS0xLTQ5OTM_16c2b4e5-abfb-47f7-a1fe-497bdd54b529"
      unitRef="usd">7900000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzIzLTYtMS0xLTQ5OTM_3ca920ec-ff5d-4010-b295-b4da54fedd6b"
      unitRef="usd">74400000</us-gaap:AssetImpairmentCharges>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI0LTItMS0xLTQ5OTg_585e7bb3-4256-4f0f-b919-bdcef9356349"
      unitRef="usd">-5700000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI0LTQtMS0xLTQ5OTg_045be707-adf0-4f32-b2f3-e7029b6823e5"
      unitRef="usd">4400000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossOnDispositionOfAssetsAndDeconsolidation
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI0LTYtMS0xLTQ5OTg_1d5b749c-6295-4946-a240-5145d025ee70"
      unitRef="usd">-31800000</sgry:GainLossOnDispositionOfAssetsAndDeconsolidation>
    <sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI1LTItMS0xLTUwMDA_bcf0818c-14b2-441b-9430-0b3621cdc2da"
      unitRef="usd">-6400000</sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts>
    <sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI1LTQtMS0xLTUwMDA_68947b05-42a1-479a-a669-2a50e13eaad1"
      unitRef="usd">-4600000</sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts>
    <sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI1LTYtMS0xLTUwMDA_ef6de306-295b-417f-873a-4058aa5ee660"
      unitRef="usd">-46000000.0</sgry:GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTItMS0xLTUwNDg_5e1e8fd9-f222-4a66-b2f1-a7b782e27b6e"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTQtMS0xLTUwNDg_253a87c9-6de0-44ea-bbe0-63f6e8f49ab1"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTYtMS0xLTUwNDg_813a1088-642b-4bf1-a4ee-ad8ac673ab5d"
      unitRef="usd">2700000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <sgry:BusinessCombinationContingentAcquisitionExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTItMS0xLTUwNzI_9df55cd4-8bcd-4e59-9220-a5523bca0cdc"
      unitRef="usd">0</sgry:BusinessCombinationContingentAcquisitionExpense>
    <sgry:BusinessCombinationContingentAcquisitionExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTQtMS0xLTUwNzI_ce84966d-eb47-42db-a2b6-1800a762fc3e"
      unitRef="usd">0</sgry:BusinessCombinationContingentAcquisitionExpense>
    <sgry:BusinessCombinationContingentAcquisitionExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTYtMS0xLTUwNzI_c2971d5d-6080-46cc-b99c-8bce670d9285"
      unitRef="usd">1500000</sgry:BusinessCombinationContingentAcquisitionExpense>
    <sgry:BusinessCombinationGainLossOnAcquisitionEscrow
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTItMS0xLTUwMDI_b7356062-b4c5-4bbc-aa72-cbc9a2c12401"
      unitRef="usd">800000</sgry:BusinessCombinationGainLossOnAcquisitionEscrow>
    <sgry:BusinessCombinationGainLossOnAcquisitionEscrow
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTQtMS0xLTUwMDI_7f9e3a5b-d5b7-4759-8f1a-6746043535e0"
      unitRef="usd">0</sgry:BusinessCombinationGainLossOnAcquisitionEscrow>
    <sgry:BusinessCombinationGainLossOnAcquisitionEscrow
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI2LTYtMS0xLTUwMDI_6ab8b4c9-c620-4e16-9db2-165e954d2980"
      unitRef="usd">0</sgry:BusinessCombinationGainLossOnAcquisitionEscrow>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTItMS0xLTUwMDQ_e37e5b7a-875d-4c76-a32a-a526beda03a5"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTQtMS0xLTUwMDQ_6c2843bc-4eed-4ab4-8dcb-8312f224a94e"
      unitRef="usd">-11700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI3LTYtMS0xLTUwMDQ_381a213e-9f44-4fc5-aad0-b193515c2ba3"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sgry:TaxReceivableAgreementExpenseBenefit
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI4LTItMS0xLTUwMDY_71baf6b9-e7fa-42b3-928f-36a1fc509b44"
      unitRef="usd">0</sgry:TaxReceivableAgreementExpenseBenefit>
    <sgry:TaxReceivableAgreementExpenseBenefit
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI4LTQtMS0xLTUwMDY_24a713ca-ade8-43c3-8968-2afe4b7103b1"
      unitRef="usd">2400000</sgry:TaxReceivableAgreementExpenseBenefit>
    <sgry:TaxReceivableAgreementExpenseBenefit
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI4LTYtMS0xLTUwMDY_1b78756c-cd6e-4bd7-9a7f-9f1014576c35"
      unitRef="usd">0</sgry:TaxReceivableAgreementExpenseBenefit>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI5LTItMS0xLTUwMDg_9d9ab873-5ec0-469d-b33c-d22a8bba39e3"
      unitRef="usd">256600000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI5LTQtMS0xLTUwMDg_8a1f1c44-ef01-415d-89af-9d02683ef30a"
      unitRef="usd">258600000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo0N2NlMjRhM2M0ZTI0NzAyYTUwODk4YmMyNzdkNzgyZC90YWJsZXJhbmdlOjQ3Y2UyNGEzYzRlMjQ3MDJhNTA4OThiYzI3N2Q3ODJkXzI5LTYtMS0xLTUwMDg_dc794037-8ed1-4611-a2a3-05692eacebe6"
      unitRef="usd">234800000</sgry:EarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5MzYy_1212cf46-8376-49b9-a3a5-94a1ff3dbc32"
      unitRef="usd">23200000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5NzEx_d6d38573-b372-4155-85ce-b255e13f5cbf"
      unitRef="usd">6600000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <sgry:StartUpActivitiesStartUpCosts
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5NDg5_c75c0b8f-c6bc-4b01-a6ae-5b7a2a0722c9"
      unitRef="usd">15000000.0</sgry:StartUpActivitiesStartUpCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5NTkw_38de6336-d33a-4b07-930c-a00bdf558b2b"
      unitRef="usd">19000000.0</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <sgry:StartUpActivitiesStartUpCosts
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzExNTQ0ODcyMDk5NzAx_a8831085-d1f0-4584-aede-8309155748c3"
      unitRef="usd">17100000</sgry:StartUpActivitiesStartUpCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzA4ODM_21e95c6b-24c1-4972-95d6-7c3f92e80167"
      unitRef="usd">31700000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzE1NjU_51437415-65ed-41a2-8dae-0e444ec56945"
      unitRef="usd">2300000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIwOTA_fcae2df5-795b-4bc1-8ac7-1e62639aa54c"
      unitRef="usd">-1200000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIwOTM_e7586ce7-e17e-4d8b-b2df-a5359a8046e4"
      unitRef="usd">-200000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIwOTY_c1f6c201-153b-4f1c-9c0e-85ce26891d11"
      unitRef="usd">-46000000.0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LitigationSettlementExpense
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIyNDM_2e0e75e4-7051-4d3c-95a8-d6e9b3c2a7c5"
      unitRef="usd">5200000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzEwOTk1MTE2MzIyNDY_8344ca1b-a5b7-4752-8eea-3a67b0ce530c"
      unitRef="usd">4400000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIxOTkwMjMyNjA5NTI_343e4ab5-17ac-4fff-8a6e-3d0fd1541aae"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIyNDA_6a249a3b-ee7a-44a7-a8ae-1786f2fe8f41">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.989%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,962.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,580.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optical Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;415.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,413.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,018.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="if35b1248a15b4a04a53222c87069bd54_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzMtMi0xLTEtMA_5f45dc57-6038-45bb-9eed-4472a337a09d"
      unitRef="usd">4962400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibe470e2b3fd645a5a04d06fd9d60eae6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzMtNC0xLTEtMA_c027f81b-c315-42c7-80f1-ac507cef2099"
      unitRef="usd">4580400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i018a6f0739764a949e8fe00e88704f6d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzQtMi0xLTEtMA_bbcbedec-0d40-407b-9aba-2f7cb70316cf"
      unitRef="usd">35000000.0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1d6d10cceadc435bbc6d90570a26a639_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzQtNC0xLTEtMA_23736fd1-c338-4188-a30f-11746d1034cd"
      unitRef="usd">69600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i51b0f35b18de46988ff6fbe8c8307369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzUtMi0xLTEtMA_4aaae996-c5d4-45f8-982a-771d9d9b9e77"
      unitRef="usd">0</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8880a4c46df641179425ee1784d1c48d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzUtNC0xLTEtMA_e3181a28-4972-4ca6-97c9-d0bfeee96185"
      unitRef="usd">17700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9b34194b9c3e45b3861a805f0ab38022_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzYtMi0xLTEtMA_33e96d62-61a7-4723-be75-2511838b4faa"
      unitRef="usd">415800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4027d5443cb745e1992a9fa9a7276711_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzYtNC0xLTEtMA_b9c18b62-c0f2-4a75-8b52-cd0a36d8e861"
      unitRef="usd">351200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id55b138001be441a9691661db6451a97_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzctMi0xLTEtMA_c4a100d0-dd5a-4919-a37a-811aa181f3b9"
      unitRef="usd">5413200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iebd694edd2e84c559ed056b5007002ce_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo2ZmEzYjQ2MjIyNTc0M2FiYmE5YjAyNzg1NmJlYzZkNi90YWJsZXJhbmdlOjZmYTNiNDYyMjI1NzQzYWJiYTliMDI3ODU2YmVjNmQ2XzctNC0xLTEtMA_aef47faf-c0b2-4599-911f-f438ebf9d989"
      unitRef="usd">5018900000</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90ZXh0cmVnaW9uOmJkZmRmYzkxZGVkMzQyY2E4YTFlNjYzNTJhZGZkZTc4XzIyNDY_5f20e688-b638-45cb-b614-ea1a14ac7adb">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash purchases of property and equipment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Surgical Facility Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ancillary Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia8e40b357c844c71bed649d3cad09653_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzQtMi0xLTEtMA_d27cae7b-cf10-48cf-95ee-cba80c4dbc48"
      unitRef="usd">38700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1a81da0560194155b4abbadf871ee362_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzQtNC0xLTEtMA_9dc41a5f-4b46-4308-a1ea-7b991bf16276"
      unitRef="usd">65900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5878e06b7b984c2699576d1a46bb44f8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzQtNi0xLTEtMA_ba8ec43a-6103-49a8-8cad-ec4de791f00b"
      unitRef="usd">34200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib03e505c471a4943901ca2907c0fa61e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzUtMi0xLTEtMA_7fc5411e-26e2-4111-a841-7f3eb616a7bc"
      unitRef="usd">400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie853ea8a85d94a4a8512ec67b36ff19c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzUtNC0xLTEtMA_e21dfedd-ee12-42de-aa85-d5285a3beea9"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i77ebaf38db0d469ebf56d6ca77dfe0d3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzUtNi0xLTEtMA_ea172abf-626c-4ae1-b81f-ea59221e2b4a"
      unitRef="usd">400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0ad8b729655c4567bc34b3b7387d4214_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzctMi0xLTEtMA_c5fb1718-d5f7-4d65-9282-8fceab1e4766"
      unitRef="usd">3800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i10a47a68bb1747c897f4f19e04584916_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzctNC0xLTEtMA_03f487d0-1d5a-45da-b0ca-0a13859af0fc"
      unitRef="usd">6600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i59ad5e2b8c5f43b0aa69ebc006430ab4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzctNi0xLTEtMA_9a387ee2-304a-4b7b-b855-f32aab12c725"
      unitRef="usd">5200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzgtMi0xLTEtMA_aaaed521-d3ab-4eda-8513-06f94029fc4e"
      unitRef="usd">42900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3405e47c71bf448ab486587ae9e103e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzgtNC0xLTEtMA_d7cacfd6-edf4-4ddd-85d5-7d6f7af278b7"
      unitRef="usd">73600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4336ce86e2b44075bb01a31acee934e1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xOTYvZnJhZzpiZGZkZmM5MWRlZDM0MmNhOGExZTY2MzUyYWRmZGU3OC90YWJsZTo4N2Q4MzE3NGZkYjY0MDI5YjVhYTA2NTlmMGMwY2E4ZS90YWJsZXJhbmdlOjg3ZDgzMTc0ZmRiNjQwMjliNWFhMDY1OWYwYzBjYThlXzgtNi0xLTEtMA_ac222d8f-9669-4923-ac91-47d8ce014457"
      unitRef="usd">39800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMDg_f1bda1de-7a65-439c-a0f0-3b32c11ad7bc">Subsequent Events&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On January 27, 2021, the Company entered into an underwriting agreement relating to a public offering of 7,500,000 shares (the &#x201c;Firm Shares&#x201d;) of the Company&#x2019;s common stock, $0.01 par value per share, at a price to the public of $30.25 per share. In addition, the Company granted the underwriters an option to purchase up to an additional 1,125,000 shares of common stock at the same price per share as the Firm Shares. On February 1, 2021, the Company completed the public offering pursuant to which the Company sold 8,625,000 shares of common stock, resulting in net proceeds of $249.2&#160;million, net of underwriting discounts and commissions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On January 27, 2021, the Company entered into an amendment to the credit agreement governing the Revolver, dated as of January 27, 2021 (the &#x201c;Amendment&#x201d;), which amended and supplemented the credit agreement, dated as of August 31, 2017, to provide for an extension of the maturity date of the Revolver to February 1, 2026 and an increase in the outstanding commitments under the Revolver in an amount equal to $50.0&#160;million. The maturity extension and the additional commitments became operative on February 1, 2021, upon satisfaction by the Borrower of certain conditions precedent set forth in the Amendment, including the closing of the offering of the Firm Shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i98564e51940c4e91a27b5a49261520cf_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMTA_c279961f-51af-40f5-9b7d-cc82d5fa600f"
      unitRef="shares">7500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaa0fb1e697bf46f98f1f119b51d1217a_I20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMjE_f3915ae8-0645-4519-ae1a-3fe1c237ccda"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iaa0fb1e697bf46f98f1f119b51d1217a_I20210201"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMjg_799e3e3a-10a7-42b2-b1c9-9e0889f3c422"
      unitRef="usdPerShare">30.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i596ba4d78eee424182ca76e6fe6f57f9_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwMzY_0d7071f2-a525-4c2d-a7bb-77a9d001dc0b"
      unitRef="shares">1125000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibf9358b8a33748d69b07ec48689f9eee_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwNDc_ba394e86-88d7-4e25-8a11-ac6c52203638"
      unitRef="shares">8625000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ibf9358b8a33748d69b07ec48689f9eee_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwNTg_32a78c68-50af-441e-b416-794c1487371f"
      unitRef="usd">249200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgry:LineOfCreditFacilityMaximumBorrowingCapacityIncrease
      contextRef="iab383708d31447d6b0f9eb47c597c2e6_I20210127"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18yMDIvZnJhZzpkNDA0YzEyZjg5Y2E0NDlhOWVhMTU5ZGZlZDg0MGVjNi90ZXh0cmVnaW9uOmQ0MDRjMTJmODljYTQ0OWE5ZWExNTlkZmVkODQwZWM2XzIxOTkwMjMyNjAwNzQ_2a8d910f-1446-4d56-8b6a-2d378c5c1ef5"
      unitRef="usd">50000000.0</sgry:LineOfCreditFacilityMaximumBorrowingCapacityIncrease>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTQtMS0xLTA_2f67ba76-2823-4860-b567-103790b87cf1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTQtMS0xLTA_2f67ba76-2823-4860-b567-103790b87cf1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in those periods.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTItMS0xLTA_aadfa437-15f9-47a9-81e6-6e754102f9e8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTQtMS0xLTA_2f67ba76-2823-4860-b567-103790b87cf1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTQtMS0xLTA_0c7ec93c-28a6-44b2-ae59-06a3ddf491c5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzExLTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTYtMS0xLTA_184a7635-4922-48c7-9079-f33bcce4fbc6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM3LTYtMS0xLTA_c58c18e7-32b1-4229-a367-722990bd8e08"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjkvZnJhZzplODE0OTI4ODRiN2M0MTBmOTBjMjc1NWViNjE5ZGE2OS90YWJsZToxMDEyNmQ2ZTRjMTM0NjE1ODZjNTY5MGRiYzg5MTA2ZC90YWJsZXJhbmdlOjEwMTI2ZDZlNGMxMzQ2MTU4NmM1NjkwZGJjODkxMDZkXzEzLTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90YWJsZToyOTJlZDk1YjRiYmU0ZGE5OWEzNjk0OWZkYWNiODQ1My90YWJsZXJhbmdlOjI5MmVkOTViNGJiZTRkYTk5YTM2OTQ5ZmRhY2I4NDUzXzM2LTItMS0xLTA_0c54f3e5-0882-4670-83de-335fb7340f7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xMjcvZnJhZzo3Mjg2NzRiNDNlNzQ0YWI5YWQyYzI1ZjNjNmFlM2Y5Yi90ZXh0cmVnaW9uOjcyODY3NGI0M2U3NDRhYjlhZDJjMjVmM2M2YWUzZjliXzIxOTkwMjMyNTU3NTY_09d892d5-ea4a-4fc8-9af8-ed17b3162004"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608234392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 03, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Surgery Partners, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3620923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">310 Seven Springs Way, Suite&#160;500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brentwood<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">234-5900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGRY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,859,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant's definitive proxy statement for the 2021 annual meeting of stockholders are incorporated by reference into Part III of this report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608826136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 317.9<span></span>
</td>
<td class="nump">$ 92.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">382.2<span></span>
</td>
<td class="nump">326.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">46.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">27.4<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">801.5<span></span>
</td>
<td class="nump">525.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">544.6<span></span>
</td>
<td class="nump">523.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,468.0<span></span>
</td>
<td class="nump">3,402.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to affiliates</a></td>
<td class="nump">90.3<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease assets</a></td>
<td class="nump">310.1<span></span>
</td>
<td class="nump">297.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Long-term deferred tax assets</a></td>
<td class="nump">124.8<span></span>
</td>
<td class="nump">98.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,413.2<span></span>
</td>
<td class="nump">5,018.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">96.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">65.4<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent', window );">Medicare accelerated payments and deferred governmental grants</a></td>
<td class="nump">109.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">217.0<span></span>
</td>
<td class="nump">191.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current maturities of long-term debt</a></td>
<td class="nump">64.4<span></span>
</td>
<td class="nump">56.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">556.8<span></span>
</td>
<td class="nump">398.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, less current maturities</a></td>
<td class="nump">2,792.4<span></span>
</td>
<td class="nump">2,524.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use operating lease liabilities</a></td>
<td class="nump">300.9<span></span>
</td>
<td class="nump">283.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">139.7<span></span>
</td>
<td class="nump">113.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Non-controlling interests&#8212;redeemable</a></td>
<td class="nump">306.8<span></span>
</td>
<td class="nump">321.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable preferred stock - Series A; shares authorized, issued and outstanding - 310,000; redemption value - $434.5 and $395.0, respectively</a></td>
<td class="nump">434.5<span></span>
</td>
<td class="nump">395.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; shares authorized - 20,000,000; shares issued or outstanding - none</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 50,461,706 and 49,298,940, respectively</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">607.9<span></span>
</td>
<td class="nump">662.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(61.0)<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(431.8)<span></span>
</td>
<td class="num">(315.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Surgery Partners, Inc. stockholders' equity</a></td>
<td class="nump">115.6<span></span>
</td>
<td class="nump">296.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests&#8212;non-redeemable</a></td>
<td class="nump">766.5<span></span>
</td>
<td class="nump">686.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">882.1<span></span>
</td>
<td class="nump">983.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 5,413.2<span></span>
</td>
<td class="nump">$ 5,018.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare Accelerated Payments And Deferred Governmental Grants, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607965240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable preferred stock, shares authorized (shares)</a></td>
<td class="nump">310,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable preferred stock, shares issued (shares)</a></td>
<td class="nump">310,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable preferred stock, shares outstanding (shares)</a></td>
<td class="nump">310,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue', window );">Redeemable preferred stock, redemption value</a></td>
<td class="nump">$ 434.5<span></span>
</td>
<td class="nump">$ 395.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (shares)</a></td>
<td class="nump">50,461,706<span></span>
</td>
<td class="nump">49,298,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (shares)</a></td>
<td class="nump">50,461,706<span></span>
</td>
<td class="nump">49,298,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption value, as if currently redeemable, of redeemable noncontrolling interest for preferred shares, units or ownership interests classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 24(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715606945864">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,860.1<span></span>
</td>
<td class="nump">$ 1,831.4<span></span>
</td>
<td class="nump">$ 1,771.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">550.3<span></span>
</td>
<td class="nump">550.0<span></span>
</td>
<td class="nump">534.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">538.4<span></span>
</td>
<td class="nump">507.9<span></span>
</td>
<td class="nump">490.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional and medical fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">191.4<span></span>
</td>
<td class="nump">154.8<span></span>
</td>
<td class="nump">145.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_OperatingAndFinanceLeaseExpense', window );">Lease expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87.4<span></span>
</td>
<td class="nump">85.6<span></span>
</td>
<td class="nump">86.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112.8<span></span>
</td>
<td class="nump">109.3<span></span>
</td>
<td class="nump">104.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,480.3<span></span>
</td>
<td class="nump">1,407.6<span></span>
</td>
<td class="nump">1,361.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">97.1<span></span>
</td>
<td class="nump">88.6<span></span>
</td>
<td class="nump">93.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">67.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income from equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(10.2)<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Loss (gain) on disposals and deconsolidations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.7<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Transaction and integration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">31.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33.5<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GrantRevenue', window );">Grant funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,677.1<span></span>
</td>
<td class="nump">1,595.5<span></span>
</td>
<td class="nump">1,693.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183.0<span></span>
</td>
<td class="nump">235.9<span></span>
</td>
<td class="nump">77.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Tax receivable agreement expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(201.8)<span></span>
</td>
<td class="num">(178.9)<span></span>
</td>
<td class="num">(147.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">(Loss) income before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18.8)<span></span>
</td>
<td class="nump">54.6<span></span>
</td>
<td class="num">(69.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20.1)<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="nump">26.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">45.1<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(117.4)<span></span>
</td>
<td class="num">(119.9)<span></span>
</td>
<td class="num">(110.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Surgery Partners, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(116.1)<span></span>
</td>
<td class="num">(74.8)<span></span>
</td>
<td class="num">(205.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Amounts attributable to participating securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39.5)<span></span>
</td>
<td class="num">(35.7)<span></span>
</td>
<td class="num">(32.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (155.6)<span></span>
</td>
<td class="num">$ (110.5)<span></span>
</td>
<td class="num">$ (238.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders - basic and diluted (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
<td class="num">$ (4.96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">48,776<span></span>
</td>
<td class="nump">48,280<span></span>
</td>
<td class="nump">48,028<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in those periods.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_OperatingAndFinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_OperatingAndFinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=114868883&amp;loc=SL114871943-224233<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715609596376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 45.1<span></span>
</td>
<td class="num">$ (95.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Derivative activity</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(28.3)<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive (loss) income</a></td>
<td class="num">(9.0)<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="num">(118.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to non-controlling interests</a></td>
<td class="num">(117.4)<span></span>
</td>
<td class="num">(119.9)<span></span>
</td>
<td class="num">(110.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Surgery Partners, Inc.</a></td>
<td class="num">$ (126.4)<span></span>
</td>
<td class="num">$ (103.1)<span></span>
</td>
<td class="num">$ (228.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608339304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Impact of adoption of ASC 842</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Deficit</div></th>
<th class="th">
<div>Retained Deficit </div>
<div>Impact of adoption of ASC 842</div>
</th>
<th class="th"><div>Non-Controlling Interests&#8212; Non-Redeemable</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, stockholders' equity (shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,687,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance, stockholders' equity at Dec. 31, 2017</a></td>
<td class="nump">$ 1,336.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 695.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 681.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net (loss) income</a></td>
<td class="num">(130.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Preferred dividends</a></td>
<td class="num">(32.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(22.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet', window );">Acquisition and disposal of shares of non-controlling interests, net</a></td>
<td class="nump">20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interests&#8212;non-redeemable holders</a></td>
<td class="num">(78.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, stockholders' equity (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, stockholders' equity at Dec. 31, 2018</a></td>
<td class="nump">$ 1,098.9<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">673.5<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
<td class="num">(247.0)<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">694.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net (loss) income</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Preferred dividends</a></td>
<td class="num">(35.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(28.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet', window );">Acquisition and disposal of shares of non-controlling interests, net</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interests&#8212;non-redeemable holders</a></td>
<td class="num">(81.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, stockholders' equity (shares) at Dec. 31, 2019</a></td>
<td class="nump">49,298,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, stockholders' equity at Dec. 31, 2019</a></td>
<td class="nump">$ 983.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">662.7<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
<td class="num">(315.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net (loss) income</a></td>
<td class="num">(30.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Preferred dividends</a></td>
<td class="num">(39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(10.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet', window );">Acquisition and disposal of shares of non-controlling interests, net</a></td>
<td class="nump">39.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interests&#8212;non-redeemable holders</a></td>
<td class="num">(73.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, stockholders' equity (shares) at Dec. 31, 2020</a></td>
<td class="nump">50,461,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, stockholders' equity at Dec. 31, 2020</a></td>
<td class="nump">$ 882.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 607.9<span></span>
</td>
<td class="num">$ (61.0)<span></span>
</td>
<td class="num">$ (431.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608331192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 45.1<span></span>
</td>
<td class="num">$ (95.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">67.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NoncashInterestIncomeExpenseNet', window );">Non-cash interest expense (income), net</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">13.2<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Loss (gain) on disposals and deconsolidations, net</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">33.5<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(21.9)<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Income from equity investments, net of distributions received</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">39.4<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(46.6)<span></span>
</td>
<td class="num">(23.5)<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants', window );">Medicare accelerated payments and deferred governmental grants</a></td>
<td class="nump">135.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other operating assets and liabilities</a></td>
<td class="num">(12.7)<span></span>
</td>
<td class="num">(45.3)<span></span>
</td>
<td class="nump">56.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">246.9<span></span>
</td>
<td class="nump">129.5<span></span>
</td>
<td class="nump">144.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(42.9)<span></span>
</td>
<td class="num">(73.6)<span></span>
</td>
<td class="num">(39.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for acquisitions, net of cash acquired</a></td>
<td class="num">(104.6)<span></span>
</td>
<td class="num">(13.8)<span></span>
</td>
<td class="num">(106.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of equity investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">58.5<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(88.4)<span></span>
</td>
<td class="num">(85.2)<span></span>
</td>
<td class="num">(128.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(216.3)<span></span>
</td>
<td class="num">(490.8)<span></span>
</td>
<td class="num">(157.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings of long-term debt</a></td>
<td class="nump">429.4<span></span>
</td>
<td class="nump">506.9<span></span>
</td>
<td class="nump">282.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DebtInstrumentPrepaymentPenaltyAmount', window );">Payment of premium on debt extinguishment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(17.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsMinorityInterest', window );">Distributions to non-controlling interest holders</a></td>
<td class="num">(109.6)<span></span>
</td>
<td class="num">(121.2)<span></span>
</td>
<td class="num">(109.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments related to ownership transactions with non-controlling interest holders</a></td>
<td class="num">(27.4)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payments of preferred dividends</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">66.7<span></span>
</td>
<td class="num">(135.9)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">225.2<span></span>
</td>
<td class="num">(91.6)<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">93.0<span></span>
</td>
<td class="nump">184.6<span></span>
</td>
<td class="nump">175.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">318.2<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="nump">184.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid, net of interest income received</a></td>
<td class="nump">203.6<span></span>
</td>
<td class="nump">180.3<span></span>
</td>
<td class="nump">145.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Non-cash purchases of property and equipment</a></td>
<td class="nump">$ 27.7<span></span>
</td>
<td class="nump">$ 30.7<span></span>
</td>
<td class="nump">$ 61.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DebtInstrumentPrepaymentPenaltyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DebtInstrumentPrepaymentPenaltyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NoncashInterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Interest Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NoncashInterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601044584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Accounting Policies</a></td>
<td class="text">Organization and Summary of Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners, Inc.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Delaware corporation (together with its subsidiaries, the "Company"), was formed April 2, 2015. On August 31, 2017, a fund advised by an affiliate of Bain Capital Private Equity LP ("Bain Capital") became the controlling stockholder of the Company, holding Series A Preferred Stock (as defined in Note 7. "Redeemable Preferred Stock") and common stock that collectively represented approximately 65.7% of the voting power of all classes of capital stock of the Company as of August 31, 2017. As of December 31, 2020, Bain Capital held approximately 67.0% of the voting power of all classes of capital stock of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company owned and operated a national network of surgical facilities and ancillary services in 30 states.&#160;The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology, general surgery, ophthalmology, orthopedics and pain management.&#160;The Company's surgical hospitals also provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of multi-specialty physician practices, urgent care facilities and anesthesia services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company owned or operated a portfolio of 127 surgical facilities, comprised of 110 ASCs and 17 surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, health care systems in the markets and communities it serves.&#160;The Company owned a majority interest in 84 of the surgical facilities and consolidated 107 of the facilities for financial reporting purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The COVID-19 global pandemic has significantly affected the Company's facilities, employees, patients, communities, business operations and financial performance, as well as the U.S. economy and financial markets. Beginning mid-March, the COVID-19 pandemic began to negatively affect the Company's net revenue and business operations. Due in part to local, state and federal guidelines, as well as recommendations from major medical societies, requiring social distancing and self-quarantines in response to the COVID-19 pandemic, surgical case volumes across most of the Company's surgical facilities were significantly impacted in the second quarter of 2020. The impact of COVID-19 on the Company's surgical facilities varies based on the market in which the facility operates, the type of surgical facility and the procedures that are typically performed. Although the Company cannot provide any certainty regarding the length and severity of the impact of the COVID-19 pandemic, surgical case volumes improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. The Company's operating structure naturally enables some flexibility in the cost structure according to the volume of surgical procedures performed, including much of its cost of revenues. In addition to the natural variability of these costs, the Company and its partners in the surgical facilities have undertaken additional steps to preserve financial flexibility. Beginning in mid-March, and for the remainder of 2020, the Company took actions that included significantly reducing cash operating expenses and deferring non-essential expenditures at the height of the crisis. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CARES Act</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law to provide stimulus funding for the U.S. economy. As part of the CARES Act, the U.S. government initially announced that it would offer $100&#160;billion of relief to eligible health care providers. On April 7, 2020, Centers for Medicare and Medicaid Services ("CMS") officials indicated they would distribute $30&#160;billion of direct grants to hospitals, ASCs and other health care providers based on how much they bill Medicare. Payments received from these grants are not required to be repaid provided the recipients attest to and comply with certain terms and conditions, including limitations on balance billing and not using funds received from the grants to reimburse expenses or losses that other sources are obligated to reimburse. The Company received approximately $59&#160;million of the grant funds distributed under the CARES Act and other governmental assistance programs during the year ended December&#160;31, 2020. The recognition of amounts received is conditioned upon attestation with terms and conditions that funds will be used for COVID-19 related healthcare expenses or lost revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company&#8217;s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the COVID-19 Economic Relief Bill, enacted on December 27, 2020, and all frequently </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">asked questions and other interpretive guidance issued by HHS, including the Post-Payment Notice of Reporting Requirements issued on January 15, 2021 (the &#8220;January 15, 2021 Notice&#8221;) and frequently asked questions issued by HHS on January 28, 2021 which clarified previously issued guidance, as well as expenses incurred attributable to COVID-19 and the Company&#8217;s results of operations during such period as compared to the Company&#8217;s budget. Such guidance, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to COVID-19 that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. As a result, the Company estimates approximately $46.2 million of grant funds received qualified for recognition as a reduction in operating expenses under the caption Grant funds in the consolidated statements of operations for the year ended December&#160;31, 2020. While the January 15, 2021 Notice and frequently asked questions issued by HHS on January 28, 2021 indicate that targeted distribution payments may be allocated or transferred to subsidiaries, distinct conditions exist for such allocations or transfers. There are significant uncertainties as to the meaning and interpretation of conditions specific to the allocation or transfer of targeted distribution payments such that, as of December 31, 2020, the Company is not reasonably assured that it can or will choose to comply with such conditions in order to allocate or transfer targeted distribution payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amounts received, but not recognized as a reduction to operating expenses as of December&#160;31, 2020, are reflected as a component of Medicare accelerated payments and deferred governmental grants in the consolidated balance sheets as of December&#160;31, 2020, and such unrecognized amounts may be recognized as a reduction in operating expenses in future periods if the underlying conditions for recognition are met. HHS&#8217; interpretation of the underlying terms and conditions of grant funds received through the CARES Act and other governmental assistance programs, including auditing and reporting requirements, may evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in the Company&#8217;s inability to recognize certain payments, changes in the estimate of amounts recognized, or the derecognition of amounts previously recognized, which may be material.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a way to increase cash flow to Medicare providers impacted by the COVID-19 pandemic, the CARES Act expanded the Medicare Accelerated and Advance Payment Program, which allows for most providers and suppliers, including the Company&#8217;s surgical hospitals and ASCs to request an advance payment of anticipated Medicare revenues. ASCs could request up to 100% of the Medicare Fee-for-Service payment amount for a three-month period. Hospitals could request up to 100% of the payment amount for a six-month period, with certain critical access hospitals able to request up to 125% of the payment for a six-month period. Under the current terms of the program, all providers will have 29 months from the date of their first program payment to repay the full amount of the accelerated or advance payments they have received. The revised terms extend the period before repayment begins from 210 days to one year from the date that payment under the program was received. Once the repayment period begins, the offset will be limited to 25% of new claims during the first 11 months of repayment and 50% of new claims during the final 6 months. The revised program terms also lower the interest rate on outstanding amounts due at the end of the repayment period from 10% to 4%.The Company received approximately $120&#160;million of accelerated payments during the year ended December&#160;31, 2020. These accelerated payments received were deferred. The current portion was approximately $95&#160;million and is included as a component of Medicare accelerated payments and deferred governmental grants in the consolidated balance sheets as of December&#160;31, 2020. The long-term portion is included as a component of other long-term liabilities in the consolidate balance sheets. The Company does not expect to receive additional Medicare accelerated payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CARES Act also provides for the deferral of the Company's portion of social security payroll taxes for the remainder of 2020. Under the CARES Act, half of the deferred amount will have to be paid in each of December 2021 and December 2022. The Company began deferring the social security payroll tax match in April 2020. As of December&#160;31, 2020, the Company has deferred approximately $16.9&#160;million. The current portion is included as a component of accrued payroll and benefits and the long term portion is included as a component of other long-term liabilities in the consolidated balance sheets as of December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is continuing to closely monitor legislative actions and regulatory guidance at the federal, state and local levels with respect to the CARES Act as other governmental assistance might become available to the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of Accounting Standards Codification 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company has the power to direct the activities that most significantly impact a variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. At December&#160;31, 2020, the variable interest entities include four surgical facilities and three physician practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The total assets (excluding goodwill and intangible assets, net) of the consolidated VIEs included in the accompanying consolidated balance sheets as of December&#160;31, 2020 and 2019, were $27.7 million and $36.2 million, respectively, and the total liabilities of the consolidated VIEs were $21.1 million and $25.2 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:13pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,539.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,533.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values in the table above were based on a Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values under Level 3 calculations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has entered into certain interest rate swap agreements (see Note 8. "Derivatives and Hedging Activity"). At December&#160;31, 2020 and 2019, the fair value of these derivative instruments was $61.0 million and $50.7 million, respectively, and was included in other long-term liabilities in the consolidated balance sheets. The fair value of these derivative financial instruments was based on a quoted market price, or a Level 2 input.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which our obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical services revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160; This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications.&#160;The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. </span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments, discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Optical service revenues consist of handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. The Company satisfies the performance obligation and recognizes revenue when the orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company sold its optical products purchasing organization on December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">948.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">701.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,803.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,737.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,771.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash reported within the consolidated statement of cash flows includes $0.3 million of restricted investments, which are reflected in other long-term assets in the consolidated balance sheet at both December&#160;31, 2020 and 2019. These restricted investments represent restricted cash held in accordance with the provisions of a long-term operating lease agreement held as security for performance under the Company's covenants and obligations within the agreement through January 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to its sale on December 31, 2020, the receivables related to the Company's optical products purchasing organization were recognized separately from patient accounts receivable and included in other current assets in the consolidated balance sheets. Such receivables were $8.6 million at December 31, 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets, Goodwill and Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value.&#160;The cash flow projection and fair value represents management&#8217;s best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation.&#160;For discussion on impairment for goodwill and indefinite-lived intangible assets, refer to Note 4. "Goodwill and Intangible Assets."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Professional and General and Workers' Compensation Insurance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional liability insurance coverage is on a claims-made basis and the general liability insurance is on an occurrence basis. The Company also maintains workers' compensation insurance, subject to a self-insured retention.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers' compensation claims which relate to (i)&#160;claims made during the policy period, which are offset by insurance recoveries and (ii)&#160;an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value.&#160;The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Unconsolidated Affiliates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless the investments are a result of the Company losing control of a previously controlled entity, but still retaining a non-controlling interest. Transactions that result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which include unobservable data, to measure the fair value of the retained non-controlling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in and advances to affiliates in the accompanying consolidated balance sheets. The Company&#8217;s share of the profits and losses from these investments is reported in income from equity investments in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-Controlling Interests &#8212; Redeemable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the consolidated balance sheets.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to the non-controlling interests&#8212;redeemable for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:70.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest &#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-04 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future London Interbank Offered Rate ("LIBOR") indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (&#8220;CECL&#8221;) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, which is primarily applicable to accounts receivable for the Company. This ASU was effective for the Company on January 1, 2020. The adoption of this ASU did not have a material impact on its consolidated financial position and results of operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, "Leases" (the "Lease Accounting Standard"). The Company adopted the Lease Accounting Standard effective January 1, 2019, using a modified retrospective transition approach. The most prominent of the changes resulting from this ASU is the recognition of right-of-use assets and lease liabilities by lessees for those leases classified as operating leases. The Company&#8217;s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. Upon adoption of the Lease Accounting Standard, the Company recorded $294.0&#160;million of operating lease liabilities and right-of-use assets on January 1, 2019. The cumulative effect of the accounting change recognized upon adoption was $6.1&#160;million reflected as an adjustment to retained deficit in our consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601144008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationsAndDisposalsAbstract', window );"><strong>Business Combinations And Disposals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock', window );">Acquisitions and Disposals</a></td>
<td class="text">Acquisitions and Disposals<div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for business combinations in accordance with the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer can be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any non-controlling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Any goodwill recognized is determined as the excess of the fair value of the consideration conveyed plus the fair value of any non-controlling interests in the acquisition over the fair value of the net assets acquired. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquired assets and assumed liabilities typically include, but are not limited to, fixed assets, intangible assets and right-of-use leases. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. Fair value attributable to non-controlling interests is based on a Level 3 computation using significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of non-controlling interests, primarily from acquisitions of surgical facilities. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. Fair value attributable to the property and equipment acquired is based on Level 3 computations using key inputs such as cost trend data and comparable asset sales. Fair value attributable to the intangible assets acquired is based on Level 3 computations using key inputs such as the Company's internally-prepared financial projections. Fair values assigned to acquired working capital are based on carrying amounts reported by the acquiree at the date of acquisition, which approximate their fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company acquired a controlling interest in three surgical facilities, including a surgical hospital, a controlling interest in five surgical facilities in existing markets, that were merged into existing facilities and a physician practice for total aggregate consideration of $120.1&#160;million, including cash consideration of $104.6&#160;million, net of cash acquired, non-cash consideration of $8.7 million and contingent consideration of $0.7 million. The non-cash consideration consisted of non-controlling interests in the Company's existing surgical facilities. The cash consideration was funded through cash from operations, proceeds from its recent divestitures and other available resources. The total consideration was allocated to the assets acquired and liabilities assumed based upon the respective acquisition date fair values.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, the Company acquired a controlling interest in one surgical facility, a clinic that was merged into an existing facility and a physician practice for total aggregate consideration of $26.7&#160;million, including cash consideration of $20.1&#160;million, net of cash acquired. The remainder of the consideration related to the forgiveness of certain amounts due to the Company from the acquired clinic. During 2020, the Company made a working capital settlement payment resulting in additional cash consideration of $0.8&#160;million related to the clinic acquisition. The additional consideration is reflected in the table below. During the year ended December&#160;31, 2020, no other significant changes were made to the purchase price allocation of assets and liabilities, existing at the date of acquisition, related to individual acquisitions completed in 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preliminary or final amounts recognized for each major class of assets acquired and liabilities assumed for acquisitions completed during the years ended December 31, 2020 and 2019, including post acquisition date adjustments, are as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">In connection with the clinic acquisition in 2019, the Company acquired the remaining non-controlling interests in one of its existing consolidated surgical facilities. As such, $6.3 million of the cash consideration for the clinic acquisition was classified as a financing activity and presented in payments related to ownership transactions with non-controlling interest holders in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The assets acquired in 2019 includes the fair value of a non-controlling investment held by the acquired clinic in one of the Company's consolidated surgical facilities of $8.8 million. This investment asset was subsequently eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values assigned to certain assets acquired and liabilities assumed by the Company in 2020 have been estimated on a preliminary basis and are subject to change as new facts and circumstances emerge that were present at the date of acquisition. The goodwill acquired in connection with the 2020 acquisitions was allocated to the Company's Surgical Facility Services reportable segment. The results of operations of the 2020 acquisitions are included in the Company&#8217;s results of operations beginning on the dates of acquisition, and were not considered significant for the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, the Company acquired non-controlling interests, primarily in four surgical facilities, for a cash investment of $15.2 million. The non-controlling interests were accounted for as equity method investments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Disposals</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company sold its interests in three surgery centers, one of which was previously accounted for as an equity method investment, sold certain assets related to its anesthesia business, certain imaging assets and its optical products purchasing organization for combined net cash proceeds of $58.5&#160;million, and recognized a net pre-tax gain of $5.2&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December&#160;31, 2020. Additionally, the Company closed its diagnostic laboratory and recognized a net pre-tax loss of $3.5&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, the Company disposed of previously owned real property associated with one of its existing non-consolidated surgical facilities. In connection with the sale, the Company recognized a $10.9&#160;million pretax gain included in loss (gain) on disposals and deconsolidations, net in the accompanying consolidated statements of operations. The sale did not impact the Company's investment in the surgical facility, which continues to be accounted for as an equity method investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, the Company disposed of four surgery centers, two surgical hospitals and its optical laboratory for net cash proceeds of $18.7&#160;million, and recognized a net pretax loss of $21.2&#160;million included in loss on disposals and deconsolidations, net in the consolidated statement of operations for the year ended December 31, 2018. The non-cash loss was primarily a result of the write-off of the net assets of the facility (net of proceeds received) and was primarily driven by the write-off of the associated goodwill.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationsAndDisposalsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations And Disposals [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationsAndDisposalsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations And Disposals Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601681800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally 20 to 40 years for buildings <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and building improvements, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzMzNA_0c1bb596-84ab-46e0-9e07-1217a9251edc">three</span> to five years for computers and software and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4MA_b602329f-ae4b-455f-ae04-0f191a8afe79">five</span> to seven years for furniture and equipment.&#160;Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also leases certain facilities and equipment under finance leases. Assets held under finance leases are stated at the present value of lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of property and equipment follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use finance lease asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:  Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense was $90.5 million, $71.9 million and $62.5 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601262264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located, Medicare licenses and certain management rights agreements. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management rights agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2MA_33fd34e1-3ee5-447f-b7a8-7df209baa23f">three</span> to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5Mw_f789f954-9fee-479a-9ce3-41a85047306b">two</span> to five years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the consolidated statements of operations over the estimated lives of the relationships, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNTk_bbc47750-6337-4405-89b2-99010957f9eb">three</span> to ten years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. During 2020, the Company identified three reporting units, which include the following: 1) Surgical Facilities, 2) Ancillary Services, and 3) Alliance, which is a component of the Optical Services operating segment. A detailed evaluation of potential impairment indicators was performed, which specifically considered the volatility observed in the prices of the Company&#8217;s outstanding debt securities and common stock, as well as the decline in surgical case volumes following the emergence of the COVID-19 pandemic, all of which improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company compares the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. To determine the fair value of the reporting units, the Company obtained valuations at the reporting unit level prepared by third-party valuation specialists which typically utilizes a combination of the income and market approaches. The discounted cash flow model is projected based on a year-by-year assessment that considers historical results, estimated market conditions, internal projections, and relevant publicly available statistics. Determining fair value requires the exercise of significant judgment, including assumptions about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows. The significant judgments are typically based upon Level 3 inputs, generally defined as unobservable inputs representing the Company's own assumptions. The cash flows employed in the discounted cash flow analysis are based on the Company's most recent budgets and business plans aligned with provided guidance and, when applicable, various growth rates are assumed for years beyond the current business plan period. Discount rate assumptions are based on an assessment of the risk inherent in the future cash flows of the respective reporting units. The variables within the discount rate, many of which are outside of the Company's control, provide the best estimate of all assumptions applied within the discounted cash flow model. There can be no assurance that operations will achieve the future cash flows reflected in the projections. In determining the fair value under the market approaches, the analysis includes a control premium, which was based on observable market data and a review of selected </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transactions of companies that operate in the Company's sector. While the Company believes that all assumptions utilized in the testing were appropriate, they may not reflect actual outcomes that could occur. Specific factors that could negatively impact the assumptions used include changes to the discount and growth rates and a change in the equity and enterprise premiums being realized in the market. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On the basis of available evidence as of August 31, 2020, the Company identified indicators of impairment related to its Ancillary Services and Alliance reporting units, including the impacts of the COVID-19 pandemic, the closure of its diagnostic laboratory (as discussed in Note 2. "Acquisitions and Disposals") and its strategic decision to sell its optical products purchasing organization. No indicators of impairment were identified for the Company's Surgical Facilities reporting unit. Based on the impairment indicators noted, the Company performed an impairment analysis for the Ancillary Services and Alliance reporting units as of August 31, 2020. As of the September 30, 2020 valuation, carrying value for both the Ancillary Services and Alliance reporting units exceeded the fair value, resulting in non-cash impairment charges of $28.6&#160;million and $4.9&#160;million, respectively. The fair values as of August 31, 2020 were determined using the adjusted book value for the Ancillary Services reporting unit and the discounted cash flow model for the Alliance reporting unit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of October 1, 2020, prior to its annual impairment testing, the Company's three reporting units with allocated goodwill were as follows: 1) Surgical Facilities - $3.3 billion, 2) Ancillary Services - no remaining goodwill after the August 31 impairment discussed above, and 3) Alliance - $4.2 million.&#160;As of the October 1, 2020 valuation, the fair value for the Surgical Facilities reporting unit was substantially in excess of its carrying value, and there were no additional indicators of impairment related to the other reporting units. The fair value of the Surgical Facilities reporting unit as of October 1, 2020 was determined using the income and market approach as discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsequent to the date of our annual impairment test, the Company considered its operating results for the fourth quarter of 2020, macroeconomic, industry and market conditions, and other market indicators including its market capitalization. Based on its evaluation of all such factors, the Company concluded that an event had not occurred or circumstances had not changed that would more likely than not reduce the fair value of its reporting units below their carrying values. On December 31, 2020, the Company disposed of the Alliance reporting unit with the sale of its optical products purchasing organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, as a result of its impairment testing, the Company recorded non-cash impairment charges of $2.5&#160;million related to the Alliance reporting unit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, as a result of its impairment testing, the Company recorded non-cash impairment charges of $60.7&#160;million and $13.7&#160;million related to the Ancillary Services and Alliance reporting units, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the changes in the carrying amount of goodwill follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.232%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,402.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,382.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals and deconsolidations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,468.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,402.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the Company's acquisitions and disposals for the years ended December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2019 is included in Note 2. "Acquisitions and Disposals." </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the components of intangible assets follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management rights agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company acquired a clinic that was previously managed by the Company. As a result of the transaction, the Company determined the management rights agreement related to the acquired clinic no longer provided a future benefit. As such, the Company recorded non-cash impairment charges of $5.4 million, which was included as a component of impairment charges on the accompanying consolidated statement of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $4.3 million, $4.6 million and $4.9 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715600001112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,539.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured revolving credit facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,856.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,792.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,524.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $3.7 million and $4.6 million as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has a credit agreement (the "Credit Agreement") providing for a $1.29&#160;billion senior secured term loan (the "Term Loan"), a $180.0&#160;million senior secured incremental term loan (the "2018 Incremental Term Loan"), a $120.0&#160;million senior secured incremental term loan (the "2020 Incremental Term Loan") and a $120.0 million senior secured revolving credit facility (the "Revolver" and, together with the Term Loan, the 2018 Incremental Term Loan and the 2020 Incremental Term Loan, the &#8220;Senior Secured Credit Facilities"). The Revolver may be utilized for working capital, capital expenditures and general corporate purposes. Subject to certain conditions and requirements set forth in the Credit Agreement, the Company may request one or more additional incremental term loan facilities or one or more increases in the commitments under the Revolver. On March 18, 2020, the Company drew down its available capacity under its Revolver, as a precautionary measure in order to increase liquidity and preserve financial flexibility in light of current uncertainty resulting from the COVID-19 pandemic. During the second quarter, the Company fully repaid the outstanding balance. As of both December 31, 2020 and 2019, the Company had no outstanding borrowing on the Revolver. As of December&#160;31, 2020, the Company's availability on the Revolver was $112.5 million (including outstanding letters of credit of $7.5 million).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Term Loan will mature on August 31, 2024 and the Revolver will mature on August 31, 2022. The Senior Secured Credit Facilities bear interest at a rate per annum equal to (x) LIBOR plus a margin ranging from 3.00% to 3.25% per annum, depending on the Company's first lien net leverage ratio or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate and (iii) one-month LIBOR plus 1.00% per annum (solely with respect to the Term Loan, the alternate base rate shall not be less than 2.00% per annum)) plus a margin ranging from 2.00% to 2.25% per annum. In addition, the Company is required to pay a commitment fee of 0.50% per annum in respect of unused commitments under the Revolver.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Term Loan amortizes in equal quarterly installments of 0.25% of the aggregate original principal amount of the Term Loan. The Term Loan is subject to mandatory prepayments based on excess cash flow for the applicable fiscal year that will depend on the first lien net leverage ratio as of the last day of the applicable fiscal year, as well as upon the occurrence of certain other events, as described in the Credit Agreement. There were no excess cash flow payments required as of December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April 22, 2020, the Company entered into a second incremental term loan amendment, which further amended and supplemented the Credit Agreement to provide for a $120.0&#160;million senior secured incremental term loan. The 2020 Incremental Term Loans were fully drawn on April 22, 2020 and bear interest at a rate per annum equal to (x) LIBOR plus a margin of 8.00% per annum or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.5% per annum above the federal funds effective rate, (iii) one-month LIBOR plus 1.00% per annum and (iv) 2.00% per annum) plus a margin of 7.00% per annum. The 2020 Incremental Term Loans were incurred as a separate tranche of term loans under the Credit Agreement, and are subject to maturity, amortization and mandatory prepayment provisions consistent with the existing terms loans outstanding under the Credit Agreement. Voluntary prepayments of the 2020 Incremental Term Loans are permitted, in whole or in part, with prior notice, without premium or penalty (except LIBOR breakage costs and a make-whole and call premium, as applicable, in the case of certain prepayments or events within a specified period of time after April 22, 2020, as set forth in the second incremental term loan amendment).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to the Revolver, the Company is required to comply with a maximum consolidated total net leverage ratio of 9.50:1.00, which covenant will be tested quarterly on a trailing four quarter basis only if, as of the last day of the applicable fiscal quarter the Revolver is drawn in an aggregate amount greater than 35% of the total commitments under the Revolver. Such financial maintenance covenant is subject to an equity cure. The Credit Agreement includes customary negative covenants restricting or limiting the ability of the Company and its restricted subsidiaries, to, among other things, sell assets, alter its business, engage in mergers, acquisitions and other business combinations, declare dividends or redeem or repurchase equity interests, incur additional indebtedness or guarantees, make loans and investments, incur liens, enter into transactions with affiliates, prepay certain junior debt, and modify or waive certain material agreements and organizational documents, in each case, subject to customary and other agreed upon exceptions. The Credit Agreement also contains customary affirmative covenants and events of default. On April 16, 2020, the Company entered into a third amendment to Credit Agreement governing the Revolver, which amended and supplemented financial covenants applicable to the Revolver. Pursuant to the third amendment, the Company's requirement to comply with a maximum consolidated total net leverage ratio was waived for the remainder of 2020. Additionally, for the first three quarters of 2021, the third amendment provides for an alternative calculation for the maximum consolidated total net leverage ratio where the trailing four quarter basis may be negatively impacted by the impacts of the COVID-19 pandemic. The third amendment became effective concurrently with the funding of the 2020 Incremental Term Loans on April 22, 2020, and are discussed in more detail above. As of December&#160;31, 2020, the Company was in compliance with the covenants contained in the Credit Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities are guaranteed, on a joint and several basis, by SP Holdco I, Inc. and each of Surgery Center Holdings, Inc.'s current and future wholly-owned domestic restricted subsidiaries (subject to certain exceptions) (the "Subsidiary Guarantors") and are secured by a first priority security interest in substantially all of Surgery Center Holdings, Inc.'s, SP Holdco I, Inc.'s and the Subsidiary Guarantors&#8217; assets (subject to certain exceptions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the 2020 Incremental Term Loans borrowings, the Company recorded debt issuance costs and discount of $6.5&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">6.750% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective June 30, 2017, the Company issued $370.0 million in gross proceeds of senior unsecured notes due July 1, 2025 (the "2025 Unsecured Notes"). The 2025 Unsecured Notes bear interest at the rate of 6.750% per year, payable semi-annually on January 1 and July 1 of each year. The 2025 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly-owned restricted subsidiaries that guarantees the Senior Secured Credit Facilities (subject to certain exceptions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2020 to June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2021 to June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2022 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If Surgery Center Holdings, Inc. experiences a change in control under certain circumstances, it must offer to purchase the 2025 Unsecured Notes at a purchase price equal to 101.000% of the principal amount, plus accrued and unpaid interest, if any, up to, but excluding, the date of repurchase.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2025 Unsecured Notes contain customary affirmative and negative covenants, which, among other things, limit the Company&#8217;s ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">10.000% Senior Unsecured Notes due 2027</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective April 11, 2019, the Company issued $430.0 million in an aggregate principal amount of senior unsecured notes due April 15, 2027 (the "2027 Unsecured Notes"). The 2027 Unsecured Notes bear interest at the rate of 10.000% per annum, payable semi-annually on April 15 and October 15 of each year, beginning on October 15, 2019. The 2027 Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly-owned restricted subsidiaries that guarantees the Senior Secured Credit Facilities (subject to certain exceptions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may redeem up to 40% of the aggregate principal amount of the 2027 Unsecured Notes at any time prior to April 15, 2022, with the net cash proceeds of certain equity issuances at a redemption price equal to 110.000% of the principal amount of notes to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may redeem the 2027 Unsecured Notes, in whole or in part, at any time prior to April 15, 2022, at a redemption price equal to 100% of the principal amount of notes to be redeemed plus the applicable premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may redeem the 2027 Unsecured Notes, in whole or in part, at any time on or after April 15, 2022, at the redemption prices set forth below (expressed as a percentage of the principal amount of notes to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2022 to April 14, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2023 to April 14, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2024 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If Surgery Center Holdings, Inc. experiences a change of control under certain circumstances, it must offer to purchase the 2027 Unsecured Notes at a purchase price equal to 101.000% of the aggregate principal amount of notes, plus accrued and unpaid interest, if any, up to, but excluding, the date of repurchase.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The indenture governing the 2027 Unsecured Notes contains customary affirmative and negative covenants, which, among other things, limit the Company&#8217;s ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 30, 2020, the Company completed the issuance and sale of $115.0&#160;million in aggregate principal amount of senior unsecured notes due 2027 at 100.75% of the principal amount. The notes were issued as part of the same series as the existing 2027 Unsecured Notes originally issued in April 2019, and have the same terms. In connection with the notes issuance, the Company recorded debt issuance costs, net of issuance premium of $1.0&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s subsidiaries have outstanding indebtedness under notes payable and other secured loans, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made, and right-of-use finance lease obligations for which the Company is liable to various vendors for several property and equipment leases classified as finance leases.&#160;The various bank indebtedness agreements contain covenants to maintain certain financial ratios and also restrict encumbrance of assets, creation of indebtedness, investing activities and payment of distributions. At December&#160;31, 2020, the Company was in compliance with its covenants contained in the credit agreements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Maturities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of maturities for the Company's long-term debt, excluding unamortized debt issuance costs and the unamortized fair value discount discussed above, for the next five years and thereafter as of December&#160;31, 2020 follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,519.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,876.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599781272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company determines if an arrangement is a lease at inception. Right-of-use assets represent the right to use the underlying assets for the lease term and the lease liabilities represent the obligation to make lease payments arising from the leases. Right-of-use assets and liabilities are recognized at commencement date based on the present value of future lease payments over the lease term, which includes <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">only payments that are fixed and determinable at the time of commencement. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company's incremental borrowing rate is used. The Company calculates its incremental borrowing rate on a periodic basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company applies its incremental borrowing rate using a portfolio approach. The right-of-use asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The Company's finance leases also include certain land, buildings and improvements as discussed in Note 3. "Property and Equipment." Real estate lease agreements typically have initial terms of ten years and may include one or more options to renew. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of the Company's medical equipment leases have a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life. The Company's lease agreements do not contain any material residual value guarantees, restrictions or covenants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company's lease agreements require the Company to pay common area maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Certain lease agreements also include escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. These variable components of lease payments are expensed as incurred and are not included in the determination of the right-of-use asset or lease liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the COVID-19 pandemic, the Company received concessions for certain of its leases primarily consisting of deferral of rental payments. The Company has elected to account for these COVID-19 related concessions as though the enforceable rights and obligations for those concessions are explicit within the underlying contract. The Company accounts for the deferred rentals as a component of other current liabilities within the consolidated balance sheets. In a few instances the Company modified the terms of the lease in exchange for lease concessions. These modifications resulted in an increase to the Company's right-of-use operating lease assets and liabilities of $27.4&#160;million during the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets at December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">573.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the weighted-average lease terms and discount rates at December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weight average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense and their classification in the consolidated statement of operations for the years ended December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company incurred lease costs of $22.8&#160;million and $20.6 million, respectively, under operating lease agreements with physician investors who are related parties. During the years ended December&#160;31, 2020 and 2019, the Company paid rent of $6.9&#160;million and $6.7 million, respectively, under a finance lease agreement with a lessor who is a related party. One of the Company's surgical facilities has a non-controlling ownership interest in the lessor. Payments are allocated to principal adjustments of the finance lease liability and interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for the years ended December&#160;31, 2020 and 2019 (dollars in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company determines if an arrangement is a lease at inception. Right-of-use assets represent the right to use the underlying assets for the lease term and the lease liabilities represent the obligation to make lease payments arising from the leases. Right-of-use assets and liabilities are recognized at commencement date based on the present value of future lease payments over the lease term, which includes <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">only payments that are fixed and determinable at the time of commencement. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company's incremental borrowing rate is used. The Company calculates its incremental borrowing rate on a periodic basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company applies its incremental borrowing rate using a portfolio approach. The right-of-use asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The Company's finance leases also include certain land, buildings and improvements as discussed in Note 3. "Property and Equipment." Real estate lease agreements typically have initial terms of ten years and may include one or more options to renew. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of the Company's medical equipment leases have a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life. The Company's lease agreements do not contain any material residual value guarantees, restrictions or covenants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company's lease agreements require the Company to pay common area maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Certain lease agreements also include escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. These variable components of lease payments are expensed as incurred and are not included in the determination of the right-of-use asset or lease liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the COVID-19 pandemic, the Company received concessions for certain of its leases primarily consisting of deferral of rental payments. The Company has elected to account for these COVID-19 related concessions as though the enforceable rights and obligations for those concessions are explicit within the underlying contract. The Company accounts for the deferred rentals as a component of other current liabilities within the consolidated balance sheets. In a few instances the Company modified the terms of the lease in exchange for lease concessions. These modifications resulted in an increase to the Company's right-of-use operating lease assets and liabilities of $27.4&#160;million during the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets at December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">573.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the weighted-average lease terms and discount rates at December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weight average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense and their classification in the consolidated statement of operations for the years ended December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company incurred lease costs of $22.8&#160;million and $20.6 million, respectively, under operating lease agreements with physician investors who are related parties. During the years ended December&#160;31, 2020 and 2019, the Company paid rent of $6.9&#160;million and $6.7 million, respectively, under a finance lease agreement with a lessor who is a related party. One of the Company's surgical facilities has a non-controlling ownership interest in the lessor. Payments are allocated to principal adjustments of the finance lease liability and interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for the years ended December&#160;31, 2020 and 2019 (dollars in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601319448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RedeemablePreferredStockTextBlock', window );">Redeemable Preferred Stock</a></td>
<td class="text">Redeemable Preferred Stock<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On August 31, 2017, the Company completed the sale issuance of 310,000 shares of the Company's preferred stock, par value $0.01 per share, designated as 10.00% Series A Convertible Perpetual Participating Preferred Stock (the "Series A Preferred Stock") to Bain Capital at a purchase price of $1,000 per share for an aggregate purchase price of $310.0 million (the "Preferred Private Placement").</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accrued value of the Series A Preferred Stock is convertible into shares of common stock at a price per share of common stock equal to $19.00, subject to certain adjustments as provided in the Certificate of Designations, Preferences, Rights and Limitations of the 10.00% Series A Convertible Perpetual Participating Preferred Stock of Surgery Partners, Inc. (the "Series A Certificate of Designation"), at any time at the option of the holder. In addition, the Company may require the conversion of all, but not less than all, of the Series A Preferred Stock pursuant to the terms and conditions of the Series A Certificate of Designation, after the second anniversary of the date of issuance, if the volume weighted average closing price of the Common Stock for any 20 out of 30 consecutive trading days prior to such date, equals or exceeds $42.00 per share. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot redeem the Series A Preferred Stock prior to the fifth anniversary of its issuance and thereafter, may redeem all, but not less than all, of the Series A Preferred Stock for cash pursuant to and subject to the terms and conditions of the Series A Certificate of Designation. The holders of Series A Preferred Stock may cause the Company to redeem the Series A Preferred Stock upon the occurrence of certain change of control transactions of the Company or the common stock ceasing to be listed or quoted on a trading market. The Company adjusts the carrying amount of the Series A Preferred Stock to equal the redemption value at the end of each reporting period as if it were also the redemption date. Changes in the redemption value are recognized immediately as they occur. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Series A Preferred Stock ranks senior to the common stock and any other capital stock of the Company with respect to dividends, redemption and any other rights upon the liquidation, dissolution or winding up of the Company, and the holders thereof are entitled to vote with the holders of common stock, together as a single class, on all matters submitted to a vote of the Company&#8217;s stockholders. In addition to participating in any dividends that may be declared with respect to the common stock on an as-converted basis, each share of Series A Preferred Stock accrues dividends daily at a dividend rate of 10.00%, compounding quarterly, and in any given quarter, subject to certain conditions, the Board of Directors of the Company may declare a cash dividend in an amount up to 50% of the amount of the dividend that has accrued and accumulated during such quarter through the end of such quarter, and the amount of any quarterly dividend paid in cash shall not compound on the applicable date and shall not be included in the accrued value of the Series A Preferred Stock. In the event of the Company&#8217;s liquidation, dissolution or winding-up (whether voluntary of involuntary), holders of Series A Preferred Stock will be entitled to receive out of the assets of the Company available for distribution to shareholders, after satisfaction of any liabilities and obligations to creditors of the Company, with respect to each Series A Preferred Share, an amount equal to the greater of (i) $1,000.00 per share, plus dividends compounded to date, plus dividends accrued but not yet compounded and (ii) the amount that a holder of one share of common stock would receive, assuming the Series A Preferred Stock had converted into shares of common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to the redeemable preferred stock for the years ended December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends accrued (there were no cash dividends declared)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There were no unpaid cash dividends declared at December&#160;31, 2020 and 2019. The aggregate and per share amounts of unpaid cumulative preferred dividends as of December&#160;31, 2020 and 2019 were $109.0 million and $351.54, and $69.5&#160;million and $224.09, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemablePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Preferred Stock [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemablePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599944152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives and Hedging Activities</a></td>
<td class="text">Derivatives and Hedging Activities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. During 2020 and 2019, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#8217;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt. Over the next 12 months, the Company estimates that $21.8 million will be reclassified as an increase to interest expense.  </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company had four interest rate swaps with a current notional amount of $1.2 billion and a termination date of November&#160;30, 2023. The derivatives are recorded at fair value (see Note 1. "Organization and Summary of Accounting Policies") and classified as a long-term liability included in other long-term liabilities in the consolidated balance sheets as of December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps on the Company's accumulated OCI and statement of operations (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss reclassified from accumulated OCI to interest expense (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601015464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The Company computes basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): </span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amounts allocated to participating securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes dividends accrued during all periods for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in each of those periods.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Transactions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 15, 2017, the Company's Board of Directors authorized a share repurchase program of up to $50.0 million of the Company's issued and outstanding common stock from time to time. The timing and size of repurchases will be determined based on market conditions and other factors. The authorization does not obligate the repurchase of any shares and the Company may repurchase shares of common stock at any time without prior notice. The share repurchases will be made in accordance with applicable securities laws in open market or privately negotiated transactions. The authorization does not have a specified expiration date, and the share repurchase program may be suspended, recommenced or discontinued at any time or from time to time without prior notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, the Company repurchased 156,818 shares of its common stock at an average price of $12.64 per share through market purchases. At December 31, 2020, the Company had $46.0 million of repurchase authorization available under the December 2017 authorization.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715596806680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes.&#160;Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160;Any change in tax rates that could impact deferred tax assets or liabilities are recognized in the same period the change occurs. If a net operating loss ("NOL") and/or interest limitation ("163(j)") carryforward exists, the Company makes a determination as to whether that NOL and/or 163(j) carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss and interest limitation carryforwards when their recoverability is deemed to be uncertain.&#160;The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions.&#160;If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2017 or state income tax examinations for years prior to 2016.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made income tax payments of $1.7 million, $1.6 million and $2.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense is comprised of the following (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax (benefit) expense computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 21% (2020, 2019 and 2018) follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax (benefit) expense at U.S.federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of U.S. federal tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in measurement of uncertain tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differences related to divested facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax return reconciling differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Receivable Agreement liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of temporary differences and the approximate tax effects that give rise to the Company&#8217;s net deferred tax asset are as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.968%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical malpractice liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and incentive compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for bad debts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 163(j) interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TRA liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Affiliate indebtedness receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other deferred assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation on property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basis differences of partnerships and joint ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had federal NOL carryforwards of $615.7 million as of December&#160;31, 2020, of which $516.2 million expire between 2026 and 2037. The remaining federal NOL carryforwards, which were generated subsequent to 2017, do not expire. The Company had state NOL carryforwards of $678.9 million as of December&#160;31, 2020, which expire between 2021 and 2040.&#160;The Company had capital loss carryforwards of $6.2 million as of December&#160;31, 2020, which expire between 2021 and 2023. The Company had federal and state credit carryforwards of $0.7 million as of December&#160;31, 2020. The federal credits do not expire, and the state credits expire between 2021 and 2031. The Company had IRC Section 163(j) interest limitation carryforwards of $278.4 million as of December&#160;31, 2020, which do not expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recorded a valuation allowance against deferred tax assets at December&#160;31, 2020 and 2019 totaling $91.1 million and $77.9 million, respectively, which represents an increase of $13.2 million. The valuation allowance continues to be provided for certain deferred tax assets for which the Company believes it is more likely than not that the tax benefits will not be realized, which are primarily Section 163(j) interest carryforwards, certain state NOLs and capital loss carryforwards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has evaluated the realizability of its deferred tax assets based on sources of positive and negative evidence, and determined that it is more likely than not that the NOL carryforwards will be realized. The determination was made based upon projections of future book and taxable income. If the Company's expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in health care regulations, general economic conditions, or other factors, the Company may need to adjust the valuation allowance, for all or a portion of its deferred tax assets. The Company's income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in its valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on the Company's future earnings. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in the increase in the valuation allowance for the year ended December&#160;31, 2020 was an increase of approximately $2.8 million that was recorded to additional-paid-in-capital as the result of the tax effect of the interest rate swap liability. Approximately $16.8 million of the valuation allowance as of December&#160;31, 2020 is recorded against deferred tax assets that, if subsequently recognized, will be credited directly to contributed capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions in its provision for income taxes in the consolidated statements of operations. For both years ended December&#160;31, 2020 and 2019, the Company had approximately $0.1 million each of accrued interest and penalties related to uncertain tax positions. The total amount of accrued liabilities related to uncertain tax positions that would affect the Company's effective tax rate, if recognized, is $0.1 million as of both December&#160;31, 2020 and 2019. The reserves are included in long-term taxes payable in the consolidated balance sheet as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601035256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text">Equity-Based Compensation<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transactions in which the Company receives employee and non-employee services in exchange for the Company&#8217;s equity instruments or liabilities that are based on the fair value of the Company&#8217;s equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. The Company&#8217;s policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Surgery Partners, Inc. 2015 Omnibus Incentive Plan, as amended and restated effective January 1, 2020 ("2015 Omnibus Incentive Plan") from which all equity-based awards will be granted. Under this plan, the Company can grant stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, performance awards, cash awards and other awards convertible into or otherwise based on shares of its common stock. As of December&#160;31, 2020, 8,315,700 shares were authorized to be granted under the 2015 Omnibus Incentive Plan and 5,285,421 were available for future equity grants. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted and Performance Share-Based Awards</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company granted 1,077,367 and 556,450 restricted stock awards ("RSAs") to certain officers, employees and non-employee directors in accordance with the 2015 Omnibus Incentive Plan, respectively. Vesting and payment of these RSAs are generally subject to continuing service of the employee or non-employee director over the ratable vesting periods beginning one year from the date of grant to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNzUvZnJhZzphYTU0NDI0NTIwNzM0NTI4OWMwYmUwNzI4NzU1Y2Q1YS90ZXh0cmVnaW9uOmFhNTQ0MjQ1MjA3MzQ1Mjg5YzBiZTA3Mjg3NTVjZDVhXzE0NjY_cd80199e-a025-45d6-ad9d-4f4ef62346f4">three</span> or five years after the date of grant. The fair values of these RSAs were determined based on the closing price of the Company&#8217;s common stock on the trading date immediately prior to the grant date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, the Company granted 854,367 and 389,972 performance-based restricted stock units ("PSUs") subject to the achievement of a combination of performance conditions, respectively. In addition to the achievement of the performance conditions, these PSUs are generally subject to the continuing service of the employee over the ratable vesting period from the earned date continuing for two years. For these PSUs, the number of shares payable at the end of the performance periods ranges from 0% to 150% of the targeted units based on the Company&#8217;s actual performance and/or market conditions results as compared to the targets. These PSUs are not considered outstanding until earned. During the years ended December&#160;31, 2020 and 2019, 309,692 and 245,301 of the PSUs previously granted were deemed to have been earned, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Performance Share-Based Activity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of non-vested restricted share-based activity for the years ended December&#160;31, 2020, 2019, and 2018 follows:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unvested Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">801,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(272,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(456,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,387,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(552,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,447,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Stock Appreciation Rights</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company granted 2,256,500 and 700,000 stock options during the years ended December&#160;31, 2019 and 2018, respectively. No stock options were granted during the year ended December&#160;31, 2020. Options to purchase shares are granted with an exercise price equal to the fair market value of the Company&#8217;s common stock on the day of grant, based on the closing price of the Company&#8217;s common stock on the trading date immediately prior to the grant date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The stock options granted during the year ended December&#160;31, 2019 are subject to the following performance and vesting criteria: (i) one-third (33.3%) of the award will vest in three equal annual installments on each of the first three anniversaries of December 31, 2019, (ii) one-third (33.3%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $25.00 over a period of thirty (30) consecutive trading days, and (iii) one-third (33.3%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $35.00 over a period of thirty (30) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The stock options granted during the year ended December&#160;31, 2018 are subject to the following performance and vesting criteria: (i) fifty percent (50%) of the stock option awards will vest in five equal annual installments on each of the first five anniversaries of the date of grant, (ii) twenty-five percent (25%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $25.00 over a period of sixty (60) consecutive trading days, and (iii) twenty-five percent (25%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $35.00 over a period of sixty (60) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 16, 2018, the Company cancelled 200,000 stock options and replaced them with 200,000 stock-settled stock appreciation right awards (the "SAR Awards"). These were the only SAR Awards granted as of December&#160;31, 2020. The SAR Awards had a base price equal to the exercise price of the cancelled stock options. Fifty percent (50%) of the SAR Awards will vest in five equal annual installments on each of the first five anniversaries of the date of grant, generally subject to continued employment on each vesting date. Twenty-five percent (25%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $25.00 over a period of sixty (60) consecutive trading days, and twenty-five percent (25%) of the award will vest based on satisfaction of the time condition and the achievement by the Company of an average closing price of a share of Common Stock on the Nasdaq Stock Market of $35.00 over a period of sixty (60) consecutive trading days, in each case, generally subject to continued employment on each vesting date. Forfeitures are recognized as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Option/SAR Valuation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In applying the Monte Carlo simulation model to value both the stock options and SAR Awards, the Company used the following assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642; &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; The risk-free interest rate is used as a component of the fair value of stock options to take into account the time value of money.&#160;For the risk-free interest rate, the Company uses the implied yield on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life, in years, of the options granted. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; Volatility, for the purpose of share-based compensation, is a measurement of the amount that a share price has fluctuated.&#160;Expected volatility involves reviewing historical volatility and determining what, if any, change the share price will have in the future. The Company used historical stock price information of certain peer group companies for a period of time equal to the expected option life period to determine estimated volatility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642; &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Expected life, in years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; A clear distinction is made between the expected life of an option and the contractual term of the option.&#160;The expected life of an option is considered the amount of time, in years, that an option is expected to be outstanding before it is exercised.&#160;Whereas, the contractual term of the stock option is the term an option is valid before it expires. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9642; &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#160; Since issuing dividends will affect the fair value of a stock option, GAAP requires companies to estimate future dividend yields or payments.&#160;The Company has not historically issued dividends and does not intend to issue dividends in the future. As a result, the Company does not apply a dividend yield component to its valuation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the assumptions used by the Company to estimate the fair value of stock options and SAR Awards granted during the years ended December&#160;31, 2019 and 2018. No stock options or SAR Awards were granted during the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60% - 65%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.30% - 2.40%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.50% - 2.90%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.83 - $6.41</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.48 - $9.44</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of options is amortized to expense on a straight-line basis over the options&#8217; vesting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock Option and Stock Appreciation Rights Activity </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of stock option and SAR Award activity for the years ended December&#160;31, 2020, 2019, and 2018 follows: </span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.363%"><tr><td style="width:1.0%"/><td style="width:64.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options/SARs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,256,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,769,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,760,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Of the outstanding stock options, 585,119 were exercisable as of December&#160;31, 2020. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other information pertaining to equity-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December&#160;31, 2020, unrecognized compensation cost related to unvested shares was approximately $20.2 million. Unrecognized compensation cost will be expensed annually based on the number of shares that vest during the year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records equity-based compensation expense to recognize the fair value of the restricted shares that vest and stock options granted. The Company recorded equity-based compensation expense of $13.2 million, $10.2 million and $9.3 million for the years ended December&#160;31, 2020, 2019, and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599920824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Surgery Partners 401(k) Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery Partners 401(k) Plan is a defined contribution plan whereby certain employees who have completed at least one month of service, including at least one hour of service during that period of time, are eligible to participate. Employees may enroll in the plan immediately upon completion of the minimum service requirement. The Surgery Partners 401(k) Plan allows eligible employees to make contributions of varying percentages or flat dollar amounts of their annual compensation, up to the maximum allowable amounts by the Internal Revenue Service ("IRS"). Eligible employees may or may not receive a match by the Company of their contributions. Employer contributions vest incrementally over a period of five years. The Company's contributions were $7.2 million for the year ended December&#160;31, 2020 and $7.6 million for each of the years ended December&#160;31, 2019 and 2018.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715703086456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current Liabilities</a></td>
<td class="text">Other Current Liabilities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.968%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">See Note 14. "Commitments and Contingencies" for further discussion.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601721000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Professional, General and Workers' Compensation Liability Risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. The Company maintains professional, general and workers' compensation liability insurance in excess of self-insured retentions, through third party commercial insurance carriers. Although management believes the coverage is sufficient for the Company's operations, some claims may potentially exceed the scope of coverage in effect. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that are reasonably possible to have a material adverse effect on the Company's business, financial position, results of operations or liquidity. Total professional, general and workers' compensation claim liabilities as of December&#160;31, 2020 and 2019 were $21.4 million and $19.4 million, respectively. Expected insurance recoveries of $10.5 million and $12.1 million as of December&#160;31, 2020 and 2019, respectively, are included as a component of other current assets and other long-term assets in the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Laws and Regulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory sanctions including fines, penalties, and exclusion from the Medicare, Medicaid and other federal health care programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Government Settlement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On April 14, 2020, Logan Laboratories, LLC ("Logan Labs"), a toxicology laboratory based in Tampa, Florida, that provides urine testing services and Tampa Pain Relief Centers, Inc. ("Tampa Pain" and, together with Logan Labs, the "Companies"), a pain management medical practice based in Tampa, Florida, both indirect wholly-owned subsidiaries of the Company, entered into a settlement agreement (the "Settlement Agreement") with the United States of America, acting through the United States Department of Justice (&#8220;DOJ&#8221;) and on behalf of the Office of Inspector General of the Department of Health and Human Services ("OIG"), the Defense Health Agency, acting on behalf of the TRICARE Program, the Office of Personnel Management, as the administrator of the Federal Employees Health Benefits Program, the Office of Workers Compensation Programs of the United States Department of Labor, which administers federal workers compensation claims for federal employees, including the United States Postal Service, and the United States Department of Veterans Affairs (collectively, the "U.S. Parties") and certain other parties to resolve the pending DOJ investigation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the Settlement Agreement, the Companies still owe payment of $30.7&#160;million plus accrued interest on April 1, 2021. The Company previously recorded a litigation-related charge of $46.0&#160;million relating to an anticipated resolution of the DOJ investigation on the consolidated statements of operations for the year ended December 31, 2018. For the year ended December 31, 2020, the Company recorded an additional litigation-related charge of $1.2&#160;million relating to the resolution of the Covered Conduct on the consolidated statement of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Acquired Facilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement laws and regulations, the Stark Law, the Anti-Kickback Statute, the FCA, and similar fraud and abuse laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other health care providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Potential Physician Investor Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 9, 2017, the Company entered into an agreement to amend that certain Income Tax Receivable Agreement, dated September&#160;30, 2015 (as amended, the "TRA"), by and between the Company, and the other parties referred to therein, which amendment became effective on August 31, 2017. Pursuant to the amendment to the TRA, the Company agreed to make payments to H.I.G., the Company's former controlling shareholder, in its capacity as the stockholders representative pursuant to a fixed payment schedule. The amounts payable under the TRA are calculated as the product of (i) an annual base amount and (ii) the maximum corporate federal income tax rate for the applicable year plus three percent. The amounts payable under the TRA are related to the Company&#8217;s projected realized tax savings over the next five years and are not dependent on the Company&#8217;s actual tax savings over such period. The calculation of amounts payable pursuant to the TRA is thus dependent on the maximum corporate federal income tax rate. To the extent that the Company is unable to make payments under the TRA, such payments will be deferred and will accrue interest at a rate of LIBOR plus&#160;500 basis points until paid. If the terms of credit agreements and other debt documents cause the Company to be unable to make payments under the TRA and such terms are not materially more restrictive than those existing as of September 30, 2015, such payments will be deferred and will accrue interest at a rate of LIBOR plus 300 basis points until paid.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assuming the Company's tax rate is 24%, calculated as the maximum corporate federal tax rate plus three percent, throughout the remaining term of the TRA, the Company estimates the total remaining amounts payable under the TRA was approximately $43.2 million and $60.1 million as of December&#160;31, 2020 and 2019, respectively. The carrying value of the liability under the TRA, reflecting a discount, was $37.0 million and $48.7 million as of December&#160;31, 2020 and 2019, respectively. The current portion of the liability was $21.2 million and $16.9 million as of December&#160;31, 2020 and 2019, respectively, and is included as a component of other current liabilities in the </span></div>consolidated balance sheets. The long-term portion is included as a component of other long-term liabilities in the consolidate balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601698920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company operates in&#160;three&#160;major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities, the operation of ancillary services and the operation of optical services. The Surgical Facility Services segment consists of the operation of ASCs and surgical hospitals and includes anesthesia services. The Ancillary Services segment consists of multi-specialty physician practices and a diagnostic laboratory, which was closed during the third quarter of 2020. The Optical Services segment consists of an optical products group purchasing organization, which was sold on December 31, 2020, as discussed in Note 2. "Acquisitions and Disposals." "All other" primarily consists of the Company's corporate general and administrative functions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,793.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,748.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,771.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement and other litigation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent acquisition compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on escrow release </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">For the year ended December 31, 2020, this amount includes transaction and integration costs of $23.2 million, of which $6.6&#160;million were acquisition related costs, and includes start-up costs related to a de novo surgical hospital of $15.0 million. For the year ended December 31, 2019, this amount includes transaction and integration costs of $19.0 million, and includes other acquisition costs and start-up costs related to a de novo surgical hospital of $17.1 million. For the year ended December 31, 2018, this amount includes transaction and integration costs of $31.7 million, and includes other acquisition costs of $2.3 million.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes litigation settlement costs of $1.2 million, $0.2 million and $46.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. This amount further includes other litigation costs of $5.2 million and $4.4 million for the years ended December 31, 2020 and 2019, respectively, with no comparable costs in 2018.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount represents adjustments to revenue in order to apply consistent policies to businesses acquired by Surgery Partners in prior periods.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Included in other income in the consolidated statement of operations for the year ended December 31, 2020, with no comparable gain in 2019 and 2018.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"/><td style="width:72.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,962.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,580.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,413.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,018.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:14pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715692829880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 27, 2021, the Company entered into an underwriting agreement relating to a public offering of 7,500,000 shares (the &#8220;Firm Shares&#8221;) of the Company&#8217;s common stock, $0.01 par value per share, at a price to the public of $30.25 per share. In addition, the Company granted the underwriters an option to purchase up to an additional 1,125,000 shares of common stock at the same price per share as the Firm Shares. On February 1, 2021, the Company completed the public offering pursuant to which the Company sold 8,625,000 shares of common stock, resulting in net proceeds of $249.2&#160;million, net of underwriting discounts and commissions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 27, 2021, the Company entered into an amendment to the credit agreement governing the Revolver, dated as of January 27, 2021 (the &#8220;Amendment&#8221;), which amended and supplemented the credit agreement, dated as of August 31, 2017, to provide for an extension of the maturity date of the Revolver to February 1, 2026 and an increase in the outstanding commitments under the Revolver in an amount equal to $50.0&#160;million. The maturity extension and the additional commitments became operative on February 1, 2021, upon satisfaction by the Borrower of certain conditions precedent set forth in the Amendment, including the closing of the offering of the Firm Shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607336312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of variable interest entities ("VIE") in which the Company is the primary beneficiary under the provisions of Accounting Standards Codification 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company has the power to direct the activities that most significantly impact a variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses from any of these entities should such expected losses occur. At December&#160;31, 2020, the variable interest entities include four surgical facilities and three physician practices.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on inputs classified into the following hierarchy:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These may include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.35pt">Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, depending on the nature of the item being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values under Level 3 calculations.</span></div>The fair values in the table above were based on a Level 2 inputs using quoted prices for identical liabilities in inactive markets. The carrying amounts related to the Company's other long-term debt obligations, including finance lease obligations, approximate their fair values under Level 3 calculations.The fair value of these derivative financial instruments was based on a quoted market price, or a Level 2 input.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's revenues generally relate to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which our obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to receive. The contractual relationships with patients, in most cases, also involve a third-party payor (e.g., Medicare, Medicaid and private insurance organizations, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by or negotiated with the third-party payors. The payment arrangements with third-party payors for the services provided to the related patients typically specify payments at amounts less than the Company's standard charges. The Company continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Patient service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160; This revenue is related to charging facility fees in exchange for providing patient care. The fee charged for health care procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications.&#160;The fee does not normally include professional fees charged by the patient&#8217;s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. </span><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patient service revenues are recognized as performance obligations are satisfied. Performance obligations are based on the nature of services provided. Typically, the Company recognizes revenue at a point in time in which services are rendered and the Company has no obligation to provide further patient services. As the Company primarily performs outpatient procedures, performance obligations are generally satisfied same day and revenue is recognized on the date of service.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines the transaction price based on gross charges for services provided, net of estimated contractual adjustments, discounts from third-party payors. The Company estimates its contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. Changes in estimated contractual adjustments and discounts are recorded in the period of change. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other service revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Optical service revenues consist of handling charges billed to the members of the Company's optical products purchasing organization. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. The Company satisfies the performance obligation and recognizes revenue when the orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company sold its optical products purchasing organization on December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. These agreements typically require the Company to provide recurring management services over a multi-year period which are billed and collected on a monthly basis. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which management services are rendered and billed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash reported within the consolidated statement of cash flows includes $0.3 million of restricted investments, which are reflected in other long-term assets in the consolidated balance sheet at both December&#160;31, 2020 and 2019. These restricted investments represent restricted cash held in accordance with the provisions of a long-term operating lease agreement held as security for performance under the Company's covenants and obligations within the agreement through January 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable from third-party payors are recorded net of estimated implicit price concessions, which are estimated based on the historical trend of the Company's surgical hospitals&#8217; cash collections and contractual write-offs, and for the Company's surgical facilities in general, established fee schedules, relationships with payors and procedure statistics. While changes in estimated reimbursement from </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">third-party payors remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on its financial condition or results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), private insurance organizations, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not considered significant. Amounts are classified outside of self-pay if the Company has an agreement with the third-party payor or has verified a patient&#8217;s coverage prior to services rendered. The Company's policy is to collect co-payments and deductibles prior to providing medical services. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of its surgical facilities to ensure the proper collection and aged category. Collection efforts include direct contact with third-party payors or patients, written correspondence and the use of legal or collection agency assistance, as required.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets, Goodwill and Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets, Goodwill and Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value.&#160;The cash flow projection and fair value represents management&#8217;s best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation.&#160;For discussion on impairment for goodwill and indefinite-lived intangible assets, refer to Note 4. "Goodwill and Intangible Assets."</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelfInsuranceReservePolicyTextBlock', window );">Professional and General and Workers' Compensation Insurance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Professional and General and Workers' Compensation Insurance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional liability insurance coverage is on a claims-made basis and the general liability insurance is on an occurrence basis. The Company also maintains workers' compensation insurance, subject to a self-insured retention.</span></div>The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers' compensation claims which relate to (i)&#160;claims made during the policy period, which are offset by insurance recoveries and (ii)&#160;an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value.&#160;The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio.</span></div>Derivatives and Hedging ActivitiesThe Company&#8217;s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. During 2020 and 2019, such derivatives have been used to hedge the variable cash flows associated with existing variable-rate debt.  For derivatives designated and that qualify as cash flow hedges of interest rate risk, the gain or loss on the derivative is recorded in accumulated other comprehensive income ("OCI") and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings, as documented at hedge inception in accordance with the Company&#8217;s accounting policy election. Amounts reported in accumulated OCI related to derivatives will be reclassified to interest expense as interest payments are made on the Company&#8217;s variable-rate debt.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments in Unconsolidated Affiliates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Unconsolidated Affiliates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless the investments are a result of the Company losing control of a previously controlled entity, but still retaining a non-controlling interest. Transactions that result in the deconsolidation of a previously consolidated entity, are measured at fair value. The fair value measurement utilizes Level 3 inputs, </span></div>which include unobservable data, to measure the fair value of the retained non-controlling interest. The fair value determination is generally based on a combination of multiple valuation methods, which can include discounted cash flow, income approach, or market value approach which incorporates estimates of future earnings and market valuation multiples for certain guideline companies. These investments are included as investments in and advances to affiliates in the accompanying consolidated balance sheets. The Company&#8217;s share of the profits and losses from these investments is reported in income from equity investments in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Non-Controlling Interests</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-Controlling Interests</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-Controlling Interests &#8212; Redeemable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each partnership and limited liability company through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement, respectively.&#160;In certain circumstances, the applicable partnership or operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physician limited partners&#8217; or physician minority members&#8217;, as applicable, ownership if certain adverse regulatory events occur, such as it becoming illegal for the physician(s) to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility.&#160;The non-controlling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">redeemable are reported outside of stockholders' equity in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-04 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future London Interbank Offered Rate ("LIBOR") indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">derivatives consistent with past presentation. The Company continues to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (&#8220;CECL&#8221;) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, which is primarily applicable to accounts receivable for the Company. This ASU was effective for the Company on January 1, 2020. The adoption of this ASU did not have a material impact on its consolidated financial position and results of operations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU 2016-02, "Leases" (the "Lease Accounting Standard"). The Company adopted the Lease Accounting Standard effective January 1, 2019, using a modified retrospective transition approach. The most prominent of the changes resulting from this ASU is the recognition of right-of-use assets and lease liabilities by lessees for those leases classified as operating leases. The Company&#8217;s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. Upon adoption of the Lease Accounting Standard, the Company recorded $294.0&#160;million of operating lease liabilities and right-of-use assets on January 1, 2019. The cumulative effect of the accounting change recognized upon adoption was $6.1&#160;million reflected as an adjustment to retained deficit in our consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and Disposals</a></td>
<td class="text">Acquisitions and Disposals<div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for business combinations in accordance with the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer can be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any non-controlling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Any goodwill recognized is determined as the excess of the fair value of the consideration conveyed plus the fair value of any non-controlling interests in the acquisition over the fair value of the net assets acquired. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquired assets and assumed liabilities typically include, but are not limited to, fixed assets, intangible assets and right-of-use leases. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed. Fair value attributable to non-controlling interests is based on a Level 3 computation using significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of non-controlling interests, primarily from acquisitions of surgical facilities. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. Fair value attributable to the property and equipment acquired is based on Level 3 computations using key inputs such as cost trend data and comparable asset sales. Fair value attributable to the intangible assets acquired is based on Level 3 computations using key inputs such as the Company's internally-prepared financial projections. Fair values assigned to acquired working capital are based on carrying amounts reported by the acquiree at the date of acquisition, which approximate their fair values.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally 20 to 40 years for buildings <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and building improvements, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzMzNA_0c1bb596-84ab-46e0-9e07-1217a9251edc">three</span> to five years for computers and software and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTEvZnJhZzo3OTdkYTk1N2M2YjM0MjllYjYyMmI0YmJlYTdkMjg4YS90ZXh0cmVnaW9uOjc5N2RhOTU3YzZiMzQyOWViNjIyYjRiYmVhN2QyODhhXzM4MA_b602329f-ae4b-455f-ae04-0f191a8afe79">five</span> to seven years for furniture and equipment.&#160;Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also leases certain facilities and equipment under finance leases. Assets held under finance leases are stated at the present value of lease payments at the inception of the related lease. Such assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located, Medicare licenses and certain management rights agreements. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management rights agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the consolidated statements of operations over the commitment period of the contract, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzc2MA_33fd34e1-3ee5-447f-b7a8-7df209baa23f">three</span> to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the consolidated statements of operations over the service lives of the agreements, typically ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzk5Mw_f789f954-9fee-479a-9ce3-41a85047306b">two</span> to five years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the consolidated statements of operations over the estimated lives of the relationships, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNTQvZnJhZzphYzgxMWIxYWFkZmE0MjM3OTIzMjc5YzNjMmVlZjc0Yy90ZXh0cmVnaW9uOmFjODExYjFhYWRmYTQyMzc5MjMyNzljM2MyZWVmNzRjXzEyNTk_bbc47750-6337-4405-89b2-99010957f9eb">three</span> to ten years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company tests its goodwill and indefinite-lived intangible assets for impairment at least annually, as of October 1, or more frequently if certain indicators arise. The Company tests for goodwill impairment at the reporting unit level, which is defined as one level below an operating segment. During 2020, the Company identified three reporting units, which include the following: 1) Surgical Facilities, 2) Ancillary Services, and 3) Alliance, which is a component of the Optical Services operating segment. A detailed evaluation of potential impairment indicators was performed, which specifically considered the volatility observed in the prices of the Company&#8217;s outstanding debt securities and common stock, as well as the decline in surgical case volumes following the emergence of the COVID-19 pandemic, all of which improved in the second half of 2020 as states began to re-open and allow for non-emergent procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company compares the carrying value of the net assets of the reporting unit to the estimated fair value of the reporting unit. To determine the fair value of the reporting units, the Company obtained valuations at the reporting unit level prepared by third-party valuation specialists which typically utilizes a combination of the income and market approaches. The discounted cash flow model is projected based on a year-by-year assessment that considers historical results, estimated market conditions, internal projections, and relevant publicly available statistics. Determining fair value requires the exercise of significant judgment, including assumptions about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows. The significant judgments are typically based upon Level 3 inputs, generally defined as unobservable inputs representing the Company's own assumptions. The cash flows employed in the discounted cash flow analysis are based on the Company's most recent budgets and business plans aligned with provided guidance and, when applicable, various growth rates are assumed for years beyond the current business plan period. Discount rate assumptions are based on an assessment of the risk inherent in the future cash flows of the respective reporting units. The variables within the discount rate, many of which are outside of the Company's control, provide the best estimate of all assumptions applied within the discounted cash flow model. There can be no assurance that operations will achieve the future cash flows reflected in the projections. In determining the fair value under the market approaches, the analysis includes a control premium, which was based on observable market data and a review of selected </span></div>transactions of companies that operate in the Company's sector. While the Company believes that all assumptions utilized in the testing were appropriate, they may not reflect actual outcomes that could occur. Specific factors that could negatively impact the assumptions used include changes to the discount and growth rates and a change in the equity and enterprise premiums being realized in the market.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company determines if an arrangement is a lease at inception. Right-of-use assets represent the right to use the underlying assets for the lease term and the lease liabilities represent the obligation to make lease payments arising from the leases. Right-of-use assets and liabilities are recognized at commencement date based on the present value of future lease payments over the lease term, which includes <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">only payments that are fixed and determinable at the time of commencement. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company's incremental borrowing rate is used. The Company calculates its incremental borrowing rate on a periodic basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company applies its incremental borrowing rate using a portfolio approach. The right-of-use asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's operating leases are primarily for real estate, including medical office buildings, and corporate and other administrative offices. The Company's finance leases are primarily for medical equipment and information technology and telecommunications assets. The Company's finance leases also include certain land, buildings and improvements as discussed in Note 3. "Property and Equipment." Real estate lease agreements typically have initial terms of ten years and may include one or more options to renew. Certain leases also include options to purchase the leased property. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The majority of the Company's medical equipment leases have a bargain purchase option that is reasonably certain of exercise, so these assets are depreciated over their useful life. The Company's lease agreements do not contain any material residual value guarantees, restrictions or covenants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company's lease agreements require the Company to pay common area maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Certain lease agreements also include escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. These variable components of lease payments are expensed as incurred and are not included in the determination of the right-of-use asset or lease liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the COVID-19 pandemic, the Company received concessions for certain of its leases primarily consisting of deferral of rental payments. The Company has elected to account for these COVID-19 related concessions as though the enforceable rights and obligations for those concessions are explicit within the underlying contract. The Company accounts for the deferred rentals as a component of other current liabilities within the consolidated balance sheets. In a few instances the Company modified the terms of the lease in exchange for lease concessions. These modifications resulted in an increase to the Company's right-of-use operating lease assets and liabilities of $27.4&#160;million during the year ended December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per ShareBasic and diluted earnings per share are calculated based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The Company computes basic and diluted earnings per share using the two-class method. The two-class method of computing earnings per share is an earnings allocation method that determines earnings per share for common shares and participating securities according to their participation rights in dividends and undistributed earnings.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes.&#160;Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160;Any change in tax rates that could impact deferred tax assets or liabilities are recognized in the same period the change occurs. If a net operating loss ("NOL") and/or interest limitation ("163(j)") carryforward exists, the Company makes a determination as to whether that NOL and/or 163(j) carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss and interest limitation carryforwards when their recoverability is deemed to be uncertain.&#160;The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions.&#160;If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2017 or state income tax examinations for years prior to 2016.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations also file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text">Equity-Based CompensationTransactions in which the Company receives employee and non-employee services in exchange for the Company&#8217;s equity instruments or liabilities that are based on the fair value of the Company&#8217;s equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. The Company&#8217;s policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReservePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReservePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599704184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the carrying amounts and fair values of the Company's long-term debt follows (in millions):</span></div><div style="margin-bottom:13pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.787%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,539.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,533.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Revenues by Service Type</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of revenues by service type as a percentage of total revenues follows:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical facilities revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary services revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical services revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue Sources for Patient Service Revenues</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patient service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">948.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">701.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-pay</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total patient service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,803.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,737.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other service revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical service revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,771.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Other is comprised of anesthesia service agreements, auto liability, letters of protection and other payor types.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Schedule of Rollforward of Non-Controlling Interests - Redeemable</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of activity related to the non-controlling interests&#8212;redeemable for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:70.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests&#8212;redeemable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and disposal of shares of non-controlling interests, net&#8212;redeemable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions to non-controlling interest &#8212;redeemable holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715597886952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationsAndDisposalsAbstract', window );"><strong>Business Combinations And Disposals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preliminary or final amounts recognized for each major class of assets acquired and liabilities assumed for acquisitions completed during the years ended December 31, 2020 and 2019, including post acquisition date adjustments, are as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate acquisition date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">In connection with the clinic acquisition in 2019, the Company acquired the remaining non-controlling interests in one of its existing consolidated surgical facilities. As such, $6.3 million of the cash consideration for the clinic acquisition was classified as a financing activity and presented in payments related to ownership transactions with non-controlling interest holders in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The assets acquired in 2019 includes the fair value of a non-controlling investment held by the acquired clinic in one of the Company's consolidated surgical facilities of $8.8 million. This investment asset was subsequently eliminated in consolidation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationsAndDisposalsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations And Disposals [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationsAndDisposalsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601249368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of property and equipment follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use finance lease asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:  Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">523.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599860056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of Activity Related to Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the changes in the carrying amount of goodwill follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.232%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,402.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,382.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including post acquisition adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposals and deconsolidations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,468.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,402.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Components of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the components of intangible assets follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management rights agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Components of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of the components of intangible assets follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management rights agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Summary of Scheduled Amortization</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total estimated amortization expense for the next five years and thereafter related to intangible assets follows (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601557592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of long-term debt follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,539.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured revolving credit facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.750% senior unsecured notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.000% senior unsecured notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable and other secured loans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,856.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current maturities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,792.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,524.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes unamortized fair value discount of $3.7 million and $4.6 million as of December&#160;31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionTableTextBlock', window );">Debt Redemption Percentages</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may redeem the 2025 Unsecured Notes, in whole or in part, at any time on or after July 1, 2020, at the redemption prices set forth below (expressed as a percentage of the principal amount to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2020 to June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103.375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2021 to June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2022 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>The Company may redeem the 2027 Unsecured Notes, in whole or in part, at any time on or after April 15, 2022, at the redemption prices set forth below (expressed as a percentage of the principal amount of notes to be redeemed), plus accrued and unpaid interest, if any, up to, but excluding, the date of redemption:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2022 to April 14, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2023 to April 14, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 15, 2024 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Summary of Scheduled Maturities of Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of maturities for the Company's long-term debt, excluding unamortized debt issuance costs and the unamortized fair value discount discussed above, for the next five years and thereafter as of December&#160;31, 2020 follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.149%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,519.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,876.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715596456312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Components of Right-of-use Assets and Liabilities Related to Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's right-of-use assets and liabilities related to leases and their classification in the consolidated balance sheets at December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.634%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification in Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_1cdb6625-e7fb-47d5-9373-2c05401c9ac0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzktMi0xLTEtMzcw_926d8af0-18cb-4eb6-8e40-e6a2191cdd85">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_48c434f4-5583-418a-a379-8fbf0057568a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZGYyZmRmMGNlZTQyZTc5ZmEwMGJiYzQ0ZDRjMjA3L3NlYzplZmRmMmZkZjBjZWU0MmU3OWZhMDBiYmM0NGQ0YzIwN18xNjAvZnJhZzozN2U0YTk0NDZkYmM0NWEzYjU1ZGFhMjVmOThmOWFhMi90YWJsZToxNmFkMTQ2OWM1MDA0YzEyOWVmMzQyYTYxMzJjODY5Yy90YWJsZXJhbmdlOjE2YWQxNDY5YzUwMDRjMTI5ZWYzNDJhNjEzMmM4NjljXzE0LTItMS0xLTM3NQ_cdf1ac19-0ad0-47c1-8093-592f71605e96">Long-term debt, less current maturities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">573.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the weighted-average lease terms and discount rates at December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weight average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense and Cash Flow Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the components of the Company's lease expense and their classification in the consolidated statement of operations for the years ended December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable and short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents supplemental cash flow information for the years ended December&#160;31, 2020 and 2019 (dollars in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash outflows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash outflows from finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Operating Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Finance Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Future maturities of lease liabilities at December&#160;31, 2020 are presented in the following table (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599669912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Activity Related to Redeemable Preferred Stock</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents a summary of activity related to the redeemable preferred stock for the years ended December&#160;31, 2020 and 2019 (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">359.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends accrued (there were no cash dividends declared)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715600011256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock', window );">Schedule of Effect of Interest Rate Swaps</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table presents the pre-tax effect of the interest rate swaps on the Company's accumulated OCI and statement of operations (in millions):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss recognized in OCI (effective portion)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss reclassified from accumulated OCI to interest expense (effective portion)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599963832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Numerator and Denominator of Basic and Diluted EPS</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (dollars in millions, except per share amounts; shares in thousands): </span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Surgery Partners, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amounts allocated to participating securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(238.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding- basic and diluted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Includes dividends accrued during all periods for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in each of those periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599978344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax (Benefit) Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense is comprised of the following (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the provision for income taxes as reported in the consolidated statements of operations and the amount of income tax (benefit) expense computed by multiplying consolidated income (loss) in each year by the U.S. federal statutory rate of 21% (2020, 2019 and 2018) follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax (benefit) expense at U.S.federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax, net of U.S. federal tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in measurement of uncertain tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differences related to divested facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax return reconciling differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Receivable Agreement liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax (benefit) expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of temporary differences and the approximate tax effects that give rise to the Company&#8217;s net deferred tax asset are as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.968%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical malpractice liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and incentive compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for bad debts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 163(j) interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TRA liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Affiliate indebtedness receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other deferred assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation on property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basis differences of partnerships and joint ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text">A reconciliation of the beginning and ending liability for gross unrecognized tax benefits for the years ended December&#160;31, 2020 and 2019 is as follows (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.266%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715684937880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of Restricted and Performance Share-Based Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of non-vested restricted share-based activity for the years ended December&#160;31, 2020, 2019, and 2018 follows:</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unvested Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(210,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">703,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">801,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(272,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(456,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted/Earned</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,387,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(552,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,447,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table sets forth the assumptions used by the Company to estimate the fair value of stock options and SAR Awards granted during the years ended December&#160;31, 2019 and 2018. No stock options or SAR Awards were granted during the year ended December&#160;31, 2020.</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60% - 65%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.30% - 2.40%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.50% - 2.90%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4.83 - $6.41</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.48 - $9.44</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of stock option and SAR Award activity for the years ended December&#160;31, 2020, 2019, and 2018 follows: </span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.363%"><tr><td style="width:1.0%"/><td style="width:64.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options/SARs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,256,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,769,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,760,515&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0</span></td></tr></table></div>(1) Of the outstanding stock options, 585,119 were exercisable as of December&#160;31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608789864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Summary of Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of other current liabilities is as follows (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.968%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.973%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued legal settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due to patients and payors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost report liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">See Note 14. "Commitments and Contingencies" for further discussion.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715685544776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Revenue and Operating Income</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables present financial information for each reportable segment (in millions):</span></div><div style="margin-bottom:14pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,793.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,748.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,860.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,831.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,771.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of Adjusted EBITDA:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction, integration and acquisition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposals and deconsolidations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation settlement and other litigation costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent acquisition compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on escrow release </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax receivable agreement expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">For the year ended December 31, 2020, this amount includes transaction and integration costs of $23.2 million, of which $6.6&#160;million were acquisition related costs, and includes start-up costs related to a de novo surgical hospital of $15.0 million. For the year ended December 31, 2019, this amount includes transaction and integration costs of $19.0 million, and includes other acquisition costs and start-up costs related to a de novo surgical hospital of $17.1 million. For the year ended December 31, 2018, this amount includes transaction and integration costs of $31.7 million, and includes other acquisition costs of $2.3 million.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount includes litigation settlement costs of $1.2 million, $0.2 million and $46.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. This amount further includes other litigation costs of $5.2 million and $4.4 million for the years ended December 31, 2020 and 2019, respectively, with no comparable costs in 2018.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">This amount represents adjustments to revenue in order to apply consistent policies to businesses acquired by Surgery Partners in prior periods.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.34pt">Included in other income in the consolidated statement of operations for the year ended December 31, 2020, with no comparable gain in 2019 and 2018.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Reconciliation of Assets from Segment to Consolidated</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"/><td style="width:72.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.989%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,962.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,580.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optical Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,413.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,018.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Financial Information by Reportable Segment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash purchases of property and equipment:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Facility Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ancillary Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607719288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Organization (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>surgical_facility </div>
<div>state</div>
</th>
<th class="th"><div>Aug. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of States in which entity operates | state</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest', window );">Number of surgical facilities owned, majority interest</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated', window );">Number of surgical facilities owned, consolidated</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember', window );">Facilities, Ambulatory Surgery Centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember', window );">Facilities, Surgical Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NumberOfSurgicalFacilitiesOwned', window );">Number of surgical facilities owned</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=sgry_BainCapitalMember', window );">Bain Capital | Surgery Partners, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of voting interest held</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">65.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwnedConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned, Consolidated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwnedConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Surgical Facilities Owned, Majority Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_FacilitiesAmbulatorySurgeryCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_FacilitiesSurgicalHospitalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sgry_BainCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sgry_BainCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=sgry_SurgeryPartnersIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=sgry_SurgeryPartnersIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608133064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - CARES ACT (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ProceedsFromGovernmentAssistance', window );">Proceeds from grants received</a></td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GrantRevenue', window );">Grant funds</a></td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments', window );">Accelerated payments</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent', window );">Accelerated payments, current portion</a></td>
<td class="nump">95.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredEmployeeRelatedLiabilitiesCurrent', window );">Deferred accrued payroll and benefits</a></td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments, Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Employee-related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ProceedsFromGovernmentAssistance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Government Assistance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ProceedsFromGovernmentAssistance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715609085960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Variable Interest Entities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>surgical_facility</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>physician_practice</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_VariableInterestEntityNumberOfFacilities', window );">Number of facilities included in VIE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 5,413.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,018.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">$ 21.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_VariableInterestEntityNumberOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, Number of Facilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_VariableInterestEntityNumberOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608849704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 11, 2019</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 2,876.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member', window );">Senior secured term loan | Secured Debt | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">1,539.4<span></span>
</td>
<td class="nump">$ 1,434.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member', window );">Senior secured term loan | Secured Debt | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,533.4<span></span>
</td>
<td class="nump">1,434.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member', window );">6.750% senior unsecured notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member', window );">6.750% senior unsecured notes due 2025 | Senior Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 370.0<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member', window );">6.750% senior unsecured notes due 2025 | Senior Notes | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 376.0<span></span>
</td>
<td class="nump">368.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member', window );">10.000% senior unsecured notes due 2027 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member', window );">10.000% senior unsecured notes due 2027 | Senior Notes | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 545.0<span></span>
</td>
<td class="nump">430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member', window );">10.000% senior unsecured notes due 2027 | Senior Notes | Fair Value | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 596.8<span></span>
</td>
<td class="nump">$ 471.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601815000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Interest rate swap agreement</a></td>
<td class="nump">$ 61.0<span></span>
</td>
<td class="nump">$ 50.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608128536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details) - Revenue Source - Revenue<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">98.70%<span></span>
</td>
<td class="nump">98.40%<span></span>
</td>
<td class="nump">98.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">95.30%<span></span>
</td>
<td class="nump">94.10%<span></span>
</td>
<td class="nump">93.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Other service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Optical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationOtherServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_HealthcareOrganizationOtherServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OpticalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OpticalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715603900424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,860.1<span></span>
</td>
<td class="nump">$ 1,831.4<span></span>
</td>
<td class="nump">$ 1,771.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember', window );">Patient service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,836.1<span></span>
</td>
<td class="nump">$ 1,803.1<span></span>
</td>
<td class="nump">$ 1,737.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember', window );">Patient service revenues | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember', window );">Private insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 989.9<span></span>
</td>
<td class="nump">$ 970.5<span></span>
</td>
<td class="nump">$ 948.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember', window );">Private insurance | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">53.90%<span></span>
</td>
<td class="nump">53.80%<span></span>
</td>
<td class="nump">54.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_GovernmentRevenueMember', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 708.5<span></span>
</td>
<td class="nump">$ 701.9<span></span>
</td>
<td class="nump">$ 653.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_GovernmentRevenueMember', window );">Government | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">38.90%<span></span>
</td>
<td class="nump">37.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember', window );">Self-pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 58.5<span></span>
</td>
<td class="nump">$ 46.1<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember', window );">Self-pay | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 79.2<span></span>
</td>
<td class="nump">$ 84.6<span></span>
</td>
<td class="nump">$ 84.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember', window );">Other | Customer | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by service type as a percentage of total revenues</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OpticalServicesMember', window );">Optical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="nump">$ 24.5<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_HealthcareOrganizationPatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_PrivateInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_GovernmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_GovernmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_SelfPayRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherPatientServiceRevenueSourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OpticalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OpticalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgry_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgry_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608397704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted invested assets included in other long-term assets</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601049880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Accounts Receivable (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_OpticalProductsReceivable', window );">Optical products receivable</a></td>
<td class="nump">$ 8.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_OpticalProductsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Optical Products Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_OpticalProductsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599791688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestRollForward', window );"><strong>Non-Controlling Interests - Redeemable [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Non-controlling interest, beginning balance</a></td>
<td class="nump">$ 321.0<span></span>
</td>
<td class="nump">$ 326.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to non-controlling interests&#8212;redeemable</a></td>
<td class="nump">31.7<span></span>
</td>
<td class="nump">39.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests', window );">Acquisition and disposal of shares of non-controlling interests, net&#8212;redeemable</a></td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to non-controlling interest &#8212;redeemable holders</a></td>
<td class="num">(36.5)<span></span>
</td>
<td class="num">(40.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Non-controlling interest, ending balance</a></td>
<td class="nump">$ 306.8<span></span>
</td>
<td class="nump">$ 321.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RedeemableNoncontrollingInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RedeemableNoncontrollingInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608423480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 340.1<span></span>
</td>
<td class="nump">$ 320.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">310.1<span></span>
</td>
<td class="nump">297.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment to retained deficit</a></td>
<td class="nump">882.1<span></span>
</td>
<td class="nump">983.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,098.9<span></span>
</td>
<td class="nump">$ 1,336.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Impact of adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment to retained deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment to retained deficit</a></td>
<td class="num">$ (431.8)<span></span>
</td>
<td class="num">$ (315.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(247.0)<span></span>
</td>
<td class="num">$ (41.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Deficit | Impact of adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Adjustment to retained deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608448360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Acquisitions (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>surgical_facility </div>
<div>physician_practice</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>surgical_facility </div>
<div>physician_practice</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total cash consideration, net of cash acquired</a></td>
<td class="nump">$ 104.6<span></span>
</td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="nump">$ 106.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired', window );">Number of surgical facilities acquired | surgical_facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash investment for purchase of equity investment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityAndPhysicianPracticeMember', window );">Surgical Facility and Physician Practice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total aggregate consideration</a></td>
<td class="nump">120.1<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total cash consideration, net of cash acquired</a></td>
<td class="nump">104.6<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Noncash consideration</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments', window );">Additional cash consideration from working capital settlement payment</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityAndPhysicianPracticeMember', window );">Surgical Facility and Physician Practice | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total aggregate consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesNewMarketMember', window );">Surgical Facilities, Including Surgical Hospital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of business entities acquired | surgical_facility</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember', window );">Surgical Facilities, Existing Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of business entities acquired | surgical_facility</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_PhysicianPracticeMember', window );">Physician Practice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of business entities acquired | physician_practice</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Working Capital Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Number Of Noncontrolling Interests Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityAndPhysicianPracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityAndPhysicianPracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesNewMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesNewMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilitiesExistingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_PhysicianPracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_PhysicianPracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608255576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,468.0<span></span>
</td>
<td class="nump">$ 3,402.4<span></span>
</td>
<td class="nump">$ 3,382.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityAndPhysicianPracticeMember', window );">Surgical Facility and Physician Practice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">120.1<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of non-controlling interests</a></td>
<td class="nump">57.3<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest', window );">Aggregate acquisition date fair value</a></td>
<td class="nump">177.4<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current Assets</a></td>
<td class="nump">24.3<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease assets</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Current liabilities</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="num">(4.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Long-term debt</a></td>
<td class="num">(40.0)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Right-of-use operating lease liabilities</a></td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(28.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Aggregate acquisition date fair value</a></td>
<td class="nump">$ 177.4<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityMember', window );">Surgical Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Fair value of non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityAndPhysicianPracticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityAndPhysicianPracticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgry_SurgicalFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608949336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Disposals - Disposals (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>surgery_center</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>optical_laboratory</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>surgery_center</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>surgical_hospital</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">$ 58.5<span></span>
</td>
<td class="nump">$ 17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupOneMember', window );">Surgery Centers, Certain Assets Related to Anesthesia Business, Certain Imaging ASsets and Optical Products Purchasing Organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed', window );">Number of interests sold | surgery_center</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="nump">$ 58.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax gain (loss)</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupTwoMember', window );">Diagnostic Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax gain (loss)</a></td>
<td class="num">$ (3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupThreeMember', window );">Previously Owned Real Property Associated with Existing Non-Consolidated Surgical Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupFourMember', window );">Surgery Centers, Surgical Hospitals, and Optical Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed', window );">Number of interests sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposals of facilities and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Number Of Interests Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=sgry_DisposalGroupFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607446984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 90.5<span></span>
</td>
<td class="nump">$ 71.9<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_FurnitureAndEquipmentMember', window );">Furniture and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_FurnitureAndEquipmentMember', window );">Furniture and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_FurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_FurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608450728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Right-of-use finance lease asset</a></td>
<td class="nump">$ 298.4<span></span>
</td>
<td class="nump">$ 259.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, at cost</a></td>
<td class="nump">733.9<span></span>
</td>
<td class="nump">634.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(189.3)<span></span>
</td>
<td class="num">(110.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">544.6<span></span>
</td>
<td class="nump">523.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, excluding right-of-use finance lease asset, at cost</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, excluding right-of-use finance lease asset, at cost</a></td>
<td class="nump">109.7<span></span>
</td>
<td class="nump">106.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_FurnitureAndEquipmentMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, excluding right-of-use finance lease asset, at cost</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, excluding right-of-use finance lease asset, at cost</a></td>
<td class="nump">80.8<span></span>
</td>
<td class="nump">59.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, excluding right-of-use finance lease asset, at cost</a></td>
<td class="nump">196.8<span></span>
</td>
<td class="nump">148.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, excluding right-of-use finance lease asset, at cost</a></td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">$ 25.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_FurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_FurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgry_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715685746680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,468,000,000.0<span></span>
</td>
<td class="nump">$ 3,402,400,000<span></span>
</td>
<td class="nump">$ 3,382,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_PhysicianIncomeGuaranteesMember', window );">Physician income guarantees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_PhysicianIncomeGuaranteesMember', window );">Physician income guarantees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_ManagementRightsMember', window );">Management rights agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=sgry_SurgicalFacilityServicesMember', window );">Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=sgry_AncillaryServicesMember', window );">Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=sgry_AllianceMember', window );">Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_PhysicianIncomeGuaranteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_PhysicianIncomeGuaranteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_ManagementRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_ManagementRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=sgry_AllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=sgry_AllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599758776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 3,402.4<span></span>
</td>
<td class="nump">$ 3,382.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions, including post acquisition adjustments</a></td>
<td class="nump">154.7<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations', window );">Disposals and deconsolidations</a></td>
<td class="num">(55.6)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairments</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 3,468.0<span></span>
</td>
<td class="nump">$ 3,402.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Written Off Related To Sale Of Business Unit And Deconsolidations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715598395864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Components of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">$ 44.7<span></span>
</td>
<td class="nump">$ 39.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(16.6)<span></span>
</td>
<td class="num">(11.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">28.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross carrying amount</a></td>
<td class="nump">63.5<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_ManagementRightsMember', window );">Management rights agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">31.1<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(10.1)<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(6.5)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_ManagementRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sgry_ManagementRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715715908584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Future Amortization of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 28.1<span></span>
</td>
<td class="nump">$ 28.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607060168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Summary of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 11, 2019</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">$ 281.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(16.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total debt</a></td>
<td class="nump">2,856.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current maturities</a></td>
<td class="nump">64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt</a></td>
<td class="nump">2,792.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,524.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember', window );">Notes payable and other secured loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">137.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member', window );">Senior secured term loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">1,539.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,434.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized fair value discount</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember', window );">Senior secured revolving credit facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member', window );">6.750% senior unsecured notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member', window );">10.000% senior unsecured notes due 2027 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 545.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sgry_NotesPayableAndSecuredLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715685712824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Senior Secured Credit Facilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt issuance costs and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member', window );">Senior secured term loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original balance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,290,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DebtInstrumentQuarterlyMaturityInstallments', window );">Quarterly installment of original principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember', window );">Senior secured revolving credit facility | Secured Debt | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original balance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Outstanding balance on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DebtInstrumentNetLeverageRatio', window );">Net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DebtInstrumentTotalCommitmentThreshold', window );">Commitment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember', window );">Senior secured revolving credit facility | Secured Debt | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Outstanding balance on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2018IncrementalTermLoanMember', window );">2018 Incremental Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original balance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2020IncrementalLoansMember', window );">2020 incremental term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DebtInstrumentAlternateBaseRateFloor', window );">Alternate base rate, floor</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt issuance costs and discount</a></td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sgry_A2020IncrementalLoansMember', window );">2020 incremental term loans | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original balance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR | 2020 incremental term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Federal Funds Effective Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Federal Funds Effective Swap Rate | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Federal Funds Effective Swap Rate | 2020 incremental term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=sgry_OneMonthLondonInterbankOfferedRateLIBORMember', window );">One Month LIBOR | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=sgry_OneMonthLondonInterbankOfferedRateLIBORMember', window );">One Month LIBOR | 2020 incremental term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate | Senior secured term loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate | 2020 incremental term loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | LIBOR | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Base Rate | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DebtInstrumentMarginInAdditionToBaseRate', window );">Debt instrument, margin in addition to base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | LIBOR | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Base Rate | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DebtInstrumentMarginInAdditionToBaseRate', window );">Debt instrument, margin in addition to base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DebtInstrumentAlternateBaseRateFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Base Rate, Floor</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DebtInstrumentAlternateBaseRateFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DebtInstrumentMarginInAdditionToBaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Margin In Addition To Base Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DebtInstrumentMarginInAdditionToBaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DebtInstrumentNetLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Net Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DebtInstrumentNetLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DebtInstrumentQuarterlyMaturityInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Quarterly Maturity Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DebtInstrumentQuarterlyMaturityInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DebtInstrumentTotalCommitmentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Total Commitment Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DebtInstrumentTotalCommitmentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017TermLoanMaturing2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2018IncrementalTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2018IncrementalTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2020IncrementalLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2020IncrementalLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=sgry_OneMonthLondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=sgry_OneMonthLondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715609635864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - 6.750% Senior Unsecured Notes due 2025 (Details) - Senior Notes - 6.750% senior unsecured notes due 2025 - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original balance of debt</a></td>
<td class="nump">$ 370,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">103.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">101.688%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Redemption Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Redemption Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607734824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - 10.000% Senior Unsecured Notes due 2027 (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 11, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt issuance costs and discount, net of issuance premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face value of debt issued</a></td>
<td class="nump">$ 430,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of debt principal redeemable</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Percentage of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt issuance costs and discount, net of issuance premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price of debt</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Redemption Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price of debt</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Redemption Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price of debt</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Redemption Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price of debt</a></td>
<td class="nump">102.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Redemption Period Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price of debt</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 10.000% senior unsecured notes due 2027 | Redemption Period Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price of debt</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_SeniorUnsecuredNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=sgry_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=sgry_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599878760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Summary of Scheduled Maturities of Debt Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 64.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">57.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">53.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">1,519.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">396.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">785.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 2,876.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715597888168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>option_to_renew</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Initial term of operating leases</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew', window );">Number of options to renew operating leases | option_to_renew</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increase in right-of-use operating lease assets and liabilities</a></td>
<td class="nump">$ 62.1<span></span>
</td>
<td class="nump">$ 56.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 310.1<span></span>
</td>
<td class="nump">$ 297.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization<span></span>
</td>
<td class="text">us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">$ 258.1<span></span>
</td>
<td class="nump">$ 237.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_LeaseRightOfUseAsset', window );">Total leased assets</a></td>
<td class="nump">$ 568.2<span></span>
</td>
<td class="nump">$ 534.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">$ 39.2<span></span>
</td>
<td class="nump">$ 37.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term</a></td>
<td class="nump">300.9<span></span>
</td>
<td class="nump">283.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 340.1<span></span>
</td>
<td class="nump">$ 320.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent<span></span>
</td>
<td class="text">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current</a></td>
<td class="nump">$ 18.9<span></span>
</td>
<td class="nump">$ 15.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:LongTermDebtAndCapitalLeaseObligations<span></span>
</td>
<td class="text">us-gaap:LongTermDebtAndCapitalLeaseObligations<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term</a></td>
<td class="nump">$ 262.3<span></span>
</td>
<td class="nump">$ 237.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">281.2<span></span>
</td>
<td class="nump">253.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 621.3<span></span>
</td>
<td class="nump">$ 573.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, operating leases</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, finance leases</a></td>
<td class="text">15 years 10 months 24 days<span></span>
</td>
<td class="text">16 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, operating leases</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, finance leases</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=sgry_COVID19PandemicMember', window );">COVID-19 Pandemic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increase in right-of-use operating lease assets and liabilities</a></td>
<td class="nump">$ 27.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Extend, Number Of Options To Renew</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=sgry_COVID19PandemicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=sgry_COVID19PandemicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608069704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Expense and Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 74.1<span></span>
</td>
<td class="nump">$ 70.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_FinanceLeaseCost1Abstract', window );"><strong>Finance lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of leased assets</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">22.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">22.2<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_FinanceLeaseCost', window );">Total finance lease costs</a></td>
<td class="nump">48.4<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_VariableAndShortTermLeaseCost', window );">Variable and short-term lease costs</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">139.4<span></span>
</td>
<td class="nump">118.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows from operating leases</a></td>
<td class="nump">68.1<span></span>
</td>
<td class="nump">67.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash outflows from finance leases</a></td>
<td class="nump">20.7<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash outflows from finance leases</a></td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">62.1<span></span>
</td>
<td class="nump">56.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">133.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_FinanceLeaseCost1Abstract', window );"><strong>Finance lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_FinanceLeasePrincipalAndInterestPayments', window );">Rent paid under finance lease agreement, allocated to principal and interest</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 22.8<span></span>
</td>
<td class="nump">$ 20.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_FinanceLeaseCost1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost1 [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_FinanceLeaseCost1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_FinanceLeasePrincipalAndInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Principal And Interest Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_FinanceLeasePrincipalAndInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_VariableAndShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable And Short-Term Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_VariableAndShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608185720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 70.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">66.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">62.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">58.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">219.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">526.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(186.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease obligations</a></td>
<td class="nump">340.1<span></span>
</td>
<td class="nump">$ 320.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">43.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">40.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">32.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">381.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">565.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(284.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease obligations</a></td>
<td class="nump">$ 281.2<span></span>
</td>
<td class="nump">$ 253.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607487192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Preferred Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends declared but unpaid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Cumulative preferred dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,000,000.0<span></span>
</td>
<td class="nump">$ 69,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears', window );">Cumulative preferred dividends (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351.54<span></span>
</td>
<td class="nump">$ 224.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at beginning of period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395,000,000.0<span></span>
</td>
<td class="nump">$ 359,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Dividends accrued (there were no cash dividends declared) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,500,000<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Cash dividends declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at end of period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,500,000<span></span>
</td>
<td class="nump">$ 395,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_TemporaryEquityThresholdTradingDays', window );">Trading days | trading_day</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_TemporaryEquityThresholdConsecutiveTradingDays', window );">Consecutive trading days | trading_day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_TemporaryEquityThresholdSharePrice', window );">Threshold share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 42.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_TemporaryEquityMaximumCashDividendDeclarable', window );">Maximum cash dividend declarable</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Redemption price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 1,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period (shares) | shares</a></td>
<td class="nump">310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share (in USD per share) | $ / shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering | $</a></td>
<td class="nump">$ 310,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_TemporaryEquityMaximumCashDividendDeclarable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Maximum Cash Dividend Declarable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_TemporaryEquityMaximumCashDividendDeclarable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_TemporaryEquityThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_TemporaryEquityThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_TemporaryEquityThresholdSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Threshold Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_TemporaryEquityThresholdSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_TemporaryEquityThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_TemporaryEquityThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAmountOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715609171608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivatives and Hedging Activities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>swap</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>swap</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Amount estimated to be reclassified as a reduction to interest expense over next 12 months</a></td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps held | swap</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Loss recognized in OCI (effective portion)</a></td>
<td class="nump">$ 30.5<span></span>
</td>
<td class="nump">$ 35.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss', window );">Loss recognized in OCI (effective portion)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Loss reclassified from accumulated OCI to interest expense (effective portion)</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion', window );">Loss reclassified from accumulated OCI to interest expense (effective portion)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Current notional amount</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of loss reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608609928">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 15, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Surgery Partners, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (116,100,000)<span></span>
</td>
<td class="num">$ (74,800,000)<span></span>
</td>
<td class="num">$ (205,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued', window );">Less: amounts allocated to participating securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39,500,000)<span></span>
</td>
<td class="num">(35,700,000)<span></span>
</td>
<td class="num">(32,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (155,600,000)<span></span>
</td>
<td class="num">$ (110,500,000)<span></span>
</td>
<td class="num">$ (238,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">48,776,000<span></span>
</td>
<td class="nump">48,280,000<span></span>
</td>
<td class="nump">48,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
<td class="num">$ (4.96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased, average price per share (in USD per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">712,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive (shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">981,000<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The impact of potentially dilutive securities for all periods were not considered because the effect would be anti-dilutive in those periods.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Undistributed Earnings (Loss) Allocated to Participating Securities, Including Dividends Accrued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607633976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">91.1<span></span>
</td>
<td class="nump">77.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">13.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital', window );">Valuation allowance that if recognized, would credit directly to contributed capital</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to uncertain tax positions</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Uncertain tax positions that would impact effective tax rate</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax', window );">Additional-paid-in-capital increase, due to tax effect of disposals of shares of noncontrolling interests</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Capital loss carryforwards</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Capital loss carryforwards</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=sgry_InterestLimitationMember', window );">Interest Limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Capital loss carryforwards</a></td>
<td class="nump">278.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">615.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Subject to expiration</a></td>
<td class="nump">516.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 678.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Controlling Interest, Acquisitions and Disposals of Interests held by Non-Controlling Interest Holders, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance for tax benefit to be credited to shareholders' equity if tax benefit subsequently becomes realizable. Includes, but is not limited to, adjustment to opening balance of retained earnings for change in accounting principle or correction of error, gain (loss) in comprehensive income (loss) but excluded from net income (loss), deductible expenditure for income tax purposes reported as reduction of shareholders' equity, and deductible temporary difference existing at date of quasi-reorganization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=sgry_InterestLimitationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=sgry_InterestLimitationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715692863416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax (Benefit) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(22.2)<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (benefit) expense</a></td>
<td class="num">$ (20.1)<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 26.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715601987720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax (benefit) expense at U.S.federal statutory rate</a></td>
<td class="num">$ (4.0)<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="num">$ (14.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of U.S. federal tax benefit</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Net income attributable to non-controlling interests</a></td>
<td class="num">(24.8)<span></span>
</td>
<td class="num">(25.2)<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther', window );">Changes in measurement of uncertain tax positions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock option compensation</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount', window );">Differences related to divested facilities</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Tax return reconciling differences</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in effective tax rate</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount', window );">Tax Receivable Agreement liability</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount', window );">Litigation settlement</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (benefit) expense</a></td>
<td class="num">$ (20.1)<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 26.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Litigation Settlement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Receivable Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_EffectiveIncomeTaxReconciliationDivestitureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Divestiture, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_EffectiveIncomeTaxReconciliationDivestitureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715602134056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Approx. Tax Effects of Temporary Differences, Deferred Tax Asset and Liability (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies', window );">Medical malpractice liability</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation', window );">Accrued vacation and incentive compensation</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">164.7<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for bad debts</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryforwards</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts', window );">Deferred financing costs</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation', window );">Section 163(j) interest</a></td>
<td class="nump">69.8<span></span>
</td>
<td class="nump">54.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsHedgingTransactions', window );">Interest rate swap liability</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredTaxAssetTaxReceivableAgreement', window );">TRA liability</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredTaxAssetsRightOfUse', window );">Right of use</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">52.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable', window );">Affiliate indebtedness receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other deferred assets</a></td>
<td class="nump">16.4<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">339.8<span></span>
</td>
<td class="nump">299.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(91.1)<span></span>
</td>
<td class="num">(77.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">248.7<span></span>
</td>
<td class="nump">221.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation on property and equipment</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures', window );">Basis differences of partnerships and joint ventures</a></td>
<td class="num">(73.6)<span></span>
</td>
<td class="num">(67.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use</a></td>
<td class="num">(47.5)<span></span>
</td>
<td class="num">(51.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other deferred liabilities</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(123.9)<span></span>
</td>
<td class="num">(122.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 124.8<span></span>
</td>
<td class="nump">$ 98.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredTaxAssetTaxReceivableAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Tax Receivable Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredTaxAssetTaxReceivableAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Affiliate Indebtedness Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredTaxAssetsRightOfUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Right Of Use</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredTaxAssetsRightOfUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Amortization Of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences and Incentive Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Deferred Financing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Interest Limitation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Basis Differences of Partnerships and Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsHedgingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from hedging transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsHedgingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715599745464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at beginning of year</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior year</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at end of year</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715597771528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2018 </div>
<div>installment </div>
<div>trading_day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options and rights granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,256,500<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.2<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted during period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,077,367<span></span>
</td>
<td class="nump">556,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted during period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854,367<span></span>
</td>
<td class="nump">389,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod', window );">Restricted units granted, earned during period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,692<span></span>
</td>
<td class="nump">245,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options and rights granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,256,500<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays', window );">Number of consecutive trading days, threshold | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays', window );">Number of consecutive trading days, threshold | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SAR Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options and rights granted (shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod', window );">Options cancelled (shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SAR Awards | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual installments | installment</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SAR Awards | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays', window );">Number of consecutive trading days, threshold | trading_day</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SAR Awards | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays', window );">Number of consecutive trading days, threshold | trading_day</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod', window );">Payable at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod', window );">Payable at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgry_A2015OmnibusIncentivePlanMember', window );">2015 Omnibus Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized under plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,315,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,285,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payable At End Of Performance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cancelled In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Earned In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgry_A2015OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgry_A2015OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607996488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Restricted and Performance Share-Based Activity (Details) - Restricted and Performance Shares - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Unvested Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning of the period (shares)</a></td>
<td class="nump">775,886<span></span>
</td>
<td class="nump">703,024<span></span>
</td>
<td class="nump">574,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted/Earned (shares)</a></td>
<td class="nump">1,387,059<span></span>
</td>
<td class="nump">801,751<span></span>
</td>
<td class="nump">519,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/Cancelled (shares)</a></td>
<td class="num">(162,635)<span></span>
</td>
<td class="num">(272,706)<span></span>
</td>
<td class="num">(180,719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(552,943)<span></span>
</td>
<td class="num">(456,183)<span></span>
</td>
<td class="num">(210,318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, end of the period (shares)</a></td>
<td class="nump">1,447,367<span></span>
</td>
<td class="nump">775,886<span></span>
</td>
<td class="nump">703,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning of the period (in USD per share)</a></td>
<td class="nump">$ 13.78<span></span>
</td>
<td class="nump">$ 16.18<span></span>
</td>
<td class="nump">$ 15.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted/Earned (in USD per share)</a></td>
<td class="nump">6.87<span></span>
</td>
<td class="nump">12.70<span></span>
</td>
<td class="nump">16.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/Cancelled (in USD per share)</a></td>
<td class="nump">13.77<span></span>
</td>
<td class="nump">12.97<span></span>
</td>
<td class="nump">15.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in USD per share)</a></td>
<td class="nump">12.78<span></span>
</td>
<td class="nump">16.20<span></span>
</td>
<td class="nump">16.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, end of the period (in USD per share)</a></td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="nump">$ 13.78<span></span>
</td>
<td class="nump">$ 16.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sgry_RestrictedStockAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sgry_RestrictedStockAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607288472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Fair Value Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,256,500<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sgry_EmployeeStockOptionsAndStockAppreciationRightsMember', window );">Employee Stock Options and Stock Appreciation Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sgry_EmployeeStockOptionsAndStockAppreciationRightsMember', window );">Employee Stock Options and Stock Appreciation Rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of stock options granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="nump">$ 8.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sgry_EmployeeStockOptionsAndStockAppreciationRightsMember', window );">Employee Stock Options and Stock Appreciation Rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of stock options granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,256,500<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SAR Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sgry_EmployeeStockOptionsAndStockAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sgry_EmployeeStockOptionsAndStockAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608610056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Summary of Options Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options/SARs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (shares)</a></td>
<td class="nump">2,769,187<span></span>
</td>
<td class="nump">512,687<span></span>
</td>
<td class="nump">12,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,256,500<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(4,199)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled (shares)</a></td>
<td class="num">(4,473)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (shares)</a></td>
<td class="nump">2,760,515<span></span>
</td>
<td class="nump">2,769,187<span></span>
</td>
<td class="nump">512,687<span></span>
</td>
<td class="nump">12,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in USD per share)</a></td>
<td class="nump">$ 13.02<span></span>
</td>
<td class="nump">$ 13.03<span></span>
</td>
<td class="nump">$ 20.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00<span></span>
</td>
<td class="nump">12.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">20.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled (in USD per share)</a></td>
<td class="nump">19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in USD per share)</a></td>
<td class="nump">$ 12.88<span></span>
</td>
<td class="nump">$ 13.02<span></span>
</td>
<td class="nump">$ 13.03<span></span>
</td>
<td class="nump">$ 20.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm', window );">Exercised</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm', window );">Forfeited/Cancelled</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding options, exercisable (shares)</a></td>
<td class="nump">585,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Options, Forfeited, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607965224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DefinedContributionPlanVestingPeriod', window );">Vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contribution expense</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DefinedContributionPlanVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DefinedContributionPlanVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608691640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Liabilities - Schedule of Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use operating lease liabilities</a></td>
<td class="nump">$ 39.2<span></span>
</td>
<td class="nump">$ 37.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued legal settlement</a></td>
<td class="nump">32.2<span></span>
</td>
<td class="nump">35.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_TaxReceivableAgreementLiabilityCurrent', window );">Tax receivable agreement liability</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_PayablesToCustomers', window );">Amounts due to patients and payors</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CostReportLiabilitiesCurrent', window );">Cost report liabilities</a></td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">62.1<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 217.0<span></span>
</td>
<td class="nump">$ 191.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CostReportLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Report Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CostReportLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_TaxReceivableAgreementLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_TaxReceivableAgreementLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PayablesToCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to customer by broker-dealer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Rule 15c3-1<br> -Number 240<br> -Section 15c3-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PayablesToCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715607438872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Professional, general and workers' compensation insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.4<span></span>
</td>
<td class="nump">$ 19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EstimatedInsuranceRecoveries', window );">Estimated insurance recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation-related charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm', window );">Projected tax savings period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">Remaining amounts payable under TRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.2<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount', window );">Carrying value of liability, net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">48.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent', window );">Deferred tax liabilities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payment under settlement agreement</a></td>
<td class="nump">$ 30.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate', window );">Interest accrued on payment under Tax Receivable Agreement, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Federal Funds Effective Swap Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_MateriallyMoreRestrictiveMember', window );">Materially More Restrictive | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_NotMateriallyMoreRestrictiveMember', window );">Not Materially More Restrictive | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Tax Agreement, Projected Tax Savings, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Liabilities, Net Of Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Liabilities, Net Of Discount, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimatedInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimatedInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_MateriallyMoreRestrictiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_MateriallyMoreRestrictiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_NotMateriallyMoreRestrictiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=sgry_NotMateriallyMoreRestrictiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715609687944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,860,100,000<span></span>
</td>
<td class="nump">$ 1,831,400,000<span></span>
</td>
<td class="nump">$ 1,771,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="nump">256,600,000<span></span>
</td>
<td class="nump">258,600,000<span></span>
</td>
<td class="nump">234,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Reconciliation of Adjusted EBITDA:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">(Loss) income before income taxes</a></td>
<td class="num">(18,800,000)<span></span>
</td>
<td class="nump">54,600,000<span></span>
</td>
<td class="num">(69,200,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to non-controlling interests</a></td>
<td class="num">(117,400,000)<span></span>
</td>
<td class="num">(119,900,000)<span></span>
</td>
<td class="num">(110,100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">94,800,000<span></span>
</td>
<td class="nump">76,500,000<span></span>
</td>
<td class="nump">67,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">201,800,000<span></span>
</td>
<td class="nump">178,900,000<span></span>
</td>
<td class="nump">147,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">13,200,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts', window );">Transaction, integration and acquisition costs</a></td>
<td class="nump">38,200,000<span></span>
</td>
<td class="nump">36,100,000<span></span>
</td>
<td class="nump">34,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">33,500,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">74,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation', window );">Loss (gain) on disposals and deconsolidations, net</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="num">(4,400,000)<span></span>
</td>
<td class="nump">31,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts', window );">Litigation settlements and other litigation costs</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="nump">46,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Reserve adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationContingentAcquisitionExpense', window );">Contingent acquisition compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_BusinessCombinationGainLossOnAcquisitionEscrow', window );">Gain on escrow release</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_TaxReceivableAgreementExpenseBenefit', window );">Tax receivable agreement expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Transaction and integration costs</a></td>
<td class="nump">23,200,000<span></span>
</td>
<td class="nump">19,000,000.0<span></span>
</td>
<td class="nump">31,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_StartUpActivitiesStartUpCosts', window );">Start-up costs related to de novo surgical hospital</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">46,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Other litigation costs</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="num">(80,700,000)<span></span>
</td>
<td class="num">(74,300,000)<span></span>
</td>
<td class="num">(80,200,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember', window );">Surgical Facility Services | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,793,400,000<span></span>
</td>
<td class="nump">1,748,200,000<span></span>
</td>
<td class="nump">1,682,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="nump">339,300,000<span></span>
</td>
<td class="nump">328,900,000<span></span>
</td>
<td class="nump">309,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember', window );">Ancillary Services | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">63,600,000<span></span>
</td>
<td class="nump">79,400,000<span></span>
</td>
<td class="nump">79,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="num">(3,400,000)<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sgry_OpticalServicesMember', window );">Optical Services | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationContingentAcquisitionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Acquisition Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationContingentAcquisitionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationGainLossOnAcquisitionEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Gain (Loss) On Acquisition Escrow</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationGainLossOnAcquisitionEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Integration Related Costs, And Merger Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Before Interest Taxes Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossOnDispositionOfAssetsAndDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition of Assets And Deconsolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossOnDispositionOfAssetsAndDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Litigation Settlement And Other Litigation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_StartUpActivitiesStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Start-Up Activities, Start-Up Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_StartUpActivitiesStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_TaxReceivableAgreementExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_TaxReceivableAgreementExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_OpticalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_OpticalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715608496216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 5,413.2<span></span>
</td>
<td class="nump">$ 5,018.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash purchases of property and equipment</a></td>
<td class="nump">42.9<span></span>
</td>
<td class="nump">73.6<span></span>
</td>
<td class="nump">$ 39.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Surgical Facility Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,962.4<span></span>
</td>
<td class="nump">4,580.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash purchases of property and equipment</a></td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">65.9<span></span>
</td>
<td class="nump">34.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Ancillary Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">69.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash purchases of property and equipment</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Optical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">All other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">415.8<span></span>
</td>
<td class="nump">351.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Cash purchases of property and equipment</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_SurgicalFacilityServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_AncillaryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sgry_OpticalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sgry_OpticalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140715598201608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>Jan. 27, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price to public (in USD per share)</a></td>
<td class="nump">$ 30.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility | Senior secured revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease', window );">Increase in outstanding commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering</a></td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from stock offering</a></td>
<td class="nump">$ 249,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Firm Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Additional Shares Granted to Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering</a></td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgry_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sgry_A2017SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgry_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgry_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgry_PublicStockOfferingFirmSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgry_PublicStockOfferingFirmSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M?#R:IF(812I5S4%KFUH515L0VR6(IZ:K".:4)LZ;&!R7N<L.Q9VFQ?F+U4%
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MQGDS3D\WP<#O*)3FW*+BW&&[G&E JKIJ0-WE<STRA%UH8)HM^A*IC#S&SD!
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M6]8GINH?2ASM&:*M4$H4]NN!)5IG&H"^OQ-"G7^8![3GUI[^#U!+ P04
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M]>41:V/ZI:VW."36"+3UACZN30H(QAO@=WP5LG[!"3#:2."]_C]02P,$%
M  @ Q(IJ4L&@JG+!"P  /24  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6S-6FUSV[@1_BL8U],Z,XHLR7;LRR69<9*FS?2NS21]^=#I!XB$)%Q(@@%
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M4<;=%\7;/)JG[M$Y'-XX54L+:<5.K*PI#[*8HA)W8FU,OM5%T;<%$<@5' ,
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MBMX>Q"1 VLCMG@[+*L)$\90>NJ+>4Q2-B,98']D/K]\SXO&2(4,#[XJA9P_
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MAP,+K4SRZB=5HVNF5G-R$=YVM'&XRYE)BIE!IGR/*.IKKE01.YP./8>1V]%
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M#Q</^# 6 [<CVC&CN4.7%<K&0;92<!57Z83U", %\.'#(%DF69Y>S^-1(RW
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M/KWH3D]VBEE'B4)??]3=NYB99(P2@OR5!JAGNV-'V1Y&Q4^<+!K1A>\$]4N
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M&4JG:*::NBS-@2&Q?\3D9&X)"4IBK&]W)">=A Q-CQ;Q6 <+\R<BO9QK>O6
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M&YTX'ORAP2XYYUIT1RZ+7=["6<2A9_NE,(,PMWJR(#(5?*[_$4X>+9#H"=6
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M16[;^.97&[2_Z_>V.]?A$P=_D$]'5R&[!B@@NJPJZ5]&"OC!V.5KA3X/D3\
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M>.VID/.$XD@J)U\GT2C<I7&IJ%'Q60%Z*FT1H9)44(]UBP1^P/,?ZN0BXKO
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M]O><_0=']'/-=..:5MGEUU^=YM-7WP5RL[^XZ$]I2UV0(]I&!FXDKR*C_#>
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M2--CC7\!V(L!WE<.I3\LQ,'ZGXK+?P!02P,$%     @ Q(IJ4JAR$Y<Y!@
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M=L*C/,AO]YTEP)+U2-8<OLAB+)\>EC;+AFD23P&^RN;%O,BAN$K?I+"U'%8
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M!TG"-;>ET+8V"#^F"^L,W9*?1R+UNTC]$*G_/\KZCU0PW;<2Z"7H "M;F#B
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M$X0+ L\/. /C(0JK6[.'W#M^-)FVA_8!E23 B?C3%6]AI31LWA1*NRI)^'V
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M DNNOZ,.I)3Z:@A_K&?,F5%M.?1&H8SK9U9(TV2&O;R(KPWU9+(D:[3;\"G
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MPG=:-D%!<PZ=4S$'%L4>.![_3HQ9,=NNRZX[TD3W,61%7Q?DWS$YUV78L2F
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M!95,C5#"GJKR*$+1R+IX/$+22E!.662N)RJ'$ACQJWFUFTYGVX'SG['VY(1
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ME!*CME%K5KB4-09UMQ%]BER'BK"$!497@QP+)C[S7VY.G8 DYD@R,5V8 .>
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M9=]W?C7T9#<+]B"OD:]/1V)&9M+(3EW9-;#>$.&?;%IT:T'1TY';.A@:,ED
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M\.OBJR=?/2R6!;P7GZ=H-=HODJPL%0*5C[*KBR-V;'G0B&J C+N?2*N3RJU
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MHK;KV.+541 U'QF9\L$:2=,^\SIW6279[]<"*FFBA[7;3.R S"@ZI]0#F6Z
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M9IJG7%-QNO;/IYEV>(SYWR5>O\+0 /3/-5*SK9"![CU]]1]02P,$%     @
MQ(IJ4MDX,=&G!   9PH  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
MG59;;]LV%/XK!UZP)4 B2[*=I%D2P$G:+4"[!4VW/0Q[H*4CBRU%NB15U_OU
M^TC)EV1U!NS!%F_G.]^YDI=+8S^YFMG3UT9I=S6HO5]<#(>NJ+D1+C$+UMBI
MC&V$Q]3.AVYA6911J%'#/$U/AXV0>G!]&=<>[/6E:;V2FA\LN;9IA%W=L#++
MJT$V6"^\E_/:AX7A]>5"S/F1_6^+!XO9<(-2RH:UDT:3Y>IJ,,TN;L;A?#SP
MN^2EVQE3L&1FS*<PN2^O!FD@Q(H+'Q $/E_XEI4*0*#QN<<<;%0&P=WQ&OU-
MM!VVS(3C6Z/^D*6OKP;G RJY$JWR[\WR9^[MF02\PB@7_VG9G3T;#ZAHG3=-
M+PP&C=3=5WSM_; C<)[N$<A[@3SR[A1%EG?"B^M+:Y9DPVF@A4$T-4J#G-0A
M*(_>8E="SE]/B\^M=#)XR)'0)=U)MS!.*$>''\1,L3NZ''HH"L>'10]ZTX'F
M>T"SG-X9[6M'KW7)Y5. (1AN:.9KFC?YBXAW7"0TRHXI3_/T!;S1QNQ1Q!OM
MP;MI'5:<HUO3S*06G?W3)_;_.9TY;Y$V?[V@<+Q1.(X*QWL4/J*:RE8QF8K>
M<V'F6O[-)=V7K+VL)(93Y]B#0PB(Q3P$XZT4,ZD0'79AOVV>.[/SW<NJ'RPK
MB=1!S9&Q5&&D2#2FU5!GMUQ0X<2BJ)%>'S$LE(!_0%=TQ,0N,;5#3'3$HKS8
M3:?"- O%'EME:Z6>DZ^95BRL(PYY08@J-S.VF\A&[#S-7AV3U(5JRR"%</A=
M8"J%9Q+E1U0'VH-WQR0L%AP8*#099*[4J!6E HNCBPXYH"+:Z"8EVQAO0G"U
MJ]@&HPZS(SJ@+$^3#-_\+!G3&R$M?1&JC4'31I\42&H+'8&5U)XM.SAF<I:,
MZ!R_Z7QN>1[)/6=;;;&@Y2S ']!HDIS1+VB\SSQ\0;<M2&F_S@D0&@/_@":0
M>[#HR-:OHJ\8$HO@!)JDR2EER3G=:R_T7*)TU[@C['S_W7F>Y3_23\:42[B&
MLLD(VO,1$&,G/C'52>M@ZB*Z!Q8J1K=;8V1!=7X._%\114O*Z/D)/-"L#QSF
M1Y0F.1SQ:D-_-TL.L]-D?$2'XP0'WVZD2YYY+*9)BKTT[+W(YBGB.$J!%<3^
ME_-#U.\U$E7K_I982E_'/"T095D\ 4-6=;D9]M$X%D*OMF41%BV'>S#0W9\N
M0#$ZII3$C+]*%^W#86>4#(1+7)%V+@N4:26*WMP$R8#UHCZF@U,D0Y_? 2?2
M%:Z.&-OT#O6XQY(EBB76=]=Z,!.Q+^@B4(DWI>PS#%>]0RQQ"L078A4K#H:J
M2-0;,DO-UM5RT=63*+KBCX[<YP6JC0+/Z(S.F3O&/WI\.C4P[C88]B:4=1)S
M[$/-_^I(?6#ZGH'4")C5D_(5W^#RA;L&0C6KDF:K*+8![=VV#==.U']P_QFO
M('$0ZJ4/5 +FTNUJC5;$4+AVYE#)6%0KZIMU[_&MFH#QK8MHN'/Y-VSG\8D3
M^*&_=^^ S>KF%37M'@_;X]T3[)V &8B=X@JB:7(V&9#MGC7=Q)M%?$K,C,?#
M) YKO 39A@/8KXSQZTE0L'E;7O\#4$L#!!0    ( ,2*:E(T3:Y4\0(  $,&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;(55VT[C,!#]E5'$ TB0
M.Z6MVDHM%^U*(%6PEX?5/KC)I+5P[& [%/Y^QTZ;+2M@7WR=.>?,.#.9;)5^
M-!M$"R^UD&8:;*QMQE%DB@W6S(2J04DWE=(UL[35Z\@T&EGIG6H1I7$\B&K&
M93";^+.EGDU4:P67N-1@VKIF^G6!0FVG01+L#^[Y>F/=032;-&R-#VB_-TM-
MNZA'*7F-TG E06,U#>;)>)$[>V_P@^/6'*S!1;)2ZM%MOI;3(':"4&!A'0*C
MZ1DO40@'1#*>=IA!3^D<#]=[]!L?.\6R8@8OE?C)2[N9!L, 2JQ8*^R]VG[!
M73SG#J]0PO@1MIUM3HQ%:ZRJ=\ZTK[GL9O:RR\.!PS#^P"'=.:1>=T?D55XQ
MRV83K;:@G36AN84/U7N3."[=HSQ83;><_.QLJ>E]M7T%)DNX?FIY0QFW</R-
MK02:DTEDB<291L4.<-$!IA\ )BG<*6DW!JYEB>5;@(C4]1+3O<1%^BGB%18A
M9,DII'$:?X*7]2%G'B_[3\BGL!2,8GT;^:_YREA-'\OO3ZCRGBKW5/D'5 ]4
M0V4K$%0%[V?ZO01_BNFJ=&P:5N TH#(TJ)\QF,WW5>68FD,F[".KE* 2-'#,
M)7U)0E!1F),Q4'JQ7J'N4TQ#,H);YWP$21(FW13#HN6BY')M/#"OB><9';2!
M)!Z%%S0.P@'<M%IRVVK\AS^-R23-".]2U4UKB=(9&%79+2/K81P.X7Q$PQV6
MO&#BP#<9#>@\R8=A!KYQG*GJK#4(%9=,%@@"J32!&4-]+!T-PQQ2@LJ(2M)S
MMET+H,!)\YJR1HH'WB8<O7V8GO(4F(5"&0L76496@RRG%-R2ZQCF1='6K6 6
M2^H ] H%9Y[@.!D2Z0G-"05[\B&T))5'<)[GE"Z:*2D9O/>Y10>%7:->^_9E
M2%8K;5?C_6G?(>==8_AKWK77.Z;77!I*5$6NI.X\ -VUK&YC5>/;Q$I9:CI^
MN:$NC]H9T'VEE-UO'$'_WYC] 5!+ P04    " #$BFI2ZK:>Z$0$  !+#0
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M3N!62;LT\+LLL7P),"2O>M>2C6M7R4'$&RQ"2., DBB)#N"E?:BIQTOWXE&
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M<VAE970S,2YX;6Q]5$UOVD 0_2LCJX=$JK QT"0(D"!)U1XB121M#U4/RWK
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M4A[(\:UB/YHML4!.\THCW/-[H'-8P -9^01GC^'8GT]28J)@GLH=Z*(%S8^
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MH-NVV4ZLJGVKVBE+C<\/"_K30.T,:'VO2*=NX@*<_UV6_P%02P,$%     @
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MH6X2GRM9!O6)@_+3\8);; 1WN86TE=PX)8S=R#)P[:-&B=@M)F-) "6F6'N
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M<;!7MT U1;FDR$-=Z2<;0AC,:UU=UQ:!IM\PQ]4*!%+SOP&_@,XPSOWC)N[
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MNQIGM'THBH*6UA9[%.DCJ3@I^N.[I&39N4AJ@(-?+%'DS,X.R?5.]TI_,3F
M)<^%D&86Y-;NKL/0I#D4S S4#B3.;)0NF,6AWH9FIX%E'E2(,(ZB<5@P+H/Y
MU'];ZOE4E59P"4M-3%D43+_<@E#[64"#PX?/?)M;]R&<3W=L"RNPO^Z6&D=A
MPY+Q J3A2A(-FUEP0Z\7=.0 ?L5O'/;FY)VX5-9*?7&#QVP61$X1"$BMHV#X
M>((%".&84,?7FC1H8CK@Z?N!_=XGC\FLF8&%$K_SS.:SX#(@&6Q8*>QGM7^
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MFQ+_FF/?"-HMP/F-4O8P<)U)TXG._P-02P,$%     @ Q(IJ4@B2,-[W @
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M^;[SG4N..]IR\20W  J]I)3)L;-1*KMP71EM(,6RPS-@^B3A(L5*;\7:E9D
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MD#N6F-@_TH1E3-?;HD_N:4T^[4%N'#6E(>I/\ Y;T]$@OJQX%W#XK72EY%W
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M PT7Y0VAG"B>%R?:&Z[T^;@8KO6M"@MCH-\O.5?W$W-(KN]ID_]02P,$%
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M G.K C=)PDF"):E2J79F7"[L&MWZX,]-F\]FY[&^,JG\B3/KAPR]MFY[O[(
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MU.I;?U'Y]),OC$S]/' OC9TN_./:3HR@W '[?BFE>5VX .4,.OD+4$L#!!0
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M7:K,.:2EP[89\T,2] 14*D]P4>BVJ_"_D$X?.TB/=C;&Z 2T1TZ*(_SMB>_
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M#2LK6-OZXDW6#4]L6R3)S2)+<O++=,J+&T7D8<7FY'XKN\TH +@@;$5QX%:
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MJLBH]*OQDL>A';H'/R5[F0"'(S@\!_:GP+TJ.0!'B7V"%8VLZ!PKF&)%QZS
M#J=9\<B*S['"*59\Q/(B+[.3:5HRTI)SM&B*EAS1@BP^!4M'6/HA[+$&U3DK
M"7P*F1XADS2RHVED-B*SCY%,8CI%RX[.IY\FL9W^AW,.>HMNTTO,MT2]\Q0J
M)73M1#GPOO7U$\EVIMULF%3-RPQK];4 K@/4?L68?)_H#C9^?_*_4$L#!!0
M   ( ,6*:E)*8Y(MR@4  -<9   9    >&PO=V]R:W-H965T<R]S:&5E=#8S
M+GAM;,U9;6_:.A3^*Q;:E3:I0.+P6E$DH)MNI6Y%Z[I]F*XF0PQ82VQF.V6=
M[H^_MA,P$,<PW?;J?FF3X'/\G-?GQ!EL&/\N5AA+\#--J+BJK:1<7S:;8K["
M*1(-ML94_;)@/$52W?)E4ZPY1K$12I,F#().,T6$UH8#\VS*AP.6R810/.5
M9&F*^-,8)VQS50MKVP<?R7(E]8/F<+!&2WR/Y<-ZRM5=<Z<E)BFF@C *.%Y<
MU4;AY20R F;%9X(W8N\::%-FC'W7-S?Q52W0B'""YU*K0.K?(Y[@)-&:%(X?
MA=+:;D\MN'^]U?[.&*^,F2&!)RSY0F*YNJKU:B#&"Y0E\B/;_(D+@]I:WYPE
MPOP%FV)M4 /S3$B6%L(*04IH_A_]+!QQC@ L!."Y E$A$!E#<V3&K&LDT7#
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M/!R7 \4+>[Z<<Z5/J_9RH_]0$&$6Z/LKSM7;P!Q9Z[\HT[]02P,$%     @
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M(E@?(R.@?]]QKEYNS .9ZHG=XE]02P,$%     @ Q8IJ4M*4M!-A P  F0H
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M,D_4L+D2WWALUY>=<0?%;$DS83^KS:^L(#1P\2(EC/^+-H5MV$%19JQ*"F=
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ML UST^GY.!;#&B;<.Y3 40EC]*,)1'9-+>)+T/=(K23_A\5G(..9B!% !J%
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M.O^^D-]8E?H3]Y.R<'[WEVM&8Z:= ;Q?*F6W-VZ \BO/[%]02P,$%     @
MQ8IJ4FK(\';6 @  X@@  !D   !X;"]W;W)K<VAE971S+W-H965T-S N>&UL
MG5;;;N(P%/P5*]J'5MKFSB45(!72:OM0J2KM[K-)#F#5L5G;%/;OUW9"FI*
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M8^FP9@<,L\/O:;#@,8J6LE#"5&Z_*HU](M>R<ML880/V[U5!@PAM+@!<V1[
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M4UU=$-782N$N](Y]__D"T'!)!]*.4HV8M'<[VK8&':UH=P%HJ*0P5.I5Z"@
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MC;F5"+!B>RJ;,V3WMKOYW)OS?N_]7-^(S"G]Y*:Y3GW%7/4D 2JR5BY]1>0
MWMQ0FH%D.W-F?V52W0#,XU;=Z@C7 O7[FC'Y-M ?Z.Z)L]]02P,$%     @
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MH3\E![JYG)L)JK*^W[8*Z;:LAP?ZH %M#>C]3BE\G-@KL_M$6OT%4$L#!!0
M   ( ,6*:E+,8?N[@ 0  %X1   9    >&PO=V]R:W-H965T<R]S:&5E=#@P
M+GAM;+5878_B-A3]*Q;:JKO2+(E#8&#%(,W ;#O23'?$[+8/51],N("[3DQM
M X/4']]K)Y,P$,RH+2^0F/MQ[KG.N0[]C53?]0+ D.=49/JJL3!F^2D(=+*
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M>)>[*,)F>P]JC5'4I/50VR74MA?J/3=%3S\J$ YSLF!J7DMH^Y"K9K0'LGT
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MK8C\6Z #$JZ/,'A)!.;;H< , &*0SGCK#7/-VKEY4R^42ULULGLONWFZ^37
MA7D'OO/\,CS)NG?Z-DSW$X/W5 ET(U#%[E7(X$VBRFC;O;7O;B1?FO?8,RXE
MK\WE@M&"M1J@/K_G7*YO]!=L?CMQ_@]02P,$%     @ Q8IJ4OMNZV;4 P
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MTXZ^3-0$BWEAH-[O&9/GFV*!>B9>_@=02P,$%     @ Q8IJ4F:)0ZN$ P
M.PT  !D   !X;"]W;W)K<VAE971S+W-H965T.#,N>&ULM5=-CZ,X$/TK%MI#
MCS0;, GY&"61II/NW1[M1ZNCWCVL]N! );':V(QMDAEI?_R6@09F.F&20W(@
M&-=[5+TR#S,]*/UB=@"6?$F%-#-O9VWVP?=-O(.4F9[*0.+,1NF461SJK6\R
M#2PI0*GPPR 8^BGCTIM/BVN/>CY5N15<PJ,F)D]3IK_>@E"'F4>]UPM/?+NS
M[H(_GV9L"RNPS]FCQI%?LR0\!6FXDD3#9N9]I!_NPL !BHB_.!Q,ZYRX4M9*
MO;C!0S+S I<1"(BMHV#XMX<%".&8,(_/%:E7W],!V^>O[/=%\5C,FAE8*/$W
M3^QNYHT]DL"&Y<(^J<.O4!44.;Y8"5,<R:&*#3P2Y\:JM )C!BF7Y3_[4@G1
M M#!"4!8 <+O =$)0+\"],^]PZ "#,X%1!6@*-TO:R^$6S++YE.M#D2[:&1S
M)X7Z!1KUXM(ME)75.,L19^>K?&W@<P[2DKL]'@VY68)E7)AWY&?RO%J2FY_>
M37V+MW( /ZYH;TO:\ 3M/:Q[)*#O21B$] A\T0W_Q&2/A*.3\&4W? EQC_3+
MNP='X'=GP^GD6[B/\M8:A[7&8<'7/U-C\L]O&$$>+*3FWP[^?LW?+_@')_@7
M*DWQF<.U$K^\)QG39,]$#N2&RZ*#&: S[)B&8XU<EMR3@MO9RGX>] (4?=\6
M[ =!WZ0]J-,>=*;]O2P=2D0U9705I8<U__!Z2M\.+Q!Q5&<TZA:1"2"9YC$0
MJTB6KP6/STQG]":=?M +H^/YC.M\QA<UE?Q'GF"OQ)[++5EH2+@E]RSF@MNO
M.+<"R14F"7&.<_CF>0V-R]!-%=K1NTF=V>0J:X,&C94&G;4_2,P:7UH$Y<=W
MLK%,)D4MN&JX39V['K7"DG7<:D04E+_CO: M<Z>7=N.Q7")_;C:@,;FNPAM_
MH]<Q.-HX'.VVN)5;Q888)9)"W:/95R^FDFG8DG,\#*/3:C9^1;L-ZP_<MV5:
MQ0")(1NMTM((NK,9O&EN.)B$7=UMS(Y&EW;WGNN4E&)UZ=[X'1U>I[.-?]$?
M&-@%G1V]Z>PHZE*R,2UZL6M]3-!_<"O+1*4G^44S:=&DT&>?90+ZH+D%W:ES
MXTWT.N84-N84=IO3!3I73&V=*3WV!/FM?:?[K/B=Z2V7A@C8(#+HC7#]ZG*G
M7@ZLRHJMZ%I9W-@6ISO\N@'M G!^HY1]';C=;?V]-/\?4$L#!!0    ( ,6*
M:E*@#]Q70P(  %H+   -    >&PO<W1Y;&5S+GAM;-5676O;,!3]*T(9HX51
MQTF;TM4V;(7"8!N%YF%O1;&O;8$^/%G.DO[Z299B.VFSA3YLR4MT[[FZYQY]
M.%=1K=<,'DL C5:<B3K&I=;5QR"HTQ(XJ2]D!<)$<JDXT<9515!7"DA6VR3.
M@LEX/ LXH0(GD6CX/=<U2F4C=(PO.PBYX4L6XW!VB9&CNY,9Q/CI[/W/1NK;
M=\B-HP^CT?AB_'1^NQLY\Z%S'+Q*?+5-W!/]+7%V@**]>O:17A^TS#^MTU$'
M?E>3*)>BW]PI=H"I33B@)6$QOB.,+A2U63GAE*T=/+% *IE42)M3-6)"B]3/
M+APZSQZXY^%42-76=A7<[\)/WPEL/"N0,M8)G& ')%%%M 8E[HW33F[!%R'D
M[?FZ,@H+1=;AY KW">U@BBRDRD!U94*\@9*(06[E*%J4=M2R"FQ0:\F-D5%2
M2$%:#9L,;QC:%!A[M%_#CWR+>Y4/3G5LSU1TIA'D34?C',L_9'/<0]JW\:**
M+J7^W)CEB-:WEP4>%.1TU?JKO!.PCSW<STZJBJT_,5H(#F[Q!Q=,(K+)0Z54
M]-E4LU<E-0 HC):@-$V'R"]%JCFL].8ZK?+]FB<GJ/G?[G,! A1A0]'F[A_S
M+K]9L6\?_T-S^[>RJ_A5D=/KX]?HV^6QBYR=@L@3..[IS5%J#'QK'/3?K>[;
MH<B^<F+\W;ZH6%\4+1K*-!7>*VF6@7C1A V])@OST-WB-_,SR$G#]+P+QKBW
MOT%&&W[3S7JP&^%G]?97N[QPUA;L7]/);U!+ P04    " #%BFI2EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( ,6*
M:E);034$&08  ,DV   /    >&PO=V]R:V)O;VLN>&ULQ9M;;^(X%(#_2H2T
M4O>A!7)EJG:D3NG,5.INJU+-:V42 ]8D=L9V>IE?O[81G1,*1_MRRA/D0OAR
M@OT='YNS9Z5_SI7Z&;TTM33G@Y6U[>EP:,H5;Y@Y42V7[LA"Z899MZF70]-J
MSBJSXMPV]3 >C?)APX0<?#[;7.M.#^&&LKRT0DFWT^_X(?BS^7/<;T9/PHBY
MJ(5]/1^$]S4?1(V0HA&_>74^& TBLU+/WY46OY6TK)Z56M7U^6"\/O"#:RO*
M=[MG'O*!S4W88]G\GCF0\T$^<A=<"&UL."-<GSG&)^Y.7F]U5GT5M>5ZRBS_
MIE77"KGTEW%W,02W$>*P>5T'\53_GS"JQ4*4?*K*KN'2KN.H>>T!I5F)U@PB
MR1I^/KA43US[^W%?<%VM[\TZ*! I?2K< 7U=!3Q*%&E4+2KW[57TA=5,ECP*
M(30 ,$8 XX,!1D=W#$ F"&3R@9 S#^$_8"*UB&[;WJ-.$<CT8)"7JFD!9(9
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MT=7UI=MW*V\4JS;_Q-K\B^SS?U!+ P04    " #%BFI2-$X[?7H"    ,0
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M7U!+ 0(4 Q0    ( ,2*:E('04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ Q(IJ4K2UC:WM    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ Q(IJ4IE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #$BFI2BRI$3ST&  !H&0  &
M        @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ Q(IJ4B!FW(4&!P  M1P  !@              ("!?PX  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,2*:E(<A1;S30,  ,4,   8
M              " @;L5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " #$BFI2D=VPJ. '  "U(   &               @($^&0  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ Q(IJ4AP[&U4] P
MP D  !@              ("!5"$  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( ,2*:E)C"Q+>2P<  !0D   8              " @<<D
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #$BFI21(I'
MJKT(  ##)@  &               @(%(+   >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ Q(IJ4K)TJ>&A*0  5H4  !@
M ("!.S4  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,2*
M:E+!H*IRP0L  #TE   8              " @1)?  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " #$BFI2GBAQ1_4#  #."   &0
M        @($):P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( ,2*:E*\L[WM4@T  !DF   9              " @35O  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ Q(IJ4O2*<-VT$   O3<
M !D              ("!OGP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " #$BFI2=!7S0YX+  " /   &0              @(&IC0
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,2*:E)ZR^D
M'P@  +\5   9              " @7Z9  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ Q(IJ4BB1#)0W!0  8 P  !D
M ("!U*$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #$
MBFI2J'(3ESD&   C#P  &0              @(%"IP  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,2*:E*%9'('] P  &(E   9
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M970R,2YX;6Q02P$"% ,4    " #$BFI25RN-B(D'  !W$P  &0
M    @(%=W@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M ,2*:E+;YTHS$@0  (\)   9              " @1WF  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ Q(IJ4LE:M,OW*@  1)(  !D
M             ("!9NH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " #$BFI22$K(Q>$%  !;#P  &0              @(&4%0$ >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,2*:E+9.#'1IP0
M &<*   9              " @:P; 0!X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ Q(IJ4C1-KE3Q @  0P8  !D              ("!
MBB ! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #$BFI2
MZK:>Z$0$  !+#0  &0              @(&R(P$ >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,2*:E*D6.WAX@0  (D+   9
M      " @2TH 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ Q(IJ4F0/M([(!0  8Q(  !D              ("!1BT! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #$BFI2>8;@R;4"  #<!0
M&0              @(%%,P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( ,2*:E*5O^YXZP(  #@&   9              " @3$V 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ Q(IJ4F4DH@P/
M!   QP@  !D              ("!4SD! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " #$BFI2:/)4A_P&  "7$0  &0
M@(&9/0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,2*
M:E*OJO=&! 4  .<,   9              " @<Q$ 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ Q(IJ4HOW#*'X @  0P8  !D
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M=#0P+GAM;%!+ 0(4 Q0    ( ,2*:E*%T&V7+00  /\3   9
M  " @<Q= 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
MQ(IJ4C==4NT^ @  W00  !D              ("!,&(! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " #%BFI2%!AE^)X#  #=$0  &0
M            @(&E9 $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( ,6*:E*^<:L?^P0  $\:   9              " @7IH 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ Q8IJ4NT3W?I- @
M!04  !D              ("!K&T! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " #%BFI2BM#8LAP"   U!   &0              @($P
M< $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,6*:E*O
MP5/0'0,  ,$(   9              " @8-R 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ Q8IJ4C_>E5=_ P  LPT  !D
M     ("!UW4! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,6*:E*C\\\>RP,  '@0   9              "
M@4^+ 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ Q8IJ
M4GT!B+.=!   JQ<  !D              ("!48\! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " #%BFI2O K<6? "  #P!P  &0
M        @($EE $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( ,6*:E)S5LJK@0,  !0.   9              " @4R7 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ Q8IJ4G945C9W @  *@<
M !D              ("!!)L! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " #%BFI2$R,:$WT$  "2$@  &0              @(&RG0$
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,6*:E)FT<U]
M& 8  ' C   9              " @6:B 0!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ Q8IJ4F&L+4CU @  M H  !D
M ("!M:@! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #%
MBFI2]B8H7>T#    $P  &0              @('AJP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ,6*:E)$[O<#<P(  (L&   9
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M970V-BYX;6Q02P$"% ,4    " #%BFI2TI2T$V$#  "9"@  &0
M    @('RQ0$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M ,6*:E*,)\>Z P4  %T2   9              " @8K) 0!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ Q8IJ4A"IO7F\!   \1$  !D
M             ("!Q,X! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " #%BFI2:LCP=M8"  #B"   &0              @(&WTP$ >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ,6*:E+O:*ZLJP0
M (\0   9              " @<36 0!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ Q8IJ4IO,N,01!0  +Q,  !D              ("!
MIML! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #%BFI2
MA*:; K@"  #^!@  &0              @('NX $ >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( ,6*:E+=N)=)ZP8  !HI   9
M      " @=WC 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ Q8IJ4NW /SOM P  ,PX  !D              ("!_^H! 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #%BFI2#1I7OC0$   /$P
M&0              @($C[P$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    ( ,6*:E+\W3IF8 0  'T2   9              " @8[S 0!X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ Q8IJ4O_HTP5J
M @  ,08  !D              ("!)?@! 'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    " #%BFI2(_TO0AL#   N"0  &0
M@('&^@$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( ,6*
M:E+,8?N[@ 0  %X1   9              " @1C^ 0!X;"]W;W)K<VAE971S
M+W-H965T.# N>&UL4$L! A0#%     @ Q8IJ4IU0$<SV!@  1R$  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #%BFI2EXJ[',     3 @  "P
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52P4&     %L 6P#T&   9B "

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>314</ContextCount>
  <ElementCount>568</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>108</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</Role>
      <ShortName>Organization and Summary of Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2115102 - Disclosure - Acquisitions and Disposals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposals</Role>
      <ShortName>Acquisitions and Disposals</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2120103 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2124104 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2130105 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2137106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2142107 - Disclosure - Redeemable Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/RedeemablePreferredStock</Role>
      <ShortName>Redeemable Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2145108 - Disclosure - Derivatives and Hedging Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivities</Role>
      <ShortName>Derivatives and Hedging Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2148109 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2151110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2158111 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2164112 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2166113 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2169114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2171115 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2175116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2316302 - Disclosure - Acquisitions and Disposals (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables</Role>
      <ShortName>Acquisitions and Disposals (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/AcquisitionsandDisposals</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2321303 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/PropertyandEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/LongTermDebt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2338306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2343307 - Disclosure - Redeemable Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/RedeemablePreferredStockTables</Role>
      <ShortName>Redeemable Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/RedeemablePreferredStock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2346308 - Disclosure - Derivatives and Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables</Role>
      <ShortName>Derivatives and Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/DerivativesandHedgingActivities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2349309 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/EarningsPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2352310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2359311 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/EquityBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2367312 - Disclosure - Other Current Liabilities - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>Other Current Liabilities - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2372313 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/SegmentReporting</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Organization and Summary of Accounting Policies - CARES ACT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - CARES ACT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Organization and Summary of Accounting Policies - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411408 - Disclosure - Organization and Summary of Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2412409 - Disclosure - Organization and Summary of Accounting Policies - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413410 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414411 - Disclosure - Organization and Summary of Accounting Policies - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails</Role>
      <ShortName>Organization and Summary of Accounting Policies - Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2417412 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails</Role>
      <ShortName>Acquisitions and Disposals - Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418413 - Disclosure - Acquisitions and Disposals - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions and Disposals - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2419414 - Disclosure - Acquisitions and Disposals - Disposals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails</Role>
      <ShortName>Acquisitions and Disposals - Disposals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2422415 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2423416 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2426417 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2427418 - Disclosure - Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2428419 - Disclosure - Goodwill and Intangible Assets - Summary of Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2429420 - Disclosure - Goodwill and Intangible Assets - Future Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Future Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2432421 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Summary of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2433422 - Disclosure - Long-Term Debt - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>Long-Term Debt - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2434423 - Disclosure - Long-Term Debt - 6.750% Senior Unsecured Notes due 2025 (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details</Role>
      <ShortName>Long-Term Debt - 6.750% Senior Unsecured Notes due 2025 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2435424 - Disclosure - Long-Term Debt - 10.000% Senior Unsecured Notes due 2027 (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details</Role>
      <ShortName>Long-Term Debt - 10.000% Senior Unsecured Notes due 2027 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2436425 - Disclosure - Long-Term Debt - Summary of Scheduled Maturities of Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails</Role>
      <ShortName>Long-Term Debt - Summary of Scheduled Maturities of Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2439426 - Disclosure - Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2440427 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails</Role>
      <ShortName>Leases - Lease Expense and Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2441428 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2444429 - Disclosure - Redeemable Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2447430 - Disclosure - Derivatives and Hedging Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails</Role>
      <ShortName>Derivatives and Hedging Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2450431 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/EarningsPerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Income Taxes - Income Tax (Benefit) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails</Role>
      <ShortName>Income Taxes - Income Tax (Benefit) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - Income Taxes - Approx. Tax Effects of Temporary Differences, Deferred Tax Asset and Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails</Role>
      <ShortName>Income Taxes - Approx. Tax Effects of Temporary Differences, Deferred Tax Asset and Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2457436 - Disclosure - Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2460437 - Disclosure - Equity-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2461438 - Disclosure - Equity-Based Compensation - Summary of Restricted and Performance Share-Based Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Restricted and Performance Share-Based Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2462439 - Disclosure - Equity-Based Compensation - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2463440 - Disclosure - Equity-Based Compensation - Summary of Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails</Role>
      <ShortName>Equity-Based Compensation - Summary of Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2465441 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2468442 - Disclosure - Other Current Liabilities - Schedule of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Current Liabilities - Schedule of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2470443 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/CommitmentsandContingencies</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2473444 - Disclosure - Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails</Role>
      <ShortName>Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2474445 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails</Role>
      <ShortName>Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="sgry-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2476446 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.surgerypartners.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.surgerypartners.com/role/SubsequentEvents</ParentRole>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sgry-20201231.htm">sgry-20201231.htm</File>
    <File>sgry-20201231.xsd</File>
    <File>sgry-20201231_cal.xml</File>
    <File>sgry-20201231_def.xml</File>
    <File>sgry-20201231_lab.xml</File>
    <File>sgry-20201231_pre.xml</File>
    <File>ye2020exhibit1012.htm</File>
    <File>ye2020exhibit1035.htm</File>
    <File>ye2020exhibit1036.htm</File>
    <File>ye2020exhibit1037.htm</File>
    <File>ye2020exhibit211.htm</File>
    <File>ye2020exhibit231.htm</File>
    <File>ye2020exhibit311.htm</File>
    <File>ye2020exhibit312.htm</File>
    <File>ye2020exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sgry-20201231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>107
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgry-20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 38,
   "contextCount": 314,
   "dts": {
    "calculationLink": {
     "local": [
      "sgry-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgry-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "sgry-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgry-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgry-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sgry-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 792,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 17,
    "http://www.surgerypartners.com/20201231": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 22
   },
   "keyCustom": 78,
   "keyStandard": 490,
   "memberCustom": 46,
   "memberStandard": 56,
   "nsprefix": "sgry",
   "nsuri": "http://www.surgerypartners.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.surgerypartners.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120103 - Disclosure - Property and Equipment",
     "role": "http://www.surgerypartners.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124104 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.surgerypartners.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130105 - Disclosure - Long-Term Debt",
     "role": "http://www.surgerypartners.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137106 - Disclosure - Leases",
     "role": "http://www.surgerypartners.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:RedeemablePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142107 - Disclosure - Redeemable Preferred Stock",
     "role": "http://www.surgerypartners.com/role/RedeemablePreferredStock",
     "shortName": "Redeemable Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:RedeemablePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145108 - Disclosure - Derivatives and Hedging Activities",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivities",
     "shortName": "Derivatives and Hedging Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148109 - Disclosure - Earnings Per Share",
     "role": "http://www.surgerypartners.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151110 - Disclosure - Income Taxes",
     "role": "http://www.surgerypartners.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158111 - Disclosure - Equity-Based Compensation",
     "role": "http://www.surgerypartners.com/role/EquityBasedCompensation",
     "shortName": "Equity-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164112 - Disclosure - Employee Benefit Plans",
     "role": "http://www.surgerypartners.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166113 - Disclosure - Other Current Liabilities",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilities",
     "shortName": "Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169114 - Disclosure - Commitments and Contingencies",
     "role": "http://www.surgerypartners.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171115 - Disclosure - Segment Reporting",
     "role": "http://www.surgerypartners.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175116 - Disclosure - Subsequent Events",
     "role": "http://www.surgerypartners.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Accounting Policies (Policies)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Accounting Policies (Tables)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables",
     "shortName": "Organization and Summary of Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316302 - Disclosure - Acquisitions and Disposals (Tables)",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables",
     "shortName": "Acquisitions and Disposals (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321303 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.surgerypartners.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Long-Term Debt (Tables)",
     "role": "http://www.surgerypartners.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338306 - Disclosure - Leases (Tables)",
     "role": "http://www.surgerypartners.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343307 - Disclosure - Redeemable Preferred Stock (Tables)",
     "role": "http://www.surgerypartners.com/role/RedeemablePreferredStockTables",
     "shortName": "Redeemable Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346308 - Disclosure - Derivatives and Hedging Activities (Tables)",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables",
     "shortName": "Derivatives and Hedging Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349309 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.surgerypartners.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.surgerypartners.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359311 - Disclosure - Equity-Based Compensation (Tables)",
     "role": "http://www.surgerypartners.com/role/EquityBasedCompensationTables",
     "shortName": "Equity-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2367312 - Disclosure - Other Current Liabilities - (Tables)",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables",
     "shortName": "Other Current Liabilities - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2372313 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.surgerypartners.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Accounting Policies - Organization (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
     "shortName": "Organization and Summary of Accounting Policies - Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "sgry:ProceedsFromGovernmentAssistance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Organization and Summary of Accounting Policies - CARES ACT (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails",
     "shortName": "Organization and Summary of Accounting Policies - CARES ACT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "sgry:ProceedsFromGovernmentAssistance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConsolidationVariableInterestEntityPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:VariableInterestEntityNumberOfFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgical_facility",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Organization and Summary of Accounting Policies - Variable Interest Entities (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails",
     "shortName": "Organization and Summary of Accounting Policies - Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConsolidationVariableInterestEntityPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgry:VariableInterestEntityNumberOfFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgical_facility",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Financial Instruments (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Carrying Amount and Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i809eef37f4e54081a6dc49a891ecdaec_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Organization and Summary of Accounting Policies - Fair Value of Financial Instruments (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails",
     "shortName": "Organization and Summary of Accounting Policies - Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ibb6553b4b74c4d84abce7d64bb6e0233_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Revenues by Service Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ibb6553b4b74c4d84abce7d64bb6e0233_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Revenues by Sources (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ia5d2f9dc0f01494986594870e8a27ffa_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndInvestmentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411408 - Disclosure - Organization and Summary of Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Organization and Summary of Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndInvestmentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iebd694edd2e84c559ed056b5007002ce_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgry:OpticalProductsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412409 - Disclosure - Organization and Summary of Accounting Policies - Accounts Receivable (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails",
     "shortName": "Organization and Summary of Accounting Policies - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iebd694edd2e84c559ed056b5007002ce_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgry:OpticalProductsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iebd694edd2e84c559ed056b5007002ce_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413410 - Disclosure - Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails",
     "shortName": "Organization and Summary of Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i80894f3165b5496ca5111f55aa3835ee_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414411 - Disclosure - Organization and Summary of Accounting Policies - Recent Accounting Pronouncements (Details)",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails",
     "shortName": "Organization and Summary of Accounting Policies - Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseRightOfUseAsset",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ifa680d2bf8ab4a2d9fb8d803777a046f_I20190101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417412 - Disclosure - Acquisitions and Disposals - Acquisitions (Details)",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
     "shortName": "Acquisitions and Disposals - Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iebd694edd2e84c559ed056b5007002ce_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sgry:EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgical_facility",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418413 - Disclosure - Acquisitions and Disposals - Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions and Disposals - Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "if311991b251d46209bd73eff519dfe38_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419414 - Disclosure - Acquisitions and Disposals - Disposals (Details)",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails",
     "shortName": "Acquisitions and Disposals - Disposals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i096eba00dd53417a97144cec06404675_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sgry:DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "surgery_center",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422415 - Disclosure - Property and Equipment - Additional Information (Details)",
     "role": "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423416 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)",
     "role": "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "idbd41b7592e6496dae5a85b154e694ac_D20201001-20201001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426417 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "role": "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "idbd41b7592e6496dae5a85b154e694ac_D20201001-20201001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iebd694edd2e84c559ed056b5007002ce_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427418 - Disclosure - Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details)",
     "role": "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428419 - Disclosure - Goodwill and Intangible Assets - Summary of Components of Intangible Assets (Details)",
     "role": "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Components of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429420 - Disclosure - Goodwill and Intangible Assets - Future Amortization of Intangible Assets (Details)",
     "role": "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Future Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432421 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Details)",
     "role": "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
     "shortName": "Long-Term Debt - Summary of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433422 - Disclosure - Long-Term Debt - Senior Secured Credit Facilities (Details)",
     "role": "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
     "shortName": "Long-Term Debt - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ieac8a7d7a560444e86b6b6bb3e1885fd_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i594520e2981546afb1cc70f2e2240d64_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i594520e2981546afb1cc70f2e2240d64_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434423 - Disclosure - Long-Term Debt - 6.750% Senior Unsecured Notes due 2025 (Details)",
     "role": "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
     "shortName": "Long-Term Debt - 6.750% Senior Unsecured Notes due 2025 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i94e9d237c8fb40c8a0e55d5afaa20dcf_I20170630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435424 - Disclosure - Long-Term Debt - 10.000% Senior Unsecured Notes due 2027 (Details)",
     "role": "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
     "shortName": "Long-Term Debt - 10.000% Senior Unsecured Notes due 2027 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i9fe84b8f841949188f4220b606568120_I20190411",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436425 - Disclosure - Long-Term Debt - Summary of Scheduled Maturities of Debt Obligations (Details)",
     "role": "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails",
     "shortName": "Long-Term Debt - Summary of Scheduled Maturities of Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439426 - Disclosure - Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)",
     "role": "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
     "shortName": "Leases - Components of Right-of-us Assets and Liabilities Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440427 - Disclosure - Leases - Lease Expense and Cash Flow Information (Details)",
     "role": "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails",
     "shortName": "Leases - Lease Expense and Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441428 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "role": "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444429 - Disclosure - Redeemable Preferred Stock - Additional Information (Details)",
     "role": "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447430 - Disclosure - Derivatives and Hedging Activities (Details)",
     "role": "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails",
     "shortName": "Derivatives and Hedging Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450431 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.surgerypartners.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sgry:UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaidNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sgry:NoncashInterestIncomeExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Income Taxes - Income Tax (Benefit) Expense (Details)",
     "role": "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails",
     "shortName": "Income Taxes - Income Tax (Benefit) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - Income Taxes - Income Tax Rate Reconciliation (Details)",
     "role": "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - Income Taxes - Approx. Tax Effects of Temporary Differences, Deferred Tax Asset and Liability (Details)",
     "role": "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails",
     "shortName": "Income Taxes - Approx. Tax Effects of Temporary Differences, Deferred Tax Asset and Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iebd694edd2e84c559ed056b5007002ce_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457436 - Disclosure - Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Details)",
     "role": "http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i80894f3165b5496ca5111f55aa3835ee_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460437 - Disclosure - Equity-Based Compensation - Additional Information (Details)",
     "role": "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
     "shortName": "Equity-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ib77a4c3d6184412d9f09f4d2864124b1_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461438 - Disclosure - Equity-Based Compensation - Summary of Restricted and Performance Share-Based Activity (Details)",
     "role": "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails",
     "shortName": "Equity-Based Compensation - Summary of Restricted and Performance Share-Based Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iafc9c624583e425f9f3f383d5de093bc_I20171231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462439 - Disclosure - Equity-Based Compensation - Fair Value Assumptions (Details)",
     "role": "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
     "shortName": "Equity-Based Compensation - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "i5c91a6349a2c4830a806d0f65bbe3d47_D20190101-20191231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iebd694edd2e84c559ed056b5007002ce_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463440 - Disclosure - Equity-Based Compensation - Summary of Options Activity (Details)",
     "role": "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails",
     "shortName": "Equity-Based Compensation - Summary of Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:DefinedContributionPlanVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465441 - Disclosure - Employee Benefit Plans (Details)",
     "role": "http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:DefinedContributionPlanVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgry:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468442 - Disclosure - Other Current Liabilities - Schedule of Other Current Liabilities (Details)",
     "role": "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails",
     "shortName": "Other Current Liabilities - Schedule of Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Accounting Policies",
     "role": "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies",
     "shortName": "Organization and Summary of Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SelfInsuranceReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470443 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SelfInsuranceReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473444 - Disclosure - Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)",
     "role": "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails",
     "shortName": "Segment Reporting - Revenues and Operating Income by Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474445 - Disclosure - Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)",
     "role": "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
     "shortName": "Segment Reporting - Assets and Cash Purchases of Property and Equipment by Operating Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "if35b1248a15b4a04a53222c87069bd54_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "id55b138001be441a9691661db6451a97_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476446 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.surgerypartners.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "iaa0fb1e697bf46f98f1f119b51d1217a_I20210201",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationsPolicy",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:BusinessCombinationsAndDisposalsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115102 - Disclosure - Acquisitions and Disposals",
     "role": "http://www.surgerypartners.com/role/AcquisitionsandDisposals",
     "shortName": "Acquisitions and Disposals",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationsPolicy",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgry-20201231.htm",
      "contextRef": "ic548acef93dd49d28c0c1cd8b992975b_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgry:BusinessCombinationsAndDisposalsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 108,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgry_A2015OmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Omnibus Incentive Plan [Member]",
        "label": "2015 Omnibus Incentive Plan [Member]",
        "terseLabel": "2015 Omnibus Incentive Plan"
       }
      }
     },
     "localname": "A2015OmnibusIncentivePlanMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_A2017SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Senior Secured Credit Facility [Member]",
        "label": "2017 Senior Secured Credit Facility [Member]",
        "terseLabel": "Senior secured revolving credit facility"
       }
      }
     },
     "localname": "A2017SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_A2017TermLoanMaturing2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Term Loan, Maturing 2024 [Member]",
        "label": "2017 Term Loan, Maturing 2024 [Member]",
        "terseLabel": "Senior secured term loan",
        "verboseLabel": "Senior secured term loan"
       }
      }
     },
     "localname": "A2017TermLoanMaturing2024Member",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_A2018IncrementalTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Incremental Term Loan",
        "label": "2018 Incremental Term Loan [Member]",
        "terseLabel": "2018 Incremental Term Loan"
       }
      }
     },
     "localname": "A2018IncrementalTermLoanMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_A2020IncrementalLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Incremental Loans [Member]",
        "label": "2020 Incremental Loans [Member]",
        "terseLabel": "2020 incremental term loans"
       }
      }
     },
     "localname": "A2020IncrementalLoansMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_AllianceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance",
        "label": "Alliance [Member]",
        "terseLabel": "Alliance"
       }
      }
     },
     "localname": "AllianceMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_AncillaryServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary Services [Member]",
        "label": "Ancillary Services [Member]",
        "terseLabel": "Ancillary Services"
       }
      }
     },
     "localname": "AncillaryServicesMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Components of Right-of-use Assets and Liabilities Related to Leases"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgry_BainCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bain Capital",
        "label": "Bain Capital [Member]",
        "terseLabel": "Bain Capital"
       }
      }
     },
     "localname": "BainCapitalMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Working Capital Adjustments",
        "label": "Business Combination, Consideration Transferred, Working Capital Adjustments",
        "terseLabel": "Additional cash consideration from working capital settlement payment"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_BusinessCombinationContingentAcquisitionExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Acquisition Expense",
        "label": "Business Combination, Contingent Acquisition Expense",
        "terseLabel": "Contingent acquisition compensation expense"
       }
      }
     },
     "localname": "BusinessCombinationContingentAcquisitionExpense",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_BusinessCombinationGainLossOnAcquisitionEscrow": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Gain (Loss) On Acquisition Escrow",
        "label": "Business Combination, Gain (Loss) On Acquisition Escrow",
        "negatedTerseLabel": "Gain on escrow release"
       }
      }
     },
     "localname": "BusinessCombinationGainLossOnAcquisitionEscrow",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_BusinessCombinationIntegrationRelatedCostsAndMergerCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Integration Related Costs, And Merger Costs",
        "label": "Business Combination, Integration Related Costs, And Merger Costs",
        "terseLabel": "Transaction, integration and acquisition costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCostsAndMergerCosts",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease, Right-Of-Use Asset",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Right-of-use operating lease assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_BusinessCombinationsAndDisposalsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations And Disposals [Abstract]",
        "label": "Business Combinations And Disposals [Abstract]",
        "terseLabel": "Business Combinations And Disposals [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAndDisposalsAbstract",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "xbrltype": "stringItemType"
    },
    "sgry_BusinessCombinationsAndDisposalsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations And Disposals Disclosure [Text Block]",
        "label": "Business Combinations And Disposals Disclosure [Text Block]",
        "terseLabel": "Acquisitions and Disposals"
       }
      }
     },
     "localname": "BusinessCombinationsAndDisposalsDisclosureTextBlock",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposals"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgry_COVID19PandemicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic",
        "label": "COVID-19 Pandemic [Member]",
        "terseLabel": "COVID-19 Pandemic"
       }
      }
     },
     "localname": "COVID19PandemicMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate",
        "label": "Collaborative Tax Agreement, Interest Rate, Basis Spread on Variable Rate",
        "terseLabel": "Interest accrued on payment under Tax Receivable Agreement, basis spread on variable rate"
       }
      }
     },
     "localname": "CollaborativeTaxAgreementInterestRateBasisSpreadonVariableRate",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgry_CollaborativeTaxAgreementProjectedTaxSavingsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Tax Agreement, Projected Tax Savings, Term",
        "label": "Collaborative Tax Agreement, Projected Tax Savings, Term",
        "terseLabel": "Projected tax savings period"
       }
      }
     },
     "localname": "CollaborativeTaxAgreementProjectedTaxSavingsTerm",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgry_CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments, Current Portion",
        "label": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments, Current",
        "terseLabel": "Accelerated payments, current portion"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPaymentsCurrent",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments",
        "label": "Coronavirus Aid, Relief, and Economic Security Act CARES Act, Government Grant Received, Accelerated Payments",
        "terseLabel": "Accelerated payments"
       }
      }
     },
     "localname": "CoronavirusAidReliefandEconomicSecurityActCARESActGovernmentGrantReceivedAcceleratedPayments",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_CostReportLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Report Liabilities, Current",
        "label": "Cost Report Liabilities, Current",
        "terseLabel": "Cost report liabilities"
       }
      }
     },
     "localname": "CostReportLiabilitiesCurrent",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DebtInstrumentAlternateBaseRateFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Base Rate, Floor",
        "label": "Debt Instrument, Alternate Base Rate, Floor",
        "terseLabel": "Alternate base rate, floor"
       }
      }
     },
     "localname": "DebtInstrumentAlternateBaseRateFloor",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgry_DebtInstrumentMarginInAdditionToBaseRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Margin In Addition To Base Rate",
        "label": "Debt Instrument, Margin In Addition To Base Rate",
        "terseLabel": "Debt instrument, margin in addition to base rate"
       }
      }
     },
     "localname": "DebtInstrumentMarginInAdditionToBaseRate",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgry_DebtInstrumentNetLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Net Leverage Ratio",
        "label": "Debt Instrument, Net Leverage Ratio",
        "terseLabel": "Net leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentNetLeverageRatio",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "sgry_DebtInstrumentPrepaymentPenaltyAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty Amount",
        "label": "Debt Instrument, Prepayment Penalty Amount",
        "negatedTerseLabel": "Payment of premium on debt extinguishment"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyAmount",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DebtInstrumentQuarterlyMaturityInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Quarterly Maturity Installments",
        "label": "Debt Instrument, Quarterly Maturity Installments",
        "terseLabel": "Quarterly installment of original principal"
       }
      }
     },
     "localname": "DebtInstrumentQuarterlyMaturityInstallments",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgry_DebtInstrumentRedemptionPeriodSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Period Six [Member]",
        "label": "Debt Instrument, Redemption, Period Six [Member]",
        "terseLabel": "Redemption Period Six"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodSixMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_DebtInstrumentTotalCommitmentThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Total Commitment Threshold",
        "label": "Debt Instrument, Total Commitment Threshold",
        "terseLabel": "Commitment threshold"
       }
      }
     },
     "localname": "DebtInstrumentTotalCommitmentThreshold",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgry_DeferredEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Employee-related Liabilities, Current",
        "label": "Deferred Employee-related Liabilities, Current",
        "terseLabel": "Deferred accrued payroll and benefits"
       }
      }
     },
     "localname": "DeferredEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredIncomeTaxLiabilitiesNetOfDiscount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Tax Liabilities, Net Of Discount",
        "label": "Deferred Income Tax Liabilities, Net Of Discount",
        "terseLabel": "Carrying value of liability, net of discount"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNetOfDiscount",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Tax Liabilities, Net Of Discount, Current",
        "label": "Deferred Income Tax Liabilities, Net Of Discount, Current",
        "terseLabel": "Deferred tax liabilities, current"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNetOfDiscountCurrent",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredTaxAssetTaxReceivableAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Tax Receivable Agreement",
        "label": "Deferred Tax Asset, Tax Receivable Agreement",
        "terseLabel": "TRA liability"
       }
      }
     },
     "localname": "DeferredTaxAssetTaxReceivableAgreement",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredTaxAssetsAffiliateIndebtednessReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Affiliate Indebtedness Receivable",
        "label": "Deferred Tax Assets, Affiliate Indebtedness Receivable",
        "terseLabel": "Affiliate indebtedness receivable"
       }
      }
     },
     "localname": "DeferredTaxAssetsAffiliateIndebtednessReceivable",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredTaxAssetsRightOfUse": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Right Of Use",
        "label": "Deferred Tax Assets, Right Of Use",
        "terseLabel": "Right of use"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUse",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Amortization Of Intangible Assets",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Amortization Of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAmortizationOfIntangibleAssets",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences and Incentive Compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences and Incentive Compensation",
        "terseLabel": "Accrued vacation and incentive compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsCompensatedAbsencesandIncentiveCompensation",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Deferred Financing Costs",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Deferred Financing Costs",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseDeferredFinancingCosts",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredTaxAssetsTaxDeferredExpenseInterestLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Interest Limitation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Interest Limitation",
        "terseLabel": "Section 163(j) interest"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseInterestLimitation",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Basis Differences of Partnerships and Joint Ventures",
        "label": "Deferred Tax Liabilities, Basis Differences of Partnerships and Joint Ventures",
        "negatedTerseLabel": "Basis differences of partnerships and joint ventures"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesBasisDifferencesofPartnershipsandJointVentures",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_DefinedContributionPlanVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Vesting Period",
        "label": "Defined Contribution Plan, Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "DefinedContributionPlanVestingPeriod",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgry_DisposalGroupFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Four",
        "label": "Disposal Group Four [Member]",
        "terseLabel": "Surgery Centers, Surgical Hospitals, and Optical Laboratory"
       }
      }
     },
     "localname": "DisposalGroupFourMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Number Of Interests Disposed",
        "label": "Disposal Group, Not Discontinued Operation, Number Of Interests Disposed",
        "terseLabel": "Number of interests sold"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationNumberOfInterestsDisposed",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_DisposalGroupOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group One [Member]",
        "label": "Disposal Group One [Member]",
        "terseLabel": "Surgery Centers, Certain Assets Related to Anesthesia Business, Certain Imaging ASsets and Optical Products Purchasing Organization"
       }
      }
     },
     "localname": "DisposalGroupOneMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_DisposalGroupThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Three",
        "label": "Disposal Group Three [Member]",
        "terseLabel": "Previously Owned Real Property Associated with Existing Non-Consolidated Surgical Facility"
       }
      }
     },
     "localname": "DisposalGroupThreeMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_DisposalGroupTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Two",
        "label": "Disposal Group Two [Member]",
        "terseLabel": "Diagnostic Laboratory"
       }
      }
     },
     "localname": "DisposalGroupTwoMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_EarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Before Interest Taxes Depreciation And Amortization",
        "label": "Earnings Before Interest Taxes Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "EarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Litigation Settlement, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Litigation Settlement, Amount",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLitigationSettlementAmount",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Receivable Agreement, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Tax Receivable Agreement, Amount",
        "terseLabel": "Tax Receivable Agreement liability"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxReceivableAgreementAmount",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_EffectiveIncomeTaxReconciliationDivestitureAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Divestiture, Amount",
        "label": "Effective Income Tax Reconciliation, Divestiture, Amount",
        "terseLabel": "Differences related to divested facilities"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationDivestitureAmount",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_EmployeeStockOptionsAndStockAppreciationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options And Stock Appreciation Rights [Member]",
        "label": "Employee Stock Options And Stock Appreciation Rights [Member]",
        "terseLabel": "Employee Stock Options and Stock Appreciation Rights"
       }
      }
     },
     "localname": "EmployeeStockOptionsAndStockAppreciationRightsMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Number Of Noncontrolling Interests Acquired",
        "label": "Equity Method Investment, Number Of Noncontrolling Interests Acquired",
        "terseLabel": "Number of surgical facilities acquired"
       }
      }
     },
     "localname": "EquityMethodInvestmentNumberOfNoncontrollingInterestsAcquired",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_FacilitiesAmbulatorySurgeryCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities, Ambulatory Surgery Centers [Member]",
        "label": "Facilities, Ambulatory Surgery Centers [Member]",
        "terseLabel": "Facilities, Ambulatory Surgery Centers"
       }
      }
     },
     "localname": "FacilitiesAmbulatorySurgeryCentersMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_FacilitiesSurgicalHospitalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facilities, Surgical Hospitals [Member]",
        "label": "Facilities, Surgical Hospitals [Member]",
        "terseLabel": "Facilities, Surgical Hospitals"
       }
      }
     },
     "localname": "FacilitiesSurgicalHospitalsMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total finance lease costs"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_FinanceLeaseCost1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost1 [Abstract]",
        "label": "Finance Lease, Cost1 [Abstract]",
        "terseLabel": "Finance lease costs:"
       }
      }
     },
     "localname": "FinanceLeaseCost1Abstract",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_FinanceLeasePrincipalAndInterestPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Principal And Interest Payments",
        "label": "Finance Lease, Principal And Interest Payments",
        "terseLabel": "Rent paid under finance lease agreement, allocated to principal and interest"
       }
      }
     },
     "localname": "FinanceLeasePrincipalAndInterestPayments",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_FurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and Equipment [Member]",
        "label": "Furniture and Equipment [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndEquipmentMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_GainLossOnDispositionOfAssetsAndDeconsolidation": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition of Assets And Deconsolidation",
        "label": "Gain (Loss) On Disposition Of Assets And Deconsolidation",
        "negatedLabel": "Loss (gain) on disposals and deconsolidations, net",
        "negatedTerseLabel": "Loss (gain) on disposals and deconsolidations, net"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsAndDeconsolidation",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related to Litigation Settlement And Other Litigation Costs",
        "label": "Gain (Loss) Related to Litigation Settlement And Other Litigation Costs",
        "negatedLabel": "Litigation settlements and other litigation costs"
       }
      }
     },
     "localname": "GainLossRelatedtoLitigationSettlementAndOtherLitigationCosts",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Written Off Related To Sale Of Business Unit And Deconsolidations",
        "label": "Goodwill, Written Off Related To Sale Of Business Unit And Deconsolidations",
        "negatedTerseLabel": "Disposals and deconsolidations"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnitAndDeconsolidations",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_GovernmentRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Revenue [Member]",
        "label": "Government Revenue [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "GovernmentRevenueMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_GrantRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Revenue",
        "label": "Grant Revenue",
        "negatedTerseLabel": "Grant funds",
        "terseLabel": "Grant funds"
       }
      }
     },
     "localname": "GrantRevenue",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_HealthcareOrganizationOtherServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Organization, Other Service [Member]",
        "label": "Healthcare Organization, Other Service [Member]",
        "terseLabel": "Other service revenues"
       }
      }
     },
     "localname": "HealthcareOrganizationOtherServiceMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_HealthcareOrganizationPatientServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Organization, Patient Service [Member]",
        "label": "Healthcare Organization, Patient Service [Member]",
        "terseLabel": "Patient service revenues"
       }
      }
     },
     "localname": "HealthcareOrganizationPatientServiceMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants",
        "label": "Increase (Decrease) In Medicare Accelerated Payments And Deferred Governmental Grants",
        "terseLabel": "Medicare accelerated payments and deferred governmental grants"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_InterestLimitationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Limitation [Member]",
        "label": "Interest Limitation [Member]",
        "terseLabel": "Interest Limitation"
       }
      }
     },
     "localname": "InterestLimitationMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_LeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Right-of-Use Asset",
        "label": "Lease, Right-Of-Use Asset",
        "totalLabel": "Total leased assets"
       }
      }
     },
     "localname": "LeaseRightOfUseAsset",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Extend, Number Of Options To Renew",
        "label": "Lessee, Operating Lease, Option To Extend, Number Of Options To Renew",
        "terseLabel": "Number of options to renew operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtendNumberOfOptionsToRenew",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_LineOfCreditFacilityMaximumBorrowingCapacityIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Increase",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Increase",
        "terseLabel": "Increase in outstanding commitments"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncrease",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_ManagementRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Rights [Member]",
        "label": "Management Rights [Member]",
        "terseLabel": "Management rights agreements"
       }
      }
     },
     "localname": "ManagementRightsMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_MateriallyMoreRestrictiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Materially More Restrictive [Member]",
        "label": "Materially More Restrictive [Member]",
        "terseLabel": "Materially More Restrictive"
       }
      }
     },
     "localname": "MateriallyMoreRestrictiveMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_MedicalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Equipment [Member]",
        "label": "Medical Equipment [Member]",
        "terseLabel": "Medical equipment"
       }
      }
     },
     "localname": "MedicalEquipmentMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Accelerated Payments And Deferred Governmental Grants, Current",
        "label": "Medicare Accelerated Payments And Deferred Governmental Grants, Current",
        "terseLabel": "Medicare accelerated payments and deferred governmental grants"
       }
      }
     },
     "localname": "MedicareAcceleratedPaymentsAndDeferredGovernmentalGrantsCurrent",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net",
        "label": "Non-Controlling Interest, Acquisitions And Disposals Of Interests Held By Non-Controlling Interest Holders, Net",
        "terseLabel": "Acquisition and disposal of shares of non-controlling interests, net"
       }
      }
     },
     "localname": "NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Controlling Interest, Acquisitions and Disposals of Interests held by Non-Controlling Interest Holders, Tax",
        "label": "Non-Controlling Interest, Acquisitions and Disposals of Interests held by Non-Controlling Interest Holders, Tax",
        "terseLabel": "Additional-paid-in-capital increase, due to tax effect of disposals of shares of noncontrolling interests"
       }
      }
     },
     "localname": "NonControllingInterestAcquisitionsandDisposalsofInterestsheldbyNonControllingInterestHoldersTax",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NoncashInterestIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Interest Income (Expense), Net",
        "label": "Noncash Interest Income (Expense), Net",
        "negatedTerseLabel": "Non-cash interest expense (income), net"
       }
      }
     },
     "localname": "NoncashInterestIncomeExpenseNet",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_NotMateriallyMoreRestrictiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not Materially More Restrictive [Member]",
        "label": "Not Materially More Restrictive [Member]",
        "terseLabel": "Not Materially More Restrictive"
       }
      }
     },
     "localname": "NotMateriallyMoreRestrictiveMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_NotesPayableAndSecuredLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable and Secured Loans [Member]",
        "label": "Notes Payable and Secured Loans [Member]",
        "terseLabel": "Notes payable and other secured loans"
       }
      }
     },
     "localname": "NotesPayableAndSecuredLoansMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned",
        "label": "Number of Surgical Facilities Owned",
        "terseLabel": "Number of surgical facilities owned"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwned",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwnedConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned, Consolidated",
        "label": "Number Of Surgical Facilities Owned, Consolidated",
        "terseLabel": "Number of surgical facilities owned, consolidated"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwnedConsolidated",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_NumberOfSurgicalFacilitiesOwnedMajorityInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Surgical Facilities Owned, Majority Interest",
        "label": "Number Of Surgical Facilities Owned, Majority Interest",
        "terseLabel": "Number of surgical facilities owned, majority interest"
       }
      }
     },
     "localname": "NumberOfSurgicalFacilitiesOwnedMajorityInterest",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_OneMonthLondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Month London Interbank Offered Rate (LIBOR) [Member]",
        "label": "One Month London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "One Month LIBOR"
       }
      }
     },
     "localname": "OneMonthLondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_OperatingAndFinanceLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Expense",
        "label": "Operating And Finance Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseExpense",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_OpticalProductsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Optical Products Receivable",
        "label": "Optical Products Receivable",
        "verboseLabel": "Optical products receivable"
       }
      }
     },
     "localname": "OpticalProductsReceivable",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_OpticalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Optical Services [Member]",
        "label": "Optical Services [Member]",
        "terseLabel": "Optical Services"
       }
      }
     },
     "localname": "OpticalServicesMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_OtherPatientServiceRevenueSourcesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Patient Service Revenue Sources [Member]",
        "label": "Other Patient Service Revenue Sources [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPatientServiceRevenueSourcesMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_OtherServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Services [Member]",
        "label": "Other Services [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherServicesMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PhysicianIncomeGuaranteesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physician Income Guarantees [Member]",
        "label": "Physician Income Guarantees [Member]",
        "terseLabel": "Physician income guarantees"
       }
      }
     },
     "localname": "PhysicianIncomeGuaranteesMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PhysicianPracticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physician Practice",
        "label": "Physician Practice [Member]",
        "terseLabel": "Physician Practice"
       }
      }
     },
     "localname": "PhysicianPracticeMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PrivateInsuranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Insurance [Member]",
        "label": "Private Insurance [Member]",
        "terseLabel": "Private insurance"
       }
      }
     },
     "localname": "PrivateInsuranceMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ProceedsFromGovernmentAssistance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Government Assistance",
        "label": "Proceeds From Government Assistance",
        "terseLabel": "Proceeds from grants received"
       }
      }
     },
     "localname": "ProceedsFromGovernmentAssistance",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCARESACTDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_PublicStockOfferingFirmSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering, Firm Shares",
        "label": "Public Stock Offering, Firm Shares [Member]",
        "terseLabel": "Firm Shares"
       }
      }
     },
     "localname": "PublicStockOfferingFirmSharesMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "label": "Redeemable Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to non-controlling interest \u2014redeemable holders"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Increase (Decrease) from Redemptions or Purchase of Interests",
        "label": "Redeemable Noncontrolling Interest, Increase (Decrease) From Redemptions Or Purchase Of Interests",
        "terseLabel": "Acquisition and disposal of shares of non-controlling interests, net\u2014redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_RedeemableNoncontrollingInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Roll Forward]",
        "label": "Redeemable Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Non-Controlling Interests - Redeemable [Roll Forward]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestRollForward",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_RedeemablePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Preferred Stock [Text Block]",
        "label": "Redeemable Preferred Stock [Text Block]",
        "terseLabel": "Redeemable Preferred Stock"
       }
      }
     },
     "localname": "RedeemablePreferredStockTextBlock",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgry_RestrictedStockAndPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock And Performance Shares",
        "label": "Restricted Stock And Performance Shares [Member]",
        "terseLabel": "Restricted and Performance Shares"
       }
      }
     },
     "localname": "RestrictedStockAndPerformanceSharesMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Obligations",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Obligations [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgry_SelfPayRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Self-Pay Revenue [Member]",
        "label": "Self-Pay Revenue [Member]",
        "terseLabel": "Self-pay"
       }
      }
     },
     "localname": "SelfPayRevenueMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SeniorUnsecuredNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2025 [Member]",
        "label": "Senior Unsecured Notes Due 2025 [Member]",
        "terseLabel": "6.750% senior unsecured notes due 2025"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2025Member",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SeniorUnsecuredNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes, Due 2027 [Member]",
        "label": "Senior Unsecured Notes, Due 2027 [Member]",
        "terseLabel": "10.000% senior unsecured notes due 2027"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2027Member",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payable At End Of Performance Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Payable At End Of Performance Period",
        "terseLabel": "Payable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPayableAtEndOfPerformancePeriod",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments",
        "terseLabel": "Number of annual installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cancelled In Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Cancelled In Period",
        "terseLabel": "Options cancelled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercised, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Options, Forfeited, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeited, Weighted Average Remaining Contractual Term",
        "terseLabel": "Forfeited/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgry_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days, threshold"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdConsecutiveTradingDays",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Earned In Period",
        "label": "Share-Based Payment Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Earned In Period",
        "terseLabel": "Restricted units granted, earned during period (shares)"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEarnedInPeriod",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgry_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgry_StartUpActivitiesStartUpCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start-Up Activities, Start-Up Costs",
        "label": "Start-Up Activities, Start-Up Costs",
        "terseLabel": "Start-up costs related to de novo surgical hospital"
       }
      }
     },
     "localname": "StartUpActivitiesStartUpCosts",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_SurgeryPartnersIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery Partners, Inc",
        "label": "Surgery Partners, Inc [Member]",
        "terseLabel": "Surgery Partners, Inc"
       }
      }
     },
     "localname": "SurgeryPartnersIncMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilitiesExistingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facilities, Existing Markets",
        "label": "Surgical Facilities, Existing Markets [Member]",
        "terseLabel": "Surgical Facilities, Existing Markets"
       }
      }
     },
     "localname": "SurgicalFacilitiesExistingMarketsMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilitiesNewMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facilities, New Market",
        "label": "Surgical Facilities, New Market [Member]",
        "terseLabel": "Surgical Facilities, Including Surgical Hospital"
       }
      }
     },
     "localname": "SurgicalFacilitiesNewMarketMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilityAndPhysicianPracticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facility And Physician Practice [Member]",
        "label": "Surgical Facility And Physician Practice [Member]",
        "terseLabel": "Surgical Facility and Physician Practice"
       }
      }
     },
     "localname": "SurgicalFacilityAndPhysicianPracticeMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facility [Member]",
        "label": "Surgical Facility [Member]",
        "terseLabel": "Surgical Facility"
       }
      }
     },
     "localname": "SurgicalFacilityMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_SurgicalFacilityServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Facility Services [Member]",
        "label": "Surgical Facility Services [Member]",
        "terseLabel": "Surgical Facility Services"
       }
      }
     },
     "localname": "SurgicalFacilityServicesMember",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgry_TaxReceivableAgreementExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement Expense (Benefit)",
        "label": "Tax Receivable Agreement Expense (Benefit)",
        "terseLabel": "Tax receivable agreement expense"
       }
      }
     },
     "localname": "TaxReceivableAgreementExpenseBenefit",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_TaxReceivableAgreementLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement Liability, Current",
        "label": "Tax Receivable Agreement Liability, Current",
        "terseLabel": "Tax receivable agreement liability"
       }
      }
     },
     "localname": "TaxReceivableAgreementLiabilityCurrent",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_TemporaryEquityMaximumCashDividendDeclarable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Maximum Cash Dividend Declarable",
        "label": "Temporary Equity, Maximum Cash Dividend Declarable",
        "terseLabel": "Maximum cash dividend declarable"
       }
      }
     },
     "localname": "TemporaryEquityMaximumCashDividendDeclarable",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgry_TemporaryEquityThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Threshold Consecutive Trading Days",
        "label": "Temporary Equity, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days"
       }
      }
     },
     "localname": "TemporaryEquityThresholdConsecutiveTradingDays",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_TemporaryEquityThresholdSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Threshold Share Price",
        "label": "Temporary Equity, Threshold Share Price",
        "terseLabel": "Threshold share price (in USD per share)"
       }
      }
     },
     "localname": "TemporaryEquityThresholdSharePrice",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgry_TemporaryEquityThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Threshold Trading Days",
        "label": "Temporary Equity, Threshold Trading Days",
        "terseLabel": "Trading days"
       }
      }
     },
     "localname": "TemporaryEquityThresholdTradingDays",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgry_UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undistributed Earnings (Loss) Allocated to Participating Securities, Including Dividends Accrued",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Including Dividends Accrued",
        "negatedTerseLabel": "Less: amounts allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedtoParticipatingSecuritiesIncludingDividendsAccrued",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_VariableAndShortTermLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable And Short-Term Lease, Cost",
        "label": "Variable And Short-Term Lease, Cost",
        "terseLabel": "Variable and short-term lease costs"
       }
      }
     },
     "localname": "VariableAndShortTermLeaseCost",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgry_VariableInterestEntityNumberOfFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, Number of Facilities",
        "label": "Variable Interest Entity, Number Of Facilities",
        "terseLabel": "Number of facilities included in VIE"
       }
      }
     },
     "localname": "VariableInterestEntityNumberOfFacilities",
     "nsuri": "http://www.surgerypartners.com/20201231",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r466",
      "r467",
      "r474",
      "r475",
      "r651",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r466",
      "r467",
      "r474",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r188",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r208",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r188",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r208",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r139",
      "r147",
      "r233",
      "r389",
      "r390",
      "r391",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Impact of adoption of ASC 842"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r139",
      "r147",
      "r233",
      "r389",
      "r390",
      "r391",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r139",
      "r147",
      "r233",
      "r389",
      "r390",
      "r391",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r349",
      "r352",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r349",
      "r352",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PayablesToCustomers": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to customer by broker-dealer.",
        "label": "Broker-Dealer, Payable to Customer",
        "terseLabel": "Amounts due to patients and payors"
       }
      }
     },
     "localname": "PayablesToCustomers",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r215",
      "r319",
      "r320",
      "r573",
      "r628",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r215",
      "r319",
      "r320",
      "r573",
      "r628",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r328",
      "r349",
      "r352",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r328",
      "r349",
      "r352",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r629",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r170",
      "r234",
      "r235",
      "r392",
      "r431",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r170",
      "r234",
      "r235",
      "r392",
      "r431",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r350",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r135",
      "r137",
      "r138",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r152",
      "r153",
      "r170",
      "r234",
      "r235",
      "r392",
      "r431",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r282",
      "r350",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r430",
      "r431",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r14",
      "r37",
      "r220",
      "r221"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r40",
      "r70",
      "r71",
      "r72",
      "r617",
      "r639",
      "r643"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r38",
      "r392"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": {
     "auth_ref": [
      "r302",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.",
        "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings",
        "negatedTerseLabel": "Preferred dividends"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r355",
      "r382",
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r112",
      "r251",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities outstanding not included in the computation of diluted loss per share as their effect is antidilutive (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r69",
      "r72",
      "r74",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r112",
      "r265"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charges",
        "verboseLabel": "Impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r125",
      "r196",
      "r203",
      "r210",
      "r229",
      "r466",
      "r474",
      "r521",
      "r593",
      "r613"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r16",
      "r18",
      "r65",
      "r125",
      "r229",
      "r466",
      "r474",
      "r521"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r348",
      "r351",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "terseLabel": "Fair value of non-controlling interests"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r456",
      "r457",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total aggregate consideration",
        "verboseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r455",
      "r458",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Transaction and integration costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "negatedTerseLabel": "Right-of-use operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Net assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "negatedLabel": "Long-term debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest",
        "terseLabel": "Aggregate acquisition date fair value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Aggregate acquisition date fair value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r122",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions and Disposals"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital Loss Carryforward"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r12",
      "r44",
      "r114"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r25",
      "r115",
      "r122",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r108",
      "r114",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r108",
      "r522"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months",
        "negatedTerseLabel": "Amount estimated to be reclassified as a reduction to interest expense over next 12 months"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r124",
      "r125",
      "r156",
      "r157",
      "r158",
      "r162",
      "r166",
      "r174",
      "r175",
      "r176",
      "r229",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r36",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, stockholders' equity (shares)",
        "periodStartLabel": "Beginning Balance, stockholders' equity (shares)",
        "terseLabel": "Common stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 50,461,706 and 49,298,940, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r77",
      "r79",
      "r80",
      "r88",
      "r606",
      "r626"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Surgery Partners, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r79",
      "r87",
      "r464",
      "r465",
      "r485",
      "r605",
      "r625"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Comprehensive income attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r79",
      "r86",
      "r463",
      "r485",
      "r604",
      "r624"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "verboseLabel": "Computer and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r218",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r218",
      "r518",
      "r519",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r218",
      "r518",
      "r519",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r180",
      "r181",
      "r218",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Revenue by service type as a percentage of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r218",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r122",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "terseLabel": "Non-Controlling Interests"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r122",
      "r473",
      "r477",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "All other",
        "verboseLabel": "All other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r424",
      "r434"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r424",
      "r434"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r178",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r594",
      "r598",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r29",
      "r288",
      "r598",
      "r612"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r532",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Original balance of debt",
        "verboseLabel": "Face value of debt issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r56",
      "r291",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Percentage of principal"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, stated rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Five [Member]",
        "terseLabel": "Redemption Period Five"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFiveMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Four [Member]",
        "terseLabel": "Redemption Period Four"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Redemption Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Redemption Period Three"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Redemption Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage",
        "verboseLabel": "Redemption price of debt"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "verboseLabel": "Percentage of debt principal redeemable"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.",
        "label": "Debt Instrument Redemption [Table Text Block]",
        "terseLabel": "Debt Redemption Percentages"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r57",
      "r128",
      "r303",
      "r305",
      "r306",
      "r307",
      "r531",
      "r532",
      "r534",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r531",
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "verboseLabel": "Unamortized fair value discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r289",
      "r533"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: unamortized debt issuance costs",
        "terseLabel": "Debt issuance costs and discount",
        "verboseLabel": "Debt issuance costs and discount, net of issuance premium"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r425",
      "r434"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Long-term deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r127",
      "r425",
      "r434",
      "r435",
      "r436"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r31",
      "r32",
      "r414",
      "r596",
      "r611"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r425",
      "r434"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsHedgingTransactions": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from hedging transactions.",
        "label": "Deferred Tax Assets, Hedging Transactions",
        "terseLabel": "Interest rate swap liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsHedgingTransactions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other deferred assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts",
        "terseLabel": "Allowance for bad debts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies",
        "terseLabel": "Medical malpractice liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right of use"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other deferred liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Depreciation on property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesApproxTaxEffectsofTemporaryDifferencesDeferredTaxAssetandLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation allowance for tax benefit to be credited to shareholders' equity if tax benefit subsequently becomes realizable. Includes, but is not limited to, adjustment to opening balance of retained earnings for change in accounting principle or correction of error, gain (loss) in comprehensive income (loss) but excluded from net income (loss), deductible expenditure for income tax purposes reported as reduction of shareholders' equity, and deductible temporary difference existing at date of quasi-reorganization.",
        "label": "Deferred Taxes, Business Combination, Valuation Allowance, Allocated to Contributed Capital",
        "terseLabel": "Valuation allowance that if recognized, would credit directly to contributed capital"
       }
      }
     },
     "localname": "DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Matching contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r112",
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r112",
      "r191"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r492",
      "r494",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivatives and Hedging Activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective portion of loss reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion",
        "terseLabel": "Loss reclassified from accumulated OCI to interest expense (effective portion)"
       }
      }
     },
     "localname": "DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Interest rate swap agreement"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r487",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Current notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r495",
      "r498",
      "r501",
      "r503",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r130",
      "r486",
      "r488",
      "r490",
      "r491",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue Sources for Patient Service Revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r112",
      "r266",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Pre-tax gain (loss)"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r28",
      "r30",
      "r597",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividends declared but unpaid"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders - basic and diluted (in USD per share)",
        "verboseLabel": "Basic and diluted loss per share (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r403",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r141",
      "r150",
      "r153",
      "r173",
      "r233",
      "r302",
      "r308",
      "r389",
      "r390",
      "r391",
      "r430",
      "r431",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r529",
      "r634",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r45",
      "r107",
      "r122",
      "r228",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments in Unconsolidated Affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimatedInsuranceRecoveries": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.",
        "label": "Estimated Insurance Recoveries",
        "verboseLabel": "Estimated insurance recoveries"
       }
      }
     },
     "localname": "EstimatedInsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r509",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r344",
      "r510",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r329",
      "r331",
      "r336",
      "r344",
      "r510",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r344",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r122",
      "r512",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Effective Swap Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r538",
      "r545",
      "r553"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 2.0,
       "parentTag": "sgry_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r541",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash outflows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r536",
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "sgry_LeaseLiability",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total lease obligations",
        "totalLabel": "Total finance lease liabilities",
        "verboseLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liability [Abstract]",
        "terseLabel": "Finance lease liabilities:"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Maturity of Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r540",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash outflows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "sgry_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r538",
      "r545",
      "r553"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 1.0,
       "parentTag": "sgry_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of leased assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Right-of-use finance lease asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r550",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r549",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term, finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful lives of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Scheduled Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r257",
      "r261",
      "r574",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r257",
      "r578"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r252",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r257",
      "r574"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsFutureAmortizationofIntangibleAssetsDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Litigation-related charge",
        "negatedTerseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r112",
      "r292",
      "r293"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on debt extinguishment",
        "negatedTerseLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralBusinessMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit.",
        "label": "General Business Tax Credit Carryforward [Member]",
        "terseLabel": "General Business Tax Credit Carryforward"
       }
      }
     },
     "localname": "GeneralBusinessMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r241",
      "r243",
      "r592"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions, including post acquisition adjustments"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r246",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r112",
      "r242",
      "r245",
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteeObligationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Guarantor Obligations [Line Items]",
        "terseLabel": "Guarantor Obligations [Line Items]"
       }
      }
     },
     "localname": "GuaranteeObligationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r112",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "negatedTerseLabel": "Impairments"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets, Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r129",
      "r437"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "(Loss) income before income taxes",
        "totalLabel": "(Loss) income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r83",
      "r112",
      "r193",
      "r227",
      "r601",
      "r621"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Income from equity investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "negatedTerseLabel": "Income from equity investments, net of distributions received"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r348",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r407",
      "r411",
      "r413",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r404",
      "r412",
      "r419",
      "r432",
      "r439",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r127",
      "r152",
      "r153",
      "r194",
      "r402",
      "r433",
      "r441",
      "r627"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax (benefit) expense",
        "totalLabel": "Total income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxBenefitExpenseDetails",
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r122",
      "r398",
      "r399",
      "r412",
      "r413",
      "r418",
      "r426",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r397",
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in effective tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax (benefit) expense at U.S.federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount",
        "negatedTerseLabel": "Net income attributable to non-controlling interests"
       }
      }
     },
     "localname": "IncomeTaxReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock option compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Tax return reconciling differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of U.S. federal tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesOther": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount",
        "terseLabel": "Changes in measurement of uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingenciesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Total intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r250",
      "r255"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "negatedTerseLabel": "Interest expense, net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r105",
      "r109",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid, net of interest income received"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r53"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r13",
      "r62"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r63",
      "r122",
      "r172",
      "r236",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in and advances to affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investor"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r551",
      "r553"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Expense and Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturity of Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Initial term of operating leases"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r52",
      "r125",
      "r204",
      "r229",
      "r467",
      "r474",
      "r475",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r43",
      "r125",
      "r229",
      "r521",
      "r600",
      "r620"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r55",
      "r125",
      "r229",
      "r467",
      "r474",
      "r475",
      "r521"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r29",
      "r598",
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Long-term line of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Outstanding balance on debt"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r59",
      "r281",
      "r283"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Accrued legal settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Payment under settlement agreement"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Other litigation costs"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r29",
      "r290",
      "r598",
      "r616"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term debt, less current maturities",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current maturities of long-term debt",
        "verboseLabel": "Less: Current maturities"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r132",
      "r286"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r132",
      "r286"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r132",
      "r286"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r132",
      "r286"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r132",
      "r286"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r132",
      "r286"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofScheduledMaturitiesofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r57",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MajorityShareholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.",
        "label": "Majority Shareholder [Member]",
        "terseLabel": "Majority Shareholder"
       }
      }
     },
     "localname": "MajorityShareholderMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r61",
      "r125",
      "r229",
      "r521",
      "r599",
      "r619"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests\u2014non-redeemable"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to non-controlling interests\u2014non-redeemable holders"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Percentage of voting interest held"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r108",
      "r110",
      "r113"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r11",
      "r75",
      "r78",
      "r84",
      "r113",
      "r125",
      "r140",
      "r145",
      "r146",
      "r147",
      "r148",
      "r152",
      "r153",
      "r159",
      "r196",
      "r202",
      "r206",
      "r209",
      "r212",
      "r229",
      "r521",
      "r602",
      "r622"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Surgery Partners, Inc.",
        "verboseLabel": "Net loss attributable to Surgery Partners, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r78",
      "r152",
      "r153",
      "r470",
      "r484"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net income attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to non-controlling interests\u2014redeemable"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148",
      "r154",
      "r155",
      "r161",
      "r166",
      "r196",
      "r202",
      "r206",
      "r209",
      "r212"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.surgerypartners.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r298",
      "r470",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r147",
      "r170",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r428",
      "r429",
      "r430",
      "r431",
      "r575",
      "r576",
      "r577",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "terseLabel": "Non-cash purchases of property and equipment"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "negatedTerseLabel": "Noncash consideration"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Non-compete agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r308",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interests\u2014 Non-Redeemable",
        "verboseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Number of business entities acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r487",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of interest rate swaps held"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of States in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Cost of revenues"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r196",
      "r202",
      "r206",
      "r209",
      "r212"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r546",
      "r553"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "sgry_LeaseLiability",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease obligations",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease, liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current",
        "verboseLabel": "Right-of-use operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term",
        "verboseLabel": "Right-of-use operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r542",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "sgry_LeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets",
        "verboseLabel": "Right-of-use operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r550",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r549",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term, operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r53"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Derivative activity"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r68",
      "r70",
      "r493",
      "r496",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Loss recognized in OCI (effective portion)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Loss reclassified from accumulated OCI to interest expense (effective portion)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r76",
      "r79",
      "r82",
      "r85",
      "r302",
      "r523",
      "r528",
      "r529",
      "r603",
      "r623"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Summary of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r53"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/OtherCurrentLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonrecurringIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature.",
        "label": "Other Nonrecurring (Income) Expense",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonrecurringIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherTaxExpenseBenefit": {
     "auth_ref": [
      "r126",
      "r402",
      "r426"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other income tax expense (benefit).",
        "label": "Other Tax Expense (Benefit)",
        "negatedTerseLabel": "Tax receivable agreement expense"
       }
      }
     },
     "localname": "OtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Additional Shares Granted to Underwriters"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r95",
      "r98",
      "r131"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsMinorityInterest": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.",
        "label": "Payments of Ordinary Dividends, Noncontrolling Interest",
        "negatedTerseLabel": "Distributions to non-controlling interest holders"
       }
      }
     },
     "localname": "PaymentsOfDividendsMinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock",
        "negatedTerseLabel": "Payments of preferred dividends"
       }
      }
     },
     "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Payments for acquisitions, net of cash acquired",
        "terseLabel": "Total cash consideration, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchase of equity investments",
        "terseLabel": "Cash investment for purchase of equity investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment",
        "terseLabel": "Cash purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Payments related to ownership transactions with non-controlling interest holders"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r328",
      "r330",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r357",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of cumulative preferred dividends in arrears.",
        "label": "Preferred Stock, Amount of Preferred Dividends in Arrears",
        "terseLabel": "Cumulative preferred dividends"
       }
      }
     },
     "localname": "PreferredStockAmountOfPreferredDividendsInArrears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "verboseLabel": "Preferred stock dividend rate"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of cumulative preferred dividends in arrears.",
        "label": "Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears",
        "terseLabel": "Cumulative preferred dividends (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockPerShareAmountsOfPreferredDividendsInArrears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; shares authorized - 20,000,000; shares issued or outstanding - none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r15",
      "r17",
      "r239",
      "r240"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Borrowings of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Proceeds from noncontrolling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r100",
      "r104",
      "r131"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from disposals of facilities and other assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsDisposalsDetails",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Revenue Source"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional and medical fees"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r11",
      "r75",
      "r78",
      "r106",
      "r125",
      "r140",
      "r152",
      "r153",
      "r196",
      "r202",
      "r206",
      "r209",
      "r212",
      "r229",
      "r463",
      "r469",
      "r471",
      "r484",
      "r485",
      "r521",
      "r608"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r269",
      "r538",
      "r545"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r66",
      "r270",
      "r545"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r26",
      "r268",
      "r535"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r48",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r47",
      "r268"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, excluding right-of-use finance lease asset, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r122",
      "r270",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r26",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r26",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r222",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r203",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r202",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Segment Revenue and Operating Income"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r296",
      "r297",
      "r299",
      "r300"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "periodEndLabel": "Non-controlling interest, ending balance",
        "periodStartLabel": "Non-controlling interest, beginning balance",
        "terseLabel": "Non-controlling interests\u2014redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofNonControllingInterestsRedeemableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityPreferredRedemptionValue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest for preferred shares, units or ownership interests classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date.",
        "label": "Redeemable Noncontrolling Interest, Equity, Preferred, Redemption Value",
        "terseLabel": "Redeemable preferred stock, redemption value"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityPreferredRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of Rollforward of Non-Controlling Interests - Redeemable"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r338",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails",
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r338",
      "r556",
      "r558",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails",
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Principal payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "verboseLabel": "Restricted invested assets included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted shares"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r39",
      "r308",
      "r392",
      "r618",
      "r638",
      "r643"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r141",
      "r150",
      "r153",
      "r233",
      "r389",
      "r390",
      "r391",
      "r430",
      "r431",
      "r634",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r187",
      "r188",
      "r201",
      "r207",
      "r208",
      "r215",
      "r216",
      "r218",
      "r318",
      "r319",
      "r573"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r548",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r548",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases",
        "verboseLabel": "Increase in right-of-use operating lease assets and liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails",
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from stock offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold in offering"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale price to public (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r180",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbySourcesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAcquisitionsDetails",
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax (Benefit) Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of Numerator and Denominator of Basic and Diluted EPS"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofRevenuesbyServiceTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r252",
      "r256",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsSummaryofComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r252",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Components of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r246",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGuaranteeObligationsTable": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties.",
        "label": "Schedule of Guarantor Obligations [Table]",
        "terseLabel": "Schedule of Guarantor Obligations [Table]"
       }
      }
     },
     "localname": "ScheduleOfGuaranteeObligationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r260",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Components of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.",
        "label": "Schedule of Interest Rate Derivatives [Table Text Block]",
        "terseLabel": "Schedule of Effect of Interest Rate Swaps"
       }
      }
     },
     "localname": "ScheduleOfInterestRateDerivativesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Summary of Scheduled Maturities of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "terseLabel": "Schedule of Restricted and Performance Share-Based Activity"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesOrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r48",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/PropertyandEquipmentAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/AcquisitionsandDisposalsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r196",
      "r199",
      "r205",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r196",
      "r199",
      "r205",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Financial Information by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r357",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r362",
      "r373",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r411",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r466",
      "r467",
      "r474",
      "r475",
      "r476",
      "r478",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r177",
      "r180",
      "r181",
      "r182",
      "r518",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Revenues by Service Type"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r183",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r185",
      "r186",
      "r196",
      "r200",
      "r206",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract]",
        "terseLabel": "Reconciliation of Adjusted EBITDA:"
       }
      }
     },
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SelfInsuranceReserve": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.",
        "label": "Self Insurance Reserve",
        "terseLabel": "Professional, general and workers' compensation insurance reserve"
       }
      }
     },
     "localname": "SelfInsuranceReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfInsuranceReservePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).",
        "label": "Self Insurance Reserve [Policy Text Block]",
        "terseLabel": "Professional and General and Workers' Compensation Insurance"
       }
      }
     },
     "localname": "SelfInsuranceReservePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LongTermDebt10000SeniorUnsecuredNotesdue2027Details",
      "http://www.surgerypartners.com/role/LongTermDebt6750SeniorUnsecuredNotesdue2025Details",
      "http://www.surgerypartners.com/role/LongTermDebtSummaryofLongTermDebtDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesScheduleofCarryingAmountandFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited/Cancelled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited/Cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted/Earned (shares)",
        "verboseLabel": "Awards granted during period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted/Earned (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, end of the period (shares)",
        "periodStartLabel": "Outstanding, beginning of the period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Unvested Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, end of the period (in USD per share)",
        "periodStartLabel": "Outstanding, beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized under plan (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Outstanding options, exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited/Cancelled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)",
        "verboseLabel": "Options and rights granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r364",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (shares)",
        "periodStartLabel": "Outstanding, beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options/SARs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in USD per share)",
        "periodStartLabel": "Outstanding, beginning of period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r354",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofRestrictedandPerformanceShareBasedActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/Cancelled (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of stock options granted (in USD per share)",
        "verboseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails",
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r378",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Purchase price per share (in USD per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r183",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r246",
      "r272",
      "r276",
      "r277",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingAssetsandCashPurchasesofPropertyandEquipmentbyOperatingSegmentDetails",
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r124",
      "r125",
      "r156",
      "r157",
      "r158",
      "r162",
      "r166",
      "r174",
      "r175",
      "r176",
      "r229",
      "r302",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r60",
      "r135",
      "r136",
      "r138",
      "r141",
      "r150",
      "r153",
      "r173",
      "r233",
      "r302",
      "r308",
      "r389",
      "r390",
      "r391",
      "r430",
      "r431",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r529",
      "r634",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/LeasesLeaseExpenseandCashFlowInformationDetails",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r173",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "SAR Awards"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails",
      "http://www.surgerypartners.com/role/EquityBasedCompensationFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r35",
      "r36",
      "r302",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Stock issued during period (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r35",
      "r36",
      "r302",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r36",
      "r302",
      "r308",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r35",
      "r36",
      "r302",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r35",
      "r36",
      "r308",
      "r356",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r35",
      "r36",
      "r302",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchase of shares (shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r35",
      "r36",
      "r302",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r36",
      "r41",
      "r42",
      "r125",
      "r223",
      "r229",
      "r521"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Surgery Partners, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r125",
      "r135",
      "r136",
      "r138",
      "r141",
      "r150",
      "r229",
      "r233",
      "r308",
      "r389",
      "r390",
      "r391",
      "r430",
      "r431",
      "r461",
      "r462",
      "r483",
      "r521",
      "r523",
      "r524",
      "r529",
      "r635",
      "r636"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance, stockholders' equity",
        "periodStartLabel": "Beginning Balance, stockholders' equity",
        "totalLabel": "Total stockholders' equity",
        "verboseLabel": "Adjustment to retained deficit"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r530",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r530",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r530",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r530",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r559",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Capital loss carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r28",
      "r595",
      "r615"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.",
        "label": "Taxes Payable",
        "terseLabel": "Remaining amounts payable under TRA"
       }
      }
     },
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends.",
        "label": "Temporary Equity, Accretion of Dividends",
        "terseLabel": "Dividends accrued (there were no cash dividends declared)"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r24",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Redeemable preferred stock - Series A; shares authorized, issued and outstanding - 310,000; redemption value - $434.5 and $395.0, respectively"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheets",
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]",
        "terseLabel": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityDividendsAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).",
        "label": "Temporary Equity, Dividends, Adjustment",
        "terseLabel": "Cash dividends declared"
       }
      }
     },
     "localname": "TemporaryEquityDividendsAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "auth_ref": [
      "r24",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Redemption Price Per Share",
        "terseLabel": "Redemption price (in USD per share)"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Redeemable preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Redeemable preferred stock, shares issued (shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Redeemable preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r24",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Activity Related to Redeemable Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/RedeemablePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Shares repurchased, average price per share (in USD per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r36",
      "r302",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r160",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedTerseLabel": "Less: Amounts attributable to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective.",
        "label": "Unrealized Gain (Loss) on Interest Rate Cash Flow Hedges, Pretax, Accumulated Other Comprehensive Income (Loss)",
        "terseLabel": "Loss recognized in OCI (effective portion)"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/DerivativesandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r396",
      "r408"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits at end of year",
        "periodStartLabel": "Unrecognized tax benefits at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesScheduleofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Uncertain tax positions that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/LeasesComponentsofRightofusAssetsandLiabilitiesRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risk or Uncertainty, Nature [Axis]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature [Axis]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyNatureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risk or Uncertainty, Nature [Domain]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature [Domain]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "verboseLabel": "Reserve adjustments"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/SegmentReportingRevenuesandOperatingIncomebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r466",
      "r467",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/OrganizationandSummaryofAccountingPoliciesVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/CommitmentsandContingenciesDetails",
      "http://www.surgerypartners.com/role/LongTermDebtSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EquityBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average common shares outstanding - basic and diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/ConsolidatedStatementsofOperations",
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.surgerypartners.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 16
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2793-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2814-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "24(b)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r653": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r654": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r655": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r656": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r657": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r658": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r659": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r661": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r662": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r663": {
   "Name": "Rule 15c3-1",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15c3-1"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>108
<FILENAME>0001638833-21-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001638833-21-000034-xbrl.zip
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MJ[W7^M?[U_"\37@OO<SC[CAA;Y=P])C?&:\ _A+ YBK I(,65H>6]=S.0,0
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M:A^?Y-L,H)N9"PB@+1%Y-%Z!- 6+=/P+G0P$ G%IH%G/>3H2@+UGV,U;@XN
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M5ISY4E^M#S"];T.LIT]:8!*VIG: $B(J&24IK9PJ*F,#U,8\V7#G(O6GY:G
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MLQJROOK1<)#XC!'6I7\ONN.CAS5_,1WT<73T&4S8H_$+[BJ#$^K0S":S;WB
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M_MS8>3]<1FZPG8@ZI>03))#&QT Q)E\B2<-O-&'F< &X<3"BI=3P 3RS@U)
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M&T44,G%P8"@:K]AK4R3%O[5>LC[S8]'DHG0G1)-#FJ[3,:"C\ 9"76>E0$2
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MUD45X2+6J,PWB%(K,'.4(9"RVE@/TDYK..J ,MM V0 T",S;'W%9T>;C)F!
M(2OMDB\11/(HR)ALINO)1$[GBX6<L(M;''*U=,RUA+U2=/)'MH03QNAHP+@B
M 6WPT:7HI9,Q8-#RO)+5E VM%2V^]MXO6"#WCVNQXV=3)*Z3Y.^/K9JH^5R]
M5AOJ,[;^76VHSP[]H<T=?(203$ H8*IZQFR$#XH\I!#4BMAW3.R=]\,5L6=
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M[9U7T.FW)3_3^[TGOQ]N;QSQ]?>._CC;/'NZLSMIOQ0?GNZLOY4>6(AHT^+
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MZ]/>V;1$:]#/QAM3,%<8E[D""<"TBKR)9W/-LR!$7:<!IVO@8SVX*@C /$.
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M@+!5C/!YE24QN>I=IS5>B=;8XV!B'BB0+VX8E8*[&$?B99O%\PK5!49"L=N
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M+FO&WK7]T81&-79UL\R-_VCO[*+[]/4+'"]Q!/./Q'ILGJ;L)^:VYWU<^'-
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MH2O;-1-G7[K$:KN;K,?8+#VU9',&FF8)AL!&FO%=&:D_I&]&5 <'KP112*%
M@]5V9'6M(BXR2)VQ"+(FN?B93B*'DVO?'6 \L."QBX>XG4654];M$3(H+?"?
M7(HJ]5HK4\8!*LQ>_)A+CXR1)I>+,14+4!!AI&[B>L%S&.H,P1X7#"#FSS@8
M]8>/IH\?#1_?A/@DFK/BA@]#110Q!L =&TQ,I7)&&[#)1S$HKD]T4=2PQ*"
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MQ+XJCY,I:0Q0(^*M<0*><B!Q//'R**&(23)OSCEY6G4Y9$0]M@[N$"6WW37
MO4SOW 1/L+UF;/3MKO:7XN4_EK-9A8MC2?0-Y6)>ZQ23GWV$&>:WWJEU KNZ
MZI*$5#]1,8VXFWT7R@6O3*L.HF(161:]<.I9#<NN!Q77IBVJ? CV<,@\TM[A
MG'HAL"R9?A[>.;=\,(HFW@]=L<(Q/J*5J-;$W4#A&(\KZHOYXMX\EOR>(^97
M>4N*C628[G'ZUR/(=&CNL7=@% /<5S%;&S')B_"Q"?$>-!SW?CAP7^T]K1K3
MJ@?Z<M!_6CDI O_L)'2V+ 'C=GD!M,]N-/= 0.\=O##L\*9J0C:LX&AQM5ND
MK]$F->PV?#ZGC#I)*C#!]X]7'5+B<>DIJ(LRGK2.^K)\QZO(L;O-CGDB>V_3
MI_2CX1,!6Z50(=XDRGBQ<BN4G(+)=9W<S8'+L0P?,S=Y($;X^U;ROYJ(/UM,
M59KCX!C4+@*=IN59%4 FB$$])X L4'ER6 @H5PMKGLSG;+Y9J@WB!SUB;><-
MIU_U;9EZCR[QV2-QE,;?0+^>N@_]\K*4Q/)-94I ] Y+7!^A7?];.Q"M47;8
M,AE60TV%E9VGJS^AEFNX?5PTA<F/R-Q2\T4*%7H$FHCW?NR8.&PVV_319O8C
MNZ[LT,4YCF@HM/]A?9?40EC&<N?MWL\P*-5JL?]1TY]3=T!C*H.1%U280K-Y
M*A#T%,QP&AG$W6T%J:*[7)3O*G& !7NWX *1$#N*DX \2H,(]QZ$M;HIL6"C
MU=>V(_FB)O,.#0(&G0WM>!4!,2B74AS4>!AZK^I-[[A/,22.!! >=7E1]0K"
M2N5=429VG14,.C2O/N8 #[@9<T"0JO'NACF,[$!8&K>VMD=&>40X+TO>VT%)
MYMBSS A<BD+XXHI2K_1?J*T?J8II>HH+L*'>1?> QODW.$P_J\ORHSI#VNTK
M/E&B$.H\B437RVG-P2"X7L->SPQVT)(FTA$F;@S$4@JON"4X_ZO7F,( QP [
MZ[0=;62_?RTYO*^IRXR6Z4LC.V+F9M] ,E!JG1>E6I@Y*7CSWT]R>G?*\!F=
M11B^QJT+6+-@VC69-K<=)*KPRS-XAUV9%Q0(33'\ZHSGB2X?-[W$AD=*4S (
M*(?/]T.YY-#KR2.@TA]^=UHT=[MHD%#+=<W H"7-I4,[)( 49T#W,X\FJRC*
MPETCYZ2L$HX(R;ZK^.SD$6Z^.2^N7_-N>2F<7D].R^NC6%[>)L$,<9>=)N&;
MK29BSDMJSHI*GB3>*4R"1G?)'R)H%D(/9MFVPY" (W/+()LU;ZQ3,\JD2(M-
M\#_*9<=1JT3./Y#GSNLM?/(S>[O_.U]OOEO\O%TC/RC'O!1L] +W/C\MPSM>
MAK=CT.2H2@D4!VNR]%_9,1Q;(Y#3S-[IS-*)TU7"A42<#(C9!%H::W?)(4(1
MU+:'!,Q,/\MI0C^BK0I+WU4#U3T)9%ZW/0O9SCL%T0<9,?Y81]W&U]G;9OY+
MU^4Y$D32?@5&3(J[AZKG+N.ZC3W?S18A.QD-NZVKEA;A!*A P("XTI[PM,P^
M(L>DG7JLJ9"!D@PCP 'ZS!HQD^S";:S(OQ_^]_$)_WOGCW+"_Y[LZMUXVE[Q
MCS^Q(A.J#8^_^,^OG0D% H@)_9$[384+JIX)K 4M5)(:@[99+0GI5I?%A? J
M:" WUE..CL1WN,[I(/Z8#N)[%UV8E!7H/<OB'J/=^XBT2MR^8K2R"(47_#1E
M9)2R&Y")\7!'56AOJN HZRD1FJZP=&W:9C\G,J>$O5,8*^'AX@ !UZ$>)5PL
MXBJOMJ"*<56X%.,3?.62IF&UKZ( 6&.ULNY.OA.Z61E!)V WP]VHC@=S-FHU
M3YTX\.YHG#BI\86WPW/-!1%5XX'W3^G6Y,-K]83K<]QZV6AE3M/= N:/5;VP
M- 7IS+:+:WR$;3%]J*-<>B\:R<!1.Z0R-2SNI7V-T22#5:\-S\;XJEC#B-1.
MKA\#TU[UEPQ@#5>4"Y6NP?3J  0F_,RZ-(.1"''F>B-Z'KVTONR]&(H?310-
MI7-+@43:3%]QS:\NKZA=$<W1PO3QOEIOUPX/@ZL!2M.#(C*\/%BO& DK%!C'
MN3S^+./KM9!$'&9^O8GQ5?B'(N%K)%*8I7U-&W^FQ'ICYDI'4QA!)RH6I7P/
MR9?XB5U?TI".0;HW)AQ;TK= /YFAB@7Z"SI_*9932\0'<!VQ(:*:O?2TJHW&
M?\?22"\VF0#/(#I'134=4-^PYJ"0C6/TF'MS?R/?:.TPC6'G,"''G!BQPTS+
MBG6 PZ;XP_R=PBI ,.^JV4K+,__@@X@UPRR24?MS_)HW3M?-5)MNAQPC/OPE
MS,US2.W0M#]%$\(O1*EQA';ZK0=-OG+HX5="\O**V7!I!Q(J)&S:1]]^\W4&
M]HLUDPP*B$0J9R]HN6,]O@IGG9(.82278/#7C^QRWWZ5+>[?^_G%JZ=/[\5.
MC<7W>4V7*1;?;XN+<'3&[W^=,9JUW(]#G0&,,C<*,%F'Q,11;5!/A&CGJ?<T
M^)VIO[&R]<%-*D2Y(H!@O$A$#/5IU=%$U!S[E[)7C[_)E"("[=96)WDWY>8W
M$Q'KFD;J(00B]_@-T%4'+B="C*>,9DX9:N[-X+E')/"JJA7*VT\NA3,0/QK#
M=)D&$['$_@E(!Y%@S%Q9+HOT+2VKK]PR.S]<N1PKVNN,$<>;;6NL<"6TVO.,
MD3;54L/RK,(X1^>XA%KSRKG9'/8_VT.,%**01&Z+W1&,099,/:U'"FW"$_*-
M_$U3& 78/ELFB38118:\"FR#F\'[:.D=TY5.O(')STL=W&*$IT^@UM&=CV0E
MQ0$V)PH(N11KK7SOJ-^1\/.7,1!##R@"2.X.Q6%4!%_DG"E"@F%MV>APN^,[
MH )"U,#D86%=9D(C$E8+?6<57LJ1H7%2*N$6L252EWDA%0&F#[&.P(0[2W[&
M8YNQ9H5JN+BWJX!+$%JP12N,UQ"%$/Y;VT1\*>-:)";7(8PFO8^EVE0#A_D+
M!8*M]"T@^.']S"5P8D(,*S!X$]9:: M-0!>8[%SZ3-T%:-NZ+OR$/5E(&*UK
M\!C=@N=N.;_!<G[555?YDH^V-\J:\-I[N$?H+_S&2J="0D<+Q*R49_4R7R!N
MJ[?&)X& Y,>PC]IU6*OHC-9F)/E=[([^^<7;'Y_]S,W1"@ F/3QK$X\] .3*
M/ WK,URH27NR7Y<.Z2%N!"E#<EM1O 6)09?-1;AQ(\=-$K# DH4I09>#XI:)
MCD*^'+T/>L%I?H*WV<8M&R/;2 B8.+7R)%O\_+.E5N+O7ZZ;*AS,B]=;THWD
M$2&!GK7FJ"KFG/ YT*^0 WVB[SN^3'1 MKUT8Q!SE4^PT_;?-@X&3?Q,8&A;
MAI_V0@W2=C[E8Z*7VP8O6A9.6T$,B#>\=#C5(1*IAJT,'(=DDJTQ,#Z'2IX2
MS;P@52RAA$RXU[GZFN8E'7P PO6?$\$9A3SAC"/1VI@& %, N*[00&5WYS6O
MG5U*Q1H&Q]5*%E0!)?SYZN8G +/Z$N#XHU1R?3O9"GJL]?!#=\(#8.26BPI-
MHZL*_FDR7"0P%1>=2G:H]+8VY8G3&7X6O;8EDS$LD0HIZS C7=MP]U*&&"#?
M\/G<@A\96Z<OW:-*!")BYI0L+DBOE9?$U3C7T82M-;V&GMZC0)XC<]#(L(^H
M9I7\<33KC#996//3Q83;[92*"&75WI,1*J*WZF9^G/)%=DSPW'+(=^!'$KOM
M[,W8H,A8L5^)%\N\U (&G*;($>$+ES'].CB]:_05:1)8(#>)Y6#B =><L=HV
M$3^&MISR,J]71YF,CUO*3I3I(N.I",=@V$:46V?%G8K)!R*KDC(&AV"OPPRD
MZSIC8BB<UC$_"7I?D:E)J3292_"B@U,<)GS%FSFWK !\[:N\JAT_<=R/4W/)
M91;.S<>D<++NO8;5W(A(@YI@"CEHR(NK=LDTUN9&1PHL5?YANS++(I4M-K72
M3$%:,FS:\!2]1N'T+*NZ?%_ID=0NEI>M; N6FG=#"PP0$[?N>0E<U!J%;9_5
M0B86_13PQS [(L0X9(L9^EKX)3O1ICMJGMUIW_3MG#+$P;&?FM-.F&EEMS;G
M[P.=R@][C#_L@D*P,&RI8LLR XOP)3ADPA3*ZT.+$S/MW%_&9NV8[F&LI)6]
M>%CTDN&WGSTZ^W*Q)JY:<>](>::D!<QBB_-^,C1*YSO=5#!=_:GP]K G< CC
M_*37!"_,IAYSSO'7)>,3SJ<>>K7QW:_+NA;6(=HOH]<Y6_S=:D9QLM5G3SKX
MJ42\74*'K&J+8%?<41]":Q&".0$+#5CXY 0LO/-'.0$+/ZILU<$-D\0[6OU@
MKV+J44\/*/7"9A(#DH ?2G74N$Y@C*%1H4DA.VK#]?3B1B\^UOQ)1C7*Z;/Q
M <?)I7[V"V1/#YR^Z9$2E;U<>N4(W9KQA,;:$Z<JGX8WZIIRUR]^8L$?##\H
M$&0P)512YAS19P;T_7<)I!!H"VT,(H9^0TJ8L7"@\W]+7T9HEL@[+?+!4B1$
M^<A)$V2S>DG;\,4LI<05A? ,./X9FU"^A\S95771=L'Q3A0(S,W20;+Z4>*-
M!3>)#O"8Y)V,W!F^  :(NFXY?1!],*+JX5K!-9QT'HI$"D'+"KS2D>:?^>LE
MJ$M(WHS)<.--6(N6^3*9+]!3U$YP@'LD3A3E!\,]4^3W5+9&/Q^C+2&^;?=>
MG[0@-1C1[$4RTDYCS;/F7K*\ZX[5I#BAJ<64Z0M%J(R^3X_0D<$9J':2?V72
M&0Z>IRHS^,)1&H67*;6$4$*M0?86T_= 7D;5$&FBK"7U8OM.QP]-E(2K7/E-
MZREHP#5H_7M7(L8^LL*:UG:%3EMF\^&1[MNSQ7.4W7):7=GB*L39M-?=*XP$
M#21T\SD0R6\KU4I2815H'O@KF4O$&R<N)\-NZM&G\*79Y!F.K3K:/^Z+#L%'
M@<.,^J.K3I(:HN6UI/I>DLXXQG(:3_G3-&7ZADP&0EN<-\=>2XM9.Z_*XI?N
M-1<TN )$2342R:$F"I<@DZ)L:?P,+CE%;+IA="U[G>Q I=NRC!*V\#Q#.OC5
M5VU-=178Z#1CSB] &!._-?REW!LZG*3_!L-)CI)R],<P01=A\I2[K'8LT0R,
MPO+_A3BYX, =X6*GT\@A6],:,JW;#QZD^_=^_/7MTU^$XIMP+%*BK\%,)Q7-
M:9M21/N49NX]UPUP/RYMDS=).ERQO7VPUR4RIG08.3V9$G5GP1\18,=T*_=U
M+Y?VZD7DH@ -J1^!3+$RRNH):5\ET];&F'@M?5#K4&! &7OV/</P_J>T!AL!
M:P.1\JX<OS7K[S"EAW\&]."8=!U?"PQI32%$QW9ICCNC9BG _1A$Q0C)$QUX
M!8X:]%D@BZWZA[4DZ8RY/"+$8L9]D^_2@3U;O%RM'BR#-['MO;=D!_A(M0%O
M6!-A\MRD]6EWBM09<+/#;Q5U6%5FS.T.7N92SB-+[#034078@.V=5_,F/)Q,
M:HB':MAAZ4Y N )2S4MMJ5F6QH,8G\\*\*X(*$/>J2_OYA^33'6YWA'-FG+Z
MS"CA33H!DM!K^*PK>X3\RK3@78<7B9;V;M60AQ^7:+US2\BODDAES_U'24MX
M$5S=73]:ZKKI?%EQ577 S[$?&8S0=O #L6>Q>5S,AV!59\E-#Y.U]R.9%HG=
MD>3G9\QF'UA(D84_N4BU*$46EXP,P2IB!!CFNV<%/,$>2O(=4!$& $[,W"0M
M0X::K,6Y2 [P"/5;8F>_( H?@4^DUSL##!X1.(X$B$8@A"YTW3!<OX=CSR$Z
M8QT'CA,5B@]\6UA.K8XP][C--SK,!)T^:-9->HS^"Z="7IOS>(3NR:^B9:EM
M69[\<Z],[(;!I]PJ2'V,9:$]72:NFN0\$UK2(3(ZTYW?F9J)M,022S;]8:S7
MD:A@'%"SMAO-N_1D9P!2-O9($"^S]$*O[+4S6B#^<F8H4J94)0S$)KV96T[
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M&*6#G;U;PFR)O1R#[<&!*P<E*L>WOAHO%E*"W6[&R:O9J)-SL>1J<@XHFW%
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M!R]>O11%)S)4;T0@\1EC@7]N:WJ<X$G^\LNSQ7TTU+^2'[W$C^Y];BQKHN!
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MLBP7O^;=\C+#;YWC:)L$0SPW.%C1#"*D9RV8C_?QP\</>5-NU,;5NB4G>_#
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M;=M51MV<M9!D98(DB  ZW2?<;R^><F>M[/O.PDQI;C^<+-_GKL9"#3/"LF)
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MWT8M[40)2Y='#@5DRAMNN=%3/#!)8]'JN=8:/T YO=9GWTC7[9-O'NN1B'1
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M_+.M-EC]H_R %0X^A:<92-7,M"FCM&^WT%(ZY!9%+D=.V6/'KS\Y'A^,Z/D
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MX8<.?3H'NT\J'Q(C935_-DB#PX%YR:Q<4:+.?$NE=4M0=M99:-@DH2?(3.
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MA_@LO9 J31J.!G-DS%I6R?D%H[4<3C(*CXER_;@<Q8U'<T!#\GH;^0!;BX#
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M5MIGE;D\!W,&7U,C/]%IGC=P^UNS+,H:R_;A;][G">-/A67>:)3L9D7Q :?
M>Q_5):7Y19%=P#>DU0<> I9VE7@S,@F,V4C^":P=-+;PTXA=R"\Y/X/G$Z<#
MWX;3A"5-:Y[(KXWG<U!4-$'3IH)EJRK+'@!" S)4(FE0='F>SLZ198$GWHRB
M96:(9@$,-=H,D]-QM/,6WA7]Q,0.._0@^NTY_H9'$MAS_/PW93$S20,KN@-3
M Z==S]26/*?\Y?_*,QP;C@OG%(2::20NT0;4FOEJ1!<@#T45[72:<>]$.Y<&
M_V]#_PT?O1-)]?T.=GJ*\Q7\/:[ ,(6UQK&D^8CYG]!Z[6_NS4Q+L(Q5,ZW2
M)(U+7*ZH9[PI&+8X\7;<;K313JS$)S A"P,;#:0(^3_X\;G\PW\'5;;U#HD)
M();RM_-TR7/^9P$K#\9RCJ1/E5M5(J(*GHR577J[<(#PE,[C&8P2Q8=F;N>\
MJ)984@;_M-,$SV?RB^(R5\81%AHR^MV'KO\ *X(\-^H1Z%N("\3^D2BW-GCH
MK8^J9S<^JNX3$\^/'\VL(<*OU^"'7:3F<@N/EU-:=T60L,90&,F(U!;)(HBL
MBN((R4H62HKF;Q8^,I;G<"+!R8!5CW&$B@B.K[3 UTSVCV&[P,0@\YK;$4CK
M <\DYANX:+(7G;Y[P3MOXMU@MTP4S\H"5,3!'A\&JN/_T-'&T2+^LRB1,RE%
MUQ&\7!SJR:%J]KY!X.N"(VZR=RS7@Z+T+D3>$7?\L:[%TV/9E.#>PFAN)R8G
M]UE,N,RZ-* #&YD"0A_!^5X:J@2>C)_]#;0+K\0WD_'S:,K%K_P7I+ZQOYV$
MO\'2[.]-GH/Q'R_,KLSTJN=MX.;9MTW^QG0Z>.=(F(2BR2'^70>%:RX/H<+;
M&=,?H7Q,#L8'?[//(U+!X-UXJ2CP:RY"KL"XKLMTVC!-#%+[H T I^*,32[\
MYXO7__/JY>[D.>P76,M%.F,K@G[B Q3LL+,8PS/(9V- N$"DJ(0XV?TM+F?G
M?#:!-!@FH").Q9JLPZ:$K_]W SO1E&MFT4W 65E<PN67<%HG)6BWG,X6$/ +
M<*&)YT8W!UV^2#_BP0Z:P(Z,=M@\KN!MQ'YT@4<&?.<Y" RRD<T:-SMP*^]1
M^3SBHMHE5B=:"31L:8'S(M\%LP[.GQSID-3(&4<_R>KSF9^;.LIP\[?GW*<&
MPG@7'G;PC2IS1T?C9UJ.S7]#I1-+>.T;4#KCH_!WECH4RU-K-V:KD97&$?P=
M-RD\X<<?7KU_>>J)Y][XQ-L,^T?/KGBYO>BD?9$W IKG?$9'M7"3X83]?'KZ
MQM-%8/Y49*& GVFP!'UJ<'J9OW/GA5BWO^N-O\GEXYTM/-C^8/,1>;APA><%
M.!9(K ;[$GN88- 33/=P0WL4GB.PSS-F)H5S+I[]NTE+O F.$I XIE-M'1X)
M[+2L6.)5.7R"^W4<O6SH9A3@%2Q,1-1A5YVZ_$+::#.V_C/9\_8TJ\]+TWN2
MC<3K(NJY[O$YNN*9<[1V^@['%!536@DO++*QD<< &NP2'0_:MPFK)'M=:WIB
M9QG _D:ZMIEA#B\Z6^*S,W3$:EJV"GO,6$G_!E9T+#W.9(/XWPB*YKSOIKW#
M\;/63:@]D$8,[] I'M%.6O.0D_&QY0,4 P&_#754]^(]=S$?'6L>3/\BQ2';
MN&\Y*EYC>SS\9^5FMF>%^(4]+T,]/V](WD!BBN;LG*^BP],% T:L<TU2R2]$
MOD94E* .,$W OH]C(8POXC0C[0M_A\MGYJJ\P<-5)+)W[=8$ S%A8LAPI70W
MXF'(&0N8U"*GH+($ 6 IEG >IT53D5*9(04(*A(,3N#<1H:9/A>F/B]P/^',
M8ZQCQ*_5 $5<5; #VV1Y<0Y7@[6:QC8D,;*W@,E^1AJ!;V4Z2[3J*<F'JY\T
M:*\(WQXIR!).;"51Q#'"J34EFDK<1R1%5FA0_H^>:TK2[H+PZ(39F\'A;?C5
MX#.?Y04L]2P".<+X?<$A$YSJ;21!_,/P[)S'B:B@7/X#E_TBSBBH5<S%(CB8
M'(,5'5@$<(,:-)-]9[#@[,,$EAPCG,5@>:(4\;G/.QEC9/0C:+RTCNR1!QJ\
M_Q@::UA5->P<3(F*U?TW^X?/W-!TR=! =;8WJ6#X@D-[F6]P$6\C<5[B>>B[
ME&V[[C>#$2HDS)G-X$3F:,@R7KF(HY"BPM=6I+) 724>9_F+T[<_OF/"<AQ^
MEM%68[;0J(X_&#)**Q"7= YORNL,C6;8#!JRHV,?;-^\L@<]!FS(8*V0P9+B
MK3$=KGQAHLJ2#7P6 O4$9N#IIJ J?\>S*)SB-*=)]@^WHF\1*$"6P&% ,\4?
M4JP_24:T:BHX!\?C [LF:LQ^UNWVQ787/;"/B6E-JH%<,$KJB?>UA4KEO>]<
MGF7%%)6Y^ICGZ'X%DLUA:]' OLUHHX*P&4'@<'>-R*EJ<KG"AKF]% )N!^=_
M!/:SM]M0[*F5(#HQQ6+5NDT,2C9ANHZR]B' >!.MJ(Z^[[V6%5;M;-P)G0(I
M?A7HV[.:M7 %MCO%BV23VI>K#T$[#+F:TSG,99/5^.\E*E.--"-B@SB!P63"
MG<6Q?+AG5<A9*YMS.X^VP-M"M8HQPZI98G3,.:;X&QSRJ'#1,Z58W)*R3SB'
MBS1/%TB4[0(HNB 7:=F A/Q@8#IR\D)<7*0_OF+C#3FZ%>+'N:0-FC :&\%W
M]T@W^FU&8YSXI*R8H?]$ 0V689-0LXJS)DV(J[+RQ5Z9H1/9+&184V02)B3A
M]A/%+#7D(KDL%/X-?D+]'G,8B"4TF^]BC"?&:6:7#+MGP(-MS*DS"6QRX;[(
M,H[B+L'@@GN8$+V9XBMJV4)HM"+#I,RXNK]>,":J9N#W-ADS6X<:1))_>&XF
MWJEU#E?101C[BBC*+6%C^!2P&.%JR5>.6J$HL&$:%%D)_R[@4_0)?3XKF2JA
M]K/Z0WRK"A52HJ$S?)C3#J'\=>4+S:XU;[[@9) E<\<'"(>YS1U1Y$ZM,(FM
M:Q9NM:15:#]Z9;,[WI+ Q7A-9J,7)H%)S)!6_.Q<EA^YSY?<N97XR#69N?*D
MKKY:(5XS&^N6BJ,MG0D_C[.YSO:GAP@'L)H%JTV&;BMW/I0OB#L+#82#-73U
MGP<>=J_MC==-Z1TRX @U,VK(E,?P/Z0-38XS"ZJE6("BS<S'=,HZ5#31#$\/
M=R-WI2!%R&<I:[! #7M:U^I:WU=;(!P ;D!,PTP.)TUBC:-7N06@Z#MDM'1>
MQ#(\FW'$)\B!H!DB!4QHSM5JU9XSB'I=D%"RC^N!7ZK:+"NQ7V'ZX3IG2GLS
MY5M;W42433^)2N>C*2WM:4IN)[RE^."\;<;K""2HQ^6V?NY5GC>%XT+O>W.O
M^SW-K;5'R48X*^.D(:%1^P6/I"O/LW'T.H].EV6:1?O[7MR>MJ!&PF.=&PJ*
M8, "'D? C*R '1.C:;B0LPS.9HJ98R0P#VYP@1T-A=L6-;P2($__;&#P2J=%
M [%=:_R%_V8R.?(:W+B0.WP(+/\2P_!$2TQY>&SMO?<W^(8<XS1-3MU9++(K
M =,8WG:,D$T3_0Y_BX[&T<ZO17ZV^QZ_\:69UCL:FKP>.W8%4HQ3[#PWV,V.
MXCT>5$R3^IM-MFWQTOM=[9!E[,Q1:_RX@)*-/IUA$C27M\95Q;:[;1L#>R&Y
M,@44N>R/O^%M."MV)-VPTM\</0_BK#A3@G,Z0_^ @F'J.+1N!0'R W=^5,V&
MVC2\-HI,S"J-;5;R<2O82E.VZ!9%2=V+XA01=2P$DW&$Q53[>]^_]L/'.))W
MS0+.%U)QIQS[QC&^P8Z#(%"[SJI\(U8E/6CR_6<4HJW,4/R(27RRY-#QMM@
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MQ>TPA@<G,5F/^J)+"@9-0>N 6E^@HLI!U>)R4TGF2"Y 97<>8V3,!B\BP_%
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MEP&I&$.+"!_:'IX-UQ<@E=Z!28+B).U 3](>"#=24@,GH!]_5A.G+K(3I[;
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MB^(M9J#93@#K&<>V8F0_(X0DBN@VSX_(#$%7F-OSJ,!5:"PRC8.I'_)0N*R
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M2X6^IZ5"21_;^M&F[0I[FS4K+*"7M[;WB_L77GHCESAO#]L2)GLCW).X18H
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M.ZNA=2;:+:-W $#2HA+9"%GX:$YU_[]X!6SNN9$;8^F9#$QB&&#Y>P'$OOO
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MN1?QICCQ\@)ZCW0E'C$XX)(;&<9#8)\%*ZXQ2K5;6'EIUP0XP'6$?R83VD3
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MO(9R*+.H.'-=O3HP40CIN#:?SKG:C#N4L=>&S<V2T7;:B0\_<TMZ_$1W&W&
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M'<R1FV95SG^(7"^[$/4;O;;1;'\PC?YIVQBT6]F&]8K9B9=/;WD4N2EG3Z?
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M/U@A==C-&T0<NMV2?1.UD)/LLT9G17)N7\#AC8A?=N7? ZZNS"&NS,=YBVE
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MVC2[&_NA?E5B5,R_?@2_ )O*(*# ^D5#5>  /X5(]8<T'QL4:NA[A!,3]')
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M@FL3^+ H>-837AYZ-BX81IZ5>(QRDWA-N/] 8_<SW*] =RK2=&J(Z%FD S"
M7.<_]"L:7 4MZMZ]T5!/N#-HQD8BWE%$?$7;0GVR2$>( 0<2:HLLTJ2KY@04
M5#A/-0MI!2G."5,SP002OA_#T_?2EZ'5@%91.E=PCX<F-=J@9-1'$OE\-,*H
M(S@5GNXVB UE_1=I)8O5Z01 KQ>^<4':(Z'8E=A E8+.HV&7E&"QL/P'V) $
MF$(E\ >0U)EMRS"O])7HCO)M?.DV$T].IQ^5O%LP('QEVBA@3^DI"J,!9+;_
M2(8H>*% R#[ZRN''C4&8;4;;2FHG5#=:H[\M,%/0MOMI:YF0+&2,=KU/G=A
MFF*(0"; 0;P(149:!36KR$:$(AU1(%EK$I\HA2;S:B_[O(AN/CBP':6CEFA8
M&7-[P,WF9!4L) ;=/I.*'C5GE*P9;Z#Y-;'&F:D.K3JM:E54S<555&6NAZJX
M?&TN5^: 7<2F>?- B7^,T4ZFLL@D9?2\O5U+6$U8EGC/8LY6'CSXX62["!-=
MU5" QBE8H&;U)T;9YA9&13\OTA*BWR\529&<S1D+2 /W7E)2,P7QB=8K>"?<
MQ>!3<,]3Z8ZU4MC<',U>U#R4AUE&:TM]NXHBMD,1P(\X[TMZ5THYY[S<4'@=
M@E!$W/44'?@"JZ)B[?=$)!89@DL=D BWXS *9C4&3.SY$\>J)386AG)'IJAK
MG7-_\Q$)B?NB. +YO 4X9YNS[VI5\F7PMCZ$'Y@:\L[^RYQ,/[$[/[8 5%=7
M-^L52F]G5@&(XP?'1</_CGN(:LYI>=D2J!W8B:HCA*<?Q,CB;'6$"LN$#J9,
M\:Q<Y3EHGD/K5<Y?8&O+E_L;W=9"?^/5SIA50QK6&]+P-N29'_U3G+ZZ_?W[
MKQ??_Y?=G'V_^W;Q_;;&+K^=+[$.2[+L\^MOM]=7EU_.[BZ^L,]G5V??SB_8
M[3\N+I8,;'B_I:^90CS^@H,?Q+$!^)XK/#_^A$7I:/VQ<$PE9:+XY&2MB,!@
MNHMS*7KM>KO3V6@NQ?)KO5[SU:==&/!@9_'E$BYVM06]_FR.A;<.5CG?*XAU
M.Q/ZYAB7Z%H_H+#)],77 %UZJV1;&D@&@H,.0S$%@YV"*Y[U6&'LXTH;/C#
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MWTI>2\O+3%YU:4[G<IL4Z.R%T9G55SAK+LYZ-ZTP":T-14:!=D$#T]&!48%
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MBN=D._5=]=O-GO^CW^Z-_DIOS[/U"L7-1W&GTRH)<]ZAG&9B4$Z_MS: QI@
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MQH6SD8(SN3<3"1YLTE% XRQ7I)) 77;PZ%+5L\)0KB<5XC0,^MX,/Q6 /RK
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MEF6T01%:O,E0R39I+%[O9W9.P6L=>)U*:SU]_4$30=+_, 04/#""/&B%:=I
MAA(N=)15=IBBC9IU]01<)9<[W2^J:A2#ZG%360MGW96S9CJSDB!U#"R M"(
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M"-CQ[%!&>>B8!AY0<)H2@0Q;VT#KZ&K=XE7GVY$9C#W UZ0[-3*M:7:WEKR
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M5=)$N $M9 3L4#J6!#&RFNV&KC$@_EF\ERN V=J-AX+9^\'LQ'I(VJ&7TGO
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M%.0V]@"NP< H!_!C('AB<$2)&"&< Z:8 /,.@W&,@HM6(6<,QPRM;5#<J,R
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MU\*#\_'@]YD$+N*IB(Z"C!X#"YZ 43@W ]8Q8B0-]3*/4)9E6L&* KAV$Z0
M^/X!/+%4DJ8BD$$,K!<)P$Q84$YK($1RZ8UDF&3_ ]:EF&1% 5Q[M*, ^/X!
M/+%$9(R(HA @"J: .:-!1^O .D]T4JLBDKF@!#<FK> )QD!R[..*P?'V>/ Q
M#$Y:K\Q@U N#X;-60LUZB9 LLRER@]-EAA$+V\W'=C,##1'GFG ?QN-8F:$!
M;,01@I(^FH!<-#2SG5B([8I3=17Q?7\E[P7?B^%[:F8ZLDD?Q0$HR@5AR3A)
MBHSE((*VE"BA&9%K&Y*5@K "[P>+F11X+P;OJ>KW1+6:$@O(FW1\9[/%$NF
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M30'C[FR[%X.4E9J#)H( 2X(%I6@$(E4"*4T6 7-9?> U11)N>7@M3]SPB=(
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MR4HL4#*@TG 5*++8:>0=]CK8Y*T)&UM&;,I:+^4'P6L[O#\=C4O*0\Z+&$8
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MN$=<68.,P0Y)1ZWW#-.4-&!_)=&1BOT'A?W;JU!>L7^+V)^9/41Z8PS)QD[
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MA6%Q,)@PW>LC.XSM8E:VNQ[;B7F;0F'01PBQB%C*04&Q!#DK+=*>!292PL:
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ME*<\9X#W3D/LV&-WVK/C0=X=K8;:> M&H.MLOWXV:E6+Z:6.!J."5+@2Z%L
M-X#&I$%N!X:#(EA"A['OSV;?.<DMI</I,&](/QR,1IWCO+-')S'[6YMA=2?U
M]D%+ R7FL#/(:B"\<6A'H%:5,0$T#T&!@JO#5NE-!OP$@'$$VD[ON'U_,!P?
M 59"US< .,G"".X(_)Z]NG,3U&+LOT=+G@\8:C28/MD4.J-3F+VLH'7M87\
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ME>-!TOO^I D37US?R:)TC,=(*"HBTG8;@.C#I-2LS^-0JGVX&BT;J4,B9V"
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M@(=E6!'C=2%4)$IQ-#XQ4[C7Y^D3P' _FE:?=QSJ>R/RQX4R7=1K)[%$,]-
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M5_,ID*C1>-KL1/4\"$Q2)'@%UVCU!6#!V&PE/)LIH &>$EPT1H,WPJ5W):7
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MC0IX NDALZ*JY+5Y):R>'\V08=6S<&EVVT^0Q'!7D[/6YN(6UL)+:2E70/D
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M>)I?>@J]EN!QB%5 &'U(E"-TL%,7/V"G31]*'["E12KM/IJ-;UG[>ZFWWLJ
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M#*>*6W=-]<K.D[Q+3W+OP[O/NP='AX+R+,K,$4E5 9XD!;/'K29YS)6S//J
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M14^4"EB=.E"BP%<C4E@5-??18^V@53QN0906X@(#F&]T]'W-7I*<P2JV@UV
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MC5V7$R71MG%5XR]$CB L)%I#8?CU[\J]-2,P,P)V5Q<%TAYR6.M90ZZ!)>Y
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MP 9KY2A#T4:'N',$644-TL0)JR(35L3,IW)#KA"?O@%WT<?ET0AU9_7'5"M
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M[UD87*J+_YSP%@B5"HV-#@:(C#/L+0N18JU!W6*6T725SO_SB<^_AVC&<A_
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M.A3#_EC>V9#UANR+[7:_SR#>%6"WX&P>NR&O<?A.'K8<(E_C2??6X@ETI=B
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M%[SK11#L(/5_.VN%P=&8@6;N&BT GMYB'<QU.+CZEIEI^@C,UGMH&"#X9SA
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M+IUULH40*&<1"15 %,88D07\1!0,4Z:TQ\ZKU>/2IW:QO0QU5KG M98AL*3
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MP_3TTH.BH>-$O--T%+J1BW#:NV9.5V:>/$-!G0(([1R:!D<A]W)V4Y A@F
M:A6D_'-+V.GY@M<NCU*,'8NI1A?=U@O._SB1_YGY&*MG<:.QCP4[T:@]+#0L
M1Y3$2C>8RM4$K.>T;,$AO>Y@Z9Y$I@);@PT11#&>B$P5E\RR0%B0)$;M;K&)
M[Y4ZEY^+[<5O@["5QKYG"\:[W>Y..8F?%KVG/\90LCZ9=C_=+MXY;\!U>]ON
MHM[<NJA?;I$#XC,GC8<E"2EA)],&&:D%<AG%1DK)+<<;'ZB\MBQW3!Y=[K!)
MZI+G!7J?@'_,&%8;DX4M /G5H\&G20+)/:E<5 9;7?_'5,@+[VJ]*/J>)1MD
MYT!%KJ7$&G&1VM<XF1<Q@G]-A+/8:Z>)63R7B-@[^-3%C 6N/-'**NVB8X2!
M]E/U.AG]TFY3D-[E(C]NQCPHC<%%T^D&)+X&><?;*L#XV-$L<@W OQESI+KR
MF.?6O2G9HM<P]Z6[)MKLMT7=1_FFY@^EY[OI,\'YRJG[.-DDV4L9;.(99 _K
ML_Q,@[W;;6^IT[FULNY1ERXI."DTZ^=45MQZ+I\KX<<KJ/1Q%I%^*Q'I:XY(
M=R@!>JWS=,4@JN9B/!=$+^N/N9 :QO(96'7EZT^ZQYUJ0JI!/LD@7U6[U>7Z
M5/@W[Y^4YZ*ZQVKN\;8(#/:6!IR>E,S@=;64_W)[^.XI9O/1=!#K-H]WKXQ>
M]H95;?-\%'8^PKH0DWWQ<=:RHOF\T?ET4F]^IGO?ZZ2^O07WW;G8^_Y7IW[Y
M^6*_N7]>O_SW\=[VOMB_6*QHWJ'[WS^?-])GE]_.ZND=FKOBQ_?]R\;VOX\:
MQSN7J4MUX[A]G$C%&A^+BN;&=IWN;1W$3*8&8!FRP@C$.;5(:2T1U9@;S0BA
MW&U\8 2O%=]K!3P5\%P//,'Z3/.0VKTH[H30P6.168$Q6+34A00\1%? \SS
MD]C M%71,8<R'CGBV"MDE0XH9 $SXXW-O-[X0+6LN R?3=\^S?5F>X3Q]P0^
MS@M XC^7=J";M/,TSHTZH^+X99)A!N)=L4>^ (-TMKJ_VA4>LRM\GC5'6>/L
M( 8;6$YLZS%#7'".= :_*JJYD]H8;CGL#$(]WAQ=(4]DI:CK:<!5BKIZ107S
M+:.&>D(]DI& SPB8B8PRX#@*GV584>=X,M_8"GJ$K"N9ZPMA01P7!:Q7)/0I
M[K&2HYS7Z^=7S(KW-?;*JJAJYWCDSO%MQL3[S&#W4%K"$F01.6HCXEPQ9+$C
M"*=D2PZ SW78^" RM4E7Y/P_.4EBA6$5AJVC'5QAV*HQ#/"+<MA: J6($@<N
MJB,:#%_C$7'<.YDI'UB66DSQQ[/ _BS\6IX$E1)O[Y$%]1+R(9[A'C.+MX2_
M]P6/<D7^U'IL4<M3G68J.!Z6[_1"G*=7<X]7E7YWMR2G]F-E=,WP\M7?8Y5Q
M*+GV8:B/1;'KNJ#G"U#PN6<FRA;4.D='+>]#]WUEI]]HIY],^S5<NK,#XKS-
M,BI0D-$B+KU FDF&J,."8^*TR1F&J_E>T7QKFGEE(D9$.9CO8#.D L<H9(:"
MF^J\5P(VL.N*X"<8,?^?*M^KRO=ZCD3322E_N855,9-[8L/,T3Y/25\JA4VL
M1-C%U#\GH\@$H9"GPFK.E0L^IA:0*PO[OJ#(;@4\Z_-JSYYH6@'/BH G@0[.
ML/%,(^F)1)Q$A[3..!)6:4LR[K2P #IRDZT1Z*PRT73]/<34GPXEKJ)UB5Z\
M /B]L5!KF4E=9:F].+.ST>NZ:@-XP :P<_9'\_.P_C5M I\O][;K!Y8)IKV*
M2$5P_SF'_< Z@A&GEAE)-"..P2Z \:9>HX2U2E]?E+56Z>L*]'7K0.K(E8\:
M.2=MR@#'R&9&(T9LQ#3B&%FBBE.L2BY][N3251L>+^&$\:Z NI*4K9>,MD]L
M'548>S^,/9^QB7#C<NL ]CY#,T<08\2D-":##)42:4FX#TH%+P%G&5]=X?=+
M2<.L]'L-K*E*OQ^LWUL'*ACF&</(F"P5Z'"#E',&5#UB8PW7 ,.@VQ1?R[>[
M=KK]!C)[YBNNJ[R>&[,45TP:]ZR#K#*"JHR@.\Q8:AHSZD](\]OCN#ELK_9I
MI_,.AM"KMG6>@CB@.N5[G,%S.1_DW3\(02HF8D0D.(RXI@1I01V*-+6PS8QE
MWFQ\(.KQ,=[URR^H-/4)F0,J35V9IFX=1,8\S8A#6&B/N&0:&8PY,HQ[J[/,
M$!U!2\7*BJ?6R/EX(09:=2!?)6W_3'S ?S1W2WRHL\;G ZX<9XD83@C%$"?*
M #I(C52T$6,A1:9,->.KG''G(S&ID!4;#Z:3= 0IK!D2FD8)H"N"SF9P(7<X
MWM7R!J#NBF^R@C3NZD1[#?R2ZCS[$>HUZYJ<'*2T9^+!-?$FXX@;0Y%2FB*P
M375&N18ZAHT/-*./3T.L\D_65EN?U#>IM'4%VKIU '!I7:*BI313B+M,(IM1
MV!,9P<JZ2&C&"FJS;(TT]4UFG\3KCDO6);)<Y9Z\2KNHPM?[X2M9S#S1C(&+
M$3$26 &R6AN0$0"T407!LQ3%M2)E^)$W1P!6:?>SVU&5=C]8N[<.I'4ARXQ
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M-I;>X[=V_?MGVH#OU"^_G#1^_]%J'.]>[!]_@GMX^.<;^W&\>[;0J?FB_OF
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M))[A&1___X6V7Z/ Y<_?W%.P$H/%I:*+B$<-F[N6$5E*#%(R9"+3/LNXN^%
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M=)"I"I((L:3R\]YQMCLGJ:UST+^"N+<#<3_I:+*"N)5#W*R7FDH@16[&<HI
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M_$^(BH7YF?EW&G NPB'Z2.$?#&C,:9 Z&HRM=9Q[[BB6!T32C?&WCB85(:>
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MR[?G8$E23#BG9@M-99YM%Q'HSQXQ+6V*)CB9L\?,W-SO+6"V@-D"YB,Y(UK
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MV9YO)[T\!VNB/N'-WKA;!URP5I9Q6/X]/O"U\7FW '<K@)L: Z.,B#@FCS#
M&>)$> 0:ID7")1],QC@B<FSJ:B'VD_?YMBS]R 9&R](/Q](3-@?&7.(4&9)8
M@LZB,4,6XX2B\-1J"NH,SPY1MB);GGZV//U81D?+TP_(TQ-BVGM&!<\Y(R:
MF$X"V2 4\IKK*%56QWQ5TKI(X]I>0*1C.P['<0X[' X*-ZHK38;]#IP!RBPY
MZ'>[N:"FR,FVL<Q5BVVP8Z'SZ6X$?%M%KS\HAF>;S;'6ES51WQ;J;@5U?M(B
MH9X'9;A%41*,N,4&Z6@H8AI;%12AA@> NEE-/Y_R-.^6@Q_;'&DY>)X</&&
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M[!UB07+G.1,IB:55<O\!R*US=&&Y^K&B&RU7/RA73UH<5A 'O(NT9J"T2)N
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M2_(ZMK[E_Q\ 9_]>?-J%WX\.V/;NWT>?UO\&\WD#GGE ]D-*G"GAD:/*(&Y
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MC<'8Y1'NRUBI929G3!FXO?#247#I79#8.>X=<]AY%AT&ZQAK;_ /DL9;0EI
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MA8R9)L*XQ,"6X-9$:ZE*2BLG"-':ZYGB<0+&\HF\"J/!*1!J&7MSP['JGX:
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MQL\C/G)S]&HLY\5]TP],U3MA>6NJ/@I#Y7NO[:M\#"X(Q BP$1? 58["3Q;
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MB\.V/< UG_%,8>HU,DGG8(;32!M,$>$D>FN]U#EKC+&5J^'.__EUS-DV;S$
M3K=;T5&GZ%TO(XM>";93-Q_/ ]#,CP5E>3 XN[N4K+V[.VFMUP,8W;QXEY<L
M)?=.MW?]/@[*"2(-4D:"9,0V@604 F&!'9@ T@6KEE:'AX,8KPK'6BK9:E<[
M$R129L$0K3\<DUHJ!D!@U5WRY:"1#4H[* ![X8(K/0*6 <7N V,N21J8$7D\
M$!<D&J%U%%82K$ E-:F%L9]/?%^WCS[L1YDD=P:.00!X<3#JD%/&(B6,<,9B
M'(VZ-8R=JS3YD,K44$QS\1 $?B:64%1_S3*TNH<_+.*7ZB0[[FQ2[\E?!%7"
MUH[0JRJ2K96X_./K6C-Z/ZD9;=LRV/\T?]NJ53:X]+_O,ALM*2(P<]:;P$G@
M5DB!B1-@5G'LK?Y.\X89Q/Q7?H&7C'[?MG?W]HF+,?@@$0N"(\ZB1,9R@PP%
M(]5+HWT>#D'%RBPCM0\T >=_4ME<-8$5@^'9=]"JT9/W00=_,,BZGZ3<!8@N
M#_M=^%X/)/$H&\^[]:K7[=F+%I??=M;?[ELII;9P"EQ("8@E\TQ?%U'V5DGE
M(K:$ V)=I99?\WF/=W3"8#HKERL4 HEW+\W=1>Z#C=P (:L(:XR!1Q=IY$([
MVFKN"T! >.O;AWWBL6',"B2=MH@KQI!6D:&@%,>2&VV%;47>.)O/6J<EII1Q
MQ0-/UBI)@+:9D/D#VHJ\6Q$@W3K:V]<,%'UJ+?*2Y\"CH\@9'U'"E(<HI/9Y
MVBY[>)$W/\AJ1=Y#$0Q<NY^BL0G0"CDI ^(\&.2<\$@8;)D/+@3F;BWRBL8^
M]' :RYV#V .LZ7;/)CU?F5B*W@B +1Z?=/O5@9W;E6/'5^U-G*A'JOQG@^C[
M![WB&WS7EO L/QH,8EAIG8ZSG8YZ'D['5"0 @I-:U-]6?>')L6A(3!HP0$MK
M5/9))&:)D,Y+<I/87ZN^/"P8B*UO8#!);N&D!'*!@/ZK7<C%:*#_!B,"UE+8
M /JON H&%\K+)+G6FDQY;R?D/.BG=4+^%*K:65_;MXY;I21#(D\7XL[;W,TU
M3\[0)$AF"!#;TFH",7)O'V2^R5479!T8&\:)R%CE@AR>PIW.4/6E.T*;H [L
M^<0%#2&_&>BS@2G0NS"C3+H?C;1OH>WAB="?[NSZ?3B$[ L">XS*[(QD!AG.
M+"*,,(4Q9=:3[ MJ[;(B)"5RTJI(+G$NI!&>8R<]LYPQ&NAWIHNW=ME5\CO;
M63_8I\)IF@1&,>;..28IY+SCB!$=5$Q.:N5N[HHL08K=S2R;'UZU9MD#T<NW
MK=T/^X(Y"JH-18IIEHO:)-)@JB$*,H^ZE PSH(G)NWHBYR#YYI'0UTJ^!R:E
M;5#J0_".,1Y0"IZ#A1\%,BE@!(='O=+*,LQ:R5?1M!5> :_I:'#D@G G6"2*
MD"B#],:P5O+=BOS(]A$H7C02:Z5'*N;^DCBE'$[12  U1J:3$+DR]Z8>R;M+
MOAQ.Y4X981CF20&^BB@ 4X6*S+/&(=E*OI]*+SN[;_<%Z.DL1HM8Y!C@RBF
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M-_MBDJ&D$R@%BN:D7BQ0PEYXY[3CVK<^K9JFJ:&<6D=LSK,C1(?$@[/<"Y6
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M5%CEUJ%"BU5"K@?PU<YC+];B>%EKME_KIBO342FBC.Q':]<YIS9CF[G&61,
M-J1[P3-670.)\U88'(X.X(F[AGB'Q[=8!YK=V>#F6R9D"P\4!&2R8-8F^%Z\
M_0$Q/+,^$S\/>Z/QG,()C5POVF-D$PSWG6V?VXO^RK^F\1^@?OAXE8%X=O8W
MSC&EQ\Q1S4Q1S</Z8J6!V;N]8KO?@=P7>T- M\LRE-IA+R/<?[1BRET20\(@
MDG(:E4EPBCOG.0_<4ZSVU<IZL^ "8($L*647X'__RZY/;^*-9S*;EFN?A_9F
MCY5YB[&R_OG+IX];G_9J?VU\:C:V/GU>K6TWWJ_=.(\E&75CI[GUN=;<J;W?
M:7S>^7-[<Z.YM5G[L-W8:+S?WOBS]KD)']2W&LW/M5^N#OY9\W#Q<^ZI:D!.
MA_/4!MAZKJ+2-!)+\S'K9!"$K]RRMW):WGH&\>I*-RD>^*XU@/WP]T"9'1 #
M>K56ISR%\V1/0<@JQ?W:H%N+_WO6&ER@0FF (W]\[MZ3JF=F+J>)_.BL/VBE
MB_*C%O!<!\:EGW%U;EV+C<$-1]<J2#\] (>##CQL>AG@C_Z@5IQ#\ TLV%GG
M6^SGWTLYJ78.9Z(]/>UUOX-,,XCMB]I_WF886HA<A<0#Q*JMD]-V]R+&S['W
MK>7C?"FKT1U.JQ"H^LTNT-?D]^]A%1K=P5Z$<8_6Z4J\DC^C>'5T@/=Q],8D
MC)'!+N1*5AXYT$*0C#3@G,HMB"BCHJ_+5D#>;?AEK?;E=M([A^MJ+HMA^0NX
MQ'8 MMI 9R7/PG59TN\4$F\^FH9T.3BT@UK>TUHH<F6*J[)=X6:<?[V<W82Y
M97*UG8M:7DT@X9N1;;24F9NOEKY8GF1;O=HWVSXKSOC\":SD %3M"7X?KROH
M5=-*5>V@3$A>JUT?#SS@[@'!2Q\"'D^,>'H0BFRTVUV?,7 ^?FR5,_BI(:%Q
MM('W@\34^A 0,<8") 2%-/442>(=Y<19CLN.3S=#PNJ#B.")510K(E@T$8#:
MG0+A+"=,6QDU@E, (T<BT 2WUCNOE<]J-[GM7"C0Y2%T\,2>WQ4=+)0.SG>:
MQZ3>W**-S0W6./JR#W("['[,I==#0CS3A1,L.X6(XM+[)&Q1B?UZD/(51<#V
M7!WB<+QU\IERDSR;67VUH*&\V:OY'#N-/IM2VA=K]['*%!MVITH,=+3R4$&"
MT+F2Q',+#O-U2D+7RJ6K+=RM,\TR?P%'9&MF)Q0:V5\@VO7BH-4K#9NQ$U-K
MT-]L]7V[VS_KQ2:\^W=@LN,?S#H[FUM#UNE>[&Q^;>W1OT_JS=^/@;3QWE$
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M+0TKZY(^/?"K,DXL+9LN+'&E8M-%LNF$K<+8)!4'8<)$4 &X)Q0YHR*R28G
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M*>FQ+,%2RDO]41\BD&]:G5PGV'?/>F776'?6AQ?T^Y,-DH:/*>NEE,V^AX'
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M2)"6E@(QJJ@8E3@1NK+.Y8W)#R,2G+19VNQ@ 6FC=5H04'$$G!4$,Q(<9@^
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MH4F:*(ZDLR!=4^F1-I8BD*JH A4N4NIG:S)IE["*FAB5$NA[Q@IG?,1"1*%
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MV6X='(QBM+S#>.E^+;?&.\VA??[0%@D_W=Z![;0N;=E58SP<D&>*.EYSJES
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M_&GI"15@/3]@-=Y? 58T-AJ7.&)"*Y0=O,A%GQ#ASL/6*APC*0"+ZQOK)U>
MM3Q<70%6!BR@91VQ=,H9S3V5Q@@E [%<.L=YTO=H9E !UC(!UEC"2I)1[EQ"
M204)$I;5R.I D$@^]ZH(6K"4 4MJNE02UILR LUGT.L._6>U!M&'+=Y<^'[-
M(.<PBP(+SQ4 F^$,!#!OJ<'*XV0EB?=0(RLD>UDD^S*I*\H0E%%>PNYHT!4=
M ]%+:XF43%12V,9HPLJZ9&ORJ3 V'TJ>5>ZJF/B>N5%P7D6KK1;!<,OA7T*C
ME\HQF1(Q_AZJ5<7$+\W$$_J3QTR#B. 15D+FB-^$#%,:>9\<Q<%C0]3*NC)/
MET4J)EY:)E8J.IN8#@X'+DUT2<@@O54JI(@#NX>Z43'QBS/Q^"16S"5I5,Z"
M501Q&1QR2G$$P S$B[EAFA5,O$PG\4_@;9L-P7T.']N]0.R^UJ#7#&).!QI"
MPM$DP3T5QE%M0+WV@C$L<:C4B:4#L;U)=8)P[CTG'C$%X@@7V" K) ,0,Y1'
MS@UV?&6=S:E:\^JMN!4/#WG82&F#! TB.,5AMH80%I+STG,EG965-K&$/#RA
M30@JHU91(6EE0)P[C0QW&&F>;**842-8YF%=\?";Y6'I64Q21:NLX8D)'6'7
M@7E]$+DXY7U\%Q4/OS@/3R@3FA"%K40Z2H6X%@EI3Q2BW#*:X&SF.JRLFS6Q
M1#R\(.=$R8ITC8KEUBN:N9+G<_@F%A)3^09]S0^>_EL!\P5T$*\<T4N#\WY2
MWV)P!AM+'=)81,2#"4B[#/LV.A69USZI[(C6<RN%/LYN=&\&^L&6X0H'*QR<
MPD'&@4FXRL'.B0,D.JZET,I&$PEF\3Z*:86#2X2#$SJK<]P1000RT0C$X5=D
M8XS()*,I@Q-/:5G@(",+<X)5.%CAX/+,^P$XR!F3/FH9J>,<@P#H,+&,Y,@U
MPW@D56#B*\/!L3SH*-;<>X*8U@9QABFR5&MD,38F$!F,T44DM2)/U_U?"@>'
MAH'10$9DSPN46[3E[X6>,;%H[#2W%SO+9346DGY9C?+N4;ZI0-CYV= ;(5>Y
MB:&V]?MV<W/CAR=%5\^XQS-^@GB**GNYRJU9ANSEB=K]6[:7FVGU?X\@U\91
M3[2B1]%F[G;NAUWW.F'C))<[+:OH57+J@^34K?,_F]N#^N<LJ^9FE8$RY3U*
ME.<BF%@BK8E#3%'&%#.4,U#8&3-K;(E<5!4H5:#TK!G*%2B]/"CM7H$2'"71
M1ZN18E(B[IQ .EJ!5/:8*^\4SI79&=5S6I)4H%2!TC*"T@*RD"M0>GE0VAN#
M4A)"BD"0M*$HCD"1"8JA: 2#+;6*B**M]YL,YEEF?*DRC9^^AK^\;*IQ'^8+
MOU60]N*0]GU2^1.8$T(\0Y;BA+@A$6G!#=*)$$H##82('&%\W5/[:Y6IN*2<
M_"/2C2O^?4G^'>M)WL#N!&D19IHA;C%%6J6 DI?>6:YMU'YEG2Y5IF+%Q$N:
M;EPQ\4LR\5BO\-AX[*Q%UEB"N"<.SE\94'#4<P&_1D?S(7R]Q7>5;ERE&[\-
M$%M8NG$%8B\&8A=3F@2E3A! +9:T0#PI B"F%#)<"1Z23SKAE?4%Q'PNG[VV
M8N)%YQM73/R23#Q6)[205&!'4-(Y69%+CBQA"2E&C-&!VT J)G[C3+RPA..*
MB5^2B<?JA);,"\X$RF99Q WC< B'@+".(4HM0<D@V290.2E>UDDQ:L99^2:>
MTS>!;=!.42.% .59*N<9=\PIIE7@E/#*-['$.'8YJ5$$Z8EG+" G54)<Y,(G
M0DDD.6:>62P"#BOK&J^IRCGQ)EF98,N5E=HYHKCRVJC$$S$1<Z&Y(?=1)RI6
M_H&L/-8K4@@8AZA1I SG<"Z-'.,4)!2E4N0\.&I6UA6?$V):L?);8&5A;!"1
M.NU%XLQA:[.CPF,L.</6\7LH%14K_T!6GG!66"^<CP%)%0CB-%BDK:+(6L*Q
MX92+)(M3^7I[F!_"R@MR5)0<R99;Q7A\(:,G1J3^K(GK#Y[^4@/ZRQ8RJF#\
MA6$<3RI77@M,B'0(4RVSSUDA;2Q&7F(A&,AC5&<CD9!/#QUY*),L>?1]A74_
M&=8MH%A1A74OCW5C[5-2HFD*'A'".>+:>>2P]$CQI!@6UMH4,M;I"NLJK/NY
ML6X!!8DJK'MYK!NKY[!=D3BA40P@W'&=$C(R:B2BBYH3XY+) <&,+ZQH^.LH
M.K1D)4>>L9Q/-<IG*#JTS-&K\XL.?8H [+FL2X&IM6ZJ+:0,T7VC:*IG+.89
M/T%@Q"]_=OO]7VNMCN^>Q)HK9(717X,L*_R(TNQO6+B=-\.EEE\?XFA:@&%R
MQM$TJI^Y75!DIM51"<U6YPP6<.<T]@J,O1)S\W6ED N_]&$5*XGV81(M'5LJ
M=\7.YO:^2=PS:4"#SYXG'FQ &G8:2>N( &$6\QP*0O0<H?8U^X\KD'H](/4C
M#(H5-/T(:-J=@B9"X8R1-""A+$-<)8PL)@GT;\IUI-APK5?6!7^+*;@5/KT>
M?'J($+4 *V E1"T!4NU-(57D3)/('7(V=ZBA@2)M4D0@($<7F2*4\)5U:98L
M<F?&[F=><ZWQZAF5R2.#<2,.1A8..QCT6NYL8+/1<M"M =NA#,:];AON.X#+
M2J])5=)JV>T&TR<=;/'XL-N8V.1FM]'M3.SPR"U6G6\/.]_XM)'@RSZFQ"@I
M'(J.&\1%P,AHR1&6,GFK ^A6=F6=$%55LWJC3+QPQ;IBXN=GXMTI)LXE!4&A
MH,@DFA#W. (3,X*<M]S@:*3W)C.QF5/XMV+BM\#$"PM!J9CXY9AX;XJ)C6))
M .PB*9U"W"6-'+$895N]Y40 %KO,Q/,ZH;[F))%E5CDF ZYJMA-J=B+DJBIM
M]1IR)4: -KF5\'L[5D%T3\8P,:U-^'TG(W9.)>2DE8A'S9%51B"0,(/&C $M
MZY5UL[@XNB4*"ZY8][D4BHIUGX5U=Z=8-W%AL5("*>8)XDDD!/*B0HEP+QT5
MVAJVLJ[D4E7 J5AW22/9*]9]5M;=FV9=QFV*GB&BN49<LAR^;C0R3'F9A.!6
M@_HOYYGPJN)5S\AX(]6X%K^?QDX_KM8Z<5!Y))9;:[C1!U_N96D4V2HWM-'M
M=$L??.>@$2L3R,. ;/M\6GTXWA=4 F+IB**7$?' )#+>1D04Y\1(++G,^=68
M/%U_J(R92\O$"] ?*B9^22;>G6)BHUGB3CB4# V(YZY?&EN#0"S!#G,BN(\K
MZT0MH MAQ<1+R\3/&0U7,?$S,/'>-!/'8 +)L;DB2<139,APT# \YHYB"YL8
M<^X 5U5_C9=EP:W_/6L-+I"S_9CG>)*IOW1/#)6,RBNQW/K%-)A]/K2]^'O>
MS/<3>UG!U\/@Z_N4(M'<V@]>4A]D0IHJC[@+#KGD$W)*29!*)"91 7RQ.5&[
ME3'SK3#KPOT0%;,NB%EWIYA5RIA8,@1Q%33BF'.DA= (X#,F[77TD0&SSBN.
M63'K6V'6A7L>*F9=$+/N33$K ^4^42T0YI8BSF _#/,<21$\$5%'8^W*NIE3
MD_KG<36$UK<?4\FV!_>6J[U:I$ <]"8BESQH#OU6\;?O]@?]VF@K%CI2L:;%
M/0;[VVFW',N[7FS#(+_%WW(I&L362+Y]=F6!C?,35M9_(>-0MV*9*^/-,JLY
M14&SW\_Z,)A^'W#8M3H%16Z/B?-3WO\,TD"2&YU0C[V#V"O^JK#Z85A],:T%
M?=E7!HB5!8S@2 4MR#.+G& .<4&LD!I+V-N5=::?+EA5AMBEY>7%%F*M>/G%
M>'EWBI>C]T*XJ')VAT$\"(<T\0PI' &BK7*">.!E.2<XO.+EM\++BRTT6O'R
MB_'RWA0O,\6-XCE*.KJ$N*$:.<^!H6D07&"<1,3 R[SRK;QPO-;)J6WU3F)G
M4/.'%NB]ZE[^*K2,D<EGH]^/@_$FOB_WL(*KA\'5Y;0:4=]G%K: Y!)RA!/$
MN</(&H\1G$54P-9%IS-<L2HR_ TSZ\*=*16S+HA9=Z>8E0!3.AX%LBZY7%E-
M(4M2!"E#N0#BA1-%T\"GQUY5O+JTO+IP7TK%JPOBU;WI@]5;0W'T*"4!IRML
M"'+4".1XL(*G&()T18//*F_C15DMESRH_7)@6YU?:\!IH=4_[?:!-0H_2L@E
MXHM^#67IO2JIXQ7H"?/:H'Z$_<T[O=/9+#:X<$?MI +KLL5C<WJC*[1[&-KA
M:37B8%]H$95S#'$J<D@I3L@98I +Q=X*R3A()F).8_+*@+G4K/Q#BDU5+/PB
M++P[Q<*89Q<$!I4B) PLS"@(+(DA^(P:)S5E4:RLSY-7JBI3R\J]/S2GH^+B
M%^'BO2DN)D$XQ8U',BL;W'")+.48"9++/U(1@9U7UMER)5F^M/OA1\5P_0G4
M?U!&;0'Y#]JQ<$=DQ:,[.(R]6GO\_2N.XJ)/B>*JS$!+H3<-'<2#[IAD/U]1
M+,#V3J;7\7>5Z_@1V$W&2M27\_KFQK[S"6NB/2+<4<0Y<<APAA%V3%+87$^#
M75F72V4QJOAZZ5PQ%5__<+[>G>)KJ0U7#H,X1FU.A#$662D-HE;@2%BT-I"L
M62VJUW;%U\O'U\^L7E5\_2)\O3?%US')$!F6"%0MASA1"6G%+ ((U]:"JB4E
MZ%I</CW4ZQ6[>'Z4KO4IPGW?8LT6/7XS&[Q2=8I523&O0IU*W=Z)'<"SO@_>
M7<9>-]C^X:RO_6_;/BL >*/=[I[;CH_9!C8DU?[&F%0K;'X8-M-)7:JQ>; O
M(HDZ!8,2I:!+@;R5K=D$6>64II$J)X&Y_L]_:$KH;TMD"JL8>^GTJ8JQ?RQC
M[TXQ-A7,:N4- MD+(\ZC1<[!;Y(E"1S/C76D8NRWS]@+CX.K6/CY6'AOBH4U
MR5'G6B/)J<O-4.!8YC$B&T &DZ!!.1%6UNE2!8O\!!DR9>_9@\(E-55/H*I#
M]I9TD9O2 \?;OS'>_6$%Q@KR'@9Y;$H=N=S>-R$)X0-'VOF >!0&&4HQLD)0
MYKS%/OB%22V5&7AI>?N9U9&*MU^$MW>G>!ND4&ZD#+G+JLI=Q!VRU$D$TB>V
M2M+DV>),#15O+RUO/WL"?\7%"^7BO6DN!MF*!!&0Q!HC+KU'('#Y?&!'J7 P
M5(N5=;)4>; _BR\G>SESLD[L^U[WO-:+[6C[\76Z<WCESGE-S>MOPN)Q7/,D
M%A?T64'Q$WPW]<WM?:>8D%A2Y+@7B#OGD;6*(N^\L=03RC%96<=S0IBK3(1E
M9=[EUY$JCGX>ITWF:)5,9%8XE+,3$%?"()V(15)QB3D3K"B*5#EMWCIK+T!%
MJEC[1[/VWA1K2^LTG-,&>4E!;XI$(A,<142*: 0/U.BE9.V?P*%3E#K(-0ZB
MRVTJL^T B/\P.S$K!\[K=>",'-89U?IYCR, V];4]NZD3=CS"MN>X+6I;^[N
M1Z8B""P6:95KN'@ED674(BNH=#%8##)-9=E]^PS]?$TK*QY^3N],YF'IJ>;,
M>1!-<I5#V#ND@W=(,T(3I=P:GCM6DJ='FU0,O+0,_,QZ1\7-+^&ER=S,-+&4
ML(@, #'BR0MD;6Z"0 P31'CJ+%O&$_DG**S6M-]KO>ACZYMU[5BS![U8UC=X
M2LQ895A9"I6C,*S !G^ZVM^-T?8._<^_QTY,K0K@'@AP?%KEV-L'$=,FZ0R*
M*EG$J6/(4)T0DY8 VF$#!]@RFE,JAEXZE:-BW>=FW=TIU@5=0A'F+;(A:L29
M9T@;J1&U*7*G8-MR9@I]>OF.BFV7EFU?PL%1,?.S,//>%#,3I[02TB,?9,Q-
MIA4R5B70.V#ON%#2L\69_I;/K5'R)5MNC:/,R8JAMO7[=G-SXSE\&G?=Y[J]
M$'NH7(5WL%ZUT#W+ZD^>_.C;'!B6U[0H<UA^<R<(+MM:_^=#M>:%K,Q;.186
M&XZV97L=6*+^[Q'.BIC;>O5B?P#'0NQOQE/0P5ME'F,G;)QT8;DNJ]*:CS@2
MQ+1J=K!O@K%.*X9$]#E"V 3D&/,H4&JU<Y:9W,J<"KFP0DZ+X*$?;(*N +0"
MT*53ARL ?2$ W9T"4&U)(IYS%!/L$R<B@()L0:8.F$K-8F+89@#5%8!6 %H!
MZ+(9)BH ?7D W9L"T."5X9@II&,  )6$($LM0UA(0R/LI8L2 )3QIU=W7P(
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MHIJ=0+JHX8J.]5;RVVPZNR&P5&(;IT#X($@VK"2,X^X2L@Y$91MM-(+2U.1
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MMEEO\ZK/<%>.'V^+#DO7^AP"3R$Y(D6Y1QAR(,6@(HDE%2P8^JC$99NKLM_
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M"3&E4KX<);'9>Q*YRB9*SL$TR?EZGK0AI9/VA:BZ\JJNKGZ9S>^2V$5W-O$
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MI:+(H>2)8SFC;9 UL4'F4AW")6IO9-( G(U[- ^IH=)@$'BX5/N(UMSKJG!
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MG)!+@P#9T)(=3X>QO>5V0HB5+"0O? S2 $G"H<[E0A*7 4A64;B4=52\20N
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MGI_7H?4UIK?-/N88@T9+.:BDB71.$&]4:6%@P6C\C0I-LC-W(V](%0DM\--
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MX3M#4DWZ0NZB0RI,$E_<O+>VAM[# N;H>)U-4U?LZ">+>Z=SH^Q\\EIGPH3
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M79*HZ8GO7TV72/-9GHFBA0'MF8 LF(8,+#J:#^:2G?>&9&3;+,%#P#]M]3L
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MK(1LG>I$=,<!3Y#[%J(>L"[=(U=^'"4JFPTSM2*M!J-8R+PP'U1-#N=:=HR
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MI@VR.Q,-NE,]F4[:!=_75/[]:.V;E[T+)P=)Y9<VY)IJ%D--3L\>6#2"O&A
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MOJW-_NZT<'5)2I4E$\&N:NE$1E:]J37^= Y%0I3="JIW'_,H3.%]V'JLM_Q
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MZOV)*JMX<K*."A3FN/1>.^1BO0S&,+KU ,GA@ZN&97PVI.0;V*7W -WTS^D
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M2I&_ N2^J"Q83,(Q9S.) D61HEM!C$<&.1%Z!Y'A6$7NHK.EU)I^5D3%=(%
MBTJMJ%H"%X('\E/:9!$?>9&[?7RWO07=J,_.IJ(O'5!]T47N>M'6L;;9#C(?
MK\@=QJ+)L+2LZ$0K7RVU6^N]U!LOR.B$T[Y)Q]9C+W+70!'ZB'J4(G>&YB%3
MS$QE#W6#\LQGJUD2M.T9Y<'))L=XQUODKA=%3Q:YZR/?!G=Y][V*J],(E2&F
M$ED6H=;@UYP%A-K,2Z7D?!%>FQ:,/X1R*IO_GD(>,-=Z,Z*;X\,.F%IN_)M
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MNU;F$# KZQG]4UOW&,Y 2(*?8G8&C2_E:\O1<32M+7D-ZG1LN@/' JJD5$U
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MK^'RW>3MJ$SPO]<UB'^&5[_=!.8&;54!;U@PCFSK'#.+'#US)J.(+M(:V>0
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MC.;'I/E).=%C':S#[+/5<=3%:'1=KU:F,[B\G.]< \!H4[">0?#U)(IG\DP
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MRE1N+X*]5H=!O,14'+DOBE=FNT"#M9X5 JM1BA),DPO1K8A^DJ@G;36I=T^
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MM$1;4XF0*6,CUH)1*,ZK$TH;.3RC9?+9'"(UX^&S<HJ[BV, 7-K@HV <-<E
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M,0*7&# ';Y_N7OGTH/?3ZM(=>(4CDMFLGC/LI[--S^E1(T_"7),W+75!%PG
M!>K$R0Q5+IJH:1::I)(:/ 6X-VD>,A$>>5Q;V7:AM$A)9"]R=CSK>A,.F.F_
MY&(I$4K>*.*^>#LO!_?Z>C(A=^2W(<0:E#[$O:2\[5']2;@3V#7I&B,<.NZP
M:-1!"!]<@9*DUS*B2F;0 7:?DIV[>WW*=_G YE+>!'Q=UBY(PY$+B%(+;B+$
ME(JQF,F5E1"WR?KA$/J4^,I)I[5_\R\<L+(<^LKF6MMO\&MZ3876_^AH.9*@
M,2:O@[/!*.,PV1S2-KWN(X:]-$\[_=5P-C]F@1'M^Z/:@1U':<^5[+'']:>Q
MSJ#7M*$"Q(R@LLY12T=>:4I.)"L])%^4&72$W[>D#YA&'9YZ%+EWVJZ-X24;
MGKG@NI BA$]9:^/)T2C6E\?$WT^%FG]=0RV+@?@N7@X_S\W;Z6\WH5$V1!ZU
MS^3<V4"N*U<LH-4,2E 1,,7BF_0Z?Q35P?<2>%G>CDBEM1;4!YSBY!L.I F"
M)^-9"(8S;:5AWF3/ ".DHIR*V*9*_@8PQ[\0[8\%#VX:#A5VB\O+Z6QX!?-Z
MU3? TO@;3FA6#2+G*GMR[LG.<[4-#,$BZYDE\A(=?1!E;E(AZ#%0+XD0O0F_
MP8WE;R35Q6 _XFRV"):\N!I?+V]7,'\:SXV/][0/?!\X""K;()E"3F EKT4?
M%#!C8A3%!*6X:<&4G5"^).JT4T^#4@+_(EG]-IY./^!E9?NG\2;T@RAD-"Y'
M)J(13/M46) V,LU-MB7EK&R3Q)A.Z%X2=_I71X.L^3<89[?E]5_!=#C]^'6"
MD-^-_H+)L'JV-5%,#)*4TI>B:KT9J*G)D8&!S#36LH?.<Y>:+#U= ;XDYC11
M2H_YXO,(DM?C2_K1>$(#_X:?X)^+SQ.<4_K]9/R_BTPJ^.<C?"/O85ISJ@9(
MVRHMCH5%U&2"N=K2-]G$G(R.>ZF 1-,IXF_7-[\$:K07>8-DZ%]*P7I1@6]'
MY+Y6Q)6VU?@B=_)R$09T,?L5Z6UP^7$&LVMZWO=[OSP(10<AH:*/J?9'1A:2
M"<Q8$A[9\;2G-JDEV /VE\"[4ZFRQV3CQZ?.W1H"=U;:\;V5=I"U2<EKPXHC
MJI!GX%A46C#ZPH+UWCKL5D[[,!PO@5''5D>#[%P"C-/W\+WB69X*7XSR'S05
M%M\,>*(5EBM+@A"*F.X%[<LI,1\L5V"4%"A;+%I/ 7L)_&FBA!XS<^?\?H,%
M"46^60#OW!K\@;-WY<UPFJH;.=#.1>E ,DS2$)7)>PPJB9I)K)U1PGLG.ZTL
MG5_Y$DC04,@/J1".0X4EB0=.9PZ^1EE+$'6OY.01ZLB,$)K,.=!^/57K4$:\
M?CFK0WN1;S@$/+PH]TT@]B:)+$*LDX8:1T;2H,V/:4%$!A":E1*TB$+:J+N$
MTAV0G[\5V[$R[QO>&?2L@'-)E_]S=#V]ALM:,.O=Y,]1PLF,YN7L^ZOO?T#M
MA#N/&0:'"J,/C,8@F58%F0?ZRF#4R6II;9O<T"[@3I\:T1,AQHT5T^!N8AO&
M!<)5#F('C"VSX[N /$VV>_\J[LBA@_5S*BYI[U&4FK>0P=$_&EB('A@&K4%F
M;W.;UFFGX] 32>?G0:%=U-)W;OGOY.Z3XW]Y^?WW\017/;:&WU;1]EQ" !L"
MX\D V?-:L*"+8@C<%Q6LAY(Z&<M/O.CXMG'_JADWDFN?&205VQ_CV5/PO-6N
M).&9TH$&[ZQ@467)O,M"V2237"_\LT7M3[_KI6F^9^DVV"ON'O7-5S@L*GM,
MR$J:][I(ED4N+4M"D..>G22'K<6^L [DI1JC!PF\02##73Q+NG=!U-+,? CI
M-$;E8:IZ1.\'R+GQ$K!$)@+(E&G!*XA$\#(_K1&6*1F%,@*Y:!,E=RS-/V$*
MME;\+N)M$0<W'N7Q:'[[$V'TGW>EX 3G-8I_>_OJW8?EQI1E\(H#9RK4>Q]M
M"*0.GHF<?=)*)^"V!0<ZH3N^H7"H&M>#W7K708-(VN45\Z_7HSR]N93^^#=\
MG1>!7T#45F0.$%CVA$ZCS&2_.,DB*/*.LE4B-&DOT ';LR=)W_+ON8! #3V8
M'Z%^3#BBD8_G:Z7T68*,@2E7R$7F()A/)C.))DM3((7U2[;]T] W(GAIEF,_
MHNXQGG$.:(GCS]'T*Z9A&6)>$KX+J+ZKNFQ%<_P:+SUH:MQ*S'W/_ZW@7 Q&
M>W*3?8VQU5P1. B&914M!&4XV"ZVPSGJ_I'*,,=2_2[2;:3R7\<33#"=+3<A
MX 0IT?YC#.T_6DG-@N.<N0@Q))5TT%T"EG?2]WT(QZU!TI-N-FC[ ,%N-0!;
ME";YN+@S_8!?QY.:M'@?1+=4S@?/Z"]Q\W%X#PI7J,(=V6,V):U+)C5%Y%JA
ML\6"$(/'@/8BO?TS_;<\J9TD.^3V>P6TP 45=4W_%B(8)+R!C)U<:C7#!_+L
M*:E__;$?\!N.KK&FUKXC.P[JSQ9A*O'[XI?J>Y=_=4!*<B_O;:>QP\6P7KLA
M%P."'!=:@C0WPCO4Q4@9E:9Y9,,#_>Z%X- LX/L0WH[*>'(%2Z$NHUAH=38B
MTJ[L(-;R4=ZRH!"9EI@":=C0UMTDS*<#N$-]]Z7,?Z5]J^:5US8L_Q[.OKR^
MGLY([A,2_^5UIG=?3*=(_]=LAH'@QDD$S[*K_56\I]TF.L.$$RF$HI*73;*D
M]\!Z@JK2?3-JW=MOK;&^KPY_@<FH9K^\0A+$37_ >:CP&[RM/7LQRA=7563_
M=_[MH 1;*R$HEE0 IHOF#(PER.3^"JB18U8_M>(>\/X71)QC::%%\>@UF<P3
M>S\./X_(EDY0/U@FNY"X2#XT'Z;CRV&NN9TW3:4J]8N,G)4Y]UW*+&:MF$4E
M1.36AYB.L7KO@?T%D?!4&FUP%;HP26H:\6H-'HZNZU 6-@LA7DVR9:@S33'Z
M8CH;IH$)M?"=\HPK8TA@"EC4Q=,_0ADPH#)O<F-V .;3D[ Y1\:G47"#!?,/
MG-VBOYC-)L-X/;>:/XUK&DZU%\:7<\$M=X"!CD&YDB0)JH9H"Y693PA,2H6T
MNEN:ZTV,VYV1_G@\;*O,!BOC74N"OK[$32:%*]Q'T(X,B1!IAH"AW2,7@@R9
M"\=3#$V2)KJ ^_$XUKO*&A3$6-%[,1EJ4]C1%&D&C%>'!#11!B5;K=!+%D0]
M I40:,W%S 2A+<K8['F3=:P+N!^/5KVKK,=2&3<RVMA@8V!0VY"Y9%$(0F4]
M,,B14&65DU5)JM(D4F$SG!^/.CVHI<>Z&7/G^=7UE)R?Z90 Q>%HCJ<2_//"
M&EP6$WH]GLX6C8WK@>O\NT'R,240-761FUI>@:Q!JRRS@1L)&J2'M0:^6PXQ
M]D7PX]#G>(KJL0[&2FCUK&[V]NHK#"=5>*]I"GRNA? L!.NT8$X$S70QA<5Z
M.RRU3 4">KM>XJ*G7KH;X?PX7.I1+3V6NI@S?%7![-WHS7#Z=3R=:^!=F2.M
MI'Y31;*40ETV)2:,8#6C';5V?W.R=H'*+  OPCGO=(9.*]".+_YQR-)<+7T7
MPE@K@C?;6 2/,,\%>/O98J$L!@N9:Z[&%_C:9;70-FP4TTI9)X1+:CUDYPD^
M[8/B!R57<X7U6&?C-M3U\GIQLW!Y.?Z[%GJMTV%9 GAZD?_W>KHH;#U(ENP[
M0]X 2:E.B918,#XSFQ5H[0O8-N<"G1'^.*QKJ[P^JW5LL_IN:J3/+M)_KX>+
M]7CIA@YDC"IK89A7F5P)C99!K5=%&[D)F?;O)+LEJ.[XXA^'0,W5LH%#AR4U
M;P![NZ??!3LE!?P]*-9YCF3] 2#Y"T(H!HKL0)FT $PJ"9/WI= C[_W)H+Z4
MLH% O11[GE9P2/!^^:>*BQ!^J?)[5VH!V4& "*HHP:1-R#0*S3SMP,R*Y(05
MI6C3Y/KO260_#K':*&L#G?;/FZC4KP4ZR4<8?JOW/3>E&)=+Y;)MUP!U\ 4Y
M,N*[8.1] @-'*Z9$K:4ML03Y9%1BY[?].!1IHX -%#GX"+O[>=<@@TO&UKK4
MCI.%IL"P6!M#*Y&\43PK+YO4F.\.\<<A6&/U;6#:P76C-T"]LP'?@QJ#=<&6
M6K0O6Z:YKLWI!6=9UQRV"$%ADTVN.\2?3.M)?1N8=EA-Z(\SF,S^_+KLI5H;
MOBU^L(#&A5)!Z4"^9<V:D5(Q;^8ME5&4VJV,BV[7*8^^YL=A1\\BW\"&@^LZ
M=^O8 5*3>PC(1#:!Z7HOZ+6JM65Y\9$V:;2QE5U]A@U43KW:]*^T#=3:^Q#\
MIK;"!E"KLPAE,D !P0IYD$P7PA91",:#2!JLDU8W"1I^!-./1Z.^%+2!/ >?
M:]]F\3\2,OWJ^_+#159_D,'8S"U#7XCPM?!YM)&^<BI% ]H*TR82?7>LQRH?
MW#[>O+&>SJ6J\$U2^<K26XYH.D\N3\)&;9UBD$ S+6QB(2O.9/3<TSP,#IJ8
MY(^B.GT!CD:46*=@;ZIIEV&S3$OO J9E2;=[:$Y3S:U';6U.?3E U,WUKU0.
MT=;;X5@BTUH&\OV<84H9S86W-BI\IGI_HI;;L=2^BX3[+MS[\7KRF0RWRU^A
M&FTS6N$FWX8)IZLJ8BX$QZ-B0CM:V:!VKN.TVJ5@2E&A""^ZW6D]_IZ3V;'[
M:&#<1GQ]Y]A>5#/\$B;KF&K88L)H6.!UP*(8YCE8YHNSUF2N@'<[,-GR@F>K
MRSX$UO?T?/=U5NFUA@A02.E$8,&2CZ.#-2QZ'YG4M.P4GH+3HI,*-S[^V2KP
M<&'UF/]4*_.\OAO?-_=;YCM'5NBC29:)F 4A,K%6@H\L1RLP9=3DJ7;843N5
M/-H,X:6;V3T)OSD=EHSO@JGONG?;P!R_[%T?BGI4[P=(N><::%NQ^6!<%$XR
M%)7DRA<6DD_,8:[%/SW]H$N"T1EJ_I&B=\=2_"[";>!.W=0M6KD/J_+]BM-P
M>&062]V8!&U,=;-+*D3.,9#1$3KH?&?':@N>XY;!ZT=9X_XEW: 6\NOQY&OM
MH5J3'9?(EL"L1IXE>G(:"9-&)5E,HFYP-&:>.9>NR1G<5D0O@ 3]2'OK.G",
MBHB+%!$8Y=<P_?+^>I*^P!2GX_)^4G-E9]_IDU_^>SW\6O\H?E]G?8_EZ/H!
MTJX^70-!K16L$PZ<X\&&@EP;X7TN(%(.G)-5"D8^N*WH!](1*MA)7:+V2;"@
ME".W-B@&)BIF0?"$10DT3;JU'*."W4() RNX5\(%9DLM?1&]8-Z1IZ(T2)V"
MUEXT&>+B]:>_G#U8[QN3'W>3:X/]]#U\G^_NG\;S>*4)KN;6^TN8)SW=3+"!
MA.RA",>,J.'?P4H6/$@:<74DHXHY-ME@NT-\@2QII)\6-QU[G$>DZ"!'LDU,
MMA4R-\R+7(,PP8/+1AG_\\:^9T:UUM.I;^P?\89Y3:$S-#DBUN)AG"ORAL$R
M*;*/- H(T*7K[P]R6+B3TI\^+-Q%^,<Z*NJ"Z8<[+-Q)45W.C/:1\K$88.JI
M-R;+R"&I/24#K:G> N/HC<QDD_E.+>;/4/.['Q;VKOA=A'O$PT*G0!BPN;:1
MJV'X)=8V<IZ)Y&O\?:95KXG5<=Z'A3LIJ^-AX2Z2/NIA842OLI3D9D5;JUTY
MLZAVE2Q/&23&I',+"IS[8>$A).A'VBT\DT=CCXH/CI3%&<8(-&[%&91@6- 0
M2ZQ=7UR;>G0O)79S'SNQ?]4T*+=Z/Y2B"Y@?.G9S)VT]&L2WCZC;Q^[Z%'62
MDH'(DNEY'01.*UF446KKBS7KX7O/1N\'Q6[VI_9=)'SDV$T;94X&.#,VN%H=
MLP:H C(7R<()*"&N=^%]EK&;.VE@A]C-7<1WK-A-2SL5.C)P2@Y(IHXDVS06
M8-'08)4@"N=N58K.-'9S;UWV(;#CQ&[F!$Z*VFPGIUHH,I'#&@6P;(7SMF2
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M!-HU:W%;5ENG]QW?"NA'.>.VDMUJ#VS)GUK^N/X388K_[__S_P-02P,$%
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M!X^PUC\/,J>PH) XUY_)B7/]V8/^-_26I+BEA:C%KV=R=OLG]<^L7/]KH^T
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MM>D&JR8B4=$T8SV#I'+1W H+0'RN)<L<PH&';OREK.F$@*I*7YT/SG>-*8]
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M,TRN+GL*P='3DV/BO4%5AV$H5MS@WL=2X'MR\@BB3RYF_#:!PS%O/LL7/@J
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M!_RN^U@SNX9 <E*+.@IL:% G=6Q8#(]"HS$!ID)9SNN"HGR%,1AZ_6P2^O%
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M'ZT\<Y1@A_'[O]$*E57ZK/<B-JO09GLLA#G[:FQ*+GYSA\1$ 2.&X87*PRZ
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M%K'J2!5V4Y(5=J'<OAG92KNWM83>=6;&N]]F+G\5LN7=8*-6JI-U2U)L\M-
M$P7&S%OE^SGS'[;X/Y]3*:A_UOX5^14-#%A &"<?J(@[WWYM/;S+'(<#PYY-
M6HF!E-)F/R>#+Q]ST,"!1).J:DA_;<RS5&UJN3=M";DDU:G1P&9G7< S>SA
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M9MXMRWW/]2;?28H+K*$%[PTJPX'\V3^(JYVFP %32/5]9F7,SS88O/R83LI
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M;7(GZNR!L26['RU4@WJ3]GON.,DC64'C6:4R0RA*(-PQ#:TH.OG*K60Q:+"
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MTHD]WJRV?JA,+%GS_5\,M,Q#^K-?5MW>.0>0."KQNG4F*SP9H(BF9:3G_G%
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M^?7KANO=!O?>^:J!5NF-Y[T$)MB"OV_K=<1V7!,M,-\QFJ-;P%6$Z:.3#J+
MSM2#6T!U._TMP#:P4ZYQ[ 89<ZDX<BFW<' SDBWG)>6UX47?.C.EITT@?K)_
M-VJ\;?GN86:M6T"_AXU6*U8]%5M8FF=[@HR0M6Q U=6JP!G,Z7X!-W#WB4E]
M-CTW<T!/SVIX_TBK655 LP03.F\XJZ=^V\JB_@)O4YV??V,/1\*Z&7-JB4,;
M]ZKR E=EP(Q>71<1D7O6X[TERU)1=..#6.69YA>4#[]^D36O]W%I(M7PDZ$
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MT^BR_W3P-=X4+="D8!=>Q>:*GUBN=EQ/*[CS5NH=ZLO.R"I_V0^Y?E,52#^
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MKL5E-,[5L3"XNT\R95-&KDJTOO^6-WEG@<\XH]B#5 @?HC1,(/%P"F-%2"C
MB8B8$?N?&6-J5/\F(P]+M4'*&% CY85^S9]M4OJ.(WF>4ASA,S!_M +6I1N
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MPD>*&!A+81JI?THI.*>(\)3:US$^.=SDV*$YG6Y3Q:ISSAYT<0%D,\YP!]W
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M"TCL,^$%4MIU=K 9?FI<V4K?*;Q;R:_W<)4&H*.";9<'JWDQH\7AT!Z8$:V
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M 5=%QE;95]%T<>.)KQLV2,C]0">8Z>IOC 8P)(A@[A&>1D9-]PS'FYP-F:_
M5F2@908=H6T,FLM8FQB*3A$<VCX\#][EGG?]WE@+:] IFF,9@=>B:FG[&6-T
MWN2[_)@1+3UCG78-///;^MEU[?,$OUOE[/?FA18BX83Z"#+F">W'\" .J8"2
M42]*XY0Q2>QZ4Q\=Q^95'Z?C]%9,4'XAA6U0]W$TS>RVJQ$:F%H[T%0"#M _
M]"P$+HVTXP.-:IJ=U77?(#M_<0\S[%X\/N4%*9[K5))[!6ZINSCI':-@:TTO
M]P71X0%OR',Y]X7'4T0D%$(@'39!81HB!+'B7#^,$Q[X1O%+/<:>FGG6D1*L
M:C$!5W):6!26X!O8:,-!.C"I; 1OLM%F8",[Z"+=2 _>#(JTA1TW'.(CV71.
MD;>S[_IA=];6LWSD>'9?/UUW;,">C^@=^-XD]MQ*W<U=+,OJ1?PDJC[OK_-R
M5=YIRXB24O"VYO(FD=^+D2]]GT&<A&JA")3-J/;K,4SC) V(3SQ?6,7772?.
MU-:.2E)8B0H:6<%-4:A+Q%4%%JZ<-,-SQ=&F8N UQ\$L] G)___)>]<FN7$L
M2_"OP&QG=S+- M5\@"30_2FDE*IEIE+()&6US>8'-SQ#[/)PCW:Z*Q7UZQ?@
MP]].!^ @@V5K/5,9BB")<P_(@PO@XMX Y 4.VK\%T=AA_0'8.Q/X'^*IGD$\
M="&ZU2,<YYF($HB1GF<CK9*0QH6"(L4%(AF11#J5HMH]>FKZ9Y YQMWL:+)3
M*3_C!U8< VJ Z?*IK4'#8W9/'S<2YL2JDZ"7TRO"%*!OSY^H3/]?Q%-8*%7H
MV2Z7D$0TUP3%.%$Q$3FSVX#H;69J'^>% NLWU',X(?;*3#8870-_SIY,W5R,
M?JBZ#B<MO&I!>IO:#A>O]LQ\\ERGU%P\UH%TV[R:;8Z/&<5%IBC14YDT4Q I
ME$(:<0QYQN*,2\&RPBDM7']SD].%!I9C=I,KC#(A5)$2&!=Y#A$O"*2YH"9N
M)(\PPPE#Q&U_(1RG(VTTE(_?UW"IX*:28-F!!_.Z*O?<.ZE,/^UV+E0X*@?6
MX2W0+DQYB_4.7'MKW9/(6+$2-'],?XOCIHZQLOXD:XS=77ZBW1P9_:]2R \+
MM5P]M7.W^O!VG23KIU;'!9V_W53KY9/)7M,%ZW/&DQQIX<&*4E-C4$$L4 PC
MDA6($L5$XJ3GWDBF)O5=1H(F/5R+&G2P;S@^X=]7=I(U2@\,OK]Z._G.JG8S
M<2$%SQ_,J%IX,V?',GG[ SUV@'\KJ^=E1>=_72TWSP^++I0ISH4LLIC#/$/:
MU\TIUUYOP<R!5D4$RW$1V9_D.-_&U%3/!$_+U0MX*TW1D4K[#G*UUI.*+M-X
MNQY8UPI=R&K]758E!5V>_MWE'Y[HHW%&[K_6MYDUGX?G=1TR_WFU%!NN?]F6
MUC67/:P>Z:+\IT/!C+Y^L]@DOKTW!E; #B"H$0(-T2=>[P)!#GN[MQ,UTAZN
M#V%N6[7]5/1NR5ZX=;RMUW[L!UNL5R[U#*TS4[P']7O59+1_8$8EI/BP>/=3
M:\#BT10_?U\N3!GT0_]XQ@1"(D\*2*,L@@AG"#*.M1(7$D=$LA2G3@ZJ-Y*I
M274+LIDFN\;F>7>'G0\Z"LE#^Z#=JH2VHAG^0&>'*>+760*TEP*ZOJB-&:+X
MT,V$!HT8] 8S;E3AK9R=1![>_$ /W_3=T_-\^2)E'>SX4!]IKNX73>SC_?/S
M2O*R\9$-N*H=X)661<J2#&*>)A"AO("8JMPH9U+(%/,D$M:>JP^"J8EE9T,;
MKMM:4?NES6_V#0&-)0Y^EE<G6;BI0U,_L(1>8/V^CW4?-]>+?@<G>.AN&,E%
M'J8[W)SH6ZCL=;&]'CR> WZ+W0?N^4T/\DQ';@)_WIC G_W0H+TPL3<ONTO:
MV*#[/^E*-$&:'Q;5>E6_WU6=.OV;'BM;X'K 5+)<;_1;_E_2 );B_H=<T4?Y
M5Y/*^#>ZEN]IN?H[G6_D3!),5*P'M2)!R"36(%#/ ! 4!8]263"5"Z<*\],P
M:VHC98M=BG][:QR9^5R[N[]H?_?WK[^!9[EJC@+]ZIA1?1),VR9MGP38"8WB
M^S&B^Y0<!(JR%W VEM00<]>5U]GC!C2U+]::G6X@N@-[!-V!CB+0<@1JDH!A
M"1B:0,U3P%STD^KWH.GNIV'9N!GUIV'SA9GDQ-#=6J7D/-9]#\6TU]A859NG
MYUUM@EV!'T$9B;E^>Y%,4CUG5012)!%4!2*,(B:$6TWQL/"F-DSO%^LX<.?O
MP-88L&>-;PF4(%UK.?"^6H<-/8#N]]7E0=*F&]L""6"0VE##=, PA5N"('RE
M&B\AV;U<#B9H*WXCQ)GZ[5\D7SXNRG]*\4%H3*4JZ;;,<9>H6D]G]Y+LU.#T
M0-D$2C57SG#!BUA&&4RPP!!EB$*,<A/ I**(IXF,4ZL%SL&13FW<Z&KU^=1D
M'ZX[[0:(2732P&-%9R/8,_(.[,P$^W9V41G;O/MF/7N_G&!K[#8$]%JW.P\9
M@W=)R-%C.+"C#B2#<WX\I@S?X*T3D'H6=&%29?(#F:/BARZI2G.>IRB%+,HX
M1*G0/[$\ATSI$42_/PE.K,XU!< RM2%BWUW=2W1CM.6S7-5!>6:ON_%D:QM!
M9YCO+,.]_URG%(/VRH@+<&<.:=^!A\VZ6NO^J2/NFLE$9]2="51HB]L\M$G+
M1YE">!,^S'S!'<XK30Z\>;L\$_!_I$>\0AOFV45YZH%"EC_J$H8XSV5""(4D
M+11$19)"G @!12(RKG(I\CRW.^C4WY#+ESO. :<N]/6Y"WU=;<$Z[')?9M8B
MDB (6P/KW$F$\)>P-#GL^ >A:Z1M?1_:W#;MK[+1NS-_^>[QMM^O6G"PQW[]
M:C^']8,)JM<>U1>ZEE__I,]=M!9&!1=) 16*N#D!BK4ORK4P9EQ*BE2<(:>D
M%^>;F9J;V:$$!B8P.-V\QPMDVCF&MU,TL!:>LC- THQ^%D(Z8A=:&M7'ZK?V
MV'VZ<K5'DHW-TV9.38:R=TI)OFX*\3VH>[&L_?+[;:7)]DU.45YDDA'(<Y4:
M64"08:T2(I)YRA*!,FEW_,BC\<F)Q9/^P]K,2&F+V/Q\__4MP"AQR,?AV@=7
M/*N!F1U88W;008/]KJW867/;XM=3R:T%(8,!;Z#NYFP?KNV.EP/$DY&#S""^
MS_"MZ_U%/I8F#]AB_4F_;#,210REE$%<R 2B2&:0%9S".):"9+Q(N"K<ZGL?
M-C U:6HP@AU(8%"ZEOL^(K%?=T)0,["V.++B407\O.DW5P,_>NS(5<'/&W5:
M'?S"=9[KZ!M6R?_9:$5X]T/_SS?]E#9)%4[BB& AH$I9!E&6<,@4TC\E6*@H
M5I0R*Q?D:DM3^ZAW0$&-%!BHC@G KM-KN8@=@K2AEZC]^')?7[[&1=#5XXN-
MC;LV?,WFDY7?JS?<%LY1;_!5I7$F/FZ3DXB$)M0,^SE*L4F+KV<KJ2!0J33)
M$Y86@BN?B(QSC4U-+;:;]GM@;\@0T\NSG6:$8F]@V? GSCM2H8^1(8(-SK;W
M*O$"?99?VO+OO2=$@L&C(&63AWBY6=2K+GKBPDVFMBR.9"I)!&5:<*TL*((D
M01R2B'&9"SVKB)SRJ+L"F)K:=(@A;0]&B!8ST&;)N^,,>C>ES;/H'CM!&I+T
MP;>ECE+KG9Q,Z?#7B[7U(@H?,-^>/7G#9>"SP/"*.?GL&>K/TN?P'(^=\L_?
M7ZJ2EW3Q8<&73_*O&VKF<U)V!Y19+GD49P6,*!,0:3\*4A474&4QB5&>4TN/
MRJ:QJ6G<%BXH:[S@<0O882OX&L-75G<#\S:P3.TH:Z""'5:?,_77N'/83 _(
MX4A;ZC=QZ;:W;DE.[P[[M6>,M\]N:<W!;KOM/3X2NUIR*45E,@?^=:E5?/'4
M!)^6)EZ.RUDA65X(D>MIJOX?A#(&:8X8C**X8!G-.,NLSI1;M38YD6WQ-FDV
M'PWK76A23^UZ#Y9M=#8@=T,+;4>;P0IV8,$.;4CR7(0V((EC*>T-9#H*K24Y
M_4I[[2$C2JVE/8=::WN3W]R^#NLW>_7ERCSW[7>Z>I353"5IQ+&DD')A IPR
M[<F*(H)I7B12L5B;SEUF\.>;F9J\[@ "WB!TFXE?(),7*HTB%<-,9#%$J<00
MBQA!(@N!>)S@*!=N]0)NIW.<,-J!"+5;P+B=I(&'I29%X1Y';Z]PY+P,T4]!
MR,6&"RV-NJ30;^WQPL&5JWT+DANLY;S)Z/2@MJL36L95N?ZXK&HA_RH?ZUP0
MWY;[56%V9V5R640\BRB,,EE 1)&"5,8"1H+11*A8_]5)?L/ FII<'YS2;Z"#
M+@]]D[^Z6P9LYBFNU="#=*6=5HW?00-KVZ%!IH=VO='8!'XQ5OW:3&4ZPTR:
M\H,"54,>?0I+>M@*[T&0C5P2/B2;IS7D@SY]Y+1Z;?J&O5-_1PO5[W[*%2\K
M^7E5<OEE.9^KY<K<.,.H4"C%&(J4:D=<)!0R(F+MC2MI_$85*;=XGM%-F-JH
M<;(7U $'-?*1\N3YOQ%V \JT^WG@P2= _KMM4I\](L[L(QZ^.X,47WZ]GIQ$
M1CM_*_XULM?=W$O!,M7=CL1CO?]6M!TF<83UBS3A<]H&[0?47^2&SK_)U=.,
M1QF*"<,P5R;[4*HX)%BF,&,\4C++,4ZL@MU?!?W4QM(M?H?E\]%[W&(O8\K]
M.,I8^:9_K'SS<I \Y-)8N:7AS$BYI0+L<0$,&5-^=QRV<J;\#HVT-33A=\EM
MY^FU^K)W)VMT4./MC+T6WP<[;:\&PF\QXFS=FM\776BI%.]^<A,/_&3^-5,%
MR9F2&"K$&41<*4C3G$&.*,]2$:&$)[.%?&R62ZR7$YQ 6"D6:13K!,IPJO51
M _QW4#X];]9UH:CF%+G;.H!;9]A-X<-S.XY'<5!:ZZ"L]3YXT* '#?QPTV4O
MUD+.=-T C#I)]>+F>'[I]Q#?H\IFYV;UO%S56OQ5.S#RK7GNZN7M4LA9A&3!
MS,F".(T41#2-(4VPV3$K!,MRACE-W$XN][8WN>E7<V3W +/)2FT2D"Q7H$4.
M#'37T\W]O/<+V !L#BQ9(8CT.!!M1<_-YZ/[6QGYN+25R:>GI^UN\UE_DG.E
M?;EVV[B+E.9($8F8*6= (2*80F**\7'*4QJ+-&6%5073BRU,34@,1OA,+;.!
M7B;.9JGE1CJ&7@XQ3&A\VT "CT#\\^^4PTK"C12--=MWILIQ$MY#0_]$^=R-
M(TYF>W ?3CC[+O1)Y&FRAG[6O:[[_JM<_3"K],VSO]:=WAT$P8E*J" ,QBK+
M($JC.KA30A1E.!>Q0!1;11>Y-#HUQ:MAN^2HM.360@$'8&Q@46PJ?[6008MY
M^]FWJ'V4TI95ESR@X=D=*RMH&)8=$X6ZT=6?-M3R62,F$76S[C"EJ..]'H+]
M-^W'KDHZG[_\;;F27>;V\L?69RBR2.980*YRHB>U/(%81@RF-&*BP)$H<ONS
M3E<:FYI [^ "@Q?L 780F&L,6\AU0-X&END>RGS$^>K;:2_* 3D<28QOXM)-
M@BW)Z97>:\\83W(MK3F06MM[;HC:K#Y4U4:*.G3E<YM;?Y:J2 MK'L,,%0*B
M.!80IT4*"QK%D4HPC7+I=C#G8ELNK_@X9W,^ZP=]IY4$SW7HVK92<)C:P6?Y
MMMOW",+A&%$3%6A WK71?QIGL[4=./BOCXO@,7IG&QL_E*[/YK,1;[TW^&=9
M+$5)5R]?:5V?KZ[8_K.L9K20B9(F66K.%$2(%1!G>0333.69DAE%D=4"X=66
MIN:5&7B[ J9_&(@>N17/DVJI#B&H&EH=7%CRRJC8RT#HC(KG&QL]HV*OS><R
M*O;?X+LC>2^$?E>JS\MJ3>?_;_E<;X@)K"AG!8&*1<:34!02KCT)D<0DSB.*
M1&*5^:>_F:FI0;MMUD+5PV -%FBT7GN.9YFUW6J\E:]Q=AB=J?+85>QCXN;-
MQ+,/'WD/L<_ TZW#WJO]'(/?I)*KE13?Z,^F+.(GN9[%.(XDBS+(8HX@*C(*
M*<WT9"(24L@HX1$FL_52@[#S"<XUXB0 VZ:&>ZN_F3: :)&"-?T)J$>9VK-\
MVKD#M[(T\&??P0,:7UO*]0YHB,8[V"L7/I\O_PR3.,6&EY#^P=EV1G4-^BP]
M]@IZK_75 K;^L*C6JWI5ZHO^U)NZW$T1AV]_+MO5,IDS5+ HA3))(XBR(H:,
MI@A2KO\@%"O2W"I4R;'=J;D,.Z!=Y1(-U54M[!BW%9#@/ ZN*6P-=I!-K>D.
M]-T>J0-4GW+D*JS.V#4]LO0X\7&J1FZW>V9O-OM86O#>_30Q[?*-7$A5KF<Y
MS:DJX@+&.,$0I;&>L0C!(<<"84Y2J><M'@'AYUNS^GK&C_PV@_*NL">@CRO9
MG%&1#7K'/,SGB;:3H1MX&S,&P##60@2_M" O+P^[ITWN92%H<N3S+8V; KG7
MVI-$Q_U7^XG#7Y=+\6<YG\]81 I*D2EA:4(>8YI ',<,IBDE*E5,\(BXN"?=
M@Z?F?W2XW#[M+4V(<BXD89!$1$'$\@+J.1Z'-.=9EN-,X22>/=?Z_75-5^OA
MR#IN9'C*[@"3C^6B/G>GIR\- $\>E:19G#,*E:),3Y9I"K$B!8Q8A(LL*G(<
M12V/[Q9B:!:[)L;@4"[$S>S9#2D^? P\B%S]^IQ'C&,C0XX1VV>/.BH<6W0\
M#IS\W2?J?;-Z-/62WU->']]IXYNZ<+N,(9022F$J2 *1BA/(<A1!Q6,4<Q$7
M",7V\>^];4UM?.C0@@YN%XCGDL7^"KW]GV]@TH;>ZKK(EU?D?#]Q+C'TP0@<
M*YK^!B(=X^JMJ.F/L.]_Q(BQ]E:V'$;=V]WBH:I="::WRR=6+NKWI;I?B-_*
MZGE9T7EEJI',E]5F)7?I(2.68BX+[7<74CM"*BH@)D1"7-"<2)62B"-KJ?4
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M76H1^EA6ZUFL,L%0CB"7*FEFM"S5 A)E4A8XSB1"D8MB6+8[00%I88,M;M
M!W_LH .#W='AL^T).Y$9@-^!-2<,M>Z!R&Y$!0TTMFQZW$!B-SY. H4=;Q]H
M&Z>ZLB3X5WWE>KL:^%^R?/RN1[O['WI>_ZBARA4O*UF7U9A%0BFDM-0)*7.(
ML(PAB2,"<4)55A2QC#.GD\4C8I^:>M;(S>9.B&([(W5_H.V?U^G4"6P+5;;[
M0@T#NRVA.]"Q %H:0,=#4WIHQ#VC\+TWZEY20/C3VF,*WR_.>T\#0/ ;$]]N
MJO7R2:[>&FX7ZZ9J_)>R^D<;U\M)FB&2QK!(XABB3":01DB_3PG3_R$TBXO,
M91R[TM[4QIX.KMM(<XU4N]$A(%4#*WJ'%!Q !0;K &==+'D)J977FAQ5WRSM
M/]8DV]M\$U6LRA_4K%KJY]?[6=_T@WY;/M%R,4L+0N-(<,@(3[0SS)$6$45-
M[@H5\X(('#DFJ[C<V-049(<5=&#!'PU4QZE^+\5VDA**N('UQ(LSCP0+U\D(
MFV2AI[V1$RU<M_PTV8+%/9X;#G*MO\0']78E1;GN3L'%"6)YE$&>Q.8H7&IR
MV\08%AE+J(Q8DBBKQ+I]C4Q-*QJ,9N.P0>FXP7".1LO-A1O)&5@/CGD9P*GH
M8R#H-L*Y=L;=0NBQ]&3[H.]:C\.O)XFS] _=[]IB#?L3)KH0;>V&:OMK/0MB
ME=265OJO'VI7IM:DW5VS/$MQ+AF#RAS<0E$N(%%ZSL(2)E.>8<GBU/H [2B0
MIR9$W8[G#\H;5[Y.!] A!WP/NL,ITG%ZOU_QIMFG@_M39[(0FI^W?VBMOCM<
MD*LS&+26[_W)K*VUQM>7;,T_N'MR+X;#$>7)O2 C'7.>UHOB=F9ZU#[K/7<]
M#I+QSFZ/RNS!^>]Q6_:;O7S:&*_H06W#>[_*QWJ)=Z8RA'-!4YA%1$"D"@Y)
MSE*H<)8Q+(HL9TY'R2^V-#7WH0%J_/5=1N&JQ>HVI[E,KMW$)@AE X_..[9V
M<?Q?K['E/,&YRD3(6<[EQD:=ZERU^7B^<_V&(2K?OM>"U$[7*9):&T0$,<\B
MB&B>0YH+ B4C>9&0@I-;TOI>;GAJ"G):^]9@#5G\=H]TV[73\%0.[O=?+W]K
M@(]>__:4K?$*X.ZU/:$*N*>,N)7 /7/_R&?=W_W/IER_[!!6317.[W1Q>*!2
MBNTAZ0)C)1F6D.&,0\1S ;' &40Y89)$),UH-N89>'<3K#[V_U^>C?=X'>QT
M>&J].YV@J2LQ4XW]>^-!!9H41VM-P<E)>RDF=<[>O_,F<?[> _ZT8J;"]TNP
M\_HW0/#WYG=UB[:GR@E%:40IA7KL,FE=T@RR3*2FK% D"Q)C*A)7W_VTF:EY
MZK6/N5^!Z_J!<Q=2[7WSVZ@:PQ-W8\G+Y;Y,0F@'^TQ+H[O3EZT]YSSW7.VQ
ME?E)PZ35]P\+_9')2GOF?/DDVS7)3W(]4WDNL8PP+)(4-_F=2)P0F&<TC0GG
MB9#"P;>U:7.BSJA&#0UL[4\TN(%L()N(?F/!KW=@(2V#':RXM]@"#$'E2,N#
M#5+0004-5O!+BU:S]RDH>P[[9 %9'&F'ZT8VW;:D+.GIW4RZ]HSQMH$LK3G8
MP+&]QT. WRY7RP7]4:XVU7TIOLAY*=7]0KS3IBR?2MX>GG^YY^NW]U_>?=7_
M_>ORAUPMS$M6A]=_D5R6/Z2XYWJ&;-9[MV[E-HMM$0LNBR*%.5.%.;^:0)P1
M#HM,%3BG<4XQL8XD&0'PU)S#/:3@N85ZMTTU_+Q<.08*C-'G%H/'Q'IRX %H
MSUJ@S36KR,;@NWI+O[.Y2XGR8I+*@MIL\],=V%G>G-4"G>UW8/_M^+Q].ZYE
M"7B=M\)A4)S8VS'2P/HZ;PGX?$5#W ;L$;NN=] ? \=XCL.(K!XX'V.VZQD[
M(M=OM7OT>;4T1;#$FY??*[-*];Y<T 4W56B:!-VEK&89SK,XC1.H)Y%"SR<I
M@BPG$8PC'%',,QR);+9>KNG<,IC$NFDGIV(+8$ 77JY![<,_M]C-NO<OFZI>
ML?X5J,X"0+<F. :=V/>*913*(%P//>_4-!O4X/,^S;]W-&_!@_OK-+M'JS@S
M%C1\Q;[U<>-9G%DY"7!Q?X*?LGV1G;__H#XN%X_?Y.K)+,+-:)'GA H!<Y0H
MB)*$0AIE$LJ$1HF(42H1]MCSO=3>1-?$/J]*S?<SG6^G16"Y ',-'.IYV9-'
M2>N+A-M)U$W\C2-(.X@F5N[CEJO?^KAR5IYK1(34F8MMC:HJURP^UI"KUWLL
MYKRGO$WU?/_$-G/31R]?-ZM'N7IY*\WB45<SDHJ4R)@+&"4\A8B+&#+&&<Q%
MG!1%GD@M+M8K,K:M3FU998=;3X^VR$$+';38'6;0UO1;+(X,0>K RF+'IT_A
M/&MB'=87AB!XI$6"4$2[S>I=">N=FEL_;+SYM:M]!Y-DYYO]_,'/VR%C6_!Y
M6^K]ZWK)_Z$GYLTOS%F-^C>S+,_TU)9I<2\XAHBI'%)5"$@X262,$Q(KZ>$J
M>D"9JA>YYP\]=R8 T5GEYD#Z])"=;SD4X>,,#OLD/ZR$GBEII=H:<@>VIH :
M>;W>N;.F^64X]_0&+D-ZKCXP1G5J;^#IV-^]Y5%^8OG[8B7Y\G%1_K,^^M:=
M:9O)(B(Y)0E,DESJN7.<0L)B!2,A4T$+_7]Q,GNN0]R^KNEJ;:>'%UIS^02/
MVQSN:]P'"];T)V M7$#7^N?'<F'RH9MO]452Q[1=EVC/,4D0I@SR.-:T4\HA
M37D&:2R*-$LI23/5TOYN(48FO6OQE2C77T-8LNV&E #T#3QL'+!FCE!W&,.-
M!5=("*GWEYH:5=.OV'NLV]<N]]-F_:0F&\I;NEJ]J.7*A"!_TB]"FXB+Y[DJ
MM'&09FD,$8\SR)36Z"(A(DUYGD3(Z03?E?:FMC1AWO0V2<\^X#M@('LF/KM&
MN9UD!"1R8.FXD4-G';%D)J2>7&MR5%VQM/]87VQO\].9]^6B7,N/9OOYPV*M
M7P^3!+U)@O"Q7,@/:_E4S1A+HT2['S")HPBB%$M($2(01T+P2,D"8Z<C!S:-
M3DUQ&LRP!@UVJ-OT)> / QS4R!UEQZH'[+0G-*]#KX<&H-19A5PX"BE%5NV.
MJD<N3!R+DM.];LHD9#G[K5TG?E]6G,[_C_;ZW^O?5+,H,BMR@L(T,2G7LDA
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MCTUGM7#@)Z2&V#0[JK(X\'"L-RZW^L;%G2PA=,L'A\4(S8:1V95>SO73'CM
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M0C(>/6"G+X/S.K#X=/A!:T";R:()7#)&U!-@T-H!?FDM^740C;J)S,#%:3R
MC%VLQI^K,\5K;GB8?Q[X!U5[8I_T"_J@OFDWN=+/U4Y9FV>*YY0PD4D8D51!
MA%()"4L83)EBF')*E+):.K=O<FJ*9Q";A:LV#X%7TC\+HBU]J:#T#>U5N3'G
ME4;>CHS0.>6OM#IZ@GD[%LYEF[>\\S:_ZT#,MD5@#R5M%L4QCWF&H<2F_(3V
MM_04C>10DES+#I4H<\OUX-+XY#1G[9$CS(%K-\<J-(-C^5-';M1^+>H39RJ\
M!^7"VA".DU7[K^(ON3!SR4UR>H9'2,)^<2U30'!&,<=4(*3IED3+DU"0\"B'
M2HJ"LR15&;,*;3[[="?]&2'R^)MIX[ <'^!+MTWZ$P8M=M5OX65@53FJJ-=;
M M2"#(>]Y5M(&6DSV(4<MPW;2\;W[K">W#3>EN@EO =[F!<O\G.S/BX7CR88
MJZX/1M>;55UV^8M\;G8_ZIPSY8*7ST8I_X^DJ_?E#SE+5,Y4%"F8"15#%&MI
MT_Y6 16+M<*16*G,J32I%XJI.5[Z7<K<_"X_\NT<L,$I'5@S#7Y81V$:"\SY
M^MJ&ESM@P *#-IS?=1-9(1TP/R"C>F(W<77LDMWV,/>T\@]_+K02?"^?VY43
M%"FJ!$X@1[F ".<(4AY+F+*48<DY(<PN>>OILZ<F3UMX'CGDCVF[XH[=1L;
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M,X<_E,D-44A3<@4E!%)--DP%BTFJ*"X$\DBR[H[$2CO&S[3^OG<I\ [0G36
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MX:=0BZX/%\MJ<;V/N.VPPX?E:E==X$'I89^7B[KHP$P4JLB*+(91EJ40D;B
M+%89Q"F.<Y05!+'LAC,/ET>>Z-&'<\5'_,X[](!NQUN!,!SY](-:KL AB(W
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M*6J'A#DA3Z)<,UJ20I4G(F,TI<RM$K_C^%,CM4Y\\$NGP-] N0#[.OP':+0
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M5)KF*"\H54ZY.Y>'FAI-WG/>U!;?B>S:O>XBJG8L& :K@4ENKQ'*'XV4PY3
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M:SSO;?#T* IL#U#8 L$6XXY<+-@>B=/"P0[W>IHD_+L4&V,"O5T^ORP7)DW
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MTRX/-W)JVE6]3U/3KM_B'4C8LM@V3-$>HZ_>;6K'G#E/(V>TB*0@-(-%$9E
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M6S6"U7>].%J:,+XX 8^UPVXSO*&=;#?E"]EGXW#X08W@?HG@MLOZKH"_:E]
MXPSX]7*'.,\,;X33YU1QJ"FCSAUOQ.MP,GGKXWR4]>UTB3YITGBKE*RE23Y*
M_;;K,?I!SI&>>18R%A";0GZ(1A$D2!&8<%Y$.)4)3YVJM3NU/K6]MIUEYMSK
MV[I<\O(;7=Q2^?<:_K;;]H%0#;Z/?U CN#,=&-MG8&L]V)D?JG*P)6KAR@E?
M,^ %:PQ;8G.Y\+#M0]P+D+Y>+:O5HA3UHL)$@59-\+=(2!$) E7,8XC2!,&"
M8 YCK)#*D"P*8A4 <;Z)J1'4GI5UK'+E%.-] <PKRV<O$(6>>[FCXU3!]#(
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M=^_L?/!#/!^&?]!CUON-?*SF/(M)1O,4YA'5(X;0"^L"1P(*)"*AHERFV"F
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M92F6$C)E-O1XH7F<YCFD)%=$1"PI<N)5-]JS U,C_!-)>N G33N_?WYC%&1
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M$J5)QKE;Z*A]VU.CT=8^H WT4OSK)-YV?!@(Q< 4>+*2UJ[RT ST$ Z@"CP
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MF,#OL+RJD&$L,"8D$!&81(<^HD//,GIV5#(O!+>L#KR>(FJ8SG/U4-6; AH
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M^+J??+8B41' XF),"2,!4,2!YX0SQZ*UP8/8<)FP5\0U5?Q4!P*/X^P0?32
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MYT0\!^^4DC:;*F?2]PD9-CO3$,8.TE"3EFP?48Z4TMZ"ET248462YTQ<BH8
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M5>EER(T"3YT"4\7F/$G5L"<E_6.H/Q6T@*=9'.^3R%MSJX.6(M.N@V'I<\&
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M'!1$7:7*^"$IC=3S])A7WT_*#>#D?@G?N^G#PZM/Z#[^,IO_Z>=I1$T9E.Z
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MJ#9_]'!JWE\]L]YD-:2FY\O1AS^+I_EU?-[A/ K.J-69Y%Q2ASQSXH3FB/C
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M;POTU>6MGU;YT<2T4S$'DIS*I>B"H;_B<:5$7AI=!>/]-G,C#S"0VQ'Z(UC
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M8A\:2H\)24LJ(UA%RH ;#%^Z@7ZX)H!KX0QWC%&S%70.V:OJ-$$X!E3Z$.O
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M;@X8B):#FP.&**Z#^_G)4N100K*(P!W62?>L+D=G$;SCQ@EEA4]'J]P^O>:
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MA, E_9:K@($'+-U5#34;)-3:^$RAA/FKAG[+:1GQ[#$3FB$FQ35XYB,%QK*
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M:UB37-K4?:4]3$(9!),#^DJ'Z*QO..XLZ5<Q:V16@F8IU(W=@J(NXC8:EF/
M$JP^=GW::?>5#L++@7VE0Y0W=]+FB?:BS*733EL0*=4]NH(N%3K!8)R1K&!1
M@>TW=.. WJUNND@'Z7./WJTAPNW =KV[^)PW/PCJN@^VQ$02J*_!DN*PP!V9
M>_) 4,:@0N*NB":N[3,T=5ML-AFVIE;,K(NP!U4X>"]99 S!%6= B>C!*\_
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M1=O1B$4&XUE$"FOJGD04Q$ID%DS2S%#($YUKTF;W#$WS7GK3*7X_1 W60K^
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M)WZ]F4V)%%]+0Y+AA;B(SH-W:""*E .2"Z5RDY3T;G)ZP=&AZOZA.N%@V7>
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MV*O5Q3)5R)/S_R''R\VVFO#7O^+99;J*&6KH?'FEP!]/S?4C.P820= 04HQ
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M=/AU.U^YRT%0^!]I^N4KXOH"+;3[DF[ZAM:[8-]?KY8K-RN'[JZJ)&=.!"5
MLT/W&9UH,(98,(H;@ZZU$ZK*.(]]"6TQO#ZQ/UA5MPVXBL_Q=X^]K8J ":/2
M.VL(:.M8J0'08!-3(!W7)BO-G:DR\.$P<L=U/NM": ^\#J3/!E#[0L'*Q*C
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M]%EIYUB5*5T'TCOZ<MK*0*VGO*8P6B;NA?F760FCD=7-I;'\>+='=8M31O
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M\; Y:I*DI'U)6W@C062BP!D,:5/6UCOO@DMU9E4^1<W(4X"'T_9V<^[1HF\
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M*[JE&_DA\T\['VDY83XI+9F$X!UZ-MH+L&7J4#"&2)69L+'*Z*<]Z6PWEJZ
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MB8=4QOFTMG\*7U.\ODSSW.7*=ZR9'J9]?;]O56I1/X+A$[2A9Z8\)]Q#"L5
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M5;KX,5U.&(O&6F_!9N.@M):A@Q4YQAZ,JB@UI[Y*4'F?B'$A.!(.Y@,II2%
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MKLN4E\\+5Y9G_.I^+B<Z$1HQY(#HG,!;0_L2E<?2?9,$"1SC$%/7:KY 83_
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M#/33Y(Q;#E8920-H8.SBJ\_NQ\<4TO1[8>#BRR)UB</'II:%:&-PX&E,()A
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M)NT)#JATHX:F[L42M!%)+R0Z>:2%LDC"%BY I64FN6SHP3,ML.NY'UK <5O
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M08X&\9EVL&<DH[AP8Q:B47)G$HN :23.WX^<@7A.ZAR4G]X*3:<,C#U/D2M
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M"!??JJ*[QZY=AP>!!N)6<DSI:6-K1MG^_T'O/?'(>1!]G594-;ULRBT74>Q
M;F/?'HGP/YF9:U36RK&Y[*4]J!)!9NA8VR5+-D@*X0"&'-Q:8YU):X)YAMP3
M=SPI/Y4B]C:2UXE$"_Q+3S,B:T1WIV7'2N(TI 1>Y4?X:F*_D&A+3-B@OI>&
ML@_WWN,ZF.LBW(0G:@!Q/&!:J",DKNN%[%\>2$X"VL58H[2IB 9G$9>>%22!
M47D7*N=.GOFPBCD"/X8'@=* SUP//5B-?5R%WB)O8<%9U_&&C>,- BX+6S&U
MON7[\P0F/$V/L9LVGTI@WXF;C2GBL)2/15:/Y2[8"58]0@7@U%JPR=RW93;:
M#&;GJ42N500&=&4[PO*Q8*UA8)(DXUE<6B$\.%P(#)W2J%&7L-V$UEV$W.#2
M-=2; 4+6##SYJI4KM]HQCVP#[;[O8XY:?TCK2(OKS<,@M*0:'GOMUP]YDP,'
MLG%8<*V$<A:[,A1[6LF5$-N(M\WF_LQ#$Z@(N25L[EQ"7C\>NNX'1@*+<[8*
MFZE%V82H5EL5^7GI,.CTN#V,P;K22\_'NO:+:;35@ X4T:6VI#JM$Z6KH6H-
M^>VJA 0DW74(.W$,K3FL&-#J6/@)8H8LE)#;N>/ :7JQ2NRH3$ILLY 6*XT-
M38F5,'F,I.2@VG7&.R*3"6X66PPR;#6[+G\@MQ5-IX0@X?7'&:4F'592#_(F
M$^_>!(4<:8WD<!EQ[@I_\T34%[!6;NBZ\<!I-^ ]N6NZ++ZC4@+QE4))A=_V
M7B[K&)>)=<2<H\/#4*C?4BNR@V".=4TCK2DS$E9 I@@[4U>>$N4<<FV##,(=
M\>5AK8Q=%[4+HFCTZN-&]3%:<!&H7W.?%Q>7,/"1A8Y/SRVLS5_Y'NM;H<4&
M]Y8? ;5BTT(?R(Y ?=W9]""ACJY;X-V-7*65.F.3,ITQ(9XUCV26-S+>I%;D
MEQ0:&[EV;'7MDLV3,(\CX$^0[<EL(EPK+[!M!Y%#,J-RR[/Y)]^5"* KQ>VO
M4E"R(YHY>UD")40R+XS%4&8&.4-DD$9QEQR>GUV@H,'.^,BG^JU4,>O@[1;4
MQ+R:S4L"HFS;(0K'_&P7:6Z)[NRQJ6H?6_6*D@VSRFVX&>7F&D")<F\'1\R^
M)5>HY\<J3>H2P<.CPEZ!&(G%IFIX!,)6SD^8AZ:&K*!&H<*C+Y';!!H@;7[G
M^RY,<F;9D0W>8#L+^LRQQJ+>EH_B!!U;$S&4-KQF!/R=/%<S-.+#4 9HA8ZU
M8[MC9SXAL O>X<U#YMAPF40CZ-5W- #5/KXL!E(A$D5)FET</44@4LM \]EX
M*> ].__9U6+02GS!%U%-,67U/,LK9=V&-%&1)]>'M;TG;2W7,H9QK5%'=Y(.
M>($+B8971*'=60X*G=FW,-XH0KM;T.U:X$FR=C$2EI-:7]1$8'W$)LC;K=D,
M> LA6[+0>7'JZ9H%[M&R9*QN^HLE8/,31MJ7YP:?%XTU@>TL!S]FI6'(#6"/
MM&5D\$RL!6J8>-ZL1-RHL;S2V><\XL(4SM(C3[IM"2_#R K>KM[[<NT<7B8[
MY^EFSA/-$_QU$H7+XHB,XE;HDA88/=_',5G.[-X:<7): YL@6[NV9)ZS0TA2
M+I1 9=8MF S)M;X2[)IV$ZL106MPQ+ID#04B+A;*61D4XHGI N71+7J][.#E
M,KW;\C"]X[U]ZL>#(75O!*LE4=D%_((Z8JB@3I=&<BP5:"UGF"4R"K:JD0A&
M@.J'S)ZM(_-J;0[KR/P/4E><YQ<#FD1VM2OA^#HX--94- QJ^<.E6;I;"43\
M;I3J4LYEB]C?5@47<$!8H5O;#T*IF*.92T0GP&<29990VD=<*=<5(<QD@*L4
MQ+D3E4..G)1K(IY"1FE13V\\GOL-"3HN%&N4NHCP@<4/VE#A( ,^SVJC!",<
M:DQ-*4]HQ 0%PB1@A_L,+"]XH>6C61YHI2JTFOZ[FQAELFMB$;.L-/JK72;]
M]>TA+D1NRK:6H$,99@]H&%$+"Y&#B!F+V*)36N- 1\$,D]70C]/##+48T1N;
M2>+VA> MEF@ZL *)+CRN.0%NH(/"10V2#L_U2=^8G,>G,\=2#G%,@D,?NR[,
M?3[S>8"/B1,R'RT?;4#,L*,"BJ.%0 X@C$9U\UJ1J4DH8@,N&\,J'J],1$:X
M,6R0<!#3\U5#67% 0W\N,-/*!R)OF*(!:</,I7<U$(CN28&MB"'1!-Z16T&M
M0;SYW;V8<>&G-0@)/8N",@1("H4L6K.T_#M^C17G23GGPD,<>?,G]'1;*6#H
M22_TV,V6S8HQY?J+1:1.L7Y9KB#RA29'H ]@$3%+3+80OFB@'BE^U>NQ]YMR
M<*2^8M;D@?N!VI>XYQD+;. FP'D=R[V;@S*/+\F;9S2]/%Q)-!4Y3)&.''LQ
M$ON_M#K/2T(TN?0K1">3R*DLI"?&PD""GO);:^Y0LS?S@0N(O?J,(Y:)@@B/
MWMPA^ -^'&4RV"[(8I]+8/@&C.?OOQV]^R3!Y4_A/\1#="ZQNJ[$QAZ=XZ-(
M(F[2E+=4 OB@H  ND01N[HF54%V;(AD5>7DT$4R1W0PM*U>AE-]GBO;UA0Z6
MSQ ,!+@NO(MC?Z@%A6O$.Z2CW76EM2-/>*(JQL[CO:A$) \15K<!$4@'6*M:
MECC<N^EDI*2<L-T'SQZ+1!J'6V#<A(]>(C@4%%RJ'2F'+#V;&>LO>"Y,4Z*E
M)TJ4J]U9T\NG/H6K3F%YCF'S_=[^QHHP03]&'+ZX)8!K&'#G=HV+?N5A@X,]
M@S>+:!GJF7UOQC$K]/#])W;N6PO6Z5QA"N<<#J 3-^?5U4HEYNC$.!Y&NE9>
M[]A46+?\F9='>_L'6\5U8E0[W0B-[:@.=JFUUAD']2_06&4F@2WQN2S$4A(C
M(<)40ASDL4]15F0#B4$JUV2"BK7P&3PQ%K6J?(ZP6\; CV!/?,RE\Z>J= YF
M0()NM6.'TOM$M !7>A-I+&9AD")U5!X@*I"8\5@JI!*0Y(A44%)]T6HEGTKT
M@,AMDRG7>%;[QGA[<J#KJR==RY*GRY*',HF2MQ\V]JD@MT_Z5:PHWD?U@*+,
M8!5:C+CX0II(%CT-GB_,'Q0"R2?2-3D.FO0C(]ZRTO#2'#D[QJXP7>NPFJ+*
MH]*'U38XZEMREEIA:*$&(#P+6/T'\]3&WFP1E7'1*1P$H7";B90C=RS;B]M"
M!'K^G>7:_XG^3IT.9,E2H$285[)YXO)K:AR-C$.C')MV!!Y)'$EE.H#@@">@
M"( K!J%6@SE0?]CD@8C'VJ">]0J3Z "9N'1JEERI0@C^C"6A1@PB,L'="($%
M9M88A9P#@_%ELV"<S JS4_*4E@/G&48M?( "FH.QJ6QY&E^U4NPJ;Q!!KJGG
M\ZK'I8S;G1/)P;)I3G.536<.1^ZG4>%H\=JQ'LEO!#H[3AAY(OQ%6@H\R[&M
MD8V..[H?])7=N!I<Y"-+\G34!X5G;$UN&KTHBBX]^U R=SZ[<[.@!Y&U)&E"
M/7 2^:4K2!V@G>^TGD@>H%RBO"*E$BP9Q"QZLS!V)8P\"X:"529L=,%BCV[<
M+?[ON?V T;(0% !82:R&!M=.%KN9Y#('I=BW_T,:@L]P31574"$:XB/1MN!0
M@3KH?&O.S(2%$;$<\ITOA7'$X&7";L+'F>,DS2W6G-O/-.$!#:,ZA.Y$XW;Z
M^D99$42KBBRI*?G85G2K9[>ALU^F2B"O&XL]5 YIM*5/=S55#"<V'45%%PDO
M#D\#NK]S$:L<9X1Z4K>2:X^"!&R41(2&Q@(?"OM1G0^U14N6!\Z>K(^$UV&)
M$'#,_\E2_5SQ'C6P#2>5DEP^,P*TI!!]%G\<3S8MF76HVMBQYD!/I*".O >>
MM'RCS%XX5NI*4.^QD'ZJU&#2(Y?%3FJ#ZJD&57GLJ8,#B;'<R)[J>B%%"./8
M=,*GCD?>>O!BTR?772$83;(+E46/UUS.]UB_+^ETQD#:Y$%GK7G2>S61YFKB
M+YX"2^4=?H));S&02P_$5C5.V%#^GM"F(BQ2PI(W* $),+_?VR,[9!?Y7>VC
MH.3XWN:W3.8G86Z#X/$-^46L!BKF'WDMU0<D6%2$V%<^ M02;1XLBWX=(0_?
MK-BHYNW1AW>3GT@H6_1;Y[>>(4&:68RA@"*$.D%F8_<DWGO]L]9&SFO6D\-Z
M2L1[CF6 >#/> Y\HA3+&F'@R^!H;]:!_S<.D:%2J>)S'0I+/]J.B*UJJG@2?
M8'EQMO#FOO1OQUVM!#V']NNIY_(% WT.'X&4ZL\=&:[R^=W<L<*HZ+UTO. @
MK@<&NS*&_79OR(QQV(BE,2GX6I0EELZ(^/%MH7(G)?2D<#0XF6A?GPSM9)3H
M:!S(H"U8/JF#((L$8;%;++@3>N-O*>X)I(%2V0)JN4:25"23DP:6PJB6IFK%
M(,I8-N&,@OU'S=!Q(K4?7JW1<>V'_V$ZRSXC90#8-V0FIF "#?;GWM4>NR2W
M-GHF,'\<5=A.IT7"YD].!T1^LJ."R9D 1W2[P>H[GFC!Z,UBC".)L6UTG=^0
M#91AA_*#^<167;!ZQE9PCQ%WS-R/(:/YS"VM">=?F4VXNJP@30(=C;X](F=!
M*LUR=WVOI;^L/F!_+X\VH(QT\K.V!, )*V_3H3VC O[X%;:ZP9IFF<5%\DJ@
M-B+#3&O)BL\L^I1D5DT2T"A46JQ-,Q[[<\TQ+>M+*U5U>6@JCSSY0/X !&W?
MDA]\ 8=K(B,3"K"I'.>8][6KZ3=Z;LY&)1KC8T0 U37QG=AWO7I:OT('+X_8
MW1075Z(J+UF K )4DT9')=/%T@&$A&\LB@O(" *&X.*PR2KZPXHT285^*6*>
M>-923Y=T%MR.5ILI/:S=V%*-DN1>;EF&N]*(@JCFYC )UERJ0*SWVHYWEW0'
MXN5PM>*Q]P*?OZ[6[<[*8K?Z:';S"J<UL;ED3LY70X1E%9(WJTF!F*2@MP5-
M@2@<A($MHYL>S4\Z=62KAZQBH6HL> _]SG/']4*:;AU6J>E6J3M0;ZD%UYKD
MJKH#5TD[< T3P=DHUHI[5C!73H'C\AOO ,W][7B_ 9/#_^+@60%ZT3AU0R'J
M\=9T8VUL>%BD>^\3&X/+WCT$5LF:'C'Z@NN%]H6PR:-D+!L=ZHXMY(FNS>PL
M=A'>JZJ7$!*+],_ (PRC-F-LSIQ?,;[N"/)+U1^S8,_VYVEO5X#F@H3&I9G2
M;=GJN$A9_\P.=FO/SJI6=FN7*-E@J]!$ZZ9V/]C4[OG;V.F]UO!-2VWMHI3S
M*)EJ/5D]9P.[S*-1@*__FL9U>:WJD@WM?L:! K%Q@[.1WGG:MPWW*;=^2.ZZ
M1RPI$W6QE@=HA4)6%0%4X6S=#I4M/6("+U)A(.V'K,-_BKN\+7WXK^S5[=;T
M%R50O)]D"H)X-VA]6U2.*P>'%2 \F1A/(2U':Y>UGI.*5\#!']\C!R"&LZ9K
M3T/UQUKBFS(IIB&>H,(/D<6R>G'U-=U$V[&TI@4N6-9!@/ALVQ5ECZ7C-J^V
MB_(9B36.@6EJ08(LC/;W72F_K6_"JL GC<="=&!C,"%Q(C<;3283YK89-43R
M)G<-'VVQ#O?<(21P_B:*:18P"*/^!86$ :9C$$@I6T+;.:7J?[7(BFH'X"U9
M7:Z*]K8JVM%J9\*%%L0GOWJND36;V4Y+&MJY95-H-?1JR\J/A+YEE>-4D-<D
MZYE$4+MLYW#S@YYF$Y5-W]_;/UIE=K]8H[M\O?20;K(J01<BA*7ZC.O/;,5K
M0A]NU>Y4_(OJ0<<NN75I[WIT1RN\D1?NI/*=52CPNU+<1C'/$D"*8B.ZZJ5K
MUVHX)5CM7]-V[.7B(-9KZS\,B-!K3/]B5(06P\L=DAR/CI7('/%?"S!1O2:E
MQ01$(U=K3R8DK3#!-E" ,L^.-$7!0A 0_@:;67XH2G)@80$'2PQ80<H&30(Y
M-L[$>M[BP\\X+QKX"^[V6[DN6)N<HS7M?V.24;J1L ,+M=1"M)*JAI FZ:S.
M?-D,7O'NNG_PMOL'Q\10 K51:[VU7,U0E$Z2GE.A1JBAJ[:!C;B\160@9T8&
MXU:E\YFB7NE[341A$_%.S5TRMD1BQ]+9HK(:RP>,"IP(92IRD I(D:CT2/@)
M/[MA9.*8B<+D^A2!=<^1V:/C/&M;EROR!A)<!5KDU%J@O$ (!AST.5;%70YQ
M9ON5]C\(Y]\HOE64<2$?V[KGD/ZF^8I'5"!$1=?EU/0;8%ESET[V5K6RUZ\A
M.X-:;B:#PE:P]@-]G<E<]\BOMQHD1-Y/!4$GQV6.A*Y#;.K$OZM@B*U<8F3G
M.UC9S;?[GW*0PT6LR$=@!G^#QT40-^7/WR1P)![R+G[(SK*W*[^PP7J_^\O5
M0DO8EO"9U-"MZI*W.$;NZTU?J5CJNL:O0=WY]1?JH,5.?WFT4DI90^)!]11'
MF6K'L]0I]NE\JZ:5=)?@"OB\_^IDHE2'O!;;&.6F^HXJ?$UY1?D."_)*J;4-
M19>@E\2"NUZ()FZ,U7$7$B*O2C?:KEHKRC6W_$7CB4C&H@Y'O;UT-K7NUL[6
MVME:_33/9U)S5V55HHL#OW/6D.4324VQ22(>/<B=Z9-25TA7R4:@QO2+K>C5
M$50KJMN5\?:EBX0[YH?G'[UKW0.BJ6>,+@,>MF8^2\]]N>?VOGSG]FQ5&O/S
M15"* O;SBE#3:4_68@Y5,>9&6E$D3ZRP/Z5OMJBX6@EBS6QGJ(Z2Y<=53?#S
M5(V2+*=QU-WF5O-F3W,RKM+.^_0"X3MSUE3>93]P9R%1E3/9>4I63T]DX H@
MA;NL3(7W E2\>J!+"E8^XB&.5<G*Z1(B@0$&PI>/97/0@,$KT+6N%1M$UB49
M5PRNQJB&2WA9PFN@&[[H]FLE"0H0R@KP[F@C5IQ3"2$+95M<]7JY'+0\E0^C
MOLWK"ES(J@^KL#_ITMA:ZO4&I)0'5\93\%RU+/0Z%EKUBKSB%2M?GD^E?[G@
MS?MJ!&_*RQB.JE0UY$\/%\S?<FV0HIGI8ZPL[/#)G2P5+%+5I9J054,AW5R\
M8.JL0!\$.@:_<%[[4_-1ZQSQC3"V4=L=J3?FE."0KC;98W*EMBB;+^I%:C+!
MK/$CG^JQBVS>0B9UID$^CY,846+*_$20-E2>O[%^IGB!P-\FFM $"4M"7P_\
M?.3-W:A[AECJ4%5 CN^3?81H4.%R_DM\H:AR**_R<7=EF[0H'3HJK;IAJ9#R
M2H?C*DF'/I^!Q<9ET7A!&S>6C_65P&3;LM!H1]FK'IQM1"EI1)VR*LD8"ZDH
MPG+37LD88$PNWJE,87'.&Q&Z7;5D3Q:=BA, H\)3H(W*91,K]BA6+$K.RAIA
M76'JESF;R->4B:O) ++HA-*("H)DU8!O)-(@_(R3\QB=G*2-8HB&C.PX%TPA
MQ9=XP3+3IG1[K>.< #F@C$+ )?9CQBXPTO<2K)Q%7">$/%>J\QGR>6]^=R^<
M7VN6X3MB]U*)K+(UV\I%X=_QZX"Z-SB4Z$+00%5(1?2QQ78.A).DYF!%'KO9
MXEAQO6G]Q6RGG I9&?*=9,WBJ.EV<C_T[5B(*^%08<$E4:$;M FIX:C-L,-%
M0^DYJ:^PB1;W T68&@17-2MR+/=N#M8IOB1OUZ/-WLDK>:"F(H<YMF(WK^WN
M)@_ ,JW\Z!FB^:2?FFY!N;I93]4E1@G+IRWM6&Z&K]*O"Y@"SR8S5BK[JV1'
MI.L7YY%/HN]G6:V2B98GK%TM7VKYLA7Y\N/GKQ9+)2PPDJU $-,O M1/VC>N
MQT[YK35W*'7&?. B!49]AMG85+W"E\E\MFC);+M8^69]7Y2J[WX),[2?5[ZN
MV7_-:Y<@@Q'7R."%U'Y_6R4_781PP4,=;3]V']ZRCPX!'EP?CZ#6I/LMB-S,
M@><@MTI[W^.*%X4[7E*A.>ZCDRWKG9.YLTBT@\YV[DG]?# ?!3:P4G\1._GR
MP23BFY;GH*+IXRD3GRY7"4N6(,QL-[TC-5)XFL+-)' :CK-<+5953LBO "8[
ME8G2MZ&>>!JO.6Z+%]?=$&78;[DOBX>H*(@ -96ZJ$XR"%B";((5<."_'-S@
M0PTW^#&:>E<E067$$7SD0UN63B]642U?O&6X)F06%\R\M?VI1'3DVS;/J_:F
M\+"B&$7"21959[!)7[$H>D=E#<BE]F@'7 ;':718WS:6_]R%IXQ$U2TY3ZI!
M*W5F<D;=B97@PLC&/J5Q-0=R1XEJ#@VE&V'3#\3W2A\8\/W QF9^.47?4S'^
MD'"WB\@_*"/V"FZ'X^]I07N\A'JGP@STSX6"H;LPT^_)7K9$@T)"OE#_08&2
M]GDZ2TEK,)YX_@O.JBFA^WO="=; 63$V:[L'F9KV;D*8&><YPM"*HPHD2?UV
MX+C(]FG*_>;*'K92)4>\F Y\B;$LL=?X 8A/< SNT@-%/\[HK=A*883U16<6
M%0&&X5$Q01YA<(0)0XD0_CI#Z^6>EO)YY4R-)Q80>PE@HW!A"V^;SQ]L_LCC
M%B&R\KI*)<VR;85#.BX\32PT^C8/8B"(9ZE8P]*3GX#!_$D2>H71K/)'114B
M8D/$<G;%85^?XJ:D'78-7J@KEH!VL8&=QUX2^Z_<Y_'VQZSG)6NC)72;FKFR
M:XFH*=<SG8*4 H<BO"S!?%-U 9)>]F4B0$8?E7I/P"OSCBL.&J5;1D 7!B./
M_]+IC_C!DX\_99C"</7\J^5,CM2-*P:;D?XI%T*M<2"Y5FK59!3M=AYBBM7Z
M&;Y<Z5>^<I<9:7VRHV92@$BAL8*O;@1=7J*[V%$:4/Y=3I4X5.[X=.984K'2
M&]ZNA.2);K@Y@BO_J?F-(/=>KA H83FL#94T*FNX2E#D:/XQ-9\K(U\(""P.
M7B0I(>:=TDN YTK>6,RN0:/:Y]8M^E:B.JQ3"YZ1:\\@?D"9/=X\P)8N=B K
M#*A'!=)58G.7W=',B-)C_PFI3Q%'3D5$HE2_$<C,6SM2377=RY;+'+\QM8Z9
MI1?RN]K):I&K=A$?<"?PVBAU<##8K"]NU#1:1%Q(&XAN9ZJ1X_)9NB>C8$:&
MME):7H:?2/,6^]=889 6"_D+H8XU,K>@Q^-=ND/)=L?.?(+733T8M:H/CX$Y
M ?/)*:D/]M!TIBP?X+D\S/=OI1-<'^^!>B<2R ,WD0V^ Y_2RR5!R)K%4]FZ
ML4%$,!YSA_N6,K\CSP%EF6JE1 F )_/QE\NAKZMLD[1PZL"1DBC-_6I$CDK<
MR$_/V%[?/W6/=:7>G^)K&3GG A$2($!N(AR\(Z&)R;/B>@^)5J>)%+&EOH%Y
M%E"^(B@CVAJGS&64.JH4):WTJ$^]B< /"NF_.:IE^SK7^RI%!L][7\Q^M]T]
M9QWCAAG=4W9CM.$CUCMC?U[WO[)AOVUTMAHP?+&Z>0G#A1?M 3,NS>XI_#<D
M<C"Z7UFK8[0O!PW6ZG6'?228P=<&.VT/KJZ')NOU6<NX'IA(,49KV.YUV<[-
MA3F\ "(:]*Z[ITA<[:ZX&2YHL&&O/\3;>GC-37M@[K(38V">LNNK7K?!C'Y[
M@/?TKH?X3+BP;W:,(7XT[+&,(<)C@$R-[D"\?D"O,B^OX"9X*+S#//G*!A=&
MI\-.3"8H'KXX@4G@[7#U8-B_AD]@E$:KU>N?&MV6R6[:PXL&/1R/!HP$?QT,
MC2%-M6O>L*^]_F>Z#(=ZWOZ"0S3/SLS6$$=**W?1:[?H>GS&5;_=;;6O.N8
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M:K#+(3O^\'[_(.]$+X6C?LR9O[U 5=$@UIN1-UG /_?AU/GC_P-02P,$%
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M]&&-V_!P; +G"(]L?0G")T\OK1(DF.E;1QT52MCA5:HQN(#-43G?9I=ZI-W
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M8]U*%'&*HQMA>+J_=[O/N(Q?+%6F\;NQ)@<HL@2NZQQ?-ZEH+\3ZL:2Y)S#
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MSM:LR?#F H;Q9G#UGH;UX6KP7]YU;X ["DV>?:R1R+<MT*%-Q;#9-HV_N1G
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M A55ID-&%\&2(]MLI/XUX1:Y+@,&YPO3B#%BP)?!2PO)&7S/7D)U]/JJTNE
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MM$2"(R:N3S^$I!.9&%6C,UML---VSV]?8Q9WRO6Y$30D&W:@C"3');^V5O*
M\JS9**JS4DDJN_.RA'W1\2Q04^*K#54CI9KJI#NP9#>H7#XL*.T5DXJI8LY4
M ()L)\?[:\JC&TMR$IR:T@I>X43?/I'5G(\2$H*8 #BX]=*_UK%!"]XSBM]9
MARJ6Z8S/D<Z.:2M4<EZ\C3/Q9DP6>.;:<49WG"D,;3.^ +E?-M5SZ "L4%"1
M+ZWA,N#KNE*,O@#W&0G6KQR98.Y8'1()QP2;S,D>_8S&9.85P5>\2 2K0\>I
M-C/,- ,V+:E-E>BOK+K!(ST4P!X7<D;! P3:IZU712EX!"4KO#H31%Z$W^;
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M%"@8 ;YWX^P=VX@.DHTNBS31KIBD:&8U&V+>(H,I7?71[/!C.?'/'\R)/RY
M:R)4L /F]_'](Z&<4XI?OFA0?:.ZTCUA=>FF=$3]8HR\(M?V:0UAAJ2+1%UH
MWB%VD%4C-N3:E"K)"[ZQ,>2 ERAVELB,@.YYO"47$7K[3*[GM?3U6&CZQ8.A
MZ0.&ZL9-N&?3B']_$7N=*0,D2;(41?K7E)%J!NWFMP']SJ.8@KK( 7UZ^#;
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M/%Z,*MWF6)M$9DR-N5DB-]7VIC)V);N*/3\^A?3#<H-V7D7;3-WZS/AS=.K
ME9WCW%J,VR*.K2\;7[3LQ(&&9 X2:X096X,K+WJ@->W3U\B@JL()QM7-/Y;;
M[+L'<YL=ZJ@OH)"W+>EF4'<:24MX]\"GA-5LENI#?:$1!$M-(IF8RJS3BDYV
MQ''7D2/&K4!:2W,]X= )9:/T-8[HAV^TL9-B!NBJT$'R5IQS@_5LM*'O5=.1
M]V(>007?R'0Z7HZ-=5+]A>UY<$U?*3F*ID.9*+*%5&</HG[?]=3M!J-:THTX
MSD8BPUWE2$NNCH=!-#1])^R(M&Q'@#=!93K^YG2[FT7BF]/MJQ;,.<A(:BO?
MQ260U<=%+\U&&J>HJ=3-1Y\KD7$OD:/6:?3@B,JD"MB4]_.F<W^%GA%,8129
MV(>^-D5H[C@\RH],U!P#FO0*V'@UBO7U_!+4F@Z$9K]!1)C1 B)/&?1D\+^*
M"-K-9()+)X_E*AY0=>E;KN))3K&"Y]&7X!QOG_LW^M^@ =KX:\G8)ZW3B(J>
MJ]NJ+0EF=#&@/.@A2[2'-WB34TGC_NAJ%$REYK*/ &%$?@GS"RH)=:%5K&$5
M-4RE-Q%&&=@0,DZ61+KZ W8!P'D ]6A'QRARI* ,VAV:]+IA *$( 9231M?P
MNBAU%4>GM=K@3M^Y83UH/&FK'&,!J&9=D?G[M8S*5>:4D_"-I-H2!4T3/)2"
MRYV]$UH#1B>D+MMLPRJM;>RF0$IJG=/3\=&Y7G]J,?2"9N.F%&E-#WQ#A4\W
M75SDC\?"L :43G8+PWJ'H=$4(WT470U*6>@#QFBYSEM!F*$Y!"0AZQ2-6";(
M_DCK<P@#)T) !T?8V/&;LY_,Z!:T@$3PH;A,KHQ27]6"H-5.2 *R!Q6BLJ'/
M"TI@U1J#X&5(GJD6SFU^B\FL@F^QO\=R;@84QWS+N?D8D9@)Z_\W1!0Z1XB1
M>SX^[\?!Z>CL?#*>!N_'9^/S$_K/FT_!Q]'DES'^/CD+SL;3T_'!.7YQ-GGW
M_GP:P'.CX&\79Y^"\[/)Z"@X>1N,CC\%!T>CR8?@Y"PX&%U,Q_0MO'9R'+P9
M3<>'P<4I_ F_CLXFT\GQN^#DXAR?.7\_F0:C=V?C\8?Q\7GOH$9'TQ,9$O;S
MYN3X$!N:7IS!&#_1G^.#B[,)_$V=3"\.WO-3']]/X,\/..PP> ,=OH6'J4=J
M[@R^A%F-_^MB<@8CI-' P.&?,QK#I_[A'/SG\<G'H_'A.URBT;G;8("3"3Z,
MSL>T,I/CPXL#FA@N&OP'GSBF]7MS :LPGDZA^Z,1+M/T_>0TY ;'(QCU^Q$T
M=70V'AU^PF<F.,!C&H_NZIA;Q,6D1OVEA+4Z=)K[.#DZ"@Y.CL\GQQ=C' VT
M^:G;HMYS&!-T^/;B'!?Y<#PZ@EZFO!P')Q].<1^P_?%_P\H3;;R].*-U^S@Z
M.QM)[V?C4Z >FKTWK;/Q+Y/QQ_&AMW(?)^?ONR1W-'XWPG%?'$_'1V%K3K@/
M,*XC'LLO)T<7Q^= 7D="P--N<P[5"C&_/3DZHE9P<:871^>T&3P:K_/=]CY/
MSF >)P>C-T?C( P^C$?'V J-;G(.-/ I.#XY1P+[<'(X>8O[-Y[0$IV<C8Z.
MB&YAP3\"W<)[>FIF+Z;OX:%@='H*3R+!P()/+]Y,@59I;V&'#W&7IR%,[WC\
M$<Y(" _ X[3Y4VR=^SU@Z@JZ!()G@5MFDC\\.;@P+YO'-(7BW$YHA.>PP5,Y
MVTA1XP^G3"[,/7:%CH+Q+]3+V^ (IOB.AA&VQX#+!$OT=@+G*4"*IP4Y'U/+
M4SDX(]DRX$Q,@$!KC^0"VW\XR0X'XG<#4>-O3O#A-[B QPD7L)G5BY#@'%!\
M%ECK9'HX8;8@(L$4N.D8N<G;\>'XC'GIV7EP!%P3^04R6>$5_"3R0[JR;6?
MO">'P,IQ");C?F(6PMP6^.+?@+_K@<B@11&=!N.C\0'S'N*H!\P.85"G9R<'
MX_$AWFQMJ01^_6;8OEM8TC?#]E<MF'^9>G<A7_EP&\I]"2=D(M(LG1N0O^RY
M&!T<C$])?CD+WD\^@(#REL\(W9S'3/(LQF O0.NG8Q)CP^ =" PL@N +%\?P
M_.$$'\?O0CI#QR?'X_\^. (9]9?NR<8'1M#O>#J:',K0J"F1NO#D'X[?CH]9
M"X G+SY@BS@P$ DF\$/8?YY)2H$%> ,BUR%>]]C4WRX.W]'Z@* #7(3$1N9
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M&2%?^*&!-2OQJ2<_#^:E4GPV[VMX3WZF%3KX<3> U5JH4DW7 9$J<)PTKXM
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M" >6'E_827=9#V#Y%+L4?@F_AC@+^LC"[;RX4B6I$%-D)CCZ,(AAE6/62Q9
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M "XZQW!V(,=26<@[$EMRD)]3'5GA9H3\T58V;&L:^PMQP;@."L9%PO>J9/<
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MRMI+>)<$"<K2);\N1RS&+/VO:FUN=#KSL\1!\T(E6I88*W.&6EN"U6ZSL@U
M(8>OP<U.^GA3:\PXYP(GPG(,T&BML;^V/"L[4;^5Z+&LAI' >J!0[[:-_QV^
M!J#OMA/ ,;)MR+J;N>/MXGP2$4NX)$;BTD"_55->N1*S,?^[LBL7V&H)IY4
MD_+9XKJ 1E3&+HE:W6J-[5R])<D%MC"AZRDC-PJ;$&7L7=&+QJMW4^DN'KTI
M*@.K>!N#=9(;'2W573PKLWBE%=NFSPY0(U<702F:F*AQ)G1%@OBG<*-*3O\M
ME&UR[L-!#-M TE] &"[/YPQ80^YR,]E2)DY!6%O!LS.)%Y4E?MNIO%E3\5.,
MU<GE?MI]Q(I/KZ(.-$:'CHBRIUQ*8U&>CZ2ZL2$NU+QVBPY$7-"+V$*1RQ;
M,46&/:W;,8H0 VVS39 ARH9C&^#X+95Q8%JVLL'=NTR50MQT:5*67UN*";QT
M*TZ/LFMA0L6$=+UHL6"'&H-E/#I[,Q[L[@>WEBSW B2^4OWR1Q),ONC-.3$6
M O>*16,8:!YHP2;&RFX#1R2];I4TZ(A%; %7:7W<:0\:T&E"H G=\"YTUV5B
M?"1EA%\^F#+"1T4^2Q/!M1[EY'2Y_WR",\O11-US'4(B>S*LDJ6=4.-5X/-C
M<2Z13T0JSVZ6915QHU3$E3?#Q#XIM4+=LU2LAY6*M#MT_K#K"J@_EA6,/;SJ
MO*@M+@A-P,O3<0HW>OJE@(V$;'CUBJ^!.HU9G\HDZ"S2,B'L:P;.KI31[76<
M#B]4I;*9#I1T7F*(DFW[#W>!P!AW&,U[+=CVD:([7;?H2S"C\R!A: \U+@7N
MW&P6I1ME[NZ.,"AD\4::=.O68VH;>2U0ZK5Q[+6*%[G&P\^+?,]^ =I01(ER
MRR:+%$>WIP*=03@#\S):HL5+75&H&QJVX!@D\!4W\H]&T<]DHPH9%J<BH<LB
MY&#>,\IQ[ O%E.9$9?C?"-W7\ >"P>>4Z\WCB6*0-"0+%<XF3'NN505GE<.M
M2UZLR-T+'QR8'GS;PO/89OF@6]<3O +'&WA#Z>\IG9]N1*O;-ZT#3K>UB:5C
M:93VL&\?,,@K0P>JR[;CX>0U,'6H#1(U=;XT3Q9T4S@?:6Y%W2KXE*/539Z"
MVQ@N9Q2N45W".*,X(D!?3K4 7?ZZ+/(YHNDQ5HP%]?>D=C?E,XJQBTPE<Q):
M3&V6+5.#(5^!3I>%F *)1')%=.L\3=9)9Q>!(KYY&.["V5X]# ]#;_P)7VC<
MV&^;METX"*I$ME&3C1,IH@9X;@D#P[ ;Y*X5L3_*C!)) E@<GH+5FKQSI5H2
M8  5#8+SV@B8!/(K$%F6JYHEI6(6ZEZVGC?,2\K714YLJ6U@U$P" UZ4CCN1
M(B1< 4P'%K6EL9ID(E(K!=ILS4 '<&S11%?5:B7:_$Q1&93M0R3)K\ S7Z.^
MBK%%HLVXJ[-,*UHQX+/P$H9#A4&&R, B.,[JS5%*R:4V'+ .'W:5_A(U];2\
MQ00@>^#<-Q*#["MWJ&O#QK&Y8PF["4IZ$F&\0$UW*\9LXS9CV#H[F8JRENRT
MAFP2T4HYG^D^QEC,1JP@53&K[9[10)(B;FRT$M[$(&53I--**N3A3NX&:CDM
MDK5@W+4EG6U[A(%.&']HW$?'"+P,2XM-=PCS6O@U@M,?E)8V+.+1FE-0Y"!1
MW1VT,++M0X##,=QF/S@MR!.T*32S@,4@L*0Z5&) M+L*+!$E/86_=?@?!!HP
MCDR50<88Q!7)I601.@ICFBK9[->A@RG8?I'<D"F?^*J&C@55A^%!;FD6)AS#
M[U);%ZG%9@G(MMX^,+$.56Z\3:$%%Z<,6XO!Z:0#]^C%42X9F10;&)=8]YZR
MS7 !TJL4_X3]M5D.E"VJ$O+1\0H !P$)+U%:X4,+V<PJ7AQBY3VQDYGZ"8X:
MR @FTG;(+=-\L<)IYJR+V0(3IL5>8AXUUCCB3_0R">;& PS-%IGB9#J1Q2BR
M%M?'UGF@5BB6=QX)0A_PLQ7[AZ[2(C.<!^;*85N'=D:1<5K5#MJ+G'@0P#-C
M5JP4E<O";(GHNFI2YWF2IA6J&G0XO( 5.B&I!KPDQPMN$4%CAZT#J'=6]M!+
M+6ERZ!;D1[P.8M8EO'TBBZ-W)5)-GD=B:^JU,JZUE3XHWUOK,KDW!B@N) X9
M?9 46;A@5G1^\N3O?WOQZD<L$H>A'?QH*3R+N2&*"7RZ@<DDP(924AQ)0% E
MZ\1U$084+[F<@A(-1WJ-/E\*\V5I'B^\]36.5*M1ESGIYY-::_08%6FJQNUQ
MJBPV0DKZH@")!1AOI7W;D2[)',#!2)M*RW#Z09,21 WI^>-?,GU%]21Y>MN4
MVC\%I^D>C]9W#\:,NUU2>D# ,#UV[D1]<NZ\\@%ZB0SH4I7H+Y0YQ2R"ND!J
M:(-5/RU"AP'(*Q&C)+JV-ETO9Q5A@B1C3*.:2-Y2;8TF^_:*:SHYLOP;QVKI
MROE_ #;>$\JU&,S%<UE)72+V<,E:(,PO3E<44X:A<U$9+PSGTLS8KL.#RM_N
MY]$VL5-$9@P?J6-GUEQ=3%PV;00'$5QA0W['BJ6ZQ@")BY619_]9K2V\N1_1
M8#B\4NBD$J4$8^,KUD0X7=OU*\5%4[*8O1E.<%- T/9YA)1 3$I-D4G"S><X
M@X-TI<@FJ<C#XRFS&V8A+*&PPCD:+Q&>?%V)CP2*MCT"Z[;BJQ@L6K6+6P?%
M5)]LKJ4EAA)4%V:$";6-*/=;;EVT!3%#0L.06D3HC#)^J9"C'>D-BF3EWEH1
ML$Y0J^%LU4+9\<\1)0(A4&=2D9:R2=<;X9NX]EMB9?&Y&V;U2.ZQ:9_N,0E2
M>#<,CL[>GP]./P:#T^-@^%_#H\N+T6_#8'#T'Z=G'TZ&Q[\,Z9?!+^/A,+AX
M-[@()L.CB]'9:? =2M&3=X.3D^#T["(8G)^?? PNSN#Q8'3ZV_"4'CI[ZS3Z
M]FP<?'@W.GH'+P3#_[P<G;^'Q\)@<@GOCH:3,'@[.!J=C"X^!O#DQ7AP/,3>
MQL,+:!%>?C^@-K]Y!^Y";Z^_>0>^:+V 4MWC  1(_WD;C"XF0*%O)J/CT6 ,
M5!I\&$R"R\GPF X&TS-^=3S\;7AR=@[?(^V/AW :@%@-]<M5-0G./IP&%Z/W
MPS"X/#T93B:8S$-=VU,#+P\NH*&=T2Z>*/SQS>5D=(I/WWV<^-/;MW">H"WZ
MM#.R[<G[6KB;W-20%@N]!O6;@Z.+R\$)_G8\?']V.H%C^^8$V<G%Z&AT3M,8
M#R?#P1B6B1ZB5>*#CV-ZLSGYR>4)#.'M^.P]#>G#V?@_@O/A&#D M/;F8XNE
M_)'E>"R72MRG2X65HZX[9")7!^S4.S@JX^'@&+X93>QE0H?I[>4)D,[EZ?%P
M/+F +R:TMR>C]Z,+8OT3.6XCN!#>GY]-H-W+<WC[W7!,[W/;1T/H'4YG<'P)
MU\H1;#>0Q_E'/CG0)]UE2(!$/?@NO',V/OZJ1'&/II-7#\9TXD:*'8&XEX,R
M><]6DYL"'<0<:/605KK0%V@>O@85VKA--[F,P=QCFVJV4!:TQ2@14X5 "BH7
M SQ[*Q(ND&F?H4!H6C,8@!DI=.A;Z_D-K:O=XL,E$!GR08AME5QS9G0F,ADK
M)6 B.'I;&@I"$E4+^I8Z!^O@*LJ:#9=3IYO>6SI*9BD5C$QB #&O3!)4,-(O
M393OY/5SU2E11^-&=>7=2Y/M<"!_Y\.V3[LSO;MK,L:XXH4>Z&^WNV>-W1QS
MCM"OR<W/BR+!#?_B*BX]ON+Z9O^[B:&=%OD>$=C])O5L-P30F26D?5V9#EW4
M*H_)9YG;G"L.'^!SRBY#^;6=O&02ATPDKXODNS*H+V3%V43$LSD9&TA_+4MA
M[].Z-N.>^V EY&O#B8S>YNB.*@.<)VG/9*E#ZV*$?SMU3&Q.=8#/[*T8'V<C
MK *;OTH3,1O[EJ7 (IM3L1WQ>H7BYPIU8$<(Q#./"%HE%)=ZP"&/V*N8GG6W
M\&Y._884ST@ULNP<V"UXE5;DT\=X$'&AR_6%YV(GRBAXBF<"%R]<6Y;M$VX(
MA6I@&&RY#%LU>R3$8C?TTR#%SF??MH]ZB>*W77UB\N4%J6098/4JO3(535V6
MLM)K64DI)5Q.\FX&:&N3<LIDHU@AP DWWDT>IL^"4"DB.96N@]9&JXGC07[3
M>Z,RI0%N/'>%\;8Z[M*]EKL47SB-J@4&DP!I7*@<7U4*XYO+8E5D:8T1&L""
MN$+TUH9H9?&Q'=YA M_A,IR4CX4_X?Q@Y7ZG\)5:.,]F1ZZ/A5[&AW>Q48M_
M=1=!L)NMVB7^\U;^063*EBGZZ/O 26\.[LXE_,R"MDFP@Q&#J6!GV4AA^I+)
MSL%>1@^.Q SI,#8-!BF4RZ)%NU18EA+$&TKE 5,0\%L'M<$MJ$;2?J(;1PO[
M'OP!,DN#;$ B[IVJ.UZP#Y ?QZAC%5';BAO#4:$H[0Z.V)C;".DF*%@+;Y6
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M9R;I<RU]/1::?O%@:/J( ;!Q$^[9RN#?7\1>I\I 2I(L12'_-:6FFD&[B6Y
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M/V[7>IXBL!O\9U$OLY__%U!+ P04    " #%BFI24R!ONNL6  "3A ( %
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M7G2.XBH*V%HI'OL6Y0XC[47O"'? ?9";%#*,61LHB?4Z[<-P2]#JC5G,\6G
M^N9=W<$39=24C[DV Y1>&EU[+7,^TP-0&,?R5P<I(9X@#EF[06$<S/.^$>J
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M@C;PNVW/M5A;"6G;>5>\X[\1C+'>NK]__-UV3R=C_Y_49?+SOP%02P,$%
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M)"H) :!+ 0)^.>/M2:C)2"K5S"R@I_E$&(O6SA+J;@:[865S!4%F8<R&M3]
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ML&K=1LI:E0W<F>#1RSTA+ _HX4Y<7G(#BY$G7V\>!E'=E<*8EF;_*:XFC3@
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M+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #%BFI2I#F6J9;A  #O=PH
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M97AH:6)I=#$P,S8N:'1M4$L! A0#%     @ Q8IJ4M>G\O=X1   JI4! !4
M             ( !!M4( 'EE,C R,&5X:&EB:70Q,#,W+FAT;5!+ 0(4 Q0
M   ( ,6*:E)3(&^ZZQ8  ).$ @ 4              "  ;$9"0!Y93(P,C!E
M>&AI8FET,C$Q+FAT;5!+ 0(4 Q0    ( ,6*:E*"%1V?.@,  /,(   4
M          "  <XP"0!Y93(P,C!E>&AI8FET,C,Q+FAT;5!+ 0(4 Q0    (
M ,6*:E(CSNI[]P<  'LC   4              "  3HT"0!Y93(P,C!E>&AI
M8FET,S$Q+FAT;5!+ 0(4 Q0    ( ,6*:E*F1U2"#P@  *$C   4
M      "  6,\"0!Y93(P,C!E>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( ,6*
M:E*+4BF($@4  /H6   4              "  :1$"0!Y93(P,C!E>&AI8FET
=,S(Q+FAT;5!+!08     $  0 "($  #H20D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
